AU2003303305A1 - Novel nucleic acids and polypeptides - Google Patents

Description

WO 2004/080148 PCT/US2003/030720 1 NOVEL NUCLEIC ACIDS AND POLYPEPTIDES 1. CROSS REFERENCE TO RELATED APPLICATIONS This application claims the priority benefit of U.S. Provisional Application Serial No. 5 60/416,186 filed October 2, 2002 entitled "Novel Nucleic Acids and Polypeptides" , which contains material previously disclosed in the following applications: U.S. Application Serial No. 10/084,643 filed February 26, 2002 entitled "Novel Nucleic Acids and Polypeptides", Attorney Docket No. 21272-502; PCT Application Serial No. PCT/US00/35017 filed December 22, 2000 entitled "Novel Contigs Obtained from Various Libraries", Attorney 10 Docket No. 784CIP3A/PCT; PCT Application Serial No. PCT/USO1/02623 filed January 25, 2001 entitled "Novel Contigs Obtained from Various Libraries", Attorney Docket No. 785CIP3/PCT; PCT Application Serial No. PCT/US01/03800 filed February 5, 2001 entitled "Novel Contigs Obtained from Various Libraries", Attorney Docket No. 787CIP3/PCT; PCT Application Serial No. PCT/USO 1/04927 filed February 26, 2001 entitled "Novel Contigs 15 Obtained from Various Libraries", Attorney Docket No. 788CIP3/PCT; PCT Application Serial No. PCT/USO1/04941 filed March 5, 2001 entitled "Novel Contigs Obtained from Various Libraries", Attorney Docket No. 789CIP3/PCT; PCT Application Serial No. PCT/US01/08631 filed March 30, 2001 entitled "Novel Contigs Obtained from Various Libraries", Attorney Docket No. 790CIP3/PCT; PCT Application Serial No. 20 PCT/USO 1/08656 filed April 18, 2001 entitled "Novel Contigs Obtained from Various Libraries", Attorney Docket No. 791CIP3/PCT; all of which are incorporated herein by reference in their entirety. 2. BACKGROUND OF THE INVENTION 25 2.1 TECHNICAL FIELD The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with uses for these polynucleotides and proteins, for example in therapeutic, diagnostic and research methods. 30 2.2 BACKGROUND Techmology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, circulating soluble factors, chemokines, and interleukins) has WO 2004/080148 PCT/US2003/030720 2 matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of 5 expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization-based cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have 10 biological activity, for example, by virtue of their secreted nature in the case of leader sequence cloning, by virtue of their cell or tissue source in the case of PCR-based techniques, or by virtue of structural similarity to other genes of known biological activity. Identified polynucleotide and polypeptide sequences have numerous applications in, for example, diagnostics, forensics, gene mapping; identification of mutations responsible 15 for genetic disorders or other traits, to assess biodiversity, and to produce many other types of data and products dependent on DNA and amino acid sequences. 3. SUMMARY OF THE INVENTION The compositions of the present invention include novel isolated polypeptides, novel 20 isolated polynucleotides encoding such polypeptides, including recombinant DNA molecules, cloned genes or degenerate variants thereof, especially naturally occurring variants such as allelic variants, antisense polynucleotide molecules, and antibodies that specifically recognize one or more epitopes present on such polypeptides, as well as hybridomas producing such antibodies. 25 The compositions of the present invention additionally include vectors, including expression vectors, containing the polynucleotides of the invention, cells genetically engineered to contain such polynucleotides and cells genetically engineered to express such polynucleotides. The present invention relates to a collection or library of at least one novel nucleic acid 30 sequence assembled from expressed sequence tags (ESTs) isolated mainly by sequencing by hybridization (SBH), and in some cases, sequences obtained from one or more public databases. The invention relates also to the proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. These WO 2004/080148 PCT/US2003/030720 3 nucleic acid sequences are designated as SEQ ID NO: 1-684, or 1369-1966 and are provided in the Sequence Listing. In the nucleic acids provided in the Sequence Listing, A is adenine; C is cytosine; G is guanine; T is thymine; and N is any of the four bases or unknown. In the amino acids provided in the Sequence Listing, an asterisk (*) corresponds to the stop codon. 5 The nucleic acid sequences of the present invention also include, nucleic acid sequences that hybridize to the complement of SEQ ID NO: 1-684, or 1369-1966 under stringent hybridization conditions; nucleic acid sequences which are allelic variants or species homologues of any of the nucleic acid sequences recited above, or nucleic acid sequences that encode a peptide comprising a specific domain or truncation of the peptides encoded by SEQ 10 TD NO: 1-684, or 1369-1966. A polynucleotide comprising a nucleotide sequence having at least 90% identity to an identifying sequence of SEQ ID NO: 1-684, or 1369-1966 or a degenerate variant or fragment thereof. The identifying sequence can be 100 base pairs in length. The nucleic acid sequences of the present invention also include the sequence 15 information from the nucleic acid sequences of SEQ ID NO: 1-684, or 1369-1966. The sequence information can be a segment of any one of SEQ ID NO: 1-684, or 1369-1966 that uniquely identifies or represents the sequence information of SEQ ID NO: 1-684, or 1369-1966. A collection as used in this application can be a collection of only one polynucleotide. The collection of sequence information or identifying information of each sequence can be 20 provided on a nucleic acid array. In one embodiment, segments of sequence information are provided on a nucleic acid array to detect the polynucleotide that contains the segment. The array can be designed to detect full-match or mismatch to the polynucleotide that contains the segment. The collection can also be provided in a computer-readable format. This invention also includes the reverse or direct complement of any of the nucleic acid 25 sequences recited above; cloning or expression vectors containing the nucleic acid sequences; and host cells or organisms transformed with these expression vectors. Nucleic acid sequences (or their reverse or direct complements) according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology, such as use as hybridization probes, use as primers for PCR, use in an array, use in computer-readable media, 30 use in sequencing full-length genes, use for chromosome and gene mapping, use in the recombinant production of protein, and use in the generation of anti-sense DNA or RNA, their chemical analogs and the like.

WO 2004/080148 PCT/US2003/030720 4 In a preferred embodiment, the nucleic acid sequences of SEQ ID NO: 1-684, or 1369 1966 or novel segments or parts of the nucleic acids of the invention are used as primers in expression assays that are well known in the art. In a particularly preferred embodiment, the nucleic acid sequences of SEQ ID NO: 1-684, or 1369-1966 or novel segments or parts of the 5 nucleic acids provided herein are used in diagnostics for identifying expressed genes or, as well known in the art and exemplified by Vollrath et al., Science 25 8:52-59 (1992), as expressed sequence tags for physical mapping of the human genome. The isolated polynucleotides of the invention include, but are not limited to, a polynucleotide comprising any one of the nucleotide sequences set forth in SEQ ID NO: 1-684, 10 or 13 69-1966; a polynucleotide comprising any of the full length protein coding sequences of SEQ ID NO: 1-684, or 1369-1966; and a polynucleotide comprising any of the nucleotide sequences of the mature protein coding sequences of SEQ ID NO: 1-684, or 1369-1966. The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent hybridization conditions to (a) the complement of any one of the 15 nucleotide sequences set forth in SEQ ID NO: 1-684, or 1369-1966; (b) a nucleotide sequence encoding any one of the amino acid sequences set forth in SEQ ID NO: 1-684, or 1369-1966; (c) a polynucleotide which is an allelic variant of any polynucleotides recited above; (d) a polynucleotide which encodes a species homologue (e.g. orthologs) of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain 20 or truncation of any of the polypeptides comprising an amino acid sequence set forth in SEQ ID NO: 685-1368, or 1967-2564, or Tables 3A, 3B, 5, 7, or 8. The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising any of the amino acid sequences set forth in the Sequence Listing; or the corresponding full length or mature protein. Polypeptides of the invention also include 25 polypeptides with biological activity that are encoded by (a) any of the polynucleotides having a nucleotide sequence set forth in SEQ ID NO: 1-684, or 1369-1966; or (b) polynucleotides that hybridize to the complement of the polynucleotides of (a) under stringent hybridization conditions. Biologically active variants of any of the polypeptide sequences in the Sequence Listing, and "substantial equivalents" thereof (e.g., with at least about 65%, 70%, 75%, 80%, 30 85%, 90%, 95%, 98% or 99% amino acid sequence identity) that preferably retain biological activity are also contemplated. The polypeptides of the invention may be wholly or partially chemically synthesized but are preferably produced by recombinant means using the genetically engineered cells (e.g. host cells) of the invention.

WO 2004/080148 PCT/US2003/030720 5 The invention also provides compositions comprising a polypeptide of the invention. Polypeptide compositions of the invention may further comprise an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier. The invention also provides host cells transformed or transfected with a 5 polynucleotide of the invention. The invention also relates to methods for producing a polypeptide of the invention comprising growing a culture of the host cells of the invention in a suitable culture medium under conditions permitting expression of the desired polypeptide, and purifying the polypeptide from the culture or from the host cells. Preferred embodiments include those in 10 which the protein produced by such processes is a mature form of the protein. Polynucleotides according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use as oligomers, or primers, for PCR, use for chromosome and gene mapping, use in the recombinant production of protein, and use in 15 generation of anti-sense DNA or RNA, their chemical analogs and the like. For example, when the expression of an mRNA is largely restricted to a particular cell or tissue type, polynucleotides of the invention can be used as hybridization probes to detect the presence of the particular cell or tissue mRNA in a sample using, e.g., in situ hybridization. In other exemplary embodiments, the polynucleotides are used in diagnostics as 20 expressed sequence tags for identifying expressed genes or, as well known in the art and exemplified by Vollrath et al., Science 258:52-59 (1992), as expressed sequence tags for physical mapping of the human genome. The polypeptides according to the invention can be used in a variety of conventional procedures and methods that are currently applied to other proteins. For example, a 25 polypeptide of the invention can be used to generate an antibody that specifically binds the polypeptide. Such antibodies, particularly monoclonal antibodies, are useful for detecting or quantitating the polypeptide in tissue. The polypeptides of the invention can also be used as molecular weight markers, and as a food supplement. Methods are also provided for preventing, treating, or ameliorating a medical 30 condition which comprises the step of administering to a mammalian subject a therapeutically effective amount of a composition comprising a polypeptide of the present invention and a pharmaceutically acceptable carrier.

WO 2004/080148 PCT/US2003/030720 6 In particular, the polypeptides and polynucleotides of the invention can be utilized, for example, in methods for the prevention and/or treatment of disorders involving aberrant protein expression or biological activity. The present invention further relates to methods for detecting the presence of the 5 polynucleotides or polypeptides of the invention in a sample. Such methods can, for example, be utilized as part of prognostic and diagnostic evaluation of disorders as recited herein and for the identification of subjects exhibiting a predisposition to such conditions. The invention provides a method for detecting the polynucleotides of the invention in a sample, comprising contacting the sample with a compound that binds to and forms a 10 complex with the polynucleotide of interest for a period sufficient to form the complex and under conditions sufficient to form a complex and detecting the complex such that if a complex is detected, the polynucleotide of interest is detected. The invention also provides a method for detecting the polypeptides of the invention in a sample comprising contacting the sample with a compound that binds to and forms a complex with the polypeptide under 15 conditions and for a period sufficient to form the complex and detecting the formation of the complex such that if a complex is formed, the polypeptide is detected. The invention also provides kits comprising polynucleotide probes and/or monoclonal antibodies, and optionally quantitative standards, for carrying out methods of the invention. Furthermore, the invention provides methods for evaluating the efficacy of drugs, 20 and monitoring the progress of patients, involved in clinical trials for the treatment of disorders as recited above. The invention also provides methods for the identification of compounds that modulate (i.e., increase or decrease) the expression or activity of the polynucleotides and/or polypeptides of the invention. Such methods can be utilized, for example, for the 25 identification of compounds that can ameliorate symptoms of disorders as recited herein. Such methods can include, but are not limited to, assays for identifying compounds and other substances that interact with (e.g., bind to) the polypeptides of the invention. The invention provides a method for identifying a compound that binds to the polypeptides of the invention comprising contacting the compound with a polypeptide of the invention in a cell 30 for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and detecting the complex by detecting the reporter gene sequence expression such that if expression of the reporter gene is detected the compound that binds to a polypeptide of the invention is identified.

WO 2004/080148 PCT/US2003/030720 7 The methods of the invention also provide methods for treatment which involve the administration of the polynucleotides or polypeptides of the invention to individuals exhibiting symptoms or tendencies. In addition, the invention encompasses methods for treating diseases or disorders as recited herein comprising administering compounds and 5 other substances that modulate the overall activity of the target gene products. Compounds and other substances can affect such modulation either on the level of target gene/protein expression or target protein activity. The polypeptides of the present invention and the polynucleotides encoding them are also useful for the same functions known to one of skill in the art as the polypeptides and 10 polynucleotides to which they have homology (set forth in Tables 2A and 2B); for which they have a signature region (as set f6rth in Tables 3A and 3B); or for which they have homology to a gene family (as set forth in Tables 4A and 4B). If no homology is set forth for a sequence, then the polypeptides and polynucleotides of the present invention are useful for a variety of applications, as described herein, including use in arrays for detection. 15 4. DETAILED DESCRIPTION OF THE INVENTION 4.1 DEFINITIONS It must be noted that as used herein and in the appended claims, the singular forms 20 "a", "an" and "the" include plural references unless the context clearly dictates otherwise. The term "active" refers to those forms of the polypeptide which retain the biologic and/or immunologic activities of any naturally occurring polypeptide. According to the invention, the terms "biologically active" or "biological activity" refer to a protein or peptide having structural, regulatory or biochemical functions of a naturally occurring molecule. 25 Likewise "immunologically active" or "immunological activity" refers to the capability of the natural, recombinant or synthetic polypeptide to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies. The term "activated cells" as used in this application are those cells which are engaged in extracellular or intracellular membrane trafficking, including the export of 30 secretary or enzymatic molecules as part of a normal or disease process. The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence 5'-AGT-3' binds to the complementary sequence 3'-TCA-5'. Complementarity between two single-stranded WO 2004/080148 PCT/US2003/030720 8 molecules may be "partial" such that only certain portion(s) of the nucleic acids bind or it may be "complete" such that total complementarity exists between the single stranded molecules. The degree of complementarity between the nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. 5 The term "embryonic stem cells (ES)" refers to a cell that can give rise to many differentiated cell types in an embryo or an adult, including the germ cells. The term "germ line stem cells (GSCs)" refers to stem cells derived from primordial stem cells that provide a steady and continuous source of germ cells for the production of gametes. The term "primordial germ cells (PGCs)" refers to a small population of cells set aside from other cell 10 lineages particularly from the yolk sac, mesenteries, or gonadal ridges during embryogenesis that have the potential to differentiate into germ cells and other cells. PGCs are the source from which GSCs and ES cells are derived. The PGCs, the GSCs and the ES cells are capable of self-renewal. Thus these cells not only populate the germ line and give rise to a plurality of terminally differentiated cells that comprise the adult specialized organs, but are 15 able to regenerate themselves. The term "expression modulating fragment," EMF, means a series of nucleotides which modulates the expression of an operably linked ORF or another EMF. As used herein, a sequence is said to "modulate the expression of an operably linked sequence" when the expression of the sequence is altered by the presence of the EMF. 20 EMFs include, but are not limited to, promoters, and promoter modulating sequences (inducible elements). One class of EMFs are nucleic acid fragments which induce the expression of an operably linked ORF in response to a specific regulatory factor or physiological event. The terms "nucleotide sequence" or "nucleic acid" or "polynucleotide" or 25 "oligonucleotide" are used interchangeably and refer to a heteropolymer of nucleotides or the sequence of these nucleotides. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA) or to any DNA-like or RNA-like material. In the sequences herein A is adenine, C is cytosine, T is thymine, G is guanine and 30 N is A, C, G, or T (U) or unknown. It is contemplated that where the polynucleotide is RNA, the T (thymine) in the sequences provided herein is substituted with U (uracil). Generally, nucleic acid segments provided by this invention may be assembled from fragments of the genome and short oligonucleotide linkers, or from a series of WO 2004/080148 PCT/US2003/030720 9 oligonucleotides, or from individual nucleotides, to provide a synthetic nucleic acid which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon, or a eukaryotic gene. The tenns "oligonucleotide fragment" or a "polynucleotide fragment", "portion," or 5 "segment" or "probe" or "primer" are used interchangeably and refer to a sequence of nucleotide residues which are at least about 5 nucleotides, more preferably at least about 7 nucleotides, more preferably at least about 9 nucleotides, more preferably at least about 11 nucleotides and most preferably at least about 17 nucleotides. The fragment is preferably less than about 500 nucleotides, preferably less than about 200 nucleotides, more preferably 10 less than about 100 nucleotides, more preferably less than about 50 nucleotides and most preferably less than 30 nucleotides. Preferably the probe is from about 6 nucleotides to about 200 nucleotides, preferably from about 15 to about 50 nucleotides, more preferably from about 17 to 30 nucleotides and most preferably from about 20 to 25 nucleotides. Preferably the fragments can be used in polymerase chain reaction (PCR), various 15 hybridization procedures or microarray procedures to identify or amplify identical or related parts of mRNA or DNA molecules. A fragment or segment may uniquely identify each polynucleotide sequence of the present invention. Preferably the fragment comprises a sequence substantially similar to any one of SEQ ID NO: 1-684, or 1369-1966. Probes may, for example, be used to determine whether specific mRNA molecules 20 are present in a cell or tissue or to isolate similar nucleic acid sequences from chromosomal DNA as described by Walsh et al. (Walsh, P.S. et al., 1992, PCR Methods Appl 1:241-250), They may be labeled by nick translation, Klenow fill-in reaction, PCR, or other methods well known in the art. Probes of the present invention, their preparation and/or labeling are elaborated in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, Cold 25 Spring Harbor Laboratory, NY; or Ausubel, F.M. et al., 1989, Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, both of which are incorporated herein by reference in their entirety. The nucleic acid sequences of the present invention also include the sequence information from the nucleic acid sequences of SEQ ID NO: 1-684, or 1369-1966. The 30 sequence information can be a segment of any one of SEQ ID NO: 1-684, or 1369-1966 that uniquely identifies or represents the sequence information of that sequence of SEQ ID NO: 1-684, or 1369-1966, or those segments identified in Tables 3A, 3B, 5, 7, or 8. One such segment can be a twenty-mer nucleic acid sequence because the probability that a twenty- WO 2004/080148 PCT/US2003/030720 10 mer is fully matched in the human genome is 1 in 300. In the human genome, there are three billion base pairs in one set of chromosomes. Because 4 possible twenty-mers exist, there are 300 times more twenty-mers than there are base pairs in a set of human chromosomes. Using the same analysis, the probability for a seventeen-mer to be fully matched in the 5 human genome is approximately 1 in 5. When these segments are used in arrays for expression studies, fifteen-mer segments can be used. The probability that the fifteen-mer is fully matched in the expressed sequences is also approximately one in five because expressed sequences comprise less than approximately 5% of the entire genome sequence. Similarly, when using sequence information for detecting a single mismatch, a segment 10 can be a twenty-five mer. The probability that the twenty-five mer would appear in a human genome with a single mismatch is calculated by multiplying the probability for a full match (1+425) times the increased probability for mismatch at each nucleotide position (3 x 25). The probability that an eighteen mer with a single mismatch can be detected in an array for expression studies is approximately one in five. The probability that a twenty-mer with a single 15 mismatch can be detected in a human genome is approximately one in five. The term "open reading frame," ORF, means a series of nucleotide triplets coding for amino acids without any termination codons and is a sequence translatable into protein. The tenns "operably linked" or "operably associated" refer to functionally related nucleic acid sequences. For example, a promoter is operably associated or operably linked 20 with a coding sequence if the promoter controls the transcription of the coding sequence. While operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements e.g. repressor genes are not contiguously linked to the coding sequence but still control transcription/translation of the coding sequence. The term "pluripotent" refers to the capability of a cell to differentiate into a number 25 of differentiated cell types that are present in an adult organism. A pluripotent cell is restricted in its differentiation capability in comparison to a totipotent cell. The terms "polypeptide" or "peptide" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide or protein sequence or fragment thereof and to naturally occurring or synthetic molecules. A polypeptide "fragment," "portion," or "segment" is a 30 stretch of amino acid residues of at least about 5 amino acids, preferably at least about 7 amino acids, more preferably at least about 9 amino acids and most preferably at least about 17 or more amino acids. The peptide preferably is not greater than about 200 amino acids, more preferably less than 150 amino acids and most preferably less than 100 amino acids.

WO 2004/080148 PCT/US2003/030720 11 Preferably the peptide is from about 5 to about 200 amino acids. To be active, any polypeptide must have sufficient length to display biological and/or immunological activity. The term "naturally occurring polypeptide" refers to polypeptides produced by cells that have not been genetically engineered and specifically contemplates various polypeptides 5 arising from post-translational modifications of the polypeptide including, but not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. The term "translated protein coding portion" means a sequence which encodes for the full-length protein which may include any leader sequence or any processing sequence. The term "mature protein coding sequence" means a sequence which encodes a 10 peptide or protein without a signal or leader sequence. The "mature protein portion" means that portion of the protein which does not include a signal or leader sequence. The peptide may have been produced by processing in the cell which removes any leader/signal sequence. The mature protein portion may or may not include the initial methionine residue. The methionine residue may be removed from the protein during processing in the cell. The 15 peptide may be produced synthetically or the protein may have been produced using a polynucleotide only encoding for the mature protein coding sequence. The term "derivative" refers to polypeptides chemically modified by such techniques as ubiquitination, labeling (e.g., with radionuclides or various enzymes), covalent polymer attachment such as pegylation (derivatization with polyethylene glycol) and insertion or 20 substitution by chemical synthesis of amino acids such as ornithine, which do not normally occur in human proteins. The term "variant"(or "analog") refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using, e g., recombinant DNA techniques. Guidance in determining which amino acid residues 25 may be replaced, added or deleted without abolishing activities of interest, may be found by comparing the sequence of the particular polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology (conserved regions) or by replacing amino acids with consensus sequence. Alternatively, recombinant variants encoding these same or similar polypeptides may 30 be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations in the polynucleotide sequence may be WO 2004/080148 PCT/US2003/030720 12 reflected in the polypeptide or domains of other peptides added to the polypeptide to modify the properties of any part of the polypeptide, to change characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate. Preferably, amino acid "substitutions" are the result of replacing one amino acid with 5 another amino acid having similar structural and/or chemical properties, i.e., conservative amino acid replacements. "Conservative" amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and 10 methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. "Insertions" or "deletions" are preferably in the range of about 1 to 20 amino acids, more preferably 1 to 10 amino acids. The variation allowed may be experimentally 15 determined by systematically making insertions, deletions, or substitutions of amino acids in a polypeptide molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity. Alternatively, where alteration of function is desired, insertions, deletions or non-conservative alterations can be engineered to produce altered polypeptides. Such 20 alterations can, for example, alter one or more of the biological functions or biochemical characteristics of the polypeptides of the invention. For example, such alterations may change polypeptide characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate. Further, such alterations can be selected so as to generate polypeptides that are better suited for expression, scale up and the like in the host cells 25 chosen for expression. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges. The terms "purified" or "substantially purified" as used herein denotes that the indicated nucleic acid or polypeptide is present in the substantial absence of other biological macromolecules, e.g., polynucleotides, proteins, and the like. In one embodiment, the 30 polynucleotide or polypeptide is purified such that it constitutes at least 95% by weight, more preferably at least 99% by weight, of the indicated biological macromolecules present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000 daltons, can be present).

WO 2004/080148 PCT/US2003/030720 13 The term "isolated" as used herein refers to a nucleic acid or polypeptide separated from at least one other component (e.g., nucleic acid or polypeptide) present with the nucleic acid or polypeptide in its natural source. In one embodiment, the nucleic acid or polypeptide is found in the presence of (if anything) only a solvent, buffer, ion, or other component 5 normally present in a solution of the same. The terms "isolated" and "purified" do not encompass nucleic acids or polypeptides present in their natural source. The term "recombinant," when used herein to refer to a polypeptide or protein, means that a polypeptide or protein is derived from recombinant (e.g., microbial, insect, or mammalian) expression systems. "Microbial" refers to recombinant polypeptides or proteins 10 made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a polypeptide or protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Polypeptides or proteins expressed in most bacterial cultures, e.g., E. coli, will be free of glycosylation modifications; polypeptides or proteins expressed in yeast will have a glycosylation pattern in general 15 different from those expressed in mammalian cells. The term "recombinant expression vehicle or vector" refers to a plasmid or phage or virus or vector, for expressing a polypeptide from a DNA (RNA) sequence. An expression vehicle can comprise a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or 20 enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport 25 sequence, it may include an amino terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product. The term "recombinant expression system" means host cells which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the 30 recombinant transcriptional unit extrachromosomally. Recombinant expression systems as defined herein will express heterologous polypeptides or proteins upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed. This term also means host cells which have stably integrated a recombinant genetic element or WO 2004/080148 PCT/US2003/030720 14 elements having a regulatory role in gene expression, for example, promoters or enhancers. Recombinant expression systems as defined herein will express polypeptides or proteins endogenous to the cell upon induction of the regulatory elements linked to the endogenous DNA segment or gene to be expressed. The cells can be prokaryotic or eukaryotic. 5 The term "secreted" includes a protein that is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence when it is expressed in a suitable host cell. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins that 10 are transported across the membrane of the endoplasmic reticulum. "Secreted" proteins are also intended to include proteins containing non-typical signal sequences (e.g. Interleukin-1 Beta, see Krasney, P.A. and Young, P.R. (1992) Cytokine 4(2): 134 -143) and factors released from damaged cells (e.g. Interleukin-1 Receptor Antagonist, see Arend, W.P. et. al. (1998) Annu. Rev. Immunol. 16:27-55) 15 Where desired, an expression vector may be designed to contain a "signal or leader sequence" which will direct the polypeptide through the membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous protein sources by recombinant DNA techniques. The tern "stringent" is used to refer to conditions that are commonly understood in 20 the art as stringent. Stringent conditions can include highly stringent conditions (i.e., hybridization to filter-bound DNA in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65*C, and washing in 0.lX SSC/0.1% SDS at 68'C), and moderately stringent conditions (i.e., washing in 0.2X SSC/0. 1% SDS at 42'C). Other exemplary hybridization conditions are described herein in the examples. 25 In instances of hybridization of deoxyoligonucleotides, additional exemplary stringent hybridization conditions include washing in 6X SSC/0.05% sodium pyrophosphate at 37 0 C (for 14-base oligonucleotides), 48'C (for 17-base oligonucleotides), 55'C (for 20 base oligonucleotides), and 60'C (for 23-base oligonucleotides). As used herein, "substantially equivalent" or "substantially similar" can refer both to 30 nucleotide and amino acid sequences, for example a mutant sequence, that varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and subject sequences. Typically, such a substantially equivalent sequence varies from one of WO 2004/080148 PCT/US2003/030720 15 those listed herein by no more than about 35% (i.e., the number of individual residue substitutions, additions, and/or deletions in a substantially equivalent sequence, as compared to the corresponding reference sequence, divided by the total number of residues in the substantially equivalent sequence is about 0.35 or less). Such a sequence is said to have 5 65% sequence identity to the listed sequence. In one embodiment, a substantially equivalent, e.g., mutant, sequence of the invention varies from a listed sequence by no more than 30% (70% sequence identity); in a variation of this embodiment, by no more than 25% (75% sequence identity); and in a further variation of this embodiment, by no more than 20% (80% sequence identity) and in a further variation of this embodiment, by no more than 10 10% (90% sequence identity) and in a further variation of this embodiment, by no more that 5% (95% sequence identity). Substantially equivalent, e.g., mutant, amino acid sequences according to the invention preferably have at least 80% sequence identity with a listed amino acid sequence, more preferably at least 85% sequence identity, more preferably at least 90% sequence identity, more preferably at least 95% sequence identity, more preferably at least 15 98% sequence identity, and most preferably at least 99% sequence identity. Substantially equivalent nucleotide sequence of the invention can have lower percent sequence identities, taking into account, for example, the redundancy or degeneracy of the genetic code. Preferably, the nucleotide sequence has at least about 65% identity, more preferably at least about 75% identity, more preferably at least about 80% sequence identity, more preferably at 20 least 85% sequence identity, more preferably at least 90% sequence identity, more preferably at least about 95% sequence identity, more preferably at least 98% sequence identity, and most preferably at least 99% sequence identity. For the purposes of the present invention, sequences having substantially equivalent biological activity and substantially equivalent expression characteristics are considered substantially equivalent. For the purposes of 25 determining equivalence, truncation of the mature sequence (e.g., via a mutation which creates a new stop codon) should be disregarded. Sequence identity may be determined, e.g., using the Jotun Hein method (Hein, J. (1990) Methods Enzymol. 183:626-645). Identity between sequences can also be determined by other methods known in the art, e.g. by varying hybridization conditions. 30 The term "totipotent" refers to the capability of a cell to differentiate into all of the cell types of an adult organism. The term "transformation" means introducing DNA into a suitable host cell so that the DNA is replicable, either as an extrachromosomal element, or by chromosomal WO 2004/080148 PCT/US2003/030720 16 integration. The term "transfection" refers to the taking up of an expression vector by a suitable host cell, whether or not any coding sequences are in fact expressed. The term "infection" refers to the introduction of nucleic acids into a suitable host cell by use of a virus or viral vector. 5 As used herein, an "uptake modulating fragment," UMF, means a series of nucleotides which mediate the uptake of a linked DNA fragment into a cell. UMFs can be readily identified using known UMFs as a target sequence or target motif with the computer-based systems described below. The presence and activity of a UMF can be confirmed by attaching the suspected UMF to a marker sequence. The resulting nucleic acid 10 molecule is then incubated with an appropriate host under appropriate conditions and the uptake of the marker sequence is determined. As described above, a UMF will increase the frequency of uptake of a linked marker sequence. Each of the above terms is meant to encompass all that is described for each, unless the context dictates otherwise. 15 4.2 NUCLEIC ACIDS OF THE INVENTION Nucleotide sequences of the invention are set forth in the Sequence Listing. The isolated polynucleotides of the invention include a polynucleotide comprising the nucleotide sequences of SEQ ID NO: 1-684, or 1369-1966; a polynucleotide encoding 20 any one of the peptide sequences of SEQ ID NO: 1-684, or 1369-1966; and a polynucleotide comprising the nucleotide sequence encoding the mature protein coding sequence of the polynucleotides of any one of SEQ ID NO: 1-684, or 1369-1966. The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent conditions to (a) the complement of any of the nucleotides sequences of SEQ ID 25 NO: 1-684, or 1369-1966; (b) nucleotide sequences encoding any one of the amino acid sequences set forth in the Sequence Listing, or Table 7; (c) a polynucleotide which is an allelic variant of any polynucleotide recited above; (d) a polynucleotide which encodes a species homologue of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of the polypeptides of SEQ ID NO: 30 685-1368, or 1967-2564 (for example, as set forth in Tables 3A, 3B, 5, 7, or 8). Domains of interest may depend on the nature of the encoded polypeptide; e.g., domains in receptor-like polypeptides include ligand-binding, extracellular, transmembrane, or cytoplasmic domains, or combinations thereof; domains in immunoglobulin-like proteins include the variable WO 2004/080148 PCT/US2003/030720 17 inununoglobulin-like domains; domains in enzyme-like polypeptides include catalytic and substrate binding domains; and domains in ligand polypeptides include receptor-binding domains. The polynucleotides of the invention include naturally occurring or wholly or 5 partially synthetic DNA, e.g., cDNA and genomic DNA, and RNA, e.g., mRNA. The polynucleotides may include entire coding region of the cDNA or may represent a portion of the coding region of the cDNA. The present invention also provides genes corresponding to the cDNA sequences disclosed herein. The corresponding genes can be isolated in accordance with known methods 10 using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. Further 5' and 3' sequence can be obtained using methods known in the art. For example, full length cDNA or genomic DNA that corresponds to any of the polynucleotides of SEQ ID NO: 15 1-684, or 1369-1966 can be obtained by screening appropriate cDNA or genomic DNA libraries under suitable hybridization conditions using any of the polynucleotides of SEQ ID NO: 1-684, or 1369-1966 or a portion thereof as a probe. Alternatively, the polynucleotides of SEQ ID NO: 1-684, or 1369-1966 may be used as the basis for suitable primer(s) that allow identification and/or amplification of genes in appropriate genomic DNA or cDNA libraries. 20 The nucleic acid sequences of the invention can be assembled from ESTs and sequences (including cDNA and genomic sequences) obtained from one or more public databases, such as dbEST, gbpri, and UniGene. The EST sequences can provide identifying sequence information, representative fragment or segment information, or novel segment information for the full-length gene. 25 The polynucleotides of the invention also provide polynucleotides including nucleotide sequences that are substantially equivalent to the polynucleotides recited above. Polynucleotides according to the invention can have, e.g., at least about 65%, at least about 70%, at least about 75%, at least about 80%, 81%, 82%, 83%, 84%, more typically at least about 85%, 86%, 87%, 88%, 89%, more typically at least about 90%, 91%, 92%, 93%, 94%, 30 and even more typically at least about 95%, 96%, 97%, 98%, 99% sequence identity to a polynucleotide recited above. Included within the scope of the nucleic acid sequences of the invention are nucleic acid sequence fragments that hybridize under stringent conditions to any of the nucleotide WO 2004/080148 PCT/US2003/030720 18 sequences of SEQ ID NO: 1-684, or 1369-1966, or complements thereof, which fragment is greater than about 5 nucleotides, preferably 7 nucleotides, more preferably greater than 9 nucleotides and most preferably greater than 17 nucleotides. Fragments of, e.g. 15, 17, or 20 nucleotides or more that are selective for (i.e. specifically hybridize to) any one of the 5 polynucleotides of the invention are contemplated. Probes capable of specifically hybridizing to a polynucleotide can differentiate polynucleotide sequences of the invention from other polynucleotide sequences in the same family of genes or can differentiate human genes from genes of other species, and are preferably based on unique nucleotide sequences. The sequences falling within the scope of the present invention are not limited to these 10 specific sequences, but also include allelic and species variations thereof. Allelic and species variations can be routinely determined by comparing the sequence provided in SEQ ID NO: 1 684, or 13 69-1966, a representative fragment thereof, or a nucleotide sequence at least 90% identical, preferably 95% identical, to SEQ ID NO: 1-684, or 1369-1966 with a sequence from another isolate of the same species. Furthermore, to accommodate codon variability, the 15 invention includes nucleic acid molecules coding for the same amino acid sequences as do the specific ORFs disclosed herein. In other words, in the coding region of an ORF, substitution of one codon for another codon that encodes the same amino acid is expressly contemplated. The nearest neighbor or homology results for the nucleic acids of the present invention, including SEQ ID NO: 1-684, or 1369-1966 can be obtained by searching a database using an 20 algorithm or a program. Preferably, a BLAST (Basic Local Alignment Search Tool) program is used to search for local sequence alignments (Altshul, S.F. J Mol. Evol. 36 290-300 (1993) and Altschul S.F. et al. J. Mol. Biol. 21:403-410 (1990)). Alternatively a FASTA version 3 search against Genpept, using FASTXY algorithm may be performed. Species homologs (or orthologs) of the disclosed polynucleotides and proteins are 25 also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which 30 also encode proteins which are identical, homologous or related to that encoded by the polynucleotides. The nucleic acid sequences of the invention are further directed to sequences which encode variants of the described nucleic acids. These amino acid sequence variants may be WO 2004/080148 PCT/US2003/030720 19 prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant polynucleotide. There are two variables in the construction of amino acid sequence variants: the location of the mutation and the nature of the mutation. Nucleic acids encoding the amino acid sequence variants are preferably constructed by mutating the 5 polynucleotide to encode an amino acid sequence that does not occur in nature. These nucleic acid alterations can be made at sites that differ in the nucleic acids from different species (variable positions) or in highly conserved regions (constant regions). Sites at such locations will typically be modified in series, e.g., by substituting first with conservative choices (e.g., hydrophobic amino acid to a different hydrophobic amino acid) and then with 10 more distant choices (e.g., hydrophobic amino acid to a charged amino acid), and then deletions or insertions may be made at the target site. Amino acid sequence deletions generally range from about 1 to 30 residues, preferably about 1 to 10 residues, and are typically contiguous. Amino acid insertions include amino- and/or carboxyl-terminal fusions ranging in length from one to one hundred or more residues, as well as intrasequence 15 insertions of single or multiple amino acid residues. Intrasequence insertions may range generally from about 1 to 10 amino residues, preferably from 1 to 5 residues. Examples of terminal insertions include the heterologous signal sequences necessary for secretion or for intracellular targeting in different host cells and sequences such as FLAG or poly-histidine sequences useful for purifying the expressed protein. 20 In a preferred method, polynucleotides encoding the novel amino acid sequences are changed via site-directed mutagenesis. This method uses oligonucleotide sequences to alter a polynucleotide to encode the desired amino acid variant, as well as sufficient adjacent nucleotides on both sides of the changed amino acid to form a stable duplex on either side of the site of being changed. In general, the techniques of site-directed mutagenesis are well 25 known to those of skill in the art and this technique is exemplified by publications such as, Edelman et al., DNA 2:183 (1983). A versatile and efficient method for producing site-specific changes in a polynucleotide sequence was published by Zoller and Smith, Nucleic Acids Res. 10:6487-6500 (1982). PCR may also be used to create amino acid sequence variants of the novel nucleic acids. When small amounts of template DNA are 30 used as starting material, primer(s) that differs slightly in sequence from the corresponding region in the template DNA can generate the desired amino acid variant. PCR amplification results in a population of product DNA fragments that differ from the polynucleotide template encoding the polypeptide at the position specified by the primer. The product DNA WO 2004/080148 PCT/US2003/030720 20 fragments replace the corresponding region in the plasmid and this gives a polynucleotide encoding the desired amino acid variant. A further technique for generating amino acid variants is the cassette mutagenesis technique described in Wells et al., Gene 34:315 (1985); and other mutagenesis techniques 5 well known in the art, such as, for example, the techniques in Sambrook et al., supra, and Current Protocols in Molecular Biology, Ausubel et al. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be used in the practice of the invention for the cloning and expression of these novel nucleic acids. Such DNA sequences include those 10 which are capable of hybridizing to the appropriate novel nucleic acid sequence under stringent conditions. Polynucleotides encoding preferred polypeptide truncations of the invention could be used to generate polynucleotides encoding chimeric or fusion proteins comprising one or more domains of the invention and heterologous protein sequences. 15 The polynucleotides of the invention additionally include the complement of any of the polynucleotides recited above. The polynucleotide can be DNA (genomic, cDNA, amplified, or synthetic) or RNA. Methods and algorithms for obtaining such polynucleotides are well known to those of skill in the art and can include, for example, methods for determining hybridization conditions that can routinely isolate polynucleotides 20 of the desired sequence identities. In accordance with the invention, polynucleotide sequences comprising the mature protein coding sequences corresponding to any one of SEQ ID NO: 1-684, or 1369-1966, or functional equivalents thereof, may be used to generate recombinant DNA molecules that direct the expression of that nucleic acid, or a functional equivalent thereof, in appropriate 25 host cells. Also included are the cDNA inserts of any of the clones identified herein. A polynucleotide according to the invention can be joined to any of a variety of other nucleotide sequences by well-established recombinant DNA techniques (see Sambrook J et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY). Useful nucleotide sequences for joining to polynucleotides include an assortment of vectors, 30 e.g., plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient WO 2004/080148 PCT/US2003/030720 21 restriction endonuclease sites, and a selectable marker for the host cell. Vectors according to the invention include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. A host cell according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism. 5 The present invention further provides recombinant constructs comprising a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-684, or 1369-1966 or a fragment thereof or any other polynucleotides of the invention. In one embodiment, the recombinant constructs of the present invention comprise a vector, such as a plasmid or viral vector, into which a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1 10 684, or 1369-1966 or a fragment thereof is inserted, in a forward or reverse orientation. In the case of a vector comprising one of the ORFs of the present invention, the vector may further comprise regulatory sequences, including for example, a promoter, operably linked to the ORF. Large numbers of suitable vectors and promoters are known to those of skill in the art and are commercially available for generating the recombinant constructs of the present 15 invention. The following vectors are provided by way of example: Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pN-Hl6a, pNH18a, pNH46a (Stratagene), pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); Eukaryotic: pWLneo, pSV2cat, pOG44, PXTI, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). 20 The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, 25 Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence. 30 Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda PR, and trc. Eukaryotic promoters include CMV immediate WO 2004/080148 PCT/US2003/030720 22 early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the 5 ampicillin resistance gene of E. coli and S. cerevisiae TRPl gene, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3 phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with 10 translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an amino tenninal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. Useful expression vectors for 15 bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for 20 transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomnyces, and Staphylococcus, although others may also be employed as a matter of choice. As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from 25 commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM 1 (Promega Biotech, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. Following transformation of a suitable host strain 30 and growth of the host strain to an appropriate cell density, the selected promoter is induced or derepressed by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, WO 2004/080148 PCT/US2003/030720 23 disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Polynucleotides of the invention can also be used to induce immune responses. For example, as described in Fan et al., Nat. Biotech 17, 870-872 (1999), incorporated herein by 5 reference, nucleic acid sequences encoding a polypeptide may be used to generate antibodies against the encoded polypeptide following topical administration of naked plasmid DNA or following injection, and preferably intra-muscular injection of the DNA. The nucleic acid sequences are preferably inserted in a recombinant expression vector and may be in the form of naked DNA. 10 4.3 ANTISENSE Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1-684, or 1369-1966, or fragments, analogs or 15 derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an 20 entire coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a protein of any of SEQ ID NO: 1-684, or 1369-1966 or antisense nucleic acids complementary to a nucleic acid sequence of SEQ ID NO: 1-684, or 1369-1966 are additionally provided. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding 25 region" of the coding strand of a nucleotide sequence of the invention. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence of the invention. The term "noncoding region" refers to 5' and 3' sequences that flank the 30 coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions). Given the coding strand sequences encoding a nucleic acid disclosed herein (e.g., SEQ ID NO: 1-684, or 1369-1966, antisense nucleic acids of the invention can be designed WO 2004/080148 PCT/US2003/030720 24 according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of an mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of an mRNA. For example, the antisense oligonucleotide can be complementary to 5 the region surrounding the translation start site of an mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using 10 naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides that can be used to generate the antisense nucleic 15 acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5 carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1 -methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3 20 methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5 methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl 2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, 25 uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following 30 subsection). The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a protein according to the invention to thereby inhibit expression of WO 2004/080148 PCT/US2003/030720 25 the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of 5 administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to 10 peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred. 15 In yet another embodiment, the antisense nucleic acid molecule of the invention is an a-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual a-units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids Res 15: 6625-6641). The antisense nucleic acid molecule can also comprise a 20 2'-o-methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res 15: 6131-6148) or a chimeric RNA -DNA analogue (Inoue et al. (1987) FEBSLett 215: 327-330). 4.4 RIBOZYMES AND PNA MOIETIES In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. 25 Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave mRNA transcripts to thereby inhibit translation of an mRNA. A ribozyme having specificity 30 for a nucleic acid of the invention can be designed based upon the nucleotide sequence of a DNA disclosed herein (i.e., SEQ ID NO: 1-684, or 1369-1966). For example, a derivative of Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a mRNA. See, e.g., WO 2004/080148 PCT/US2003/030720 26 Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, mRNA of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418. 5 Alternatively, gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene in target cells. See generally, Helene. (1991) Anticancer Drug Des. 6: 569-84; Helene. et al. (1992) Ann. N. Y Acad. Sci. 660:27-36; and Maher (1992) Bioassays 14: 807-15. 10 In various embodiments, the nucleic acids of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) Bioorg Med Chem 4: 5-23). As used herein, the terms "peptide nucleic acids" 15 or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis 20 protocols as described in Hyrup et al. (1996) above; Perry-O'Keefe et al. (1996) PNAS 93: 14670-675. PNAs of the invention can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting 25 replication. PNAs of the invention can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup et al. (1996), above; Perry-O'Keefe (1996), above). 30 In another embodiment, PNAs of the invention can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated that may WO 2004/080148 PCT/US2003/030720 27 combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in tens of 5 base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) above and Finn et al. (1996) NuclAcids Res 24: 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine 10 phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag et al. (1989) NuclAcidRes 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn et al. (1996) above). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, Petersen et al. (1975) Bioorg Med Chen Lett 5: 15 1119-11124. In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Nat. Acad. Sci. US.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Nat!. A cad. Sci. 84:648-652; PCT Publication 20 No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, Pharmi. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport 25 agent, a hybridization-triggered cleavage agent, etc. 4.5 HOSTS The present invention further provides host cells genetically engineered to contain the polynucleotides of the invention. For example, such host cells may contain nucleic acids 30 of the invention introduced into the host cell using known transformation, transfection or infection methods. The present invention still further provides host cells genetically engineered to express the polynucleotides of the invention, wherein such polynucleotides are WO 2004/080148 PCT/US2003/030720 28 in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell. Knowledge of nucleic acid sequences allows for modification of cells to permit, or increase, expression of endogenous polypeptide. Cells can be modified (e.g., by 5 homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the polypeptide at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to the encoding sequences. See, for example, PCT International Publication No. W094/12650, PCT International Publication 10 No. W092/20808, and PCT International Publication No. W091/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the coding sequence, 15 amplification of the marker DNA by standard selection methods results in co-amplification of the desired protein coding sequences in the cells. The host cell can be a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by 20 calcium phosphate transfection, DEAE, dextran mediated transfection, or electroporation (Davis, L. et al., Basic Methods in Molecular Biology (1986)). The host cells containing one of the polynucleotides of the invention, can be used in conventional manners to produce the gene product encoded by the isolated fragment (in the case of an ORF) or can be used to produce a heterologous protein under the control of the EMF. 25 Any host/vector system can be used to express one or more of the ORFs of the present invention. These include, but are not limited to, eukaryotic hosts such as HeLa cells, Cv-1 cell, COS cells, 293 cells, and Sf9 cells, as well as prokaryotic host such as E. coli and B. subtilis. The most preferred cells are those which do not normally express the particular polypeptide or protein or which expresses the polypeptide or protein at low natural level. 30 Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and WO 2004/080148 PCT/US2003/030720 29 eukaryotic hosts are described by Sambrook, et al., in Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, New York (1989), the disclosure of which is hereby incorporated by reference. Various mammalian cell culture systems can also be employed to express 5 recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell 23:175 (1981). Other cell lines capable of expressing a compatible vector are, for example, the C127, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal 10 diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived 15 from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements. Recombinant polypeptides and proteins produced in bacterial culture are usually isolated by initial extraction from cell pellets, followed by one or more salting-out, aqueous ion exchange or size exclusion chromatography steps. Protein refolding steps can be used, 20 as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Alternatively, it may be possible to produce the protein in lower eukaryotes such as 25 yeast or insects or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pomnbe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or 30 bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

WO 2004/080148 PCT/US2003/030720 30 In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene 5 targeting can be used to replace a gene's existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, and regulatory protein binding sites or combinations of said sequences. 10 Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequence include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA 15 molecules. The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, e.g., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory 20 clement. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are 25 contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the host cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting 30 sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.

WO 2004/080148 PCT/US2003/030720 31 The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Patent No. 5,272,071 to Chappel; U.S. Patent No. 5,578,461 to Sherwin et al.; International Application No. PCT/US92/09627 (W093/09222) by Selden et al.; and International Application No. 5 PCT/US90/06436 (W091/06667) by Skoultchi et al., each of which is incorporated by reference herein in its entirety. 4.6 POLYPEPTIDES OF THE INVENTION The isolated polypeptides of the invention include, but are not limited to, a 10 polypeptide comprising: the amino acid sequences set forth as any one of SEQ ID NO: 685 1368, or 1967-2564 or an amino acid sequence encoded by any one of the nucleotide sequences SEQ ID NO: 1-684, or 1369-1966 or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides preferably with biological or immunological activity that are encoded by: (a) a polynucleotide having any one of the 15 nucleotide sequences set forth in SEQ ID NO: 1-684, or 1369-1966 or (b) polynucleotides encoding any one of the amino acid sequences set forth as SEQ ID NO: 685-1368, or 1967 2564 or (c) polynucleotides that hybridize to the complement of the polynucleotides of either (a) or (b) under stringent hybridization conditions. The invention also provides biologically active or immunologically active variants of any of the amino acid sequences set forth as 20 SEQ ID NO: 685-1368, or 1967-2564 or the corresponding full length or mature protein; and "substantial equivalents" thereof (e.g., with at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, 86%, 87%, 88%, 89%, at least about 90%, 91%, 92%, 93%, 94%, typically at least about 95%, 96%, 97%, more typically at least about 98%, or most typically at least about 99% amino acid identity) that retain biological 25 activity. Polypeptides encoded by allelic variants may have a similar, increased, or decreased activity compared to polypeptides comprising SEQ ID NO: 685-1368, or 1967 2564. Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein 30 may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, et al., Bio/Technology 10, 773-778 (1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as WO 2004/080148 PCT/US2003/030720 32 immunoglobulins for many purposes, including increasing the valency of protein binding sites. Fragments are also identified in Tables 3A, 3B, 5, 7, or 8. The present invention also provides both full-length and mature forms (for example, without a signal sequence or precursor sequence) of the disclosed proteins. The protein 5 coding sequence is identified in the sequence listing by translation of the disclosed nucleotide sequences. The predicted signal sequence is set forth in Table 5. The mature form of such protein may be obtained and confirmed by expression of a full-length polynucleotide in a suitable mammalian cell or other host cell and sequencing of the cleaved product. One of skill in the art will recognize that the actual cleavage site may be different 10 than that predicted in Table 5. The sequence of the mature form of the protein is also determinable from the amino acid sequence of the full-length form. Where proteins of the present invention are membrane bound, soluble forms of the proteins are also provided. In such forms, part or all of the regions causing the proteins to be membrane bound are deleted so that the proteins are fully secreted from the cell in which they are expressed (See, e.g., 15 Sakal et al., Prep. Biochem. Biotechnol. (2000), 30(2), pp. 107-23, incorporated herein by reference). Protein compositions of the present invention may further comprise an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier. The present invention further provides isolated polypeptides encoded by the nucleic 20 acid fragments of the present invention or by degenerate variants of the nucleic acid fragments of the present invention. By "degenerate variant" is intended nucleotide fragments which differ from a nucleic acid fragment of the present invention (e.g., an ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the 25 ORFs that encode proteins. A variety of methodologies known in the art can be utilized to obtain any one of the isolated polypeptides or proteins of the present invention. At the simplest level, the amino acid sequence can be synthesized using commercially available peptide synthesizers. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or 30 tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. This technique is particularly useful in producing small peptides and fragments of larger polypeptides. Fragments are useful, for example, in generating antibodies against the native polypeptide. Thus, they may WO 2004/080148 PCT/US2003/030720 33 be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies. The polypeptides and proteins of the present invention can alternatively be purified 5 from cells which have been altered to express the desired polypeptide or protein. As used herein, a cell is said to be altered to express a desired polypeptide or protein when the cell, through genetic manipulation, is made to produce a polypeptide or protein which it normally does not produce or which the cell normally produces at a lower level. One skilled in the art can readily adapt procedures for introducing and expressing either recombinant or synthetic 10 sequences into eukaryotic or prokaryotic cells in order to generate a cell which produces one of the polypeptides or proteins of the present invention. The invention also relates to methods for producing a polypeptide comprising growing a culture of host cells of the invention in a suitable culture medium, and purifying the protein from the cells or the culture in which the cells are grown. For example, the 15 methods of the invention include a process for producing a polypeptide in which a host cell containing a suitable expression vector that includes a polynucleotide of the invention is cultured under conditions that allow expression of the encoded polypeptide. The polypeptide can be recovered from the culture, conveniently from the culture medium, or from a lysate prepared from the host cells and further purified. Preferred embodiments 20 include those in which the protein produced by such process is a full length or mature form of the protein. In an alternative method, the polypeptide or protein is purified from bacterial cells which naturally produce the polypeptide or protein. One skilled in the art can readily follow known methods for isolating polypeptides and proteins in order to obtain one of the isolated 25 polypeptides or proteins of the present invention. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography, and immuno-affinity chromatography. See, e.g., Scopes, Protein Purification: Principles and Practice, Springer-Verlag (1994); Sambrook, et al., in Molecular Cloning: A Laboratory Manual; Ausubel et al., Current Protocols in Molecular 30 Biology. Polypeptide fragments that retain biological/immunological activity include fragments comprising greater than about 100 amino acids, or greater than about 200 amino acids, and fragments that encode specific protein domains.

WO 2004/080148 PCT/US2003/030720 34 The purified polypeptides can be used in in vitro binding assays which are well known in the art to identify molecules which bind to the polypeptides. These molecules include but are not limited to, for e.g., small molecules, molecules from combinatorial libraries, antibodies or other proteins. The molecules identified in the binding assay are then 5 tested for antagonist or agonist activity in in vivo tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells. In addition, the peptides of the invention or molecules capable of binding to the peptides may be complexed with toxins, e.g., ricin or cholera, or with other compounds that 10 are toxic to cells. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for SEQ ID NO: 685-1368, or 1967-2564. The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the 15 protein. The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications, in the peptide or DNA sequence, can be made by those skilled in the art using known techniques. Modifications of 20 interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. 25 Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein. Regions of the protein that are important for the protein function can be determined by various methods known in the art including the alanine-scanning method which involved systematic substitution of single or strings of amino acids with alanine, followed by testing the resulting alanine-containing variant for 30 biological activity. This type of analysis determines the importance of the substituted amino acid(s) in biological activity. Regions of the protein that are important for protein function may be determined by the eMATRIX program.

WO 2004/080148 PCT/US2003/030720 35 Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and are useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are encompassed by the present invention. 5 The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBatTM kit), and such methods are well known in the art, as described 10 in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed." The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting 15 expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearlTM or Cibacrom blue 3GA SepharoseTM; 20 one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography. Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX), or as 25 a His tag. Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and Invitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope flagAG®) is commercially available from Kodak (New Haven, Conn.). 30 Finally, one or more reverse-phase high performance liquid chromatography (RP HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide WO 2004/080148 PCT/US2003/030720 36 a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein." The polypeptides of the invention include analogs (variants). This embraces 5 fragments, as well as peptides in which one or more amino acids has been deleted, inserted, or substituted. Also, analogs of the polypeptides of the invention embrace fusions of the polypeptides or modifications of the polypeptides of the invention, wherein the polypeptide or analog is fused to another moiety or moieties, e.g., targeting moiety or another therapeutic agent. Such analogs may exhibit improved properties such as activity and/or stability. 10 Examples of moieties which may be fused to the polypeptide or an analog include, for example, targeting moieties which provide for the delivery of polypeptide to pancreatic cells, e.g., antibodies to pancreatic cells, antibodies to immune cells such as T-cells, monocytes, dendritic cells, granulocytes, etc., as well as receptor and ligands expressed on pancreatic or immune cells. Other moieties which may be fused to the polypeptide include therapeutic 15 agents which are used for treatment, for example, immunosuppressive drugs such as cyclosporin, SK506, azathioprine, CD3 antibodies and steroids. Also, polypeptides may be fused to immune modulators, and other cytokines such as alpha or beta interferon. 4.6.1 DETERMINING POLYPEPTIDE AND POLYNUCLEOTIDE 20 IDENTITY AND SIMILARITY Preferred identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in computer programs including, but are not limited to, the GCG program package, including GAP (Devereux, J., et al., Nucleic Acids Research 12(l):387 (1984); Genetics Computer Group, 25 University of Wisconsin, Madison, WI), BLASTP, BLASTN, BLASTX, FASTA (Altschul, S.F. et al., J. Molec. Biol. 215:403-410 (1990), PSI-BLAST (Altschul S.F. et al., Nucleic Acids Res. vol. 25, pp. 3389-3402, herein incorporated by reference), eMatrix software (Wu et al., J. Comp. Biol., Vol. 6, pp. 219-235 (1999), herein incorporated by reference), eMotif software (Nevill-Manning et al, ISMB-97, Vol. 4, pp. 202-209, herein incorporated by 30 reference), Pfam software (Sonnhammer et al., Nucleic Acids Res., Vol. 26(1), pp. 320-322 (1998), herein incorporated by reference) and the Kyte-Doolittle hydrophobocity prediction algorithn (J. Mol Biol, 157, pp. 105-31 (1982), the GeneAtlas software (Molecular Simulations Inc. (MSI), San Diego, CA) (Sanchez and Sali (1998) Proc. Natl. Acad. Sci., 95, WO 2004/080148 PCT/US2003/030720 37 13597-13602; Kitson DII et al, (2000) "Remote homology detection using structural modeling - an evaluation" Submitted; Fischer and Eisenberg (1996) Protein Sci. 5, 947 955), Neural Network SignalP V1.1 program (from Center for Biological Sequence Analysis, The Technical University of Denmark) incorporated herein by reference). 5 Polypeptide sequences were examined by a proprietary algorithm, SeqLoc that separates the proteins into three sets of locales: intracellular, membrane, or secreted. This prediction is based upon three characteristics of each polypeptide, including percentage of cysteine residues, Kyte-Doolittle scores for the first 20 amino acids of each protein, and Kyte Doolittle scores to calculate the longest hydrophobic stretch of the said protein. Values of 10 predicted proteins are compared against the values from a set of 592 proteins of known cellular localization from the Swissprot database (http://www.expasy.ch/srot). Predictions are based upon the maximum likelihood estimation. Pesence of transmembrane region(s) was detected using the TMpred program (http://www.ch.embnet.org/software/TMPRED form.htinl). 15 The BLAST programs are publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul, S., et al. NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990). 4.7 CHIMERIC AND FUSION PROTEINS 20 The invention also provides chimeric or fusion proteins. As used herein, a "chimeric protein" or "fusion protein" comprises a polypeptide of the invention operatively linked to another polypeptide. Within a fusion protein the polypeptide according to the invention can correspond to all or a portion of a protein according to the invention. In one embodiment, a fusion protein comprises at least one biologically active portion of a protein according to the 25 invention. In another embodiment, a fusion protein comprises at least two biologically active portions of a protein according to the invention. Within the fusion protein, the term "operatively linked" is intended to indicate that the polypeptide according to the invention and the other polypeptide are fused in-frame to each other. The polypeptide can be fused to the N-terminus or C-terminus, or to the middle. 30 For example, in one embodiment a fusion protein comprises a polypeptide according to the invention operably linked to the extracellular domain of a second protein.

WO 2004/080148 PCT/US2003/030720 38 In another embodiment, the fusion protein is a GST-fusion protein in which the polypeptide sequences of the invention are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences. In another embodiment, the fusion protein is an immunoglobulin fusion protein in 5 which the polypeptide sequences according to the invention comprise one or more domains fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand and a protein of the invention on the surface of a cell, to thereby suppress signal transduction in 10 vivo. The immunoglobulin fusion proteins can be used to affect the bioavailability of a cognate ligand. Inhibition of the ligand/protein interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, e.g., cancer as well as modulating (e.g., promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies in a 15 subject, to purify ligands, and in screening assays to identify molecules that inhibit the interaction of a polypeptide of the invention with a ligand. A chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional 20 techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of 25 gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety 30 (e.g., a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the protein of the invention.

WO 2004/080148 PCT/US2003/030720 39 4.8 GENE THERAPY Mutations in the polynucleotides of the invention gene may result in loss of nonnal function of the encoded protein. The invention thus provides gene therapy to restore normal activity of the polypeptides of the invention; or to treat disease states involving polypeptides 5 of the invention. Delivery of a functional gene encoding polypeptides of the invention to appropriate cells is effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, Nature, supplement to vol. 392, no. 6679, pp.

2 5

-

20 (1998). For 10 additional reviews of gene therapy technology see Friedmann, Science, 244: 1275-1281 (1989); Verma, Scientific American: 68-84 (1990); and Miller, Nature, 357: 455-460 (1992). Introduction of any one of the nucleotides of the present invention or a gene encoding the polypeptides of the present invention can also be accomplished with extrachromosomal substrates (transient expression) or artificial chromosomes (stable expression). Cells may 15 also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes. Alternatively, it is contemplated that in other human disease states, preventing the expression of or inhibiting the activity of polypeptides of the invention will be useful in treating the disease states. It is contemplated that antisense 20 therapy or gene therapy could be applied to negatively regulate the expression of polypeptides of the invention. Other methods inhibiting expression of a protein include the introduction of antisense molecules to the nucleic acids of the present invention, their complements, or their translated RNA sequences, by methods known in the art. Further, the polypeptides of the present 25 invention can be inhibited by using targeted deletion methods, or the insertion of a negative regulatory element such as a silencer, which is tissue specific. The present invention still further provides cells genetically engineered in vivo to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of 30 the polynucleotides in the cell. These methods can be used to increase or decrease the expression of the polynucleotides of the present invention. Knowledge of DNA sequences provided by the invention allows for modification of cells to permit, increase, or decrease, expression of endogenous polypeptide. Cells can be WO 2004/080148 PCT/US2003/030720 40 modified (e.g., by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the protein at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to the desired protein encoding sequences. 5 See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with 10 the heterologous promoter DNA. If linked to the desired protein coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the desired protein coding sequences in the cells. In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control 15 of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene's existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment 20 regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequences include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion 25 properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules. The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, e.g., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple 30 deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are WO 2004/080148 PCT/US2003/030720 41 deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the cell genome. The identification of the targeting event may also be facilitated by the use 5 of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the 10 Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene. The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Patent No. 5,272,071 to Chappel; U.S. Patent No. 5,578,461 to Sherwin et al.; International Application No. 15 PCT/US92/09627 (W093/09222) by Selden et al.; and International Application No. PCT/US90/06436 (WO91/06667) by Skoultchi et al., each of which is incorporated by reference herein in its entirety. 4.9 TRANSGENIC ANIMALS 20 In preferred methods to determine biological functions of the polypeptides of the invention in vivo, one or more genes provided by the invention are either over expressed or inactivated in the germ line of animals using homologous recombination [Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene is over expressed, under the regulatory control of exogenous or endogenous promoter elements, are known as transgenic animals. 25 Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as "knockout" animals. Knockout animals, preferably non-human mammals, can be prepared as described in U.S. Patent No. 5,557,032, incorporated herein by reference. Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model 30 systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Patent No 5,489,743 and PCT Publication No. W094/28122, incorporated herein by reference.

WO 2004/080148 PCT/US2003/030720 42 Transgenic animals can be prepared wherein all or part of a promoter of the polynucleotides of the invention is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by 5 supplementing or even replacing the homologous promoter to provide for increased protein expression. The homologous promoter can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue. The polynucleotides of the present invention also make possible the development, through, e.g., homologous recombination or knock out strategies, of animals that fail to 10 express polypeptides of the invention or that express a variant polypeptide. Such animals are useful as models for studying the in vivo activities of polypeptide as well as for studying modulators of the polypeptides of the invention. In preferred methods to determine biological functions of the polypeptides of the invention in vivo, one or more genes provided by the invention are either over expressed or 15 inactivated in the germ line of animals using homologous recombination [Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene is over expressed, under the regulatory control of exogenous or endogenous promoter elements, are known as transgenic animals. Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as "knockout" animals. Knockout animals, preferably non-human mammals, 20 can be prepared as described in U.S. Patent No. 5,557,032, incorporated herein by reference. Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Patent No 25 5,489,743 and PCT Publication No. W094/28122, incorporated herein by reference. Transgenic animals can be prepared wherein all or part of the polynucleotides of the invention promoter is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by supplementing or 30 even replacing the homologous promoter to provide for increased protein expression. The homologous promoter can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue.

WO 2004/080148 PCT/US2003/030720 43 4.10 USES AND BIOLOGICAL ACTIVITY The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified herein. Uses or activities described for proteins of the present invention 5 may be provided by administration or use of such proteins or of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA). The mechanism underlying the particular condition or pathology will dictate whether the polypeptides of the invention, the polynucleotides of the invention or modulators (activators or inhibitors) thereof would be beneficial to the subject in need of treatment. 10 Thus, "therapeutic compositions of the invention" include compositions comprising isolated polynucleotides (including recombinant DNA molecules, cloned genes and degenerate variants thereof) or polypeptides of the invention (including full length protein, mature protein and truncations or domains thereof), or compounds and other substances that modulate the overall activity of the target gene products, either at the level of target 15 gene/protein expression or target protein activity. Such modulators include polypeptides, analogs, (variants), including fragments and fusion proteins, antibodies and other binding proteins; chemical compounds that directly or indirectly activate or inhibit the polypeptides of the invention (identified, e.g., via drug screening assays as described herein); antisense polynucleotides and polynucleotides suitable for triple helix formation; and in particular 20 antibodies or other binding partners that specifically recognize one or more epitopes of the polypeptides of the invention. The polypeptides of the present invention may likewise be involved in cellular activation or in one of the other physiological pathways described herein. 25 4.10.1 RESEARCH USES AND UTILITIES The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage 30 of tissue differentiation or development or in disease states); as molecular weight markers on gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA WO 2004/080148 PCT/US2003/030720 44 sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies 5 using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the 10 other protein with which binding occurs or to identify inhibitors of the binding interaction. The polypeptides provided by the present invention can similarly be used in assays to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or 15 its receptor) in biological fluids; as markers for tissues in which the corresponding polypeptide is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. 20 Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products. Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. 25 Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987. 4.10.2 NUTRITIONAL USES Polynucleotides and polypeptides of the present invention can also be used as 30 nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the polypeptide or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid WO 2004/080148 PCT/US2003/030720 45 preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the polypeptide or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured. 5 4.10.3 CYTOKINE AND CELL PROLIFERATION/DIFFERENTIATION ACTIVITY A polypeptide of the present invention may exhibit activity relating to cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. 10 A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of therapeutic compositions of the present invention is evidenced by any one of a number of routine factor dependent cell 15 proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DAl, 123, Ti 165, HT2, CTLL2, TF-1, Mo7e, CMK, H-UVEC, and Caco. Therapeutic compositions of the invention can be used in the following: Assays for T-cell or thymocyte proliferation include without limitation those 20 described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 25 133:327-341, 1991; Bertagnolli, et al., I. Immunol. 149:3778-3783, 1992; Bowman et al., I. Immunol. 152:1756-1761, 1994. Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in Immunology. J. E. e.a. Coligan 30 eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human interleukin-7, Schreiber, R. D. In Current Protocols in Innunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, Jolm Wiley and Sons, Toronto. 1994.

WO 2004/080148 PCT/US2003/030720 46 Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and 5 Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6--Nordan, R. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Aced. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human 10 Interleukin 11 --Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9--Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991. 15 Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience 20 (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988. 25 4.10.4 STEM CELL GROWTH FACTOR ACTIVITY A polypeptide of the present invention may exhibit stem cell growth factor activity and be involved in the proliferation, differentiation and survival of pluripotent and totipotent stem cells including primordial germ cells, embryonic stem cells, hematopoietic stem cells 30 and/or germ line stem cells. Administration of the polypeptide of the invention to stem cells in vivo or ex vivo is expected to maintain and expand cell populations in a totipotential or pluripotential state which would be useful for re-engineering damaged or diseased tissues, transplantation, manufacture of bio-pharmaceuticals and the development of bio-sensors.

WO 2004/080148 PCT/US2003/030720 47 The ability to produce large quantities of human cells has important working applications for the production of human proteins which currently must be obtained from non-human sources or donors, implantation of cells to treat diseases such as Parkinson's, Alzheimer's and other neurodegenerative diseases; tissues for grafting such as bone marrow, skin, cartilage, 5 tendons, bone, muscle (including cardiac muscle), blood vessels, cornea, neural cells, gastrointestinal cells and others; and organs for transplantation such as kidney, liver, pancreas (including islet cells), heart and lung. It is contemplated that multiple different exogenous growth factors and/or cytokines may be administered in combination with the polypeptide of the invention to achieve the 10 desired effect, including any of the growth factors listed herein, other stem cell maintenance factors, and specifically including stem cell factor (SCF), leukemia inhibitory factor (LIF), Flt-3 ligand (Flt-3L), any of the interleukins, recombinant soluble IL-6 receptor fused to IL 6, macrophage inflammatory protein 1-alpha (MIP-1-alpha), G-CSF, GM-CSF, thrombopoietin (TPO), platelet factor 4 (PF-4), platelet-derived growth factor (PDGF), 15 neural growth factors and basic fibroblast growth factor (bFGF). Since totipotent stem cells can give rise to virtually any mature cell type, expansion of these cells in culture will facilitate the production of large quantities of mature cells. Techniques for culturing stem cells are known in the art and administration of polypeptides of the invention, optionally with other growth factors and/or cytokines, is expected to 20 enhance the survival and proliferation of the stem cell populations. This can be accomplished by direct administration of the polypeptide of the invention to the culture medium. Alternatively, stroma cells transfected with a polynucleotide that encodes for the polypeptide of the invention can be used as a feeder layer for the stem cell populations in culture or in vivo. Stromal support cells for feeder layers may include embryonic bone 25 marrow fibroblasts, bone marrow stromal cells, fetal liver cells, or cultured embryonic fibroblasts (see U.S. Patent No. 5,690,926). Stem cells themselves can be transfected with a polynucleotide of the invention to induce autocrine expression of the polypeptide of the invention. This will allow for generation of undifferentiated totipotential/pluripotential stem cell lines that are useful as is 30 or that can then be differentiated into the desired mature cell types. These stable cell lines can also serve as a source of undifferentiated totipotential/pluripotential mRNA to create cDNA libraries and templates for polymerase chain reaction experiments. These studies WO 2004/080148 PCT/US2003/030720 48 would allow for the isolation and identification of differentially expressed genes in stem cell populations that regulate stem cell proliferation and/or maintenance. Expansion and maintenance of totipotent stem cell populations will be useful in the treatment of many pathological conditions. For example, polypeptides of the present 5 invention may be used to manipulate stem cells in culture to give rise to neuroepithelial cells that can be used to augment or replace cells damaged by illness, autoimmune disease, accidental damage or genetic disorders. The polypeptide of the invention may be useful for inducing the proliferation of neural cells and for the regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as 10 well as mechanical and traumatic disorders which involve degeneration, death or trauma to neural cells or nerve tissue. In addition, the expanded stein cell populations can also be genetically altered for gene therapy purposes and to decrease host rejection of replacement tissues after grafting or implantation. Expression of the polypeptide of the invention and its effect on stem cells can also be 15 manipulated to achieve controlled differentiation of the stem cells into more differentiated cell types. A broadly applicable method of obtaining pure populations of a specific differentiated cell type from undifferentiated stem cell populations involves the use of a cell type specific promoter driving a selectable marker. The selectable marker allows only cells of the desired type to survive. For example, stem cells can be induced to differentiate into 20 cardiomyocytes (Wobus et al., Differentiation, 48: 173-182, (1991); Klug et al., J. Clin. Invest., 98(1): 216-224, (1998)) or skeletal muscle cells (Browder, L W. In: Principles of Tissue Engineering eds. Lanza et al., Academic Press (1997)). Alternatively, directed differentiation of stem cells can be accomplished by culturing the stem cells in the presence of a differentiation factor such as retinoic acid and an antagonist of the polypeptide of the 25 invention which would inhibit the effects of endogenous stem cell factor activity and allow differentiation to proceed. in vitro cultures of stem cells can be used to determine if the polypeptide of the invention exhibits stem cell growth factor activity. Stem cells are isolated from any one of various cell sources (including hematopoietic stem cells and embryonic stem cells) and 30 cultured on a feeder layer, as described by Thompson et al. Proc. Natl. Acad. Sci, U.S.A., 92: 7844-7848 (1995), in the presence of the polypeptide of the invention alone or in combination with other growth factors or cytokines. The ability of the polypeptide of the WO 2004/080148 PCT/US2003/030720 49 invention to induce stem cells proliferation is determined by colony formation on semi-solid support e.g. as described by Bernstein et al., Blood, 77: 2316-2321 (1991). 4.10.5 HEMATOPOIESIS REGULATING ACTIVITY 5 A polypeptide of the present invention may be involved in regulation of hematopoiesis and, consequently, in the treatment of mycloid or lymphoid cell-disorders. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, 10 thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in 15 supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and 20 therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or 25 heterologous)) as normal cells or genetically manipulated for gene therapy. Therapeutic compositions of the invention can be used in the following: Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above. Assays for embryonic stem cell differentiation (which will identify, among others, 30 proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

WO 2004/080148 PCT/US2003/030720 50 Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M. G. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; 5 Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I. K. and Briddell, R. A. In Culture of Hematopoietic Cells. R. . Freshney, et al. eds. Vol pp. 23-3 9, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R. E. In Culture of Hematopoietic Cells. 10 R. I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, H. J. In Culture of Hematopoietic Cells. R. I. Freslmey, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., 15 New York, N.Y. 1994. 4.10.6 TISSUE GROWTH ACTIVITY A polypeptide of the present invention also may be involved in bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as in wound healing and 20 tissue repair and replacement, and in healing of burns, incisions and ulcers. A polypeptide of the present invention which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Compositions of a polypeptide, antibody, binding partner, or other modulator of the invention may have 25 prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery. A polypeptide of this invention may also be involved in attracting bone-forming 30 cells, stimulating growth of bone-forming cells, or inducing differentiation of progenitors of bone-forming cells. Treatment of osteoporosis, osteoarthritis, bone degenerative disorders, or periodontal disease, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast WO 2004/080148 PCT/US2003/030720 51 activity, etc.) mediated by inflammatory processes may also be possible using the composition of the invention. Another category of tissue regeneration activity that may involve the polypeptide of the present invention is tendon/ligament formation. Induction of tendon/ligament-like tissue 5 or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or 10 ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide 15 environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions 20 may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art. The compositions of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and 25 traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a composition may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager 30 syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from WO 2004/080148 PCT/US2003/030720 52 chemotherapy or other medical therapies may also be treatable using a composition of the invention. Compositions of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with 5 vascular insufficiency, surgical and traumatic wounds, and the like. Compositions of the present invention may also be involved in the generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising 10 such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring may allow normal tissue to regenerate. A polypeptide of the present invention may also exhibit angiogenic activity. A composition of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and 15 conditions resulting from systemic cytokine damage. A composition of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above. Therapeutic compositions of the invention can be used in the following: 20 Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. W095/16035 (bone, cartilage, tendon); International Patent Publication No. W095/05846 (nerve, neuronal); International Patent Publication No. W091/07491 (skin, endothelium). Assays for wound healing activity include, without limitation, those described in: 25 Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, H. I. and Rovee, D. T., eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978). 4.10.7 IMMUNE STIMULATING OR SUPPRESSING ACTIVITY 30 A polypeptide of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A polynucleotide of the invention can encode a polypeptide exhibiting such activities. A protein may be useful in the treatment of various immune deficiencies and WO 2004/080148 PCT/US2003/030720 53 disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from 5 autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpes viruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, proteins of the present invention may also be useful where a boost to the immune system generally may 10 be desirable, i.e., in the treatment of cancer. Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, 15 graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein (or antagonists thereof, including antibodies) of the present invention may also to be useful in the treatment of allergic reactions and conditions (e.g., anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic 20 contact dermatitis, erythema multiforme, Stevens-Johnson syndrome, allergic conjunctivitis, atopic keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis and contact allergies), such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein (or antagonists 25 thereof) of the present invention. The therapeutic effects of the polypeptides or antagonists thereof on allergic reactions can be evaluated by in vivo animals models such as the cumulative contact enhancement test (Lastbom et al., Toxicology 125: 59-66, 1998), skin prick test (Hoffmann et al., Allergy 54: 446-54, 1999), guinea pig skin sensitization test (Vohr et al., Arch. Toxocol. 73: 501-9), and murine local lymph node assay (Kimber et al., 30 J. Toxicol. Environ. Health 53: 563-79). Using the proteins of the invention it may also be possible to modulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of WO 2004/080148 PCT/US2003/030720 54 an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Iminunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing 5 non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent. Down regulating or preventing one or more antigen functions (including without 10 limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition 15 as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a therapeutic composition of the invention may prevent cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, a lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may 20 avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens. The efficacy of particular therapeutic compositions in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in 25 humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., 30 Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of therapeutic compositions of the invention on the development of that disease.

WO 2004/080148 PCT/US2003/030720 55 Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self-tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of 5 autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block stimulation of T cells can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of 10 blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia 15 gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856). Upregulation of an antigen function (e.g., a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting 20 an initial immune response. For example, enhancing an immune response may be useful in cases of viral infection, including systemic viral diseases such as influenza, the common cold, and encephalitis. Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed 25 APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the 30 protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.

WO 2004/080148 PCT/US2003/030720 56 A polypeptide of the present invention may provide the necessary stimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient mounts of MHC class I or MHC class II molecules, can be transfected 5 with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I alpha chain protein and P2 microglobulin protein or an MHC class II alpha chain protein and an MHC class II beta chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., 10 B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T 15 cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject. The activity of a protein of the invention may, among other means, be measured by the following methods: Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, 20 those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. 25 Immunol. 135:1564-1572, 1985; Takai et al., I. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bowman et al., J. Virology 61:1992-1998; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994. Assays for T-cell-dependent immunoglobulin responses and isotype switching 30 (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro WO 2004/080148 PCT/US2003/030720 57 antibody production, Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994. Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Thl and CTL responses) include, without limitation, 5 those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 10 1992. Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 15 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990. 20 Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, 25 Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992. Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; 30 Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991. 4.10.8 ACTIVIN/INHIBIN ACTIVITY WO 2004/080148 PCT/US2003/030720 58 A polypeptide of the present invention may also exhibit activin- or inhibin-related activities. A polynucleotide of the invention may encode a polypeptide exhibiting such characteristics. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate 5 the release of follicle stimulating hormone (FSH). Thus, a polypeptide of the present invention, alone or in heterodimers with a member of the inhibin family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the polypeptide of the 10 invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, U.S. Pat. No. 4,798,885. A polypeptide of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime 15 reproductive performance of domestic animals such as, but not limited to, cows, sheep and pigs. The activity of a polypeptide of the invention may, among other means, be measured by the following methods. Assays for activin/inhibin activity include, without limitation, those described in: 20 Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986. 4.10.9 CHEMOTACTIC/CHEMOKINETIC ACTIVITY 25 A polypeptide of the present invention may be involved in chemotactic or chemokinetic activity for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Chemotactic and chemokinetic receptor activation can be used to mobilize or attract a 30 desired cell population to a desired site of action. Chemotactic or chemokinetic compositions (e.g. proteins, antibodies, binding partners, or modulators of the invention) provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to WO 2004/080148 PCT/US2003/030720 59 tumors or sites of infection may result in improved immune responses against the tumor or infecting agent. A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell 5 population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis. Therapeutic compositions of the invention can be used in the following: 10 Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. 15 Coligan, A. M. Kruisbeek, D. H. Marguiles, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25:1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153:1762-1768, 1994. 20 4.10.10 HEMOSTATIC AlD THROMBOLYTIC ACTIVITY A polypeptide of the invention may also be involved in hemostatis or thrombolysis or thrombosis. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Compositions may be useful in treatment of various coagulation disorders 25 (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A composition of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke). 30 Therapeutic compositions of the invention can be used in the following: Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis WO 2004/080148 PCT/US2003/030720 60 Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988. 4.10.11 CANCER DIAGNOSIS AND THERAPY 5 Polypeptides of the invention may be involved in cancer cell generation, proliferation or metastasis. Detection of the presence or amount of polynucleotides or polypeptides of the invention may be useful for the diagnosis and/or prognosis of one or more types of cancer. For example, the presence or increased expression of a polynucleotide/polypeptide of the invention may indicate a hereditary risk of cancer, a precancerous condition, or an ongoing 10 malignancy. Conversely, a defect in the gene or absence of the polypeptide may be associated with a cancer condition. Identification of single nucleotide polymorphisms associated with cancer or a predisposition to cancer may also be useful for diagnosis or prognosis. Cancer treatments promote tumor regression by inhibiting tumor cell proliferation, 15 inhibiting angiogenesis (growth of new blood vessels that is necessary to support tumor growth) and/or prohibiting metastasis by reducing tumor cell motility or invasiveness. Therapeutic compositions of the invention may be effective in adult and pediatric oncology including in solid phase tumors/malignancies, locally advanced tumors, human soft tissue sarcomas, metastatic cancer, including lymphatic metastases, blood cell malignancies 20 including multiple myeloma, acute and chronic leukemias, and lymphomas, head and neck cancers including mouth cancer, larynx cancer and thyroid cancer, lung cancers including small cell carcinoma and non-small cell cancers, breast cancers including small cell carcinoma and ductal carcinoma, gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer and polyps associated with colorectal 25 neoplasia, pancreatic cancers, liver cancer, urologic cancers including bladder cancer and prostate cancer, malignancies of the female genital tract including ovarian carcinoma, uterine (including endometrial) cancers, and solid tumor in the ovarian follicle, kidney cancers including renal cell carcinoma, brain cancers including intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, gliomas, metastatic tumor cell invasion in the central 30 nervous system, bone cancers including osteomas, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, basal cell carcinoma, hemangiopericytoma and Karposi's sarcoma. Polypeptides, polynucleotides, or modulators of polypeptides of the invention WO 2004/080148 PCT/US2003/030720 61 (including inhibitors and stimulators of the biological activity of the polypeptide of the invention) may be administered to treat cancer. Therapeutic compositions can be administered in therapeutically effective dosages alone or in combination with adjuvant cancer therapy such as surgery, chemotherapy, radiotherapy, thermotherapy, and laser 5 therapy, and may provide a beneficial effect, e.g. reducing tumor size, slowing rate of tumor growth, inhibiting metastasis, or otherwise improving overall clinical condition, without necessarily eradicating the cancer. The composition can also be administered in therapeutically effective amounts as a portion of an anti-cancer cocktail. An anti-cancer cocktail is a mixture of the polypeptide or 10 modulator of the invention with one or more anti-cancer drugs in addition to a pharmaceutically acceptable carrier for delivery. The use of anti-cancer cocktails as a cancer treatment is routine. Anti-cancer drugs that are well known in the art and can be used as a treatment in combination with the polypeptide or modulator of the invention include: Actinomycin D, Aminoglutethimide, Asparaginase, Bleomycin, Busulfan, Carboplatin, 15 Carmustine, Chlorambucil, Cisplatin (cis-DDP), Cyclophosphamide, Cytarabine HCI (Cytosine arabinoside), Dacarbazine, Dactinomycin, Daunorubicin HCl, Doxorubicin HC1, Estramustine phosphate sodium, Etoposide (V16-213), Floxuridine, 5-Fluorouracil (5-Fu), Flutamide, Hydroxyurea (hydroxycarbamide), Ifosfamide, Interferon Alpha-2a, Interferon Alpha-2b, Leuprolide acetate (LHRH-releasing factor analog), Lomustine, Mechlorethamine 20 HCl (nitrogen mustard), Melphalan, Mercaptopurine, Mesna, Methotrexate (MTX), Mitomycin, Mitoxantrone HCl, Octreotide, Plicamycin, Procarbazine HC1, Streptozocin, Tamoxifen citrate, Thioguanine, Thiotepa, Vinblastine sulfate, Vincristine sulfate, Amsacrine, Azacitidine, Hexamethylmelamine, Interleukin-2, Mitoguazone, Pentostatin, Semustine, Teniposide, and Vindesine sulfate. 25 In addition, therapeutic compositions of the invention may be used for prophylactic treatment of cancer. There are hereditary conditions and/or environmental situations (e.g. exposure to carcinogens) known in the art that predispose an individual to developing cancers. Under these circumstances, it may be beneficial to treat these individuals with therapeutically effective doses of the polypeptide of the invention to reduce the risk of 30 developing cancers. In vitro models can be used to determine the effective doses of the polypeptide of the invention as a potential cancer treatment. These in vitro models include proliferation assays of cultured tumor cells, growth of cultured tumor cells in soft agar (see Freshney, (1987) WO 2004/080148 PCT/US2003/030720 62 Culture of Animal Cells: A Manual of Basic Technique, Wily-Liss, New York, NY Ch 18 and Ch 21), tumor systems in nude mice as described in Giovanella et al., J. Natl. Can. Inst., 52: 921-30 (1974), mobility and invasive potential of tumor cells in Boyden Chamber assays as described in Pilkington et al., Anticancer Res., 17: 4107-9 (1997), and angiogenesis 5 assays such as induction of vascularization of the chick chorioallantoic membrane or induction of vascular endothelial cell migration as described in Ribatta et al., Intl. J. Dev. Biol., 40: 1189-97 (1999) and Li et al., Clin. Exp. Metastasis, 17:423-9 (1999), respectively. Suitable tumor cells lines are available, e.g. from American Type Tissue Culture Collection catalogs. 10 4.10.12 RECEPTOR/LIGAND ACTIVITY A polypeptide of the present invention may also demonstrate activity as receptor, receptor ligand or inhibitor or agonist of receptor/ligand interactions. A polynucleotide of the invention can encode a polypeptide exhibiting such characteristics. Examples of such 15 receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and 20 humoral immune responses. Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions. The activity of a polypeptide of the invention may, among other means, be measured 25 by the following methods: Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 30 7.28.1- 7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

WO 2004/080148 PCT/US2003/030720 63 By way of example, the polypeptides of the invention may be used as a receptor for a ligand(s) thereby transmitting the biological activity of that ligand(s). Ligands may be identified through binding assays, affinity chromatography, dihybrid screening assays, BIAcore assays, gel overlay assays, or other methods known in the art. 5 Studies characterizing drugs or proteins as agonist or antagonist or partial agonists or a partial antagonist require the use of other proteins as competing ligands. The polypeptides of the present invention or ligand(s) thereof may be labeled by being coupled to radioisotopes, colorimetric molecules or a toxin molecules by conventional methods. ("Guide to Protein Purification" Murray P. Deutscher (ed) Methods in Enzymology Vol. 182 10 (1990) Academic Press, Inc. San Diego). Examples of radioisotopes include, but are not limited to, tritium and carbon-14 . Examples of colorimetric molecules include, but are not limited to, fluorescent molecules such as fluorescamine, or rhodamine or other colorimetric molecules. Examples of toxins include, but are not limited, to ricin. 15 4.10.13 DRUG SCREENING This invention is particularly useful for screening chemical compounds by using the novel polypeptides or binding fragments thereof in any of a variety of drug screening techniques. The polypeptides or fragments employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One 20 method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or a fragment thereof. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between polypeptides of the invention or 25 fragments and the agent being tested or examine the diminution in complex formation between the novel polypeptides and an appropriate cell line, which are well known in the art. Sources for test compounds that may be screened for ability to bind to or modulate (i.e., increase or decrease) the activity of polypeptides of the invention include (1) inorganic and organic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries 30 comprised of either random or mimetic peptides, oligonucleotides or organic molecules. Chemical libraries may be readily synthesized or purchased from a number of commercial sources, and may include structural analogs of known compounds or compounds that are identified as "hits" or "leads" via natural product screening.

WO 2004/080148 PCT/US2003/030720 64 The sources of natural product libraries are microorganisms (including bacteria and fungi), animals, plants or other vegetation, or marine organisms, and libraries of mixtures for screening may be created by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of the organisms themselves. Natural product 5 libraries include polyketides, non-ribosomal peptides, and (non-naturally occurring) variants thereof. For a review, see Science 282:63-68 (1998). Combinatorial libraries are composed of large numbers of peptides, oligonucleotides or organic compounds and can be readily prepared by traditional automated synthesis methods, PCR, cloning or proprietary synthetic methods. Of particular interest are peptide 10 and oligonucleotide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, Curr. Opin. Biotechnol. 8:701-707 (1997). For reviews and examples of peptidomimetic libraries, see Al-Obeidi et al., Mol. Biotechnol, 9(3):205-23 (1998); Hruby 15 et al., Curr Opin Chein Biol, l(1):114-19 (1997); Dorner et al., Bioorg Med CIen, 4(5):709-15 (1996) (alkylated dipeptides). Identification of modulators through use of the various libraries described herein permits modification of the candidate "hit" (or "lead") to optimize the capacity of the "hit" to bind a polypeptide of the invention. The molecules identified in the binding assay are then 20 tested for antagonist or agonist activity in in vivo tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells. The binding molecules thus identified may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells such as radioisotopes. The 25 toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for a polypeptide of the invention. Alternatively, the binding molecules may be complexed with imaging agents for targeting and imaging purposes. 4.10.14 ASSAY FOR RECEPTOR ACTIVITY 30 The invention also provides methods to detect specific binding of a polypeptide e.g. a ligand or a receptor. The art provides numerous assays particularly useful for identifying previously unknown binding partners for receptor polypeptides of the invention. For example, expression cloning using mammalian or bacterial cells, or dihybrid screening WO 2004/080148 PCT/US2003/030720 65 assays can be used to identify polynucleotides encoding binding partners. As another example, affinity chromatography with the appropriate immobilized polypeptide of the invention can be used to isolate polypeptides that recognize and bind polypeptides of the invention. There are a number of different libraries used for the identification of 5 compounds, and in particular small molecules, that modulate (i.e., increase or decrease) biological activity of a polypeptide of the invention. Ligands for receptor polypeptides of the invention can also be identified by adding exogenous ligands, or cocktails of ligands to two cells populations that are genetically identical except for the expression of the receptor of the invention: one cell population expresses the receptor of the invention whereas the other does 10 not. The responses of the two cell populations to the addition of ligands(s) are then compared. Alternatively, an expression library can be co-expressed with the polypeptide of the invention in cells and assayed for an autocrine response to identify potential ligand(s). As still another example, BLAcore assays, gel overlay assays, or other methods known in the art can be used to identify binding partner polypeptides, including, (1) organic and inorganic 15 chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules. The role of downstream intracellular signaling molecules in the signaling cascade of the polypeptide of the invention can be determined. For example, a chimeric protein in which the cytoplasmic domain of the polypeptide of the invention is fused to the 20 extracellular portion of a protein, whose ligand has been identified, is produced in a host cell. The cell is then incubated with the ligand specific for the extracellular portion of the chimeric protein, thereby activating the chimeric receptor. Known downstream proteins involved in intracellular signaling can then be assayed for expected modifications i.e. phosphorylation. Other methods known to those in the art can also be used to identify 25 signaling molecules involved in receptor activity. 4.10.15 ANTI-INFLAMMATORY ACTIVITY Compositions of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in 30 the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an WO 2004/080148 PCT/US2003/030720 66 inflammatory response. Compositions with such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation intimation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, 5 complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Compositions of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material. Compositions of this invention may be utilized to prevent or treat conditions such as, but not limited to, sepsis, 10 acute pancreatitis, endotoxin shock, cytokine induced shock, rheumatoid arthritis, chronic inflammatory arthritis, pancreatic cell damage from diabetes mellitus type 1, graft versus host disease, inflanunatory bowel disease, inflamation associated with pulmonary disease, other autoimmune disease or inflammatory disease, an antiproliferative agent such as for acute or chronic mylegenous leukemia or in the prevention of premature labor secondary to 15 intrauterine infections. 4.10.16 LEUKEMIAS Leukemias and related disorders may be treated or prevented by administration of a therapeutic that promotes or inhibits function of the polynucleotides and/or polypeptides of 20 the invention. Such leukemias and related disorders include but are not limited to acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia (for a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia). 25 4.10.17 NERVOUS SYSTEM DISORDERS Nervous system disorders, involving cell types which can be tested for efficacy of intervention with compounds that modulate the activity of the polynucleotides and/or polypeptides of the invention, and which can be treated upon thus observing an indication of 30 therapeutic utility, include but are not limited to nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the invention include WO 2004/080148 PCT/US2003/030720 67 but are not limited to the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (i) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or 5 compression injuries; (ii) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (iii) infectious lesions, in which a portion of the nervous system is destroyed or 10 injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (iv) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration 15 associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis; (v) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B 12 deficiency, folic acid deficiency, 20 Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (vi) neurological lesions associated with systemic diseases including but not limited to diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; 25 (vii) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (viii) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including but not limited to multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various 30 etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis. Therapeutics which are useful according to the invention for treatment of a nervous system disorder may be selected by testing for biological activity in promoting the survival WO 2004/080148 PCT/US2003/030720 68 or differentiation of neurons. For example, and not by way of limitation, therapeutics which elicit any of the following effects may be useful according to the invention: (i) increased survival time of neurons in culture; (ii) increased sprouting of neurons in culture or in vivo; 5 (iii) increased production of a neuron-associated molecule in culture or in vivo, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (iv) decreased symptoms of neuron dysfunction in vivo. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may be measured by the method 10 set forth in Arakawa et al. (1990, J. Neurosci. 10:3507-3515); increased sprouting of neurons may be detected by methods set forth in Pestronk et al. (1980, Exp. Neurol. 70:65-82) or Brown et al. (1981, Ann. Rev. Neurosci. 4:17-42); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., depending on the molecule to be measured; and motor 15 neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability. In specific embodiments, motor neuron disorders that may be treated according to the invention include but are not limited to disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor 20 neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including but not limited to progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory 25 Neuropathy (Charcot-Marie-Tooth Disease). 4.10.18 OTHER ACTIVITIES A polypeptide of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, 30 infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, WO 2004/080148 PCT/US2003/030720 69 change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, co-factors or other nutritional factors or component(s); 5 effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of 10 the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein. 15 4.10.19 IDENTIFICATION OF POLYMORPHISMS The demonstration of polymorphisms makes possible the identification of such polymorphisms in human subjects and the pharmacogenetic use of this information for diagnosis and treatment. Such polymorphisms may be associated with, e.g., differential 20 predisposition or susceptibility to various disease states (such as disorders involving inflammation or immune response) or a differential response to drug administration, and this genetic infonnation can be used to tailor preventive or therapeutic treatment appropriately. For example, the existence of a polymorphism associated with a predisposition to inflammation or autoimmune disease makes possible the diagnosis of this condition in 25 humans by identifying the presence of the polymorphism. Polymorphisms can be identified in a variety of ways known in the art which all generally involve obtaining a sample from a patient, analyzing DNA from the sample, optionally involving isolation or amplification of the DNA, and identifying the presence of the polymorphism in the DNA. For example, PCR may be used to amplify an appropriate 30 fragment of genomic DNA which may then be sequenced. Alternatively, the DNA may be subjected to allele-specific oligonucleotide hybridization (in which appropriate oligonucleotides are hybridized to the DNA under conditions permitting detection of a single base mismatch) or to a single nucleotide extension assay (in which an oligonucleotide that WO 2004/080148 PCT/US2003/030720 70 hybridizes immediately adjacent to the position of the polymorphism is extended with one or more labeled nucleotides). In addition, traditional restriction fragment length polymorphism analysis (using restriction enzymes that provide differential digestion of the genomic DNA depending on the presence or absence of the polymorphism) may be performed. Arrays with 5 nucleotide sequences of the present invention can be used to detect polymorphisms. The array can comprise modified nucleotide sequences of the present invention in order to detect the nucleotide sequences of the present invention. In the alternative, any one of the nucleotide sequences of the present invention can be placed on the array to detect changes from those sequences. 10 Alternatively a polymorphism resulting in a change in the amino acid sequence could also be detected by detecting a corresponding change in amino acid sequence of the protein, e.g., by an antibody specific to the variant sequence. 4.10.20 ARTHRITIS AND INFLAMMATION 15 The immunosuppressive effects of the compositions of the invention against rheumatoid arthritis is determined in an experimental animal model system. The experimental model system is adjuvant induced arthritis in rats, and the protocol is described by J. Holoshitz, et at., 1983, Science, 219:56, or by B. Waksman et al., 1963, Int. Arch. Allergy Appl. Immunol., 23:129. Induction of the disease can be caused by a single 20 injection, generally intradermally, of a suspension of killed Mycobacterium tuberculosis in complete Freund's adjuvant (CFA). The route of injection can vary, but rats may be injected at the base of the tail with an adjuvant mixture. The polypeptide is administered in phosphate buffered solution (PBS) at a dose of about 1-5 mg/kg. The control consists of administering PBS only. 25 The procedure for testing the effects of the test compound would consist of intradermally injecting killed Mycobacterium tuberculosis in CFA followed by immediately administering the test compound and subsequent treatment every other day until day 24. At 14, 15, 18, 20, 22, and 24 days after injection of Mycobacterium CFA, an overall arthritis score may be obtained as described by J. Holoskitz above. An analysis of the data would 30 reveal that the test compound would have a dramatic affect on the swelling of the joints as measured by a decrease of the arthritis score. 4.11 THERAPEUTIC METHODS WO 2004/080148 PCT/US2003/030720 71 The compositions (including polypeptide fragments, analogs, variants and antibodies or other binding partners or modulators including antisense polynucleotides) of the invention have numerous applications in a variety of therapeutic methods. Examples of therapeutic applications include, but are not limited to, those exemplified herein. 5 4.11.1 EXAMPLE One embodiment of the invention is the administration of an effective amount of the polypeptides or other composition of the invention to individuals affected by a disease or disorder that can be modulated by regulating the peptides of the invention. While the mode 10 of administration is not particularly important, parenteral administration is preferred. An exemplary mode of administration is to deliver an intravenous bolus. The dosage of the polypeptides or other composition of the invention will normally be determined by the prescribing physician. It is to be expected that the dosage will vary according to the age, weight, condition and response of the individual patient. Typically, the amount of 15 polypeptide administered per dose will be in the range of about 0.01 p.g/kg to 100 mg/kg of body weight, with the preferred dose being about 0.1 pg/kg to 10 mg/kg of patient body weight. For parenteral administration, polypeptides of the invention will be formulated in an injectable form combined with a pharmaceutically acceptable parenteral vehicle. Such vehicles are well known in the art and examples include water, saline, Ringer's solution, 20 dextrose solution, and solutions consisting of small amounts of the human serum albumin. The vehicle may contain minor amounts of additives that maintain the isotonicity and stability of the polypeptide or other active ingredient. The preparation of such solutions is within the skill of the art. 25 4.12 PHARMACEUTICAL FORMULATIONS AND ROUTES OF ADMINISTRATION A protein or other composition of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources and including antibodies and other binding partners of the polypeptides of the invention) may be 30 administered to a patient in need, by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s) at doses to treat or ameliorate a variety of disorders. Such a composition may optionally contain (in addition to protein or other active ingredient and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other WO 2004/080148 PCT/US2003/030720 72 materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, 5 or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNFO, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the disease or disorder in question. These agents include various growth factors 10 such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factors (TGF-cc and TGF-3), insulin-like growth factor (IGF), as well as cytokines described herein. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or other active ingredient or complement its activity or 15 use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein or other active ingredient of the invention, or to minimize side effects. Conversely, protein or other active ingredient of the present invention may be included in formulations of the particular clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic 20 factor, or anti- inflammatory agent to minimize side effects of the clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent (such as IL-IRa, IL-I Hy1, IL-1 Hy2, anti-TNF, corticosteroids, immunosuppressive agents). A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, 25 pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form. As an alternative to being included in a pharmaceutical composition of the invention including a first protein, a second protein or a therapeutic agent may be concurrently administered with the first protein (e.g., at the same time, or at differing times provided that 30 therapeutic concentrations of the combination of agents is achieved at the treatment site). Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition. A therapeutically effective dose further refers to that amount of the compound WO 2004/080148 PCT/US2003/030720 73 sufficient to result in amelioration of symptoms, e.g., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, a therapeutically effective dose refers to that ingredient 5 alone. When applied to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein or other active ingredient of the present invention 10 is administered to a mammal having a condition to be treated. Protein or other active ingredient of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co- administered with one or more cytokines, lymphokines or other hematopoietic factors, protein or other 15 active ingredient of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein or other active ingredient of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic 20 factor(s), thrombolytic or anti-thrombotic factors. 4.12.1 ROUTES OF ADMINISTRATION Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, 25 subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. Administration of protein or other active ingredient of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, 30 intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred. Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a arthritic joints or in WO 2004/080148 PCT/US2003/030720 74 fibrotic tissue, often in a depot or sustained release formulation. In order to prevent the scarring process frequently occurring as complication of glaucoma surgery, the compounds may be administered topically, for example, as eye drops. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with a specific 5 antibody, targeting, for example, arthritic or fibrotic tissue. The liposomes will be targeted to and taken up selectively by the afflicted tissue. The polypeptides of the invention are administered by any route that delivers an effective dosage to the desired site of action. The determination of a suitable route of administration and an effective dosage for a particular indication is within the level of skill 10 in the art. Preferably for wound treatment, one administers the therapeutic compound directly to the site. Suitable dosage ranges for the polypeptides of the invention can be extrapolated from these dosages or from similar studies in appropriate animal models. Dosages can then be adjusted as necessary by the clinician to provide maximal therapeutic benefit. 15 4.12.2 COMPOSITIONS/FORMULATIONS Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active 20 compounds into preparations which can be used pharmaceutically. These pharmaceutical compositions may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen. When a therapeutically effective amount of protein or 25 other active ingredient of the present invention is administered orally, protein or other active ingredient of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein or other active ingredient of the present 30 invention, and preferably from about 25 to 90% protein or other active ingredient of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical WO 2004/080148 PCT/US2003/030720 75 composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein or other active ingredient of the present invention, and preferably from 5 about 1 to 50% protein or other active ingredient of the present invention. When a therapeutically effective amount of protein or other active ingredient of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein or other active ingredient of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally 10 acceptable protein or other active ingredient solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein or other active ingredient of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride 15 Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or 20 physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the fonnulation. Such penetrants are generally known in the art. For oral administration, the compounds can be formulated readily by combining the active compounds with phannaceutically acceptable carriers well known in the art. Such 25 carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained from a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable 30 excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, WO 2004/080148 PCT/US2003/030720 76 disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, 5 and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol 10 or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration 15 should be in dosages suitable for such administration. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner. For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., 20 dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. The compounds may be 25 formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. 30 Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such WO 2004/080148 PCT/US2003/030720 77 as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the 5 preparation of highly concentrated solutions. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. The compounds may also be fonnulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or 10 other glycerides. In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion 15 exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. A pharmaceutical carrier for the hydrophobic compounds of the invention is a co solvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 20 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD: 5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. 25 Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose. Alternatively, other delivery systems for hydrophobic pharmaceutical compounds 30 maybe employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable WO 2004/080148 PCT/US2003/030720 78 matrices of solid hydrophobic polymers containing the therapeutic agent. Various types of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the 5 biological stability of the therapeutic reagent, additional strategies for protein or other active ingredient stabilization may be employed. The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, 10 gelatin, and polymers such as polyethylene glycols. Many of the active ingredients of the invention may be provided as salts with pharmaceutically compatible counter ions. Such pharmaceutically acceptable base addition salts are those salts which retain the biological effectiveness and properties of the free acids and which are obtained by reaction with inorganic or organic bases such as sodium hydroxide, magnesium hydroxide, ammonia, 15 trialkylamine, dialkylamine, monoalkylamine, dibasic amino acids, sodium acetate, potassium benzoate, triethanol amine and the like. The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) or other active ingredient(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T 20 lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be 25 supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be in the form of a liposome in 30 which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, WO 2004/080148 PCT/US2003/030720 79 diglycerides, sulfatides, lysolecithins, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent Nos. 4,235,871; 4,501,728; 4,837,028; and 4,737,323, all of which are incorporated herein by reference. 5 The amount of protein or other active ingredient of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein or other active ingredient of the present invention with which to treat each individual patient. 10 Initially, the attending physician will administer low doses of protein or other active ingredient of the present invention and observe the patient's response. Larger doses of protein or other active ingredient of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to 15 practice the method of the present invention should contain about 0.01 pg to about 100 mg (preferably about 0.1 pg to about 10 mg, more preferably about 0.1 pg to about 1 mg) of protein or other active ingredient of the present invention per kg body weight. For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition 20 topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically 25 useful agents other than a protein or other active ingredient of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing or other active 30 ingredient-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

WO 2004/080148 PCT/US2003/030720 80 The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, 5 tricalcium phosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised 10 of combinations of any of the above-mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciurn phosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having 15 diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix. A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, 20 ethyleellulose, hydroxyethyleellulose, hydroxypropyleellulose, hydroxypropyl-methyleellulose, and carboxymethyleellulose, the most preferred being cationic salts of carbox:ymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful 25 herein is 0.5-20 wt %, preferably 1-10 wt % based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells. In further compositions, 30 proteins or other active ingredients of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet WO 2004/080148 PCT/US2003/030720 81 derived growth factor (PDGF), transforming growth factors (TGF-c and TGF-p), and insulin-like growth factor (IGF). The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired 5 patients for such treatment with proteins or other active ingredients of the present invention. The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue 10 (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by 15 periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling. Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other 20 known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA). Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes. 25 4.12.3 EFFECTIVE DOSAGE Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount 30 effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. For any compound used in the method of the invention, the therapeutically effective dose can be WO 2004/080148 PCT/US2003/030720 82 estimated initially from appropriate in vitro assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that can be used to more accurately determine useful doses in humans. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC 5 0 as 5 determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the protein's biological activity). Such information can be used to more accurately determine useful doses in humans. A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic 10 efficacy of such contpounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 5 0 (the dose lethal to 50% of the population) and the ED 5 0 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50 and ED 5 0 . Compounds which exhibit high therapeutic 15 indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 5 0 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of 20 administration and dosage can be chosen by the individual physician in view of the patients condition, See, e.g., Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1. Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the desired effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in 25 vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations. Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of 30 the time, preferably between 30-90% and most preferably between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

WO 2004/080148 PCT/US2003/030720 83 An exemplary dosage regimen for polypeptides or other compositions of the invention will be in the range of about 0.01 pig/kg to 100 mg/kg of body weight daily, with the preferred dose being about 0.1 ptg/kg to 25 mg/kg of patient body weight daily, varying in adults and children. Dosing may be once daily, or equivalent doses may be delivered at 5 longer or shorter intervals. The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's age and weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. 10 4.12.4 PACKAGING The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a 15 compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. 4.13 ANTIBODIES 20 Also included in the invention are antibodies to proteins, or fragments of proteins of the invention. The term "antibody" as used herein refers to imnimunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen-binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, 25 Fab, Fab, and F(ab')2 fragments, and an Fab expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG1, IgG2, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a 30 reference to all such classes, subclasses and types of human antibody species. An isolated related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for WO 2004/080148 PCT/US2003/030720 84 polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence shown in 5 SEQ ID NO: 685-1368, or 1967-2564, or Tables 3A, 3B, 5, 7, or 8, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. 10 Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions. In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a surface region of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human related protein sequence will indicate which regions of 15 a related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and 20 Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein. A protein of the invention, or a derivative, fragment, analog, homolog or ortholog 25 thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components. The term "specific for" indicates that the variable regions of the antibodies of the invention recognize and bind polypeptides of the invention exclusively (i.e., able to distinguish the polypeptide of the invention from other similar polypeptides despite sequence 30 identity, homology, or similarity found in the family of polypeptides), but may also interact with other proteins (for example, S. aureus protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the molecule. Screening assays to determine WO 2004/080148 PCT/US2003/030720 85 binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow et al. (Eds), Antibodies A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988), Chapter 6. Antibodies that recognize and bind fragments of the polypeptides of the 5 invention are also contemplated, provided that the antibodies are first and foremost specific for, as defined above, full-length polypeptides of the invention. As with antibodies that are specific for full length polypeptides of the invention, antibodies of the invention that recognize fragments are those which can distinguish polypeptides from the same family of polypeptides despite inherent sequence identity, homology, or similarity found in the family 10 of proteins. Antibodies of the invention are useful for, for example, therapeutic purposes (by modulating activity of a polypeptide of the invention), diagnostic purposes to detect or quantitate a polypeptide of the invention, as well as purification of a polypeptide of the invention. Kits comprising an antibody of the invention for any of the purposes described 15 herein are also comprehended. In general, a kit of the invention also includes a control antigen for which the antibody is immunospecific. The invention further provides a hybridoma that produces an antibody according to the invention. Antibodies of the invention are useful for detection and/or purification of the polypeptides of the invention. Monoclonal antibodies binding to the protein of the invention may be useful 20 diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and 25 preventing the metastatic spread of the cancerous cells, which may be mediated by the protein. The labeled antibodies of the present invention can be used for in vitro, in vivo, and in situ assays to identify cells or tissues in which a fragment of the polypeptide of interest is expressed. The antibodies may also be used directly in therapies or other diagnostics. The 30 present invention further provides the above-described antibodies immobilized on a solid support. Examples of such solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and Sepharose@, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known WO 2004/080148 PCT/US2003/030720 86 in the art (Weir, D.M. et al., "Handbook of Experimental Immunology" 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10 (1986); Jacoby, W.D. et al., Meth. Enzym. 34 Academic Press, N.Y. (1974)). The immobilized antibodies of the present invention can be used for in vitro, in vivo, and in situ assays as well as for immuno-affinity 5 purification of the proteins of the present invention. Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, 10 Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below. 4.13.1 POLYCLONAL ANTIBODIES For the production of polyclonal antibodies, various suitable host animals (e.g., 15 rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated 20 to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., 25 aluminum hydroxide), surface-active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants that can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). 30 The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific WO 2004/080148 PCT/US2003/030720 87 antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 5 (April 17, 2000), pp. 25-28). 4.13.2 MONOCLONAL ANTIBODIES The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular 10 species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen-binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it. 15 Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256, 495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be 20 immunized in vitro. The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell 25 line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59 103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that 30 preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas WO 2004/080148 PCT/US2003/030720 88 typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells. Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a 5 medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); 10 Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63). The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined 15 by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107, 220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target 20 antigen are isolated. After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal. 25 The monoclonal antibodies secreted by the subelones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. The monoclonal antibodies can also be made by recombinant DNA methods, such as 30 those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as WO 2004/080148 PCT/US2003/030720 89 a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA 5 also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted 10 for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody. 4.13.3 HUMANIZED ANTIBODIES 15 The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', 20 F(ab') 2 or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321, 522-525 (1986); Riechmann et al., Nature, 332, 323-327 (1988); Verhoeyen et al., Science, 239, 1534-1536 (1988)), by substituting 25 rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539). In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise 30 substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion WO 2004/080148 PCT/US2003/030720 90 of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2, 593-596 (1992)). 5 4.13.4 HUMAN ANTIBODIES Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. 'Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human 10 B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80, 15 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227, 381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by 20 introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 25 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779 783 (1992)); Lonberg et al. (Nature 368, 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al, (Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13, 65-93 (1995)). 30 Human antibodies may additionally be produced using transgenic nonhuman animals that are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication W094/02602). The endogenous genes encoding the heavy and light immunoglobulin chains WO 2004/080148 PCT/US2003/030720 91 in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then 5 obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomousem as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells that secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after 10 immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for 15 example, single chain Fv molecules. An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent 20 rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker. 25 A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The 30 hybrid cell expresses an antibody containing the heavy chain and the light chain. In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that WO 2004/080148 PCT/US2003/030720 92 binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049. 4.13.5 FAB FRAGMENTS AND SINGLE CHAIN ANTIBODIES 5 According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989 Science 246, 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or 10 derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F(ab')2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F(ab')2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papain and a reducing 15 agent and (iv) F, fragments. 4.13.6 BISPECIFIC ANTIBODIES Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of 20 the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit. Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two 25 immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305, 537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished 30 by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May'1993, and in Traunecker et al., 1991 EMBO J., 10, 3655-3659. Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to inmunoglobulin constant domain sequences. The fusion WO 2004/080148 PCT/US2003/030720 93 preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the 5 immunoglobulin light chain, are inserted into separate expression vectors, and are co transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121, 210 (1986). According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers 10 that are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody 15 molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g. F(ab') 2 bispecific antibodies). Techniques for generating bispecific antibodies from 20 antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229, 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. 25 The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes. 30 Additionally, Fab' fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175, 217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab') 2 molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical WO 2004/080148 PCT/US2003/030720 94 coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets. Various techniques for making and isolating bispecific antibody fragments directly 5 from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5), 1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody 10 heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90, 6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker which is too short to allow pairing between the 15 two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152, 5368 (1994). 20 Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147, 60 (1991). Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic ann of an immunoglobulin molecule can be combined with an arm which binds to a triggering 25 molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcyR), such as FcyRI (CD64), FcyRII (CD32) and Fc-yRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds 30 a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

WO 2004/080148 PCT/US2003/030720 95 4.13.7 HETEROCONJUGATE ANTIBODIES Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells 5 (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include 10 iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980. 4.13.8 EFFECTOR FUNCTION ENGINEERING It can be desirable to modify the antibody of the invention with respect to effector 15 function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fe region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et 20 al., J. Exp Med., 176, 1191-1195 (1992) and Shopes, J. Immunol., 148, 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53, 2560 2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., 25 Anti-Cancer Drug Design, 3, 219-230 (1989). 4.13.9 IMMUNOCONJUGATES The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active 30 toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate). Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used WO 2004/080148 PCT/US2003/030720 96 include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria 5 officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 212 Bi, 1311, 3 1 In, 90 Y, and 186 Re. Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate 10 (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro 15 2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3 methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See W094/11026. In another embodiment, the antibody can be conjugated to a "receptor" (such 20 streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent. 25 4.14 COMPUTER READABLE SEQUENCES In one application of this embodiment, a nucleotide sequence of the present invention can be recorded on computer readable media. As used herein, "computer readable media" refers to any medium which can be read and accessed directly by a computer. Such media 30 include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. A skilled artisan can readily appreciate how any of the WO 2004/080148 PCT/US2003/030720 97 presently known computer readable mediums can be used to create a manufacture comprising computer readable medium having recorded thereon a nucleotide sequence of the present invention. As used herein, "recorded" refers to a process for storing information on computer readable medium. A skilled artisan can readily adopt any of the presently known 5 methods for recording information on computer readable medium to generate manufactures comprising the nucleotide sequence information of the present invention. A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon a nucleotide sequence of the present invention. The choice of the data storage structure will generally be based on the means 10 chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable medium. The sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, or represented in the form of an ASCII file, stored in a database 15 application, such as DB2, Sybase, Oracle, or the like. A skilled artisan can readily adapt any number of data processor structuring formats (e.g. text file or database) in order to obtain computer readable medium having recorded thereon the nucleotide sequence information of the present invention. By providing any of the nucleotide sequences SEQ ID NO: 1-684, or 1369-1966 or a 20 representative fragment thereof; or a nucleotide sequence at least 95% identical to any of the nucleotide sequences of SEQ ID NO: 1-684, or 1369-1966 in computer readable form, a skilled artisan can routinely access the sequence information for a variety of purposes. Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium. The examples which follow 25 demonstrate how software which implements the BLAST (Altschul et al., J. Mol. Biol. 215:403-410 (1990)) and BLAZE (Brutlag et al., Comp. Chem. 17:203-207 (1993)) search algorithms on a Sybase system is used to identify open reading frames (ORFs) within a nucleic acid sequence. Such ORFs may be protein-encoding fragments and may be useful in producing commercially important proteins such as enzymes used in fermentation reactions 30 and in the production of commercially useful metabolites. As used herein, "a computer-based system" refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware means of the computer-based systems of the WO 2004/080148 PCT/US2003/030720 98 present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based systems are suitable for use in the present invention. As stated above, the computer-based systems of the present invention comprise a data storage means 5 having stored therein a nucleotide sequence of the present invention and the necessary hardware means and software means for supporting and implementing a search means. As used herein, "data storage means" refers to memory which can store nucleotide sequence information of the present invention, or a memory access means which can access manufactures having recorded thereon the nucleotide sequence information of the present 10 invention. As used herein, "search means" refers to one or more programs which are implemented on the computer-based system to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or regions of a known sequence which match a particular target 15 sequence or target motif. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the computer-based systems of the present invention. Examples of such software includes, but is not limited to, Smith-Waterman, MacPattern (EMBL), BLASTN and BLASTA (NPOLYPEPTIDEIA). A skilled artisan can readily recognize that any one of the available 20 algorithms or implementing software packages for conducting homology searches can be adapted for use in the present computer-based systems. As used herein, a "target sequence" can be any nucleic acid or amino acid sequence of six or more nucleotides or two or more amino acids. A skilled artisan can readily recognize that the longer a target sequence is, the less likely a target sequence will be present as a random occurrence in the database. The 25 most preferred sequence length of a target sequence is from about 10 to 300 amino acids, more preferably from about 30 to 100 nucleotide residues. However, it is well recognized that searches for commercially important fragments, such as sequence fragments involved in gene expression and protein processing, may be of shorter length. As used herein, "a target structural motif," or "target motif," refers to any rationally 30 selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration which is formed upon the folding of the target motif. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, WO 2004/080148 PCT/US2003/030720 99 but are not limited to, promoter sequences, hairpin structures and inducible expression elements (protein binding sequences). 4.15 TRIPLE HELIX FORMATION 5 In addition, the fragments of the present invention, as broadly described, can be used to control gene expression through triple helix formation or antisense DNA or RNA, both of which methods are based on the binding of a polynucleotide sequence to DNA or RNA. Polynucleotides suitable for use in these methods are preferably 20 to 40 bases in length and are designed to be complementary to a region of the gene involved in transcription (triple 10 helix-see Lee et al., Nucl. Acids Res. 6, 3073 (1979); Cooney et al., Science 15241, 456 (1988); and Dervan et al., Science 251, 1360 (1991)) or to the mRNA itself (antisense Ohnno, J. Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization 15 blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide. 20 4.16 DIAGNOSTIC ASSAYS AND KITS The present invention further provides methods to identify the presence or expression of one of the ORFs of the present invention, or homolog thereof, in a test sample, using a nucleic acid probe or antibodies of the present invention, optionally conjugated or otherwise associated with a suitable label. 25 In general, methods for detecting a polynucleotide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polynucleotide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polynucleotide of the invention is detected in the sample. Such methods can also comprise contacting a sample under stringent hybridization 30 conditions with nucleic acid primers that anneal to a polynucleotide of the invention under such conditions, and amplifying annealed polynucleotides, so that if a polynucleotide is amplified, a polynucleotide of the invention is detected in the sample.

WO 2004/080148 PCT/US2003/030720 100 In general, methods for detecting a polypeptide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polypeptide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polypeptide of the invention is detected in the sample. 5 In detail, such methods comprise incubating a test sample with one or more of the antibodies or one or more of the nucleic acid probes of the present invention and assaying for binding of the nucleic acid probes or antibodies to components within the test sample. Conditions for incubating a nucleic acid probe or antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods 10 employed, and the type and nature of the nucleic acid probe or antibody used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or immunological assay formats can readily be adapted to employ the nucleic acid probes or antibodies of the present invention. Examples of such assays can be found in Chard, T., An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science 15 Publishers, Amsterdam, The Netherlands (1986); Bullock, G.R. et al., Techniques in Immunocytochemistry, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985). The test samples of the present invention include cells, protein or 20 membrane extracts of cells, or biological fluids such as sputum, blood, serum, plasma, or urine. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is 25 compatible with the system utilized. In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention. Specifically, the invention provides a compartment kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the probes or antibodies 30 of the present invention; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound probe or antibody.

WO 2004/080148 PCT/US2003/030720 101 In detail, a compartment kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not 5 cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the antibodies used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound 10 antibody or probe. Types of detection reagents include labeled nucleic acid probes, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody. One skilled in the art will readily recognize that the disclosed probes and antibodies of the present invention can be readily incorporated into one of the established kit formats which are well 15 known in the art. 4.17 MEDICAL IMAGING The novel polypeptides and binding partners of the invention are useful in medical imaging of sites expressing the molecules of the invention (e.g., where the polypeptide of the 20 invention is involved in the immune response, for imaging sites of inflammation or infection). See, e.g., Kunkel et al., U.S. Pat. NO. 5,413,778. Such methods involve chemical attachment of a labeling or imaging agent, administration of the labeled polypeptide to a subject in a pharmaceutically acceptable carrier, and imaging the labeled polypeptide in vivo at the target site. 25 4.18 SCREENING ASSAYS Using the isolated proteins and polynucleotides of the invention, the present invention further provides methods of obtaining and identifying agents which bind to a polypeptide encoded by an ORF corresponding to any of the nucleotide sequences set forth 30 in SEQ ID NO: 1-684, or 1369-1966, or bind to a specific domain of the polypeptide encoded by the nucleic acid. In detail, said method comprises the steps of: (a) contacting an agent with an isolated protein encoded by an ORF of the present invention, or nucleic acid of the invention; and WO 2004/080148 PCT/US2003/030720 102 (b) determining whether the agent binds to said protein or said nucleic acid. In general, therefore, such methods for identifying compounds that bind to a polynucleotide of the invention can comprise contacting a compound with a polynucleotide of the invention for a time sufficient to form a polynucleotide/compound complex, and 5 detecting the complex, so that if a polynucleotide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified. Likewise, in general, therefore, such methods for identifying compounds that bind to a polypeptide of the invention can comprise contacting a compound with a polypeptide of the invention for a time sufficient to form a polypeptide/compound complex, and detecting 10 the complex, so that if a polypeptide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified. Methods for identifying compounds that bind to a polypeptide of the invention can also comprise contacting a compound with a polypeptide of the invention in a cell for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression 15 of a receptor gene sequence in the cell, and detecting the complex by detecting reporter gene sequence expression, so that if a polypeptide/compound complex is detected, a compound that binds a polypeptide of the invention is identified. Compounds identified via such methods can include compounds which modulate the activity of a polypeptide of the invention (that is, increase or decrease its activity, relative to 20 activity observed in the absence of the compound). Alternatively, compounds identified via such methods can include compounds which modulate the expression of a polynucleotide of the invention (that is, increase or decrease expression relative to expression levels observed in the absence of the compound). Compounds, such as compounds identified via the methods of the invention, can be tested using standard assays well known to those of skill in 25 the art for their ability to modulate activity/expression. The agents screened in the above assay can be, but are not limited to, peptides, carbohydrates, vitamin derivatives, or other pharmaceutical agents. The agents can be selected and screened at random or rationally selected or designed using protein modeling techniques. 30 For random screening, agents such as peptides, carbohydrates, pharmaceutical agents and the like are selected at random and are assayed for their ability to bind to the protein encoded by the ORF of the present invention. Alternatively, agents may be rationally selected or designed. As used herein, an agent is said to be "rationally selected or designed" WO 2004/080148 PCT/US2003/030720 103 when the agent is chosen based on the configuration of the particular protein. For example, one skilled in the art can readily adapt currently available procedures to generate peptides, pharmaceutical agents and the like, capable of binding to a specific peptide sequence, in order to generate rationally designed antipeptide peptides, for example see Hurby et al., 5 Application of Synthetic Peptides: Antisense Peptides," In Synthetic Peptides, A User's Guide, W.H. Freeman, NY (1992), pp. 289-307, and Kaspezak et al., Biochemistry 28:9230-8 (1989), or pharmaceutical agents, or the like. In addition to the foregoing, one class of agents of the present invention, as broadly described, can be used to control gene expression through binding to one of the ORFs or 10 EMFs of the present invention. As described above, such agents can be randomly screened or rationally designed/selected. Targeting the ORF or EMF allows a skilled artisan to design sequence specific or element specific agents, modulating the expression of either a single ORF or multiple ORFs which rely on the same EMF for expression control. One class of DNA binding agents are agents which contain base residues which hybridize or form a triple 15 helix formation by binding to DNA or RNA. Such agents can be based on the classic phosphodiester, ribonucleic acid backbone, or can be a variety of sulfhydryl or polymeric derivatives which have base attachment capacity. Agents suitable for use in these methods preferably contain 20 to 40 bases and are designed to be complementary to a region of the gene involved in transcription (triple helix 20 see Lee et al., Nucl. Acids Res. 6, 3073 (1979); Cooney et al., Science 241, 456 (1988); and Dervan et al., Science 251, 1360 (1991)) or to the mRNA itself (antisense-Okano, J. Neurochem. 56, 560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks 25 translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide and other DNA binding agents. Agents which bind to a protein encoded by one of the ORFs of the present invention 30 can be used as a diagnostic agent. Agents which bind to a protein encoded by one of the ORFs of the present invention can be formulated using known techniques to generate a pharmaceutical composition.

WO 2004/080148 PCT/US2003/030720 104 4.19 USE OF NUCLEIC ACIDS AS PROBES Another aspect of the subject invention is to provide for polypeptide-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences. The hybridization probes of the subject invention may be derived from any of 5 the nucleotide sequences SEQ ID NO: 1-684, or 1369-1966. Because the corresponding gene is only expressed in a limited number of tissues, a hybridization probe derived from any of the nucleotide sequences SEQ ID NO: 1-684, or 1369-1966 can be used as an indicator of the presence of RNA of cell type of such a tissue in a sample. Any suitable hybridization technique can be employed, such as, for example, in situ 10 hybridization. PCR as described in US Patents Nos. 4,683,195 and 4,965,188 provides additional uses for oligonucleotides based upon the nucleotide sequences. Such probes used in PCR may be of recombinant origin, may be chemically synthesized, or a mixture of both. The probe will comprise a discrete nucleotide sequence for the detection of identical sequences or a degenerate pool of possible sequences for identification of closely related 15 genomic sequences. Other means for producing specific hybridization probes for nucleic acids include the cloning of nucleic acid sequences into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or 20 SP6 RNA polymerase and the appropriate radioactively labeled nucleotides. The nucleotide sequences may be used to construct hybridization probes for mapping their respective genomic sequences. The nucleotide sequence provided herein may be mapped to a chromosome or specific regions of a chromosome using well-known genetic and/or chromosomal mapping techniques. These techniques include in situ hybridization, linkage 25 analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like. The technique of fluorescent in situ hybridization of chromosome spreads has been described, among other places, in Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York NY. 30 Fluorescent in situ hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of Science (265:1981f). Correlation between the location of a nucleic acid on a physical chromosomal WO 2004/080148 PCT/US2003/030720 105 map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals. 5 4.20 PREPARATION OF SUPPORT BOUND OLIGONUCLEOTIDES Oligonucleotides, i.e., small nucleic acid segments, may be readily prepared by, for example, directly synthesizing the oligonucleotide by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer. Support bound oligonucleotides may be prepared by any of the methods known to those 10 of skill in the art using any suitable support such as glass, polystyrene or Teflon. One strategy is to precisely spot oligonucleotides synthesized by standard synthesizers. Immobilization can be achieved using passive adsorption (Inouye & Hondo, (1990) J. Clin. Microbiol. 28(6), 1469 72); using UV light (Nagata et al., 1985; Dahlen et al., 1987; Morrissey & Collins, (1989) Mol. Cell Probes 3(2) 189-207) or by covalent binding of base modified DNA (Keller et al., 1988; 15 1989); all references being specifically incorporated herein. Another strategy that may be employed is the use of the strong biotin-streptavidin interaction as a linker. For example, Broude et al. (1994) Proc. Natl. Acad. Sci. USA 91(8), 3072-6, describe the use of biotinylated probes, although these are duplex probes, that are immobilized on streptavidin-coated magnetic beads. Streptavidin-coated beads may be 20 purchased from Dynal, Oslo. Of course, this same linking chemistry is applicable to coating any surface with streptavidin. Biotinylated probes may be purchased from various sources, such as, e.g., Operon Technologies (Alameda, CA). Nunc Laboratories (Naperville, IL) is also selling suitable material that could be used. Nunc Laboratories have developed a method by which DNA can be covalently bound to the 25 microwell surface termed Covalink NH. CovaLink NH is a polystyrene surface grafted with secondary amino groups (>NH) that serve as bridgeheads for further covalent coupling. CovaLink Modules may be purchased from Nunc Laboratories. DNA molecules may be bound to CovaLink exclusively at the 5'-end by a phosphoramidate bond, allowing immobilization of more than 1 pmol of DNA (Rasmussen et al., (1991) Anal. Biochem. 198(1) 138-42). 30 The use of CovaLink NH strips for covalent binding of DNA molecules at the 5'-end has been described (Rasmussen et al., (1991). In this technology, a phosphoramidate bond is employed (Chu et al., (1983) Nucleic Acids Res. 11(8) 6513-29). This is beneficial as immobilization using only a single covalent bond is preferred. The phosphoramidate bond joins WO 2004/080148 PCT/US2003/030720 106 the DNA to the CovaLink NH secondary amino groups that are positioned at the end of spacer arms covalently grafted onto the polystyrene surface through a 2 nm long spacer arm. To link an oligonucleotide to CovaLink NH via an phosphoramidate bond, the oligonucleotide terminus must have a 5'-end phosphate group. It is, perhaps, even possible for biotin to be covalently 5 bound to CovaLink and then streptavidin used to bind the probes. More specifically, the linkage method includes dissolving DNA in water (7.5 ng/pl) and denaturing for 10 min. at 95*C and cooling on ice for 10 min. Ice-cold 0.1 M 1 methylimidazole, pH 7.0 (1-MeIm 7 ), is then added to a final concentration of 10 mM 1-MeIm 7 . A ss DNA solution is then dispensed into CovaLink NH strips (75 pl/well) standing on ice. 10 Carbodiimide 0.2 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), dissolved in 10 mM I-MeIm 7 , is made fresh and 25 pl added per well. The strips are incubated for 5 hours at 50'C. After incubation the strips are washed using, e.g., Nunc-Immuno Wash; first the wells are washed 3 times, then they are soaked with washing solution for 5 min., and finally they are washed 3 times (where in the washing solution is 0.4 N NaOH, 0.25% SDS 15 heated to 50"C). It is contemplated that a further suitable method for use with the present invention is that described in PCT Patent Application WO 90/033 82 (Southern & Maskos), incorporated herein by reference. This method of preparing an oligonucleotide bound to a support involves attaching a nucleoside 3'-reagent through the phosphate group by a covalent phosphodiester link 20 to aliphatic hydroxyl groups carried by the support. The oligonucleotide is then synthesized on the supported nucleoside and protecting groups removed from the synthetic oligonucleotide chain under standard conditions that do not cleave the oligonucleotide from the support. Suitable reagents include nucleoside phosphoramidite and nucleoside hydrogen phosphorate. An on-chip strategy for the preparation of DNA probe for the preparation of DNA probe 25 arrays may be employed. For example, addressable laser-activated photodeprotection may be employed in the chemical synthesis of oligonucleotides directly on a glass surface, as described by Fodor et aL. (1991) Science 251(4995), 767-73, incorporated herein by reference. Probes may also be immobilized on nylon supports as described by Van Ness et al. (1991) Nucleic Acids Res., 19(12) 3345-50; or linked to Teflon using the method of Duncan & Cavalier (1988) 30 Anal. Biochem. 169(1), 104-8; all references being specifically incorporated herein. To link an oligonucleotide to a nylon support, as described by Van Ness et aL. (1991), requires activation of the nylon surface via alkylation and selective activation of the 5'-amine of oligonucleotides with cyanuric chloride.

WO 2004/080148 PCT/US2003/030720 107 One particular way to prepare support bound oligonucleotides is to utilize the light-generated synthesis described by Pease et al., (1994) Proc. Natl. Acad. Sci., USA 91(11), 5022-6, incorporated herein-by reference). These authors used current photolithographic techniques to generate arrays of immobilized oligonucleotide probes (DNA chips). These 5 methods, in which light is used to direct the synthesis of oligonucleotide probes in high-density, miniaturized arrays, utilize photolabile 5'-protected N-acyl-deoxynucleoside phosphoramidites, surface linker chemistry and versatile combinatorial synthesis strategies. A matrix of 256 spatially defined oligonucleotide probes may be generated in this manner. 4.21 PREPARATION OF NUCLEIC ACID FRAGMENTS 10 The nucleic acids may be obtained from any appropriate source, such as cDNAs, genomic DNA, chromosomal DNA, microdissected chromosome bands, cosmid or YAC inserts, and RNA, including mRNA without any amplification steps. For example, Sambrook et al. (1989) describes three protocols for the isolation of high molecular weight DNA from mammalian cells (p. 9.14-9.23). 15 DNA fragments may be prepared as clones in M13, plasmid or lambda vectors and/or prepared directly from genomic DNA or cDNA by PCR or other amplification methods. Samples may be prepared or dispensed in multiwell plates. About 100-1000 ng of DNA samples may be prepared in 2-500 ml of final volume. The nucleic acids would then be fragmented by any of the methods known to those of 20 skill in the art including, for example, using restriction enzymes as described at 9.24-9.28 of Sambrook et al. (1989), shearing by ultrasound and NaOH treatment. Low pressure shearing is also appropriate, as described by Schriefer et al. (1990) Nucleic Acids Res. 18(24), 7455-6, incorporated herein by reference). In this method, DNA samples are passed through a small French pressure cell at a variety of low to intermediate 25 pressures. A lever device allows controlled application of low to intermediate pressures to the cell. The results of these studies indicate that low-pressure shearing is a useful alternative to sonic and enzymatic DNA fragmentation methods. One particularly suitable way for fragmenting DNA is contemplated to be that using the two base recognition endonuclease, CviJI, described by Fitzgerald et al. (1992) Nucleic Acids 30 Res. 20(14) 3753-62. These authors described an approach for the rapid fragmentation and fractionation of DNA into particular sizes that they contemplated to be suitable for shotgun cloning and sequencing.

WO 2004/080148 PCT/US2003/030720 108 The restriction endonuclease CviJI normally cleaves the recognition sequence PuGCPy between the G and C to leave blunt ends. Atypical reaction conditions, which alter the specificity of this enzyme (CviJI**), yield a quasi-random distribution of DNA fragments form the small molecule pUC19 (2688 base pairs). Fitzgerald et al. (1992),quantitatively evaluated 5 the randomness of this fragmentation strategy, using a CviJI** digest of pUC 19 that was size fractionated by a rapid gel filtration method and directly ligated, without end repair, to a lac Z minus M13 cloning vector. Sequence analysis of 76 clones showed that CviJI** restricts pyGCPy and PuGCPu, in addition to PuGCPy sites, and that new sequence data is accumulated at a rate consistent with random fragmentation. 10 As reported in the literature, advantages of this approach compared to sonication and agarose gel fractionation include: smaller amounts of DNA are required (0.2-0.5 gg instead of 2-5 pg); and fewer steps are involved (no preligation, end repair, chemical extraction, or agarose gel electrophoresis and elution are needed). Irrespective of the manner in which the nucleic acid fragments are obtained or prepared, 15 it is important to denature the DNA to give single stranded pieces available for hybridization. This is achieved by incubating the DNA solution for 2-5 minutes at 80-90'C. The solution is then cooled quickly to 2'C to prevent renaturation of the DNA fragments before they are contacted with the chip. Phosphate groups must also be removed from genomic DNA by methods known in the art. 20 4.22 PREPARATION OF DNA ARRAYS Arrays may be prepared by spotting DNA samples on a support such as a nylon membrane. Spotting may be performed by using arrays of metal pins (the positions of which correspond to an array of wells in a microtiter plate) to repeated by transfer of about 20 nl of a DNA solution to a nylon membrane. By offset printing, a density of dots higher than the density 25 of the wells is achieved. One to 25 dots may be accommodated in 1 mm 2 , depending on the type of label used. By avoiding spotting in some preselected number of rows and columns, separate subsets (subarrays) may be formed. Samples in one subarray may be the same genomic segment of DNA (or the same gene) from different individuals, or may be different, overlapped genomic clones. Each of the subarrays may represent replica spotting of the same samples. In 30 one example, a selected gene segment may be amplified from 64 patients. For each patient, the amplified gene segment may be in one 96-well plate (all 96 wells containing the same sample). A plate for each of the 64 patients is prepared. By using a 96-pin device, all samples may be WO 2004/080148 PCT/US2003/030720 109 spotted on one 8 x 12 cm membrane. Subarrays may contain 64 samples, one from each patient. Where the 96 subarrays are identical, the dot span may be 1 nm 2 and there may be a 1 mm space between subarrays. Another approach is to use membranes or plates (available from NUNC, Naperville, 5 Illinois) which may be partitioned by physical spacers e.g. a plastic grid molded over the membrane, the grid being similar to the sort of membrane applied to the bottom of multiwell plates, or hydrophobic strips. A fixed physical spacer is not preferred for imaging by exposure to flat phosphor-storage screens or x-ray films. The present invention is illustrated in the following examples. Upon consideration of 10 the present disclosure, one of skill in the art will appreciate that many other embodiments and variations may be made in the scope of the present invention. Accordingly, it is intended that the broader aspects of the present invention not be limited to the disclosure of the following examples. The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, and compositions and 15 methods which are functionally equivalent are within the scope of the invention. Indeed, numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the present preferred embodiments. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims. 20 All references cited within the body of the instant specification are hereby incorporated by reference in their entirety. 5.0 EXAMPLES 5.1 EXAMPLE 1 Novel Nucleic Acid Sequences Obtained From Various Libraries 25 A plurality of novel nucleic acids were obtained from cDNA libraries prepared from various human tissues and in some cases isolated from a genomic library derived from human chromosome using standard PCR, SBH sequence signature analysis and Sanger sequencing techniques. The inserts of the library were amplified with PCR using primers specific for the vector sequences which flank the inserts. Clones from cDNA libraries were spotted on nylon 30 membrane filters and screened with oligonucleotide probes (e.g., 7-mers) to obtain signature sequences. The clones were clustered into groups of similar or identical sequences. Representative clones were selected for sequencing.

WO 2004/080148 PCT/US2003/030720 110 In some cases, the 5' sequence of the amplified inserts was then deduced using a typical Sanger sequencing protocol. PCR products were purified and subjected to fluorescent dye terminator cycle sequencing. Single pass gel sequencing was done using a 377 Applied Biosystems (ABI) sequencer to obtain the novel nucleic acid sequences. 5 5.2 EXAMPLE 2 Assemblage of Novel Nucleic Acids The contigs or nucleic acids of the present invention, designated as SEQ ID NO: 1369 1966 were assembled using an EST sequence as a seed. Then a recursive algorithm was used to extend the seed EST into an extended assemblage, by pulling additional sequences from 10 different databases (i.e., Hyseq's database containing EST sequences, dbEST, gb pri, and UniGene, and exons from public domain genomic sequences predicated by GenScan) that belong to this assemblage. The algorithm terminated when there were no additional sequences from the above databases that would extend the assemblage. Further, inclusion of component sequences into the assemblage was based on a BLASTN hit to the extending assemblage with 15 BLAST score greater than 300 and percent identity greater than 95%. Table 7 sets forth the novel predicted polypeptides (including proteins), SEQ ID NO: 1967-2564, encoded by the novel polynucleotides (SEQ ID NO: 1369-1966) of the present invention, and their corresponding translation start and stop nucleotide locations to each of SEQ ID NO: 1369-1966. Table 7 also indicates the method by which the polypeptide was predicted. 20 Method A refers to a polypeptide obtained by using a software program called FASTY (available from http://fasta.bioch.virginiaedu) which selects a polypeptide based on a comparison of the translated novel polynucleotide to known polynucleotides (W.R. Pearson, Methods in Enzymology, 183:63-98 (1990), herein incorporated by reference). Method B refers to a polypeptide obtained by using a software program called GenScan for 25 human/vertebrate sequences (available from Stanford University, Office of Technology Licensing) that predicts the polypeptide based on a probabilistic model of gene structure/compositional properties (C. Burge and S. Karlin, J. Mol. Biol., 268:78-94 (1997), incorporated herein by reference). Method C refers to a polypeptide obtained by using a Hyseq proprietary software program that translates the novel polynucleotide and its complementary 30 strand into six possible amino acid sequences (forward and reverse frames) and chooses the polypeptide with the longest open reading frame.

WO 2004/080148 PCT/US2003/030720 111 5.3 EXAMPLE 3 Novel Nucleic Acids The novel nucleic acids of the present invention were assembled from sequences that were obtained from a cDNA library by methods described in Example 1 above, and in some 5 cases sequences obtained from one or more public databases. The nucleic acids were assembled using an EST sequence as a seed. Then a recursive algorithm was used to extend the seed EST into an extended assemblage, by pulling additional sequences from different databases (Hyseq's database containing EST sequences, dbEST, gb pri, and UniGene) that belong to this assemblage. The algorithm terminated when there was no additional sequences 10 from the above databases that would extend the assemblage. Inclusion of component sequences into the assemblage was based on a BLASTN hit to the extending assemblage with BLAST score greater than 300 and percent identity greater than 95%. Using PHRAP (Univ. of Washington) or CAP4 (Paracel), a full-length gene cDNA sequence and its corresponding protein sequence were generated from the assemblage. Any 15 frame shifts and incorrect stop codons were corrected by hand editing. During editing, the sequences were checked using FASTY and/or BLAST against Genebank (i.e., dbEST, gb pri, UniGene, and Genpept) and the Geneseq (Derwent). Other computer programs which may have been used in the editing process were phredPhrap and Consed (University of Washington) and ed-ready, ed-ext and cg-zip-2 (Hyseq, Inc.). The full-length nucleotide and amino acid 20 sequences, including splice variants resulting from these procedures are shown in the Sequence Listing as SEQ ID NO: 1-1368. The nucleic acid sequences of the present invention were confirmed to have at least one transmembrane domain using the TMpred program (http://www.ch.embnet.ora/software/TMPRED form.html). One of skill in the art will 25 recognize that the proteins of the present invention may be utilized as either a membrane bound target or a soluble protein. Table 1 shows the various tissue sources of SEQ 1D NO: 1-684. The homologs for polypeptides SEQ ID NO: 685-1368 that correspond to nucleotide sequences SEQ ID NO: 1-684 were obtained by a BLASTP version 2.Oal 19MP-WashU 30 searches against Genpept and Geneseq (Derwent) using BLAST algorithm. The results showing homologues for SEQ ID NO: 685-1368 are shown in Tables 2A and 2B. Using eMatrix software package (Stanford University, Stanford, CA) (Wu et al., J. Comp. Biol., Vol. 6, 219-235 (1999), http://motif.stanford.edu/ematrix-searcli/ herein WO 2004/080148 PCT/US2003/030720 112 incorporated by reference), all the polypeptide sequences were examined to determine whether they had identifiable signature regions. Scoring matrices of the eMatrix software package are derived from the BLOCKS, PRINTS, PFAM, PRODOM, and DOMO databases. Tables 3A and 3B show the accession number of the homologous eMatrix 5 signature found in the indicated polypeptide sequence, its description, and the results obtained which include accession number subtype; raw score; p-value; and the position of signature in amino acid sequence. Using the Pfam software program (Sonnhammer et al., Nucleic Acids Res., Vol. 26(1) pp. 320-322 (1998) herein incorporated by reference) all the polypeptide sequences 10 were examined for domains with homology to certain peptide domains. Tables 4A and 4B show the name of the Pfam model found, the description, the e-value and the Pfam score for the identified model within the sequence. Further description of the Pfam models can be found at http://pfam.wustl.edu/. Table 5 shows the position of the signal peptide in each of the polypeptides and the 15 maximum score and mean score associated with that signal peptide using Neural Network SignalP V1. 1 program (from Center for Biological Sequence Analysis, The Technical University of Denmark). The process for identifying prokaryotic and eukaryotic signal peptides and their cleavage sites are also disclosed by Henrik Nielson, Jacob Engelbrecht, Soren Brunak, and Gunnar von Heijne in the publication " Identification of prokaryotic and 20 eukaryotic signal peptides and prediction of their cleavage sites" Protein Engineering, Vol. 10, no. 1, pp. 1-6 (1997), incorporated herein by reference. A maximum S score and a mean S score, as described in the Nielson et al reference, was obtained for the polypeptide sequences. Table 6 correlates nucleotide sequences of the invention to a specific chromosomal 25 location when assignable. Table 8 shows the number of transmembrane regions, their location(s), and TMPred score obtained, for each of the SEQ ID NO: 685-1368 that had a TMPred score of 500 or greater, using the TMpred program (http://www.ch.embnet.org/software/TMPRED form.html). 30 Table 9 is a correlation table of the novel polynucleotide sequences SEQ ID NO: 1 684, their corresponding polypeptide sequences SEQ ID NO: 685-1368, their corresponding priority contig nucleotide sequences SEQ ID NO: 1369-1966, their corresponding priority contig polypeptide sequences SEQ ID NO: 1967-2564, and the US serial number of the WO 2004/080148 PCT/US2003/030720 113 priority application (all of which are herein incorporated in their entirety), in which the contig sequence was filed.

WO 2004/080148 PCT/US2003/030720 114 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: adult brain GIBCO AB3001 39-40 56 68 93 154-155 189 205 215 221 229 245 289-290 296 298 305 307 314 324 346 362 376 384 438 444 493 499 502 532 563 612 624 654 668 adult brain GIBCO ABDO03 10 13 15 17-20 27 29 34 40 47-49 56 61-63 66 68 75 80 82 86 93-94 96 98 102 106 137 150 154 156-159 161 168-169 173-174 179 188 205 210 212 215 221 229 231 243 245 290 296 302 305 307 313-315 319-320 323 325 331 346 349 352 359 362 367 371 376 384 420-421 428 438 444 447 461-462 473-474 487 493 499 516 519 522 523 529 532 541 550 563 587-588 601 612 616 624 627 635 643 652 654 660 669 672 673 677-678 adult brain Clontech ABR001 7 18 22 24 29 47 50 56 68 70 75 79 112-113 152 161 186 205-206 212 220 230 259-262 280 282 296 302 346 361 376 384 420 465 488-489 492 518 520 587 595 620-621 652 660 682 adult brain Clontech ABRO06 7-8 10 13 16 20-21 23 27 34 37 40 53 56 64-65 69-70 73 74 79 88-89 92 100 104-105 147-150 160-161 170 186 200 207 212 229 230 243 256 259 262 266 275-278 280 282-283 287 289-290 307 309 314-315 317-318 1_ 1321-322 325 337- WO 2004/080148 PCT/US2003/030720 115 TABLE 1 Tissue Oilgin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 338 349-352 357 359-360 364 377 384 430 447-448 461 466 484 499 501 503 518 520 530 532 542-546 552 556 562-563 569-571 600 607 616 620-621 623 625 628-629 641 642 653 660 672 673 677-678 682 adult brain Clontech ABRO08 7-8 10 14 19 21 23 25-28 30-33 37-39 43 46-50 52-53 56 57 59 62-65 67-68 73-76 86-89 92-94 104-105 118 131 134 139-140 144 147-148 150 153 154'160-165 170 180 186 189 205 206 208-212 218 219 223 229-230 232-234 236 242 245 249 259-263 266 268 270 273 283-289 293 298 302 305 307-308 313-316 318-324 334-335 337-341 343 346 349 351 356 359 361-364 367 371 377 381 384 387-388 390 403-404 419 423 425 431 435-436 438 440-441 445 451 462 473-475 484 493 498-501 504-506 509 512 514-522 525 527 529-530 532 534 543-545 550 558 562-564 569 576 583-584 591 597 599 601-602 605 607-610 620-621 624-625 627-628 631-632 638-640 652-653 660 663 665 670-671 adult brain Clontech ABRO11 289 384 537 adult brain BioChain ABRO12 26 384 607 adult brain BioChain ABR013 20 79 153 220 289 384 465 526 adult brain Invitrogen ABRO14 48-50 52 106 170 230 335 384 430 WO 2004/080148 PCT/US2003/030720 116 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 438 501 530 536 635 643 adult brain Invitrogen ABROS46 106 150 153 216 371 384 401 461 526 643 adult brain Invitrogen ABRO16 60 69 153 368 384 385 507 522 587 654 adult brain Invitrogen ABT004 10 16 24 29 43 47 49 56 60 64 67-69 73 79 97-98 165 168-170 179 186 189 205 230 242 247 249 259-263 289-290 296 298 305 308-310 314 315 319 329-330 332-333 349 359 380 384-385 387 388 390 428 451 456-457 475 487 490 492-493 499 500 512 519-520 522 529-530 587 612 620-621 643 654 663 665 cultured Stratagene ADPOO1 10 19-20 23 26 36 preadipocytes 68 70 106 116-117 147-148 165 171 172 189 220 246 247 256 273 289 305 316-319 329 330 349 351 361 365 392 394-398 400 423-424 428 451 465 487 499 507 522 529 534 543 587 643 672 673 682 adrenal gland Clontech ADR002 10 18 25 27 29 47 49 52-53 56 64 73 75 83 87 90 100 106 110 124 130 137 144 160-161 163 182 189 198 200 202-203 208 211-212 215 217 220 237-241 249 251 259-263 280 289-293 296 317 319 329-331 344 345 359 362 371 377 384 390 403 404 423-424 426 465 499-501 507 516 522 525 539 570 572-573 585 600-601 611 620- WO 2004/080148 PCT/US2003/030720 117 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 621 623-624 635 643 660 663 672 673 675 adult heart GIBCO AHROO1 5 16 18 24-26 34 37 39 46 56 64 66 68 75 77 83 86-89 92 94-97 101-102 104-106 110 134 150 154 158-159 162 168-170 194 196 202-203 212 215 224-226 229 269 289 296 302 306 308-309 314 320 323-324 331 336-338 342 346 356 367 371 377 378 384-385 390 400 402 417-418 421 428 431 436 438 447 461-462 475 479 484-485 491 498 501 507 516 518 522-525 530 532 534 541 554 564 570 572 573 586-587 601 605 607 610 613 614 635 643 652 662 669 672-673 adult kidney GIBCO AKDO01 5 10 12-13 16 18 20 24-26 29 39 43 52 54 56 62-64 66 68 71-72 75-76 83 89-96 98 106-109 112-114 116-117 122-126 131 137 139 155 158-159 162 170 172-174 177 183-184 188 200 202-203 205 208 215-216 218 219 229-230 245 247 256 268 272 275-278 289-290 296 298-299 302 308-309 314 316 319-320 323 329 330 332-333 336 350 359-360 364 367-368 371 377 384 392-393 400 402 420 423-424 428 431 435-436 438 444 451 461 473-474 484-486 492-493 499-500 504-507 510 516 WO 2004/080148 PCT/US2003/030720 118 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 518-519 521-522 524 526 529-530 532 534 537 539 541 567-568 587 588 613 620-621 623 631-632 635 643 652 654 664 668 672-673 adult kidney Invitrogen AKTO02 6 8 10 14-15 17 20 24-25 29 33-34 40 46-50 64 67 75 80 82 85 88 93-94 106 116-117 126 150 154 157 162-164 168-169 188 199 216-219 222 232 234 255-256 271 275-278 289 296 298 308 312 317 319 332-333 337 338 348 358 360 368 370-371 384 390 400 421 430 435 438 451 461 462 491-493 499 501 507 509 516 518 520 522 524 530 535-537 552 564 567-568 580 587 597-599 607 631-632 635 643 652 662 666 669 672-673 675 677 679 adult lung GIBCO ALGOO1 13 22 26 63 66 68 75 93 106 112-114 127-130 137 144 150 165 177 230 256 271 289 302 314 323 327 337 342-343 368 371 384 390 392-393 421 484 488-489 504-507 539 564 638-639 643 661 675 lymph node Clontech ALN001 13 26 33 54 56 128-131 135 150 166 173-174 202 203 211 215-216 256 259-262 289 320 327 350 367 368 371 465 507 509 526 643 669 young liver GIBCO ALVO01 5 10 13 24-25 43 44 56 67-68 71 80 82 89 106 110-111 132-133 137 154 WO 2004/080148 PCT/US2003/030720 119 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 168-170 179 183 184 205 218-219 221 229 275-278 296 302 320 367 371 390 428 438 487-490 498 502 507 525 530 538 635 641-643 651 666 adult liver Invitrogen ALVO02 5 14 16-17 19 24 25 37 52 64 66 68 80-82 87 90 93 97 98 104-105 132-133 137 140 150 170 183 186 188 215 218-220 229 232 234 249 256 272 275-278 289 294 295 311-312 314 319 332-333 351 358-359 364 366 371 377 381 386 387 392-393 428 449 451 465 487 489 495-498 518 522 538 593 601 607 610 631-632 643 666 adult liver Clontech ALVO03 7 18-19 24 38 46 180 186 216 220 222 249 275-278 371 390 427 465 495 499 530 538 623 627 632 666 679-620 adult ovary Invitrogen AOV001 5 7-8 10 12 14 16 18 20 25-27 29 33 36 38-40 47-49 53 54 56 59 61-62 64 67-68 73-76 79-83 87 89 92-94 96 98 106-107 111-114 116-118 121 128 131 134-135 137 139-142 150 153 154 157-161 171 177 179-180 182 187 189 194-198 200 202-203 205 206 211 218-219 222 229-230 235 241 245 249 251 254-256 259-264 267 272 282 289 290 296 298-299 302 305-306 308 311-314 316 320 323-325 327 331- WO 2004/080148 PCT/US2003/030720 120 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 333 336 342 346 347 349-351 358 362 367-368 371 377 380 383-384 390 392-393 400 402 420-423 425 427-428 435-436 438 444 451 454 459-462 471 473 474 484 487-489 491 493 498-499 501-502 504-507 511 516 518 521 522 524 530 532 539 543 547-550 555-556 564-565 581 587 593 595 602 605 607 616 620-621 623-624 631-632 635 643 652-654 660 667 669 679-680 adult placenta Clontech APLOO 1-4 63-64 66 143 145-146 178 211 216 289 296 323 351 384 537 630 placenta Invitrogen APL002 1-4 7 51 68 85 98 151-152 192 208 215 256 259-262 305 319 332-333 384 428 499 533 602 627 654 666 adult spleen GIBCO ASPOO1 7 13-14 17 26 32 52 54 56 63 75 89 106 109 112-115 120 135 137 141 142 144 154 157 173-174 179-180 186 205 208 216 220-222 229 252 256 259-262 272 279 289 296 298 302 308 312 319 320 337-338 347 364 367-368 371 384 400 427 438 451 459-461 465 484 487 500 504 507 522 525-526 530 534 555 587 593 617-618 631 633 635 638-639 643 663 669 675 676 679 adult testis GIBCO ATS001 5 10 19 29 39 64 68 93 100 106 116 117 137 145-146 150 153 172 175- WO 2004/080148 PCT/US2003/030720 121 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 176 181-182 198 202-203 229 249 256 267 289 296 298 302 305 307 308 314 316 323 331 356 359 362 364 371 384 402 426 43B 451 485 500 507 518-519 591 597-599 619 621 643 654 662 adult bladder Invitrogen BLDOO1 5 10 26 51 65 68 84 89 93 131 175 176 211 256 259 262 267 289 314 317-318 332-333 351 383-384 395 398 423-424 426 499 501 522 525 580 593 643 661 682 bone marrow Clontech BMD001 5 7 30-31 34 37 40 47-49 54-56 62 68 75-80 83 93 96 100 131 136 147-148 150 158-159 163 165 172 177 198 204 206 211 216 229 289 302 308 316 319-320 324 325 337-338 350 358 364 367-368 371 400 422 428 438 452 454 461 478 484 487 491 499-502 507 509 510 520 530 536 537 541 543 554 587 624 638-639 643 651-652 654 667-669 672-673 bone marrow GF BMD002 7-8 12 14 17 20 25 27-28 32-33 37 43 52 57 63-64 66-68 77 87 100 102 106 107 112-114 116 118 120 131 136 137 144 147-148 150-153 157-159 163 172 179 199 206 215-216 222 256 259-263 268 272 275-278 286 289 298 302-303 305 308 317-318 325 337-338 341 343 347-348 368 371 390 400 427- WO 2004/080148 PCT/US2003/030720 122 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 428 430-431 434 435 437 444 451 461-462 488-489 491-492 499 501 502 504-507 509 511 516 520 525 526 530 537 543 554 558 560-561 585 587 595 600 610 623 629 631 633 635 638-640 643 667-669 672 673 679 bone marrow Clontech BMD004 507 522 bone marrow Clontech BMD007 368 504-506 672 *Mixture of 16 Various Vendors CGdO1O 99 132-133 165 tissues - mRNA 237-241 275-278 290 298 306 336 368 380 402 423 424 509 556 586 610 *Mixture of 16 Various Vendors CGdO11 33 42 153 168-169 tissues - mRNA 178 213-214 245 247 467 526 537 572-573 675 *Mixture of 16 Various Vendors CGd012 5 14 18 21 24 31 tissues - mRNA 33 35 39 42 44 46 51 53 58 61-62 70 72 75 80 84-85 90 92-93 96 98 100 103 127 131 144 146 153-154 157 160-161 163 165 168-169 175-176 178-179 183 185 189 193 200 218 219 221 229 232 234 245 247 256 259-262 275-278 280 289-292 298 300-301 308 311 317-318 325 335 338 342 344-347 349 352 355-356 359-360 368 370 375 380 384-386 388 391 394-399 401-402 405-407 410 412-413 419 428 450-451 464 467-469 471 504 507 512 516 518 524 526 532 537 541 545 547-549 554 556 563-564 572-573 586 590 591 600 602 605 1623-625 627-628 WO 2004/080148 PCT/US2003/030720 123 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 652 654 659-660 664 667 670-671 676 682 *Mixture of 16 Various Vendors CGd013 56 58 61-62 70 131 tissues - mRNA 160-161 163-164 193 247 290 311 345 348 360 368 370 394-398 512 537 556 660 682 *Mixture of 16 Various Vendors CGd015 1-5 8 14 17 52 59 tissues - mRNA 68 87 215 228 259 262 272 275-278 289 309 371 377 392-393 400 402 420 446-447 451 492 498 504-506 514 521 537-538 588 620-621 637 643 654 672-675 *Mixture of 16 Various Vendors CGdO16 10 14 19 24-28 33 tissues - mRNA 57 65 70 76 112 114 121 131 151 153 163 183 206 218-219 325 328 332-333 394-398 435 440-441 488 489 500 510 518 520 532 569 590 641-643 653 662 663 668 671-673 682 adult colon Invitrogen CLN001 5 10 14 29 35 47 50 56 112-114 135 175-176 179 220 230 254 256 289 290 308 332-333 343 368 371 385 386 415 427-428 436 465 498 510 518 534 572-573 580 597-599 607 643 651 661 663 669 adult cervix BioChain CVX001 7 10 14 16 18 20 23-26 30-31 40 47 49 56 62 66 70 73 76 83 85 87 89 93 94 97 103 106 126 131 137 141-142 144 147-148 154 175 177 179 182 188-189 197-198 202-203 206 211 221 229 245 249 259-263 267 282 287 289 296 298 302 305 308 314 320 323-325 329- WO 2004/080148 PCT/US2003/030720 124 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 333 350 356 358 362 367-368 371 377 382 384 390 400 438 451 454 459-460 462 465 484 487-490 492 493 499-502 507 516 522 524-525 530 532 534-535 541 550 555 572 573 580 587 602 605 610 613-614 616 623-624 626 628 643 652 661 663-664 668 680 682 diaphragm BioChain DIA002 93 134 308 402 endothelial Stratagene EDTOO1 7 10 12 17 19 23 cells 29 34 36 39 52 54 56 63-64 66 68 75 80-84 86-89 92-93 95-97 106-107 116 117 127 131 137 139 147-148 150 154 157-159 168 169 172 179 182 192 198-199 202 203 208 211 215 217 220-221 230 234 249 254 256 259-262 264 270 272 289-290 296 298 313-314 316 320 323-324 348 350 364 367 371 376-377 390 392 430 435 438 445 446 465 473-475 484 487-489 492 498-499 502 504 507 510 518 522 524 532 541 543 552 554-555 587 588 595 602 610 631-632 643 651 654 662 668-669 672-673 fetal brain Clontech FBR001 8 24 54 56 59 69 88 229 384 428 440-441 541 628 671 fetal brain Clontech FBR004 20 53 160-161 170 293 385 461 530 605 620-621 654 660 fetal brain Clontech FBROO6 7-8 10 15 18-19 24-26 29 33 46 53 56 59 62-64 66 68 WO 2004/080148 PCT/US2003/030720 125 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 70 73 79 84 87 131 140,147-148 155 163 165 170 179 180 189-190 208 211 218-219 229 230 232-234 236 245 249 259-262 267 284-287 293 298 305 308 313 314 316-319 322 324 337-338 343 346 350-351 354 359-362 376 380 381 384 387-398 403-404 423-424 428 431 435 438 440-441 445-447 451 462 473-475 484 492 498-501 504-507 509 512 516 518-519 521 522 529-530 532 541 543 550 554 558 566 568-570 576 591 597-599 603 605 607-609 623-625 627-632 640 643 652-653 662-663 665 667 671-673 675 682 fetal brain Clontech FBRs03 17 371 fetal brain Invitrogen FBT002 7 10 29 43 47-49 52 60 64-65 67-68 79 83 86 92 94 131 139-140 168-169 180 202-203 205 218-219 230 242 243 259-262 289 296 298 302 305 307 319 329-330 332-333 364 380 390 392-393 451 473-474 484 492 499-500 518 520 537 553 607 619 643 654 fetal heart Invitrogen FHR001 8 14-15 20 24-26 34 37 39 46 53 56 57 60 63 70 75 80 82 96-98 101 106 120 127 131 134 153 161 168-169 171 180 202-203 216 229 236 266 267 289-290 303 305 308 314 316 325 344-345 356 I_._....__ ._... 358-359 363 366 WO 2004/080148 PCT/US2003/030720 126 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 371 384 392-393 395-398 400 402 419 422 431 434 436 438 451 453 461-462 478 484 500 504-506 518 522 525-526 530 535 537 539 541 550 570-573 586 588 590-591 597 601 605 610 613 614 626 630-632 640 643 652 669 672-673 675 682 fetal kidney Clontech FKDO01 26 62 96 106 115 150 153 217-219 259-262 289 308 323-324 350 371 428 435 507 522 537 643 fetal kidney Clontech FKDO02 46 54 64 68 85 107-108 126 131 155 158-159 163 164 167-169 188 224-226 229 232 234 236 245 282 284-285 289-290 293 298 340-341 343 350 370 417 418 431 436 438 461 484 499-500 516 518 532 567 568 572-574 589 596-599 613 624 626 628 640 671 673 fetal kidney Invitrogen FKDO07 227 fetal lung Clontech FLGOO1 25 40 56 75 93 106 112-114 131 229 316 428 436 484 499 572-573 623 fetal lung Invitrogen FLG003 5 7 10 16 22 25-26 44 47-50 57 75 79 102 106 148 157 175-176 189 191 256 259-262 314 356 359 371 384 399-400 423-424 428 430 451 488 490 500 504-507 518 529-530 534 539 550 556 620 621 fetal lung Clontech FLGO04 305 fetal liver- Columbia FLSO1 1-5 7-8 10 12 14 spleen University 17 19-20 24-27 29 54 56-57 62-64 68 71 75 80-83 85 87- WO 2004/080148 PCT/US2003/030720 127 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 97 99-100 104-107 109-110 131 137 141-142 150-153 155 168-169 177 180 183-184 188 198 200 202-203 205 208 212 215 220 222 229 245 251-252 256-262 264 267 271-273 275-279 289-290 296 298 302 306 308 314 316-318 320 324-325 331 333 337-338 349 352 359 364 366 368 371 377 383 386-387 390 392 393 400-401 403 404 420-421 423 424 428 434-435 438 440-441 445 446 451 455-457 459-462 475 479 481 484 487 491 492 498-507 510 511 516 518 521 524 526 530 533 536-538 541 543 550 554-556 558 588 593 595-598 601-602 605 607 610 613 620-621 623-624 629 634 641-643 651-652 667-668 671-673 675 681 fetal liver- Columbia FLS002 2-5 7-8 10 12 14 spleen University 17 19 24 26-27 34 36 38 40-42 44 47 49 52-54 56-57 62 64 66 68 71 75-76 80-83 85-86 88-89 91-93 96 98-100 106-108 110 112 113 115-117 128 131 135 137 139 142 150 153 157 159 163 171-174 179 183-184 186 188-189 192 198 200 202-203 206 208 212 216 218 220 229-230 236 241 245 249 252 256-262 275-279 290 294-295 298 1302 305-306 308 WO 2004/080148 PCT/US2003/030720 128 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 312-314 316-320 324-325 327 335 337-338 342 349 350 357-360 366 368 376-379 387 390 400 419-420 426 428 434 436 438 440-441 444 456-457 459-462 478 481-482 486 492 498-499 501 504-506 508-509 516 518 521-522 527 530 534 536 537 543 554-555 564 581 587-588 595 597-598 601 605 610 613 620 621 623-625 627 629 631-632 634 641-643 651-652 662 666-668 671 673 675 683 fetal liver- Columbia FLS003 2-5 14 18 20 24 26 spleen University 44 62 64 68 80-83 88 93 99-100 106 137 153 157 163 183 197 222 229 236 245 256 275 278 289 298 306 315-318 331 337 338 346 350 359 366 371 419-420 428 436 438 491 492 502 507 518 521-522 530 538 543 555-556 593 623-624 652 667 672-673 679 fetal liver Invitrogen FLVO01 5 10 24 46 52 64 67-68 157 168-169 180 202-203 211 216 218-219 222 237-241 256 259 262 272 275-278 317-318 321 324 332-333 342 347 351 371 401 421 428 434 451 488 490 498 593 623 643 679 fetal liver Clontech FLVO02 10 24 140 153 170 230 249 256 275 278 284-285 325 358 366 392-393 500 518 538 576 577 613 623 641 S642 666 WO 2004/080148 PCT/US2003/030720 129 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: fetal liver Clontech FLV004 5 13-14 18 20 24 35 46-50 56 63-64 68 75 100 102 106 108 116-118 137 140 144 147-148 170-172 218-219 236 256 259-262 275-278 318 323 325 329-330 340 341 356-357 371 390 428 431 436 438 440-441 453 461-462 498-499 518 530 537-538 543 587-588 623 629 632 638-639 643 651-652 662 666 671-673 fetal muscle Invitrogen FMSO01 5 16 24-26 64 93 139 144 168-169 171 175-176 181 202-203 212 218 219 256 289-290 296 298 317-318 349 356 364 371 377 380 392-393 402-404 427 444 518 523 564 586 623 661-662 fetal muscle Invitrogen FMS002 6 15-16 21 26 29 37 41 52 57 75 87 96 101-102 106 116-118 131 158 159 167-169 171 180 189 256-258 272 289-290 293 298 306 308 316 325 332-333 343 351 353 356 380 382 388 400 402 411 416 419 428 429 431 453 499 516 522 525 530 532 541 543 550 563 565-568 572 573 584 586 603 613 623 643 662 663 fetal skin Invitrogen FSK001 5 7-8 10 14-17 20 23 25-26 29 36-37 39 41 46 51 53 68 70 80-82 84 86 90 92-93 96 111 127 130 132-133 141 142 147-148 151 152 158-161 163 165 173-174 202 203 205-207 218- WO 2004/080148 PCT/US2003/030720 130 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 220 224-226 229 230 245 254 256 262 289-290 296 298 302 305 308 309 315-316 319 324-325 327 358 359 364 369 371 388 392-393 400 405-413 417-418 436 438 440-441 451 45B-465 467 472 476 487 492 499 518-520 525 530-532 547-549 558 564 571 580 583 591 607 610 617-618 620-621 623 627 643 652 659-663 671-673 680 682 fetal skin Invitrogen FSK002 5 10 16 18 20 23 26 36-37 39 41 46 52-53 56 61-65 68 70 80-83 87 94 96 100 130-131 148 158-159 162-164 168-169 182 188 193 201 220 224 226 229 235-241 245 249 254 257 262 289-290 293 298 302 316 318 325 331-333 335 340-341 350 359 361 363-364 371 390 392-398 400 403-404 408-409 411 417-418 422 428 431 436 440 441 451 453..462 464-465 467 471 476 478 484 499 502 504-506 512 516 518 521-522 530 532 541 543 547-549 556 564 565 568 587 589 591 593-594 597 598 613-614 616 624-625 629 631 632 637 640 643 652 662 667 669 671-673 681-682 fetal spleen BioChain FSPOO1 26 87 371 461 667 umbilical cord BioChain FUC001 5 18 20 26 40 47 49 70 72 83 86-87 93 96 106 110-111 S116-117 124 126- WO 2004/080148 PCT/US2003/030720 131 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 127 134 144 152 153 155 157-159 161 165 171 182 206 218-219 224 226 229 243 247 249 256 259-262 289 296 298 303 305-306 308 314 316 325 332-333 337-338 344-345 349 352 359 364 371 394-398 400 417-421 427 431 436 438 453 473 474 477 479 499 500 507 512 522 525 535 537 565 593 595 613 620 621 623-624 637 643 653-654 660 661 668-669 682 fetal brain GIECO HFBOO1 5 10 18-21 27 34 38-40 47-49 52 56 60 62 64 66-70 72 76 80 83 86 92-93 134 139 141-142 149-150 155 170 172 179-180 185 186 188 202-203 205 207 209-212 216 229-230 256 286-287 289 294 296 298 314 319 320 323 325 337 338 346 350 357 367 371 376 381 384 420 436 438 444 447 454 459 462 475 484 487 492-493 499-500 507 518-519 522 529-530 532 534 541 543 563 570 571 580 597-598 601 607 616 619 621 623-624 643 653-654 662 664 668 671-673 675 677-678 682 macrophage Invitrogen HMP001 18 26 43 64 118 144 179 211 245 329-330 347 371 427 435 461 502 530 537 620-621 635 638-639 infant brain Columbia ID2002 7 14 16-17 21 23 University 25-26 29 40 47-50 56-57 59-60 64 67- WO 2004/080148 PCT/US2003/030720 132 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 68 70 73-74 79 83 88 91-92 94 98 103 115 127 137 139 150-152 156 158 159 161-163 173 174 182 186 188 189 197 202-203 205-215 230 245 259-262 264 268 280 285 289 296 298 305 307-308 313-316 319 322 324 326 334 346 347 349-351 359 363-364 367 371 376-377 390 420 431 436 438 444 447-449 451 453 461-462 479 487 492 498-501 504 506 516 519 522 529-530 537 541 543 545 556 564 572-573 588 592 593 597-598 600 604-605 607 610 619 622 624 627 628 643 652-654 660 663 674-675 682 infant brain Columbia IB2003 7 10 16 19-20 25 University 29 35 43 46-50 56 57 59-60 64 68 70 79-82 87 92 106 139 150 158-159 162-163 165 173 174 181 196 189 202-203 205 210 214 229-230 245 256 259-263 289 290 298 305 307 308 314-315 319 322 328 334 337 338 347 349 351 359 364 371 380 385 428 436 438 444 447 449 451 462 475 484 487 492-493 498-502 519 522 529-530 532 537 540 550 556 593 602-605 607 616 622 627 631-632 643 652 654 663 672-673 682 infant brain Columbia IBM002 47-50 84 151-152 University 157 188-189 209 WO 2004/080148 PCT/US2003/030720 133 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 289 390 423-424 453 628 infant brain Columbia IB001 10 16 29 46-50 56 University 58 67 78 80-82 156 163 186 259-262 285 305 315 334 349 452 488-489 522 532 540 lung, Stratagene LFBOO1 5 7 16 19 40 54 56 fibroblast 61-62 68 83 93 106 116 121 137 172 191 198 205 223 256 289 325 329 349 371 400 438 484 501-502 507 518 522 525 532 541 610 631-632 643 651 669 lung tumor Invitrogen LGTO02 5-7 10 15-16 18-19 26 29 34-36 38 40 41 46-50 52 56 59 64 68 75 86 89 91 96 103-106 112-114 116-117 120 128 130 135 141-142 144 147-148 150 154-155 157-159 162-164 172-174 179-180 190-192 198 202-203 208 215 220-221 223 229 236 249 255 258 263 271 275 278 284-285 291 292 296 302 309 314 316 319 323 327 331 342 349 351 353 358 364 368-369 371 390 392-393 399-400 420-421 427 431 436 438 444 453 454 459-462 465 470 484 486 488 492 499-500 502 507 511 518 522 525-526 530 537 539 543 550 580 597-599 605 623 625 627 637 643 652 661-662 665 666 lymphocytes ATCC LPCO01 13 16 18 20 27 43 47-49 54 62-64 66 68 80 87 90 96 98 115 118 120 131 144 163 202-203 211 252 256 259- WO 2004/080148 PCT/US2003/030720 134 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 262 265 290 296 308 324-325 347 350 358 371 377 384 400 420 428 436 462 467 470 483-487 499-502 504-507 509 518 522 525 530 543 545 550 588 600 605 607 624-625 633 635 643 645 654 669 672-673 675 leukocyte GIBCO LUCOO 10 16 18 24 34 38 40 43-44 47-50 52 54-57 62-64 66 68 78 80-82 86-89 93 94 98 106 109 111 120 131 134 137 139 144 150-152 154 163 165 177 179 186 189 198 202-203 208 211 218-219 221 229 236 247 249 252 256 259-264 270 275-278 289-290 298 302 305 308 315 317-318 323 325 328 337-338 342 347 350 358 364 368 371 390 392-393 421 427 428 430 433-435 437-438 440-441 444 451-452 454 461 475 484-487 491 493 498-500 502 504-507 509 518-519 522 525 526 530 535 541 543 550 555 586 588 597-598 605 607 610 620-621 624 627 631-633 638-639 643 652 654 668-669 672 673 675-676 leukocyte Clontech LUC003 20 47-49 52 56 100 112-114 198-199 314 337-338 348 371 438 484 502 530 537 602 633 643 melanoma from- Clontech MEL004 14 25 34 47-49 56 cell-line-ATCC- 64 66 83 92 106 #CRL-1424 111 131 134 137 139 150 162 173- WO 2004/080148 PCT/US2003/030720 135 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 174 189 192 210 229 249 259-262 290 321 337-338 350 364 371 392 393 438 440-441 444 475 493 499 507 554 587 643 651 667 669 671 mammary gland Invitrogen MMG001 5 7 10 16-17 19 25 46-53 56 64 68 70 79-82 85-86 89 92 95 98-100 106 121 127 137 139-142 144 150-152 158 159 161-164 180 189 192-193 198 202-203 205-206 216 218-220 230 245 249 252 259 263 267 270-272 275-278 289-290 298 302 305 308 313 315 319 324 329-330 336 346 349 351 355-356 359 364 368 370 371 377 384 390 392-393 421 425 427-428 436 444 451 455-460 462 465 473-474 487 492 499 502 507 516 518 524-526 529-530 533-534 539 543 583 590 592 602 605 613 623 627 631-632 643 646 660 677 678 682 induced neuron- Stratagene NTDOO1 17 20 23 68 79 89 cells 153 155 181-182 212 218-219 235 298 346 352 358 376 438 478 484 488-489 492-493 499-501 541 570 619 627 643 662 672-673 retinoic acid- Stratagene NTRO01 7 23 56 68 70 131 induced- 186 189 213-214 neuronal-cells 290 293 342 461 499 504-506 530 601-602 607 682 neuronal cells Stratagene NTUO01 7 29 42 68 70 84 85 92 131 140 147 148 202-203 259 262 305 316 319 336 371 395-398 WO 2004/080148 PCT/US2003/030720 136 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 461 493 499 502 537 550 553 592 652 672-673 682 pituitary gland Clontech PIT004 2-4 47-49 56 68 72 93 137-138 141-142 150 154 158-159 177 182 192 221 229 272-273 290 298 308 316 325 329-331 342 346 356 360 436 459 460 462 473-474 484 504-507 524 532 534 541 543 564 623 631-632 635 643 662 placenta Clontech PLA003 1-5 7 12 26 37 41 53 64 75 85 87 96 106-107 112-114 131 151-152 157 223 236 256-262 303 306 316 335 350-351 359 371 400 428 431 435 438 445-446 462 499 502 516 520 530 532 537 543 550 556 565 579 587 594-595 626 635 638-639 prostate Clontech PRT001 20 25 56 173-174 205 250 256 280 284-285 299 302 309 320 323-324 331 342 349 362 367 384 386 392 400 415 438 484 498 507 524 532 534 590 620-621 623 631-632 654 677-678 680 rectum Invitrogen RECO01 7 10 20 47-50 52 85-87 89 109-110 126 128-130 157 163 170 173-174 177 205 220 229 256 259-262 289 319 324 327 340 341 347 364 368 371 377 415-416 423-424 427 436 465 504-506 581 582 602 610 679 salivary gland Clontech SAL001 5 10 22 25 43 52 63-64 67 89 95 97 99 137 140 161 165 167-169 180 205 229 252 256 290 WO 2004/080148 PCT/US2003/030720 137 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 323 351 368 371 430 436 438 487 502 507 516 525 564 580 613 617 618 631-632 saliva gland Clontech SALs03 20 skin fibroblast ATCC SF3001 208 skin fibroblast ATCC SF3002 208 small intestine Clontech SIN001 5 7-8 10 15 24 26 37-38 47-49 51-54 56-57 59 64 67-68 72 75 88 93 96-97 100 106 108 111 116-117 121 128 131 137 140 153 158-159 177 189 191 202-203 206 215 229 253 255 256 259-262 264 265 272 280 296 300-301 308-309 316-318 325 327 332-333 335 337 338 344-345 347 352 359 368 371 386 390 392-393 423 431 435 438 444 462 479 484 492 507 509 522 525-526 532 534 550 572-573 581 593 605 620-621 623 628 632 643 650 652-654 672 673 skeletal muscle Clontech SKM001 5 62 101 104 134 165 254 272 289 300-301 308 316 323 356 377 402 428 431 438 444 451 462 541 543 550 572-573 5B6 skeletal muscle Clontech SKM002 208 507 spinal cord Clontech SPCO1 13 15 26-27 33-34 38-40 46-50 52-53 56 68 80-82 87 89 92-95 131 150 155 163 175-176 180 186 197 199 202 203 205 211 213 214 229 231 235 254 263 289 307 311 314-316 323 324 329 340-342 348-349 352 359 364 371 384 400 438 451 484 493 500 507 509 511 WO 2004/080148 PCT/US2003/030720 138 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 516 522 525 530 532 537 562-563 567-568 580 595 597 603 607 610 612-613 616 620 622 627 643 653 672-673 675 677 678 adult spleen Clontech SPLcOl 7 9 13 17 26 37 43 64 75 106 112-114 118 131 163 212 216 218-219 256 259-262 308 314 329-330 349 368 390 392-393 422 424 427 431 435 436 451 453 484 500-501 509 525 530 532 535-536 541 592 600 G10 613 623 628 631 632 635 645 654 663 668 672-673 679 bone marrow null STM001 7 43 162 252 256 305 371 427 438 530 607 651 658 stomach Clontech STO001 67 93 95 135 230 259-262 284-285 289 302-303 308 320 323 390 392 393 420 428 436 484 507 524-525 530 536 587 631 632 637 thalamus Clontech THAO02 10 18 24 33 47-50 54 58 60 68 90 92 93 98 100 102 160 161 180 205 208 229-230 242 259 262 272 296 302 305 325 331 342 359 384 386 390 425 511 532 543 572-573 587 602 608-610 612 616 620-621 631-632 660 thymus Clontech THMOO1 5 12 39-40 43 47 50 54 56 66 68 70 79 87-88 93 106 107 131 135 144 162 173-174 177 192 198 205 211 218-219 229 256 281 289-290 293 306 308 314 317 1__ 1318 321 323 325 WO 2004/080148 PCT/US2003/030720 139 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name SEQ ID NOS: 331-333 347 349 352 368 371 384 389 420 425 438 440-441 484 487 493 498-499 502 509 530 532 541 554-555 558 597 599 610 613 616 620-621 624 643 671-673 682 thymus Clontech THMc02 5 8 10 12 25 32 34 37 39 43 45-46 48 50 53 55-56 61 63 65-67 70 83 85 87 88 94 106-107 112 114 116-118 120 131 135 140-142 144 150-152 158 159 163-165 179 189 208 229 232 234 256 259-262 273 289-290 302 305 316-318 324 325 335 349 361 363-364 371 384 389 392-393 421 424 437-441 443 445-446 451 459 461 473-474 498 500 504-507 509 518 522 526 530 541 554 564 583 592 600 607 610 613 624-625 627 630-632 634 637 643-645 651 667 669 671-673 682 thyroid gland Clontech THR001 6 14-15 19 26 29 32 34 39-40 47-52 56 61-63 66-68 72 75 87 93 95 100 104-106 115 128 131 137 141-142 154 157 162 165 168-169 175 177 182 189 191-193 202-203 211 217 219 221 229 231 234 249 254 256 282 289-290 298 302 306-308 314 318 323-324 327 329-330 342 350 353-358 368 371 377 380 383-384 400 423-424 426 431 436-438 440 441 446 451 459- WO 2004/080148 PCT/US2003/030720 140 TABLE 1 Tissue Origin Library/RNA Source HYSEQ Library Name ' SEQ ID NOS: 461 475 478 484 487-489 491-492 499-500 502-506 509 518-519 521 522 530 532-533 541 543 567-568 586 588 597-600 605 607 610 617 618 620-621 624 626 631-632 635 643 651 654 662 668 671-672 680 trachea Clontech TRC001 7 22 38 40 56 68 83 94 229 259-262 289 296 298 360 371-375 438 484 499 511 521 541 571-573 588 613 624 627 uterus Clontech UTROO1 17 36 70 76 103 106 109 112-114 131 150 157 179 180 189 290 296 308 314 320 329 330 356 364 366 368 390 395-398 415 438 447 507 509 519 525 529 532 564 620-621 631-632 662 668 669 682 *The 16 tissue/mRNAs and their vendor sources are as follows: 1) Normal adult brain mRNA (Invitrogen), 2) Normal adult kidney mRNA (Invitrogen), 3) Normal fetal brain mRNA (Invitrogen) , 4) Normal adult liver mRTA (Invitrogen) , 5) Normal fetal kidney mRNA (Invitrogen) , 6) Normal fetal liver mRNA (Invitrogen), 7) normal fetal skin mRNA (Invitrogen), 8) human adrenal gland mRNA (Clontech), 9) Human bone marrow mRNA (Clontech), 10) Human leukemia lymphoblastic mRNA (Clontech) , 11) Human thymus mRNA (Clontech), 12) human lymph node mRNA (Clontech), 13) human so\spinal cord mRNA (Clontech), 14) human thyroid mRNA (Clontech), 15) human esophagus mRNA (BioChain), 16) human conceptional umbilical cord mRNA (BioChain).

WO 2004/080148 PCT/US2003/030720 141 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 685 gi183150 Homo sapiens chorionic somatomammotropin CS-5 320 100 685 gil81127 Homo sapiens chorionic somatomammotropin precursor 275 96 685 gi183153 Homo sapiens chorionic somatomammotropin CS-2 275 96 686 gil83178 Homo sapiens hGH-V2 1033 78 686 gi183153 Homo sapiens chorionic somatomammotropin CS-2 710 | 87 686 gi387024 Homo sapiens placental lactogen hormone precursor 710 87 688 gil83178 Homo sapiens hGH-V2 1051 79 688 gi181121 Homo sapiens chorionic somatomammotropin 788 95 688 gi18315_1 Homo sapiens chorionic somatomammotropin CS-I 788 95 689 gi12653501 Homo sapiens Similar to shrine (or cysteine) proteinase 1242 99 inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor). member 1 689 gi15217079 Homo sapiens pigment epithelium-derived factor 1242 99 689 gi189778 Homo sapiens pigment epithelial-differentiating factor 1242 99 690 gil7128288 synthetic Primer 1 1150 99 construct 690 gi20269957 Sus scrofa phospholipase C delta 4 1033 88 690 gi21307610 Mus musculus phospholipase C delta 4 909 77 691 gil7864023 Homo sapiens KCCR13L 3524 100 691 gi21483462 Drosophila LD44686p 533 36 melanogaster 691 gi21741717 Oryza sativa oj991113_30.22 127 29 692 gil7428818 Ralstonia GALA PROTEIN 3 117 32 solanacearum 692 gi21536497 Arabidopsis F-box protein family, AtFBL4 115 30 thaliana 692 gil2581504 Trypanosoma GUI 115 33 brucei 693 gi437662 Oryctolagus interleukin-8 receptor subtype B 194 61 cuniculus 693 gil86378 Homo sapiens interleuldn 8 receptor B 178 57 693 gil 109691 Homo sapiens interleukin-8 receptor type B 178 57 694 gi3335098 Homo sapiens CD39L2 2520 100 694 gil 1230487 Rattus NTPDase6 2065 86 norvegicus 694 gi5139519 Mus musculus nucleoside diphosphatase (ER-UDPase) 1008 53 695 gi21928620 Homo sapiens seven transmembrane helix receptor 1858 100 695 gi16566319 Homo sapiens G protein-coupled receptor 1843 99 695 gi6644328 Rattus orphan G protein-coupled receptor 822 50 norvegicus GPR26 696 gi7110216 Homo sapiens C-type lectin-like receptor-1 851 99 696 gi7109731 Homo sapiens C-type lectin-like receptor-2 256 31 696 gi20381202 Mus musculus Similar to C-type (calcium dependent, 196 27 carbohydrate recognition domain) lectin, superfamily member 12 697 gi22449809 Chaoborus cytochrome oxidase I 50 44 trivitattus 697 gi2351328 Newcastle fusion protein 59 44 disease virus 697 gi21311450 Galleria i antifungal peptide gallerimycin 55 33 mellonella 698 gil8089247 Homo sapiens Similar to ectonucleoside triphosphate 2104 100 diphosphohydrolase 5 WO 2004/080148 PCT/US2003/030720 142 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 698 gi3335102 Homo sapiens CD39L4 2104 100 698 gil5076827 Homo sapiens Pcph proto-oncogene protein 2090 99 699 gi151242 Pseudomonas heat shock protein 79 38 aeruginosa 699 gi9950616 Pseudomonas GroES protein 79 38 aeruginosa 699 gi2564287 Pseudomonas Hsp10 protein 79 44 stutzeri 701 gi20521055 Homo sapiens Start codon is not identified 724 32 701 gil7225457 Homo sapiens autism-related protein 1 676 32 701 gil5145797 Sus scrofa basic proline-rich protein 156 27 702 gi20810589 Homo sapiens similar to arsenite inducible RNA 833 99 associated protein 702 gi9651711 Mus musculus arsenite inducible RNA associated protein 687 80 702 gil7390981 Homo sapiens Similar to RIKEN cDNA 1110060018 535 59 gene 703 gi6624130 Rattus similar to 45 kDa secretory protein; 2150 100 norvegicus 703 gi13241652 Rattus supernatant protein factor 2040 93 norvegicus 703 gil9548982 Bos taurus tocopherol-associated protein 1930 90 704 gil3177766 Homo sapiens Similar to presenilins associated 1761 99 rhomboid-like protein 704 gil5559382 Homo sapiens presenilins associated rhomboid-like 1094 98 protein 704 gi7959883 Homo sapiens PR02207 671 82 705 gil864091 Rattus PSD-95/SAP90-associated protein-3 5005 95 norvegicus 705 gi24545 10 Homo sapiens PSD-95/SAP90-associated protein-2 1338 55 705 gi6979173 Homo sapiens discs, large (Drosophila) homolog- 1011 45 associated protein 2 706 gil1877274 Homo sapiens dJ726C3.2 (novel protein) 2260 99 706 gi21667210 Homo sapiens bactericidal/penneability-inereasing 2260 99 protein-like 1 706 gi20387087 Oncorhynchus LBP (LPS binding protein)/BPI 349 26 mykiss (bactericidal/permeability-increasing protein) like-2 707 gi7291716 Drosophila CG11388-PA 648 39 melanogaster 707 gi16768190 Drosophila GH22974p 647 39 melanogaster 707 gi3954938 Homo sapiens acetylglucosaminyltransferase-like 171 23 protein 708 gil4334082 Mus musculus thymus LIM protein TLP-A 479 87 708 gil4334084 Mus musculus thymus LIM protein TLP-B 397 79 708 gi487284 Rattus CRP2 (cysteine-rich protein 2) 367 75 norvegicus 710 gi556299 Mus musculus alpha-2 type IV collagen 8129 83 710 gi30076 Homo sapiens alpha-2 chain precursor (AA -25 to 1018) 5916 100 (3416 is 2nd base in codon) 710 gil5991848 Homo sapiens A type IV collagen 4239 51 711 gi7861733 Homo sapiens low density lipoprotein receptor related 2583 99 protein-deleted in tumor 1 711 gi8926243 Mus musculus low density lipoprotein receptor related 2409 91 protein LRP IB/LRP-DIT 6 WO 2004/080148 PCT/US2003/030720 143 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 711 gi438007 Gallus gallus alpha-2-macroglobulin receptor 1419 63 7 712 gi17298315 Homo sapiens candidate tumor suppressor protein 848 100 712 gi7861733 Homo sapiens low density lipoprotein receptor related 848 100 protein-deleted in tumor 712 gi8926243 Mus musculus low density lipoprotein receptor related 731 83 protein LRP1B/LRP-DIT 713 gil6877754 Homo sapiens Similar to RIKEN cDNA 4930434H03 574 56 gene 713 gi20071811 Mus musculus Similar to RIKEN cDNA 4930434H03 493 60 gene 713 gil340174 Homo sapiens type III procollagen (aa 892-1023) 97 40 714 gi157409 Drosophila fat protein 1802 31 melanogaster 714 gi4887715 Drosophila adherin 1500 36 melanogaster 714 gil107687 Homo sapiens homologue of Drosophila Fat protein 1514 30 715 gil57409 Drosophila fat protein 1808 31 melanogaster 715 gi4887715 Drosophila adherin 1500 36 melanogaster 715 gil107687 Homo sapiens homologue of Drosophila Fat protein 1514 30 716 gil7865311 Homo sapiens dipeptidyl peptidase-like protein 9 2562 99 716 gi3513303 Homo sapiens R26984 1 2700 98 716 gil1095188 Homo sapiens dipeptidyl peptidase 8 1397 53 717 gi2689444 Homo sapiens ZNF134 1160 54 717 gi21314977 Homo sapiens Similar to zinc finger protein 17 (HPF3, 1038 51 KOX 10) 717 gil3543419 Homo sapiens Similar to zinc finger protein 304 1000 51 718 gi7582294 Homo sapiens BM-011 881 100 718 gil3937769 Homo sapiens Similar to RIKEN cDNA 1200013F24 781 98 gene 718 gil 78997 Homo sapiens arginine-rich nuclear protein 224 38 719 gi1620870 Ciona myoplasmin-C1 412 28 intestinalis 719 gi7416980 Argopecten myosin heavy chain catch (smooth) 279 23 irradians muscle specific isoform 719 gi7416982 Argopecten myosin heavy chain cardiac muscle 279 23 irradians specific isoform 1 720 gil3872813 Homo sapiens fibulin-6 1376 100 4 720 gil4575679 Homo sapiens hemicentin 1372 99 0 720 gi3328186 Caenorhabditis hemicentin precursor 1695 30 elegans 721 gi3822553 Gallus gallus nuclear calmodulin-binding protein 1492 64 721 gi3329496 Mus musculus heterogenous nuclear ribonucleoprotein U 1501 45 721 gi624918 Rattus SP120 1498 45 norvegicus 722 gil7223626 Homo sapiens ATP-binding cassette A10 7966 99 722 gi17223624 Homo sapiens ATP-binding cassette A9 5160 61 722 gil7223622 Homo sapiens ATP-binding cassette A6 5108 61 723 gil3374079 Homo sapiens TAFII140 protein 3677 99 723 gil3374178 Mus musculus TAFII140 protein 3202 84 WO 2004/080148 PCT/US2003/030720 144 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 723 gi205686 Rattus heavy neurofilament subunit 335 26 norvegicus 724 gi17429038 Ralstonia PROBABLE ACYL-COA 661 61 solanacearum DEHYDROGENASE OXIDOREDUCTASE PROTEIN 724 gi9948609 Pseudomonas probable acyl-CoA dehydrogenase 619 62 aeruginosa 724 gi13421911 Caulobacter acyl-CoA dehydrogenase family protein 559 59 crescentus CB15 725 gi6752658 Homo sapiens epidermal growth factor repeat containing 3055 99 protein 725 gi16040981 Mus musculus POEM 884 51 725 gil5430246 Mus musculus nephronectin short isoform 884 51 726 gi6531661 Caenorhabditis LIN-41A 844 50 elegans 726 gi6531663 Caenorhabditis LIN-41B 844 50 elegans 726 gil2407367 Homo sapiens tripartite motif protein TRIM2 769 30 727 gil504026 Homo sapiens similar to C.elegans protein (Z37093) 5833 99 727 gi2896796 Homo sapiens D1013901 5115 99 727 gi2522322 Homo sapiens PTPL1-associated RhoGAP 1497 36 728 gi13274120 Homo sapiens dJ55C23.5.1 (vanin 3, isoform 1) 1467 99 728 gi7160973 Homo sapiens VNN3 protein 1213 96 728 gi6102996 Mus musculus Vanin-3 1018 79 729 gi9581879 Homo sapiens disintegrin metalloproteinase with 5723 99 thrombospondin repeats 729 gi19171176 Homo sapiens metalloprotease disintegrin 15 with 1669 50 thrombospondin domains 729 gil1095299 Rattus ADAMTS-1 1772 40 norvegicus 730 gi21063967 Drosophila AT05453p 396 32 melanogaster 730 gi5911409 Drosophila fuzzy 396 32 melanogaster 730 gi2564657 Drosophila Fuzzy 396 32 melanogaster 731 gil5217171 Homo sapiens CD81 partner 3 2302 100 731 gil5488017 Homo sapiens EWI2 2302 100 731 gil5593237 Mus musculus immunoglobulin superfamily receptor 2186 92 PGRL 732 gil5217171 Homo sapiens CD81 partner 3 3200 100 732 gil5488017 Homo sapiens EWI2 3200 100 732 gi15593237 Mus musculus immunoglobulin superfamily receptor 2867 88 PGRL 733 gi15217171 Homo sapiens CD81 partner 3 1303 96 733 gil5488017 Homo sapiens EWI2 1303 96 733 gi22266726 Homo sapiens LIR-DI precursor 1303 96 734 gi21748480 Homo sapiens FLJO0271 protein 605 100 734 gi22266726 Homo sapiens LIR-DI precursor 514 79 734 gil5217171 Homo sapiens CD81 partner 3 514 79 735 gi2196872 Homo sapiens Lsc homologue 203 30 735 gil389756 Mus musculus Lsc 199 31 735 gi11276027 | Rattus LSC 199 31 WO 2004/080148 PCT/US2003/030720 145 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity norvegicus 736 gil4336728 Homo sapiens possible integral membrane 331 32 736 gil8043242 Mus musculus RIKEN cDNA 240001OG15 gene 331 31 736 gi8895014 Hepatitis B HBsAg 68 48 virus 737 gi20071204 Mus musculus Similar to paraspeckle protein 1 185 28 737 gil8104577 Homo sapiens paraspeckle protein I alpha isoform 175 27 737 gil3528666 Homo sapiens Similar to splicing factor 179 31 proline/glutamine rich (polypyrimidine tract-binding protein-associated) 738 gi12002000 Homo sapiens My029 protein 415 100 738 gi348140 Human T- rex 68 39 lymphotropic virus 2 738 gi404041 Human T- rex protein 68 39 lymphotropic virus 2 739 gi4680090 Human envelope glycoprotein 89 31 immunodeficien cy virus type 1 740 gi21627272 Drosophila CG12765-PA 166 38 melanogaster 740 gil9528077 Drosophila AT24025p 166 38 melanogaster 740 gil066820 Murray Valley nonstructural protein 66 28 encephalitis virus 741 gi9916 Plasmodium liver stage antigen 468 26 falciparum _ 741 gi1747 Oryctolagus trichohyalin 414 24 cuniculus 741 gi295941 Ovis aries trichohyalin 395 24 742 gi9845485 Homo sapiens protocadherin-9 6235 100 742 gi15054521 Homo sapiens protocadherin-S 3390 58 742 gi13161060 Homo sapiens protocadherin 11 3382 58 743 gi5688958 Homo sapiens PMMLP 2405 100 743 gi21594625 Mus musculus RIKEN cDNA 4931406N15 gene 2241 92 743 gil6797814 Drosophila phosphomannomutase 45A 1194 51 melanogaster 744 gi21734445 Rattus BMP/Retinoic acid-inducible neurai- 3987 94 norvegicus specific protein-2 744 gi20988899 Mus musculus similar to deleted in bladder cancer 2952 70 chromosome region candidate 1 744 gi21734447 Rattus BMP/Retinoic acid-inducible neural- 2951 70 norvegicus specific protein-3 745 gi2739353 Homo sapiens ZNF91L 2075 69 745 gil017722 Homo sapiens repressor transcriptional factor 2044 71 745 gi4559318 Homo sapiens BC273239_1 2031 67 746 gi1017722 Homo sapiens repressor transcriptional factor 2144 73 746 gi2739353 Homo sapiens ZNF91L 2054 70 746 gi186774 Homo sapiens zinc finger protein 2035 70 747 gil9683999 Homo sapiens coated vesicle membrane protein 1010 99 747 gi12129 6 5 Homo sapiens transmembrane protein 1010 99 N7 gil213221 Rattus transmembrane protein 1006 98 norvegicus WO 2004/080148 PCT/US2003/030720 146 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 748 gi1199524 Homo sapiens acid phosphatase 2'036 98 748 gi34263 Homo sapiens acid phosphatase precursor protein 2036 98 748 gil3111975 Homo sapiens acid phosphatase 2, lysosomal 2032 98 749 gil5625570 Homo sapiens centaurin beta5 2970 83 749 gi4688902 Homo sapiens centaurin beta2 1708 64 749 gi436228 Homo sapiens Start codon is not identified 1387 70 750 gi10197642 Homo sapiens MDSO22 647 100 750 gil9683046 Dictyostelium HYPOTHETICAL 21.8 KDA PROTEIN, 94 26 discoideum 3/101 750 gi6841554 Homo sapiens HSPC166 93 24 751 gi5630080 Homo sapiens similar to HUB 1; similar to BAA24380 696 48 (PID:g2789430) 751 gi2789430 Homo sapiens repressor protein 702 39 751 gi18614026 Homo sapiens zinc finger DNA binding protein p71 1004 41 752 gil2140290 Homo sapiens bA12M19.2.1 (vacuolar protein sorting 2885 92 protein 16 (VPS16)) 752 gil1345382 Homo sapiens vacuolar protein sorting protein 16 2885 92 752 gi19343731 Mus musculus vacuolar protein sorting 16 (yeast 2803 89 homolog) 753 gi20987877 Mus musculus similar to Nogo receptor 905 58 753 gi9280025 Macaca Nogo receptor 808 49 fascicularis 753 gil5080005 Homo sapiens nogo receptor 796 48 754 gil77870 Homo sapiens alpha-2-macroglobulin precursor 2714 39 754 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 2708 39 754 gi579594 Homo sapiens alpha 2-macroglobulin 690-740 2700 39 755 gi4929790 Homo sapiens angiopoietin-related protein 3 1423 89 755 gil3159474 Homo sapiens CGO06-alt2 1416 88 755 gi5639997 Mus musculus angiopoietin-related protein 3 1109 77 756 gi200057 Mus musculus neuronal glycoprotein 4821 87 756 gi563133 Rattus BIG-I protein 4778 87 norvegicus 756 gil016012 Rattus neural cell adhesion protein BIG-2 3867 68 norvegicus precursor 757 gi6273399 Homo sapiens melanoma-associated antigen MG50 344 33 757 gi1504040 Homo sapiens similar to D.melanogaster 344 33 peroxidasin(U1 1052) 757 gil4495561 Homo sapiens brain tumor associated protein LRRC4 324 27 758 gi6273399 Homo sapiens melanoma-associated antigen MG50 344 33 758 gil504040 Homo sapiens similar to D.melanogaster 344 33 peroxidasin(U 11052) 758 gil4495561 Homo sapiens brain tumor associated protein LRRC4 329 26 759 gi5525078 Rattus seven transmembrane receptor 5062 72 norvegicus 759 gi21929093 Homo sapiens seven transmembrane helix receptor 1712 88 759 gi4164023 Bos taurus latrophilin 2 splice variant baaaf 383 27 760 gil0440398 Homo sapiens FLJO0032 protein 1261 57 760 gil1917507 Homo sapiens HPF1 protein 1258 60 760 gi13752754 Homo sapiens zinc finger 1111 1253 60 761 gi3628757 Homo sapiens FICI 1436 54 761 gil3097633 Homo sapiens Similar to ATPase, Class I, type 8B, 1221 60 member 1 761 gi20147219 Arabidopsis Atlg59820/F23H11_14 1637 41 thaliana WO 2004/080148 PCT/US2003/030720 147 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 762 gil1527987 Gallus gallus immunoglobulin-like receptor CHIR-A 97 30 762 gi432214 Human envelope glycoprotein gp120 43 39 immunodeficien cy virus type 1 762 gi15026993 Homo sapiens MUC5AC protein 64 38 763 gil1558486 Homo sapiens B-cell lyrnphoma/leukaemia 11A short 1314 99 form 763 gi7546791 Mus musculus CTIP1 protein 1149 99 763 gi7650184 Mus musculus ecotropic viral integration site 9 isoform 1155 95 C 764 gi22085890 Rattus FHA-HIT 1426 82 norvegicus 764 gi21430028 Drosophila GM01362p 338 40 melanogaster 764 gi21166012 Dictyostelium 2410016G21RIK PROTEIN 279 26 discoideum 765 gi22085890 Rattus FHA-HIT 214 88 norvegicus 765 gi5764101 Homo sapiens polynucleotide kinase-3'-phosphatase 95 50 765 gi5712131 Homo sapiens DEM1 protein 93 50 766 gi22085890 Rattus FHA-HIT 278 89 norvegicus 766 gi5764101 Homo sapiens polynucleotide kinase-3'-phosphatase 109 46 766 gi5712131 Homo sapiens DEMI protein 107 46 768 gi15186770 Homo sapiens lysyl oxidase-like protein 1818 96 768 gil4009597 Homo sapiens lysyl oxidase-like 3 protein 1818 96 768 gi15030096 Mus musculus Similar to lysyl oxidase-like 2 1715 92 769 gi3954938 Homo sapiens acetylglucosaminyltransferase-like 2298 70 protein 769 gi3954978 Mus musculus acetylglucosaminyltransferase-like 2298 70 protein 769 gil0834722 Homo sapiens PP5656 892 91 770 gi7209723 Homo sapiens WD-repeat like sequence 2476 99 770 gi8217485 Homo sapiens dJ1092A1 1.3 (WD repeat domain) 2473 99 770 gi7209721 Mus musculus DD57 2243 88 771 gil8676632 Homo sapiens FLJO0215 protein 1943 99 771 gil8447198 Drosophila GH09355p 140 19 melanogaster 771 gi295671 Saccharomyces selected as a weak suppressor of a mutant 119 22 cerevisiae of the subunit AC40 of DNA dependant RNA polymerase I and III 772 gi10799166 Homo sapiens protein kinase Njmu-R1 1915 99 772 gi21104460 Homo sapiens OK/SW-CL.19 549 100 772 gil4290030 Human pol protein 68 30 immunodeficien cy virus type I 773 gi4186023 Homo sapiens CDS2 protein 2376 100 773 gi19344052 Homo sapiens similar to PHOSPHATIDATE 2376 100 CYTIDYLYLTRANSFERASE 2 (CDP DIGLYCERIDE SYNTHETASE 2) (CDP-DIGLYCERIDE PYROPHOSPHORYLASE 2) (CDP D1ACYLGLYCEROL SYNTHASE 2) (CDS 2) (CTP:PHOSPHATIDATE CYTIDYLYLTRANSFERASE 2) (CDP- WO 2004/080148 PCT/US2003/030720 148 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity DAG SYNTHASE 2) (CDP-DG SYNTHETASE 2)... 773 gil3277972 Mus musculus Similar to CDP-diacylglycerol synthase 2289 96 (phosphatidate cytidylyltransferase) 2 774 gil7862928 Drosophila SD03549p 125 35 melanogaster 774 gil8077663 Mus musculus cockayne syndrome group A 117 38 774 gi14091657 Mangifera F6N15.8-like protein 107 29 indica 776 gil8676664 Homo sapiens FLJO0231 protein 1473 99 776 gi16303748 Homo sapiens tweety-like protein 2 1053 41 776 gil6303750 Mus musculus tweety homolog 2 987 39 777 gi8118032 Homo sapiens orphan G-protein coupled receptor 939 98 777 gil6877193 Homo sapiens G protein-coupled receptor, family C, 939 98 group 5, member C 777 gi9588669 Homo sapiens GPRC5C 939 98 778 gi20380605 Mus musculus RIKEN cDNA 8430424D23 gene 836 91 778 gil6769562 Drosophila LD38910p 333 47 melanogaster 778 gi7302978 Drosophila CG8441-PA 333 47 melanogaster 779 gil6041781 Homo sapiens Similar to RIKEN cDNA 0710001C05 776 99 gene 779 gi21430012 Drosophila GH27470p 333 53 melanogaster 779 gil5074454 Sinorhizobium CONSERVED HYPOTHETICAL 239 43 meliloti PROTEIN 780 gi13959018 Homo sapiens endothelial cell-selective adhesion 902 100 molecule 780 gil3991773 Mus musculus endothelial cell-selective adhesion 643 70 molecule 780 gi1814277 Homo sapiens A33 antigen precursor 229 34 781 gi8164184 Homo sapiens 22kDa peroxisomal membrane protein- 1013 100 like 781 gil5422171 Homo sapiens 22 kDa peroxisomal membrane protein 2 1013 100 781 gi297437 Rattus peroxisomal membrane protein 798 76 norvegicus 782 gi7621329 Streptococcus Sicl.245 214 39 pyogenes 782 gi7620883 Streptococcus Sicl.23 215 39 pyogenes 782 gi7620875 Streptococcus Sicl.19 215 39 pyogenes 783 gi62877 Gallus gallus type VI collagen alpha-2 subunit 751 41 preprotein 783 gi62882 Gallus gallus type VI collagen subunit alpha2 751 41 783 gi211616 Gallus gallus type VI collagen, alpha-2 subunit 747 45 784 gil7945608 Drosophila RE26969p 829 48 melanogaster 784 gi3877350 Caenorhabditis contains similarity to Pfam domain: 572 38 elegans PF01598 (Sterol desaturase), I Score=307.6, E-value=4.7c-89, N=1 784 gi3877351 Caenorhabditis contains similarity to Pfam domain: 546 38 elegans PF01598 (Sterol desaturase), Score=303.0, E-valuc=l.le-87, N=1 WO 2004/080148 PCT/US2003/030720 149 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 785 gil7066106 Homo sapiens Novex-3 Titin Isoform 8832 99 785 gi21238628 Sparisoma titin-like protein 519 62 viride 785 gi21238630 Sparisoma titin-like protein 519 62 aurofrenatum_ 787 gi2230840 Ginkgo biloba ndhB 54 54 787 gi2230828 Dioon edule ndhB 52 50 787 gi9279991 Sequoia maturase 60 36 sempervirens 788 gi18676610 Homo sapiens FLJO0204 protein 204 27 788 gi3002588 Mus musculus Plenty of SH3s; POSH 206 25 788 gi1407665 Mus musculus SH3P3 134 45 789 gil8676610 Homo sapiens FLJ00204 protein 262 27 789 gi3002588 Mus musculus Plenty of SH3s; POSH 220 25 789 gil407665 Mus musculus SH3P3 140 33 790 gi182483 Homo sapiens prefibroblast collagenase inhibitor 531 88 790 gi490094 Homo sapiens TIMP 531 88 790 gil89382 Homo sapiens collagenase inhibitor 531 88 791 gi7110216 Homo sapiens C-type lectin-like receptor-1 851 99 791 gi7109731 Homo sapiens C-type lectin-like receptor-2 256 31 791 gi1902982 Bos taurus lectin-like oxidized LDL receptor 303 31 792 gi5802604 Cavia porcellus UDP glucuronosyltransferase UGT2A3 1783 73 792 gi19387963 Mus musculus RIKEN cDNA 2010321J07 gene 1709 69 792 gi4753766 Homo sapiens UDP glucuronosyltransferase 1598 67 793 gi3688090 Homo sapiens R32611 2 786 91 793 gi6841228 Homo sapiens HSPC289 638 78 793 gi21618688 Mus musculus RIKEN cDNA 5830498C14 gene 445 52 794 gi9963861 Homo sapiens Cyt19 1729 99 794 gil5488645 Mus musculus methyltransferase Cyt19 1555 76 794 gil8150409 Rattus S-adenosylmethionine:arsenic (I1) 1516 76 norvegicus methyltransferase 795 gi 11877243 Homo sapiens SSF1/P2Y11 chimeric protein 1957 95 795 gi21619996 Homo sapiens peter pan homolog (Drosophila) 2080 99 795 gil4602631 Homo sapiens peter pan (Drosophila) homolog 2080 99 796 gi20330550 Homo sapiens NK inhibitory receptor precursor 799 98 796 gi20380183 Homo sapiens similar to CMRF35 leukocyte 727 92 immunoglobulin-like receptor 796 gi20381405 Homo sapiens similar to CMRF35 leukocyte 423 57 immunoglobulin-like receptor; CMRF35 antigen 797 gi20330550 Homo sapiens NK inhibitory receptor precursor 799 98 797 gi20380183 Homo sapiens similar to CMRF35 leukocyte 727 92 immunoglobulin-like receptor 797 gi20381405 Homo sapiens similar to CMRF35 leukocyte 423 57 immunoglobulin-like receptor; CMRF35 antigen 798 gi20330550 Homo sapiens NK inhibitory receptor precursor 1469 94 798 gi20380183 Homo sapiens similar to CMRF35 leukocyte 690 84 immunoglobulin-like receptor 798 gi20330544 Mus musculus polymeric immunoglobulin receptor 3 416 52 precursor 799 gi18307481 Homo sapiens phosphoinositide-binding proteins 2122 100 799 gi3930781 Homo sapiens connector enhancer of KSR-like protein 346 34 ______________CNK1 I___ WO 2004/080148 PCT/US2003/030720 150 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 799 gi4151807 Rattus membrane-associated guanylate kinase- 455 37 norvegicus interacting protein 2 Maguin-2 800 gi15929988 Homo sapiens Similar to TLH29 protein precursor 417 89 800 gil 1493982 Homo sapiens TLH29 protein precursor 274 72 800 gi20147034 Mus musculus interferon stimulated gene 12 235 68 801 gil5929988 Homo sapiens Similar to TLH29 protein precursor, 445 100 clone MGC:21991 IMAGE:4398045, mRNA, complete cds. 801 AAW54040 Homo sapiens Human interferon-inducible protein, 432 97 HIFI 801 gil1493982 Homo sapiens TLH29 protein precursor (TLH29) 303 70 mRNA, complete eds. 802 gil2082725 Mus musculus B cell phosphoinositide 3-kinase adaptor 3561 84 802 gil2082723 Gallus gallus B cell phosphoinositide 3-kinase adaptor 2840 69 802 gi20987486 Homo sapiens similar to B cell phosphoinositide 3- 1830 97 kinase adaptor 803 gi7959809 Homo sapiens PRO1082 545 100 803 gi7767407 Avian 5a protein 61 26 infectious bronchitis virus 803 gil5073792 Sinorhizobium PUTATIVE FOSMIDOMYCIN 71 38 meliloti RESISTANCE ANTIBIOTIC RESISTANCE TRANSMEMBRANE PROTEIN 804 gi15384843 Homo sapiens NTB-A receptor 1700 100 804 gil5384841 Homo sapiens activating NK receptor 1687 99 804 gi9887089 Mus musculus lymphocyte antigen 108 isoform 1 637 44 805 gi17979255 Arabidopsis AT5g49550/K6M13_10 211 72 thaliana 805 gil0177621 Arabidopsis phytoene dehydrogenase-like 195 75 thaliana 805 gi14023915 Mesorhizobium phytoene dehydrogenase 182 62 loti 806 gil4270364 Mus musculus Epigen protein 386 71 806 gi755468 Xenopus laevis transmernbrane protein 120 36 806 gi7799191 Mus musculus tomoregulin-1 125 52 807 gil4270364 Mus musculus Epigen protein 386 71 807 gi755468 Xenopus laevis transmembrane protein 120 36 807 gi7799191 Mus musculus tomoregulin-1 125 52 808 gil4270364 Mus musculus Epigen protein 386 71 808 gi755468 Xenopus laevis transmembrane protein 120 36 808 gi7799191 Mus musculus tomoregulin-1 125 52 809 gi3068592 Mus musculus punch 201 41 809 gi22003417 Danio rerio neogenin 193 40 809 gil881477 Mus musculus neogenin protein 167 33 810 gil5072404 Raja erinacea organic solute transporter beta 92 41 810 gil43486 Bacillus subtilis levansucrase 59 37 810 gi143484 Bacillus subtilis levansucrase (sacB) 58 35 811 gil8650588 Homo sapiens retinoic acid early transcript 1 1124 99 811 gi13128925 Homo sapiens ULBP2 protein 1070 94 811 gi21961213 Homo sapiens UL16 binding protein 2 1070 94 812 gi9280405 Homo sapiens adlican 1372 46 812 gi3328186 Caenorhabditis hemicentin precursor 475 29 elegans WO 2004/080148 PCT/US2003/030720 151 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 812 gil4575679 Homo sapiens hemicentin 493 28 814 gi9280405 Homo sapiens adlican 2438 35 814 gil4575679 Homo sapiens hemicentin 688 25 814 gi3328186 Caenorhabditis hemicentin precursor 586 26 elegans 815 gi21619635 Homo sapiens similar to Alu subfamily SQ sequence 270 60 contamination warning entry 815 gi6650810 Homo sapiens PRO1902 264 63 815 gi3002527 Homo sapiens neuronal thread protein AD7c-NTP 247 62 816 gi6707435 Homo sapiens apolipoprotein A5 1864 100 816 gil2240284 Mus musculus apolipoprotein A5 1310 72 816 gi6707431 Rattus apolipoprotein A5 1293 72 norvegicus 817 gi6707435 Homo sapiens apolipoprotein A5 1864 100 817 gi12240284 Mus musculus apolipoprotein A5 1310 72 817 gi6707431 Rattus apolipoprotein A5 1293 72 norvegicus 818 gi12751065 Homo sapiens PNAS-25 360 81 818 gi1208732 Drosophila ovary2 276 33 melanogaster 818 gi21428518 Drosophila LD33046p 275 33 melanogaster 819 gi5771420 Homo sapiens group IID secretory phospholipase A2 852 100 819 gi6453793 Homo sapiens phospholipase A2 846 99 819 gil0862736 Homo sapiens dJ169023.3 (phospholipase A2 group 846 99 IID) 820 gi6015448 Hylobates lar dopamine receptor D4 79 35 820 gi5059331 Human major capsid protein 85 29 papillomavirus type 83 820 gil3278034 Mus musculus Similar to selectin, platelet (p-selectin) 83 35 ligand 821 gil2654883 Horno sapiens rTS beta protein 2112 96 821 gi1150421 Homo sapiens rTSbeta 2112 96 821 gil1094019 Homo sapiens RTS beta 2106 96 822 gi12803167 Homo sapiens nucleosome assembly protein 1-like 1 1728 99 822 gi189067 Homo sapiens NAP 1728 99 822 gi220496 Mus musculus nucleosome assembly protein-1 1718 98 823 gil3432042 Homo sapiens integrin-linked kinase-associated 2009 99 serine/threonine phosphatase 2C 823 gi20072498 Mus musculus Similar to protein phosphatase 2C 1926 94 823 gi3777604 Rattus protein phosphatase 2C 1922 94 norvegicus 824 gi7768636 Xenopus laevis Kielin 242 36 824 gi6979313 Mus musculus cysteine-rich repeat-containing protein 183 30 CRIMI 824 gil1527817 Homo sapiens CRIMI protein 178 30 825 gi21928259 Homo sapiens seven transmembrane helix receptor 1023 100 825 gil8480746 Mus musculus olfactory receptor MOR261-10 864 84 825 gil8480744 Mus musculus olfactory receptor MOR261-9 858 82 826 gi21928655 Homo sapiens seven transmembrane helix receptor 1458 93 826 gil8480746 Mus musculus olfactory receptor MOR261-10 1280 79 826 gil8480744 Mus musculus olfactory receptor MOR261-9 1258 78 827 gi6760369 Mus musculus ODZ3 364 95 WO 2004/080148 PCT/US2003/030720 152 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 827 gi4760780 Mus musculus Ten-m3 364 95 827 gi5307761 Danio rerio ten-m3 310 78 828 gi21205852 Homo sapiens T-cell activation Rho GTPase activating 3756 100 protein; TA-GAP 828 gi21205854 Homo sapiens T-cell activation Rho GTPase activating 2850 100 protein splice variant 1; TA-GAP 828 gi16265938 Homo sapiens FKSG15 2439 98 829 gil0432396 Homo sapiens dJ947L8.1.5 (novel CUB domain protein) 383 62 829 gi14787176 Mus musculus CSMD1 373 61 829 gil4787181 Homo sapiens CUB and sushi multiple domains protein 369 60 1 short form 830 gil0432396 Homo sapiens dJ947L8.1.5 (novel CUB domain protein) 383 62 830 gi14787176 Mus musculus CSMD1 373 61 830 gil4787181 Homo sapiens CUB and sushi multiple domains protein 369 60 I short form 831 gi532124 Dictyostelium myosin IC 525 41 discoideum 831 gi6472600 Chara corallina unconventional myosin heavy chain 511 43 831 gi9453839 Chara corallina myosin 511 43 832 gi8953751 Arabidopsis myosin heavy chain MYA2 646 40 thaliana 832 gi6472600 Chara corallina unconventional myosin heavy chain 646 39 832 gi9453839 Chara corallina myosin 646 39 833 gi17066528 Canis familiaris immunoglobulin gamma heavy chain C 42 38 833 gi21113238 Xanthomonas IS1595 transposase 50 43 campestris pv. campestris str. ATCC 33913 833 gi16413516 Listeria innocua similar to B. subtilis YlaI protein 56 37 834 gi7248845 Homo sapiens testican-1 2429 99 834 gi793845 Homo sapiens testican 2429 99 834 gi21265163 Homo sapiens spare/osteonectin, cwcv and kazal-like 2425 99 domains proteoglycan (testican) 835 gil2804465 Homo sapiens prostate cancer overexpressed gene 1 1632 59 835 gi3462515 Homo sapiens PB39 1632 59 835 gi13111981 Homo sapiens Similar to selectively expressed in 283 34 embryonic epithelia protein-i 836 gil2804465 Homo sapiens prostate cancer overexpressed gene 1 1637 59 836 gi3462515 Homo sapiens PB39 1637 59 836 gi13111981 Homo sapiens Similar to selectively expressed in 283 34 embryonic epithelia protein-I 837 gi7689029 Homo sapiens uncharacterized hypothalamus protein 664 100 HBEX2 837 gil7391348 Homo sapiens Similar to brain expressed, X-linked 1 664 100 837 gi9963771 Homo sapiens ovarian granulosa cell 13.0 kDa protein 664 100 hGR74 homolog 838 gi4585574 Rattus Slit1 287 35 norvegicus 838 gil7380582 Homo sapiens SLIT1 isoform B 279 35 838 gi4049587 Homo sapiens Slit-2 protein 297 35 839 gil5488920 Homo sapiens Similar to RIKEN cDNA 2010107G23 632 100 gene 839 gil9354289 Mus musculus RIKEN cDNA 2010107G23 gene 570 92 839 gi2267416 Hepatitis D hepatitis delta antigen 76 33 WO 2004/080148 PCT/US2003/030720 153 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity virus 840 gi21619776 Homo sapiens Similar to RIKEN cDNA 2600011E07 2491 100 gene 840 gi20988071 Mus musculus Similar to RIKEN cDNA 2600011E07 921 80 gene 840 gil4531291 Mus musculus high mobility group protein isoform I 87 34 841 gi21667649 Drosophila myosin binding subunit of myosin 231 29 melanogaster phosphatase 841 gi213921 6 8 Drosophila RE63915p 231 29 melanogaster 841 gi3929221 Homo sapiens TRF 1-interacting ankyrin-related ADP- 183 32 ribose polymerase 842 gil2408286 Homo sapiens apolipoprotein L-IV splice variant a 1742 100 842 gil3374351 Homo sapiens apolipoprotein L4 1728 99 842 gil2408285 Homo sapiens apolipoprotein L-IV splice variant b 1683 98 843 gil24082 8 6 Homo sapiens apolipoprotein L-IV splice variant a 1737 99 843 gil3374351 Homo sapiens apolipoprotein L4 1723 99 843 gi12408285 Homo sapiens apolipoprotein L-IV splice variant b 1678 98 844 gi21744725 Homo sapiens glycosyl-phosphatidyl-inositol-MAM 2296 100 844 gi7529598 Homo sapiens dJ402N21.3 (novel protein with 1048 100 Immunoglobulin domains) 844 gi7529599 Homo sapiens dJ402N21.1 (novel protein) 662 100 845 gi21744725 Homo sapiens glycosyl-phosphatidyl-inositol-MAM 5051 100 845 gi7529598 Homo sapiens dJ402N21.3 (novel protein with 1548 99 Immunoglobulin domains) 845 gi7529597 Homo sapiens dJ402N21.2 (novel protein with MAM 1474 100 domain) 846 gi4007758 Schizosaccharo conserved protein; similar to S. cerevisiae 633 34 myces pombe YPR144C 846 gi106 64 9 3 Saccharomyces Weak similarity near C-terminus to RNA 482 32 cerevisiae Polymerase beta subunit (Swiss Prot. accession number P11213) and CCAAT binding transcription factor (PIR accession number A36368) 846 gil8086412 Arabidopsis At2g17250/T23A1.11 420 44 thaliana 847 gi14701768 Homo sapiens Vam6/Vps39-like protein 3499 96 847 gi14280050 Homo sapiens Vps39/Vam6-like protein 3499 96 847 gil8857927 Mus musculus VPS39 long isoform 3409 93 848 gi3811347 Homo sapiens cytosolic phospholipase A2 beta 1209 44 848 gi4886978 Homo sapiens cytosolic phospholipase A2 beta; 1209 44 cPLA2beta 848 gi190004 Homo sapiens phosphatidylcholine 2-acylhydrolase 512 35 849 gi7291437 Drosophila CG4071-PA 516 51 melanogaster 849 gi17946619 Drosophila RH31535p 217 42 melanogaster 849 gi21645615 Drosophila CG4071-PB 217 42 melanogaster 850 gil3161409 Mus musculus family 4 cytochrome P450 444 73 850 gi5263306 Coptotermes family 4 cytochrome P450 200 41 acinaciformis 850 gi13182964 Mus musculus cytochrome P450 CYP4F13 196 38 851 gi13447749 Homo sapiens fibroblast growth factor receptor 5 2475 98 851 gi10944887 Homo sapiens FGFR-like protein 2475 98 WO 2004/080148 PCT/US2003/030720 154 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 851 gil3183618 Homo sapiens FGF homologous factor receptor 2421 97 852 gil3447749 Homo sapiens fibroblast growth factor receptor 5 2701 99 852 gil0944887 Homo sapiens FGFR-like protein 2701 99 852 gi13183618 Homo sapiens FGF homologous factor receptor 2647 98 853 gi13183618 Homo sapiens FGF homologous factor receptor 583 98 853 gil3447749 Homo sapiens fibroblast growth factor receptor 5 583 98 853 gil0944887 Homo sapiens FGFR-like protein 583 98 854 gi643656 Rattus synaptotagmin VII 2035 95 norvegicus 854 gil2667446 Rattus synaptotagmin VIIs 2035 95 norvegicus 854 gi6136786 Mus musculus synaptotagmin VII 2026 95 855 gi12053709 Homo sapiens a disintegrin-like and metalloprotease 8842 100 (reprolysin type) with thrombospondin type 1 motif, 12 855 gi5923788 Homo sapiens zinc metalloprotease ADAMTS7 2489 58 855 gi19171178 Homo sapiens metalloprotease disintegrin 16 with 1598 39 thrombospondin type I motif 856 gil5929988 Homo sapiens Similar to TLH29 protein precursor 155 86 856 gi7649139 Homo sapiens pIFI27-like protein 83 44 856 gil 1493982 Homo sapiens TLH29 protein precursor 83 44 857 gil3542874 Mus musculus Similar to CGI-67 protein 1299 74 857 gi21707079 Homo sapiens similar to RIKEN cDNA 2210412D01 1278 75 857 gi4929603 Homo sapiens CGI-67 protein 1087 81 858 gil3542874 Mus musculus Similar to CGI-67 protein 1299 74 858 gi21707079 Homo sapiens similar to RIKEN cDNA 2210412D01 1279 73 858 gi4929603 Homo sapiens CGI-67 protein 1087 81 859 gi21595166 Mus musculus RIKEN cDNA 4933425F03 gene 1823 83 859 gil6359267 Mus musculus Similar to RIKEN cDNA 4933425F03 1822 83 gene 859 gi21619888 Homo sapiens Similar to RIKEN cDNA 4933425F03 1542 98 gene 860 gi21595166 Mus musculus RIKEN cDNA 4933425F03 gene 2278 88 860 gil6359267 Mus musculus Similar to RIKEN eDNA 4933425F03 2277 88 gene 860 gi21619888 Homo sapiens Similar to RIKEN cDNA 4933425F03 1958 99 gene 861 gil1493463 Homo sapiens PR02852 301 75 861 gil4189960 Homo sapiens PR00764 271 65 861 gi21104464 Homo sapiens OK/SW-CL.41 264 70 863 gi21320872 Mus musculus Cogs 2747 88 863 gi17862986 Drosophila SD07339p 795 45 melanogaster 863 gi5922593 Schizosaccharo piO08 230 21 myces pombe 864 gi21618851 Mus musculus RIKEN cDNA 261051OLO1 gene 882 92 864 gi20977573 Danio rerio Ul small nuclear ribonucleoprotein C 75 32 864 gil562574 Mus musculus U1 snRNP-specific protein C 75 32 865 gil7862312 Drosophila LD21841p 646 41 melanogaster 865 gi22294210 Thermosynecho WD-40 repeat protein 123 27 coccus elongatus BP-1 865 gi886024 Thermomonosp PkwA 124 25 WO 2004/080148 PCT/US2003/030720 155 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity ora curvata 866 gi3878846 Caenorhabditis R05D7.3 119 37 elegans 866 gi1685056 Xenopus laevis Pax6 87 24 866 gi8132389 Xenopus laevis paired domain transcription factor variant 81 23 A 867 gil2406973 Homo sapiens alanine-glyoxylate aminotransferase 2 2740 100 867 gil944136 Rattus beta-alanine-pyruvate aminotransferase 2255 83 norvegicus 867 gil000448 Rattus Rat kidney AGT2 precursor 2208 81 norvegicus 868 gil2406973 Homo sapiens alanine-glyoxylate aminotransferase 2 1870 98 868 gi1944136 Rattus beta-alanine-pyruvate aminotransferase 1630 86 norvegicus 868 gil000448 Rattus Rat kidney AGT2 precursor 1583 84 norvegicus 869 gi4165315 Sus scrofa kallikrein 468 42 869 gi190263 Homo sapiens plasma prekallikrein 467 38 869 gi8809781 Homo sapiens plasma kallikrein precursor 467 38 870 gi17985046 Brucella GLYCOSYL TRANSFERASE 137 28 melitensis 870 gi5478237 Brucella Bme7 137 28 melitensis 870 gi20906785 Methanosarcina Transposase 126 25 mazei Goel 871 gi4565840 Cnemidophorus cytochrome b oxidase 76 41 tigris 871 gi15023030 Clostridium Uncharacterized membrane protein, 72 44 acetobutylicun ortholog YYAS B.subtilis 871 gi7549241 Barbatia tenera cytochrome oxidase subunit 1 71 28 872 gi8705222 Homo sapiens IL-17B receptor 1998 100 872 gi9246433 Homo sapiens IL-17 receptor homolog precursor 1996 99 872 gi9246429 Mus musculus IL-17 receptor homolog precursor 1504 75 873 gil8676472 Homo sapiens FLJO0133 protein 6475 100 873 gil8676498 Homo sapiens FLJO0146 protein 2352 100 873 gi161467 Strongylocentro fibropellin Ia 1246 38 tus purpuratus 874 gi213198 Petromyzon fibrinogen alpha chain 89 39 marinus 874 gil5292317 Drosophila LD46863p 87 34 melanogaster 874 gi4877921 Streptococcus serum opacity factor precursor 81 33 pyogenes 875 gil4249936 Homo sapiens Similar to S-adenosylhomocysteine 2582 97 hydrolase-like 1 875 gi17390493 Mus musculus S-adenosylhomocysteine hydrolase-like 1 2429 92 875 gi2852125 Homo sapiens S-adenosyl homocysteine hydrolase 2429 92 homolog 876 gi14279990 Homo sapiens ubiquitin UBF-fl 458 100 876 gi6706799 Homo sapiens dJ447F3.2.1 (ubiquitin-conjugating 214 74 , enzyme E2 HIO (isoform 1)) 876 gil4043322 Homo sapiens ubiquitin carrier protein E2-C 214 74 877 gi20086516 Homo sapiens prominin-related protein 4241 99 877 gi20086520 Mus musculus prominin-related protein 3157 73 WO 2004/080148 PCT/US2003/030720 156 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 877 gi19909067 Rattus testosterone-regulated prominin-related 2920 69 norvegicus protein 878 gil3159480 Homo sapiens Translation may initiate at the ATG 2104 100 codon at nucleotides 40-42 or the ATG at nucleotides 43-45 878 gi21483846 Sus scrofa fibrinogen-like protein 2 406 36 878 gi9229906 Ciona fibrinogen-like protein 408 36 intestinalis 879 gil3159480 Homo sapiens Translation may initiate at the ATG 2100 99 codon at nucleotides 40-42 or the ATG at nucleotides 43-45 879 gi21483846 Sus scrofa fibrinogen-like protein 2 406 36 879 gi9229906 Ciona fibrinogen-like protein 408 36 intestinalis 880 gil3159480 Homo sapiens Translation may initiate at the ATG 2100 99 codon at nucleotides 40-42 or the ATG at nucleotides 43-45 880 gi21483846 Sus scrofa fibrinogen-like protein 2 406 36 880 gi9229906 Ciona fibrinogen-like protein 408 36 intestinalis 881 gi11493483 Homo sapiens PR02550 322 66 881 gi7770139 Homo sapiens PRO1722 318 69 881 gil872200 Homo sapiens alternatively spliced product using exon 304 72 13A 882 gil0175777 Bacillus protease specific for phage lambda elI 67 34 halodurans repressor 882 gi15558903 Xenopus laevis Tob 64 51 882 gi21998835 Rattus monocarboxylate transporter 8 67 33 norvegicus 883 gil8073362 Homo sapiens cystine/glutamate transporter 2552 100 883 gil1493652 Homo sapiens calcium channel blocker resistance 2552 100 protein CCBR1 883 gi13924720 Homo sapiens cystine/glutamate transporter xCT 2552 100 884 gi507213 Homo sapiens serine kinase 1797 97 884 gil4252988 Homo sapiens SRPKI a protein kinase 1797 97 884 gi3135975 Homo sapiens dJ422H11.1.1 (Serine Kinase) (isoform 1) 1796 98 885 gi9837288 Homo sapiens C-type lectin 271 54 885 gi6651065 Homo sapiens lectin-like NK cell receptor LLTl 271 54 885 gi18044358 Homo sapiens Similar to lectin-like NK cell receptor 270 57 886 gi22164066 Homo sapiens neuroblastoma-amplified protein 7571 99 886 gi5833317 Oryzias latipes mixed lineage leukemia-like protein 89 23 886 gi7108717 Nicotiana MAR-binding protein MFP1 homolog 89 31 tabacum 887 gi22164066 Homo sapiens neuroblastoma-amplified protein 6897 98 887 gi5833317 Oryzias latipes mixed lineage liukemia-like protein 89 23 888 gil7430957 Ralstonia HYPOTHETICAL TRANSMEMBRANE 453 40 solanacearumum PROTEIN 888 gil3421965 Caulobacter M20/M25/M40 family peptidase 377 38 crescentus CB15 888 gi2330791 Schizosaccharo carboxypeptidase s precursor 352 33 myces pombe 889 gil1558029 Homo sapiens organic cation transporter 1860 99 889 gil8088251 Homo sapiens Similar to hBOIT for potent brain type 1206 97 organic ion transporter WO 2004/080148 PCT/US2003/030720 157 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 889 gi9663117 Homo sapiens organic cation transporter 1852 99 890 gi344112 synthetic chloramphenicol acetyltransferase and 57 28 construct carboxy terminal fusion protein 890 gi412284 synthetic carboxy terminal fusion protein 57 28 construct 890 gi13122523 Barbus ATP synthase 8 56 28 brachycephalus 891 gi13375149 Homo sapiens dJ1118M15.2 (Novel protein) 538 98 891 gi7259265 Mus musculus contains transmembrane (TM) region 269 48 891 gil806278 Rattus glycoprotein 56 143 35 norvegicus 892 gil6589003 Homo sapiens bromodomain-containing 4 6353 99 892 gi9931486 Mus musculus cell proliferation related protein CAP 5635 90 892 gil8308125 Mus musculus bromodomain-containing protein BRD4 5633 90 long variant 893 gi15420828 Homo sapiens NOE3-1 2504 99 893 gil9386926 Rattus optimedin form B 2484 98 norvegicus 893 gil9386930 Mus musculus optimedin form B 2484 98 894 gil0336599 Xenopus laevis follistatin-related protein 234 32 894 gi349006 Mus musculus TGF-beta-inducible protein 225 29 894 gi20810033 Mus musculus follistatin-like 223 29 895 gi5002565 Takifugu cysteine conjugate beta-lyase 1244 55 rubripes 895 gi758591 Homo sapiens glutamine--phenylpyruvate 1201 51 aminotransferase 895 gil5425868 Aedes aegypti kynurenine aminotransferase 1188 55 896 gi20522012 Homo sapiens similar to an actin bundling protein, 1312 57 dematn. 896 gi2337952 Homo sapiens actin-binding double-zinc-finger protein 1312 57 896 gi21666433 Mus musculus actin-binding LIM protein 1 medium 1305 57 isoform 898 gi6716518 Mus musculus doublecortin-like kinase 821 52 898 gi21619202 Homo sapiens Similar to doublecortin and CaM kinase- 810 51 like 1 898 gi20152113 Drosophila RE56868p 778 45 melanogaster 899 gi9280108 Macaca membrane-associated prostaglandin E 1907 97 fascicularis synthase-2 899 gi9757960 Arabidopsis contains similarity to glutathione-S- 396 50 thaliana transferase/glutaredoxin-geneid:MJC20. 26 899 gil7944528 Drosophila RH17614p 566 42 melanogaster 900 gi4894854 Homo sapiens complement C1q A chain precursor 1308 99 900 gi20988805 Homo sapiens complement component 1, q 1308 99 subcomponent, alpha polypeptide 900 gil2805247 Mus musculus complement component 1, q 945 70 subcomponent, alpha polypeptide 901 gil0176989 Arabidopsis contains similarity to hedgehog- 86 34 thaliana interacting protein-gene id:MYH19.17 901 gi456384 Blastocrithidia apocytochrome B 41 50 culicis 902 gi2565046 Homo sapiens CAGF28 3775 97 902 gi21707458 Homo sapiens PAX transcription activation domain 2709 87 WO 2004/080148 PCT/US2003/030720 158 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity interacting protein 1 like 902 gi4336734 Mus musculus Pax transcription activation domain 2473 80 interacting protein PTIP 903 gi4336734 Mus musculus Pax transcription activation domain 531 93 interacting protein PTIP 903 gi14164561 Xenopus laevis Swift 467 79 903 gil2382298 Human OrfKlO 48 34 herpesvirus 8 904 gi19353375 Mus musculus RIKEN cDNA 1110031102 gene 745 78 904 gil5929776 Homo sapiens growth suppressor 1 137 41 904 gi5805194 Rattus leprecan 137 41 norvegicus 905 gi2443352 Mus musculus platelet glycoprotein lb beta 150 45 905 gi21355064 Homo sapiens platelet glycoprotein Ib beta chain 146 43 905 gi306792 Homo sapiens platelet glycoprotein Ib beta chain 146 43 precursor 906 gil3991166 Homo sapiens sialic acid-binding immunoglobulin-like 1174 100 lectin-like short splice variant 906 gi13991167 Homo sapiens sialic acid-binding immunoglobulin-like 1174 100 lectin-like long splice variant 906 gil4625822 Homo sapiens Siglec-L1 1174 100 907 gi21708018 Mus musculus RIKEN cDNA 2700029E10 gene 626 66 907 gi7547035 Homo sapiens SGC32445 protein 474 63 907 gi21626575 Drosophila CG30193-PA 457 55 melanogaster 908 gi6273399 Homo sapiens melanoma-associated antigen MG50 2748 60 908 gi1504040 Homo sapiens similar to D.melanogaster 2748 60 peroxidasin(U11052) 908 gi531385 Drosophila peroxidasin precursor 1721 42 melanogaster 909 gi6273399 Homo sapiens melanoma-associated antigen MG50 2748 60 909 gi1504040 Homo sapiens similar to Dmelanogaster 2748 60 peroxidasin(U 11052) 909 gi531385 Drosophila peroxidasin precursor 1721 42 melanogaster 910 gi6273399 Homo sapiens melanoma-associated antigen MG50 2799 59 910 gi1504040 Homo sapiens similar to D.melanogaster 2799 59 peroxidasin(U1 1052) 910 gi531385 Drosophila peroxidasin precursor 1708 41 melanogaster 911 gil8182323 Mus musculus crumbs-like protein 1 precursor 777 31 911 gi6014482 Homo sapiens CRB1 754 30 911 gil8175289 Homo sapiens CRB1 isoform I precursor 754 30 912 gi6650802 Homo sapiens PRO1848 205 56 912 gi21104464 Homo sapiens OK/SW-CL.41 188 61 912 gil1493463 Homo sapiens PR02852 175 54 913 gi6808611 Homo sapiens 88-kDa Golgi protein 3237 99 913 gi6969980 Homo sapiens golgin 67 2345 98 913 gi7211438 Homo sapiens golgin-67 2330 98 914 gi307377 Homo sapiens cAMP-dependent protein kinase RI-beta 1957 99 regulatory subunit 914 gi200365 Mus musculus cAMP-dependent protein kinase 1886 94 regulatory subunit 914 gi15030299 Mus musculus Similar to protein kinase, cAMP 1881 94 WO 2004/080148 PCT/US2003/030720 159 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity dependent regulatory, type I beta 915 gi20306468 Mus musculus Similar to RIKEN cDNA 2610025P08 382 41 gene 915 gi7161798 Homo sapiens dJ470B24.1.1 (myeloid/lymphoid or 130 32 mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 4 (AF-6) (isoform 1)) 915 gi7161797 Homo sapiens dJ470B24.1.2 (mycloid/lymphoid or 130 32 mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 4 (AF-6) (isoform 2)) 916 gil845577 Mus musculus arachidonate 12(S)-lipoxygenase 2633 77 916 gi3645913 Mus musculus 12(S)-lipoxygenase 2633 77 916 gil5489302 Mus musculus Similar to arachidonate 15-lipoxygenase 2631 77 917 gi15489302 Mus musculus Similar to arachidonate 15-lipoxygenase 751 78 917 gil845577 Mus musculus arachidonate 12(S)-lipoxygenase 748 78 917 gil101886 Mus musculus arachidonate lipoxygenase 748 78 918 gil5489302 Mus musculus Similar to arachidonate 15-lipoxygenase 1266 75 918 gil845577 Mus musculus arachidonate 12(S)-lipoxygenase 1263 75 918 gil101886 Mus musculus arachidonate lipoxygenase 1263 75 919 gi13661964 Leishmania L344.3 108 21 major 919 gil7135639 Nostoc sp. PCC WD-repeat protein 95 21 7120 919 gil 1139242 Homo sapiens meiotic recombination protein REC14 93 25 920 gi17862298 Drosophila LD21662p 627 42 melanogaster 920 gi2425 111 Dictyostelium ZipA 122 28 discoideum 920 gi641958 Homo sapiens non-muscle myosin B 118 24 921 gi8132683 Homo sapiens cytokine-like protein C17 241 64 921 gil2751073 Homo sapiens PNAS-31 74 92 921 gil1323101 Saint Croix VP4 79 32 river virus 922 gi8132683 Homo sapiens cytokine-like protein C17 241 64 922 gi12751073 Homo sapiens PNAS-31 74 92 922 gi11323101 Saint Croix VP4 79 32 river virus 923 gi8132683 Homo sapiens cytokine-like protein C17 384 73 923 gil2751073 Homo sapiens PNAS-31 74 92 923 gi216168 Bacteriophage promoter 3 protein 56 37 SPP 1 924 gi8132683 Homo sapiens cytokine-like protein C17 263 98 924 gil143067 Canis familiaris alpha-L-fucosidase 69 59 924 gi309444 Mus musculus MRK 58 65 925 gi8132683 Homo sapiens cytokine-like protein C17 591 100 925 gi3406819 Mus musculus growth factor receptor 64 60 925 gi12724591 Lactococcus UNKNOWN PROTEIN 41 37 lactis subsp. lactis 926 gil7975777 Homo sapiens vesicular inhibitory amino acid 2741 99 transporter 926 gil3396317 Homo sapiens bA12201.1 (A novel protein (ortholog of 2741 99 the mouse vesicular inhibitory amino acid transporter, VIAAT)) WO 2004/080148 PCT/US2003/030720 160 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 926 gi2587061 Rattus vesicular GABA transporter 2694 98 norvegicus 927 gi3097285 Rattus ZOG 670 39 norvegicus 927 gi802014 Rattus preadipocyte factor 1 665 39 norvegicus 927 gil3365691 Mus musculus dlk (Delta like) 649 39 928 gi6624073 Homo sapiens similar to hepatitis delta antigen 1757 93 interacting protein A; similar to AAB05928.1 (PID:g1488314) 928 gi1488314 Homo sapiens hepatitis delta antigen interacting protein 274 45 A 928 gil6768374 Drosophila GM03282p 359 37 melanogaster 929 gi4337106 Homo sapiens BAT4 864 98 929 gil4250638 Homo sapiens Similar to DNA segment, Chr 17, human 864 98 D6S54E 929 gi3941733 Mus musculus BAT4 581 71 930 gi9759107 Arabidopsis phosphate/phosphoenolpyruvate 289 30 thaliana translocator protein-like 930 gi21536504 Arabidopsis phosphate/phosphoenolpyruvate 245 27 thaliana translocator-like protein 930 gi8778643 Arabidopsis F5011.25 235 29 thaliana 931 gi5852981 Homo sapiens cardiotrophin-like cytokine CLC 1204 99 931 gi6007641 Homo sapiens neurotrophin- 1/B-cell stimulating factor-3 1204 99 931 gil5277895 Homo sapiens Similar to cardiotrophin-like cytokine; 1204 99 neurotrophin-1/B-cell stimulating factor-3 932 gi22003732 Homo sapiens MTLC 853 99 932 gil8490933 Homo sapiens Similar to RIKEN cDNA 1110020B04 846 98 gene 932 gi20453974 Mus musculus MT-MCi 718 82 933 gi9958075 Arabidopsis Putative methionine aminopeptidase 739 53 thaliana 933 gil1320956 Arabidopsis methionine aminopeptidase-like protein 739 53 thaliana 933 gi21553973 Arabidopsis methionyl aminopeptidase-like protein 717 52 thaliana 934 gi4104963 Rattus neurexophilin 4 1493 90 norvegicus 934 gil336013 Mus musculus neurexophilin 2 327 65 934 gi4105164 Homo sapiens neurexophilin 2 323 65 935 gi15025812 Clostridium Methyl-accepting chemotaxis protein 65 38 acetobutylicum with HAMP domain 935 gil7224936 Trypanosoma corset-associated protein 15 63 31 brucei 935 gi15025892 Clostridium Ribosome-associated protein Y (PSrp-1) 48 38 acetobutylicum 936 gi16197625 Arabidopsis anaphase promoting complex subunit 11 64 32 thaliana 936 gil0834682 Homo sapiens PP3958 74 46 937 gil9387136 Homo sapiens PYRIN-containing APAF1-like protein 5 874 99 937 gi202806 Rattus vasopressin receptor 561 68 norvegicus 937 gi21410402 Mus musculus expressed sequence A1504961 532 67 WO 2004/080148 PCT/US2003/030720 161 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 938 gil1321325 Homo sapiens Lin-7b 1030 100 938 gi20381193 Homo sapiens Lin-7b protein; likely ortholog of mouse 1030 100 LIN-7B; mammalian L1N-7 protein 2 938 gi3885828 Rattus lin-7-A 1019 98 norvegicus 939 gil4349125 Homo sapiens alpha2-glucosyltransferase 738 96 939 gi3513451 Rattus potassium channel regulator 1 718 93 norvegicus 939 gi21711799 Drosophila RH44301p 142 32 melanogaster 940 gil2803183 Homo sapiens polypyrimidine tract binding protein 1527 91 (heterogeneous nuclear ribonucleoprotein I) 940 gi32354 Homo sapiens nuclear ribonucleoprotein 1527 91 940 gi35772 Homo sapiens polypirimidine tract binding protein 1527 91 941 gi6752658 Homo sapiens epidermal growth factor repeat containing 3046 99 protein 941 gil6040981 Mus musculus POEM 884 51 941 gil5430246 Mus musculus nephronectin short isoform 884 51 942 gi6752658 Homo sapiens epidermal growth factor repeat containing 3036 98 protein 942 gi16040981 Mus musculus POEM 884 51 942 gi15430246 Mus musculus nephronectin short isoform 884 51 943 gil7980969 Homo sapiens sel4-3r protein 5146 99 943 gil1385648 Homo sapiens CTCL tumor antigen sel4-3 3867 99 943 gi7960216 Homo sapiens RACK-like protein PRKCBPI 3124 99 944 gil7980969 Homo sapiens sel4-3r protein 3140 99 944 gil3677201 Homo sapiens dJ569M23.1.2 (protein kinase C binding 2771 100 protein 1, isoform 2) 944 gi13677198 Homo sapiens dJ569M23.1.3 (protein kinase C binding 2638 96 protein 1, isoform 3 (DKFZp564P1772)) 945 gil7980969 Homo sapiens sel4-3r protein 3550 84 945 gil3677201 Homo sapiens dJ569M23.1.2 (protein kinase C binding 2771 100 protein 1, isoform 2) 945 gil3677198 Homo sapiens dJ569M23.1.3 (protein kinase C binding 2638 96 protein 1, isoform 3 (DKFZp564P1772)) 946 gil7980969 Homo sapiens se14-3r protein 3550 84 946 gi13677198 Homo sapiens dJ569M23.1.3 (protein kinase C binding 2380 90 protein 1, isoform 3 (DKFZp564P1772)) 946 gi13677201 Homo sapiens dJ569M23.1.2 (protein kinase C binding 2377 90 protein 1, isoform 2) 947 gil4043211 Homo sapiens Similar to RIKEN cDNA 4931428F04 2410 98 gene 947 gi22204070 Macaca mulatta metabotropic glutamate receptor 1 91 42 947 gil70454 Lycopersicon cell wall hydroxyproline-rich 70 39 esculentum glycoprotein 948 gil4972753 Streptococcus alcohol dehydrogenase, zinc-containing 51 33 pneumoniae TIGR4 948 gi20152351 Avian spike glycoprotein S1 subunit 68 34 infectious bronchitis virus 948 gi9658106 Vibrio cholera polyhydroxyalkanoic acid synthase 67 26 949 gil9387136 Homo sapiens PYRIN-containing APAF1-like protein 5 1738 99 949 gi202806 Rattus vasopressin receptor 1037 64 WO 2004/080148 PCT/US2003/030720 162 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity norvegicus 949 gi21410402 Mus musculus expressed sequence A1504961 988 63 950 gi3978472 Rattus potassium channel subunit 5393 88 norvegicus 950 gi20338417 Gallus gallus potassium channel subunit 4792 88 950 gi7303760 Drosophila CG12904-PA 981 62 melanogaster 951 gil8147612 Homo sapiens metalloprotease disintegrin 3535 99 951 gi21908028 Homo sapiens a disintegrin and metalloprotease domain 3535 99 33 951 gil3157560 Homo sapiens dJ964F7.1 (novel disintegrin and 3078 99 reprolysin metalloproteinase family protein) 952 gil8606367 Mus musculus RIKEN cDNA 4930570C03 gene 715 92 952 gi9971130 Schizosaceharo human downs syndrome critical region- 72 31 myces pombe like 952 gi5708224 Rhodoblastus LH2alpha5 60 31 acidophilus 953 gil5420879 Mus musculus ankyrin repeat-containing SOCS box 2053 82 protein 10 953 gil8092200 Homo sapiens ASB-10 1909 98 953 gil8031949 Mus musculus SOCS box protein ASB-18 816 45 954 gi491284 synthetic IFN-pseudo-omega 2 799 98 construct 954 gi386800 Homo sapiens interferon-alpha 330 72 954 gi490 110 Homo sapiens interferon-omega 1 330 72 955 gi9844580 Homo sapiens dJ1 153D9.4 (novel protein) 623 84 955 gi9844579 Homo sapiens dJ1153D9.3 (novel protein) 450 97 955 gil5928971 Homo sapiens Similar to neuronal thread protein 430 90 956 gil2804321 Homo sapiens peroxisomal short-chain alcohol 685 100 dehydrogenase 956 gi19113668 Homo sapiens NADP-dependent retinol dehydrogenase 878 100 short isoform 956 gil 1559412 Homo sapiens NADPH-dependent retinol 587 100 dehydrogenase/reductase 957 gil2718818 Mus musculus sulfhydryl oxidase 496 49 957 gil2718820 Rattus sulfhydryl oxidase 489 47 norvegicus 957 gil2483919 Rattus FAD-dependent sulfhydryl oxidase-2 489 47 norvegicus 958 gi12958660 Homo sapiens acid phosphatase 2252 100 958 gil2958663 Homo sapiens acid phosphatase variant 3 1285 99 958 gi52871 Mus musculus lysosomal acid phosphatase 837 45 959 gi28966 Homo sapiens alpha 1-antitrypsin 1703 100 959 gi6855601 Homo sapiens PR00684 1703 100 959 gil1493443 Homo sapiens PR02209 1703 100 960 gi28966 Homo sapiens alpha 1-antitrypsin 1080 100 960 gil1493443 Homo sapiens PR02209 1080 100 960 gil77829 Homo sapiens alpha-1-antitrypsin 1080 100 961 gi28966 Homo sapiens alpha 1-antitrypsin 1239 100 961 gil 1493443 Homo sapiens PR02209 1239 100 961 gil77829 Homo sapiens alpha-1-antitrypsin 1239 100 962 gi28966 Homo sapiens alpha 1-antitrypsin 1574 93 962 gil 1493443 Homo sapiens PR02209 1574 93 WO 2004/080148 PCT/US2003/030720 163 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 962 gi177829 Homo sapiens alpha-1-antitrypsin 1574 93 963 gi6706993 Streptomyces methyltransferase 83 26 coelicolor A3(2) 963 gi7303904 Drosophila CG13954-PA 85 53 melanogaster 964 gi2632092 Pongo fertilin alpha protein 4128 92 pygmaeus 964 gi794073 Macaca fertilin alpha-I 3136 74 fascicularis 964 gi1841702 Macaca fertilin alpha-I isoform 3136 74 fascicularis 965 gi4107229 Homo sapiens lipophilin A 454 100 965 gi4107231 Homo sapiens lipophilin B 267 60 965 gil7887359 Oryctolagus lipophilin AL2 248 54 cuniculus 966 gi3335100 Homo sapiens CD39L3 2816 100 966 gil3817037 Homo sapiens E-type ATPase 2812 99 966 gi20988653 Homo sapiens Similar to ectonucleoside triphosphate 2413 99 diphosphohydrolase 3 967 gi6942096 Mus musculus CBLN3 936 93 967 gil80251 Homo sapiens precerebellin 549 57 967 gi5702371 Mus musculus precerebellin-1 542 56 968 gil7390957 Mus musculus Similar to RIKEN cDNA 2010001E11 129 32 gene 968 gil6410838 Listeria similar to multidrug-efflux transporter 95 27 monocytogenes 968 gi4914624 Listeria multidrug resistance transporter 95 27 monocytogenes 969 gil7390957 Mus musculus Similar to RIKEN cDNA 2010001E1 1 191 26 gene 969 gi2828808 Bacillus subtilis glucose transporter 100 23 969 gi14023 148 Mesorhizobium probable fosmidomycin resistance protein 112 25 loti 970 gil3161123 Homo sapiens transcript Y 10 151 54 970 gi4545317 Acipenser immunoglobulin light chain precursor 160 25 ruthenus 970 gi9937599 Salmo trutta MHC class I heavy chain 160 31 971 gi4160197 Homo sapiens dJ327J16.2 (supported by GENSCAN 2515 99 and GENEWISE) 971 gi2253263 Rattus neuronal pentraxin receptor 2238 89 norvegicus 971 gil2744624 Mus musculus neuronal pentraxin receptor 2212 88 972 gi4760782 Mus musculus Ten-m4 4188 96 972 gi3170615 Mus musculus DOC4 4166 96 972 gi5307785 Danio rerio ten-m4 3537 78 973 gi14714932 Homo sapiens Similar to nuclear factor (erythroid- 3770 100 derived 2)-like 1 973 gi473090 Mus musculus NFE2-related factor 1 3644 96 973 gi3978250 Mus musculus Nrfl splice variant D 3280 96 974 gi7716100 Rattus selective LIM binding factor 8413 95 norvegicus 974 gil7044301 Leishmania possible LIM-binding factor 2139 36 major 974 gil0440379 |Homo sapiens FLJO0025 protein 135 25 WO 2004/080148 PCT/US2003/030720 164 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 975 gi20799661 Mus musculus mucolipin-2 1593 72 975 gi20987535 Mus musculus RIKEN cDNA 3300002C04 gene 1590 71 975 gi19072756 Mus musculus mucolipin-3 1136 51 976 gi20799661 Mus musculus mucolipin-2 2394 83 976 gi20987535 Mus musculus RIKEN cDNA 3300002C04 gene 2391 82 976 gi19072754 Homo sapiens mucolipin-3 1674 59 977 gi403020 Mus musculus En-2/lacZ fusion protein 988 96 977 gil4193747 Mus musculus zinc finger 142 258 24 977 gil510147 Homo sapiens similar to Human zinc finger 223 20 protcin(ZNF142) 978 gi10581238 Halobacterium Vngl783h 54 46 sp. NRC- 1 1 978 gil9699294 Arabidopsis AT3g48750/T21J18_20 73 30 thaliana 979 gi7959724 Homo sapiens PR00929 63 30 979 gil3540242 Anopheles NADH dehydrogenase subunit 5 62 31 stephensi 979 gi20904847 Methanosarcina 8-oxoguanine DNA glycosylase 64 40 mazei Goel 980 gi5281519 Homo sapiens HTRA serine protease 2164 100 980 gil513059 Homo sapiens serin protease with IGF-binding motif 2164 100 980 gi1621244 Homo sapiens novel serine protease, PRSS1 1 2164 100 981 gi7008025 Callithrix prochymosin 832 68 jacchus 981 gi19851892 Bos taurus chymosin precursor 515 77 981 gi162860 Bos taurus preprochymosin b 752 62 982 gi18461371 Rattus sulfatase FP 276 68 norvegicus 982 gi21961489 Mus musculus Similar to sulfatase FP 276 68 982 gil5430244 Coturnix N-acetylglucosamine-6-sulfatase 263 68 coturnix 983 gi3043872 Lactococcus transmembrane protein Tmp3 69 32 lactis 983 gil7428881 Ralstonia CONSERVED HYPOTHETICAL 62 34 solanacearum PROTEIN 983 gi433707 Zea mays prolin rich protein 63 48 984 gi6013463 Bothrops carboxypeptidase homolog 826 46 jararaca 984 gi9558448 Mus musculus carboxypeptidase R 812 45 984 gi7416967 Mus musculus thrombin-activatable fibrinolysis inhibitor 812 45 985 gi6013463 Bothrops carboxypeptidase homolog 826 46 j araraca 985 gi9558448 Mus musculus carboxypeptidase R 812 45 985 gi7416967 Mus musculus thrombin-activatable fibrinolysis inhibitor 812 45 986 gil1545707 Homo sapiens ISCU2 845 100 986 gi20381021 Mus musculus RIKEN cDNA 2310020H20 gene 807 96 986 gil1545705 Homo sapiens ISCUl 663 99 987 gil2314022 Homo sapiens dJ553F4.4 (Novel protein similar to 881 89 Drosophila CG8055 protein) 987 gi22417143 Homo sapiens CGI-301 protein 853 100 987 gil3182765 Homo sapiens CDA04 560 60 988 gi52959 Mus musculus precursor polypeptide (AA -26 to 108) 146 34 988 gi198922 Mus musculus lymphocyte differentiation antigen 145 34 988 gil98926 Mus musculus Ly-6A.2 alloantigen 145 34 WO 2004/080148 PCT/US2003/030720 165 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 990 gi15990480 Homo sapiens Similar to AE-binding protein 2 1570 100 990 gi4106464 Mus musculus AE-1 binding protein AEBP2 1555 98 990 gi21595036 Mus musculus AE binding protein 2 1555 98 991 gi23903 Homo sapiens 63kDa protein kinase 2897 99 991 gi204058 Rattus extracellular signal-related kinase 3 1499 62 norvegicus 991 gil6306437 Homo sapiens ERK-3 1492 62 992 gi17016967 Homo sapiens NUANCE 3403 90 992 gil7861384 Homo sapiens nesprin-2 gamma 3403 90 992 gi21748548 Homo sapiens FLJ00347 protein 3403 90 993 gi20070711 Homo sapiens similar to RIKEN cDNA 2310044D20 997 100 993 gil8204756 Mus musculus Similar to RIKEN cDNA 2310044D20 626 68 gene 993 gi7304139 Drosophila CG12159-PA 111 28 melanogaster 994 gi14278927 Mus musculus gliacolin 866 68 994 gil0566471 Mus musculus Gliacolin 866 68 994 gi3747099 Mus musculus Clq-related factor 734 67 995 gi20987689 Homo sapiens Similar to allantoicase 1838 99 995 gil4718648 Homo sapiens allantoicase 1633 99 995 gi9255889 Mus musculus allantoicase 1476 77 997 gi2522208 Homo sapiens Ras-GRF2 6407 99 997 gi5882290 Homo sapiens Ras guanine nucleotide exchange factor 2 6401 99 997 gi57665 Rattus rattus P140 RAS-GRF 4121 65 998 gi22038159 Homo sapiens ziziminl 8544 100 998 gil4597976 Homo sapiens human CLASP-4 3533 56 998 gi550420 Rattus trg 2842 87 norvegicus 999 gil7861850 Drosophila GM03763p 334 70 melanogaster 999 gil7862036 Drosophila LD05823p 265 47 melanogaster 999 gi10178624 Mus musculus SETA binding protein 1; SB1 215 45 1000 gi21594273 Homo sapiens SAC2 suppressor of actin mutations 2- 3626 100 like (yeast) 1000 gi14041697 Homo sapiens dJ1033B10.5.1 (SAC2 (suppressor of 3587 99 actin mutations 2, yeast, homolog)-like (AREI), isoform 1) 1000 gi3850063 Rattus AREl 3576 98 norvegicus 1001 gil438534 Rattus rA9 4002 61 norvegicus 1001 gil438532 Rattus rAl 430 36 norvegicus 1001 gi9438033 Homo sapiens ser/arg-rich pre-mRNA splicing factor 407 35 SR-Al 1002 gil438534 Rattus rA9 4002 61 norvegicus 1002 gi9438033 Homo sapiens ser/arg-rich pre-mRNA splicing factor 407 35 SR-Al 1002 gil0440402 Homo sapiens FLJO0034 protein 407 35 1003 gi1675220 Cricetulus SREBP cleavage activating protein 6200 92 griseus 1003 gi20378357 Drosophila ER-golgi escort protein 810 39 WO 2004/080148 PCT/US2003/030720 166 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity melanogaster 1003 gil0728147 Drosophila CG8356-PA 810 39 melanogaster 1004 gil2652851 Homo sapiens potassium channel modulatory factor 1987 100 1004 gi4838557 Mus musculus DEBT-91 1453 96 1004 gil6768790 Drosophila LD03515p 876 63 melanogaster 1005 gi7270532 Arabidopsis DNA-directed RNA polymerase (EC 173 29 thaliana 2.7.7.6) II largest chain 1005 gi16505 Arabidopsis RNA polymerase II 173 29 thaliana 1005 gi16494 Arabidopsis DNA-directed RNA polymerase 173 29 thaliana 1006 gil1875318 Mus musculus synaptotagmin XIII 2004 89 1006 gi21410154 Mus musculus synaptotagmin 13 2004 89 1006 gil1119239 Rattus synaptotagmin 13 2000 89 norvegicus 1007 gi3800881 Homo sapiens RanBP7/importin 7 5447 100 1007 gil 1342591 Mus musculus RanBP7/importin 7 5418 99 1007 gi11544639 Homo sapiens importin7 5307 100 1008 gi5578958 Homo sapiens dJ475B7.2 (novel protein) 3770 99 1008 gil8676522 Homo sapiens FLJO0158 protein 1512 100 1008 gi21595156 Mus musculus Similar to RIKEN cDNA 5830482G23 1151 71 gene 1009 gi4406393 Bos taurus differentiation enhancing factor 1 4699 95 1009 gi4063614 Mus musculus ADP-ribosylation factor-directed GTPase 4694 94 activating protein isoform a 1009 gi4063616 Mus musculus ADP-ribosylation factor-directed GTPase 3186 79 activating protein isoform b 1010 gi16411927 Listeria 1mo2439 57 52 monocytogenes 1010 gi16415055 Listeria innocua lin2533 61 57 1010 gi2983786 Aquifex glucose-l-phosphate 70 39 aeolicus thymidylyltransferase 1011 gi9280405 Homo sapiens adlican 1631 47 1011 gil3872813 Homo sapiens fibulin-6 502, 28 1011 gi3328186 Caenorhabditis hemicentin precursor 539 27 elegans 1012 gi4001698 Sus scrofa mat-8 67 30 1012 gi2622724 Methanothermo conserved protein 82 29 bacter thermautotrophi cus str. Delta H 1012 gi498166 Mus musculus zona-pellucida-binding protein (sp38) 85 27 1013 gil7511816 Homo sapiens Similar to RIKEN cDNA 1110032022 1468 99 gene 1013 gi7211438 Homo sapiens golgin-67 100 30 1013 gi6003208 Human p17 protein 84 29 immunodeficien cy virus type 1 1014 gil7511816 Homo sapiens Similar to RIKEN cDNA 1110032022 878 100 gene 1014 gi6003208 Human p17 protein 84 29 immunodeficien cy virus type 1 WO 2004/080148 PCT/US2003/030720 167 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1014 gi21957065 Yersinia pestis uroporphyrinogen III methylase 90 34 KIM 1015 gi2246401 Homo sapiens centrin 842 100 1015 gil3529248 Homo sapiens centrin, EF-hand protein, 3 (CDC31 yeast 839 99 homolog) 1015 gi2246424 Mus musculus centrin 832 98 1016 gil7428765 Ralstonia CONSERVED HYPOTHETICAL 530 43 solanacearum PROTEIN 1016 gi15155946 Agrobacterium AGRC_1725p, 379 41 tumefaciens str. C58 (Cereon) 1016 gi15073913 Sinorhizobium CONSERVED HYPOTHETICAL 372 39 meliloti PROTEIN 1017 gil7428765 Ralstonia CONSERVED HYPOTHETICAL 381 43 solanacearum PROTEIN 1017 gil5073913 Sinorhizobium CONSERVED HYPOTHETICAL 367 48 meliloti PROTEIN 1017 gi12543118 Corynebacteriu RXC01693 265 30 m glutamicum 1018 gi6693701 Homo sapiens melanopsin 2234 91 1018 gi21928729 Homo sapiens seven transmembrane helix receptor 2190 99 1018 gi6693703 Mus musculus melanopsin 1735 73 1019 gi439296 Homo sapiens garp 822 37 1019 gi6572272 Homo sapiens dJ756G23.1 (novel Leucine Rich Protein) 243 34 1019 gi19344010 Homo sapiens insulin-like growth factor binding protein, 293 29 acid labile subunit 1020 gil5706421 Homo sapiens middle-chain acyl-CoA synthetasel 1346 99 1020 gil5487302 Homo sapiens medium-chain acyl-CoA synthetase 1346 99 1020 gi5019275 Bos taurus xenobiotic/medium-chain fatty acid:CoA 1088 78 ligase form XL-III 1021 gi6650766 Homo sapiens PDZ domain-containing guanine 6216 100 nucleotide exchange factor I 1021 gi20386206 Homo sapiens PDZ domain-containing guanine 5822 98 nucleotide exchange factor PDZ-GEF2 1021 gil8874700 Homo sapiens Rap1 guanine nucleotide-exchange factor 5803 98 PDZ-GEF2B 1022 gi20386206 Homo sapiens PDZ domain-containing guanine 5942 100 nucleotide exchange factor PDZ-GEF2 1022 gil8874700 Homo sapiens Rap1 guanine nucleotide-exchange factor 5923 99 PDZ-GEF2B 1022 gil8874698 Homo sapiens Rap1 guanine nucleotide-exchange factor 5923 99 PDZ-GEF2A 1023 gil3810306 Homo sapiens transmembrane protein 7 268 37 1023 gil8250724 Mus musculus transmembrane protein 7 264 37 1023 gi20270907 Oncorhynchus VHSV-induced protein-5 243 33 mykiss 1024 gi21779869 Homo sapiens IL-17RE 2896 100 1024 gi21779866 Mus musculus IL-17RE 1394 74 1024 gi21779857 Homo sapiens IL-17RC 246 29 1025 gi21779869 Homo sapiens IL-17RE 2928 100 1025 gi21779866 Mus musculus IL-17RE 1388 75 1025 gi21779857 Homo sapiens IL-17RC 246 29 1026 gil4150450 Rattus UDP-GalNAc:polypeptide N- 1352 93 norvegicus acetylgalactosaminyltransferase T9 1026 gil6769916 Drosophila SD10722p 473 38 WO 2004/080148 PCT/US2003/030720 168 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity melanogaster 1026 gi21627105 Drosophila CG30463-PA 417 38 melanogaster 1027 gil5217067 Homo sapiens stem cell factor isoform 1 1013 95 1027 gi337934 Homo sapiens stem cell factor 1013 95 1027 gil827477 Felis catus stem cell factor 893 84 1028 gil377894 Homo sapiens OB-cadherin-1 1478 64 1028 gil377895 Homo sapiens OB-cadherin-2 1478 64 1028 gi506404 Homo sapiens cadherin-11 1474 63 1029 gil377894 Homo sapiens OB-cadherin-1 1628 56 1029 gil377895 Homo sapiens OB-cadherin-2 1628 56 1029 gi506404 Homo sapiens cadherin-1 1 1623 56 1030 gi1398903 Mus musculus Ca2+ dependent activator protein for 6314 90 secretion 1030 gi577428 Rattus Ca2+-dependcnt activator protein; 5003 96 norvegicus calcium-dependent actin-binding protein 1030 gi6980012 Drosophila secretion calcium-dependent activator 3540 60 melanogaster protein 1031 gi217705 Sus scrofa dipeptidase precursor 781 51 1031 gi2102 Sus scrofa dipeptidase 781 51 1031 gi8248922 Homo sapiens renal dipeptidase; RDP 762 50 1032 gil8073362 Homo sapiens cystine/glutamate transporter 2552 100 1032 gi11493652 Homo sapiens calcium channel blocker resistance 2552 100 protein CCBR1 1032 gil3924720 Homo sapiens cystine/glutamate transporter xCT 2552 100 1033 gi17028348 Homo sapiens Similar to methylenetetrahydrofolate 3748 100 dehydrogenase (NADP+ dependent), methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase 1033 gi20987924 Mus musculus Similar to DKFZP586G15i7 protein 3473 92 1033 gi307178 Homo sapiens MDMCSF (EC 1.5.1.5; EC 3.5.4.9; EC 2839 62 6.3.4.3) 1034 gi632676 Saccharomyces Ylr4lOwp 598 44 cerevisiae 1034 gi4070 Saccharomyces nufi 120 20 cerevisiae 1034 gi312175 Saccharomyces SPC110/NUFI 120 20 cerevisiae 1035 gil1066463 Rattus RhoGEF glutamate transport modulator 5589 80 norvegicus GTRAP48 1035 gi19387126 Mus musculus guanine nucleotide exchange factor 1794 37 1035 gi7110160 Homo sapiens guanine nucleotide exchange factor 1792 37 1036 gi2921821 Rattus cytochrome P450 IIE1 68 28 norvegicus 1036 gi8S515399 Human attachment glycoprotein G 64 29 respiratory syncytial virus 1036 gi5901834 Drosophila BcDNA.GH09358 95 23 melanogaster 1037 gi17128288 synthetic Primer 1 1689 100 construct 1037 gi20269957 Sus scrofa phospholipase C delta 4 1469 85 1037 gi21307610 Mus musculus phospholipase C delta 4 1327 77 1038 gi6978948 Homo sapiens vaccinia related kinase 3 76 24 WO 2004/080148 PCT/US2003/030720 169 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1038 gi349667 Carnobacterium carnobacteriocin A 60 41 piscicola 1038 gi406315 Camobacterium piscicolin 61 60 41 piscicola 1039 gi4159884 Homo sapiens similar to mouse olfactory receptor 13; 1597 99 similar to P34984 (PID:g464305) 1039 gi9368991 Homo sapiens dJ1005H11.1 (7 TRANSMEMBRANE 1410 100 RECEPTOR (RHODOPSIN FAMILY) (OLFACTORY RECEPTOR LIKE) PROTEIN)) 1039 gil8480186 Mus musculus olfactory receptor MOR261-6 1323 81 1040 gi311626 Homo sapiens thrombospondin-4 4787 99 1040 gi3860231 Mus musculus thrombospondin-4 4557 93 1040 gi929835 Rattus thrombospondin-4 4547 93 norvegicus 1041 gi14043083 Homo sapiens sperm associated antigen 9 660 100 1041 gi3116015 Homo sapiens sperm specific protein 273 98 1041 gil0801 148 Mus musculus JNK/SAPK-associated protein 1 98 41 1042 gi21654741 Homo sapiens peptide/histidine transporter 1746 98 1042 gi2208839 Rattus peptide/histidine transporter 1469 79 norvegicus 1042 gi16740719 Mus musculus Similar to peptide transporter 3 1453 83 1043 gi21392228 Drosophila RH61354p 1221 41 melanogaster 1043 gi19353264 Homo sapiens Similar to dishevelled associated activator 2224 65 of morphogenesis 2 1043 gi2947238 Homo sapiens diaphanous 1 717 32 1044 gi15929979 Homo sapiens Similar to zinc finger protein 345 2476 100 1044 gil8643896 Homo sapiens zinc finger protein 1656 53 1044 gil020145 Homo sapiens DNA binding protein 1656 53 1045 gil2655913 Homo sapiens sprouty-4A 386 98 1045 gi4850326 Mus musculus sprouty-4 323 81 1045 gi5917720 Mus musculus sprouty 4 323 81 1046 gi4539525 Homo sapiens NAALADase II protein 3881 100 1046 gi3211746 Sus scrofa folylpoly-gamma-glutamate 2824 70 carboxypeptidase 1046 gi2897946 Homo sapiens prostate-specific membrane antigen 2787 69 1047 gi5420389 Leishmania proteophosphoglycan 139 23 major 1047 gi915207 Sus scrofa gastric mucin 123 22 1047 gil3592175 Leishmania ppg3 125 23 major 1048 gi5918167 Homo sapiens plexin-B1/SEP receptor 2104 54 1048 gi6010211 Homo sapiens semaphorin receptor 2103 54 1048 gi1655432 Mus musculus plexin 2 1517 30 1049 gi15990515 Homo sapiens Similar to RIEN cDNA 0610020102 3035 100 gene 1049 gi18380977 Mus musculus RIEN cDNA 0610020102 gene 2792 92 1049 gi2384732 Rattus NAC-1 protein 1269 57 norvegicus 1050 gi15088540 Homo sapiens sterolin-2 3127 99 1050 gi11692802 Homo sapiens ABCG8 3123 99 1050 gi15146444 Homo sapiens stcrolin-2 3120 99 1051 gi12652851 Homo sapiens potassium channel modulatory factor 1987 100 WO 2004/080148 PCT/US2003/030720 170 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1051 gi4838557 Mus musculus DEBT-91 1453 96 1051 gi16768790 Drosophila LD03515p 876 63 melanogaster 1052 gi33730 Homo sapiens immunoglobulin lambda light chain 716 71 1052 gi33395 Homo sapiens lambda-chain precursor (AA -20 to 215) 703 70 1052 gi33744 Homo sapiens immunoglobulin lambda light chain 697 68 1053 gi21388773 Homo sapiens kringle-containing protein 1552 100 1053 gi21623530 Homo sapiens kringle-containing transmembrane protein 1238 99 1053 gi21388775 Homo sapiens kringle-containing protein 1241 100 1054 gi14495324 Homo sapiens CMRF35A 421 48 1054 gi18490143 Homo sapiens CMRF35 leukocyte immunoglobulin-like 421 48 receptor 1054 gi396170 Homo sapiens CMRF-35 antigen 421 48 1055 gi4468256 Homo sapiens MHC class I antigen 1974 100 1055 gi32139 Homo sapiens HLA-A11 E protein precursor (AA -24 to 1912 97 341) 1055 gi487909 Homo sapiens HLA-A1 1 antigen Al1.1 1912 97 1056 gi21667214 Homo sapiens bactericidal/permeability-increasing 741 100 protein-like 3 1056 gi57732 Rattus rattus potential ligand-binding protein 215 35 1056 gil1877276 Homo sapiens dJ726C3.5 (ortholog of potential 176 32 ligand binding protein RY2G5 (Rat)) 1057 gi21667214 Homo sapiens bactericidal/permeability-increasing 2226 99 protein-like 3 1057 gi57732 Rattus rattus potential ligand-binding protein 579 32 1057 gi11877276 Homo sapiens dJ726C3.5 (ortholog of potential 540 31 ligand binding protein RY2G5 (Rat)) 1058 gi21667214 Homo sapiens bactericidal/permeability-increasing 1919 99 protein-like 3 1058 gi57732 Rattus rattus potential ligand-binding protein 485 33 1058 gil1877276 Homo sapiens dJ726C3.5 (ortholog of potential 447 31 ligand binding protein RY2G5 (Rat)) 1059 gi21667214 Homo sapiens bactericidal/penneability-increasing 1842 100 protein-like 3 1059 gi57732 Rattus rattus potential ligand-binding protein 485 33 1059 gil1877276 Homo sapiens dJ726C3.5 (ortholog of potential 447 31 ligand binding protein RY2G5 (Rat)) 1060 gi23911 Homo sapiens polypeptide 7B2 precursor 1148 100 1060 gi7718079 Homo sapiens neuroendocrine protein 7B2 1148 100 1060 gil3529158 Homo sapiens secretory granule, neuroendocrine protein 1131 99 1 (7B2 protein) 1061 gil8698601 Homo sapiens Smith-Magenis syndrome chromosome 2325 100 region candidate 7 protein 1061 gil5073752 Sinorhizobium HYPOTHETICAL TRANSMEMBRANE 90 29 meliloti SIGNAL PEPTIDE PROTEIN 1061 gi13623063 Streptococcus heat shock protein - cochaperonin 70 32 pyogenes Ml GAS 1062 gi4128041 Homo sapiens claudin-9 protein 1116 100 1062 gi4325296 Mus musculus claudin-9 1078 95 1062 gil4286272 Homo sapiens claudin 6 826 71 1063 gil4286258 Homo sapiens ribosomal protein L29 432 65 1063 gi1215742 Homo sapiens HIP 432 65 1063 gi793843 Homo sapiens I ribosomal protein L29 432 , 65 WO 2004/080148 PCT/US2003/030720 171 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1064 gi6601555 Rattus glutamate receptor interacting protein 2 3560 86 norvegicus 1064 gi3639077 Rattus AMPA receptor binding protein 2743 88 norvegicus 1064 gil890856 Rattus AMPA receptor interacting protein GRIP 1925 59 norvegicus 1065 gi3288852 Homo sapiens disabled-1 2865 99 1065 gil771282 Mus musculus mbab555 protein 2797 96 1065 gi22095317 Gallus gallus disabled-1 2630 90 1066 gi3002527 Homo sapiens neuronal thread protein AD7c-NTP 164 86 1066 gi4336401 Homo sapiens beta glucuronidase isoform d 127 72 1066 gi4336402 Homo sapiens beta glucuronidase isoform c 127 72 1067 gil5430703 Homo sapiens testis specific serine/threonine kinase 2 1858 99 1067 gi2738898 Mus musculus protein kinase 1686 89 1067 gil5283993 Homo sapiens testis-specific serine/threonine kinase 1 1230 77 1068 gil3543568 Homo sapiens prostaglandin D2 synthase (2lkD, brain) 977 96 1068 gil2963879 Homo sapiens prostaglandin D synthase 977 96 1068 gil89772 Homo sapiens prostaglandin D2 synthase 977 96 1069 gi13279311 Homo sapiens Similar to RIKEN cDNA 1500017E18 1416 96 gene 1069 gi14336718 Homo sapiens similar to HAGH 1157 100 1069 gi20988885 Mus musculus RIKEN cDNA 1500017E18 gene 1151 79 1070 gil3397835 Homo sapiens annexin A13 isoform b 1795 99 1070 gi757784 Canis familiaris annexin XIIIb 1621 89 1070 gi21218387 Oryctolagus annexin XII1b 1589 88 cuniculus 1071 gi21707908 Homo sapiens solute carrier family 6 (neurotransmitter 3129 98 transporter, GABA), member 1 1071 gi31658 Homo sapiens GABA transporter 3114 98 1071 gi204222 Rattus GABA transporter protein 3097 96 norvegicus 1072 gi7160975 Homo sapiens voltage-gated sodium channel beta-3 834 100 subunit 1072 gi7161889 Rattus voltage-gated sodium channel beta-3 823 98 norvegicus subunit 1072 gil4165176 Rattus sodium channel beta 3 subunit 823 98 norvegicus 1074 gil8676470 Homo sapiens FLJO0132 protein 2515 99 1074 gi21430928 Drosophila SD27341p 324 38 melanogaster 1074 gi20197056 Arabidopsis expressed protein 206 29 thaliana 1075 gi452751 Gallus gallus Gal beta 1,4 GIcNAc alpha 2,6- 949 54 sialyltransferase 1075 gi2295223 unidentified GALACTOSYLTRANSFERASE- 856 48 SIALYLTRANSFERASE HYBRID PROTEIN 1075 gi29434 Homo sapiens beta-galactoside alpha-2,6- 856 48 sialyltransferase 1076 gil3344997 Homo sapiens Cat Eye Syndrome critical region protein 2223 100 isoform 2 1076 gi13344995 Homo sapiens Cat Eye Syndrome critical region protein 2002 99 isoform 1 1076 gil5928451 Mus musculus Similar to cat eye syndrome chromosome 1649 76 region, candidate 5 WO 2004/080148 PCT/US2003/030720 172 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1077 gil3344997 Homo sapiens Cat Eye Syndrome critical region protein 1662 96 isoform 2 1077 gil3344995 Homo sapiens Cat Eye Syndrome critical region protein 1662 96 isoform 1 1077 gil5928451 Mus musculus Similar to cat eye syndrome chromosome 1294 75 region, candidate 5 1078 gi 177870 Homo sapiens alpha-2-macroglobulin precursor 2714 39 1078 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 2708 39 1078 gi579594 Homo sapiens alpha 2-macroglobulin 690-740 2700 39 1079 gi671864 Gallus gallus ovomacroglobulin, ovostatin 1300 34 1079 gi579594 Homo sapiens alpha 2-macroglobulin 690-740 1297 35 1079 gil77870 Homo sapiens alpha-2-macroglobulin precursor 1296 35 1080 gi671865 Gallus gallus ovomacroglobulin, ovostatin 806 32 1080 gil77870 Homo sapiens alpha-2-macroglobulin precursor 769 31 1080 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 769 31 1081 gil77870 Homo sapiens alpha-2-macroglobulin precursor 2732 40 1081 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 2726 40 1081 gi579594 Homo sapiens alpha 2-macroglobulin 690-740 2718 39 1082 gi579594 Homo sapiens alpha 2-macroglobulin 690-740 1297 35 1082 gil77870 Homo sapiens alpha-2-macroglobulin precursor 1296 35 1082 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 1296 35 1083 gi404389 Mus sp. carboxylesterase; Es-male 2006 66 1083 gi213101 Anas thioesterase B 1261 46 platyrhynchos 1083 gi2058318 Homo sapiens carboxylesterase 1253 47 1084 gi207286 Rattus TGF-beta masking protein large subunit 8731 89 norvegicus 1 1084 gi3493176 'Mus musculus latent TGF beta binding protein 8640 88 1084 gil9909128 Homo sapiens transforming growth factor-beta binding 7763 99 protein-IS 1085 gi17985371 Homo sapiens 13 binding protein 861 100 1085 gi21961229 Homo sapiens BRI3 binding protein 861 100 1085 gil8466808 Homo sapiens cervical cancer I proto-oncogene-binding 853 99 protein KG 19 1086 gi222833 Gallus gallus M-protein 2953 42 1086 gi407097 Homo sapiens 165kD protein 2933 42 1086 gi2950347 Mus musculus M-protein 2931 42 1087 gil2655165 Homo sapiens zinc finger protein 256 696 65 1087 gi4894364 Homo sapiens zinc finger protein 3 696 65 1087 gi21327296 Homo sapiens zinc finger protein 382 495 46 1088 gi2689441 Homo sapiens F18547_1 188 37 1088 gil613848 Homo sapiens zinc finger protein zfp6 316 49 1088 gi21327296 Homo sapiens zinc finger protein 382 203 38 1089 gil2655460 Homo sapiens keratin associated protein 4.12 929 75 1089 gil3278825 Homo sapiens Similar to RIKEN cDNA 11 10054P19 929 75 gene 1089 gil2655464 Homo sapiens keratin associated protein 4.15 900 83 1090 gil2655460 Homo sapiens keratin associated protein 4.12 403 85 1090 gil3278825 Homo sapiens Similar to RIKEN cDNA 11 10054P19 403 85 gene 1090 gil2655442 Homo sapiens keratin associated protein 4.2 397 84 1091 gil2655464 Homo sapiens keratin associated protein 4.15 1260 100 1091 gi12655452 Homo sapiens keratin associated protein 4.7 1222 90 1091 gil2655460 Homo sapiens keratin associated protein 4.12 1156 88 WO 2004/080148 PCT/US2003/030720 173 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1092 gil5722084 Homo sapiens bA304I5.1 (novel lipase) 1991 100 1092 gi21594466 Mus musculus RIKEN cDNA 4632427C23 gene 1928 87 1092 gi460143 Homo sapiens lysosomal acid lipase/cholesteryl ester 1290 60 hydrolase 1093 gi21594466 Mus musculus RIKEN cDNA 4632427C23 gene 1957 88 1093 gi15722084 Homo sapiens bA304I5.1 (novel lipase) 1935 100 1093 gi460143 Homo sapiens lysosomal acid lipase/cholesteryl ester 1290 60 hydrolase 1094 gi8118040 Homo sapiens orphan G-protein coupled receptor 1804 99 1094 gi8118052 Mus musculus orphan G-protein coupled receptor 1306 82 1094 gi13177796 Homo sapiens retinoic acid induced 3 728 45 1095 gil8129609 Homo sapiens diacylglycerol acyltransferase 2 600 49 1095 gi15099951 Mus musculus diacylglycerol acyltransferase 2 599 49 1095 gi17426446 Homo sapiens bA351K23.5 (novel protein) 572 54 1096 gil7225337 Homo sapiens dendritic lectin 1134 95 1096 gil7224598 Homo sapiens blood dendritic cell antigen 2 protein 1134 95 1096 gi17225339 Homo sapiens dendritic lectin b isoform 918 94 1097 gi17225337 Homo sapiens dendritic lectin 1182 99 1097 gi17224598 Homo sapiens blood dendritic cell antigen 2 protein 1182 99 1097 gil7225339 Homo sapiens dendritic lectin b isoform 966 99 1098 gi21929119 Homo sapiens seven transmembrane helix receptor 1595 100 1098 gil8479834 Mus musculus olfactory receptor MOR144-1 1223 77 1098 gil8480806 Mus musculus olfactory receptor MOR143-1 1163 70 1099 gi5911169 Homo sapiens transmembrane mucin 12 3049 99 1099 gi19526645 Homo sapiens intestinal membrane mucin MUC17 815 32 1099 gi5911171 Homo sapiens mucin 11 684 47 1100 gi37198 Homo sapiens TMl-CEA preprotein 455 34 1100 gi179440 Homo sapiens biliary glycoprotein I precursor 455 34 1100 gi550031 Homo sapiens BGPc 455 34 1101 gi6273399 Homo sapiens melanoma-associated antigen MG50 4733 60 1101 gi1504040 Homo sapiens similar to D.melanogaster 4733 60 peroxidasin(U11052) 1101 gi531385 Drosophila peroxidasin precursor 2013 39 melanogaster 1102 gi6273399 Homo sapiens melanoma-associated antigen MG50 4458 60 1102 gi1504040 Homo sapiens similar to D.melanogaster 4458 60 peroxidasin(U1 1052) 1102 gi531385 Drosophila peroxidasin precursor 2013 39 melanogaster 1103 gi7264653 Mus musculus Kiaa0575 2398 61 1103 gi11611734 Homosapiens GREBla 513 46 1103 gi915208 Sus scrofa gastric mucin 128 30 1104 gi20219008 Chlamydomona coiled-coil flagellar protein 682 36 s reinhardtii 1104 gil6519041 Drosophila occludin-like protein 203 23 melanogaster 1104 gi3549261 Dictyostelium interaptin 175 22 discoideum 1105 gi12654511 Homo sapiens ATP-dependant interferon response 693 96 protein 1 1105 gil7390689 Homo sapiens ATP-dependant interferon responsive 693 96 1105 gil0862826 Homo sapiens ADIRI 689 95 1106 gi15215375 Homo sapiens RNA binding motif protein 12 325 72 1106 gi21666372 Homo sapiens swan 325 72 WO 2004/080148 PCT/US2003/030720 174 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1106 gi19070194 Homo sapiens SWAN 325 72 1107 gil8157547 Mus musculus pecanex-like 3 3262 97 1107 gi6650377 Mus musculus pecanex 1 2530 74 1107 gi15076843 Homo sapiens pecanex-like protein 1 2526 74 1108 gil8157547 Mus musculus pecanex-like 3 3138 97 1108 gi6650377 Mus musculus pecanex 1 2409 73 1108 gil5076843 Homo sapiens pecanex-like protein 1 2405 73 1109 gi7770237 Homo sapiens PR02822 233 59 1109 gi21595759 Homo sapiens similar to HC6 211 71 1109 gi3002527 Homo sapiens neuronal thread protein AD7c-NTP 209 67 1110 gil8159337 Pyrobaculum paREP8 77 30 aerophilum 1110 gil658310 Homo sapiens leukocyte surface protein 97 26 1110 gi7638235 Mus musculus immunoglobulin heavy chain variable 77 25 domain 1111 gi4263743 Homo sapiens similar to UNC-93; similar to U89424 1575 100 (PID:g3642687) 1111 gi12043567 Homo sapiens unc-93 related protein 1571 99 1111 gil7390915 Mus musculus Similar to unc93 (C.elegans) homolog B 1372 87 1113 gi4153873 Homo sapiens similar to weel-like protein kinase; 2810 100 similar to P30291 (PID:g1351419) 1113 gi644770 Xenopus laevis WeelA kinase 1166 64 1113 gi2827996 Xenopus laevis weel homolog 1166 64 1114 gi6606119 Dothidea DNA-dependent RNA polymerase II 81 32 insculpta RPB140 1114 gi2796053 Mus musculus T cell receptor beta chain 54 48 1115 gi20372871 Clarkia similis cytosolic phosphoglucose isomerase 56 28 1116 gi21708029 Homo sapiens similar to Alu subfamily SQ sequence 135 70 contamination warning entry 1116 gi11493409 Homo sapiens PR00898 129 59 1116 gi6650818 Homo sapiens PRO1992 110 70 1117 gi13810898 Rattus inhibin binding protein long isoform 310 37 norvegicus 1117 gi2645890 Homo sapiens IGSFI 326 40 1117 gi2370143 Homo sapiens immunoglobulin-like domain-containing 326 40 1118 gil3810898 Rattus inhibin binding protein long isoform 310 37 norvegicus 1118 gi2645890 Homo sapiens IGSF1 312 38 1118 gi2370143 Homo sapiens immunoglobulin-like domain-containing 312 38 1 1119 gi21707128 Homo sapiens Ran binding protein 11 5047 99 1119 gi20987296 Mus musculus Similar to Ran binding protein 11 4898 96 1119 gil7862636 Drosophila LD41918p 1191 38 melanogaster 1120 gil8652832 Homo sapiens ASPP1 protein 5703 99 1120 gi16197705 Homo sapiens ASPP2 protein 1556 42 1120 gi1399805 Homo sapiens Bbp/53BP2 1556 42 1121 gil8448478 Aotus chorionic gonadotropin beta subunit 47 59 trivirgatus 1121 gi5670272 Human KI glycoprotein 67 38 herpesvirus 8 1121 gi9886851 Human K1 protein 63 36 herpesvirus 8 WO 2004/080148 PCT/US2003/030720 175 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1122 gi2598461 Homo sapiens dJ408N23.1 (suppression of 1887 97 tumorigenicity 13 (colon carcinoma) (Hsp70-interacting protein) (Progesterone receptor associated P48 protein)) 1122 gi904032 Homo sapiens p48 1869 96 1122 gi21218374 Homo sapiens FAM1OA5 1814 93 1123 gi8927428 Homo sapiens otoraplin 676 100 1123 gi12619173 Homo sapiens melanoma inhibitory activity like protein 676 100 1123 gi11323317 Homo sapiens dJ705D16.2 (Otoraplin) 676 100 1124 gi12034719 Mus musculus ankyrin-like protein 462 46 1124 gil3469729 Homo sapiens breast cancer antigen NY-BR-1 448 50 1124 gi21618588 Homo sapiens testis-specific ankyrin motif containing 381 47 protein 1125 gil3469729 Homo sapiens breast cancer antigen NY-BR-1 364 51 1125 gi12034719 Mus musculus ankyrin-like protein 379 46 1125 gi21618588 Homo sapiens testis-specific ankyrin motif containing 345 49 protein 1126 gi7770139 Homo sapiens PRO1722 263 60 1126 gi11493483 Homo sapiens PR02550 263 67 1126 gi8572229 Homo sapiens ubiquitous TPR-motif protein Y isoform 249 61 1127 gi6907090 Oryza sativa Similar to Oryza sativa root-specific 86 35 (japonica RCc3 mRNA. (L27208) cultivar-group) 1127 gi5902450 Cercopithecine glycoprotin G 58 41 herpesvirus 1 1127 gi2750734 Homo sapiens L-typce voltage-dependent calcium 56 48 channel 1128 gil6878260 Homo sapiens Similar to angiotensin II, type I receptor- 726 100 associated protein 1128 gil6588454 Homo sapiens AGTRAP protein 705 95 1128 gi9621816 Homo sapiens ATRAP 705 95 1129 gil7986216 Homo sapiens cell recognition molecule CASPR3 1864 98 1129 gil2330704 Mus musculus cell recognition molecule CASPR4 1376 71 1129 gi21961652 Mus musculus cell recognition protein CASPR4 1376 71 1130 gil7986216 Homo sapiens cell recognition molecule CASPR3 6812 99 1130 gil8390059 Homo sapiens cell recognition protein CASPR4 4754 70 1130 gi21961652 Mus musculus cell recognition protein CASPR4 4724 68 1131 gi21552969 Mus musculus Williams-Beuren syndrome critical region 3100 97 gene 17 1131 gi10336504 Homo sapiens UDP-GalNAc: polypeptide N- 2020 61 acetylgalactosaminyltransferase 1131 gi11041469 Macaca UDP-GalNAc: polypeptide N- 1913 58 fascicularis acetylgalactosaminyltransferase 1132 gi13625176 Homo sapiens thrombospondin 586 46 1132 gil4627121 Homo sapiens dJ824F16.3 (novel protein similar to 544 46 mouse thrombospondin type 1 domain protein R-spondin) 1132 gi4519541 Mus musculus thrombospondin type 1 domain 511 43 1133 gi5305333 Mus musculus protein kinase Myak-S 865 50 1133 gi18314319 Mesocricetus Mx-interacting protein kinase PKM 865 50 auratus 1133 gi58 15143 Mus musculus nuclear body associated kinase 2a 865 50 1134 gi14022292 Mesorhizobium cell division protein 45 36 loti WO 2004/080148 PCT/US2003/030720 176 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1134 gi180143 Homo sapiens CD53 glycoprotein 45 53 1134 gi180141 Homo sapiens cell surface antigen 45 53 1135 gi14571502 Homo sapiens calcium-promoted Ras inactivator 4174 99 1135 gi2822157 Homo sapiens similar to GTPase-activating proteins; 3961 99 35% similar to JC5047 (PID:g2136083) 1135 gi4185294 Homo sapiens rasGAP-activating-like protein 1898 49 1136 gil1527987 Gallus gallus immunoglobulin-like receptor CHIR-A 97 30 1136 gi432214 Human envelope glycoprotein gp120 43 39 immunodeficien cy virus type 1 1136 gil5026993 Homo sapiens MvUC5AC protein 64 38 1137 gi15128103 Mus musculus nephronectin 2971 87 1137 gi15430248 Mus musculus nephronectin long isoform 2640 80 1137 gi16040981 Mus musculus POEM 2374 87 1139 gi7638247 Homo sapiens mesenchymal stem cell protein DSCD75 595 100 1139 gil7946258 Drosophila RE58349p 165 34 melanogaster 1139 gi21464462 Drosophila RH58440p 158 36 melanogaster 1140 gi21619491 Homo sapiens similar to expressed sequence AW049604 235 83 1140 gi6572294 Homo sapiens bA262A13.1 (novel protein) 126 48 1140 gi215692 Bacteriophage gop protein 87 28 P4 1141 gi21619491 Homo sapiens similar to expressed sequence AW049604 454 82 1141 gi6572294 Homo sapiens bA262A13.1 (novel protein) 239 48 1141 gi215692 Bacteriophage gop protein 84 33 P4 1142 gi20306274 Homo sapiens testicular haploid expressed gene 1487 80 1142 gi10443967 Homo sapiens THEG protein 1487 80 1142 gi7416134 Homo sapiens testis-specific gene 1487 80 1143 gi21928259 Homo sapiens seven transmembrane helix receptor 1023 100 1143 gil8480746 Mus musculus olfactory receptor MOR261-10 864 84 1143 gi18480744 Mus musculus olfactory receptor MOR261-9 858 82 1144 gi21928655 Homo sapiens seven transmembrane helix receptor 1458 93 1144 gil8480746 Mus musculus olfactory receptor MOR261-10 1280 79 1144 gil8480744 Mus musculus olfactory receptor MOR261-9 1258 78 1145 gi1707674 Streptomyces elongation factor G 52 34 cinnamoneus 1146 gi15779092 Homo sapiens Similar to syntaxin 18 1295 100 1146 gi7707424 Homo sapiens syntaxin 18 1295 100 1146 gi18203931 Mus musculus Similar to syntaxin 18 873 90 1147 gil4573319 Homo sapiens interleukin-1 HY2 812 99 1147 gi18025344 Homo sapiens interleukin-1 receptor antagonist-like 809 99 FILl theta 1147 gi19068192 Mus musculus IL-IF1O 662 82 1148 gi4103158 Mus musculus hair keratin acidic 5; Ha5 keratin 1116 72 1148 gi3724107 Homo sapiens keratin, type I 1114 72 1148 gi1668744 Homo sapiens HHa5 hair keratin type I intermediate 1114 72 filament 1149 gil9353375 Mus musculus RIKEN cDNA 111003102 gene 1417 84 1149 gi6166378 Mus musculus growth suppressor 1L 141 30 1149 gil5929776 Homo sapiens growth suppressor 1 137 41 1150 gil3623421 Homo sapiens Similar to RIKEN cDNA 5730589L02 1336 90 gene WO 2004/080148 PCT/US2003/030720 177 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1150 gil9484086 Mus musculus RIKEN cDNA 5730589L02 gene 1287 86 1150 gi1699265 Homo sapiens malignant cell expression-enhanced 392 57 gene/tumor progression-enhanced gene 1151 gil5419605 Canis familiaris masticatory epithelia keratin 2p 1204 55 1151 gi14595019 Homo sapiens keratin 6 irs 1175 54 1151 gi6092075 Mus musculus type II cytokeratin 1116 51 1152 gil 1066090 Homo sapiens matrix metalloprotease MMP-27 1382 96 1152 gi12006364 Tupaia matrix metalloproteinase-27 1121 80 belangeri 1152 gi3511149 Gallus gallus matrix metalloproteinase 663 57 1153 gil1066090 Homo sapiens matrix metalloprotease MMP-27 1382 96 1153 gil2006364 Tupaia matrix metalloproteinase-27 1121 80 belangeri 1153 gi3511149 Gallus gallus matrix metalloproteinase 663 57 1154 gi6689894 Homo sapiens Suppressor of Fused 2599 100 1154 gi5739507 Homo sapiens suppressor of fused 2594 99 1154 gi4468628 Mus musculus Su(fu) protein 2541 97 1155 gi21667212 Homo sapiens bactericidal/permeability-increasing 2600 100 protein-like 2 1155 gi20387085 Oncorhynchus LBP (LPS binding protein)/BPI 690 31 mykiss (bactericidal/permeability-increasing protein)-1 1155 gi20387087 Oncorhynchus LBP (LPS binding protein)/BPI 685 30 mykiss (bactericidal/permeability-increasing protein) like-2 1156 gi11229139 Homo sapiens bB152015.3 (SRY (sex determining 2066 100 region Y)-box 18) 1156 gil2082687 Homo sapiens Sry-related HMG-box protein 2066 100 1156 gi8894593 Homo sapiens SOX18 protein 2066 100 1157 gi19526647 Homo sapiens oxidored-nitro domain-containing protein 837 85 1157 gi7303522 Drosophila CG13178-PA 172 31 melanogaster 1157 gi16304788 Mus musculus bendless-like ubiquitin conjugating 83 28 enzyme 1158 gi19526647 Homo sapiens oxidored-nitro domain-containing protein 837 85 1158 gi7303522 Drosophila CG13178-PA 172 31 melanogaster 1158 gi16304788 Mus musculus bendless-like ubiquitin conjugating 83 28 enzyme 1159 gi1794221 Mus musculus DNA ligase IlI-beta 2987 89 1159 gil794223 Mus musculus DNA ligase II-alpha 2987 89 1159 gi19550955 Homo sapiens ligase II1, DNA, ATP-dependent 2875 100 1160 gil5667919 Homo sapiens SERPINB12 1678 99 1160 gi12597188 Homo sapiens squamous cell carcinoma antigen 2 749 48 1160 gil235617 Homo sapiens squamous cell carcinoma antigen 749 48 1161 gil5141587 Eulemur olfactory receptor 67 34 rubriventer 1161 gi21739229 Oryza sativa OSJNBaOO72FI6.8 67 43 1161 gi21629328 Leishmania L3561.8 65 37 major 1162 gi2589190 Homo sapiens skin-specific protein 68 39 1162 gi38232 Pan troglodytes immunoglobulin alpha heavy chain 61 39 1162 gi14021730 Mesorhizobium c-type cytochrome biogenesis protein 68 31 loti WO 2004/080148 PCT/US2003/030720 178 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1163 gi7228149 Mus musculus ATFa-associated factor 354 50 1163 gi7303705 Drosophila CG12340-PA 193 24 melanogaster 1163 gi5052666 Drosophila BcDNA.LD26050 193 24 melanogaster 1164 gi20901968 Caenorhabditis C. elegans RPL-36 protein 71 34 elegans (corresponding sequence F37C12.4) 1165 gi5911451 Drosophila cytochrome oxidase 1II 43 41 nannoptera 1165 gi13276253 Homo sapiens T-cell receptor beta chain VJ region 56 34 1165 gi3928896 Homo sapiens SH2 domain protein IA isoform C 55 38 1166 20381326 Homo sapiens Similar to caspase 8, apoptosis-related 263 100 cysteine protease 1166 gil4211398 Homo sapiens caspase-8L 263 100 1166 gil9401524 Homo sapiens procaspase-8 223 95 1167 gil0440448 Homo sapiens FLJO0060 protein 1204 98 1167 gi3983420 Homo sapiens KIR3DL1-like natural killer cell receptor 693 47 1167 gi13560453 Homo sapiens killer cell immunoglobulin-like receptor 693 47 3DL1 1168 gil799570 Rattus TIP120 4573 99 norvegicus 1168 gi7688703 Homo sapiens TIP120 protein 4573 99 1168 gi5811583 Rattus TIP120-family protein TIP120B 2735 57 norvegicus 1169 gil3016701 Homo sapiens activating coreceptor NKp80 1226 100 1169 gi7188567 Homo sapiens lectin-like receptor F1 1226 100 1169 gi22449867 Macaca NKp8O NKreceptor 1122 90 fascicularis 1170 gi14027275 Mesorhizobium nodulation protein nodG, 3-oxoacyl-(acyl 70 27 loti carrier protein) reductase 1170 gil531618 Rhizobium sp. NodG 68 26 N33 1170 gi6899062 Ureaplasma seryl-tRNA synthetase 70 31 urealyticum 1171 gi3021409 Homo sapiens transducin (beta) like 1 protein 3057 100 1171 gi13161069 Homo sapiens transducin beta-like 1 2548 91 1171 gil2642596 Homo sapiens nuclear receptor co-repressor/HDAC3 2431 86 complex subunit TBLR1 1172 gil3623421 Homo sapiens Similar to RIKEN cDNA 5730589L02 380 69 gene, clone MGC:13124 IMAGE:4110925, mRNA, complete cds. 1172 gil2803383 Homo sapiens clone MGC:2099 IMAGE:3051525, 376 68 mRNA, complete eds. 1172 gi13111983 Homo sapiens clone MGC:4221 IMAGE:2958347, 376 68 mRNA, complete cds. 1173 gil3623421 Homo sapiens Similar to RIKEN cDNA 5730589L02 380 69 gene, clone MGC:13124 IMAGE:4110925, mRNA, complete cds. 1173 gil2803383 Homo sapiens clone MGC:2099 IMAGE:3051525, 376 68 mRNA, complete cds. 1173 gil3111983 Homo sapiens clone MGC:4221 IMAGE:2958347, 376 68 mRNA, complete cds. 1174 gil3623421 Homo sapiens Similar to RIKEN cDNA 5730589L02 1830 99 gene 1174 gil9484086 Mus musculus RIKEN cDNA 5730589L02 gene 1802 95 WO 2004/080148 PCT/US2003/030720 179 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score Ienti 1174 gil699265 Homo sapiens malignant cell expression-enhanced 930 81 gene/tumor progression-enhanced gene 1175 gil3182755 Homo sapiens HPHRP 1210 100 1175 gi15929309 Homo sapiens phosphotriesterase related 1210 100 1175 gi881499 Mus musculus parathion hydrolase (phosphotriesterase)- 1069 86 __ related protein 1176 gi552075 Chironomus giant secretory protein 71 28 tentans 1176 gil5419013 Toxoplasma subtilisin-like protein _ - gondii 1176 gi156534 Chironomus giant secretory protein (gsp) 6 tentans 1177 gi5458910 Pyrococcus FLAGELLA-RELATED PROTEIN C 103 24 abyssi 1177 gi487272 Enterococcus Na+ -ATPase subunit F 90 31 hirae 1177 gi9229886 Ciona ezrin/radixin/moesin (ERM)-like protein 111 27 intestinalis 1178 gi21554060 Arabidopsis phytocyanin thaliana 1178 gi205640 Rattus acetylcholine receptor alpha subunit 53 44 norvegicus 1178 gi4028904 Rattus nicotinic acetylcholine receptor alpha 4 5 44 norvegicus subunit 1179 gil8375961 Neurospora related to ARCA protein 53 44 crassa 1179 gi2935025 Rhodococcus protocatechuate dioxygenase alpha opacus subunit 1179 gil3421646 Caulobacter spoU rRNA methylase family protein 39 crescentus CB15 1180 gil4348558 Homo sapiens cDNA encoding protease domain of endotheliase 1 1180 gi1245184 Danio rerio ZgO1 66 33 1180 gi6137097 Homo sapiens serine protease DESC1 82 38 1181 gil9528151 Drosophila AT26759p melanogaster 1181 gi16768554 Drosophila GM08606p 59 35 melanogaster 1181 gi7291750 Drosophila CG4065-PA 59 35 melanogaster 1182 gil3377880 Cricetulus arginine N-methyltransferase p82 isoform longicaudatus 1182 gil3377882 Cricetulus arginine N-methyltransferase p77 isoform 3 longicaudatus 1182 gi21626587 Drosophila CG9882-PA 1213 melanogaster 1183 gi191185 Cricetulus phosphatidylserine decarboxylase 1130 griseus 1183 gi5921491 Homo sapiens dJ858B16.2 (phosphatidylserine 1220 96 decarboxylase (PSSC, EC 4.1.1.65)) 1183 gi16306618 Homo sapiens phosphatidylserine decarboxylase 1220 96 1184 gil 1907580 Mus musculus TSC22-related inducible leucine zipper 894 87 3c F 11-84 gi523 1131 Homo _sapiens TSC-22 related protein 460 9 8 WO 2004/080148 PCT/US2003/030720 180 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1184 gi5919161 Homo sapiens TSC-22-like Protein 460 98 1185 gil3874437 Homo sapiens cerebral protein-11 1461 68 1185 gil5292367 Drosophila LD47668p 510 41 melanogaster 1185 gi2443444 Homo sapiens TEX28 310 40 1186 gil3543940 Homo sapiens Similar to RIKEN cDNA 2610017G09 2568 99 gene 1186 gi18204520 Mus musculus RIKEN cDNA 2610017G9 gene 2381 91 1186 gi16923351 Homo sapiens RbBP-35 1434 99 1187 gil8676660 Homo sapiens FLJ00229 protein 931 91 1187 gi5824711 Caenorhabditis similar to 7TM chemoreceptor (srd- 80 20 elegans family) 1187 gi8825622 Rattus T cell receptor 68 36 norvegicus 1188 gil7865311 Homo sapiens dipeptidyl peptidase-like protein 9 4646 100 1188 gil 1095188 Homo sapiens dipeptidyl peptidase 8 2876 60 1188 gi21265133 Homo sapiens Similar to dipeptidylpeptidase 8 2217 58 1189 gi17865311 Homo sapiens dipeptidyl peptidase-like protein 9 4069 100 1189 gil1095188 Homo sapiens dipeptidyl peptidase 8 2454 59 1189 gi21265133 Homo sapiens Similar to dipeptidylpeptidase 8 2455 56 1190 gi17865311 Homo sapiens dipeptidyl peptidase-like protein 9 4542 98 1190 gil1095188 Homo sapiens dipeptidyl peptidase 8 2810 60 1190 gi21265133 Homo sapiens Similar to dipeptidylpeptidase 8 2151 57 1191 gi337508 Homo sapiens ribosomal protein 554 99 1191 gi57724 Rattus rattus ribosomal protein S25 554 99 1191 gi12805251 Mus musculus ribosomal protein S25 554 99 1192 gi208176 synthetic D2-T antigen 61 40 construct 1193 gi7328583 Drosophila mechanosensory transduction channel 851 28 melanogaster NOMPC 1193 gi7385113 Bos taurus ankyrin 1 777 30 1193 gi11065673 Caenorhabditis Y71A12B.4 778 28 elegans 1194 gi7672669 Homo sapiens shrine protease Htra2 1890 100 1194 gi12652695 Homo sapiens HtrA-like serine protease 1890 100 1194 gi5870865 Homo sapiens serine protease 1890 100 1195 gi349449 Homo sapiens A3 adenosine receptor 904 100 1195 gil3559064 Homo sapiens bA552M11.6 (adenosine A3 receptor) 904 100 1195 gi20988265 Homo sapiens adenosine A3 receptor 904 100 1196 gi21645219 Drosophila CG15671-PA 299 37 melanogaster 1196 gi9864185 Drosophila Crossveinless 2 299 37 melanogaster 1196 gi7768636 Xenopus laevis Kielin 276 34 1197 gil8480772 Mus musculus olfactory receptor MOR101-2 1415 84 1197 gil8479346 Mus musculus olfactory receptor MOR101-1 1334 82 1197 gi3769616 Rattus olfactory receptor 973 86 norvegicus 1198 gi498768 Serratia Deoxyadenosyl-methyltransferase 339 51 marcescens 1198 gil0799034 Vibrio cholera DNA adenine methylase 332 54 1198 gil0799036 Yersinia DNA adenine methylase 331 52 pseudotubercul osis WO 2004/080148 PCT/US2003/030720 181 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1199 gil6974751 Gallus gallus CALI 1199 gi666121 Xenopus laevis cpl-1 33 1199 gil213589 Xenopus laevis Prostaglandin D Synthase33 1200 gi22296200 Thermosynecho asparaginyl-tRNA synthetase 1057 46 coccus elongatus BP-1 1200 gi17132791 Nostoc sp. PCC asparaginyl-tRNA synthetase 7120 1200 gi19713460 Fusobacterium Asparaginyl-tRNA synthetase 013 43 nucleatum subsp. nucleatum ATCC 25586 1201 gil8088970 Homo sapiens Similar to RIKEN cDNA 4933400E14 263 99 gene 1201 gi20067381 Homo sapiens ALMS1 protein 249 41 1201 gi21552774 Mus musculus Almstrom syndrome 1 protein 219 38 1202 gi347134 Homo sapiens succinate dehydrogenase flavoprotein 495 92 subunit 1202 gil2655061 Homo sapiens succinate dehydrogenase complex, |__subunit A, flavoprotein (Fp) 1202 gi506338 Homo sapiens flavoprotein subunit of complex II 495 92 1203 gil8490322 Homo sapiens Similar to RIKEN cDNA 6330404M18 241 9 gene 1203 gi21928186 Mus musculus GPI-gamma 4; GPlgamma4 1471 61 1203 gil7946082 Drosophila RE54096p 688 47 melanogaster 1204 gi9957165 Homo sapiens alphaCP-3 1722 00 1204 gi9957161 Mus musculus alphaCP-3 1708 99 1204 gi15082311 Homo sapiens Similar to poly(rC)-binding protein 3 840 99 1205 gi14574118 Cacnorhabditis C. elegans DPY-19 protein 239 31 elegans (corresponding sequence F22B7. 10) 1205 gil2328595 Heterodoxus NADH dehydrogenase subunit 2 79 29 macropus 1205 gil8378695 Bufo macuatus NADH dehydrogenase subunit 2 75 24 1206 _i89760 Homo sapiens pyruvate dehydrogcnasc beta-subunit 7 1206 gil89762 Homo sapiens pyruvate dehydrogenase El-beta subunit 1710 96 1206 gi190792 Homo sapiens pyruvate dehydrogenase El-beta subunit 1710 96 precursor 1207 gi688292 Homo sapiens calmitine; calsequestrine 2029 100 1207 gi2618621 Mus musculus skeletal muscle calsequestrin 1938 94 1207 gil64842 Oryctolagus calsequestrin 1908 94 cuniculus 1208 gi22295775 Thermosynecho periplasmic sugar-binding protein of 65 35 coccus sugar ABC transporter elongatus BP- I 1208 gi2622963 Methanothermo conserved protein 59 30 bacter thermautotrophi cus str. Delta H 1208 gil8377999 Drysdalia NADH dehydrogenase subunit 1 61 34 coronata 1209 gil1034760 Homo sapiens NIBAN 3692 99 1209 gil0432376 Homo sapiens bG56G5.1 (novel protein) 3334 99 1209 gi1l022733--Mus mus'culus Niban 2320 67 WO 2004/080148 PCT/US2003/030720 182 TABLE 2 A S1Q Hit ID H Species Description eS 129nt0 1210 gi29250 Hom sapensscore identity 1210 gi298925 Homo sapiens TCR beta chain 1292 93 12103 gi300295 Homo sapiens T cell receptor beta chain 12381 47 93 1210 g136 ..Homo sapiens T cell antigen receptor beta chain 028 75 1211 gi12006041 Homo sapiens AD038 761 98 1211 g14189960 Homo sapiens PRO764 141 53 1211 gi19072857 Homo sapiens lung sqamous cell cancer related protein 129 60 LSCC-3 1213 gi2995719 omo sapiens protocadherin 43 492 100 1218 g12072790 Homo sapiens protocadherin gamma subfamily C, 3 4777 99 1213 g15456977 Homuses protocadherin gamma C3 4777 99 1214 gi337487 Homo sapiens Re ribonucleoprotein autoantigen (Ro/SS- 1747 99 A) precursor. 1214 gil79882 Homo sapiens calreticulin 1747 99 f214maricescens 1214 g22203354 Crctls calreticulin 1687 95 griseus 1215 gi200964___ Msm cina sCrin 2 ultra high sulfur protein 319 52 1215 gi283 _Homo sapiens _ultra high sulfur keratin 281 49 1215 g200962 Mus musculus serine ultra hig sulfur protein 281 50 1216 g113940422 Macaca ATPase subunit 8 56 31 sylvanus 1217 gi5917716 Illsal sprout 2 60 45 1217 gil4275701 Influenza virus matrix protein 2 62 32 1217 gi2738577 Homo sapiens connexin46.6 54 50 1218 gil7223709 Homo sapiens elenoprotein SelM 235 100 1218 gil722371 Mus musculus selenoprotein SelM 188 78 1218 gi7380925 Bos taurus Fecgamma receptor III 73 45 1219 gil5025778 Clostridium Predicted membrane protein 50 36 acetobutylicum 1219 gil3752743 Serratia TrpG 65 51 marcescens 1219 gi20906991 Methanosarcina Cation transporter 62 29 mazei GoelI 1220 gi535358 Neisseria Opa15063G 60 |50M -i-gonorrhoeae 8 4 -220 gil-480793 Neisseri-a Opall58 4 meningitidis 1221 gi992950 Homo sapiens OPN-c 1426 98 1221 gil89151 Homo sapiens nephropontin precursor 1377 90 1221 gil001963 Homo sapiens osteopontin - 1377 90 1223 gil808836l3 Homo sapiens advanced glycosylation end product- 2004 9 specific receptor |1223 gjil1841550 Homo sapiens receptor for advanced glycosylation end 2004 9 products 1223 gi612 Homo sapiens advanced glycation endproducts receptor 2004 99 1224 g13157464 Thermus sp. A4_ integral membrane protein 77 38 1224 g18778370 Arabidopsis F1504.23 65 37 thaliana 9 1224 gil5156782 Agrobacterium AGRC 3106p 59 34 tumefaciens str. 1225 gi37231 HoTmoin s DNA topoisomerase II 8061 99, 1225 gi3869382 Homo sapiens DNA topoisomerase II beta 8048 99 1225 g1790988 Cricetulus DNA topoisomerase (ATP-hydrolysing) 7 892 97 longicaudatus WO 2004/080148 PCT/US2003/030720 183 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1226 gil0041309 Homo sapiens hFATP1 3336 98 1226 gil881713 Rattus fatty acid transport protein 3031 87 norvegicus 1226 gil0041307 Rattus sp. rFATP 3031 87 1227 gi3309176 Mus musculus COP9 complex subunit 7b 796 94 1227 gil5215085 Mus musculus Similar to COP9 (constitutive 793 93 photomorphogenic), subunit 7b (Arabidopsis) 1227 gil9909525 Homo sapiens DERP10 (dermal papilla derived protein 467 56 10) 1228 gi6942096 Mus musculus CBLN3 938 93 1228 gil80251 Homo sapiens precerebellin 551 58 1228 gi5702371 Mus musculus precerebellin-1 544 57 1229 gil7861952 Drosophila LD01947p 1384 50 melanogaster 1229 gi6850946 Homo sapiens dJ322I12.1 (novel protein similar to C. 336 100 elegans C05C8.6 (Tr:016313)) 1229 gi21411108 Mus musculus Similar to BTB domain protein BDPL 211 32 1230 gi8132557 Drosophila ankyrin 2 729 30 melanogaster 1230 gi710551 Mus musculus ankyrin 3 734 29 1230 gii841966 Rattus ankyrin 700 30 norvegicus 1231 gi21667212 Homo sapiens bactericidal/permeability-increasing 2384 98 protein-like 2 1231 gi20387085 Oncorhynchus LBP (LPS binding protein)/BPI 672 31 mykiss (bactericidal/permeability-increasing protein)-1 1231 gi20387087 Oncorhynchus LBP (LPS binding protein)/BPI 667 30 mykiss (bactericidal/permeability-increasing protein) like-2 1232 gi2166721 2 Homo sapiens bactericidal/permeability-increasing 2389 99 protein-like 2 1232 gi20387085 Oncorhynchus LBP (LPS binding protein)/BPI 664 31 mykiss (bactericidal/permeability-increasing protein)-1 1232 gi20387087 Oncorhynchus LBP (LPS binding protein)/BPI 659 30 mykiss (bactericidal/permeability-increasing protein) like-2 1233 gi21667212 Homo sapiens bactericidal/permeability-increasing 2595 99 protein-like 2 1233 gi20387085 Oncorhynchus LBP (LPS binding protein)/BPI 698 31 mykiss (bactericidal/permeability-increasing protein)-1 1233 gi20387087 Oncorhynchus LBP (LPS binding protein)/BPI 693 30 mykiss (bactericidal/permeability-increasing protein) like-2 1234 gil9569876 Dictyostelium SIMILAR TO HYPOTHETICAL 26.2 247 26 discoideum KD PROTEIN t234 gi2191168 Arabidopsis contains similarity to myosin heavy chain 187 27 thaliana 1234 gi603379 Saccharomyces Yer139cp 145 28 cerevisiae 1235 gil1493528 Homo sapiens PRO1953 671 100 1235 gil9912632 Eulemur MHC class II antigen 56 33 WO 2004/080148 PCT/US2003/030720 184 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity rubriventer 1235 gi19912630 Eulemur MHC class II antigen 55 33 macaco macaco 1236 gi17065951 Ostertagia collagen 70 35 ostertagi 1236 gi158077 Drosophila period protein 69 38 robusta 1236 gi497417 Glycine max dehydrin-like protein 81 27 1237 gi3068592 Mus musculus pune 2396 94 1237 gi19570398 Homo sapiens hDDM36 890 41 1237 gil1862941 Mus musculus DDM36E 892 41 1238 gi12667401 Homo sapiens NUF2R 2347 99 1238 gi14317902 Homo sapiens kinetochore protein Nuf2 2347 99 1238 gi12667403 Mus musculus NUF2R 1754 73 1239 gi2494126 Arabidopsis Contains similarity to Chlamydia outer 94 23 thaliana membrane protein (gblX53512). 1239 gil9887475 Methanopyrus Uncharacterized protein conserved in 68 34 kandleri AV19 archaea 1239 gi21646173 Chlorobium ribosomal protein S20 67 29 tepidum TLS 1240 gi21634825 Homo sapiens semaphorin 6D isoform 4 5658 98 1240 gi21634823 Homo sapiens semaphorin 6D isoform 3 3106 96 1240 gi21634827 Homo sapiens semaphorin 6D isoform 1 3106 99 1241 gi9949555 Pseudomonas probable pyruvate dehydrogenase El 71 35 aeruginosa component, alpha subunit 1241 gi48708 Mycobacterium ORFa1 (AA 1 - 74) 58 37 tuberculosis 1241 gi307352 Homo sapiens prothymosin alpha 54 35 1242 gi9106331 Xylella 3-dehydroquinate synthase 43 34 fastidiosa 9a5c 1242 gil3700302 Staphylococcus xanthine phosphoribosyltransferase 45 35 aureus subsp. aureus N315 1242 gi21203529 Staphylococcus xanthine phosphoribosyltransferase 45 35 aureus subsp. aureus MW2 1243 gi21671105 Homo sapiens RAD52B 1134 100 1243 gi20070921 Mus musculus RIKEN cDNA 2410008M22 gene 829 74 1243 gi21594785 Homo sapiens Similar to RIKEN cDNA 2410008M22 572 97 gene 1244 gi6013381 Rattus TM6P1 147 47 norvegicus 1244 gil9353944 Mus musculus RIKEN cDNA 2610318G18 gene 127 31 1244 gi20270909 Oncorhynchus VHSV-induced protein-6 118 31 mykiss 1245 gi6013381 Rattus TM6P1 272 36 norvegicus 1245 gi21428644 Drosophila LP10820p 256 42 melanogaster 1245 gi20270909 Oncorhynchus VHSV-induced protein-6 190 29 mykiss 1246 gil1993700 Homo sapiens melastatin 2 1194 100 1246 gi3243075 Homo sapiens melastatin 1 1057 83 1246 gi3047242 Mus musculus melastatin 1050 83 1247 gil8044366 Homo sapiens Similar to MEGF10 protein 3468 99 WO 2004/080148 PCT/US2003/030720 185 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1247 gil7386053 Mus musculus Jedi protein 2280 51 1247 gil8252658 Mus musculus Jedi-736 protein 2280 51 1248 gi20987880 Mus musculus Similar to PTH-responsive osteosarcoma 3586 87 B1 protein 1248 gi4588087 Homo sapiens PTH-responsive osteosarcoma B1 protein 2264 92 1248 gi21595711 Homo sapiens Similar to PTH-responsive osteosarcoma 1546 100 B1 protein 1249 gil9913471 Homo sapiens similar to dJ84N20.1.1 (novel protein, 1265 99 isoform 1) 1249 gil3591434 Homo sapiens dJ84N20.1.2 (novel protein, isoform 2) 1160 100 1249 gi13591435 Homo sapiens dJ84N20.1.1 (novel protein, isoform 1) 976 99 1250 gi 16605581 Homo sapiens H-revl07-like protein 5 1451 100 1250 gi21707989 Homo sapiens Similar to H-rev107-like protein 5 1376 96 1250 gi6048565 Homo sapiens retinoid inducible gene 1 382 54 1251 gi21263094 Rattus tramdorin 1 1667 81 norvegicus 1251 gi21263092 Mus musculus tramdorin 1 1664 82 1251 gi21908026 Mus musculus proton/amino acid transporter 2 1664 82 1252 gil4571904 Rattus lysosomal amino acid transporter 1 1690 87 norvegicus 1252 gi21908024 Mus musculus proton/amino acid transporter 1 1685 87 1252 gi21263092 Mus musculus tramdorin 1 1294 66 1253 gi21595630 Homo sapiens Similar to forehead box L2 75 44 1253 gil0580569 Halobacterium trans lesion repair; YqjH 69 51 sp. NRC-1 1253 gi557673 Sus scrofa BM88 antigen 72 41 1254 gil669500 Mus musculus fibroblast growth factor homologous 917 90 factor 1 1254 gil563885 Homo sapiens fibroblast growth factor homologous 917 90 factor 1 1254 gil4317951 Rattus fibroblast growth factor homologous 916 98 norvegicus factor 1B 1255 gi13529143 Homo sapiens Similar to RIKEN cDNA 1700010H15 779 100 gene 1255 gi19263005 Ciona leucine-rich repeat dynein light chain 759 75 intestinalis 1255 gi2760161 Anthocidaris outer arm dynein light chain 2 656 68 crassispina 1256 gil2666529 Mus musculus b,b-carotene-9',10'-dioxygenase 2356 80 1256 gi4001821 Ambystoma RPE65 protein; retinal pigment 1125 44 tigrinum epithelium 65-protein 1256 gil1990268 Mus musculus beta,beta-carotene 15,15'-dioxygenase 1110 42 1257 gil2666529 Mus musculus b,b-carotene-9',10'-dioxygenase 2305 81 1257 gi4001821 Ambystoma RPE65 protein; retinal pigment 1122 44 tigrinum epithelium 65-protein 1257 gil1990268 Mus musculus beta,beta-carotene 15,15'-dioxygenase 1113 42 1258 gi18490501 Mus musculus RIKEN cDNA 2010002A20 gene 868 76 1258 gi6l Bos taurus calmodulin-independent adenylate 166, 29 cyclase 1258 gil5559697 Homo sapiens Similar to neural cell adhesion molecule 1 165 29 1259 gi21748488 Homo sapiens FLJ00277 protein 50 52 1259 gi2331293 Mus musculus preprocortistatin 73 40 1259 gi1335910 Rattus preprocortistatin 58 36 norvegicus WO 2004/080148 PCT/US2003/030720 186 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1260 gi1079734 Mus musculus citron 1291 94 1260 gi3599509 Mus musculus rho/rac-interacting citron kinase 1286 94 1260 gi2745840 Rattus postsynaptic density protein; citron 1262 93 norvegicus 1261 gil4715029 Mus musculus serine (or cysteine) proteinase inhibitor, 407 39 clade E (nexin, plasminogen activator inhibitor type 1), member 2 1261 gi551065 Mus musculus protease-nexin 1 406 38 1261 gi412157 Homo sapiens glia-derived neurite-promoting factor 397 38 (GdNPF) 1262 gi4323581 Homo sapiens senescence-associated epithelial 223 97 membrane protein 1262 gi15214678 Homo sapiens claudin 1 223 97 1262 gi7381083 Homo sapiens claudin-1 223 97 1263 gi21634445 Homo sapiens GTP-binding protein Sara 449 57 1263 gi13542685 Mus musculus SARI protein 446 54 1263 gi8926205 Homo sapiens SARI 445 54 1264 gi11558264 Homo sapiens sphingosine-1-pbosphatase 697 37 1264 gi13447199 Homo sapiens sphingosine-1-phosphate phosphatase 683 37 1264 gi9623190 Mus musculus sphingosine-1-phosphate 691 38 phosphohydrolase 1265 gil4 Bos taurus BoWC1.1 1026 37 1265 gi5107945 Homo sapiens CD163 1093 40 1265 gi312142 Homo sapiens M130 antigen 1093 40 1266 gil4 Bos taurus BoWC1.1 1026 37 1266 gi5107945 Homo sapiens CD163 1093 40 1266 gi312142 Homo sapiens M130 antigen 1093 40 1267 gi18873700 Necator NADH dehydrogenase subunit 2 69 32 americanus 1267 gi20338417 Gallus gallus potassium channel subunit 57 31 1267 gi396416 Escherichia coli similar to Neurospora crassa phosphate- 72 42 repressible phosphate permease 1268 gi21619491 Homo sapiens similar to expressed sequence AW049604 778 100 1268 gi6572294 Homo sapiens bA262A13.1 (novel protein) 251 49 1268 gi161662 Tribolium zinc finger protein 60 26 castaneum 1269 gi21591552 Haemophilus cell filamentation-like protein 55 31 influenza biotype aegyptius 1269 gil762771 Pleurodeles homeodomain-containing protein 66 35 waltl 1269 gil9528253 Drosophila GH13327p 53 41 melanogaster 1270 gil8033185 Danio rerio UNC45-related protein 3103 73 1270 gil2248757 Homo sapiens SMAP-1 2393 57 1270 gil2248771 Homo sapiens SMAP-lb 2393 57 1271 gi21064657 Drosophila RHO1479p 185 39 melanogaster 1271 gi7304173 Drosophila CG1577-PA 185 39 I melanogaster 1 1271 gi20150011 Pseudomonas MmpIV 89 36 fluorescens 1272 gi9366656 Trypanosoma probable similar to ring-h2 finger protein 76 55 WO 2004/080148 PCT/US2003/030720 187 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity brucei rhala. 1272 gi6714271 Arabidopsis F6N18.7 59 36 thaliana 1272 gi10440424 Homo sapiens FLJ00047 protein 74 50 1273 gil5823642 Homo sapiens ALS2CR7 2038 100 1273 gi2645810 Mus musculus Pftaire-1 1195 68 1273 gi2392814 Mus musculus PFTAIRE kinase 1190 67 1274 gi2407911 Homo sapiens differentially expressed in Fanconi 714 96 anemia 1274 gi21595389 Homo sapiens similar to FYVE finger-containing 89 27 phosphoinositide kinase (1 phosphatidylinositol-4-phosphate kinase) (PIP5K) (Ptdlns(4)P-5-kinase) (p235) 1274 gi330134 human latency-related protein 1 87 46 herpesvirus 1 1275 gi21908028 Homo sapiens a disintegrin and metalloprotease domain 4205 97 33 1275 gil8147612 Homo sapiens metalloprotease disintegrin 4204 97 1275 gil3157560 Homo sapiens dJ964F7.1 (novel disintegrin and 3916 97 reprolysin metalloproteinase family protein) 1276 gi530876 Chlamydomona amino acid feature: Rod protein domain, 138 35 s reinhardtii aa 266 .. 468; amino acid feature: globular protein domain, aa 32 .. 265 1276 gi141852 Actinomyces sialidase 137 30 viscosus 1276 gil3926258 Arabidopsis AT5g10430/F12B17_220 110 34 thaliana 1277 gi15291913 Drosophila LD31582p 201 36 melanogaster 1277 gi16648042 Drosophila GH07105p 131 39 melanogaster 1277 gi16416111 Neurospora related to suppressor protein SPT23 129 43 crassa 1278 gi544755 Oryctolagus aminopeptidase N; APN 1016 38 cuniculus 1278 gi525287 Sus scrofa aminopeptidase N. 1012 39 1278 gi205109 Rattus kidney Zn-peptidase precursor 1004 39 norvegicus 1279 gil3559063 Homo sapiens bA552M11.5 (novel protein) 747 100 1279 gi9963863 Homo sapiens AD026 738 98 1279 gil9263987 Homo sapiens similar to CMRF35 ANTIGEN 131 32 PRECURSOR 1280 gi2773306 Equus caballus type II collagen 69 31 1280 gi3687594 Canis familiaris type IIB procollagen 69 31 1280 gi8918871 YccA of 96 pct identical to gp:AB021078 30 64 26 plasmid ColIb P9 [Plasmid F 1281 gi9927307 Mus musculus junctophilin type 3 59 42 1281 gi5881591 Gallus gallus homeodomain protein 78 38 1281 gil1095167 Bacteriophage gp38 76 34 ARI 1282 gil3938232 Homo sapiens Similar to RIKEN cDNA 2610005H 11 78 32 gene 1282 gil3883774 Mycobacterium NAD-dependent epimerase/dehydratase 83 31 WO 2004/080148 PCT/US2003/030720 188 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity tuberculosis family protein CDC1551 1282 gi5881591 Gallus gallus homeodomain protein 78 38 1283 gi13938232 Homo sapiens Similar to RIKEN cDNA 2610005H11 78 32 gene 1283 gil3883774 Mycobacterium NAD-dependent epimerase/dehydratase 83 31 tuberculosis family protein CDC1551 1283 gi5881591 Gallus gallus homeodomain protein 78 38 1284 gil5779156 Homo sapiens Similar to RIKEN cDNA 1810073N04 4057 100 gene 1284 gi13097045 Mus musculus Similar to RIKEN cDNA 1810073N04 1727 91 gene 1284 gil8447388 Drosophila RE05944p 716 32 melanogaster 1285 gi21626874 Drosophila CG9410-PB 354 46 melanogaster 1285 gi7302281 Drosophila CG9410-PA 354 46 melanogaster 1285 gi2l166086 Dictyostelium Nucleoside diphosphate kinase 164 30 discoideum 1286 gi20977688 Xenopus laevis tumorhead 146 33 1286 gil9070822 Mus musculus Myb protein P42POP 132 29 1286 gi9652255 Ovis aries DNA binding protein pur-alpha 76 26 1287 gi1006932 Visna virus envelope polyprotein 61 48 1287 gi6469042 Mus musculus C1 84M protein 73 28 1287 gi20988388 Mus musculus Similar to mammary tumor virus receptor 73 28 2 1288 gi12309630 Homo sapiens bA438B23.1 (neuronal leucine-rich 319 31 repeat protein) 1288 gi6273399 Homo sapiens melanoma-associated antigen MG50 322 31 1288 gil504040 Homo sapiens similar to D.melanogaster 322 31 peroxidasin(UI 1052) 1289 gil6769274 Drosophila LD22423p 222 24 melanogaster 1289 gil8700635 Homo sapiens importin 4 113 23 1289 gil3277562 Homo sapiens Similar to RIKEN cDNA 8430408015 113 23 gene 1290 gi21391486 Mus musculus leucine-rich repeat domain-containing 430 43 protein 1290 gi21623740 Rattus Leucine-rich repeat-containing protein 3 425 43 norvegicus 1290 gi21391484 Homo sapiens leucine-rich repeat domain-containing 392 39 protein 1291 gi21624340 Homo sapiens ceramide kinase 1611 100 1291 gi21624342 Mus musculus ceramide kinases 1374 86 1291 gil6768660 Drosophila HL01538p 292 41 melanogaster 1292 gi50369 Mus musculus precursor protein (AA -34 to 244) 204 32 1292 gi312590 Mus musculus biliary glycoprotein 204 32 1292 gi3549152 Homo sapiens R29124 1 187 32 1293 gi50369 Mus musculus precursor protein (AA -34 to 244) 204 32 1293 gi312590 Mus musculus biliary glycoprotein 204 32 1293 gi3549152 Homo sapiens R29124_1 187 32 1294 gi21411450 Mus musculus similar to FLJOO179 protein 1159 91 WO 2004/080148 PCT/US2003/030720 189 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1294 gil8676564 Homo sapiens FLJO 179 protein 993 99 1294 gil7945392 Drosophila RE17452p 486 59 melanogaster 1295 gi7708438 Homo sapiens dJ885A10.1 (similar to cerebellin 1020 100 precursor) 1295 gi5702371 Mus musculus precerebellin-1 699 70 1295 gil80251 Homo sapiens precerebellin 696 74 1296 gi3901028 Homo sapiens neurotensin receptor 2 1436 100 1296 gil483580 Rattus NTR2 receptor 1073 76 norvegicus 1296 gil7646096 Mus musculus low affinity neurotensin receptor 1072 77 1298 gi6624583 Homo sapiens dJ61B2.1 (bullous pemphigoid antigen 1 1342 100 (230/240kD) isoform 3) 6 1298 gi403124 Homo sapiens bullous pemphigoid antigen 9121 92 1298 gi15077861 Mus musculus bullous pemphigoid antigen 1-e 6442 67 1299 gi2114176 Homo sapiens p97 homologous protein 100 23 1299 gi12654337 Homo sapiens craniofacial development protein 1 100 23 1299 gi3341899 Homo sapiens BCNT 100 23 1300 gi6572294 Homo sapiens' bA262A13.1 (novel protein) 499 100 1300 gi21619491 Homo sapiens similar to expressed sequence AW049604 260 42 1300 gi2460196 Monodelphis immunoglobulin Igh@ variable domain 65 37 domestica 1301 gi18676652 Homo sapiens FLJ00225 protein 779 100 1301 gi2632952 Bacillus subtilis yebD 66 51 1301 gi20749947 Drosophila fruitless class I male isoform 50 40 virilis 1302 gil8676652 Homo sapiens FLJ00225 protein 444 97 1302 gi2632952 Bacillus subtilis yebD 59 48 1303 gi342299 Macaca preprosomatostatin 226 100 fascicularis 1303 gi338288 Homo sapiens preprosomatostatin I 226 100 1303 gi21619156 Homo sapiens somatostatin 226 100 1304 gil4249944 Homo sapiens Similar to bromodomain-containing 4 109 30 1304 gi2865615 Leishmania acidic ribosomal protein P1 93 36 peruviana 1304 gi343452 Tarsius involucrin 114 24 bancanus 1305 gi219894 Homo sapiens 80K-L protein 124 26 1305 gil87387 Homo sapiens myristoylated alanine-rich C-kinase 122 26 substrate 1305 gil3562004 Nephila major ampullate spidroin 2-like protein 140 33 madagascariens is 1306 gi21744725 Homo sapiens glycosyl-phosphatidyl-inositol-MAM 1548 48 1306 gi7529597 Homo sapiens dJ402N21.2 (novel protein with MAM 657 53 domain) 1306 gi7529598 Homo sapiens dJ402N21.3 (novel protein with 591 52 Immunoglobulin domains) 1307 gi4455102 Brassica rapa pollen-specific protein BAN102 72 44 1307 gi4096227 Oryctolagus Ig heavy chain 68 31 cuniculus 1307 gi17017359 Talaromyces 60S ribosomal protein L2 60 43 emersonn 1308 gil7429038 Ralstonia PROBABLE ACYL-COA 1166 56 WO 2004/080148 PCT/US2003/030720 190 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity solanacearum DEHYDROGENASE OXIDOREDUCTASE PROTEIN 1308 gi9948609 Pseudomonas probable acyl-CoA dehydrogenase 1121 57 aeruginosa 1308 gi13421911 Caulobacter acyl-CoA dehydrogenase family protein 1058 54 crescentus CB15 1309 gil7429038 Ralstonia PROBABLE ACYL-COA 1166 56 solanacearum DEHYDROGENASE OXIDOREDUCTASE PROTEIN 1309 gi9948609 Pseudomonas probable acyl-CoA dehydrogenase 1121 57 aeruginosa 1309 gi13421911 Caulobacter acyl-CoA dehydrogenase family protein 1058 54 crescentus CB15 1310 gi19070124 Mus musculus zinc transporter-like 3 protein 1087 95 1310 gi20563194 Mus musculus zinc transporter 6 1075 94 1310 gi9803033 Caenorhabditis C. elegans TOC-1 protein (corresponding 279 38 elegans sequence ZC395.3) 1311 gi854065 Human U88 260 33 herpesvirus 6 1311 gi21928439 Homo sapiens seven transmembrane helix receptor 174 29 1311 gil8893248 Pyrococcus smc-like 177 24 furiosus DSM 3638 1312 gi5295832 Homo sapiens dJ21018.2 (protein similar to collagen) 1142 100 1312 gi6526769 Homo sapiens HRIHFB2003 1055 97 1312 gi7291408 Drosophila CG11206-PA 738 41 melanogaster 1313 gil9263985 Homo sapiens Similar to RIKEN cDNA 1300017EO9 1565 99 gene 1313 gi19528309 Drosophila LD02310p 573 55 melanogaster 1313 gi7106870 Homo sapiens HSPC240 227 30 1314 gi22090626 Homo sapiens HECT domain protein LASU1 1169 99 0 1314 gi6841194 Homo sapiens HSPC272 9665 99 1314 gi20151907 Drosophila SD03277p 1833 75 melanogaster 1315 gi21542541 Homo sapiens Similar to HTPAP protein 766 100 1315 gi13182757 Homo sapiens HTPAP 473 100 1315 gi14020949 Arabidopsis phosphatidic acid phosphatase 317 50 thaliana 1316 gi21542541 Homo sapiens Similar to HTPAP protein 1204 99 1316 gi13182757 Homo sapiens HTPAP 915 100 1316 gi14020949 Arabidopsis phosphatidic acid phosphatase 460 41 thaliana 1317 gil80164 Homo sapiens CD7 antigen protein 1135 93 1317 gi732757 Homo sapiens CD7 antigen 1135 93 1317 gi14424540 Homo sapiens CD7 antigen (p41) 1135 93 1319 gi16416764 Homo sapiens FKSG16 2369 99 1319 gi13905212 Mus musculus RIKEN cDNA 1200006FO2 gene 1833 75 1319 gi14715055 Homo sapiens Similar to RIKEN cDNA 1110002C08 418 32 gene 1320 gi16416764 Homo sapiens FKSG16 323 98 WO 2004/080148 PCT/US2003/030720 191 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1320 gi13905212 Mus musculus RIKEN cDNA 1200006F02 gene 257 77 1320 gil4715055 Homo sapiens Similar to RIKEN cDNA 1110002C08 97 33 gene 1321 gi10834558 Rattus proline arginine-rich end leucine-rich 392 32 norvegicus repeat protein 1321 gi21618473 Homo sapiens proline arginine-rich end leucine-rich 389 32 repeat protein 1321 gil 145773 Homo sapiens prolargin 389 32 1322 gi20258604 Homo sapiens sialic acid binding Ig-like lectin 5 1473 84 1322 gi2411475 Homo sapiens OB binding protein-2 1473 84 1322 gi5759106 Homo sapiens sialic acid binding Ig-like lectin-5; siglec- 1473 84 5 1323 gi20258604 Homo sapiens sialic acid binding Ig-like lectin 5 1375 87 1323 gi2411475 Homo sapiens OB binding protein-2 1375 87 1323 gi5759106 Homo sapiens sialic acid binding Ig-like lectin-5; siglec- 1375 87 5 1324 gi20987759 Homo sapiens Similar to ADAMTS-like 1 886 99 1324 gi15099921 Homo sapiens ADAM-TS related protein 1 874 98 1324 gil3183078 Homo sapiens a disintegrin-like and metalloprotease 603 73 domain with thrombospondin type I motifs-like 3 1326 gi757915 Homo sapiens apoCII protein 427 89 1326 gi178836 Homo sapiens apolipoprotein C-Il 427 89 1326 gi342077 Macaca apolipoprotein C-II 371 78 fascicularis 1327 gi21619424 Homo sapiens Similar to LOC150580 477 100 1327 gi12656449 Plasmodium erythrocyte membrane protein 1 63 25 falciparum 1327 gi15384029 uncultured extracellular protein 64 31 crcnarchaeote 74A4 1329 gi16033597 Homo sapiens SH2 domain-containing phosphatase 1003 99 anchor protein 2d 1329 gi16033591 Homo sapiens SH2 domain-containing phosphatase 991 99 anchor protein 2b 1329 gil8092655 Homo sapiens immunoglobulin superfamily receptor 985 99 translocation associated protein 3 1330 gi4877582 Homo sapiens lipoma HMGIC fusion partner 728 63 1330 gi14272235 Homo sapiens bA183L8.1 lipomaa HMGIC fusion 445 61 partner) 1330 gi15292437 Drosophila LP10272p 187 25 melanogaster 1331 gil7426418 Mus musculus calmodulin-related protein 788 100 1331 gi12060826 Homo sapiens serologically defined breast cancer 610 77 antigen NY-BR-20 1331 gi5932428 Myxine calmodulin 316 44 glutinosa 1332 gi17862436 Drosophila LD27564p 152 26 melanogaster 1332 gi13311009 Homo sapiens NYD-SP16 78 26 1333 gi13279251 Homo sapiens Similar to wingless-related MMTV 2000 100 integration site 6 1333 gil1693044 Homo sapiens WNT6 precursor 2000 100 1333 gi14133265 Homo sapiens WNT6 2000 100 1334 gi20135611 Homo sapiens zinc transporter ZnT-5 463 94 WO 2004/080148 PCT/US2003/030720 192 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1334 gil9744304 Homo sapiens zinc transporter 5 463 94 1334 gi19744306 Mus musculus zinc transporter 5 407 85 1335 gil8480366 Mus musculus olfactory receptor MOR145-1 310 74 1335 gi21928214 Homo sapiens seven transmembrane helix receptor 301 77 1335 gi2447219 Homo sapiens OLF4 295 71 1336 gi20988856 Homo sapiens protein inhibitor of activated STAT3 3277 100 1336 gi4996563 Homo sapiens protein inhibitor of activatied STAT3 3277 100 1336 gi17149822 Rattus potassium channel regulatory protein 3211 96 norvegicus KChAP 1337 gi4469173 Gallus gallus delta-9 desaturase 1149 71 1337 gil9908266 Chanos chanos stearoyl-CoA desaturase 1140 65 1337 gi5738564 Ctenopharyngo delta-9-desaturase 1132 70 don idella 1338 gi14030861 Homo sapiens paraneoplastic neuronal antigen MAI 1830 99 1338 gil8478557 Rattus paraneoplastic onconeuronal protein MA1 1752 93 norvegicus 1338 gi15929183 Homo sapiens modulator of apoptosis 1 990 56 1339 gi5452942 Mus musculus glucosidase II beta-subunit 134 56 1339 gil63157 Bos taurus high-mobility-group protein 120 43 1339 gi15076513 Mus musculus 22 kDa neuronal tissue-enriched acidic 131 26 protein 1341 gill177514 Homo sapiens tandem pore domain potassium channel 2234 100 THIK-2 1341 gil1177510 Rattus tandem pore domain potassium channel 2215 98 norvegicus THIK-2 1341 gil5215363 Homo sapiens potassium channel, subfamily K, member 1346 65 13 1342 gil4336716 Homo sapiens similar to FBan0003337 1216 100 1342 gi20987336 Mus musculus RIKEN cDNA A930016P21 gene 427 50 1342 gil9886829 Methanopyrus SAM-dependent methyltransferase 104 31 kandleri AV19 1343 gil9570398 Homo sapiens hDDM36 1138 43 1343 gil1862939 Mus musculus DDM36 1134 43 1343 gil1862941 Mus musculus DDM36E 1125 43 1344 gi21744725 Homo sapiens glycosyl-phosphatidyl-inositol-MAM 4898 98 1344 gi7529598 Homo sapiens dJ402N21.3 (novel protein with 1548 99 Immunoglobulin domains) 1344 gi7529597 Homo sapiens dJ402N21.2 (novel protein with MAM 1321 94 domain) 1345 gil2276198 Homo sapiens FKSG40 1020 100 1345 gil2408250 Homo sapiens FKSG28 1020 100 1345 gil8652934 Xenopus laevis Mig30 649 49 1346 gil6769552 Drosophila LD38375p 1354 41 melanogaster 1346 gi7523707 Arabidopsis Putative membrane protein 1105 39 thaliana 1346 gil632829 Plasmodium AARP2 protein 467 36 falciparum 1347 gi20987450 Homo sapiens LOC146433 1162 95 1347 gi3093373 Mus musculus small proline-rich protein 21 64 39 1347 gi912799 Homo sapiens type I hair keratin 63 33 1348 gil016012 Rattus neural cell adhesion protein BIG-2 5093 93 norvegicus precursor 1348 gil9913548 Homo sapiens similar to axonal-associated cell adhesion 3630 99 WO 2004/080148 PCT/US2003/030720 193 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity molecule 1348 gi200057 Mus musculus neuronal glycoprotein 3630 64 1349 gil5292437 Drosophila LP10272p 441 39 melanogaster 1349 gi4877582 Homo sapiens lipoma HMGIC fusion partner 221 28 1349 gil6648454 Drosophila SD01285p 162 24 melanogaster 1350 gi13097705 Homo sapiens serine (or cysteine) proteinase inhibitor, 1925 97 clade A (alpha-1 antiproteinase, antitrypsin), member 3 1350 gi1340142 Homo sapiens alphal-antichymotrypsin 1921 97 1350 gi4165890 Homo sapiens alpha-1-antichymotrypsin precursor 1850 97 1351 gi21618556 Homo sapiens trophinin associated protein (tastin) 3134 84 1351 gi905356 Homo sapiens tastin 3129 84 1351 gi7861746 Mus musculus GABA-A receptor epsilon-like subunit 165 40 1352 gi12053849 Homo sapiens DREV protein 1689 100 1352 gi12053851 Homo sapiens DREVI protein 1676 99 1352 gi12055091 Mus musculus DREV protein 1655 97 1353 gil4627081 Homo sapiens caspase-1 dominant-negative inhibitor 492 100 Pseudo-ICE 1353 gi21707335 Homo sapiens Similar to CARD only protein 462 100 1353 gil86286 Homo sapiens interleukin 1-beta convertase 445 92 1354 gil7431573 Ralstonia PUTATIVE LIPOPROTEIN 82 42 solanacearum TRANSMEMBRANE 1354 gi995704 Saccharomyces L3149 69 23 cerevisiae 1354 gil256899 Saccharomyces Yrl138wp 69 23 cerevisiae 1355 gi12034719 Mus musculus ankyrin-like protein 413 43 1355 gi13469729 Homo sapiens breast cancer antigen NY-BR-1 415 49 1355 gi21618588 Homo sapiens testis-specific ankyrin motif containing 362 46 protein 1356 gi8272557 Rattus protein kinase WNK1 5439 73 norvegicus 1356 gi6933864 Homo sapiens kinase deficient protein KDP 3408 100 1356 gi19032238 Homo sapiens protein kinase WNK3 1664 56 1357 gi8272557 Rattus protein kinase WNKI 5439 73 norvegicus 1357 gi6933864 Homo sapiens kinase deficient protein KDP 1159 98 1357 gi19032238 Homo sapiens protein kinase WNK3 530 40 1358 gi10946203 Homo sapiens neuromedin U receptor 2 785 100 1358 gi9944990 Homo sapiens neuromedin U receptor-type 2 785 100 1358 gil6877377 Homo sapiens neuromedin U receptor 2 785 100 1359 gi17861592 Drosophila GH13807p 1234 45 melanogaster 1359 gil8376566 Caenorhabditis Y105E8A.20 964 49 elegans 1359 gi9368514 Leishmania methionyl-tRNA synthetase 963 42 major 1360 gil7389919 Homo sapiens Similar to major histocompatibility 819 100 complex, class II, DP beta 1 1360 gi575494 Homo sapiens MHC class II lymphocyte antigen beta 437 72 chain 1360 gil88479 Homo sapiens | HLA-DPB1 437 | 72 WO 2004/080148 PCT/US2003/030720 194 TABLE 2 A SEQ Hit ID Species Description S Percentage ID score identity 1361 gi3342737 Homo sapiens R26660 2, partial CDS 1025 97 1361 gil4625940 Homo sapiens interleukin-10 42 53 1361 gi3005997 okra yellow AC2 77 35 vein mosaic virus 1362 gi3342737 Homo sapiens R26660 2, partial CDS 1001 94 1362 gil4625940 Homo sapiens interleukin-10 42 53 1362 gi3005997 okra yellow AC2 77 35 vein mosaic virus 1363 gil3991167 Homo sapiens sialic acid-binding immunoglobulin-like 2879 99 lectin-like long splice variant 1363 gil4625822 Homo sapiens Siglec-L1 2879 99 1363 gi15824310 Pan troglodytes sialic acid-binding lectin Siglec-L1 2804 97 1364 gi20072749 Homo sapiens similar to interferon alpha/beta receptor 1 879 100 1364 gi571296 Homo sapiens CRFB4 188 27 1364 gi4028135 Gallus gallus interferon alpha/beta receptor 1 195 27 1365 gi8572055 Homo sapiens interleukin-1 receptor antagonist homolog 823 100 1 1365 gi6049805 Homo sapiens interleukin-1 receptor antagonist homolog 823 100 1365 gi6165334 Homo sapiens interleukin-1-like protein-i 823 100 1366 gil77870 Homo sapiens alpha-2-macroglobulin precursor 2780 40 1366 gi579594 Homo sapiens alpha 2-macroglobulin 690-740 2775 40 1366 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 2774 40 1367 gi4574224 Fundulus multidrug resistance transporter homolog 287 49 heteroclitus 1367 gil9743730 Rattus ATP-binding cassette protein BIb 285 50 norvegicus 1367 gi34525 Homo sapiens P-glycoprotein (431 AA) 273 50 1368 gil98922 Mus musculus lymphocyte differentiation antigen 713 100 1368 gi198926 Mus musculus Ly-6A.2 alloantigen 713 100 1368 gil98930 | Mus musculus differentiation antigen Ly-6E/A 713 100 WO 2004/080148 PCT/US2003/030720 195 TABLE 2 B SEQID HitID Species Description S score Percentage_ Identity 685 gi183150 Homo sapiens chorionic somatomammotropin 320 100 CS-5 685 gi23271170 Homo sapiens chorionic somatomammotropin 275 96 hormone 2 685 gi28188743 Pan troglodytes placental lactogen PL-B 279 98 686 gi183178 Homo sapiens hGH-V2 1033 78 686 gi23271170 Homo sapiens chorionic somatomammotropin 707 92 hormone 2 686 gi28188743 Pan troglodytes placental lactogen PL-B 715 94 688 gi18088830 Homo sapiens AAH20756 785 100 688 gi183178 Homo sapiens hGH-V2 1051 79 688 gi30582691 Homo sapiens 785 100 689 gil2653501 Homo sapiens SERPINF1 protein 2003 95 689 gi30583283 Homo sapiens , member 1 2003 95 689 gi30585311 synthetic construct ,member 1 2003 95 690 gi20269957 Sus scrofa AF4987591 phospholipase C 1033 88 delta 4 690 gi21307610 Mus musculus phospholipase C delta 4 909 77 690 gi571466 Rattus norvegicus phospholipase C delta-4 893 76 691 gil7864023 Homo sapiens AF450090_1 KCCR13L 3524 100 691 gi22760385 Homo sapiens unnamed protein product 3515 99 691 gi22761016 Homo sapiens unnamed protein product 3524 100 692 gi12697933 Homo sapiens KIAA1694 protein 3850 100 692 gi20380030 Mus musculus 4933407C03Rik protein 3251 98 692 gi27652547 Homo sapiens truncated c-Maf-inducing 3506 99 protein 693 gi437662 Oryctolagus interleukin-8 receptor subtype 188 61 cuniculus B 693 gi511803 Homo sapiens interleukin-8 receptor type B 172 57 693 gi576679 Homo sapiens interleukin 8 receptor B 172 57 694 gi32966069 Homo sapiens CD39L2 nucleotidase 2514 99 694 gi3335098 Homo sapiens CD39L2 2520 100 694 gi4691263 Homo sapiens 2513 99 695 gil6566319 Homo sapiens AF411107_1 G protein- 1843 99 coupled receptor 695 gi21928620 Horno sapiens seven transmembrane helix 1858 100 receptor 695 gi22293641 Homo sapiens putative orphan G protein- 845 51 coupled receptor 26 696 gi24660226 Homo sapiens C-type lectin-like receptor-1 1460 90 696 gi7110216 Homo sapiens AF200949_1 C-type lectin-like 1458 90 receptor-I 696 gi7110218 Mus musculus AF2014571 C-type lectin-like 322 29 receptor 2 698 gil8089247 Homo sapiens AAH20966 Similar to 2104 100 ectonucleoside triphosphate diphosphohydrolase 5 698 gi30584801 synthetic construct Homo sapiens ectonucleoside 2104 100 triphosphate diphosphohydrolase 5 698 gi3335102 Horno sapiens CD39L4 2104 100 699 gi804761 Homo sapiens putative 247 77 700 gi16184225 Drosophila LD24527p 666 42 melanogaster WO 2004/080148 PCT/US2003/030720 196 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 700 gi27447597 Drosophila transcriptional adapter 2S 666 42 melanogaster 700 gi7298997 Drosophila CG9638-PA 666 42 melanogaster 701 gil7225457 Homo sapiens AF326917_1 autism-related 1272 36 protein 1 701 gi27817314 Danio rerio 1234 36 701 gi29468246 Homo sapiens XTP9 3605 99 702 gi20810589 Homo sapiens similar to arsenite inducible 833 99 RNA associated protein 702 gi22945274 Drosophila CG12795-PA 455 54 melanogaster 702 gi9651711 Mus musculus AF224494 I arsenite inducible 687 80 RNA associated protein 703 gil3241652 Rattus norvegicus AF309558_1 supernatant 2040 93 protein factor 703 gil3543184 Mus musculus SEC14-like 2 2038 93 703 gi6624130 Rattus norvegicus AC004832_1 similar to 45 kDa 2150 100 secretory protein 704 gil1066250 Homo sapiens AF1979371 presenilins 1693 86 associated rhomboid-like protein 704 gil3177766 Homo sapiens AAH03653 Similar to 1761 99 presenilins associated rhomboid-like protein 704 gil5559382 Homo sapiens AAH14058 presenilins 1696 86 associated rhomboid-like protein 705 gil864091 Rattus norvegicus PSD-95/SAP90-associatcd 4997 95 protein-3 705 gi2454510 Homo sapiens PSD-95/SAP90-associated 2105 47 protein-2 705 gi6979175 Homo sapiens AF119818_1 homolog- 2089 47 associated protein 2 706 gil11877274 Homo sapiens associatedprotein_2_2260 99 706 gi21667210 Homo sapiens AF465765_1 2260 99 bactericidal/permeability increasing protein-like 1 706 gi21706776 Homo sapiens Bactericidal/permeability- 2253 99 increasing protein-like 1 707 gi16768190 Drosophila GH22974p 647 41 melanogaster 707 gi24659527 Homo sapiens 2006 100 707 gi7291716 Drosophila CG11388-PA 648 41 melanogaster 708 gil4334082 Mus musculus AF367970_1 thymus LIM 479 87 protein TLP-A 708 gil4335908 Mus musculus thymus LIM protein TLP-A 479 87 708 gil4335909 Mus musculus thymus LIM protein TLP-B 396 90 709 gi12804105 Homo sapiens AAH02905 Similar to 2090 100 CG15084 gene product 709 gil3649459 Homo sapiens AF250306_1 putative SB 115 2090 100 protein 709 gi18204670 Mus musculus 4930527D15Rik protein 1015 96 710 gil674440 Homo sapiens collagen type IV a6 chain 4222 51 WO 2004/080148 PCT/US2003/030720 197 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 710 gil674441 Homo sapiens collagen type IV a6 chain 4222 51 710 gi556299 Mus musculus alpha-2 type IV collagen 8126 83 711 gi438007 Gallus gallus alpha-2-macroglobulin receptor 15742 60 711 gi7861733 Homo sapiens AF176832_1 low density 23654 99 lipoprotein receptor related protein-deleted in tumor 711 gi8926243 Mus musculus AF270884 1 low density 23098 92 lipoprotein receptor related protein LRP1B/LRP-DIT 712 gi17298315 Homo sapiens candidate tumor suppressor 848 100 protein 712 gi7861733 Homo sapiens AF176832_1 low density 848 100 lipoprotein receptor related protein-deleted in tumor 712 gi8926243 Mus musculus AF270884_1 low density 731 83 lipoprotein receptor related protein LRP1B/LRP-DIT 713 gil3544080 Homo sapiens AAH06171 hypothetical 1133 100 protein MGC2731 713 gi20071811 Mus musculus 5830411ElORik protein 492 55 713 gi33589496 Drosophila LD31278p 401 44 melanogaster 714 gil57409 Drosophila fat protein 3001 40 melanogaster 714 gi22945533 Drosophila CG17941-PA 2292 34 melanogaster 714 gi7295732 Drosophila CG3352-PA 3015 40 mel anogaster 715 gil57409 Drosophila fat protein 3007 40 melanogaster 715 gi22945533 Drosophila CG17941-PA 2289 34 melanogaster 715 gi7295732 Drosophila CG3352-PA 3021 40 melanogaster 716 gil7865311 Homo sapiens AF452102_1 dipeptidyl 4370 95 peptidase-like protein 9 716 gi27549552 Homo sapiens dipeptidyl peptidase IV-related 4370 95 protein-2 716 gi29293087 Homo sapiens dipeptidyl peptidase 9 4511 95 717 gi2689444 Homo sapiens ZNF134 1252 57 717 gi31565347 Homo sapiens LOC284018 protein 1252 57 717 gi996 8290 Homo sapiens zinc finger protein 304 1094 47 718 gi23468368 Mus musculus 1200013F24Rik protein 690 90 718 gi27695305 Mus musculus 1200013F24Rik protein 715 91 718 gi7582294 Homo sapiens AF208853 1 BM-011 881 100 719 gil620870 Ciona intestinalis myoplasmin-C1 410 27 719 gi7416982 Argopecten irradians myosin heavy chain cardiac 255 20 muscle specific isoform 1 719 gi7416983 Argopecten irradians myosin heavy chain cardiac 255 20 muscle specific isoform 2 720 gil3872813 Homo sapiens fibulin-6 13764 100 720 gil4575679 Homo sapiens AF156100 1 hemicentin 13720 99 720 gi3879658 Caenorhabditis 1636 29 elegans 721 gil3177673 Homo sapiens AAH03621 1520 45 WO 2004/080148 PCT/US2003/030720 198 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 721 gi19354327 Homo sapiens 1520 45 721 gi3822553 Gallus gallus nuclear calmodulin-binding 2238 61 protein 722 gil7223626 Homo sapiens ATP-binding cassette A1O 7963 99 722 gi32350914 Homo sapiens ATP-binding cassette sub- 7943 99 family A member 10 722 gi32350969 Homo sapiens ATP-binding cassette sub- 7943 99 family A member 10 723 gi13374079 Homo sapiens TAFII140 protein 3677 99 723 gi13374178 Mus musculus TAFII140 protein 3193 84 723 gi28175603 Homo sapiens TAF3 protein 2772 99 724 gil7429038 Ralstonia PROBABLE ACYL-COA 658 61 solanacearum DEHYDROGENASE OXIDOREDUCTASE PROTEIN 724 gi22776354 Oceanobacillus acyl-CoA dehydrogenase 638 63 iheyensis HTE831 724 gi28280023 Mus musculus 5730439E10Rik protein 946 85 725 gi21522768 Homo sapiens unnamed protein product 3060 100 725 gi24047224 Homo sapiens Similar to EGF-like-domain, 3060 100 multiple 6 725 gi6752658 Homo sapiens AF186084 1 epidermal growth 3055 99 factor repeat containing protein 726 gil14530342 Cacnorhabditis 1008 36 elegans 726 gi6531661 Caenorhabditis AF195610 1 LIN-41A 1008 36 elegans 726 gi6531663 Caenorhabditis AF195611_1 LIN-41B 1008 36 elegans 727 gi1504026 Homo sapiens 5833 99 727 gi22725157 Homo sapiens minor histocompatibility 5833 99 antigen HA-i 727 gi23272016 Homo sapiens Similar to PTPLI-associated 5690 98 RhoGAP 1 728 gi13274120 Homo sapiens 1467 99 728 gi6102996 Mus musculus Vanin-3 1018 79 728 gi7160973 Homo sapiens VNN3 protein 1213 96 729 gi27463365 Homo sapiens a disintegrin-like and 8961 99 metalloprotease with thrombospondin type 1 motifs 9B 729 gi28804249 Mus musculus metalloprotease-disintegrin 4974 55 protease 729 gi9581879 Homo sapiens AF2619181 disintegrin 5723 99 metalloproteinase with thrombospondin repeats 730 gi21063967 Drosophila AT05453p 382 31 melanogaster 730 gi5911409 Drosophila fuzzy 382 31 melanogaster 730 gi7297412 Drosophila CG13396-PA 382 31 melanogaster 731 gil5488017 Homo sapiens AF407274_1 EWI2 2302 100 731 gi27497567 Homo sapiens keratinocytes associated 2302 100 transmembrane protein 4 WO 2004/080148 PCT/US2003/030720 199 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 731 gi31753233 Homo sapiens Immunoglobulin superfamily, 2302 100 member 8 732 gil5488017 Homo sapiens AF407274_1 EWI2 3200 100 732 gi27497567 Homo sapiens keratinocytes associated 3200 100 transmembrane protein 4 732 gi31753233 Homo sapiens Immunoglobulin superfamily, 3200 100 member 8 733 gi22266726 Homo sapiens AF311906_1 LIR-D1 1303 96 precursor 733 gi27497567 Homo sapiens keratinocytes associated 1303 96 transmembrane protein 4 733 gi31753233 Homo sapiens Immunoglobulin superfamily, 1303 96 member 8 734 gi21748480 Homo sapiens FLJO0271 protein 605 100 734 gi27497567 Homo sapiens keratinocytes associated 513 79 transmembrane protein 4 734 gi31753233 Homo sapiens Immunoglobulin superfamily, 513 79 member 8 735 gi31455457 Homo sapiens putative NFkB activating 583 44 protein 735 gi7022838 Homo sapiens unnamed protein product 1794 99 735 gi7293694 Drosophila CG7323-PA 339 36 melanogaster 736 gi12804169 Homo sapiens AAH02942 3494 97 736 gi15779178 Homo sapiens AAH14652 Similar to 3532 97 hypothetical protein BC002942 736 gil8088939 Homo sapiens AAH21143 3494 97 737 gil2836469 Mus musculus unnamed protein product 3495 87 737 gi26351115 Mus musculus unnamed protein product 3466 87 737 gi30721603 Mus musculus RAVERI 3466 87 738 gi12002000 Homo sapiens AF061732 1 My029 protein 415 100 739 gil5489209 Mus musculus BC013712 protein 266 31 739 gi21757804 Homo sapiens unnamed protein product 1226 96 739 gi26354220 Mus musculus unnamed protein product 1130 79 740 gil5341806 Homo sapiens AAH13073 2008 100 740 gi19528077 Drosophila AT24025p 165 38 melanogaster 740 gi21627272 Drosophila CG12765-PA 167 24 melanogaster 741 gi23495223 Plasmodium AE014834 50 liver stage 407 23 falciparum 3D7 antigen, putative 741 gi32492940 Homo sapiens medulloblastoma antigen MU- 536 25 MB-20.201 741 gi9916 Plasmodium liver stage antigen 393 24 falciparum 742 gil3161060 Homo sapiens AF332217_1 protocadherin 11 3354 58 742 gi15054521 Homo sapiens AF217288_1 protocadherin-S 3362 58 742 gi9845485 |lomo sapiens AF169692_1 protocadherin-9 6235 100 743 gil6552038 Homo sapiens unnamed protein product 2404 99 743 gi21410124 Mus musculus 3230402E02Rik protein 1501 61 743 gi5688958 Homo sapiens PMMLP 2405 100 744 gi21734445 Rattus norvegicus BMP/Retinoic acid-inducible 3987 94 neurai-specific protein-2 744 gi21734447 Rattus norvegicus BMP/Retinoic acid-inducible 2948 70 WO 2004/080148 PCT/US2003/030720 200 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity ___ _ neural-specific protein-3 744 gi30348610 Gallus gallus BMP/retinoic acid-inducible 2090 52 neural-specific protein 745 gi2739353 Homo sapiens ZNF91L 2077 69 745 gi27693081 Homo sapiens 2054 71 745 gi30421228 Homo sapiens zinc finger protein 430 2486 96 746 gi23272677 Homo sapiens Similar to zinc finger protein 2472 78 208 746 gi26251755 Homo sapiens ZNF431 protein 2480 79 746 gi30421228 Homo sapiens zinc finger protein 430 3174 100 747 gil212965 Homo sapiens transmembrane protein 1010 99 747 gil213221 Rattus norvegicus transmembrane protein 1006 95 747 gi19683999 Homo sapiens coated vesicle membrane 1010 99 protein 748 gil 199524 Homo sapiens acid phosphatase 2147 95 748 gi13111975 Homo sapiens AAH03160 acid phosphatase 2143 95 2, lysosomal 748 gi30584617 synthetic construct Home sapiens acid 2143 95 phosphatase 2, lysosomal 749 gi15625570 Homo sapiens AF411981_1 centaurinbeta5 3851 95 749 gi28422704 Homo sapiens CENTB5 protein 2912 100 749 gi30109272 Homo sapiens CENTB5 protein 4175 99 750 gil0197642 Homo sapiens AF182421 I MDSO22 647 100 750 gi15929423 Homo sapiens Hypothetical protein FLJ20502 938 100 750 gi30277696 Mus musculus D5Buc26e protein 423 78 751 gil8614026 Homo sapiens zinc finger DNA binding 998 40 protein p71 751 gi27693858 Homo sapiens zinc finger protein 398 998 40 751 gi5630080 Homo sapiens AC004890 2 984 36 752 gil 1345382 Homo sapiens AF308801_1 vacuolar protein 3724 95 sorting protein 16 752 gi12140290 Homo sapiens 3724 95 752 gi15553046 Mus musculus Vpsl6 3628 92 753 gi30141048 Homo sapiens Nogo-66 receptor homolog-1 2226 100 753 gi30141052 Rattus norvegicus Nogo-66 receptor homolog-1 2130 95 753 gi32351287 Rattus norvegicus Nogo-66 receptor homolog 2 916 51 754 gil77870 Homo sapiens alpha-2-macroglobulin 2718 39 precursor 754 gi25303946 Homo sapiens alpha-2-macroglobulin 2718 39 754 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 2712 39 755 gi18044501 Mus musculus angiopoietin-like 3 1692 70 755 gi4929790 Homo sapiens AF1525621 angiopoietin- 2210 93 related protein 3 755 gi5639997 Mus musculus AF162224-1 angiopoietin- 1692 70 related protein 3 756 gi200057 Mus musculus neuronal glycoprotein 4821 87 756 gi29837411 Homo sapiens BIG-2 3898 69 756 gi563133 Rattus norvegicus BIG-I protein 4778 87 757 gi16550078 Homo sapiens unnamed protein product 3710 99 757 gi28175743 Homo sapiens similar to hypothetical protein 3714 100 FLJ30803 757 gi30354720 Mus musculus A1427653 protein 3609 96 758 gi26329813 Mus musculus unnamed protein product 3627 93 758 gi28175743 Homo sapiens similar to hypothetical protein 3612 | 98 WO 2004/080148 PCT/US2003/030720 201 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity FLJ30803 758 gi30354720 Mus musculus A1427653 protein 3520 95 759 gi21929093 Homo sapiens seven transmembrane helix 1718 88 receptor 759 gi24286029 Homo sapiens G-protein coupled receptor 6772 98 GPR116 759 gi5525078 Rattus norvegicus seven transmembrane receptor 5048 72 760 gi10440398 Homo sapiens FLJO0032 protein 1257 61 760 gil 1917507 Homo sapiens HPF1 protein 1254 62 760 gil5929737 Mus musculus similar to KRAB zinc finger 1249 58 protein KR1 8 761 gil3097633 Homo sapiens AAH03534 Similar to ATPase, 2325 53 Class I, type 8B, member 1 761 gi33440008 Homo sapiens possible aminophospholipid 3473 66 translocase ATP8B2 761 gi3628757 Homo sapiens FIC1 2576 53 763 gil 1558486 Homo sapiens B-cell lymphoma/leukaemia 1314 99 _ I 1A short form 763 gil8089267 Homo sapiens AAH21098 1153 100 763 gi30410854 Mus musculus 1312 98 764 gi32394378 Homo sapiens forkhead-associated domain 1808 100 ________________histidine-triad like protein 764 gi32394380 Bos taurus forkhead-associated domain 1638 89 histidine-triad like protein 764 gi32394382 Sus scrofa forkhead-associated domain 1681 91 histidine-triad like protein 765 gi31455403 Homo sapiens aprataxin 241 97 765 gi31455405 Homo sapiens aprataxin 235 100 765 gi32394378 Homo sapiens forkhead-associated domain 241 97 histidine-triad like protein 766 gi31455403 Homo sapiens aprataxin 318 100 766 gi32394378 Homo sapiens forkhead-associated domain 318 100 histidine-triad like protein 766 gi32394382 SLs scrofa forkhead-associated domain 307 93 histidine-triad like protein 767 gi26454883 -Homo sapiens hypothetical protein HSPC48 1181 100 767 gi6523797 Homo sapiens AF1107751 adrenal gland 1181 100 protein AD-002 767 gi6431518 Homo sapiens AF161497 HSPC148 1178 99 768 gi14009597 Homo sapiens AF2826191 lysyl oxidase-like 116 98 3 l protein 768 gi14486600 Homo sapiens AF3113131 lysyl oxidase-like 1816 98 3 protein 768 gil4186770 Homo sapiens AF2848151 lysyl oxidase-like 1816 98 protein 769 gi22713410 Homo sapiens GYLTL1B protein 3229 100 769 gi3954938 Homo sapiens acetylglucosaminyltransferase- 2292 70 like protein 769 gi3954978 Mus musculus acetylglucosaminyltransferase- 2292 70 like protein 770 gi7209721 Mus musculus DD57 2243 88 770 gi7209723 Homo sapiens WD-repeat like sequence 2476 99 770 gi8217485 Homo sapiens 2473 99 771 gil6552001 Homo sapiens unnamed protein product 3169 100 WO 2004/080148 PCT/US2003/030720 202 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity 771 gil8676632 Homo sapiens FLJO0215 protein 1943 99 771 gi21706685 Mus musculus 9630058J23Rik protein 860 59 772 gil0799166 Homo sapiens AF305686_1 protein kinase 1915 99 Njmu-RI 772 gi32425794 Homo sapiens NJMU-R1 protein 1888 100 772 gi32450708 Homo sapiens NJMU-R1 protein 1888 100 773 gil3277972 Mus musculus phosphatidate 2286 96 cytidylyltransferase 2 773 gil9344052 Homo sapiens ... 2376 100 773 gi4186023 Homo sapiens CDS2 protein 2376 100 774 gi17511840 Homo sapiens AAH18769 2251 99 774 gi20988879 Homo sapiens Similar to hypothetical gene 2251 99 supported by AL133057; BC018769; BC009436; AL133057; AL133057; AL133057 774 gi29387317 Mus musculus 1200011022Rik protein 1792 79 775 gil3936996 Human herpesvirus 8 ORF73 219 21 775 gi2246532 Human herpesvirus 8 ORF 73, contains large 226 19 complex repeat CR 73 775 gi30526291 Saimiriine latency associated nuclear 219 31 herpesvirus 2 antigen 776 gil3477379 Homo sapiens TTYH2 protein 1037 41 776 gil8676664 Homo sapiens FLJ00231 protein 1796 91 776 gi28422735 Xenopus laevis 1054 40 777 gil6877193 Homo sapiens AAH16860 G protein-coupled 939 98 receptor, family C, group 5, member C 777 gi30583709 Homo sapiens G protein-coupled receptor, 939 98 family C, group 5, member C 777 gi8118032 Homo sapiens AF2079891 orphan G-protein 939 98 coupled receptor 778 gil5679980 Homo sapiens Cl 14 protein 930 99 778 gil6769562 Drosophila LD38910p 328 47 melanogaster 778 gi7302978 Drosophila CG8441-PA 328 47 melanogaster 779 gil0726751 Drosophila CG13623-PA 333 53 melanogaster 779 gi21430012 Drosophila GH27470p 333 53 melanogaster 779 gi7406400 Arabidopsis thaliana putative protein 317 45 780 gil3959018 Homo sapiens AF361746 1 endothelial cell- 902 100 selective adhesion molecule 780 gil3991773 Mus musculus AF361882 1 endothelial cell- 640 70 selective adhesion molecule 780 gi29165726 Mus musculus Endothelial cell-selective 640 70 adhesion molecule 781 gil5422171 Homo sapiens 22 kDa peroxisomal membrane 1013 100 protein 2 781 gi297437 Rattus norvegicus peroxisomal membrane protein 795 76 781 giS164184 Homo sapiens 22kDa peroxisomal membrane 1013 100 protein-like 782 gi7620875 Streptococcus AF232324_1 Sicl.19 203 41 pyogenes WO 2004/080148 PCT/US2003/030720 203 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity 782 gi7620883 Streptococcus AF232328_1 Sicl.23 203 39 pyogenes 782 gi7621271 Streptococcus AF232522_1 Sicl.217 203 39 pyogenes 783 gi62877 Gallus gallus type VI collagen alpha-2 734 42 subunit preprotein 783 gi62881 Gallus gallus type VI collagen subunit 734 42 alpha2 783 gi62882 Gallus gallus type VI collagen subunit 734 42 alpha2 784 gil7945608 Drosophila RE26969p 829 48 melanogaster 784 gi7292879 Drosophila CG1998-PA 829 48 melanogaster 784 gi7292910 Drosophila CG11162-PA 597 42 melanogaster 785 gi17066106 Homo sapiens Novex-3 Titin Isoform 8832 99 785 gi21238650 Calotomus carolinus titin-like protein 519 62 785 gi27696390 Xenopus laevis Similar to titin 816 48 786 gi17979434 Arabidopsis thaliana putative adenylate kinase 193 22 786 gi22136756 Arabidopsis thaliana putative adenylate kinase 193 22 786 gi30180922 Nitrosomonas Adenylate kinase 201 27 europaea ATCC 19718 787 gi9967224 Macaca fascicularis hypothetical protein 337 98 788 gil8676610 Homo sapiens FLJO0204 protein 195 25 788 gi26389725 Mus musculus unnamed protein product 1390 76 788 gi3002588 Mus musculus Plenty of SH3s; POSH 197 24 789 gil8676610 Homo sapiens FLJ00204 protein 250 26 789 gi26329287 Mus musculus unnamed protein product 1646 75 789 gi26389725 Mus musculus unnamed protein product 1646 75 790 gil2654107 Homo sapiens AAH00866 531 88 790 gil3937969 Homo sapiens TIMP1 protein 531 88 790 gil89382 Homo sapiens collagenase inhibitor 531 88 791 gi24660226 Homo sapiens C-type lectin-like receptor-1 1367 90 791 gi7110216 Homo sapiens AF200949-1 C-type lectin-like 1365 90 receptor-1 791 gi7110218 Mus musculus AF201457_1 C-type lectin-like 312 29 receptor 2 792 gil0441350 Mus musculus olfactory UDP 1557 68 glucuronosyltransferase 792 gi4753766 Homo sapiens UDP glucuronosyltransferase 1593 67 792 gi5802604 Cavia porcellus UDP glucuronosyltransferase 1781 72 UGT2A3 793 gil3325266 Homo sapiens AAH04450 hypothetical 888 100 protein MGC2650 793 gi3688090 Homo sapiens R32611_2 796 91 793 gi6841228 Homo sapiens AF161407_I HSPC289 645 77 794 gil5488645 Mus musculus methyltransferase Cyt19 1552 76 794 gil8150409 Rattus norvegicus AF393243_1 methyltransferase 1518 76 794 gi9963861 Homo sapiens AF226730 1 Cyt19 1729 99 795 gi11877243 Homo sapiens SSF1/P2Y11 chimeric protein 3802 95 795 gil4602631 Homo sapiens Peter pan homolog 2080 99 795 gi21619996 Homo sapiens 2080 99 WO 2004/080148 PCT/US2003/030720 204 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 796 gi20330550 Homo sapiens AF251706_1 NK inhibitory 799 98 receptor precursor 796 gi30962593 Homo sapiens AF375481_1 immune receptor 800 99 expressed on myeloid cells splice variant 2 796 gi31790204 Homo sapiens inhibitory receptor IREMI 805 99 797 gi20330550 Homo sapiens AF251706_1 NK inhibitory 799 98 receptor precursor 797 gi30962593 Homo sapiens AF375481 1 immune receptor 800 99 expressed on myeloid cells splice variant 2 797 gi31790204 Homo sapiens inhibitory receptor IREMI 805 99 798 gi20330550 Homo sapiens AF251706_1 NK inhibitory 1480 94 receptor precursor 798 gi30962591 Homo sapiens AF375480 1 immune receptor 1401 93 expressed on myeloid cells splice variant 1 798 gi31790204 Homo sapiens inhibitory receptor IREMI 1478 94 799 gil8307481 Homo sapiens phosphoinositide-binding 2122 100 proteins 799 gi27695704 Mus musculus Connector enhancer of KSR2 678 36 799 gi29691916 Rattus norvegicus interactor protein for cytohesin 1651 79 _ exchange factors 1 800 gi11493982 Homo sapiens AF208232_1 TLH29 protein 274 72 precursor 800 gil5929988 Homo sapiens AAH15423 Similar to TLH29 424 89 protein precursor 800 gi21618549 Homo sapiens TLH29 protein precursor 274 72 801 gil1493982 Homo sapiens AF208232 1 TLH29 protein 303 70 precursor 801 gil5929988 Homo sapiens AAH15423 Similar to TLH29 445 100 protein precursor 801 gi21618549 Homo sapiens TLH29 protein precursor 303 70 802 gi12082723 Gallus gallus AF293805_1 B cell 2825 69 phosphoinositide 3-kinase adaptor 802 gil2082725 Mus musculus AF293806 1 B cell 3557 84 phosphoinositide 3-kinase adaptor 802 gil2082811 Gallus gallus AF315784_1 B cell 2330 73 phosphoinositide 3-kinase adaptor 803 gi7959809 Homo sapiens AF116721_55 PRO1082 545 100 804 gil5384841 Homo sapiens activating NK receptor 1684 99 804 gi15384843 Homo sapiens NTB-A receptor 1700 100 804 gi9887089 Mus musculus AF248635_1 lymphocyte 615 43 antigen 108 isoform 1 805 gi10177621 Arabidopsis thaliana phytoene dehydrogenase-like 195 75 805 gil7979255 Arabidopsis thaliana AT5g49550/K6M13_10 211 72 805 gi29028742 Arabidopsis thaliana At5g49550/K6M13 10 211 72 806 gi14270364 Mus musculus Epigen protein 378 71 806 gi6272269 Rattus norvegicus NC1 protein 122 52 806 gi7799191 Mus musculus tomoregulin-1 122 52 807 gil4270364 Mus musculus Epigen protein 378 71 807 gi6272269 , Rattus norvegicus NC1 protein 122 52 WO 2004/080148 PCT/US2003/030720 205 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity 807 gi7799191 Mus musculus tomoregulin-1 122 52 808 gil4270364 Mus musculus Epigen protein 378 71 808 gi6272269 Rattus norvegicus NCI protein 122 52 808 gi7799191 Mus musculus tomoregulin-I 122 52 809 gi27469556 Homo sapiens Putative neuronal cell adhesion 212 39 molecule 809 gi29289929 Danio rerio neogenin 185 39 809 gi3068592 Mus musculus punch 198 41 810 gi30348897 Homo sapiens organic solute transporter beta 643 99 810 gi30348901 Mus musculus organic solute transporter beta 365 62 811 gil8650584 Homo sapiens retinoic acid early transcript 1 1070 94 811 gi18650588 Homo sapiens retinoic acid early transcript 1 1124 99 811 gi21961213 Homo sapiens UL16 binding protein 2 1070 94 812 gi13872813 Homo sapiens fibulin-6 485 30 812 gil4575679 Homo sapiens AF156100_1 hemicentin 485 30 812 gi9280405 Homo sapiens AF245505_1 adlican 1372 46 813 gil3872813 Homo sapiens fibulin-6 861 29 813 gi14575679 Homo sapiens AF156100_1 hemicentin 857 29 813 gi9280405 Homo sapiens AF245505 I adlican 2436 35 814 gil3872813 Homo sapiens fibulin-6 861 29 814 gil4575679 Homo sapiens AF156100_1 hemicentin 857 29 814 gi9280405 Homo sapiens AF245505 1 adlican 2436 35 815 gi21619635 Homo sapiens similar to Alu subfamily SQ 267 60 sequence contamination warning entry 815 gi3002527 Horno sapiens neuronal thread protein AD7c- 244 62 NTP 815 gi6650810 Homo sapiens AF118094 21 PRO1902 261 3 816 gi12240284 Mus musculus AF3270591 apolipoprotein 1300 72 A5 816 gi6707433 Homo sapiens AF2028891 apolipoprotein 1864 100 A5 816 gi6707435 Homo sapiens AF202890_1 apolipoprotein 1864 10 A5 817 gil2240284 Mus musculus AF327059_1 apolipoprotein 1300 2 A5 817 gi6707433 Homo sapiens AF2028891 apolipoprotein 1864 100 A5 817 gi6707435 Homo sapiens AF2028901 apolipoprotein 1864 100 A5 818 gil3111784 Homo sapiens AAH03081 hypothetical 1720 9 protein FLJ10637 818 gi13543037 Mus musculus 4933424B01Rik protein 958 80 818 gil4249965 Homo sapiens AAH08368 hypothetical 1724 100 protein FLJ10637 819 gil9344001 Homo sapiens phospholipase A2, group IID 846 99 819 gi5771420 Homo sapiens AF1129821 group IID 852 100 secretory phospholipase A2 819 gi6453793 Homo sapiens AF188625_1 phospholipase 846 99 A2 820 gi21751722 Homo sapiens unnamed protein product 688 84 820 gi26342939 Mus musculus unnamed protein product 496 59 821 gil1094019 Homo sapiens AF305057 2 RTS beta 2116 96 821 gi1150421 I Homo sapiens rTSbeta 2122 96_ WO 2004/080148 PCT/US2003/030720 206 TABLE 2 B SEQ_ID HitID Species Description S_score Percentage_ Identity 821 gil2654883 Homo sapiens AAH01285 rTS beta protein 2122 96 822 gil2803167 Homo sapiens AAH02387 nucleosome 1728 99 assembly protein 1-like 1 822 gi189067 Homo sapiens NAP 1728 99 822 gi30582885 Homo sapiens nucleosome assembly protein 1728 99 1-like 2 823 gil3432042 Homo sapiens integrin-linked kinase- 2009 99 associated serine/threonine phosphatase 2C 823 gil6306907 Homo sapiens AAH06576 integrin-linked 2009 99 kinase-associated serine/threonine phosphatase 2C 823 gi20072498 Mus musculus 0710007A14Rik protein 1926 94 824 gi28175169 Mus musculus 1300015BO4Rik protein 835 73 824 gi28848867 Homo sapiens URGI1 1164 100 824 gi7768636 Xenopus laevis Kielin 239 36 825 gi21928259 Homo sapiens seven transmembrane helix 1023 100 receptor 825 gi21928496 Homo sapiens seven transmembrane helix 1023 100 receptor 825 gi21928655 Homo sapiens seven transmembrane helix 916 89 receptor 826 gil8480746 Mus musculus olfactory receptor MOR261-10 1278 79 826 gi21928655 Homo sapiens seven transmembrane helix 1456 93 receptor 826 gi32052225 Mus musculus olfactory receptor 1278 79 GA x6K02T2P3E9-4341246 4340281 827 gi4760780 Mus musculus Ten-m3 364 95 827 gi5307761 Danio rerio ten-m3 310 78 827 gi6760369 Mus musculus AF195418 1 ODZ3 364 95 828 gil6265938 Homo sapiens AF314817_I FKSG15 2437 98 828 gi21205852 Homo sapiens AF385429_1 T-cell activation 3756 100 Rho GTPase activating protein; TA-GAP 828 gi21205854 Homo sapiens AF385430_1 T-cell activation 2850 100 Rho GTPase activating protein splice variant 1; TA-GAP 829 gi10432396 Homo sapiens splicevariant_1; ________383 62 829 gi30908443 Homo sapiens CUB and sushi multiple 388 63 domains 2 829 gi30908445 Homo sapiens CUB and sushi multiple 549 100 domains 3 830 gil0432396 Homo sapiens 383 62 830 gi30908443 Homo sapiens CUB and sushi multiple 388 63 domains 2 830 gi30908445 Homo sapiens CUB and sushi multiple 549 100 domains 3 831 gi3342148 Chlamydomonas myosin heavy chain 499 37 reinhardtii 831 gi532124 Dictyostelium myosin IC 517 41 discoideum 831 gi8953751 Arabidopsis thaliana myosin heavy chain MYA2 492 41 832 gi6472600 Chara corallina unconventional myosin heavy 621 38 WO 2004/080148 PCT/US2003/030720 207 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity chain 832 gi8953751 Arabidopsis thaliana myosin heavy chain MYA2 621 38 832 gi9453839 Chara corallina myosin 621 38 834 gi21265163 Homo sapiens 2424 99 834 gi7248845 Homo sapiens AF231124 1 testican-1 2428 99 834 gi793845 Homo sapiens testican 2428 99 835 gi20380774 Homo sapiens 2930 99 835 gi22761091 Homo sapiens unnamed protein product 2350 99 835 gi27502762 Mus musculus hypothetical protein 2712 90 MGC28931 836 gi20380774 Homo sapiens 2946 100 836 gi22761091 Homo sapiens unnamed protein product 2366 100 836 gi27502762 Mus musculus hypothetical protein 2728 91 MGC28931 837 gil7391348 Homo sapiens AAH18615 Similartobrain 664 100 expressed, X-linked 1 837 gi7689029 Homo sapiens AF220189 1 uncharacterized 664 100 hypothalamus protein HBEX2 837 gi9963771 Homo sapiens AF183416_I ovarian granulosa 664 100 cell 13.0 kDa protein hGR74 homolog 838 gi15215122 Mus musculus chondroadherin 428 31 838 gi29571143 Mus musculus 5430427N11Rik protein 430 27 838 gi30908853 Homo sapiens synleurin 3201 100 839 gil2842465 Mus musculus unnamed protein product 567 92 839 gil5488920 Homo sapiens AAH13587 Similar to RIKEN 632 100 cDNA 2010107G23 gene 839 gil9354289 Mus musculus RIKEN cDNA 2010107G23 567 92 gene 840 gil6549697 Homo sapiens unnamed protein product 2483 99 840 gi20988071 Mus musculus 2600011E07Rik protein 919 80 840 gi21619776 Homo sapiens Similar to RIKEN cDNA 2491 100 2600011E07 gene 841 gil2963869 Mus musculus gene trap ankyrin repeat 223 30 containing protein 841 gi28565117 Drosophila myosin phosphatase DMBS-S 228 22 melanogaster 841 gi30138665 Nitrosomonas Ankyrin-repeat 228 31 europaea ATCC 19718 842 gil2408272 Homo sapiens apolipoprotein L-IV splice 1742 100 variant a 842 gil2408286 Homo sapiens apolipoprotein L-IV splice 1742 100 variant a 842 gil3374351 Homo sapiens AF305226_1 apolipoprotein 1725 99 L4 843 gil2408272 Homo sapiens apolipoprotein L-IV splice 1737 99 variant a 843 gil2408286 Homo sapiens apolipoprotein L-IV splice 1737 99 variant a 843 gil3374351 Homo sapiens AF3052261 apolipoprotein 1720 99 L4 844 gi21744725 Homo sapiens AF478693_1 glycosyl- 2296 100 phosphatidyl-inositol-MAM 844 gi25005318 Sus scrofa MAM domain containing 1804 93 WO 2004/080148 PCT/US2003/030720 208 TABLE 2 B SEQ ID HitID Species Description Sscore Percentage._ Identity glycosylphosphatidylinositol anchor 1 844 gi25005320 Sus scrofa glycosylphosphatidylinositol 1673 92 anchor 1 protein 845 gi21744725 Homo sapiens AF478693_1 glycosyl- 5051 100 phosphatidyl-inositol-MAM 845 gi25005318 Sus scrofa MAM domain containing 4481 95 glycosylphosphatidylinositol anchor 1 845 gi25005320 Sus scrofa glycosylphosphatidylinositol 4350 95 anchor 1 protein 846 gil066493 Saccharomyces Yprl44cp 572 30 cerevisiae 846 gi32487557 Oryza sativa OSJNBaOO13KI6.9 565 32 (japonica cultivar group) 846 gi4007758 Schizosaccharomyce SPBC1604.06c 613 33 s pombe 847 gil4280050 Homo sapiens Vps39/Vam6-like protein 3913 88 847 gil4701768 Homo sapiens Vam6/Vps39-like protein 3990 89 847 gi23273399 Homo sapiens 4079 98 848 gi23273399 Homo sapiens 4095 99 848 gi25059032 Mus musculus 3128 72 848 gi29467442 Homo sapiens cytosolic phospholipase A2 1512 41 delta 849 gil4603301 Homo sapiens Hypothetical protein FLJ11749 986 100 849 gi7291437 Drosophila CG4071-PA 510 49 melanogaster 849 gi9955513 Arabidopsis thaliana putative protein 340 36 850 gil3161409 Mus musculus family 4 cytochrome P450 444 73 850 gi13182964 Mus musculus AF233643_1 cytochrome P450 196 38 CYP4F13 850 gil3278244 Mus musculus cytochrome P450, family 4, 196 38 subfamily f, polypeptide 13 851 gil0944887 Homo sapiens FGFR-like protein 2475 98 851 gil3183618 Homo sapiens AF312678_1 FGF homologous 2424 97 factor receptor 851 gil3447749 Homo sapiens AF279689 I fibroblast growth 2475 98 factor receptor 5 852 gil0944887 Homo sapiens FGFR-like protein 2701 99 852 gi13183618 Homo sapiens AF312678_1 FGF homologous 2650 98 factor receptor 852 gi13447749 Homo sapiens AF279689_1 fibroblast growth 2701 99 factor receptor 5 853 gil0944887 Homo sapiens FGFR-like protein 583 98 853 gi13183618 Homo sapiens AF312678_1 FGF homologous 583 98 factor receptor 853 gil3447749 Homo sapiens AF279689_1 fibroblast growth 583 98 factor receptor 5 854 gil2667446 Rattus norvegicus AF336854_1 synaptotagmin 2034 95 VIIs 854 gi6136786 Mus musculus synaptotagmin VII 2025 95 854 gi643656 Rattus norvegicus synaptotagmin VII 2034 95 855 gi12053709 Homo sapiens with thrombospondin type 1 8842 100 motif, 12 WO 2004/080148 PCT/US2003/030720 209 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 855 gi27817773 Mus musculus metalloprotease disintegrin 12 7094 80 protein 855 gi5923788 Homo sapiens AF140675_1 zinc 2471 51 metalloprotease ADAMTS7 856 gi15929988 Homo sapiens AAH15423 Similar to TLH29 179 48 protein precursor 857 gil3542874 Mus musculus Similar to RIKEN cDNA 1301 74 2210412D01 857 gi17391206 Mus musculus RIKEN cDNA 2210412DO1 1591 94 857 gi28277574 Danio rerio Similar to RIKEN cDNA 1377 79 2210412D01 gene 858 gil3542874 Mus musculus Similar to RIKEN cDNA 1301 72 2210412D01 858 gi17391206 Mus musculus RIKEN cDNA 2210412DO1 1591 94 858 gi28277574 Danio rerio Similar to RIKEN cDNA 1343 79 2210412D01 gene 859 gi20071312 Mus musculus 4933425F03Rik protein 1219 80 859 gi217732 Oryctolagus macrophage scavenger receptor 602 38 cuniculus type I subunit 859 gi33391740 Homo sapiens MGC45780 1521 98 860 gi20071312 Mus musculus 4933425F03Rik protein 1321 86 860 gi33391740 Homo sapiens MGC45780 1656 87 860 gi6478784 Mus musculus scavenger receptor type A SR- 679 34 A 861 gi11493463 Homo sapiens AF130117 38 PR02852 298 75 861 gi21748687 Homo sapiens unnamed protein product 319 72 861 gi28801453 Homo sapiens unnamed protein product 325 77 862 gi14456629 Homo sapiens 1232 50 862 gi15081398 Homo sapiens AF3955411 kruppel-like zinc '1245 54 finger protein 862 gi29476835 Homo sapiens 1222 47 863 gil6551721 Homo sapiens unnamed protein product 3124 99 863 gi21320872 Mus musculus Cogs 2744 87 863 gi7297851 Drosophila CG6488-PA 1143 43 melanogaster 864 gi16307258 Homo sapiens AAH09717 hypothetical 942 100 protein 864 gi22945521 Drosophila CG31922-PA 165 33 melanogaster 864 gi7242597 Homo sapiens hypothetical protein 942 100 865 gi23274241 Homo sapiens KIAA1892-like 2039 86 865 gi26332114 Mus musculus unnamed protein product 1964 82 865 gi26345386 Mus musculus unnamed protein product 1964 82 866 gi15620885 Homo sapiens KIAA1913 protein 2495 100 866 gi26339494 Mus musculus unnamed protein product 2312 90 866 gi28279830 Homo sapiens KIAA1913 protein 2495 100 867 gil000448 Rattus norvegicus Rat kidney AGT2 precursor 2202 81 867 gi12406973 Homo sapiens alanine-glyoxylate 2740 100 aminotransferase 2 867 gi1944136 Rattus norvegicus beta-alanine-pyruvate 2249 83 aminotransferase 868 gil000448 Rattus norvegicus Rat kidney AGT2 precursor 1583 84 868 gi12406973 Homo sapiens alanine-glyoxylate 1870 98 aminotransferase 2 WO 2004/080148 PCT/US2003/030720 210 TABLE 2 B SEQ_ID HitID Species Description Sscore Percentage_ Identity 868 gil944136 Rattus norvegicus beta-alanine-pyruvate 1630 86 aminotransferase 869 gi26892205 Homo sapiens 1 448 39 869 gi29436673 Mus musculus 1700049K14Rik protein 1732 99 869 gi4165315 Sus scrofa kallikrein 452 41 870 gil7985046 Brucella melitensis GLYCOSYL TRANSFERASE 130 28 16M 870 gi20515259 Thermoanaerobacter predicted glycosyltransferases 133 32 tengcongensis 870 gi4455730 Streptomyces putative transferase 140 32 coelicolor A3(2) 872 gil3649477 Homo sapiens AF2503091 putative cytokine 1998 100 receptor CRL4 precusor 872 gi30584223 synthetic construct Homo sapiens interleukin 17B 1998 100 receptor 872 gi8705222 Homo sapiens AF212365 1 IL-17B receptor 1998 100 873 gil8676472 Homo sapiens FLJOO133 protein 6475 100 873 gi20379832 Homo sapiens FLJOO 133 protein 3072 94 873 gi29568116 Mus musculus secreted protein SST3 3973 84 875 gi14249936 Homo sapiens AAH08349 Similar to S- 2581 100 adenosylhomocysteine hydrolase-like 1 875 gil6588687 Homo sapiens AF315687 1 S- 2429 92 adenosylhomocysteine hydrolase-like protein 875 gi27692283 Mus musculus S-adenosylhomocysteine 2429 92 hydrolase-like 1 876 gil4279990 Homo sapiens AF294842_1 ubiquitin UBF-fl 458 100 876 gi29791813 Homo sapiens Ubiquitin-conjugating enzyme 212 74 E2C, isoform 1 876 gi30583439 Homo sapiens ubiquitin-conjugating enzyme 212 74 E2C 877 gi20086516 Homo sapiens AF245303_1 prominin-2 4241 99 variant A 877 gi20086518 Horno sapiens AF245304_1 prominin-2 4241 99 variant B 877 gi24637566 Rattus norvegicus prominin-2 3224 74 878 gi29351676 Homo sapiens Angiopoietin-like 5 2104 100 878 gi29468510 Homo sapiens putative fibrinogen-like protein 2099 99 878 gi29791750 Homo sapiens angiopoietin-like 1 392 37 879 gi29351676 Homo sapiens Angiopoietin-like 5 2100 99 879 gi29468510 Homo sapiens putative fibrinogen-like protein 2095 99 879 gi29791750 Homo sapiens angiopoietin-like 1 392 37 880 gi29351676 Homo sapiens Angiopoictin-like 5 2100 99 880 gi29468510 Homo sapiens putative fibrinogen-like protein 2095 99 880 gi29791750 Homo sapiens angiopoietin-like 1 392 37 881 gi11493483 Homo sapiens AF130117_48 PR02550 319 66 881 gil872200 Homo sapiens alternatively spliced product 303 56 using exon 13A 881 gi7770139 Homo sapiens AF119917 13 PRO1722 318 69 882 gil3543706 Homo sapiens AAH06003 349 100 882 gi20988061 Mus musculus 1810013DORik protein 333 92 882 gi21619079 Homo sapiens 349 100 883 gi11493652 Homo sapiens AF200708 I calcium channel 2552 100 WO 2004/080148 PCT/US2003/030720 211 TABLE 2 B SEQID Hit_ID Species Description Sscore Percentage_ Identity blocker resistance protein CCBR1 883 gil3924720 Homo sapiens AF2528721 cystine/glutamate 2552 100 transporter xCT 883 gi15082352 Homo sapiens AAH12087 member 11 2552 100 884 gil4252988 Homo sapiens SRPKla protein kinase 2297 86 884 gi23468345 Homo sapiens SFRS protein kinase 1 2304 87 884 gi507213 Homo sapiens serine kinase 2297 86 885 gi18044358 Homo sapiens AAH19883 Similar to lectin- 270 57 like NK cell receptor 885 gi9837288 Homo sapiens C-type lectin 270 57 885 gi9837292 Homo sapiens C-type lectin 270 57 886 gi22164066 Homo sapiens AF388385 1 neuroblastoma- 7571 99 amplified protein 886 gi30353863 Homo sapiens NAG protein 7227 99 886 gi4337460 Homo sapiens neuroblastoma-amplified 6886 99 protein 887 gi22164066 Homo sapiens AF388385 1 neuroblastoma- 7309 96 amplified protein 887 gi30353863 Homo sapiens NAG protein 6965 96 887 gi4337460 Homo sapiens neuroblastoma-amplified 6624 96 protein 888 gil8645094 uncultured M20/M25/M40 family 383 38 proteobacterium peptidase, putative 888 gi19387947 Mus musculus LOC212933 protein 510 73 888 gi28806353 Vibrio putative M20/M25/M40 family 387 35 parahaemolyticus peptidase 889 gil 1558029 Homo sapiens organic cation transporter 1857 99 889 gil8088251 Homo sapiens AAH20565 Similar to hBOIT 1839 95 for potent brain type organic ion transporter 889 gi9663117 Homo sapiens organic cation transporter 1849 99 890 gi21732438 Homo sapiens hypothetical protein 977 100 890 gi26330392 Mus musculus unnamed protein product 765 80 890 gi26390211 Mus musculus unnamed protein product 765 80 891 gil3375149 Homo sapiens 853 90 891 gi20072584 Mus musculus cDNA sequence BC027127 259 37 891 gi7259265 Mus musculus region 277 47 892 gil6589003 Homo sapiens AF386649_1 bromodomain- 6353 99 containing 4 892 gil8308125 Mus musculus AF461395 1 bromodomain- 5992 92 containing protein BRD4 long variant 892 gi9931486 Mus musculus AF2732171 cell proliferation 5994 92 related protein CAP 893 gil5420828 Homo sapiens AF397392 1 NOE3-1 2504 99 893 gil9386926 Rattus norvegicus AF442822_1 optimedin form B 2484 98 893 gil9386930 Mus musculus AF442824,1 optimedin form B 2484 98 894 gi22209078 Homo sapiens hypothetical protein 4474 99 DKFZp566D234 894 gi26337809 Mus musculus unnamed protein product 4135 91 894 gi6330966 Homo sapiens KIAA1263 protein 4492 100 895 gi12654031 Homo sapiens AAH00819 Similar to CG6950 1538 99 gene product WO 2004/080148 PCT/US2003/030720 212 TABLE 2 B SEQ ID HitID Species Description Sscore Percentage Identity 895 gi5002565 Takifugu rubripes cysteine conjugate beta-lyase 1235 55 895 gi758591 Homo sapiens glutamine--phenylpyruvate 1193 51 aminotransferase 896 gil4017833 Homo sapiens KIAA1808 protein 2905 99 896 gi21666433 Mus musculus AF404775_I actin-binding 1498 60 _ _ LIM protein 1 medium isoform 896 gi30259308 Mus musculus actin-binding LIM protein 2 2799 86 897 gi2062399 Rattus norvegicus protein serine/threonine kinase 818 52 CPG16 897 gi6716518 Mus musculus AF1551 doublecortin-like 818 52 kinase 897 gi6716522 Mus musculus AF155821 1 CPG16 818 52 898 gi2062399 Rattus norvegicus protein serine/threonine kinase 818 52 CPG16 898 gi6716518 Mus musculus AF1551 doublecortin-like 818 52 kinase 898 gi6716522 Mus musculus AF155821 1 CPG16 818 52 899 gi13436035 Mus musculus prostaglandin E synthase 2 1583 83 899 gi29179467 Danio rerio Similar to prostaglandin E 1079 60 synthase 2 899 gi9280108 Macaca fascicularis membrane-associated 1907 97 prostaglandin E synthase-2 900 gi12805247 Mus musculus Complement component 1, q 945 70 subcomponent, alpha polypeptide 900 gi20988805 Homo sapiens complement component 1, q 1308 99 subcomponent, alpha polypeptide 900 gi4894854 Homo sapiens AF1351571 complement Clq 1308 99 A chain precursor 901 gi12841760 Mus musculus unnamed protein product 928 80 901 gi12846817 Mus musculus unnamed protein product 931 80 901 gi30802090 Homo sapiens Similar to RIKEN cDNA 1127 100 1810059G22 gene 902 gi21707458 Homo sapiens PAX transcription activation 2704 87 domain interacting protein 1 like 902 gi2565046 Homo sapiens CAGF28 3771 97 902 gi4336734 Mus musculus Pax transcription activation 4115 77 domain interacting protein PTIP 903 gi14164561 Xenopus laevis AF172855 I Swift 467 79 903 gi4336734 Mus musculus Pax transcription activation 531 93 domain interacting protein PTIP 904 gil5929776 Homo sapiens AAH15309 growth suppressor 135 41 1 904 gi23271416 Mus musculus Leprel protein 135 41 904 gi30582917 Homo sapiens 1 135 41 905 gi2443352 Mus musculus platelet glycoprotein lb beta 149 45 905 gi30908853 Homo sapiens synleurin 1549 100 905 gi6808603 Homo sapiens AF169675 1 leucine-rich 147 40 repeat transmembrane protein FLRT1 906 gi13991167 Homo sapiens sialic acid-binding 1174 100 immunoglobulin-like lectin-like long splice variant WO 2004/080148 PCT/US2003/030720 213 TABLE 2 B SEQID Hit ID Species Description S_score Percentage Identity 906 gil4625822 Homo sapiens AF282256 1 Siglec-LI 1174 100 906 gi23272769 Homo sapiens SIGLEC-like 1 1174 100 907 gil3435476 Mus musculus DNA segment, Chr 10, 900 95 University of California at Los Angeles 1 907 gi28279553 Danio rerio Similar to DNA segment, Chr 750 87 10, University of California at __ 7 Los Angeles 1 907 gi29144983 Mus musculus DNA segment, Chr 6, ERATO 657 67 Doi 253, expressed 908 gil504040 Homo sapiens 4470 56 908 gi6273399 Homo sapiens AF200348_1 melanoma- 4470 56 associated antigen MG50 908 gi7292259 Drosophila CG12002-PA 2536 36 melanogaster 909 gil504040 Homo sapiens 4470 56 909 gi6273399 Homo sapiens AF200348_1 melanoma- 4470 56 associated antigen MG50 909 gi7292259 Drosophila CG12002-PA 2536 36 melanogaster 910 gi1504040 Homo sapiens 4112 56 910 gi6273399 Homo sapiens AF200348_1 melanoma- 4112 56 ___associated antigen MG50 910 gi7292259 Drosophila CG12002-PA 2388 36 melanogaster 911 gi 175295 Homo sapiens CRB1 isoform II precursor 1258 28 911 gi18182323 Mus musculus AF406641 1 crumbs-like 1242 29 protein 1 precursor 911 gi29144951 Mus musculus 5930402A21 protein 4084 72 912 gil1493463 -Homno sapiens AF130117 38 PR02852 173 54 912 gi21104464 Homo sapiens OKISW-CL.41 184 61 912 gi6650802 -Homo sapiens , AF118094 17 PR01848 200 56 913 gi6808611 Homo sapiens AF204231 1 88-kDa Golgi 3237 99 protein 913 gi6969980 Homo sapiens AF163441 _1 golgin 67 2345 98 913 gi7211438 Homo sapiens AF164622 1 golgin-67 2327 98 914 gil5030299 Mus musculus protein kinase, cAMP 1881 94 dependent regulatory, type I beta 914 gi200365 Mus musculus cAMP-dependent protein 1886 94 kinase regulatory subunit 914 gi307377 Homo sapiens cAMP-dependent protein 1957 99 kinase RI-beta regulatory _ _ subunit 915 gi14017915 _Homo sapiens KIAA1849 protein 3460 100 915 gi7022002 Homo sapiens unnamed protein product 3074 100 915 gi7022284 Homo sapiens unnamed protein product 3460 100 916 gil845577 Mus musculus -lipoxygenase 2619 77 916 gi30047223 Mus musculus Arachidonate lipoxygenase, 2617 77 epidermal 916 gi3645913 Mus musculus -lipoxygenase 2619 77 917 gil5489302 Mus musculus arachidonate lipoxygenase, 1142 69 epidermal 917 gil845577 Mus musculus -lipoxygenase 1139 69 917 gi30047223 Mus musculus Arachidonate lipoxygenase, 1142 69 WO 2004/080148 PCT/US2003/030720 214 TABLE 2 B SEQ ID HitID Species Description S_score Percentage_ Identity epidermal 918 gil5489302 Mus musculus arachidonate lipoxygenase, 1263 75 epidermal 918 gi1845577 Mus musculus -lipoxygenase 1260 75 918 gi30047223 Mus musculus Arachidonate lipoxygenase, 1263 75 epidermal 919 gi12053299 Homo sapiens hypothetical protein 2183 100 919 gi22478033 Homo sapiens hypothetical protein FLJ22944 3409 91 919 gi22945612 Drosophila CG31652-PA 131 23 melanogaster 920 gil4198207 Mus musculus hypothetical protein BC008163 1599 98 920 gi1934369 2 Homo sapiens 1625 100 920 gi7294965 Drosophila CG4452-PA 615 40 melanogaster 921 gi21594983 Homo sapiens cytokine-like protein C17 238 74 921 gi8132683 Homo sapiens AF193766.1 cytokine-like 238 74 protein C17 922 gi21594983 Homo sapiens cytokine-like protein C17 238 74 922 gi8132683 Homo sapiens AF193766 1 cytokine-like 238 74 protein C17 923 gi21594983 Homo sapiens cytokine-like protein C17 381 81 923 gi8132683 Homo sapiens AF1937661 cytokine-like 381 81 protein C17 924 gi21594983 Homo sapiens cytokine-like protein C17 263 98 924 gi8132683 Homo sapiens AF193766 1 cytokine-like 263 98 protein C17 925 gi21594983 Homo sapiens cytokine-like protein C17 591 100 925 gi8132683 Homo sapiens AF193766_1 cytokine-like 591 100 protein C17 926 gil3396317 Homo sapiens 2741 99 926 gil7975777 Homo sapiens vesicular inhibitory amino acid 2741 99 transporter 926 gi31566392 Homo sapiens Vesicular inhibitory amino acid 2741 99 transporter 927 gi22507470 Mus musculus A1413481 protein 2042 92 927 gi3097285 Rattus norvegicus ZOG 658 39 927 gi802014 Rattus norvegicus preadipocyte factor 1 653 39 928 gil6768374 Drosophila GM03282p 357 36 melanogaster 928 gi18088059 Mus musculus E030025D05Rik protein 1600 89 928 gi6624073 Homo sapiens AC007743_1 similar to 1755 93 hepatitis delta antigen interacting protein A 929 gil4250638 Homo sapiens AAH08783 Similar to DNA 864 97 segment, Chr 17, human D6S54E 929 gi3941733 Mus musculus AAC82476 BAT4 582 70 929 gi4337106 Homo sapiens AAD18082 BAT4 864 97 930 gi27476065 Oryza sativa Putative 266 30 (japonica cultivar- phosphate/phosphoenolpyruvate group) translocator protein 930 gi5911433 Rattus norvegicus AF182714_1 putative 621 88 phosphate/phosphoenolpyruvate translocator 90 gi9759 107 |Arabidopsis thaliana |______________ 282 30 WO 2004/080148 PCT/US2003/030720 215 TABLE 2 B SEQID HitID Species Description S score Percentage_ Identity phosphate/phosphoenolpyruvate translocator protein-like 931 gil5277895 Homo sapiens AAH12939 Similar to 1204 99 cardiotrophin-like cytokine; neurotrophin- 1/B-cell stimulating factor-3 931 gil6356643 Homo sapiens cardiotrophin-like cytokine 1204 99 931 gi6007643 Homo sapiens neurotrophin-1/B-cell 1204 99 stimulating factor-3 932 gil8490933 Homo sapiens FLJ21269 protein 846 98 932 gi20268674 Mus musculus MT-MCI 715 82 932 gi22003732 Homo sapiens AF527367_1 MTLC 853 99 933 gil5982236 Mus musculus putative methionyl 1095 94 aminopeptidase 933 gi23306398 Arabidopsis thaliana putative 744 50 933 gi24899771 Arabidopsis thaliana putative 744 50 934 gil336013 Mus musculus neurexophilin 2 550 45 934 gi22477181 Homo sapiens Similar to neurexophilin 4 1649 99 934 gi4104963 Rattus norvegicus neurexophilin 4 1493 90 935 gil2852913 Mus musculus unnamed protein product 193 75 935 gi26326067 Mus musculus unnamed protein product 193 75 937 gil9387136 Homo sapiens AF479748_1 PYRIN- 874 99 containing APAF 1-like protein 5 937 gi202806 Rattus norvegicus vasopressin receptor 561 68 937 gi28436366 Homo sapiens NALP6 874 99 938 gill321325 Homo sapiens AF311862 1 Lin-7b 1030 100 938 gi20381193 Homo sapiens Lin-7b protein; likely ortholog 1030 100 of mouse LIN-7B; mammalian LIN-7 protein 2 938 gi3885828 Rattus norvegicus lin-7-A 1019 98 939 gil4349125 Homo sapiens alpha2-glucosyltransferase 738 96 939 gi32490259 Oryza sativa OSJNBbO116KO7.1 190 36 (japonica cultivar group) 939 gi3513451 Rattus norvegicus potassium channel regulator 1 718 93 940 gil3325140 Homo sapiens AAH04383 2693 100 940 gi35768 Homo sapiens polypirimidine tract binding 2693 100 protein 940 gi35774 Homo sapiens 2693 100 941 gi21522774 Homo sapiens unnamed protein product 3068 100 941 gi24047224 Homo sapiens Similar to EGF-like-domain, 3048 99 multiple 6 941 gi6752658 Homo sapiens AF186084 1 epidermal growth 3043 99 factor repeat containing protein 942 gi21522772 Homo sapiens unnamed protein product 3102 100 942 gi24047224 Homo sapiens Similar to EGF-like-domain, 3043 98 multiple 6 942 gi6752658 Homo sapiens AF186084_1 epidermal growth 3038 98 factor repeat containing protein 943 gil 1385648 Homo sapiens AF273045_1 CTCL tumor 3867 99 antigen se14-3 943 gil7980969 Homo sapiens AF454056_1 sel4-3r protein 5146 99 943 gi29165763 Mus musculus 3632413B07Rik protein 5213 82 WO 2004/080148 PCT/US2003/030720 216 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity 944 gil3677201 Homo sapiens 2771 100 944 gil7980969 Homo sapiens AF454056 1 sel4-3r protein 3140 99 944 gi29165763 Mus musculus 3632413B07Rik protein 3613 89 945 gil1385648 Homo sapiens AF273045_1 CTCL tumor 3806 94 antigen sel4-3 945 gii7980969 Homo sapiens AF454056_1 sel4-3r protein 5085 95 945 gi29165763 Mus musculus 3632413B07Rik protein 5492 85 946 gil 1385648 Homo sapiens AF273045 1 CTCL tumor 3806 94 antigen se14-3 946 gil7980969 Homo sapiens AF454056_1 sel4-3r protein 5085 95 946 gi29165763 Mus musculus 3632413B07Rik protein 5566 87 947 gil4043211 Homo sapiens AAH07594 Similar to RIKEN 2410 98 cDNA 4931428F04 gene 947 gi21739633 Homo sapiens hypothetical protein 2430 97 947 gi25058997 Mus musculus 11 10003Nl2Rik protein 941 63 949 gil9387136 Homo sapiens AF479748_1 PYRIN- 1735 99 containing APAFI-like protein 5 949 gi202806 Rattus norvegicus vasopressin receptor 1030 64 949 gi28436366 Homo sapiens NALP6 1735 99 950 gi20338417 Gallus gallus potassium channel subunit 5079 88 950 gi3875660 Caenorhabditis 2164 45 elegans 950 gi3978472 Rattus norvegicus potassium channel subunit 5376 90 951 gi18147612 Homo sapiens metalloprotease disintegrin 4376 96 951 gi21908028 Homo sapiens AF466287_1 a disintegrin and 4360 96 metalloprotease domain 33 951 gi21908030 Homo sapiens a disintegrin and 4360 96 metalloprotease domain 33 952 gi12841733 Mus musculus unnamed protein product 715 92 952 gil8606367 Mus musculus RIKEN cDNA 4930570C03 715 92 952 gi31581976 Homo sapiens FLJ20489 protein 472 100 953 gil5420879 Mus musculus AF398971_1 ankyrin repeat- 2049 83 containing SOCS box protein 10 953 gil8031949 Mus musculus SOCS box protein ASB-18 800 44 953 gil8092200 Homo sapiens AF417920_1 ASB-10 2174 91 954 gi32707 Homo sapiens interferon-omega 1 337 51 954 gi386800 Homo sapiens interferon-alpha 340 51 954 gi491284 synthetic construct IFN-pseudo-omega 2 799 98 955 gil5928971 Homo sapiens AAH14951 Similar to neuronal 430 90 thread protein 955 gi9844579 Homo sapiens 450 97 955 gi9844580 Homo sapiens 623 84 956 gil1559412 Homo sapiens NADPH-dependent retinol 587 100 dehydrogenase/reductase 956 gil2804321 Homo sapiens AAH03019 peroxisomal short- 685 100 chain alcohol dehydrogenase 956 gil9113668 Homo sapiens NADP-dependent retinol 878 100 dehydrogenase short isoform 957 gi22658418 Mus musculus cDNA sequence BC030934 1499 68 957 gi28838433 Homo sapiens DIGZp762A2013 protein 1759 82 957 gi30842594 Homo sapiens putative sulfhydryl oxidase 1668 78 precursor WO 2004/080148 PCT/US2003/030720 217 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 958 gil2958660 Homo sapiens AF321918 1 acid phosphatase 2252 100 958 gil2958663 Homo sapiens AF321918 4 acid phosphatase 1285 99 variant 3 958 gi52871 Mus musculus lysosomal acid phosphatase 832 45 959 gi11493443. Homo sapiens AF130117 27 PR02209 1703 100 959 gi28966 Homo sapiens alpha 1-antitrypsin 1703 100 959 gi6855601 Homo sapiens AF113676_1 PR00684 1703 100 960 gi11493443 Homo sapiens AF130117 27 PR02209 2040 95 960 gil77829 Homo sapiens alpha-1-antitrypsin 2040 95 960 gi28966 Homo sapiens alpha 1-antitrypsin 2040 95 961 gil1493443 Homo sapiens AF130117 27 PR02209 2025 95 961 gil77829 Homo sapiens alpha-1-antitrypsin 2025 95 961 gi28966 Homo sapiens alpha 1-antitrypsin 2025 95 962 gil1493443 Homo sapiens AF130117 27 PR02209 2036 95 962 gil77829 Homo sapiens alpha-1-antitrypsin 2036 95 962 gi28966 Homo sapiens alpha 1-antitrypsin 2036 95 964 gi1841702 Macaca fascicularis fertilin alpha-I isoform 3138 70 964 gi2632092 Pongo pygmaeus fertilin alpha protein 4125 92 964 gi794073 Macaca fascicularis fertilin alpha-I 3138 70 965 gil7887359 Oryctolagus lipophilin AL2 248 54 cuniculus 965 gi4107229 Homo sapiens lipophilin A 454 100 965 gi4107231 Homo sapiens lipophilin B 267 60 966 gi13817037 Homo sapiens E-type ATPase 2812 99 966 gi20988653 Homo sapiens Similar to ectonucleoside 2413 99 triphosphate diphosphohydrolase 3 966 gi3335100 Homo sapiens CD39L3 2816 100 967 gi 180251 Homo sapiens precerebellin 542 57 967 gi6942096 Mus musculus CBLN3 936 93 967 gi6942098 Mus musculus AF218380 1 CBLN3 936 93 968 gil8255724 Mus musculus LOC215928 protein 131 28 968 gi21750370 Homo sapiens unnamed protein product 1136 100 968 gi28460663 Rattus norvegicus Na+ dependent glucose 185 30 transporter 1 969 gi21750370 Homo sapiens unnamed protein product 2545 99 969 gi22328120 Homo sapiens hypothetical protein 2077 99 DKFZp761NI114 969 gi26332881 Mus musculus unnamed protein product 2116 86 970 gil3161123 Homo sapiens AF332239_1 transcript Y 10 147 54 970 gi4545317 Acipenser ruthenus AF129437_1 immunoglobulin 149 25 light chain precursor 970 gi9937599 Salmo trutta AF296378_1 MHC class 1 153 31 heavy chain 971 gil2964746 Mus musculus AF316612_1 neuronal 2207 88 pentraxin receptor 971 gi2253263 Rattus norvegicus neuronal pentraxin receptor 2232 89 971 gi4160197 Homo sapiens 2512 99 972 gi27884137 Danio rerio 3553 78 972 gi3170615 Mus musculus DOC4 4166 96 972 gi4760782 Mus musculus Ten-m4 4188 96 973 gil4714932 Homo sapiens AAH10623 -like 1 3770 100 973 gi21748606 Homo sapiens FLJO0380 protein 3729 96 973 gi541678 Homo sapiens hbZ17 3729 96 WO 2004/080148 PCT/US2003/030720 218 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 974 gi17044301 Leishmania major possible LIM-binding factor 2875 36 974 gi23095182 Drosophila CG13809-PA 3997 46 melanogaster 974 gi7716100 Rattus norvegicus AF226993_1 selective LIM 8413 95 binding factor 975 gi20799661 Mus musculus AF503575 1 mucolipin-2 1593 71 975 gi24417793 Mus musculus mucolipin 2 1593 71 975 gi24417795 Homo sapiens mucolipin 2 1912 86 976 gi20799661 Mus musculus AF503575_1 mucolipin-2 2394 83 976 gi24417793 Mus musculus mucolipin 2 2394 83 976 gi24417795 Homo sapiens mucolipin 2 2817 99 977 gil510147 Homo sapiens 309 23 977 gi22477432 Homo sapiens DKIFZP762N2316 protein 4532 91 977 gi403020 Mus musculus En-2/lacZ fusion protein 988 96 980 gil513059 Homo sapiens serin protease with IGF- 2203 92 binding motif 980 gi1621244 Homo sapiens novel serine protease, PRSS1 1 2203 92 980 gi5281519 Homo sapiens AF157623_1 HTRA serine 2203 92 protease 981 gi11990126 Camelus chymosin 1187 56 dromedarius 981 gi540097 Sus scrofa preprochymosin 1187 58 981 gi7008025 Callithrix jacchus prochymosin 1346 64 982 gi27356934 Homo sapiens extracellular sulfatase SULF-2 293 100 982 gi27356938 Mus musculus extracellular sulfatase SULF-2 288 100 982 gi28191290 Homo sapiens sulfatase SULF1 precursor 276 68 984 gi27124671 Homo sapiens Zn-carboxypeptidase 2008 99 984 gi27529696 Paralichthys carboxypeptidase B 808 49 olivaceus 984 gi6013463 Bothrops jararaca carboxypeptidase homolog 817 46 985 gi27124671 Homo sapiens Zn-carboxypeptidase 2008 99 985 gi27529696 Paralichthys carboxypeptidase B 808 49 olivaccus 985 gi6013463 Bothropsjararaca carboxypeptidase homolog 817 46 986 gil 1545705 Homo sapiens ISCUl 663 99 986 gil1545707 Homo sapiens ISCU2 845 100 986 gi20381021 Mus musculus Nifu-pending protein 807 96 987 gil2314022 Homo sapiens 883 89 987 gi22417143 Homo sapiens CGI-301 protein 853 100 987 gi32879760 Homo sapiens Snf7 homologue associated 883 89 with Alix 1 988 gil2805221 Mus musculus Lymphocyte antigen 6 137 33 complex, locus A 988 gil98924 Mus musculus Ly-6A.2 137 33 988 gi201113 Mus musculus T-cell activation protein 137 33 989 gi17512406 Mus musculus differential display and 1063 67 activated by p53 989 gi25166615 Homo sapiens AF223000 1 DDA3-like 1673 99 protein 989 gi25166621 Homo sapiens AF322891_I DDA3-like 1673 99 protein 990 gil5990480 Homo sapiens -binding protein 2 1570 100 990 gi21961217 Homo sapiens -binding protein 2 1570 100 990 gi22213050 Mus musculus B230313N05Rik protein 1555 98 WO 2004/080148 PCT/US2003/030720 219 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 991 gi204058 Rattus norvegicus extracellular signal-related 1497 62 kinase 3 991 gi23903 Homo sapiens 63kDa protein kinase 2894 99 991 gi27882123 Danio rerio Similar to mitogen-activated 1670 61 protein kinase 4 992 gi17016967 Homo sapiens AF435011 1 NUANCE 5643 97 992 gi17861384 Homo sapiens nesprin-2 gamma 5643 97 992 gi24417711 Homo sapiens nesprin-2 5643 97 993 gi18204756 Mus musculus 2310044D20Rik protein 626 68 993 gi21706580 Mus musculus A830073021Rik protein 170 29 993 gi33328302 Homo sapiens NS5ATP6 997 100 994 gil9353133 Mus musculus Cl q-like 961 66 994 gi26996600 Mus musculus Similar to Clq-like 1468 94 994 gi32401227 Homo sapiens AF525315_1 Clq-domain 1528 98 containing protein 995 gil4718648 Homo sapiens allantoicase 1633 99 995 gi20987689 Homo sapiens Similar to allantoicase 1838 99 995 gi9255889 Mus musculus AF278712 1 allantoicase 1465 77 996 gil5617341 Homo sapiens LAG-3 protein precursor 2813 99 996 gi30851187 Homo sapiens LAG3 protein 1906 99 996 gi579596 Homo sapiens lymphocyte protein 2651 98 997 gi13810285 Rattus norvegicus guanine nucleotide 5813 91 release/exchange factor 997 gi2522208 Homo sapiens Ras-GRF2 6407 99 997 gi5882290 Homo sapiens Ras guanine nucleotide 6401 99 exchange factor 2 998 gi22038159 Homo sapiens AF527605 1 zizimini 8544 100 998 gi28374168 Mus musculus AA959601 protein 8001 92 998 gi31419757 Mus musculus AA959601 protein 8001 92 999 gil0433672 Homo sapiens unnamed protein product 1530 100 999 gil9263505 Homo sapiens hypothetical protein FLJ12242 1530 100 999 gi23272394 Homo sapiens KCTD2 protein 728 67 1000 gil4041697 Homo sapiens 3585 99 1000 gi21594273 Homo sapiens 3626 100 1000 gi25303955 Homo sapiens 3600 100 1001 gi1438532 Rattus norvegicus rAl 527 25 1001 gil438534 Rattus norvegicus rA9 4640 67 1001 gi27371336 Homo sapiens Similar to CTD-binding SR- 2008 97 like protein rA9 1002 gil438534 Rattus norvegicus rA9 4640 67 1002 gi27371336 Homo sapiens Similar to CTD-binding SR- 2008 97 like protein rA9 1002 gi7296722 Drosophila CG2926-PA 536 23 melanogaster 1003 gil675220 Cricetulus griseus SREBP cleavage activating 6194 92 protein 1003 gi23240172 Drosophila CG33131-PA 1077 32 melanogaster 1003 gi30048445 Mus musculus Similar to SREBP 2600 89 CLEAVAGE-ACTIVATING PROTEIN 1004 gil2652851 Homo sapiens AAH00178 potassium channel 1987 100 modulatory factor 1004 gi26453336 Homo sapiens FIGC1 1983 99 WO 2004/080148 PCT/US2003/030720 220 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 1004 gi7677058 Homo sapiens AF155652_1 potassium 1983 99 channel modulatory factor 1005 gi26341968 Mus musculus unnamed protein product 654 54 1005 gi27695389 Mus musculus MGC58017 protein 1058 98 1005 gi30481648 Homo sapiens 654 54 1006 gil1875318 Mus musculus synaptotagmin XIII 2004 89 1006 gi14210274 Rattus norvegicus AF375466_1 synaptotagmin 13 2000 89 1006 gi21410154 Mus musculus synaptotagmin 13 2004 89 1007 gil 1342591 Mus musculus RanBP7/importin 7 5415 99 1007 gi32330683 Mus musculus importin 7 5427 99 1007 gi3800881 Homo sapiens RanBP7/importin 7 5447 100 1008 gil7939650 Homo sapiens AAH19302 hypothetical 3770 99 protein FLJ12525 1008 gil8676522 Homo sapiens FLJ00158 protein 1512 100 1008 gi27462078 Homo sapiens AFI 16730 1 MSTP060 3739 96 1009 gi28981429 Mus musculus Ddefl protein 4690 95 1009 gi4063614 Mus musculus ADP-ribosylation factor- 4701 94 directed GTPase activating protein isoform a 1009 gi4406393 Bos taurus differentiation enhancing factor 4700 95 1 1011 gil3872813 Homo sapiens fibulin-6 541 29 1011 gi14575679 Homo sapiens AF156100 I hemicentin 537 29 1011 gi9280405 Homo sapiens AF245505_1 adlican 1631 47 1012 gil2843704 Mus musculus unnamed protein product 1005 72 1013 gi12833251 Mus musculus unnamed protein product 710 58 1013 gi17511816 Homo sapiens AAH18758 SimilartoRIKEN 1468 99 cDNA 1110032022 gene 1013 gi20071678 Mus musculus 710 58 1014 gil2833251 Mus musculus unnamed protein product 748 65 1014 gil7511816 Homo sapiens AAH18758 SimilartoRIKEN 1288 90 cDNA 1110032022 gene 1014 gi20071678 Mus musculus 748 65 1015 gil3529248 Homo sapiens Centrin 3 839 99 1015 gi2246401 Homo sapiens centrin 842 100 1015 gi30582215 Homo sapiens 839 99 1016 gi31455256 Homo sapiens IMAGE3510317 protein 2496 100 1016 gi32492907 Homo sapiens selenoprotein 0 2496 100 1016 gi6572230 Homo sapiens 1879 99 1017 gi31455256 Homo sapiens IMAGE3510317 protein 2142 100 1017 gi32492907 Homo sapiens selenoprotein 0 2142 100 1017 gi6572230 Homo sapiens 3997 99 1018 gi21928729 Homo sapiens seven transmembrane helix 2190 99 receptor 1018 gi6693701 Homo sapiens AF147788 1 melanopsin 2226 91 1018 gi6693703 Mus musculus AF147789_1 melanopsin 1729 74 1019 gi20072741 Mus musculus E430025L02Rik protein 2634 80 1019 gi28380382 Drosophila CG4168-PA 309 29 melanogaster 1019 gi439296 Homo sapiens garp 793 37 1020 gil5487302 Homo sapiens medium-chain acyl-CoA 1346 99 synthetase 1020 gil5706421 Homo sapiens middle-chain acyl-CoA 1346 99 1__ .synthetasel WO 2004/080148 PCT/US2003/030720 221 TABLE 2 B SEQID Hit_ID Species Description Sscore Percentage Identity 1020 gi5019275 Bos taurus xenobiotic/medium-chain fatty 1088 78 acid:CoA ligase form XL-III 1021 gil8874700 Homo sapiens AF4784691 RapI guanine 5803 98 nucleotide-exchange factor PDZ-GEF2B 1021 gi20386206 Homo sapiens AF478567 1 PDZ domain- 5822 98 containing guanine nucleotide exchange factor PDZ-GEF2 1021 gi6650766 Homo sapiens AF117947_1 PDZ domain- 6216 100 containing guanine nucleotide exchange factor I 1022 gil8874698 Homo sapiens AF478468_1 Rap1 guanine 5923 99 nucleotide-exchange factor PDZ-GEF2A 1022 gil8874700 Homo sapiens AF4784691 Rap1 guanine 5923 99 nucleotide-exchange factor PDZ-GEF2B 1022 gi20386206 Homo sapiens AF478567_1 PDZ domain- 5942 100 containing guanine nucleotide exchange factor PDZ-GEF2 1023 gil3810306 Homo sapiens transmembrane protein 7 261 37 1023 gil8250724 Mus musculus transmembrane protein 7 257 36 1023 gi20270907 Oncorhynchus AF483531 1 VHSV-induced 233 33 mykiss protein-5 1024 gi20071315 Mus musculus AA589509 protein 1116 76 1024 gi21779866 Mus musculus AF458068_1 ILr17RE 2052 66 1024 gi21779869 Homo sapiens AF458069_ I L-17RE 2896 100 1025 gi20071315 Mus musculus AA589509 protein 1116 76 1025 gi21779866 Mus musculus AF458068_1 IL-17RE 2028 72 1025 gi21779869 Homo sapiens AF458069_1 IL-17RE 2928 100 1026 gi14150450 Rattus norvegicus AF241241_1 UDP- 1350 93 GaINAc:polypeptide N acetylgalactosaminyltransferase T9 1026 gi25809274 Homo sapiens polypeptide N- 1390 97 acetylgaladtosaminyltransferase 10 1026 gi28268676 Homo sapiens UDP-N-acetyl-alpha-D- 1384 96 galactosamine:polypeptide N acetylgalactosaminyltransferase 10 1027 gil5217067 Homo sapiens AF400436 1 stem cell factor 1019 95 isoform 1 1027 gi1827477 Felis catus stem cell factor 896 84 1027 gi337934 Homo sapiens stem cell factor 1019 95 1028 gil377895 Homo sapiens OB-cadherin-2 1572 56 1028 gi30171995 Homo sapiens cadherin-24 2721 93 1028 gi30171998 Homo sapiens cadherin-24 variant 2987 99 1029 gil377895 Homo sapiens OB-cadherin-2 1621 60 1029 gi30171995 Homo sapiens cadherin-24 2770 99 1029 gi30171998 Homo sapiens cadherin-24 variant 2721 93 1030 gil398903 Mus musculus Ca2+ dependent activator 6763 94 protein for secretion 1030 gi21541504 Homo sapiens AF458662 1 calcium- 6440 93 dependent activator protein for WO 2004/080148 PCT/US2003/030720 222 TABLE 2 B SEQID Hit_ID Species Description S_score Percentage IIdentity secretion protein 1030 giS77428 Rattus norvegicus Ca2+-dependent activator 6449 93 protein; calcium-dependent actin-binding protein 1031 gil1071729 Homo sapiens putative dipeptidase 1847 99 1031 gil1125344 Homo sapiens putative metallopeptidase 1319 72 1031 gi32490515 Mus musculus putative membrane-bound 1313 71 dipeptidase-3 1032 gil 1493652 Homo sapiens AF200708_1 calcium channel 2552 100 blocker resistance protein CCBR1 1032 gil3924720 Homo sapiens AF252872 1 cystine/glutamate 2552 100 transporter xCT 1032 gi15082352 Homo sapiens AAH12087 member 11 2552 100 1033 gi17028348 Homo sapiens DKFZP586G1517 protein 3748 100 1033 gi20987924 Mus musculus 2410004L15Rik protein 3473 92 1033 gi29612455 Mus musculus 2410004L15Rik protein 3807 92 1034 gi19352987 Homo sapiens Similar to KIAA0433 protein 6348 98 1034 gi2887437 Homo sapiens KIAA0433 6487 99 1034 gi31418648 Mus musculus 4981 97 1035 gil1066463 Rattus norvegicus AF225961_1 RhoGEF 6385 80 glutamate transport modulator GTRAP48 1035 gi19387126 Mus musculus AF467766_1 guanine 1778 33 nucleotide exchange factor 1035 gi7110160 Homo sapiens guanine nucleotide exchange 1792 38 factor 1036 gi10726794 Drosophila CG5521-PA 508 35 melanogaster 1036 gi24061707 Mus musculus GAP-related interacting partner 986 97 to E12 1036 gi4240257 Homo sapiens KIAA0884 protein 2491 100 1037 gi20269957 Sus scrofa AF498759-1 phospholipase C 1472 85 delta 4 1037 gi21307610 Mus musculus phospholipase C delta 4 1327 77 1037 gi571466 Rattus norvegicus phospholipase C delta-4 1295 76 1038 gil6552885 Homo sapiens unnamed protein product 2084 99 1038 gi26326051 Mus musculus unnamed protein product 1085 54 1038 gi26327387 Mus musculus unnamed protein product 1085 54 1039 gi18480186 Mus musculus olfactory receptor MR261-6 1323 81 1039 gi32052343 Mus musculus olfactory receptor M 6 1323 81 GAx6K02T2P3E9-4384160 4383228 1039 gi9368991 Homo sapiens 1410 100 1040 gi29791964 Homo sapiens Thrombospondin 4 4798 99 1040 gi311626 Homo sapiens thrombospondin-4 4787 99 1040 gi3860231 Mus musculus thrombospondin-4 4557 93 1041 gi14043083 Homo sapiens AAH07524 sperm associated 660 100 antigen 9 1041 gi24460121 Homo sapiens AF327452_1 JNK-associated 273 98 leucine-zipper protein 1041 gi29169179 Homo sapiens PHET 343 98 1042 gi21654741 Homo sapiens peptide/histidine transporter 2771 95 1042 gi2208839 Rattus norvegicus peptide/histidine transporter 2344 82 WO 2004/080148 PCT/US2003/030720 223 TABLE 2 B SEQID HitID Species Description S score Percentage Identity 1042 gi33126130 Homo sapiens peptide/histidine transporter 2736 94 1043 gi22831474 Drosophila CG14622-PC 2508 47 melanogaster 1043 gi22831475 Drosophila CG14622-PB 2508 47 melanogaster 1043 gi29477075 Mus musculus Similar to dishevelled 2521 93 associated activator of morphogenesis 1 1044 gil5929979 Homo sapiens AAH15418 Similar to zinc 2476 100 finger protein 345 1044 gi33417243 Mus musculus B230312118Rik protein 1788 57 1044 gi5080758 Homo sapiens AC007842 3 BC331191_1 1922 52 1045 gi12655913 Homo sapiens AF227516_1 sprouty-4A 386 98 1045 gil2655915 Homo sapiens AF227517 1 sprouty-4C 386 98 1045 gi29747900 Mus musculus Sprouty homolog 4 320 81 1046 gi29692498 Mus musculus NAAG-peptidase II 3447 88 1046 gi3211746 Sus scrofa folylpoly-gamma-glutamate 2819 70 carboxypeptidase 1046 gi4539525 Homo sapiens NAALADase II protein 3881 100 1047 gi21750009 Homo sapiens unnamed protein product 1414 99 1047 gi23512248 Homo sapiens Similar to DISCO Interacting 676 53 Protein 2 1047 gi26449269 Macaca fascicularis hypothetical protein 1421 99 1048 gi5918167 Homo sapiens plexin-BI/SEP receptor 3578 42 1048 gi6651051 Mus musculus AF133093 2 plexin 6 3147 40 1048 gi9885259 Homo sapiens AF149019 1 plexin-B3 3140 40 1049 gi15081392 Homo sapiens AF395817 I NACI protein 1268 55 1049 gi30931339 Mus musculus Nac1-pending protein 1254 57 1049 gi33392751 Homo sapiens NACI protein 1268 55 1050 gi11692802 Homo sapiens AF320294 1 ABCG8 3123 99 1050 gi15088540 Homo sapiens AF324494 1 sterolin-2 3127 99 1050 gi15146444 Homo sapiens AF351824 1 sterolin-2 3117 99 1051 gil2652851 Homo sapiens AAH00178 potassium channel 1987 100 modulatory factor 1051 gi26453336 Homo sapiens FIGCI 1983 99 1051 gi7677058 Homo sapiens AF1556521 potassium 1983 99 channel modulatory factor 1052 gi33395 Homo sapiens 703 70 1052 gi33730 Homo sapiens immunoglobulin lambda light 716 71 chain 1052 gi33734 Homo sapiens immunoglobulin lambda light 716 71 chain 1053 gi21388773 Homo sapiens kringle-containing protein 1764 80 1053 gi21388775 Homo sapiens kringle-containing protein 1453 78 1053 gi21623530 Homo sapiens kringle-containing 1458 68 transmembrane protein 1054 gil4495324 Homo sapiens CMRF35A 432 48 1054 gi18490143 Homo sapiens CMRF35 leukocyte 432 48 immunoglobulin-like receptor 1054 gi396170 Homo sapiens CMRF-35 antigen 432 48 1055 gi4468255 Homo sapiens MHC class I antigen 1925 98 1055 gi4468256 Homo sapiens MHC class I antigen 1974 100 1055 gi487909 Homo sapiens HLA-AlI antigen A11.1 1914 97 1056 gi21667214 Homo sapiens AF465767_1 741 100 WO 2004/080148 PCT/US2003/030720 224 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity bactericidal/permeability increasing protein-like 3 1056 gi32490539 Homo sapiens RY2G5 171 32 1056 gi57732 Rattus rattus potential ligand-binding 210 35 protein 1057 gi21667214 Homo sapiens AF465767_1 2223 99 bactericidal/permeability increasing protein-like 3 1057 gi32490539 Homo sapiens RY2G5 524 31 1057 gi57732 Rattus rattus potential ligand-binding 564 32 protein 1058 gi21667214 Homo sapiens AF465767 1 1916 99 bactericidal/permeability increasing protein-like 3 1058 gi32490539 Homo sapiens RY2G5 434 31 1058 gi57732 Rattus rattus potential ligand-binding 473 33 protein 1059 gi21667214 Homo sapiens AF465767 1 1842 100 bactericidal/permeability increasing protein-like 3 1059 gi32490539 Homo sapiens RY2G5 434 31 1059 gi57732 Rattus rattus potential ligand-binding 473 33 protein 1060 gil3529158 Homo sapiens AAH05349 1128 99 1060 gi529514 Sus scrofa neuronal endocrine protein 1092 95 1060 gi7718079 Homo sapiens neuroendocrine protein 7B2 1148 100 1061 gil5929030 Homo sapiens AAH14973 2325 100 1061 gi16551493 Homo sapiens unnamed protein product 2321 99 1061 gil8698601 Homo sapiens AF467443_1 Smith-Magenis 2325 100 syndrome chromosome region candidate 7 protein 1062 gil3543081 Mus musculus claudin 6 822 70 1062 gi4128041 Homo sapiens claudin-9 protein 1116 100 1062 gi4325296 Mus musculus claudin-9 1078 95 1063 gi1215742 Homo sapiens HIP 434 65 1063 gil4286258 Homo sapiens AAH08926 ribosomal protein 434 65 L29 1063 gi793843 Homo sapiens ribosomal protein L29 434 65 1064 gi4587895 Rattus norvegicus AF072509_1 glutamate 3549 86 receptor interacting protein 2 1064 gi4731287 Rattus norvegicus glutamate receptor interacting 3281 81 protein 2 1064 gi6601555 Rattus norvegicus glutamate receptor interacting 3549 86 protein 2 1065 gi23496442 Rattus norvegicus disabled-I 2807 96 1065 gi3288852 Homo sapiens disabled-1 2865 99 1065 gi8118615 Homo sapiens AF263547_1 disabled-1 2842 99 1066 gil6877456 Homo sapiens AAH16974 1711 100 1066 gi20810324 Homo sapiens 1410 86 1066 gi26351033 Mus musculus unnamed protein product 1236 76 1067 gi15430703 Horno sapiens AF362953_1 testis specific 1858 99 serine/threonine kinase 2 1067 gi2738898 Mus musculus protein kinase 1683 89 1067 gi33590489 Rattus norvegicus serine/threonine kinase 22B 1754 92 WO 2004/080148 PCT/US2003/030720 225 TABLE 2 B SEQ_ID Hit_ID Species Description S score Percentage_ Identity 1068 gil2963879 Homo sapiens prostaglandin D synthase 980 96 1068 gi13543568 Homo sapiens PTGDS protein 980 96 1068 gil89772 Homo sapiens prostaglandin D2 synthase 980 96 1069 gil4336718 Homo sapiens AE006464_18 similar to 1157 100 HAGH 1069 gi20988885 Mus musculus 2810014123Rik protein 1153 79 1069 gi2459803 Rattus norvegicus RSP29 645 48 1070 gil3397835 Homo sapiens annexin Al3 isoform b 1795 99 1070 gi21218387 Oryctolagus AF510726_1 annexing XIlIb 1589 88 cuniculus 1070 gi757784 Canis familiaris annexin XIIIb 1621 89 1071 gi204222 Rattus norvegicus GABA transporter protein 3094 96 1071 gi21707908 Homo sapiens ,member 1 3126 98 1071 gi31658 Homo sapiens GABA transporter 3111 98 1072 gil4165176 Rattus norvegicus AF378093 1 sodium channel 823 98 beta 3 subunit 1072 gi7160975 Homo sapiens voltage-gated sodium channel 834 100 beta-3 subunit 1072 gi7161889 Rattus norvegicus voltage-gated sodium channel 823 98 beta-3 subunit 1073 gi20381266 Homo sapiens Glypican 2 3040 100 1073 gi440127 Rattus norvegicus cerebroglycan 2506 82 1073 gi5911320 Mus musculus AF105268 1 glypican-6 1164 44 1074 gil8676470 Homo sapiens FLJOO132 protein 2515 99 1074 gil9344068 Mus musculus 2700038E08Rik protein 3407 77 1074 gi23274106 Mus musculus 2700038E08Rik protein 3407 77 1075 gi25396387 Homo sapiens alpha 2,6-sialyltransferase 2844 100 1075 gi27650880 Homo sapiens beta-galactoside alpha-2,6- 1183 100 sialyltransferase 1075 gi452751 Gallus gallus Gal beta 1,4 GlcNAc alpha 2,6- 943 54 1_ sialyltransferase 1076 gil3344995 Homo sapiens Cat Eye Syndrome critical 2002 99 region protein isoform 1 1076 gil3344997 Homo sapiens Cat Eye Syndrome critical 2223 100 region protein isoform 2 1076 gi27503696 Homo sapiens Similar to cat eye syndrome 2223 100 chromosome region, candidate 5 1077 gil3344995 Homo sapiens Cat Eye Syndrome critical 1662 96 region protein isoform 1 1077 gil3344997 Homo sapiens Cat Eye Syndrome critical 1662 96 region protein isoform 2 1077 gi27503696 Homo sapiens Similar to cat eye syndrome 1662 96 chromosome region, candidate 5 1078 gi177870 Homo sapiens alpha-2-macroglobulin 2718 39 precursor 1078 gi25303946 Homo sapiens alpha-2-nacroglobulin 2718 39 1078 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 2712 39 1079 gi25303946 Homo sapiens alpha-2-macroglobulin 1290 35 1079 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 1290 35 1079 gi579594 Homo sapiens alpha 2-macroglobulin 690-740 1291 36 1080 gi25303946 Homo sapiens alpha-2-macroglobulin 761 31 1080 gi671864 Gallus gallus ovomacroglobulin, ovostatin 792 32 WO 2004/080148 PCT/US2003/030720 226 TABLE 2 B SEQ ID HitID Species Description S score Percentage_ Identity 1080 gi671865 Gallus gallus ovomacroglobulin, ovostatin 792 32 1081 gil77870 Homo sapiens alpha-2-macroglobulin 2736 39 precursor 1081 gi25303946 Homo sapiens alpha-2-macroglobulin 2736 39 1081 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 2730 39 1082 gi25303946 Homo sapiens alpha-2-macroglobulin 1290 35 1082 gi579592 Homo sapiens alpha 2-macroglobulin 690-730 1290 35 1082 gi579594 Homo sapiens alpha 2-macroglobulin 690-740 1291 36 1083 gi17512361 Mus musculus esterase 31 2029 66 1083 gi29476863 Mus musculus Similar to esterase 31 2022 66 1083 gi404389 Mus sp. carboxylesterase; Es-male 2001 66 1084 gi207286 Rattus norvegicus TGF-beta masking protein 8721 89 large subunit 1084 gi26006334 Mus musculus latent transforming growth 8630 88 factor beta binding protein IL 1084 gi3493176 Mus musculus latent TGF beta binding protein 8627 88 1085 gil7985371 Homo sapiens 13 binding protein 861 100 1085 gil8466808 Homo sapiens AF283671 1 cervical cancer 1 853 99 proto-oncogene-binding protein KG19 1085 gi21961229 Homo sapiens BRI3 binding protein 861 100 1086 gi222833 Gallus gallus M-protein 2924 42 1086 gi2950347 Mus musculus M-protein 2908 42 1086 gi407097 Homo sapiens 165kD protein 2912 42 1087 gil2655165 Homo sapiens AAH01438 zinc finger protein 693 65 256 1087 gi30582545 Homo sapiens zinc finger protein 256 693 65 1087 gi4894364 Homo sapiens AF0671651 zinc finger 693 65 protein 3 1088 gil613848 Homo sapiens zinc finger protein zfp6 311 49 1088 gi305825 4 5 Homo sapiens zinc finger protein 256 309 56 1088 gi4894364 Homo sapiens AF067165_1 zinc finger 309 56 protein 3 1089 gil2655452 Homo sapiens keratin associated protein 4.7 981 76 1089 gil2655460 Homo sapiens keratin associated protein 4.12 970 77 1089 il2655464 Homo sapiens keratin associated protein 4.15 973 81 1090 gil2655446 Homo sapiens keratin associated protein 4.4 400 69 1090 gi12655452 Homo sapiens keratin associated protein 4.7 383 81 1090 gil2655460 Homo sapiens keratin associated protein 4.12 400 61 1091 gil2655452 Homo sapiens keratin associated protein 4.7 1219 90 1091 gil2655460 Homo sapiens keratin associated protein 4.12 1158 88 1091 gi12655464 Homo sapiens keratin associated protein 4.15 1260 100 1092 gil5722084 Homo sapiens 1991 100 1092 gi434306 Homo sapiens lysosomal acid lipase; sterol 1289 63 esterase 1092 gi506431 Homo sapiens lysosomal acid lipase 1289 63 1093 gil5722084 Homo sapiens 1935 100 1093 gi434306 Homo sapiens lysosomal acid lipase; sterol 1289 63 esterase 1093 gi506431 Homo sapiens lysosomal acid lipase 1289 63 1094 gi20152322 Homo sapiens putative G-protein coupled 1558 99 receptor 1094 gi32526601 Homo sapiens GPRC5D 1558 99 1094 gi8118040 Homo sapiens AF209923 1 orphan G-protein 1804 99 WO 2004/080148 PCT/US2003/030720 227 TABLE 2 B SEQ_ID Hit_ID Species Description Sscore Percentage Identity coupled receptor 1095 gil5099951 Mus musculus AF3841601 diacylglycerol 596 49 acyltransferase 2 1095 gi18129609 Homo sapiens AF3841611 diacylglycerol 597 49 acyltransferase 2 1095 gi27693972 Mus musculus diacylglycerol 0- 596 49 acyltransferase 2 1096 gil7224598 Homo sapiens AF293615_1 blood dendritic 1134 95 cell antigen 2 protein 1096 gil7225337 Homo sapiens AF325459_1 dendritic lectin 1134 95 1096 gil7225339 Homo sapiens AF325460_1 dendritic lectin b 930 80 isoform 1097 gil7224598 Homo sapiens AF293615_1 blood dendritic 1182 99 __ cell antigen 2 protein 1097 gil7225337 Homo sapiens AF325459_1 dendritic lectin 1182 99 1097 gil7225339 Homo sapiens AF325460 1 dendritic lectin b 978 84 isoform 1098 gil8479834 Mus musculus olfactory receptor MOR144-1 1220 77 1098 gi21929119 Homo sapiens seven transmembrane helix 1595 100 receptor 1098 gi32063297 Mus musculus olfactory receptor 1220 77 GA x6KO2T2PVTD 14025733-14026668 1099 gi19526645 Homo sapiens AF430017 1 intestinal 775 33 membrane mucin MUC17 1099 gi5911169 Homo sapiens AF147790_I transmembrane 3049 99 mucin 12 1099 gi5911171 Homo sapiens AF147791_1 mucin 11 671 54 1100 gi219497 Homo sapiens biliary glycoprotein 446 34 1100 gi3172151 Homo sapiens BGPg HUMAN 446 34 1100 gi37198 Homo sapiens TMI-CEA preprotein 446 34 1101 gi1504040 Homo sapiens 4709 60 1101 gi6273399 Homo sapiens AF200348_1 melanoma- 4709 60 associated antigen MG50 1101 gi7292259 Drosophila CG12002-PA 2660 38 melanogaster 1102 gi1504040 Homo sapiens 4596 59 1102 gi6273399 Homo sapiens AF200348_1 melanoma- 4596 59 associated antigen MG50 1102 gi7292259 Drosophila CG12002-PA 2606 38 melanogaster 1103 gil0435776 Homo sapiens unnamed protein product 4413 99 1103 gi11611734 Homo sapiens AF245388 1 GREBla 510 46 1103 gi7264653 Mus musculus AF180470_1 Kiaa0575 3121 53 1104 gil6519041 Drosophila AF427496_1 occludin-like 184 23 melanogaster protein 1104 gi20219008 Chlamydomonas AF394181_1 coiled-coil 673 36 reinhardtii flagellar protein 1104 gi7301551 Drosophila CG6059-PA 169 19 melanogaster 1105 gil2654511 Homo sapiens Torsin family 3, member A 693 96 1105 gil4043167 Homo sapiens Torsin family 3, member A 693 96 1105 gil5079904 Homo sapiens Torsin family 3, member A 693 96 1106 gi21666374 Mus musculus swan 325 72 1106 gi21666376 Mus musculus swan 325 72 WO 2004/080148 PCT/US2003/030720 228 TABLE 2 B SEQ ID HitID Species Description Sscore Percentage_ Identity 1106 gi29747798 Mus musculus 3000004N20Rik protein 704 86 1107 gi15076843 Homo sapiens AF233450 1 pecanex-like 2759 68 protein 1 1107 gil8157547 Mus musculus AF237953_1 pecanex-like 3 4201 93 1107 gi6650377 Mus musculus AF096286_1 pecanex 1 2767 67 1108 gi15076843 Homo sapiens AF233450 1 pecanex-like 2402 73 protein 1 1108 gil8157547 Mus musculus AF237953 1 pecanex-like 3 3138 97 1108 gi6650377 Mus musculus AF096286 1 pecanex 1 2406 73 1109 gi21595759 Homo sapiens similar to HC6 211 71 1109 gi7020440 Homo sapiens unnamed protein product 215 57 1109 gi7770237 Homo sapiens AF119917 62 PR02822 232 61 1110 gi26333913 Mus musculus unnamed protein product 749 83 1110 gi26343633 Mus musculus unnamed protein product 749 83 1110 gi27370621 Homo sapiens Similar to hypothetical protein 828 95 FLJ31737 1111 gi12043567 Homo sapiens unc-93 related protein 1571 99 1111 gi17390915 Mus musculus unc93 homolog B 1367 87 1111 gi23271746 Mus musculus Unc93b protein 1367 87 1112 gil5990461 Homo sapiens AAH15612 ring finger protein 2465 100 25 1112 gil8490513 Mus musculus Rnf25 protein 1983 82 1112 gi29179411 Mus musculus Ring finger protein 25 1988 82 1113 gil9716048 Xenopus laevis WeelB kinase 1123 45 1113 gi2827996 Xenopus laevis weel homolog 1291 51 1113 gi644770 Xenopus laevis WeelA kinase 1296 51 1115 gil5030119 Mus musculus 3110057012Rik protein 777 97 1115 gi23093574 Drosophila CG32112-PA 366 42 melanogaster 1115 gi23093575 Drosophila CG32112-PB 397 47 melanogaster 1116 gil1493 40 9 Homo sapiens AF130117 10 PR00898 129 59 1116 gi21708029 Homo sapiens similar to Alu subfamily SQ 135 70 sequence contamination warning entry 1116 gi28800991 Homo sapiens unnamed protein product 124 67 1117 gi13810898 Rattus norvegicus AF322216_1 inhibin binding 515 32 protein long isoform 1117 gi2370143 Homo sapiens immunoglobulin-like domain- 503 32 containing 1 1117 gi2645890 Homo sapiens 1GSF1 503 32 1118 gi2370143 Homo sapiens immunoglobulin-like domain- 307 38 containing 1 1118 gi32330685 Mus musculus inhibin binding protein/p120 310 38 long isoform 1118 gi32330691 Mus musculus inhibin binding protein/p120 310 38 variant 4 1119 gi21595190 Mus musculus 25100O1A17Rik protein 4878 95 1119 gi21707128 Homo sapiens Ran binding protein 11 5047 99 1119 gi6650612 Homo sapiens AF111109 1 Ran binding 5047 99 protein 11 1120 gil399805 Homo sapiens Bbp/53BP2 2078 46 1120 gi16197705 Homo sapiens ASPP2 protein 2439 47 1120 gi18652832 Homo sapiens ASPP1 protein 5703 99 WO 2004/080148 PCT/US2003/030720 229 TABLE 2 B SEQID HitID Species Description Sscore Percentage _ _ Identity 1122 gi2598461 Homo sapiens 1893 97 1122 gi31418316 Homo sapiens Heat shock 70kD protein 1893 97 binding protein 1122 gi4049268 Homo sapiens putative tumor suppressor 1893 97 ST13 1123 gil1991844 Homo sapiens AF2435051 fibrocyte-derived 676 100 protein 1123 gil2619173 Homo sapiens melanoma inhibitory activity 676 100 like protein 1123 gil2668328 Homo sapiens melanoma inhibitory activity 676 100 like protein 1124 gi22760096 Homo sapiens unnamed protein product 1047 89 1124 gi27883913 Homo sapiens POTE 525 46 1124 gi28279813 Homo sapiens Similar to hypothetical protein 743 85 DKFZp434A171 1125 gil1990779 Homo sapiens 548 43 1125 gi22760096 Homo sapiens unnamed protein product 831 87 1125 gi28279813 Homo sapiens Similar to hypothetical protein 743 85 DKFZp434A171 1126 gil1493483 Homo sapiens AF130117_48 PR02550 265 67 1126 gi1872200 Homo sapiens alternatively spliced product 259 66 using exon 13A 1126 gi7770139 Homo sapiens AF119917 13 PRO1722 266 60 1128 gil6588454 Homo sapiens AF312374 1 AGTRAP protein 708 95 1128 gil6878260 Homo sapiens AAH17328 Similar to 726 100 angiotensin II, type I receptor associated protein 1128 gi9621816 Homo sapiens AF165187 1 ATRAP 708 95 1129 gil2330704 Mus musculus AF333770_1 cell recognition 1376 71 molecule CASPR4 1129 gi17986216 Homo sapiens AF333769-1 cell recognition 1864 98 molecule CASPR3 1129 gi21961652 Mus musculus contactin associated protein 4 1376 71 1130 gil7986216 Homo sapiens AF333769_1 cell recognition 6812 99 molecule CASPR3 1130 gil8390059 Homo sapiens AF463518_1 cell recognition 4738 70 protein CASPR4 1130 gi21961652 Mus musculus contactin associated protein 4 4709 68 1131 gil0336504 Homo sapiens UDP-GalNAc: polypeptide N- 2014 61 acetylgalactosaminyltransferase 1131 gi21552746 Homo sapiens AF4104571 putative 3157 99 polypeptide N acetylgalactosaminyltransferase 1131 gi21552969 Mus musculus AF467979 1 Williams-Beuren 3098 97 syndrome critical region gene 17 1132 gi13625176 Homo sapiens AF251057 1 thrombospondin 575 46 1132 gil8490857 Homo sapiens Thrombospondin 575 46 1132 gi31127148 Mus musculus 2610028F08Rik protein 860 96 1133 gil 1907599 Homo sapiens AF208291_1 protein kinase 857 50 HIPK2 1133 gi5305331 Mus musculus AF0710701 protein kinase 856 49 Myak-L 1133 gi5815145 Musmusculus AF170304_1 nuclearbody 856 49 associated kinase 2b WO 2004/080148 PCT/US2003/030720 230 TABLE 2 B SEQ_ID HitID Species Description Sscore Percentage_ Identity 1134 gi22267965 Homo sapiens Similar to KIAA1423 protein 322 100 1134 gi7243227 Homo sapiens KIAA1423 protein 322 100 1134 gi7300805 Drosophila CG13409-PA 171 51 melanogaster 1135 gil3529338 Mus musculus 1862 48 1135 gi14571502 Homo sapiens calcium-promoted Ras 4174 99 inactivator 1135 gi4185294 Homo sapiens rasGAP-activating-like protein 1891 48 1137 gil5128103 Mus musculus AF397007 1 nephronectin 2962 87 1137 gi15128105 Mus musculus AF397008.1 nephronectin 2934 85 1137 gil5430246 Mus musculus nephronectin short isoform 2802 83 1138 gi16041675 Homo sapiens AAH15704 joinedtoJAZF1 2622 100 1138 gil7862954 Drosophila SD04959p 904 42 melanogaster 1138 gi30046920 Mus musculus D11Ertd53Oe protein 1941 96 1139 gil2654929 Homo sapiens AAH01311 mesenchymal stem 719 74 cell protein DSCD75 1139 gi17512251 Homo sapiens AAH19104 mesenchymal stem 716 74 cell protein DSCD75 1139 gi7638247 Homo sapiens AF242773_1 mesenchymal 719 74 stem cell protein DSCD75 1140 gi32967231 Homo sapiens TAFA3 481 100 1140 gi32967237 Homo sapiens TAFA3.2 923 100 1140 gi32967243 Mus musculus TAFA3 390 82 1141 gi32967231 Homo sapiens TAFA3 738 100 1141 gi32967237 Homo sapiens TAFA3.2 481 100 1141 gi32967243 Mus musculus TAFA3 634 87 1142 gi10443967 Homo sapiens AF268610 1 THEG protein 1934 88 1142 gi20306274 Homo sapiens testicular haploid expressed 1934 88 gene 1142 gi7416134 Homo sapiens testis-specific gene 1934 88 1143 gi21928259 Homo sapiens seven transmembrane helix 1023 100 receptor 1143 gi21928496 Homo sapiens seven transmembrane helix 1023 100 receptor 1143 gi21928655 Homo sapiens seven transmembrane helix 916 89 receptor 1144 gi18480746 Mus musculus olfactory receptor MOR261-10 1278 79 1144 gi21928655 Homo sapiens seven transmembrane helix 1456 93 receptor 1144 gi32052225 Mus musculus olfactory receptor 1278 79 GA x6K02T2P3E9-4341246 4340281 1146 gil5779092 Homo sapiens AAH14613 Similar to syntaxin 1295 100 18 1146 gi30583139 Homo sapiens syntaxin 18 1295 100 1146 gi30585223 synthetic construct Homo sapiens syntaxin 18 1295 100 1147 gil4573319 Homo sapiens AF334755_1 interleukin-1 812 99 HY2 1147 gil4573321 Homo sapiens AF334756_1 interleukin-1 812 99 HY2 1147 gil8025344 Homo sapiens interleukin-1 receptor 809 99 antagonist-like FIL1 theta 1148 gil668744 Homo sapiens HHa5 hair keratin type I 1114 72 WO 2004/080148 PCT/US2003/030720 231 TABLE 2 B SEQID Hit_ID Species Description Sscore Percentage Identity intermediate filament 1148 gi3724107 Homo sapiens type I hair keratin 5 1114 72 1148 gi4103158 Mus musculus hair keratin acidic 5; Ha5 1116 72 keratin 1149 gi23271416 Mus musculus Lepre1 protein 141 30 1149 gi30582917 Homo sapiens 1 139 30 1149 gi6166378 Mus musculus AF165163_1 growth 143 30 suppressor IL 1150 gi16550754 Homo sapiens unnamed protein product 1337 90 1150 gil699265 Homo sapiens malignant cell expression- 389 57 enhanced gene/tumor progression-enhanced gene 1150 gi27529955 Mus musculus mBB1 1284 86 1151 gil14595019 Homo sapiens keratin 6 irs 1990 76 1151 gil8031724 us allus keratin protein airs 1948 75 1151 g127901522 Homo sapiens keratin 6 irs3 '2519 94 1152 gil1066090 Homo sapiens AF195192 1 matrix 2233 84 metalloprotease MMP-27 1152 gil2006364 Tupaia belangeri AF281673_I matrix 1859 71 metalloproteinase-27 1152 gi3511149 Gallus gallus matrix metalloproteinase 1213 50 1153 gil16090 Homo sapiens AF195192_ matrix 233 8 4 metalloprotease MMP-27 1153 gil2006364 Tupaia belangeri AXF281673-1I matrix 1859 71 metalloproteinase-27 1153 gi3511149 Gallus gallus matrix metalloproteinase 1213 50 1154 gi24710913 -Homo sapiens suppressor of fused 2599 100 1154 gi5739507 Homo sapiens AF1757701 suppressor of 2594 99 fused 1154 gi6689894 Homo sapiens AF159447_1 Suppressor of 2599 100 Fused 1155 gi20387085 Oncorhynchus -1 680 31 mykiss 1155 gi21667212 Homo sapiens AF465766 I 2ei6r00 842 00 bactericidal/permeability-i increasing protein-like 2 1155 gi28173296 Cyprinus carpio bactericidal permeability- 902 31 mncreasmng protcin/lipopolysaccharide binding protein 1156 gi12082687 M s s Sry-related HMG-box protein 2066 100 1156 gi124047297 Homo sapiens SRY-box 18 2066 1 0 1156 gt8 8 945 93 -Homo sapiens SOX18S protein 2066 100 1157 gil19526647 Homo sapiens AF462348_1 oxidored-nitro 842 92 - domain-containing protein 1157 _g2175854_ Hom _aiesunnamed protein product 922 97 1157 gi7303522 Drosophila CG13178-PA 173 32 - - melanogaster 1158 gil9526647 Homo sapiens AF462348_-1 oxidored-nitro 8 42 9 domain-containing protein 1158 gi21758574 Homo sapiens unnamed protein product 922 97 1158 gi7303522 Drosophila CG13178-PA 173 32 melanogaster 1159 gil794221 .Mus musculus DNA ligase III-beta 2977 89 1159 gil794223 Mus musculus DNA ligase III-alpha 2977 89 WO 2004/080148 PCT/US2003/030720 232 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity 1159 gi29165722 Mus musculus ligase III, DNA, ATP- 3010 89 dependent 1160 gil052871 Homo sapiens squamous cell carcinoma 879 45 antigen 2 1160 gil5667919 Homo sapiens AF411191_1 SERPINB12 2063 95 1160 gi887465 Homo sapiens leupin 879 45 1163 gi29611342 Homo sapiens AF425650 1 MBDI- 352 52 containing chromatin associated factor 1163 gi7228149 Mus musculus ATFa-associated factor 357 29 1163 gi7303705 Drosophila CG12340-PA 187 31 melanogaster 1166 gil4211398 Homo sapiens AF380342 1 caspase-8L 263 100 1166 gil9401527 Homo sapiens procaspase-8 223 95 1166 gi20381326 Homo sapiens Similar to caspase 8, apoptosis- 263 100 related cysteine protease 1167 gil0440448 Homo sapiens FLJO0060 protein 1204 98 1167 gi30466084 Bos taurus killer cell immunoglobulin-like 800 53 receptor KIR3DS1 1167 gi30466086 Bos taurus killer cell immunoglobulin-like 783 53 receptor KIR3DLI 1168 gi1799570 Rattus norvegicus TIP120 4573 99 1168 gi29792160 Homo sapiens TIP120 protein 4586 99 1168 gi7688703 Homo sapiens AF157326 I TIP120 protein 4573 99 1169 gi]3016701 Homo sapiens activating coreceptor NKp8O 1226 100 1169 gi22449867 Macaca fascicularis NKp8O NK receptor 1122 90 1169 gi7188567 Homo sapiens AF175206 1 lectin-like 1226 100 receptor F1 1171 gi21619190 Homo sapiens -like 1X-linked 2785 100 1171 gi3021409 Homo sapiens like 1 protein 3057 100 1171 gi30353941 Homo sapiens TBL1X protein 3057 100 1172 gi1699265 Homo sapiens malignant cell expression- 671 65 enhanced gene/tumor progression-enhanced gene 1172 gi27529955 Mus musculus m1BB1 646 67 1172 gi33355691 Homo sapiens transmembrane channel-like 642 100 protein 4 1173 gil699265 Homo sapiens malignant cell expression- 671 65 enhanced gene/tumor progression-enhanced gene 1173 gi27529955 Mus musculus mBB1 646 67 1173 gi33355691 Homo sapiens transmembrane channel-like 642 100 protein 4 1174 gil6550754 Homo sapiens unnamed protein product 1881 100 1174 gi1699265 Homo sapiens malignant cell expression- 930 81 enhanced gene/tumor progression-enhanced gene 1174 gi27529955 Mus musculus mBB1 1810 95 1175 gi13182755 Homo sapiens AF212237_I HPHRP 1210 100 1175 gi15929309 Homo sapiens Phosphotriesterase related 1210 100 1175 gi29791939 Homo sapiens phosphotriesterase related 1210 100 1177 gil0047271 Homo sapiens KIAA1598 protein 789 99 1177 gi22539701 Mus musculus 4930506M07Rik protein 818 96 1177 gi26349641 Mus musculus unnamed protein product 818 96 WO 2004/080148 PCT/US2003/030720 233 TABLE 2 B SEQID Hit_ID Species Description Sscore Percentage Identity 1178 gil4272704 Homo sapiens unnamed protein product 157 96 1178 gil9575509 Homo sapiens unnamed protein product 164 100 1178 gil9575655 Homo sapiens unnamed protein product 164 100 1182 gil3377880 Cricetulus AF336043_1 arginine N- 3253 85 longicaudatus methyltransferase p82 isoform 1182 gil3377882 Cricetulus AF3360441 arginine N- 3253 85 longicaudatus methyltransferase p77 isoform 1182 gil3879453 Mus musculus cDNA sequence BC006705 3260 85 1183 gil4424574 Homo sapiens AAH09315 phosphatidylserine 777 100 decarboxylase 1183 gi16306618 Homo sapiens AAH01482 phosphatidylserine 1218 96 decarboxylase 1183 gil,91185 Cricetulus griseus phosphatidylserine 1128 88 decarboxylase 1184 gil0086253 Homo sapiens glucocorticoid-induced GILZ 460 98 1184 gi11907580 Mus musculus AF201289_1 TSC22-related 891 87 inducible leucine zipper 3c 1184 gi5919161 Homo sapiens AF183393_1 TSC-22-like 460 98 Protein 1185 gil3874437 Homo sapiens cerebral protein-11 1457 68 1185 gi20987344 Mus musculus LOC212904 protein 3064 89 1185 gi24980850 Homo sapiens 3283 100 1186 gi14035978 Homo sapiens unnamed protein product 2577 100 1186 gi14272784 Homo sapiens unnamed protein product 2577 100 1186 gi16923351 Homo sapiens AF204270 I RbBP-35 1431 99 1187 gil8676660 Homo sapiens FLJ00229 protein 930 97 1187 gil9343701 Mus musculus RIKEN cDNA A630054L15 913 93 1187 gi25955706 Homo sapiens Similar to hypothetical protein 936 97 MGC38041 1188 gil7865311 Homo sapiens AF452102_1 dipeptidyl 4646 100 peptidase-like protein 9 1188 gi27549552 Homo sapiens dipeptidyl peptidase IV-related 4646 100 protein-2 1188 gi29293087 Homo sapiens dipeptidyl peptidase 9 4787 99 1189 gi17865311 Homo sapiens AF452102_1 dipeptidyl 4384 95 peptidase-like protein 9 1189 gi27549552 Homo sapiens dipeptidyl peptidase IV-related 4384 95 protein-2 1189 gi29293087 Homo sapiens dipeptidyl peptidase 9 4525 95 1190 gil7865311 Homo sapiens AF4521021 dipeptidyl 4551 98 peptidase-like protein 9 1190 gi27549552 Homo sapiens dipeptidyl peptidase IV-related 4551 98 protein-2 1190 gi29293087 Homo sapiens dipeptidyl peptidase 9 4692 98 1191 gi13097642 Homo sapiens Ribosomal protein S25 554 99 1191 gil3279149 Homo sapiens Ribosomal protein S25 554 99 1191 gil3436422 Homo sapiens Ribosomal protein S25 554 99 1192 gil6549206 Homo sapiens unnamed protein product 680 100 1193 gi21756739 Homo sapiens unnamed protein product 4771 97 1193 gi6453538 Homo sapiens hypothetical protein 4159 99 1193 gi6634025 Homo sapiens KIAA0379 protein 3467 67 1194 gi12652695 Homo sapiens AAH00096 HtrA-like serine 2116 93 protease 1194 gi5870865 Homo sapiens serine protease 2116 93 WO 2004/080148 PCT/US2003/030720 234 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 1194 gi7672669 Homo sapiens AF1413051 serine protease 2116 93 I-Itra2 1195 gil387985 Homo sapiens A3 adenosine receptor 904 100 1195 gi20988265 Homo sapiens adenosine A3 receptor 904 100 1195 gi22658481 Homo sapiens adenosine receptor A3 904 100 1196 gi24078514 Mus musculus AF454954 1 crossveinless-2 988 91 1196 gi32816043 Mus musculus BMP-binding endothelial 988 91 regulator precursor protein 1196 gi32892146 Homo sapiens crossveinless-2 1085 100 1197 gil8479346 Mus musculus olfactory receptor MORIO1-1 1334 82 1197 gil8480772 Mus musculus olfactory receptor MOR101-2 1415 84 1197 gi32054443 Mus musculus olfactory receptor 1415 84 GA x6KO2T2PBJ9-2443810 2444775 1198 gi16502169 Salmonella enterica putative DNA methylase 751 93 subsp. enterica serovar Typhi 1198 gi29137981 Salmonella enterica putative DNA methylase 751 93 subsp. enterica serovar Typhi Ty2 1198 gi498768 Serratia marcescens Deoxyadenosyl- 330 51 methyltransferase 1199 gi1213589 Xenopus laevis Prostaglandin D Synthase 290 33 1199 gil6974751 Gallus gallus CALII 335 37 1199 gi666121 Xenopus laevis cpl-1 291 33 1200 gi20987993 Mus musculus MGC41336 protein 1212 90 1200 gi22296200 Thermosynechococc asparaginyl-tRNA synthetase 1046 46 us elongatus BP-1 1200 gi32448516 Pirellula sp. asparaginyl-tRNA synthetase 1034 47 1201 gi20067381 Homo sapiens ALMS1 protein 242 41 1201 gi21552774 Mus musculus AF425257_1 Almstrom 217 38 syndrome I protein 1201 gi32693320 Homo sapiens ALMS 1 protein 242 41 1202 gil2655061 Homo sapiens AAHO1380 495 92 1202 gi23574788 Macaca fascicularis succinate dehydrogenase 502 93 flavoprotein subunit 1202 gi5759173 Homo sapiens succinate dehydrogenase 495 92 flavoprotein subunit 1203 gi21928186 Mus musculus GPI-gamma 4; GPlgamma4 1466 61 1203 gi21928188 Mus musculus GPI-gamma 4; GPlgamma4 1466 61 1203 gi30931171 Mus musculus GPlgamma4 protein 1466 61 1204 gi15082311 Homo sapiens AAH12061 -binding protein 3 1534 92 1204 gi9957161 Mus musculus AF176327_1 alphaCP-3 1708 99 1204 gi9957165 Homo sapiens AF176329_1 alphaCP-3 1722 100 1205 gi14574118 Caenorhabditis Dumpy: shorter than wild-type 233 31 elegans protein 19 1205 gi16553246 Homo sapiens unnamed protein product 881 99 1205 gi21739662 Homo sapiens hypothetical protein 830 95 1206 gil2653341 Homo sapiens AAH00439 beta 1742 94 1206 gil2804943 Homo sapiens AAH01924 beta 1742 94 1206 gi31071 Homo sapiens E-I beta subunit of the 1742 94 pyruvate dehydrogenase complex 1207 gil64851 Oryctolagus calsequestrin precursor 1908 94 WO 2004/080148 PCT/US2003/030720 235 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity cuniculus 1207 gi2618621 Mus musculus skeletal muscle calsequestrin 1938 94 1207 gi688292 Homo sapiens calmitine; calsequestrine 2029 100 1209 gi10432376 Homo sapiens 3334 99 1209 gil1034760 Homo sapiens NIBAN 3692 99 1209 gil2620192 Homo sapiens AF288391 1 Clorf24 4775 99 1210 gi2982508 Homo sapiens TCR beta chain 1290 93 1210 gi3002925 Homo sapiens T cell receptor beta chain 1277 93 1210 gi3089433 Homo sapiens T cell receptor beta chain 1028 75 1211 gi12006041 Homo sapiens AF267857 1 AD038 761 98 1211 gi14189960 Homo sapiens AF305818_1 PR00764 141 53 1211 gi33338042 Homo sapiens AF173896 1 MSTP121 143 46 1213 gi17939498 Homo sapiens AAH19299 protocadherin 4777 99 gamma subfamily C, 3 1213 gi20072790 Homo sapiens protocadherin gamma 4777 99 subfamily C, 3 1213 gi2995719 Homo sapiens protocadherin 43 4792 100 1214 gi12803363 Homo sapiens CALR protein 1747 99 1214 gi18088117 Homo sapiens AAH20493 calreticulin 1747 99 1214 gi30583735 Homo sapiens calreticulin 1747 99 1215 gi200962 Mus musculus serine 1 ultra high sulfur 254 38 protein 1215 gi200964 Mus musculus serine 2 ultra high sulfur 299 43 protein 1215 gi3228237 Homo sapiens ultra high sulfer keratin 248 36 1218 gi17223709 Homo sapiens selenoprotein SelM 235 100 1218 gi17223711 Mus musculus selenoprotein SelM 188 78 1218 gi26351 995 Mus musculus unnamed protein product 162 76 1221 gil001963 Homo sapiens osteopontin 1400 90 1221 gil89151 Homo sapiens nephropontin precursor 1400 90 1221 gi992950 Homo sapiens OPN-c 1426 98 1222 gil4326586 Homo sapiens AF386078_1 serine-cysteine 2252 95 proteinase inhibitor clade C member I 1222 gi179130 Homo sapiens antithrombin III 2252 95 1222 gi583741 synthetic construct Antithrombin III 2252 95 1223 gil8088363 Homo sapiens AAH20669 advanced 2004 99 glycosylation end product specific receptor 1223 gil841550 Homo sapiens AAB47491 receptor for 2004 99 advanced glycosylation end products 1223 gi561659 Homo sapiens receptor of advanced 2004 99 glycosylation end products of proteins 1224 gi13359193 Homo sapiens KIAA1660 protein 598 100 1225 gi37231 Homo sapiens DNA topoisomerase II 8661 99 1225 gi3869382 Homo sapiens DNA topoisomerase II beta 8048 99 1225 gi790988 Cricetulus 7886 97 longicaudatus 1226 gil881713 Rattus norvegicus fatty acid transport protein 3039 87 1226 gi20810561 Mus musculus , member 1 3031 87 1226 gi563829 Mus musculus fatty acid transport protein 3031 87 1227 gil5080010 Homo sapiens AAH11789 Similar to COP9 503 44 WO 2004/080148 PCT/US2003/030720 236 TABLE 2 B SEQID HitID Species Description S score Percentage Identity complex subunit 7a 1227 gi15215085 Mus musculus Cops7b protein 885 71 1227 gi3309176 Mus musculus COP9 complex subunit 7b 888 71 1228 gil80251 Homo sapiens precerebellin 544 58 1228 gi6942096 Mus musculus CBLN3 938 93 1228 gi6942098 Mus musculus AF218380 1 CBLN3 938 93 1229 gi15620819 Homo sapiens KIAA1880 protein 2851 99 1229 gi17861952 Drosophila LD01947p 1382 50 melanogaster 1229 gi7291183 Drosophila CG1826-PA 1382 50 melanogaster 1230 gi21756739 Homo sapiens unnamed protein product 2878 58 1230 gi26354957 Mus musculus unnamed protein product 5453 95 1230 gi6634025 Homo sapiens KIAA0379 protein 3166 57 1231 gi20387085 Oncorhynchus -1 662 31 mykiss 1231 gi21667212 Homo sapiens AF465766_1 2384 98 bactericidal/permeability increasing protein-like 2 1231 gi28173296 Cyprinus carpio bactericidal permeability- 680 31 increasing protein/lipopolysaccharide binding protein 1232 gi20387085 Oncorhynchus -1 654 31 mykiss 1232 gi21667212 Homo sapiens AF465766_1 2389 99 bactericidal/permeability increasing protein-like 2 1232 gi28173296 Cyprinus carpio bactericidal permeability- 672 30 increasing protein/lipopolysaccharide binding protein 1233 gi20387085 Oncorhynchus -1 688 31 mykiss 1233 gi21667212 Homo sapiens AF465766_1 2595 99 bactericidal/permeability increasing protein-like 2 1233 gi28173296 Cyprinus carpio bactericidal permeability- 710 31 increasing protein/lipopolysaccharide binding protein 1234 gil8257341 Mus musculus Expressed sequence 2106 69 AW060207 1234 gi2191168 Arabidopsis thaliana contains similarity to myosin 207 26 heavy chain 1234 gi2879804 Schizosaccharomyce SPAC23A1.16c 163 28 s pombe 1235 gil1493528 Homo sapiens AF130117 71 PRO1953 671 100 1236 gi21754036 Homo sapiens unnamed protein product 998 99 1236 gi30411057 Mus musculus RIKEN cDNA B230219D22 954 93 1236 gi31565787 Homo sapiens FLJ37562 protein 1002 100 1237 gi27469556 Homo sapiens Putative neuronal cell adhesion 3516 99 molecule 1237 gi3068592 Mus musculus punc 2976 86 1237 gi4206390 Homo sapiens putative neuronal cell adhesion 1569 98 WO 2004/080148 PCT/US2003/030720 237 TABLE 2 B SEQ_ID HitID Species Description Sscore Percentage_ Identity molecule 1238 gil2667401 Homo sapiens AF326731_1 NUF2R 2347 99 1238 gi14317902 Homo sapiens kinetochore protein Nuf2 2347 99 1238 gi18043223 Mus musculus NUF2R protein 1754 73 1239 gil0435493 Homo sapiens unnamed protein product 2702 99 1239 gi7022901 Homo sapiens unnamed protein product 3682 99 1239 gi7688176 Homo sapiens hypothetical protein 3688 99 1240 gi21634823 Homo sapiens AF389428_1 semaphorin 6D 5142 91 isoform 3 1240 gi21634825 Homo sapiens AF3894291 semaphorin 6D 5667 98 isoform 4 1240 gi21634827 Homo sapiens AF3894301 semaphorin 6D 3112 63 isoform 1 1241 gil4036200 Homo sapiens unnamed protein product 245 97 1243 gi21671105 Homo sapiens RAD52B 1134 100 1243 gi23468352 Homo sapiens Similar to RAD52B 963 99 1243 gi32967621 Mus musculus 2410008M22Rik protein 828 74 1244 gil5928404 Mus musculus Fasting-inducible integral 185 36 membrane protein TM6P1 1244 gil8490578 Mus musculus A630041N19 protein 449 71 1244 gi20379926 Mus musculus Fasting-inducible integral 185 36 membrane protein TM6P 1 1245 gil8490578 Mus musculus A630041N19 protein 875 70 1245 gi29792229 Homo sapiens FLJ90024 protein 297 33 1245 gi6013381 Rattus norvegicus AF186469_1 TM6P1 296 33 1246 gi28626251 Homo sapiens calcium-permeable store- 1194 100 operated channel TRPM3c 1246 gi28626253 Homo sapiens calcium-permeable store- 1194 100 operated channel TRPM3d 1246 gi28626255 Homo sapiens calcium-permeable store- 1194 100 operated channel TRPM3e 1247 gil7386053 Mus musculus AF444274_1 Jedi protein 2269 50 1247 gi18044366 Homo sapiens AAH20198 Similar to 3468 99 MEGF10 protein 1247 gil8252658 Mus musculus AF461685 1 Jedi-736 protein 2269 50 1248 gi20987880 Mus musculus E130103Il7Rikprotcin 3580 87 1248 gi28204917 Mus musculus E130103I17Rik protein 3801 86 1248 gi4588087 Homo sapiens AF095771_1 PTH-responsive 4080 94 osteosarcoma B1 protein 1249 gil3591434 Homo sapiens 1160 100 1249 gi13591435 Homo sapiens 976 99 1249 gil9913471 Homo sapiens 1265 99 1250 gil6605581 Homo sapiens H-rev107-like protein 5 1451 100 1250 gi21707989 Homo sapiens Similar to H-revl07-like 1382 96 protein 5 1250 gi6048565 Homo sapiens AF092922_1 retinoid inducible 376 54 gene 1 1251 gi21263094 Rattus norvegicus AF512430 1 tramdorin 1 1665 81 1251 gi27924388 Mus musculus Tramdorin 1 1668 82 1251 gi31871293 Homo sapiens proton/amino acid transporter 2 2010 99 1252 gil4571904 Rattus norvegicus AF3612391 lysosomal amino 1931 78 __ _ Iacid transporter 1 1252 gi31324239 Homo sapiens proton-coupled amino acid 2174 90 1____ _transporter WO 2004/080148 PCT/US2003/030720 238 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 1252 gi31871291 Homo sapiens proton/amino acid transporter 1 2195 90 1254 gil563885 Homo sapiens fibroblast growth factor 917 90 homologous factor 1 1254 gi1669500 Mus musculus fibroblast growth factor 917 90 homologous factor 1 1254 gi20988932 Mus musculus Fgfl2 protein 916 98 1255 gil9263005 Ciona intestinalis leucine-rich repeat dynein light 759 75 chain 1255 gi2760161 Anthocidaris outer arm dynein light chain 2 658 67 crassispina 1255 gi7303901 Drosophila CG8800-PA 554 58 melanogaster 1256 gi12666529 Mus musculus b,b-carotene-9',10'- 2356 80 dioxygenase 1256 gil2666531 Homo sapiens putative b,b-carotene-9',10'- 2982 99 dioxygenase 1256 gil4582265 Homo sapiens AF276432_1 putative carotene 2918 99 dioxygenase 1257 gil2666529 Mus musculus b,b-carotene-9',10'- 2305 81 dioxygenase 1257 gil2666531 Homo sapiens putative b,b-carotene-9',10'- 2850 96 dioxygenase 1257 gil4582265 Homo sapiens AF2764321 putative carotene 2786 95 dioxygenase 1258 gil5559697 Homo sapiens AAH14205 Similar to neural 157 28 cell adhesion molecule 1 1258 gi28703938 Homo sapiens Similar to neural cell adhesion 157 28 molecule 1 1258 gi6l Bos taurus calmodulin-independent 158 28 adenylate cyclase 1260 gi1079734 Mus musculus citron 1291 94 1260 gi2745840 Rattus norvegicus postsynaptic density protein; 1262 93 citron 1260 gi3599509 Mus musculus rho/rac-interacting citron 1286 94 kinase 1261 gi28277755 Danio rerio proteinase inhibitor, clade E, 479 30 member 2 1261 gi28435507 Sus scrofa nexin-1 467 30 1261 gi32485107 Homo sapiens nexin-related serine protease 2002 92 inhibitor 1262 gil3383364 Homo sapiens claudin-1 223 97 1262 gil5214678 Homo sapiens AAH12471 claudin 1 223 97 1262 gi7381083 Homo sapiens AF134160 1 claudin-1 223 97 1263 gi13542685 Mus musculus SARIa gene homolog 441 54 1263 gi21634445 Homo sapiens AF274026 1 GTP-binding 446 57 protein Sara 1263 gi33150636 Homo sapiens AF087897 1 GTP binding 446 57 protein 1264 gi22902436 Mus musculus Sphingosine-1-phosphate 717 38 phosphatase 1 1264 gi23345324 Homo sapiens sphingosine 1-phosphate 2073 100 phosphohydrolase 2 1264 gi29436890 Mus musculus Similar to sphingosine-1- 1624 80 phosphate phosphotase 2 1265 gi14 Bos taurus BoWC1.1 1214 39 WO 2004/080148 PCT/US2003/030720 239 TABLE 2 B SEQ_ID HitID Species Description S score Percentage __ Identity 1265 gil480365 Sus scrofa scavenger-receptor protein 1327 42 1265 gi27464818 Mus musculus scavenger receptor cysteine- 1339 44 rich type 1 protein CD163c alpha precursor 1266 gil4 Bos taurus BoWC1.1 1214 39 1266 gil480365 Sus scrofa scavenger-receptor protein 1327 42 1266 gi27464818 Mus musculus scavenger receptor cysteine- 1339 44 rich type 1 protein CD163c _ _ alpha precursor 1268 gi21619491 Homo sapiens similar to expressed sequence 778 100 AW049604 1268 gi32967233 Homo sapiens TAFA4 778 100 1268 gi32967245 Mus musculus TAFA4 698 93 1270 gil8033185 Danio rerio AF330001_1 UNC45-related 3100 73 protein 1270 gi27436424 Mus musculus striated muscle UNC45 3937 94 1270 gi27436426 Homo sapiens striated muscle UNC45 4092 99 1271 gi21064657 Drosophila RH01479p 182 39 melanogaster 1271 gi28375475 Homo sapiens unnamed protein product 639 99 1271 gi7304173 Drosophila CG1577-PA 182 39 melanogaster 1272 gil6876958 Homo sapiens AAH16754 hypothetical 410 100 protein MGC12217 1273 gil5823642 Homo sapiens ALS2CR7 2038 100 1273 gi32485022 Homo sapiens serine/threonine protein kinase 2038 100 1273 gi32485027 Homo sapiens serine/threonine protein kinase 2320 100 1274 gil2654893 Homo sapiens AAH01291 400 97 1274 gi2407911 Homo sapiens C016 714 96 1274 gi6733554 unidentified unnamed protein product 710 96 1275 gil8147612 Homo sapiens metalloprotease disintegrin 4434 95 1275 gi21908028 Homo sapiens AF466287 1 a disintegrin and 4434 95 metalloprotease domain 33 1275 gi21908030 Homo sapiens a disintegrin and 4434 95 metalloprotease domain 33 1276 gil6551401 Homo sapiens unnamed protein product 2735 100 1276 gi4972116 Arabidopsis thaliana putative proline-rich protein 133 44 1276 gi7269638 Arabidopsis thaliana putative proline-rich protein 133 44 1277 gi15291913 Drosophila LD31582p 204 23 melanogaster 1277 gi22477165 Homo sapiens 2783 100 1277 gi26326895 Mus musculus unnamed protein product 1752 69 1278 gi3452275 Pseudopleuronectes aminopeptidase N 1008 37 americanus 1278 gi525287 Sus scrofa aminopeptidase N. 1014 38 1278 gi544755 Oryctolagus aminopeptidase N; APN 1021 37 cuniculus 1279 gi13559063 Homo sapiens 747 100 1279 gi24416538 Mus musculus 1700001D09Rik protein 708 71 1279 gi9963863 Homo sapiens AF226731_1 AD026 738 98 1281 gi20810533 Homo sapiens hypothetical gene supported by 414 100 AK054745; AK054745; AK054745; AK054745 1282 gi20810533 Homo sapiens hypothetical gene supported by 795 100 WO 2004/080148 PCT/US2003/030720 240 TABLE 2 B SEQ_ID HitID Species Description Sscore Percentage Identity AK054745; AK054745; AK054745; AK054745 1282 gi26345254 Mus musculus unnamed protein product 367 63 1282 gi33244011 Mus musculus 374 64 1283 gi20810533 Homo sapiens hypothetical gene supported by 789 99 AK054745; AK054745; AK054745; AK054745 1283 gi26345254 Mus musculus unnamed protein product 396 64 1283 gi33244011 Mus musculus 403 65 1284 gil8447388 Drosophila RE05944p 700 31 melanogaster 1284 gi21645210 Drosophila CG30394-PA 700 31 melanogaster 1284 gi21645211 Drosophila CG30394-PB 700 31 melanogaster 1285 gil4035874 Homo sapiens unnamed protein product 910 99 1285 gil4035876 Homo sapiens unnamed protein product 853 99 1285 gi20070842 Homo sapiens similar to hypothetical protein 997 99 FLJ13448 1286 gil9070822 Mus musculus AF3648681 Myb protein 145 23 P42POP 1286 gi20977688 Xenopus laevis tumorhead 146 33 1286 gi27881626 Homo sapiens LOC339344 protein 150 25 1287 gil0433236 Homo sapiens unnamed protein product 721 99 1288 gil3278415 Mus musculus cDNA sequence BC004018 2402 98 1288 gi26355239 Mus musculus unnamed protein product 2256 97 1288 gi30354720 Mus musculus A1427653 protein 1357 57 1289 gil2698037 Homo sapiens KIAA1746 protein 5541 100 1289 gil6769274 Drosophila LD22423p 210 24 melanogaster 1289 gi7298509 Drosophila CG18398-PA 214 24 melanogaster 1290 gi21391484 Homo sapiens leucine-rich repeat domain- 397 39 containing protein 1290 gi21391486 Mus musculus leucine-rich repeat domain- 433 40 containing protein 1290 gi21623740 Rattus norvegicus Leucine-rich repeat-containing 428 40 protein 3 1291 gi20269073 Homo sapiens putative lipid kinase 2006 76 1291 gi21624340 Homo sapiens ceramide kinase 2006 76 1291 gi21624342 Mus musculus ceramide kinases 1617 64 1292 gi312590 Mus musculus biliary glycoprotein 193 32 1292 gi3549152 Homo sapiens R29124 1 175 31 1292 gi7414626 Rattus norvegicus carcinoembryonic antigen- 176 31 related cell adhesion molecule, secreted isoform CEACAMla 4C1 1293 gil197500 Homo sapiens T-cell surface antigen 182 22 1293 gi21707370 Homo sapiens , sheep red blood cell receptor 182 22 1293 gi312590 Mus musculus biliary glycoprotein 193 32 1294 gil8676564 Homo sapiens FLJOO 179 protein 993 99 1294 gi21411450 Mus musculus C230093N12Rik protein 1159 91 1294 gi28839684 Homo sapiens Similar to expressed sequence 1242 99 AI426465 WO 2004/080148 PCT/US2003/030720 241 TABLE 2 B SEQ_ID Hit_ID Species Description Sscore Percentage_ Identity 1295 gi27923578 Mus musculus cerebellin 4 precursor 970 96 1295 gi33416458 Mus musculus Cerebellin 2 precursor protein 725 73 1295 gi7708438 Homo sapiens 1020 100 1296 gil8490912 Homo sapiens neurotensin receptor 2 1950 93 1296 gi23138725 Homo sapiens Similar to neurotensin receptor 1984 99 2 1296 gi3901028 Homo sapiens neurotensin receptor 2 1955 93 1297 gil5077861 Mus musculus AF396877_1 bullous 11308 84 pemphigoid antigen 1-e 1297 gi179519 Homo sapiens bullous pemphigoid antigen 10559 98 1297 gi403124 Homo sapiens bullous pemphigoid antigen 13047 97 1298 gil5077861 Mus musculus AF396877_1 bullous 11308 84 pemphigoid antigen 1-e 1298 gil79519 Homo sapiens bullous pemphigoid antigen 10559 98 1298 gi403124 Homo sapiens bullous pemphigoid antigen 13047 97 1299 gi27469519 Homo sapiens Similar to KIAA0476 gene 1506 100 product 1299 gi30268290 Homo sapiens hypothetical protein 1506 100 1299 gi33330327 Homo sapiens c-MYC promoter-binding 1501 100 protein IRLB 1300 gil5929770 Mus musculus expressed sequence 666 100 AW049604 1300 gi32967235 Homo sapiens TAFA5 666 100 1300 gi32967247 Mus musculus TAFA5 666 100 1301 gi16041156 Macaca fascicularis X-ray radiation resistance 729 95 associated 1 protein 1301 gil8676652 Homo sapiens FLJ00225 protein 779 100 1301 gi33150874 Homo sapiens AF439934 1 unknown 779 100 1302 gi16041156 Macaca fascicularis X-ray radiation resistance 411 93 associated I protein 1302 gil8676652 Homo sapiens FLJ00225 protein 444 97 1302 gi33150874 Homo sapiens AF439934 1 unknown 444 97 1303 gi21619156 Homo sapiens somatostatin 226 100 1303 gi338288 Homo sapiens preprosomatostatin 1 226 100 1303 gi342299 Macaca fascicularis preprosomatostatin 226 100 1304 gi22761332 Homo sapiens unnamed protein product 2052 82 1304 gi24981080 Mus musculus 1810005HO9Rik protein 1103 55 1304 gi33417011 Mus musculus 2037 93 1305 gi22761332 Homo sapiens unnamed protein product 3143 100 1305 gi26331032 Mus musculus unnamed protein product 2468 81 1305 gi33417011 Mus musculus 2453 85 1306 gi21744725 Homo sapiens AF4786931 glycosyl- 1541 48 - phosphatidyl-inositol-MAM 1306 gi25005320 Sus scrofa glycosylphosphatidylinositol 1536 48 anchor 1 protein 1306 gi33149988 Homo sapiens MAM domain containing 1 3035 100 1307 gil6550524 Homo sapiens unnamed protein product 799 100 1308 gi20379980 Mus musculus 2410021P16Rik protein 1731 44 1308 gi22137453 |Mus musculus 2410021P16Rik protein 1734 44 1308 gi28280023 Mus musculus 5730439E10Rik protein 3348 80 1309 gi20379980 Mus musculus 2410021P16Rik protein 1634 42 1309 gi22137453 Mus musculus 2410021P16Rik protein 1637 43 1309 gi28280023 Mus musculus 5730439E10Rik protein 3226 78 1310 gi19070124 Mus musculus AF233346 1 zinc transporter- 1087 95 WO 2004/080148 PCT/US2003/030720 242 TABLE 2 B SEQ_ID HitID Species Description Sscore Percentage_ Identity like 3 protein 1310 gi20563194 Mus musculus AF395840 1 zinc transporter 6 1075 94 1310 gi33338012 Homo sapiens AF173387_1 MSTP103 942 95 1311 gil2053097 Homo sapiens hypothetical protein 2127 99 1311 gi23170343 Drosophila CG31556-PA 199 29 melanogaster 1311 gi854065 Human herpesvirus 6 U88 223 32 1312 gil8605758 Mus musculus 9030409G11 Rik protein 1343 98 1312 gi6526769 Homo sapiens HRIHFB2003 1055 97 1312 gi7291408 Drosophila CG11206-PA 822 36 melanogaster 1313 gi19263985 Homo sapiens Hypothetical protein 1565 99 MGC26766 1313 gi19528309 Drosophila LD02310p 573 55 melanogaster 1313 gi7294955 Drosophila CG4080-PA 573 55 melanogaster 1314 gil5030250 Mus musculus UrebI-pending protein 5270 95 1314 gi22090626 Homo sapiens HECT domain protein LASU1 11690 99 1314 gi6841194 Homo sapiens AF161390_1 HSPC272 9665 99 1315 gil3182757 Homo sapiens AF212238_1 HTPAP 781 89 1315 gi21542541 Homo sapiens Similar to HTPAP protein 1074 91 1315 gi28381093 Drosophila CG12746-PD 421 37 melanogaster 1316 gil3182757 Homo sapiens AF212238 1 HTPAP 915 100 1316 gi21542541 Homo sapiens Similar to HTPAP protein 1204 99 1316 gi28381093 Drosophila CG12746-PD 539 43 melanogaster 1317 gil4424540 Homo sapiens AAH09293 1146 93 1317 gil5342051 Homo sapiens AAH13297 1146 93 1317 gi30582231 Homo sapiens 1146 93 1319 gil4715055 Homo sapiens MGC9564 protein 487 31 1319 gil6416764 Homo sapiens AF315594 I FKSG16 2369 99 1319 gi29436772 Danio rerio Similar to DNA segment, Chr 514 30 11, ERATO Doi 18, expressed 1320 gil3905212 Mus musculus RIKEN cDNA 1200006F02 257 77 1320 gi16416764 Homo sapiens AF315594 1 FKSG16 323 98 1320 gi31873637 Homo sapiens hypothetical protein 323 98 1321 gi32330803 Mus musculus podocan protein 2839 91 1321 gi32330805 Homo sapiens podocan protein 3143 99 1321 gi33636569 Drosophila RE27764p 397 27 melanogaster 1322 gi20258604 Homo sapiens sialic acid binding Ig-like 1470 84 lectin 5 1322 gi20988662 Homo sapiens sialic acid binding Ig-like 1470 84 lectin 5 1322 gi9454520 Homo sapiens AC018755_5 SIGLEC5 1470 84 1323 gi20258604 Homo sapiens sialic acid binding Ig-like 1372 87 lectin 5 1323 gi20988662 Homo sapiens sialic acid binding Ig-like 1372 87 lectin 5 1323 gi9454520 Homo sapiens AC018755 5 SIGLEC5 1372 87 1324 gil3183078 Homo sapiens AF237652_I a disintegrin-like 602 74 and metalloprotease domain WO 2004/080148 PCT/US2003/030720 243 TABLE 2 B SEQ_ID HitID Species Description Sscore Percentage_ Identity with thrombospondin type I motifs-like 3 1324 gil5099921 Homo sapiens AF176313_1 ADAM-TS 874 98 related protein 1 1324 gi20987759 Homo sapiens Similar to ADAMTS-like 1 886 99 1325 gil78836 Homo sapiens apolipoprotein C-II 424 89 1325 gi30582255 Homo sapiens apolipoprotein C-II 418 88 1325 gi757915 Homo sapiens apoCII protein 424 89 1326 gil78836 Homo sapiens apolipoprotein C-II 424 89 1326 gi30584853 synthetic construct Homo sapiens apolipoprotein 422 88 C-II 1326 gi757915 Homo sapiens apoCII protein 424 89 1327 gil5779162 Homo sapiens AAH14644 477 100 1327 gi21619424 Homo sapiens Similar to LOC150580 477 100 1328 gi14715231 Homo sapiens DMBT1/8kb.2 protein 1486 40 1328 gi4105084 Oryctolagus hensin 1428 39 cuniculus 1328 gi6624922 Homo sapiens DMBT1/8kb.1 protein 1494 41 1329 gil6033591 Homo sapiens AF416902 1 SH2 domain- 991 99 containing phosphatase anchor protein 2b 1329 gil6033597 Homo sapiens AF416904_1 SH2 domain- 1003 99 containing phosphatase anchor protein 2d 1329 gi20810036 Homo sapiens Fc receptor-like protein 3 985 99 1330 gi28974490 Homo sapiens lipoma HMGIC fusion-partner- 1183 100 like protein 1330 gi30102428 Rattus norvegicus HMGIC fusion-partner-like 1147 95 protein 1330 gi30411045 Mus musculus Similar to lipoma HMGIC 1143 94 fusion partner 1331 gil2060826 Homo sapiens AF3082871 serologically 607 77 defined breast cancer antigen NY-BR-20 1331 gil.7426418 Mus musculus calmodulin-related protein 788 100 1331 gil9484098 Mus musculus calmodulin-like 4 783 99 1332 gil0726831 Drosophila CG9986-PA 141 25 melanogaster 1332 gil6741164 Mus musculus DNA segment, Chr 6, Wayne 938 100 State University 163, expressed 1332 gil7862436 Drosophila LD27564p 141 25 melanogaster 1333 gil1693044 Homo sapiens WNT6 precursor 2000 100 1333 gil3279251 Homo sapiens AAH04329 Similar to 2000 100 wingless-related MMTV integration site 6 1333 gi30583751 Homo sapiens wingless-type MMTV 2000 100 integration site family, member 6 1334 gil9744304 Homo sapiens AF461760 1 zinc transporter 5 463 94 1334 gi20135611 Homo sapiens zinc transporter ZnT-5 463 94 1334 gi23270961 Mus musculus Similar to zinc transporter 405 85 ZTLI 1335 gi18480366 Mus musculus olfactory receptor MOR145-1 310 74 1335 gi21928214 Homo sapiens seven transmembrane helix 301 77 WO 2004/080148 PCT/US2003/030720 244 TABLE 2 B SEQID Hit_ID Species Description Sscore Percentage_ Identity receptor 1335 gi32063318 Mus musculus olfactory receptor 310 74 GA x6KO2T2PVTD 14054886-14053957 1336 gil2654633 Homo sapiens Protein inhibitor of activated 3277 100 STAT3 1336 gi20988856 Homo sapiens protein inhibitor of activated 3277 100 STAT3 1336 gi30582911 Homo sapiens protein inhibitor of activated 3277 100 STAT3 1337 gi27449075 Oreochromis stearoyl-CoA desaturase 1176 71 mossambicus 1337 gi30350098 Homo sapiens AF3893381 acyl-CoA- 1769 99 desaturase 1337 gi4469173 Gallus gallus delta-9 desaturase 1149 71 1338 gi14030861 Homo sapiens paraneoplastic neuronal 1830 99 antigen MA1 1338 gi22726261 Homo sapiens AF320308_1 paraneoplastic 1834 100 antigen; MAl 1338 gi24658774 Homo sapiens paraneoplastic antigen MAl 1834 100 1339 gi29468118 Homo sapiens AF357888_1 PAP-2-like 1695 100 protein 2 1339 gi31580553 Homo sapiens plasticity related gene 2 1695 100 1339 gi32186953 Homo sapiens lipid phosphate phosphatase- 1695 100 related protein type 3 1340 gil 1137605 Homo sapiens 1931 100 1340 gi20809333 Homo sapiens actin like protein 1928 99 1340 gi684936 Homo sapiens peptide with resemblance to 1362 88 the actin family; the actual start of the coding region has not been determined 1341 gil1177510 Rattus norvegicus AF287300_1 tandem pore 2215 98 domain potassium channel THIK-2 1341 gi11177514 Homo sapiens AF287302_1 tandem pore 2234 100 domain potassium channel THIK-2 1341 gi28839529 Homo sapiens Potassium channel, subfamily 2234 100 K, member 12 1342 gil4198194 Mus musculus CDNA sequence BCO08155 606 77 1342 gil4336716 Homo sapiens AE006464_16 similar to 1216 100 FBan0003337 1342 gi7300722 Drosophila CG3337-PA 326 40 melanogaster 1343 gi11862939 Mus musculus DDM36 1117 43 1343 gil1862941 Mus musculus DDM36E 1105 43 1343 gil9570398 Homo sapiens hDDM36 1120 43 1344 gi21744725 Homo sapiens AF478693_1 glycosyl- 4898 98 phosphatidyl-inositol-MAM 1344 gi25005318 Sus scrofa MAM domain containing 4355 95 glycosylphosphatidylinositol anchor 1 1344 gi25005320 Sus scrofa glycosylphosphatidylinositol 4224 94 anchor 1 protein 1345 gil2276198 Homo sapiens AF333487 I FKSG40 1020 100 WO 2004/080148 PCT/US2003/030720 245 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 1345 gil2408250 Homo sapiens FKSG28 1020 100 1345 gil8652934 Xenopus laevis Mig3O 634 49 1346 gi21410151 Mus musculus LOC213895 protein 1657 73 1346 gi27696627 Homo sapiens Ribosome biogenesis protein 4190 99 BMS1 homolog 1346 gi7294027 Drosophila CG7728-PA 1345 43 melanogaster 1347 gil2842044 Mus musculus unnamed protein product 554 71 1347 gil8921437 Mus musculus 2010004A3Rik protein 850 70 1347 gi20987450 Homo sapiens LOC146433 1160 95 1348 gil016012 Rattus norvegicus neural cell adhesion protein 5147 92 BIG-2 precursor 1348 gi26891535 Homo sapiens contactin 4 5366 98 1348 gi29837411 Homo sapiens BIG-2 5366 98 1349 gi30102449 Homo sapiens lipoma HMGIC fusion-partner- 1161 97 like protein 1349 gi30908798 Homo sapiens lipoma HMGIC fusion partner- 952 80 like protein 4 1349 gi30908800 Rattus norvegicus lipoma HMGIC fusion partner- 951 80 like protein 4 1350 gi13097705 Homo sapiens AAH03559, member 3 2028 95 1350 gi1340142 Homo sapiens alpha1-antichymotrypsin 2024 95 1350 gi21961493 Homo sapiens , member 3 2025 95 1351 gil850850 Murid herpesvirus 4 shrine threonine rich 166 30 glycoprotein 1351 gi21618556 Homo sapiens 3529 91 1351 gi33304372 Homo sapiens tastin 3524 91 1352 gi12053849 Homo sapiens DREV protein 1689 100 1352 gi12053851 Homo sapiens DREVI protein 1673 99 1352 gi12053853 Homo sapiens DREV protein 1689 100 1353 gil4627081 Homo sapiens AF367017_1 caspase-1 492 100 dominant-negative inhibitor Pseudo-ICE 1353 gi21707335 Homo sapiens Similar to CARD only protein 462 100 1353 gi33793 Homo sapiens interleukin-IB converting 445 92 enzyme 1355 gi22760096 Homo sapiens unnamed protein product 1051 93 1355 gi27883913 Homo sapiens POTE 497 48 1355 gi28279813 Homo sapiens Similar to hypothetical protein 860 99 DKFZp434A171 1356 gil1125348 Homo sapiens putative protein kinase 11920 99 1356 gi6933864 Homo sapiens kinase deficient protein KDP 3408 100 1356 gi8272557 Rattus norvegicus AF227741_1 protein kinase 5436 73 WNK1 1357 gil1125348 Homo sapiens putative protein kinase 9671 99 1357 gi20987908 Mus musculus LOC269796 protein 1553 82 1357 gi8272557 Rattus norvegicus AF227741_1 protein kinase 5436 73 WNK1 1358 gil0946203 Homo sapiens AF272363_1 neuromedin U 785 100 receptor 2 1358 gi16877377 Homo sapiens AAH16938 neuromedin U 785 100 receptor 2 1358 gi9944990 Homo sapiens AF292402_1 neuromedin U 785 100 receptor-type 2 WO 2004/080148 PCT/US2003/030720 246 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity 1359 gi15020809 Takifugu rubripes putative methionyl tRNA 1823 64 synthetase 1359 gil7861592 Drosophila GH13807p 1212 45 melanogaster 1359 gi23 171238 Drosophila CG31322-PA 1212 45 melanogaster 1360 gil5341975 Homo sapiens AAH13184 Similar to major 437 72 histocompatibility complex, class II, DP beta 1 1360 gi17389919 Homo sapiens AAH17967 Similartomajor 819 100 histocompatibility complex, class II, DP beta 1 1360 gi188479 Homo sapiens HLA-DPB1 437 72 1361 gil9701013 Homo sapiens unnamed protein product 1143 99 1361 gi3342737 Homo sapiens R26660 2, partial CDS 1024 100 1361 gi3478640 Homo sapiens R26660 2, partial CDS 154 100 1362 gil5779083 Homo sapiens AAH14609 1172 99 1362 gi3342737 Homo sapiens R26660 2, partial CDS 1002 96 1362 gi3478640 Homo sapiens R26660_2, partial CDS 154 100 1363 gil3991167 Homo sapiens sialic acid-binding 2879 99 immunoglobulin-like lectin-like long splice variant 1363 gil4625822 Homo sapiens AF282256_1 Siglec-L1 2879 99 1363 gi23272769 Homo sapiens SIGLEC-like 1 2879 99 1364 gil5132186 Homo sapiens unnamed protein product 1644 100 1364 gi15132529 Homo sapiens unnamed protein product 1644 100 1364 gi21439502 Homo sapiens unnamed protein product 1644 100 1365 gil9353230 Homo sapiens interleukin 1, delta 823 100 1365 gi6165336 Homo sapiens interleukin-1-like protein 1 823 100 1365 gi9651789 Homo sapiens AF230377_1 interleukin-1 823 100 delta 1366 gil77870 Homo sapiens alpha-2-macroglobulin 2765 40 precursor 1366 gi25303946 Homo sapiens alpha-2-macroglobulin 2765 40 1366 gi579594 Homo sapiens alpha 2-macroglobulin 690-740 2760 40 1367 gi25990364 Homo sapiens AF3196221 P-glycoprotein 555 98 1367 gi27656757 Takifugu rubripes Mdr3 311 52 1367 gi4574224 Fundulus heteroclitus AF099732_1 multidrug 287 49 resistance transporter homolog 1368 gi12805221 Mus musculus Lymphocyte antigen 6 713 100 complex, locus A 1368 gi198924 Mus musculus Ly-6A.2 713 100 1368 gi201113 Mus musculus T-cell activation protein 713 100 1967 gi13543526 Homo sapiens AAH05921 616 96 1967 gil8088830 Homo sapiens AAH20756 616 96 1967 gi30582691 Homo sapiens 616 96 1968 gi13543526 Homo sapiens AAH05921 616 96 1968 gil8088830 Homo sapiens AAH20756 616 96 1968 gi30582691 Homo sapiens 616 96 1969 gil3543526 Homo sapiens AAH05921 616 96 1969 gi18088830 Homo sapiens AAH20756 616 96 1969 gi30582691 Homo sapiens 616 96 1970 gil3543526 Homo sapiens AAH05921 616 96 1970 gil8088830 Homo sapiens AAH20756 616 96 WO 2004/080148 PCT/US2003/030720 247 TABLE 21B SEQID HitID Species Description S_score Percentage Identity 1970 gi30582691 Homo sapiens 616 96 1971 gil2653501 Homo sapiens SERPINF1 protein 2119 99 1971 gil5217079 Homo sapiens AF400442_1 pigment 2125 99 epithelium-derived factor 1971 gi30583283 Homo sapiens , member 1 2119 99 1972 gi20269957 Sus scrofa AF498759_1 phospholipase C 166 96 delta 4 1972 gi21307610 Mus musculus phospholipase C delta 4 158 90 1972 gi571466 Rattus norvegicus phospholipase C delta-4 151 84 1973 gil7864023 Homo sapiens AF450090 1 KCCR13L 3299 94 1973 gi22760385 Homo sapiens unnamed protein product 3290 94 1973 gi22761016 Homo sapiens unnamed protein product 3299 94 1975 gil9684107 Homo sapiens 120 92 1975 gi32966069 Homo sapiens CD39L2 nucleotidase 120 92 1975 gi4691263 Homo sapiens 120 92 1976 gi11493483 Homo sapiens AF130117_ 48 PR02550 364 71 1976 gi2580578 Homo sapiens ubiquitous TPR motif, Y 339 75 isoform 1976 gi8572229 Homo sapiens ubiquitous TPR-motif protein 339 75 Y isoform 1977 gil8848355 Mus musculus Coq6 protein 2085 87 1977 gi30047245 Mus musculus Coq6 protein 2090 85 1977 gi4680659 Homo sapiens AF132944 1 CGI-10 protein 2378 98 1978 gil2654881 Homo sapiens AAH01284| 331 78 1978 gi1710216 Homo sapiens unknown 311 73 1978 gi28799226 Homo sapiens unnamed protein product 252 65 1979 gil1493483 Homo sapiens AF130117_48 PR02550 143 48 1979 gi3002527 Homo sapiens neuronal thread protein AD7c- 161 63 NTP 1979 gi32486167 Homo sapiens AD7C-NTP 161 63 1980 gi20810589 Homo sapiens similar to arsenite inducible 833 99 _ - RNA associated protein 1980 gi22945274 Drosophila CG12795-PA 455 54 melanogaster 1980 gi9651711 Mus musculus AF224494_1 arsenite inducible 687 80 RNA associated protein 1981 gi13241652 Rattus norvegicus AF309558-1 supernatant 162 87 protein factor 1981 gi13543184 Mus musculus SEC14-like 2 162 87 1981 gi6624130 Rattus norvegicus AC004832_1 similar to 45 kDa 169 96 secretory protein 1982 gil 1066250 Homo sapiens AF1979371 presenilins 1392 100 associated rhomboid-like protein 1982 gi13177766 Homo sapiens AAH03653 Similar to 1068 80 presenilins associated rhomboid-like protein 1982 gil5559382 Homo sapiens AAH14058 presenilins 1389 99 associated rhomboid-like protein 1983 gil864091 Rattus norvegicus PSD-95/SAP90-associated 160 100 protein-3 1984 gil.1877274 Homo sapiens 2265 100 1984 gi21667210 Homo sapiens AF465765 1 2265 100 WO 2004/080148 PCT/US2003/030720 248 TABLE 2 B SEQID Hit_ID Species Description S_score Percentage_ Identity bactericidal/permeability increasing protein-like 1 1984 gi21706776 Homo sapiens Bactericidal/permeability- 2258 99 increasing protein-like 1 1985 gi3879547 Caenorhabditis 125 36 elegans 1986 gi21307771 Homo sapiens organic anion transporter 2 733 100 1986 gi21707474 Homo sapiens , member 7 733 100 1986 gi5001689 Homo sapiens AF0975181 liver-specific 733 100 transporter 1987 gil2804105 Homo sapiens AAH02905 Similar to 589 79 _ _ CG15084 gene product 1987 gil3649459 Homo sapiens AF250306_1 putative SB115 589 79 protein 1987 gil8204670 Mus musculus 4930527D15Rik protein 569 75 1988 gil022323 Mus musculus chain 3354 87 1988 gi537329 Homo sapiens alpha-2 type IV collagen 3752 99 1988 gi556299 Mus musculus alpha-2 type IV collagen 3351 87 1989 gil7298315 Homo sapiens candidate tumor suppressor 1360 98 protein 1989 gi7861733 Homo sapiens AF176832_1 low density 1360 98 lipoprotein receptor related protein-deleted in tumor 1989 gi8926243 Mus musculus AF270884_1 low density 1181 84 lipoprotein receptor related protein LRP 1B/LRP-DIT 1990 gi17298315 Homo sapiens candidate tumor suppressor 1360 98 protein 1990 gi7861733 Homo sapiens AF176832_1 low density 1360 98 lipoprotein receptor related protein-deleted in tumor 1990 gi8926243 Mus musculus AF270884_1 low density 1181 84 lipoprotein receptor related protein LRP 1 B/LRP-DIT 1991 gi11493483 Homo sapiens AF130117_48 PR02550 408 78 1991 gil872200 Homo sapiens alternatively spliced product 328 75 using exon 13A 1991 gi7770139 Homo sapiens AF119917_13 PRO1722 328 72 1992 gi157409 Drosophila fat protein 370 37 melanogaster 1992 gi23093109 Drosophila CG7749-PA 367 41 melanogaster 1992 gi7295732 Drosophila CG3352-PA 367 38 melanogaster 1993 gil57409 Drosophila fat protein 370 37 melanogaster 1993 gi23093109 Drosophila CG7749-PA 367 41 melanogaster 1993 gi7295732 Drosophila CG3352-PA 367 38 melanogaster 1994 gi27549552 Homo sapiens dipeptidyl peptidase IV-related 410 89 protein-2 1994 gi29293087 Homo sapiens dipeptidyl peptidase 9 410 89 1994 gi3513303 Homo sapiens R26984 1 476 100 1995 gi32493172 Homo sapiens pheromone receptor 170 96 WO 2004/080148 PCT/US2003/030720 249 TABLE 2 B SEQ ID HitID Species Description Sscore Percentage_ Identity 1995 gi32493174 Homo sapiens pheromone receptor 170 96 1995 gi32493176 Homo sapiens pheromone receptor 178 100 1996 gi23468368 Mus musculus 1200013F24Rik protein 799 63 1996 gi27695305 Mus musculus 1200013F24Rik protein 825 76 1996 gi7582294 Homo sapiens AF208853_1 BM-011 781 98 1997 gil620870 Ciona intestinalis myoplasmin-CI 190 29 1997 gi31419817 Mus musculus Golgi autoantigen, golgin 124 26 subfamily a, 3 1997 gi4582571 Gallus gallus Hyperion protein, 419 kD 125 26 isoform 1998 gil3872813 Homo sapiens fibulin-6 1099 48 1998 gil4575679 Homo sapiens AF156100 1 hemicentin 2159 86 1998 gi3879658 Caenorhabditis 636 32 elegans 1999 gi14044052 Homo sapiens AAH07950 1105 51 1999 gil7390825 Mus musculus heterogenous nuclear 1104 51 ribonucleoprotein U 1999 gi3822553 Gallus gallus nuclear calmodulin-binding 1554 64 protein 2000 gil7223626 Homo sapiens ATP-binding cassette A1O 1683 93 2000 gi32350914 Homo sapiens ATP-binding cassette sub- 1675 92 family A member 10 2000 gi32350969 Homo sapiens ATP-binding cassette sub- 1675 92 family A member 10 2001 gil3374079 Homo sapiens TAFII140 protein 3747 99 2001 gil3374178 Mus musculus TAFII140 protein 3454 85 2001 gi28175603 Homo sapiens TAF3 protein 2775 99 2002 gil7429038 Ralstonia PROBABLE ACYL-COA 676 61 solanacearum DEHYDROGENASE OXIDOREDUCTASE PROTEIN 2002 gi22776354 Oceanobacillus acyl-CoA dehydrogenase 660 63 iheyensis HTE831 2002 gi28280023 Mus musculus 5730439E10Rik protein 974 84 2003 gi21522776 Homo sapiens unnamed protein product 2998 98 2003 gi24047224 Homo sapiens Similar to EGF-like-domain, 2982 98 multiple 6 2003 gi6752658 Homo sapiens AF1860841 epidermal growth 2984 98 factor repeat containing protein 2004 gil4530342 Caenorhabditis 389 51 elegans 2004 gi6531661 Caenorhabditis AF195610_1 LIN-41A 389 51 elegans 2004 gi6531663 Caenorhabditis AF195611_1 LIN-41B 389 51 elegans 2005 gil504026 Homo sapiens 5996 99 2005 gi22725157 Homo sapiens minor histocompatibility 5835 99 antigen HA-1 2005 gi23272016 Homo sapiens Similar to PTPLI-associated 5675 98 RhoGAP 1 2006 gil3274120 Homo sapiens 995 91 2006 gi6102996 Mus musculus Vanin-3 884 78 2006 gi7160973 Homo sapiens VNN3 protein 995 91 2007 gi27463365 Homo sapiens a disintegrin-like and 345 93 metalloprotease with WO 2004/080148 PCT/US2003/030720 250 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity thrombospondin type 1 motifs 9B 2007 gi3876367 Caenorhabditis 148 39 elegans 2007 gi3879882 Caenorhabditis 148 39 elegans 2008 gi15963476 Homo sapiens AF289221_1 alpha-adaptin A 2085 94 related protein 2008 gil5963477 Homo sapiens AF2892212 alpha-adaptin A 2118 99 related protein 2008 gi4314340 AA 159-977 Human alpha-adaptin A 2085 94 homolog 2009 gil5488017 Homo sapiens AF407274 1 EWI2 3200 100 2009 gi27497567 Homo sapiens keratinocytes associated 3200 100 transmembrane protein 4 2009 gi31753233 Homo sapiens Immunoglobulin superfamily, 3200 100 member 8 2010 gil5488017 Homo sapiens AF407274_1 EWI2 3200 100 2010 gi27497567 Homo sapiens keratinocytes associated 3200 100 transmembrane protein 4 2010 gi31753233 Homo sapiens Immunoglobulin superfamily, 3200 100 member 8 2011 gil5488017 Homo sapiens AF407274_1 EWI2 3200 100 2011 gi27497567 Homo sapiens keratinocytes associated 3200 100 transmembrane protein 4 2011 gi31753233 Homo sapiens Immunoglobulin superfamily, 3200 100 member 8 2012 gil5488017 Homo sapiens AF407274_1 EWI2 3200 100 2012 gi27497567 Homo sapiens keratinocytes associated 3200 100 transmembrane protein 4 2012 gi31753233 Homo sapiens Immunoglobulin superfamily, 3200 100 member 8 2013 gil405723 Homo sapiens type X collagen 198 30 2013 gi30095 Homo sapiens 3 198 30 2013 gi7573532 Homo sapiens 198 30 2014 gil5145793 Sus scrofa basic proline-rich protein 233 26 2014 gil5145795 Sus scrofa basic proline-rich protein 205 26 2014 gi25056007 Zea mays AF159297 I extensin-like 203 26 protein 2015 gi21992 Volvox carteri extensin 158 37 2015 gi2429362 Santalum album proline rich protein 166 39 2015 gi32488576 Oryza sativa OSJNBaOO67KO8.27 157 35 (japonica cultivar group) 2016 gi12002042 Homo sapiens AF063606_1 brain my048 659 70 protein 2016 gil7225331 Homo sapiens AF325115_1 MY0876G05 659 70 protein 2016 gi17646146 Homo sapiens AF3145421 B lymphocyte 727 56 activation-related protein 2018 gil3161063 Homo sapiens AF332218_1 protocadherin 11 746 56 2018 gil3161066 Homo sapiens AF332219_1 protocadherin 11 746 56 2018 gi9845485 Homo sapiens AF169692_1 protocadherin-9 1349 100 2019 gi16552038 Homo sapiens unnamed protein product 2139 99 2019 gi21410124 Mus musculus 3230402B02Rik protein 1334 60 WO 2004/080148 PCT/US2003/030720 251 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity 2019 gi5688958 Homo sapiens PMMLP 2140 100 2020 gi21734445 Rattus norvegicus BMP/Retinoic acid-inducible 3958 95 neurai-specific protein-2 2020 gi21734447 Rattus norvegicus BMP/Retinoic acid-inducible 2948 70 neural-specific protein-3 2020 gi30348610 Gallus gallus BMP/retinoic acid-inducible 2090 52 neural-specific protein 2021 gi23272677 Homo sapiens Similar to zinc finger protein 467 80 208 2021 gi26251755 Homo sapiens ZNF431 protein 449 78 2021 gi30421228 Homo sapiens zinc finger protein 430 572 100 2022 gi23272677 Homo sapiens Similar to zinc finger protein 467 80 208 2022 gi26251755 Homo sapiens ZNF431 protein 449 78 2022 gi30421228 Homo sapiens zinc finger protein 430 572 100 2023 gil212965 Homo sapiens transmembrane protein 358 70 2023 gil213221 Rattus norvegicus transmembranc protein 354 69 2023 gil9683999 Homo sapiens coated vesicle membrane 358 70 protein 2024 gil199524 Homo sapiens acid phosphatase 2246 99 2024 gil3111975 Homo sapiens AAH03160 acid phosphatase 2242 99 2, lysosomal 2024 gi30584617 synthetic construct Homo sapiens acid 2242 99 phosphatase 2, lysosomal 2025 gil5625570 Homo sapiens AF411981_1 centaurin beta5 353 100 2025 gi30109272 Homo sapiens CENTB5 protein 505 99 2025 gi4688902 Homo sapiens centaurin beta2 270 48 2026 gi27693942 Homo sapiens Similar to expressed sequence 1083 42 A1449432 2026 gi2789430 Homo sapiens repressor protein 1084 42 2026 gi5630080 Homo sapiens AC004890 2 1077 42 2027 gil 1345382 Homo sapiens AF308801_1 vacuolar protein 2977 99 sorting protein 16 2027 gi12140290 Homo sapiens 2983 99 2027 gil5553046 Mus musculus Vps16 2932 97 2028 gi30141048 Homo sapiens Nogo-66 receptor homolog-1 294 100 2028 gi30141052 Rattus norvegicus Nogo-66 receptor homolog-1 270 92 2028 gi32351287 Rattus norvegicus Nogo-66 receptor homolog 2 149 53 2029 gi202592 Rattus norvegicus prealpha-2-macroglobulin 238 40 2029 gi671864 Gallus gallus ovomacroglobulin, ovostatin 230 40 2029 gi671865 Gallus gallus ovomacroglobulin, ovostatin 230 40 2030 gil5778556 Homo sapiens AF4144291 alpha-I-B 131 92 glycoprotein precursor 2031 gi200057 Mus musculus neuronal glycoprotein 698 94 2031 gi29837411 Homo sapiens BIG-2 554 75 2031 gi563133 Rattus norvegicus BIG-i protein 692 94 2032 gil6550078 Homo sapiens unnamed protein product 763 100 2032 gi28175743 Homo sapiens similar to hypothetical protein 763 100 FLJ30803 2032 gi30354720 Mus musculus A1427653 protein 756 100 2033 gi16550078 Homo sapiens unnamed protein product 763 100 2033 gi28175743 Homo sapiens similar to hypothetical protein 763 100 FLJ30803 2033 gi30354720 Mus musculus A1427653 protein 756 100 WO 2004/080148 PCT/US2003/030720 252 TABLE 2 B SEQID HitID Species Description S_score Percentage Identity 2034 gi21929093 Homo sapiens seven transmembrane helix 1711 88 receptor 2034 gi24286029 Homo sapiens G-protcin coupled receptor 6754 97 GPR116 2034 gi5525078 Rattus norvegicus seven transmembrane receptor 5038 72 2035 gi11917507 Homo sapiens HPF1 protein 434 59 2035 gil3938351 Homo sapiens AAH07307 Similar to zinc 432 63 finger protein 268 2035 gi3135968 Homo sapiens 440 58 2036 gil3097633 Homo sapiens AAH03534 Similar to ATPase, 373 84 Class I, type 8B, member 1 2036 gi33440008 Homo sapiens possible aminophospholipid 406 91 translocase ATP8B2 2036 gi3628757 Homo sapiens FICI 373 84 2038 gi11558486 Homo sapiens B-cell lymphoma/leukaemia 1314 99 11A short form 2038 gil2150278 Homo sapiens AF080216_1 C2H2-type zinc- 1197 98 finger protein; EVI-9 2038 gi30410854 Mus musculus 1312 98 2039 gi32394378 Homo sapiens forkhead-associated domain 1735 94 histidine-triad like protein 2039 gi32394380 Bos taurus forkhead-associated domain 1540 83 histidine-triad like protein 2039 gi32394382 Sus scrofa forkhead-associated domain 1575 84 histidine-triad like protein 2040 gi32394378 Homo sapiens forkhead-associated domain 1735 94 histidine-triad like protein 2040 gi32394380 Bos taurus forkhead-associated domain 1540 83 histidine-triad like protein 2040 gi32394382 Sus scrofa forkhead-associated domain 1575 84 histidine-triad like protein 2041 gi32394378 Homo sapiens forkhead-associated domain 1735 94 histidine-triad like protein 2041 gi32394380 Bos taurus forkhead-associated domain 1540 83 histidine-triad like protein 2041 gi32394382 Sus scrofa forkhead-associated domain 1575 84 histidine-triad like protein 2042 gi26454883 Homo sapiens hypothetical protein HSPC148 1181 100 2042 gi6523797 Homo sapiens AF110775_1 adrenal gland 1181 100 protein AD-002 2042 gi6841518 Homo sapiens AF161497 1 HSPC148 1178 99 2043 gil4009597 Homo sapiens AF282619_1 lysyl oxidase-like 1569 98 3 protein 2043 gil4486600 Homo sapiens AF311313_1 lysyl oxidase-like 1569 98 3 protein 2043 gil5186770 Homo sapiens AF284815_1 lysyl oxidase-like 1569 98 protein 2044 gil0834722 Homo sapiens AF258588_1 PP5656 892 89 2044 gi21706836 Mus musculus Gyltllb protein 1056 87 2044 gi22713410 Homo sapiens GYLTL1B protein 1205 100 2045 gi7209721 Mus musculus DD57 2242 88 2045 gi7209723 Homo sapiens WD-repeat like sequence 2483 100 2045 gi8217485 Homo sapiens 2480 99 2046 gil3592175 Leishmania major AC084329 1 ppg3 140 28 2046 gi28828184 Dictyostelium similar to Leishmania major. 179 28 WO 2004/080148 PCT/US2003/030720 253 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity discoideum Ppg3 2046 gi3873550 Schizosaccharomyce SPBC215.13 147 24 s pombe 2047 gi21104460 Homo sapiens OK/SW-CL.19 206 100 2047 gi32425794 Homo sapiens NJMU-R1 protein 206 100 2047 gi32450708 Homo sapiens NJMU-R1 protein 206 100 2048 gil3277972 Mus musculus phosphatidate 2270 95 cytidylyltransferase 2 2048 gil9344052 Homo sapiens ... 2360 99 2048 gi4186023 Homo sapiens CDS2 protein 2360 99 2049 gil7862928 Drosophila SD03549p 121 35 melanogaster 2049 gi29387317 Mus musculus 1200011022Rik protein 670 89 2049 gi7297878 Drosophila CG14941-PA 121 35 melanogaster 2050 gil3562004 Nephila AF3502761 major ampullate 251 33 madagascariensis spidroin 2-like protein 2050 gi7106224 Nephila clavipes flagelliform silk protein 252 32 2050 gi7106228 Nephila inaurata flagelliforn silk protein 277 34 madagascariensis [Nephila madagascariensis] 2051 gi12018147 Chlamydomonas AF3094941 vegetative cell 198 31 reinhardtii wall protein gpl 2051 gil5145793 Sus scrofa basic proline-rich protein 204 29 2051 gi15145797 Sus scrofa basic proline-rich protein 200 30 2052 gi16877193 Homo sapiens AAH16860 G protein-coupled 2320 99 receptor, family C, group 5, member C 2052 gi30583709 Homo sapiens G protein-coupled receptor, 2320 99 family C, group 5, member C 2052 gi8 118032 Homo sapiens AF2079891 orphan G-protein 2320 99 coupled receptor 2053 gil5679980 Homo sapiens C 114 protein 930 99 2053 gi16769562 Drosophila LD38910p 328 47 melanogaster 2053 gi7302978 Drosophila CG8441-PA 328 47 melanogaster 2054 gil0726751 Drosophila CG13623-PA 333 53 melanogaster 2054 gi21430012 Drosophila GH27470p 333 53 melanogaster 2054 gi7406400 Arabidopsis thaliana putative protein 317 45 2055 gi13959018 Homo sapiens AF361746_1 endothelial cell- 1578 99 selective adhesion molecule 2055 gil3991773 Mus musculus AF361882 1 endothelial cell- 1188 76 selective adhesion molecule 2055 gi29165726 Mus musculus Endothelial cell-selective 1188 76 adhesion molecule 2056 gi15422171 Homo sapiens 22 kDa peroxisomal membrane 862 99 protein 2 2056 gi297437 Rattus norvegicus peroxisomal membrane protein 680 76 2056 gi8164184 Homo sapiens 22kDa peroxisomal membrane 862 99 protein-like 2057 gi11994465 Arabidopsis thaliana contains similarity to late 141 39 embryogenesis abundant protein-gene_id:MLD14.16 WO 2004/080148 PCT/US2003/030720 254 TABLE 2 B SEQjD HitID Species Description S score Percentage Identity 2057 gi21326031 Oryzias latipes choriogenin H 159 35 2057 gi22093906 Oryzias latipes AF396668 1 choriogenin H 157 35 2058 gi62877 Gallus gallus type VI collagen alpha-2 320 42 subunit preprotein 2058 gi62881 Gallus gallus type VI collagen subunit 320 42 alpha2 2058 gi62882 Gallus gallus type VI collagen subunit 320 42 alpha2 2059 gil7945608 Drosophila RE26969p 600 60 melanogaster 2059 gi7292879 Drosophila CG1998-PA 600 60 melanogaster 2059 gi7292910 Drosophila CG11162-PA 423 50 melanogaster 2060 gi17066106 Homo sapiens Novex-3 Titin Isoform 964 99 2060 gi27696390 Xenopus laevis Similar to titin 251 37 2060 gi992994 Gallus gallus myosin light chain kinase 228 35 2061 gi14089982 Mycoplasma 143 33 pulmonis 2061 gi2649941 Archaeoglobus 151 30 fulgidus DSM 4304 2061 gi30180922 Nitrosomonas Adenylate kinase 143 28 europaea ATCC 19718 2062 gi29477024 Mus musculus Similar to RIKEN cDNA 464 44 9130023G24 gene 2062 gi3002588 Mus musculus Plenty of SH3s; POSH 148 25 2062 gi7453547 Homo sapiens glioma tumor suppressor 125 25 candidate region protein 1 2063 gi29477024 Mus musculus Similar to RIKEN cDNA 464 44 9130023G24 gene 2063 gi3002588 Mus musculus Plenty of SH3s; POSH 148 25 2063 gi7453547 Homo sapiens glioma tumor suppressor 125 25 candidate region protein 1 2064 gil0441350 Mus musculus olfactory UDP 241 70 glucuronosyltransferase 2064 gi4580602 Macaca fascicularis AFI 12112_1 UDP- 244 73 glucuronosyltransferase 2B 19 precursor 2064 gi4753766 Homo sapiens UDP glucuronosyltransferase 266 76 2065 gil3325266 Homo sapiens AAH04450 hypothetical 796 91 protein MGC2650 2065 gi3688090 Homo sapiens R32611 2 827 100 2065 gi6841228 Homo sapiens AF161407 1 HSPC289 703 84 2066 gi11493483 Homo sapiens AF130117 48 PR02550 282 56 2066 gi3002527 Homo sapiens neuronal thread protein AD7c- 497 62 NTP 2066 gi32486167 Homo sapiens AD7C-NTP 497 62 2067 gil6552274 Homo sapiens unnamed protein product 276 45 2067 gi57516 Rattus rattus ASM15 437 57 2067 gi7107346 Peromyscus 1-119 280 43 maniculatus bairdii 2068 gi20330550 Homo sapiens AF251706 1 NK inhibitory 1480 94 receptor precursor 2068 gi30962591 Homo sapiens AF375480 1 immune receptor 1401 93 WO 2004/080148 PCT/US2003/030720 255 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity expressed on myeloid cells splice variant 1 2068 gi31790204 Homo sapiens inhibitory receptor IREM1 1478 94 2069 gi20330550 Homo sapiens AF251706 1 NK inhibitory 1480 94 receptor precursor 2069 gi30962591 Homo sapiens AF375480_1 immune receptor 1401 93 expressed on myeloid cells splice variant 1 2069 gi31790204 Homo sapiens inhibitory receptor IREM1 1478 94 2D70 gi20330550 Homo sapiens AF251706_1 NK inhibitory 1480 94 receptor precursor 2D70 gi30962591 Homo sapiens AF375480_1 immune receptor 1401 93 expressed on myeloid cells splice variant 1 2070 gi31790204 Homo sapiens inhibitory receptor IREM1 1478 94 2D71 gil8307481 Homo sapiens phosphoinositide-binding 2206 97 proteins 2071 gi27695704 Mus musculus Connector enhancer of KSR2 705 35 2071 gi29691916 Rattus norvegicus interactor protein for cytohesin 1651 79 exchange factors 1 2072 gil1493982 Homo sapiens AF2082321 TLH29 protein 303 70 precursor 2072 gil5929988 Homo sapiens AAH15423 Similar to TLH29 497 100 protein precursor 2072 gi21618549 Homo sapiens TLH29 protein precursor 303 70 2073 gi11493982 Homo sapiens AF2082321 TLH29 protein 303 70 precursor 2073 gil5929988 Homo sapiens AAH15423 SimilartoTLH29 497 100 protein precursor 2073 gi21618549 Homo sapiens TLH29 protein precursor 303 70 2074 gil2804693 Homo sapiens AAH01773 Similar to 591 100 ribosomal protein L34 2074 gil7932958 Homo sapiens ribosomal protein L34 591 100 2074 gi20306434 Mus musculus 1100001I22Rik protein 587 99 2075 gil5384841 Homo sapiens activating NK receptor 738 99 2075 gi15384843 Homo sapiens NTB-A receptor 754 100 2D75 gi20988099 Mus musculus lymphocyte antigen 108 240 39 2D76 gil0177621 Arabidopsis thaliana phytoene dehydrogenase-like 573 42 2076 gil7979255 Arabidopsis thaliana AT5g49550/K6M13 10 589 42 2076 gi29028742 Arabidopsis thaliana At5g49550/K6M13 10 589 42 2D77 gil4270364 Mus musculus Epigen protein 378 71 2077 gi6272269 Rattus norvegicus NCI protein 122 52 2077 gi7799191 Mus musculus tomoregulin-1 122 52 2078 gil4270364 Mus musculus Epigen protein 378 71 2D78 gi6272269 Rattus norvegicus NCl protein 122 52 2D78 gi7799191 Mus musculus tomoregulin-1 122 52 2079 gi14270364 Mus musculus Epigen protein 378 71 2079 gi6272269 Rattus norvegicus NC1 protein 122 52 2079 gi7799191 Mus musculus tomoregulin-1 122 52 2080 gi27469556 Homo sapiens Putative neuronal cell adhesion 206 34 molecule 2080 gi29289929 Danio rerio neogenin 176 37 2080 gi3068592 Mus musculus punc 192 35 2081 gi31753150 Homo sapiens Ras family member Ris 665 65 WO 2004/080148 PCT/US2003/030720 256 TABLE 2 B SEQjD HitID Species Description Sscore Percentage_ Identity 2081 gi4416181 Mus musculus ES18 1276 84 2081 gi7331127 Homo sapiens AF233588 I Ris 665 65 2082 gil3128925 Homo sapiens AF304378 1 ULBP2 protein 1312 99 2082 gil8650584 Homo sapiens retinoic acid early transcript 1 1312 99 2082 gi21961213 Homo sapiens UL16 binding protein 2 1312 99 2083 gil3872813 Homo sapiens fibulin-6 513 29 2083 gil4575679 Homo sapiens AF156100 1 hemicentin 513 29 2083 gi9280405 Homo sapiens AF245505 1 adlican 1462 46 2084 gi13872813 Homo sapiens fibulin-6 513 29 2084 gi14575679 Homo sapiens AF156100_1 hemicentin 513 29 2084 gi9280405 Homo sapiens AF245505 _1 adlican 1462 46 2085 gil3872813 Homo sapiens fibulin-6 513 29 2085 gil4575679 Homo sapiens AF156100 1 hemicentin 513 29 2085 gi9280405 Homo sapiens AF245505_1 adlican 1462 46 2086 gi3041867 Homo sapiens p53 162 96 2086 gi4731632 Homo sapiens AF135121_1 tumor suppressor 162 96 protein p53 2086 gi4732147 Homo sapiens AF136271_1 tumor suppressor 162 96 protein p53 2087 gil2240284 Mus musculus AF327059_1 apolipoprotein 1300 72 A5 2087 gi6707433 Homo sapiens AF202889_1 apolipoprotein 1864 100 A5 2087 gi6707435 Homo sapiens AF2028901 apolipoprotein 1864 100 A5 2088 gil2240284 Mus musculus AF3270591 apolipoprotein 1300 72 A5 2088 gi6707433 Homo sapiens AF2028891 apolipoprotein 1864 100 A5 2088 gi6707435 Homo sapiens AF2028901 apolipoprotein 1864 100 A5 2089 gi13111784 Homo sapiens AAH03081 hypothetical 1509 99 protein FLJ10637 2089 gil3543037 Mus musculus 4933424B01Rik protein 958 80 2089 gil4249965 Homo sapiens AAH08368 hypothetical 1513 100 protein FLJ10637 2090 gil9344001 Homo sapiens phospholipase A2, group IID 846 99 2090 gi5771420 Homo sapiens AF1129821 group IID 852 100 secretory phospholipase A2 2090 gi6453793 Homo sapiens AF188625_1 phospholipase 846 99 A2 2091 gil674069 Mycoplasma 30K adhesin-related protein 132 35 pneumoniae 2091 gi1684932 Mycoplasma adhesin protein 132 35 pncumoniae 2091 gi5114063 Mycoplasma AF090172 1 revertant 128 35 pneumoniae adhesin-related protein P30 2092 gil1094019 Homo sapiens AF305057_2 RTS beta 2047 94 2092 gi1150421 Homo sapiens rTSbeta 2053 94 2092 gil2654883 Homo sapiens AAH01285 rTS beta protein 2053 94 2094 gil3432042 Homo sapiens integrin-linked kinase- 2018 100 associated serine/threonine phosphatase 2C 2094 gil6306907 Homo sapiens AAH06576 integrin-linked 2018 100 WO 2004/080148 PCT/US2003/030720 257 TABLE 2 B SEQID HitID Species Description S score Percentage_ Identity kinase-associated serine/threonine phosphatase 2C 2094 gi20072498 Mus musculus 0710007A14Rik protein 1935 95 2095 gil8490682 Homo sapiens fibulin 1 281 37 2095 gi28175169 Mus musculus 1300015B04Rik protein 589 74 2095 gi31419 Homo sapiens fibulin-1 C 281 37 2096 gil8480746 Mus musculus olfactory receptor MOR261-10 1336 80 2096 gi21928655 Homo sapiens seven transmembrane helix 1427 90 receptor 2096 gi32052225 Mus musculus olfactory receptor 1336 80 GA x6K02T2P3E9-4341246 4340281 2097 gil8480746 Mus musculus olfactory receptor MOR261-10 1336 80 2097 gi21928655 Homo sapiens seven transmembrane helix 1427 90 receptor 2097 gi32052225 Mus musculus olfactory receptor 1336 80 GA x6K02T2P3E9-4341246 4340281 2098 gi4760780 Mus musculus Ten-m3 401 95 2098 gi5307761 Danio rerio ten-m3 347 80 2098 gi6760369 Mus musculus AF195418_1 ODZ3 401 95 2099 gi21205852 Homo sapiens AF385429_1 T-cell activation 989 100 Rho GTPase activating protein; TA-GAP 2099 gi21410139 Mus musculus T-cell activation Rho GTPase- 813 82 activating protein 2099 gi24980955 Mus musculus T-cell activation Rho GTPase- 813 82 activating protein 2100 gil872200 Homo sapiens alternatively spliced product 242 58 using exon 13A 2100 gi3002527 Homo sapiens neuronal thread protein AD7c- 283 59 NTP 2100 gi32486167 Homo sapiens AD7C-NTP 283 59 2101 gil 872200 Homo sapiens alternatively spliced product 242 58 using exon 13A 2101 gi3002527 Homo sapiens neuronal thread protein AD7c- 283 59 NTP 2101 gi32486167 Homo sapiens AD7C-NTP 283 59 2102 gi20196856 Arabidopsis thaliana putative myosin heavy chain 387 47 2102 gi3142302 Arabidopsis thaliana Z34293 from A. thaliana. 389 47 2102 gi532124 Dictyostelium myosin IC 388 46 discoideum 2103 gi20196856 Arabidopsis thaliana putative myosin heavy chain 387 47 2103 gi3142302 Arabidopsis thaliana Z34293 from A, thaliana. 389 47 2103 gi532124 Dictyostelium myosin IC 388 46 discoideum 2104 gi29564894 Homo sapiens unnamed protein product 174 39 2104 gi3002527 Homo sapiens neuronal thread protein AD7c- 174 39 NTP 2104 gi32486167 Homo sapiens AD7C-NTP 174 39 2105 gi21265163 Homo sapiens 1893 95 2105 gi7248845 Homo sapiens AF231124_1 testican-1 1893 95 2105 gi793845 Homo sapiens testican 1893 95 2106 gil2804465 Homo sapiens AAH01639 prostate cancer 686 66 WO 2004/080148 PCT/US2003/030720 258 TABLE 2 B SEQID Hit_ID Species Description Sscore Percentage_ Identity overexpressed gene 1 2106 gi20380774 Homo sapiens 1098 99 2106 gi3462515 Homo sapiens PB39 686 66 2107 gil2804465 Homo sapiens AAH01639 prostate cancer 686 66 1 overexpressed gene 1 2107 gi20380774 Homo sapiens 1098 99 2107 gi3462515 Homo sapiens PB39 686 66 2108 gil7391348 Homo sapiens AAH18615 Similar to brain 664 100 expressed, X-linked 1 2108 gi7689029 Homo sapiens AF220189_1 uncharacterized 664 100 hypothalamus protein HBEX2 2108 gi9963771 Homo sapiens AF183416_1 ovarian granulosa 664 100 cell 13.0 kDa protein hGR74 homolog 2109 gi26353296 Mus musculus unnamed protein product 711 76 2109 gi28799187 Homo sapiens unnamed protein product 1463 98 2109 gi30908853 Homo sapiens synleurin 1463 98 2111 gi20988071 Mus musculus 260001 1E07Rik protein 445 89 2111 gi23274133 Homo sapiens Similar to serine/arginine 161 27 repetitive matrix 1 2111 gi3153821 Mus musculus plenty-of-prolines-101; 164 30 POP101; SH3-philo-protein 2112 gi9651079 Macaca fascicularis hypothetical protein 291 75 2113 gil2408272 Homo sapiens apolipoprotein L-IV splice 1726 99 variant a 2113 gil2408286 Homo sapiens apolipoprotein L-IV splice 1726 99 variant a 2113 gi13374351 Homo sapiens AF305226_1 apolipoprotein 1709 98 L4 2114 gil2408272 Homo sapiens apolipoprotein L-IV splice 1726 99 variant a 2114 gi12408286 Homo sapiens apolipoprotein L-IV splice 1726 99 variant a 2114 gil3374351 Homo sapiens AF305226_1 apolipoprotein 1709 98 L4 2115 gi21744725 Homo sapiens AF478693_1 glycosyl- 717 97 phosphatidyl-inositol-MAM 2115 gi25005318 Sus scrofa MAM domain containing 672 91 glycosylphosphatidylinositol anchor 1 2115 gi25005320 Sus scrofa glycosylphosphatidylinositol 672 91 anchor I protein 2116 gi21744725 Homo sapiens AF478693_1 glycosyl- 717 97 phosphatidyl-inositol-MAM 2116 gi25005318 Sus scrofa MAM domain containing 672 91 glycosylphosphatidylinositol anchor 1 2116 gi25005320 Sus scrofa glycosylphosphatidylinositol 672 91 anchor 1 protein 2117 gil6769264 Drosophila LD21615p 219 40 melanogaster 2117 gi7290426 Drosophila CG2875-PB 219 40 melanogaster 2117 gi7290427 Drosophila CG2875-PA 219 40 melanogaster WO 2004/080148 PCT/US2003/030720 259 TABLE 2 B SEQ_ID HitID Species Description S score Percentage_ Identity 2118 gi23273399 Homo sapiens 963 100 2118 gi25059032 Mus musculus 686 72 2118 gi28385965 Mus musculus Similar to phospholipase A2 488 77 2119 gi23273399 Homo sapiens 963 100 2119 gi25059032 Mus musculus 686 72 2119 gi28385965 Mus musculus Similar to phospholipase A2 488 77 2120 gil3562004 Nephila AF3502761 major ampullate 228 27 madagascariensis spidroin 2-like protein 2120 gil3562008 Nephila AF3502781 major ampullate 238 29 madagascariensis spidroin 2 2120 gil59714 Nephila clavipes dragline silk fibroin 224 29 2121 gil3161409 Mus musculus family 4 cytochrome P450 445 76 2121 gil3182964 Mus musculus AF233643_1 cytochrome P450 191 38 CYP4F13 2121 gil3278244 Mus musculus cytochrome P450, family 4, 191 38 subfamily f, polypeptide 13 2122 gi10944887 Homo sapiens FGFR-like protein 1858 97 2122 gi13183618 Homo sapiens AF312678_1 FGF homologous 1807 96 factor receptor 2122 gil3447749 Homo sapiens AF279689_1 fibroblast growth 1858 97 factor receptor 5 2123 gi10944887 Homo sapiens FGFR-like protein 1858 97 2123 gi13183618 Homo sapiens AF312678_1 FGF homologous 1807 96 factor receptor 2123 gil3447749 Homo sapiens AF279689_1 fibroblast growth 1858 97 factor receptor 5 2124 gil0944887 Homo sapiens FGFR-like protein 1858 97 2124 gi13183618 Homo sapiens AF312678_1 FGF homologous 1807 96 factor receptor 2124 gil3447749 Homo sapiens AF279689_1 fibroblast growth 1858 97 factor receptor 5 2125 gil2667454 Rattus norvegicus AF336858_1 synaptotagmin 949 88 VIle 2125 gil2667456 Rattus norvegicus AF336859_1 synaptotagmin 949 88 VIld 2125 gil2667458 Rattus norvegicus AF336860_1 synaptotagmin 949 88 VIe_ 2126 gi12053709 Homo sapiens with thrombospondin type 1 1143 98 motif, 12 2126 gi27817773 Mus musculus metalloprotease disintegrin 12 873 76 protein 2126 gi5923788 Homo sapiens AF140675_1 zinc 271 39 metalloprotease ADAMTS7 2127 gil1493982 Homo sapiens AF208232_1 TLH29 protein 303 70 precursor 2127 gil5929988 Homo sapiens AAH15423 Similar to TLH29 497 100 protein precursor 2127 gi21618549 Homo sapiens TLH29 protein precursor 303 70 2128 gi17391206 Mus musculus RIKEN cDNA 2210412DO1 1267 99 2128 gi23468210 Homo sapiens Similar to CGI-67 protein 1096 81 2128 gi9368522 Homo sapiens CGI-67 protein 1267 99 2129 gil7391206 Mus musculus RIKEN cDNA 2210412D01 1267 99 2129 gi23468210 Homo sapiens Similar to CGI-67 protein 1096 81 2129 gi9368522 Homo sapiens CGI-67 protein 1267 99 WO 2004/080148 PCT/US2003/030720 260 TABLE 2 B SEQJD HitID Species Description S_score Percentage Identity 2130 gi20071312 Mus musculus 4933425F03Rik protein 614 85 2130 gi33391740 Homo sapiens MGC45780 426 96 2130 gi735 Bos taurus scavenger receptor type I 336 51 2131 gi20071312 Mus musculus 4933425F03Rik protein 614 85 2131 gi33391740 Homo sapiens MGC45780 426 96 2131 gi735 Bos taurus scavenger receptor type I 336 51 2132 gi5870866 Homo sapiens TATA element modulatory 4531 99 factor 2132 gi6650548 Rattus norvegicus AF107843 1 TATA element 2583 82 modulatory factor 2132 gi7290766 Drosophila CG4557-PA 692 25 melanogaster 2133 gi1020145 Homo sapiens -DNA binding protein 1483 43 2133 gil8643896 Homo sapiens zinc finger protein 1486 43 2133 gi29476835 Homo sapiens 1486 43 2134 gi16198520 Homo sapiens Saccharomyces cerevisiae 944 100 Nip7p homolog 2134 gi4680713 Homo sapiens AF132971 I CGI-37 protein 944 100 2134 gi5114055 Homo sapiens HSPC031 944 100 2135 gi23274241 Homo sapiens KIAA1892-like 563 86 2135 gi263321 14 Mus musculus unnamed protein product 577 89 2135 gi26345386 Mus musculus unnamed protein product 577 89 2136 gi15620885 Homo sapiens KIAA1913 protein 1627 99 2136 gi26339494 Mus musculus unnamed protein product 1480 90 2136 gi28279830 Homo sapiens KIAA1913 protein 1598 99 2137 gil000448 Rattus norvegicus Rat kidney AGT2 precursor 1578 84 2137 gil2406973 Homo sapiens alanine-glyoxylate 1865 98 aminotransferase 2 2137 gi1944136 Rattus norvegicus beta-alanine-pyruvate 1625 85 aminotransferase 2138 gil000448 Rattus norvegicus Rat kidney AGT2 precursor 1578 84 2138 gil2406973 Homo sapiens alanine-glyoxylate 1865 98 aminotransferase 2 2138 gil944136 Rattus norvegicus beta-alanine-pyruvate 1625 85 aminotransferasc 2139 gi29436673 Mus musculus 1700049K14Rik protein 648 100 2139 gi4204421 Euroglyphus maynei group 3 allergen Eur m 3 0101 212 40 precursor 2139 gi5441861 Paralichthys chymotrypsinogen 2 210 36 olivaceus 2140 gil7985046 Brucella melitensis GLYCOSYL TRANSFERASE 130 28 16M 2140 gi20515259 Thermoanaerobacter predicted glycosyltransferases 133 32 tengcongensis 2140 gi4455730 Streptomyccs putative transferase 140 32 coelicolor A3(2) 2141 gil3649477 Homo sapiens AF250309_1 putative cytokine 2694 100 receptor CRL4 precusor 2141 gi30584223 synthetic construct Homo sapiens interleukin 17B 2694 100 receptor 2141 gi9246433 Homo sapiens AF208110_1 IL-17 receptor 2688 99 homolog precursor 2142 gi18676472 Homo sapiens FLJ00133 protein 855 76 2142 gi29568116 Mus musculus secreted protein SST3 725 64 WO 2004/080148 PCT/US2003/030720 261 TABLE 2 B SEQID HitID Species Description S score Percentage Identity 2142 gi499686 Heliocidaris fibropellin la 390 40 erythrogramma 2143 gil6588687 Homo sapiens AF315687_1 S- 147 100 adenosylhomocysteine hydrolase-like protein 2143 gi27692283 Mus musculus S-adenosylhomocysteine 147 100 hydrolase-like 1 2143 gi2852125 Homo sapiens S-adenosyl homocysteine 147 100 hydrolase homolog 2144 gil6740861 Homo sapiens AAH16292 ubiquitin- 521 66 conjugating enzyme E2C 2144 gi29791813 Homo sapiens Ubiquitin-conjugating enzyme 521 66 E2C, isoform 1 2144 gi30583439 Homo sapiens ubiquitin-conjugating enzyme 521 66 E2C 2145 gi20086516 Homo sapiens AF245303_1 prominin-2 2480 91 variant A 2145 gi20086518 Homo sapiens AF245304_1 prominin-2 2480 91 variant B 2145 gi24637566 Rattus norvegicus prominin-2 1876 68 2146 gi29351676 Homo sapiens Angiopoietin-like 5 1310 99 2146 gi29468510 Homo sapiens putative fibrinogen-like protein 1305 99 2146 gi9229906 Ciona intestinalis fibrinogen-like protein 392 39 2147 gi29351676 Homo sapiens Angiopoietin-like 5 1310 99 2147 gi29468510 Homo sapiens putative fibrinogen-like protein 1305 99 2147 gi9229906 Ciona intestinalis fibrinogen-like protein 392 39 2148 gi29351676 Homo sapiens Angiopoietin-like 5 1310 99 2148 gi29468510 Homo sapiens putative fibrinogen-like protein 1305 99 2148 gi9229906 Ciona intestinalis fibrinogen-like protein 392 39 2150 gil3543706 Homo sapiens AAH06003 349 100 2150 gi20988061 Mus musculus 1810013DlORik protein 333 92 2150 gi21619079 Homo sapiens 349 100 2151 gil1493652 Homo sapiens AF200708_1 calcium channel 2168 100 blocker resistance protein CCBRI 2151 gil3924720 Homo sapiens AF2528721 cystine/glutamate 2168 100 transporter xCT 2151 gi15082352 Homo sapiens AAH12087 member 11 2168 100 2152 gil8043214 Mus musculus serine/arginine-rich protein 132 67 specific kinase 2 2152 gi23270876 Homo sapiens Similar to SFRS protein kinase 132 67 2 2152 gi3406050 Homo sapiens serine kinase SRPK2 132 67 2153 gi22164066 Homo sapiens AF388385 1 neuroblastoma- 4284 99 amplified protein 2153 gi30353863 Homo sapiens NAG protein 4298 99 2153 gi4337460 Homo sapiens neuroblastoma-amplified 4272 99 protein 2154 gi22164066 Homo sapiens AF388385_1 neuroblastoma- 4284 99 amplified protein 2154 gi30353863 Homo sapiens NAG protein 4298 99 2154 gi4337460 Homo sapiens neuroblastoma-amplified 4272 99 protein 2155 gil008367 Saccharomyces CPS1 131 48 cerevisiae WO 2004/080148 PCT/US2003/030720 262 TABLE 2 B SEQ_ID HitID Species Description Sscore Percentage_ Identity 2155 gi3594 Saccharomyces carboxypeptidase s 131 48 cerevisiae 2155 gi3596 Saccharomyces carboxypeptidase yscS 131 48 cerevisiae 2156 gil 1558029 Homo sapiens organic cation transporter 1876 100 2156 gi18088251 Homo sapiens AAH20565 Similar to hBOIT 1838 95 for potent brain type organic ion transporter 2156 gi9663117 Homo sapiens organic cation transporter 1868 99 2157 gi21732438 Homo sapiens hypothetical protein 567 100 2157 gi26330392 Mus musculus unnamed protein product 486 85 2157 gi26390211 Mus musculus unnamed protein product 486 85 2158 gi23893591 Human herpesvirus 4 BHLF1 early reading frame 169 28 2158 gi30844300 Cercopithecine immediate early protein ICPO 166 23 herpesvirus 1 2158 gi30844317 Cercopithecine immediate early protein ICPO 166 23 herpesvirus 1 2159 gi27804346 Homo sapiens BRD4-NUT fusion 3773 99 oncoprotein 2159 gi3115204 Homo sapiens HJNKI 3787 99 2159 gi3184498 Homo sapiens R31546_1 3837 99 2160 gil5420832 Homo sapiens AF397394 1 NOE3-3 535 96 2160 gil5420834 Homo sapiens AF397395 1 NOE3-4 535 96 2160 gi18490927 Homo sapiens olfactomedin 3 531 95 2161 gi22209078 Homo sapiens hypothetical protein 773 98 DKFZp566D234 2161 gi6330966 Homo sapiens KIAA1263 protein 773 98 2161 gi6808053 Homo sapiens hypothetical protein 766 97 2162 gil2654031 Homo sapiens AAH00819 Similar to CG6950 158 93 gene product 2162 gi21707106 Homo sapiens 120 56 2162 gi758591 Homo sapiens glutamine--phenylpyruvate 120 56 aminotransferase 2163 gi21666433 Mus musculus AF404775_1 actin-binding 302 54 LIM protein I medium isoform 2163 gi2337952 Homo sapiens actin-binding double-zinc- 303 54 finger protein 2163 gi30259308 Mus musculus actin-binding LIM protein 2 498 79 2164 gi2062399 Rattus norvegicus protein serine/threonine kinase 404 50 CPG16 2164 gi6716518 Mus musculus AF1551 doublecortin-like 404 50 kinase 2164 gi6716522 Mus musculus AF155821 1 CPG16 404 50 2165 gi2062399 Rattus norvegicus protein serine/threonine kinase 404 50 CPG16 2165 gi6716518 Mus musculus AF1551 doublecortin-like 404 50 kinase 2165 gi6716522 Mus musculus AF155821 1 CPG16 404 50 2166 gil3436035 Mus musculus prostaglandin E synthase 2 1321 87 2166 gi29179467 Danio rerio Similar to prostaglandin E 988 66 synthase 2 2166 gi9280108 Macaca fascicularis membrane-associated 1449 97 I prostaglandin E synthase-2 2167 gil2805247 Mus musculus Complement component 1, q 955 70 I_ subcomponent, alpha WO 2004/080148 PCT/US2003/030720 263 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity polypeptide 2167 gi20988805 Homo sapiens complement component 1, q 1318 100 subcomponent, alpha polypeptide 2167 gi4894854 Homo sapiens AF1351571 complement Clq 1318 100 A chain precursor 2168 gil491621 Bovine herpesvirus 1 UL36 126 38 2168 gi15145795 Sus scrofa basic proline-rich protein 123 38 2168 gi2653311 Bovine herpesvirus 126 38 type 1.1 (strain Cooper) 2169 gi21707458 Homo sapiens PAX transcription activation 2470 81 domain interacting protein 1 like 2169 gi2565046 Homo sapiens CAGF28 3770 97 2169 gi4336734 Mus musculus Pax transcription activation 2945 70 domain interacting protein PTIP 2170 gi21707458 Homo sapiens PAX transcription activation 2470 81 domain interacting protein 1 like 2170 gi2565046 Homo sapiens CAGF28 3770 97 2170 gi4336734 Mus musculus Pax transcription activation 2945 70 domain interacting protein PTIP 2171 gi32488718 Oryza sativa OSJNBaOO88HO9.19 121 41 (japonica cultivar group) 2172 gi26353296 Mus musculus unnamed protein product 711 76 2172 gi28799187 Homo sapiens unnamed protein product 1463 98 2172 gi30908853 Homo sapiens synleurin 1463 98 2173 gi13991167 Homo sapiens sialic acid-binding 1231 99 immunoglobulin-like lectin-like long splice variant 2173 gil4625822 Homo sapiens AF282256 I Siglec-LI 1231 99 2173 gi23272769 Homo sapiens SIGLEC-like 1 1231 99 2174 gil3435476 Mus musculus DNA segment, Chr 10, 1206 91 University of California at Los Angeles 1 2174 gi28279553 Danio rerio Similar to DNA segment, Chr 865 69 10, University of California at Los Angeles 1 2174 gi29144983 Mus musculus DNA segment, Chr 6, ERATO 668 67 Doi 253, expressed 2175 gi27924102 Mus musculus 2310075M15Rik protein 944 68 2175 gi29436830 Mus musculus 2310075M15Rik protein 944 68 2175 gi6273399 Homo sapiens AF200348_1 melanoma- 940 67 associated antigen MG50 2176 gi27924102 Mus musculus 2310075M15Rik protein 944 68 2176 gi29436830 Mus musculus 2310075M15Rik protein 944 68 2176 gi6273399 Homo sapiens AF200348_1 melanoma- 940 67 associated antigen MG50 2177 gi27924102 Mus musculus 2310075M15Rik protein 944 68 2177 gi29436830 Mus musculus 2310075M15Rik protein 944 68 2177 gi6273399 Homo sapiens AF200348_1 melanoma- 940 67 associated antigen MG50 2178 gil1493483 Homo sapiens AF130117 48 PR02550 220 56 WO 2004/080148 PCT/US2003/030720 264 TABLE 2 B SEQ_ID Hit_ID Species Description Sscore Percentage_ Identity 2178 gi1872200 Homo sapiens alternatively spliced product 220 51 using exon 13A 2178 gi8572229 Homo sapiens ubiquitous TPR-motif protein 217 53 Y isoform 2179 gi6808611 Homo sapiens AF204231_1 88-kDa Golgi 3209 97 protein 2179 gi6969980 Homo sapiens AF163441_1 golgin 67 2339 98 2179 gi7211438 Homo sapiens AF1646221 golgin-67 2321 97 2180 gil5030299 Mus musculus protein kinase, cAMP 1881 94 dependent regulatory, type I beta 2180 gi200365 Mus musculus cAMP-dependent protein 1886 94 kinase regulatory subunit 2180 gi307377 Homo sapiens cAMP-dependent protein 1957 99 kinase RI-beta regulatory subunit 2181 gil0945428 Homo sapiens membrane-associated 156 41 guanylate kinase MAGI3 2181 gil2003994 Homo sapiens AF213259 1 membrane- 156 41 associated guanylate kinase related MAGI-3 2181 gi7650497 Rattus norvegicus AF255614_1 scaffolding 156 41 protein SLIPR 2182 gil845577 Mus musculus -lipoxygenase 2559 74 2182 gi30047223 Mus musculus Arachidonate lipoxygenase, 2557 74 epidermal 2182 gi3645913 Mus musculus -lipoxygenase 2559 74 2183 gil845577 Mus musculus -lipoxygenase 2559 74 2183 gi30047223 Mus musculus Arachidonate lipoxygenase, 2557 74 epidermal 2183 gi3645913 Mus musculus -lipoxygenase 2559 74 2184 gil845577 Mus musculus -lipoxygenase 2559 74 2184 gi30047223 Mus musculus Arachidonate lipoxygenase, 2557 74 epidermal 2184 gi3645913 Mus musculus -lipoxygenase 2559 74 2185 gil0439485 Homo sapiens unnamed protein product 481 87 2185 gil2853469 Mus musculus unnamed protein product 395 62 2185 gi18027736 Hono sapiens AF318322 1 unknown 330 50 2186 gil4198207 Mus musculus hypothetical protein BC008163 1599 98 2186 gil9343692 Homo sapiens 1625 100 2186 gi7294965 Drosophila CG4452-PA 615 40 melanogaster 2192 gi22209089 Homo sapiens Similar to vesicular inhibitory 308 98 amino acid transporter 2192 gi30354125 Mus musculus Viaat protein 308 98 2192 gi31566392 Homo sapiens Vesicular inhibitory amino acid 308 98 transporter 2193 gi22507470 Mus musculus AI413481 protein 997 92 2193 gi3097285 Rattus norvegicus ZOG 481 48 2193 gi802014 Rattus norvegicus preadipocyte factor 1 481 48 2194 gil488314 Homo sapiens hepatitis delta antigen 442 49 interacting protein A 2194 gil8088059 Mus musculus E030025DO5Rik protein 1622 83 2194 gi6624073 Homo sapiens AC007743_1 similar to 1903 94 hepatitis delta antigen WO 2004/080148 PCT/US2003/030720 265 TABLE 2 B SEQjD HitID Species Description S score Percentage_ Identity interacting protein A 2195 gil4250638 Homo sapiens AAH08783 Similar to DNA 1886 99 segment, Chr 17, human D6S54E 2195 gi3941733 Mus musculus AAC82476 BAT4 1453 76 2195 gi4337106 Homo sapiens AAD18082 BAT4 1886 99 2196 gil5277895 Homo sapiens AAH12939 Similar to 1226 100 cardiotrophin-like cytokine; neurotrophin-1/B-cell stimulating factor-3 2196 gil6356643 Homo sapiens cardiotrophin-like cytokine 1226 100 2196 gi6007643 Homo sapiens neurotrophin-1/B-cell 1226 100 stimulating factor-3 2197 gil5982236 Mus musculus putative methionyl 1069 92 aminopeptidase 2197 gi23306398 Arabidopsis thaliana , putative 739 50 2197 gi24899771 Arabidopsis thaliana , putative 739 50 2198 gi13592175 Leishmania major AC084329_1 ppg3 196 24 2198 gi28828184 Dictyostelium similar to Leishmania major. 180 24 discoideum Ppg3 2198 gi5420387 Leishmania major proteophosphoglycan 202 24 2199 gil9387136 Homo sapiens AF479748_1 PYRIN- 4151 91 containing APAFI-like protein 5 2199 gi21410402 Mus musculus PYRIN-containing APAFI-like 1191 54 protein 5 2199 g28436366 Homo sapiens NALP6 4151 91 2200 gil1321325 Homo sapiens AF311862 1 Lin-7b 684 98 2200 gi20381193 Homo sapiens Lin-7b protein; likely ortholog 684 98 of mouse LIN-7B; mammalian LIN-7 protein 2 2200 gi3885828 Rattus norvegicus lin-7-A 673 96 2201 gil4349125 Homo sapiens alpha2-glucosyltransferase 567 97 2201 gi32490259 Oryza sativa OSJNBbOI16KO7.1 181 46 (japonica cultivar group) 2201 gi3513451 Rattus norvegicus potassium channel regulator 1 549 96 2202 gi13325140 Homo sapiens AAH04383 2693 100 2202 gi35768 Homo sapiens polypirimidine tract binding 2693 100 protein 2202 gi35774 Homo sapiens 2693 100 2203 gi21522776 Homo sapiens unnamed protein product 2998 98 2203 gi24047224 Homo sapiens Similar to EGF-like-domain, 2982 98 multiple 6 2203 gi6752658 Homo sapiens AF1860841 epidermal growth 2984 98 factor repeat containing protein 2204 gi21522776 Homo sapiens unnamed protein product 2998 98 2204 gi24047224 Homo sapiens Similar to EGF-like-domain, 2982 98 multiple 6 2204 gi6752658 Homo sapiens AF1860841 epidermal growth 2984 98 factor repeat containing protein 2205 gil1385648 Homo sapiens AF273045_1 CTCL tumor 3622 95 antigen sel4-3 2205 gi17980969 Homo sapiens AF454056 1 se14-3r protein 3858 95 2205 gi29165763 Mus musculus 3632413B07Rik protein 3261 75 WO 2004/080148 PCT/US2003/030720 266 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity 2206 gi11385648 Homo sapiens AF273045_1 CTCL tumor 3622 95 antigen sel4-3 2206 gil7980969 Homo sapiens AF454056_1 se14-3r protein 3858 95 2206 gi29165763 Mus musculus 3632413BO7Rik protein 3261 75 2207 gil1385648 Homo sapiens AF273045 1 CTCL tumor 3622 95 antigen se14-3 2207 gil7980969 Homo sapiens AF454056 1 sel4-3r protein 3858 95 2207 gi29165763 Mus musculus 3632413B07Rik protein 3261 75 2208 gil1385648 Homo sapiens AF273045_1 CTCL tumor 3622 95 antigen sel4-3 2208 gil7980969 Homo sapiens AF454056_1 sel4-3r protein 3858 95 2208 gi29165763 Mus musculus 3632413BO7Rik protein 3261 75 2209 gil4043211 Homo sapiens AAH07594 Similar to RIKEN 975 97 cDNA 4931428F04 gene 2209 gi21750866 Homo sapiens unnamed protein product 975 97 2209 gi25058997 Mus musculus 11 10003N12Rik protein 641 62 2210 gi19387136 Homo sapiens AF479748_1 PYRIN- 3078 100 containing APAF1-like protein 5 2210 gi202806 Rattus norvegicus vasopressin receptor 969 67 2210 gi28436366 Homo sapiens NALP6 3078 100 2211 gi13157560 Homo sapiens 2246 99 2211 gil8147612 Homo sapiens metalloprotease disintegrin 2246 99 2211 gi21908030 Homo sapiens a disintegrin and 2230 98 metalloprotease domain 33 2212 gil3592175 Leishmaniamajor AC084329_1 ppg3 163 34. 2212 gil5145803 Chlamydomonas hydroxyproline-rich 150 28 reinhardtii glycoprotein VSP4 2212 gi5420387 Leishmania major proteophosphoglycan 157 32 2213 gil5420879 Mus musculus AF3989711 ankyrin repeat- 1986 83 containing SOCS box protein 10 2213 gil8031949 Mus musculus SOCS box protein ASB-18 808 44 2213 gil8092200 Homo sapiens AF417920 I ASB-10 2062 91 2214 gi32707 Homo sapiens interferon-omega 1 331 51 2214 gi386800 Homo sapiens interferon-alpha 334 51 2214 gi491284 synthetic construct IFN-pseudo-omega 2 806 99 2215 gi6841550 Homo sapiens AF161513 I HSPC164 1594 99 2215 gi6841560 Homo sapiens AF161518 1 HSPC169 1604 100 2215 gi9844577 Homo sapiens 1601 99 2216 gil1493483 Homo sapiens AF130117_48 PR02550 408 79 2216 gi1872200 Homo sapiens alternatively spliced product 352 74 using exon 13A 2216 gi7020440 Homo sapiens unnamed protein product 396 76 2217 gi22658418 Mus nusculus cDNA sequence BC030934 365 71 2217 gi28838433 Homo sapiens DKFZp762A2013 protein 443 87 2217 gi30842594 Homo sapiens putative sulfhydryl oxidase 360 74 precursor 2218 gil2958660 Homo sapiens AF321918 1 acid phosphatase 573 89 2218 gil2958663 Homo sapiens AF321918_4 acid phosphatase 573 89 variant 3 2218 gi202934 Rattus norvegicus 207 43 2219 gil5866260 Homo sapiens AF411132 I MRIP2 2479 97 2219 gi29476839 Homo sapiens Similar to centaurin, gamma 2 2124 98 WO 2004/080148 PCT/US2003/030720 267 TABLE 2 B SEQID HitID Species Description Sscore Percentage_ Identity 2219 gi30354556 Homo sapiens MRIP2 protein 2466 97 2220 gil5866260 Homo sapiens AF411132_1 MRIP2 2479 97 2220 gi29476839 Homo sapiens Similar to centaurin, gamma 2 2124 98 2220 gi30354556 Homo sapiens MRIP2 protein 2466 97 2221 gi15866260 Homo sapiens AF411132 I MRIP2 2479 97 2221 gi29476839 Homo sapiens Similar to centaurin, gamma 2 2124 98 2221 gi30354556 Homo sapiens MRIP2 protein 2466 97 2222 gil5866260 Homo sapiens AF411132 1 MRIP2 2479 97 2222 gi29476839 Homo sapiens Similar to centaurin, gamma 2 2124 98 2222 gi30354556 Homo sapiens MRIP2 protein 2466 97 2223 gil841702 Macaca fascicularis fertilin alpha-I isoform 655 83 2223 gi2632092 Pongo pygmaeus fertilin alpha protein 745 94 2223 gi2655944 Papio anubis fertilin alpha-I 661 85 2224 gi17887359 Oryctolagus lipophilin AL2 248 54 cuniculus 2224 gi4107229 Homo sapiens lipophilin A 454 100 2224 gi4107231 Homo sapiens lipophilin B 267 60 2225 gil80251 Homo sapiens precerebellin 183 48 2225 gi6942096 Mus musculus CBLN3 472 90 2225 gi6942098 Mus musculus AF218380 1 CBLN3 472 90 2226 gil8255724 Mus musculus LOC215928 protein 131 28 2226 gi21750370 Homo sapiens unnamed protein product 917 85 2226 gi28460663 Rattus norvegicus Na+ dependent glucose 185 30 transporter 1 2227 gil8255724 Mus musculus LOC215928 protein 131 28 2227 gi21750370 Homo sapiens unnamed protein product 917 85 2227 gi28460663 Rattus norvegicus Na+ dependent glucose 185 30 transporter 1 2228 gi5726236 multiple sclerosis gag polyprotein 173 53 associated retrovirus element 2228 gi5726238 multiple sclerosis AF123881_1 gag polyprotein 163 57 associated retrovirus element 2228 gi8272464 Homo sapiens AF156961_1 gag 191 56 2229 gil2964746 Mus musculus AF316612 1 neuronal 2225 88 pentraxin receptor 2229 gi2253263 Rattus norvegicus neuronal pentraxin receptor 2250 88 2229 gi4160197 Homo sapiens 2559 99 2230 gi3170615 Mus musculus DOC4 1520 95 2230 gi4760782 Mus musculus Ten-m4 1520 95 2230 gi9909617 Gallus gallus teneurin-4 1333 89 2232 gi14124993 Homo sapiens 232 83 2232 gi30704639 Mus musculus 4930553F24Rik protein 210 74 2232 gi7716100 Rattus norvegicus AF226993_1 selective LIM 213 76 binding factor 2233 gi20987535 Mus musculus Mcoln2 protein 804 92 2233 gi24417793 Mus musculus mucolipin 2 804 92 2233 gi24417795 Homo sapiens mucolipin 2 857 99 2234 gi20987535 Mus musculus Mcoln2 protein 804 92 2234 gi24417793 Mus musculus mucolipin 2 804 92 2234 gi24417795 Homo sapiens mucolipin 2 857 99 2235 gi22477432 Homo sapiens DKFZP762N2316 protein 1002 100 2235 gi27370669 Homo sapiens Similar to REl-silencing 159 36 WO 2004/080148 PCT/US2003/030720 268 TABLE 2 B SEQ_ID HitID Species Description S score Percentage_ Identity transcription factor 2235 gi403020 Mus musculus En-2/lacZ fusion protein 330 92 2238 gil 1990126 Camelus chymosin 294 83 dromedarius 2238 gi491952 synthetic construct preprochymosin 291 83 2238 gi7008025 Callithrixjacchus prochymosin 314 91 2239 gi27356934 Homo sapiens extracellular sulfatase SULF-2 560 100 2239 gi27356938 Mus musculus extracellular sulfatase SULF-2 499 90 2239 gi29165845 Mus musculus Extracellular sulfatase SULF-1 375 70 2240 gi27124671 Homo sapiens Zn-carboxypeptidase 877 96 2240 gi2960072 Homo sapiens procarboxypeptidase B 488 55 2240 gi32880163 Homo sapiens 487 55 2241 gi27124671 Homo sapiens Zn-carboxypeptidase 877 96 2241 gi2960072 Homo sapiens procarboxypeptidase B 488 55 2241 gi32880163 Homo sapiens 487 55 2242 gil1545705 Homo sapiens ISCU 663 99 2242 gil1545707 Homo sapiens ISCU2 845 100 2242 gi20381021 Mus musculus Nifu-pending protein 807 96 2243 gil7512406 Mus musculus differential display and 188 52 activated by p53 2243 gi25166615 Homo sapiens AF223000_1 DDA3-like 427 56 protein 2243 gi25166621 Homo sapiens AF322891_1 DDA3-like 427 56 protein 2244 gil5990480 Homo sapiens -binding protein 2 1200 99 2244 gi21961217 Homo sapiens -binding protein 2 1200 99 2244 gi22213050 Mus musculus B230313N05Rik protein 1189 97 2245 gi204058 Rattus norvegicus extracellular signal-related 1497 62 kinase 3 2245 gi23903 Homo sapiens 63kDa protein kinase 2886 98 2245 gi27882123 Danio rerio Similar to mitogen-activated 1670 61 protein kinase 4 2246 gi24417711 Homo sapiens nesprin-2 354 100 2246 gi28195679 Homo sapiens nesprin-2 alpha 2 354 100 2246 gi28195681 Homo sapiens nesprin-2 beta 2 354 100 2248 gil9353133 Mus musculus Clq-like 560 80 2248 gi26996600 Mus musculus Similar to CIq-like 692 96 2248 gi32401227 Homo sapiens AF5253151 Clq-domain 711 99 containing protein 2249 gil4718648 Homo sapiens allantoicase 967 99 2249 gi20987689 Homo sapiens Similar to allantoicase 1162 99 2249 gi9255889 Mus musculus AF278712_I allantoicase 932 78 2250 gil5617341 Homo sapiens LAG-3 protein precursor 2796 99 2250 gi30851187 Homo sapiens LAG3 protein 1906 99 2250 gi579596 Homo sapiens lymphocyte protein 2634 98 2251 gil3810285 Rattus norvegicus guanine nucleotide 5807 91 release/exchange factor 2251 gi2522208 Homo sapiens Ras-GRF2 6407 99 2251 gi5882290 Homo sapiens Ras guanine nucleotide 6401 99 exchange factor 2 2252 gi22038159 Homo sapiens AF527605 1 zizimin1 7984 100 2252 gi28374168 Mus musculus AA959601 protein 7520 93 2252 gi31419757 Mus musculus AA959601 protein 7520 93 2253 gil0433672 Homo sapiens unnamed protein product 1325 89 WO 2004/080148 PCT/US2003/030720 269 TABLE 2 B SEQID HitID Species Description Sscore Percentage. Identity 2253 gi19263505 Homo sapiens hypothetical protein FLJ12242 1325 89 2253 gi23272394 Homo sapiens KCTD2 protein 728 67 2254 gi14041697 Homo sapiens 3330 94 2254 gi21594273 Homo sapiens 3371 95 2254 gi25303955 Homo sapiens 3371 95 2255 gil438532 Rattus norvegicus rAl 393 51 2255 gi1438534 Rattus norvegicus rA9 857 70 2255 gi9438033 Homo sapiens AF254411_1 ser/arg-rich pre- 386 51 mRNA splicing factor SR-Al 2256 gil438532 Rattus norvegicus rA1 393 51 2256 gil438534 Rattus norvegicus rA9 857 70 2256 gi9438033 Homo sapiens AF254411_1 ser/arg-rich pre- 386 51 mRNA splicing factor SR-Al 2257 gil872200 Homo sapiens alternatively spliced product 242 58 using exon 13A 2257 gi3002527 Homo sapiens neuronal thread protein AD7c- 283 59 NTP 2257 gi32486167 Homo sapiens AD7C-NTP 283 59 2258 gil2652851 Homo sapiens AAH00178 potassium channel 1987 100 modulatory factor 2258) gi26453336 Homo sapiens FIGCI 1983 99 2258 gi7677058 Homo sapiens AF1556521 potassium 1983 99 channel modulatory factor 2259 gi27695389 Mus musculus MGC58017 protein 1050 97 2259 gi28558964 Human herpesvirus 4 nuclear antigen-3B 138 28 type 2 2259 gi30481648 Homo sapiens 660 55 2260 gil 1119239 Rattus norvegicus AF313453,1 synaptotagmin 13 792 86 2260 gi14210274 Rattus norvegicus AF375466 1 synaptotagmin 13 792 86 2260 gi21410154 Mus musculus synaptotagmin 13 779 84 2261 gil 1342591 Mus musculus RanBP7/importin 7 5301 97 2261 gi32330683 Mus musculus importin 7 5313 97 2261 gi3800881 Homo sapiens RanBP7/importin 7 5333 98 2262 gi17939650 Homo sapiens AAH19302 hypothetical 3660 97 protein FLJ12525 2262 gil8676522 Homo sapiens FLJO0158 protein 1599 100 2262 gi27462078 Homo sapiens AFl 16730 1 MSTP060 3629 94 2263 gi28981429 Mus musculus Ddefl protein 879 94 2263 gi4063614 Mus musculus ADP-ribosylation factor- 879 94 directed GTPase activating protein isoform a 2263 gi4406393 Bos taurus differentiation enhancing factor 876 94 1 2264 gi59500 Human herpesvirus I RL2 139 37 2264 gi59557 Human herpesvirus I immediate early protein 139 37 2264 gi59833 Human herpesvirus I IE110 139 37 2265 gil3872813 Homo sapiens fibulin-6 513 29 2265 gi14575679 Homo sapiens AF156100 1 hemicentin 513 29 2265 gi9280405 Homo sapiens AF245505 1 adlican 1462 46 2266 gil5145797 Sus scrofa basic proline-rich protein 178 25 2266 gi27348769 Bradyrhizobium b1r0521 191 29 japonicum USDA 110 2266 gi30844278 Cercopithecine very large tegument protein 178 25 WO 2004/080148 PCT/US2003/030720 270 TABLE 2 B SEQ_ID HitID Species Description Sscore Pcrcentage Identity herpesvirus 1 2267 gi21748983 Homo sapiens unnamed protein product 128 65 2267 gi522145 Homo sapiens B-cell growth factor 129 71 2268 gi21748983 Homo sapiens unnamed protein product 128 65 2268 gi522145 Homo sapiens B-cell growth factor 129 71 2269 gil3529248 Homo sapiens Centrin 3 842 100 2269 gi30582215 Homo sapiens 842 100 2269 gi30584861 synthetic construct 842 100 2270 gi31455256 Homo sapiens IMAGE3510317 protein 2259 91 2270 gi32492907 Homo sapiens selenoprotein 0 2259 91 2270 gi6572230 Homo sapiens 1768 98 2271 gi31455256 Homo sapiens IMAGE3510317 protein 2259 91 2271 gi32492907 Homo sapiens selenoprotein 0 2259 91 2271 gi6572230 Homo sapiens 1768 98 2272 gi21928729 Homo sapiens seven transmembrane helix 661 99 receptor 2272 gi6693701 Homo sapiens AF147788 1 melanopsin 661 99 2272 gi6693703 Mus musculus AF147789_1 melanopsin 529 83 2273 gi20072741 Mus musculus E430025L02Rik protein 538 81 2273 gi2104856 Rattus norvegicus platelet glycoprotein V 143 41 2273 gi439296 Homo sapiens garp 166 43 2274 gil5487302 Homo sapiens medium-chain acyl-CoA 727 97 synthetase 2274 gil5706421 Homo sapiens middle-chain acyl-CoA 727 97 synthetase1 2274 gi5019275 Bos taurus xenobiotic/medium-chain fatty 529 70 acid:CoA ligase form XL-I1I 2275 gi15077826 Homo sapiens AF3947821 rap guanine 2149 100 nucleotide exchange factor 2275 gi20386206 Homo sapiens AF478567 1 PDZ domain- 2149 100 containing guanine nucleotide exchange factor PDZ-GEF2 2275 gi6650766 Homo sapiens AF117947_1 PDZ domain- 2149 100 containing guanine nucleotide exchange factor I 2276 gi15077826 Homo sapiens AF394782_1 rap guanine 2149 100 nucleotide exchange factor 2276 gi20386206 Homo sapiens AF478567 1 PDZ domain- 2149 100 containing guanine nucleotide exchange factor PDZ-GEF2 2276 gi6650766 Homo sapiens AF 17947 1 PDZ domain- 2149 100 containing guanine nucleotide exchange factor I 2277 gi13592175 Leishmania major AC084329 1 ppg3 165 29 2277 gi5420387 Leishmania major proteophosphoglycan 163 26 2277 gi5420389 Leishmania major proteophosphoglycan 151 30 2278 gil8676788 Homo sapiens unnamed protein product 875 88 2278 gi21779866 Mus musculus AF458068 1 IL-17RE 234 38 2278 gi21779869 Homo sapiens AF458069 1 IL-17RE 875 88 2279 gil8676788 Homo sapiens unnamed protein product 875 88 2279 gi21779866 Mus musculus AF458068 1 IL-17RE 234 38 2279 gi21779869 Homo sapiens AF458069 1 IL-17RE 875 88 2280 gi14150450 Rattus norvegicus AF241241 _1 UDP- 197 85 1_ _ 1_ _ _GaINAc:polypeptide N- II WO 2004/080148 PCT/US2003/030720 271 TABLE 2 B SEQID HitID Species Description S score Percentage_ Identity acetylgalactosaminyltransferase T9 2280 gi25809274 Homo sapiens polypeptide N- 219 97 acetylgalactosaminyltransferase 10 2280 gi28268676 Homo sapiens UDP-N-acetyl-alpha-D- 219 97 galactosamine:polypeptide N acetylgalactosaminyltransferase 10 2281 gil7384577 Escherichia coli orfl176 1087 99 2281 gi28629348 Escherichia coli SopA 1087 99 2281 gi42431 Escherichia coli 1087 99 2282 gi1377895 Homo sapiens OB-cadherin-2 540 51 2282 gi30171995 Homo sapiens cadherin-24 990 100 2282 gi30171998 Homo sapiens cadherin-24 variant 990 100 2283 gil377895 Homo sapiens OB-cadherin-2 540 51 2283 gi30171995 Homo sapiens cadherin-24 990 100 2283 gi30171998 Homo sapiens cadherin-24 variant 990 100 2284 gil398903 Mus musculus Ca2+ dependent activator 1303 89 protein for secretion 2284 gi21541504 Homo sapiens AF458662_1 calcium- 1185 83 dependent activator protein for secretion protein 2284 gi577428 Rattus norvegicus Ca2+-dependent activator 1247 85 protein; calcium-dependent actin-binding protein 2285 gil 1071729 Homo sapiens putative dipeptidase 526 100 2285 gil 1125344 Homo sapiens putative metallopeptidase 263 58 2285 gi32490515 Mus musculus putative membrane-bound 245 55 dipeptidase-3 2286 gil 1493652 Homo sapiens AF200708_1 calcium channel 2168 100 blocker resistance protein CCBRI 2286 gil3924720 Homo sapiens AF252872_1 eystine/glutamate 2168 100 transporter xCT 2286 gi15082352 Homo sapiens AAH12087 member 11 2168 100 2287 gi17028348 Homo sapiens DKFZP586G1517 protein 3748 100 2287 gi20987924 Mus musculus 2410004L15Rik protein 3473 92 2287 gi29612455 Mus musculus 2410004L15Rik protein 3819 92 2288 gil9352987 Homo sapiens Similar to KIAA0433 protein 6283 97 2288 gi2887437 Homo sapiens KIAA0433 6416 98 2288 gi31418648 Mus musculus 4916 95 2289 gi24061707 Mus musculus GAP-related interacting partner 766 88 to E12 2289 gi26334941 Mus musculus unnamed protein product 783 89 2289 gi4240257 Homo sapiens KIAA0884 protein 725 75 2290 gi20269957 Sus scrofa AF498759_1 phospholipase C 166 96 delta 4 2290 gi21307610 Mus musculus phospholipase C delta 4 158 90 2290 gi571466 Rattus norvegicus phospholipase C delta-4 151 84 2291 gi12839717 Mus musculus unnamed protein product 238 62 2291 gi16552885 Homo sapiens unnamed protein product 382 92 2291 gi26327387 Mus musculus unnamed protein product 238 62 2292 gil8480186 Mus musculus olfactory receptor MOR261-6 1330 81 WO 2004/080148 PCT/US2003/030720 272 TABLE 2 B SEQjD Hit_ID Species Description S score Percentage_ Identity 2292 gi32052343 Mus musculus olfactory receptor 1330 81 GA x6K02T2P3E9-4384160 4383228 2292 gi9368991 Homo sapiens 1397 99 2293 gi29791964 Homo sapiens Thrombospondin 4 2097 100 2293 gi311626 Homo sapiens thrombospondin-4 2090 99 2293 gi4895079 Mus musculus thrombospondin 4 2047 96 2294 gi24460119 Mus musculus AF32745 1_1 JNK-associated 6108 95 leucine-zipper protein 2294 gi24460121 Homo sapiens AF327452_1 JNK-associated 6282 98 leucine-zipper protein 2294 gi3116015 Homo sapiens sperm specific protein 3848 100 2295 gi21654741 Homo sapiens peptide/histidine transporter 2861 100 2295 gi2208839 Rattus norvegicus peptide/histidine transporter 2484 87 2295 gi33126130 Homo sapiens peptide/histidine transporter 2826 99 2296 gil9353264 Homo sapiens Similar to dishevelled 193 34 associated activator of morphogenesis 2 2296 gi2224703 Homo sapiens KIAA0381 291 50 2296 gi30268369 Homo sapiens hypothetical protein 291 50 2297 gi22760046 Homo sapiens unnamed protein product 918 95 2297 gi27769120 Homo sapiens Similar to hypothetical protein 918 95 FLJ30921 2297 gi33417243 Mus musculus B230312118Rik protein 621 62 2298 gi12655913 Homo sapiens AF227516 1 sprouty-4A 494 97 2298 gil2655915 Homo sapiens AF227517 I sprouty-4C 413 100 2298 gi29747900 Mus musculus Sprouty homolog 4 347 83 2299 gi29692498 Mus musculus NAAG-peptidase II 3438 87 2299 gi3211746 Sus scrofa folylpoly-gamma-glutamate 2813 70 carboxypeptidase 2299 gi4539525 Homo sapiens NAALADase II protein 3872 99 2300 gi21750009 Homo sapiens unnamed protein product 501 100 2300 gi23092685 Drosophila CG7020-PA 150 76 melanogaster 2300 gi23512248 Homo sapiens Similar to DISCO Interacting 238 56 Protein 2 2301 gi21410507 Mus musculus Plxnb2 protein 465 75 2301 gi6010211 Homo sapiens semaphorin receptor 225 47 2301 gi9885259 Homo sapiens AF149019 1 plexin-B3 228 47 2302 gil 1692802 Homo sapiens AF320294 I ABCG8 287 88 2302 gi15088540 Homo sapiens AF324494 I sterolin-2 287 88 2302 gi15146444 Homo sapiens AF351824 1 sterolin-2 287 88 2303 gil2652851 Homo sapiens AAH00178 potassium channel 1987 100 modulatory factor 2303 gi26453336 Homo sapiens FIGC1 1983 99 2303 gi7677058 Homo sapiens AF155652_1 potassium 1983 99 channel modulatory factor 2305 gi24430369 Mus musculus MMAC8 280 47 2305 gi31338848 Mus musculus MAIR-la 285 46 2305 gi31338850 Mus musculus MAIR-Ib 280 47 2306 gi31414326 Homo sapiens MHC class I antigen 1941 99 2306 gi33187148 Homo sapiens HLA-A2 1941 99 2306 gi403144 Homo sapiens MHC class I lymphocyte 1941 99 antigen WO 2004/080148 PCT/US2003/030720 273 TABLE 2 B SEQ_ID HitID Species Description Sscore Percentage Identity 2307 gi21667214 Homo sapiens AF465767_1 743 90 bactericidal/permeability increasing protein-like 3 2307 gi32490539 Homo sapiens RY2G5 191 29 2307 gi57732 Rattus rattus potential ligand-binding 231 32 protein 2308 gi21667214 Homo sapiens AF465767_1 743 90 bactericidal/permeability increasing protein-like 3 2308 gi32490539 Homo sapiens RY2G5 191 29 2308 gi57732 Rattus rattus potential ligand-binding 231 32 protein 2309 gi21667214 Homo sapiens AF465767_1 743 90 bactericidal/permeability increasing protein-like 3 2309 gi32490539 Homo sapiens RY2G5 191 29 2309 gi57732 Rattus rattus potential ligand-binding 231 32 protein 2310 gi21667214 Homo sapiens AF465767_1 743 90 bactericidal/permeability increasing protein-like 3 2310 gi32490539 Homo sapiens RY2G5 191 29 2310 gi57732 Rattus rattus potential ligand-binding 231 32 protein 2311 gil3529158 Homo sapiens AAH05349 1137 99 2311 gi529514 Sus scrofa neuronal endocrine protein 1073 94 2311 gi7718079 Homo sapiens neuroendocrine protein 7B2 1129 99 2312 gil5029903 Mus musculus Similar to proline-rich protein 175 31 BstNI subfamily 2 2312 gi31746553 Caenorhabditis Collagen protein 51 171 35 elegans 2312 gi32698037 Caenorhabditis 174 33 elegans 2313 gil3543081 Mus musculus claudin 6 822 70 2313 gi4128041 Homo sapiens claudin-9 protein 1116 100 2313 gi4325296 Mus musculus claudin-9 1078 95 2314 gil8676638 Homo sapiens FLJO0218 protein 574 95 2314 gi4587895 Rattus norvegicus AF0725091 glutamate 667 84 receptor interacting protein 2 2314 gi6601555 Rattus norvegicus glutamate receptor interacting 667 84 protein 2 2315 gi23496442 Rattus norvegicus disabled-1 2807 96 2315 gi3288852 Homo sapiens disabled-I 2865 99 2315 gi8118615 Homo sapiens AF263547 1 disabled-1 2842 99 2316 gil6877456 Homo sapiens AAH16974 493 100 2316 gi20810324 Homo sapiens 493 100 2316 gi26351033 Mus musculus unnamed protein product 444 91 2317 gil5430703 Homo sapiens AF362953_1 testis specific 1854 99 serine/threonine kinase 2 2317 gi2738898 Mus musculus protein kinase 1684 89 2317 gi33590489 Rattus norvegicus serine/threonine kinase 22B 1755 92 2318 gil2963879 Homo sapiens prostaglandin D synthase 998 100 2318 gil3543568 Homo sapiens PTGDS protein 998 100 2318 gil89772 Homo sapiens prostaglandin D2 synthase 998 100 WO 2004/080148 PCT/US2003/030720 274 TABLE 2 B SEQjD HitID Species Description Sscore Percentage Identity 2319 gil4336718 Homo sapiens AE006464 18 similar to 656 99 HAGH 2319 gil4336766 Homo sapiens AE006639_8 339 47 hydroxyacylglutathione hydrolase 2319 gi20988885 Mus musculus 2810014I23Rik protein 583 78 2320 gil3397835 Homo sapiens annexin A13 isoform b 1245 98 2320 gi33980 Homo sapiens intestine-specific annexin 1252 98 2320 gi757784 Canis familiaris annexin XIIIb 1151 91 2321 gi204222 Rattus norvegicus GABA transporter protein 2124 90 2321 gi21707908 Homo sapiens , member 1 2132 99 2321 gi31658 Homo sapiens GABA transporter 2117 99 2323 gi20381266 Homo sapiens Glypican 2 602 90 2323 gi440127 Rattus norvegicus cerebroglycan 548 81 2323 gi5911318 Homo sapiens AF105267_1 glypican-6 265 47 2324 gil8676470 Homo sapiens FLJ00132 protein 1361 100 2324 gil9344068 Mus musculus 2700038E08Rik protein 2403 74 2324 gi23274106 Mus musculus 2700038E08Rik protein 2403 74 2325 gi25396387 Homo sapiens alpha 2,6-sialyltransferase 467 98 2325 gi27650880 Homo sapiens beta-galactoside alpha-2,6- 467 98 sialyltransferase 2325 gi452751 Gallus gallus Gal beta 1,4 GlcNAc alpha 2,6- 268 58 sialyltransferase 2326 gil3344995 Homo sapiens Cat Eye Syndrome critical 2004 99 region protein isoform 1 2326 gil3344997 Homo sapiens Cat Eye Syndrome critical 2001 100 region protein isoform 2 2326 gi27503696 Homo sapiens Similar to cat eye syndrome 2001 100 chromosome region, candidate 5 2327 gil3344995 Homo sapiens Cat Eye Syndrome critical 2004 99 region protein isoform I 2327 gi13344997 Homo sapiens Cat Eye Syndrome critical 2001 100 region protein isoform 2 2327 gi27503696 Homo sapiens Similar to cat eye syndrome 2001 100 chromosome region, candidate 5 2328 gi202592 Rattus norvegicus prealpha-2-macroglobulin 238 40 2328 gi671864 Gallus gallus ovomacroglobulin, ovostatin 230 40 2328 gi671865 Gallus gallus ovomacroglobulin, ovostatin 230 40 2329 gi202592 Rattus norvegicus prealpha-2-macroglobulin 238 40 2329 gi671864 Gallus gallus ovomacroglobulin, ovostatin 230 40 2329 gi671865 Gallus gallus ovomacroglobulin, ovostatin 230 40 2330 gi202592 Rattus norvegicus prealpha-2-macroglobulin 238 40 2330 gi671864 Gallus gallus ovomacroglobulin, ovostatin 230 40 2330 gi671865 Gallus gallus ovomacroglobulin, ovostatin 230 40 2331 gi202592 Rattus norvegicus prealpha-2-macroglobulin 238 40 2331 gi671864 Gallus gallus ovomacroglobulin, ovostatin 230 40 2331 gi671865 Gallus gallus ovomacroglobulin, ovostatin 230 40 2332 gi202592 Rattus norvegicus prealpha-2-macroglobulin 238 40 2332 gi671864 Gallus gallus ovomacroglobulin, ovostatin 230 40 2332 gi671865 Gallus gallus ovomacroglobulin, ovostatin 230 40 2333 gil4789873 Mus musculus Es3l protein 508 70 2333 gil7512361 Mus musculus esterase 31 508 70 WO 2004/080148 PCT/US2003/030720 275 TABLE 2 B SEQID HitID Species Description Sscore Percentage Identity 2333 gi29476863 Mus musculus Similar to esterase 31 516 69 2334 gil9909128 Homo sapiens AF489528_1 transforming 189 100 growth factor-beta binding protein-I S 2334 gi207286 Rattus norvegicus TGF-beta masking protein 179 90 large subunit 2334 gi339548 Homo sapiens transforming growth factor- 189 100 beta 1 binding protein precursor 2336 gil388158 Gallus gallus myomesin 429 37 2336 gi31418212 Homo sapiens Myomesin 2 439 36 2336 gi407097 Homo sapiens 165kD protein 439 36 2339 gil2655442 Homo sapiens keratin associated protein 4.2 706 86 2339 gil2655460 Homo sapiens keratin associated protein 4.12 732 86 2339 gil2655464 Homo sapiens keratin associated protein 4.15 761 99 2340 gil2655442 Horno sapiens keratin associated protein 4.2 706 86 2340 gi12655460 Homo sapiens keratin associated protein 4.12 732 86 2340 gil2655464 Homo sapiens keratin associated protein 4.15 761 99 2341 gil2655442 Homo sapiens keratin associated protein 4.2 706 86 2341 gil2655460 Homo sapiens keratin associated protein 4.12 732 86 2341 gil2655464 Homo sapiens keratin associated protein 4.15 761 99 2342 gil5722084 Homo sapiens 1930 99 2342 gi434306 Homo sapiens lysosomal acid lipase; sterol 1288 63 esterase 2342 gi506431 Homo sapiens lysosomal acid lipase 1288 63 2343 gil5722084 Homo sapiens 1930 99 2343 gi434306 Homo sapiens lysosomal acid lipase; sterol 1288 63 esterase 2343 gi506431 Homo sapiens lysosomal acid lipase 1288 63 2344 gi20152322 Homo sapiens putative G-protein coupled 1570 100 receptor 2344 gi32526601 Homo sapiens GPRC5D 1576 100 2344 gi8118040 Homo sapiens AF209923_1 orphan G-protein 1570 100 coupled receptor 2345 gil7224598 Homo sapiens AF293615 1 blood dendritic 1147 95 cell antigen 2 protein 2345 gil7225337 Homo sapiens AF325459 1 dendritic lectin 1147 95 2345 gil7225339 Homo sapiens AF325460_1 dendritic lectin b 953 82 isoform 2346 gil7224598 Homo sapiens AF293615_1 blood dendritic 1147 95 cell antigen 2 protein 2346 gil7225337 Homo sapiens AF325459_1 dendritic lectin 1147 95 2346 gil7225339 Homo sapiens AF325460 1 dendritic lectin b 953 82 isoform 2347 gi21929119 Homo sapiens seven transmembrane helix 1588 100 receptor 2347 gi2792016 Homo sapiens olfactory receptor 1393 100 2347 gi4092819 Homo sapiens BC319430 5 1386 100 2348 gi2589172 Rattus norvegicus mucin Muc3 308 36 2348 gi28436742 Mus musculus Muc3 protein 295 37 2348 gi5911169 Homo sapiens AF147790 1 transmembrane 719 81 mucin 12 2349 gi3549152 Homo sapiens R29124 1 180 36 2349 gi8101840 Papio hamadryas AF259559_1 182 35 1 1___1 _____ Icarcinoembryonic antigen- WO 2004/080148 PCT/US2003/030720 276 TABLE 2 B SEQ_ID HitID Species Description S score Percentage_ Identity family cell adhesion molecule w; CEACAMw 2349 gi8101856 Cercopithecus AF259567_1 179 33 aethiops carcinoembryonic antigen family cell adhesion molecule 1-1; CEACAM1 2350 gi27924102 Mus musculus 2310075M15Rik protein 944 68 2350 gi29436830 Mus musculus 2310075M15Rik protein 944 68 2350 gi6273399 Homo sapiens AF200348_1 melanoma- 940 67 associated antigen MG50 2351 gi27924102 Mus musculus 2310075M15Rik protein 944 68 2351 gi29436830 Mus musculus 2310075M15Rik protein 944 68 2351 gi6273399 Homo sapiens AF200348_1 melanoma- 940 67 associated antigen MG50 2352 gil0435776 Homo sapiens unnamed protein product 1132 99 2352 gi32451585 Homo sapiens 681 60 2352 gi7264653 Mus musculus AF180470 1 Kiaa0575 694 62 2353 gi20219008 Chlamydomonas AF394181 1 coiled-coil 280 29 reinhardtii flagellar protein 2353 gi23497711 Plasmodium AE01482649 rhoptry protein, 149 25 falciparum 3D7 putative 2353 gi5457791 Pyrococcus abyssi smcl chromosome segregation 150 22 protein 2354 gi12654511 Homo sapiens Torsin family 3, member A 1438 100 2354 gil4043167 Homo sapiens Torsin family 3, member A 1438 100 2354 gil5079904 Homo sapiens Torsin family 3, member A 1438 100 2356 gil5076843 Homo sapiens AF233450_1 pecanex-like 948 72 protein 1 2356 gil8157547 Mus musculus AF237953_1 pecanex-like 3 1325 98 2356 gi6650377 Mus musculus AF096286_1 pecanex 1 948 71 2357 gi15076843 Homo sapiens AF2334501 pecanex-like 948 72 protein 1 2357 gil8157547 Mus musculus AF2379531 pecanex-like 3 1325 98 2357 gi6650377 Mus musculus AF096286_1 pecanex 1 948 71 2358 gi1872200 Homo sapiens alternatively spliced product 298 72 using exon 13A 2358 gi2580578 Homo sapiens ubiquitous TPR motif, Y 301 70 isoform 2358 gi8572229 Homo sapiens ubiquitous TPR-motif protein 301 70 Y isoform 2359 gi12043567 Homo sapiens unc-93 related protein 1544 97 2359 gil7390915 Mus musculus unc93 homolog B 1350 85 2359 gi23271746 Mus musculus Unc93b protein 1350 85 2360 gil5990461 Homo sapiens AAH15612 ring finger protein 2465 100 25 2360 gi18490513 Mus musculus Rnf25 protein 1983 82 2360 gi29179411 Mus musculus Ring finger protein 25 1988 82 2361 gil4714684 Mus musculus 2810423E13Rik protein 632 83 2361 gi33086578 Rattus norvegicus Ab2-276 385 82 2361 gi7295255 Drosophila CG8596-PA 307 46 melanogaster 1 2362 gil6930383 Pan troglodytes AF3831691 leukocyte 172 38 immunoglobulin-like receptor e 2362 gi32396010 Bos taurus immunoglobulin A Fc receptor 179 33 WO 2004/080148 PCT/US2003/030720 277 TABLE 2 B SEQjD HitID Species Description S score Percentage. Identity 2362 gi6563042 Homo sapiens AF1096831 leukocyte- 179 24 associated Ig-like receptor lb 2363 gil6930383 Pan troglodytes AF3831691 leukocyte 172 38 immunoglobulin-like receptor e 2363 gi32396010 Bos taurus immunoglobulin A Fc receptor 179 33 2363 gi6563042 Homo sapiens AF1096831 leukocyte- 179 24 associated Ig-like receptor lb 2364 gi21595190 Mus musculus 251000lA17Rik protein 366 98 2364 gi21707128 Homo sapiens Ran binding protein 11 370 100 2364 gi6650612 Homo sapiens AF111109 1 Ran binding 370 100 protein 11 2367 gil1493419 Homo sapiens AF130117 15 PRO1367 128 51 2367 gi6690223 Homo sapiens AF090928_1 PR00470 118 50 2367 gi6855613 Homo sapiens AF113685 1 PR00974 154 51 2369 gi3002527 Homo sapiens neuronal thread protein AD7c- 404 48 NTP 2369 gi32486167 Homo sapiens AD7C-NTP 404 48 2369 gi6650810 Homo sapiens AF118094 21 PRO1902 258 64 2370 gil3278391 Mus musculus RIKEN eDNA 9430015G1O 595 71 2370 gil4250646 Homo sapiens FLJ20584 protein 803 98 2370 gi7020791 Homo sapiens unnamed protein product 834 99 2371 gil6588454 Homo sapiens AF312374 1 AGTRAP protein 823 100 2371 gil6878260 Homo sapiens AAH17328 Similar to 776 95 angiotensin II, type I receptor associated protein 2371 gi9621816 Homo sapiens AF165187 I ATRAP 822 99 2372 gil2330704 Mus musculus AF333770 I cell recognition 539 82 molecule CASPR4 2372 gil7986216 Homo sapiens AF333769_1 cell recognition 633 97 molecule CASPR3 2372 gi21961652 Mus musculus contactin associated protein 4 539 82 2373 gil2330704 Mus musculus AF333770_I cell recognition 539 82 molecule CASPR4 2373 gil7986216 Homo sapiens AF333769_1 cell recognition 633 97 molecule CASPR3 2373 gi21961652 Mus musculus contactin associated protein 4 539 82 2374 gi11041469 Macaca fascicularis UDP-GalNAc: polypeptide N- 1116 63 acetylgalactosaminyltransferase 2374 gi21552746 Homo sapiens AF4104571 putative 1670 100 polypeptide N acetylgalactosaminyltransferase 2374 gi21552969 Mus musculus AF467979 I Williams-Beuren 1656 98 syndrome critical region gene 17 2375 gil6198335 Drosophila SD08329p 411 47 melanogaster 2375 gi23092707 Drosophila CG17090-PA 411 47 melanogaster 2375 gi23092708 Drosophila CG17090-PB 411 47 melanogaster 2377 gil4571502 Homo sapiens calcium-promoted Ras 1022 81 inactivator 2377 gil5680152 Homo sapiens AAH14420 317 41 2377 gi4185294 Homo sapiens rasGAP-activating-like protein 289 36 2379 gil5128105 Mus musculus AF397008_1 nephronectin 737 82 WO 2004/080148 PCT/US2003/030720 278 TABLE 2 B SEQID Hit_ID Species Description S score Percentage_ Identity 2379 gil5430246 Mus musculus nephronectin short isoform 737 82 2379 gil5430248 Mus musculus nephronectin long isoform 737 82 2380 gil6041675 Homo sapiens AAH15704 joined to JAZF1 2131 99 2380 gil7862954 Drosophila SD04959p 311 31 melanogaster 2380 gi28839713 Homo sapiens Similar to joined to JAZF1 363 81 2381 gi29387355 Xenopus laevis 263 28 2381 gi3242649 Rana catesbeiana alpha 1 type I collagen 297 28 2381 gi4140029 Cynops pyrrhogaster alpha 1 type I collagen 277 27 2382 gi32967231 Homo sapiens TAFA3 481 100 2382 gi32967237 Homo sapiens TAFA3.2 619 100 2382 gi32967243 Mus musculus TAFA3 390 82 2383 gi32967231 Homo sapiens TAFA3 481 100 2383 gi32967237 Homo sapiens TAFA3.2 619 100 2383 gi32967243 Mus musculus TAFA3 390 82 2384 gil0443967 Homo sapiens AF268610_1 THEG protein 298 60 2384 gi20306274 Homo sapiens testicular haploid expressed 298 60 gene 2384 gi7416134 Homo sapiens testis-specific gene 298 60 2385 gil8480746 Mus musculus olfactory receptor MOR261-10 1336 80 2385 gi21928655 Homo sapiens seven transmembrane helix 1427 90 receptor 2385 gi32052225 Mus musculus olfactory receptor 1336 80 GAx6K02T2P3E9-4341246 4340281 2386 gil8480746 Mus musculus olfactory receptor MOR261-10 1336 80 2386 gi21928655 Homo sapiens seven transmembrane helix 1427 90 receptor 2386 gi32052225 Mus musculus olfactory receptor 1336 80 GA x6K02T2P3E9-4341246 4340281 2387 gil3937888 Homo sapiens AAH07052 Similar to 196 97 heterogeneous nuclear ribonucleoprotein C 2387 gi337455 Homo sapiens hnRNP C2 protein 196 97 2387 gi4139188 Mus musculus heterogeneous nuclear 190 95 ribonucleoprotein C1/C2; hnRNP C1/C2 2388 gil90259 Homo sapiens neuron-specific protein 335 100 2388 gi190261 Homo sapiens 21 kDa protein 335 100 2388 gi56877 Rattus norvegicus reading frame 1 331 98 2389 gil4573319 Homo sapiens AF334755_1 interleukin-1 818 100 HY2 2389 gil4573321 Homo sapiens AF334756_1 interleukin-1 818 100 HY2 2389 gil8025344 Homo sapiens interleukin-1 receptor 804 98 antagonist-like FILl theta 2390 gi27694303 Homo sapiens Similar to keratin, hair, acidic, 694 69 6 2390 gi3724099 Homo sapiens type I hair keratin 1 692 69 2390 gi3724114 Homo sapiens type I hair keratin 6 694 69 2391 gi32488718 Oryza sativa OSJNBaOO88HO9.19 121 41 (japonica cultivar group) WO 2004/080148 PCT/US2003/030720 279 TABLE 2 B SEQID Hit_ID Species Description Sscore Percentage Identity 2393 gil4595019 Homo sapiens keratin 6 irs 362 98 2393 gi27901522 Homo sapiens keratin 6 irs3 361 98 2393 gi27901524 Homo sapiens keratin 6 irs4 353 95 2394 gil1066090 Homo sapiens AF195192_1 matrix 507 100 metalloprotease MMP-27 2394 gi12006364 Tupaia belangeri AF281673_1 matrix 458 91 metalloproteinase-27 2394 gi3511149 Gallus gallus matrix metalloproteinase 353 60 2395 gil1066090 Homo sapiens AF195192_1 matrix 507 100 metalloprotease MMP-27 2395 gi12006364 Tupaia belangeri AF281673_1 matrix 458 91 metalloproteinase-27 2395 gi3511149 Gallus gallus matrix metalloproteinase 353 60 2396 gi24710913 Homo sapiens suppressor of fused 2599 100 2396 gi5739507 Homo sapiens AF1757701 suppressor of 2594 99 fused 2396 gi6689894 Homo sapiens AF1594471 Suppressor of 2599 100 Fused 2397 gi20387087 Oncorhynchus like-2 155 32 mykiss 2397 gi21667212 Homo sapiens AF465766_1 535 100 bactericidal/permeability increasing protein-like 2 2397 gi28173296 Cyprinus carpio bactericidal permeability- 161 36 increasing protein/lipopolysaccharide binding protein 2398 gil9526647 Homo sapiens AF462348 I oxidored-nitro 2019 99 domain-containing protein 2398 gi28175624 Mus musculus RIKEN cDNA 1810007P19 1704 86 gene 2398 gi7303522 Drosophila CG13178-PA 214 29 melanogaster 2399 gi19526647 Homo sapiens AF462348_1 oxidored-nitro 2019 99 domain-containing protein 2399 gi28175624 Mus musculus RIKEN cDNA 1810007P19 1704 86 gene 2399 gi7303522 Drosophila CG13178-PA 214 29 melanogaster 2400 gi2072977 Homo sapiens putative p150 151 100 2400 gi339771 Homo sapiens ORF2 151 100 2400 gi339777 Homo sapiens ORF2 contains a reverse 151 100 transcriptase domain. 2402 gil1493483 Homo sapiens AF130117 48 PR02550 303 64 2402 gi7020440 Homo sapiens unnamed protein product 310 57 2402 gi7770139 Homo sapiens AF119917_13 PRO1722 289 60 2404 gi1403325 Homo sapiens MACH-beta-1 122 92 2404 gil403327 Homo sapiens MACH-beta-2 122 92 2405 gil799570 Rattus norvegicus TIP120 6200 99 2405 gi29792160 Homo sapiens TIP120 protein 6213 99 2405 gi7688703 Homo sapiens AF157326 1 TIP120 protein 6200 99 2406 gi13016701 Homo sapiens activating coreceptor NKp8O 1209 97 2406 gi22449867 Macaca fascicularis NKp8O NK receptor 1105 87 2406 gi7188567 Homo sapiens AF175206 1 lectin-like 1209 97 receptor Fl WO 2004/080148 PCT/US2003/030720 280 TABLE 2 B SEQID Hit ID Species Description S score Percentage Identity 2408 gi21619190 Homo sapiens -like 1X-linked 233 80 2408 gi27695407 Mus musculus Tbl1x protein 233 80 2408 gi30353941 Homo sapiens TBLIX protein 233 80 2409 gil2804613 Homo sapiens AAH01728 670 82 2409 gil3279113 Homo sapiens AAH04281 670 82 2409 gi14043598 Homo sapiens AAH07776 670 82 2410 gi12804613 Homo sapiens AAH01728 670 82 2410 gil3279113 Homo sapiens AAH04281 670 82 2410 gil4043598 Homo sapiens AAH07776 670 82 2411 gil2804613 Homo sapiens AAH01728 670 82 2411 gil3279113 Homo sapiens AAH04281 670 82 2411 gil4043598 Homo sapiens AAH07776 670 82 2412 gil3182755 Homo sapiens AF212237 1 HPHRP 1816 99 2412 gil5929309 Homo sapiens Phosphotriesterase related 1824 100 2412 gi29791939 Homo sapiens phosphotriesterase related 1824 100 2414 gi22539701 Mus musculus 4930506M07Rik protein 2153 93 2414 gi4778 Saccharomyces Usol protein 215 23 cerevisiae 2414 gi677198 Saccharomyces putative 217 23 cerevisiae 2415 gi27899969 Homo sapiens unnamed protein product 208 66 2415 gi27900262 Homo sapiens unnamed protein product 208 66 2415 gi6690248 Homo sapiens AF090942_1 PR00657 192 57 2419 gil3377880 Cricetulus AF3360431 arginine N- 2585 85 longicaudatus methyltransferase p82 isoform 2419 gil3377882 Cricetulus AF3360441 arginine N- 2534 86 longicaudatus methyltransferase p77 isoform 2419 gil3879453 Mus musculus cDNA sequence BC006705 2565 87 2420 gil6306618 Homo sapiens AAH01482 phosphatidylserine 1645 99 decarboxylase 2420 gi191185 Cricetulus griseus phosphatidylserine 1544 93 decarboxylase 2420 gi27371042 Xenopus laevis Similar to phosphatidylserine 958 57 decarboxylase 2421 gi30041 Homo sapiens COL2A1 122 28 2421 gi450394 Homo sapiens alpha-1 type II collagen 122 28 2421 gi930050 Homo sapiens 122 28 2422 gil3874437 Homo sapiens cerebral protein-11 159 75 2422 gi20987344 Mus musculus LOC212904 protein 618 69 2422 gi24980850 Homo sapiens 765 100 2423 gi13543940 Homo sapiens Hypothetical protein 2094 99 DKFZp434B195 2423 gil4035978 Homo sapiens unnamed protein product 2080 98 2423 gil6923351 Homo sapiens AF204270 1 RbBP-35 1419 98 2424 gil8676660 Homo sapiens FLJ00229 protein 665 99 2424 gi25955706 Homo sapiens Similar to hypothetical protein 665 99 MGC38041 2424 gi32484169 Homo sapiens 665 99 2425 gi27549552 Homo sapiens dipeptidyl peptidase IV-related 410 89 protein-2 2425 gi29293087 Homo sapiens dipeptidyl peptidase 9 410 89 2425 gi3513303 Homo sapiens R26984 1 476 100 2426 gi27549552 Homo sapiens dipeptidyl peptidase IV-related 410 89 protein-2 WO 2004/080148 PCT/US2003/030720 281 TABLE 2 B SEQ_ID HitID Species Description S score Percentage Identity 2426 gi29293087 Homo sapiens dipeptidyl peptidase 9 410 89 2426 gi3513303 Homo sapiens R26984 1 476 100 2427 gi27549552 Homo sapiens dipeptidyl peptidase IV-related 410 89 protein-2 2427 gi29293087 Homo sapiens dipeptidyl peptidase 9 410 89 2427 gi3513303 Homo sapiens R26984 1 476 100 2428 gi13097642 Homo sapiens Ribosomal protein S25 169 100 2428 gi13279149 Homo sapiens Ribosomal protein S25 169 100 2428 gil3436422 Homo sapiens Ribosomal protein S25 169 100 2429 gi21756739 Homo sapiens unnamed protein product 2539 96 2429 gi23270822 Homo sapiens 2427 96 2429 gi6453538 Homo sapiens hypothetical protein 2061 99 2430 gi12652695 Homo sapiens AAH00096 HtrA-like serine 1611 92 protease 2430 gi5870865 Homo sapiens serine protease 1611 92 2430 gi7672669 Homo sapiens AF1413051 serine protease 1611 92 Htra2 2431 gi24078514 Mus musculus AF454954_1 crossveinless-2 561 95 2431 gi32816043 Mus musculus BMP-binding endothelial 561 95 regulator precursor protein 2431 gi32892146 Homo sapiens crossveinless-2 595 100 2432 gi16502169 Salmonella enterica putative DNA methylase 756 85 subsp. enterica serovar Typhi 2432 gi29137981 Salmonella enterica putative DNA methylase 756 85 subsp. enterica serovar Typhi Ty2 2432 gi498768 Serratia marcescens Deoxyadenosyl- 337 47 metbyltransferase 2433 gil6974751 Gallus gallus CALII 184 44 2433 gil9908346 Gallus gallus chondrogenesis associated 137 37 lipocalin 2433 gi22090638 Gallus gallus lipocalin-type prostaglandin D 137 37 synthase 2434 gil7132791 Nostoc sp. PCC 7120 asparaginyl-tRNA synthetase 766 44 2434 gi22296200 Thermosynechococc asparaginyl-tRNA synthetase 767 41 us elongatus BP-1 2434 gi30259286 Bacillus anthracis str. asparaginyl-tRNA synthetase 774 43 Ames 2435 gi12655061 Homo sapiens AAH01380 532 88 2435 gi23574788 Macaca fascicularis succinate dehydrogenase 539 89 flavoprotein subunit 2435 gi5759173 Homo sapiens succinate dehydrogenase 532 88 flavoprotein subunit 2436 gi21928188 Mus musculus GPI-gamma 4; GPIgamma4 853 67 2436 gi29747988 Mus musculus GPI-gamma 4 853 67 2436 gi30931171 Mus musculus GPIgamma4 protein 853 67 2437 gi15082311 Homo sapiens AAH12061 -binding protein 3 631 98 2437 gi27503479 Mus musculus Pcbp3 protein 631 98 2437 gi9957165 Homo sapiens AF176329 1 alphaCP-3 631 98 2438 gil6553246 Homo sapiens unnamed protein product 254 98 2438 gi21739662 Homo sapiens hypothetical protein 218 88 2438 gi21752375 Homo sapiens unnamed protein product 218 88 2439 gil2804943 Homo sapiens AAH01924 beta 1660 90 WO 2004/080148 PCT/US2003/030720 282 TABLE 2 B SEQ ID Hit_ID Species Description S score Percentage Identity 2439 gi189762 Homo sapiens pyruvate dehydrogenase El- 1663 91 beta subunit 2439 gi190792 Homo sapiens pyruvate dehydrogenase El- 1663 91 beta subunit precursor 2440 gil64851 Oryctolagus calsequestrin precursor 1903 92 cuniculus 2440 gi2618621 Mus musculus skeletal muscle calsequestrin 1921 93 2440 gi688292 Homo sapiens calmitine; calsequestrine 2012 99 2441 gi1177622 Saccharomyces AOFIOO 177 30 cerevisiae 2441 gi13592175 Leishmania major AC084329 1 ppg3 193 26 2441 gi28828184 Dictyostelium similar to Leishmania major. 192 26 discoideum Ppg3 2442 gi20380863 Homo sapiens Similar to T cell receptor beta 1364 84 locus 2442 gi307487 Homo sapiens T-cell receptor beta 1498 93 2442 gi8515902 Homo sapiens T cell receptor beta chain 1300 84 2444 gil4599484 Homo sapiens AF3339521 small proline-rich 453 98 protein 2B 2444 gi3367693 Homo sapiens small proline-rich protein 458 100 2444 gi385227 Homo sapiens small proline-rich protein 2 453 98 2445 gil3876336 Mus musculus protocadherin gamma A5 4081 84 2445 gi5456942 Homo sapiens protocadherin gamma A5 4744 99 2445 gi5457072 Homo sapiens AF1525121 protocadherin 4109 100 gamma A5 short form protein 2447 gi200962 Mus musculus serine I ultra high sulfur 262 45 protein 2447 gi200964 Mus musculus serine 2 ultra high sulfur 296 49 protein 2447 gi3228237 Homo sapiens ultra high sulfer keratin 261 48 2448 gi14764499 Homo sapiens zinc finger protein 849 66 2448 gi1504006 Homo sapiens similarto human ZFY protein. 442 36 2448 gi28204954 Mus musculus Similar to zinc finger protein 771 70 2450 gil7223709 Homo sapiens selenoprotein SelM 235 100 2450 gil7223711 Mus musculus selenoprotein SeIM 188 78 2450 gi26351995 Mus musculus unnamed protein product 162 76 2451 gi28848644 Homo sapiens p02 protein 181 100 2451 gi30354510 Homo sapiens TPTI protein 181 100 2451 gi33285832 Homo sapiens TCTP 181 100 2452 gil3937829 Homo sapiens AAH07016 946 100 2452 gil8606299 Homo sapiens 946 100 2452 gi3360432 Homo sapiens osteopontin 946 100 2453 gil4326586 Homo sapiens AF386078_1 serine-cysteine 360 92 proteinase inhibitor clade C member 1 2453 gil79130 Homo sapiens antithrombin III 360 92 2453 gil8490839 Homo sapiens , member 1 360 92 2454 gi37231 Homo sapiens DNA topoisomerase II 8439 99 2454 gi3869382 Homo sapiens DNA topoisomerase II beta 8299 99 2454 gi790988 Cricetulus 8167 96 longicaudatus 2455 gil881713 Rattus norvegicus fatty acid transport protein 222 84 2455 gi20810561 Mus musculus , member 1 219 82 |2455 gi563829 Mus musculus fatty acid transport protein 219 82 WO 2004/080148 PCT/US2003/030720 283 TABLE 2 B SEQjD HitID Species Description Sscore Percentage Identity 2456 gil3277626 Mus musculus homolog, subunit 7a 247 57 2456 gil5215085 Mus musculus Cops7b protein 428 98 2456 gi3309176 Mus musculus COP9 complex subunit 7b 428 98 2457 gi180251 Homo sapiens precerebellin 183 48 2457 gi6942096 Mus musculus CBLN3 472 90 2457 gi6942098 Mus musculus AF218380_1 CBLN3 472 90 2458 gi17861952 Drosophila LD01947p 196 55 melanogaster 2458 gi31432182 Oryza sativa putative RIM2 protein 158 42 (japonica cultivar group) 2458 gi7291183 Drosophila CG1826-PA 196 55 melanogaster 2459 gi20387087 Oncorhynchus like-2 155 32 mykiss 2459 gi21667212 Homo sapiens AF465766_1 535 100 bactericidal/permeability increasing protein-like 2 2459 gi28173296 Cyprinus carpio bactericidal permeability- 161 36 increasing protein/lipopolysaccharide binding protein 2460 gi20387087 Oncorhynchus like-2 155 32 mykiss 2460 gi21667212 Homo sapiens AF465766_1 535 100 bactericidal/permeability increasing protein-like 2 2460 gi28173296 Cyprinus carpio bactericidal permeability- 161 36 increasing protein/lipopolysaccharide binding protein 2461 gi20387087 Oncorhynchus like-2 155 32 mykiss 2461 gi21667212 Homo sapiens AF465766_1 535 100 bactericidal/permeability increasing protein-like 2 2461 gi28173296 Cyprinus carpio bactericidal permeability- 161 36 increasing protein/lipopolysaccharide binding protein 2462 gi10435038 Homo sapiens unnamed protein product 1718 96 2462 gil8257341 Mus musculus Expressed sequence 1044 63 AW060207 2462 gi24659229 Homo sapiens hypothetical protein FLJ13150 1727 97 2464 gi27469556 Homo sapiens Putative neuronal cell adhesion 180 94 molecule 2464 gi4206390 Homo sapiens putative neuronal cell adhesion 180 94 molecule 2465 gi12667401 Homo sapiens AF326731 1 NUF2R 2336 99 2465 gi14317902 Homo sapiens kinetochore protein Nuf2 2336 99 2465 gil8043223 Mus musculus NUF2R protein 1744 72 2466 gi23321257 Homo sapiens ezrin-binding partner PACE-1 3482 97 2466 gi24209887 Homo sapiens ezrin-binding protein PACE-1 3381 90 2466 gi29144929 Mus musculus Ezrin-binding partner PACE-1 2738 75 2467 gi21634823 Homo sapiens AF389428_1 semaphorin 6D 1487 97 WO 2004/080148 PCT/US2003/030720 284 TABLE 2 B SEQID HitID Species Description Sscore Percentage. Identity isoform 3 2467 gi21634825 Homo sapiens AF389429_1 semaphorin 6D 1487 97 isoform 4 2467 gi21634827 Homo sapiens AF389430_1 semaphorin 6D 1487 97 isoform 1 2468 gil3543141 Mus musculus Slc37a3 protein 141 52 2469 gi21671105 Homo sapiens RAD52B 511 100 2469 gi23468352 Homo sapiens Similar to RAD52B 511 100 2469 gi32967621 Mus musculus 2410008M22Rik protein 311 66 2470 gi28626251 Homo sapiens calcium-permeable store- 289 91 operated channel TRPM3c 2470 gi28626253 Homo sapiens calcium-permeable store- 289 91 operated channel TRPM3d 2470 gi28626255 Homo sapiens calcium-permeable store- 289 91 operated channel TRPM3e 2472 gi20987880 Mus musculus E130103I17Rik protein 1605 71 2472 gi28204917 Mus musculus E130103Il7Rik protein 1594 71 2472 gi4588087 Homo sapiens AF095771_1 PTH-responsive 1864 89 osteosarcoma B1 protein 2473 gil3591434 Homo sapiens 413 74 2473 gil3591435 Homo sapiens 416 87 2473 gil9913471 Homo sapiens 413 74 2474 gi28372402 Homo sapiens truncated transmembrane 1271 100 transport protein 2474 gi31324239 Homo sapiens proton-coupled amino acid 1263 100 transporter 2474 gi31871291 Homo sapiens proton/amino acid transporter 1 1263 100 2475 gi28372402 Homo sapiens truncated transmembrane 1271 100 transport protein 2475 gi31324239 Homo sapiens proton-coupled amino acid 1263 100 transporter 2475 gi31871291 Homo sapiens proton/amino acid transporter 1 1263 100 2476 gil1138040 Homo sapiens rat myornegalin mRNA is 828 97 reported in Acc# AF139185-similar to rat myomegalin 2476 gil1138042 Homo sapiens rat myomegalin mRNA is 1091 93 reported in Acc# AF139185-similar to rat myomegalin 2476 gil9263586 Homo sapiens similar to rat myomegalin 1085 93 2477 gi19263005 Ciona intestinalis leucine-rich repeat dynein light 367 66 chain 2477 gi2760161 Anthocidaris outer arm dynein light chain 2 338 63 crassispina 2477 gi7303901 Drosophila CG8800-PA 265 51 melanogaster 2478 gil2666531 Homo sapiens putative b,b-carotene-9',10'- 917 99 dioxygenase 2478 gil4582265 Homo sapiens AF276432_1 putative carotene 930 100 dioxygenase 2478 gi27370671 Homo sapiens Similar to beta-carotene 930 100 dioxygenase 2 2479 gil2666531 Homo sapiens putative b,b-carotene-9',10'- 917 99 dioxygenase WO 2004/080148 PCT/US2003/030720 285 TABLE 2 B SEQjD Hit_ID Species Description S score Percentage Y_______14Identity 2479 gil4582265 Homo sapiens AF2764321 putative carotene 930 100 dioxygenase 2479 gi27370671 Homo sapiens Similar to beta-carotene 930 100 dioxygenase 2 2480 gi1079734 Mus musculus citron 718 97 2480 gi30088970 Homo sapiens rho/rac-interacting citron 696 99 kinase 2480 gi3599509 Mus musculus rho/rac-interacting citron 689 97 kinase 2481 gi24980821 Homo sapiens box polypeptide 26 258 100 2481 gi32485107 Homo sapiens nexin-related serine protease 731 94 inhibitor 2481 gi6062874 Homo sapiens candidate tumor suppressor 258 100 protein DICEI 2482 gil3383364 Homo sapiens claudin-1 1095 99 2482 gil5214678 Homo sapiens AAH12471 claudin 1 1095 99 2482 gi7381083 Homo sapiens AF134160 1 claudin-1 1095 99 2483 gi22902436 Mus musculus Sphingosine-1-phosphate 616 40 phosphatase 1 2483 gi23345324 Homo sapiens sphingosine 1-phosphate 1513 99 phosphohydrolase 2 2483 gi29436890 Mus musculus Similar to sphingosine-1- 1406 90 phosphate phosphotase 2 2484 gi2072977 Homo sapiens putative p150 137 79 2484 gi339771 Homo sapiens ORF2 137 79 2484 gi339777 Homo sapiens ORF2 contains a reverse 137 79 transcriptase domain. 2485 gi2072977 Homo sapiens putative p150 137 79 2485 gi339771 Homo sapiens ORF2 137 79 2485 gi339777 Homo sapiens ORF2 contains a reverse 137 79 transcriptase domain. 2487 gi18033185 Danio rerio AF330001 1 UNC45-related 1491 79 protein 2487 gi27436424 Mus musculus striated muscle UNC45 1757 95 2487 gi27436426 Homo sapiens striated muscle UNC45 1800 98 2488 gi26801168 Gallus gallus condensin complex subunit 1330 44 2488 gi3851586 Homo sapiens chromosome-associated 1123 63 protein-C 2488 gi4092846 Homo sapiens chromosome-associated 1123 63 polypeptide-C 2489 gi2407911 Homo sapiens C016 1252 99 2489 gi29437323 Mus musculus Similar to cDNA for 226 40 differentially expressed C016 gene 2489 gi6013073 Mus musculus HemT-3 protein 141 27 2490 gil3157560 Homo sapiens 2246 99 2490 gil8147612 Homo sapiens metalloprotease disintegrin 2246 99 2490 gi21908030 Homo sapiens a disintegrin and 2230 98 metalloprotease domain 33 2491 gil5145793 Sus scrofa basic proline-rich protein 186 34 2491 gi3858883 Acanthamoeba myosin I heavy chain kinase 218 37 castellanii 2491 gi4206769 Acanthamoeba myosin I heavy chain kinase 218 37 castellanii 2492 gil136434 Homo sapiens KIAA0187 198 72 WO 2004/080148 PCT/US2003/030720 286 TABLE 2 B SEQ_ID Hit_ID Species Description Sscore Percentage Identity 2492 gi21410151 Mus musculus LOC213895 protein 173 62 2492 gi27696627 Homo sapiens Ribosome biogenesis protein 198 72 BMS 1 homolog 2493 gil3559063 Homo sapiens 747 100 2493 gi24416538 Mus musculus 1700001D09Rik protein 631 72 2493 gi9963863 Homo sapiens AF226731_1 AD026 688 99 2495 gi156258 Caenorhabditis collagen 139 33 elegans 2495 gi21105301 Mytilus AF448525_1 precollagen-P 152 28 galloprovincialis 2495 gi2388676 Mytilus edulis precollagen P 148 29 2496 gi156258 Caenorhabditis collagen 139 33 elegans 2496 gi21105301 Mytilus AF448525_1 precollagen-P 152 28 galloprovincialis 2496 gi2388676 Mytilus edulis precollagen P 148 29 2497 gi156258 Caenorhabditis collagen 139 33 elegans 2497 gi21105301 Mytilus AF4485251 precollagen-P 152 28 galloprovincialis 2497 gi2388676 Mytilus edulis precollagen P 148 29 2498 gi20380052 Homo sapiens 372 32 2498 gi20380522 Mus musculus Col3al protein 368 31 2498 gi29144943 Mus musculus Col3al protein 368 31 2499 gi14035874 Homo sapiens unnamed protein product 1100 99 2499 gi14035876 Homo sapiens unnamed protein product 1043 99 2499 gi20070842 Homo sapiens similar to hypothetical protein 1297 99 FLJ13448 2501 gi2072964 Homo sapiens putative p150 399 81 2501 gi2072967 Homo sapiens putative p150 400 81 2501 gi339777 Homo sapiens ORF2 contains a reverse 399 81 transcriptase domain. 2502 gi30040280 Shigella flexneri 2a IS 103 orf 731 98 str. 2457T 2502 gi30041139 Shigella flexneri 2a IS103 orf 731 98 str. 2457T 2502 gi466695 Escherichia coli orfA in IS 150 731 98 2503 gi12698037 Homo sapiens KIAA1746 protein 341 100 2503 gi26344121 Mus musculus unnamed protein product 318 92 2503 gi26351415 Mus musculus unnamed protein product 318 92 2504 gi20269073 Homo sapiens putative lipid kinase 1035 99 2504 gi21624340 Homo sapiens ceramide kinase 1035 99 2504 gi21624342 Mus musculus ceramide kinases 829 81 2505 gi312584 Mus musculus biliary glycoprotein 165 27 2505 gi312586 Mus musculus biliary glycoprotein 165 27 2505 gi312590 Mus musculus biliary glycoprotein 174 30 2506 gi312584 Mus musculus biliary glycoprotein 165 27 2506 gi312586 Mus musculus biliary glycoprotein 165 27 2506 gi312590 Mus musculus biliary glycoprotein 174 30 2507 gi1480744 Equus caballus type II collagen 346 29 2507 gi30041 Homo sapiens COL2A1 344 29 2507 gi450394 Homo sapiens alpha-1 type II collagen 344 29 2508 gi1483580 Rattus norvegicus NTR2 receptor 911 81 2508 gil8490912 Homo sapiens neurotensin receptor 2 1072 95 WO 2004/080148 PCT/US2003/030720 287 TABLE 2 B SEQ_ID Hit_ID Species Description Sscore Percentage Identity 2508 gi3901028 Homo sapiens neurotensin receptor 2 1074 95 2509 gi1049104 Homo sapiens dystonin isoform 1 221 100 2509 gi14530942 Homo sapiens dystonin 2 221 100 2509 gi14530944 Homo sapiens dystonin 2 221 100 2510 gi1049104 Homo sapiens dystonin isoform 1 221 100 2510 gi14530942 Homo sapiens dystonin 2 221 100 2510 gi14530944 Homo sapiens dystonin 2 221 100 2512 gi1572721 Homo sapiens megakaryocyte stimulating 203 23 factor; MSF 2512 gi16041156 Macaca fascicularis X-ray radiation resistance 710 66 associated 1 protein 2512 gil8676652 Homo sapiens FLJ00225 protein 761 70 2513 gi1572721 Homo sapiens megakaryocyte stimulating 203 23 factor; MSF 2513 gi16041156 Macaca fascicularis X-ray radiation resistance 710 66 associated 1 protein 2513 gil8676652 Homo sapiens FLJ00225 protein 761 70 2514 gi26346328 Mus musculus unnamed protein product 965 93 2514 gi33417011 Mus musculus 965 93 2514 gi6330169 Homo sapiens KIAA 1164 protein 1005 99 2515 gi26346328 Mus musculus unnamed protein product 965 93 2515 gi33417011 Mus musculus 965 93 2515 gi6330169 Homo sapiens KIAA1164 protein 1005 99 2516 gil2857668 Mus musculus unnamed protein product 123 43 2516 gi26327823 Mus musculus unnamed protein product 123 43 2517 gi17429038 Ralstonia PROBABLE ACYL-COA 676 61 solanacearum DEHYDROGENASE OXIDOREDUCTASE PROTEIN 2517 gi22776354 Oceanobacillus acyl-CoA dehydrogenase 660 63 iheyensis HTE831 2517 gi28280023 Mus musculus 5730439E10Rik protein 974 84 2518 gil7429038 Ralstonia PROBABLE ACYL-COA 676 61 solanacearum DEHYDROGENASE OXIDOREDUCTASE PROTEIN 2518 gi22776354 Oceanobacillus acyl-CoA dehydrogenase 660 63 iheyensis HTE831 2518 gi28280023 Mus musculus 5730439E10Rik protein 974 84 2519 gi19070124 Mus musculus AF233346_1 zinc transporter- 895 95 like 3 protein 2519 gi20563194 Mus musculus AF395840 1 zinc transporter 6 883 93 2519 gi33338012 Homo sapiens AF173387 1 MSTP103 759 94 2520 gi212451 Gallus gallus nonmuscle myosin heavy chain 182 20 2520 gi212452 Gallus gallus nonmuscle myosin heavy chain 182 20 2520 gi4115748 Bos taurus nonmuscle myosin heavy chain 182 19 B 2521 gil8605758 Mus musculus 9030409G11Rik protein 1257 94 2521 gi6526769 Homo sapiens HRIHFB2003 1200 96 2521 gi7291408 Drosophila CG1 1206-PA 263 26 melanogaster 2524 gi13182757 Homo sapiens AF212238 1 HTPAP 843 100 2524 gi21542541 Homo sapiens Similar to HTPAP protein 808 100 2524 gi28381093 Drosophila CG12746-PD 410 50 WO 2004/080148 PCT/US2003/030720 288 TABLE 2 B SEQ_ID HitID Species Description S score Percentage_ Identity melanogaster 2525 gil3182757 Homo sapiens AF212238 1 HTPAP 843 100 2525 gi21542541 Horno sapiens Similar to HTPAP protein 808 100 2525 gi28381093 Drosophila CG12746-PD 410 50 melanogaster 2527 gil6416764 Homo sapiens AF315594_1 FKSG16 1027 100 2527 gil9353603 Mus musculus D1lErtd1Se protein 337 41 2527 gi31873637 Homo sapiens hypothetical protein 1014 100 2528 gil6416764 Homo sapiens AF315594 I FKSG16 1027 100 2528 gil9353603 Mus musculus D1lErtdl8e protein 337 41 2528 gi31873637 Homo sapiens hypothetical protein 1014 100 2529 gi32330803 Mus musculus podocan protein 1095 90 2529 gi32330805 Homo sapiens podocan protein 1205 97 2529 gi3786312 Homo sapiens extracellular matrix protein 281 33 2530 gi20258604 Homo sapiens sialic acid binding Ig-like 2913 99 lectin 5 2530 gi2411475 Homo sapiens OB binding protein-2 2913 99 2530 gi9454520 Homo sapiens AC018755 5 SIGLEC5 2913 99 2531 gi20258604 Homo sapiens sialic acid binding Ig-like 2913 99 lectin 5 2531 gi2411475 Homo sapiens OB binding protein-2 2913 99 2531 gi9454520 Homo sapiens AC018755 5 SIGLEC5 2913 99 2532 gil3183078 Homo sapiens AF2376521 a disintegrin-like 602 74 and metalloprotease domain with thrombospondin type I motifs-like 3 2532 gil5099921 Homo sapiens AF176313 I ADAM-TS 874 98 related protein 1 2532 gi20987759 Homo sapiens Similar to ADAMTS-like 1 886 99 2533 gil78836 Homo sapiens apolipoprotein C-II 506 100 2533 gi30582255 Homo sapiens apolipoprotein C-II 500 99 2533 gi757915 Homo sapiens apoCII protein 506 100 2534 gil78836 Homo sapiens apolipoprotein C-II 506 100 2534 gi30582255 Homo sapiens apolipoprotein C-II 500 99 2534 gi757915 Homo sapiens apoClI protein 506 100 2536 gi17389292 Homo sapiens LDL induced EC protein 914 98 2536 gi5924319 Homo sapiens AF184939 1 LDL induced EC 914 98 protein 2536 gi8518179 Homo sapiens LDL induced endothelial cell 941 76 protein 2537 gi28974490 Homo sapiens lipoma HMGIC fusion-partner- 1071 100 like protein 2537 gi30102428 Rattus norvegicus HMGIC fusion-partner-like 1038 95 protein 2537 gi30411045 Mus musculus Similar to lipoma HMGIC 1037 94 fusion partner 2538 gil4603353 Homo sapiens AAH10130 CGI-43 protein 2362 94 2538 gi23092946 Drosophila CG14980-PB 537 28 melanogaster 2538 gi4929555 Homo sapiens AF151801_1 CGI-43 protein 2219 89 2539 gi12654633 Homo sapiens Protein inhibitor of activated 179 84 STAT3 2539 gil8606318 Mus musculus Protein inhibitor of activated 179 84 STAT 3, isoform 1 1 1 WO 2004/080148 PCT/US2003/030720 289 TABLE 2 B SEQ_ID HitID Species Description Sscore Percentage_ Identity 2539 gi3058291 1 Homo sapiens protein inhibitor of activated 179 84 STAT3 2540 gi27449075 Oreochromis stearoyl-CoA desaturase 743 69 mossambicus 2540 gi29294686 Homo sapiens SCD4 protein 737 100 2540 gi30350098 Homo sapiens AF3893381 acyl-CoA- 1016 100 desaturase 2541 gi1000867 Homo sapiens DNA mismatch repair protein 1931 100 2541 gil000869 Homo sapiens DNA mismatch repair protein 1931 100 2541 gil8204306 Homo sapiens AAH21566 1931 100 2542 gil1862941 Mus musculus DDM36E 430 48 2542 gi19570398 Homo sapiens hDDM36 439 49 2542 gi7650186 Mus musculus AF1766941 neighbor of Punc 430 48 elI protein 2543 gi21744725 Homo sapiens AF478693_1 glycosyl- 717 97 phosphatidyl-inositol-MAM 2543 gi25005318 Sus scrofa MAM domain containing 672 91 glycosylphosphatidylinositol anchor 1 2543 gi25005320 Sus scrofa glycosylphosphatidylinositol 672 91 anchor 1 protein 2544 gil2276198 Homo sapiens AF333487_1 FKSG40 543 96 2544 gil2408250 Homo sapiens FKSG28 543 96 2544 gil8652934 Xenopus laevis Mig3O 514 48 2545 gil6769552 Drosophila LD38375p 367 51 melanogaster 2545 gi27696627 Homo sapiens Ribosome biogenesis protein 684 93 BMS I homolog 2545 gi7294027 Drosophila CG7728-PA 367 51 melanogaster 2546 gil2842044 Mus musculus unnamed protein product 375 72 2546 gil8921437 Mus musculus 2010004AO3Rik protein 375 72 2546 gi20987450 Homo sapiens LOC146433 468 91 2547 gilO16012 Rattus norvegicus neural cell adhesion protein 543 93 BIG-2 precursor 2547 gi26891535 Homo sapiens contactin 4 570 100 2547 gi29837411 Homo sapiens BIG-2 570 100 2548 gi30102449 Homo sapiens lipoma HMGIC fusion-partner- 822 100 like protein 2548 gi30908798 Homo sapiens lipoma HMGIC fusion partner- 676 78 like protein 4 2548 gi30908800 Rattus norvegicus lipoma HMGIC fusion partner- 675 78 like protein 4 2549 gil3097705 Homo sapiens AAI-103559 , member 3 237 52 2549 gil340142 Homo sapiens alpha1-antichymotrypsin 237 52 2549 gi4165890 Homo sapiens alpha-1-antichymotrypsin 237 52 precursor 2550 gil850850 Murid herpesvirus 4 serine threonine rich 207 33 glycoprotein 2550 gi21618556 Homo sapiens 4040 97 2550 gi33304372 Homo sapiens tastin 4035 97 2551 gil2053849 Homo sapiens DREV protein 1649 98 2551 gi12053851 Homo sapiens DREVI protein 1633 98 2551 gi12053853 Homo sapiens DREV protein 1649 98 WO 2004/080148 PCT/US2003/030720 290 TABLE 2 B SEQID HitID Species Description S score Percentage_ Identity 2553 gil1990779 Homo sapiens 273 50 2553 gi22760096 Homo sapiens unnamed protein product 538 100 2553 gi28279813 Homo sapiens Similar to hypothetical protein 515 97 DKFZp434A171 2554 gil 1125348 Homo sapiens putative protein kinase 2419 99 2554 gi6933864 Homo sapiens kinase deficient protein KDP 2419 99 2554 gi8272557 Rattus norvegicus AF227741_1 protein kinase 2340 96 WNK1 2555 gil1125348 Homo sapiens putative protein kinase 2419 99 2555 gi6933864 Homo sapiens kinase deficient protein KDP 2419 99 2555 gi8272557 Rattus norvegicus AF227741_1 protein kinase 2340 96 WNK1 2556 gi3599339 Mus musculus ORF2 138 60 domesticus 2556 gi3599342 Mus musculus ORF2 138 60 domesticus 2556 gi3599347 Mus musculus ORF2 138 60 domesticus 2557 gi15020809 Takifugu rubripes putative methionyl tRNA 674 74 synthetase 2557 gil7861592 Drosophila GH13807p 567 61 melanogaster 2557 gi23171238 Drosophila CG31322-PA 567 61 melanogaster 2558 gil5341975 Homo sapiens AAH13184 Similar to major 432 72 histocompatibility complex, class 11, DP beta 1 2558 gil7389919 Homo sapiens AAH17967 Similar to major 814 100 histocompatibility complex, class 11, DP beta 1 2558 gil88479 Homo sapiens HLA-DPB1 432 72 2559 gil5779083 Homo sapiens AAH14609 1122 90 2559 gi3342737 Homo sapiens R26660_2, partial CDS 967 86 2559 gi3478640 Homo sapiens R26660_2, partial CDS 138 89 2560 gil5779083 Homo sapiens AAH14609 1122 90 2560 gi3342737 Homo sapiens R26660 2, partial CDS 967 86 2560 gi3478640 Homo sapiens R26660_2, partial CDS 138 89 2561 gil3991167 Homo sapiens sialic acid-binding 661 99 immunoglobulin-like lectin-like long splice variant 2561 gil4625822 Homo sapiens AF2822561 Siglec-L1 661 99 2561 gi23272769 Homo sapiens SIGLEC-like 1 661 99 2562 gil5132186 Homo sapiens unnamed protein product 1122 88 2562 gil5132529 Homo sapiens unnamed protein product |1122 88 2562 gi21439502 Homo sapiens unnamed protein product 1122 88 2563 gi202592 Rattus norvegicus prealpha-2-macroglobulin 238 40 2563 gi671864 Gallus gallus ovomacroglobulin, ovostatin 230 40 2563 gi671865 Gallus gallus ovomacroglobulin, ovostatin 230 40 2564 gi25990364 Homo sapiens AF319622 1 P-glycoprotein 191 100 WO 2004/080148 PCT/US2003/030720 291 TABLE 3A SEQ Database Description Result* ID entry ID 685 BL00266 Somatotropin, prolactin and related hormones BL00266AJI-;0,qq47e1135-61 proteins. 686 PR00836 SOMATOTROPIN HORMONE FAMILY PR00836A 14.40 2.862e-1179-92 SIGNATURE PR00836B 16.59 7.OO0e-11 101-119 686 BL00266 Somatotropin, prolactin and related hormones BL00266B 24.48 8.714e-2179-116 proteins. BL00266A 15.69 1,923e-14 35-61 BL00266D 12.72 4.000e-1 1201-224

-

BL00266C 13.66 3.700e-10 135-151 688 PR00836 SOMATOTROPIN HORMONE FAMILY PROO836B 16.59 2.895e-16 101-119 SIGNATURE PR00836A 14.40 2.800e-13 79-92 688 BL00266 Somatotropin, prolactin and related hormones BL00266B 24.48 4.000e-29 79-116 proteins. BL00266A 15.69 9.047e-19 35-61 BL00266D 12.72 4.000e-11 201-224 BL00266C 13.66 4.000e-10 135-151 689 BL00284 Serpins proteins. BL00284C 28.56 3.700e-26 185-226 BL00284E 19.15 1.333e-17 373-397 BL00284A 15.64 8.7 14e-16 77-100 BL00284D 16.34 7.279e-12 294-320 BL00284B 17.99 4.825e-10 158-178 690 PR00390 PHOSPHOLIPASE C SIGNATURE PR0039A 15.09 1.439e-20 191-209 690 BL00303 S-I 00/ICaBP type calcium binding protein. BL00363B 26.15 4.97e-09 31-67 690 BL00292 Cyclins proteins. BL00292A 22.87 5.114e-09 116-149 691 PF00756 Putative esterase PF0076C 14.12 1.100e-09 438-467 691 BLOO128 Lipases, serine proteins. BLOO12B 11.37 4.462e-09 435-449 693 PR0B573 INTERLEUKIN 8B RECEPTOR PR00573C 9.99 7.300e-10 38-46 SIGNATURE 693 PR00427 INTERLEUKTN-8 RECEPTOR PR00427A 16.30 9.700e-10 34-48 ____________SIGNATURE 694 BL01238 GDA1ICD39 family of nucleoside BL01238A 11.72 8.200e-16 104-118 pliosphatases proteins. BL0 123 8D 10. 19 4.130e- 15 248-261 BL01238C 14.36 6.677e-12 219-240 BL01238B 10.99 2.07e-10 176-186 695 PR00237 RHODOPSN-LIKE GPCR SUPERFAMILY PR00237F 13.57 5.636e-10 239-263 ____ SIGNATURE 695 BL00237 G-protein coupled receptors proteins. BL00237C 13.19 5.034e-12 234-260 BL00237A 27.68 8.600e-10 72-111 695 PR00172 GLUCOSE TRANSPORTER SIGNATURE PROO72C 9.51 2.612e-09 8-28 696 BL00615 C-tpe lectin domainproteins. BL0061A 16.68 2.080e- 1 175-192 698 BL01238 GDA1/CD39 family of nucleoside BL01238A 11.72 4.240e-16 51-65 phosphatases proteins. BL01238D 10.19 2.703e-14 196-209 BL01238C 14.36 2.662e-12 167-188 BL01238B 10.99 6.538e-12 124-134 700 BL0037 Myb DNA-binding domain proteins repeat BLOO37A 16.68 3.57e-11 231-254 proteins proteins. BL00237C_13.19_5.034.e-12_234-260 700 PF00569 Zinc finger present in dystrophin, CBP/p3 00. PF00569 13.42 4.214e-10 184-200 700 PR00608 CLASS 11 CYTOCHROME C SIGNATURE PR0028A 13.74 6.434e-10 118-141 700 PR00456 RIBOSOMAL PROTEIN P2 SIGNATURE PR0046E 3.06 8.861e-09 123-137 PR00456E 3.06 9.772e-09 122-136 701 PR0049 WILM'S TUMOR PROTEIN SIGNATURE PROO049D 0.00 1.42e-09 280-294 703 PF00650 CRAL/TRIO domain proteins. PF0065D 24.34 1.776e-12 177-210 703 PROO18P CELLULARRETINALDEHYDE BINDING PROO18OA 10.11 7.231e-1137-59 WO 2004/080148 PCT/US2003/030720 292 TABLE 3A SEQ Database Description Result* ID entry ID PROTEIN SIGNATURE PR0O180D 12.78 9.769e-10 202-221 705 PRO0910 LUTEOVIRUS ORF6 PROTEIN PR00910A 2.51 8.286e-09 756-768 SIGNATURE 705 BL00291 Prion protein. BL00291A 4.49 8.552e-09 196-230 706 BLOO400 LBP / BPI / CETP family proteins. BL00400D 23.26 7.222e-12 251-287 708 BL00478 LIM domain proteins. BL00478B 14.79 3.000e-12 31-45 710 BL00604 Synaptophysin / synaptoporin proteins. BL00604F 5.96 7.718e-10 1379-1423 710 PR00524 CHOLECYSTOKININ TYPE A RECEPTOR PR00524F 5.36 7.415e-09 1220-1233 SIGNATURE 710 BL00242 Integrins alpha chain proteins. BL00242B 8.13 8.615e-09 469-478 710 BL00420 Speract receptor repeat proteins domain BL00420A 20.42 3.571e-13 1043-1071 proteins. BL00420A 20.42 9.082e-13 1125-1153 BL00420A 20.42 2.038e-12 142-170 BL00420A 20.42 4.462e-12 714-742 BL00420A 20.42 8.962e-12 454-482 BL00420A 20.42 9.135e-12 935-963 BL00420A 20.42 9.827e-12 797-825 BL00420A 20.42 1.327e-11 202-230 BL00420A 20.42 3.291e-11 803-831 BL00420A 20.42 3.618e-11 521-549 BLOO420A 20.42 4.927e-11 589-617 BL00420A 20.42 6.400e-11 64-92 BL00420A 20.42 8.036e-11 451-479 BL00420A 20.42 8.691e-11 1323-1351 BL00420A 20.42 9.345e-11 199-227 BLOO420A 20.42 2.623e-10 944-972 BLOO420A 20.42 2.770e-10 100-128 BL00420A 20.42 2.770e-10 842-870 BL00420A 20.42 2.918e-10 741-769 BL00420A 20.42 4.098e-10 1137-1165 BLOO420A 20.42 4.393e-10 696-724 BL00420A 20.42 4.541e-10 1170-1198 BL00420A 20.42 5.279e-10 1046-1074 BL00420A 20.42 5.426e-10 296-324 BL00420A 20.42 5.426e-10 1149-1177 BL00420A 20.42 6.754e-10 747-775 BL00420A 20.42 6.754e-10 1061-1089 BL00420A 20.42 6.902e-10 1278-1306 BL00420A 20.42 7.049e-10 624-652 BL00420A 20.42 7.492e-10 1055-1083 BL00420A 20.42 8.082e-10 1037-1065 BL00420A 20.42 8.525e-10 836-864 BL00420A 20.42 8.672e-10 187-215 BL00420A 20.42 8.672e-10 598-626 BL00420A 20.42 8.820e-10 139-167 BLOO420A 20.42 8.820e-10 896-924 BLOO420A 20.42 8.967e-10 717-745 BLOO420A 20.42 9.115e-10 314-342 BLOO420A 20.42 9.705e-10 923-951 BL00420A 20.42 9.852e-10 369-397 BL00420A 20.42 9.852e-10 806-834 BL00420A 20.42 9.852e-10 1179-1207 WO 2004/080148 PCT/US2003/030720 293 TABLE 3A SEQ Database Description Result* ID entry ID BL00420A 20.42 1.138e-09 863-891 BL00420A 20.42 1.415e-09 509-537 BL00420A 20.42 1.415e-09 530-558 BL00420A 20.42 2.523e-09 857-885 BL00420A 20.42 2.800e-09 1182-1210 BL00420A 20.42 2.938e-09 1426-1454 BL00420A 20.42 3.077e-09 630-658 BL00420A 20.42 3.354e-09 103-131 BL00420A 20.42 3.492e-09 782-810 BL00420A 20.42 3.492e-09 1064-1092 BL00420A 20.42 3.63le-09 860-888 BL00420A 20.42 3.769e-09 920-948 BL00420A 20.42 4.185e-09 869-897 BL00420A 20.42 4.600e-09 518-546 BL00420A 20.42 5.015e-09 1317-1345 BL00420A 20.42 5.292e-09 524-552 BL00420A 20.42 5.43le-09 633-661 BL00420A 20.42 5.569e-09 729-757 BL00420A 20.42 5.569e-09 824-852 BL00420A 20.42 5.569e-09 1049-1077 BL00420A 20.42 6.123e-09 366-394 BL00420A 20.42 6.262e-09 491-519 BLOO420A 20.42 6.538e-09 914-942 BL00420A 20.42 6.954e-09 566-594 BL00420A 20.42 6.954e-09 711-739 BL00420A 20.42 6.954e-09 893-921 BL00420A 20.42 7.369e-09 818-846 BL00420A 20.42 7.923e-09 1471-1499 BL00420A 20.42 8.062e-09 735-763 BL00420A 20.42 8.477e-09 1347-1375 BL00420A 20.42 8.754e-09 1095-1123 BL00420A 20.42 9.03 1e-09 61-89 BL00420A 20.42 9.308e-09 311-339 BL00420A 20.42 9.308e-09 938-966 BL00420A 20.42 9.446e-09 1299-1327 BL00420A 20.42 9.585e-09 363-391 BL00420A 20.42 9.723e-09 794-822 BL00420A 20.42 9.862e-09 1302-1330 710 BLO1113 C1q domain proteins. BLO 11 13A 17.99 1.290e-15 423-449 BLO1113A 17.99 6.455e-14 1170-1196 BLO1113A 17.99 8.909e-14 509-535 BLO 11 13A 17.99 8.909e-14 812-838 BLO1113A 17.99 8.909e-14 815-841 BLO1113A 17.99 3.676e-13 854-880 BLO1113A 17.99 5.622e-13 1040-1066 BLO1113A 17.99 8.054e-13 788-814 BLO1113A 17.99 9.514e-13 589-615 BLO1I13A 17.99 9.757e-13 363-389 BLO1113A 17.99 1.923e-12 1405-1431 BLO1113A 17.99 2.154e-12 845-871 BLO1113A 17.99 2.615e-12 932-958 BLO1113A 17.99 3.077e-12 953-979 WO 2004/080148 PCT/US2003/030720 294 TABLE 3A SEQ Database Description Result* ID entry ID BLO1113A 17.99 3.308e-12 524-550 BLO1113A 17.99 3.769e-12 566-592 BLO1113A 17.99 3.769e-12 797-823 BLO1113A 17.99 4.231e-12 624-650 BLO1113A 17.99 4.462e-12 1242-1268 BLO1113A 17.99 5.154e-12 639-665 BLO1 113A 17.99 5.846e-12 779-805 BLO1113A 17.99 6.308e-12 598-624 BLO1113A 17.99 6.538e-12 923-949 BLO1113A 17.99 6.538e-12 1046-1072 BLO1113A 17.99 7.462e-12 112-138 BLO1113A 17.99 7.692e-12 705-731 BLO1113A 17.99 8.615e-12 211-237 BLO1113A 17.99 8.846e-12 196-222 BLOI 1 13A 17.99 9.769e-12 460-486 BLO1113A 17.99 1.000e-11 1296-1322 BLO1113A 17.99 1.205e-11 1043-1069 BLOI13A 17.99 1.409e-11 821-847 BLO1113A 17.99 1.614e-11 1182-1208 BLO1113A 17.99 1.818e-11 747-773 BLO1113A 17.99 3.659e-11 451-477 BLO1113A 17.99 4.273e-11 914-940 BLO1113A 17.99 4.477e-11 836-862 BLO1113A 17.99 4.886e-11 729-755 BLO1113A 17.99 5.091e-11 744-770 BL01113A 17.99 5.091e-11 1179-1205 BLO1113A 17.99 5.500e-11 633-659 BLO I1 13A 17.99 5.500e-1 1 714-740 BLO1113A 17.99 6.523e-11 1468-1494 BLO1I13A 17.99 6.727e-11 205-231 BLO1113A 17.99 6.727e-11 824-850 BLO1113A 17.99 7.341e-11 1423-1449 BLO1113A 17.99 8.364e-11 595-621 BLO1113A 17.99 9.386e-11 687-713 BLO1113A 17.99 9.795e-11 690-716 BLO1113A 17.99 1.000e-10 806-832 BLO1113A 17.99 1.383e-10 494-520 BLO1113A 17.99 1.383e-10 803-829 BLO1113A 17.99 1.766e-10 560-586 BLO1113A 17.99 1.766e-10 1414-1440 BLO1113A 17.99 2.149e-10 938-964 BLO1113A 17.99 2.340e-10 208-234 BLO1113A 17.99 2.723e-10 64-90 BLO1113A 17.99 2.915e-10 372-398 BLO1113A 17.99 2.915e-10 592-618 BLO1113A 17.99 2.915e-10 1368-1394 BLO1113A 17.99 3.298e-10 750-776 BLO1113A 17.99 3.872e-10 518-544 BLO1113A 17.99 5.404e-10 842-868 BLO1113A 17.99 5.596e-10 857-883 BLO1113A 17.99 6.170e-10 794-820 BLO1113A 17.99 6.745e-10 148-174 WO 2004/080148 PCT/US2003/030720 295 TABLE 3A SEQ Database Description Result* ID entry ID BLO1113A 17.99 6.745e-10 202-228 BLO1113A 17.99 6.745e-10 1251-1277 BLOl 1 13A 17.99 7.319e-10 929-955 BL01113A 17.99 7.319e-10 1305-1331 BLO1113A 17.99 7.511e-10 432-458 BLO1113A 17.99 7.702e-10 563-589 BLO1113A 17.99 7.702e-10 896-922 BLO1113A 17.99 8.085e-10 1176-1202 BLO 11 13A 17.99 8.277e-10 296-322 BLO1113A 17.99 8.660e-10 1317-1343 BLO1113A 17.99 9.234e-10 121-147 BLO1113A 17.99 9.426e-10 863-889 BLO1113A 17.99 1.346e-09 426-452 BLO1113A 17.99 1.519e-09 454-480 BLO1113A 17.99 1.692e-09 500-526 BLO1113A 17.99 1.692e-09 911-937 BLO1113A 17.99 1.865e-09 782-808 BLO1113A 17.99 2.038e-09 1284-1310 BLO1113A 17.99 2.212e-09 94-120 BLO1113A 17.99 2.212e-09 1365-1391 BLO1113A 17.99 2.385e-09 604-630 BLO1113A 17.99 2.385e-09 893-919 BLO1113A 17.99 2.385e-09 1098-1124 BLO1113A 17.99 2.731e-09 1161-1187 BLO1I13A 17.99 2.904e-09 1465-1491 BL01113A 17.99 3.077e-09 506-532 BLO1113A 17.99 3.423e-09 1143-1169 BLO1I13A 17.99 3.423e-09 1320-1346 BLOl 113A 17.99 3.769e-09 1408-1434 BLO1I13A 17.99 3.769e-09 1462-1488 BLO 11 13A 17.99 3.942e-09 366-392 BLO 11 13A 17.99 3.942e-09 902-928 BLO1113A 17.99 3.942e-09 1037-1063 BLO1113A 17.99 3.942e-09 1185-1211 BLO1113A 17.99 4.115e-09 1290-1316 BLO1 113A 17.99 4.462e-09 557-583 BLO 11 13A 17.99 4.462e-09 575-601 BLO1113A 17.99 4.981e-09 1055-1081 BLO1113A 17.99 5.154e-09 533-559 BLO1113A 17.99 5.327e-09 678-704 BLO1113A 17.99 5.327e-09 1031-1057 BLO1113A 17.99 5.500e-09 187-213 BLO 11 13A 17.99 5.500e-09 497-523 BLO1113A 17.99 5.500e-09 1332-1358 BLO1113A 17.99 5.673e-09 329-355 BLO1113A 17.99 5.673e-09 899-925 BL01113A 17.99 6.192e-09 1006-1032 BLO1113A 17.99 6.192e-09 1155-1181 BL01113A 17.99 6.365e-09 681-707 BLO 1113A 17.99 6.538e-09 723-749 BL01113A 17.99 6.538e-09 833-859 BLO1113A 17.99 6.712e-09 199-225 WO 2004/080148 PCT/US2003/030720 296 TABLE 3A SEQ Database Description Result* ID entry ID BLO 1113A 17.99 6.712e-09 720-746 BLO1113A 17.99 6.885e-09 839-865 BLO1113A 17.99 7.058e-09 145-171 BLO1113A 17.99 7.058e-09 190-216 BL01113A 17.99 7.231e-09 1236-1262 BLO1113A 17.99 7.404e-09 830-856 BLO 1113A 17.99 7.750e-09 684-710 BLO1113A 17.99 7.923e-09 905-931 BLO 1113A 17.99 8.096e-09 696-722 BLO1I113A 17.99 8.269e-09 630-656 BLO1113A 17.99 8.269e-09 1257-1283 BLO 1113A 17.99 9.308e-09 299-325 BLO1113A 17.99 9.308e-09 944-970 BLO 111 3A 17.99 9.654e-09 457-483 BLO1113A 17.99 1.000e-08 67-93 BLO1113A 17.99 1.000e-08 908-934 711 PR00010 TYPE II EGF-LIKE SIGNATURE PROO010C 11.16 4.545e-10 211-221 711 PD02283 PROTEIN SPORULATION REPEAT PD02283C 17.54 9.408e-10 3649-3676 PRECU. 711 PR00873 ECHINOIDEA (SEA URCHIN) PR00873D 8.43 5.500e-09 4326-4344 METALLOTHIONEIN SIGNATURE 711 PR00907 THROMBOMODULIN SIGNATURE PR00907B 11.29 4.974e-10 4218-4234 PR00907B 11.29 5.720e-09 162-178 711 BL00425 Arthropod defensins proteins. BL00425 10.48 5.78le-09 1216-1234 711 PR00261 LOW DENSITY LIPOPROTEIN (LDL) PR00261C 11.37 4.000e-20 1015-1036 RECEPTOR SIGNATURE PR00261D 12.47 5.125e-20 892-913 PR00261B 14.12 5.588e-20 3600-3621 PR00261B 14.12 9.294e-20 1101-1122 PR00261B 14.12 2.667e-19 1053-1074 PR00261C 11.37 3.250e-19 2852-2873 PR00261A 11.02 7.058e-19 1101-1122 PR00261A 11.02 8.615e-19 1015-1036 PR00261B 14.12 9.500e-19 933-954 PR00261D 12.47 1.500e-18 3721-3742 PR00261B 14.12 2.263e-18 3523-3544 PR00261B 14.12 2.421e-18 2729-2750 PR00261A 11.02 2.833e-18 1144-1165 PR00261D 12.47 3.000e-18 1015-1036 PR00261D 12.47 3.167e-18 1053-1074 PR00261C 11.37 3.618e-18 1053-1074 PR00261A 11.02 5.000e-18 3600-3621 PR00261C 11.37 5.582e-18 2809-2830 PR00261A 11.02 6.000e-18 1053-1074 PR00261C 11.37 6.236e-18 1101-1122 PR00261C 11.37 6.891e-18 3562-3583 PR00261A 11.02 7.000e-18 892-913 PR00261D 12.47 8.167e-18 1144-1165 PR00261D 12.47 8.333e-18 1101-1122 PR00261C 11.37 8.527e-18 3484-3505 PR00261C 11.37 9.018e-18 2767-2788 PR00261C 11.37 1.310e-17 1144-1165 PR00261D 12.47 2.579e-17 3600-3621 WO 2004/080148 PCT/US2003/030720 297 TABLE 3A SEQ Database Description Result* ID entry ID PR00261B 14.12 2.650e-17 3680-3701 PR00261D 12.47 2.737e-17 3680-3701 PR00261C 11.37 3.017e-17 892-913 PR00261B 14.12 3.250e-17 892-913 PR00261A 11.02 4.158e-17 3562-3583 PR00261F 11.57 5.673e-17 2938-2959 PR00261A 11.02 6.368e-17 2809-2830 PR00261A 11.02 6.684e-17 3680-3701 PR00261A 11.02 6.842e-17 3364-3385 PR00261C 11.37 8.138e-17 3680-3701 PR00261A 11.02 8.895e-17 2729-2750 PR00261C 11.37 9.845e-17 974-995 PR00261D 12.47 1.153e-16 2767-2788 PR00261D 12.47 1.153e-16 3364-3385 PR00261F 11.57 1.321e-16 1015-1036 PR00261D 12.47 1.610e-16 2687-2708 PR00261D 12.47 1.915e-16 974-995 PR00261F 11.57 1.964e-16 2599-2620 PR00261D 12.47 2.83le-16 2852-2873 PR00261B 14.12 2.887e-16 3364-3385 PR00261B 14.12 3.032e-16 2809-2830 PR00261A 11.02 3.136e-16 80-101 PR00261D 12.47 3.441e-16 2809-2830 PR00261D 12.47 3.441e-16 3484-3505 PR00261C 11.37 3.951e-16 2938-2959 PR00261C 11.37 4.246e-16 80-101 PR00261D 12.47 4.356e-16 3523-3544 PR00261E 11.08 5.000e-16 892-913 PR00261C 11.37 5.279e-16 2729-2750 PR00261D 12.47 7.407e-16 80-101 PR00261E 11.08 7.500e-16 3680-3701 PR00261B 14.12 7.532e-16 2767-2788 PR00261A 11.02 7.712e-16 3484-3505 PR00261F 11.57 8.071e-16 1053-1074 PR00261B 14.12 8.403e-16 1015-1036 PR00261C 11.37 8.525e-16 3364-3385 PR00261F 11.57 8.714e-16 3809-3830 PR00261A 11.02 8.932e-16 2767-2788 PR00261F 11.57 9.357e-16 3523-3544 PR00261D 12.47 1.429e-15 2599-2620 PR00261B 14.12 1.554e-15 1144-1165 PR00261A 11.02 1.726e-15 2852-2873 PR00261D 12.47 1.857e-15 933-954 PR00261C 11.37 2.000e-15 3523-3544 PR00261B 14.12 2.108e-15 2599-2620 PR00261B 14.12 2.246e-15 974-995 PR00261F 11.57 2.397e-15 3444-3465 PR00261D 12.47 2.714e-15 3404-3425 PR00261E 11.08 3.211e-15 974-995 PR00261A 11.02 3.323e-15 2687-2708 PR00261E 11.08 3.526e-15 1053-1074 PR00261D 12.47 4.429e-15 3562-3583 WO 2004/080148 PCT/US2003/030720 298 TABLE 3A SEQ Database Description Result* ID entry ID PR00261E 11.08 4.632e-15 1015-1036 PR00261D 12.47 5.000e-15 2938-2959 PR00261C 11.37 5.286e-15 3404-3425 PR00261E 11.08 5.579e-15 2599-2620 PR00261A 11.02 5.645e-15 3523-3544 PR00261F 11.57 5.966e-15 2638-2659 PR00261B 14.12 6.262e-15 2938-2959 PR00261F 11.57 6.276e-15 2852-2873 PR00261C 11.37 6.286e-15 2638-2659 PR00261E 11.08 6.684e-15 1101-1122 PR00261C 11.37 7.286e-15 3809-3830 PR00261B 14.12 8.062e-15 3444-3465 PR00261E 11.08 8.421e-15 1144-1165 PR00261F 11.57 9.690e-15 2767-2788 PR00261B 14.12 1.000e-14 80-101 PR00261F 11.57 1.145e-14 974-995 PR00261F 11.57 1.581e-14 3364-3385 PR00261A 11.02 2.246e-14 933-954 PR00261C 11.37 2.478e-14 3641-3662 PR00261B 14.12 2.853e-14 3721-3742 PR00261A 11.02 3.631e-14 2938-2959 PR00261D 12.47 3.813e-14 2729-2750 PR00261D 12.47 3.813e-14 3809-3830 PR00261E 11.08 3.850e-14 2767-2788 PR00261E 11.08 4.300e-14 2729-2750 PR00261C 11.37 4.358e-14 3444-3465 PROO261E 11.08 4.450e-14 2938-2959 PR00261D 12.47 4.797e-14 2558-2579 PR00261E 11.08 4.900e-14 3809-3830 PR00261F 11.57 4.919e-14 1101-1122 PR00261F 11.57 5.355e-14 3641-3662 PR00261C 11.37 6.104e-14 2599-2620 PR00261E 11.08 6.400e-14 3641-3662 PR00261A 11.02 7.092e-14 3809-3830 PR00261B 14.12 7.221e-14 3809-3830 PR00261B 14.12 7.353e-14 3641-3662 PR00261F 11.57 7.823e-14 1144-1165 PR00261B 14.12 7.882e-14 2687-2708 PR00261E 11.08 8.350e-14 3721-3742 PR00261E 11.08 8.650e-14 2809-2830 PR00261D 12.47 9.016e-14 3641-3662 PR00261C 11.37 9.328e-14 3721-3742 PR00261D 12.47 9.719e-14 2638-2659 PR00261C 11.37 1.522e-13 3600-3621 PR00261F 11.57 2.688e-13 2729-2750 PR00261E 11.08 2.828e-13 3404-3425 PR00261A 11.02 2.853e-13 2558-2579 PR00261B 14.12 2.901e-13 2852-2873 PR00261E 11.08 2.969e-13 2852-2873 PR00261E 11.08 2.969e-13 3764-3785 PR00261A 11.02 3.515e-13 974-995 PR00261C 11.37 3.609e-13 2687-2708 WO 2004/080148 PCT/US2003/030720 299 TABLE 3A SEQ Database Description Result* ID entry ID PR00261E 11.08 3.813e-13 3364-3385 PR00261A 11.02 3.912e-13 3721-3742 PR00261E 11.08 4.094e-13 1185-1206 PR00261E 11.08 4.094e-13 2638-2659 PR00261A 11.02 6.162e-13 3404-3425 PR00261A 11.02 6.956e-13 2893-2914 PR00261E 11.08 7.328e-13 3523-3544 PR00261A 11.02 7.485e-13 2599-2620 PR00261F 11.57 7.891e-13 2558-2579 PR00261B 14.12 7.972e-13 2638-2659 PR00261E 11.08 9.016e-13 3562-3583 PR00261E 11.08 9.297e-13 2558-2579 PR00261F 11.57 9.578e-13 3404-3425 PR00261F 11.57 9.578e-13 3680-3701 PR00261D 12.47 1.254e-12 3444-3465 PR00261F 11.57 1.265e-12 2809-2830 PR00261C 11.37 1.370e-12 933-954 PR00261E 11.08 1.545e-12 2687-2708 PR00261F 11.57 1.926e-12 3562-3583 PR00261F 11.57 2.456e-12 3721-3742 PR00261B 14.12 2.603e-12 3562-3583 PR00261F 11.57 3.382e-12 1185-1206 PR00261B 14,12 4.205e-12 3404-3425 PR00261E 11.08 4.955e-12 2893-2914 PR00261A 11.02 5.3 10e-12 3641-3662 PROO261C 11.37 6.178e-12 125-146 PR00261C 11.37 6.301e-12 1185-1206 PR00261F 11.57 8.147e-12 3484-3505 PR00261E 11.08 8.364e-12 80-101 PR00261E 11.08 8.500e-12 125-146 PR00261B 14.12 8.644e-12 3484-3505 PR00261F 11.57 8.676e-12 892-913 PR00261D 12.47 9.493e-12 2893-2914 PR00261A 11.02 1.365e-11 3444-3465 PR00261F 11.57 1.625e-11 3764-3785 PR00261E 11.08 1.643e-11 3484-3505 PR00261E 11.08 1.771e-11 3600-3621 PR00261A 11.02 2.581e-11 2638-2659 PR00261A 11.02 2.824e-11 1185-1206 PR00261F 11.57 3.500e-11 933-954 PR00261C 11.37 5.263e-11 2558-2579 PR00261F 11.57 5.375e-11 2687-2708 PR00261D 12.47 7.081e-11 125-146 PR00261A 11.02 7.811e-11 125-146 PR00261F 11.57 8.500e-11 3600-3621 PR00261E 11.08 9.871e-11 3444-3465 PR00261F 11.57 2.320e-10 80-101 PR00261F 11.57 2.920e-10 125-146 PR00261C 11.37 3.813e-10 2893-2914 PR00261B 14.12 5.11le-10 2558-2579 PR00261D 12.47 6.377e-10 3764-3785 PR00261D 12.47 6.610e-10 1185-1206 WO 2004/080148 PCT/US2003/030720 300 TABLE 3A SEQ Database Description Result* ID entry ID PR00261B 14.12 7.667e-10 125-146 PR00261B 14.12 8.889e-10 1185-1206 PR00261A 11.02 8.962e-10 3764-3785 PR00261E 11.08 9.137e-10 933-954 PR00261B 14.12 1.321e-09 2893-2914 PR00261C 11.37 7.429e-09 3764-3785 711 BL01177 Anaphylatoxin domain proteins. BL01177C 17.39 7.429e-09 2973-2991 BLO1177C 17.39 8.286e-09 200-218 711 BL00799 Granulins proteins. BL00799E 14.64 8.627e-09 1201-1249 711 PR00764 COMPLEMENT C9 SIGNATURE PR00764B 13.56 3.593e-15 1048-1068 PR00764B 13.56 2.227e-13 3636-3656 PR00764B 13.56 8.091e-13 1139-1159 PR00764B 13.56 5.565e-12 928-948 PR00764B 13.56 7.652e-12 1010-1030 PR00764B 13.56 8.043e-12 3399-3419 PR00764B 13.56 2.250e-11 3595-3615 PR00764B 13.56 4.000e-11 3557-3577 PR00764B 13.56 4.500e-11 2762-2782 PR00764B 13.56 6.000e-11 969-989 PR00764B 13.56 7.125e-11 2633-2653 PR00764B 13.56 8.875e-11 2724-2744 PR00764B 13.56 9.625e-11 887-907 PR00764B 13.56 6.377e-10 2804-2824 PR00764B 13.56 1.338e-09 3479-3499 PR00764B 13.56 1.563e-09 120-140 PR00764B 13.56 3.025e-09 3439-3459 PR00764B 13.56 3.925e-09 75-95 PR00764B 13.56 5.388e-09 2594-2614 PR00764B 13.56 6.963e-09 2553-2573 PR00764B 13.56 8.425e-09 2933-2953 PR00764B 13.56 8.763e-09 3518-3538 711 BL01187 Calcium-binding EGF-like domain proteins BLO1I187B 12.04 8.412e-15 206-221 pattern proteins. BL01 187B 12.04 2.333e-12 3019-3034 BLO1187B 12.04 7.300e-11 3895-3910 BL01 187B 12.04 4.600e-10 2979-2994 BL01187B 12.04 4.825e-09 3855-3870 BL01187A 9.98 5.500e-09 3003-3014 BLO1187A 9.98 9.625e-09 190-201 711 BL01209 LDL-receptor class A (LDLRA) domain BL01209 9.31 8.313e-16 89-101 proteins. BL01209 9.31 9.438e-16 1062-1074 BL01209 9.31 3.368e-15 2818-2830 BL01209 9.31 3.842e-15 1110-1122 BL01209 9.31 4.316e-15 901-913 BL01209 9.31 4.000e-14 2608-2620 BL01209 9.31 4.000e-14 3413-3425 BL01209 9.31 5.125e-14 3571-3583 BL01209 9.31 5.500e-14 1194-1206 BL01209 9.31 7.750e-14 2902-2914 BL01209 9.31 8.125e-14 3650-3662 BL01209 9.31 9.250e-14 1153-1165 BL01209 9.31 1.000e-13 3730-3742 BL01209 9.31 6.700e-13 2738-2750 WO 2004/080148 PCT/US2003/030720 301 TABLE 3A SEQ Database Description Result* ID entry ID BL01209 9.31 7.000e-13 3689-3701 BL01209 9.31 8.500e-13 2696-2708 BL01209 9.31 3.605e-12 2567-2579 BL01209 9.31 7.632e-12 3453-3465 BL01209 9.31 8.105e-12 2776-2788 BL01209 9.31 8.579e-12 1024-1036 BL01209 9.31 1.196e-11 2861-2873 BL01209 9.31 3.543e-11 134-146 BL01209 9.31 5.109e-11 3373-3385 BL01209 9.31 6.087e-1 1 2947-2959 BL01209 9.31 6.478e-11 3609-3621 BL01209 9.31 9.413e-11 3773-3785 BL01209 9.31 1.346e-10 3818-3830 BL01209 9.31 3.769e-10 3493-3505 BL01209 9.31 4.115e-10 3532-3544 BL01209 9.31 4.98le-10 942-954 BL01209 9.31 7.23 le-10 983-995 BL01209 9.31 9.679e-09 2647-2659 711 PR00054 FUNGAL ZN-CYS BINUCLEAR PROO054B 8.73 1.000e-08 3605-3611 CLUSTER SIGNATURE 712 BL01209 LDL-receptor class A (LDLRA) domain BL01209 9.31 8.313e-16 89-101 proteins. BL01209 9.31 3.543e-11 134-146 712 PR00261 LOW DENSITY LIPOPROTEIN (LDL) PR00261A 11.02 3.288e-16 80-101 RECEPTOR SIGNATURE PR00261C 11.37 9.115e-16 80-101 PR00261D 12.47 3.286e-15 80-101 PR00261B 14.12 5.985e-15 80-101 PR00261C 11.37 6.178e-12 125-146 PR00261E 11.08 8.227e-12 80-101 PR00261E 11.08 8.500e-12 125-146 PR00261F 11.57 6.875e-11 80-101 PR00261D 12.47 7.081e-11 125-146 PR00261A 11.02 7.811e-11 125-146 PR00261F 11.57 2.920e-10 125-146 PR00261B 14.12 7.667e-10 125-146 712 PR00764 COMPLEMENT C9 SIGNATURE PR00764B 13.56 1.563e-09 120-140 712 PR00907 THROMBOMODULIN SIGNATURE PR00907B 11.29 5.720e-09 162-178 714 BL00232 Cadherins extracellular repeat proteins BL00232B 32.79 2.765e-25 233-280 domain proteins. BL00232B 32.79 8.263e-22 458-505 BL00232B 32.79 4.571e-19 1193-1240 BL00232B 32.79 8.857e-19 1083-1130 BL00232B 32.79 2.662e-18 1403-1450 BL00232B 32.79 5.292e-18 979-1026 BL00232B 32.79 9.585e-18 1298-1345 BL00232B 32.79 1.265e-17 672-719 BL00232B 32.79 1.529e-17 118-165 BL00232B 32.79 2.588e-17 776-823 BL00232B 32.79 1.386e-16 876-923 BL00232C 10.65 5.390e-12 1081-1098 BL00232C 10.65 1.391e-11 334-351 BL00232C 10.65 2.174e-11 1296-1313 BL00232C 10.65 4.522e-11 1401-1418 BL00232C 10.65 4.115e-10 977-994 WO 2004/080148 PCT/US2003/030720 302 TABLE 3A SEQ Database Description Result* ID entry ID BL00232B 32.79 7.200e-10 341-388 BL00232C 10.65 9.827e-10 670-687 BL00232C 10.65 4.474e-09 874-891 BL00232C 10.65 8.737e-09 231-248 714 PR00205 CADHERIN SIGNATURE PR00205B 11.39 4.353e-11 977-994 PR00205B 11.39 4.529e-11 231-248 PR00205B 11.39 7.529e-11 1081-1098 PR00205B 11.39 1.655e-10 1296-1313 PR00205B 11.39 4.764e-10 1191-1208 PR00205B 11.39 5.091e-10 1401-1418 PR00205B 11.39 6.400e-10 456-473 PR00205B 11.39 1.000e-09 334-351 PR00205B 11.39 1.763e-09 874-891 PR00205B 11.39 7.712e-09 563-580 PROO205B 11.39 9.085e-09 670-687 715 BL00232 Cadherins extracellular repeat proteins BL00232B 32.79 2.765e-25 233-280 domain proteins. BL00232B 32.79 8.263e-22 458-505 BL00232B 32.79 4.571e-19 1193-1240 BL00232B 32.79 8.857e-19 1083-1130 BL00232B 32.79 2.662e-18 1403-1450 BL00232B 32.79 5.292e-18 979-1026 BL00232B 32.79 9.585e-18 1298-1345 BL00232B 32.79 1.265e-17 672-719 BL00232B 32.79 1.529e-17 118-165 BL00232B 32.79 2.588e-17 776-823 BL00232B 32.79 1.386e-16 876-923 BL00232C 10.65 5.390e-12 1081-1098 BL00232C 10.65 1.391e-11 334-351 BL00232C 10.65 2.174e-11 1296-1313 BL00232C 10.65 4.522e-11 1401-1418 BL00232C 10.65 4.115e-10 977-994 BL00232B 32.79 7.200e-10 341-388 BL00232C 10.65 9.827e-10 670-687 BL00232C 10.65 4.474e-09 874-891 BL00232C 10.65 8.737e-09 231-248 715 PR0020s CADHERIN SIGNATURE PR00205B 11.39 4.353e-11 977-994 PR00205B 11.39 4.529e-11 231-248 PR00205B 11.39 7.529e-11 1081-1098 PR00205B 11.39 1.655e-10 1296-1313 PR00205B 11.39 4.764e-10 1191-1208 PR00205B 11.39 5.091e-10 1401-1418 PR00205B 11.39 6.400e-10 456-473 PR00205B 11.39 1.000e-09 334-351 PR00205B 11.39 1.763e-09 874-891 PR00205B 11.39 7.712e-09 563-580 PR00205B 11.39 9.085e-09 670-687 716 BL00708 Prolyl endopeptidase family serine proteins. BL00708B 24.91 7.197e-12 706-736 716 PF00930 Dipeptidyl peptidase IV (DPP IV) N-terminal PF009301 15.96 6.373e-17 748-775 region. PF00930H 20.16 2.482e-13 669-711 PF00930J 8.78 1.000e-1 1 800-820 PF00930G 21.30 9.613e-09 629-666 717 BL00028 Zinc finger, C2H2 type, domainproteins. BL00028 16.07 3.118e-14 156-172 WO 2004/080148 PCT/US2003/030720 303 TABLE 3A SEQ Database Description Result* ID entry ID BL00028 16.07 1.900e-13 352-368 BL00028 16.07 2.565e-12 240-256 BL00028 16.07 4.130e-12 212-228 BL00028 16.07 8.435e-12 324-340 BL00028 16.07 5.154e-11 268-284 BL00028 16.07 6.192e-11 296-312 BL00028 16.07 6.885e-11 184-200 717 PD00066 PROTEIN ZINC-FINGER METAL-BTNDTI. PD00066 13.92 8.800e-14 172-184 PD00066 13.92 4.857e-12 200-212 PD00066 13.92 5.286e-12 228-240 PD00066 13.92 6.143e-12 340-352 PD00066 13.92 7.000e-12 256-268 PD00066 13.92 2.957e-11 312-324 PD00066 13.92 5.304e-11 50-62 PD00066 13.92 7.23 1e-10 78-90 PD00066 13.92 3.100e-09 284-296 717 PR00048 C2H2-TYPE ZINC FINGER SIGNATURE PROO048A 10.52 5.909e-15 321-334 PROO048A 10.52 1.000e-14 181-194 PROO048A 10.52 1.000e- 14 349-362 PR00048A 10.52 3.571e-13 237-250 PR00048A 10.52 4.857e-13 153-166 PROO048A 10.52 1.947e-11 209-222 PROO048A 10.52 3.842e- 11 265-278 PROO048A 10.52 5.737e-11 293-306 PROO048B 6.02 9.308e-11 197-206 PR00048B 6.02 6.063e-10 225-234 PR00048B 6.02 6.063e-10 365-374 PR00048B 6.02 8.875e-10 169-178 PROO048B 6.02 5.737e-09 337-346 PR00048B 6.02 9.053e-09 309-318 718 DM01206 CORONAVIRUS NUCLEOCAPSID DMO1206B 10.69 3.278e-09 70-89 PROTEIN. DMO1206B 10.69 4.418e-09 105-124 718 BL00048 Protamine P1 proteins. BL00048 6.39 7.107e-16 64-90 BL00048 6.39 9.196e-16 63-89 BL00048 6.39 1.132e-12 62-88 BL00048 6.39 2.059e 12 66-92 BL00048 6.39 3.250e-12 65-91 BL00048 6.39 7.618e-12 92-118 BL00048 6.39 2.625e-11 60-86 BL00048 6.39 6.500e-11 113-139 BL00048 6.39 6.750e-11 78-104 BLOO048 6.39 6.875e 11 104-130 BL00048 6.39 7.125e-11 112-138 BL00048 6.39 8.625e-11 74-100 BL00048 6.39 2.539e-10 108-134 BL00048 6.39 4.434e-10 61-87 BL00048 6.39 5.855e-10 110-136 BL00048 6.39 6.921e-10 98-124 BL00048 6.39 7.158e 10 109-135 BL00048 6.39 7.750e-10 97 123 BL00048 6.39 8.105e-10 79-105 BL00048 6.39 8.579e-10 19-45 BL00048 6.39 8.934e-10 94-120 BLOO048 6.39 9.526e-10 103-129 BL00048 6.39 1.675e-09 101-127 BL00048 6.39 WO 2004/080148 PCT/US2003/030720 304 TABLE 3A SEQ Database Description Result* ID entry ID 1.900e-09 73-99 BL00048 6.39 3.250e 09 81-107 BL00048 6.39 3.475e-09 111 137 BL00048 6.39 3.700e-09 82-108 BL00048 6.39 3.700e-09 96-122 BL00048 6.39 4.263e-09 99-125 BL00048 6.39 5.163e-09 107-133 BL00048 6.39 5.275e-09 67-93 BL00048 6.39 5.275e-09 80-106 BL00048 6.39 5.388e-09 49-75 BL00048 6.39 6.738e 09 116-142 BL00048 6.39 7.975e-09 124-150 BL00048 6.39 8.650e-09 52-78 BL00048 6.39 8.763e-09 18-44 BL00048 6.39 9.100e-09 21-47 BL00048 6.39 9.550e-09 76-102 BL00048 6.39 9.550e 09 100-126 BL00048 6.39 9.663e-09 102-128 BL00048 6.39 1.000e-08 77-103 720 PD01719 PRECURSOR GLYCOPROTEIN SIGNAL PDO1719A 12.89 5.875e-20 1548-1575 RE. PD01719A 12.89 8.200e-17 1719-1746 PDO1719A 12.89 9.182e-17 1491-1518 PDO1719A 12.89 4.569e-16 1434-1461 PDO1719A 12.89 7.286e-14 1605-1632 PDO1719A 12.89 2.364e-13 1662-1689 720 BLO1187 Calcium-binding EGF-like domain proteins BLO1 187B 12.04 6.538e-16 2348-2363 pattern proteins. BL01 187B 12.04 3.647e-15 2191-2206 BL01187B 12.04 5.696e-13 2108-2123 BLO1187B 12.04 7.261e-13 2232-2247 BLO1187A 9.98 4.316e-11 2172-2183 BLO 187A 9.98 1.429e-10 2047-2058 BL01187B 12.04 2.286e-10 2023-2038 BLO1 187A 9.98 1.750e-09 2332-2343 720 BLO1177 Anaphylatoxin domain proteins. BLO I177D 17.50 5.167e-09 2042-2059 720 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 2.256e-10 1000-1023 BLOO240B 24.70 5.395e-10 450-473 BL00240B 24.70 3.681e-09 1090-1113 BL00240B 24.70 6.170e-09 634-657 720 PR00010 TYPE II EGF-LIKE SIGNATURE PROO010C 11.16 2.091e-10 2353-2363 PROO010C 11.16 6.357e-09 2196-2206 720 PD02870 RECEPTOR INTERLEUKIN-1 PD02870B 18.83 6.294e-11 763-795 PRECURSOR. PD02870B 18.83 8.306e-11 1126-1158 PD02870D 15.74 4.800e-10 1126-1160 PD02870B 18.83 7.400e-10 393-425 PD02870B 18.83 9.600e-10 670-702 PD02870B 18.83 1.862e-09 945-977 PD02870B 18.83 3.585e-09 1215-1247 PD02870D 15.74 6.553e-09 854-888 PD02870B 18.83 6.745e-09 1306-1338 720 BL00281 Bowman-Birk serine protease inhibitors BL00281A 14.18 6.754e-09 2018-2034 family proteins. 720 BL00022 EGF-like domain proteins. BLOO022B 7.54 1.900e-09 2357-2363 BLOO022B 7.54 7.300e-09 2200-2206 720 BL00799 Granulins proteins. BL00799B 11.02 7.429e-09 2014-2049 720 DM00864 EGF-LIKE DOMAIN. DM00864B 11.34 7.465e-09 2196-2214 WO 2004/080148 PCT/US2003/030720 305 TABLE 3A SEQ Database Description Result* ID entry ID 720 PD02327 GLYCOPROTEIN ANTIGEN PRECURSOR PD02327B 19.84 7.818e-09 450-471 IMMUNOGLO. 720 DM01688 2 POLY-IG RECEPTOR. DM01688D 13.44 2.756e-09 679-701 DM01688G 16.45 6.040e-09 1210-1241 DM01688D 13.44 8.244e-09 26-48 720 DM00179 w KINASE ALPHA ADHESION T-CELL. DM00179 13.97 5.737e-10 119-128 DM00179 13.97 9.053e-10 494-503 DM00179 13.97 6.870e-09 25-34 DM00179 13.97 8.043e-09 1223-1232 DM00179 13.97 8.435e-09 401-410 720 PR00907 THROMBOMODULIN SIGNATURE PR00907B 11.29 2.479e-11 2344-2360 PR00907B 11.29 3.688e-10 2228-2244 PR00907G 11.63 9.660e-10 2348-2374 PR00907G 11.63 9.745e-10 2232-2258 PR00907G 11.63 9.027e-09 2108-2134 720 PDO0015 GLYCOPROTEIN PRECURSOR CELL SI. PD00015B 5.21 1.000e-08 1279-1285 721 BL00674 AAA-protein family proteins. BL00674B 4.46 1.122e-09 452-473 721 BL00300 SRP54-type proteins GTP-binding domain BL00300B 20.56 3.228e-09 452-497 proteins. 722 BL00211 ABC transporters family proteins. BL00211B 13.37 9.053e-22 618-649 BL00211B 13.37 3.314e-13 1430-1461 BL00211A 12.23 2.385e- 11 515-526 BL00211A 12.23 1.529e-10 1327-1338 722 PR00326 GTP1/OBG GTP-BINDING PROTEIN PR00326A 8.75 1.129e-09 513-533 FAMILY SIGNATURE PR00326A 8.75 2.671e-09 1325-1345 722 BL00649 G-protein coupled receptors family 2 proteins. BL00649F 14.99 4.76le-09 857-878 723 BL00130 Uracil-DNA glycosylase proteins. BLOO130A 13.75 1.000e-08 576-588 724 BL00072 Acyl-CoA dehydrogenases proteins. BLOO072E 24.12 5,014e-12 156-198 BLOO072D 30.08 7.136e-10 67-117 725 BL00740 MAM domain proteins. BL00740A 13.87 7.188e-12 409-421 725 PROO020 MAM DOMAIN SIGNATURE PROO020A 18.17 9.816e-12 407-425 725 PR00907 THROMBOMODULIN SIGNATURE PR00907B 11.29 4.082e-11 143-159 725 PF00094 von Willebrand factor type D domain PF00094A 11.09 5.109e-09 138-147 proteins. 725 BL00243 Integrins beta chain cysteine-rich domain BL00243H 17.53 7.632e-09 68-93 proteins. 725 BLO1177 Anaphylatoxin domain proteins. BLO I177E 20.64 9.882e-09 145-171 725 BL01187 Calcium-binding EGF-like domain proteins BLO1187B 12.04 9.1OOe-14 236-251 pattern proteins. BL01187B 12.04 5.333e-12 191-206 BLO1187B 12.04 6.333e-12 109-124 BLO1 187A 9.98 9.250e-09 172-183 BLO1187A 9.98 1.000e-08 217-228 727 PD00930 PROTEIN GTPASE DOMAIN PDO0930B 33.72 6.108e-22 898-938 ACTIVATION. PDO0930A 25.62 3.415e-14 775-800 727 BL00479 Phorbol esters / diacylglycerol binding BL00479B 12.57 4.706e- 12 724-739 domain proteins. 727 PF00620 GTPase-activator protein for Rho-like PF00620B 14.20 6.000e-10 825-841 GTPases. 727 BL01240 Purine and other phosphorylases family 2 BLO1240C 25.01 1.414e-09,36-77 proteins. 729 BL00142 Neutral zinc metallopeptidases, zinc-binding BL00142 8.38 8.875e-10 412-422 WO 2004/080148 PCT/US2003/030720 306 TABLE 3A SEQ Database Description Result* ID entry ID region proteins. 729 PD01719 PRECURSOR GLYCOPROTEIN SIGNAL PDO1719A 12.89 4.150e-15 572-599 RE. PDO1719A 12.89 3.487e-10 1222-1249 PD01719A 12.89 6.447e-10 1166-1193 PD01719A 12.89 1.778e-09 1425-1452 PDO1719A 12.89 7.556e-09 1091-1118 735 BL00741 Guanine-nucleotide dissociation stimulators BL00741B 14.27 1.333e-14 302-324 CDC24 family sign. 742 PR00205 CADHERIN SIGNATURE PR00205B 11.39 3.571e-13 656-673 PR00205B 11.39 9.357e-13 233-250 PR00205B 11.39 9.413e-12 339-356 PR00205B 11.39 7.055e-10 450-467 PR00205B 11.39 8.691e-10 553-570 742 BL00232 Cadherins extracellular repeat proteins BL00232B 32.79 8.615e-24 235-282 domain proteins. BL00232B 32.79 3.63le-18 555-602 BL00232B 32.79 9.862e-18 452-499 BL00232B 32.79 2.11Oe-15 125-172 BL00232C 10.65 6.500e-13 233-250 BL00232C 10.65 8.750e-13 656-673 BL00232C 10.65 6.087e-11 339-356 BL00232C 10.65 9.827e-10 450-467 745 BL00028 Zinc finger, C2H2 type, domain proteins. BL00028 16.07 4.375e-15 216-232 BL00028 16.07 8.313e-15 518-534 BL00028 16.07 1.529e-14 244-260 BL00028 16.07 1.000e-13 188-204 BL00028 16.07 2.350e-13 272-288 BL00028 16.07 1.000e-12 412-428 BL00028 16.07 2.957e-12 356-372 BL00028 16.07 2.957e-12 490-506 BL00028 16.07 2.957e-12 546-562 BL00028 16.07 3.348e-12 384-400 BL00028 16.07 4.522e-12 300-316 BL00028 16.07 6.870e-12 328-344 BL00028 16.07 1.000e-11 160-176 BL00028 16.07 3.400e-10 440-456 BL00028 16.07 1.000e-09 132-148 745 PR00048 C2H2-TYPE ZINC FINGER SIGNATURE PROO048A 10.52 5.091e-15 381-394 PROO048A 10.52 6.727e-15 269-282 PROO048A 10.52 6.727e-15 543-556 PROO048A 10.52 7.545e-15 487-500 PROO048A 10.52 9.182e-15 185-198 PROO048A 10.52 6.143e-13 213-226 PROO048A 10.52 7.429e-13 409-422 PROO048A 10.52 8.714e-13 241-254 PROO048A 10.52 8.714e-13 297-310 PROO048A 10.52 4.706e-12 353-366 PROO048B 6.02 6.000e-12 173-182 PROO048B 6.02 3.077e-11 341-350 PROO048B 6.02 7.923e-11 503-512 PROO048B 6.02 1.000e-10 229-238 PROO048A 10.52 4.522e-10 515-528 PROO048A 10.52 6.870e-10 129-142 WO 2004/080148 PCT/US2003/030720 307 TABLE 3A SEQ Database Description Result* ID entry ID PR00048B 6.02 8.875e-10 531-540 PROO048A 10.52 1.720e-09 157-170 PROO048A 10.52 2.800e-09 437-450 PROO048B 6.02 2.895e-09 453-462 PROO048B 6.02 5.737e-09 313-322 PROO048A 10.52 6.760e-09 325-338 745 PD00066 PROTEIN ZINC-FINGER METAL-BINDI. PD00066 13.92 5.200e-14 176-188 PD00066 13.92 8.200e-14 344-356 PD00066 13.92 4.000e-13 232-244 PD00066 13.92 1.857e-12 456-468 PD00066 13.92 3.571e-12 534-546 PD00066 13.92 4.000e-12 400-412 PD00066 13.92 1.000e-11 260-272 PD00066 13.92 1.000e-11 372-384 PD00066 13.92 4.522e-11 204-216 PD00066 13.92 1.000e-10 288-300 PD00066 13.92 7.300e-09 506-518 746 PDO1066 PROTEIN ZINC FINGER ZINC-FINGER PDO1066 19.43 8.250e-35 37-75 METAL-BINDING NU. 746 PD00066 PROTEIN ZINC-FINGER METAL-BINDI. PD00066 13.92 5.200e-14 251-263 PD00066 13.92 8.200e-14 419-431 PD00066 13.92 4.000e-13 307-319 PD00066 13.92 1.857e-12 531-543 PD00066 13.92 4.000e-12 475-487 PD00066 13.92 1.000e-11 335-347 PD00066 13.92 1.000e-11 447-459 PD00066 13.92 4.522e-11 279-291 PD00066 13.92 1.000e-10 363-375 746 BL00028 Zinc finger, C2H2 type, domain proteins. BL00028 16.07 4.375e-15 291-307 BL00028 16.07 1.529e-14 319-335 BL00028 16.07 1.000e-13 263-279 BL00028 16.07 2.350e-13 347-363 BL00028 16.07 1,000e-12 487-503 BL00028 16.07 2.957e-12 431-447 BL00028 16.07 3.348e-12 459-475 BL00028 16.07 4.522e-12 375-391 BL00028 16.07 6.870e-12 403-419 BL00028 16.07 1.000e-11 235-251 BL00028 16.07 3.400e-10 515-531 BL00028 16.07 1.000e-09 207-223 746 PR00048 C2H2-TYPE ZINC FINGER SIGNATURE PROO048A 10.52 5.091e-15 456-469 PR00048A 10.52 6.727e-15 344-357 PROO048A 10.52 9.182e-15 260-273 PROO048A 10.52 6.143e-13 288-301 PROO048A 10.52 7.429e-13 484-497 PROO048A 10.52 8.714e-13 316-329 PROO048A 10.52 8.714e-13 372-385 PROO048A 10.52 4.706e-12 428-441 PROO048B 6.02 6.000e-12 248-257 PROO048B 6.02 3.077e-11 416-425 PROO048B 6.02 1.000e-10 304-313 PROO048A 10.52 6.870e-10 204-217 WO 2004/080148 PCT/US2003/030720 308 TABLE 3A SEQ Database Description Result* ID entry ID PROO048A 10.52 1.720e-09 232-245 PR00048A 10.52 2.800e-09 512-525 PR00048B 6.02 2.895e-09 528-537 PROO048B 6.02 5.737e-09 388-397 PROO048A 10.52 6.760e-09 400-413 747 PF01105 emp24/gp25L/p24 family. PF01105B 25.12 2.868e-25 144-195 749 PR00405 HIV REV INTERACTING PROTEIN PR00405C 19.41 1.000e-18 579-600 SIGNATURE PR00405A 17.71 8.147e-18 539-558 PR00405B 11.83 7.300e-17 558-575 749 PF00791 Domain present in ZO-1 and Unc5-like netrin PF00791B 28.49 7.688e-09 831-885 receptors. 751 PD01066 PROTEIN ZINC FINGER ZINC-FINGER PD01066 19.43 6.143e-21 344-382 METAL-BINDING NU. 751 PD00066 PROTEIN ZINC-FINGER METAL-BINDI. PD00066 13.92 8.500e-13 769-781 PD00066 13.92 4.857e-12 711-723 751 PR00048 C2H2-TYPE ZINC FINGER SIGNATURE PROO048A 10.52 4.706e-12 778-791 PROO048B 6.02 6.538e-11 766-775 PROO048A 10.52 1.000e-10 750-763 PROO048A 10.52 4.130e-10 602-615 PROO048B 6.02 6.063e-10 708-717 PROO048A 10.52 8.043e-10 630-643 PROO048A 10.52 8.435e-10 692-705 PROO048A 10.52 1.360e-09 720-733 751 BL00028 Zinc finger, C2H2 type, domain proteins. BL00028 16.07 3.118e-14 753-769 BL00028 16.07 1.346e-11 781-797 BL00028 16.07 3.769e-11 605-621 BL00028 16.07 9.400e-10 723-739 BL00028 16.07 1.771e-09 695-711 754 BL01177 Anaphylatoxin domain proteins. BLO1177E 20.64 4.541e-13 790-816 754 BL00477 Alpha-2-macroglobulin family thiolester BL00477J 19.04 3.382e-27 1241-1271 region proteins. BL00477F 17.34 8.500e-25 785-814 BL00477G 19.43 8.826e-23 983-1014 BL00477A 13.50 9.800e-23 122-150 BL00477L 23.51 5.500e-16 1437-1469 BL00477K 17.42 4.529e-14 1382-1405 BL00477E 17.53 6.538e-13 755-775 BL00477B 9.05 6.625e-13 209-221 BL00477I 18.76 2.650e-12 1085-1111 BL00477D 12.73 4.073e-12 729-738 BL00477H 9.07 5.395e-12 1054-1065 BL00477C 15.70 1.161e-10 236-252 755 BL00514 Fibrinogen beta and gamma chains C- BL00514E 14.28 7.750e-12 299-315 terminal domain proteins. BL00514D 15.35 9.824e-11 280-292 BL00514G 15.98 4.273e-10 362-391 BL00514H 14.95 6.217e-09 397-421 756 BL00790 Receptor tyrosine kinase class V proteins. BL00790I 20.01 7.638e-10 868-898 756 PD02870 RECEPTOR INTERLEUKIN-1 PD02870B 18.83 5.309e-09 371-403 PRECURSOR. 756 DM00179 w KINASE ALPHA ADHESION T-CELL. DM00179 13.97 7.261e-09 189-198 756 PROO014 FIBRONECTIN TYPE III REPEAT PROO014B 14.77 6.400e-10 832-842 SIGNATURE PROO014D 12.04 3.700e-09 671-685 WO 2004/080148 PCT/US2003/030720 309 TABLE 3A SEQ Database Description Result* ID entry ID PROO014C 15.44 4.522e-09 857-875 PR00014D 12.04 8.200e-09 875-889 PRO0014D 12.04 9.550e-09 774-788 757 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 2.149e-09 306-329 757 PROO019 LEUC1NE-RICH REPEAT SIGNATURE PROO019A 11.19 1.450e-11 149-162 PROO019B 11.36 5.050e-10 98-111 PROO019B 11.36 7.840e-09 122-135 758 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 2.149e-09 306-329 758 PR00019 LEUC1NE-RICH REPEAT SIGNATURE PROO019A 11.19 1.450e-l1 149-162 PROO019B 11.36 5.050e-10 98-111 PROO019B 11.36 7.840e-09 122-135 759 BL00649 G-protein coupled receptors family 2 proteins. BL00649C 17.82 4.339e-11 1086-1111 759 PR00249 SECRETIN-LIKE GPCR SUPERFAMILY PR00249C 17.08 4.185e-10 1088-1111 SIGNATURE 760 BL00028 Zinc finger, C2H2 type, domain proteins. BL00028 16.07 8.313e-15 277-293 BL00028 16.07 1.900e-13 193-209 BLOO028 16.07 6.400e-13 137-153 BL00028 16.07 6.400e-13 389-405 BL00028 16.07 4.913e-12 109-125 BLOO028 16.07 8.826e-12 333-349 BL00028 16.07 1.000e-11 361-377 BL00028 16.07 1.692e-11 249-265 BL00028 16.07 3.077e-11 221-237 BL00028 16.07 6.538e-11 305-321 BL00028 16.07 7.577e-11 165-181 760 PD00066 PROTEIN ZINC-FINGER METAL-BINDI. PD00066 13.92 4.000e-14 265-277 PD00066 13.92 5.200e-14 97-109 PD00066 13.92 5.200e-14 293-305 PD00066 13.92 5.200e-14 321-333 PD00066 13.92 2.000e-13 209-221 PD00066 13.92 3.500e-13 181-193 PD00066 13.92 1.000e-12 377-389 PD00066 13.92 4.857e-12 237-249 PD00066 13.92 7.857e-12 125-137 PD00066 13.92 8.826e-1 1 405-417 PD00066 13.92 5.200e-09 349-361 760 PR00048 C2H2-TYPE ZINC FINGER SIGNATURE PROO048A 10.52 5.500e-14 330-343 PROO048A 10.52 7.000e-14 246-259 PROO048A 10.52 9.250e-14 190-203 PROO048A 10.52 1.643e-13 218-231 PROO048A 10.52 4.857e-13 274-287 PROO048A 10.52 1.000e-12 106-119 PR00048B 6.02 6.000e-12 94-103 PROO048B 6.02 6.000e-12 402-411 PROO048A 10.52 4.789e-11 134-147 PROO048B 6.02 5.846e-11 290-299 PR00048B 6.02 5.846e-11 374-383 PROO048A 10.52 9.526e-11 386-399 PR00048A 10.52 1.391e-10 302-315 PR00048A 10.52 1.783e-10 162-175 PROO048A 10.52 7.261e-10 414-427 PROO048B 6.02 8.875e-10 318-327 WO 2004/080148 PCT/US2003/030720 310 TABLE 3A SEQ Database Description Result* ID entry ID PROO048B 6.02 5.737e-09 262-271 760 PD02462 PROTEIN BOLA TRANSCRIPTION PD02462A 22.48 1.768e-09 270-304 REGULATION AC. PD02462A 22.48 6.488e-09 298-332 761 PROO121 SODIUM/POTASSIUM-TRANSPORTING PROO121D 16.72 6.844e-15 173-194 ATPASE SIGNATURE 761 BL00154 El-E2 ATPases phosphorylation site proteins. BL00154E 20.37 2.929e-13 446-486 BL0O154C 12.38 1.540e-12 176-194 761 PR00119 P-TYPE CATION-TRANSPORTING PR0O119B 13.94 7.245e-12 180-194 ATPASE SUPERFAMILY SIGNATURE 761 BL01228 Hypothetical cof family proteins. BL01228D 17.44 6.348e-09 595-619 763 BL00028 Zinc finger, C2H2 type, domain proteins. BL00028 16.07 7.686e-09 172-188 764 BL00892 HIT family proteins. BL00892A 18.17 2.125e-10 177-207 764 BL00064 L-lactate dehydrogenase proteins. BLOO064F 25.14 7.720e-09 295-339 767 PD02102 SUBUNIT E V-ATPASE VACUOLAR ATP PD02102A 16.74 8.318e-09 121-164 SYNTHASE HYDROL. 768 BL00926 Lysyl oxidase copper-binding region BL00926E 14.42 2.976e-22 306-342 proteins. BL00926D 9.03 6.336e-14 260-306 768 PR00074 LYSYL OXIDASE SIGNATURE PROO074C 8.72 2.674e-18 311-339 PR00074A 9.55 2.514e-10 255-283 768 BL00420 Speract receptor repeat proteins domain BL00420B 22.67 5.500e-29 33-87 proteins. BL00420C 11.90 8.017e-11 118-128 BL00420B 22.67 3.526e-10 147-201 768 PR00258 SPERACT RECEPTOR SIGNATURE PR00258A 11.46 5.721e- 11 139-155 PR00258E 13.33 7.000e-l1 117-129 PR00258B 9.63 2.180e-10 48-59 PR00258C 9.05 2.469e-10 63-73 PR00258A 11.46 2.746e-10 29-45 PR00258D 14.41 4.724e-10 94-108 PR00258D 14.41 7.429e-09 210-224 773 BL01315 Phosphatidate cytidylyltransferase proteins. BLO1315C 18.61 1.000e-40 342-385 BLO1315A 22.47 8.650e-28 221-252 BLO1315B 10.40 1.000e-17 253-266 774 PR00320 G-PROTEIN BETA WD-40 REPEAT PR00320A 16.74 5.655e-11 190-204 SIGNATURE PR00320C 13.01 8.560e-10 190-204 PR00320B 12.19 8.425e-09 190-204 779 BLO1 152 Hypothetical hesB/yadR/yfhF family proteins. BLO1152B 20.12 1.581e-17 70-95 BLO1152C 25.93 1.659e-11 103-149 783 BL00280 Pancreatic trypsin inhibitor (Kunitz) family BL00280 24.61 7.070e-26 547-590 proteins. 783 PR00453 VON WILLEBRAND FACTOR TYPE A PR00453A 12.79 3.483e-14 265-282 DOMAIN SIGNATURE 783 PR00759 BASIC PROTEASE (KUNITZ-TYPE) PR00759C 14.15 1.205e-10 575-590 INHIBITOR FAMILY SIGNATURE PR00759B 11.26 7.968e-10 565-575 783 BLO1113 CIq domain proteins. BLO 113A 17.99 4.447e-10 54-80 BLO1113A 17.99 4.638e-10 100-126 BLO1113A 17.99 7.702e-10 57-83 BLO1113A 17.99 1.865e-09 106-132 BLO1113A 17.99 3.250e-09 60-86 BLO I1l13A 17.99 3.250e-09 213-239 BLO1113A 17.99 3.423e-09 34-60 BLO1113A 17.99 6.365e-09 198-224 WO 2004/080148 PCT/US2003/030720 311 TABLE 3A SEQ Database Description Result* ID entry ID BLO1l113A 17.99 7.231le-09 109-135 783 BL00420 Speract receptor repeat proteins domain BLOO420A 20.42 3.213e-10 16-44 proteins. BLOO420A 20.42 1.415e-09 100-128 BLOO420A 20.42 7.923e-09 2 16-244 BL00420A 20.42 8.477e-09 169-197 785 BL00240 Receptor tyrosine kinase class III proteins. BLOO240B 24.70 5.404e-09 336-359 786 PR00918 CALICIVIRUS NON-STRUCTURAL PR00918A 13.76 4.284e-12 27-47 POLYPROTEIN FAMILY SIGNATURE 786 BLO1 128 Shikimate kinase proteins. BLO1128A 18.84 6.684e-11 394-427 786 BL00795 Involucrin proteins. BL00795C 17.06 8.000e-11 191-235 786 BL00300 SRP54-type proteins GTP-binding domain BL00300B 20.56 4.032e-10 391-436 proteins. 786 PR0830 ENDOPEPTlDASE LA (LON) SERINE PRO830A 8.41 4.452e-09 37-56 ____________PROTEASE (S16) SIGNATURE 786 BL00113 Adenylate kinase proteins. BLOO0113A 12.74 3.782e-1 134-50 BLOO113 20.49 4.974e-11 58-101 BLOO113A 12.74 5.43e-09 395-411 786 BL00674 AAA-protein familyproteins. BL00674B 4.46 5.986e-09 30-51 786 PR00819 CBXX/CFQX SUPERFAMILY PROO819B 10.83 7.247e-09 32-47 SIGNATURE 786 PR00364 DISEASE RESISTANCE PROTEIN PR00364A 8.19 8.057e-09 32-47 SIGNATURE 786 PR00449 TRANSFORMING PROTEIN P21 RAS PR00449A 13.20 8.914e-09 31-52 SIGNATURE 788 BL50012 Src homology 3 (13) domain proteins BL50012B 15.18 1.782e-10 42-55 profile. BL50012A 14.19 3.813e-09 4-22 789 BL50002 Src homology 3 (SH3) domain proteins BL50002B 15.18 l.OO0e-10 115-128 profile. BL50002A 14.19 3.813e-09 77-95 790 BL00288 Tissue inhibitors of metalloproteinases BL00288A 17.47 9.143e-21 10-39 proteins. BL00288C 14.62 6.86e-18 73-87 BL00288B 9.44 7.24e-15 54-64 791 BL0061 C-type lectin domain proteins. BL00615A 16.68 2.080e-1 156-173 792 BL00375 UDP-glycosyltransferases proteins. BL00375F 16.99 1.000e-40 270-314 BL00375G 13.01 1.83e-40 369-4-08 BL00375E 18.75 3.250e-37 215-264 BL00375D 14.56 5.622e-24 175-202 BL0037C 18.27 6.478e-24 110-133 BL00375B 21.22 5.000e-22 47-87 794 BL01183 ubiE/COQ5 methyltransferase family BLO1083B 21.31 6.660e-12 143-187 proteins. 794 BL01279 Protein-L-isoaspartate(D-aspartate) 0- BL01279A 24.27 5.862e-0 57-104 _____ ____________methyltransferase signa. 795 BL00237 G-protein coupled receptors proteins. BL00237A 27.68 3.045e-21 494-533 795 PR00237 RHODOPSIN-LIKE GPCR SUPER-FAMILY PR00237C 15.69 2.000e-12 508-530 SIGNATURE PR00237B 13.50 4.414e-2 1463-484 PR00237D 8.94 5.478e- 11544-565 796 DM01688 2BPOLY-IG RECEPTOR. DM01688B 15.06 2.500e-10 82-129 797 DM01688 2POLY-IG RECEPTOR DM01688B 15.06 2.500e-10 82-129 798 DM01688 2POLY-IG RECEPTOR. DM01688B 15.06 3.628e-09 82-129 802 PF00997 Kappa casein. PF00997D 9.95 8.306e-09 506-540 04 PD02080 T-CELL GLYCOPROTEIN CD8 CHAIN PD028B 20.69 9.716e-09 20-58 WO 2004/080148 PCT/US2003/030720 312 TABLE 3A SEQ Database Description Result* ID entry ID SURFACE ALPHA PRE. 804 PD01270 RECEPTOR FC IMMUNOGLOBULIN PDO1270A 17.22 9.806e-09 19-58 AFFIN. 805 BL00982 Bacterial-type phytoene dehydrogenase BL00982E 9.88 4.857e-1 1 24-39 proteins. 806 BL00243 Integrins beta chain cysteine-rich domain BL00243H 17.53 8.696e-1 1 72-97 proteins. 807 BL00243 Integrins beta chain cysteine-rich domain BL00243H 17.53 8.696e-1 1 72-97 proteins. 808 BL00243 Integrins beta chain cysteine-rich domain BL00243H 17.53 8.696e-1 1 72-97 proteins. 812 BL00240 Receptor tyrosine kinase class III proteins. BLOO240B 24.70 2.674e-10 279-302 BL00240B 24.70 8.535e-10 374-397 BL00240B 24.70 7.702e-09 470-493 812 PD02870 RECEPTOR INTERLEUKIN-1 PD02870B 18.83 4.600e-10 512-544 PRECURSOR. PD02870B 18.83 7.894e-09 120-152 813 PD02870 RECEPTOR INTERLEUKIN-1 PD02870B 18.83 4.600e-10 2395-2427 PRECURSOR. PD02870B 18.83 4.160e-09 1707-1739 PD02870B 18.83 5.883e-09 1806-1838 PD02870B 18.83 7.894e-09 2003-2035 PD02870B 18.83 7.989e-09 435-467 813 PDO0015 GLYCOPROTEIN PRECURSOR CELL SI. PDO0015B 5.21 8.000e-09 1481-1487 813 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 2.256e-10 1667-1690 BL00240B 24.70 2.674e-10 2162-2185 BL00240B 24.70 8.535e-10 2257-2280 BL00240B 24.70 4.064e-09 1570-1593 BL00240B 24.70 5.213e-09 300-323 BL00240B 24.70 7.702e-09 2353-2376 BL00240B 24.70 8.85le-09 1473-1496 814 PR00500 POLYCYSTIC KIDNEY DISEASE PROO500B 7.74 6.305e-09 220-240 PROTEIN SIGNATURE 814 PD02870 RECEPTOR INTERLEUKIN-1 PD02870B 18.83 4.600e-10 2590-2622 PRECURSOR. PD02870B 18.83 4.160e-09 1902-1934 PD02870B 18.83 5.883e-09 2001-2033 PD02870B 18.83 7.894e-09 2198-2230 PD02870B 18.83 7.989e-09 630-662 814 PDO0015 GLYCOPROTEIN PRECURSOR CELL SI. PDO0015B 5.21 8.000e-09 1676-1682 814 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 2.256e-10 1862-1885 BL00240B 24.70 2.674e-10 2357-2380 BL00240B 24.70 8.535e-10 2452-2475 BL00240B 24.70 4.064e-09 1765-1788 BL00240B 24.70 5.213e-09 495-518 BL00240B 24.70 7.702e-09 2548-2571 BL00240B 24.70 8.851e-09 1668-1691 816 PD01733 APOLIPOPROTEIN PLASMA LIPID PD01733B 20.44 6.600e-14 75-129 TRANSPORT H. 816 PD02807 APOLIPOPROTEIN E PRECURSOR APO- PD02807D 7.99 4.779e-09 92-141 E GLYCOPROTEIN PLAS. 817 PD01733 APOLIPOPROTEIN PLASMA LIPID PD01733B 20.44 6.600e-14 75-129 TRANSPORT H. 817 PD02807 APOLIPOPROTEIN E PRECURSOR APO- PD02807D 7.99 4.779e-09 92-141 WO 2004/080148 PCT/US2003/030720 313 TABLE 3A SEQ Database Description Result* ID entry ID E GLYCOPROTEIN PLAS. 819 PR00389 PHOSPHOLIPASE A2 SIGNATURE PR00389C 18.33 3.172e-20 56-74 PR00389B 10.70 8.154e-15 37-55 PR00389E 12.52 5.385e-14 104-120 819 BLOO118 Phospholipase A2 histidine proteins. BLOO 118B 16.33 5.875e-33 44-71 BLO0118D 12.85 7.500e-14 104-119 BLOO I18C 13.90 8.342e-10 79-97 821 BL00908 Mandelate racemase / muconate lactonizing BL00908B 37.71 1.900e-15 209-263 enzyme family signa. BL00908A 15.14 5.310e-10 87-113 822 PF00956 Nuclesosome assembly protein (NAP). PF00956B 23.14 1.000e-40 99-139 PF00956C 7.72 6.850e-22 153-170 PF00956A 11.88 1.000e-13 58-68 PF00956D 7.51 3.700e-12 232-242 822 BL00824 Elongation factor 1 beta/beta'/delta chain BL00824B 9.21 3.676e-09 286-305 proteins. 823 BL01032 Protein phosphatase 2C proteins. BLO1032C 6.14 3.195e-12 147-156 BLO1032H 11.25 5.680e-11 318-330 BLO1032G 8.33 8.932e-11 282-295 BL01032I 10.42 8.902e-09 379-388 824 PF00094 von Willebrand factor type D domain PF00094C 12.88 1.918e-09 124-133 proteins. 824 PD02576 PRECURSOR GLYCOPROTEIN SIGNAL PD02576A 27.60 9.057e-09 101-149 CELL. 825 PR00245 OLFACTORY RECEPTOR SIGNATURE PR00245C 7.84 5.355e-17 121-136 PR00245B 10.38 3.919e-12 60-74 PR00245E 12.40 1.000e-10 174-188 825 BL00237 G-protein coupled receptors proteins. BL00237D 11.23 2.091e-09 165-181 825 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237G 19.63 8.714e-11 155-181 SIGNATURE PR00237E 13.03 9.735e-09 82-105 826 PR00245 OLFACTORY RECEPTOR SIGNATURE PR00245C 7.84 5.355e-17 235-250 PR00245A 18.03 8.615e-15 58-79 PR00245B 10.38 3.919e-12 174-188 PR00245E 12.40 1.000e-10 288-302 826 BL00237 G-protein coupled receptors proteins. BL00237A 27.68 1.581e-15 89-128 BL00237D 11.23 2.091e-09 279-295 826 PR00896 VASOPRESSIN RECEPTOR SIGNATURE PR00896B 9.01 8.962e-09 54-65 826 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237G 19.63 8.714e-11 269-295 SIGNATURE PR00237C 15.69 3.829e-10 103-125 PR00237E 13.03 9.735e-09 196-219 827 BL00243 Integrins beta chain cysteine-rich domain BL00243H 17.53 5.650e-14 39-64 proteins. BL00243H 17.53 4.261e-11 5-30 828 PD00930 PROTEIN GTPASE DOMAIN PDO0930B 33.72 7.070e-19 201-241 ACTIVATION. 831 PR00193 MYOSIN HEAVY CHAIN SIGNATURE PROO193C 12.60 1.383e-23 177-204 PROO193B 11.69 2.212e-18 125-150 PROO193A 15.41 5.925e-12 65-84 831 BL00567 Phosphoribulokinase proteins. BL00567A 10.66 9.03le-10 127-145 832 PR00193 MYOSIN HEAVY CHAIN SIGNATURE PROO193C 12.60 1.383e-23 177-204 PROO193B 11.69 2.212e-18 125-150 PROO193A 15.41 5.925e-12 65-84 832 BL00567 Phosphoribulokinase proteins. BL00567A 10.66 9.031e-10 127-145 WO 2004/080148 PCT/US2003/030720 314 TABLE 3A SEQ Database Description Result* ID entry ID 834 BL00484 Thyroglobulin type-1 repeat proteins proteins. BL00484C 17.01 3.647e-12 358-372 BL00484B 9.04 4.529e-1 1 338-351 834 BL00282 Kazal serine protease inhibitors family BL00282 16.88 3.880e-09 143-165 proteins. 834 BL00612 Osteonectin domain proteins. BL00612E 13.12 8.230e-09 274-318 835 BL00817 Erythropoietin / thrombopoeitin proteins. BLOO817A 18.03 8.200e-10 515-545 835 PR00251 BACTERIAL OPSIN SIGNATURE PR00251A 12.15 8.820e-10 515-534 835 PR00807 POLLEN ALLERGEN AMB FAMILY PROO807A 16.64 8.151e-09 459-476 SIGNATURE 836 BLOO817 Erythropoietin / thrombopoeitin proteins. BL00817A 18.03 8.200e-10 515-545 836 PR00251 BACTERIAL OPSIN SIGNATURE PR00251A 12.15 8.820e-10 515-534 836 PR00807 POLLEN ALLERGEN AMB FAMILY PR00807A 16.64 8.15le-09 459-476 SIGNATURE 838 PROO019 LEUCINE-RICH REPEAT SIGNATURE PROO019A 11.19 8.435e-10 327-340 PROO019A 11.19 9.217e-10 182-195 PROO019A 11.19 3.333e-09 278-291 PROO019B 11.36 3.520e-09 227-240 PROO19B 11.36 9.280e-09 299-312 841 PF00023 Ank repeat proteins. PF00023A 16.03 6.464e-09 135-150 844 PDO1270 RECEPTOR FC IMMUNOGLOBULIN PD01270D 24.66 5.378e-09 292-327 AFFIN. 844 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 9.809e-09 155-178 845 PROO020 MAM DOMAIN SIGNATURE PROO020A 18.17 5.776e-12 759-777 PROO020C 13.66 6.932e-10 832-843 845 PD01270 RECEPTOR FC IMMUNOGLOBULIN PDO1270D 24.66 5.378e-09 292-327 AFFIN. 845 BL00740 MAM domain proteins. BL00740A 13.87 8.313e-12 761-773 BL00740B 19.76 8.500e-09 901-921 845 PD02080 T-CELL GLYCOPROTEIN CD8 CHAIN PD02080B 20.69 9.621e-09 538-576 SURFACE ALPHA PRE. 845 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 9.809e-09 155-178 847 PR00360 C2 DOMAIN SIGNATURE PR00360B 13.61 4.273e-09 839-852 847 PF00780 Domain found in NIKI-like idnases, mouse PF007801 14.69 4.825e-09 165-194 citron and yeast ROM. 848 PR00360 C2 DOMAIN SIGNATURE PR00360B 13.61 4.273e-09 88-101 851 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 8.250e-12 174-197 851 DM00179 w KINASE ALPHA ADHESION T-CELL. DM00179 13.97 3.842e-10 218-227 851 PD02870 RECEPTOR INTERLEUKIN-1 PD02870B 18.83 5.500e-10 327-359 PRECURSOR. 851 PROO021 SMALL PROLINE-RICH PROTEIN PROO021A 4.31 8.405e-09 402-414 SIGNATURE 852 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 8.250e-12 170-193 852 DM00179 w KINASE ALPHA ADHESION T-CELL. DM00179 13.97 3.842e-10 214-223 852 PD02870 RECEPTOR INTERLEUKIN-1 PD02870B 18.83 5.500e-10 323-355 PRECURSOR. 852 PROO021 SMALL PROLINE-RICH PROTEIN PROO021A 4.31 8.405e-09 398-410 SIGNATURE 854 PF00168 C2 domain proteins. PF00168C 27.49 2.636e-10 183-208 PF00168C 27.49 6.318e-10 316-341 854 PR00399 SYNAPTOTAGMIN SIGNATURE PR00399C 12.82 7.324e-12 216-231 PR00399A 9.52 8.239e-11 145-160 WO 2004/080148 PCT/US2003/030720 315 TABLE 3A SEQ Database Description Result* ID entry ID PR00399B 14.27 8.277e-11 160-173 PR00399D 14.48 3.930e-10 236-246 PR00399B 14.27 1.915e-09 291-304 854 PR00360 C2 DOMAIN SIGNATURE PR00360B 13.61 6.897e-12 200-213 PR00360A 14.59 6.538e-11 304-316 PR00360B 13.61 8.636e-11 333-346 PR00360A 14.59 2.184e-09 173-185 855 PD01719 PRECURSOR GLYCOPROTEIN SIGNAL PDO1719A 12.89 3.483e-16 545-572 RE. 855 BL00142 Neutral zinc metallopeptidases, zinc-binding BL00142 8.38 7.545e-11 389-399 region proteins. 855 PR00480 ASTACIN FAMILY SIGNATURE PR00480B 15.41 9.182e-10 384-402 857 PR00833 POLLEN ALLERGEN POA PI PR00833H 2.30 3.077e-09 58-72 SIGNATURE 857 PF00930 Dipeptidyl peptidase IV (DPP IV) N-terminal PF00930J 8.78 1.OOOe-08 267-287 region. 858 PR00833 POLLEN ALLERGEN POA PI PR00833H 2.30 3.077e-09 51-65 SIGNATURE 858 PF00930 Dipeptidyl peptidase IV (DPP IV) N-terminal PF00930J 8.78 1.000e-08 260-280 region. 859 PR00258 SPERACT RECEPTOR SIGNATURE PR00258A 11.46 8.054e-16 333-349 PR00258B 9.63 1.509e-12 352-363 PR00258E 13.33 1.833e-10 421-433 859 BL00420 Speract receptor repeat proteins domain BL00420B 22.67 7.582e-30 337-391 proteins. BL00420C 11.90 9.100e-13 422-432 BLOO420A 20.42 8.269e-12 249-277 BL00420A 20.42 7.3 82e-1 1 264-292 BL00420A 20.42 1.885e- 10 288-316 BLOO420A 20.42 7.344e-10 246-274 BL00420A 20.42 2.246e-09 261-289 859 BLO1113 C1q domain proteins. BLO1113A 17.99 3.189e-13 264-290 BLO1113A 17.99 5.909e-11 246-272 BLO1113A 17.99 1.383e-10 273-299 BLO1113A 17.99 2.149e-10 258-284 BL011 13A 17.99 2.915e-10 261-287 BLO1113A 17.99 5.596e-10 252-278 BLO 11 13A 17.99 7.128e- 10 267-293 BL01113A 17.99 1.692e-09 282-308 BL01113A 17.99 5.154e-09 255-281 860 BL00420 Speract receptor repeat proteins domain BL00420B 22.67 8.333e-39 397-451 proteins. BL00420C 11.90 9. 100e-13 482-492 BL00420A 20.42 9.135e-12 309-337 BL00420A 20.42 7.382e-11 324-352 BL00420A 20.42 1.885e-10 348-376 BLOO420A 20.42 7.639e-10 306-334 BL00420A 20.42 2.246e-09 321-349 860 PR00258 SPERACT RECEPTOR SIGNATURE PR00258A 11.46 8.054e-16 393-409 PR00258B 9.63 1.509e-12 412-423 PR00258E 13.33 1.833e-10 481-493 PR00258C 9.05 3.667e-09 427-437 860 BLO1113 C1q domain proteins. BLO1I13A 17.99 3.189e-13 324-350 WO 2004/080148 PCT/US2003/030720 316 TABLE 3A SEQ Database Description Result* ID entry ID BLO1113A 17.99 5.295e-11 306-332 BLO1113A 17.99 1.383e-10 333-359 BLO1113A 17.99 2.149e-10 318-344 BLO1113A 17.99 2.915e-10 321-347 BLO1113A 17.99 7.128e-10 327-353 BL01113A 17.99 1.692e-09 342-368 BLO1113A 17.99 4.115e-09 312-338 BLO1113A 17.99 5.673e-09 315-341 862 BL00028 Zinc finger, C2H2 type, domain proteins. BL00028 16.07 1.450e-13 222-238 BL00028 16.07 1.000e-12 474-490 BL00028 16.07 8.435e-12 502-518 BL00028 16.07 1.346e-11 306-322 BL00028 16.07 2.73 le-11 362-378 BL00028 16.07 2.731e-11 390-406 BL00028 16.07 3.423e-1 1 250-266 BL00028 16.07 3.423e-11 334-350 BL00028 16.07 7.577e-11 418-434 BL00028 16.07 1.600e-10 194-210 BL00028 16.07 9.400e-10 278-294 862 PDO0066 PROTEIN ZINC-FINGER METAL-BINDI. PD00066 13.92 8.200e-16 322-334 PD00066 13.92 7.231e-15 406-418 PD00066 13.92 7.923e-15 462-474 PD00066 13.92 4.600e-14 378-390 PD00066 13.92 5.200e-14 490-502 PD00066 13.92 1.000e-13 210-222 PD00066 13.92 1.000e-13 294-306 PD00066 13.92 3.000e-13 238-250 PD00066 13.92 5.304e-11 266-278 PD00066 13.92 7.652e-1 1 350-362 PD00066 13.92 7.000e-09 434-446 862 PR00048 C2H2-TYPE ZINC FINGER SIGNATURE PROO048A 10.52 7.545e-15 415-428 PROO048A 10.52 2.929e-13 387-400 PROO048A 10.52 6.786e-13 219-232 PR00048A 10.52 8.714e-13 443-456 PR00048A 10.52 2.059e-12 247-260 PROO048A 10.52 2.059e-12 331-344 PROO048A 10.52 5.235e-12 471-484 PROO048A 10.52 9.47le-12 499-512 PROO048B 6.02 2.385e-11 319-328 PROO048B 6.02 2.385e-11 487-496 PROO048A 10.52 9.053e-11 303-316 PROO048B 6.02 1.563e-10 375-384 PROO048A 10.52 2.957e-10 359-372 PROO048A 10.52 3.348e-10 191-204 PROO048B 6.02 8.313e-10 459-468 PROO048A 10.52 9.217e-10 275-288 PROO048B 6.02 9.43 8e-10 207-216 PROO048B 6.02 1.947e-09 263-272 PROO048B 6.02 3.368e-09 235-244 PROO048B 6.02 3.368e-09 291-300 PROO048B 6.02 7.158e-09 403-412 863 PD01234 PROTEIN NUCLEAR BROMODOMAIN PD01234B 15.53 3.250e-09 568-585 WO 2004/080148 PCT/US2003/030720 317 TABLE 3A SEQ Database Description Result* ID entry ID TRANS. 865 PR00320 G-PROTEIN BETA WD-40 REPEAT PR00320B 12.19 1.257e-10 225-239 SIGNATURE PR00320A 16.74 4.441e-10 225-239 865 BL00678 Trp-Asp (WD) repeat proteins proteins. BL00678 9.67 9.053e-09 227-237 867 BL00600 Aminotransferases class-III pyridoxal- BL00600E 16.43 1.771e-17 302-330 phosphate attachment si. BL00600A 17.98 3.880e-17 98-121 BL00600G 12.43 9.625e-17 377-395 BL00600B 19.60 5.091e-15 160-185 BL00600F 8.77 2.421e-12 343-355 BL00600C 16.18 6.040e-12 190-205 BL00600D 8.71 1.000e-10 281-294 868 BL00600 Aminotransferases class-IL pyridoxal- BL00600E 16.43 1.771e-17 199-227 phosphate attachment si. BL00600G 12.43 9.625e-17 274-292 BL00600B 19.60 2.703e-14 57-82 BL00600F 8.77 2.421e-12 240-252 BL00600C 16.18 6.040e-12 87-102 BL00600D 8.71 1.000e-10 178-191 869 BL00021 Kringle domain proteins. BLOO021D 24.56 1.188e-24 248-289 BLOO021B 13.33 2.983e-13 88-105 869 BL00134 Serine proteases, trypsin family, histidine BLOO134C 13.45 8.800e-15 276-289 proteins. BLOO134A 11.96 9.438e-15 88-104 BLOO 134B 15.99 3.676e- 12 237-260 869 BL00495 Apple domain proteins. BL004950 13.75 8.597e-16 267-295 BL00495N 11.04 2.235e-11 229-263 BL00495K 12.58 4.990e-10 90-122 869 PR00722 CHYMOTRYPSIN SERINE PROTEASE PR00722C 10.87 3.571e-14 236-248 FAMILY (S1) SIGNATURE PR00722A 12.27 5.966e-14 89-104 PR00722B 12.51 9.571e-10 145-159 869 BL01253 Type I fibronectin domain proteins. BLO1253H 13.15 3.609e-23 258-292 BLO1253G 11.34 4.103e-15 236-249 BLO1253D 4.84 4.360e-09 88-101 870 BL00188 Biotin-requiring enzymes attachment site BL00188 30.29 9.122e-09 154-199 proteins. 873 DM00758 AGRIN. DM00758 13.12 6.459e-10 93-108 873 BL00612 Osteonectin domain proteins. BL00612B 11.35 1.284e-09 86-118 873 DM00060 338 kw NEUREXIN ALPHA III CYSTEINE. DM00060 6.92 8.000e-1 1 1048-1057 DM00060 6.92 4.060e-09 128-137 873 BLO1185 C-terminal cystine knot proteins. BLO1 185B 21.14 4.388e-09 234-282 873 PROO010 TYPE II EGF-LIKE SIGNATURE PROO010A 11.79 1.450e-12 46-57 PROO010C 11.16 2.333e-11 184-194 PROO010C 11.16 9.333e-11 296-306 PROOO1OC 11.16 4.273e-10 66-76 PROO010C 11.16 7.000e-10 28-38 PROO010A 11.79 7.097e-10 488-499 PROO010C 11.16 3.571e-09 546-556 PROO010A 11.79 4.231e-09 564-575 PROOO1OC 11.16 5.929e-09 374-384 873 PR00764 COMPLEMENT C9 SIGNATURE PR00764F 16.89 4.699e-10 52-72 PR00764F 16.89 5.562e-10 170-190 PR00764F 16.89 6.301e-10 321-341 PR00764F 16.89 9.753e-10 360-380 WO 2004/080148 PCT/US2003/030720 318 TABLE 3A SEQ Database Description Result* ID entry ID PR00764F 16.89 2.052e-09 570-590 PR00764F 16.89 2.636e-09 398-418 PR00764F 16.89 7.312e-09 128-148 PR00764F 16.89 7.662e-09 282-302 PR00764F 16.89 7.662e-09 532-552 873 PROO011 TYPE III EGF-LIKE SIGNATURE PROO011B 13.08 6,425e-09 63-81 PROO011B 13.08 8.521e-09 25-43 873 BL00203 Vertebrate metallothioneins proteins. BL00203 13.94 8.53 le-09 75-120 873 BL00022 EGF-like domain proteins. BLOO022B 7.54 1.000e-09 378-384 BLOO022A 7.48 9.000e-09 173-179 BLOO022A 7.48 9.000e-09 363-369 873 BL00279 Membrane attack complex components ! BL00279E 37.11 2.000e-13 553-600 perforin proteins. BL00279E 37.11 6.875e-13 343-390 BL00279E 37.11 6.803e-12 1031-1078 BL00279E 37.11 2.962e-11 35-82 BL00279E 37.11 5.731e-11 304-351 BL00279E 37.11 7.115e-11 73-120 BL00279E 37.11 7.462e-11 515-562 BL00279E 37.11 1.217e-10 265-312 BL00279E 37.11 4.349e-09 153-200 BL00279E 37.11 9.163e-09 381-428 873 BLO1 187 Calcium-binding EGF-like domain proteins BLO1 187B 12.04 3.333e-12 541-556 pattern proteins. BLO1187B 12.04 4.000e-12 179-194 BLO1187B 12.04 8.000e-12 291-306 BLO1187B 12.04 4.300e-11 617-632 BLO1l 87B 12.04 7.900e- 11 407-422 BLO1187B 12.04 1.514e-10 23-38 BLO1187B 12.04 3.829e-10 369-384 BLO1187B 12.04 5.371e-10 503-518 BL01187B 12.04 7.171e-10 137-152 BL01187A 9.98 7.429e-10 486-497 BL01187B 12.04 7.429e-10 61-76 BL01187B 12.04 2.800e-09 1057-1072 BLOI 187B 12.04 3.475e-09 579-594 BL01187A 9.98 4.375e-09 44-55 BLO1187B 12.04 7.300e-09 255-270 BLO1187B 12.04 9.550e-09 330-345 873 PD00919 CALCIUM-BINDING PRECURSOR PD00919A 11.53 8.820e-10 280-291 SIGNAL R. PDO0919A 11.53 9.864e-09 568-579 874 PR00960 LMBP PROTEIN SIGNATURE PR00960A 10.63 4.667e-09 78-93 875 BL00738 S-adenosyl-L-homocysteine hydrolase BL00738J 18.61 1.000e-40 459-508 proteins. BL00738H 23.08 5.320e-36 335-387 BL00738F 12.23 7.261e-29 254-285 BL00738A 16.27 9.660e-27 83-122 BL00738C 16.53 7.923e-25 148-185 BL00738G 14.29 6.268e-23 313-334 BL00738B 12.28 8.085e-21 123-147 BL00738E 14.18 9.200e-19 228-250 BL007381 14.57 5.135e-17 412-449 BL00738D 7.16 5.109e-13 202-216 875 BL00836 Alanine dehydrogenase & pyridine nucleotide BL00836D 22.30 8.622e-09 291-327 transhydrogenase.

WO 2004/080148 PCT/US2003/030720 319 TABLE 3A SEQ Database Description Result* ID entry ID 877 PR00425 BRADYKININ RECEPTOR SIGNATURE PR00425C 13.23 3.586e-09 426-445 878 BL00514 Fibrinogen beta and gamma chains C- BLOO514C 17.41 2.579e-24 181-217 terminal domain proteins. BL00514G 15.98 9.111e-12 324-353 BL00514F 11.65 8.914e-09 271-285 BL00514D 15.35 9.565e-09 222-234 879 BL00514 Fibrinogen beta and gamma chains C- BL00514C 17.41 2.579e-24 181-217 terminal domain proteins. BLOO514G 15.98 9.11le-12 324-353 BL00514F 11.65 8.914e-09 271-285 BL00514D 15.35 9.565e-09 222-234 880 BL00514 Fibrinogen beta and gamma chains C- BL00514C 17.41 2.579e-24 181-217 terminal domain proteins. BL00514G 15.98 9.11le-12 324-353 BL00514F 11.65 8.914e-09 271-285 BL00514D 15.35 9.565e-09 222-234 883 BL00218 Amino acid permeases proteins. BL00218D 21.49 7.446e-11 244-288 BLOO218E 23.30 3.640e-10 325-364 884 BLOO107 Protein kinases ATP-binding region proteins. BLOO107A 18.39 3.172e-11 158-188 885 BL00615 C-type lectin domain proteins. BL00615A 16.68 6.538e-10 41-58 889 BL00216 Sugar transport proteins. BL00216B 27.64 4.900e-10 239-288 891 DM00179 w KINASE ALPHA ADHESION T-CELL. DM00179 13.97 9.526e-10 118-127 891 PR00049 WILM'S TUMOUR PROTEIN SIGNATURE PROO049D 0.00 1.305e-09 155-169 PROO049D 0.00 6.797e-09 156-170 892 BL00633 Bromodomain proteins. BL00633B 13.82 5.950e-21 95-119 BL00633A 14.69 5.154e-14 74-86 BL00633C 15.24 8.07le-14 421-433 BL00633B 13.82 4.600e-13 388-412 892 DM00406 GLIADIN. DM00406 7.73 5.135e-10 970-982 DM00406 7.73 8.054e-10 753-765 892 PR00049 WILM'S TUMOUR PROTEIN SIGNATURE PROO049D 0.00 8.866e-11 755-769 PROO049D 0.00 9.471e-11 756-770 PROO049D 0.00 2.220e-09 748-762 PROO049D 0.00 3.288e-09 972-986 892 DM00250 kw ANNEXIN ANTIGEN PROLINE DM00250B 13.84 8.03 e-11 1009-1032 TUMOR. DM00250A 10.52 6.607e-09 772-787 DM00250B 13.84 7.568e-09 754-777 DM00250B 13.84 7.689e-09 755-778 892 PROO021 SMALL PROLINE-RICH PROTEIN PROO021A 4.31 3.734e-09 967-979 SIGNATURE PROO021A 4.31 6.582e-09 771-783 PROO021A 4.31 7.722e-09 769-781 892 PR00910 LUTEOVIRUS ORF6 PROTEIN PR00910A 2.51 7.750e-09 255-267 SIGNATURE 892 BL00415 Synapsins proteins. BL00415N 4.29 3.231e-12 749-792 BL00415N 4.29 6.504e-12 750-793 BL00415N 4.29 4.857e-11 748-791 BL00415N 4.29 1.824e-10 1003-1046 BL00415N 4.29 6.221e-10 1002-1045 BL00415N 4.29 9.313e-10 964-1007 BL00415N 4.29 2.314e-09 958-1001 BL00415P 2.37 8.200e-09 747-782 892 PR00209 ALPHA/BETA GLIADIN FAMILY PR00209B 4.88 3.837e-10 966-984 SIGNATURE PR00209B 4.88 5.696e-10 968-986 PR00209B 4.88 8.141e-10 752-770 WO 2004/080148 PCT/US2003/030720 320 TABLE 3A SEQ Database Description Result* ID entry ID PR00209B 4.88 8.594e-09 758-776 892 BL00904 Protein prenyltransferases alpha subunit BL00904A 8.30 5.340e-09 768-817 repeat proteins proteins. BL00904A 8.30 9.489e-09 752-801 892 PD02059 CORE POLYPROTEIN PROTEIN GAG PD02059B 24.48 9.746e-09 867-901 CONTAINS: P. 892 DM00215 PROLINE-RICH PROTEIN 3. DM00215 19.43 2.313e-12 750-782 DM00215 19.43 7.000e-12 748-780 DM00215 19.43 9.438e-12 754-786 DM00215 19.43 7.000e-11 749-781 DM00215 19.43 8.412e-11 752-784 DM00215 19.43 1.161e-10 953-985 DM00215 19.43 7.429e-10 948-980 DM00215 19.43 1.000e-09 751-783 DM00215 19.43 2.678e-09 759-791 DM00215 19.43 3.441e-09 753-785 DM00215 19.43 4.508e-09 240-272 DM00215 19.43 4.661e-09 241-273 DM00215 19.43 4.966e-09 765-797 DM00215 19.43 6.492e-09 954-986 DM00215 19.43 8.322e-09 945-977 DM00215 19.43 9.847e-09 747-779 892 PR00503 BROMODOMAIN SIGNATURE PR00503D 20.81 1.409e-18 421-440 PR00503B 9.96 7.750e-18 94-110 PR00503C 19.84 1.720e-15 110-128 PR00503A 14.39 6.824e-13 78-91 PR00503B 9.96 4.400e-12 387-403 PR00503D 20.81 1.188e-11 128-147 PR00503C 19.84 1.000e-08 403-421 894 BL00282 Kazal serine protease inhibitors family BL00282 16.88 2.397e-14 92-114 proteins. 894 PR00290 KAZAL-TYPE SERINE PROTEASE PR00290A 10.88 2.286e-11 92-102 INHIBITOR SIGNATURE 894 PR00450 RECOVERIN FAMILY SIGNATURE PR00450C 12.22 4.532e-09 182-203 895 PR00753 1-AMINOCYCLOPROPANE-1- PR00753E 8.01 8.522e-11 171-195 CARBOXYLATE SYNTHASE SIGNATURE 896 BL00478 LIM domain proteins. BL00478B 14.79 4.000e-12 102-116 BL00478B 14.79 6.000e-12 173-187 BL00478B 14.79 6.200e-11 43-57 BL00478B 14.79 9.135e-10 231-245 897 PR0109 TYROSINE KINASE CATALYTIC PROO109B 12.27 5.787e-13 467-485 DOMAIN SIGNATURE 897 BL00479 Phorbol esters / diacylglycerol binding BL00479C 12.01 7.300e-13 512-524 domain proteins. 897 BL00239 Receptor tyrosine kinase class II proteins. BL00239B 25.15 8.948e-13 402-449 897 BLo01o7 Protein kinases ATP-binding region proteins. BLOO107A 18.39 9.217e-14 467-497 BLOO107B 13.31 8.714e-11 533-548 897 PF00564 Octicosapeptide repeat proteins. PF00564B 24.74 6.442e-09 418-468 898 PROO109 TYROSINE KINASE CATALYTIC PROO109B 12.27 5.787e-13 654-672 DOMAIN SIGNATURE 898 BL00479 Phorbol esters / diacylglycerol binding BL00479C 12.01 7.300e-13 699-711 WO 2004/080148 PCT/US2003/030720 321 TABLE 3A SEQ Database Description Result* ID entry ID ___ domain proteins. 898 BL00239 Receptor tyrosine kinase class II proteins. BL00239B 25.15 8.948e-13 589-636 898 BL00107 Protein kinases ATP-binding region proteins. BLOO107A 18.39 9.217e-14 654-684 BLOO107B 13.31 8.714e-11 720-735 898 PF00564 Octicosapeptide repeat proteins. PF00564B 24.74 6.442e-09 605-655 900 PR0007 COMPLEMENT C1Q DOMAIN PR0007C 15.60 3.993e-18 199-220 SIGNATURE PR00007A 19.33 7.500e-17 124-150 PR00007B 14.16 2.688e-16 151-170 PR00007D 9.64 5.154e-11 232-242 900 BL00420 Speract receptor repeat proteins domain BLOO420A 20.42 6.400e-1 1 77-105 proteins. BL00420A 20.42 6.164e-10 25-53 BL00420A 20.42 9.262e-10 68-96 BL00420A 20.42 1.277e-09 65-93 900 BLO1113 CIq domain proteins. BLO1113B 18.26 8.031e-28 130-165 BLO1113C 13.18 7.000e-18 199-218 BLO1113A 17.99 5.135e-13 95-121 BLO1113D 7.47 7.231e-12 234-243 BLO1113A 17.99 3.864e-11 34-60 BLO1113A 17.99 1.191c-10 71-97 BLO1113A 17.99 1.957e-10 77-103 BLO1113A 17.99 1.000e-09 28-54 BLO1113A 17.99 5.154e-09 68-94 BLO1113A 17.99 7.577e-09 74-100 BLO1113A 17.99 8.615e-09 83-109 901 PR00927 ADENINE NUCLEOTIDE PR00927A 7.98 9.667e-09 14-26 TRANSLOCATOR 1 SIGNATURE 902 PR00209 ALPHA/BETA GLIADIN FAMILY PR00209B 4.88 4.494e-12 427-445 SIGNATURE 902 BL00415 Synapsins proteins. BL00415N 4.29 6.771e-10 425-468 902 PROO021 SMALL PROLINE-RICH PROTEIN PROO021A 4.31 3.278e-09 448-460 SIGNATURE 902 DM00406 GLLADIN. DM00406 7.73 3.919e-10 427-439 DM00406 7.73 6.400e-09 448-460 902 PR00208 GLIADIN AND LMW GLUTENIN PR00208A 12.59 5.438e-09 402-419 SUPERFAMILY SIGNATURE PR00208A 12.59 7.534e-09 420-437 PR00208A 12.59 8.521e-09 419-436 902 BL00795 Involucrin proteins. BL00795C 17.06 1.105e-10 396-440 BL00795C 17.06 6.651e-10 411-455 BL00795C 17.06 6.965e-10 394-438 BL00795C 17.06 7.698e-10 422-466 BL00795C 17.06 2.900e-09 408-452 BL00795C 17.06 3.800e-09 395-439 BL00795C 17.06 5.200e-09 425-469 BL00795C 17.06 9.200e-09 424-468 905 PROOO19 LEUCINE-RICH REPEAT SIGNATURE PROO019A 11.19 8.435e-10 5-18 908 BL01208 VWFC domain proteins. BLO1208B 15.83 3.250e-10 1480-1494 908 PR00457 ANIMAL HAEM PEROXIDASE PR00457E 20.67 3.118e-22 1041-1067 SIGNATURE PR00457D 16.81 4.194e-21 1016-1036 PR00457C 19.25 1.675e-13 998-1016 PR00457H 15.90 5.680e-13 1292-1306 PR00457F 13.69 4.750e-12 1094-1104 WO 2004/080148 PCT/US2003/030720 322 TABLE 3A SEQ Database Description Result* ID entry ID PR00457G 17.45 8.615e-12 1221-1241 PR00457B 13.29 3.411e-10 846-861 908 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 1.000e-09 325-348 908 PD01270 RECEPTOR FC IMMUNOGLOBULIN PDO1270A 17.22 4.581e-09 304-343 AFFIN. 908 PROO019 LEUCINE-RICH REPEAT SIGNATURE PROO019B 11.36 7.480e-09 73-86 909 BL01208 VWFC domain proteins. BLO1208B 15.83 3.250e-10 1511-1525 909 PR00457 ANIMAL HAEM PEROXIDASE PR00457E 20.67 3.118e-22 1072-1098 SIGNATURE PR00457D 16.81 4.194e-21 1047-1067 PR00457C 19.25 1.675e-13 1029-1047 PR00457H 15.90 5.680e-13 1323-1337 PR00457F 13.69 4.750e-12 1125-1135 PR00457G 17.45 8.615e-12 1252-1272 PR00457B 13.29 3.411e-10 877-892 909 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 1.000e-09 356-379 909 PD01270 RECEPTOR FC IMMUNOGLOBULIN PDO1270A 17.22 4.581e-09 335-374 AFFIN. 909 PROO019 LEUCINE-RICH REPEAT SIGNATURE PROO019B 11.36 7.480e-09 104-117 910 BL01208 VWFC domain proteins. BLO1208B 15.83 3.250e-10 1373-1387 910 PR00457 ANIMAL HAEM PEROXIDASE PR00457E 20.67 3.118e-22 934-960 SIGNATURE PR00457D 16.81 4.194e-21 909-929 PR00457C 19.25 1.675e-13 891-909 PR00457H 15.90 5.680e-13 1185-1199 PR00457F 13.69 4.750e-12 987-997 PR00457G 17.45 8.615e-12 1114-1134 PR00457B 13.29 3.411e-10 739-754 910 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 1.000e-09 302-325 910 PD01270 RECEPTOR FC IMMUNOGLOBULIN PDO1270A 17.22 7.677e-09 281-320 AFFIN. 910 PROO019 LEUCINE-RICH REPEAT SIGNATURE PROO019B 11.36 8.920e-09 73-86 911 BL00022 EGF-like domain proteins. BLOO022B 7.54 3.250e-10 881-887 BLOO022B 7.54 1.000e-09 88-94 911 PR00764 COMPLEMENT C9 SIGNATURE PR00764F 16.89 8.274e-10 942-962 PR00764F 16.89 6.377e-09 576-596 911 PROO010 TYPE II EGF-LIKE SIGNATURE PROO010A 11.79 3.700e-12 43-54 PROO010C 11.16 5.636e-10 84-94 PROO010C 11.16 6.727e-10 122-132 PROO010A 11.79 8.258e-10 168-179 PROO010A 11.79 1.231e-09 102-113 PROO010C 11.16 5.500e-09 877-887 PRO0010C 11.16 7.000e-09 230-240 911 DM00060 338 kw NEUREXIN ALPHA III CYSTEINE. DM00060 6.92 7.250e-1 1 942-951 DM00060 6.92 8.740e-09 576-585 911 BL00279 Membrane attack complex components / BL00279E 37.11 1.000e-10 925-972 perforin proteins. BL00279E 37.11 4.470e-10 846-893 BL00279E 37.11 8.744e-09 559-606 911 BL01187 Calcium-binding EGF-like domain proteins BLO1187B 12.04 9.667e-12 117-132 patten proteins. BLO1187A 9.98 9.053e-11 166-177 BLO1187B 12.04 6.175e-09 834-849 BLO1187A 9.98 8.125e-09 41-52 BLO1187B 12.04 9.325e-09 183-198 WO 2004/080148 PCT/US2003/030720 323 TABLE 3A SEQ Database Description Result* ID entry ID 911 PD00919 CALCIUM-BINDING PRECURSOR PD00919A 11.53 9.410e-10 574-585 SIGNAL R. PDO0919A 11.53 9.864e-09 47-58 914 BL00888 Cyclic nucleotide-binding domain proteins. BLOO888B 14.79 4.000e-16 161-184 BL00888B 14.79 1.692e-14 279-302 914 DM01513 CAMP-DEPENDENT PROTEIN KINASE DMO1513B 6.81 8.457e-34 198-249 REGULATORY CHAIN. DM01513B 6.81 2.500e-14 322-373 914 PROO103 CAMP-DEPENDENT PROTEIN KINASE PROO103B 13.39 1.000e-16 173-187 SIGNATURE PROO103A 9.59 8.105e-15 276-290 PROO103E 17.80 9.591e-15 355-367 PROO103D 10.83 3.700e-14 334-345 PROO103B 13.39 5.935e-13 291-305 PROO103A 9.59 1.500e-12 158-172 PROO103C 15.68 1.000e-11 322-331 PROO103D 10.83 4.349e-10 210-221 915 PD00289 PROTEIN SH3 DOMAIN REPEAT PD00289 9.97 8.920e-10 602-615 PRESYNA. 916 PR00087 LIPOXYGENASE SIGNATURE PR00087C 15.00 3.057e-21 373-393 PR00087A 18.37 7.955e-18 335-352 PROO087B 15.25 1.000e-16 353-370 916 BL00711 Lipoxygenases iron-binding region proteins. BL0071 1E 19.66 8.909e-35 364-400 BL007111 18.56 4.250e-34 526-563 BL00711D 17.56 2.800e-24 296-321 BL00711H 23.34 5.091e-23 484-522 BL00711C 20.75 2.227e-21 221-249 BL00711F 19.79 5.065e-16 434-450 BL00711B 14.24 1.290e-15 160-175 BL00711G 21.83 8.636e-12 452-483 BL00711A 15.87 5.645e-11 94-103 916 PR00467 MAMMALIAN LIPOXYGENASE PR00467F 11.25 4.661e-18 418-440 SIGNATURE PR00467E 9.00 5.500e-17 293-312 PR00467A 8.04 4.000e-13 11-28 PR00467D 16.69 5.210e-12 196-217 PR00467B 17.25 1.83le-11 57-76 PR00467C 12.06 1.662e-09 134-148 917 PR00467 MAMMALIAN LIPOXYGENASE PR00467E 9.00 5.500e-17 266-285 SIGNATURE PR00467A 8.04 4.000e-13 11-28 PR00467D 16.69 5.210e-12 169-190 PR00467B 17.25 1.831e-11 57-76 917 BL00711 Lipoxygenases iron-binding region proteins. BL0071 1C 20.75 2.227e-21 194-222 BL00711B 14.24 1.290e-15 131-146 BL00711A 15.87 5.645e-11 94-103 918 BL00711 Lipoxygenases iron-binding region proteins. BL00711C 20.75 2.227e-21 223-251 BL00711B 14.24 1.290e-15 160-175 BL00711A 15.87 5.645e-11 94-103 918 PR00467 MAMMALIAN LIPOXYGENASE PR00467E 9.00 5.500e-17 295-314 SIGNATURE PR00467A 8.04 4.000e-13 11-28 PR00467D 16.69 5.210e-12 198-219 PR00467B 17.25 1.831e-11 57-76 PR00467C 12.06 1.662e-09 134-148 927 PD00919 CALCIUM-BINDING PRECURSOR PDO0919A 11.53 8.377e-10 216-227 SIGNAL R.

WO 2004/080148 PCT/US2003/030720 324 TABLE 3A SEQ Database Description Result* ID entry ID 927 BL01187 Calcium-binding EGF-like domain proteins BLO1187B 12.04 7.429e- 10 108-123 pattern proteins. BLO I187B 12.04 9,486e-10 189-204 BLO1187B 12.04 2.800e-09 227-242 927 PROO 11 TYPE III EGF-LIKE SIGNATURE PROM011D 14.03 4.158e-12 39-57 PROW011B 13.08 2.973e-09 39-57 927 BL00243 Integrins beta chain cysteine-rich domain BL00243H 17.53 7.276e-09 65-90 proteins. 927 PR00010 TYPE II EGF-LIKE SIGNATURE PRO0010C 11.16 5.929e-09 194-204 PROO010C 11.16 8.286e-09 113-123 927 BL01185 C-terminal cystine knot proteins. BLO1185B 21.14 9.047e-09 168-216 927 DM00060 338 kw NEUREXIN ALPHA III CYSTEINE. DM00060 6.92 9.460e-09 139-148 927 BL01248 Laminin-type EGF-like (LE) domain proteins. BL01248 11.02 9.660e-09 48-60 928 PR00456 RIBOSOMAL PROTEIN P2 SIGNATURE PR00456E 3.06 7.835e-09 1-15 933 BL00680 Methionine aminopeptidase subfamily 1 BL00680 14.37 5.304e-17 173-194 proteins. 933 BL01202 Methionine aminopeptidase subfamily 2 BLO1202B 26.24 9.671e-10 173-210 proteins. 933 PR00599 METHIONINE AMINOPEPTIDASE-1 PR00599B 12.01 4.600e-20 173-189 SIGNATURE PR00599A 11.65 1.273e-14 151-164 PR00599D 12.92 3.340e-10 273-285 PR00599C 11.34 6.471e-09 243-255 938 PD00289 PROTEIN SH3 DOMAIN REPEAT PD00289 9.97 4.960e-10 137-150 PRESYNA. 940 PD02784 PROTEIN NUCLEAR PD02784B 26.46 1.000e-40 217-259 RIBONUCLEOPROTEIN. PD02784C 20.76 1.000e-40 335-380 PD02784A 21.09 4.176e-36 178-214 PD02784B 26.46 7.683e-10 370-412 940 BLOO030 Eukaryotic RNA-binding region RNP-1 BLOO030A 14.39 1.857e-09 456-474 proteins. BLOO030A 14.39 1.000e-08 186-204 941 BL00740 MAM domain proteins. BL00740A 13.87 7.188e-12 410-422 941 PROO020 MAM DOMAIN SIGNATURE PROO020A 18.17 9.816e-12 408-426 941 PR00907 THROMBOMODULIN SIGNATURE PR00907B 11.29 4.082e- 11 144-160 941 PF00094 von Willebrand factor type D domain PF00094A 11.09 5.109e-09 139-148 proteins. 941 BL00243 Integrins beta chain cysteine-rich domain BL00243H 17.53 7.632e-09 69-94 proteins. 941 BLO1 177 Anaphylatoxin domain proteins. BLO I177E 20.64 9.882e-09 146-172 941 BLO1187 Calcium-binding EGF-like domain proteins BLO1187B 12.04 9.100e-14 237-252 pattern proteins. BLO 1187B 12.04 5.333e- 12 192-207 BLO1187B 12.04 6.333e-12 110-125 BL01187A 9.98 9.250e-09 173-184 BL01187A 9.98 1.000e-08 218-229 942 BL00740 MAM domain proteins. BL00740A 13.87 7.188e-12 415-427 942 PROO020 MAM DOMAIN SIGNATURE PROO020A 18.17 9.816e-12 413-431 942 PR00907 THROMBOMODULIN SIGNATURE PR00907B 11.29 4.082e-11 149-165 942 PF00094 von Willebrand factor type D domain PFOO94A 11.09 5.109e-09 144-153 proteins. 942 BL00243 Integrins beta chain cysteine-rich domain BL00243H 17.53 7.632e-09 74-99 proteins. 942 BL01177 Anaphylatoxin domain proteins. BLO1177E 20.64 9.882e-09 151-177 942 BLO1187 Calcium-binding EGF-like domain proteins BLO1 187B 12.04 9. 1OOc-14 242-257 WO 2004/080148 PCT/US2003/030720 325 TABLE 3A SEQ Database Description Result* ID entry ID pattern proteins. BL01187B 12.04 5.333e-12 197-212 BLO1187B 12.04 6.333e-12 115-130 BL01187A 9.98 9.250e-09 178-189 BLO1 187A 9.98 1.000e-08 223-234 943 PF00855 PWWP domain proteins. PF00855 13.75 8.403e-13 274-290 943 BL00633 Bromodomain proteins. BL00633B 13.82 8.977e-12 178-202 943 BL00479 Phorbol esters / diacylglycerol binding BL00479B 12.57 9.460e-10 94-109 domain proteins. 943 PR00503 BROMODOMAIN SIGNATURE PR00503B 9.96 8.667e-10 177-193 PR00503D 20.81 9.069e-09 211-230 944 PF00855 PWWP domain proteins. PF00855 13.75 8.403e-13 274-290 944 BL00633 Brornodomain proteins. BL00633B 13.82 8.977e-12 178-202 944 BL00479 Phorbol esters / diacylglycerol binding BL00479B 12.57 9.460e-10 94-109 domain proteins. 944 PR00503 BROMODOMAIN SIGNATURE PR00503B 9.96 8.667e-10 177-193 PR00503D 20.81 9.069e-09 211-230 945 PF00855 PWWP domain proteins. PF00855 13.75 8.403e-13 274-290 945 BL00633 Bromodomain proteins. BL00633B 13.82 8.977e-12 178-202 945 BL00479 Phorbol esters / diacylglycerol binding BL00479B 12.57 9.460e-10 94-109 domain proteins. 945 PR00208 GLIADIN AND LMW GLUTENIN PR00208A 12.59 9.868e-10 835-852 SUPERFAMILY SIGNATURE PR00208A 12.59 2.233e-09 838-855 945 DM00406 GLIADIN. DM00406 7.73 9.000e-09 836-848 945 PR00503 BROMODOMAIN SIGNATURE PR00503B 9.96 8.667e-10 177-193 PR00503D 20.81 9.069e-09 211-230 946 PF00855 PWWP domain proteins. PF00855 13.75 8.403e-13 279-295 946 BL00633 Bromodomain proteins. BL00633B 13.82 8.977e-12 183-207 946 BL00479 Phorbol esters / diacylglycerol binding BL00479B 12.57 9.460e-10 99-114 domain proteins. 946 PR00208 GLIADIN AND LMW GLUTENIN PR00208A 12.59 9.868e-10 840-857 SUPERFAMILY SIGNATURE PR00208A 12.59 2.233e-09 843-860 946 DM00406 GLIADIN. DIV00406 7.73 9.000e-09 841-853 946 PR00503 BROMODOMAIN SIGNATURE PR00503B 9.96 8.667e-10 182-198 PR00503D 20.81 9.069e-09 216-235 950 PR00907 THROMBOMODULIN SIGNATURE PR00907B 11.29 4.039e-10 677-693 950 PR00206 CONNEXIN SIGNATURE PR00206F 16.77 4.250e-09 498-521 950 PROO 169 POTASSIUM CHANNEL SIGNATURE PROO169G 9.39 7.932e-09 467-489 951 BL00427 Disintegrins proteins. BL00427 13.93 7.592e-26 443-497 951 PR00138 MATRIXIN SIGNATURE PROO138D 16.56 5.101e- 11342-367 951 BL0O142 Neutral zinc metallopeptidases, zinc-binding BL00142 8.38 7.545e-11 342-352 region proteins. 951 PR00289 DISINTEGRIN SIGNATURE PR00289A 13.62 2.500e-14 457-476 PR00289B 11.79 4.226e-10 486-498 951 PR00480 ASTACIN FAMILY SIGNATURE PR00480B 15.41 8.909e-10 337-355 951 BL00546 Matrixins cysteine switch. BL00546C 16.41 4.255e-09 336-367 951 BL00024 Hemopexin domain proteins. BL00024D 17.28 5.596e-09 336-367 951 PR00907 THROMBOMODULIN SIGNATURE PR00907E 11.70 7.353e-09 629-651 953 PD00078 REPEAT PROTEIN ANK NUCLEAR PDO0078B 13.14 5.500e-11 360-372 ANKYR. 953 PF00023 Ank repeat proteins. PF00023A 16.03 6.000e-12 334-349 PF00023A 16.03 1.857e-11 156-171 WO 2004/080148 PCT/US2003/030720 326 TABLE 3A SEQ Database Description Result* ID entry ID PF00023A 16.03 3.143e-11 255-270 PF00023B 14.20 3.455e-09 363-372 PF00023A 16.03 5.821e-09 188-203 953 PF00791 Domain present in ZO-1 and Unc5-like netrin PF00791B 28.49 4.273e-11 334-388 receptors. PF00791B 28.49 4.818e-11 301-355 PF0079 1B 28.49 4.845e-10 188-242 PF00791B 28.49 9.339e-09 222-276 954 BL00252 Interferon alpha, beta and delta family BL00252A 18.49 6.657e-23 35-71 proteins. BL00252B 19.78 2.846e-14 73-123 954 PR00266 INTERFERON ALPHA AND BETA PR00266A 13.61 1.000e-13 67-79 SUBUNIT SIGNATURE 956 PR00081 GLUCOSE/RIBITOL DEHYDROGENASE PROO081A 10.53 6.226e-13 34-51 FAMILY SIGNATURE PROO081F 15.71 7.632e-12 152-172 PROO081B 10.38 2.895e-10 108-119 958 PR00885 BACTERIAL GENERAL SECRETION PR00885B 8.16 9.143e-10 394-408 PATHWAY PROTEIN H SIGNATURE 958 BL00616 Histidine acid phosphatases phosphohistidine BL00616A 11.86 7.81 le-09 40-47 proteins. 959 BL00284 Serpins proteins. BL00284C 28.56 1.000e-34 118-159 BL00284D 16.34 4.857e-21 224-250 BL00284B 17.99 5.800e-19 91-111 BL00284E 19.15 7.577e-18 305-329 960 BL00284 Serpins proteins. BL00284C 28.56 2.588e-23 186-227 BL00284A 15.64 7.750e-22 73-96 BL00284D 16.34 4.857e-21 292-318 BL00284E 19.15 7.577e-18 373-397 961 BL00284 Serpins proteins. BL00284C 28.56 1.000e-34 186-227 BL00284A 15.64 7.750e-22 73-96 BL00284D 16.34 4.857e-21 292-318 BL00284B 17.99 6.625e-18 159-179 BL00284E 19.15 7.577e-18 373-397 962 BL00284 Serpins proteins. BL00284C 28.56 1.000e-34 204-245 BL00284A 15.64 7.750e-22 73-96 BL00284B 17.99 5.800e-19 177-197 BL00284E 19.15 7.577e-18 373-397 964 BL00427 Disintegrins proteins. BL00427 13.93 2.739e-16 459-5 13 964 PR00480 ASTACIN FAMILY SIGNATURE PR00480B 15.41 9.045e-10 359-377 964 BL00142 Neutral zinc metallopeptidases, zinc-binding BL00142 8.38 1.429e-09 364-374 region proteins. 964 PR00289 DISINTEGRIN SIGNATURE PR00289A 13.62 7.000e-14 473-492 PR00289B 11.79 2.579e-09 502-514 964 BL00412 Neuromodulin (GAP-43) proteins. BL00412D 16.54 3.966e-1 1 763-813 BL00412D 16.54 7.065e-10 759-809 BL00412D 16.54 4.857e-09 764-814 BL00412D 16.54 9.357e-09 762-812 966 BL01238 GDA1/CD39 family of nucleoside BL01238C 14.36 2.174e-17 177-198 phosphatases proteins. BL01238D 10.19 3.302e-13 216-229 BL01238A 11.72 6.936e-12 59-73 BL01238B 10.99 1.529e-09 133-143 967 BLO1113 C1q domain proteins. BLO 113B 18.26 9.438e-20 95-130 1_ ,__ BLO1113D 7.47 9.308e-12 195-204 WO 2004/080148 PCT/US2003/030720 327 TABLE 3A SEQ Database Description Result* ID entry ID 1BL01113C 13.18 4.750e-10 163-182 967 PR007 COMPLEMENT C1Q DOMAIN PR0007B 14.16 7.698e-13 116-135 SIGNATURE PR0007D 9.64 9.654e-1 1 193-203 PRO007C 15.60 3.656e-10 163-184 PR0007A 19.33 1.571e-09 89-115 969 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237A 11.48 5.355e-09 408-432 SIGNATURE 970 BL00290 Immunoglobulins and major BL00290A 20.89 7.480e-10 160-182 histocompatibility complex proteins. BL00290B 13.17 2.875e-09 226-243 970 PR00939 C2HC-TYPE ZINC-FINGER SIGNATURE PR00939B 13.27 8.412e-09 532-540 971 BL00289 Pentaxin family proteins. BL00289D 17.60 1.947e-31 409-447 BL00289C 12.56 8.615e-16 370-388 BL00289A 30.36 7.457e-14 282-312 BL00289B 15.96 8.364e-12 327-341 971 PR00895 PENTAXIN SIGNATURE PR00895E 12.74 5.065e-18 417-436 PROO895D 14.28 3.769e-17 397-416 PRO0895C 12.29 4.273e-17 370-388 PR00895A 14.53 8.826e-13 305-319 PR00895B 14.20 2.154e-12 327-341 PR00895F 15.41 1.439e-10 436-450 972 PF00992 Troponin. PF00992A 16.67 6.447e-09 741-775 973 BL00036 bZIP transcription factors basic domain BL00036 9.02 5.737e-1 1 633-645 proteins. 973 PR00043 JUN TRANSCRIPTION FACTOR PROO043B 8.73 9.241e-11 633-649 SIGNATURE 973 PF00624 Flocculin repeat proteins. PF006241 9.10 5.125e-10 461-490 PF006241 9.10 5.800e-10 462-491 PF006241 9.10 4.33 1e-09 458-487 PF006241 9.10 6.457e-09 456-485 PF006241 9.10 6.811e-09 453-482 PF006241 9.10 8.44le-09 454-483 977 PR00048 C2H2-TYPE ZINC FINGER SIGNATURE PROO048A 10.52 2.174e-10 2473-24-86 977 DM00406 GLIADIN. DM00406 7.73 1.400e-09 537-549 977 PROO021 SMALL PROLINE-RICH PROTEIN PROO021A 4.31 2.253e-09 538-550 SIGNATURE 977 BL00904 Protein prenyltransferases alpha subunit BL00904A 8.30 2.660e-09 537-586 repeat proteins proteins. 977 DM00215 PROLINE-RICH PROTEIN 3. DM00215 19.43 5.821e-10 543-575 DM00215 19.43 7.750e-10 531-563 DM00215 19.43 7.750e-10 559-591 DM00215 19.43 2.525e-09 536-568 DM00215 19.43 4.508e-09 533-565 977 PR00049 WILM'S TUMOUR PROTEIN SIGNATURE PROO049D 0.00 9.017e- 1 540-554 PROO049D 0.00 9.168e-11 541-555 PROO049D 0.00 2.983e-09 538-552 PROO049D 0.00 3.288e-09 539-553 PROO049D 0.00 3.898e-09 543-557 PROO049D 0.00 4.814e-09 537-551 PROO049D 0.00 6.034e-09 191-205 977 PR00239 MOLLUSCAN RHODOPSIN C- PR00239E 1.58 6.318e-09 542-553 TERMINAL TAIL SIGNATURE WO 2004/080148 PCT/US2003/030720 328 TABLE 3A SEQ Database Description Result* ID entry ID 977 BL00415 Synapsins proteins. BL00415N 4.29 8.143e-11 556-599 BL00415N 4.29 8.357e-1 1 550-593 BL00415N 4.29 6.702e-10 543-586 BL00415N 4.29 8.145e-10 532-575 BL00415N 4.29 8.969e-10 548-591 BL00415N 4.29 3.562e-09 555-598 BL00415N 4.29 4.088e-09 531-574 BLOO415N 4.29 9.869e-09 539-582 977 PR00211 GLUTELIN SIGNATURE PR00211B 0.86 9.917e-09 551-571 980 BL00282 Kazal serine protease inhibitors family BL00282 16.88 4.234e-12 73-95 proteins. 980 PR00834 HTRA/DEGQ PROTEASE FAMILY PR00834C 15.43 3.613e-20 237-261 SIGNATURE PR00834D 12.14 6.455e-18 275-292 PR00834B 10.09 5.500e-14 196-216 PR00834E 13.63 5.355e-13 297-314 PR00834F 10.91 9.526e-12 389-401 PR00834A 9.80 3.659e-11 175-187 980 BL00222 Insulin-like growth factor binding proteins. BL00222B 11.09 4.420e-10 22-37 980 PR00290 KAZAL-TYPE SERINE PROTEASE PR00290B 9.78 4.326e-09 84-95 INHIBITOR SIGNATURE 980 BL00273 Heat-stable enterotoxins proteins. BL00273 12.24 8.286e-09 26-38 981 PR00792 PEPSIN (Al) ASPARTIC PROTEASE PR00792A 11.54 5.500e-18 80-100 FAMILY SIGNATURE PR00792D 12.74 9.069e-13 395-410 PR00792C 9.10 4.214e-12 312-323 981 BLOO141 Eukaryotic and viral aspartyl proteases BLOO141A 12.10 4.789e-15 87-102 proteins. BLOO141E 14.32 6.850e-15 396-419 BLOO141D 6.28 7.300e-11 312-321 BLOO141B 12.14 2.929e-10 228-239 982 BL00523 Sulfatases proteins. BL00523A 13.36 6.65 le-10 44-60 984 PR00765 CARBOXYPEPTIDASE A PR00765B 15.57 7.857e-16 99-113 METALLOPROTEASE (M14) FAMILY PR00765D 14.16 5.500e-11 233-246 SIGNATURE PR00765C 12.55 1.290e-10 179-187 984 BLOO132 Zinc carboxypeptidases, zinc-binding region BLOO132C 21.35 3.308e-28 129-169 1 proteins. BLOO132B 15.93 1.871e-16 99-112 BLOO132A 26.07 1.682e-14 50-90 BLOO132F 13.26 7.254e-14 228-249 BLOO132D 12.70 2.875e-12 173-187 BLOO132E 17.72 3.552e-12 199-225 BLOO132G 10.94 4.541e-10 285-302 985 PR00765 CARBOXYPEPTIDASE A PR00765B 15.57 7.857e-16 99-113 METALLOPROTEASE (M14) FAMILY PR00765D 14.16 5.500e- 11233-246 SIGNATURE PR00765C 12.55 1.290e-10 179-187 985 BL00132 Zinc carboxypeptidases, zinc-binding region BLOO132C 21.35 3.308e-28 129-169 1 proteins. BLOO132B 15.93 1.871e-16 99-112 BLOO132A 26.07 1.682e-14 50-90 BLOO132F 13.26 7.254e-14 228-249 BLOO132D 12.70 2.875e-12 173-187 BLOO132E 17.72 3.552e-12 199-225 BLOO132G 10.94 4.541e-10 285-302 990 PD00066 PROTEIN ZINC-FINGER METAL-BINDI. PD00066 13.92 5.304e-11 110-122 991 BLOO107 Protein kinases ATP-binding region proteins. BLOO107A 18.39 1.000e-15 139-169 WO 2004/080148 PCT/US2003/030720 329 TABLE 3A SEQ Database Description Result* ID entry ID BLOO107B 13.31 4.273e-13 209-224 991 PROO109 TYROSINE KINASE CATALYTIC PROO109B 12.27 7.894e-13 139-157 DOMAIN SIGNATURE 991 BL00240 Receptor tyrosine kinase class III proteins. BL00240E 11.56 6.580e-10 125-162 994 PR00007 COMPLEMENT C1Q DOMAIN PRO007A 19.33 6.936e-13 168-194 SIGNATURE PR00007C 15.60 9.250e-13 243-264 PRO0007B 14.16 9.372e-13 195-214 PR00007D 9.64 5.500e-1 1 275-285 994 PR00524 CHOLECYSTOKININ TYPE A RECEPTOR PR00524F 5.36 1.766e-09 94-107 SIGNATURE 994 BL00420 Speract receptor repeat proteins domain BL00420A 20.42 7.058e-12 79-107 proteins. BL00420A 20.42 4.689e-10 97-125 BL00420A 20.42 6.902e-10 82-110 BL00420A 20.42 1.277e-09 85-113 BL00420A 20.42 5.292e-09 76-104 994 BLO1113 CIq domain proteins. BLO1 113B 18.26 1.675e-24 174-209 BLO1113A 17.99 1.871e-15 85-111 BLO1113A 17.99 5.091e-14 82-108 BL01113D 7.47 3.250e-13 277-286 BLO1113A 17.99 4.892e-13 76-102 BLO1113A 17.99 6.108e-13 94-120 BLO1113A 17.99 9.757e-13 79-105 BLO1113A 17.99 3.769e-12 88-114 BLO1113A 17.99 6.308e-12 91-117 BLO1113C 13.18 9.294e-12 243-262 BL01113A 17.99 8.159e-11 70-96 BL01113A 17.99 9.795e-11 97-123 BLO I1 13A 17.99 9.809e-10 73-99 BLO1113A 17.99 6.019e-09 103-129 995 DM01595 kw ALLANTOICASE SPAC1F7.09C. DM01595D 10.94 8.269e-16 116-140 DM01595I 8.91 2.714e-15 300-317 DM015951 8.91 9.727e-14 117-134 DMO1595D 10.94 3.274e-11 299-323 DM01595E 14.67 6.299e-09 152-184 997 BL00720 Guanine-nucleotide dissociation stimulators BL00720B 16.57 4.103e-18 1089-1112 CDC25 family sign. 997 BL00741 Guanine-nucleotide dissociation stimulators BL00741B 14.27 4.326e-16 377-399 CDC24 family sign. 1001 BL00048 Protamine P1 proteins. BL00048 6.39 6.684e-10 949-975 BL00048 6.39 3.363e-09 947-973 BL00048 6.39 9.888e-09 781-807 1002 PF00628 PHD-figer. PF00628 15.84 8.412e-14 201-215 1002 BL00048 Protamine P1 proteins. BL00048 6.39 6.684e-10 1158-1184 BL00048 6.39 3.363e-09 1156-1182 BL00048 6.39 9.888e-09 990-1016 1003 PR00320 G-PROTEIN BETA WD-40 REPEAT PR00320A 16.74 4.103e-1 11132-1146 SIGNATURE PR00320C 13.01 8.200e-10 1132-1146 PR00320A 16.74 9.735e-10 1091-1105 PR00320C 13.01 2.500e-09 1091-1105 PROO320B 12.19 6.625e-09 1132-1146 1004 PF00569 Zinc finger present in dystrophin, CBP/p300. PF00569 13.42 1.545e-16 21-37 WO 2004/080148 PCT/US2003/030720 330 TABLE 3A SEQ Database Description Result* ID entry ID 1004 PD00306 PROTEIN GLYCOPROTEIN PRECURSOR PDO0306A 10.26 2.929e-09 257-270 RE. 1006 PR00399 SYNAPTOTAGMIN SIGNATURE PR00399A 9.52 1.964e-09 162-177 1007 PR00806 VINCULIN SIGNATURE PROO806D 11.95 3.963e-09 564-579 1008 BL00319 Amyloidogenic glycoprotein extracellular BL00319C 17.12 5.625e-10 565-598 domain proteins. BL00319C 17.12 4.316e-09 563-596 BL00319C 17.12 5.382c-09 560-593 1008 PF00922 Vesiculovirus phosphoprotein. PF00922A 19.17 8.862e-09 571-604 1009 PR00405 HIV REV INTERACTING PROTEIN PR00405B 11.83 8.385e-15 281-298 SIGNATURE PR00405A 17.71 4.306e-14 262-281 1009 PR00452 SH3 DOMAIN SIGNATURE PR00452B 11.65 5.500e-09 895-910 1009 PROO910 LUTEOVIRUS ORF6 PROTEIN PR00910A 2.51 9.036e-09 335-347 SIGNATURE 1011 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 2.674e-10 384-407 BL00240B 24.70 8.535e-10 479-502 BL00240B 24.70 7.702e-09 575-598 1011 PD02870 RECEPTOR INTERLEUKIN-1 PD02870B 18.83 4.600e-10 617-649 PRECURSOR. PD02870B 18.83 5.883e-09 28-60 PD02870B 18.83 7.894e-09 225-257 1015 BL00018 EF-hand calcium-binding domain proteins. BLOW018 7.41 5.765e-11 147-159 1015 PR00450 RECOVERIN FAMILY SIGNATURE PR00450C 12.22 1.228e-09 33-54 1015 BL00303 S-100/ICaBP type calcium binding protein. BL00303B 26.15 6.559e-09 26-62 1018 BL00237 G-protein coupled receptors proteins. BL00237A 27.68 1,474e-24 136-175 BL00237C 13.19 6.400e-14 289-315 BL00237B 5.28 3.077e-12 244-255 BL00237D 11.23 9.654e-11 342-358 1018 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237E 13.03 2.588e-16 236-259 SIGNATURE PR00237D 8.94 8.800e-14 186-207 PR00237B 13.50 2.636e-13 105-126 PR00237C 15.69 4.960e-13 150-172 PR00237F 13.57 6.040e-13 294-318 PR00237A 11.48 3.143e-12 72-96 PR00237G 19.63 3.53le-12 332-358 PR00237E 13.03 4.441e-09 234-257 1018 PR00238 OPSIN SIGNATURE PR00238B 16.24 2.667e-14 208-220 PR00238A 13.79 8.286e-09 93-105 1018 PR00667 RETINAL PIGMENT EPITHELIUM- PR00667B 10.86 8.800e-09 91-106 RETINAL GPCR SIGNATURE 1019 PROO019 LEUCINE-RICH REPEAT SIGNATURE PROO019A 11.19 5.500e-15 378-391 PROO019A 11.19 3.739e-10 134-147 PROO019B 11.36 1.000e-09 535-548 PROO019B 11.36 2.440e-09 375-388 PROW19A 11.19 3.333e-09 252-265 PROO019B 11.36 4.960e-09 225-238 PROO019A 11.19 7.000e-09 560-573 PROO019B 11.36 7.840e-09 351-364 PROO019B 11.36 9.640e-09 180-193 1021 BL00720 Guanine-nucleotide dissociation stimulators BL00720B 16.57 6.595e-15 996-1019 CDC25 family sign. 1021 PF00791 Domain present in ZO-1 and Unc5-like netrin PF00791C 20.98 6.01le-12 606-644 receptors. I WO 2004/080148 PCT/US2003/030720 331 TABLE 3A SEQ Database Description Result* ID entry ID 1021 PD00289 PROTEIN SH3 DOMAIN REPEAT PD00289 9.97 5.050e-11 625-638 PRESYNA. 1021 PR00834 HTRA/DEGQ PROTEASE FAMILY PR00834F 10.91 2.946e-09 621-633 SIGNATURE 1021 BLOO888 Cyclic nucleotide-binding domain proteins. BL00888B 14.79 4.682e-09 355-378 1022 BL00720 Guanine-nucleotide dissociation stimulators BL00720B 16.57 6.595e-15 946-969 CDC25 family sign. 1022 PF00791 Domain present in ZO-1 and Unc5-like netrin PF00791C 20.98 6.011e-12 556-594 receptors. 1022 PD00289 PROTEIN SH3 DOMAIN REPEAT PD00289 9.97 5.050e-11 575-588 PRESYNA. 1022 PR00834 HTRA/DEGQ PROTEASE FAMILY PR00834F 10.91 2.946e-09 571-583 SIGNATURE 1022 BL00888 Cyclic nucleotide-binding domain proteins. BL00888B 14.79 4.682e-09 305-328 1024 BL00476 Fatty acid desaturases family 1 proteins. BL00476B 18.34 5.420e-09 365-408 1024 PR00669 INHIBIN ALPHA CHAIN SIGNATURE PR00669B 8.27 6.488e-09 204-220 1025 BL00476 Fatty acid desaturases family 1 proteins. BL00476B 18.34 5.420e-09 327-370 1025 PR00669 INHIBIN ALPHA CHAIN SIGNATURE PR00669B 8.27 6.488e-09 166-182 1028 BL00232 Cadherins extracellular repeat proteins BL00232B 32.79 9.419e-36 133-180 domain proteins. BL00232B 32.79 5.345e-21 242-289 BL00232A 27.72 3.727e-20 39-71 BL00232C 10.65 2.742e-14 240-257 BL00232B 32.79 6.566e-14 357-404 1028 PR00205 CADHERIN SIGNATURE PR00205B 11.39 2.909e-15 240-257 PR00205A 14.73 8.457e-11 165-180 1029 BL00232 Cadherins extracellular repeat proteins BL00232B 32.79 9.419e-36 133-180 domain proteins. BL00232B 32.79 5.345e-21 242-289 BL00232A 27.72 3.727e-20 39-71 BL00232C 10.65 2.742e-14 240-257 BL00232B 32.79 6.566e-14 357-404 1029 PR00205 CADHERIN SIGNATURE PR00205B 11.39 2.909e-15 240-257 1__ PR00205A 14.73 8.457e- 11 165-180 1030 PF00816 H-NS histone family. PF00816B 13.84 9.284e-09 102-131 1030 PR00124 ATP SYNTHASE C SUBUNIT PROO124A 8.81 9.000e-10 41-60 SIGNATURE PROO124A 8.81 9.379e-09 43-62 1030 BL00604 Synaptophysin / synaptoporin proteins. BL00604F 5.96 9.696e-09 41-85 1031 BL00869 Renal dipeptidase proteins. BL00869C 12.58 3.172e-19 112-147 BL00869E 13.12 9.129e-18 173-209 BL00869J 15.60 6.032e-17 323-362 BL00869H 11.08 1.840e-16 272-294 BL00869G 13.55 2.543e-16 245-266 BL00869F 12.77 7.03le-14 210-244 BL008691 12.92 3.274e-12 295-322 BL00869D 14.02 5.282e-10 148-176 BL00869B 15.55 9.382e-10 84-113 1032 BL00218 Amino acid permeases proteins. BL00218D 21.49 7.446e-11 244-288 BL00218E 23.30 3.640e-10 325-364 1033 BL00721 Formate--tetrahydrofolate ligase proteins. BL00721B 13.21 1.000e-40 456-510 BL00721D 13.90 1.000e-40 648-701 BL00721E 13.46 1.000e-40 707-755 BL00721I 18.79 2.500e-40 924-969 WO 2004/080148 PCT/US2003/030720 332 TABLE 3A SEQ Database Description Result* ID entry ID BL00721H 21.20 8.239e-39 873-923 BL00721A 15.31 9.719e-32 397-430 BL00721C 16.92 4.000e-30 608-644 BL00721F 15.96 8.232e-27 770-811 BL00721G 7.97 3.017e-10 831-843 1033 PR00085 TETRAHYDROFOLATE PROO085C 15.23 4.906e-15 169-190 DEHYDROGENASE/CYCLOHYDROLASE PROO085B 15.92 7.488e-10 136-163 FAMILY SIGNATURE PROO085E 15.79 6.216e-09 266-295 1033 BL00415 Synapsins proteins. BLOO415N 4.29 8.489e-09 18-61 1035 PR00834 HTRA/DEGQ PROTEASE FAMILY PR00834F 10.91 2.946e-09 82-94 SIGNATURE 1035 BL00741 Guanine-nucleotide dissociation stimulators BL00741B 14.27 2.962e-09 911-933 CDC24 family sign. 1035 PR00049 WILM'S TUMOUR PROTEIN SIGNATURE PROO049D 0.00 4.814e-09 1125-1139 PROO049D 0.00 5.729e-09 147-161 1035 PR00554 ADENOSINE A2B RECEPTOR PR00554B 12.52 8.855e-09 724-732 SIGNATURE 1037 PR00390 PHOSPHOLIPASE C SIGNATURE PR00390A 15.09 1.439e-20 295-313 1037 BL00303 S-100/ICaBP type calcium binding protein. BL00303B 26.15 4.971e-09 135-171 1037 BL00292 Cyclins proteins. BL00292A 22.87 5.114e-09 220-253 1039 PR00245 OLFACTORY RECEPTOR SIGNATURE PR00245B 10.38 5.821e-14 176-190 PR00245A 18.03 6.891e-14 58-79 PR00245E 12.40 6.170e-11 290-304 PR00245C 7.84 2.286e-10 237-252 1039 BL00237 G-protein coupled receptors proteins. BL00237A 27.68 5.408e-09 89-128 1039 PR00896 VASOPRESSIN RECEPTOR SIGNATURE PR00896B 9.01 7.577e-09 54-65 1039 PR00534 MELANOCORTIN RECEPTOR FAMILY PROO534A 11.49 8.586e-09 50-62 SIGNATURE 1039 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237B 13.50 6.000e-09 58-79 SIGNATURE PR00237E 13.03 8.941e-09 198-221 1040 BLO 1187 Calcium-binding EGF-like domain proteins BL01 187A 9.98 2.125e-12 233-244 pattern proteins. BLO1187A 9.98 4.789e-11 286-297 BL01187B 12.04 3.057e-10 348-363 1040 PD00919 CALCIUM-BINDING PRECURSOR PDO0919D 17.80 1.000e-40 406-456 SIGNAL R. PDO0919D 17.80 1.000e-40 465-515 PDO0919G 15.92 1.000e-40 590-633 PDO0919H 17.48 1.000e-40 634-675 PD009191 18.44 1.000e-40 676-724 PDO0919J 16.09 1.000e-40 737-775 PDO0919K 18.26 1.000e-40 776-810 PDO0919L 16.90 1.000e-40 812-851 PDO0919C 12.28 9.250e-34 357-386 PDO0919F 11.63 7.000e-33 555-583 PDO0919E 11.16 1.000e-32 521-549 PDO0919G 15.92 4.197e-23 453-496 PDO0919G 15.92 1.556e-20 394-437 PDO0919F 11.63 5.103e-20 399-427 PDO0919G 15.92 9.111e-20 550-593 PDO0919D 17.80 3.793e-19 526-576 PDO0919F 11.63 8.397e-18 458-486 PDO0919B 9.47 3.455e-17 308-322 WO 2004/080148 PCT/US2003/030720 333 TABLE 3A SEQ Database Description Result* ID entry ID PD00919D 17.80 6.967e-17 566-616 PD00919A 11.53 3.520e-15 199-210 PD00919F 11.63 6.000e-15 595-623 PDO0919D 17.80 3.970e-14 488-538 PDO0919D 17.80 8.11Oe-14 429-479 PDO0919F 11.63 3.379e-13 517-545 PDO0919G 15.92 4.757e-12 489-532 PDO0919D 17.80 6.094e-12 370-420 PD00919D 17.80 9.915e-12 562-612 PDO0919E 11.16 2.517e-11 403-431 PDO0919B 9.47 3.714e-1 1 215-229 PDO0919G 15.92 7.224e-11 512-555 PDO0919F 11.63 8.372e-11 494-522 PDO0919E 11.16 8.382e-11 498-526 PDO0919E 11.16 9.899e-11 462-490 PDO0919E 11.16 2.663e-10 559-587 PD00919D 17.80 9.061e-10 501-551 PDO0919E 11.16 1.092e-09 599-627 PDO0919D 17.80 1.525e-09 503-553 PD00919G 15.92 3.638e-09 430-473 PDO0919E 11.16 4.582e-09 439-467 PD00919D 17.80 6.625e-09 524-574 PDO0919A 11.53 6.727e-09 239-250 PDO0919D 17.80 6.775e-09 442-492 1042 BL01022 PTR2 family proton/oligopeptide symporters BL1022B 22.19 2.241e-15 74-119 proteins. BLO1022E 23.51 3.739e-14 440-475 BLO1022A 11.58 2.212e-12 44-62 BLO1022D 9.42 2.946e-12 195-207 BLO1022C 16.62 6.226e-10 160-183 1042 PR00308 TYPE I ANTIFREEZE PROTElN PR00308C 3.83 2.169e-09 20-29 SIGNATURE 1043 PF01140 Matrix protein (MA), p15. PF01140D 15.54 3.700e-10 977-1011 1043 DM00215 PROLINE-RICH PROTEIN 3. DM00215 19.43 5.018e-10 542-574 DM00215 19.43 8.322e-09 537-569 DM00215 19.43 8.322e-09 541-573 DM00215 19.43 8.627e-09 530-562 DM00215 19.43 9.542e-09 540-572 1044 PD01066 PROTEIN ZINC FINGER ZINC-FINGER PD01066 19.43 9.727e-36 10-48 METAL-BINDING NU. 1044 PD00066 PROTEIN ZINC-FINGER METAL-BINDI. PD00066 13.92 3.769e-15 384-396 PD00066 13.92 4.462e-15 244-256 PD00066 13.92 6.538e-15 468-480 PD00066 13.92 1.000e-13 300-312 PD00066 13.92 1.000e-13 608-620 PD00066 13.92 9.000e-13 160-172 PD00066 13.92 3.571e-12 216-228 PD00066 13.92 4.000e-12 580-592 PD00066 13.92 5.714e-12 496-508 PD00066 13.92 2.957e-11 524-536 PD00066 13.92 7.652e-11 328-340 PD00066 13.92 2.385e-10 552-564 PD00066 13.92 1.600e-09 272-284 WO 2004/080148 PCT/US2003/030720 334 TABLE 3A SEQ Database Description Result* ID entry ID 1044 PR00048 C2H2-TYPE ZINC FINGER SIGNATURE PROO048A 10.52 2.636e-15 589-602 PROO048A 10.52 4.273e-15 253-266 PROO048A 10.52 5.500e-14 533-546 PROO048A 10.52 4.214e-13 225-238 PROO048A 10.52 5.765e-12 281-294 PR00048A 10.52 7.882e-12 477-490 PROO048A 10.52 1.474e-11 169-182 PROO048A 10.52 1.947e-11 141-154 PROO048A 10.52 3.368e-11 309-322 PROO048A 10.52 8.105e-11 561-574 PROO048A 10.52 9.526e-1 1 393-406 PROO048B 6.02 1.000e-10 297-306 PROO048B 6.02 1.563e-10 577-586 PROO048B 6.02 3.250e-10 353-362 PR00048B 6.02 3.250e-10 409-418 PR00048B 6.02 3.250e-10 437-446 PROO048A 10.52 4.522e-10 617-630 PROO048B 6.02 4.938e-10 241-250 PROO048B 6.02 7.750e-10 493-502 PROO048B 6.02 8.875e-10 381-390 PROO048B 6.02 8.875e-10 465-474 PROO048A 10.52 2.440e-09 197-210 PROO048B 6.02 4.789e-09 605-614 1044 BL00028 Zinc finger, C2H2 type, domain proteins. BL00028 16.07 7.429e-16 536-552 BL00028 16.07 2.125e-15 592-608 BL00028 16.07 4.938e-15 256-272 BL00028 16.07 5.950e-13 228-244 BL00028 16.07 1.000e-11 452-468 BL00028 16.07 2.73 le- 11396-412 BL00028 16.07 4.115e-11 172-188 BL00028 16.07 5.154e- 11 284-300 BL00028 16.07 5.846e-11 480-496 BL00028 16.07 6.538e-11 564-580 BL00028 16.07 9.654e-11 620-636 BL00028 16.07 1.300e-10 144-160 BL00028 16.07 1.900e-10 340-356 BL00028 16.07 1.900e-10 424-440 BL00028 16.07 9.100e-10 116-132 BL00028 16.07 9.100e-10 200-216 BL00028 16.07 9.700e-10 368-384 BL00028 16.07 5.629e-09 508-524 BL00028 16.07 7.943e-09 312-328 1046 PD01795 PROTEIN AMINOPEPTIDASE PD01795A 10.27 6.667e-09 362-370 PRECURSOR HYDROLASE SIGNA. 1049 PF00651 BTB (also known as BR-C/Ttk) domain PF00651 15.00 7.840e-09 43-55 proteins. 1049 PR00766 AMILORIDE-SENSITIVE AMINE PR00766G 11.62 9.905e-09 91-111 OXIDASE SIGNATURE 1050 BL00211 ABC transporters family proteins. BL00211B 13.37 7.429e-20 141-172 1051 PF00569 Zinc finger present in dystrophin, CBP/p300. PF00569 13.42 1.545e-16 21-37 1051 PD00306 PROTEIN GLYCOPROTEIN PRECURSOR PDO0306A 10.26 2.929e-09 257-270

RE.

WO 2004/080148 PCT/US2003/030720 335 TABLE 3A SEQ Database Description Result* ID entry ID 1052 DM00031 IMMUNOGLOBULIN V REGION. DM0003 1B 15.41 5.500e-12 77-110 1052 BL00290 Inimunoglobulins and major BLOO290A 20.89 9.100e-12 154-176 histocompatibility complex proteins. 1053 PROO018 KRINGLE DOMAIN SIGNATURE PRO0018A 14.52 3.423e-09 36-51 1054 DM01688 2 POLY-IG RECEPTOR, DM01688B 15.06 4.504e-09 85-132 DM01688J 14.69 8.364e-09 32-68 1055 BL00290 Immunoglobulins and major BL00290B 13.17 4.000e-21 281-298 histocompatibility complex proteins. BL00290A 20.89 4.600e-16 34-56 BL00290A 20.89 4.375e-15 224-246 1064 PD00289 PROTEIN SH3 DOMAIN REPEAT PD00289 9.97 1.000e-09 453-466 PRESYNA. PD00289 9.97 5.034e-09 47-60 PD00289 9.97 5.034e-09 258-271 1064 PF00595 PDZ domain proteins (Also known as DHR PF00595 13.40 9.250e-10 450-460 or GLGF). PF00595 13.40 7.000e-09 255-265 1067 PR00109 TYROSINE KINASE CATALYTIC PROO109B 12.27 9.471e-12 126-144 DOMAIN SIGNATURE 1067 BLOO107 Protein kinases ATP-binding region proteins. BLOO107A 18.39 2.800e-22 126-156 BLOO107B 13.31 6.786e-11 196-211 1067 BL00479 Phorbol esters / diacylglycerol binding BL00479C 12.01 3.000e-09 174-186 domain proteins. 1067 BL00790 Receptor tyrosine kinase class V proteins. BL00790M 8.74 4.857e-09 117-138 1068 PR00179 LIPOCALIN SIGNATURE PROO179B 9.56 1.000e-12 120-132 PROO179C 19.02 1.000e-10 148-163 PROO179A 13.78 5.680e-10 37-49 1068 BL00213 Lipocalin proteins. BL00213B 8.78 8.000e-10 120-130 BL00213A 12.95 9.526e-10 37-50 1070 PR00200 ANNEXIN TYPE IV SIGNATURE PR00200G 9.43 5.602e-17 299-325 PR00200E 10.00 6.160e-16 136-157 PR00200E 10.00 3.012e-13 295-316 PR00200F 13.72 6.157e-13 219-245 PR00200E 10.00 4.742e-12 64-85 PR00200B 7.39 9.063e-12 69-91 PR00200G 9.43 1.991e-11 140-166 PR00200D 10.01 5.304e-11 109-125 PR00200H 13.68 5.050e-10 343-356 PR00200B 7.39 2.865e-09 141-163 1070 PR00202 ANNEXIN TYPE VI SIGNATURE PR00202G 8.01 1.563e-14 299-325 PR00202E 13.00 9.613e-13 219-245 PR00202D 5.58 8.636e-11 136-157 PR00202G 8.01 2.525e-09 140-166 PR00202D 5.58 3.560e-09 64-85 1070 PR00199 ANNEXIN TYPE III SIGNATURE PROO199F 16.19 7.387e-18 219-245 PROO199D 5.65 1.409e-16 295-316 PR00199G 9.09 6.354e-16 300-325 PROO199D 5.65 6.455e-16 136-157 PROO199D 5.65 1.474e-13 64-85 PROO199B 6.86 2.346e-10 69-91 PROO199B 6.86 5.458e-10 300-322 PR00199B 6.86 8.234e-10 141-163 PROO199C 13.84 6.464e-09 109-125 1070 PR00197 ANNEXIN TYPE I SIGNATURE PROO197D 7.50 5.629e-16 136-157 WO 2004/080148 PCT/US2003/030720 336 TABLE 3A SEQ Database Description Result* ID entry ID PROO197F 9.03 7.395e-15 299-319 PROO197D 7.50 1.234e-14 295-316 PROO197E 11.89 3.541e-13 219-245 PR00197D 7.50 6.379e-11 64-85 PR00197B 7.56 7.124e-09 69-91 1070 PROO198 ANNEXIN TYPE II SIGNATURE PR00198D 7.65 2.222e-15 136-157 PR00198D 7.65 3.647e-13 295-316 PR00198G 8.09 4.375e-13 299-319 PROO198D 7.65 9.165e-10 64-85 PROO198B 8.71 7.529e-09 69-91 PROO198C 14.32 7.900e-09 109-125 PROO198G 8.09 8.125e-09 140-160 1070 BL00223 Annexins repeat proteins domain proteins. BL00223C 24.79 1.000e-40 278-332 BL00223B 28.47 9.679e-39 201-250 BL00223A 15.59 1.000e-27 132-165 BL00223A 15.59 6.936e-22 60-93 BL00223C 24.79 3.077e-17 119-173 BL00223A 15.59 4.194e- 16 291-324 BL00223C 24.79 2.514e-09 47-101 BL00223B 28.47 8.533e-09 117-166 1070 PR00201 ANNEXIN TYPE V SIGNATURE PR0020IG 11.02 7.692e-19 299-325 PR00201D 10.49 1.656e-11 136-157 PR00201A 6.05 6.242e-11 69-91 PR00201E 12.37 8.040e-11 219-245 PR00201C 11.13 3.897e-10 109-125 PR00201D 10.49 5.050e-10 64-85 PR00201G 11.02 6.215e-10 140-166 PR00201D 10.49 9.910e-10 295-316 PR00201A 6.05 4.297e-09 300-322 PR00201H 12.04 7.506e-09 343-356 PR00201A 6.05 8.842e-09 141-163 1070 PR00196 ANNEXIN FAMILY SIGNATURE PR00196D 21.86 2895e-21 219-245 PROO196E 9.19 3.077e-20 299-319 PROO196C 10.36 5.500e-20 136-157 PR00196A 11.16 7.632e-19 69-91 PR00196C 10.36 1.500e-15 295-316 PROO196B 10.68 8.875e-15 109-125 PR00196C 10.36 8.071e-14 64-85 PROO196A 11.16 2.714e-12 141-163 PROO196G 11.72 4.250e-12 343-356 PR00196E 9.19 9.735e-12 140-160 PROO196F 13.89 1.000e-11 327-342 PROO196A 11.16 8.859e-10 300-322 PROO196F 13.89 7.938e-09 168-183 PROO196D 21.86 9.775e-09 135-161 1071 BL00610 Sodium:neurotransmitter symporter family BL00610A 17.73 1.OOOe-40 52-101 proteins. BL00610B 23.65 1.OOOe-40 115-164 BL00610C 12.94 1.OOOe-40 212-263 BL00610E 20.34 1.000e-40 372-414 BL0061OF 29.02 1.000e-40 469-523 BL0061OG 12.89 9.217e-22 528-550 BL00610D 20.97 4.822e-19 278-330 WO 2004/080148 PCT/US2003/030720 337 TABLE 3A SEQ Database Description Result* ID entry ID 1071 PR00176 SODIUM/NEUROTRANSMITTER PROO176A 16.82 1.529e-26 52-73 SYMPORTER SIGNATURE PR00176C 10.84 5.500e-25 124-150 PR00176G 12.48 2.688e-22 458-478 PR00176E 11.41 2.000e-21 322-342 PROO176F 10.73 3.333e-20 376-395 PROO176B 7.31 1.600e-19 81-100 PR00176D 9.02 1.321e-18 239-256 PR00176H 15.27 2.440e-18 498-518 1072 DM00179 w KINASE ALPHA ADHESION T-CELL. DM00179 13.97 7.652e-09 113-122 1073 BL01207 Glypicans proteins. BLO1207C 19.08 6.538e-31 250-285 BLO1207B 23.69 9.122e-28 191-236 BLO1207D 23.23 1.692e-24 429-463 BLO1207A 12.21 1.000e-16 62-77 BLO1207E 13.70 1.214e-11 487-503 1073 PR00049 WILM'S TUMOUR PROTEIN SIGNATURE PROO049D 0.00 3.898e-09 515-529 1073 BL00291 Prion protein. BL00291A 4.49 7.724e-09 530-564 1073 PR00829 MAJOR POLLEN ALLERGEN LOL PI PR00829E 10.81 9.597e-09 306-320 FAMILY SIGNATURE 1075 PF00777 Sialyltransferase family. PF00777C 18.60 2.58le-28 294-348 1078 BLO1177 Anaphylatoxin domain proteins. BLO I177E 20.64 4.541e-13 790-816 1078 BL00477 Alpha-2-macroglobulin family thiolester BL00477J 19.04 3.382e-27 1241-1271 region proteins. BL00477F 17.34 8.500e-25 785-814 BL00477G 19.43 8.826e-23 983-1014 BL00477A 13.50 9.800e-23 122-150 BL00477L 23.51 5.500e-16 1437-1469 BL00477K 17.42 4.529e-14 1382-1405 BL00477E 17.53 6.538e-13 755-775 BL00477B 9.05 6.625e-13 209-221 BL00477I 18.76 2.650e-12 1085-1111 BL00477D 12.73 4.073e-12 729-738 BL00477H 9.07 5.395e-12 1054-1065 BL00477C 15.70 1.161e-10 236-252 1079 BLO1 177 Anaphylatoxin domain proteins. BLO 177E 20.64 4.541e-13 804-830 1079 BL00477 Alpha-2-macroglobulin family thiolester BL00477F 17.34 8.500e-25 799-828 region proteins. BL00477A 13.50 9.800e-23 135-163 BL00477E 17.53 6.538e-13 769-789 BL00477B 9.05 6.625e-13 222-234 BL00477D 12.73 4.073e-12 743-752 BL00477C 15.70 1.161e-10 249-265 1080 BL00477 Alpha-2-macroglobulin family thiolester BL00477A 13.50 9.800e-23 122-150 region proteins. BL00477B 9.05 6.625e-13 209-221 BL00477C 15.70 1.161e-10 236-252 1081 BLO 177 Anaphylatoxin domain proteins. BLO1177E 20.64 4.541e-13 790-816 1081 BL00477 Alpha-2-macroglobulin family thiolester BL00477J 19.04 3.382e-27 1241-1271 region proteins. BL00477F 17.34 8.500e-25 785-814 BL00477G 19.43 8.826e-23 983-1014 BL00477A 13.50 9.800e-23 122-150 BL00477L 23.51 8.800e-22 1437-1469 BL00477K 17.42 4.529e-14 1382-1405 BL00477E 17.53 6.538e-13 755-775 BL00477B 9.05 6.625e-13 209-221 WO 2004/080148 PCT/US2003/030720 338 TABLE 3A SEQ Database Description Result* ID entry ID BL00477I 18.76 2.650e-12 1085-1111 BL00477D 12.73 4.073e-12 729-738 BL00477H 9.07 5.395e-12 1054-1065 BL00477C 15.70 1.161e-10 236-252 1081 BLOO115 Eukaryotic RNA polymerase II heptapeptide BLOO115V 21.32 5.745e-09 1422-1471 repeat proteins. 1082 BL01177 Anaphylatoxin domain proteins. BL01177E 20.64 4.541e-13 791-817 1082 BL00477 Alpha-2-macroglobulin family thiolester BL00477F 17.34 8.500e-25 786-815 region proteins. BL00477A 13.50 9.800e-23 122-150 BL00477E 17.53 6.538e-13 756-776 BL00477B 9.05 6.625e-13 209-221 BL00477D 12.73 4.073e-12 730-739 BL00477C 15.70 1.161e-10 236-252 1083 BL00122 Carboxylesterases type-B serine proteins. BLOO122E 22.02 9.027e-31 195-235 BLOO122A 12.04 5.500e-16 60-80 BLOO122D 12.53 7.545e-16 171-186 BL00122C 7.91 8.125e-13 142-152 BLOO122B 16.84 4.830e-10 122-132 BLOO122F 11.10 5.500e-10 247-256 BLOO122G 11.67 9.625e-10 500-510 1083 PR00878 CHOLINESTERASE SIGNATURE PR00878F 5.37 7.17le-09 460-472 1084 PD00919 CALCIUM-BINDING PRECURSOR PDO0919B 9.47 7.485e-10 1019-1033 SIGNAL R. 1084 BL00203 Vertebrate metallothioneins proteins. BL00203 13.94 9.138e-10 175-220 1084 BL00279 Membrane attack complex components BL00279E 37.11 9.241e-10 387-434 perform proteins. 1084 PROO011 TYPE III EGF-LIKE SIGNATURE PRO011D 14.03 2.696e-09 413-431 1084 PR00907 THROMBOMODULIN SIGNATURE PR00907G 11.63 7.973e-09 890-916 1084 PR00049 WILM'S TUMOUR PROTEIN SIGNATURE PROO049D 0.00 8.017e-09 92-106 1084 BL00022 EGF-like domain proteins. BLOO022B 7.54 8.200e-09 1187-1193 1084 PRoo01o TYPE II EGF-LIKE SIGNATURE PROM01OC 11.16 7.667e-11 1183-1193 PROO010C 11.16 1.857e-09 937-947 PROM01OC 11.16 4.857e-09 1687-1697 PRO0010C 11.16 8.286e-09 1642-1652 1084 PR0009 TYPE I EGF SIGNATURE PR0009C 14.11 9.118e-09 1058-1069 1084 BL01187 Calcium-binding EGF-like domain proteins BL01187B 12.04 7.000e-17 1682-1697 pattern proteins. BLO1187B 12.04 2.350e-14 1178-1193 BLO1187B 12.04 5.500e-14 1136-1151 BLO1187B 12.04 1.391e-13 642-657 BLO1187B 12.04 4.130e-13 1219-1234 BLO1187B 12.04 4.913e-13 1095-1110 BLO1187B 12.04 9.609e-13 932-947 BL01187B 12.04 9.667e-12 1054-1069 BLO1187B 12.04 4.600e-11 1261-1276 BLO1 187A 9.98 9.526e- 1 997-1008 BLO1187B 12.04 1.257e-10 1483-1498 BLO1187A 9.98 7.857e-10 1078-1089 BLO1187A 9.98 2.875e-09 1243-1254 BL01 187B 12.04 3.250e-09 1637-1652 BLO1187A 9.98 7.000e-09 914-925 BLO1187A 9.98 1.000e-08 1037-1048 WO 2004/080148 PCT/US2003/030720 339 TABLE 3A SEQ Database Description Result* ID entry ID 1086 PROO014 FIBRONECTIN TYPE III REPEAT PROO014A 8.22 8.941e-10 816-825 SIGNATURE PROO014D 12.04 5.950e-09 872-886 PR00014C 15.44 6.478e-09 854-872 1086 BL00790 Receptor tyrosine kinase class V proteins. BL00790I 20.01 6.250e-12 865-895 BL00790I 20.01 7.750e-09 662-692 1087 PD01066 PROTEIN ZINC FINGER ZINC-FINGER PDO1066 19.43 2.737e-24 16-54 METAL-BINDING NU. 1087 BL00028 Zinc finger, C2H2 type, domain proteins. BL00028 16.07 4.150e-13 219-235 BL00028 16.07 7.300e-13 191-207 BL00028 16.07 4.522e-12 163-179 BL00028 16.07 2.038e-11 247-263 1087 PD00066 PROTEIN ZINC-FINGER METAL-BINDI. PD00066 13.92 7.23 1c-15 235-247 PD00066 13.92 6.143e-12 179-191 PD00066 13.92 7.923e-10 207-219 1087 PR00048 C2H2-TYPE ZINC FINGER SIGNATURE PROO048A 10.52 3.250e-14 188-201 PROO048A 10.52 4.000e-14 244-257 PROO048A 10.52 4.706e-12 216-229 PROO048B 6.02 3.250e-10 232-241 PROO048A 10.52 2.440e-09 160-173 PROO048B 6.02 9.053e-09 260-269 1088 PD01066 PROTEIN ZINC FINGER ZINC-FINGER PD01066 19.43 2.737e-24 16-54 METAL-BINDING NU. 1088 BL00028 Zinc finger, C2H2 type, domain proteins. BL00028 16.07 8.043e-12 163-179 1088 PR00048 C2H2-TYPE ZINC FINGER SIGNATURE PROO048A 10.52 2.800e-09 160-173 PR00048B 6.02 9.053e-09 176-185 1089 BL00243 Integrins beta chain cysteine-rich domain BL002431 31.77 1.127e-09 86-128 proteins. BL00243I 31.77 2.775e-09 30-72 BL00243I 31.77 5.437e-09 89-131 1089 BL01208 VWFC domain proteins. BLO1208B 15.83 5.865e-09 114-128 1089 PD02283 PROTEIN SPORULATION REPEAT PD02283C 17.54 5.613e-09 24-51 PRECU. PD02283C 17.54 5.613e-09 68-95 PD02283C 17.54 7.188e-09 93-120 PD02283C 17.54 7.750e-09 103-130 1089 BL00269 Mammalian defensins proteins. BL00269C 16.52 9.289e-09 28-56 BL00269C 16.52 9.289e-09 72-100 1089 BL00203 Vertebrate metallothioneins proteins. BL00203 13.94 6.897e-12 66-111 BL00203 13.94 3.769e-11 70-115 BL00203 13.94 4.165e-11 40-85 BL00203 13.94 6.835e-11 65-110 BL00203 13.94 1.096e-10 61-106 BL00203 13.94 2.723e-10 21-66 BL00203 13.94 2.723e-10 22-67 BL00203 13.94 5.213e-10 91-136 BL00203 13.94 5.883e-10 26-71 BL00203 13.94 7.032e-10 114-159 BL00203 13.94 1.643e-09 85-130 BL00203 13.94 1.735e-09 105-150 BL00203 13.94 2.745e-09 80-125 BL00203 13.94 3.388e-09 56-101 BL00203 13.94 4.214e-09 81-126 BL00203 13.94 5.500e-09 60-105 WO 2004/080148 PCT/US2003/030720 340 TABLE 3A SEQ Database Description Result* ID entry ID BL00203 13.94 6.694e-09 100-145 BL00203 13.94 6.969e-09 17-62 BL00203 13.94 7.612e-09 47-92 BL00203 13.94 7.704e-09 101-146 BL00203 13.94 8.53le-09 75-120 BL00203 13.94 8.714e-09 95-140 BL00203 13.94 9.541e-09 25-70 1090 PD02283 PROTEIN SPORULATION REPEAT PD02283C 17.54 5.613e-09 28-55 PRECU. 1090 BL00203 Vertebrate metallothioneins proteins. BL00203 13.94 3.069e-12 26-71 BL00203 13.94 6.266e-10 30-75 BL00203 13.94 4.398e-09 21-66 BL00203 13.94 8.071e-09 25-70 1090 BL00269 Mammalian defensins proteins. BL00269C 16.52 9.289e-09 32-60 1091 BL00243 hitegrins beta chain cysteine-rich domain BL00243I 31.77 8.676e-10 121-163 proteins. BL00243I 31.77 3.915e-09 124-166 BL00243I 31.77 5.690e-09 30-72 1091 BL01208 VWFC domain proteins. BL01208B 15.83 5.865e-09 149-163 1091 BL00203 Vertebrate metallothioneins proteins. BL00203 13.94 3.670e-1 1 66-111 BL00203 13.94 4.659e-11 40-85 BL00203 13.94 7.429e-11 70-115 BL00203 13.94 1.862e-10 105-150 BL00203 13.94 2.723e-10 21-66 BL00203 13.94 2.723e-10 61-106 BL00203 13.94 2.915e-10 126-171 BL00203 13.94 4.064e-10 22-67 BL00203 13.94 6.457e-10 26-71 BL00203 13.94 7.032e-10 149-194 BL00203 13.94 7.319e-10 95-140 BL00203 13.94 1.735e-09 140-185 BL00203 13.94 1.827e-09 115-160 BL00203 13.94 1.918e-09 80-125 BL00203 13.94 3.020e-09 100-145 BL00203 13.94 3.204e-09 65-110 BL00203 13.94 4.306e-09 120-165 BL00203 13.94 5.041e-09 47-92 BL00203 13.94 5.500e-09 116-161 BL00203 13.94 6.694e-09 135-180 BL00203 13.94 6.969e-09 17-62 BL00203 13.94 7.429e-09 71-116 BL00203 13.94 7.704e-09 136-181 BL00203 13.94 8.163e-09 85-130 BL00203 13.94 8.714e-09 130-175 1091 PD02283 PROTEIN SPORULATION REPEAT PD02283C 17.54 5.613e-09 24-51 PRECU. PD02283C 17.54 5.613e-09 68-95 PD02283C 17.54 7.188e-09 128-155 PD02283C 17.54 7.750e-09 138-165 PD02283C 17.54 8.875e-09 123-150 1091 BL00269 Mammalian defensins proteins. BL00269C 16.52 9.289e-09 28-56 BL00269C 16.52 9.289e-09 72-100 1091 BL00799 Granulins proteins. BL00799D 12.41 7.661e-09 49-95 BL00799G 9.41 1.000e-08 39-79 WO 2004/080148 PCT/US2003/030720 341 TABLE 3A SEQ Database Description Result* ID entry ID 1094 PR00248 METABOTROPIC GLUTAMATE GPCR PR00248A 9.91 7.522e-09 24-45 SIGNATURE 1094 PR00354 7FE FERREDOXIN SIGNATURE PR00354C 5.72 8.157e-09 258-275 1096 PR00356 TYPE II ANTIFREEZE PROTEIN PR00356G 10.80 9.862e- 11 193-206 SIGNATURE 1096 BL00615 C-type lectin domain proteins. BL00615B 12.25 2.73le-09 193-206 BL00615A 16.68 9.400e-09 94-111 1097 PR00356 TYPE II ANTIFREEZE PROTEIN PR00356G 10.80 7.658e-09 193-206 SIGNATURE 1097 BL00615 C-type lectin domain proteins. BL00615A 16.68 9.400e-09 94-111 1098 PR00245 OLFACTORY RECEPTOR SIGNATURE PR00245A 18.03 6.870e-24 59-80 PR00245C 7.84 2.421e-19 238-253 PR00245E 12.40 8.714c-16 291-305 PR00245D 10.47 6.786e-13 274-285 PR00245B 10.38 6.906e-13 177-191 1098 BL00237 G-protein coupled receptors proteins. BL00237A 27.68 8.839e-15 90-129 BL00237D 11.23 2.364e-09 282-298 1098 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237B 13.50 1.750e-09 59-80 SIGNATURE PR00237C 15.69 4.600e-09 104-126 PR00237A 11.48 5.065e-09 26-50 PR00237G 19.63 5.605e-09 272-298 1098 PR00023 ZONA PELLUCIDA SPERM-BINDING PROO023E 22.27 9.813e-09 128-145 PROTEIN SIGNATURE 1099 DM00191 w SPAC8A4.04C RESISTANCE DMOO191D 13.94 9.083e-10 163-201 SPAC8A4.05C DAUNORUBICIN. 1099 PR00346 TISSUE FACTOR SIGNATURE PR00346H 10.74 8.179e-09 542-565 1099 BL00022 EGF-like domain proteins. BLOO022B 7.54 1.000e-08 306-312 1100 DM00372 CARCINOEMBRYONIC ANTIGEN DM00372B 20.31 8.920e-15 363-407 PRECURSOR AMINO-TERMINAL DM00372B 20.31 3.329e-12 68-112 DOMAIN. 1101 BL01208 VWFC domain proteins. BLO1208B 15.83 3.250e-10 1436-1450 1101 PR00457 ANIMAL HAEM PEROXIDASE PR00457E 20.67 3.118e-22 997-1023 SIGNATURE PR00457D 16.81 4.194e-21 972-992 PR00457C 19.25 1.675e-13 954-972 PR00457H 15.90 5.680e-13 1248-1262 PR00457F 13.69 4.750e-12 1050-1060 PR00457G 17.45 8.615e-12 1177-1197 PR00457B 13.29 3.411e-10 802-817 1101 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 1.000e-09 349-372 1101 PD01270 RECEPTOR FC IMMUNOGLOBULIN PDO1270A 17.22 7.677e-09 328-367 AFFIN. 1101 PROO019 LEUCINE-RICH REPEAT SIGNATURE PROO019B 11.36 8.920e-09 73-86 1102 BL01208 VWFC domain proteins. BLO1208B 15.83 3.250e-10 1412-1426 1102 PR00457 ANIMAL HAEM PEROXIDASE PR00457E 20.67 3.11 Se-22 973-999 SIGNATURE PR00457D 16.81 4.194e-21 948-968 PR00457C 19.25 1.675e-13 930-948 PR00457H 15.90 5.680e-13 1224-1238 PR00457F 13.69 4.750e-12 1026-1036 PR00457G 17.45 8.615e-12 1153-1173 PR00457B 13.29 3.411e-10 778-793 1102 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 1.000e-09 325-348 WO 2004/080148 PCT/US2003/030720 342 TABLE 3A SEQ Database Description Result* ID entry ID 1102 PROO019 LEUCINE-RICH REPEAT SIGNATURE PROO019B 11.36 7.480e-09 73-86 1102 PD01270 RECEPTOR FC IMMUNOGLOBULIN PDO1270A 17.22 7.677e-09 304-343 AFFIN. 1103 BLOO815 Alpha-isopropylmalate and homocitrate BLOO815C 21.36 3.118e-09 786-814 synthases proteins. 1107 PD02059 CORE POLYPROTEIN PROTEIN GAG PD02059B 24.48 8.352e-09 682-716 CONTAINS: P. 1113 BLOO107 Protein kinases ATP-binding region proteins. BLOO107A 18.39 6.885e-12 311-341 1113 PR00109 TYROS1NE KINASE CATALYTIC PR0O109B 12.27 7.750e-09 311-329 DOMAIN SIGNATURE 1117 PD01652 RECEPTOR CELL NK GLYCOPROTEIN PD01652B 8.50 4.021e-09 99-150 IMMUNOGLOB. PDO1652B 8.50 5.050e-09 2-53 PD01652A 15.35 7.769e-09 12-47 1120 BL50002 Src homology 3 (SH3) domain proteins BL50002A 14.19 1.750e-12 1026-1044 profile. 1120 PR00452 SH3 DOMAIN SIGNATURE PR00452B 11.65 4.115e-11 1036-1051 1120 PF00023 Ank repeat proteins. PF00023B 14.20 3.000e-10 954-963 PF00023A 16.03 2.286e-09 925-940 1120 PD00078 REPEAT PROTEIN ANK NUCLEAR PDO0078B 13.14 8.000e-11 951-963 ANKYR. PDO0078B 13.14 4.522e-09 918-930 1120 PF00791 Domain present in ZO-1 and Unc5-like netrin PF00791B 28.49 8.024e-16 925-979 receptors. PF00791C 20.98 4.971e-09 939-977 1120 PR00499 NEUTROPHIL CYTOSOL FACTOR 2 PR00499D 10.18 6.965e-09 1024-1044 SIGNATURE 1122 PF00992 Troponin. PF00992A 16.67 8,461e-09 245-279 1124 PF00023 Ank repeat proteins. PF00023A 16.03 7.000e-11 69-84 PF00023B 14.20 2.636e-09 131-140 1124 PD00078 REPEAT PROTEIN ANK NUCLEAR PDO0078B 13.14 6.087e-09 128-140 ANKYR. 1124 PF00791 Domain present in ZO-1 and Unc5-like netrin PF00791B 28.49 2.569e-09 135-189 receptors. PF00791B 28.49 9.835e-09 69-123 1125 PF00023 Ank repeat proteins. PF00023A 16.03 7.000e-11 69-84 PF00023B 14.20 2.636e-09 131-140 1125 PD00078 REPEAT PROTEIN ANK NUCLEAR PDO0078B 13.14 6.087e-09 128-140 ANKYR. 1125 PF00791 Domain present in ZO-1 and Unc5-like netrin PF00791B 28.49 2.569e-09 135-189 receptors. PF00791B 28.49 9.835e-09 69-123 1128 PR00248 METABOTROPIC GLUTAMATE GPCR PR00248G 12.67 2.688e-09 53-77 SIGNATURE 1129 DM00516 186 DISCOIDIN I N-TERMINAL. DM00516 30.53 8.606e-13 131-175 1130 DM00516 186 DISCOIDIN I N-TERMINAL. DM00516 30.53 8.606e-13 131-175 1130 DM01077 SEX HORMONE-BINDING GLOBULIN. DMO1077A 16.30 3.143e-11 386-432 1132 BL00243 Integrins beta chain cysteine-rich domain BL002431 31.77 4.930e-09 87-129 proteins. . 1133 BLOO107 Protein kinases ATP-binding region proteins. BLOO107B 13.31 5.909e-13 195-210 1133 PROO109 TYROSINE KINASE CATALYTIC PROO109D 17.04 7.609e-09 196-218 DOMAIN SIGNATURE PROO109B 12.27 9.297e-09 126-144 1135 PR00402 TEC/BTK DOMAIN SIGNATURE PR00402A 16.09 2.950e-10 664-683 1135 BL00509 Ras GTPase-activating proteins. BL00509B 10.28 9.800e-09 502-512 1137 PR00907 THROMBOMODULIN SIGNATURE PR00907B 11.29 3.959e-11 168-184 1137 DM00215 PROLINE-RICH PROTEIN 3. DM00215 19.43 3.893e-10 333-365 WO 2004/080148 PCT/US2003/030720 343 TABLE 3A SEQ Database Description Result* ID entry ID DM00215 19.43 4.054e-10 328-360 DM00215 19.43 8.232e-10 332-364 1137 BL01187 Calcium-binding EGF-like domain proteins BLO1187B 12.04 2.957e-13 134-149 pattern proteins. BLO 1 187B 12.04 3.739e- 13 261-276 BL01187B 12.04 2.333e-12 216-231 BLO1187A 9.98 3.250e-09 197-208 1137 PR00049 WILM'S TUMOUR PROTEIN SIGNATURE PROO049D 0.00 3.288e-09 348-362 PROO049D 0.00 3.288e-09 350-364 1137 BLO 1177 Anaphylatoxin domain proteins. BLO 1 177C 17.39 4.714e-09 128-146 1137 BL00243 Integrins beta chain cysteine-rich domain BL00243H 17.53 5.855e-09 63-88 proteins. 1137 PF00094 von Willebrand factor type D domain PF00094A 11.09 9.022e-09 163-172 proteins. 1137 BL00022 EGF-like domain proteins. BLOO022B 7.54 9.100e-09 75-81 1137 PR00910 LUTEOVIRUS ORF6 PROTEIN PR00910A 2.51 9.357e-09 348-360 SIGNATURE 1143 PR00245 OLFACTORY RECEPTOR SIGNATURE PR00245C 7.84 5.355e-17 121-136 PR00245B 10.38 3.919e-12 60-74 PR00245E 12.40 1.000e-10 174-188 1143 BL00237 G-protein coupled receptors proteins. BL00237D 11.23 2.091e-09 165-181 1143 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237G 19.63 8.714e-11 155-181 SIGNATURE PR00237E 13.03 9.735e-09 82-105 1144 PR00245 OLFACTORY RECEPTOR SIGNATURE PR00245C 7.84 5.355e-17 235-250 PR00245A 18.03 8.615e-15 58-79 PR00245B 10.38 3.919e-12 174-188 PR00245E 12.40 1.000e-10 288-302 1144 BL00237 G-protein coupled receptors proteins. BL00237A 27.68 1.581e-15 89-128 BL00237D 11.23 2.091e-09 279-295 1144 PR00896 VASOPRESSIN RECEPTOR SIGNATURE PR00896B 9.01 8.962e-09 54-65 1144 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237G 19.63 8.714e- 11 269-295 SIGNATURE PR00237C 15.69 3.829e-10 103-125 PR00237E 13.03 9.735e-09 196-219 1146 BL00914 Syntaxin / epirnorphin family proteins. BL00914 24.91 6.172e-09 168-217 1147 PR00264 INTERLEUKIN-1 SIGNATURE PR00264B 20.98 8.453e-11 56-82 PR00264C 17.77 1.851e-10 96-124 1148 BL00226 Intermediate filaments proteins. BL00226B 23.86 5.050e-24 96-143 BL00226D 19.10 8.200e-18 262-308 BL00226C 13.23 5.610e-14 161-191 BL00226A 12.77 5.065e-13 380-394 1151 BL00226 Intermediate filaments proteins. BL00226D 19.10 5.500e-38 367-413 BL00226C 13.23 4.130e-23 266-296 BL00226A 12.77 9.129e-13 131-145 BL00226B 23.86 1.338e-10 183-230 1152 PR00138 MATRIXIN SIGNATURE PR00138A 15.14 7.136e-16 86-99 PROO138B 15.82 3.824e-11 131-146 1152 BL00546 Matrixins cysteine switch. BL00546A 19.62 7.667e-26 66-95 BL00546E 10.23 3.475e-19 231-251 BL00546B 20.11 7.720e-19 155-198 BL00546F 12.40 6.400e-13 268-280 BL00546G 16.84 9.449e-1 1 288-307 1152 BL00024 Hemopexin domain proteins. BLOO024B 21.53 3.143e-23 105-138 WO 2004/080148 PCT/US2003/030720 344 TABLE 3A SEQ Database Description Result* ID entry ID BLOO024C 22.98 8.320e-20 154-202 BL00024F 11.30 2.184e-18 231-251 BLOO024G 13.31 6.192e-13 268-280 BL00024A 11.49 9.100e-13 86-96 BL00024H 11.35 8.154e-10 335-346 1153 PR00138 MATRIXIN SIGNATURE PROO138A 15.14 7.136e-16 86-99 PROO138B 15.82 3.824e-11 131-146 1153 BL00546 Matrixins cysteine switch. BL00546A 19.62 7.667e-26 66-95 BL00546E 10.23 3.475e-19 231-251 BL00546B 20.11 7.720e-19 155-198 BLOO546F 12.40 6.400e-13 268-280 BL00546G 16.84 9.449e- 11 288-307 1153 BL00024 Hemopexin domain proteins. BLOO024B 21.53 3.143e-23 105-138 BLOO024C 22.98 8.320e-20 154-202 BLOO024F 11.30 2.184e-18 231-251 BLOO024G 13.31 6.192e-13 268-280 BLOO024A 11.49 9.100e-13 86-96 BLOO024H 11.35 8.154e-10 335-346 1154 PR00049 WILM'S TUMOUR PROTEIN SIGNATURE PROO049D 0.00 2.068e-09 10-24 1155 BL00400 LBP / BPI / CETP family proteins. BL00400C 24.53 6.029e-17 210-253 BL00400D 23.26 2.080e-14 274-310 BL00400A 21.59 1.600e-10 27-58 1156 PD02448 TRANSCRIPTION PROTEIN DNA- PD02448A 9.37 1.700e-19 90-128 BINDIN. PD02448B 10.17 2.311e-17 129-176 1156 BL00415 Synapsins proteins. BL004150 3.44 7.395e-09 22-59 1159 BL00347 Poly(ADP-ribose) polymerase zinc finger BL00347A 12.35 9.795e-15 93-135 domain proteins. 1159 BL00697 ATP-dependent DNA ligase AMP-binding BL00697D 18.99 1.346e-23 591-617 site proteins. BL00697A 21.27 2.929e-19 471-499 BL00697B 13.40 4.774e- 14 506-517 1160 BL00284 Serpins proteins. BL00284C 28.56 7.600e-25 203-244 BL00284E 19.15 4.375e-23 401-425 BL00284D 16.34 5.286e-21 317-343 BL00284A 15.64 6.192e-17 27-50 BL00284B 17.99 4.414e-13 174-194 1166 BLO1 121 Caspase family histidine proteins. BLO1121A 9.11 5.500e-13 7-17 1166 PR00376 INTERLEUKIN-1B CONVERTING PR00376A 14.23 7.980c-11 5-18 ENZYME SIGNATURE 1167 PD02870 RECEPTOR INTERLEUKIN-1 PD02870D 15.74 7.000e-10 79-113 PRECURSOR. 1167 PD01652 RECEPTOR CELL NK GLYCOPROTEIN PD01652B 8.50 3.143e-29 209-260 IMMUNOGLOB. PD01652B 8.50 5.457e-18 107-158 PD01652A 15.35 6.438e-14 117-152 PDO1652A 15.35 3.732e-10 24-59 PDO1652B 8.50 7.448e-10 14-65 PDO1652A 15.35 4.23 1e-09 219-254 1169 BL00615 C-type lectin domain proteins. BL00615A 16.68 7.231e-10 125-142 1171 PR00308 TYPE I ANTIFREEZE PROTEIN PR00308A 5.90 9.156e-13 158-172 SIGNATURE PR00308C 3.83 6.640e-12 161-170 PR00308B 4.28 1.806e-10 161-172 PR00308A 5.90 4.873e-10 162-176 WO 2004/080148 PCT/US2003/030720 345 TABLE 3A SEQ Database Description Result* ID entry ID PR00308C 3.83 8.062e-10 165-174 1171 PR00456 RIBOSOMAL PROTEIN P2 SIGNATURE PR00456E 3.06 5.671e-09 163-177 1171 BL00678 Trp-Asp (WD) repeat proteins proteins. BL00678 9.67 2.800e-10 429-439 BL00678 9.67 5.263e-09 480-490 _ _ _ BL00678 9.67 6.21 le-09 249-259 1171 PR00833 POLLEN ALLERGEN POA PI PR00833H 2.30 7.750e-10 164-178 SIGNATURE PR00833H 2.30 7.923e-09 161-175 1171 PR00320 G-PROTEIN BETA WD-40 REPEAT PR00320A 16.74 4.000e-13 427-441 SIGNATURE PR00320B 12.19 8.269e-12 478-492 PR00320A 16.74 5.966e-11 478-492 PR00320C 13.01 6.478e-11 478-492 PR00320C 13.01 9.217e-11 427-441 PR00320A 16.74 9.690e-11 247-261 PR00320B 12.19 3.057e-10 247-261 PR00320C 13.01 6.040e-10 247-261 PR00320B 12.19 6.657e-10 427-441 PR00320B 12.19 1.450e-09 520-534 PR00320C 13.01 2.500e-09 303-317 PR00320A 16.74 4.732e-09 520-534 PR00320A 16.74 6.488e-09 344-358 PR00320C 13.01 1.000e-08 344-358 1172 PD01652 RECEPTOR CELL NK GLYCOPROTEIN PD01652A 15.35 6.625e-10 24-60 IMMUNOGLOB. PD01652B 8.50 1.836e-09 14-66 PD01652B 8.50 4.02le-09 111-163 1173 PD01652 RECEPTOR CELL NK GLYCOPROTEIN PD01652A 15.35 6.625e-10 24-60 IMMUNOGLOB. PDO1652B 8.50 1.836e-09 14-66 PD01652B 8.50 4.02 1e-09 111-163 1183 PD02876 DECARBOXYLASE PD02876C 8.80 2.723e-13 316-328 PHOSPHATIDYLSERINE. PD02876D 12.13 2.588e-12 427-443 1184 BL01289 TSC-22 / dip / bun family proteins. BL01289A 12.18 8.200e-33 124-150 BL01289B 10.45 8.071e-30 151-180 1184 DM00475 w LOW TRANSPOSASE SAPA 12K. DM00475B 12.12 5.891e-10 145-164 1187 PR00901 PHEROMONE B ALPHA-1 RECEPTOR PR00901H 14.99 4.706e-09 56-66 SIGNATURE 1188 BL00708 Prolyl endopeptidase family shrine proteins. BL00708B 24.91 7.197e-12 734-764 1188 PF00930 Dipeptidyl peptidase IV (DPP IV) N-terminal PF00930I 15.96 6.373e-17 776-803 region. PF00930H 20.16 2.482e-13 697-739 PF00930J 8.78 1.000e-11 828-848 PF00930G 21.30 9.613e-09 657-694 1189 BL00708 Prolyl endopeptidase family serine proteins. BL00708B 24.91 7.197e-12 734-764 1189 PF00930 Dipeptidyl peptidase IV (DPP IV) N-terminal PF00930H 20.16 2.482e-13 697-739 region. PF00930J 8.78 1.000e-11 790-810 PF00930G 21.30 9.613e-09 657-694 1190 BL00708 Prolyl endopeptidase family serine proteins. BL00708B 24.91 7.197e-12 721-751 1190 PF00930 Dipeptidyl peptidase IV (DPP IV) N-terminal PF009301 15.96 6.373e-17 763-790 region. PF00930H 20.16 2.482e-13 684-726 PF00930J 8.78 1.000e-11 815-835 PF00930G 21.30 9.613e-09 644-681 1193 PF00791 Domain present in ZO-1 and Unc5-like netrin PF00791B 28.49 6.612e-15 153-207 receptors. PF00791B 28.49 7.955e-14 186-240 PF00791B 28.49 3.653e-12 436-490 WO 2004/080148 PCT/US2003/030720 346 TABLE 3A SEQ Database Description Result* ID entry ID PF00791B 28.49 9.337e-12 54-108 PF00791B 28.49 4.273e-11 319-373 PF00791B 28.49 7.818e-11 252-306 PF00791B 28.49 1.524e-10 219-273 PF00791B 28.49 2.398e-10 120-174 PF00791C 20.98 3.559e-09 200-238 PF00791C 20.98 5.235e-09 333-371 PF00791C 20.98 5.235e-09 544-582 PF00791B 28.49 6.202e-09 352-406 PF00791B 28.49 7.028e-09 598-652 PF00791C 20.98 7.265e-09 101-139 PF00791B 28.49 8.679e-09 530-584 PF00791B 28.49 1.000e-08 87-141 1193 PD00078 REPEAT PROTEIN ANK NUCLEAR PDO0078B 13.14 4.600e-12 345-357 ANKYR. PDO0078B 13.14 2.000e-11 462-474 PDO0078B 13.14 3.500e-11 796-808 PDO0078B 13.14 8.500e-11 863-875 PDO0078B 13.14 4.600e-10 495-507 PDO0078B 13.14 5.950e-10 760-772 PDO0078B 13.14 4.522e-09 212-224 PDO0078B 13.14 6.087e-09 278-290 PDO0078B 13.14 1.000e-08 146-158 PDO0078B 13.14 1.000e-08 245-257 1193 PF00023 Ank repeat proteins. PF00023A 16.03 2.500e-12 186-201 PF00023B 14.20 5.154e-11 465-474 PF00023B 14.20 5.154e- 11 763-772 PF00023A 16.03 6.571e-11 153-168 PF00023A 16.03 1.750e-10 54-69 PF00023B 14.20 8.000e-10 866-875 PF00023B 14.20 1.409e-09 348-357 PF00023B 14.20 2.636e-09 281-290 PF00023A 16.03 3.250e-09 219-234 PF00023B 14.20 3.455e-09 498-507 PF00023B 14.20 3.864e-09 799-808 PF00023A 16.03 4.536e-09 252-267 PF00023B 14.20 5.500e-09 248-257 PF00023A 16.03 6.464e-09 598-613 PF00023B 14.20 7.955e-09 432-441 PF00023A 16.03 8.071e-09 631-646 PF00023A 16.03 8.071e-09 767-782 PF00023A 16.03 1.000e-08 701-716 1194 PR00834 HTRA/DEGQ PROTEASE FAMILY PR00834C 15.43 6.226e-20 253-277 SIGNATURE PR00834D 12.14 4.316e-17 291-308 PR00834B 10.09 7.188e-14 212-232 PR00834E 13.63 1.000e-12 313-330 PR00834A 9.80 5.737e-12 191-203 PR00834F 10.91 1.730e-09 374-386 1195 PR00555 ADENOSINE A3 RECEPTOR SIGNATURE PR00555E 11.12 5.629e-20 105-122 PR00555F 11.18 6.114e-20 152-169 PR00555D 10.11 4.717e-18 60-76 1195 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237G 19.63 8.560e-15 119-145 1 SIGNATURE PR00237F 13.57 3.520e-13 83-107 WO 2004/080148 PCT/US2003/030720 347 TABLE 3A SEQ Database Description Result* ID entry ID PR00237E 13.03 4.960e-12 33-56 1195 PR00424 ADENOSINE RECEPTOR SIGNATURE PR00424D 14.32 9.400e-23 21-40 PR00424E 15.73 6.211e-14 74-87 PR00424F 8.50 9.156e-12 119-129 1195 BL00237 G-protein coupled receptors proteins. BL00237C 13.19 3.864e-15 78-104 BL00237D 11.23 1.346e-11 129-145 1197 BL00237 G-protein coupled receptors proteins. BL00237A 27.68 3.455e-14 95-134 1197 PR00237 PIODOPSIN-LIKE GPCR SUPERFAMILY PR00237C 15.69 1.257e-10 109-131 SIGNATURE PR00237E 13.03 9.100e-10 204-227 1197 PR00245 OLFACTORY RECEPTOR SIGNATURE PR00245A 18.03 9.58le-18 64-85 PR00245C 7.84 4.780e-13 243-258 PR00245E 12.40 6.74le-09 296-310 PR00245B 10.38 8.163e-09 182-196 1197 PR00534 MELANOCORTIN RECEPTOR FAMILY PR00534A 11.49 9.229e-09 56-68 SIGNATURE 1198 PR00505 D12 CLASS N6 ADENINE-SPECIFIC DNA PR00505A 14.15 4.857e-13 30-46 METHYLTRANSFERASE SIGNATURE PR00505B 11.49 1.621e-12 51-65 1199 PR00179 LIPOCALIN SIGNATURE PROO179B 9.56 2.071e-09 111-123 PROO179C 19.02 9.455e-09 138-153 1200 PF00152 tRNA synthetases class II. PF00152D 21.30 8.364e-28 431-469 PFOO152C 28.03 9.250e-21 220-256 PF00152B 15.67 2.658e-13 159-183 PFOO152A 19.68 5.714e-11 44-66 1202 BL00504 Fumarate reductase / succinate dehydrogenase BL00504D 10.43 5.390e-17 31-48 FAD-binding site proteins. 1203 BL00720 Guanine-nucleotide dissociation stimulators BL00720B 16.57 5.065e-17 309-332 CDC25 family sign. 1204 PF00013 KH domain proteins family of RNA binding PF00013 5.78 4.150e-09 112-123 proteins. 1206 DM00893 YRUVATE DEHYDROGENASE DM00893A 19.01 1.000e-40 47-93 (LIPOAMIDE) BETA CHAIN. DM00893E 29.52 1.000e-40 234-287 DM00893C 20.28 2.452e-40 143-184 DM00893B 27.53 3.483e-31 105-142 DM00893D 23.36 1.545e-26 197-230 DM00893F 21.02 6.897e-21 292-316 1207 PR00312 CALSEQUESTRIN SIGNATURE PR00312E 8.32 3.423e-36 163-192 PR00312I 15.78 5.286e-35 326-354 PR00312F 15.06 5.865e-35 193-222 PR00312H 13.31 8.313e-35 257-284 PR00312J 13.73 5.688e-34 357-385 PR00312D 9.43 2.636e-33 122-151 PR00312C 15.14 8.839e-33 86-115 PR00312B 15.08 8.941e-33 56-85 PR00312G 11.11 6.657e-32 224-251 PR00312A 11.70 6.914e-27 29-52 1207 BL00863 Calsequestrin proteins. BL00863G 12.17 1.000e-40 192-233 BL00863H 14.03 1.000e-40 240-276 BL00863J 10.84 1.000e-40 304-341 BL00863A 15.14 7.387e-40 28-64 BL00863B 12.89 4.300e-32 65-92 BL00863F 11.27 3.172e-31 161-187 WO 2004/080148 PCT/US2003/030720 348 TABLE 3A SEQ Database Description Result* ID entry ID BL00863I 10.28 6.786e-31 277-303 BL00863E 8.49 1.462e-28 135-160 BL00863C 13.93 7.387e-24 93-114 BL00863D 11.58 5.629e-19 115-132 1209 BL00781 Phosphoenolpyruvate carboxylase proteins 1. BL00781C 12.88 7.031e-09 233-287 1209 PR00985 LEUCYL-TRNA SYNTHETASE PR00985A 12.10 7.716e-09 515-532 SIGNATURE 1209 PR00563 BETA-3 ADRENERGIC RECEPTOR PR00563E 7.48 8.768e-09 782-800 SIGNATURE 1210 BL00290 Immunoglobulins and major BL00290A 20.89 1.818e-11 158-180 histocompatibility complex proteins. 1213 BL00232 Cadherins extracellular repeat proteins BL00232B 32.79 2.125e-26 227-274 domain proteins. BL00232B 32.79 8.521e-15 440-487 BL00232B 32.79 1.346e-13 118-165 BL00232B 32.79 5.500e-13 335-382 BL00232C 10.65 7.923e-10 333-350 BL00232C 10.65 9.308e-10 438-455 BL00232C 10.65 9.827e-10 225-242 1213 PR00205 CADHERIN SIGNATURE PR00205B 11.39 3.945e-10 438-455 PR00205B 11.39 2.220e-09 333-350 PR00205B 11.39 9.542e-09 548-565 1214 PR00626 CALRETICULIN SIGNATURE PR00626D 8.30 8.071e-30 242-264 PR00626E 11.30 7.632e-24 280-299 PR00626B 14.12 2.200e-20 126-142 PR00626E 11.30 3.676e-19 266-285 PR00626A 14.35 1.500e-18 100-118 PR00626C 9.70 9.1OOe-18 215-228 PR00626C 9.70 7.882e-14 232-245 PR00626D 8.30 8.017e-13 256-278 PR00626D 8.30 6.520c-09 208-230 1214 BL00803 Calreticulin family proteins. BLOO803G 14.33 1.000e-40 258-302 BLOO803F 10.95 2.000e-37 225-255 BL00803E 16.55 2.588e-31 166-196 BLOO803C 11.13 6.063e-26 91-113 BL00803F 10.95 7.268e-22 208-238 BLOO803G 14.33 1.127e-19 244-288 BLOO803B 17.08 8.714e-18 63-81 BLOO803D 16.08 1.000e-15 128-138 BL00803G 14.33 3.962e-15 272-316 BL00803A 14.83 2.688e-14 35-48 BL00803F 10.95 2.179e-11 191-221 BLOO803F 10.95 9.516e-09 242-272 1215 PF00711 Beta defensins. PF00711 15.76 7.915e-11 45-77 1215 PD00866 GLYCOPROTEIN PROTEIN SPIKE E2 PD00866L 3.73 7.709e-10 59-68 PRECURSOR PEPLOMER. 1215 PR00858 CRUSTACEAN METALLOTHIONEIN PR00858B 5.93 1.479e-09 40-58 SIGNATURE 1215 BL00317 WAP-type 'four-disulfide core' domain BL00317B 14.58 2.216e-09 48-69 proteins. 1215 BL00264 Neurohypophysial hormones proteins. BL00264 8.98 5.642e-09 79-105 1215 DM01724 kw ALLERGEN POLLEN CIM1 HOL-LI. DM01724 8.14 7.968e-12 16-35 WO 2004/080148 PCT/US2003/030720 349 TABLE 3A SEQ Database Description Result* ID entry ID DM01724 8.14 1.409e-11 20-39 DM01724 8.14 1.507e-10 4-23 DM01724 8.14 6.684e-09 12-31 1215 BL00243 Integrins beta chain cysteine-rich domain BL002431 31.77 2.000e-1 1 42-84 proteins. BL00243I 31.77 1.265e-10 54-96 BL00243I 31.77 1.254e-09 45-87 BL00243I 31.77 8.225e-09 58-100 1215 BL00203 Vertebrate metallothioneins proteins. BL00203 13.94 2.862e-12 32-77 BL00203 13.94 3.690e-12 39-84 BL00203 13.94 4.758e-11 35-80 BL00203 13.94 3.663e-09 42-87 BL00203 13.94 5.592e-09 50-95 BL00203 13.94 6.235e-09 36-81 BL00203 13.94 6.786e-09 40-85 BL00203 13.94 9.357e-09 60-105 1218 PR00946 MERCURY SCAVENGER PROTEIN PR00946A 5.58 6.516e-10 6-24 SIGNATURE 1220 DM01071 OPACITY PROTEIN. DMO1071A 1.92 8.990e-09 5-20 1221 BL00884 Osteopontin proteins. BL00884C 22.45 1.000e-40 119-160 BL00884B 12.47 4.673e-33 24-67 BL00884A 11.35 8.615e-32 1-30 BL00884D 8.79 4.857e-19 248-264 1221 PR00216 OSTEOPONTIN SIGNATURE PR00216A 10.94 5.000e-35 2-31 PR00216C 9.63 1.391e-32 41-66 PR00216G 12.39 9.550e-31 231-256 PR00216F 11.79 3.700e-23 152-170 PR00216E 8.44 3.250e-19 120-134 PR00216D 2.74 1.200e-18 88-102 PR00216D 2.74 2.209e-12 82-96 1222 BL00284 Serpins proteins. BL00284C 28.56 6.538e-29 225-266 BL00284A 15.64 3.739e-18 107-130 BL00284D 16.34 3.793e-17 332-358 BL00284E 19.15 2.909e-15 419-443 1223 PD02327 GLYCOPROTEIN ANTIGEN PRECURSOR PD02327B 19.84 8.941e-23 143-164 IMMUNOGLO. PD02327A 8.89 1.000e-13 115-126 PD02327C 15.47 5.500e-13 209-223 1225 PR00418 DNA TOPOISOMERASE II SIGNATURE PR00418F 12.01 3.813e-20 470-486 PR00418G 14.68 7.000e-19 488-505 PR00418C 10.02 8.200e-18 100-114 PR00418I 16.64 4.682e-17 550-566 PR00418A 12.34 3.739e-16 20-35 PR00418B 12.52 6.571e-15 57-70 PR00418E 15.56 7.300e-15 397-411 PRO04 18D 14.93 7.OOOe-14 252-265 PR00418H 13.54 2.385e-12 508-520 1225 BL00177 DNA topoisomerase II proteins. BL00177H 21.42 3.647e-39 471-506 BLOC177G 24.83 4.706e-36 417-455 BL00177B 19.24 1.000e-35 79-114 BL001771 21.82 2.200e-21 732-757 BLOO177F 12.98 2.500e-18 395-412 BLOO177D 14.66 9.591e-15 252-265 BLOO177E 12.43 7.000e-13 310-321 WO 2004/080148 PCT/US2003/030720 350 TABLE 3A SEQ Database Description Result* ID entry ID BL00177C 13.16 5.950e-12 155-166 1225 BLO1190 Ribosomal protein L36e proteins. BLO1190B 16.17 6.929e-10 1140-1194 1225 PF00521 DNA gyrase/topoisomerase IV, subunit A. PF00521D 9.77 9.591e-09 788-811 1226 BL00455 Putative AMP-binding domain proteins. BL00455 13.31 6.684e-13 248-263 1226 PR00154 AMP-BINDING SIGNATURE PROO154A 8.88 7.375e-10 241-252 1228 PR00007 COMPLEMENT C1Q DOMAIN PR0007B 14.16 7.698e-13 116-135 SIGNATURE PR0007D 9.64 9.654e-11 193-203 PR0007A 19.33 2.552e-10 89-115 PR0007C 15.60 3.656e-10 163-184 1228 BL01113 CIq domain proteins. BLO1113B 18.26 1.563e-20 95-130 BLO1113D 7.47 9.308e-12 195-204 BLO1113C 13.18 4.750e-10 163-182 1230 PD00078 REPEAT PROTEIN ANK NUCLEAR PDO0078B 13.14 1.000e-11 378-390 ANKYR. PDO0078B 13.14 4.500e- 11 495-507 PDO0078B 13.14 8.200e-10 897-909 PDO0078B 13.14 4.522e-09 528-540 1230 PR00665 OXYTOCIN RECEPTOR SIGNATURE PR00665E 5.60 5.390e-09 756-769 1230 PF00791 Domain present in ZO-1 and Unc5-like netrin PF00791B 28.49 1.890e-13 186-240 receptors. PF00791B 28.49 3.368e-12 469-523 PF00791B 28.49 2.273e-11 219-273 PF00791B 28.49 2.922e-10 352-406 PF00791B 28.49 3.534e-10 904-958 PF00791C 20.98 5.361e-10 366-404 PF00791B 28.49 8.427e-10 12-66 PF00791B 28.49 8.95le-10 734-788 PF0079 1B 28.49 2.156e-09 153-207 PF00791B 28.49 7.028e-09 563-617 1230 PF00023 Ank repeat proteins. PF00023A 16.03 1.600e-13 219-234 PF00023A 16.03 2.500e-12 252-267 PF00023B 14.20 5.154e-11 498-507 PF00023A 16.03 7.750e-10 631-646 PF00023B 14.20 8.000e-10 900-909 PF00023A 16.03 1.321e-09 186-201 PF00023B 14.20 1.409e-09 381-390 PF00023A 16.03 2.607e-09 698-713 PF00023B 14.20 4.273e-09 465-474 PF00023A 16.03 4.536e-09 1007-1022 PF00023B 14.20 5.500e-09 281-290 PF00023B 14.20 7.545e-09 531-540 PF00023A 16.03 1.000e-08 800-815 1231 BL00400 LBP / BPI / CETP family proteins. BL00400C 24.53 6.029e-17 210-253 BL00400D 23.26 2.080e-14 274-310 BL00400A 21.59 1.600e-10 27-58 1232 BL00400 LBP / BPI / CETP family proteins. BL00400C 24.53 6.029e-17 210-253 BL00400D 23.26 2.080e-14 274-310 BL00400A 21.59 1.600e-10 27-58 1233 BL00400 LBP / BPI / CETP family proteins. BL00400C 24.53 6.029e-17 210-253 BL00400D 23.26 2.080e-14 274-310 BL00400A 21.59 1.600e-10 27-58 1237 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 9.809e-09 132-155 1247 BL01248 Laminin-type EGF-like (LE) domain proteins. BL01248 11.02 1.340e-09 289-301 WO 2004/080148 PCT/US2003/030720 351 TABLE 3A SEQ Database Description Result* ID entry ID 1247 PR00764 COMPLEMENT C9 SIGNATURE PR00764F 16.89 6.610e-09 237-257 1247 BL00812 Glycosyl hydrolases family 8 proteins. BL00812B 13.49 6.667e-09 917-931 1247 PROO011 TYPE III EGF-LIKE SIGNATURE PROO011B 13.08 9.386e-17 767-785 PRO01 1B 13.08 8.875e-16 289-307 PROO011D 14.03 5.800e-15 550-568 PROO011D 14.03 8.000e-15 767-785 PROO011D 14.03 3.388e-14 289-307 PROO011B 13.08 7.833e-14 160-178 PROO011B 13.08 9.000e-14 550-568 PROO01 1A 14.06 9.345e- 14 289-307 PROM011B 13.08 5.119e-13 203-221 PROO011B 13.08 5.576e-13 421-439 PROOO11D 14.03 6.943e-13 421-439 PROO011B 13.08 7.102e-13 638-656 PROO011A 14.06 9.237e-13 203-221 PROO011B 13.08 9.542e-13 378-396 PROO011D 14.03 9.830e-13 638-656 PROO011D 14.03 3.211e-12 378-396 PROOO11B 13.08 4.339e-12 810-828 PROMI01A 14.06 6.516e-12 378-396 PROO011D 14.03 6.842e-12 810-828 PROO011D 14.03 7.158e-12 160-178 PROW011A 14.06 8.548e-12 421-439 PROO011A 14.06 1.554e-11 550-568 PROO011D 14.03 2.770e-11 593-611 PROO011D 14.03 3.213e-l1 507-525 PROOOI1D 14.03 3.361e-11 203-221 PROW011B 13.08 4.877e-11 246-264 PROOO11B 13.08 6.400e-11 332-350 PROOO11B 13.08 6.815e-11 593-611 PROO011D 14.03 7.049e-11 332-350 PROOO11B 13.08 8.062e-11 724-742 PROO011B 13.08 2.174e-10 507-525 PROO01 1D 14.03 2.523e- 10 464-482 PROM11A 14.06 3.348e-10 767-785 PRW001D 14.03 4.462e-10 724-742 PROO011A 14.06 5.304e-10 810-828 PROO011A 14.06 8.304e-10 638-656 PROO011D 14.03 8.892e-10 246-264 PROO011D 14.03 1.913e-09 681-699 PROO011B 13.08 2.356e-09 464-482 PROM011A 14.06 2.726e-09 160-178 PROO11IA 14.06 2.849e-09 246-264 PROO011B 13.08 5.685e-09 681-699 PROO011A 14.06 5.808e-09 681-699 PROO011A 14.06 6.055e-09 724-742 PROM11A 14.06 6.425e-09 464-482 PROO011A 14.06 6.671e-09 507-525 1247 DM00758 AGRIN. DM00758 13.12 7.485e-09 197-212 DM00758 13.12 8.412e-09 240-255 1247 PROO173 GLUTAMATE-ASPARTATE PROO173F 10.44 8.820e-09 859-878 SYMPORTER SIGNATURE WO 2004/080148 PCT/US2003/030720 352 TABLE 3A SEQ Database Description Result* ID entry ID 1247 BL00022 EGF-like domain proteins. BL00022B 7.54 3.250e-10 210-216 BL00022A 7.48 9.000e-09 283-289 1247 BL00243 Integrins beta chain cysteine-rich domain BL00243H 17.53 4.67le-09 284-309 proteins. BL00243H 17.53 7.750e-09 327-352 BL00243H 17.53 8.816e-09 198-223 BL00243H 17.53 9.053e-09 241-266 1254 BL00247 HBGF/FGF family proteins. BL00247B 31.59 3.077e-35 82-128 BL00247C 21.54 8.333e-22 137-164 1254 PR00262 IL1/HBGF FAMILY SIGNATURE PR00262A 28.26 8.588e-1 1 77-104 1254 PR00263 HEPARIN BINDING GROWTH FACTOR PR00263D 12.89 5.078e- 11 106-125 FAMILY SIGNATURE PR00263C 9.90 7.188e-10 90-102 1260 PR00345 STATHMIN FAMILY SIGNATURE PR00345B 7.12 1.371e-11 207-235 1260 BL00563 Stathmin family proteins. BL00563B 6.08 6.021e-11 213-239 1260 PF00780 Domain found in NIKl-like kinases, mouse PF00780A 10.77 7.857e-10 68-76 citron and yeast ROM. 1260 BL00326 Tropomyosins proteins. BL00326B 7.68 1.235e-09 161-209 1260 PR0O194 TROPOMYOSIN SIGNATURE PROO194C 6.38 9.703e-09 120-148 1261 BL00284 Serpins proteins. BL00284C 28.56 7.000e-17 212-253 BL00284D 16.34 1.692e-13 324-350 BL00284A 15.64 1.200e-1 1 49-72 1262 BL00873 Sodium:alanine symporter family proteins. BL00873B 20.93 9.029e-10 2-53 1263 BLO1020 SARI family proteins. BLO1020C 15.35 3.506e-20 83-133 BLO1020A 11.87 3.821e-19 7-37 BLO1020B 11.70 5.393e-15 41-75 1263 PR00328 GTP-BINDING SARI PROTEIN PR00328B 9.04 2.112e-12 55-79 SIGNATURE PR00328A 10.62 4.857e-12 27-50 1265 PR00258 SPERACT RECEPTOR SIGNATURE PR00258B 9.63 2.800e-14 493-504 PR00258C 9.05 1.257e-12 62-72 PR00258C 9.05 7.17le-12 508-518 PR00258D 14.41 8.500e-12 539-553 PR00258D 14.41 8.875e-12 93-107 PR00258A 11.46 3.418e-10 229-245 PR00258D 14.41 5.034e-10 294-308 PR00258E 13.33 2.500e-09 215-227 PR00258A 11.46 3.000e-09 133-149 PR00258C 9.05 7.000e-09 163-173 1265 BL00420 Speract receptor repeat proteins domain BL00420B 22.67 1.000e-40 478-532 proteins. BL00420B 22.67 7.689e-25 233-287 BL00420B 22.67 6.625e-18 32-86 BL00420B 22.67 8.863e-15 133-187 BL00420B 22.67 5.585e-12 361-415 BL00420C 11.90 8.625e-09 216-226 BL00420C 11.90 9.000e-09 563-573 1266 PR00258 SPERACT RECEPTOR SIGNATURE PR00258B 9.63 2.800e-14 493-504 PR00258C 9.05 1.257e-12 62-72 PR00258C 9.05 7.171e-12 508-518 PR00258D 14.41 8.500e-12 539-553 PR00258D 14.41 8.875e-12 93-107 PR00258A 11.46 3.418e-10 229-245 PR00258D 14.41 5.034e-10 294-308 PR00258E 13.33 2.500e-09 215-227 WO 2004/080148 PCT/US2003/030720 353 TABLE 3A SEQ Database Description ID entry ID 1266 BL00420 Speract receptor repeat proteins domain BLOO420B 22.67 1.000e-40 478-532 proteins.P002 9.5 7.00e- 63-7 BL00420B 22.67 6.625e-18 32-86 BL00420B 22.67 8.863e-15 133-187 BL00420B 22.67 5.585e-12 361-415 BL00420C 11.90 8.625e-09 216-226 BL00420C 11.90 9.000e-09 563-573 1272 PROO170 SODIUM CHANNEL SIGNATURE PROO170E 6.48 8.533e-09 34-63 1273 BLOO107 Protein kinases ATP-binding region proteins. BLOO107A 18.39 5.500e-21 214-244 1273 PROO109 TYROSINE KINASE CATALYTIC PROO109B 12.27 9.294e-12 214-232 DOMAIN SIGNATURE 1273 BL00239 Receptor tyrosine kinase class II proteins. BL00239B 25.15 2.935e-09 149-196 1273 BL00240 Receptor tyrosine kinase class III proteins. BL00240E 11.56 1.000e-08 200-237 1275 BL00427 Disintegrins proteins. BL00427 13.93 7.592e-26 460-514 1275 PR00138 MATRIXIN SIGNATURE PROO138D 16.56 5.10le-l 359-384 1275 BL00142 Neutral zinc metallopeptidases, zinc-binding BL00142 8.38 7.545e-11 359-369 region proteins. 1275 PR00289 DISINTEGRIN SIGNATURE PR00289A 13.62 2.500e-14 474-493 PR00289B 11.79 4.226e-10 503-515 1275 PR00480 ASTACIN FAMILY SIGNATURE PR00480B 15.41 8.909e-10 354-372 1275 PR00907 THROMBOMODULIN SIGNATURE PR00907E 11.70 3.647e-09 672-694 1275 BL00546 Matrixins cysteine switch. BL00546C 16.41 4.255e-09 353-384 1275 BL00024 Hemopexin domain proteins. BLOO024D 17.28 5.596e-09 353-384 1277 PF00023 Ank repeat proteins. PF00023A 16.03 1.600e-13 345-360 PF00023B 14.20 6.318e-09 302-311 PF00023A 16.03 6.464e-09 306-321 1278 BL00142 Neutral zinc metallopeptidases, zinc-binding BL00142 8.38 1.857e-09 412-422 region proteins. 1278 PR00756 MEMBRANE ALANYL DIPEPTIDASE PR00756A 12.90 5.091e-17 245-260 (Ml) FAMILY SIGNATURE PR00756D 10.58 8.258e-17 412-427 PR00756B 14.06 7.333e-14 297-312 PR00756E 11.91 3.769e-09 431-443 1279 DM01688 2 POLY-IG RECEPTOR. DM01688K 17.19 8.640e-11 78-116 DM01688G 16.45 5.680e-09 76-107 1288 PROO019 LEUCINE-RICH REPEAT SIGNATURE PROO019A 11.19 8.043e-10 164-177 PROO019B 11.36 7.120e-09 136-149 1288 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 7.319e-09 319-342 1290 PROO019 LEUCINE-RICH REPEAT SIGNATURE PROW19A 11.19 3.400e-12 86-99 PROO019B 11.36 9.357e-12 83-96 PROW19A 11.19 4.333e-09 111-124 1295 BL01113 CIq domain proteins. BLO1113C 13.18 9.617e-13 159-178 BLO1113D 7.47 2.174e-11 191-200 BL01113B 18.26 7.658e-11 91-126 BLO1113A 17.99 3.106e-10 22-48 1295 PR0007 COMPLEMENT C1Q DOMAIN PR0007B 14.16 9.769e-14 112-131 SIGNATURE PR0007C 15.60 5.688e-13 159-180 PR0007D 9.64 1.419e-09 189-199 PR0007A 19.33 4.429e-09 86-112 1295 PR00513 5-HYDROXYTRYPTAMINE 1B PR00513D 11.06 8.085e-09 50-67 WO 2004/080148 PCT/US2003/030720 354 TABLE 3A SEQ Database Description Result* ID entry ID RECEPTOR SIGNATURE 1296 PR00665 OXYTOCIN RECEPTOR SIGNATURE PR00665D 9.93 9.012e- 11 108-124 1296 BL00896 LacY family proton/sugar symporters BL00896A 14.92 2.552e-09 300-332 proteins. 1296 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237F 13.57 8.667e-12 269-293 SIGNATURE PR00237G 19.63 7.395e-10 314-340 PR00237A 11.48 8.333e-10 34-58 PR00237B 13.50 4.250e-09 68-89 1296 BL00237 G-protein coupled receptors proteins. BL00237C 13.19 4.414e-12 264-290 BL00237D 11.23 9.727e-09 324-340 1297 BL00019 Actinin-type actin-binding domain proteins. BLOO019C 14.66 6.250e-28 285-320 BLOO019D 15.33 2.309e-15 348-377 BL00019B 13.34 2.976e-13 240-262 BLOO019A 12.56 2.286e-12 215-225 1297 PF00435 Spectrin repeat proteins. PF00435A 32.05 2.000e-14 991-1019 PF00435B 13.41 9.609e-11 1496-1511 PF00435C 20.73 3.571e-09 2006-2025 1297 DM00588 8 kw CHO2 ALPHA ANTIGEN DM00588B 9.45 6.870e-09 1259-1268 PARAMYOSIN. 1297 BL00326 Tropomyosins proteins. BL00326B 7.68 9.296e-09 2110-2158 1297 BL00226 Intermediate filaments proteins. BL00226B 23.86 5.605e-09 1734-1781 BL00226B 23.86 9.895e-09 2042-2089 1298 BLOO019 Actinin-type actin-binding domain proteins. BLOO019C 14.66 6.250e-28 297-332 BLOO019D 15.33 2.309e-15 360-389 BLOO019B 13.34 2.976e-13 240-262 BLOO019A 12.56 2.286e-12 215-225 1298 PF00435 Spectrin repeat proteins. PF00435A 32.05 2.000e-14 1003-1031 PF00435B 13.41 9.609e-11 1508-1523 PF00435C 20.73 3.571e-09 2018-2037 1298 DM00588 8 kw CHO2 ALPHA ANTIGEN DM00588B 9.45 6.870e-09 1271-1280 PARAMYOSIN. 1298 BL00326 Tropomyosins proteins. BL00326B 7.68 9.296c-09 2122-2170 1298 BL00226 Intermediate filaments proteins. BL00226B 23.86 5.605e-09 1746-1793 BL00226B 23.86 9.895e-09 2054-2101 1304 PR00700 PROTEIN TYROSINE PHOSPHATASE PR00700C 13.17 8.535e-09 125-142 SIGNATURE 1305 PR00700 PROTEIN TYROSINE PHOSPHATASE PR00700C 13.17 8.535e-09 240-257 SIGNATURE 1306 PD02929 ADHESION GLYCOPROTEIN PD02929A 28.27 4.433e-10 207-260 PRECURSOR I. 1306 PROO020 MAM DOMAIN SIGNATURE PROO020A 18.17 9.211e-10 428-446 PROO020C 13.66 3.340e-09 509-520 1306 BL00740 MAM domain proteins. BL00740B 19.76 4.682e-10 578-598 BL00740A 13.87 5.588e-09 430-442 1308 BL00072 Acyl-CoA dehydrogenases proteins. BLOO072E 24.12 5.014e-12 724-766 BLOO072D 30.08 7.136e-10 635-685 1309 BL00072 Acyl-CoA dehydrogenases proteins. BLOO072E 24.12 5.014e-12 706-748 BLOO072D 30.08 7.136e-10 617-667 1311 PR00215 NEUROMODULIN SIGNATURE PR00215C 13.98 6.779e-10 743-763 1311 BL00412 Neuromodulin (GAP-43) proteins. BL00412B 10.60 1.681e-09 735-771 1311 PF00992 Troponin. PF00992A 16.67 9.746e-10 609-643 WO 2004/080148 PCT/US2003/030720 355 TABLE 3A SEQ Database Description Result* ID entry ID PF00992A 16.67 5.145e-09 613-647 PF00992A 16.67 7.395e-09 615-649 PF00992A 16.67 1.000e-08 608-642 1314 PF00632 HECT-domain (ubiquitin-transferase). PF00632C 20.66 1.000e-29 2270-2301 PF00632B 18.45 2.800e-21 2215-2242 1314 PF00624 Flocculin repeat proteins. PF00624J 6.21 7.000e-09 1424-1478 1314 BL00412 Neuromodulin (GAP-43) proteins. BL00412D 16.54 9.022e-10 350-400 BL00412D 16.54 1.55 1e-09 342-392 BLOO412D 16.54 7.429e-09 349-399 BL00412D 16.54 8.53le-09 328-378 1314 DM00191 w SPAC8A4.04C RESISTANCE DM00191D 13.94 6.635e-09 1410-1448 SPAC8A4.05C DAUNORUBICIN. DMOO191D 13.94 9.374e-09 1404-1442 1317 DM00179 w KINASE ALPHA ADHESION T-CELL. DM00179 13.97 5.263e-10 107-116 1321 PROO019 LEUCINE-RICH REPEAT SIGNATURE PROO019B 11.36 4.000e-11 335-348 PROO019B 11.36 1.450e-10 193-206 PROO019B 11.36 3.250e-10 167-180 PROO019A 11.19 4.130e-10 338-351 PROW19A 11.19 4.522e-10 480-493 PROO019B 11.36 7.300e-10 309-322 PROO019B 11.36 1.720e-09 569-582 PR019B 11.36 3.880e-09 477-490 PROOO19A 11.19 5.667e-09 170-183 1321 DM01551 kw OSTEOINDUCTIVE YOPM DMO1551C 14.62 6.280e-09 568-587 MEMBRANE OUTER. DMO1551C 14.62 8.320e-09 355-374 1322 BL00290 Immunoglobulins and major BL00290B 13.17 9.250e-09 317-334 histocompatibility complex proteins. 1324 PD01719 PRECURSOR GLYCOPROTEIN SIGNAL PDO1719A 12.89 1.740e-1 1 36-63 RE. 1328 BL00420 Speract receptor repeat proteins domain BL00420B 22.67 4.696e-38 15-69 proteins. BL00420B 22.67 6.949e-36 189-243 BL00420B 22.67 1.300e-35 301-355 BL00420B 22.67 4.358e-30 639-693 BL00420B 22.67 1.863e-26 406-460 BL00420C 11.90 1.360e-13 100-110 BL00420C 11.90 6.797e-11 274-284 BL00420C 11.90 8.322e-11 492-502 BL00420C 11.90 1.545e-10 386-396 1328 PR00258 SPERACT RECEPTOR SIGNATURE PR00258B 9.63 7.188e-15 654-665 PR00258B 9.63 8.875e-15 30-41 PR00258B 9.63 8.875e-15 204-215 PR00258B 9.63 6.400e-14 316-327 PR00258B 9.63 3.543e-13 421-432 PR0025S8E 13.33 7.81le-13 99-111 PR00258D 14.41 7.500e-11 468-482 PR00258E 13.33 9.625e-11 273-285 PR00258D 14.41 2.552e-10 700-714 PR00258E 13.33 3.000e-10 491-503 PR00258A 11.46 8.791e-10 635-651 PR00258C 9.05 1.000e-09 45-55 PR00258A 11.46 2.375e-09 185-201 PR00258A 11.46 6.500e-09 11-27 PR00258A 11.46 6.500e-09 297-313 WO 2004/080148 PCT/US2003/030720 356 TABLE 3A SEQ Database Description Result* ID entry ID PR00258E 13.33 7.450e-09 385-397 PR00258C 9.05 8.500e-09 436-446 PR00258A 11.46 9.625e-09 402-418 1329 PD01270 RECEPTOR FC IMMUNOGLOBULIN PDO1270A 17.22 7.500e-15 21-60 AFFIN. PD01270B 22.18 6.288e-13 72-108 PDO1270C 19.54 7.608e-09 114-142 1333 BL00246 Wnt-1 family proteins. BL00246D 23.97 1.000e-40 202-254 BL00246E 20.32 8.636e-35 319-364 BL00246B 13.69 6.806e-29 101-135 BL00246C 15.56 9.036e-22 167-191 BL00246A 15.75 6.870e-21 68-87 1335 PR00245 OLFACTORY RECEPTOR SIGNATURE PR00245A 18.03 7.300e-19 26-47 1337 BL00476 Fatty acid desaturases family 1 proteins. BL00476C 13.87 1.000e-40 80-132 BL00476E 12.10 1.000e-40 231-283 BL00476D 11.28 2.125e-30 171-221 BL00476B 18.34 4.494e-16 36-79 BL00476F 12.75 6.333e-16 285-329 1337 PROO075 FATTY ACID DESATURASE FAMILY 1 PR00075D 11.41 3.538e-33 131-160 SIGNATURE PROO075C 10.31 3.813e-20 94-114 PROO075G 8.85 2.047e-19 268-282 PROO075E 12.60 7.585e-16 192-210 PROO075F 16.07 6.952e-15 225-246 PROO075A 16.97 4.429e-14 47-67 PROO075B 12.16 7.047e-11 71-93 1339 PDO0301 PROTEIN REPEAT MUSCLE CALCIUM- PDO0301A 10.24 6.400e-09 55-65 BI. 1339 BL00422 Granins proteins. BL00422C 16.18 6.647e-09 44-71 BL00422C 16.18 8.235e-09 45-72 1339 BL00319 Amyloidogenic glycoprotein extracellular BL00319C 17.12 5.836e-11 48-81 domain proteins. BL00319C 17.12 5.974e-09 47-80 BL00319C 17.12 8.342e-09 44-77 BL00319C 17.12 9.053e-09 45-78 1340 BL00406 Actins proteins. BL00406C 6.75 4.286e-20 137-191 BL00406B 5.47 8.130e-14 78-132 BL00406D 12.58 3.734e-13 267-321 BL00406A 9.95 1.290e-12 5-39 1340 PROO190 ACTIN SIGNATURE PROO19OF 7.80 4.803e-12 135-154 PROO190C 11.49 1.878e-09 57-79 1341 BL00048 Protamine P1 proteins. BL00048 6.39 3.588e-09 4-30 1343 BL00790 Receptor tyrosine kinase class V proteins. BL007901 20.01 9.520e-11 555-585 1343 PROOO14 FIBRONECTIN TYPE III REPEAT PROO014C 15.44 2.565e-09 544-562 SIGNATURE 1344 PROO020 MAM DOMAIN SIGNATURE PROO020A 18.17 5.776e-12 759-777 PROO020C 13.66 6.932e-10 832-843 1344 PD01270 RECEPTOR FC IMMUNOGLOBULIN PDO1270D 24.66 5.378e-09 292-327 AFFIN. 1344 BL00740 MAM domain proteins. BLOO740A 13.87 8.313e-12 761-773 BL00740B 19.76 8.500e-09 901-921 1344 PD02080 T-CELL GLYCOPROTEIN CD8 CHAIN PD02080B 20.69 9.621e-09 538-576 SURFACE ALPHA PRE. 1344 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 9.809e-09 155-178 WO 2004/080148 PCT/US2003/030720 357 TABLE 3A SEQ Database Description Result* ID entry ID 1345 BL00282 Kazal serine protease inhibitors family BL00282 16.88 6.577e-10 127-149 proteins. 1345 BL00222 Insulin-like growth factor binding proteins. BL00222B 11.09 6.940e-10 74-89 1345 BL00621 Tissue factor proteins. BL00621A 8.69 6.473e-09 5-22 1346 PR00326 GTP1/OBG GTP-BINDING PROTEIN PR00326A 8.75 1.386e-09 85-105 FAMILY SIGNATURE 1346 PF00922 Vesiculovirus phosphoprotein. PF00922A 19.17 1.724e-09 437-470 1346 PR00449 TRANSFORMING PROTEIN P21 RAS PR00449A 13.20 1.931e-09 83-104 SIGNATURE 1346 PR00905 HYPOTHETICAL MYCOPLASMA PR00905H 6.88 5.886e-09 343-363 LIPOPROTEIN (MG045) SIGNATURE 1348 PR00406 CYTOCHROME B5 REDUCTASE PR00406F 3.97 3.520e-10 158-166 SIGNATURE 1348 PROO014 FIBRONECTIN TYPE III REPEAT PROO014B 14.77 2.500e-09 848-858 SIGNATURE 1348 PD02870 RECEPTOR INTERLEUIGN-1 PD02870B 18.83 3.202e-09 480-512 PRECURSOR. 1348 DM00179 w KINASE ALPHA ADHESION T-CELL. DM00179 13.97 7.261e-09 205-214 1348 BL00240 Receptor tyrosine kinase class III proteins. BL00240B 24.70 8.277e-09 263-286 1348 PD02520 RECEPTOR PRECURSOR PD02520C 10.48 9.203e-09 881-897 TRANSMEMBRANE. 1349 PR00698 C.ELEGANS SRG FAMILY INTEGRAL PR00698E 14.43 8.714e-09 97-122 MEMBRANE PROTEIN SIGNATURE 1350 BL00284 Serpins proteins. BL00284C 28.56 5.714e-32 203-244 BL00284D 16.34 9.640e-19 311-337 BL00284A 15.64 1.783e-18 72-95 BL00284B 17.99 3.045e-16 176-196 BL00284E 19.15 6.250e-14 378-402 1355 PF00023 Ank repeat proteins. PF00023A 16.03 7.000e-11 69-84 PF00023B 14.20 2.636e-09 131-140 1355 PD00078 REPEAT PROTEIN ANK NUCLEAR PDO0078B 13.14 2.957e-09 128-140 ANKYR. 1355 PF00791 Domain present in ZO-1 and Unc5-like netrin PF00791B 28.49 9.587e-09 69-123 receptors. 1356 BLOO107 Protein kinases ATP-binding region proteins. BLOO107A 18.39 4.000e-10 339-369 1356 PROO109 TYROSINE KINASE CATALYTIC PROO109D 17.04 4.234e-09 403-425 DOMAIN SIGNATURE PROO109B 12.27 1.000e-08 339-357 1358 PR00237 RHODOPSIN-LIKE GPCR SUPERFAMILY PR00237G 19.63 3.793e-13 41-67 SIGNATURE 1358 BL00237 G-protein coupled receptors proteins. BL00237D 11.23 3.348e-12 51-67 1359 BL00178 Aminoacyl-transfer RNA synthetases class-I BLOO178B 7.11 3.700e-12 344-354 proteins. 1360 PF00969 Class II histocompatibility antigen, beta PF00969A 22.07 5.846e-29 12-54 domain proteins. PF00969B 9.97 6.21 le-25 56-91 PF00969C 27.72 7.324e-16 95-144 1361 BL00520 Interleukin-10 family proteins. BL00520A 6.21 6.471e-09 1-13 1362 BL00520 Interleukin-10 family proteins. BL00520A 6.21 6.471e-09 1-13 1365 BL00253 Interleukin-1 proteins. BL00253D 25.67 3.464e-1 1 95-134 1365 PR00264 INTERLEUKIN-1 SIGNATURE PR00264C 17.77 3.294e-17 95-123 PR00264B 20.98 6.250e-09 56-82 1366 BLO1177 Anaphylatoxin domain proteins. BLO1 177E 20.64 4.541e-13 791-817 WO 2004/080148 PCT/US2003/030720 358 TABLE 3A SEQ Database Description Result* ID entry ID 1366 BL00477 Alpha-2-macroglobulin family thiolester BL00477J 19.04 7.207e-29 1221-1251 region proteins. BL00477F 17.34 8.500e-25 786-815 BL00477G 19.43 8.826e-23 963-994 BL00477A 13.50 9.800e-23 122-150 BL00477L 23.51 8.800e-22 1417-1449 BL00477K 17.42 4.529e-14 1362-1385 BL00477E 17.53 6.538e-13 756-776 BL00477B 9.05 6.625e-13 209-221 BL004771 18.76 2.650e- 12 1065-1091 BL00477D 12.73 4.073e-12 730-739 BL00477H 9.07 5.395e-12 1034-1045 BL00477C 15.70 1.161e-10 236-252 1366 BLOO115 Eukaryotic RNA polymerase II heptapeptide BL001 15V 21.32 5.745e-09 1402-1451 repeat proteins. 1366 BL00713 Sodium:dicarboxylate symporter family BL00713F 16.13 8.989e-09 917-958 proteins. 1368 BL00983 Ly-6 /u-PAR domain proteins. BL00983C 12.69 8.714e-16 90-105 BL00983B 8.19 2.161e-10 23-32 1368 BL00272 Snake toxins proteins. BL00272C 8.27 9.79le-09 94-105 * Results include in order: accession number subtype; raw score; p-value; position of signature in amino acid sequence WO 2004/080148 PCT/US2003/030720 359 TABLE 3B SEQ Database Description Result ID entry ID 685 IPBOO1400 Somatotropin hormone family IPBOO1400A 14.85 1.90e-13 35-58 686 IPB001400 Somatotropin hormone family IPBOO1400B 23.62 9.25e-24 79-115 IPBO01400A 14.85 4.33e-14 35-58 686 PR00836 Somatotropin hormone family PR00836A 15.53 1.96e-11 79-92 signature I PR00836B 17.50 9.31e-11 101-119 IPBOO1400C 13.76 6.28e-10 135-151 688 IPBOO1400 Somatotropin hormone family IPBOO1400B 23.62 1.90e-28 79-115 IPBOO1400A 14.85 4.91e-16 35-58 688 PR00836 Somatotropin hormone family PR00836B 17.50 1.43e-15 101-119 signature II PR00836A 15.53 2.35e-13 79-92 IPBOO1400C 13.76 4.72e-10 135-151 689 IPBOO0215 Serpins IPBOO0215E 15.36 5.76e-17 373-397 IPB000215A 13.01 3.42e-15 77-100 IPB000215D 15.35 8.05e-11 294-320 IPB000215B 9.87 6.04e-10 162-174 IPB000215C 13.90 7.97e-10 189-203 690 PR00390 Phospholipase C signature I PR00390A 14.24 6.34e-20 191-209 690 1PB002048 EF-hand family IPB002048 7.91 3.84e-09 43-55 691 IPB000734 Lipase IPB000734 10.25 8.50e-09 435-449 693 PR00573 Interleukin 8B receptor signature III PROO573C 9.83 2.15e-09 38-46 693 PR00427 Interleukin-8 receptor signature I PR00427A 15.48 4.46e-09 34-48 694 1PB000407 GDA1/CD39 family of nucleoside IPBOO0407C 15.11 4.09e-19 217-239 phosphatase IPBOO0407D 11.44 4.27e-15 248-261 IPBOO0407A 11.93 1.62e-11 101-112 IPB000407B 8.75 2.70e- 11 175-186 IPB000407G 17.95 2.80e-11 460-474 IPBOO0407F 16.53 8.54e-10 430-444 695 PR00237 Rhodopsin-like GPCR superfamily PR00237F 14.34 3.20e-09 239-263 signature VI 695 PR01066 P2Y4 purinoceptor signature II PRO1066B 4.51 6.03e-09 111-126 696 IPB001304 C-type lectin domain IPBOO1304A 17.98 3.00e-17 168-192 696 PR01408 Macrophage scavenger receptor PR01408F 9.76 4.87e-09 83-107 signature VI 698 IPB000407 GDAI/CD39 family of nucleoside IPBOO0407C 15.11 3.30e-16 165-187 phosphatase IPBOO0407D 11.44 9.59e-15 196-209 IPBOO0407B 8.75 9.68e-12 123-134 IPBOO0407A 11.93 4.50e-10 48-59 IPBOO0407F 16.53 7.57e-10 377-391 700 IPB000433 ZZ Zinc finger IPB000433 14.10 4.60e-1 1 184-200 700 PR00608 Class II cytochrome C signature I PR00608A 12.75 8.07e-10 118-141 700 IPBOO0102 Neuraxin / MAP1B repeat IPBOO0102A 10.50 5.59e-09 116-144 700 IPB002989 Mycobacterial pentapeptide repeats IPB002989B 10.80 5.76e-09 110-135 700 PRO1286 Orphan nuclear receptor NOR1 PRO1286E 5.27 7.14e-09 133-154 signature V 700 PR00456 Ribosomal protein P2 signature V PR00456E 3.08 8.64e-09 123-137 700 IPBOO1119 S-layer protein (SLH domain) IPB01 119B 14.79 9.28e-09 115-127 PR00456E 3.08 9.69e-09 122-136 700 IPBOO1005 Myb DNA binding domain IPBO01005A 11.39 9.71e-09 231-251 701 PR00049 Wilm's tumour protein signature IV PROO049D 0.00 1.00e-09 280-294 701 PR01217 Proline rich extensin signature VIII PR01217H 5.61 1.67e-09 309-321 702 IPB000345 Cytochrome c family heme-binding IPB000345 9.03 7.19e-09 107-119 site 703 IPB001251 Cellular retinaldehyde-binding IPB001251A 7.40 5.05e-12 38-49 protein (CRAL)/Triple function IPB001251B 14.78 7.14e-12 195-209 domain (TRIO) WO 2004/080148 PCT/US2003/030720 360 TABLE 3B 703 PROO180 Cellular retinaldehyde-binding PROO180A 11.19 6.24e-11 37-59 protein signature I PR0O180D 13.13 1.92e-09 202-221 704 IPB002610 Rhomboid family IPBOO261OC 5.81 3.81e-10 284-294 IPBOO261OB 5.33 6.8 1e-09 225-235 705 PR01256 Otx1 transcription factor signature II PR01256B 5.92 5.97e-11 221-233 PR01256B 5.92 7.51e-11 218-230 PRO1256B 5.92 2.35e-10 219-231 PRO1256B 5.92 2.1le-09 220-232 PRO1256B 5.92 2.3le-09 222-234 PRO1256B 5.92 2.62e-09 217-229 705 IPB001541 SUR2-type hydroxylase/desaturase IPBOO1541B 11.65 3.14e-09 223-232 catalytic domain IPBOO1541B 11.65 3.14e-09 224-233 IPBOO1541B 11.65 3.14e-09 225-234 IPBOO1541B 11.65 6.57e-09 222-231 705 PR00910 Luteovirus ORF6 protein signature I PR00910A 2.74 9.04e-09 756-768 706 IPBOO 1124 Lipid-binding serum glycoprotein IPBOO1124D 21.85 2.50e-12 251-287 IPBOO1124C 25.71 5.08e-11 184-227 707 IPB002495 Glycosyltransferase family 8 [PB002495B 11.16 4.77e-09 273-283 708 IPB001781 LIM domain IPB001781 11.42 8.77e-11 31-41 710 IPBOO1442 C-terminal tandem repeated domain IPB001442F 15.05 1.00e-40 1624-1667 in type 4 procollagen IPB001442C 14.98 4.82e-40 1537-1571 IPB001442A 26.12 4.09e-39 1298-1350 IPB001442A 26.12 5.40e-35 114-166 IPB001442D 15.34 1.00e-34 1572-1603 1PB001442A 26.12 7.1le-29 799-851 IPB001442A 26.12 1.47e-28 781-833 IPB001442A 26.12 3.48e-28 790-842 1PB001442A 26.12 4.57e-28 814-866 710 IPB000885 Fibrillar collagen C-terminal domain IPB000885B 19.15 1.93e-27 1339-1392 IPB000885B 19.15 2.24e-27 783-836 IPBOO1442A 26.12 2.53e-27 683-735 IPB001442A 26.12 3.59e-27 796-848 IPB000885B 19.15 4.26e-27 780-833 IPB001442A 26.12 4.81e-27 925-977 IPB001442A 26.12 5. 710 IPBOO1073 Complement Clq protein IPBOO1073A 22.14 9.1 8e-19 1413-1447 IPBOO0885A 11.46 9.29e-19 744-781 IPBOO0885B 19.15 9.40e-19 1348-1401 IPB000885B 19.15 9.40e-19 1412-1465 IPB001442A 26.12 9.42e-19 538-590 IPB001442A 26.12 9.42e-19 1304-1356 IPBOO0885B 19 710 IPB000817 Prion protein IPBOO0817A 8.34 7.23e-10 777-819 IPBOO0885A 11.46 7.26e-10 1064-1101 IPB001442B 12.38 7.30e-10 735-755 IPB001442B 12.38 7.30e-10 938-958 IPB001442B 12.38 7.30e-10 962-982 IPB001442A 26.12 7.36e-10 582-634 IPBOO1073A 22.14 7.4 710 IPB001285 Synaptophysin/synaptoporin IPB001285F 6.39 4.08e-09 1379-1423 IPB0885B 19.15 4.1le-09 462-515 IPB000885B 19.15 4.1le-09 1087-1140 IPB001442B 12.38 4.28e-09 103-123 IPB000885A 11.46 4.31e-09 612-649 IPB0885B 19.15 4.35e-09 1213-1266 IPB001442B 12.38 710 IPB003778 DUF183 IPB003778B 27.11 7.31e-09 302-344 IPB001442B 12.38 7.32e-09 794-814 WO 2004/080148 PCT/US2003/030720 361 TABLE 3B IPB001442A 26.12 7.34e-09 629-681 IPB000885B 19.15 7.38e-09 598-651 IPB001442A 26.12 7.42e-09 444-496 IPB001073A 22.14 7.47e-09 975-1009 IPBOO0885B 19.15 7.5 710 IPB003531 Short hematopoietin receptor family IPB003531C 15.87 9.76e-09 518-535 1 IPBOO0817A 8.34 9.81e-09 309-351 IPB000885B 19.15 9.84e-09 1451-1504 IPB001442B 12.38 9.88e-09 302-322 IPBOO0817A 8.34 9.91e-09 1026-1068 IPB000885B 19.15 1.00e-08 658-711 711 PR00261 Low density lipoprotein (LDL) PR00261B 15.12 4.13e-22 1101-1122 receptor signature 11 PR00261C 18.72 2.87e-21 1015-1036 PR00261B 15.12 4.46e-21 1015-1036 PR00261E 18.62 5.74e-21 1144-1165 PR00261B 15.12 1.32e-20 3523-3544 711 IPB000033 "Low-density lipoprotein (idl) IPB00033D 30.18 2.03e-20 2057-2095 receptor, YWTD repeat" PR00261B 15.12 2.61e-20 892-913 PR00261A 15.49 2.73e-20 1053-1074 PR00261D 16.87 6.40e-20 892-913 PR00261B 15.12 6.46e-20 1053-1074 PR00261F 15.46 7.92e-20 892-913 PR00261D 16.87 8.56e-20 3 711 IPB002172 Low density lipoprotein (LDL)- 1PB002172 7.37 1.00e-16 2818-2830 receptor class A (LDLRA) domain PR00261F 15.46 2.10c-16 1185-1206 PR00261D 16.87 2.15e-16 3721-3742 PR00261A 15.49 2.38e-16 2729-2750 PR00261D 16.87 2.38e-16 933-954 PR00261E 18.62 2.97e-16 2729-2750 PR00261F 15.46 3.41e-16 711 IPB000152 Aspartic acid and asparagine IPB000152 8.86 6.14e-16 206-221 hydroxylation site PR00261C 18.72 7.57e-16 2729-2750 PR00261A 15.49 7.92e-16 3562-3583 PR00261F 15.46 8.02e-16 2729-2750 PR00261C 18.72 8.30e-16 3600-3621 IPB000033A 21.82 8.33c-16 2731-2753 PR00261B 15.12 8.53e-16 933-954 PR00261F 15.46 8.68e-16 3562-3583 PR00261C 18.72 9.27e-16 80-101 PR00261F 15.46 9.56e-16 3404-3425 PR00261E 18.62 9.72e-16 3562-3583 PR00261C 18.72 9.76e-16 2938-2959 PR00261E 18.62 1.53e-15 3404-3425 PR00261E 18.62 1.53e-15 3484-3505 PR00261D 16.87 1.63e-15 3641-3662 PR00261C 18.72 1.68e-15 3484-3505 PR00261E 18.62 1.79e-15 3809-3830 PR00261D 16.87 1.84e-15 3364-3385 PR00261A 15.49 2.29e-15 2767-2788 IPB002172 7.37 2.64c-15 89-101 PR00261F 15.46 2.80e-15 2687-2708 PR00261E 18.62 3.12e-15 3523-3544 PR00261C 18.72 3.25e-15 3641-3662 711 PR00764 Complement C9 signature II PR00764B 12.47 3.36e-15 1048-1068 IPB002172 7.37 3.45e-15 1110-1122 PR00261B 15.12 3.74e-15 3600-3621 PR00261B 15.12 4.33e-15 2893-2914 PR00261C 18.72 4.60e-15 2687-2708 WO 2004/080148 PCT/US2003/030720 362 TABLE 3B IPB000033C 11.58 4.81e-15 3128-3142 IPB00033D 30.18 5. 711 IPB001774 Delta serrate ligand IPB001774D 19.23 9.89e-14 4240-4286 IPB002172 7.37 1.00e-13 2902-2914 PR00261E 18.62 1.00e-13 2558-2579 PR00261D 16.87 1.53e-13 1185-1206 PR00261C 18.72 1.96e-13 125-146 PR00261F 15.46 2.19e-13 2558-2579 IPB00033C 11.58 2.29e-13 1376-1390 PR00261B 15.12 2.53e-13 2558-2579 IPB002172 7.37 2.59e-13 1062-1074 IPB002172 7.37 2.59e-13 2947-2959 IPB002172 7.37 3.12e-13 2861-2873 PR00764B 12.47 3.38e-13 3636-3656 IPB002172 7.37 3.65e-13 3650-3662 711 IPB001881 Calcium-binding EGF-like domain IPBoo 188 1B 12.28 4.00e- 13 206-217 PR00261A 15.49 4.60e-13 1185-1206 IPB000152 8.86 5.09e-13 3019-3034 PR00261B 15.12 5.25e-13 3444-3465 PR00261E 18.62 5.61e-13 125-146 IPB002172 7.37 5.76e-13 2776-2788 1PB002172 7.37 6.29e-13 711 PROO010 Type II EGF-like signature III PROOO1OC 6.98 8.13e-11 211-221 IPB002172 7.37 8.43e-11 3532-3544 IPB000033A 21.82 8.71e-11 1187-1209 IPB00033C 11.58 9.00e-l 1 1774-1788 IPB000152 8.86 9.04e-11 2979-2994 PR00261C 18.72 9.18e-11 2558-2579 IPB00033C 11.58 5.86e-10 2081-2095 711 PR00907 Thrombomodulin signature II PR00907B 11.50 6.04e-10 4218-4234 IPB00033C 11.58 6.40e-10 411-425 IPB002172 7.37 6.54e-10 942-954 IPB00033C 11.58 6.58e-10 1466-1480 IPB00033A 21.82 7.26e-10 2560-2582 PR00261C 18.72 7.67e-10 2893-2914 PROQOlOC 6.98 8.55e-10 3024-3034 PR00764B 12.47 8.62e-10 120-140 PR00764B 12.47 8.73e-10 2804-2824 PR00764B 12.47 8.85e-10 3439-3459 IPB002172 7.37 9.31e-10 3493-3505 IPB00033C 11.58 9.46e-10 3084-3098 IPB002172 7.37 1.00e-09 2647-2659 PR00764B 12.47 1.22e-09 3479-3499 IPB00033C 11.58 1.48e-09 736-750 PR00764B 12.47 1.65e-09 2594-2614 IPB00033B 7.05 2.42e-09 3024-3034 PR00764B 12.47 2.63e-09 75-95 711 1PB000970 "Developmental signaling protein, IPBOO097OF 23.43 4.19e-09 4241-4289 Wnt-1 family" IPB00033C 11.58 4.21e-09 2404-2418 711 PR00873 Echinoidea (sea urchin) PR00873D 8.25 4.88e-09 4326-4344 metallothionein signature IV PR00764B 12.47 5.23e-09 2933-2953 IPB00033D 30.18 5.37e-09 4044-4082 PR00764B 12.47 5.66e-09 2553-2573 PR00764B 12.47 5.99e-09 3518-3538 IPBOO1881B 12.28 6.87e-09 2979-2990 711 IPB001169 "Integrin beta, C-terminus" IPBOO1169K 27.45 6.96e-09 2547-2589 IPB00033C 11.58 7.91e-09 1647-1661 711 IPB002557 Chitin binding domain . IPB002557B 12.64 7.92e-09 1236-1249 WO 2004/080148 PCT/US2003/030720 363 TABLE3B IPB00033C 11.58 8.07e-09 324-338 IPB000033C 11.58 8.07e-09 367-381 IPB00033C 11.58 8.23e-09 1329-1343 IPB001774C 18.25 8.26e-09 4301-4343 PR00010C 6.98 8.46e-09 3900-3910 711 IPB003886 Extracellular domain in nidogen 1PB003886D 13.91 8.62e-09 206-225 PR00764B 12.47 8.70e-09 1096-1116 IPB00033B 7.05 8.82e-09 2984-2994 IPB003886E 12.94 8.88e-09 4100-4110 PR00764B 12.47 9.46e-09 2847-2867 711 IPBOOO118 Granulin IPBOOO118C 7.41 9.65e-09 3822-3863 PR00907B 11.50 9.66e-09 162-178 712 PR00261 Low density lipoprotein (LDL) PR00261B 15.12 7.43e-18 80-101 receptor signature II PR00261D 16.87 7.25e-17 80-101 PR00261E 18.62 3.53e-16 80-101 PR00261F 15.46 5.39e-16 80-101 PR00261A 15.49 6.08e-16 80-101 712 IPB002172 Low density lipoprotein (LDL)- IPB002172 7.37 2.64e-15 89-101 receptor class A (LDLRA) domain PR00261C 18.72 3.47e-15 80-101 PR00261A 15.49 7.64e-15 125-146 PR00261F 15.46 8.80e-15 125-146 PR00261D 16.87 1.98e-14 125-146 712 IPB000033 "Low-density lipoprotein (Idl) IPB00033A 21.82 3.53e-14 82-104 receptor, YWTD repeat" PR00261C 18.72 1.96e-13 125-146 PR00261E 18.62 5.61e-13 125-146 IPB002172 7.37 6.40e-12 134-146 PR00261B 15.12 9.37e-12 125-146 712 PR00764 Complement C9 signature II PR00764B 12.47 8.62e-10 120-140 712 PR00907 Thrombomodulin signature II PR00907B 11.50 9.66e-09 162-178 PR00764B 12.47 1.00e-08 75-95 713 IPBOO3164 Alpha adaptin carboxyl-terminal IPB003164M 10.25 8.22e-09 164-195 domain 714 PR00205 Cadherin signature VI PR00205F 19.57 3.86e-16 741-767 PR00205F 19.57 2.13e-15 301-327 PR00205B 20.09 7.30e-15 996-1025 PR00205B 20.09 9.70e-15 250-279 PR00205B 20.09 1.84c-14 475-504 PR00205D 12.22 4.12e-14 332-351 714 IPB002126 Cadherin domain IPB002126B 12.04 4.79e-14 238-255 PR00205B 20.09 4.94c-14 1210-1239 PR00205B 20.09 7.19e-14 1315-1344 PR00205D 12.22 9.31e-14 1294-1313 IPB002126B 12.04 3.57e-13 463-480 PR00205F 19.57 4.90e-13 1368-1394 IPB002126B 12.04 5.29 715 PR00205 Cadherin signature VI PR00205F 19.57 3.86e-16 741-767 PR00205F 19.57 2.13e-15 301-327 PR00205B 20.09 7.30e-15 996-1025 PR00205B 20.09 9.70e-15 250-279 PR00205B 20.09 1.84e-14 475-504 PR00205D 12.22 4.12e-14 332-351 715 IPB002126 Cadherin domain IPB002126B 12.04 4.79e-14 238-255 PR00205B 20.09 4.94e-14 1210-1239 PR00205B 20.09 7.19e-14 1315-1344 PR00205D 12.22 9.31e-14 1294-1313 IPB002126B 12.04 3.57e-13 463-480 PR00205F 19.57 4.90e-13 1368-1394 IPB002126B 12.04 5.29 WO 2004/080148 PCT/US2003/030720 364 TABLE 3B 716 IPB002469 "Dipeptidyl peptidase IV, N- IPB0024691 10.99 4.86e-16 719-737 terminus" IPB002469H 21.17 6.14e-16 674-709 IPB002469J 8.97 3.52e-12 801-817 716 IPB002471 Prolyl endopeptidase family serine IPB002471B 24.90 3.66e-11 706-737 active site IPB002469G 26.76 9.24e-11 629-667 717 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 1.00e-21 156-181 IPB000822 14.67 4.75e-19 324-349 IPB000822 14.67 4.46e-18 212-237 IPB000822 14.67 3.57e-17 184-209 IPB000822 14.67 7.43e-17 240-265 IPB000822 14.67 1.00e-16 296-321 IPB000822 14.67 2.69e-15 62-87 IPB000822 14.67 4.38e-15 352-377 717 PR00048 C2H2-type zinc finger signature I PR00048A 9.94 8.20e-15 181-194 717 IPB001275 DM DNA binding domain IPB001275 19.17 9.07e-15 172-211 PR00048A 9.94 3.77e-14 321-334 PROO048A 9.94 8.62e-14 349-362 PR00048A 9.94 3.57e-13 153-166 IPB001275 19.17 9.71e-13 144-183 IPB000822 14.67 1.95e-12 268-293 PROO048A 9.94 2.06e-12 237-250 PR00048A 9.94 4.18e-12 209-222 IPB000822 14.67 9.53e-12 34-59 PROO048A 9.94 6.21e-11 265-278 IPB001275 19.17 8.71e-11 200-239 PROO048A 9.94 1.41e-10 293-306 IPB001275 19.17 4.16e-10 312-351 PROO048B 5.52 5.50e-10 197-206 PROO048A 9.94 7.55e-10 59-72 PR00048B 5.52 9.36e-10 337-346 PROO048B 5.52 1.00e-09 169-178 PR00048B 5.52 3.50e-09 225-234 IPB001275 19.17 3.62e-09'256-295 PROO048B 5.52 4.50e-09 365-374 IPB001275 19.17 5.22e-09 228-267 IPBOO1275 19.17 8.75c-09 284-323 718 IPB000221 Protamine P1 IPB000221 5.48 2.97e-12 74-100 IPB000221 5.48 9.30e-12 63-89 IPB000221 5.48 2.19e-11 103-129 IPB000221 5.48 2.59e-11 64-90 IPB000221 5.48 3.91e-11 78-104 718 IPB000492 Protamine 2 (PRM2) IPB000492B 5.26 5.88e-11 98-132 IPB000221 5.48 6.16e-11 92-118 IPB000221 5.48 6.43e-11 99-125 IPB000221 5.48 7.62e-11 60-86 IPB000492B 5.26 9.35e-11 79-113 IPB000492B 5.26 9.35e- 11 102-136 IPB000221 5.48 2.73e-10 118-144 IPB000221 5.48 4.70e-10 62-88 IPB000221 5.48 4.70e-10 94-120 IPB000492B 5.26 6.97e-10 103-137 IPB000492B 5.26 8.12e-10 106-140 IPB000492B 5.26 8.53e-10 105-139 IPB000221 5.48 8.89e-10 101-127 IPB000492B 5.26 9.06e-10 78-112 IPB000492B 5.26 9.69e-10 100-134 IPB000221 5.48 1.00e-09 83-109 IPB000221 5.48 1.46e-09 65-91 WO 2004/080148 PCT/US2003/030720 365 TABLE 3B IPB000221 5.48 3.3le-09 109-135 IPB000221 5.48 3.3le-09 122-148 IPB000492B 5.26 3.84e-09 75-109 IPB000221 5.48 5.15e-09 107-133 IPB000221 5.48 5.27e-09 52-78 718 PR00055 HIV TAT domain signature III PROO055C 9.12 5.92e-09 16-32 IPB000221 5.48 6.19e-09 116-142 IPB000492B 5.26 6.38e-09 94-128 1PB000492B 5.26 6.67e-09 107-141 IPB000221 5.48 6.88e-09 97-123 IPB000221 5.48 6.88e-09 111-137 1PB000492B 5.26 7.75e-09 77-111 IPB000492B 5.26 8.34e-09 65-99 718 IPB000271 Ribosomal protein L34 IPB000271 15.87 9.78e-09 111-148 IPB000221 5.48 9.88e-09 124-150 IPB000492B 5.26 9.90e-09 111-145 IPB000221 5.48 1.00e-08 76-102 720 IPB000152 Aspartic acid and asparagine IPB000152 8.86 6.54e-17 2348-2363 hydroxylation site IPB000152 8.86 4.18e-15 2191-2206 IPB000152 8.86 3.84e-14 2232-2247 IPB000152 8.86 3.86e-13 2108-2123 720 IPB003886 Extracellular domain in nidogen IPB003886D 13.91 4.78e-13 2232-2251 720 IPBOO1881 Calcium-binding EGF-like domain IPBOO1881B 12.28 5.50e-13 2191-2202 720 IPB003006 Immunoglobulin and major IPBO03006B 20.23 8.29e-13 1028-1065 histocompatibility complex domain 720 PROO010 Type II EGF-like signature III PROD010C 6.98 9.47e-13 2353-2363 IPB003006B 20.23 1.00e-12 1119-1156 720 IPB000033 "Low-density lipoprotein (ldl) IPB000033B 7.05 3.70e-12 2196-2206 receptor, YWTD repeat" IPBOO1881B 12.28 5.20e-12 2348-2359 720 IPB002861 Reeler domain IPB002861B 10.50 6.52e-12 1435-1463 IPB002861B 10.50 7.12e-12 1606-1634 720 PR01303 Plasmodium circumsporozoite PRO1303D 10.57 7.20e-12 1441-1458 protein signature IV PROO010C 6.98 1.75e-11 2196-2206 1PB000152 8.86 1.96e-11 2023-2038 IPBOO1881B 12.28 4.79e-11 2232-2243 IPBOO3006B 20.23 4.9le-11 386-423 IPBOO3006B 20.23 5.30e-11 1208-1245 IPB002861B 10.50 7.08e-11 1549-1577 IPBOO3006B 20.23 8.43e-11 199-236 IPB001881B 12.28 8.58e-11 2066-2077 IPBOO1881B 12.28 9.53e-11 2023-2034 IPBOO3006B 20.23 9.61e-11 756-793 720 IPB000981 Neurohypophysial hormone IPBOO0981A 17.34 1.60e-10 1594-1621 IPBOO3006B 20.23 2.08e-10 847-884 IPB003886D 13.91 2.33e-10 2191-2210 IPB00033B 7.05 4.48e-10 2353-2363 720 IPB003367 Thrombospondin type 3 repeat IPB003367A 11.78 5.83e-10 2116-2136 PRO1303D 10.57 5.90e-10 1612-1629 IPB000033B 7.05 7.10e-10 2113-2123 720 IPB001862 Membrane attack complex IPB001862A 12.54 8.02e-10 1714-1729 components/perforin/complement C9 720 PR00907 Thrombomodulin signature VII PR00907G 10.43 8.09e-10 2348-2374 IPBOO3006B 20.23 8.56e-10 104-141 IPBOO1881B 12.28 8.71e-10 2108-2119 PR00907G 10.43 8.85e-10 2232-2258 IPBOO3006B 20.23 8.92e-10 938-975 IPB003886D 13.91 9.41e-10 2348-2367 WO 2004/080148 PCT/US2003/030720 366 TABLE 3B PR00907B 11.50 9.64e-10 2228-2244 IPB003006B 20.23 1.35e-09 479-516 PRO1303D 10.57 2.00e-09 1726-1743 720 PR01472 Intercellular adhesion PR01472C 14.40 3.41e-09 994-1009 molecule/vascular cell adhesion 1PB003886D 13.91 3.49e-09 2108-2127 molecule- 1 signature III 720 IPB000561 EGF-like domain IPBOO0561 4.89 3.57e-09 2357-2365 PROO010C 6.98 3.63e-09 2113-2123 IPBOO3006B 20.23 3.77e-09 1299-1336 IPB00033A 21.82 4.35e-09 2053-2075 IPB002861B 10.50 4.48e-09 1663-1691 IPBOO3006B 20.23 4.81e-09 10-47 IPB003367A 11.78 5.13e-09 2318-2338 IPBOO3006B 20.23 5.50e-09 572-609 720 PR01474 Vascular cell adhesion molecule-I PR01474F 14.81 5.76e-09 1221-1234 (VCAM-1) signature VI IPBOO3006B 20.23 5.85e-09 293-330 720 PR01536 Interleukin-1 receptor type I and type PR01536C 19.92 5.85e-09 393-416 II family signature III PRO1536C 19.92 6.08e-09 1126-1149 PR01536C 19.92 7.46e-09 763-786 PRO1536C 19.92 7.58e-09 1215-1238 PROO010C 6.98 8.02e-09 2237-2247 IPB001862A 12.54 8.55c-09 1486-1501 IPB002861B 10.50 8.98e-09 1720-1748 IPB002861C 23.17 9.02e-09 1650-1704 720 IPB000967 Zinc finger NF-XI type IPB000967E 21.88 9.20c-09 1443-1483 720 IPBOO0118 Granulin IPBOOO118B 7.94 9.20e-09 2011-2049 PR00907G 10.43 9.27e-09 2108-2134 PR00907B 11.50 9.43e-09 2344-2360 IPB002861B 10.50 9.59e-09 1492-1520 721 IPB000135 High mobility group proteins HMGl IPBOO0135D 2.13 8.05e-14 71-95 and HMG2 IPBOO0135D 2.13 5.27e-13 72-96 IPBOO0135D 2.13 9.46e-12 73-97 IPBOOO135D 2.13 4.78e-11 70-94 721 IPB003874 CDC45-like protein IPB003874C 5.49 8.27e-11 74-85 721 IPB000897 GTP-binding signal recognition IPB000897A 9.15 8.60e-l1 454-473 particle (SRP54) domain IPBOO0135D 2.13 3.05e-10 74-98 721 IPB001580 Calreticulin family IPBOO158OF 2.93 8.3le-10 78-87 IPBOOO135D 2.13 9.02e-10 69-93 IPBOO0135D 2.13 1.00e-09 65-89 IPBOO158OF 2.93 1.45e-09 76-85 IPBOO0135D 2.13 5.09e-09 66-90 IPBOO158OF 2.93 6.85e-09 74-83 IPBOO0135D 2.13 7.00e-09 75-99 IPBOO0135D 2.13 -8.00e-09 68-92 IPBOO0135D 2.13 9.36e-09 63-87 722 IPBOO1140 ABC transporter transmembrane IPBOO1 140A 21.73 8.36e-20 1311-1357 region IPBOO140A 21.73 9.29e-18 499-545 IPB001140B 15.62 4.79e-15 615-653 IPBOO1140B 15.62 1.16e-10 1427-1465 722 PR00326 GTPl/OBG GTP-binding protein PR00326A 8.70 6.66e-10 513-533 family signature I 722 IPB000795 GTP-binding elongation factor IPB000795A 10.67 7.88e-10 1324-1339 722 IPB000897 GTP-binding signal recognition IPB000897A 9.15 1.54e-09 512-531 particle (SRP54) domain IPB000795A 10.67 2.85e-09 512-527 PR00326A 8.70 4.49e-09 1325-1345 IPB000897A 9.15 5.57e-09 1324-1343 722 IPB001324 Phosphoribulokinase family IPB001324A 18.12 8.00e-09 1321-1342 WO 2004/080148 PCT/US2003/030720 367 TABLE 3B 722 PR00364 Disease resistance protein signature I PR00364A 8.29 8.00e-09 512-527 722 PR01014 Neuropeptide Y2 receptor signature PRO1014F 15.22 8.74c-09 647-663 VI 723 PR01217 Proline rich extensin signature VII PRO1217G 4.02 7.16e-09 242-267 PR01217D 4.57 7.49c-09 495-516 723 IPB001084 Microtubule associated Tau protein IPBOO1084C 7.66 9.64e-09 308-325 723 IPBOO1101 Plectin repeat IPB0O1101K 8.53 9.92e-09 29-72 724 IPBOO1552 Acyl-CoA dehydrogenase IPBOO1552E 22.77 2.46e-19 158-198 IPB001552D 24.88 5.35e-19 67-109 IPB001552C 25.04 7.75e-15 13-53 725 IPB000998 MAM domain IPB000998D 18.66 1.96e-15 526-549 725 IPB003886 Extracellular domain in nidogen IPB003886D 13.91 8.77e-15 236-255 725 IPB000152 Aspartic acid and asparagine IPB000152 8.86 2.89e-14 109-124 hydroxylation site 725 IPB001881 Calcium-binding EGF-like domain IPB001881B 12.28 5.00e-14 191-202 IPB000152 8.86 1.00e-13 236-251 IPB000152 8.86 1.82e-13 191-206 IPBOO1881B 12.28 4.75e-13 109-120 725 IPB001774 Delta serrate ligand IPB001774C 18.25 9.13e-13 71-113 IPB000998B 17.20 1.00e-12 409-421 725 PROO020 MAM domain signature I PROO020A 20.48 2.88e-11 407-425 IPB000998C 18.63 5.30e-11 463-478 IPBOO1881B 12.28 8.58e-11 236-247 725 PR00907 Thrombomodulin signature II PR00907B 11.50 2.44e-10 143-159 725 IPB000561 EGF-like domain IPBOO0561 4.89 3.25c-10 80-88 725 IPB00033 "Low-density lipoprotein (Idl) IPB00033B 7.05 5.35e-10 241-251 receptor, YWTD repeat" IPB00033B 7.05 5.97e-09 196-206 725 1P3000167 Dehydrin IPBOO0167A 8.58 7.14e-09 323-350 725 1PB003367 Thrombospondin type 3 repeat IPB003367A 11.78 9.79e-09 158-178 726 IPB001258 NHL repeat IPBOO1258B 28.61 4.30e-17 619-653 IPBOO1258B 28.61 7.00e-17 525-559 IPB001258B 28.61 1.27e-16 431-465 IPB001258B 28.61 5.91e-16 478-512 726 PR01406 B-box zinc finger signature I PRO1406A 20.90 8.36e-12 112-129 IPB001258B 28.61 5.60e-11 572-606 726 IPB003649 B-Box C-terminal domain IPB003649B 22.16 3.68e-10 115-134 726 IPB001869 Thiol-activated cytolysins IPB001869C 15.61 6.06e-09 396-419 727 IPB000198 RhoGAP domain IPBOO0198C 16.49 8.31e-16 923-940 IPBOO0198B 12.47 9.10e-15 833-850 727 IPB002219 Phorbol esters/diacylglycerol binding IPB002219B 12.53 3.89e-11 724-739 domain IPBOO0198A 15.95 9.61e-10 781-797 727 IPB002551 Coronavirus Si glycoprotein IPB002551J 18.56 3.60e-09 470-511 727 IPB001369 Purine and other phosphorylases IPB001369C 24.81 4.27e-09 36-76 family 2 727 IPB003351 Dishevelled specific domain IPB003351C 13.82 7.24e-09 1025-1064 729 IPB002870 Reprolysin family propeptide IPB002870B 24.73 6.23e-24 131-169 IPB002870F 18.81 6.54e-16 456-480 729 IPB001762 Disintegrin IPB001762A 23.93 6.50e-15 359-399 IPB002870E 11.90 8.67e-14 414-426 IPB002870D 16.31 8.77e-13 383-398 729 PR01303 Plasmodium circumsporozoite PRO1303D 10.57 1.42e-11 1173-1190 protein signature IV PRO1303D 10.57 1.40e-10 1488-1505 IPB002870A 12.22 2.29e-10 81-97 IPB002870C 11.01 2.80c-10 344-354 PRO1303D 10.57 3.91e-10 1098-1115 729 IPBOO0130 "Neutral zinc metallopeptidases, IPBOO0130 5.86 7.19e-10 412-422 zinc-binding region" WO 2004/080148 PCT/US2003/030720 368 TABLE 3B 729 IPBOO0118 Granulin IPBOO0118G 12.18 4.31e-09 1471-1519 729 IPB002861 Reeler domain 1PB002861C 23.17 5.34e-09 969-1023 PR01303D 10.57 6.50e-09 1229-1246 IPB002861B 10.50 7.75e-09 1223-1251 729 PR00269 Pleiotrophin/midkine family PR00269A 12.42 9.33e-09 1162-1186 signature I 730 PR01478 Leukotriene B4 type 2 receptor PR01478E 5.85 7.56e-10 149-177 signature V 735 IPB001331 Guanine-nucleotide dissociation IPB001331C 16.09 7.35e-14 302-327 stimulators CDC24 family 737 IPB002004 "Poly-adenylate binding protein, IPBOO2004C 13.84 8.14e-10 189-231 unique domain" 741 PR01276 Type II keratin signature II PR01276B 9.79 9.27e-10 147-159 742 PR00205 Cadherin signature II PR00205B 20.09 5.95e-20 252-281 PR00205D 12.22 3.25e-16 654-673 PR00205B 20.09 7.60e-15 142-171 PR00205F 19.57 1.00e-14 520-546 PR00205G 13.05 1.37e-13 657-674 PR00205F 19.57 3.10e-13 623-649 PR00205D 12.22 5.80e-13 231-250 PR00205D 12.22 5.80e-13 551-570 PR00205B 20.09 6.40e-13 469-498 742 IPB002126 Cadherin domain IPB002126B 12.04 8.71e-13 560-577 PR00205F 19.57 1.26e-12 308-334 PR00205G 13.05 1.30e-12 340-357 PR00205G 13.05 4.90e-12 554-571 PR00205D 12.22 5.37e-12 337-356 PR00205D 12.22 8.20e-12 448-467 PR00205G 13.05 8.50e-12 234-251 PR00205G 13.05 6.84e-11 451-468 IPBOO2126B 12.04 7.43e-11 240-257 PR00205F 19.57 7.63e-11 417-443 PR00205A 17.38 8.56e-11 301-320 IPB002126B 12.04 3.03e-10 457-474 IPB002126B 12.04 9.42e-10 130-147 IPB002126A 14.68 3.67e-09 312-328 PR00205A 17.38 4.71e-09 513-532 PR00205E 10.82 5.50e-09 570-583 IPB002126A 14.68 6.33e-09 204-220 PR00205C 13.59 6.62e-09 640-652 PR00205B 20.09 7.06e-09 572-601 PR00205D 12.22 8.27e-09 121-140 PR00205G 13.05 9.82e-09 124-141 744 IPB001862 Membrane attack complex IPB001862C 26.48 8.94e-09 119-167 components/perforin/complement C9 745 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 6.00e-24 216-241 IPB000822 14.67 9.18e-21 160-185 IPB000822 14.67 1.75e-20 328-353 IPB000822 14.67 4.00e-20 518-543 IPB000822 14.67 8.50e-20 244-269 IPB000822 14.67 9.25e-19 490-515 IPB000822 14.67 7.92e-18 188-213 IPB000822 14.67 9.31e-18 356-381 IPB000822 14.67 9.36e-17 272-297 IPB000822 14.67 3.40e-16 384-409 IPB000822 14.67 8.80e-16 300-325 745 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 5.50e-15 381-394 PROO048A 9.94 1.00e-14 269-282 WO 2004/080148 PCT/US2003/030720 369 TABLE 3B PROO048A 9.94 1.00e-14 543-556 PR00048A 9.94 3.08e-14 185-198 PR00048A 9.94 4.46e-14 487-500 IPB000822 14.67 6.06e-14 440-465 IPB000822 14.67 2.50e-13 412-437 PR00048A 9.94 3.57e-13 297-310 PR00048A 9.94 6.79e-13 213-226 PR00048A 9.94 7.43e-13 409-422 IPB000822 14.67 8.00e-13 132-157 745 IPB001275 DM DNA binding domain IPB001275 19.17 8.00e-13 148-187 PR00048A 9.94 3.12e-12 241-254 PR00048A 9.94 5.76e-12 515-528 PR00048B 5.52 7.00e-12 173-182 IPBO01275 19.17 7.58e-12 204-243 PR00048A 9.94 8.41e-12 353-366 IPBO0 1275 19.17 3.96e- 11 506-545 IPB000822 14.67 4.43e-11 546-571 IPB001275 19.17 5.76e-11 176-215 PR00048A 9.94 6.2le-11 325-338 PR00048B 5.52 7.00e-11 341-350 PR00048B 5.52 9.25e-11 503-512 PR00048B 5.52 1.00e-10 229-238 IPB001275 19.17 1.49e-10 344-383 IPB001275 19.17 4.41e-10 316-355 745 IPB001222 TFIIS zinc ribbon domain IPB001222 24.63 5.16e-10 490-526 IPB001275 19.17 5.50e-10 232-271 PROO048A 9.94 7.14e-10 129-142 PROO048A 9.94 7.14e-10 157-170 PR00048A 9.94 1.38e-09 437-450 IPB001275 19.17 1.46e-09 372-411 IPB001275 19.17 3.39e-09 288-327 PR00048B 5.52 5.50e-09 531-540 IPB001222 24.63 8.35e-09 160-196 IPB001275 19.17 9.09e-09 260-299 745 IPBOO 1142 Yeast membrane protein DUP IPB001 142B 22.92 9.60e-09 290-335 745 IPB002867 Cysteine-rich domain (C6HC) IPB002867C 19.46 9.76e-09 129-146 PR00048B 5.52 1.00e-08 313-322 746 IPB001909 KRAB box IPB001909 17.37 8.65e-30 37-71 746 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 6.00e-24 291-316 IPB000822 14.67 9.18e-21 235-260 IPB000822 14.67 1.75e-20 403-428 IPB000822 14.67 8.50e-20 319-344 IPB000822 14.67 7.92e-18 263-288 IPB000822 14.67 9.3le-18 431-456 IPB000822 14.67 9.36e-17 347-372 IPB000822 14.67 3.40e-16 459-484 IPB000822 14.67 8.80e-16 375-400 746 PR00048 C2H2-type zinc finger signature I PR00048A 9.94 5.50e-15 456-469 PROO048A 9.94 1.00e-14 344-357 PR00048A 9.94 3.08e-14 260-273 IPB000822 14.67 6.06e-14 515-540 IPB000822 14.67 2.50e-13 487-512 PR00048A 9.94 3.57e-13 372-385 PR00048A 9.94 6.79e-13 288-301 PR00048A 9.94 7.43e-13 484-497 IPB000822 14.67 8.00e-13 207-232 746 IPB001275 DM DNA binding domain IPB001275 19.17 8.00e-13 223-262 PROO048A 9.94 3.12e-12 316-329 WO 2004/080148 PCT/US2003/030720 370 TABLE 3B PR00048B 5.52 7.00e-12 248-257 1PB001275 19.17 7.58e-12 279-318 PROO048A 9.94 8.41e-12 428-441 IPB001275 19.17 5.76e-11 251-290 PROO048A 9.94 6.21e-11 400-413 PR048B 5.52 7.00e-11 416-425 PROO048B 5.52 1.00e-10 304-313 IPB00 1275 19.17 1.49e- 10 419-458 IPB001275 19.17 4.41e-10 391-430 IPB001275 19.17 5.50e-10 307-346 PROO048A 9.94 7.14e-10 204-217 PROO048A 9.94 7.14e-10 232-245 PROO048A 9.94 1.38e-09 512-525 IPB001275 19.17 1.46e-09 447-486 IPB001275 19.17 3.39e-09 363-402 746 IPB001222 TFIIS zinc ribbon domain IPB001222 24.63 8.35e-09 235-271 IPB001275 19.17 9.09e-09 335-374 746 IPB001142 Yeast membrane protein DUP IPBOO1142B 22.92 9.60e-09 365-410 746 IPB002867 Cysteine-rich domain (C6HC) IPB002867C 19.46 9.76e-09 204-221 PROO048B 5.52 1.00e-08 388-397 747 IPB000348 emp24/gp25L/p24 family IPBOO0348B 26.69 5.33e-31 143-188 IPB000348A 15.21 3.63e-12 78-96 748 IPB000560 Histidine acid phosphatase IPB000560 17.02 1.00e-16 31-53 749 PR00405 HIV Rev interacting protein PR00405B 10.10 8.29e-19 558-575 signature II PR00405C 18.05 9.55e-19 579-600 PR00405A 18.83 4.00e-18 539-558 749 IPB000906 ZU5 domain IPBOO0906G 25.85 4.32e-12 827-875 LPBOO0906D 23.89 7.43e-09 846-900 751 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 7.00e-24 753-778 751 IPB001909 KRAB box IPB001909 17.37 2.86e-21 344-378 IPB000822 14.67 3.57e-17 695-720 IPB000822 14.67 3.25e-14 605-630 IPB000822 14.67 9.44e-14 781-806 IPB000822 14.67 2.50e-13 723-748 751 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 3.37e-11 602-615 PROO048A 9.94 4.32e-11 778-791 PROO048A 9.94 5.26e-11 692-705 IPB000822 14.67 6.14e-11 633-658 PROO048A 9.94 9.53e-11 750-763 PROO048B 5.52 1.00e-10 766-775 PROO048A 9.94 3.86e-10 720-733 751 IPBOO1580 Calreticulin family IPBOO158OF 2.93 1.00e-09 514-523 PROO048A 9.94 6.25e-09 630-643 PROO048B 5.52 6.50e-09 708-717 751 PRO1073 Presenilin 1 signature III PRO1073C 1.45 6.62e-09 509-520 751 IPB001275 DM DNA binding domain IPB001275 19.17 8.18e-09 769-808 751 IPB000135 High mobility group proteins HMG1 IPBOO0135D 2.13 8.45e-09 507-531 and HMG2 753 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 8.11e-14 261-275 domain 753 PR00364 Disease resistance protein signature PR00364D 14.89 4.60e-09 103-119 IV 753 PROO019 Leucine-rich repeat signature II PROO019B 11.42 8.91e-09 154-167 754 IPB001599 Alpha-2-macroglobulin family IPB001599L 18.66 7.84e-26 1244-1271 IPB001599F 18.95 7.00e-24 785-814 IPBOO1599H 18.42 6.40e-20 1019-1046 IPB001599A 10.97 9.69e-18 123-141 WO 2004/080148 PCT/US2003/030720 371 TABLE 3B IPB001599N 24.85 2.24e-14 1437-1469 754 iPBOO1134 "Netrin, C-terminus" IPBOO1134C 17.82 4.13e-13 1257-1271 1PB001599M 13.29 4.71e-13 1384-1395 IPB001599G 13.87 8.94e-13 987-996 IPB001599B 7.45 4.89e-12 209-221 IPB001599D 11.61 6.90e-12 728-738 IPB001599J 20.99 3.00e-11 1085-1110 IPB001599I 10.83 7.60e-11 1054-1063 IPB001599K 8.15 1.46e-10 1214-1225 IPB001599C 14.40 3.55e-09 236-252 IPB001599E 11.06 9.77e-09 755-764 755 IPBO2181 Fibrinogen beta and gamma chais IPB002181E 27.75 4.44e-21 344-376 C-terminal globular domain IPBOO2181D 29.18 5.14e-19 298-338 IPBOO2181F 18.85 2.13e-14 398-421 IPBOO2181C 15.87 5.78e-12 280-292 IPB002181A 18.44 2.32e-10 244-260 756 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 5.30e-11 457-494 histocompatibility complex domain 756 PROO014 Fibronectin type III repeat signature PROO014D 15.12 5.26e-10 671-685 IV IPBOO3006B 20.23 5.68e-10 174-211 IPBOO3006B 20.23 5.68e-10 275-312 756 PR00406 Cytochrome B5 reductase signature PR00406F 4.29 6.03e-09 140-148 VI 756 IPB003866 Isoflavone reductase IPB003866D 19.80 9.48e-09 454-506 757 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 6.85c-13 240-254 domain 757 PROO019 Leucine-rich repeat signature I PROO019A 11.72 7.14e-11 149-162 PROO019B 11.42 8.00e-10 98-111 PROO019B 11.42 7.55e-09 122-135 PROO019B 11.42 8.09e-09 146-159 757 IB002889 WSC domain IPB002889B 11.76 8.97e-09 599-645 757 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 9.3le-09 335-372 histocompatibility complex domain IPB002889B 11.76 9.44e-09 598-644 758 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 6.85e-13 240-254 domain 758 PROO019 Leucine-rich repeat signature I PROM19A 11.72 7.14e-11 149-162 PROO019B 11.42 8.00e-10 98-111 PROO019B 11.42 7.55e-09 122-135 PROO019B 11.42 8.09e-09 146-159 758 IPB002889 WSC domain IPB002889B 11.76 8.97e-09 603-649 758 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 9.31e-09 335-372 histocompatibility complex domain IPB002889B 11.76 9.44e-09 602-648 759 IPB000203 GPS domain IPBOO0203A 18.40 9.25e-20 966-996 IPBOO0203B 13.98 8.88e-15 1086-1107 759 IPB000832 G-protein coupled receptors family 2 IPB000832C 19.53 9.46e-13 1086-1115 (secretin-like) 759 PR00249 Secretin-like GPCR superfamily PR00249C 15.44 1.73e-10 1088-1111 signature III IPB000832G 15.17 7.81e-09 1256-1281 760 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 4.00e-24 277-302 IPB000822 14.67 3.45e-21 361-386 IPB000822 14.67 1.75e-20 193-218 IPB000822 14.67 3.25e-19 109-134 IPB000822 14.67 4.00e-19 389-414 IPB000822 14.67 8.50e-19 165-190 IPB000822 14.67 1.00e-18 249-274 IPB000822 14.67 5.85e-18 305-330 IPB000822 14.67 1.60e-16 137-162 WO 2004/080148 PCT/US2003/030720 372 TABLE 3B IPB000822 14.67 3.40e-16 333-358 IPB000822 14.67 5.50e-15 221-246 760 PR00048 C2H2-type zinc finger signature I PR00048A 9.94 6.54e-14 330-343 760 IPB001275 DM DNA binding domain IPBOO1275 19.17 6.55e-14 237-276 IPB001275 19.17 8.05e-14 321-360 IPB001275 19.17 8.20e-14 153-192 IPB001275 19.17 2.14e-13 349-388 IPB001275 19.17 4.57e-13 265-304 PROO048A 9.94 4.86e-13 218-231 PR00048A 9.94 4.86e-13 274-28 760 IPB002867 Cysteine-rich domain (C6HC) IPB002867C 19,46 8.1le-09 274-291 PROO048A 9.94 8.12e-09 358-371 760 IPB002634 BolA-like protein IPB002634A 23.30 8.25e-09 298-332 760 PR00995 36kDa capillovirus serine protease PR00995F 16.50 9.73e-09 311-329 (S35) signature VI 761 PR00121 Sodium/potassium-transporting PROO121D 16.73 7.12e-15 173-194 ATPase signature IV 761 IPB001757 El-E2 ATPases IPBOO1757B 13.64 9.65e-13 588-617 IPBOO1757A 14.16 4.18e-12 179-190 761 PROO119 P-type cation-transporting ATPase PRO0119B 12.03 9.61e-12 180-194 superfamily signature II 761 IPBOO0150 Cof protein IPBOOO150C 20.72 7.47e-09 595-627 763 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 8.88e-09 172-197 764 IPBOO1310 HIT (Histidine triad) family IPBOO1310A 18.76 3.25e-18 177-207 IPBOO13 1OB 21.00 2.93e-12 241-267 764 PR00332 Histidine triad family signature II PR00332B 14.02 6.26e-10 189-207 767 IPB000135 High mobility group proteins HMG1 IPBOO0135D 2.13 4.52e-10 101-125 and HMG2 IPBOO0135D 2.13 9.71e-10 103-127 IPBOO0135D 2.13 9.90e-10 100-124 IPBOO0135D 2.13 3.18e-09 104-128 IPBOO0135D 2.13 9.55e-09 102-126 768 PR00074 Protein-lysine 6-oxidase precursor PROO074E 11.34 9.46e-14 327-347 signature V PROO074B 7.56 4.98e-12 260-284 768 IPB001695 Lysyl oxidase IPBOO1695E 9.12 5.70e-12 244-285 768 PR00258 Speract receptor signature IV PR00258D 14.29 7.39e-12 94-108 PR00258E 14.06 3.38e-11 117-129 PR00258A 13.56 1.54e-10 29-45 PROO074D 21.66 2.94e-10 305-326 PR00258A 13.56 3.70e-10 139-155 PR00258C 9.05 4.95e-10 177-187 PR00258D 14.29 6.29e-10 210-224 PR00258C 9.05 9.34e-10 63-73 PR00258B 7.94 6.14e-09 48-59 IPB001695F 11.10 6.87e-09 285-313 771 IPB001084 Microtubule associated Tau protein IPBOO1084C 7.66 1.00e-08 105-122 773 IPB000374 Phosphatidate cytidylyltransferase IPB000374B 15.86 2.06e-27 358-385 IPB000374A 12.59 3.65e-16 254-266 774 PR00320 G protein beta WD-40 repeat PR00320A 13.15 7.95e-11 190-204 signature I PR00320B 12.82 2.08e-10 190-204 PR00320C 12.32 4.33e-09 190-204 775 IPBOO1422 Neuromodulin (GAP-43) IPBOO1422C 16.82 1.95e-10 155-190 775 1PB001990 Granins (chromogranin or IPBOO1990C 33.59 S.Ole-10 150-197 secretogranin) 776 IPB002549 Domain of unknown function DUF20 IPB002549B 19.59 9.27e-09 229-266 778 IPB002884 Proprotein convertase P-domain IPB002884B 15.69 6.33e-09 114-131 779 IPB000361 Hypothetical hesB/yadR/yfhF family IPBOO0361B 19.14 3.08e-19 119-150 IPBOO0361A 17.83 2.71e-16 70-90 WO 2004/080148 PCT/US2003/030720 373 TABLE 3B 780 IPB003006 Immunoglobulin and major IPB003006B 20.23 9.28e-10 131-168 histocompatibility complex domain 783 IPB002223 Pancreatic trypsin inhibitor (Kunitz) IPB002223 17.66 3.88e-25 556-590 family 783 IPB000885 Fibrillar collagen C-terminal domain IPBOO0885A 11.46 5.57e-19 13-50 783 IPB001442 C-terminal tandem repeated domain IPB001442A 26.12 6.26e-19 6-58 in type 4 procollagen IPB001442A 2 6 .12 4.44e-18 3-55 IPB001442A 26.12 3.17e-17 185-237 IPB001442A 26.12 3.60e-17 191-243 1PBOO0885B 19.15 5.72e-17 2-55 IPB000885B 19.15 6.29e-17 11-64 IPB001442A 26.12 7.51e-17 12-64 1PB001442A 26.12 1.21e-16 197-249 IPB000885B 19.15 2.19e-16 193-246 IPB001442A 26.12 3.51e-16 9-61 IPB000885A 11.46 5.06e-16 198-235 IPB001442A 26.12 6.02e-16 188-240 IPB000885B 19.15 7.83e-16 8-61 IPB000885A 11.46 1.61e-15 19-56 IPB000885B 19.15 3.65e-15 202-255 IPB000885B 19.15 4.39e-15 184-237 IPB000885B 19.15 4.49e-15 190-243 IPB000885B 19.15 8.09e-15 17-70 IPB001442A 26.12 9.29e-15 182-234 IPB001442A 26.12 9.80e-15 15-67 783 PR00453 Von Willebrand factor type A PR00453A 11.78 1.75e-14 265-282 domain signature I IPB000885A 11.46 2.29c-14 201-238 IPB000885A 11.46 3.92e-14 210-247 IPB000885B 19.15 6.76e-14 14-67 IPBOO0885B 19.15 6.97e-14 187-240 IPB000885A 11.46 7.08e-14 22-59 IPB001442A 26.12 7.65e-14 200-252 IPB000885B 19.15 7.78e-14 5-58 IPB001442A 26.12 8.63e-14 203-255 IPBOO0885A 11.46 9.77e-14 25-62 IPB001442A 26.12 1.00e-13 194-246 IPB000885A 11.46 1.44e-13 10-47 IPB000885A 11.46 2.89e-13 195-232 1PB001442B 12.38 4.67e-13 60-80 IPB000885A 11.46 6.33e-13 207-244 IPB000885B 19.15 7.07e-13 196-249 IPB000885A 11.46 7.33e-13 16-53 IPB000885B 19.15 7.46e-13 199-252 IPB001442B 12.38 1.31e-12 22-42 783 IPB001073 Complement Clq protein IPBOO1073A 22.14 1.36e-12 56-90 IPBOO1073A 22.14 1.72e-12 203-237 IPBOO1073A 22.14 2.80e-12 119-153 IPB000885A 11.46 2.93e-12 7-44 IPB001442A 26.12 5.05e-12 24-76 IPB000885A 11.46 5.93e-12 213-250 IPB000885A 11.46 6.04e-12 20 783 PR00759 Basic protease (Kunitz-type) PR00759C 12.43 6.28e-1 1 575-590 inhibitor family signature III IPBOO1073A 22.14 7.00e-1 1 59-93 IPB000885A 11.46 7.57e-11 28-65 IPBOO1073A 22.14 8.17e-11 142-176 IPBOO1073A 22.14 8.33e-11 50-84 1PB001073A 22.14 8.67e-11 15-49 IPB001442B 12.38 8.71e-11 37-57 WO 2004/080148 PCT/US2003/030720 374 TABLE 3B 783 IPB000817 Prion protein IPBO00817A 8.34 9.70e-10 132-174 PR00759B 12.35 9.72e-10 565-575 7PB1442A 26.12 9.92e-10 30-82 IPB000885A 11.46 1.83e-09 189-226 7PB1442B 12.38 1.97e-09 210-230 IPB000873A 22.14 2.27e-09 128-162 IPBOO085B 19.15 2.47e-09 784 IPB001541 SUR2-type hydroxylase/desaturase IPB001541A 12,30 5.50e- 1 164-176 catalytic domain IPBOO1541B 11.65 4.86e-09 251-260 784 IPB001369 Purine and other phosphorylases IPB001369A 12.23 8.71e-09 2-15 family 222.14 2.27e-09 128-162 785 IPBOO3006 lInmunoglobulin and major IPB003006B 20.23 4.96e-10 367-404 histocompatibility complex domain IPB003006B 20.23 6.19c-09 1589-1626 786 PR00918 Calicivirus non-structural polyprotein PR00918A 13.81 3.59e-12 27-47 family signature I 786 IPB000135 High mobility group proteins HMG1 IPBOO0135D 2.13 4.25e-12 186-210 and HMG2 IPBOO0135D 2.13 9.24e-12 187-211 IPBOOO135D 2.13 6.42e-11 188-212 IPBOO0135D 2.13 1.68e-10 185-209 786 IPB002078 Sigma-54 factor interaction protein IPB002078A 20.43 6.3le-10 33-67 family 786 PR00364 Disease resistance protein signature I PR00364A 8.29 7.1 le-10 32-47 786 IPB000765 GTP1/OBG family IPB000765 26.91 7.67c-10 31-74 786 IPB000897 GTP-binding signal recognition IPB000897A 9.15 8.26e-10 393-412 particle (SRP54) domain 786 IPBOO1580 Calreticulin family IPBOO158OF 2.93 8.3 1e-10 200-209 IPBOO158OF 2.93 9.44e-10 201-210 786 IPB000623 Shikimate kinase IPB000623A 19.06 1.64e-09 394-423 786 IPB000619 Guanylate kinase IPBOO0619A 18.08 1.86e-09 394-411 IPBOO158OF 2.93 1.90c-09 199-208 786 PR00094 Adenylate kinase signature I PROO094A 9.62 2.43e-09 34-47 786 PR00830 Endopeptidase La (Lon) serine PR00830A 8.52 4.50e-09 37-56 protease (S16) signature I 786 IPB001482 Bacterial type II secretion system IPB001482B 12.05 4.60e-09 390-412 protein E IPBOOO 35D 2.13 4.73e-09 191-215 786 IPB000850 Adenylate kinase IPBOO0850C 18.89 5.03e-09 149-179 IPBOO0135D 2.13 6.00e-09 190-214 788 PR00452 SH3 domain signature II PR00452B 11.47 6.03e-09 14-29 789 PR00452 SH3 domain signature II PR00452B 11.47 6.03e-09 87-102 790 IPB001820 Tissue inhibitors of IPBOO1820C 11.81 1.56e-15 73-85 metalloproteinases IPBOO1820B 10.75 2.44e-14 54-64 IPBOO1820D 16.18 9.1Oe-14 91-105 IPBOO1820A 8.17 2.52e-11 16-29 791 IPB001304 C-type lectin domain IPB001304A 17.98 3.00e-17 149-173 791 PR01408 Macrophage scavenger receptor PRO1408F 9.76 4.87e-09 64-88 signature VI 792 IPB002213 UDP-glucoronosyl and UDP- IPB002213 27.73 3.37e-40 276-322 glucosyl transferase 794 IPB000339 ubiE/COQ5 methyltransferase family IPB000339D 24.04 6.07e-14 146-188 794 PR00508 S21 class N4 adenine-specific DNA PROO508B 17.31 3.88c-09 167-187 methyltransferase signature II 794 IPB000682 Protcin-L-isoaspartate(D-aspartate) IPBO00682C 16.46 6.79e-09 68-92 0-methyltransferase 795 PR00237 Rhodopsin-like GPCR superfamily PR00237C 14.77 1.30e-12 508-530 signature 111 PR00237B 12.45 8.62e-12 463-484 PR00237D 9.76 3.37c-11 544-565 795 IPB000276 | Rhodopsin-like GPCR superfamily IPB000276A 11.56 2.42e-10 522-533 WO 2004/080148 PCT/US2003/030720 375 TABLE 3B 795 PR01157 P2 purinoceptor signature IV PROI157D 16.03 2,98e-09 662-674 795 PR00173 Glutamate-aspartate symporter PR00173F 10.23 9.45e-09 705-724 signature VI PR00237F 14.34 9.56e-09 645-669 799 PR01539 Interleukin-1 receptor type II PR01539I 14.65 9.06e-09 162-185 precursor signature IX 802 IPB000117 Kappa casein IPBOOO117D 10.18 8.71e-09 506-540 805 IPBOO0171 Bacterial-type phytoene IPBOO0171E 7.19 8.20e-09 29-39 dehydrogenase 806 IPB001774 Delta serrate ligand IPB001774D 19.23 5.91e-09 50-96 806 IPB000034 Laminin B IPB00034C 12.97 7.3 le-09 84-102 806 IPB000561 EGF-like domain IPB000561 4.89 8.07e-09 84-92 807 IPB001774 Delta serrate ligand IPB001774D 19.23 5.91e-09 50-96 807 IPB000034 Laminin B IPB00034C 12.97 7.3 1e-09 84-102 807 IPB000561 EGF-like domain IPB000561 4.89 8.07e-09 84-92 808 1PB001774 Delta serrate ligand IPB001774D 19.23 5.9 1e-09 50-96 808 1PB000034 Laminin B IPB00034C 12.97 7.3 1e-09 84-102 808 IPB000561 EGF-like domain IPB000561 4.89 8.07e-09 84-92 809 PR00436 Interleukin-8 signature I PR00436A 15.20 9.36e-10 14-37 810 IPB001187 Tissue Factor (TF) IPBOO1187G 15.20 7.00e-10 40-76 811 IPB001039 "Major histocompatibility complex IPBOO1039B 27.55 8.79e-09 98-149 protein, Class I" 812 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 8.71e-12 113-150 histocompatibility complex domain IPBOO3006B 20.23 9.14e-12 406-443 IPBOO3006B 20.23 1.00e-11 213-250 812 PR01536 Interleukin-1 receptor type I and type PR01536C 19.92 9.23e-I 1512-535 11 family signature III IPBOO3006B 20.23 6.40e-10 19-56 IPBOO3006B 20.23 9.64e-10 505-542 IPBOO3006B 20.23 8.62e-09 311-348 PRO1536C 19.92 9.19e-09 120-143 813 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 8.71e-12 428-465 histocompatibility complex domain IPBOO3006B 20.23 8.71e-12 1996-2033 IPBOO3006B 20.23 9.14e-12 2289-2326 IPBOO3006B 20.23 1.00e-11 2096-2133 813 PR01536 Interleukin-1 receptor type I and type PR01536C 19.92 9.lOe-1 11707-1730 II family signature III PR01536C 19.92 9.23e-11 2395-2418 IPBOO3006B 20.23 4.60e-10 1700-1737 IPBOO3006B 20.23 6.40e-10 1902-1939 IPBOO3006B 20.23 8.92e-10 1603-1640 IPBOO3006B 20.23 9.64e-10 2388-2425 IPBOO3006B 20.23 3.42e-09 1506-1543 813 PR01076 Caldesmon signature IV PRO1076D 8.07 5.07e-09 1457-1478 IPBOO3006B 20.23 7.58e-09 1799-1836 IPBOO3006B 20.23 8.62e-09 2194-2231 PR01536C 19.92 9.19e-09 2003-2026 813 PR01472 Intercellular adhesion PR01472A 16.78 9.64e-09 1755-1771 molecule/vascular cell adhesion molecule-I signature I 814 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 7.60e-16 219-233 domain 814 IPB003006 Immunoglobulin and major IPBO3006B 20.23 8.71e-12 623-660 histocompatibility complex domain IPBOO3006B 20.23 8.71e-12 2191-2228 IPBOO3006B 20.23 9.14e-12 2484-2521 IPBOO3006B 20.23 1.00e-11 2291-2328 814 PR01536 Interleukin-1 receptor type I and type PR01536C 19.92 9. 1Oe-1 1 1902-1925 II family signature III PR01536C 19.92 9.23e-11 2590-2613 IPBOO3006B 20.23 4.60e-10 1895-1932 IPBO3006B 20.23 6.40e-10 2097-2134 WO 2004/080148 PCT/US2003/030720 376 TABLE 3B IPB003006B 20.23 8.92e-10 1798-1835 IPB003006B 20.23 9.64e-10 2583-2620 IPBOO3006B 20.23 3.42e-09 1701-1738 814 PR01076 Caldesmon signature IV PR01076D 8.07 5.07e-09 1652-1673 IPB003006B 20.23 7.58e-09 1994-2031 IPB003006B 20.23 8.62e-09 2389-2426 PR01536C 19.92 9.19e-09 2198-2221 814 PR01472 Intercellular adhesion PR01472A 16.78 9.64e-09 1950-1966 molecule/vascular cell adhesion molecule-1 signature I 816 IPB000074 Apolipoprotein Al/A4/E IPB00074B 29.17 7.49e-10 117-170 IPB00074B 29.17 8.75e-10 95-148 IPB00074B 29.17 9.20e-10 62-115 IPB00074C 22.23 2.62e-09 90-127 IPB00074C 22.23 4.35e-09 112-149 IPB00074B 29.17 8.48e-09 201-254 817 IPB000074 Apolipoprotein Al/A4/E IPB00074B 29.17 7.49e-10 117-170 IPB00074B 29.17 8.75e-10 95-148 IPB00074B 29.17 9.20e-10 62-115 IPB000074C 22.23 2.62e-09 90-127 IPB00074C 22.23 4.35e-09 112-149 IPB00074B 29.17 8.48e-09 201-254 819 IPB001211 Phospholipase A2 IPB00121 1B 17.16 3.12e-31 44-71 819 PR00389 Phospholipase A2 signature III PR00389C 17.85 2.50e-20 56-74 PR00389B 10.67 6.91e-16 37-55 IPBOO1211D 11.66 5.50e-14 104-119 PR00389E 13.06 8.20e-14 104-120 IPB01211C 14.62 1.56e-11 79-97 821 IPB001354 Mandelate racemase/muconate IPB001354C 32.55 1.00e-24 210-251 lactonizing enzyme family IPB001354D 32.92 2.07e-18 281-326 IPB001354B 18.16 3.91e-18 87-113 IPBOO1354E 9.47 6.23e-09 370-382 822 IPB002164 Nucleosome assembly protein (NAP) IPB002164B 25.75 1.00e-36 102-138 IPB002164A 24.21 6.40e-34 21-58 IPB002164C 11.48 6.68e-21 151-170 822 IPB000135 High mobility group proteins HMG1 IPBOO0135D 2.13 5.27e-13 285-309 and HMG2 IPBOOO 135D 2.13 1.41e-11 286-310 IPBOO0135D 2.13 1.82e-11 283-307 IPBOO0135D 2.13 3.76e-11 289-313 IPBOO0135D 2.13 3.97e-11 287-311 IPBOO0135D 2.13 4.27e-11 288-312 IPB002164D 9.19 7.65e-11 232-242 IPBOO0135D 2.13 1.68e-10 282-306 IPBOO0135D 2.13 4.03e-10 281-305 IPBOO0135D 2.13 4.91e-10 284-308 822 IPB001580 Calreticulin family IPBOO158OF 2.93 2.35e-09 300-309 IPB0135D 2.13 2.64e-09 280-304 IPBOO0135D 2.13 6.27e-09 291-315 IPBOO0135D 2.13 7.27e-09 292-316 IPBOO0135D 2.13 7.55e-09 279-303 IPBOO0135D 2.13 8.91e-09 290-314 822 IPB001326 Elongation factor I beta/beta'/delta IPB001326C 9.19 9.16e-09 286-301 chain 823 IPB000222 Protein phosphatase 2C subfamily IPB000222F 19.87 4.94e-15 256-276 IPB000222E 14.28 6.33e-15 228-246 IPB000222G 9.17 1.95e-12 282-295 IPB000222C 6.84 2.08e-12 147-156 IPB000222H 9.33 7.97e-12 318-330 WO 2004/080148 PCT/US2003/030720 377 TABLE 3B IPB000222B 15.80 2.86e-10 115-125 IPB000222D 11.74 2.74e-09 186-203 1PB0002221 8.91 4.72e-09 379-388 824 IPBOO1007 "von Willebrand factor, type C IPBOO1007B 10.03 1.00e-08 183-192 repeat" 825 PR00245 Olfactory receptor signature III PR00245C 14.65 9.53e-17 59-75 825 IPB000276 Rhodopsin-like GPCR superfamily IPB000276A 11.56 9.25e-14 1-12 PR00245D 9.34 1.53e-13 119-128 PR00245E 8.96 6.81e-12 166-177 PR00245B 13.73 1.00e-10 12-24 IPB000276D 9.40 3.08e-09 165-181 825 PR00237 Rhodopsin-like GPCR superfamily PR00237E 13.03 3.83e-09 82-105 signature V PR00237G 19.23 1.00e-08 155-181 826 PR00245 Olfactory receptor signature III PR00245C 14.65 9.53e-17 173-189 826 IPB000276 Rhodopsin-like GPCR superfamily IPB000276A 11.56 9.25e-14 117-128 PR00245D 9.34 1.53e-13 233-242 PR00245E 8.96 6.81e-12 280-291 PR00245A 10.98 7.14e-12 91-102 PR00245B 13.73 8.14e-10 128-140 826 PR00237 Rhodopsin-like GPCR superfamily PR00237C 14.77 2.02e-09 103-125 signature III IPB000276D 9.40 3.08e-09 279-295 PR00237E 13.03 3.83e-09 196-219 826 PR00534 Melanocortin receptor family PR00534A 12.77 5.17e-09 50-62 signature I 826 PR00896 Vasopressin receptor signature II PR00896B 9.36 7.23e-09 54-65 PR00237G 19.23 1.00e-08 269-295 827 IPBOO1169 "Integrin beta, C-terminus" IPBOOI 169J 7.42 4.63e-10 40-53 827 PR01186 Integrin beta subunit signature XI PR01186K 7.39 7.27e-10 40-53 IPB001169K 27.45 5.50e-09 42-84 PR01186K 7.39 9.75e-09 6-19 828 IPB000198 RhoGAP domain IPBOO0198C 16.49 1.28e-10 226-243 829 IPB000859 CUB domain IPB000859 19.99 7.00e-23 10-45 830 IPB000859 CUB domain IPB000859 19.99 7.00e-23 10-45 831 PR00193 Myosin heavy chain signature III PROO193C 11.66 9.77e-24 177-204 831 IPB000857 Core domain in kinesin and myosin IPBOO0857C 10.82 4.84c-19 175-197 motors PROO193B 12.36 6.81e-18 125-150 IPB000857D 12.93 8.28e-18 204-242 PR00193A 14.87 8.50e-12 65-84 IPB000857A 15.90 5.58e-11 42-95 IPB000857B 11.35 1.00e-10 106-152 831 PR00364 Disease resistance protein signature I PR00364A 8.29 4.86e-09 127-142 832 PR00193 Myosin heavy chain signature III PROO193C 11.66 9.77e-24 177-204 832 1PB000857 Core domain in kinesin and myosin IPB000857C 10.82 4.84e-19 175-197 motors PR00193B 12.36 6.8le-18 125-150 IPB000857D 12.93 8.28e-18 204-242 IPB000857E 25.07 1.47e-12 288-341 PR00193A 14.87 8.50e-12 65-84 JPB000857A 15,90 5.58e-11 42-95 IPB000857B 11.35 1.00e-10 106-152 832 PR00364 Disease resistance protein signature I PR00364A 8.29 4.86e-09 127-142 IPB000857F 15.97 6.50e-09 365-397 834 IPB002350 Kazal-type serine protease inhibitor 1PB002350 31.78 2.86e-18 143-183 family 834 IPB000716 Thyroglobulin type-1 repeat IPBOO0716C 17.62 2.88e-18 336-354 IPBOO0716D 15.49 7.16e-15 358-372 834 IPB001999 Osteonectin domain IPB001999E 15.70 7.99e-11 272-318 835 IPB001323 Erythropoietin/thrombopoeitin IPB001323A 17.37 8.31e-10 515-547 WO 2004/080148 PCT/US2003/030720 378 TABLE 3B 835 PR00251 Bacterial opsin signature I PR00251A 13.93 9.75e-10 515-534 835 PR00807 Pollen allergen Amb family signature PR00807A 16.15 7.41e-09 459-476 I 836 IPBOO1323 Erythropoietin/thrombopoeitin IPB001323A 17.37 8.3le-10 515-547 836 PR00251 Bacterial opsin signature I PR00251A 13.93 9.75e-10 515-534 836 PR00807 Pollen allergen Amb family signature PR00807A 16.15 7.41e-09 459-476 I 838 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 5.50e-13 359-373 domain 838 PROO019 Leucine-rich repeat signature I PROO019A 11.72 9.33e-10 278-291 PR00019A 11.72 9.33e-10 327-340 PROO019B 11.42 6.73e-09 179-192 PROO019A 11.72 7.27e-09 182-195 840 IPB000243 Proteasome B-type subunit IPB000243C 13.61 8.80e-09 345-355 841 IPB002889 WSC domain IPB002889B 11.76 9.36e-11 527-573 841 PR01217 Proline rich extensin signature V PRO1217E 3.04 2.99e-10 534-550 PRO1217B 4.82 5.65e-10 533-549 PRO1217D 4.57 7.86e-10 529-550 841 IPB000906 ZU5 domain IPBOO0906A 22.49 8.91e-10 158-200 PRO1217C 4.49 4.80e-09 538-550 IPBOO0906B 22.11 4.83e-09 162-202 PRO1217G 4.02 5.03e-09 529-554 841 PRO1415 Ankyrin repeat signature II PRO1415B 10.23 5.88e-09 177-189 PRO1415A 12.73 8.00e-09 165-177 PRO1415A 12.73 8.75e-09 131-143 841 IPB000925 Pneumovirus attachment IPBOO0925D 14.69 9.33e-09 404-426 glycoprotein G PRO1217A 5.97 9.62e-09 539-551 842 IPB000416 Outer Capsid protein VP4 IPBOO0416P 15.37 7.40e-09 185-223 (Hemagglutinin) 843 IPB000416 Outer Capsid protein VP4 IPBOO0416P 15.37 7.00e-09 185-223 (Hemagglutinin) 844 IPB003006 Immunoglobulin and major IPBOO3006A 17.51 7.1le-09 354-376 histocompatibility complex domain 845 IPB000998 MAM domain IPB000998C 18.63 1.95e-12 833-848 IPB000998B 17.20 1.62e-11 761-773 845 PROO020 MAM domain signature I PROO020A 20.48 3.62e-11 759-777 PROO020C 12.01 8.12e-10 832-843 IPB000998D 18.66 9.61e-10 898-921 845 IPB003006 Immunoglobulin and major IPBOO3006A 17.51 7.1le-09 354-376 histocompatibility complex domain 845 PR00096 Glutamine amidotransferase PROO096C 15.85 9.28e-09 534-547 superfamily signature III 846 IPBOO3160 p53-associated protein (MDM2) IPBOO3160A 14.23 8.Ole-09 82-129 847 IPB002642 Lysophospholipase catalytic domain IPB002642B 11.84 4.38e-15 1134-1158 IPB002642A 18.37 1.69e-13 1106-1131 847 PR00360 C2 domain signature II PR00360B 11.64 8.67e-12 839-852 IPB002642G 34.11 6.72e-10 1429-1477 847 IPBOOOOO8 C2 domain IPB00008C 23.37 2.44e-09 812-851 848 IPB002642 Lysophospholipase catalytic domain IPB002642B 11.84 4.38e-15 383-407 IPB002642A 18.37 1.69e-13 355-380 848 PR00360 C2 domain signature II PR00360B 11.64 8.67e-12 88-101 IPB002642G 34.11 6.72e-10 678-726 IPB002642E 18.19 6.91e-10 509-534 848 IPB00008 C2 domain IPBO00008C 23.37 2.44e-09 61-100 851 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 1.43e-13 203-240 histocompatibility complex domain 851 IPB003531 Short hematopoietin receptor family IPB00353 IC 15.87 9.38e-11 449-466 WO 2004/080148 PCT/US2003/030720 379 TABLE 3B IPBOO3006B 20.23 6.54e-09 81-118 852 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 1.43c-13 199-236 histocompatibility complex domain 852 IPB003531 Short hematopoietin receptor family IPB003531C 15.87 9.38e-11 445-462 1 IPBOO3006B 20.23 6.54e-09 77-114 854 IPBO0008 C2 domain IPB00008C 23.37 7.94e-25 306-345 IPB000008C 23.37 1.17e-16 173-212 854 PR00360 C2 domain signature II PR00360B 11.64 8.20e-14 200-213 PR00360A 15.18 1.60e-13 304-316 854 PR00399 Synaptotagmin signature II PR00399B 14.30 1.69e-12 291-304 IPB00008D 14.83 3.45e-11 229-247 IPB00008D 14.83 3.86e-11 361-379 PR00360B 11.64 5.94e-11 333-346 PR00399A 15.05 6.40e-11 145-160 PR00360A 15.18 8.36e-11 173-185 PR00399C 15.89 4.98e-10 348-363 PR00399D 12.72 6.33e-10 368-378 IPB00008C 23.37 9.76e-10 175-214 PR00399B 14.30 6.57e-09 160-173 PR00399A 15.05 8.65e-09 276-291 854 IPB002618 UTP--glucose-1-phosphate IPB002618D 29.24 9.88e-09 182-224 uridylyltransferase 855 IPB002870 Reprolysin family propeptide IPB002870B 24.73 3.78e-14 141-179 IPB002870E 11.90 4.67e-14 391-403 IPB002870F 18.81 7.00e-13 432-456 IPBOO2870D 16.31 6.62c-12 360-375 855 IPB001762 Disintegrin IPB001762A 23.93 1.40e-11 336-376 855 IPBOOO3O "Neutral zinc metallopeptidases, IPB000130 5.86 5.15e-I 389-399 zinc-binding region" 855 PR00480 Astacin family signature 11 PR00480B 14.35 4.54e-10 384-402 855 PR01303 Plasmodium circumsporozoite PRO1303D 10.57 4.71e-10 953-970 protein signature IV PRO1303D 10.57 2.75e-09 833-850 855 IPB001670 Iron-containing alcohol IPBOO1670D 13.90 5.50e-09 157-172 dehydrogenase IPB002870C 11.01 5.68e-09 317-327 PRO1303D 10.57 6.38e-09 552-569 855 IPBOO1862 Membrane attack complex IPB001862A 12.54 6.66e-09 540-555 components/perforin/complement C9 856 IPB003952 Fumarate reductase / succinate IPB003952A 6.70 8.00e-09 14-28 dehydrogenase FAD-binding site 857 PR00833 Pollen allergen Poa p1 signature VIII PR00833H 2.61 4.1 le-09 58-72 857 IPB002989 Mycobacterial pentapeptide repeats IPB002989C 13.82 8.67e-09 48-87 858 PR00833 Pollen allergen Poa pI signature VIII PR00833H 2.61 4.1 le-09 51-65 859 IPB001442 C-terminal tandem repeated domain IPB001442A 26.12 8.26e-26 254-306 in type 4 procollagen 859 IPB000885 Fibrillar collagen C-terminal domain IPBOO0885B 19.15 6.77e-24 265-318 IPB000885B 19.15 9.30e-24 247-300 IPB000885B 19.15 1.42e-23 244-297 1PB001442A 26.12 5.96e-23 257-309 IPB001442A 26.12 8.83e-23 266-318 IPB001442A 26.12 8.96e-23 239-291 IPB000885B 19.15 9.45 859 PRO1408 Macrophage scavenger receptor PRO1408H 14.32 5.76e-16 227-246 signature VIII 859 PR00258 Speract receptor signature I PR00258A 13.56 6.32e-16 333-349 IPB001442A 26.12 8.12e-16 272-324 IPB000885A 11.46 4.16e-15 255-292 IPBOO0885B 19.15 5.76e-15 274-327 WO 2004/080148 PCT/US2003/030720 380 TABLE 3B IPB000885A 11.46 5.86e-15 270-307 IPB001442A 26.12 7.88e-15 230-282 IPB000885A 11.46 2.87e-14 276-313 IPB000885B 19.15 3.43e-14 229-282 IPB000885B 19.15 4.13e-14 277-330 IPBOO0885A 11.46 5.44e-14 243-280 IPB000885A 11.46 7.78e-14 285-322 IPB000885B 19.15 7.88e-14 280-333 859 IPB001073 Complement Clq protein IPBOO1073A 22.14 8.40e-14 263-297 IPB000885B 19.15 5.21e-13 226-279 IPBOO1073A 22.14 5.79e-13 269-303 PR00258B 7.94 8.42e-13 352-363 IPB001442B 12.38 9.00e-13 270-290 IPB001442A 26.12 9.16e-13 227-279 IPBOO1073A 22.14 1.54e-1 859 IPB000817 Prion protein IPB000817A 8.34 5.85e-10 244-286 IPBOO1073A 22.14 6.80e-10 287-321 IPBOO0817A 8.34 8.22e-10 247-289 IPB0O 1442B 12.38 8.46e-10 246-266 IPB000885A 11.46 9.32e-10 234-271 IPB001442A 26.12 9.42e-10 284-336 1PB000885A 11.46 9.61e-10 288-325 IPB001442B 12.38 1.24e-09 264-284 IPBOO 1442A 26.12 1.63e-09 221-273 IPB001073A 22.14 2.83e-09 251-285 IPB001073A 22.14 3.53e-09 284-318 IPB001442B 12.38 4.65e-09 291-311 IPB001442B 12.38 4.77e-09 249-269 IPB001073A 22.14 5.64e-09 278-312 IPBOO0885A 11.46 5.87c-09 291-328 IPB0O1442B 12.38 6.1 le-09 273-293 IPB001442B 12.38 6.84e-09 294-314 IPBOO1073A 22.14 7.61e-09 239-273 860 IPB001442 C-terminal tandem repeated domain IPB001442A 26.12 8.26e-26 314-366 in type 4 procollagen 860 IPB000885 Fibrillar collagen C-terminal domain IPB000885B 19.15 4.52c-24 307-360 IPB000885B 19.15 6.77e-24 325-378 IPB000885B 19.15 1.69e-23 304-357 IPBOO 1442A 26.12 5.96e-23 317-369 IPBOO 1442A 26.12 6.35e-23 299-351 IPB001442A 26.12 8.83e-23 326-378 IPB000885B 19.15 1.26 860 PR01408 Macrophage scavenger receptor PR01408H 14.32 5.76e-16 287-306 signature VIII 860 PR00258 Speract receptor signature I PR00258A 13.56 6.32e-16 393-409 IPB001442A 26.12 8.12e-16 332-384 IPB000885A 11.46 4.16e-15 315-352 IPB000885B 19.15 5.76e-15 334-387 IPBOO0885A 11.46 5.86e-15 330-367 IPB000885B 19.15 7.35e-15 289-342 IPB001442A 26.12 7.88e-15 290-342 IPBOO0885A 11.46 2.87e-14 336-373 IPB000885B 19.15 4.13e-14 337-390 IPB000885A 11.46 5.91e-14 303-340 IPB000885A 11.46 7.78e-14 345-382 IPB000885B 19.15 7.88e-14 340-393 860 IPBOO1073 Complement CIq protein IPB001073A 22.14 8.40e-14 323-357 IPB000885B 19.15 5.70e-13 286-339 WO 2004/080148 PCT/US2003/030720 381 TABLE 3B IPBO0I073A 22.14 5.79e-13 329-363 IPB001442A 26.12 7.28e-13 287-339 PR00258B 7.94 8.42e-13 412-423 IPB001442B 12.38 9.00e-13 330-350 IPB001073A 22.14 1.54e-1 860 IPB000817 Prion protein IPBOO0817A 8.34 5.65e-10 304-346 IPB001073A 22.14 6.03e-10 311-345 IPBOO1073A 22.14 6.80e-10 347-381 PR00258C 9.05 7.15e-10 427-437 PR00258D 14.29 8.06e-10 458-472 IPBOO0817A 8.34 8.42e-10 307-349 1PB001442A 26.12 9.42e-10 344-396 IPB000885A 11.46 9.61e-10 348-385 IPBOO1073A 22.14 9.69e-10 299-333 IPB000885B 19.15 9.83e-10 283-336 IPB000885A 11.46 9.90e-10 294-331 IPB001442B 12.38 1.24e-09 324-344 IPB001442A 26.12 2.41e-09 281-333 IPB001442B 12.38 2.70e-09 309-329 IPBOO1073A 22.14 3.53e-09 344-378 IPB001442B 12.38 4.65e-09 351-371 IPBOO1073A 22.14 5.64e-09 338-372 IPB000885A 11.46 5.87e-09 351-388 IPB001442B 12.38 6.1le-09 333-353 IPB001442B 12.38 6.84e-09 354-374 PR01408B 9.21 9.84e-09 58-83 862 IPB000822 "Zinc finger, C2H2 type" IPBOO822 14.67 8.20e-22 222-247 IPB000822 14.67 5.09e-21 306-331 IPB000822 14.67 5.50e-20 474-499 IPB000822 14.67 7.00e-20 446-471 IPB000822 14.67 3.25e-19 390-415 IPB000822 14.67 4.00e-19 194-219 IPB000822 14.67 7.00e-19 278-303 IPB000822 14.67 4.46e-18 362-387 IPB000822 14.67 6.14e-17 250-275 IPB000822 14.67 3.40e-16 418-443 IPB000822 14.67 4.00e-16 334-359 862 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 5.85e-14 415-428 PROO048A 9.94 8.07e-13 219-232 PROO048A 9.94 3.12e-12 387-400 PROO048A 9.94 4.71e-12 247-260 PROO048A 9.94 4.71e-12 331-344 PROO048B 5.52 7.00e-12 487-496 862 TPB001275 DM DNA binding domain IPB001275 19.17 7.04e-12 266-305 PROO048A 9.94 7.88e-12 499-512 PROO048A 9.94 1.95e-11 471-484 PROO048A 9.94 4.32e-11 443-456 PROO048B 5.52 5.50e-11 319-328 PROO048A 9.94 1.00e-10 191-204 IPB001275 19.17 1.36e-10 294-333 1PB001275 19.17 1.49e-10 350-389 PR048A 9.94 5.09e-10 303-316 IPB001275 19.17 5.14e-10 378-417 862 IPB002817 ThiC family IPB002817H 11.39 5.42e-10 217-232 PROO048A 9.94 5.91e-10 359-372 IPB001275 19.17 8.18e-10 182-221 IPB001275 19.17 9.15e-10 322-361 PR048B 5.52 9.36e-10 375-384 WO 2004/080148 PCT/US2003/030720 382 TABLE 3B IPB001275 19.17 9.39e-10 210-249 IPB001275 19.17 9.39e-10 238-277 PR00048B 5.52 2.00e-09 207-216 IPB000822 14.67 2.13e-09 502-527 PROO048B 5.52 2.50e-09 459-468 IPB001275 19.17 2.71e-09 462-501 PR00048B 5.52 3.00e-09 403-412 IPB001275 19.17 3.62e-09 406-445 PROO048A 9.94 4.38e-09 275-288 862 IPB000306 "FYVE Zn-finger, IPB000306 8.96 4.71e-09 218-230 rabphilin/VPS27/FAB1 type" PROO048B 5.52 5.50e-09 291-300 IPB000306 8.96 5.76e-09 498-510 IPB000306 8.96 6.03e-09 302-314 PROO048B 5.52 7.00e-09 235-244 IPB002817H 11.39 7.34e-09 301-316 IPB001275 19.17 8.18e-09 434-473 862 IPB002634 BoIA-like protein IPB002634A 23.30 8.62e-09 243-277 864 IPBO00571 Zinc finger C-x8-C-x5-C-x3-H type IPB000571 11.41 6.54e-10 66-76 864 PR01218 Pistil-specific extensin-like signature PRO1218B 8.47 9.12e-09 140-163 II 865 PR00320 G protein beta WD-40 repeat PR00320B 12.82 5.68e-10 225-239 signature II PR00320A 13.15 7.48e-10 225-239 865 IPB001680 G-protein beta WD-40 repeats 1PB001680 10.43 4.15e-09 227-238 PROO320C 12.32 9.67e-09 225-239 867 IPB000954 Aminotransferase class-III pyridoxal- IPB000954B 21.02 9.25e-25 291-330 phosphate IPB000954A 20.25 7.12e-18 98-127 IPBOO0954D 13.61 5.74e-17 377-395 IPB000954C 12.88 9.44e-14 340-355 868 IPB000954 Aminotransferase class-III pyridoxal- IPB000954B 21.02 9.25e-25 188-227 phosphate IPB000954D 13.61 5.74e-17 274-292 IPB000954C 12.88 9.44e-14 237-252 869 IPB001254 "Serine proteases, trypsin family" IPB001254C 16.54 2.50e-17 270-289 869 IPB000177 Apple domain IPB0001770 14.39 1.11e-15 267-295 IPB001254A 9.98 6.14e-15 88-104 869 PR00722 Chymotrypsin serine protease family PR00722C 10.74 3.08e-14 236-248 (Sl) signature Ill PR00722A 12.06 4.54e-14 89-104 IPBOO1254B 15.01 7.14e-14 237-260 869 IPBOO0001 Kringle IPB00001D 11.31 7.56e-12 88-104 IPBOOOOO1H 12.24 2.50e-11 239-249 IPB000177N 10.17 3.23e-1l 229-263 IPBOO0177K 13.19 2.57e-10 90-122 PR00722B 12.69 6.85e-10 145-159 873 IPB001862 Membrane attack complex IPB001862F 29.39 6.19e-15 343-390 components/perforin/complement C9 873 PROO010 Type II EGF-like signature I PRO0O10A 12.91 4.94e-13 46-57 873 IPB000152 Aspartic acid and asparagine IPB000152 8.86 7.55e-13 541-556 hydroxylation site IPB001862F 29.39 8.07e-13 553-600 IPB001862F 29.39 9.14e-13 515-562 IPB001862F 29.39 3.07e-12 35-82 IPBOO1862F 29.39 3.79e-12 73-120 IPB001862F 29.39 4.10e-12 304-351 IPBOO0152 8.86 6.04e-12 61-76 IPB001862F 29.39 8.45e-12 477-524 IPB001862F 29.39 8.45e-12 1031-1078 IPB000152 8.86 3.89e-11 137-152 IPB0O I 862F 29.39 4.00e-1 1 153-200 IPB000152 8.86 4.86e-1 1 179-194 WO 2004/080148 PCT/US2003/030720 383 TABLE 3B IPB001862F 29.39 6.70e-11 381-428 PR00010C 6.98 7.38e-11 374-384 873 IPB001881 Calcium-binding EGF-like domain IPB001881B 12.28 7.63e-11 137-148 PRO01OC 6.98 9.25e-11 66-76 IPB001862F 29.39 9.50e-11 265-312 PROOO1OA 12.91 1.00e-10 564-575 IPB000152 8.86 1.84e-10 369-384 PROO010A 12.91 2.38e-10 354-365 IPB001862F 29.39 2.63e-10 111-158 PR00010A 12.91 2.73e-10 488-499 873 PR00764 Complement C9 signature VI PR00764F 15.74 2.92e-10 170-190 873 IPB000033 "Low-density lipoprotein (Idl) IPB00033B 7.05 3.03e-10 374-384 receptor, YWTD repeat" PR00764F 15.74 3.16e-10 52-72 PR00764F 15.74 3.52e-10 321-341 PROOO1OC 6.98 3.90e-10 546-556 IPBOO1881B 12.28 4.00e-10 541-552 IPB000152 8.86 4.66e-10 503-518 IPB001881A 8.72 4.86e-10 280-289 PROOO1OA 12.91 5.50e-10 122-133 873 IPB002899 EB module IPB002899B 11.81 5.59e-10 243-255 IPB000152 8.86 6.06e-10 407-422 IPB00033B 7.05 6.23e-10 296-306 IPB000152 8.86 6.63e-10 291-306 IPB001881A 8.72 7.43e-10 319-328 IPBOO1881A 8.72 7.43e-10 530-539 IPBOO1881A 8.72 8.07e-10 126-135 IPB001881B 12.28 8.29e-10 255-266 IPB000152 8.86 8.3 le-10 23-38 PR00764F 15.74 8.44e-10 360-380 PR00764F 15.74 8.44e-10 570-590 IPBOO1881A 8.72 9.36e-10 168-177 PR00764F 15.74 9.52e-10 398-418 IPB000152 8.86 9.72e-10 255-270 PROOO1OC 6.98 1.00e-09 296-306 IPBOO1881A 8.72 2.20e-09 1046-1055 873 PROOO1 Type III EGF-like signature II PROM011B 13.08 2.23e-09 63-81 IPBOO1881B 12.28 2.57e-09 179-190 IPBOO1881A 8.72 2.80e-09 358-367 873 IPB003884 Factor I membrane attack complex IPB003884C 13.00 2.83e-09 572-590 873 IPBOO0561 EGF-like domain 1PB000561 4.89 2.93e-09 626-634 PROO010C 6.98 3.63e-09 28-38 IPB000561 4.89 4.21e-09 378-386 873 IPB000359 Cystine-knot domain IPB000359A 23.24 4.33e-09 70-94 IPB000561 4.89 4.86e-09 108-116 IPB000359A 23.24 4.91e-09 108-132 PROOOOC 6.98 6.05e-09 184-194 IPBOO1881A 8.72 6.40e-09 50-59 873 IPB000034 Laminin B IPB000034C 12.97 6.49e-09 70-88 PROOO1OA 12.91 7.27e-09 164-175 PROO010A 12.91 7.27e-09 315-326 873 IPB001886 Laminin N-terminal (Domain VI) IPB001886C 24.54 7.40e-09 300-339 IPB000561 4.89 7.43e-09 223-231 IPB000561 4.89 7.43e-09 550-558 PRO00I0D 12.12 7.81e-09 371-389 IPB000152 8.86 8.11e-09 330-345 IPB000359A 23.24 8.24e-09 512-536 873 IPBO0006 "Vertebrate metallothionein, family IPBO0006 13.41 8.62e-09 75-120 1" PROO1C 6.98 8.68e-09 412-422 WO 2004/080148 PCT/US2003/030720 384 TABLE3B PR00764F 15.74 9.20e-09 282-302 IPB00033B 7.05 9.29e-09 546-556 IPB001862F 29.39 9.36e-09 591-638 IPB001881A 8.72 9.40e-09 568-577 PR00764F 15.74 9.43e-09 532-552 PROO010A 12.91 9.45e-09 526-537 PR00011D 12.12 9.74e-09 25-43 IPB00033B 7.05 1.00e-08 66-76 874 PR00960 LmbP protein signature I PR00960A 10.63 4.67e-09 78-93 875 IPB000043 S-adenosyl-L-homocysteine IPB00043D 24.21 1.00e-40 235-289 hydrolase IPB00043E 21.11 1.00e-40 298-350 IPB00043A 16.26 4.72e-33 119-156 IPB00043H 17.16 1.72e-29 459-493 IPB00043F 16.20 2.55e-24 351-377 IPB00043G 18.51 3.25e-24 411-448 IPB000043B 18.62 5.95e-23 158-191 IPB000043G 18.51 7.16e-15 412-449 IPB00043C 8.96 9.61e-15 202-216 878 IPB002181 Fibrinogen beta and gamma chains IPB002181B 20.16 7.49e-24 181-217 C-terminal globular domain IPB002181D 29.18 7.32e-15 243-283 IPBOO2181C 15.87 2.64e-10 222-234 879 IPB002181 Fibrinogen beta and gamma chains IPB002181B 20.16 7.49e-24 181-217 C-terminal globular domain IPB002181D 29.18 7.32e-15 243-283 IPB002181C 15.87 2.64e-10 222-234 880 IPBOO2181 Fibrinogen beta and gamma chains IPBOO2181B 20.16 7.49e-24 181-217 C-terminal globular domain IPBOO2181D 29.18 7.32e-15 243-283 IPBOO2181C 15.87 2.64e-10 222-234 883 IPB002027 Amino acid permease IPB002027D 22.00 4.13e-25 325-364 IPB002027C 19.67 2.74e-22 244-282 IPB002027A 18.88 3.77e-16 47-75 IPB002027B 12.67 7.97e-12 180-199 884 IPB001772 Kinase associated domain 1 IPB001772E 24.88 4.03e-10 620-659 884 IPB000861 PKN/rhophilin/rhotekin rho-binding IPB000861D 13.61 7.34e-10 97-133 repeat 884 IPB000961 Protein kinase C-terminal domain IPB000961A 16.82 8.45e-09 99-133 884 JPB003527 MAP kinase IPB003527D 21.53 9.15e-09 462-503 885 IPB001304 C-type lectin domain IPBOO1304A 17.98 8.04e-14 34-58 891 IPB003006 Immunoglobulin and major IPB003006B 20.23 1.72e-10 103-140 histocompatibility complex domain 891 PR00049 Wilm's tumour protein signature IV PROO049D 0.00 1.3le-09 155-169 PROO049D 0.00 6.80e-09 156-170 892 PR00503 Bromodomain signature IV PR00503D 19.24 3.57e-21 421-440 892 IPB001487 Bromodomain IPB001487B 17.44 2.13e-19 412-433 PR00503B 10.44 4.37e-19 94-110 IPB001487A 11.44 5.20e-19 95-113 PROO503C 19.09 4.00e-17 110-128 IPB001487A 11.44 9.53e-16 388-406 PR00503A 14.57 4.00e-14 78-91 PR00503B 10.44 8.64e-14 387-403 892 IPB001359 Synapsin IPBOO1359H 22.58 1.65e-13 752-802 PR00503D 19.24 9.25e-13 128-147 IPB001487B 17.44 1.58e-12 119-140 PROO503C 19.09 6.70e-11 403-421 892 PR00049 Wilm's tumour protein signature IV PR00049D 0.00 8.87e-11 755-769 PROO049D 0.00 9.47e-11 756-770 IPB001359H 22.58 9.70e-11 979-1029 892 PR00209 Alpha/beta gliadin family signature II PR00209B 4.73 4.80e-10 966-984 WO 2004/080148 PCT/US2003/030720 385 TABLE 3B 892 |PB003861 E4 protein IPB003861B 9.06 4.86e-10 979-993 892 IPB001505 "Cu(A) centre of cytochrome c IPBOO1505B 15.93 5.94e-10 406-455 oxidase, subunit II and nitrous oxide PR00209B 4.73 6.90e-10 968-986 reductase" IPBOO1359H 22.58 7.40e-10 753-803 892 PR01471 Histamine H3 receptor signature V PRO1471E 5.41 7.44e-10 765-780 IPB001359H 22.58 7.77e-10 962-1012 PR00209B 4.73 9.80e-10 752-770 IPBO01505A 18.04 1.17e-09 93-140 PROO049D 0.00 2.22e-09 748-762 IPB003861B 9.06 3.15e-09 763-777 PROO049D 0.00 3.29c-09 972-986 IPB001359H 22.58 3.88e-09 757-807 PR01471E 5.41 4.03e-09 981-996 PRO1471E 5.41 4.23e-09 1019-1034 IPB003861B 9.06 4.52e-09 754-768 892 IPB003351 Dishevelled specific domain IPBOO335IC 13.82 5.13e-09 485-524 IPB001359H 22.58 5.19e-09 941-991 PRO1471E 5.41 5.99e-09 755-770 PR00503A 14.57 6.8le-09 371-384 IPB001359H 22.58 7.03e-09 765-815 IPBOO1359H 22.58 7.03e-09 970-1020 892 PR01217 Proline rich extensin signature IV PRO1217D 4.57 7.49c-09 239-260 892 PRO1503 Treacher Collins syndrome protein PRO1503B 3.77 7.64e-09 702-715 Treacle signature [I 892 IPB000574 Tymovirus coat protein 1PB000574A 32.18 7.78e-09 254-301 892 PRO0910 Luteovirus ORF6 protein signature I PRO0910A 2.74 8.07e-09 255-267 IPB001359H 22.58 8.25e-09 978-1028 IPB001359H 22.58 8.5 le-09 193-243 IPBOO1359H 22.58 8.51e-09 745-795 IPBOO1359H 22.58 9.04e-09 754-804 892 IPB001978 Troponin IPB001978B 22.99 9.15e-09 530-561 PR00209B 4.73 9.90e-09 758-776 893 IPB03112 Olfactomedin-like domain IPBOO3112C 13.54 4.69e-33 343-383 IPBOO3112E 16.12 5.24e-33 416-458 IPBOO3112B 14.91 6.65e-27 269-320 IPBOO3112D 17.44 9.58e-23 384-410 IPB003112A 14.44 2.97e-13 230-245 893 PR01444 Latrophilin receptor signature V PR01444E 11.17 7.70e-12 346-361 893 PR00952 Type III secretion system inner PR00952C 21.25 2.04e-09 7-29 membrane Q protein family signature III 893 IPB002862 Protein of unknown function DUF16 IPB002862C 11.30 9.59e-09 80-102 894 IPB002350 Kazal-type serine protease inhibitor IPB002350 31.78 4.12e-21 92-132 family 894 PR00290 Kazal-type serine protease inhibitor PR00290A 13.80 3.61e-12 92-102 signature I 894 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 1.36e-10 390-427 histocompatibility complex domain 894 PR00450 Recoverin family signature III PR00450C 11.99 5.04e-09 182-203 895 IPBOO1511 Aminotransferases class-I IPBOO1511B 11.54 3.14e-11 177-191 895 PR00753 1-aminocyclopropane-1-carboxylate PR00753B 10.09 9.22e-11 171-195 synthase signature V IPBOO151 IC 12.45 9.07e-10 243-256 896 IPB001781 LIM domain IPB001781 11.42 3.37c-12 102-112 IPB001781 11.42 2.04e-10 173-183 IPB001781 11.42 4.60e-09 43-53 IPB001781 11.42 7.90e-09 231-241 896 IPB003452 Stem cell factor IPB003452C 13.68 9.29e-09 525-558 WO 2004/080148 PCT/US2003/030720 386 TABLE 3B 897 IPB000961 Protein kinase C-terminal domain IPB000961D 21.23 5.29e-29 512-553 897 IPB001772 Kinase associated domain 1 IPB001772B 18.27 4.79e-24 409-454 897 IPB0O1245 Tyrosine kinase catalytic domain IPB001245B 21.68 2.80e-19 516-554 897 IPB000861 PKN/rhophilin/rhotekin rho-binding IPB000861G 13.73 9.60e-16 518-567 repeat 897 IPB000959 POLO box duplicated region IPB000959C 23.49 8.03e-15 491-543 897 IPB003527 MAP kinase IPB003527G 17.26 8.94e-15 586-623 IPB001772E 24.88 2.25e-14 574-613 IPB000961B 17.79 2.37e-14 412-443 IPB001245A 22.45 6.88e-14 460-500 IPB000961A 16.82 7.75e-14 355-389 IPB001772C 20.66 9.62e-14 455-485 IPB001772D 21.67 4.73e-13 523-562 IPB000959B 15.68 3.18e-11 444-484 IPB001772A 13.64 5.22e-11 353-384 IPB003527D 21.53 6.02e-11 509-550 IPB00086 1E 16.40 9.36e-11 399-444 897 IPB000095 PAK-box /P2 1-Rho-binding IPB00095F 16.47 9.65e-10 520-574 IPB003527C 14.70 2.54e-09 452-500 IPBOO0861D 13.61 2.99e-09 353-389 IPBOO0961C 15.48 3.45e-09 467-501 897 PROO 109 Tyrosine kinase catalytic domain PROO109B 11.07 3.8le-09 467-485 signature 11 IPB000959D 27.01 5.3 1e-09 567-619 IPBOO0959A 7.12 7.62e-09 356-368 898 IPB000961 Protein kinase C-terminal domain IPBOO0961D 21.23 5.29e-29 699-740 898 IPB001772 Kinase associated domain 1 IPB001772B 18.27 4.79e-24 596-641 898 IPB001245 Tyrosine kinase catalytic domain IPB001245B 21.68 2.80e-19 703-741 898 IPB000861 PKN/rhophilin/rhotekin rho-binding IPBOO0861G 13.73 9.60e-16 705-754 repeat 898 IPB000959 POLO box duplicated region IPBOO0959C 23.49 8.03e-15 678-730 898 IPB003527 MAP kinase IPB003527G 17.26 8.94e-15 773-810 IPB001772E 24.88 2.25e-14 761-800 IPBOO0961B 17.79 2.37e-14 599-630 IPB001245A 22.45 6.88e-14 647-687 IPBOO0961A 16.82 7.75e-14 542-576 JPB001772C 20.66 9.62e-14 642-672 IPBOO 1772D 21.67 4.73e-13 710-749 898 IPB003533 Doublecortin IPB003533F 11.80 5.30e-12 161-194 IPB000959B 15.68 3.18e-11 631-671 IPB001772A 13.64 5.22e-11 540-571 IPB003527D 21.53 6.02e-11 696-737 IPBOO0861E 16.40 9.36e-11 586-631 898 IPB000095 PAK-box /P21-Rho-binding IPB00095F 16.47 9.65e-10 707-761 IPB003527C 14.70 2.54e-09 639-687 IPBOO0861D 13.61 2.99e-09 540-576 IPBOO0961C 15.48 3.45e-09 654-688 898 PROO109 Tyrosine kinase catalytic domain PROO109B 11.07 3.81e-09 654-672 signature 11 IPB000959D 27.01 5.31e-09 754-806 IPBOO0959A 7.12 7.62e-09 543-555 IPB003533E 7.28 8.25e-09 105-144 900 IPB001073 Complement Clq protein IPBOO1073B 20.88 6.00e-26 131-165 IPB001073A 22.14 4.48e-20 85-119 900 IPB000885 Fibrillar collagen C-terminal domain IPB000885B 19.15 9.63e-20 54-107 900 IPB001442 C-terminal tandem repeated domain IPB001442A 26.12 4.27e-19 55-107 in type 4 procollagen IPB000885B 19.15 7.48e-19 60-113 IPBOO0885A 11.46 1.97e-18 62-99 IPB0885A 11.46 2.94e-18 68-105 WO 2004/080148 PCT/US2003/030720 387 TABLE 3B 900 PR0007 Complement C1Q domain signature PR0007C 16.13 3.67e-18 199-220 III IPB001442A 26.12 1.1le-17 64-116 PR0007A 20.64 1.84e-17 124-150 IPB001442A 26.12 1.87e-17 70-122 IPB000885B 19.15 5.39e-17 57-110 IPB000885A 11.46 6.96e-17 65-102 IPB000885B 19.15 8.87e-17 51 900 IPB000817 Prion protein IPBOO0817A 8.34 3.27e-09 51-93 IPB000885A 11.46 3.66e-09 19-56 IPB001442A 26,12 4.13e-09 12-64 IPB000885B 19.15 4.19e-09 26-79 IPB000885A 11.46 4.77e-09 86-123 IPB001442A 26.12 4.83e-09 24-76 IPB001442B 12.38 5.99e-09 37-57 IPB001442A 26.12 6.17e-09 21-73 1PB000885B 19.15 7.55e-09 36-89 IPB001442B 12.38 7.57e-09 71-91 IPB001442A 26.12 8.36e-09 9-61 IPB001442B 12.38 8.54e-09 89-109 IPBOO1073A 22.14 8.59e-09 30-64 IPB000885B 19.15 8.69e-09 78-131 IPB001442B 12.38 9.64e-09 74-94 901 IPB000074 Apolipoprotein A1/A4/E IPB00074A 11.45 9.84e-09 7-24 902 IPB002360 Involucrin IPB002360C 15,36 3.06e-14 407-448 902 PR00209 Alpha/beta gliadin family signature II PR00209B 4.73 5.94e-12 427-445 902 IPB000135 High mobility group proteins HMGI IPBOO0135D 2.13 8.67e-11 183-207 and HMG2 IPBOO0135D 2.13 2.96e-10 184-208 902 IPB001580 Calreticulin family IPBOO158OF 2.93 4.94e-10 189-198 IPBOO158OF 2.93 4.94e-10 190-199 IPBOO158OF 2.93 4.94e-10 191-200 IPB002360C 15.36 5.93e-10 416-457 IPBOO0135D 2.13 7.46e-10 186-210 IPBOO0135D 2.13 7.46e-10 187-211 IPBOO0135D 2.13 9.22e-10 185-209 IPB002360C 15.36 2.50e-09 396-437 IPB002360C 15.36 2.50e-09 415-456 IPBOO0135D 2.13 3.55e-09 182-206 IPBOO0135D 2.13 4.27e-09 188-212 IPBOO0135D 2.13 4.91e-09 181-205 902 IPB001359 Synapsin IPBOO1359H 22.58 5.19e-09 421-471 IPB002360C 15.36 5.20e-09 404-445 902 IPB001422 Neuromodulin (GAP-43) IPB001422C 16.82 5.61e-09 184-219 IPB002360C 15.36 5.70e-09 413-454 IPB002360C 15.36 6.10e-09 389-430 902 IPB003753 "Exonuclease VII, large subunit" IPB003753F 28.29 7.54e-09 382-432 IPB002360C 15.36 8.80e-09 419-460 905 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 5.50e-13 37-51 domain 905 PROO019 Leucine-rich repeat signature I PROO019A 11.72 9.33e-10 5-18 906 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 8.83e-11 55-92 histocompatibility complex domain 908 PR00457 Animal haem peroxidase signature V PR00457E 19.97 8.45c-24 1041-1067 PR00457D 18.35 1.53e-20 1016-1036 PR00457C 18.81 9.42e-15 998-1016 PR00457G 14.17 4.48e-14 1221-1241 PR00457H 14.82 5.85e-13 1292-1306 PR00457F 14.42 6.32e-12 1094-1104 WO 2004/080148 PCT/US2003/030720 388 TABLE3B 908 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 1.00e-10 156-170 domain PR00457B 12.43 2.29e-10 846-861 908 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 2.80e-10 352-389 histocompatibility complex domain IPBOO3006B 20.23 8.92e-10 448-485 IPB003006B 20.23 9.28e-10 259-296 909 PR00457 Animal haem peroxidase signature V PR00457E 19.97 8.45e-24 1072-1098 PR00457D 18.35 1.53e-20 1047-1067 PR00457C 18.81 9.42e-15 1029-1047 PR00457G 14.17 4.48e-14 1252-1272 PR00457H 14.82 5.85e-13 1323-1337 PR00457F 14.42 6.32e-12 1125-1135 909 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 1.00e-10 187-201 domain PR00457B 12.43 2.29e-10 877-892 909 IPB003006 Immunoglobulin and major IPB003006B 20.23 2.80e-10 383-420 histocompatibility complex domain IPB003006B 20.23 8.92e-10 479-516 IPB003006B 20.23 9.28e-10 290-327 910 PR00457 Animal haem peroxidase signature V PR00457E 19.97 8.45e-24 934-960 PR00457D 18.35 1.53e-20 909-929 PR00457C 18.81 9.42e-15 891-909 PR00457G 14.17 4.48e-14 1114-1134 PR00457H 14.82 5.85e-13 1185-1199 PR00457F 14.42 6.32e-12 987-997 PR00457B 12.43 2.29e-10 739-754 910 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 2.80e-10 329-366 histocompatibility complex domain IPBOO3006B 20.23 8.92e-10 425-462 IPBOO3006B 20.23 9.28e-10 236-273 910 PROO019 Leucine-rich repeat signature II PROO019B 11.42 6.73e-09 73-86 911 PR00010 Type 11 EGF-like signature I PRO001OA 12.91 7.75e-13 43-54 911 IPB001862 Membrane attack complex IPB001862F 29.39 5.45e-12 925-972 components/perforin/complement C9 IPB001862F 29.39 7.21e-12 559-606 911 IPB000152 Aspartic acid and asparagine IPB000152 8.86 7.48e-12 117-132 hydroxylation site PR0001OA 12.91 1.00e-11 102-113 PROOO1OA 12.91 4.27e-11 168-179 911 IPB000561 EGF-like domain IPB000561 4.89 8.00e-11 88-96 IPB001862F 29.39 8.70e-11 846-893 911 IPB000359 Cystine-knot domain IPB000359A 23.24 2.71e-10 843-867 PROO010C 6.98 3.61e-10 122-132 911 IPB001881 Calcium-binding EGF-like domain IPB001881A 8.72 4.21e-10 574-583 IPB000152 8.86 4.66e-10 183-198 IPB000561 4.89 4.75e-10 126-134 IPBOO1881A 8.72 6.79e-10 940-949 PROO1C 6.98 7.lOe-10 877-887 PROO1C 6.98 7.68e-10 230-240 PROOIOC 6.98 1.22e-09 590-600 911 PR00764 Complement C9 signature VI PR00764F 15.74 1.34e-09 942-962 IPB001881B 12.28 1.78e-09 183-194 PR00764F 15.74 3.28e-09 576-596 IPB000359A 23.24 3.35e-09 88-112 IPB000561 4.89 4.21e-09 881-889 IPBOO152 8.86 4.79e-09 834-849 IPB001862F 29.39 6.23e-09 91-138 IPB001881A 8.72 7.00e-09 106-115 IPBOO1881B 12.28 7.65e-09 117-128 PROOIOC 6.98 7.80e-09 84-94 911 IPB000033 "Low-density lipoprotein (ldl) IPB00033B 7.05 8.34e-09 877-887 receptor, YWTD repeat" IPB000152 8.86 8.58e-09 872-887 911 IPB003884 Factor I membrane attack complex IPB003884F 16.26 8.71e-09 177-192 WO 2004/080148 PCT/US2003/030720 389 TABLE 3B 913 IPB002151 Kinesin light chain repeat IPB00215 1B 14.23 8.Ole-10 240-292 913 1PB000421 Coagulation factor 5/8 type C IPBOO0421A 21.21 7.85e-09 43-62 domain (FA58C) 913 IPB002360 Involucrin IPB002360C 15.36 8.00e-09 373-414 914 IPBOO3117 Regulatory subunit of type II PICA R- IPBOO3117C 17.01 1.00e-40 147-187 subunit IPB003117D 18.87 1.00e-40 198-238 IPBOO3117G 17.45 8.50e-33 341-375 IPBOO3117A 22.23 5.50e-26 24-56 IPB003117E 18.84 5.85e-23 287-315 914 IPB000595 Cyclic nucleotide-binding domain IPBOO0595C 23.31 6.82e-21 321-346 914 PROO103 cAMP-dependent protein kinase PROD103B 10.32 7.00e-18 173-187 signature II IPB000595B 15.72 7.50e-18 279-302 IPB003117F 17.26 1.00e-17 323-337 IPB000595B 15.72 4.43e-16 161-184 PROO103A 9.07 7.75e-16 158-172 IPBOO3117C 17.01 2.96e-15 265-305 IPBOO3117D 18.87 4.14e-15 322-362 PROO103E 12.91 5.91e-14 355-367 PROO103D 10.18 2.93e-13 334-345 IPBOO0595C 23.31 4.60e-13 197-222 PROO103C 13.28 1.84e-11 322-331 PROO103D 10.18 2.98e-10 210-221 IPBOO3117E 18.84 3.57e-10 157-185 IPBOO3117E 18.84 5.43e-10 275-303 IPBOO3117F 17.26 1.50e-09 199-213 PROO103A 9.07 8.11e-09 276-290 915 IPB001478 PDZ domain (also known as DHR or 1PB001478B 6.12 4.94e-09 602-611 GLGF) 916 IPB000907 Lipoxygenase IPBOO0907J 20.31 5.50e-37 521-563 IPBOO0907G 22.23 1.87e-34 371-413 IPBOO0907F 21.29 1.00e-28 338-370 IPBOO0907I 27.52 9.79e-28 460-513 916 PR00467 Mammalian lipoxygenase signature PR00467F 12.25 9.41e-22 418-440 VI 916 PR00087 Lipoxygenase signature III PROO087C 13.32 1.39e-21 373-393 IPB000907C 16.09 7.17e-21 221-247 IPBOO0907E 15.16 1.O0e-18 296-320 PR00467E 9.17 2.10e-17 293-312 PR00467D 17.16 9.57e-17 196-217 IPBOO0907D 18.70 2.67e-16 262-289 PROO087A 20.06 3.52e-15 335-352 PROO087B 13.69 5.11e-15 353-370 IPBOO0907B 14.10 2.50e-13 160-175 PR00467A 8.38 3.29e-13 11-28 IPBOO0907H 18.37 5.86e-13 434-450 PR00467B 14.98 5.88e-12 57-76 PR00467G 16.61 3.37e-11 576-593 IPBOO0907A 16.20 4.21e-10 94-103 PR00467C 9.34 7.65e-10 134-148 917 1PB000907 Lipoxygenase IPBOO0907C 16.09 7.17e-21 194-220 IPBOO0907E 15.16 1.00e-18 269-293 917 PR00467 Mammalian lipoxygenase signature PR00467E 9.17 2.1Oc-17 266-285 V PR00467D 17.16 9.57e-17 169-190 IPBOO0907D 18.70 2.67e-16 235-262 IPBOO0907B 14.10 2.50e-13 131-146 PR00467A 8.38 3.29e-13 11-28 PR00467B 14.98 5.88e-12 57-76 IPBOO0907A 16.20 4.21e-10 94-103 WO 2004/080148 PCT/US2003/030720 390 TABLE 3B 918 IPB000907 Lipoxygenase IPBOO0907C 16.09 7.17e-21 223-249 IPBOO0907E 15.16 1.00e-18 298-322 918 PR00467 Mammalian lipoxygenase signature PR00467B 9.17 2. lOe-17 295-314 V PR00467D 17.16 9.57e-17 198-219 IPB000907D 18.70 2.67e-16 264-291 IPB000907B 14.10 2.50e-13 160-175 PR00467A 8.38 3.29e-13 11-28 PR00467B 14.98 5.88e-12 57-76 IPBOO0907A 16.20 4.21e-10 94-103 PR00467C 9.34 7.65e-10 134-148 927 IPB001774 Delta serrate ligand IPB001774C 18.25 1.71e-31 37-79 IPB001774D 19.23 3.32e-25 83-129 927 PR00011 Type III EGF-like signature IV PROW1 ID 12.12 4.57e-12 39-57 927 IPB000152 Aspartic acid and asparagine IPB000152 8.86 1.00e-10 189-204 hydroxylation site IPB001774C 18.25 2.15e-10 68-110 927 PR00010 Type II EGF-like signature III PROO010C 6.98 3.90e-10 113-123 927 IPB000359 Cystine-knot domain IPB000359A 23.24 4.86e-10 160-184 927 IPB000034 Laminin B IPB000034C 12.97 6.42e-10 236-254 PR00011B 13.08 7.88e-10 39-57 927 IPB000561 EGF-like domain IPB000561 4.89 9.25e-10 46-54 927 IPB001886 Laminin N-terminal (Domain VI) IPB001886E 10.90 9.67e-10 44-60 PR00010A 12.91 1.27e-09 174-185 PRO0010C 6.98 2.54e-09 194-204 927 IPBOO1862 Membrane attack complex IPB001862F 29.39 2.65e-09 201-248 components/perforin/complement C9 IPB000152 8.86 6.21e-09 108-123 PR00011A 14.05 6.88e-09 39-57 927 PR01217 Proline rich extensin signature VII PRO1217G 4.02 7.79e-09 252-277 IPB001862F 29.39 8.53e-09 163-210 IPB00034A 22.21 9.00e-09 96-131 IPBOO0152 8.86 9.29e-09 227-242 927 IPB001762 Disintegrin IPB001762A 23.93 9.65e-09 126-166 928 PR00456 Ribosomal protein P2 signature V PR00456E 3.08 7.80e-09 1-15 930 IPBOO1248 "Permeases for cytosine/purines, IPB001248A 28.27 5.94e-10 238-273 uracil, thiamine, allantoin" 930 IPB000390 "Integral membrane protein, DUF7" IPBOO0390B 26.91 6.96e-10 217-271 931 IPB001359 Synapsin IPB001359H 22.58 9.63e-10 47-97 932 PR00336 Lysosome-associated membrane PR00336D 10.26 5.99e-09 2-24 glycoprotein signature IV 933 IPB002467 "Methionine aminopeptidase, IPB002467C 17.56 2.29e-30 169-197 subfamily 1" IPB002467B 12.68 2.50e-23 143-164 IPB002467F 18.38 1.71e-21 299-329 933 PR00599 Methionine aminopeptidase-1 PR00599B 10.21 8.00e-17 173-189 signature II IPB002467D 14.78 5.50e-15 242-267 PR00599A 11.84 9.63e-14 151-164 IPB002467E 11.05 7.75e-12 275-287 PR00599D 14.43 5.03e-10 273-285 IPB002467A 15.75 2.87e-09 115-132 933 IPB001131 Proline dipeptidase IPB001131D 11.56 5.18e-09 275-288 IPB001131B 18.96 8.10e-09 173-194 934 IPB001463 Sodium:alanine symporter family IPBOO1463A 16.70 5.87e-09 174-224 938 IPB001478 PDZ domain (also known as DHR or IPB001478A 11.55 5.09e-09 119-129 GLGF) IPB001478B 6.12 1.00e-08 137-146 940 PR01286 Orphan nuclear receptor NOR1 PR01286E 5.27 9.26e-09 307-328 signature V 941 IPB000998 MAM domain IPB000998D 18.66 1.96e-15 527-550 941 IPB003886 Extracellular domain in nidogen IPB003886D 13.91 8.77e-15 237-256 941 IPB000152 Aspartic acid and asparagine IPB000152 8.86 2.89e-14 110-125 WO 2004/080148 PCT/US2003/030720 391 _____TABLE 3B hydroxylation site 941 IPBOO1881 Calcium-binding EGF-like domain IPBOO1881B 12.28 5.00e-14 192-203 IPB000152 8.86 1.00e-13 237-252 IPB000152 8.86 1.82e-13 192-207 IPBOO1881B 12.28 4.75e-13 110-121 941 IPB001774 Delta serrate ligand IPB001774C 18.25 9.13e-13 72-114 _______IPB000998B 17.20 1 .00e- 12 410-422 941 PROO020 MAM domain signature I PROO020A 20.48 2.88e- 11408-426 IPB000998C 18.63 5.30e- 11 464-479 IPBOO1881B 12.28 8.58e- 1237-248 941 PR00907 Thrombomodulin signature II PROO907B 11.50 2.44e-10 144-160 941 IPB000561 EGF-like domain IPB000561 4.89 3.25e-10 81-89 941 IPB000033 "Low-density lipoprotein (Idl) IPBOO0033B 7.05 5.35e-10 242-252 receptor, YWTD repeat" IPBOO0033B 7.05 5.97e-09 197-207 941 IPB000167 Dehydrin IPBOO0167A 8.58 7.14e-09 324-351 941 IPB003367 Thrombospondin type 3 repeat IPB003367A 11.78 9.79e-09 159-179 942 IPB000998 MAM domain IPB000998D 18.66 1.96e-15 532-555 942 IPB003886 Extracellular domain in nidogen IPB003886D 13.91 8.77e-15 242-261 942 IPB000152 Aspartic acid and asparagine IPBOO0152 8.86 2.89e-14 115-130 hydroxylation site 9_42 IPB01881 Calcium-binding EGF-like domain IPBOO1881B 12.28 5.00e-14 197-208 IPBOO0152 8.86 1.00e-13 242-257 IPBOO0152 8.86 1.82e-13 197-212 IPB001881B 12.28 4.75e-13 115-126 942 IPBO01774 Delta serrate ligand IPB001774C 18.25 9.13e-13 77-119 IPB000998B 17.20 1.00e-12 415-427 942 PROOOO MAM domain signature I PROO020A 20.48 2.88e-11 413-431 IPB000998C 18.63 5.30e-11 469-484 IPBOO1881B 12.28 8.58e-11 242-253 942 PR00907 Thrombomodulin signature 11 PR00907B 11.50 2.44e-10 149-165 942 IPB000561 EGF-like domain IPB000561 4.89 3.25e-10 86-94 9 42 IPBOO0033 "Low-density lipoprotein (Idi) IPBO0033B 7.05 5.35e-10 247-257 receptor, YWTD repeat" _____________________ 942 PR01256 OtxlI transcription factor -signature 11 PR01256B 5.92 2.Ole-09 23-35 IPBO0033B 7.05 5.97e-09 202-212 _____PRO0I256B 5.92 6.46e-09 24-3 6 942 1PB000167 Dehydrin IPBOO0167A 8.58 7.14e-09 329-356 942 IPB0D3367 Thrombospondin type 3 repeat IPB003367A 11.78 9.79e-09 164-184 94.3 IPB002893 MYND zinc finger (ZnF) domain IPB002893 16.28 4.52e-17 986-1004 943 IPBOO0313 PWWP domain IPBOO0313A 8.15 6.88e-15 276-290 943 IPB001487 Bromodomain IPB001487B 17.44 1.32e-13 202-223 IPB001487A 11.44 9.33e-12 178-196 943 IPB002219 Phorbol esters/diacyiglycerol binding IPB002219B 12.53 5.14e-10 94-109 domain 943 PR00503 Bromodomain signature 11 PR00503B 10.44 7.38e-09 177-193 943 IPB002889 WSC domain IPB002889C 9.89 8.12-09 762-783 IPB002889B 11.76 9.9e-09 744-790 944 IPB000313 PWWP domain IPBOO0313A 8.15 6.88e-15 276-290 944 IPB001487 Bromodomain IPB0051487 17.44 1.32e-13 202-223 ______________________IPBOO1487A 11.44 9.33e-12 178-196 944 1PB002219 Phorbol esters/diacylglycerol binding IPB002219B 12.53 5.14e-10 94-109 domain 944 PR00503 Bromodomain signature II PR0153B 10.44 7.38e-09 177-9-3 945 IPB002893 MYND zinc finger (ZnF) domain IPB002893 16.28 4.52e-17 1032-1050 945 IPB000313 PWWP domain IPBOO0313A 8.15 6.88e-15 276-290 945 IPB001487 Bromodomain IPB001487B 17.44 1.32e-13 202-223 94PB401487A 11.44 9.33e-12 178-196 WO 2004/080148 PCT/US2003/030720 392 TABLE 3B 945 IPB002219 Phorbol esters/diacylglycerol binding IPB002219B 12.53 5.14e-10 94-109 domain 945 PR00503 Bromodomain signature II PR00503B 10.44 7.38e-09 177-193 945 IPB002889 WSC domain IPB002889C 9.89 8.12e-09 762-783 IPB002889B 11.76 9.91e-09 744-790 946 IPB002893 MYND zinc finger (ZnF) domain IPB002893 16.28 4,52e-17 1037-1055 946 IPB000313 PWWP domain IPBOOO313A 8.15 6.88e-15 281-295 946 IPB001487 Bromodomain IPB001487B 17.44 1.32e-13 207-228 IPB001487A 11.44 9.33e-12 183-201 946 IPB002219 Phorbol esters/diacylglycerol binding IPB002219B 12.53 5.14e-10 99-114 domain 946 PR00503 Bromodomain signature II PR00503B 10.44 7.38e-09 182-198 946 IPB002889 WSC domain IPB002889C 9.89 8.12e-09 767-788 IPB002889B 11.76 9.91e-09 749-795 950 PR00169 Potassium channel signature VII PROO169G 11.30 5.96e-11 467-489 950 PR01333 Two pore domain K+ channel PR01333A 18.74 7.08e-10 479-507 signature I PR01333B 10.39 5.95e-09 482-491 950 PR00206 Connexin signature VI PR00206F 15.67 6.0 le-09 498-521 951 IPB001762 Disintegrin IPB001762A 23.93 4.33e-23 441-481 951 IPB002870 Reprolysin family propeptide IPB002870B 24.73 3.54e-20 114-152 951 PR00289 Disintegrin signature I PR00289A 14.29 1.16e-14 457-476 IPB002870F 18.81 3.03e-14 385-409 IPB002870E 11.90 2.46e-12 344-356 IPB001762B 10.06 3.40e-12 488-498 IPB001762A 23.93 9.20e-11 409-449 951 IPBOO0130 "Neutral zinc metallopeptidases, IPB000130 5.86 1.56e-10 342-352 zinc-binding region" 951 PR00138 Matrixin signature IV PROO138D 14.57 2.54e-10 342-367 1PB002870D 16.31 4.77e-10 310-325 951 PR00480 Astacin family signature II PR00480B 14.35 5.57e-10 337-355 951 PR00436 Interleukin-8 signature I PR00436A 15.20 7.43e-10 5-28 951 IPB001818 Matrixin IPBOO1818D 14.91 1.72e-09 336-367 PR00289B 11.74 3.80e-09 486-498 IPB002870A 12.22 6.54e-09 68-84 951 PR01236 Tumour necrosis factor beta PR01236A 4.92 7.49e-09 17-33 (lymphotoxin-alpha) signature I IPB002870C 11.01 9.64e-09 278-288 953 IPB000906 ZU5 domain IPBOO0906E 22.11 5.55e-l 248-288 953 PR01415 Ankyrin repeat signature I PRO1415A 12.73 6.46e-11 251-263 IPBOO0906D 23.89 6.59e-11 316-370 PRO1415A 12.73 7.1le-11 184-196 PRO1415A 12.73 7.43e-11 152-164 IPB000906F 35.93 5.85e-10 194-247 PRO1415B 10.23 5.88e-09 263-275 IPBOO0906G 25.85 6.69c-09 330-378 953 PR00898 Vasopressin V2 receptor signature II PR00898B 4.91 7.69e-09 46-60 IPBOO0906A 22.49 7.84e-09 177-219 954 IPB000471 "Interferon alpha, beta and delta IPBOO0471A 27.36 3.61e-32 45-98 family" 954 PR00266 Interferon alpha and beta subunit PR00266A 13.41 9.59e-14 67-79 signature 1 955 PR01136 Gap junction alpha-6 protein (Cx45) PROI136A 6.68 5.05e-09 203-209 signature I 956 PROOO81 Glucose/ribitol dehydrogenase family PROOO8F 13.94 5.50e-13 152-172 signature VI PROO081A 10.07 5.67e-13 34-51 PR00081B 8.91 5.66e-11 108-119 956 PR01397 "2,3-dihydro-2,3-dihydroxybenzoate PR01397F 12.91 9.53e-11 168-187 dehydrogenase signature VI" WO 2004/080148 PCT/US2003/030720 393 TABLE 3B 956 PR00080 Short-chain dehydrogenase/reductase PRO0080A 7.98 3.73e-09 108-119 (SDR) superfamily signature I PR01397A 13.33 4.65e-09 39-56 958 IPB000560 Histidine acid phosphatase IPB000560 17.02 7.55e-13 30-52 958 PR00885 Bacterial general secretion pathway PROO885B 8.16 9.14e-10 394-408 protein H signature II 958 PR01319 Glial cell line-derived neurotrophic PRO1319A 3.85 3.93e-09 10-22 factor receptor alpha 3 signature I 959 IPB000215 Serpins IPBOO0215D 15.35 7.00e-22 224-250 IPBOO0215E 15.36 6.06e-18 305-329 IPBOO0215C 13.90 4.75e-17 122-136 IPBOO0215B 9.87 3.84c-12 95-107 960 IPB000215 Serpins IPBOO0215D 15.35 7.00e-22 292-318 IPBOO0215A 13.01 4.18e-20 73-96 IPBOO0215E 15.36 6.06e-18 373-397 IPBOO0215C 13.90 5.82e-11 190-204 961 IPB000215 Serpins IPBOO0215D 15.35 7.00e-22 292-318 IPBOO0215A 13.01 4.18e-20 73-96 IPBOO0215E 15.36 6.06e-18 373-397 IPB000215C 13.90 4.75e-17 190-204 IPB000215B 9.87 3.84c-12 163-175 962 IPBOO0215 Serpins IPBOO0215A 13.01 4.18e-20 73-96 IPBOO0215E 15.36 6.06e-18 373-397 IPB000215C 13.90 4.75c-17 208-222 IPB000215B 9.87 3.84e-12 181-193 964 IPB001762 Disintegrin IPB001762A 23.93 4.33e-23 457-497 964 IPB002870 Reprolysin family propeptide IPB002870F 18.81 2.35e-19 402-426 IPB002870E 11.90 3.37e-16 366-378 IPB002870B 24.73 8.16e-16 145-183 964 IPB000135 High mobility group proteins HMG1 IPBOO0135D 2.13 8.05e-14 789-813 and HMG2 964 PR00289 Disintegrin signature I PR00289A 14.29 2.80e-13 473-492 IPBOO0135D 2.13 6.08e-13 788-812 IPBOO0135D 2.13 9.08e-13 785-809 IPBOO0135D 2.13 2.30e-12 786-810 IPBOO0135D 2.13 6.10e-12 787-811 IPBOO0135D 2.13 6.75e-12 790-814 964 IPB001580 Calreticulin family IPBOO158OF 2.93 5.50e-1 1 794-803 IPB002870A 12.22 8.80e-11 100-116 IPB000135D 2.13 3.64e-10 783-807 IPB001762B 10.06 4.86e-10 504-514 IPB001580F 2.93 4.94e-10 801-810 IPBOO158OF 2.93 4.94e-10 802-811 IPBOO0135D 2.13 6.09e-10 784-808 IPB0135D 2.13 9.71e-10 782-806 IPB002870D 16.31 9.71e-10 332-347 IPBOO158OF 2.93 1.00e-09 798-807 964 IPBOO0130 "Neutral zinc metallopeptidases, IPBOO0130 5.86 1.86e-09 364-374 zinc-binding region" PR00289B 11.74 1.89e-09 502-514 IPB002870C 11.01 3.16e-09 300-310 964 IPBOO3191 Guanylate-binding protein IPB003191N 9.33 3.37e-09 779-809 964 PR00480 Astacin family signature II PR00480B 14.35 3.45e-09 359-377 964 IPB001422 Neuromodulin (GAP-43) IPB001422C 16.82 4.49e-09 777-812 965 IPB000329 Uteroglobin family IPB000329A 11.99 3.57e-10 1-16 965 PR00486 Uteroglobin signature I PR00486A 6.53 9.03e-09 2-16 966 IPB000407 GDA1/CD39 family of nucleoside IPB000407C 15.11 5.50e-24 175-197 phosphatase IPBOO0407D 11.44 2.16e-14 216-229 IPBOO0407B 8.75 3.86e-13 132-143 WO 2004/080148 PCT/US2003/030720 394 TABLE 3B IPBOO0407F 16.53 3.89e-12 422-436 IPBOO0407A 11.93 5.30e-12 56-67 IPBO00407E 19.08 8.20e-11 342-358 IPBOO0407G 17.95 8.20c-1 1 455-469 967 IPB001073 Complement Clq protein 1PB001073B 20.8 5.78e-23 96-130 IPB001I073C. 13,07 4.50e- 13 163-182 IPB00 1073A 22.14 6.55e- 13 42-76 967 P R00007 Complement ClQ domain signature PR00007B 15.63 9.56e-13 116-135 II IPBO01073D 7.60 1.00e-11 195-204 PROO007D 9.66 2.O0e-1 1 193-203 PROO007C 16.13 7.38e-11 163-184 PROO007A 20.64 9.32e- 10 89-115 970 IPB000721 Gag gene protein p24 (core IPBOO0721E 14.33 1.57e-12 525-538 nucleocapsid protein) 970 1PB003006 Immunoglobulin and major IPBO03006B 20.23 6.09e-11 206-243 histocompatibility complex domain IPBOO3006A 17.51 1.00c-10 160-182 970 IPBOO1020 Histidine phosphorylation site in HPr IPBOO1020B 19.38 4.53e-09 378-416 protein 971 IPB001759 Pentaxin family IPB001759D 18.25 4.67e-33 409-447 971 PR00895 Pentaxin signature V PR00895E 12.84 4,19e-1I 417-436 PR7895D 14.46 2.38-17 397-416 PR00895C 12.82 3.18e-17 370-388 IPB001759C 13.49 4.30e-17 370-388 9PB'1759A 29.51 b.82e-14 113-147 PRR895A 14.28 8.83c-13 305-319 PR7895B 14.42 .45e-12 327-341 9PB01759B 14.85 3.30e-B d327-341 9PB3 1759E 18.14 5.34R- 1459-473 PR00895F 15 .53 3.80e-11 436-450 973 IPB002889 WSC domain IPB002889B 11.76 5.15e-13 453-499 IPB002889B 11.76 1.55c-12 445-491 IPB002889B 11.76 4.18e-12 458-504 973 IPB001871 bZIP (Basic-leucine zipper) IPB001871 8.42 8.65e-12 633-645 transcription factor family IPB002889B 11.76 8.79e-12 447-493 1PB002889B 11.76 9. 89e-12 440-486 IPB002889B 11.76 2.59e- 11439-485 IPB002889B 11.76 4.49e-11 441-487 IP002889B 11.76 5.13c-11 454-500 IPB002889B 11.76 5.87e-12 437-483 IPB002889B 11.76 6.72e-11 448-494 9 _73 PR0043 Jun transcription factor signature 11 PROO43B 8.71 8.92e-1 11 633-649 973 PRO 1449 Calcium-activated BK potassium PR01449H 2.34 9.85e- 1 3468-483 channel alpha subunit signature VIII IPB200889B 11.76 2.19e-10 449-495 IPB002889B 11.76 2.58e-10 443-489 IPB002889B 11.76 3.87e- 10 456-502 IPB002889B 11.76 4.46e-10 452-498 IPB002889B 11.76 6.44e-10 444-490 973 IPB002546 Myogenic Basic domain PB002546 13.48 9.04e-10 464-481 IPB002889B 11.76 9.4e-10 457-503 IPB002889B 11.76 1.15e-09 461-507 IPB002889B 11.76 1.28e-09 436-482 973 PB000684 Eukaryotic RNA polymerase I I PBOO0684L 3.49 2. lOe-09 445-487 heptapeptide repeat IPB002889C 9.89 2.2le-09 466-487 PRO1449H 2.34 2.579e-09 469-484 PR01449H 2.34 2.50e-09 472-487 PR01449H 2.34 2.59e-09 466-481 PR01449H 2.34 2.59e-09 467-482 PRO01449H 2.34 3.03e-09 463-478 WO 2004/080148 PCT/US2003/030720 395 TABLE 3B IPB002889B 11.76 4.09e-09 438-484 PR01449H 2.34 4.18e-09 461-476 PR01449H 2.34 4.18e-09 464-479 PR01449H 2.34 4.35e-09 473-488 IPB002889B 11.76 4.47e-09 455-501 PR01449H 2.34 4.53e-09 453-468 IPB002889B 11.76 5.13e-09 442-488 IPB002889B 11.76 5.3 1e-09 431-477 IPB002546E 13.48 5.50e-09 469-486 IPB002889B 11.76 6.62e-09 463-509 IPB002889B 11.76 7.19e-09 462-508 IPB002889B 11.76 8.69e-09 450-496 IPB000684L 3.49 8.83e-09 447-489 977 IPB001359 Synapsin IPBOO1359H 22.58 1.95e-15 545-595 977 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 3.00e-13 2087-2112 IPB000822 14.67 1.86e-11 2476-2501 IPBOO1359H 22.58 4.46e-11 539-589 IPB000822 14.67 5.29e-11 2362-2387 IPB000822 14.67 6.57e-11 472-497 IPB000822 14.67 8.7 1e-1 1 2253-2278 977 PR00049 Wilm's tumour protein signature IV PR00049D 0.00 9.02e-1 1 540-554 PROO049D 0.00 9.17e-11 541-555 977 IPB003861 E4 protein IPB003861B 9.06 1.43e-10 547-561 977 1PB002999 Tudor domain IPB002999C 10.33 2.00e-10 546-555 IPB000822 14.67 2.29e-10 110-135 IPBOO1359H 22.58 2.67e-10 537-587 977 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 3.45e-10 2473-2486 IPB001359H 22.58 5.08e-10 551-601 IPBOO1359H 22.58 5.36e-10 541-591 977 PR01217 Proline rich extensin signature VII PRO1217G 4.02 6.94e-10 545-570 IPB000822 14.67 1.00e-09 602-627 PR00049D 0.00 2.98e-09 538-552 PROO049D 0.00 3.29e-09 539-553 977 IPBO2000 Lysosome-associated membrane IPBOO2000D 5.87 3.72e-09 192-205 glycoprotein (Lamp) PR00049D 0.00 3.90e-09 543-557 977 IPB000413 Integrins alpha chain IPBOO0413A 13.51 4.33e-09 1509-1519 IPB001359H 22.58 4.41 e-09 547-597 PROO049D 0.00 4.8 le-09 537-551 977 PROO021 Small proline-rich protein signature I PROO021A 3.31 5.38e-09 538-550 IPB000822 14.67 5.50e-09 1894-1919 IPB000822 14.67 5.88e-09 1579-1604 IPB001359H 22.58 5.89e-09 543-593 PROO049D 0.00 6.03e-09 191-205 IPB000822 14.67 6.62e-09 1662-1687 977 PR00239 Molluscan rhodopsin C-terminal tail PR00239E 1.29 6.97e-09 542-553 signature V IPB000822 14.67 7.00e-09 2053-2078 IPBOO1359H 22.58 7.03e-09 546-596 PROO048B 5.52 7.50e-09 2100-2109 IPB002999B 7.50 7.55e-09 545-553 IPB002999B 7.50 7.55e-09 546-554 IPB000822 14.67 8.12e-09 2116-2141 IPB000822 14.67 8.50e-09 1267-1292 977 PR00776 Hemogbinase (C13) cysteine PR00776D 11.72 8.62e-09 2447-2466 protease signature IV IPBOO1359H 22.58 8.95e-09 558-608 IPBOO2000D 5.87 9.49e-09 542-555 977 PR00211 Glutelin signature II PR00211B 0.86 9.92e-09 551-571 IPB000822 14.67 1.00e-08 1032-1057 WO 2004/080148 PCT/US2003/030720 396 TABLE3B 980 PR00834 HtrA/DegQ protease family signature PR00834C 15.48 6.8le-20 237-261 III PR00834D 11.75 9.45e-18 275-292 980 IPB002350 Kazal-type serine protease inhibitor IPB002350 31.78 6.52e-17 73-113 family PR00834B 10.17 6.63e-14 196-216 PR00834E 13.43 9.13e-13 297-314 980 IPB000867 Insulin-like growth factor-binding IPB000867B 11.44 1.94e-12 23-39 protein 980 IPB000126 "Serine proteases, V8 family" IPBOOO126B 12.50 3.32e-12 280-296 PR00834F 11.11 3.25e-11 389-401 PR00834A 8.79 5.83e-11 175-187 IPBOO0126A 11.75 5.69e-10 173-188 980 PR00290 Kazal-type serine protease inhibitor PR00290B 16.63 2.80e-09 84-95 signature II 980 PR00722 Chymotrypsin serine protease family PR00722C 10.74 4.10e-09 283-295 (Si) signature III 980 PR01424 Transforming growth factor beta 1 PR01424A 6.58 8.24e-09 8-27 precursor signature I 980 IPBOO1489 Heat-stable enterotoxin IPB001489 13.51 8.78e-09 26-38 981 PR00792 Pepsin (Al) aspartic protease family PR00792A 11.02 5.32e-17 80-100 signature I 981 1PB001969 Eukaryotic and viral aspartic protease IPB001969A 16.37 5.15e-13 87-103 active site PR00792D 11.77 1.00e-12 395-410 PR00792C 8.65 6.29e-12 312-323 IPB001969A 16.37 7.00e-10 310-326 982 IPB000917 Sulfatase IPBOO0917A 9.52 5.26e-10 44-55 984 IPB000834 "Zinc carboxypeptidases, IPB000834B 13.51 2.50c-17 103-117 carboxypeptidase A metalloprotease (M14) family" 984 PR00765 Carboxypeptidase A metalloprotease PR00765B 14.48 1.39e-15 99-113 (M14) family signature II IPB000834C 17.20 2.80e-15 172-188 IPB000834G 14.46 4.50e-15 318-333 IPB000834D 18.95 4.72e-12 199-225 PR00765D 14.06 9.45e-12 233-246 PR00765C 10.88 1.82e-10 179-187 IPB000834F 12.40 4.21e-10 285-297 IPB000834E 9.80 2.15e-09 228-242 985 IPB000834 "Zinc carboxypeptidases, IPB000834B 13.51 2.50e-17 103-117 carboxypeptidase A metalloprotease (M14) family" 985 PR00765 Carboxypeptidase A metalloprotease PR00765B 14.48 1.39e-15 99-113 (M14) family signature II IPB000834C 17.20 2.80e-15 172-188 IPB000834G 14.46 4.50e-15 318-333 IPB000834D 18.95 4.72e-12 199-225 PR00765D 14.06 9.45e-12 233-246 PR00765C 10.88 1.82e-10 179-187 IPB000834F 12.40 4.2 1e-10 285-297 IPBOO0834E 9.80 2.15e-09 228-242 986 1PB002871 NifU-Iike N terminal domain IPB002871C 16.51 1.60e-33 81-113 IPBOO2871D 14.11 6.87e-21 131-153 IPB002871A 14.39 2.17e-17 35-50 IPB002871B 12.43 6.79e-14 62-74 990 1PB000822 "Zinc finger, C2H2 type" IPB000822 14.67 8.29e-1 1 94-119 90 PR00048 C2H2-type zinc finger signature II PROO048B 5.52 9.50e-09 107-116 991 IPB3527 MAP kIPB003527D 21.53 5.58e-23 185-226 IPB003527G 17.26 8.24e-22 285-322 IPB003527C 14.70 3.05e-19 124-172 991 |PB001245 Tyrosine kinase catalytic domain IPB001245A 22.45 5.50e-17 132-172 WO 2004/080148 PCT/US2003/030720 397 TABLE 3B 991 IPB000959 POLO box duplicated region IPB000959B 15.68 7.19e-17 116-156 IPB001245B 21.68 1.39e-15 192-230 991 IPB001772 Kinase associated domain 1 IPB001772C 20.66 3.92e-14 127-157 991 IPBOO0095 PAK-box /P21-Rho-binding IPB00095C 13.36 7.91e-13 46-82 IPB003527A 17.00 6.14e-12 26-51 991 IPB000861 PKN/rhophilin/rhotekin rho-binding IPB00086IG 13.73 7.44e-12 194-243 repeat 991 IPB000961 Protein kinase C-terminal domain IPBOO0961D 21.23 5.91e-11 188-229 IPB003527B 11.51 9.15e-11 98-116 991 PR00109 Tyrosine kinase catalytic domain PRO0109B 11.07 9.10e-10 139-157 signature II IPBOO0961C 15.48 8.83e-09 139-173 992 PR01432 Rabaptin signature XI PR01432K 2.19 8.43e-09 976-998 994 IPB001073 Complement Clq protein IPBOO1073B 20.88 7.26e-29 175-209 994 IPB001442 C-terminal tandem repeated domain IPB001442A 26.12 8.93e-27 75-127 in type 4 procollagen 994 IPB000885 Fibrillar collagen C-terminal domain IPB000885B 19.15 2.83e-26 74-127 IPB000885B 19.15 7.37e-23 80-133 IPB001442A 26.12 7.39e-23 72-124 IPB000885B 19.15 8.75e-23 77-130 IPB000885A 11.46 1.79e-21 82-119 IPBOO 1 073A 22.14 2.24e-21 78-112 IPB000885A 11.46 3.84e-21 79-116 IPB000885A 11.46 5.1le-21 76-113 IPB000885B 19.15 5.89e-21 71-124 IPB000885B 19.15 7.56e-21 68-121 IPB001442A 26.12 8.15e-21 66-118 IPBOO 1442A 26.12 8.40e-21 69-121 IPB000885B 19.15 2.97e-20 62-115 IPB001442A 26.12 3.72e-20 78-130 IPB000885A 11.46 4.00e-20 70-107 IPBOO1442A 26.12 5.62e-20 63-115 994 PR00007 Complement C1Q domain signature I PR0007A 20.64 6.54e-20 168-194 IPB000885A 11.46 8.20e-20 73-110 IPB001442A 26.12 9.64e-20 84-136 IPB001442A 26.12 3.69c-19 87-139 IPB00 1442A 26.12 5.09e-19 60-112 IPB00 1442A 26.12 7.43e-19 81-133 IPB000885B 19.15 3.81e-18 83 994 IPB000817 Prion protein IPBOO08 17A 8.34 9.5 le-10 76-118 IPB001442B 12.38 1.00e-09 106-126 1PB000885A 11.46 4.12e-09 58-95 IPB001442B 12.38 5.01e-09 97-117 IPB000817A 8.34 6.12e-09 77-119 IPBOO1442B 12.38 7.32e-09 73-93 IPB000885A 11.46 7.34e-09 106-143 IPB001442B 12.38 7.93e-09 70-90 IPB000885A 11.46 8.16e-09 55-92 IPB000885B 19.15 8.77e-09 101-154 IPBOO0817A 8.34 9.43e-09 65-107 996 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 4.24e-10 311-348 histocompatibility complex domain 997 IPB001895 Guanine-nucleotide dissociation IPB001895C 20.83 7.84e-30 1077-1112 stimulators CDC25 family IPB001895D 18.68 1.00e-20 1174-1197 997 IPB001331 Guanine-nucleotide dissociation IPBOO1331C 16.09 1.00e-18 377-402 stimulators CDC24 family IPB001895B 16.80 3.10e-15 1005-1025 IPBOO1331B 19.33 7.00e-09 326-341 999 IPB002360 Involucrin IPB002360C 15.36 3.70e-09 198-239 WO 2004/080148 PCT/US2003/030720 398 TABLE 3B 999 IPB000135 High mobility group proteins HMG1 IPBOO0135D 2.13 3.91e-09 202-226 and HMG2 999 PR00169 Potassium channel signature I PROO169A 17.48 5.50e-09 68-87 999 PR01083 Lymphocyte-specific protein PR01083A 8.60 9.61e-09 214-237 signature I 1001 IPB000492 Protamine 2 (PRM2) IPB000492B 5.26 5.1le-09 788-822 1001 IPB000221 Protamine P1 IPB000221 5.48 7.46e-09 945-971 IPB000221 5.48 8.85e-09 831-857 1002 IPB003403 Herpesvirus immediate early protein iPB003403E 17.25 6.47e-10 52-79 1002 IPB001841 RING finger IPB001841 10.69 3.84e-09 126-135 1002 IPB000492 Protamine 2 (PRM2) IPB000492B 5.26 5.1le-09 997-1031 1002 IPB000221 Protamine P1 IPB000221 5.48 7.46e-09 1154-1180 IPB000221 5.48 8.85e-09 1040-1066 1003 PR00320 G protein beta WD-40 repeat PR00320A 13.15 4.32e-12 1132-1146 signature I PR00320C 12.32 3.14e-11 1132-1146 PR00320B 12.82 7.55e-11 1132-1146 PR00320A 13.15 8.92e-10 1091-1105 PR00320C 12.32 1.33e-09 1091-1105 1003 IPB001680 G-protein beta WD-40 repeats IPB001680 10.43 1.45e-09 1134-1145 PR00320B 12.82 2.24e-09 1091-1105 PR00320A 13.15 4.86e-09 789-803 1003 PR01472 Intercellular adhesion PR01472A 16.78 9.82e-09 1154-1170 molecule/vascular cell adhesion molecule-I signature I 1004 IPB000433 ZZ Zinc finger IPB000433 14.10 8.20e-18 21-37 1004 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 7.86e-10 80-105 1006 IPBO0008 C2 domain IPBO00008C 23.37 8.91e-26 323-362 IPBOO0008D 14.83 1.23e-12 378-396 IPB00008B 17.91 3.09e-09 281-298 IPBO00008E 14.84 3.90e-09 401-411 1007 1PB000135 High mobility group proteins HMG1 IPBOO0135D 2.13 5.91e-11 877-901 and HMG2 IPB000135D 2.13 7.44e-11 885-909 IPBOO0135D 2.13 7.85e-11 887-911 IPB000135D 2.13 3.05e-10 883-907 IPBOO0135D 2.13 5.1le-10 881-905 IPBOOO135D 2.13 8.14e-10 888-912 IPBOO0135D 2.13 2.27e-09 876-900 IPBOO0135D 2.13 2.27e-09 882-906 IPBOO0135D 2.13 2.36e-09 880-904 1007 PR00806 Vinculin signature IV PR00806D 11.95 3.78e-09 564-579 IPBOO135D 2.13 3.91e-09 874-898 IPB000135D 2.13 4.45e-09 889-913 IPBOO0135D 2.13 6.36e-09 884-908 IPBOO0135D 2.13 7.00e-09 879-903 IPBOO0135D 2.13 7.18e-09 886-910 IPBOO0135D 2.13 9.27e-09 920-944 1008 IPB000135 High mobility group proteins HMG1 IPBOO0135D 2.13 8.85e-21 560-584 and HMG2 IPBOO0135D 2.13 2.47e-19 559-583 IPBOO0135D 2.13 7.87e-19 561-585 IPBOO0135D 2.13 8.53e-19 563-587 IPBOO0135D 2.13 9.35e-19 558-582 IPBOO0135D 2.13 7.25e-18 564-588 IPBOO0135D 2.13 7.43e-17 55 1008 IPB003403 Herpesvirus immediate early protein IPB003403E 17.25 6.8le-10 560-587 1008 IPB003874 CDC45-like protein IPB003874C 5.49 1.24e-09 571-582 1008 IPB001990 Granins (chromogranin or IPBOO1990C 33.59 3.49e-09 538-585 secretogranin) WO 2004/080148 PCT/US2003/030720 399 TABLE 3B 1008 IPB000637 HMG-I and HMG-Y DNA-binding IPB000637B 14.21 5.64e-09 568-586 domain (A+T-hook) IPBOO0135D 2.13 6.09e-09 545-569 1008 IPBOO1580 Calreticulin family IPBOO158OF 2.93 9.10e-09 573-582 1009 PR00405 HIV Rev interacting protein PR00405B 10.10 2.93e-17 281-298 signature II PR00405A 18.83 3.86e-14 262-281 1009 PR00452 SH3 domain signature II PR00452B 11.47 9.70e-10 895-910 PR00405C 18.05 3.95e-09 302-323 1009 IPBOO3134 Repeat in HSI/Cortactin 1PB003134H 12.06 4.27e-09 880-929 1009 PRO0910 Luteovirus ORF6 protein signature I PR00910A 2.74 8.71e-09 335-347 1011 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 8.71e-12 218-255 histocompatibility complex domain IPBOO3006B 20.23 9.14e-12 511-548 IPBOO3006B 20.23 1.00e-11 318-355 1011 PR01536 Interleukin-1 receptor type I and type PR01536C 19.92 9.23e-11 617-640 II family signature III IPBOO3006B 20.23 6.40e-10 124-161 IPBOO3006B 20.23 9.64e-10 610-647 IPBOO3006B 20.23 7.58e-09 21-58 IPBOO3006B 20.23 8.62c-09 416-453 PRO1536C 19.92 9.19e-09 225-248 1015 IPB002048 EF-hand family IPB002048 7.91 2.29e- 11 147-159 1015 PR00450 Recoverin family signature 1II PR00450C 11.99 1.58e-09 33-54 IPB002048 7.91 8.58e-09 74-86 1016 IPB003846 Uncharacterized protein family IPB003846E 18.41 1.00e-40 136-174 UPF0061 IPB003846F 24.67 9.36e-31 175-210 IPB003846D 28.31 1.61e-17 52-94 IPB003846G 13.31 5.09e-09 268-278 1017 IP3003846 Uncharacterized protein family IPB003846C 15.01 1.00e-40 176-219 UPF0061 IPB003846E 18.41 1.00e-40 468-506 IPB003846F 24.67 9.36e-31 507-542 IPB003846D 28.31 7.86e-25 235-277 IPB003846B 13.03 2.00e-11 148-159 IPB003846A 5.99 3.25e-11 140-146 IPB003846G 13.31 5.09e-09 600-610 1017 PRO1548 Meiotic recombination protein PR01548A 10.11 6.52e-09 238-258 reel 14 signature I 1018 PR00237 Rhodopsin-like GPCR superfamily PR00237E 13.03 3.12e-16 236-259 signature V 1018 PR00238 Opsin signature 11 PR00238B 16.77 4.52e-14 208-220 PR00237D 9.76 7.92e-14 186-207 PR00237B 12.45 1.39e-13 105-126 PR00237F 14.34 1.67e-13 294-318 PR00237C 14.77 2.00e-13 150-172 PR00237G 19.23 4.00e-13 332-358 1018 IPB000276 Rhodopsin-like GPCR superfamily IPB000276B 4.97 6.62e-13 244-255 PR00237A 9.81 7.00e-12 72-96 IPB000276A 11.56 5.24e-11 164-175 IPB000276D 9.40 4.52e-10 342-358 PR00238A 12.47 6.65e-09 93-105 1018 PR00667 Retinal pigment epithelium-retinal PR00667B 10.86 8.80e-09 91-106 GPCR signature II 1019 PROOC 19 Leucine-rich repeat signature I PROO019A 11.72 2.80e-13 378-391 PROO019B 11.42 2.33e-10 131-144 PROO019B 11.42 6.33e-10 375-388 PR00019B 11.42 3.73c-09 225-238 PROO019B 11.42 4.00e-09 249-262 PROO019A 11.72 4.55e-09 252-265 PROO019A 11.72 8.09e-09 134-147 1021 1 IPB001895 Guanine-nucleotide dissociation IPBOO1895C 20.83 3.00e-28 984-1019 WO 2004/080148 PCT/US2003/030720 400 TABLE3B stimulators CDC25 family IPB001895D 18.68 8.56e-17 1082-1105 IPB001895B 16.80 4.30c-15 913-933 1021 IPB000595 Cyclic nucleotide-binding domain IPB000595B 15.72 6.40e-11 355-378 1021 IPB003351 Dishevelled specific domain IPB003351F 12.17 4.43e-10 615-641 1021 IPB001478 PDZ domain (also known as DHR or IPB001478B 6.12 3.25e-09 625-634 GLGF) 1021 PR00834 HtrA/DegQ protease family signature PR00834F 11.11 6.03e-09 621-633 VI 1022 IPB001895 Guanine-nucleotide dissociation IPB001895C 20.83 3.00c-28 934-969 stimulators CDC25 family IPB001895D 18.68 8.56e-17 1032-1055 IPBOO1895B 16.80 4.30e-15 863-883 1022 IPB000595 Cyclic nucleotide-binding domain IPB000595B 15.72 6.40c-1 1 305-328 1022 IPB003351 Dishevelled specific domain IPB003351F 12.17 4.43e-10 565-591 1022 IPB001478 PDZ domain (also known as DHR or IPB001478B 6.12 3.25e-09 575-584 GLGF) 1022 PR00834 HtrA/DegQ protease family signature PR00834F 11.11 6.03e-09 571-5 83 VI 1024 PR00907 Thrombomodulin signature VIII PR00907H 1.34 7.64e-09 376-400 1025 PR00907 Thrombomodulin signature VIII PR00907H 1.34 7.64e-09 338-362 1027 IPB003452 Stem cell factor IPB003452A 12.58 1.00e-40 1-41 IPB003452D 16.80 1.00e-40 173-211 IPB003452C 13.68 6.76e-37 131-164 1PB003452B 19.11 2.09e-18 53-101 IPB003452B 19.11 8.06e-17 43-91 1028 PR00205 Cadherin signature 11 PR00205B 20.09 1.00e-19 150-179 PR00205D 12.22 9.3 1e-19 238-257 PR00205F 19.57 3.37e-17 316-342 PR00205B 20.09 6.67c-16 374-403 PR00205B 20.09 2.20e-15 259-288 PR00205A 17.38 6.82e-14 90-109 PR00205F 19.57 1.00e-13 97-123 PR00205F 19.57 6.70e-13 427-453 1028 IPB002126 Cadherin domain IPB002126A 14.68 9.40e-13 101-117 1PB002126B 12.04 1.75e-12 247-264 PR00205G 13.05 4.30e-12 241-258 PR002050 13.05 4.65e-11 499-516 IPB002126B 12.04 1.29e-10 138-155 PR00205E 10.82 2.17e-10 372-385 PR00205E 10.82 3.35e-10 257-270 IPB002126A 14.68 6.09e-10 431-447 PR00205D 12.22 6.55e-10 496-515 PR00205A 17.38 3.12c-09 420-439 PR00205D 12.22 5.33e-09 129-148 1029 PR00205 Cadherin signature 11 PR00205B 20.09 1.00e-19 150-179 PR00205D 12.22 9.31c-19 238-257 PR00205F 19.57 3.37e-17 316-342 PR00205B 20.09 6.67e-16 374-403 PR00205B 20.09 2.20e-15 259-288 PR00205A 17.38 6.82e-14 90-109 PR00205F 19.57 1.00e-13 97-123 PR00205F 19.57 6.70e-13 427-453 1029 IPB002126 Cadherin domain IPB002126A 14.68 9.40e-13 101-117 IPB002126B 12.04 1.75e- 12 247-264 PR00205G 13.05 4.30e-12 241-258 PRO0205G 13.05 4.65e-11 461-478 IPB002126B 12.04 1.29e-10 138-155 PR00205E 10.82 2.17e-10 372-385 WO 2004/080148 PCT/US2003/030720 401 TABLE 3B PR00205E 10.82 3.35e-10 257-270 IPB002126A 14.68 6.09e-10 431-447 PR00205D 12.22 6.55e-10 458-477 PR00205A 17.38 3.12e-09 420-439 PR00205D 12.22 5.33e-09 129-148 1030 PR00124 ATP synthase C subunit signature I PROO124A 8.69 9.33e-10 41-60 1030 PRO1131 Connexin36 (Cx36) signature II PR01131B 3.45 3.17e-09 58-70 PR00124A 8.69 6.70e-09 43-62 1030 IPB003836 Glucokinase IPB003836D 23.37 7.59e-09 48-81 1030 PR01516 Kv4.1 voltage-gated K+ channel PRO1516G 4.80 8.98e-09 79-90 signature VII 1031 IPBOO0180 Renal dipeptidase IPBOO0180B 21.72 7.92e-34 242-281 IPBOO0180A 30.29 1.00e-33 172-215 IPBOOO180C 22.01 5.67e-27 287-321 1032 IPB002027 Amino acid permease IPB002027D 22.00 4.13e-25 325-364 IPB002027C 19.67 2.74e-22 244-282 IPB002027A 18.88 3.77e-16 47-75 IPB002027B 12.67 7.97e-12 180-199 1033 IPB000559 Formate-tetrahydrofolate ligase IPB000559C 13.05 1.00e-40 453-502 IPBOO0559F 12.78 1.00e-40 653-703 IPB000559G 15.54 1.00e-40 707-755 IPBOO0559D 22.27 4.33e-37 554-594 IPBOO0559E 17.08 7.39e-36 595-636 IPB000559K 15.77 8.96e-35 933-968 IPB000559B 12.60 2.88e-32 413-441 IPBOO0559J 17.25 5.94e-32 900-932 IPB000559H 20.31 2.72e-26 770-8 10 IPB000559A 24.17 6.1le-25 368-412 IPBOO0559I 15.05 6.35e-18 856-880 1033 PROO085 Tetrahydrofolate PROO085C 13.81 5.70e-14 169-190 dehydrogenase/cyclohydrolase PROO085B 16.65 1.23e-09 136-163 family signature III 1034 IPB000560 Histidine acid phosphatase IPBOO0560 17.02 1.00e-11 378-400 1035 IPB001331 Guanine-nucleotide dissociation IPBOO1331C 16.09 2.40e-12 911-936 stimulators CDC24 family 1035 PR00049 Wilm's tumour protein signature IV PROO049D 0.00 4.8 le-09 1125-1139 1035 PR00834 HtrA/DegQ protease family signature PR00834F 11.11 5.24e-09 82-94 VI PROO049D 0.00 5.73e-09 147-161 1035 IPB001478 PDZ domain (also known as DHR or IPB001478B 6.12 7.19e-09 86-95 GLGF) 1035 IPB002532 Hantavirus glycoprotein G2 IPB002532J 16.97 8.37e-09 936-972 1035 PR00554 Adenosine A2B receptor signature II PR00554B 12.52 8.85e-09 724-732 1037 PR00390 Phospholipase C signature I PR00390A 14.24 6.34e-20 295-313 1037 IPB002048 EF-hand family IPB002048 7.91 3.84e-09 147-159 1039 PR00245 Olfactory receptor signature III PR00245C 14.65 5.26e-17 175-191 PR00245E 8.96 2.73e-13 282-293 PROO245B 13.73 1.39e-12 128-140 PR00245D 9.34 9.33e-11 235-244 1039 IPB000276 Rhodopsin-like GPCR superfamily IPB000276A 11.56 1.47e-10 117-128 PR00245A 10.98 8.80e-10 91-102 IPB000276D 9.40 9.6 1e- 10 281-297 1039 PR00896 Vasopressin receptor signature II PR00896B 9,36 5.50e-09 54-65 1039 PR00534 Melanocortin receptor family PR00534A 12.77 5.70e-09 50-62 signature I 1039 PR00237 Rhodopsin-like GPCR superfamily PR00237B 12.45 7.16e-09 58-79 signature II PR00237E 13.03 8.20e-09 198-221 1039 1IPB003211 AmiS/UreI family transporter IPBOO3211A 15.05 9.43e-09 27-66 WO 2004/080148 PCT/US2003/030720 402 TABLE 3B 1040 IPB003367 Thrombospondin type 3 repeat IPB003367C 20.73 1.00e-40 428-478 IPB003367D 18.41 1.00e-40 479-521 IPB003367E 16.82 1.00e-40 522-569 IPB003367F 16.21 1.00e-40 580-629 IPB003367G 17.08 1.00e-40 630-671 IPB003367H 15.25 1.00e-40 672-704 IPB003367J 18.60 1.00 1040 IPB001881 Calcium-binding EGF-like domain IPBOO1881B 12.28 4.79e-11 303-314 IPB003367E 16.82 5.67e-11 404-451 IPB003367C 20.73 5.96e-.11 510-560 IPB003367E 16.82 6.83e-11 425-472 IPB003367C 20.73 2.38e-10 588-638 IPB003367C 20.73 6.35e-10 548-598 1040 IPB003129 Thrombospondin N-terminal -like IPB003129B 23.30 7.86e-10 33-58 domains IPB003367C 20.73 8.46e-10 451-501 IPB003367E 16.82 8.88e-10 560-607 IPB003367C 20.73 6.20e-09 392-442 IPB003367E 16.82 6.95e-09 463-510 1040 IPB001774 Delta serrate ligand IPB001774D 19.23 9.91e-09 226-272 1042 IPBOO0109 PTR peptide transporters (PTR2) IPBOO0109D 25.09 6.67e-32 430-477 IPBOO0109B 29.23 4.18e-23 67-119 IPBOO0109A 10.85 3.79e-15 44-62 IPBOO0109C 8.21 7.00e-14 195-207 1042 PR00308 Type I antifreeze protein signature III PR00308C 2.79 2.78e-09 20-29 1042 PR01471 Histamine H3 receptor signature II PRO1471B 12.38 9.63e-09 24-42 1043 IPB003104 Formin Homology 2 Domain IPBOO3104B 18.83 6.87e-21 785-814 IPBOO3104C 20.33 1.27e-14 957-984 1043 IPB001073 Complement Clq protein IPBOO1073A 22.14 3.25e-09 545-579 1043 IPB001359 Synapsin IPB001359H 22.58 7.99e-09 553-603 1043 PRO 1471 Histamine H3 receptor signature V PRO1471E 5.41 8.14e-09 543-558 1044 IPB001909 KRAB box IPB001909 17.37 6.32e-28 10-44 1044 1PB000822 "Zinc finger, C2H2 type" IPB000822 14.67 9.1Oe-22 592-617 1PB000822 14.67 9.18e-21 228-253 IPB000822 14.67 5.50e-19 452-477 IPB000822 14.67 6.25e-19 284-309 IPB000822 14.67 7.23e-18 368-393 IPB000822 14.67 9.31e-18 144-169 IPB000822 14.67 2.29e-17 536-561 IPB000822 14.67 8.07e-17 480-505 IPB000822 14.67 9.36e-17 256-281 IPB000822 14.67 2.20e-16 340-365 IPB000822 14.67 5.20e-16 172-197 IPB000822 14.67 5.20e-16 200-225 IPBOO822 14.67 5.80e-16 564-589 IPB000822 14.67 8.20e-16 396-421 IPB000822 14.67 8.80e-16 424-449 IPB000822 14.67 3.25e-15 508-533 IPB000822 14.67 4.94e-15 620-645 1044 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 5.50e-15 589-602 PROO048A 9.94 6.40e-15 253-266 IPB000822 14.67 1.00e-14 312-337 PROO048A 9.94 5.15e-14 533-546 PROO048A 9.94 6.79e-13 393-406 IPB000822 14.67 7.50e-13 116-141 1044 IPB001275 DM DNA binding domain IPB001275 19.17 9.86e-13 580-619 PROO048A 9.94 1.53e-12 477-490 PROO048A 9.94 5.24e-12 561-574 WO 2004/080148 PCT/US2003/030720 403 TABLE 3B PROO048A 9.94 5.76e-12 225-238 IPB0O1275 19.17 8.66e-12 244-283 PR00048A 9.94 9.47e-12 281-294 PROO048A 9.94 1.00e-11 141-154 1044 IPB001222 TFIIS zinc ribbon domain IPBO0 1222 24.63 5.69e-09 116-152 PROO048B 5.52 7.00e-09 493-502 PROO048A 9.94 7.37e-09 421-434 PROO048A 9.94 9.25e-09 449-462 IPBOO1222 24.63 9.49e-09 144-180 1044 IPB002801 Aspartate carbamoyltransferase IPB002801C 14.18 9.50e-09 254-270 regulatory chain PR00048B 5.52 9.50e-09 381-390 1046 IPB003137 Protease associated (PA) domain IPB003137 22.40 2.50e-19 188-218 1048 IPB001627 Sema domain IPB001627J 11.43 2.40e- 11403-419 IPB001627K 13.76 6.58e-11 477-489 1048 IPB002165 Plexin repeat IPBOO2165D 14.72 7.91e-11 477-489 1049 IPB000243 Proteasome B-type subunit IPB000243C 13.61 8.80e-09 52-62 1049 PR00766 Amiloride-sensitive amine oxidase PR00766G 10.85 9.23e-09 91-111 signature VII 1050 IPBOO1140 ABC transporter transmembrane IPBOO1 140B 15.62 4.95e-14 138-176 region 1051 IPB000433 ZZ Zinc finger IPB000433 14.10 8.20e-18 21-37 1051 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 7.86e-10 80-105 1052 IPB000353 "Class II histocompatibility antigen, IPBOO0353B 19.16 9.22e-14 133-182 beta chain, beta-1 domain" 1052 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 4.43e-12 86-123 histocompatibility complex domain IPBOO3006A 17.51 4.00e-11 154-176 1052 IPBOO1003 "MHC Class II, alpha chain, alpha- I IPBOO1003B 14.72 5.40e-10 141-184 domain" 1053 PROO018 Kringle domain signature I PROOO18A 12.23 4.19e-09 36-51 1055 IPB001039 "Major histocompatibility complex IPB001039A 17.17 1.00e-40 15-68 protein, Class I" IPB001039B 27.55 1.OOe-40 96-147 IPB001039C 19.82 1.00e-40 177-230 IPB001039D 16.49 1.00e-40 255-309 1055 IPB003006 Immunoglobulin and major IPB003006B 20.23 8.00e-30 261-298 histocompatibility complex domain IPB003006A 17.51 1.00e-21 224-246 1055 IPB000353 "Class 11 histocompatibility antigen, IPB000353B 19.16 7.65e-14 203-252 beta chain, beta-1 domain" 1055 IPB003363 Glycoprotein GG/GX IPB003363E 13.35 8.75e-11 308-340 1055 IPB003705 Cobalt transport protein CbiN IPB003705A 9.20 6.25e-09 316-332 IPB000353C 20.11 7.97e-09 254-308 1062 PR01382 Claudin-9 signature IV PR01382D 12.38 1.1le-16 201-213 1062 JPB000729 PMP-22/EMP/MP2O family IPB000729D 18.96 2.96e-16 160-187 IPB000729C 37.83 7.91e-16 80-132 PR01382A 12.00 1.17e-15 37-47 1062 PR01077 Claudin signature III PRO1077C 13.60 1.47e-14 63-73 PR01382C 5.67 5.14e-13 190-199 PR01382B 7.06 1.12e-12 91-100 PRO1077B 14.12 1.OOe-10 49-55 PR01077D 11.20 4.00e-10 146-152 PR01077A 9.72 8.16e-09 21-30 1064 IPB001478 PDZ domain (also known as DHR or IPB001478B 6.12 5.50e-09 453-462 GLGF) IPB001478B 6.12 7.75e-09 258-267 1066 IPB002659 Galactosyltransferase IPB002659A 26.24 4.80e-11 92-133 1067 IPBOO1245 Tyrosine kinase catalytic domain IPBOO1245A 22.45 7.60e-28 119-159 1067 IPB001772 Kinase associated domain 1 IPB001772C 20.66 9.25e-24 114-144 1067 IPB000961 Protein kinase C-terminal domain IPB000961C 15.48 2.13e-22 126-160 IPB001772D 21.67 4.55e-17 186-225 WO 2004/080148 PCT/US2003/030720 404 TABLE 3B 1067 IPB000959 POLO box duplicated region IPB000959B 15.68 8.60e-17 103-143 1067 IPBOO0095 PAK-box /P21-Rho-binding IPB00095E 17.62 9.03e-17 127-172 1067 IPB003527 MAP kinase IPB003527C 14.70 1.95e-16 111-159 1067 IPB000861 PIN/rhophilin/rhotekin rho-binding IPB000861F 16.50 1.55e-15 120-174 repeat 1067 IPB000494 "Epidermal growth-factor receptor IPB000494C 24.40 7.35e-14 113-159 (EGFR), L domain" IPB000959D 27.01 4.26e-13 226-278 IPBOO0961D 21.23 7.19e-13 175-216 IPB001245B 21.68 8.96e-13 179-217 IPB003527A 17.00 7.85e-1 1 18-43 IPB001772E 24.88 8.46e-11 233-272 IPB001772A 13.64 2.29e-10 9-40 IPB003527G 17.26 3.37e-09 245-282 1067 PROO109 Tyrosine kinase catalytic domain PROO109B 11.07 4.23e-09 126-144 signature II IPB003527D 21.53 4.60e-09 172-213 1068 PR01254 Prostaglandin D synthase signature I PR01254A 12.32 3.37e-29 31-54' PR01254D 13.80 7.97e-27 109-132 PR01254C 10.60 4.68e-22 74-92 PR01254F 10.08 7.58e-21 162-180 PR01254E 14.07 1.00e-18 145-159 1068 PR00179 Lipocalin signature II PROO179B 7.67 5.26e-13 120-132 PROO179C 17.26 3.84e-12 148-163 PR01254B 12.05 9.04e-12 57-67 1068 PR01275 Neutrophil gelatinase lipocalin PR01275E 6.38 1.72e-10 115-133 signature V PROO 179A 13.97 3.25e-10 37-49 1068 PR01215 Alpha-1-microglobulin signature IV PRO1215D 12.88 9.78e-10 111-130 1068 IPB000566 Lipocalin and cytosolic fatty-acid IPB000566B 8.91 1.47e-09 120-130 binding protein 1068 PR01174 Retinol binding protein signature VI PROI174F 11.76 3.96e-09 119-135 1068 PR01273 Invertebrate colouration protein PR01273D 11.48 4.41e-09 120-134 signature IV PR01275B 9.02 8.57e-09 39-49 1069 IPB000704 "Casein kinase II, regulatory subunit" IPBOO0704B 17.35 6.26e-09 90-128 1070 IPB001464 Annexin family IPB001464D 25.42 1.OOe-40 281-335 IPB001464B 28.31 6.76e-40 151-203 IPB001464A 31.17 1.27e-35 79-133 IPBOO 1464C 24.68 6.40e-30 214-253 1070 PR00196 Annexin family signature IV PROO196D 21.41 3.81e-22 219-245 PROO196E 9.70 7.75e-21 299-319 1070 PR00201 Annexin type V signature VII PR00201G 12.46 1.00e-20 299-325 PROO196C 9.01 7.09e-20 136-157 IPB001464B 28.31 4.88e-19 79-131 PROO196A 12.07 2.42e-18 69-91 1070 PR00199 Annexin type III signature VI PROO199F 15.67 5.1Oe-18 219-245 IPBOO1464D 25.42 9.21e-18 122-176 IPB001464B 28.31 3.86e-17 235-287 IPB001464A 31.17 6.68e-17 151-205 1070 PR00200 Annexin type IV signature VII PR002000 9.20 8.41e-17 299-325 PROO199D 4.74 2.11e-16 295-316 PROO199G 9.85 5.29e-16 300-325 PROO196C 9.01 5.96e-16 295-316 PROO199D 4.74 7.04e-16 136-157 1070 PR00197 Annexin type I signature IV PROO197D 7.59 7.56e-16 136-157 PROO196B 11.03 9.31e-16 109-125 1070 PR00198 Annexin type II signature IV PROO198D 7.41 9.88e-16 136-157 PR00200E 8.88 5.88e-15 136-157 PROO197F 9.40 7.39e-15 299-319 1070 PR00202 Annexin type VI signature VII PR00202G 8.03 9.7le-15 299-325 WO 2004/080148 PCT/US2003/030720 405 TABLE 3B IPB001464A 31.17 1.85e-14 235-289 PR00197D 7.59 1.94e-14 295-316 PR00196C 9.01 5.02e-14 64-85 PR00201D 8.61 9.29e-14 136-157 PR00199D 4.74 2.84e-13 64-85 PR00198D 7.41 3.15e-13 295-316 PR0O 1071 IPB000175 Sodium:neurotransmitter symporter IPB000175A 16.29 1.00e-40 52-101 family IPB000175C 15.09 1.00e-40 212-263 IPBOO0175F 25.63 4.50e-38 467-506 IPBOO0175E 21.88 5.95e-35 372-411 IPB000175B 19.12 9.05e-33 139-173 1071 PROO176 Sodium/chloride neurotransmitter PR00176A 16.97 3.25e-27 52-73 symporter signature I PR00176C 10.57 7.86e-25 124-150 1071 PR01195 GAT-1 GABA neurotransmitter PRO1195B 13.58 1.22e-24 194-211 transporter signature 11 PROO176G 13.12 3.77e-22 458-478 PRO1195D 9.00 3.75e-21 583-600 PROD176E 11.14 5.20e-21 322-342 PROO176F 11.11 1.36e-19 376-395 IPBOO0175G 16.18 5.13e-19 528-550 PROD176B 7.07 9.63e-19 81-100 PRO1195A 7.44 1.90e-18 18-32 PROO176D 8.96 6.48e-18 239-256 PROO176H 15.94 7.63e-18 498-518 IPBOO0175D 23.45 1.28e-17 278-330 PRO1195C 15.62 1.14e-13 348-357 1072 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 8.92e-10 98-135 histocompatibility complex domain 1073 IPB001863 Glypican IPB001863D 26.43 5.62e-33 250-294 IPBOO 1 863E 33.79 3.08e-29 298-350 IPBOO1863B 38.78 1.45e-25 134-186 IPB001863F 26.99 6.59e-22 429-463 IPB001863C 20.17 1.37e-16 191-220 IPB001863A 13.95 5.03e-15 56-71 IPB001863G 11.32 4.68e-12 487-505 1073 PR00436 Interleukin-8 signature I PR00436A 15.20 7.91e-10 1-24 1073 PR00049 Wilm's tumour protein signature IV PRO0049D 0.00 3.90e-09 515-529 1073 IPB001702 General diffusion Gram-negative IPB001702D 9.64 1.00e-08 536-546 porins 1075 IPB001675 Glycosyltransferase family 29 IPB001675A 26.48 5.76e-31 296-340 IPB001675B 15.84 6.50e-15 434-456 1075 PR01329 Kir3.3 inward rectifier K+ channel PR01329B 8.30 9.29e-09 7-21 signature I 1078 IPB001599 Alpha-2-macroglobulin family IPB001599L 18.66 7.84e-26 1244-1271 IPBOO1599F 18.95 7.00e-24 785-814 IPB001599H 18.42 6.40e-20 1019-1046 IPB001599A 10.97 9.69e-18 123-141 IPBOO1599N 24.85 2.24e-14 1437-1469 1078 IPBOO1134 "Netrin, C-terminus" IPB001 134C 17.82 4.13e-13 1257-1271 IPB001599M 13.29 4.71e-13 1384-1395 IPB001599G 13.87 8.94e-13 987-996 IPB001599B 7.45 4.89e-12 209-221 IPB001599D 11.61 6.90e-12 728-738 IPB001599J 20.99 3.00e-1l 1085-1110 IPB0015991 10.83 7.60e-11 1054-1063 IPB001599K 8.15 1.46e-10 1214-1225 IPB001599C 14.40 3.55e-09 236-252 IPB001599E 11.06 9.77e-09 755-764 1079 IPB001599 Alpha-2-macroglobulin family IPBOO1599F 18.95 7.00e-24 799-828 WO 2004/080148 PCT/US2003/030720 406 TABLE 3B IPB001599A 10.97 9.69e-18 136-154 IPB001599B 7.45 4.89e-12 222-234 IPB001599D 11.61 6.90e-12 742-752 IPB001599C 14.40 3.55e-09 249-265 IPB001599E 11.06 9.77e-09 769-778 1080 IPB001599 Alpha-2-macroglobulin family IPB001599A 10.97 9.69e-18 123-141 IPB001599B 7.45 4.89e-12 209-221 IPB0O 1599C 14.40 3.55e-09 236-252 1081 IPB001599 Alpha-2-macroglobulin family IPBOO1599L 18.66 7.84e-26 1244-1271 IPB001599F 18.95 7.00e-24 785-814 IPB001599H 18.42 6.40e-20 1019-1046 1PB001599N 24.85 7.69e-20 1437-1469 IPB001599A 10.97 9.69e-18 123-141 1081 IPBOO1134 "Netrin, C-terminus" IPBOO1134C 17.82 4.13e-13 1257-1271 1PB001599M 13.29 4.71e-13 1384-1395 IPB001599G 13.87 8.94e-13 987-996 1PB001599B 7.45 4.89e-12 209-221 IPB001599D 11.61 6.90e-12 728-738 IPB001599J 20.99 3.00e-11 1085-1110 IPB001599I 10.83 7.60e-11 1054-1063 IPB001599K 8.15 1.46e-10 1214-1225 IPB001599C 14.40 3.55e-09 236-252 IPB001599B 11.06 9.77e-09 755-764 1082 IPB001599 Alpha-2-macroglobulin family IPB001599F 18.95 7.00e-24 786-815 1PB001599A 10.97 9.69e-18 123-141 IPB001599B 7.45 4.89e-12 209-221 IPB001599D 11.61 6.90e-12 729-739 IPB001599C 14.40 3.55e-09 236-252 IPB001599E 11.06 9.77e-09 756-765 1083 IPB002018 Carboxylesterases type-B IPB002018 21.41 2.38e-27 195-235 IPB002018 21.41 2.47e-12 504-544 1083 PR00878 Cholinesterase signature VI PR00878F 4.95 8.07e-09 460-472 1084 IPB000152 Aspartic acid and asparagine IPB000152 8.86 1.64e-16 1682-1697 hydroxylation site IPBOO0152 8.86 1.53e-15 1178-1193 IPB000152 8.86 1.47e-14 1136-1151 IPBOOO152 8.86 2.89e-14 1095-1110 IPB000152 8.86 3.84e-14 932-947 IPB000152 8.86 4.79e-14 1219-1234 IPB000152 8.86 5.74e-14 642-657 IPBOO0152 8.86 3.05e-13 1054-1069 1084 IPB001881 Calcium-binding EGF-like domain IPBOO1881B 12.28 4.00e-13 1682-1693 1084 IPB003367 Thrombospondin type 3 repeat IPB003367A 11.78 7.72e-13 1023-1043 IPBOO1881B 12.28 7.75e-13 1095-1106 IPB000152 8.86 9.18e-13 1261-1276 IPBOO1881B 12.28 1.00e-12 642-653 IPBOO1881B 12.28 2.20e-12 1483-1494 IPB000152 8.86 6.40e-12 1483-1498 IPBOO1881B 12.28 6.40e-12 1178-1189 IPBOO1881B 12.28 8.20e-12 1261-1272 IPBOO1881B 12.28 9.40e-12 1136-1147 1084 IPB003886 Extracellular domain in nidogen IPB003886D 13.91 1.00e-11 1136-1155 1084 PROO010 Type II EGF-like signature III PROOO1OC 6.98 1.37e-1 1 1687-1697 IPBOO1881B 12.28 3.84e-11 1219-1230 PROO01OC 6.98 4.00e-11 1183-1193 1084 IPB000033 "Low-density lipoprotein (idl) IPB00033B 7.05 4.24e-11 1059-1069 receptor, YWTD repeat" IPBOO1881B 12.28 6.68e-11 932-943 1PB003886D 13.91 2.92e-10 1219-1238 1084 1 IPB003306 WIF domain IPB003306E 25.51 4.00e-10 176-221 WO 2004/080148 PCT/US2003/030720 407 TABLE 3B 108 I -PB000034 LainB 1084 3 Laminin B IPB000034A 22.21 4.62e-10 187-222 IPBOO1881B 12.28 5.29e-10 1054-1065 IPB000152 8.86 5.50e-10 1303-1318 IPB000033B 7.05 5.65e-10 1266-1276 IPB000033B 7.05 6.23e-10 1100-1110 IPBO01881B 12.28 6.57e-10 1303-1314 IPBOO1881B 12.28 7.43e-10 1014-1025 IPBOO0152 8.86 7.75e-10 890-905 IPB00033B 7.05 8.26e-10 1687-1697 PROO010C 6.98 8.55e-10 937-947 1084 IB000006 "Vertebrate metallothionein, family IPBO0006 13.41 8.94e-10 175-220 1" IPB003886D 13.91 1.00e-09 1682-1701 IPB00033B 7.05 1.24e-09 647-657 IPB00033B 7.05 1.47e-09 1141-1151 IPB00033B 7.05 1.95e-09 1183-1193 IPB003306D 23.91 2.18e-09 194-242 PROO010C 6.98 2.32e-09 647-657 IPB003886D 13.91 2.52e-09 1178-1197 1084 PROOO11 Type III EGF-like signature IV PROM ID 12.12 4.21e-09 413-431 IPB003886D 13.91 4.32e-09 1095-1114 IPBOO1881B 12.28 4.52e-09 890-901 IPBOO033B 7.05 4.79e-09 937-947 PROOO1OC 6.98 4.95e-09 1059-1069 PROOO1OC 6.98 5.39e-09 1224-1234 IPB00034A 22.21 5.89e-09 399-434 PROOO1OC 6.98 6.71e-09 1266-1276 IPBOO188IB 12.28 6.87e-09 1442-1453 IPB00033B 7.05 6.92e-09 1224-1234 IPB003886D 13.91 7.09e-09 1261-1280 1084 IPB002221 WAP-type (Whey Acidic Protein) IPB002221B 17.12 7.75e-09 1466-1487 four-disulfide core domain 1084 PR00049 Wilm's tumour protein signature IV PROO049D 0.00 8.02e-09 92-106 1084 PR00009 Type I EGF signature III PR0009C 11.70 8.20e-09 1058-1069 IPBOO0152 8.86 8.58e-09 1637-1652 1084 IPB002557 Chitin binding domain 1PB002557B 12.64 9.31e-09 1453-1466 1084 IPB000561 EGF-like domain IPB000561 4.89 9.36e-09 1187-1195 1084 IPB002919 Trypsin Inhibitor-like cysteine rich IPB002919B 21.14 9.5le-09 899-921 domain 1PB000152 8.86 9.76e-09 1442-1457 IPB003886D 13.91 9.86e-09 642-661 IPB003886D 13.91 9.86e-09 932-951 IPBOO0561 4.89 1.00e-08 420-428 PRO0OlOC 6.98 1.00e-08 1141-1151 1086 PROO014 Fibronectin type III repeat signature PROO014D 15.12 9.25e-13 571-585 IV PROM14C 14.47 6.63e-11 651-669 PROM014D 15.12 7.75e-11 872-886 PROO014D 15.12 5.74e-10 443-457 PROO014C 14.47 6.50e-10 854-872 PROO014A 8.22 1.00e-08 816-825 PROO014D 15.12 1.00e-08 770-784 1087 IPB001909 KRAB box IPB001909 17.37 7.75e-31 16-50 1087 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 7.55e-21 219-244 IPB000822 14.67 4.21e-17 191-216 IPB000822 14.67 8.80e-16 163-188 1087 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 5.85e-14 188-201 PROO048A 9.94 9.3 1e-14 244-257 PR00048A 9.94 8.41e-12 216-229 1087 IPB001275 DM DNA binding domain IPB001275 19.17 5.24e-1 1 207-246 PROO048A 9.94 7.16e-11 160-173 WO 2004/080148 PCT/US2003/030720 408 TABLE 3B PR00048B 5.52 6.14e-10 232-241 IPB001275 19.17 7.45e-10 151-190 IPB001275 19.17 8.06e-09 179-218 1088 IPB001909 KRAB box IPB001909 17.37 7.75e-31 16-50 1088 PR00048 C2H2-type zinc finger signature I PR00048A 9.94 6.21e-11 160-173 1089 IPB002494 "Keratin, high sulfur B2 protein" IPB002494C 14.46 8.36e-35 20-63 IPB002494C 14.46 5.74e-34 89-132 IPB002494C 14.46 1.44e-30 99-142 IPB002494C 14.46 7.86e-29 64-107 IPB002494C 14.46 1.41e-27 74-117 IPB002494C 14.46 4.7le-25 30-73 IPB002494C 14.46 6.69e-25 79 1089 IPB000359 Cystine-knot domain IPB000359B 19.26 9.57e-13 24-42 IPB000359B 19.26 9.57e-13 68-86 IPB002494C 14.46 9.61e-13 73-116 IPB002494B 10.58 2.50e-12 51-65 IPB002494B 10.58 2.50e-12 95-109 IPB002494C 14.46 4.37e-12 34-77 IPB002494A 12.44 5.22e-12 91-124 IPB002494C 14.46 6.06e-12 93-136 IPB002494C 14.46 7.47e-12 83-126 1089 IPBO0006 "Vertebrate metallothionein, family IPB000006 13.41 7.62e-12 66-111 1" IPB002494B 10.58 7.75e-12 65-79 1089 IPB001271 Mammalian defensin IPB001271 19.97 7.95e-12 58-86 IPB002494B 10.58 9.55e-12 120-134 IPB001271 19.97 9.59e-12 19-47 IPB002494B 10.58 1.28e-11 26-40 IPB002494B 10.58 1.28e-11 70-84 IPB002494A 12.44 1.86e-11 121-154 IPB002494A 12.44 2.82e-11 56-89 IPB001271 19.97 3.06e-11 103-131 IPB000006 13.41 4.50e-11 70-115 IPBO0006 13.41 5.50e-11 40-85 IPB002494C 14.46 6.64e-11 98-141 IPB002494C 14.46 6.73e-11 78-121 IPBO0006 13.41 8.20e-11 65-110 IPB002494A 12.44 9.14e-11 57-90 IPB001271 19.97 1.88e-10 28-56 IPB001271 19.97 1.88e-10 72-100 IPB002494C 14.46 2.14e-10 14-57 IPB002494B 10.58 2.48e-10 56-70 IPBO0006 13.41 2.65e-10 61-106 IPB001271 19.97 2.94e-10 67-95 IPB001271 19.97 3.12e-10 18-46 IPBO0006 13.41 3.42e-10 22-67 IPB002494B 10.58 4.22e-10 110-124 1089 IPB001762 Disintegrin IPB001762A 23.93 4.26e-10 39-79 IPB002494A 12.44 4.27e-10 46-79 IPBO0006 13.41 4.29e-10 21-66 IPB001762A 23.93 4.45e-10 44-84 IPB001271 19.97 5.41e-10 117-145 IPB000006 13.41 6.23e-10 91-136 IPB001271 19.97 6.47e-10 123-151 IPB000006 13.41 6.61e-10 26-71 IPB002494B 10.58 6.64e-10 31-45 IPB002494B 10.58 6.64e-10 75-89 IPB002494B 10.58 6.91e-10 41-55 IPB002494B 10.58 6.91e-10 85-99 WO 2004/080148 PCT/US2003/030720 409 TABLE 3B IPB002494C 14.46 7.64e-10 108-151 IPB002494A 12.44 7.65e-10 67-100 IPB002494B 10.58 7.72e-10 100-114 IPB002494A 12.44 8.06e-10 82-115 IPB002494C 14.46 8.25e-10 19-62 1089 IPB000967 Zinc finger NF-X1 type IPB000967E 21.88 8.67e-10 51-91 IPB000359B 19.26 8.76e-10 59-77 IPB001271 19.97 8.76e-10 88-116 IPB000006 13.41 9.03e-10 114-159 IPB001762A 23.93 9.04e-10 45-85 IPBOO1762A 23.93 9.04e-10 94-134 IPB002494C 14.46 9.48e-10 4-47 1089 IPB0O1169 "Integrin beta, C-terminus" IPBOO 1169K 27.45 4.89e-09 86-128 IPBOO 1271 19.97 4.93e-09 29-57 IPB001271 19.97 4.93e-09 73-101 IPB001271 19.97 4.93e-09 97-125 IPB001271 19.97 4.93e-09 102-130 IPB002494C 14.46 4.95e-09 65-108 IPBO0006 13.41 5.22e-09 81-126 1090 IPB002494 "Keratin, high sulfur B2 protein" IPB002494C 14.46 9.43e-29 24-67 IPB002494C 14.46 3.22e-22 14-57 IPB002494C 14.46 8.08e-21 29-72 IPB002494C 14.46 7.99e-20 19-62 IPB002494A 12.44 3.29e-19 31-64 IPB002494C 14.46 8.65e-18 9-52 IPB002494A 12.44 8.15e-17 21-54 IPB002494A 12.44 7.17e-16 36-69 IPB002494A 12.44 6.12e-15 2-35 IPB002494A 12.44 4.96e-14 26-59 IPB002494C 14.46 2.86e-13 5-48 IPB002494C 14.46 4.72e-13 28-71 IPB002494C 14.46 5.30e-13 4-47 IPB002494A 12.44 6.19e-13 12-45 IPB002494A 12.44 6.54e-13 41-74 IPB002494A 12.44 8.15e-13 1-34 IPB002494C 14.46 9.5le-13 20-63 1090 IPB000359 Cystine-knot domain IPB000359B 19.26 9.57e-13 28-46 1090 IPBO0006 "Vertebrate metallothionein, family IPB000006 13.41 4.21e-12 26-71 1" 1090 IPB001271 Mammalian defensin IPB001271 19.97 7.75e-12 18-46 IPB002494A 12.44 1.1le-11 11-44 IPB002494B 10.58 1.28e-11 30-44 IPB002494A 12.44 6.25e-11 16-49 IPB002494C 14.46 8.27e-11 15-58 IPB002494A 12.44 8.39e-11 6-39 IPB002494C 14.46 9.82e-11 10-53 1090 IPB001762 Disintegrin IPB001762A 23.93 9.65e-09 34-74 IPB002494A 12.44 9.90e-09 27-60 IPBO0006 13.41 1.00e-08 25-70 1091 IPB002494 "Keratin, high sulfur B2 protein" IPB002494C 14.46 8.36e-35 20-63 IPB002494C 14.46 7.86e-32 124-167 IPB002494C 14.46 6.55e-31 64-107 IPB002494C 14.46 8.95e-31 89-132 IPB002494C 14.46 1.44e-30 134-177 IPB002494C 14.46 4.23e-28 99-142 IPB002494C 14.46 9.46e-26 1091 1PB000359 Cystine-knot domain IPB000359B 19.26 9.57e-13 24-42 IPBOO0359B 19.26 9.57e-13 68-86 WO 2004/080148 PCT/US2003/030720 410 TABLE 3B 1PB002494A 12.44 1.56e-12 42-75 IPB002494B 10.58 2.50e-12 51-65 IPB002494B 10.58 2.50e-12 95-109 IPB002494B 10.58 2.50e-12 130-144 IPB002494C 14.46 5.41e-12 34-77 IPB002494C 14.46 6.06e-12 128-171 IPB002494C 14.46 7.28e-12 118-161 1091 IPB001271 Mammalian defensin IPB001271 19.97 7.95e-12 58-86 IPB002494C 14.46 9.25e-12 103-146 IPB002494B 10.58 9.55e-12 155-169 IPB001271 19.97 9.59e-12 19-47 IPB002494B 10.58 1.28e-11 26-40 IPB002494B 10.58 1.28e-11 70-84 IPB002494A 12.44 1.86e-11 156-189 IPB001271 19.97 3.06e-11 138-166 IPB002494A 12.44 4.00e-11 56-89 1091 IPB00006 "Vertebrate metallothionein, family IPBO0006 13.41 4.1Oe-1 1 66-111 1" IPB002494C 14.46 4.91e-11 113-156 IPB001271 19.97 5.13e-11 97-125 IPB002494C 14.46 6.64e-11 133-176 IPBO0006 13.41 6.80e-1 1 40-85 IPB000359B 19.26 7.48e-11 103-121 IPB002494C 14.46 7.91e-11 98 1091 IPB001762 Disintegrin IPB001762A 23.93 9.04e-10 129-169 IPB002494C 14.46 9.21e-10 65-108 IPBO0006 13.41 9.42e-10 95-140 IPB002494C 14.46 9.48e-10 4-47 IPB000359B 19.26 9.69e-10 158-176 IPBOO0359B 19.26 1.28e-09 153-171 IPBO0006 13.41 1.55e-09 115-160 1091 IPB000967 Zinc finger NF-X1 type IPB000967E 21.88 1.56e-09 51-91 IPB002494A 12.44 1.58e-09 147-180 IPB001762A 23.93 1.88e-09 39-79 IPB001271 19.97 2.15e-09 98-126 IPB002494A 12.44 2.55e-09 62-95 IPB002494A 12.44 3.13e-09 41-74 IPB002494A 12.44 3.23e-09 28-61 IPB002494A 12.44 3.23e-09 72-105 IPB002494A 12.44 3.23e-09 77-110 IPB002494B 10.58 3.41e-09 16-30 IPB001271 19.97 3.78e-09 23-51 IPB001271 19.97 3.78e-09 67-95 1091 IPBOO1169 "Integrin beta, C-terminus" IPBOO1 169K 27.45 3.92e-09 121-163 IPBO0006 13.41 3.94e-09 80-125 IPBO0006 13.41 4.03e-09 140-185 IPB001762A 23.93 4.18e-09 44-84 IPB002494B 10.58 4.42e-09 125-139 IPB002494A 12.44 4.48e-09 33-66 IPBO0006 13.41 4.86e-09 65 1092 IPB000734 Lipase IPB000734 10.25 8.12e-09 164-178 1093 IPB000734 Lipase IPB000734 10.25 8.12e-09 224-238 1094 PR01223 Bride of sevenless protein signature PR01223F 4.19 9.78e-11 203-227 VI 1094 PR00354 7Fe ferredoxin signature III PR00354C 6.24 8.06e-09 258-275 1096 IPB001304 C-type lectin domain IPBOO1304A 17.98 8.04e-14 87-111 1096 PR00356 Type II antifreeze protein signature PR00356G 10.21 1.42e-10 193-206 VII 1097 1PB001304 C-type lectin domain IPBOO1304A 17.98 8.04e-14 87-111 WO 2004/080148 PCT/US2003/030720 411 TABLE 3B 1097 PR00356 Type II antifreeze protein signature PR00356G 10.21 8.15e-09 193-206 VII 1098 PR00245 Olfactory receptor signature V PR00245E 8.96 5.15e-16 283-294 PR00245B 13.73 3.77e-15 129-141 PR00245C 14.65 2.73e-14 176-192 PR00245D 9.34 2.59e-13 236-245 1098 IPB000276 Rhodopsin-like GPCR superfamily IPB000276A 11.56 7.00e-12 118-129 PR00245A 10.98 1.72e-11 92-103 IPB000276D 9.40 6.09e-10 282-298 1098 PR00534 Melanocortin receptor family PR00534A 12.77 2.83e-09 51-63 signature I 1098 PR00237 Rhodopsin-like GPCR superfamily PR00237C 14.77 3.86e-09 104-126 signature III PR00237B 12.45 6.92e-09 59-80 PR00237A 9.81 8.3 le-09 26-50 1099 IPB002889 WSC domain IPB002889B 11.76 3.44e-09 56-102 1099 IPB000561 EGF-like domain IPB000561 4.89 4.86e-09 306-314 1099 IPB000034 Laminin B IPB00034C 12.97 7.43e-09 306-324 1099 PR00346 Tissue factor signature VIII PR00346H 10.74 8.18e-09 542-565 1101 PR00457 Animal haem peroxidase signature V PR00457E 19.97 8.45e-24 997-1023 PR00457D 18.35 1.53e-20 972-992 PR00457C 18.81 9.42e-15 954-972 PR00457G 14.17 4.48e-14 1177-1197 PR00457H 14.82 5.85e-13 1248-1262 PR00457F 14.42 6.32e-12 1050-1060 1101 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 1.00e-10 180-194 domain PR00457B 12.43 2.29e-10 802-817 1101 IPB003006 Immunoglobulin and major IPBO3006B 20.23 2.80e-10 376-413 histocompatibility complex domain IPBOO3006B 20.23 8.92e-10 466-503 IPBOO3006B 20.23 9.28e-10 283-320 1101 PROO019 Leucine-rich repeat signature It PROO019B 11.42 6.73e-09 73-86 1102 PR00457 Animal haem peroxidase signature V PR00457E 19.97 8.45e-24 973-999 PR00457D 18.35 1.53e-20 948-968 PR00457C 18.81 9.42e-15 930-948 PR00457G 14.17 4.48e-14 1153-1173 PR00457H 14.82 5.85e-13 1224-1238 PR00457F 14.42 6.32e-12 1026-1036 1102 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 1.00e-10 156-170 domain PR00457B 12.43 2.29e-10 778-793 1102 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 2.80e-10 352-389 histocompatibility complex domain IPBOO3006B 20.23 8.92e-10 442-479 IPBOO3006B 20.23 9.28e-10 259-296 1103 IPB002034 Alpha-isopropylmalate and IPB002034D 19.67 7.61e-09 786-814 homocitrate synthase 1107 IPB001359 Synapsin IPB001359H 22.58 1.80e-14 741-791 1107 IPB000885 Fibrillar collagen C-tenninal domain IPB000885A 11.46 8.16e-09 765-802 1107 IPB001442 C-terminal tandem repeated domain IPB001442A 26.12 9.14e-09 746-798 in type 4 procollagen 1110 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 3.52e-10 31-68 histocompatibility complex domain 1112 IPB001841 RING finger IPB001841 10.69 1.95e-09 153-162 1113 IPB000961 Protein kinase C-terminal domain IPBOO0961A 16.82 2.64e-12 193-227 1113 IPB000959 POLO box duplicated region IPB000959B 15.68 9.22e-12 288-328 1113 IPB001245 Tyrosine kinase catalytic domain IPB001245A 22.45 1.87e-11 304-344 1113 IPB001772 Kinase associated domain 1 IPB001772C 20.66 6.11e-11 299-329 1113 IPB003527 MAP kinase IPB003527C 14.70 3.43e-09 296-344 1119 PRO1137 Gap junction alpha-8 protein (Cx5O) PR01 137B 18.37 8.83e-09 368-380 signature

II

WO 2004/080148 PCT/US2003/030720 412 TABLE 3B 1120 IPB000906 ZU5 domain IPB000906G 25.85 2.58e-13 921-969 IPB000906F 35.93 9.00e-12 931-984 IPB000906D 23.89 1.57e-11 940-994 1120 PR00452 SH3 domain signature II PR00452B 11.47 2.73e-11 1036-1051 1120 PR01415 Ankyrin repeat signature I PRO1415A 12.73 6,46e-1 1 954-966 IPB000906A 22.49 7.53e-10 914-956 PRO1415A 12.73 7.97e-10 921-933 1120 PR00499 Neutrophil cytosol factor 2 signature PR00499D 11.47 4.2 1e-09 1024-1044 IV 1120 [PB002360 Involucrin IPB002360C 15.36 4.90e-09 125-166 IPBOO0906F 35.93 7.41e-09 898-951 1120 IPB000237 GRIP domain IPB000237B 30.66 8.14e-09 142-192 1124 IPB000906 ZU5 domain IPBOO0906D 23.89 7.66e-10 117-171 IPBOO0906A 22.49 3.72e-09 58-100 IPBOO0906G 25.85 6.69e-09 164-212 1125 IPB000906 ZU5 domain IPB000906D 23.89 7.66e-10 117-171 IPBOO0906A 22.49 3.72e-09 58-100 1129 IPB000421 Coagulation factor 5/8 type C IPBOO0421C 36.74 1.93e-16 131-175 domain (FA58C) IPBOO0421B 20.70 1.36e-14 79-99 1130 IPB000421 Coagulation factor 5/8 type C IPBOO0421C 36.74 1.93e-16 131-175 domain (FA58C) IPBOO0421B 20.70 1.36e-14 79-99 1130 PR01435 NADH-plastoquinone PR01435B 5.98 7.37e-10 1059-1083 oxidoreductase chain 5 signature II 1131 IPBOO2119 Histone H2A IPBOO2119A 4.97 1.00e-08 92-98 1133 IPB001245 Tyrosine kinase catalytic domain IPBOO1245B 21.68 4.43e-18 178-216 1133 IPB003527 MAP kinase IPB003527D 21.53 3.41e-16 171-212 1133 IPB000961 Protein kinase C-terminal domain IPBOO0961A 16.82 6.56e-15 10-44 1133 IPB000861 PKN/rhophilin/rhotekin rho-binding IPBOO0861D 13.61 6.92e-15 8-44 repeat 1133 IPB000959 POLO box duplicated region IPB000959C 23.49 6.34e-14 153-205 IPB003527G 17.26 4.28e-13 320-357 IPBOO1245A 22.45 8.07e-13 119-159 1133 IPB001772 Kinase associated domain 1 IPB001772C 20.66 4.51e-12 114-144 IPBOO0861G 13.73 5.06e-12 180-229 1133 IPB000095 PAK-box /P21-Rho-binding IPB00095F 16.47 1.18e-11 182-236 IPBOOO961D 21.23 1.00e-10 174-215 IPB001772A 13.64 1.86e-10 8-39 IPB003527A 17.00 2.75c-10 17-42 IPB000959B 15.68 9.10e-10 103-143 1135 PR00402 Tec/Btk domain signature I PR00402A 20.14 8.15e-15 664-683 PR00402B 12.26 4.69e-13 683-695 1135 PR00360 C2 domain signature II PR00360B 11.64 9.25e-13 174-187 PR00402C 13.13 8.03e-12 695-708 1135 1PB000008 C2 domain IPB00008D 14.83 1.61e-11 200-218 PR00360A 15.18 6.00e-10 150-162 PR00360A 15.18 8.33e-10 22-34 1135 PR00399 Synaptotagmin signature IV PR00399D 12.72 4.89e-09 79-89 PR00360C 7.35 5.50e-09 196-204 1137 IPB003886 Extracellular domain in nidogen IPB003886D 13.91 8.57e-15 261-280 1137 IPBOO0152 Aspartic acid and asparagine IPB000152 8.86 7.16e-14 134-149 hydroxylation site IPB000152 8.86 9.05e-14 216-231 IPB000152 8.86 5.91e-13 261-276 1137 IPB001881 Calcium-binding EGF-like domain IPBOO1881B 12.28 9.25e-13 216-227 1137 IPB001774 Delta serrate ligand IPB001774C 18.25 9.69e-12 66-108 IPBOO1881B 12.28 1.95e-11 134-145 1137 IPB000033 "Low-density lipoprotein (ldl) IPB00033B 7.05 4.96e-11 266-276 receptor, YWTD repeat" WO 2004/080148 PCT/US2003/030720 413 TABLE 3B 1137 PR01217 Proline rich extensin signature VII PR01217G 4.02 5.15e-11 340-365 1137 PR00907 Thrombomodulin signature II PROO907B 11.50 6.70e-1 1 168-184 IPBOO1881B 12.28 1.00e-10 261-272 1137 IPB000925 Pneumovirus attachment IPB000925F 15.07 3.60e-10 336-372 glycoprotein G 1137 IPB000561 EGF-like domain IPB000561 4.89 6.25e-10 75-83 1137 PROO010 Type II EGF-like signature III PROO010C 6.98 1.66e-09 266-276 1137 PR00049 Wilm's tumour protein signature IV PROO049D 0.00 3.29e-09 348-362 PROO049D 0.00 3.29e-09 350-364 IPB00033B 7.05 3.84e-09 221-231 PRO1217E 3.04 4.48e-09 348-364 PRO1217B 4.82 6.55e-09 347-363 IPB000561 4.89 6.79e-09 270-278 PROO010C 6.98 7.15e-09 139-149 PRO1217D 4.57 7.16e-09 343-364 PROO010C 6.98 7.80e-09 221-231 IPB000033B 7.05 8.le-09 139-149 1137 IPB003367 Thrombospondin type 3 repeat IPB003367A 11.78 8.62e-09 183-203 1137 PR00910 Luteovirus ORF6 protein signature I PR00910A 2.74 8.71e-09 348-360 PR00910A 2.74 9.46e-09 346-358 PRO1217G 4.02 9.92e-09 343-368 1138 IPBOO1 156 Transferrin IPBOO1156H 23.81 7.75e-09 118-172 1143 PR00245 Olfactory receptor signature III PR00245C 14.65 9.53e-17 59-75 1143 IPB000276 Rhodopsin-like GPCR superfamily IPB000276A 11.56 9.25e-14 1-12 PR00245D 9.34 1.53e-13 119-128 PR00245E 8.96 6.81e-12 166-177 PR00245B 13.73 1.00e-10 12-24 IPB000276D 9.40 3.08e-09 165-181 1143 PR00237 Rhodopsin-like GPCR superfamily PR00237E 13.03 3.83e-09 82-105 signature V PR00237G 19.23 1.00e-08 155-181 1144 PR00245 Olfactory receptor signature III PR00245C 14.65 9.53e-17 173-189 1144 IPB000276 Rhodopsin-like GPCR superfamily IPB000276A 11.56 9.25e-14 117-128 PR00245D 9.34 1.53e-13 233-242 PR00245E 8.96 6.8 1e-12 280-291 PR00245A 10.98 7.14e-12 91-102 PR00245B 13.73 8.14e-10 128-140 1144 PR00237 Rhodopsin-like GPCR superfamily PR00237C 14.77 2.02e-09 103-125 signature III IPB000276D 9.40 3.08e-09 279-295 PR00237E 13.03 3.83e-09 196-219 1144 PR00534 Melanocortin receptor family PR00534A 12.77 5.17e-09 50-62 signature I 1144 PR00896 Vasopressin receptor signature 11 PR00896B 9.36 7.23e-09 54-65 PR00237G 19.23 1.00e-08 269-295 1146 IPBO0017 Syntaxin / epimorphin family IPBO00017 23.80 1.84e-09 168-217 1147 PR01360 Interleukin-1 receptor antagonist PRO136OF 14.44 3.1le-12 117-135 precursor IL-1RA signature VI PRO1360C 10.33 4.84e-11 58-75 1147 IPB000975 Interleukin-1 IPB000975D 24.45 5.55e-09 52-91 IPBOO0975E 28.12 9.80e-09 96-135 1147 PR00264 Interleukin-1 precursor family PR00264A 18.63 1.00e-08 55-75 signature I 1148 PR01248 Type I keratin signature V PR01248E 12.72 3.67e-21 248-274 1148 IPB001664 Intermediate filament proteins IPB001664B 17.44 9.16e-20 104-143 IPB001664A 11.94 8.13e-19 381-406 PR01248C 10.07 8.34e-17 150-170 1148 IPB001322 Intermediate filament tail domain IPB001322A 30.52 2.23e-14 370-423 IPB001664C 11.32 3.25e-13 161-188 PR01248B 8.42 3.29e-13 96-119 WO 2004/080148 PCT/US2003/030720 414 TABLE 3B PR01248D 9.34 3.60e-12 222-237 PR01248A 8.12 6.14e-11 75-88 1148 PROl 177 Metabotropic gamma-aminobutyric PROI 177J 6.10 4.96e-10 397-415 acid type B1 receptor signature X PROI177J 6.10 3.63e-09 13-31 IPB001664D 12.63 5.36e-09 279-305 1151 IPB001664 Intermediate filament proteins IPB001664D 12.63 4.75e-28 384-410 1151 PR01276 Type II keratin signature IV PR01276D 13.08 8.3 le-24 222-241 IPB001664A 11.94 9.50e-23 132-157 1151 IPB001322 Intermediate filament tail domain IPB001322C 22.70 4.75e-22 374-419 IPB001664C 11.32 8.20e-21 266-293 PR01276E 12.04 4.75e-15 301-318 IPB001322A 30.52 4.08e-14 121-174 PR01276F 10.92 3.21e-11 352-367 PR01276C 10.16 8.66e-11 208-221 IPB001664B 17.44 5.27e-10 191-230 PR01276B 9.79 5.96e-10 161-173 PR01276A 10.31 7.16e-10 134-142 1151 IPB003743 DUF164 IPB003743B 20.16 9.21e-10 300-338 1152 IPB001818 Matrixin IPBOO1818C 24.38 8.03e-32 157-202 IPBOO1818B 26.48 6.04e-31 112-153 IPBOO1818A 14.60 2.13e-29 66-95 IPB001818H 15.46 3.25e-23 332-358 IPBOO1818F 11.19 4.91e-20 231-251 1152 PR00138 Matrixin signature I PR00138A 12.54 1.64e-16 86-99 PROO138C 20.07 1.78e-16 155-183 IPBOO1818G 14.71 1.96e-12 268-280 PROO138B 14.84 5.21e-10 131-146 1153 IPB001818 Matrixin IPBOO1818C 24.38 8.03e-32 157-202 IPBOO1818 26.48 6.04e-31 112-153 IPBOOI818A 14.60 2.13e-29 66-95 IPBOO1818H 15.46 3.25e-23 332-358 IPBOO1818F 11.19 4.91e-20 231-251 1153 PR00138 Matrixin signature I PROO138A 12.54 1.64e-16 86-99 PROO138C 20.07 1.78e-16 155-183 IPBOO1818G 14.71 1.96e-12 268-280 PROO138B 14.84 5.21e-10 131-146 1154 PR00049 Wilm's tumour protein signature IV PROO049D 0.00 2.07e-09 10-24 1154 IPBOO2000 Lysosome-associated membrane IPBOO2000D 5.87 5.25e-09 12-25 glycoprotein (Lamp) 1155 IPB001124 Lipid-binding serum glycoprotein IPBOO1124C 25.71 7.71e-17 210-253 IPBOO1124D 21.85 5.71e-14 274-310 1156 IPB000135 High mobility group proteins HMG1 IPBO00135B 13.24 9.39e-10 84-128 and HMG2 IPBOO0135A 11.69 6.19e-09 111-165 1156 IPB003533 Doublecortin IPB003533H 6.52 7.5le-09 49-72 1159 IPBOO1510 Poly(ADP-ribose) polymerase zinc IPBOO151OD 30.92 1.00e-40 490-543 finger domain IPBOO151OE 22.53 1.00e-40 570-624 IPBOO1510A 34.80 7.21e-40 92-137 IPBO01510B 23.09 6.14e-34 306-348 IPBOO151OC 15.91 6.54e-27 363-396 1159 IPB000977 ATP-dependent DNA ligase IPB000977B 14.05 4.60e-13 508-517 IPB000977C 7.51 1.OOe-12 590-599 IPB000977A 8.89 1.47e-09 480-487 1160 IPB000215 Serpins IPBOO0215E 15.36 5.50e-23 401-425 IPB000215D 15.35 6.82e-21 317-343 IPBOO0215A 13.01 7.43e-18 27-50 IPBOO0215C 13.90 3,16e-12 207-221 IPBOO0215B 9.87 9.59e- 11 178-190 WO 2004/080148 PCT/US2003/030720 415 TABLE 3B 1166 IPB001309 ICE-like protease (caspase) p20 IPB001309A 10.71 3.57e-14 7-17 domain 1166 PR00376 Interleukin-1B converting enzyme PR00376A 12.81 1.61e-10 5-18 signature I 1168 IPB000364 Phosphoenolpyruvate carboxykinase IPB000364M 26.08 1.40e-09 589-623 (GTP) 1169 IPB001304 C-type lectin domain IPB001304A 17.98 6.50e-17 118-142 1171 PR00320 G protein beta WD-40 repeat PR00320B 12.82 6.62e-13 478-492 signature II 1171 PR00308 Type I antifreeze protein signature I PR00308A 3.72 8.17e-13 158-172 PR00320A 13.15 2.89e-12 478-492 PR00320C 12.32 4.18e-12 247-261 PR00320C 12.32 4.71e-12 478-492 PR00320B 12.82 7.75e-12 247-261 PR00320A 13.15 8.1le-12 427-441 PR00320A 13.15 9.05e-12 247-261 PR00308B 3.38 9.27e-12 161-172 PR00308A 3.72 9.76e-12 162-176 PR00308C 2.79 1.00e-11 161-170 1171 PRO1511 Kvl.4 voltage-gated K+ channel PRO151ID 3.91 3.02e-11 163-173 signature IV PR00320C 12.32 3.57e-1 1 427-441 PR00320B 12.82 5.09e-11 520-534 PR00320B 12.82 7.14e-11 427-441 PR00320A 13.15 7.55e-11 520-534 PR00320C 12.32 4.52e-10 520-534 1171 PR00833 Pollen allergen Poa pI signature VIII PR00833H 2.61 8.56e-10 164-178 PR00308C 2.79 8.77e-10 165-174 PRO1511D 3.91 9.88e-10 159-169 1171 IPB001680 G-protein beta WD-40 repeats IPB001680 10.43 1.45e-09 429-440 PR00308B 3.38 1.76e-09 165-176 IPB001680 10.43 3.70e-09 480-491 IPB001680 10.43 4.15e-09 249-260 1171 PR00456 Ribosomal protein P2 signature V PR00456E 3.08 5.08e-09 163-177 PR00308A 3.72 6.74e-09 159-173 PR00320A 13.15 7.75e-09 303-317 PR00833H 2.61 7.78e-09 161-175 PR00320B 12.82 8.45e-09 344-358 1171 IPBOO0102 Neuraxin / MAPIB repeat IPBOO0102A 10.50 8.88e-09 156-184 IPB001680 10.43 9.10e-09 522-533 IPBOO0102A 10.50 9.22e-09 160-188 PR00308B 3.38 9.75e-09 162-173 1175 IPB001559 Phosphotriesterase family IPB001559D 19.17 5.00e-20 176-202 IPB001559C 16.25 5.34e-16 141-162 IPB001559E 16.18 5.35e-16 214-232 IPB001559A 10.81 1.23e-11 18-29 IPB001559B 12.98 8.50e-10 122-132 1183 IPB003817 Phosphatidylserine decarboxylase IPB003817D 23.34 8.71e-25 338-364 IPB003817C 10.66 4.00e-15 316-328 IPB003817E 13.21 2.67e-14 427-443 IPB003817A 12.64 4.15e-13 162-176 1184 IPB000580 TSC-22 / Dip / Bun family IPB000580 14.33 1.00e-40 116-170 1185 PR00072 Malic enzyme signature IV PROO072D 12.09 9.29e-09 571-589 1187 PROO901 Pheromone B alpha-I receptor PR00901H 14.75 4.05e-09 56-66 signature VIII 1188 IPB002469 "Dipeptidyl peptidase IV, N- IPB002469I 10.99 4.86e-16 747-765 terminus" IPB002469H 21.17 6.14e-16 702-737 IPB002469J 8.97 3.52e-12 829-845 WO 2004/080148 PCT/US2003/030720 416 TABLE 3B 1188 IPB002471 Prolyl endopeptidase family serine IPB002471B 24.90 3.66e- 1 734-765 active site IPB002469G 26.76 9.24e-11 657-695 1189 IPB002469 "Dipeptidyl peptidase IV, N- IPB002469I 10.99 4.86e-16 747-765 terminus" IPB002469H 21.17 6.14e-16 702-737 IPB002469J 8.97 3.52e-12 791-807 1189 IPB002471 Prolyl endopeptidase family serine IPB002471B 24.90 3.66e- 1 734-765 active site IPB002469G 26.76 9.24e-11 657-695 1190 IPB002469 "Dipeptidyl peptidase IV, N- IPB002469I 10.99 4.86e-16 734-752 terminus" IPB002469H 21.17 6.14e-16 689-724 IPB002469J 8.97 3.52e-12 816-832 1190 IPB002471 Prolyl endopeptidase family serine IPB002471B 24.90 3.66e-11 721-752 active site IPB002469G 26.76 9.24e-11 644-682 1191 IPB000524 "Bacterial regulatory proteins, GntR IPB000524 18.80 7.19e-10 54-94 family" 1193 IPB000906 ZU5 domain IPB000906A 22.49 6.14e-19 241-283 JPB000906F 35.93 3.09e-16 159-212 IPBOO0906F 35.93 7.91e-16 192-245 1193 PR01415 Ankyrin repeat signature I PRO1415A 12.73 3.70e-15 348-360 IPBOO0906A 22.49 1.71e-14 142-184 PRO1415A 12.73 9.10e-13 799-811 IPBOO0906F 35.93 1.00e-12 442-495 IPBOO0906A 22.49 5.66e-12 208-250 IPBOO0906G 25.85 9.36e-12 149-197 PRO1415A 12.73 1.00e-11 1 1194 PR00834 HtrA/DegQ protease family signature PR00834C 15.48 7.35e-19 253-277 III PR00834D 11.75 7.39e-17 291-308 PR00834B 10.17 3.25e-13 212-232 PR00834E 13.43 6.03e-12 313-330 1194 IPB000126 "Serine proteases, V8 family" IPBOO0126B 12.50 6.81e-12 296-312 PR00834A 8.79 1.44e-11 191-203 PR00834F 11.11 1.53e-09 374-386 IPBOO0126A 11.75 9.83e-09 183-198 1195 PR00424 Adenosine receptor signature IV PR00424D 13.35 4.34e-22 21-40 1195 PR00555 Adenosine A3 receptor signature V PR00555E 7.35 4.75e-21 105-122 PR00555F 11.48 2.74e-20 152-169 PR00555D 10.79 9.36e-19 60-76 PR00424E 14.23 3.75e-14 74-87 1195 PR00237 Rhodopsin-like GPCR superfamily PR00237G 19.23 4.21e-14 119-145 signature VII PR00237F 14.34 9.28e-14 83-107 PR00237E 13.03 4.60e-12 33-56 1195 IPB000276 Rhodopsin-like GPCR superfamily IPB000276D 9.40 7.30e-12 129-145 PR00424F 8.75 9.07e-12 119-129 1197 PR00245 Olfactory receptor signature IV PR00245D 9.34 1.53e-13 241-250 PR00245C 14.65 1.56e-12 181-197 1197 IPB000276 Rhodopsin-like GPCR superfamily IPBOO0276A 11.56 5.20e-12 123-134 1197 PR00237 Rhodopsin-like GPCR superfamily PR00237C 14.77 6.73e-11 109-131 signature III PR00245E 8.96 3.30e-10 288-299 PR00237E 13.03 4.77e-10 204-227 PR00245A 10.98 3.65e-09 97-108 PR00245B 13.73 4.60e-09 134-146 1197 PR00534 Melanocortin receptor family PR00534A 12.77 8.43e-09 56-68 signature I 1198 PR00505 D12 class N6 adenine-specific DNA PR00505A 15.44 3.67e-12 30-46 methyltransferase signature I PR00505B 11.79 8.88e-12 51-65 1199 PR01254 Prostaglandin D synthase signature I PR01254A 12.32 6.38e-10 25-48 1199 PR00179 Lipocalin signature II PROO179B 7.67 2.35e-09 111-123 PROO179A 13.97 5.80e-09 31-43 WO 2004/080148 PCT/US2003/030720 417 TABLE 3B PR00179C 17.26 6.70e-09 138-153 1199 PRO 1174 Retinol binding protein signature VI PROI 174F 11.76 6.82e-09 110-126 PR01254E 14.07 8.23e-09 135-149 1199 PR01275 Neutrophil gelatinase lipocalin PR01275B 9.02 1.OOe-08 33-43 signature II 1200 PR01042 Aspartyl-tRNA synthetase signature PRO1042D 11.70 2.67e-14 432-446 IV PR01042B 12.76 4.69e-11 233-246 PRO1042C 16.81 5.50e-11 393-409 PR01042A 9.01 9.77e-10 217-229 1200 IPB002106 Aminoacyl-transfer RNA synthetases IPB002106A 13.35 1.00e-08 169-181 class-II 1201 PR01217 Proline rich extensin signature VII PRO1217G 4.02 8.03e-09 528-553 1202 IPB003952 Fumarate reductase / succinate 1PB003952E 9.04 2.46e-16 31-48 dehydrogenase FAD-binding site 1203 IPB001895 Guanine-nucleotide dissociation IPB001895C 20.83 8.50e-23 297-332 stimulators CDC25 family 1204 IPB000958 KH domain IPB000958 6.84 5.09e-12 112-125 1PB000958 6.84 2.29e-1 1 28-41 IPB000958 6.84 7.88e-10 276-289 1207 IPB001393 Calsequestrin IPB001393A 16.72 1.00e-40 29-78 IPB001393B 11.93 1.00e-40 132-185 IPB001393C 16.33 1.00e-40 188-240 IPBOO1393D 11.26 1.00e-40 283-335 1207 PR00312 Calsequestrin signature V PR00312E 8.61 7.75e-36 163-192 PR00312I 15.97 5.71e-35 326-354 PR00312F 16.12 7.87e-35 193-222 PR00312H 13.19 2.80e-34 257-284 PR00312J 13.61 6.48e-34 357-385 PR00312D 9.10 7.17e-33 122-151 PR00312B 14.57 4.41e-32 56-85 PR00312C 16.48 5.62e-32 86-115 PR00312G 11.43 1.49c-31 224-251 PR00312A 11.96 7.94e-27 29-52 1209 IPB002151 Kinesin light chain repeat IPBOO2151A 11.63 5.55e-10 275-305 1209 PR00985 Leucyl-tRNA synthetase signature I PR00985A 10.14 8.25e-09 515-532 1210 IPB000353 "Class II histocompatibility antigen, IPBOO0353B 19.16 7.89e-16 137-186 beta chain, beta-1 domain" 1210 IPB003006 Immunoglobulin and major IPB003006A 17.51 7.63e-15 158-180 histocompatibility complex domain 1210 IPBOO1003 "MHC Class I1, alpha chain, alpha-I IPBOO1003B 14.72 3.87e-10 145-188 domain" 1213 PR00205 Cadhcrin signature II PR00205B 20.09 8.31e-23 244-273 1213 IPB002126 Cadherin domain IPB002126B 12.04 5.80e-16 232-249 PR00205D 12.22 7.26e-15 436-455 PR00205F 19.57 1.64e-14 515-541 PR00205G 13.05 4.86e-14 549-566 PR00205A 17.38 7.88e-14 75-94 PR00205D 12.22 3.40e-13 331-350 PR00205D 12.22 5.80e-13 223-242 1214 IPB001580 Calreticulin family IPBO1580D 12.66 2.71e-38 259-294 IPBOO1580B 18.74 1.90e-35 166-201 1214 PR00626 Calreticulin signature IV PR00626D 7.86 9.00e-30 242-264 IPB001580A 12.93 8.71e-28 91-113 PR00626E 10.35 4.68e-23 280-299 PR00626B 14.56 6.06e-20 126-142 PR00626E 10.35 8.00e-19 266-285 PR00626A 14.93 6.50e-18 100-118 WO 2004/080148 PCT/US2003/030720 418 TABLE 3B PR00626C 9.33 8.71e-18 215-228 IPBOO1580C 9.76 1.56e-17 242-254 IPB001580D 12.66 2.38e-16 245-280 IPBOO1580D 12.66 8.34e-16 273-308 IPB0O1580C 9.76 4.30e-15 208-220 IPB001580C 9.76 4.16e-14 225-237 PR00626C 9.33 7.75e-12 232-245 PR00626D 7.86 9.14e-09 208-230 1215 IPB000006 "Vertebrate metallothionein, family IPB000006 13.41 3.90e-12 32-77 1" IPBO0006 13.41 4.41e-12 39-84 IPB000006 13.41 6.70e-11 35-80 1215 PR01228 Eggshell protein signature III PR01228C 5.69 1.22e-10 26-41 PR01228C 5.69 1.98e-10 10-25 1215 IPB001271 Mammalian defensin IPB001271 19.97 3.29e-10 51-79 1215 IPB002494 "Keratin, high sulfur B2 protein" IPB002494C 14.46 3.36e-10 45-88 IPB001271 19.97 3.47e-10 29-57 IPB002494A 12.44 6.11e-10 70-103 1215 IPB002174 Furin-like cysteine rich region IPB002174A 30.51 7.32e-10 11-42 IPB002174A 30.51 7.81e-10 3-34 PR01228C 5.69 8.05e-10 19-34 1215 IPB003571 Snake toxin IPB003571B 18.08 8.07e-10 76-99 IPB002494A 12.44 9.08e-10 25-58 1215 PR00858 Crustacean metallothionein signature PR00858B 5.93 1.48e-09 40-58 II IPB000006 13.41 3.1le-09 36-81 1215 IPBOO 169 "Integrin beta, C-terminus" IPBOOI 169K 27.45 3.19e-09 42-84 1215 IPB002919 Trypsin Inhibitor-like cysteine rich IPB002919A 15.56 3.57e-09 52-64 domain IPBOO2174A 30.51 4.15e-09 27-58 IPB001271 19.97 4.44e-09 58-86 IPB002494A 12.44 4.97e-09 32-65 PR01228C 5.69 5.03e-09 18-33 PRO1228C 5.69 5.03e-09 22-37 IPB002174A 30.51 5.28e-09 19-50 1215 IPB000254 "Cellulose-binding domain, fungal IPB000254 18.11 5.36e-09 28-58 type' IPB000006 13.41 5.59e-09 42-87 IPB002174A 30.51 5.72e-09 36-67 PR01228C 5.69 5.76e-09 27-42 1215 IPB000564 2Fe-2S Ferredoxin IPB000564A 17.31 6.49e-09 1-19 1215 IPB000867 Insulin-like growth factor-binding IPB000867B 11.44 6.55e-09 5-21 protein IPB002174A 30.51 6.62e-09 7-38 1215 IPB002867 Cysteine-rich domain (C6HC) IPB002867D 24.88 7.19e-09 38-69 IPB000006 13.41 7.24e-09 50-95 1215 IPB000967 Zinc finger NF-X1 type 1PB000967D 10.42 7.37e-09 60-95 IPBO0 1169K 27.45 7.81e-09 35-77 IPB000006 13.41 8.07e-09 3-48 1PB000006 13.41 8.07e-09 40-85 IPB002494A 12.44 8.35e-09 29-62 IPBO0006 13.41 8.44e-09 55-100 1215 PRO1117 CLC-6 chloride channel signature I PROI 1 17A 7.79 9.47e-09 51-63 IPB001271 19.97 9.5 1e-09 67-95 IPB002174A 30.51 9.77e-09 39-70 1215 IPB002221 WAP-type (Whey Acidic Protein) IPB002221B 17.12 1.00e-08 48-69 four-disulfide core domain 1218 PR00946 Mercury scavenger protein signature PR00946A 4.14 8.16e-09 6-24 1221 IPB002038 Osteopontin IPB002038C 22.35 1.00e-40 119-160 1221 PR00216 Osteopontin signature I PR00216A 11.45 9.71e-34 2-31 IPB002038B 15.58 2.06e-32 23-67 WO 2004/080148 PCT/US2003/030720 419 TABLE 3B PR00216C 9.12 5.85e-32 41-66 IPB002038A 12.23 5.15e-31 1-30 PR00216G 12.73 8.50e-30 231-256 PR00216F 12.92 1.62e-22 152-170 PR00216D 3.16 3.30e-18 88-102 PR00216E 6.95 3.81e-18 120-134 IPB002038D 9.52 5.50e-17 248-263 PR00216D 3.16 3.69e-12 82-96 1221 IPB003403 Herpesvirus immediate early protein IPB003403E 17.25 9.26e-09 63-90 1222 IPB000215 Serpins IPBOO0215A 13.01 9.14e-18 107-130 IPBOO0215D 15.35 3.74e-17 332-358 IPBOO0215E 15.36 6.68e-16 419-443 IPB000215C 13.90 7.88e-15 229-243 1223 IPB003006 Immunoglobulin and major 1PB003006B 20.23 3.52e-10 279-316 histocompatibility complex domain IPBOO3006A 17.51 7.75e-09 141-163 1225 IPBOO1241 DNA topoisomerase II family IPBOO1241F 23.94 8.36e-37 399-447 1225 PRO1158 Topoisomerase II signature VIII PROI 158H 13.39 5.50e-30 728-750 IPBOO124IG 14.13 1.00e-29 471-497 PRO1 158K 14.14 5.24e-27 947-973 PROI 158G 9.37 5.91e-27 681-704 1225 1PB002205 "DNA gyrase/topoisomerase IV, IPB002205B 14.49 4.79e-24 684-719 subunit A" IPBOO1241E 20.94 3.00e-22 295-321 PROI158I 13.95 7.00e-22 758-778 PRO1158D 11.94 5.24e-21 489-504 1225 PR00418 DNA topoisomerase II family PR00418F 13.13 3.40e-20 470-486 signature VI IPB001241B 10.04 2.71e-19 96-114 PR00418G 12.91 8.94e-19 488-505 IPB001241H 17.27 1.96e-18 732-755 1225 PR00615 CCAAT-binding transcription factor PR00615A 17.09 2.93c-18 243-261 subunit A signature I PRO1 158J 13.56 3.45e-18 863-877 IPB002205D 10.13 3.54e-18 791-812 PR00615B 18.03 3.77e-18 631-649 PRO0418C 9.38 1.82e-17 100-114 PR00418I 17.21 4.60e-17 550-566 IPBOO2205A 8.13 9.54e-17 653-671 PR00418A 13.58 7.65e-16 20-35 PRO1158C 11.35 1.00e-15 443-456 PRO1158E 8.11 2.29e-15 509-520 PROI158F 10.39 4.71e-15 556-568 PR00615C 17.93 8.50e-15 1072-1090 PR00418E 14.82 1.37e-14 397-411 IPBOO1241D 14.87 1.43e-14 252-265 PR00418B 12.37 2.57e-14 57-70 PR00418D 14.25 2.71e-14 252-265 PRO1158A 7.61 4.60e-13 380-390 IPB002205C 11.89 5.09e--12 736-750 PR00418H 10.58 5.91e-12 508-520 IPBOO1241C 13.37 1.31e-11 154-166 1225 IPB000509 Ribosomal protein L36E IPB000509B 20.29 7.85e-11 1140-1194 PRO1158B 8.30 1.27e-10 395-402 1225 IPB000135 High mobility group proteins HMGl IPBOO0135D 2.13 5.64e-09 1286-1310 and HMG2 IPBOO0135D 2.13 7.45e-09 1287-1311 IPBOO0135D 2.13 8.09e-09 1288-1312 1225 PR01469 Bacterial carbamate kinase signature PR01469E 10,60 8.43e-09 52-70 V IPBOO0135D 2.13 8.73e-09 1284-1308 1226 IPB000873 AMP-dependent synthetase and IPB000873A 11.08 1.50e-12 248-263 ligase 1226 PR00154 AMP-binding signature I. PROO154A 8.79 5.14e-09 241-252 WO 2004/080148 PCT/US2003/030720 420 TABLE 3B 1227 IPB001043 "Vinculin, type 1" IPBOO1043E 22.70 9.08e-09 136-173 1228 IPB001073 Complement Clq protein IPBOO1073B 20.88 3.48e-24 96-130 IPBOO1073C 13.07 4.50e-13 163-182 IPBOO1073A 22.14 6.55e-13 42-76 1228 PRO007 Complement CIQ domain signature PR0007B 15.63 9.56e-13 116-135 II IPBOO1073D 7.60 1.00e-11 195-204 PR00007D 9.66 2.00e-11 193-203 PR00007C 16.13 7.38e-11 163-184 PR0007A 20.64 3.04e-10 89-115 1230 IPB000906 ZU5 domain IPBOO0906A 22.49 1.99e-15 274-316 1230 PR01415 Ankyrin repeat signature I PRO1415A 12.73 3.70e-15 381-393 IPBOO0906G 25.85 6.04e-12 900-948 IPBOO0906A 22.49 2.24e-1 1 893-935 PRO1415A 12.73 1.00e-10 281-293 IPBOO0906F 35.93 1.61e-10 225-278 PRO1415A 12.73 2.45e-10 796-808 IPBOO0906D 23.89 3.88e-10 3 1230 PR00665 Oxytocin receptor signature V PR00665E 6.24 6.76e-09 756-769 IPBOO0906E 22.11 7.22e-09 278-318 PRO1415B 10.23 7.75e-09 260-272 PRO1415B 10.23 9.25e-09 227-239 1231 IPB001124 Lipid-binding serum glycoprotein IPBOO124C 25.71 7.71e-17 210-253 IPB001124D 21.85 5.71e-14 274-310 1232 1PBOO1 124 Lipid-binding serum glycoprotein IPB0O1 124C 25.71 7.71e-17 210-253 IPB001124D 21.85 5.71e-14 274-310 1233 IPB001124 Lipid-binding serum glycoprotein IPBO1124C 25.71 7.71e-17 210-253 IPB001124D 21.85 5.71e-14 274-310 1234 PR00053 Fork head domain signature 11 PROO053B 12.24 8.50e-09 523-540 1236 IPB000258 Bacterial ice-nucleation proteins IPB000258G 8.61 7.77e-09 92-145 octamer repeat 1237 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 6.57e-13 253-290 histocompatibility complex domain 1240 IPB001627 Sema domain IPB001627F 22.05 5.09e-29 255-288 IPB001627G 21.49 2.17e-28 311-344 IPB001627C 21.13 1.22e-21 162-193 IPB001627B 18.84 1.79e-21 117-145 1240 IPB002165 Plexin repeat IPB002165C 18.49 3.45e-19 255-287 IPB0016271 10.67 6.57e-15 386-399 IPB001627A 16.97 5.26e-14 98-113 IPB001627H 10.22 1.35e-13 358-370 IPB001627K 13.76 7.92e-13 524-536 1PB001627J 11.43 1.22c-12 436-452 IPB002165C 18.49 3.64e-12 254-286 IPB002165D 14.72 3.65e-12 524-536 IPB001627D 16.04 6.70e-12 209-224 [PB002165B 13.59 7.57e-12 136-145 IPB001627E 8.70 9.59e-12 230-239 1247 PROO011 Type III EGF-like signature IV PR0001ID 12.12 8.93e-16 767-785 PROO011D 12.12 1.00e-15 550-568 PRO01l1B 13.08 5.06e-15 767-785 PROM11B 13.08 6.65e-15 289-307 PRO00I0D 12.12 6.67e-15 289-307 PROOI A 14.05 2.53e-14 289-307 PRO00I0D 12.12 5.86e-14 638-656 PRO011B 13.08 8.50e-14 550-568 PRO0011B 13.08 1.93e-13 160-178 PRO01l1B 13.08 2.55e-13 203-221 WO 2004/080148 PCT/US2003/030720 421 TABLE 3B PR00011B 13.08 2.86e-13 421-439 PROOID 12.12 3.83e-13 378-396 PR00011D 12.12 6.00e-13 421-439 PROO011A 14.05 7.83e-13 378-396 PROO011A 14.05 9.53e-13 203-221 PROOOI1B 13.08 9.53e-13 378-396 PR001D 12.12 1.00e-12 810-828 PROO1B 13.08 1.59e-12 810-828 PR00011A 14.05 2.05e-12 550-568 PROM011D 12.12 3.02e-12 203-221 PROM1l1B 13.08 4.84e-12 638-656 PROM11D 12.12 5.50e-12 160-178 PROM01D 12.12 7.67e-12 507-525 1247 1PB000561 EGF-like domain IPB000561 4.89 7.75e-12 210-218 PRM001D 12.12 8.29e-12 332-350 PROOO11A 14.05 8.65e-12 421-439 PROO011A 14.05 1.55e-11 767-785 PROOIlD 12.12 1.73e-11 593-611 PROOO1A 14.05 3.08e-11 638-656 PROM011B 13.08 5.43e-11 593-611 PROOO11D 12.12 6.66e-11 464-482 PROW011B 13.08 7.78e-11 332-350 PROO0ID 12.12 7.82e-11 724-742 1247 IPB000034 Laminin B IPB00034C 12.97 8.04e-11 210-228 PROM011A 14.05 8.34e-11 724-742 PROMI0IA 14.05 8.62e-11 160-178 PROM011B 13.08 9.03e-11 246-264 PROOO11A 14.05 1.40e-10 810-828 PROO011B 13.08 1.53e-10 724-742 PR00011A 14.05 1.93e-10 507-525 PROO011D 12.12 2.25e-10 246-264 PROO011B 13.08 2.59e-10 507-525 PR000 I1A 14.05 4.04e-10 464-482 1247 IPB001774 Delta serrate ligand IPB001774C 18.25 4.35e-10 115-157 IPB000561 4.89 4.75e-10 296-304 PROM011A 14.05 5.63e-10 246-264 1247 IPB001886 Laminin N-terminal (Domain VI) IPB001886E 10.90 7.17e-10 294-310 PROOO1ID 12.12 8.20e-10 681-699 PR00011B 13.08 1.25e-09464-482 IPB000561 4.89 1.64e-09 731-739 PROO01A 14.05 2.00e-09 332-350 PROW0 I0A 14.05 2.75e-09 681-699 1247 PR00764 Complement C9 signature VI PR00764F 15.74 3.96e-09 237-257 1247 IPB002174 Furin-like cysteine rich region IPB002174A 30.51 4.60e-09 785-816 PROM011A 14.05 4.87e-09 593-611 1247 IPB002899 EB module IPB002899A 6.67 6.32e-09 415-421 IPB002899A 6.67 6.32e-09 761-767 1247 IPB002494 "Keratin, high sulfur B2 protein" IPB002494A 12.44 6.32e-09 652-685 1247 IPB003884 Factor I membrane attack complex [PB003884F 16.26 7.27e-09 587-602 IPB00034C 12.97 7.55e-09 296-314 IPB001886E 10.90 7.83c-09 772-788 IPB000561 4.89 8.71e-09 645-653 IPB000561 4.89 8.71e-09 688-696 PR00011B 13.08 8.77e-09 681-699 IPB000561 4.89 1.00e-08 253-261 1249 IPB002867 Cysteine-rich domain (C6HC) IPB002867D 24.88 5.04e-18 129-160 1249 PR01475 Parkin signature IX PR01475I 10.01 8.01e-09 86-108 1254 IPB002209 HBGF (heparin binding growth IPB002209B 26.84 8.50e-31 90-128 WO 2004/080148 PCT/US2003/030720 422 TABLE 3B factor)/FGF (fibroblast growth IPB002209C 23.35 1.00e-19 137-164 factor) family 1254 PR00262 ILI/HBGF family signature I PR00262A 25.25 4.38e-il 77-104 1254 PR00263 Heparin binding growth factor family PR00263D 13.56 5.57e-1 1 106-125 signature IV PR00263C 8.53 7.51e-10 90-102 PR00262B 23.59 1.00e-08 108-128 1258 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 7.48e-10 165-202 histocompatibility complex domain 1260 IPB000956 Stathmin IPB000956B 9.49 7.36e-11 208-241 1260 PR00345 Stathmin family signature II PR00345B 6.89 9.15e-11 207-235 1260 IPB000533 Tropomyosin IPB000533C 10.81 3.06e-09 113-154 1261 IPBOO0215 Serpins IPB000215D 15.35 5.03e-14 324-350 IPB000215A 13.01 2.91e-12 49-72 IPBOO0215C 13.90 5.00e-09 216-230 1262 PR01377 Claudin-1 signature I PR01377A 7.94 1.00e-16 22-33 1263 PR00328 GTP-binding SARI protein signature PR00328A 12.43 5.14e-12 27-50 1 PR00328B 7.64 2.38e-11 55-79 1263 IPBOO0251 ADP-ribosylation factors family IPBOO0251A 23.98 9.70e-09 55-108 1264 IPB001919 "Cellulose-binding domain, bacterial IPB001919B 14.22 2.97e-09 270-294 type" 1265 PR00258 Speract receptor signature II PR00258B 7.94 3.00e-16 493-504 PR00258C 9.05 3.70e-14 62-72 PR00258C 9.05 7.30e-14 508-518 PR00258A 13.56 4.34e-13 474-490 PR00258D 14.29 2.66e-12 93-107 PR00258D 14.29 4.55e-12 539-553 PR00258A 13.56 7.20e-11 133-149 PR00258D 14.29 4.53e-10 294-308 PR00258A 13.56 6.22e-10 229-245 PR00258C 9.05 4.83e-09 163-173 PR00258E 14.06 5.72e-09 215-227 PR00258E 14.06 7.20e-09 562-574 1266 PR00258 Speract receptor signature II PR00258B 7.94 3.00e-16 493-504 PR00258C 9.05 3.70e-14 62-72 PR00258C 9.05 7.30e-14 508-518 PR00258A 13.56 4.34e-13 474-490 PR00258D 14.29 2.66e-12 93-107 PR00258D 14.29 4.55e-12 539-553 PR00258A 13.56 7.20e-11 133-149 PR00258D 14.29 4.53e-10 294-308 PR00258A 13.56 6.22e-10 229-245 PR00258C 9.05 4.83e-09 163-173 PR0025S8E 14.06 5.72e-09 215-227 PR00258E 14.06 7.20e-09 562-574 1270 PR01305 Invasion protein B family signature PRO1305D 7.82 6.19e-09 423-436 IV 1273 IPB001245 Tyrosine kinase catalytic domain IPB001245A 22.45 1.00e-27 207-247 1273 IPB003527 MAP kinase iPB003527C 14.70 2.94e-27 199-247 1273 IPB000961 Protein kinase C-terminal domain IPBOO0961C 15.48 5.95e-22 214-248 IPB003527D 21.53 2.80e-17 256-297 1273 IPB001772 Kinase associated domain 1 IPB001772C 20.66 3.29c-17 202-232 1273 IPB000095 PAK-box /P21-Rbo-binding IPB00095E 17.62 6.35e-17 215-260 1273 IPB000861 PKN/rhophilin/rhotekin rho-binding IPBOO0861F 16.50 9.81e-16 208-262 repeat 1273 IPB000959 POLO box duplicated region IPB000959B 15.68 3.Ole-14 191-231 1273 IPB000494 "Epidermal growth-factor receptor IPB000494C 24.40 7.88e-14 201-247 (EGFR), L domain" IPB001245B 21.68 6.19e-13 263-301 WO 2004/080148 PCT/US2003/030720 423 TABLE 3B IPB003527G 17.26 3.20e-10 360-397 IPB000961D 21.23 5.27e-10 259-300 IPBOO0961A 16.82 3.33e-09 102-136 1273 PR00109 Tyrosine kinase catalytic domain PR00109B 11.07 7.75e-09 214-232 signature II 1275 IPB001762 Disintegrin IPB001762A 23.93 4.33e-23 458-498 1275 IPB002870 Reprolysin family propeptide IPB002870B 24.73 3.54e-20 131-169 1275 PR00289 Disintegrin signature I PR00289A 14.29 1.16e-14 474-493 IPB002870F 18.81 3.03e-14 402-426 fPB002870E 11.90 2.46e-12 361-373 IPB001762B 10.06 3.40e-12 505-515 IPB001762A 23.93 9.20e-11 426-466 1275 IPBOO0130 "Neutral zinc metallopeptidases, IPBOO0130 5.86 1.56e-10 359-369 zinc-binding region" 1275 PR00138 Matrixin signature IV PR00138D 14.57 2.54e-10 359-384 IPB002870D 16.31 4.77e-10 327-342 1275 IPB001774 Delta serrate ligand IPB001774C 18.25 5.31e-10 677-719 1275 PR00480 Astacin family signature II PR00480B 14.35 5.57e-10 354-372 1275 PR00436 Interleukin-8 signature I PR00436A 15.20 7.43e-10 5-28 1275 IPB001818 Matrixin IPBOO1818D 14.91 1.72e-09 353-384 PR00289B 11.74 3.80e-09 503-515 IPB002870A 12.22 6.54e-09 85-101 1275 IPB003306 WIF domain IPB003306E 25.51 7.40e-09 654-699 1275 PR01236 Tumour necrosis factor beta PR01236A 4.92 7.49e-09 17-33 (lymphotoxin-alpha) signature I IPB002870C 11.01 9.64e-09 295-305 1277 PR01415 Ankyrin repeat signature I PR01415A 12.73 1.00e-12 341-353 PR01415A 12.73 2.29e-11 302-314 1277 PR01256 Otx1 transcription factor signature II PR01256B 5.92 4.44e-09 431-443 PR01256B 5.92 9.39e-09 432-444 1278 PR00756 Membrane alanyl dipeptidase (M1) PR00756D 10.78 7.75e-18 412-427 family signature IV PR00756A 12.71 1.45e-17 245-260 PR00756B 15.53 2.04e-14297-312 PR00756E 10.37 5.68e-09 431-443 1278 IPBOO0130 "Neutral zinc metallopeptidases, IPBOO0130 5.86 6.57e-09 412-422 zinc-binding region" 1278 IPB002594 Glycoside hydrolase family 12 IPB002594A 4.24 1.00e-08 26-35 1288 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 6.85e-13 252-266 domain 1288 PROO019 Leucine-rich repeat signature I PROO019A 11.72 5.64e-09 164-177 1288 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 6.19e-09 348-385 histocompatibility complex domain PROO019B 11.42 8.91e-09 112-125 1290 PROO019 Leucine-rich repeat signature 1I PROO019B 11.42 4.18e-12 83-96 PROO019A 11.72 1.00e-10 86-99 PROO019A 11.72 1.67e-10 111-124 1290 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 7.43e-10 131-145 domain 1290 IPB000267 Asparaginase/glutaminase family IPB000267A 12.78 7.67e-09 11-27 1290 PR01528 EDG-4 lysophosphatidic acid PR01528B 3.89 8.48e-09 130-144 receptor signature II 1292 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 5.85e-09 195-232 histocompatibility complex domain 1293 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 5.85e-09 195-232 histocompatibility complex domain 1295 IPB001073 Complement Clq protein IPBOO1073B 20.88 6.35e-20 92-126 1295 PROO07 Complement CIQ domain signature PR0007C 16.13 5.93e-14 159-180 III PR0007B 15.63 1.66e-13 112-131 IPBOO1073C 13.07 2.25c-13 159-178 WO 2004/080148 PCT/US2003/030720 424 TABLE 3B IPB001073D 7.60 6.40e-12 191-200 IPBOO1073A 22.14 4.67e-11 32-66 PRO007D 9.66 6.29e-10 189-199 PRO007A 20.64 3.68e-09 86-112 1295 PR00513 5-hydroxytryptamine 1B receptor PR00513D 10.60 9.80e-09 50-67 signature IV 1296 PR01481 Neurotensin type 2 receptor signature PR01481F 11.66 8.46e-28 236-259 VI PRO1481E 6.05 7.87e-25 214-235 PRO1481C 15.05 1.OOe-17 150-163 1296 PR01479 Neurotensin receptor signature II PR01479B 12.40 2.43e-17 89-101 PRO1481A 7.58 3.54e-16 1-13 PRO1481B 6.68 1.45e-15 14-26 PRO1481D 4.62 2.19e-15 164-175 PR01479E 8.74 3.70e-15 305-3 15 PR01479D 13.10 6.57e-14 294-304 PR01479A 8.89 1.00e-13 29-39 1296 PR00237 Rhodopsin-like GPCR superfamily PR00237F 14.34 9.33e-13 269-293 signature VI PR00237G 19.23 4.44e-12 314-340 1296 PR00665 Oxytocin receptor signature IV PR00665D 10.30 1.32e-1 1108-124 PR01479F 8.03 5.19e-11 342-352 PR00237A 9.81 7.33e-10 34-58 __ _ PR00237D 9.76 7.43e-10 125-146 1297 IPBOO11 Plectin repeat IPBOO1101C 6.05 3.42e-35 894-946 1297 IPBOO1589 Actinin-type actin-binding domain IPBOO1589C 16.73 1.78e-31 285-316 IPB001589D 26.07 2.55e-27 340-383 IPBOO1101M 9.29 7.80e-27 1607-1657 IPBOO10Z 7.76 2.12e-25 3013-3066 IPBOO1101B 12.20 1.00e-24 791-844 IPBOO1101F 10.86 3.20e-22 1078-1126 IPBOO1101E 6.00 7 1297 IPBOO2017 Spectrin repeat IPBOO2017A 14.19 3.25e-11 246-262 IPBOO1101Q 7.28 8.69e-11 2855-2892 IPBOO1101S 8.38 9.52e-11 2695-2738 IPBO011O01N 4.86 2.32e-10 1779-1833 IPB00101N 4.86 3.81e-10 1758-1812 IPBOO1101N 4.86 3.87e-10 1737-1791 IPB00101R 5.90 3.91e-10 3112-3165 IPBOOI1T 7.36 5.Ole-10 2720-2774 IPBO0I 101W 10.36 5.46e-10 3033-3062 IPBOOI 101T 7.36 5.53e-10 3067-3121 IPBOO1IOIR 5.90 2.07e-09 2727-2780 1297 IPB000237 GRIP domain IPB000237B 30.66 2.76e-09 2392-2442 IPB011OIQ 7.28 3.27e-09 3166-3203 1297 IPB001664 Intermediate filament proteins IPB001664B 17.44 5.92e-09 1742-1781 IPBOO110 8.21 6.25e-09 1767-1800 1297 IPB002079 "Gag polyprotein, inner coat protein IPB002079J 10.53 6.85e-09 1766-1794 p 12 " 1297 IPB001715 Calponin homology (CH) domain IPBOO1715A 10.74 7.00e-09 241-251 IPBOO11O1W 10.36 7.63e-09 2798-2827 IPBOO1589E 11.55 8.94e-09 389-398 1297 IPB003865 Prolyl 4-hydroxylase alpha subunit IPB003865A 20.35 9.33e-09 2093-2137 C-terminus IPBOO11O1X 9.00 9.86e-09 3063-3096 1298 IPBOO1101 Plectin repeat IPBOO1101C 6.05 3.42e-35 906-958 1298 IPB001589 Actinin-type actin-binding domain IPBOO1589C 16.73 1.78e-31 297-328 IPBOO1589D 26.07 2.55e-27 352-395 IPBOO11O1M 9.29 7.80e-27 1619-1669 IPBOO1101Z 7.76 2.12e-25 3025-3078 WO 2004/080148 PCT/US2003/030720 425 TABLE 3B IPBOO1101B 12.20 1.00e-24 803-856 IPBOO1101F 10.86 3.20e-22 1090-1138 IPBOO11O1E 6.00 7 1298 IPB002017 Spectrin repeat IPB002017A 14.19 3.25e-11 246-262 IPBO01101Q 7.28 8.69e-11 2867-2904 IPBOO11OIS 8.38 9.52e-11 2707-2750 IPBOOI11N 4.86 2.32e-10 1791-1845 IPBOO110IN 4.86 3.81e-10 1770-1824 IPB01101N 4.86 3.87e-10 1749-1803 IPBOO1101R 5.90 3.91e-10 3124-3177 IPB0O11O1T 7.36 5.01e-10 2732-2786 IPBOO1101W 10.36 5.46e-10 3045-3074 IPBOOIIO1T 7.36 5.53e-10 3079-3133 IPBOO1101R 5.90 2.07e-09 2739-2792 1298 1PB000237 GRIP domain IPB000237B 30.66 2.76e-09 2404-2454 IPBOO1101Q 7.28 3.27e-09 3178-3215 1298 IPB001664 Intermediate filament proteins IPB001664B 17.44 5.92e-09 1754-1793 IPBOO11010 8.21 6.25e-09 1779-1812 1298 IPB002079 "Gag polyprotein, inner coat protein IPB002079J 10.53 6.85e-09 1778-1806 p12" 1298 IPBOO1715 Calponin homology (CH) domain IPBOO1715A 10.74 7.00e-09 241-251 IPBOOI 101W 10.36 7.63e-09 2810-2839 IPB001589E 11.55 8.94e-09 401-410 1298 IPB003865 Prolyl 4-hydroxylase alpha subunit IPB003865A 20.35 9.33e-09 2105-2149 C-terminus IPBOOI1O1X 9.00 9.86e-09 3075-3108 1306 IPB000998 MAM domain 1PB000998C 18.63 9.65e-15 510-525 IPB000998D 18.66 2.41e-14 575-598 IPB000998B 17.20 4.55e-10 430-442 1306 PROO020 MAM domain signature I PROO020A 20.48 7.62e-10 428-446 PROO020C 12.01 4.78e-09 509-520 1308 IPBOO1552 Acyl-CoA dehydrogenase IPBOO1552E 22.77 2.46e-19 726-766 IPBOO1552D 24.88 5.35e-19 635-677 IPBOO1552C 25.04 7.75e-15 581-621 IPBOO1552B 18.05 3,19e-12 530-552 IPBOO1552A 11.25 6.90e-10 503-514 1309 IPBOO1552 Acyl-CoA dehydrogenase IPB001552E 22.77 2.46e-19 708-748 IPBOO1552D 24.88 5.35e-19 617-659 IPBOO1552C 25.04 7.75e-15 563-603 IPB001552B 18.05 3.19e-12 512-534 IPBOO1552A 11.25 6.90e-10 485-496 1310 IPB002524 Cation efflux family IPB002524B 23.89 5.20e-17 86-125 1310 IPB003452 Stem cell factor IPB003452B 19.11 6.63e-09 145-193 1311 PR00215 Neuromodulin signature III PR00215C 13.82 7.58e-10 743-763 1311 PR00194 Tropomyosin signature IV PRO0194D 9.54 7.19e-09 622-645 1311 IPB001422 Neuromodulin (GAP-43) IPB001422A 13.23 7.43e-09 718-762 1314 IPB000569 HECT domain (Ubiquitin-protein IPB000569C 20.19 8.94e-30 2270-2299 ligase) 1314 IPBOO0135 High mobility group proteins HMGI IPB000135D 2.13 9.00e-17 361-385 and HMG2 IPBOO0135D 2.13 7.04e-16 370-394 IPBOO0135D 2.13 3.70e-15 360-384 IPBOO0135D 2.13 5.50e-15 364-388 IPBOO0135D 2.13 7.43e-15 367-391 IPBOOO135D 2.13 7.94e-15 365-389 IPB000569A 16.82 8.58e-15 2 1314 IPBOO1580 Calreticulin family IPBOO158OF 2.93 5.50e-10 370-379 1314 IPB001990 Granins (chromogranin or IPBOO1990C 33.59 6.26e-10 352-399 secretogranin) IPB00158OF 2.93 7.75e-10 369-378 WO 2004/080148 PCT/US2003/030720 426 TABLE 3B IPB000135D 2.13 8.34e-10 351-375 IPBOO0569B 18.58 8.92e-10 2233-2249 1314 IPB003403 Herpesvirus immediate early protein IPB003403E 17.25 8.97e-10 359-386 1314 IPB002889 WSC domain IPB002889B 11.76 2.88e-09 1392-1438 IPB000135D 2.13 4.09e-09 381-405 IPB000135D 2.13 4.18e-09 352-376 IPB000135D 2.13 4.36e-09 353-377 IPB002889B 11.76 4.66e-09 1440-1486 1314 IPB002000 Lysosome-associated membrane IPB002000D 5.87 6.26e-09 1429-1442 glycoprotein (Lamp) IPBOO0135D 2.13 6.27e-09 349-373 IPBOO158OF 2.93 6.40e-09 374-383 IPB000135D 2.13 6.45e-09 382-406 IPB002889B 11.76 6.81e-09 1458-1504 IPBOO2000D 5.87 7.1 1e-09 1434-1447 IPB002889B 11.76 7.47e-09 1417-1463 IPBOO1990C 33.59 7.5le-09 347-394 IPBOO0135D 2.13 8.36e-09 350-374 IPB002889B 11.76 9.53e-09 1402-1448 1314 IPB000637 HMG-I and HMG-Y DNA-binding IPB000637B 14.21 9.73e-09 369-387 domain (A+T-hook) 1314 PR01073 Presenilin 1 signature III PRO1073C 1.45 9.89e-09 367-378 1317 PR01145 Thyrotropin receptor precursor PR01145A 6.74 9.1Oe-11 3-22 signature I 1317 PR01472 Intercellular adhesion PR01472A 16.78 7.66e-09 35-51 molecule/vascular cell adhesion molecule-I signature I 1321 PROO019 Leucine-rich repeat signature II PROO019B 11.42 7.88e-12 335-348 PROO019B 11.42 1.33e-10477-490 PROO019A 11.72 4.00e-10 480-493 PROO019A 11.72 4.33e-10 338-351 1321 IPB001580 Calreticulin family IPBOO158OF 2.93 4.94e-10 648-657 IPBOO158OF 2.93 4.94e-10 649-658 IPBOO158OF 2.93 4.94c-10 650-659 PROO019B 11.42 5.33e-10 167-180 PROO019A 11.72 4.00e-09 454-467 1321 IPB000135 High mobility group proteins HMG1 IPBO00135D 2.13 4.64e-09 637-661 and HMG2 PROO019B 11.42 7.55e-09 193-206 PRO0019B 11.42 7.55e-09 309-322 PRO0019B 11.42 7.82e-09 451-464 IPBOO0135D 2.13 8.55e-09 635-659 1322 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 9.14e-12 297-334 histocompatibility complex domain 1322 IPB0OIOOO Glycoside hydrolase family 10 IPBOOOOOH 10.38 7.80e-09 8-21 1323 IPB0O1000 Glycoside hydrolase family 10 IPBOOOOOH 10.38 7.80e-09 8-21 1324 IPB003884 Factor I membrane attack complex IPB003884A 12.20 7.06e-09 34-45 1328 PR00258 Speract receptor signature II PR00258B 7.94 5.00e-16 654-665 PR00258B 7.94 6.50e-16 30-41 PR00258B 7.94 6.50e-16 204-215 PR00258A 13.56 9.70e-14 635-651 PR00258B 7.94 2.58e-13 316-327 PR00258E 14.06 4.16e-13 491-503 PR00258A 13.56 5.63e-13 402-418 PR00258A 13.56 6.14e-13 185-201 PR00258B 7.94 6.62e-13 421-432 PR00258C 9.05 9.18e-13 45-55 PR00258A 13.56 1.22c-12 11-27 PR00258A 13.56 1.22e-12 297-313 WO 2004/080148 PCT/US2003/030720 427 TABLE 3B PR00258E 14.06 1.98e-12 99-111 PR00258E 14.06 9.22e-12 273-285 PR00258D 14.29 2.00e-11 468-482 PR00258D 14.29 3.20e-11 700-714 PR00258D 14.29 2.76e-10 250-264 PR00258C 9.05 4.95e-10 219-229 PR00258C 9.05 4.95e-10 331-341 PR00258E 14.06 5.42e-10 385-397 PR00258D 14.29 8.06e-10 362-376 PR00258C 9.05 7.5 1e-09 436-446 1333 IPB000970 "Developmental signaling protein, IPBOO0970E 22.74 1.00e-40 202-255 Wnt-1 family" IPBOO097OF 23.43 1.5le-40 307-355 IPBOO0970C 13.22 2.80e-25 101-132 IPBOO0970B 14.73 6.14e-23 65-88 1333 PR01349 Wnt protein signature IV PR01349D 8.90 3.81e-20 222-237 IPBOO0970D 13.85 3.48e-17 167-186 PR01349C 10.34 3.86e-15 167-179 PR01349A 11.18 8.55e-14 103-117 PR01349B 10.00 3.32e-12 122-135 PR01349E 12.39 5.61e-11 283-294 1333 IPBOO1073 Complement CIq protein IPBOO1073A 22.14 4.20e-10 137-171 IPBOO0970A 13.08 5.78e-10 41-56 1335 PR00245 Olfactory receptor signature I PR00245A 10.98 8.92e-11 59-70 1335 PR00534 Melanocortin receptor family PR00534A 12.77 3.61e-09 18-30 signature I 1337 IPB001522 "Fatty acid desaturase, type 1" IPBOO1522D 12.81 1.00e-40 119-154 IPB001522F 22.32 1.00e-40 241-295 IPB001522E 20.55 5.85e-36 163-216 IPBOO1522C 14.10 2.89e-33 81-117 1337 PR00075 Fatty acid desaturase family I PROO075D 13.27 3.57e-33 131-160 signature IV PROO075C 10.51 3.40e-22 94-114 PROO075G 10.50 6.62e-20 268-282 PROO075E 11.60 6.46e-18 192-210 PROO075A 16.73 9.44e-17 47-67 PR075F 14.62 8.8 1e-16 225-246 PR00075B 13.44 4.56e-14 71-93 IPB001522B 29.55 6.82e-12 29-80 1339 IPB000135 High mobility group proteins HMGI IPBOO0135D 2.13 2.57e-17 46-70 and HMG2 IPBOO0135D 2.13 9.86e-17 43-67 IPBOO0135D 2.13 6.lOe-16 45-69 IPBOO0135D 2.13 1.77e-15 47-71 IPB000135D 2.13 2.93c-15 44-68 IPBOO0135D 2.13 3.83e-15 41-65 IPB000135D 2.13 2.95e-14 48-72 IPB000135D 2.13 7.93e-14 42-66 IPBOO0135D 2.13 7.81e-13 49-73 1339 IPBOO1422 Neuromodulin (GAP-43) IPB001422C 16.82 3.41e-11 40-75 IPBOO0135D 2.13 9.08e-11 40-64 IPBOO0135D 2.13 9.69e-11 50-74 1339 IPB001580 Calreticulin family IPB001580F 2.93 1.00e-10 50-59 IPB000135D 2.13 2.17e-10 51-75 IPB000135D 2.13 3.15e-10 39-63 IPBOO158OF 2.93 4.94e-10 57-66 IPBOO158OF 2.93 4.94e-10 58-67 IPBOO158OF 2.93 5.50e-10 56-65 IPBOO158OF 2.93 6.06c-10 54-63 IPBOO158OF 2.93 7.75e-10 49-58 IPB001422C 16.82 7.99e-10 43-78 WO 2004/080148 PCT/US2003/030720 428 TABLE 3B IPB001422C 16.82 8.58e-10 42-77 IPB000135D 2.13 8.63e-10 38-62 IPB001580F 2.93 8.88e-10 51-60 IPB001422C 16.82 9.05e-10 46-81 IPB001580F 2.93 9.44e-10 59-68 IPB001422C 16.82 5.61e-09 48-83 IPB000135D 2.13 6.27e-09 37-61 IPB001422C 16.82 6.40e-09 44-79 IPB001580F 2.93 6.40e-09 52-61 IPB001422C 16.82 8.99e-09 47-82 1339 IPB000637 HMG-I and HMG-Y DNA-binding IPB000637B 14.21 1.00e-08 45-63 domain (A+T-hook) IPB001580F 2.93 1.00e-08 61-70 1340 1PB004000 Actin and actin-like IPB004000C 8.66 4.86e-20 137-191 IPB004000D 13.38 5.70e-16 267-321 1340 PR00190 Actin signature VI PR00190F 7.36 2.20e-14 135-154 IPBOO4000A 9.97 4.64e-13 5-43 IPB004000B 6.57 5.80e-12 83-133 1341 PR01333 Two pore domain K+ channel PR01333A 18.74 4.00e-18 125-153 signature I 1341 PR01463 EAG/ELK/ERG potassium channel PR01463F 4.09 1.95e-12 243-260 family signature VI PR01333B 10.39 9.71e-10 255-264 1341 PR01526 EDG-6 sphingosine 1-phosphate PRO1526D 5.56 9.71e-09 1-16 receptor signature IV 1343 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 8.20e-10 348-385 histocompatibility complex domain 1344 IPB000998 MAM domain IPB000998C 18.63 1.95c-12 833-848 IPB000998B 17.20 1.62e-11 761-773 1344 PROO020 MAM domain signature I PROO020A 20.48 3.62e-11 759-777 PROO020C 12.01 8.12e-10 832-843 IPB000998D 18.66 9.61e-10 898-921 1344 IPB003006 Immunoglobulin and major IPB003006A 17.51 7.1le-09 354-376 histocompatibility complex domain 1344 PR00096 Glutamine amidotransferase PR00096C 15.85 9.28e-09 534-547 superfamily signature III 1345 IPB002350 Kazal-type shrine protease inhibitor IPB002350 31.78 3.92e-13 127-167 family 1345 IPB000867 Insulin-like growth factor-binding IPB000867B 11.44 1.37e-12 75-91 protein 1345 IPB003006 Immunoglobulin and major IPB003006B 20.23 3.88e-10 231-268 histocompatibility complex domain 1345 IPB002328 Zinc-containing alcohol IPB002328C 11.03 8.84e-10 76-90 dehydrogenase 1346 IPB000224 Vesiculovirus phosphoprotein IPB000224A 7.26 6.74e-10 437-470 1346 IPB000135 High mobility group proteins HMG1 IPBOO0135D 2.13 7.16e-10 430-454 and HMG2 1346 PR00449 Transforming protein P21 ras PR00449A 12.48 8.16e-10 83-104 signature I 1346 PR00326 GTP1/OBG GTP-binding protein PR00326A 8.70 9.13e-10 85-105 family signature I IPBOO0135D 2.13 3.09e-09 434-458 1346 IPB000619 Guanylate kinase IPBOO0619A 18.08 4.21e-09 85-102 1346 PR00905 Hypothetical mycoplasmalipoprotein PR00905H 6.88 5.89e-09 343-363 (MG045) signature VIII 1346 PR00364 Disease resistance protein signature I PR00364A 8.29 7.14e-09 84-99 1346 PR00094 Adenylate kinase signature I PROO094A 9.62 9.57e-09 86-99 1346 PR00918 Calicivirus non-structural polyprotein PR00918A 13.81 9.69e-09 79-99 family signature I 1346 IPB000795 GTP-binding elongation factor IPBOO0795A 10.67 9.77e-09 84-99 WO 2004/080148 PCT/US2003/030720 429 TABLE 3B IPBOO0135D 2.13 9.82e-09 429-453 1348 PR00406 Cytochrome B5 reductase signature PR00406F 4.29 4.86e-1 1 158-166 VI 1348 1PB003006 Immunoglobulin and major IPB003006B 20.23 6.48e-11 473-510 histocompatibility complex domain IPBOO3006B 20.23 4.60e-10 291-328 IPBOO3006B 20.23 3.08e-09 190-227 1348 PR00014 Fibronectin type III repeat signature PROO014D 15.12 8.83e-09 891-905 IV 1349 PR00698 C.elegans Srg family integral PR0069SE 14.65 2.76e-09 97-122 membrane protein signature V 1349 IPB002146 ATP synthase B/B' CF(0) IPB002146 21.39 6.94e-09 174-212 1350 IPB000215 Serpins IPBOO0215D 15.35 1.41e-18 311-337 IPBOO0215A 13.01 8.29e-18 72-95 IPBOO0215C 13.90 1.53e-15 207-221 IPBOO0215E 15.36 7.00e-13 378-402 IPBOO0215B 9.87 4.68e-11 180-192 1352 1PB001737 Ribosomal RNA adenine IPB001737A 27.11 8.54e-10 134-179 dimethylase 1355 IPB000906 ZU5 domain IPBOO0906G 25.85 6.28e-10 164-212 IPBOO0906A 22.49 3.16e-09 58-100 1356 IPB001245 Tyrosine kinase catalytic domain IPBOO1245B 21.68 6.54e-13 385-423 1356 IPB000095 PAK-box /P21-Rho-binding IPBOO0095F 16.47 3.97e- 1 389-443 1356 IPBOO0961 Protein kinase C-terminal domain IPBOO0961D 21.23 2.22e-10 381-422 IPB001245A 22.45 3.18e-10 332-372 1356 1PB001359 Synapsin IPB001359H 22.58 7.12e-10 696-746 IPB001359H 22.58 4.84e-09 695-745 1356 IPB002889 WSC domain IPB002889B 11.76 6.81e-09 1510-1556 IPB002889B 11.76 9.25e-09 1491-1537 1357 IPBOO359 Synapsin IPB001359H 22.58 7.12e-10 289-339 IPBOO1359H 22.58 4.84e-09 288-338 1357 IPB002889 WSC domain IPB002889B 11.76 6.81e-09 1103-1149 IPB002889B 11.76 9.25e-09 1084-1130 1358 PR00237 Rhodopsin-like GPCR superfamily PR00237G 19.23 9.64e-15 41-67 signature VII 1358 IPB000276 Rhodopsin-like GPCR superfamily IPB000276D 9.40 5.05e-12 51-67 IPB000276C 8.03 8.50e- 11 8-19 1359 PRO1041 Methionyl-tRNA synthetase PRO1041E 16.72 2.69e-17 306-321 signature V PRO1041D 11.02 7.43e-13 276-287 PRO1041A 11.40 8.68e-13 47-60 1359 IPB001412 Aminoacyl-transfer RNA synthetases IPBOO1412B 6.33 8.71e-12 344-354 class-I PRO1041B 11.59 4.06e-09 82-96 1359 PRO1038 Arginyl-tRNA synthetase signature II PRO1038B 9.12 7.68e-09 59-75 1360 IPB000353 "Class II histocompatibility antigen, IPBOO0353A 18.51 7.30e-27 42-91 beta chain, beta-1 domain" 1363 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 8.83e-11 374-411 histocompatibility complex domain 1365 PR01360 Interleukin-1 receptor antagonist PRO136OF 14.44 9.86e-18 116-134 precursor IL-lRA signature VI 1365 PR00264 Interleukin-1 precursor family PR00264C 19.37 4.90e-16 108-123 signature III PRO1360E 9.69 9.33e-13 95-115 1365 IPB000975 Interleuldn-1 IPBOO0975E 28.12 3.57e-12 95-134 1365 PR01357 Interleukin-1 alpha/beta precursor PRO1357F 17.87 7.15e-10 108-123 family signature VI PR00264A 18.63 9.85e-09 55-75 1366 IPB001599 Alpha-2-macroglobulin family IPB001599L 18.66 4.15e-28 1224-1251 IPB001599F 18.95 7.00e-24 786-815 IPB001599H 18.42 6.40e-20 999-1026 IPBOO1599N 24.85 7.69e-20 1417-1449 WO 2004/080148 PCT/US2003/030720 430 TABLE 3B 1PB001599A 10.97 9.69e-18 123-141 1366 IPB001134 "Netrin, C-terminus" 1PB001134C 17.82 4.13e-13 1237-1251 IPB001599M 13.29 4.71e-13 1364-1375 IPB001599G 13.87 8.94e-13 967-976 IPB001599B 7.45 4.89e-12 209-221 IPB001599D 11.61 6.90e-12 729-739 IPB001599J 20.99 3.00e-11 1065-1090 IPB0015991 10.83 7.60e-11 1034-1043 IPB001599K 8.15 1.46e-10 1194-1205 IPB001599C 14,40 3.55e-09 236-252 IPB001599E 11.06 9.77e-09 756-765 1368 IPB001526 Ly-6/u-PAR domain IPB001526C 13.04 7.55e-15 90-105 IPB001526A 13.24 9.14e-11 12-27 IPB001526B 12.26 7.75e-10 46-55 1967 IPBOO1400 Somatotropin hormone family IPB001400B 23.62 1.90e-28 99-135 IPBOO1400A 14.85 4.91e-16 55-78 1967 PR00836 Somatotropin hormone family PR00836B 17.50 2.44e-14 121-139 signature II PR00836A 15.53 2.35e-13 99-112 1968 IPB001400 Somatotropin hormone family IPBOO1400B 23.62 1.90e-28 99-135 IPB001400A 14.85 4.91e-16 55-78 1968 . PR00836 Somatotropin hormone family PR00836B 17.50 2.44e-14 121-139 signature II PR00836A 15.53 2.35e-13 99-112 1969 IPB001400 Somatotropin hormone family IPBOO1400B 23.62 1.90e-28 99-135 IPBO01400A 14.85 4.91e-16 55-78 1969 PR00836 Somatotropin hormone family PR00836B 17.50 2.44e-14 121-139 signature II PR00836A 15.53 2.35e-13 99-112 1970 IPB001400 Somatotropin hormone family IPBOO1400B 23.62 1.90e-28 99-135 IPBOO1400A 14.85 4.91e-16 55-78 1970 PR00836 Somatotropin honnone family PROO836B 17.50 2.44e-14 121-139 signature II PR00836A 15.53 2.35e-13 99-112 1971 IPB000215 Serpins IPBOO0215E 15.36 5.76e-17 425-449 IPBOO0215A 13.01 3.42e-15 111-134 IPBOO0215D 15.35 8.05e-11 346-372 IPBOO0215C 13.90 1.29e-10 241-255 IPBOO0215B 9.87 6.04e-10 214-226 1972 PR00390 Phospholipase C signature I PR00390A 14.24 6.34e-20 2-20 1973 IPB000734 Lipase IPB000734 10.25 8.50e-09 468-482 1977 IPB000689 UbiH/COQ6 monooxygenase family IPB000689D 28.07 7.83e-39 377-427 IPB000689B 27.03 9.59e-28 217-251 IPB000689C 18.76 3.74e-24 262-286 IPB000689A 9.11 1.25e-11 52-64 1977 PR00420 Aromatic-ring hydroxylase PR00420C 12.44 8.53e-11 373-388 (flavoprotein monooxygenase) signature III 1977 PRO1001 FAD-dependent glycerol-3- PRO1001A 8.45 1.60e-09 51-63 phosphate dehydrogenase family PR00420A 15.97 3.95e-09 52-74 signature I PR00420B 13.97 8.53e-09 215-230 1980 IPB000345 Cytochrome c family heme-binding IPB000345 9.03 7.19e-09 153-165 site 1982 IPB002610 Rhomboid family IPBOO2610C 5.81 3.81e-10 262-272 IPBOO2610B 5.33 6.81e-09 203-213 1984 IPB001124 Lipid-binding serum glycoprotein IPBOO1124D 21.85 2.50e-12 251-287 IPBOO1124C 25.71 5.08e-11 184-227 1985 IPBOO0817 Prion protein IPBOO0817A 8.34 6.40e-09 70-112 IPBOO0817A 8.34 8.67e-09 64-106 1988 IPB001442 C-terminal tandem repeated domain IPB001442F 15.05 1.00e-40 585-628 in type 4 procollagen IPB001442C 14.98 4.82e-40 498-532 WO 2004/080148 PCT/US2003/030720 431 TABLE 3B IPB001442A 26.12 4.09e-39 259-3 11 IPB001442D 15.34 1.00e-34 533-564 1988 IPB000885 Fibrillar collagen C-terminal domain IPB000885B 19.15 1.93e-27 300-353 IPB001442A 26.12 8.93e-27 103-155 IPB001442A 26.12 9.69e-27 106-158 IPBO01442A 26.12 4.19e-26 368-420 IPB000885A 11.46 4.80e-26 363-400 IPB001442A 26.12 6.52e-26 112-164 IPB001442A 26.12 9.71 1988 IPB001073 Complement Clq protein IPBOO1073A 22.14 9.18e-19 374-408 IPBOO0885B 19.15 9.40e-19 309-362 IPB000885B 19.15 9.40e-19 373-426 IPB001442A 26.12 9.42e-19 265-317 IPB001442A 26.12 9.77e-19 133-185 IPB000885B 19.15 1.12e-18 81-134 IPB001442A 26.12 1.33e 1988 IPB001285 Synaptophysin/synaptoporin IPB001285F 6.39 4.08e-09 340-384 IPB000885B 19.15 4.1le-09 48-101 IPB000885B 19.15 4.35e-09 174-227 IPB001442B 12.38 4.41e-09 257-277 IPB001442B 12.38 4.41e-09 417-437 IPB000885B 19.15 4.68e-09 147-200 IPB000885B 19.15 4.68e 1988 IPB000817 Prion protein IPBOO0817A 8.34 7.73e-09 258-300 IPBOO I 073A 22.14 7.75e-09 76-110 IPBOO1442B 12.38 7.8le-09 25-45 IPBOOI073A 22.14 7.89e-09 151-185 IPBOO1073A 22.14 8.31e-09 416-450 IPBOO0817A 8.34 8.39e-09 255-297 IPBOO1442B 12.38 8.42e-09 363-383 IPB001442A 26.12 8.59e-09 160-212 IPBOO1442A 26.12 8.90e-09 40-92 IPB001442B 12.38 8.91e-09 429-449 IPB000885B 19.15 8.94e-09 324-377 IPBOO1073A 22.14 9.30e-09 82-116 IPBOOI 073A 22.14 9.30e-09 307-341 IPBOO1442B 12.38 9.64e-09 323-343 IPBOO1073A 22.14 9.72e-09 148-182 IPB000885B 19.15 9.84e-09 412-465 1989 IPB000033 "Low-density lipoprotein (Idl) IPB00033D 30.18 1.18e-14 111-149 receptor, YWTD repeat" IPB00033D 30.18 6.25e-11 67-105 IPB00033C 11.58 6.40e-10 135-149 IPB00033C 11.58 8.07e-09 48-62 IPB00033C 11.58 8.07e-09 91-105 1990 IPB000033 "Low-density lipoprotein (ldl) IPB00033D 30.18 1.18e-14 111-149 receptor, YWTD repeat" IPB00033D 30.18 6.25e-11 67-105 IPB00033C 11.58 6.40e-10 135-149 IPB00033C 11.58 8.07e-09 48-62 IPB00033C 11.58 8.07e-09 91-105 1992 PR00205 Cadherin signature II PR00205B 20.09 4.94e-14 114-143 PR00205D 12.22 9.31e-14 198-217 PR00205F 19.57 1.53e-12 167-193 PR00205D 12.22 8.20e-12 93-112 PR00205G 13.05 2.46e-11 201-218 PR00205G 13.05 3.93e-10 96-113 1992 IPB002126 Cadherin domain IPB002126B 12.04 7.68e-10 102-119 PR00205A 17.38 8.15e-09 160-179 1993 PR00205 Cadherin signature II PR00205B 20.09 4.94e-14 114-143 WO 2004/080148 PCT/US2003/030720 432 TABLE 3B PR00205D 12.22 9.3 1e-14 198-217 PR00205F 19.57 1.53e-12 167-193 PR00205D 12.22 8.20e-12 93-112 PR00205G 13.05 2.46e-11 201-218 PR00205G 13.05 3.93e-10 96-113 1993 IPB002126 Cadherin domain IPB002126B 12.04 7.68e-10 102-119 PR00205A 17.38 8.15e-09 160-179 1994 IPB002469 "Dipeptidyl peptidase IV, N- IPB002469J 8.97 3.52e-12 17-33 terminus" 1995 PR01534 Vomeronasal type 1 receptor family PR01534E 7.16 123e-09 5-19 signature V 1996 IPB000221 Protamine P1 IPB000221 5.48 2.97e-12 124-150 IPB000221 5.48 9.30e-12 113-139 IPB000221 5.48 2.19e-11 153-179 IPB000221 5.48 2.59e-11 114-140 IPB000221 5.48 3.91e-11 128-154 1996 IPB000492 Protamine 2 (PRM2) IPB000492B 5.26 5.88e-11 148-182 IPB000221 5.48 6.16e-11 142-168 IPBOOQ221 5.48 6.43e-11 149-175 IPB000221 5.48 7.62e-11 110-136 IPB000492B 5.26 9.35e-11 129-163 IPB000492B 5.26 9.35e-11 152-186 IPB000221 5.48 2.73e-10 168-194 IPB000221 5.48 4.70e-10 112-138 IPB000221 5.48 4.70e-10 144-170 IPB000492B 5.26 6.97e-10 153-187 IPB000492B 5.26 8.12e-10 156-190 IPB000492B 5.26 8.53e-10 155-189 IPB000221 5.48 8.89e-10 151-177 IPB000492B 5.26 9.06e-10 128-162 IPB000492B 5.26 9.69e-10 150-184 IPB000221 5.48 1.00e-09 133-159 IPB000221 5.48 1.46e-09 115-141 IPB000221 5.48 3.31e-09 159-185 IPB000221 5.48 3.3 1e-09 172-198 IPB000492B 5.26 3.84c-09 125-159 IPB000221 5.48 5.15e-09 157-183 IPB000221 5.48 5.27e-09 102-128 1996 PROO055 HIV TAT domain signature III PROO055C 9.12 5.92e-09 66-82 IPB000221 5.48 6.19e-09 166-192 IPB000492B 5.26 6.38e-09 144-178 IPB000492B 5.26 6.67e-09 157-191 IPB000221 5.48 6.88e-09 147-173 IPB000221 5.48 6.88e-09 161-187 IPB000492B 5.26 7.75e-09 127-161 IPB000492B 5.26 8.34e-09 115-149 1996 IPB000271 Ribosomal protein L34 IPB000271 15.87 9.78e-09 161-198 IPB000492B 5.26 9.90e-09 161-195 IPB000221 5.48 1.00e-08 126-152 1998 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 4.91e-11 52-89 histocompatibility complex domain IPBOO3006B 20.23 3.52e-10 155-192 IPBOO3006B 20.23 1.69e-09 250-287 IPBOO3006B 20.23 4.8le-09 437-474 1998 PR01536 Interleukin-1 receptor type I and type PR01536C 19.92 5.85e-09 59-82 II family signature III 1999 IPB000897 GTP-binding signal recognition IPB000897A 9.15 8.60e-11 313-332 _ particle (SRP54) domain 2000 IPBOO1140 ABC transporter transmembrane IPBOO1140A 21.73 2.00e-19 107-153 WO 2004/080148 PCT/US2003/030720 433 TABLE 3B region JPBO01140B 15.62 4.44e-10 222-260 2000 IPB000795 GTP-binding elongation factor IPB000795A 10.67 7.88e-10 120-135 2000 PR00326 GTPI/OBG GTP-binding protein PR00326A 8.70 4.49e-09 121-141 family signature I 2000 IPB000897 GTP-binding signal recognition IPB000897A 9.15 5.57e-09 120-139 particle (SRP54) domain 2000 IPB001324 Phosphoribulokinase family IPBO01324A 18.12 8.00e-09 117-138 2001 IPB001422 Neuromodulin (GAP-43) IPB001422C 16.82 5.26e-10 778-813 2001 PR01217 Proline rich extensin signature VII PRO1217G 4.02 7.16e-09 309-334 2001 IPBOO3134 Repeat in HS1/Cortactin IPB003134F 15.66 7.29e-09 776-824 PRO1217D 4.57 7.49e-09 562-583 2001 IPB000996 Clathrin light chain IPB000996B 20.25 7.82e-09 752-804 2001 IPB002079 "Gag polyprotein, inner coat protein IPB002079J 10.53 9.19e-09 779-807 p12" 2001 IPB000135 High mobility group proteins HMG1 IPBOO0135A 11.69 9.62e-09 763-817 and HMG2 2001 IPB001084 Microtubule associated Tau protein IPBOO1084C 7.66 9.64e-09 375-392 2001 IPBOO1101 Plectin repeat IPB001101K 8.53 9.92e-09 96-139 2002 IPB001552 Acyl-CoA dehydrogenase IPB001552E 22.77 2.46e-19 523-563 IPB001552D 24.88 5.35e-19 432-474 IPB001552C 25.04 7.75e-15 378-418 IPB001552B 18.05 3.43e-12 124-146 IPB001552A 11.25 6.90e-10 97-108 2003 IPB000998 MAM domain IPB000998D 18.66 1.96e-15 546-569 2003 IPB003886 Extracellular domain in nidogen IPB003886D 13.91 8.77e-15 253-272 2003 IPB000152 Aspartic acid and asparagine IPB000152 8.86 2.89e-14 126-141 hydroxylation site 2003 IPB001881 Calcium-binding EGF-likc domain IPBOO1881B 12.28 5.00e-14 208-219 IPB000152 8.86 1.00e-13 253-268 IPB000152 8.86 1.82e-13 208-223 IPBOO1881B 12.28 4.75e-13 126-137 2003 IPB001774 Delta serrate ligand IPB001774C 18.25 9.13e-13 88-130 IPB000998B 17.20 1.00e-12 428-440 2003 PROO020 MAM domain signature I PROO020A 20.48 2.88e-1 1 426-444 IPB000998C 18.63 5.30e-l1 483-498 IPBOO1881B 12.28 8.58e-11 253-264 2003 PR00907 Thrombomodulin signature 11 PR00907B 11.50 2.44e-10 160-176 2003 IPBOO0561 EGF-like domain IPB000561 4.89 3.25e-10 97-105 2003 IPB000033 "Low-density lipoprotein (ldl) IPB00033B 7.05 5.35e-10 258-268 receptor, YWTD repeat" IPB00033B 7.05 5.97e-09 213-223 2003 IPB00 167 Dehydrin IPBOO0167A 8.58 7.14e-09 340-367 2003 IPB003367 Thrombospondin type 3 repeat IPB003367A 11.78 9.79e-09 175-195 2004 IPB001258 NHL repeat IPB001258B 28.61 4.30e-17 102-136 IPB001258B 28.61 7.00e-17 8-42 IPB001258B 28.61 5.60c-11 55-89 2005 IPB000198 RhoGAP domain IPBOO0198C 16.49 8.3le-16 952-969 IPB000198B 12.47 9.10e-15 862-879 2005 IPB002219 Phorbol esters/diacylglycerol binding IPB002219B 12.53 3.89e-11 753-768 domain IPBOO0198A 15.95 9.61e-10 810-826 2005 IPB002551 Coronavirus SI glycoprotein IPB002551J 18.56 3.60e-09 499-540 2005 IPB001369 Purine and other phosphorylases IPB001369C 24.81 4.27e-09 65-105 family 2 2005 IPB003351 Dishevelled specific domain IPB003351C 13.82 7.24e-09 1054-1093 2007 PR01303 Plasmodium circumsporozoite PRO1303D 10.57 9.21e-10 5-22 protein signature IV 2008 IPBOO3164 Alpha adaptin carboxyl-terminal IPB003164L 9.84 1.00e-40 48-82 domain IPBOO3164N 8.78 1.00e-40 184-222 WO 2004/080148 PCT/US2003/030720 434 TABLE 3B IPBOO3164Q 13.71 1.00e-40 285-319 IPB003164S 13.40 1.00e-40 353-394 1PB003164R 10,50 2.35e-38 320-352 IPB0031640 13.89 8.62e-35 223-255 IPB003164P 12.26 7.65e-33 256-284 1PB003164M 10.25 5.18e-31 107-138 IPB003164T 10.57 4.86e-25 395-414 213 1PB01359 Synapsin IPB001359H 22.58 2.75e-09 14-64 IPB001359H 22.58 3.62e-09 40-90 2015 PR_00456 Ribosomal protein P2 signature V PR00456E 3.08 5.71e-09 22-36 2016 IPB003134 Repeat in HS1/Cortactin IPB003134F 15.66 1.48e-09 145-193 2017 PR 01297 Colicin lysis protein signature I PR01297A 6.60 6.02e-09 16-29 2018 PR00205 Cadherin signature IV PR00205D 12.22 3.25e-16 37-56 PR00205G 13.05 1.37e-13 40-57 PR00205F 19.57 3.1Oe-13 6-32 PR00205C 13.59 6.62e-09 23-35 2020 IPB001862 Membrane attack complex IPB001862C 26.48 8.94e-09 113-161 components/perforin/complement C9 2021 IPB001909 KRAB box IPBOO1909 17.37 8.65e-30 56-90 2022IPB001909 _KRAB box 2022 1iPB0O090 IRBbo PBOO1909 17.37 8.65e-30 56-90 2024 IPB000560 Histidine acid phosphatase IPBOO0560 17.02 1.00e-16 35-57 2026 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 7.00e-24 545-570 2026 1PBO01909 KRAB box IPBOO 1909 17.37 2.86e-21 134-168 IPB000822 14.67 2.29e-17 573-598 IPB000822 14.67 3.57e-17 487-512 IPB000822 14.67 2.50e-13 515-540 2026 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 4.32e- 1 570-583 PROO048A 9.94 5.26e-1 1 484-497 PROO048A 9.94 9.53e-1 1542-555 PROO048B 5.52 1.OOe-10 558-567 PROO048A 9.94 3.86e-10 512-525 2026 IPBOO1012 UBX domain IPBOO1012A 12.95 7.00e-10 297-312 2026 IPB001580 Calreticulin family IPBOO158OF 2.93 1.00e-09 305-314 PROO048B 5.52 6.50e-09 500-509 2026 PRO 1073 Presenilin 1 signature III PRO1073C 1.45 6.62e-09 300-311 2026 IPB000135 High mobility group proteins HMG1 IPBOOO135D 2.13 9.73e-09 298-322 and HMG2 2029 IPBOO1599 Alpha-2-macroglobulin family IPB001599L 18.66 4.15e-28 59-86 2029 IPB001134 "Netrin, C-terminus" IPB001134C 17.82 4.13e-13 72-86 IPBOO1599K 8.15 1.46e-10 29-40 2031 PROO14 Fibronectin type III repeat signature PROO014D 15.12 5.26e-10 17-31 IV 2032 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 6.85e-13 118-132 domain 2032 PROO019 Leucine-rich repeat signature I PROO019A 11.72 7.14e-11 27-40 PROO019B 11.42 8.09e-09 24-37 2033 IPB000483 Leucine rich repeat C-terminal 1PB000483 11.18 6.85e-13 118-132 domain 2033 PROO019 Leucine-rich repeat signature I PRO0019A 11.72 7.14e-11 27-40 PROOOI9B 11.42 8.09e-09 24-37 2034 IPB000203 GPS domain IPBOO0203A 18.40 9.25e-20 991-1021 IPBOO0203B 13.98 8.88e-15 1111-1132 2034 IPB000832 G-protein coupled receptors family 2 IPB000832C 19.53 9.46e-13 1111-1140 (secretin-like) 2034 PR00249 Secretin-like GPCR superfamily PR00249C 15.44 1.73e-10 1113-1136 signature III IPB000832G 15.17 7.8 le-09 1281-1306 2035 IPB000822 "Zinc finger, C21-12 type" IPB000822 14.67 3.45e-21 51-76 WO 2004/080148 PCT/US2003/030720 435 TABLE 3B IPB000822 14.67 4.00e-19 79-104 IPB000822 14.67 3.40e-16 23-48 20O35 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 6.54e-14 20-33 2035 IPB001275 DM DNA binding domain IPB001275 19.17 8.05e-14 11-50 IPB001275 19.17 2.14e-13 39-78 PROO048B 5.52 4.00e-11 92-101 PROO048A 9.94 6.2 1e-1 1 76-89 PR00048B 5.52 6.25e- 11 64-73 PROO048A 9.94 5.09e-10 104-117 PR00048B 5.52 2.00e-09 8-17 IPB001275 19.17 4.53e-09 67-106 PROO048A 9.94 8.12e-09 48-61 2035 PR00995 36kDa capillovirus series protease PR00995F 16.50 9.73e-09 1-19 (S35) signature VI 2038 PR00049 Wilm's tumour protein signature IV PROO049D 0.00 8.71e-10 8-22 PROO049D 0.00 9.43e-10 9-23 2038 IPB003861 E4 protein IPB003861B 9.06 1.98e-09 17-31 PROO049D 0.00 2.37e-09 12-26 PROO049D 0.00 2.53e-09 11-25 PR00049D 0.00 4.36e-09 10-24 2038 1PB002999 Tudor domain IPB002999B 7.50 7.55e-09 13-21 IPB002999B 7.50 7.55e-09 14-22 IPB002999B 7.50 8.36e-09 11-19 2038 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 8.88e-09 199-224 2039 IPB001310 HIT (Histidine triad) family IPBOO1310A 18,76 3.25e-18 197-227 2039 PR00332 Histidine triad family signature II PR0032B 1.02.93e-12 29-27 2039 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 2.13e-09 339-364 2040 IPB001310 H1T (Histidine triad) family IPBOOI3IOA 18.76 3.25e-18 197-227 - - -F -IPBOO1310B 21.00 2.93e-12 261-287 2040 PR00332 Histidine triad family signature II PR00332B 14.02 6.26e-10 209-227 2040 IPB000822 "Zinc finger, C2H2 type" PB000822 14.67 2.13e-09 339-364 2041 IPB001310 HIT (Histidine triad) family IPBOOI31OA 18.76 3.25e-18 197-227 ________________________IPBOO1310B 21.00 2.93e-12 261-287 2041 PR00332 Histidine triad family signature II PR00332B 1402 6.26e-1 209-227 2041 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 2.13c-09 339-364 2042 1PB000135 High mobility group proteins HMG1 IPBOOOI35D 2.13 4.52e-10 102-126 and HMG2 IPBOO0135D 2.13 9.7e-10 104-128 IPBOOO131D 2.13 9.90e-10 101-125 IPBOO0135D 2.13 3.18e-09 105-129 IPB00013D 2.13 9.55e-09 103-127 2043 PR00074 Protein-lysine 6-oxidase precursor PROO074H 17.29 8.1 le-19 264-283 signature VIII PRB0074 11.34 3.88e-16 193-213 PROO074F 11.47 6.65e-16 217-238 PROO074B 7.56 4.98e-12 126-150 2043 1PB001695 Lysyl oxidase IPB001695E 9.12 5.70e-12 110-151 _ PROO074D 21.66 2.94e-10 171-192 2043 PR00258 Speract receptor signature I PR00258A 13.56 3.70e-10 5-21 PR00258 9.05 4.95e-10 43-53 PR00258D 14.29 6.29e-10 76-90 IPB002695F 11.10 6.24e-09 151-179 20O46 PRO 1254 Prostaglandin D synthase signature II PR01254B 12.05 1.17e-09 339-349 2048 PB00374 Phosphatidate cytidylyltransferase IPB000374B 15.86 2,06e-27 375-402 andHMG2I IPB000374A 12.59 3.65e-16 271-283 2049 PR00320 GIprotein beta WD-40 repeat PR00320A 13.15 7.95e-11 118-132 signature I PRII320B 12.82 2,08e-10 118-132 PR00320 12.32 4.33e-09 118-132 WO 2004/080148 PCT/US2003/030720 436 TABLE 3B _2052 _PR 1446 Claudin-8 signature III PR01446C 9.62 2.27e-09 119-131 2053 IPB002884 Proprotein convertase P-domain IPB002884B 15.69 6.33e-09 114-131 2054 IPB000361 Hypothetical hesB/yadR/yfhF family IPB000361B 19.14 3.08e-19 122-153 -f - IPBOO0361A 17.83 2.71e-16 73-93 2055 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 9.28c-10 133-170 histocompatibility complex domain 2055 IPB000920 Myelin PO protein IPBOO0920C 15.78 3.92e-09 161-213 2055 PR00213 Myelin PO protein signature V PROO213E 5.51 8.97e-09 179-203 2058 IPB001442 C-terminal tandem repeated domain 1PB001442A 26.12 3.17e-17 27-79 in type 4 procollagen IPB001442A 26.12 3.60e-17 33-85 IPB001442A 26.12 1.21e-16 39-91 2058 IPB000885 Fibrillar collagen C-terminal domain IPB000885B 19.15 2.19e-16 35-88 IPBOO088A 11.46 5.06e- 16 40-77 IPB001442A 26.12 6.02e-16 30-82 IPBOO088B 19.15 3.65e-15 44-97 IPBOO0885B 19.15 4.39e-15 26-79 IPB000885B 19.15 4.49e-15 32-85 IPB001442A 26.12 9.29e-15 24-76 20io58 PR00453 Von Willebrand factor type A PR00453A 11.78 1.75e-14 107-124 domain signature I IPB000885A 11.46 2.29c-14 43-80 IPB000885A 11.46 3.92e-14 52-89 IPB000885B 19.15 6.97e-14 29-82 IPB001442A 26.12 7.65e-14 42-94 IPB001442A 26.12 8.63e-14 45-97 PB001442A 26.12 1.5e-13 36-88 1PB000885A 11.46 2.89e-13 37-74 IPB000885A 11.46 6.33e-13 49-86 IPB000885B 19.15 7.07e-13 38-91 IPB000885B 19.15 7.46e-13 41-94 2058 1PB001073 Complement C2q protein IPBOO1073A 22.14 1.72e-12 45-79 IPB000885A 11.46 5.93e-12 55-92 IPB000885A 11.46 6.04e-12 46-83 IPBOO1O73A 22.14 7.48e-12 48-82 IPBOO0885B 19.15 7.84e-12 23-76 IPBOO0885B 19.15 8.88e-1247-100 20587 CPBot1442B 12.38 9.85e-1m e 61-81 2059 1PB001541 SUR2-type hydroxylase/desaturase IPBOO154IA 12.30 5.50e-1140-52 _ catalytic domain IPBOO1541B 11.65 4.86e-09 127-136 2060 IPBOO3006 Immunoglobulin and major IPBOO3006B 20.23 6.19e-09 134-171 - histocompatibility complex domain 2061 PR00918 Calicivirus non-structural polyprotein PR00918A 13.81 3.59e-12 37-57 family signature I 206-1 1PB0I2078 Sigma-54 factor interaction protein IPB002078A 20.43 6.31e-10 43-77 family 2061 PR00c4 Disease resistance protein signature I PR00364A 8.29 7.18 e- 9 1 42-57 2061 IPB000765 GTPI/OBG family IPB000765 26.91 7.67e-10 41-84 2061 PR00094 Adenylate kinase signature I PROO094A 9.62 2.43e-09 44-57 2061 PR00830 Endopeptidase La (Lon) serine PROO830A 852 4..50e-09 47-66 protea e (816) signature I 2067 PR00364 Fungi-IV metallothionein signature PR00874C 4.37 6.50e-09 7-21 III 2071 PR01539 Interleukin-a1 receptor tye II PR01539I 14.65 9.06e-09 223-2 precursor signature IX 2074 IPB001284 Ribosomal protein L34e IPBOO1284A 18.97 3.48e-31 15-50 IPB001284B 26.99 1.41e-28 53-85 2074 PR01250 Ribosomal protein L34 signature IV PRO1250D 13.87 2.69e-23 73-95 PRO1250B 13.36 7.92e-17 33-50 WO 2004/080148 PCT/US2003/030720 437 TABLE 3B PRO1250A 11.25 2.25e-13 20-33 PRO1250C 9.53 4.52e-12 53-63 IPB001284B 26.99 3.75e-09 82-114 2076 IPB000171 Bacterial-type phytoene IPBOO0171E 7.19 8.20e-09 294-304 dehydrogenase 2077 IPB001774 Delta serrate ligand IPB001774D 19.23 5.91e-09 50-96 2077 IPB000034 Laminin B IPB000034C 12.97 7.3 1e-09 84-102 2077 IPB000561 EGF-like domain IPB000561 4.89 8.07e-09 84-92 2078 IPB001774 Delta serrate ligand IPB001774D 19.23 5.91e-09 50-96 2078 IPB000034 Laminin B IPB00034C 12.97 7.3 1e-09 84-102 2078 IPB000561 EGF-like domain IPB000561 4.89 8.07e-09 84-92 2079 IPBO01774 Delta serrate ligand IPB001774D 19.23 5.91e-09 50-96 2079 IPB000034 Laminin B IPB00034C 12.97 7.3 1e-09 84-102 2079 IPBOO0561 EGF-like domain |IPBOOO561 4.89 8.07e-09 84-92 2080 PR00436 Interleukin-8 signature I PR00436A 15.20 9.36e-10 14-37 2081 IPB001187 Tissue Factor (TF) IPB001187G 15.20 7.00e-10 33-69 2081 IPB001073 Complement Clq protein IPBOO1073A 22.14 2.69e-09 146-180 2081 PR00049 Wilm's tumour protein signature IV PROO049D 0.00 6.03e-09 205-219 PROO049D 0.00 6.34e-09 207-221 PROO049D 0.00 7.41e-09 203-217 2081 PR00499 Neutrophil cytosol factor 2 signature PR00499A 7.48 7.60e-09 791-808 1 2081 IPB001359 Synapsin IPB001359H 22.58 8.08e-09 772-822 2081 IPB003036 Gag P30 core shell protein IPB003036C 11.53 9.63e-09 155-171 2082 IPB001039 "Major histocompatibility complex IPB001039B 27.55 3.01e-09 103-154 protein, Class I" 2083 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 8.71e-12 148-185 histocompatibility complex domain IPBOO3006B 20.23 9.14e-12 441-478 IPBOO3006B 20.23 1.00e-11 248-285 2083 PR01536 Interleukin-l receptor type I and type PRO1536C 19.92 9.23e-11 547-570 11 family signature III IPBOO3006B 20.23 6.40e-10 54-91 IPBOO3006B 20.23 9.64e-10 540-577 IPBOO3006B 20.23 8.62e-09 346-383 PR01536C 19.92 9.19e-09 155-178 2084 IPBOO3006 Immunoglobulin and major IPBOO3006B 20.23 8.71e-12 148-185 histocompatibility complex domain IPB003006B 20.23 9.14e-12 441-478 IPBOO3006B 20.23 1.00e-1l 248-285 2084 PR01536 Interleukin-1 receptor type I and type PR01536C 19.92 9.23e-1 1 547-570 11 family signature III IPBOO3006B 20.23 6.40e-10 54-91 IPBOO3006B 20.23 9.64e-10 540-577 IPBOO3006B 20.23 8.62e-09 346-383 PR01536C 19.92 9.19e-09 155-178 2085 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 8.71e-12 148-185 histocompatibility complex domain IPBOO3006B 20.23 9.14e-12 441-478 IPB003006B 20.23 1.OOe- 11 248-285 2085 PR01536 Interleukin-1 receptor type I and type PR01536C 19.92 9.23e-1 1 547-570 II family signature III IPBOO3006B 20.23 6.40e-10 54-91 IPBOO3006B 20.23 9.64e-10 540-577 IPBOO3006B 20.23 8.62e-09 346-383 PR01536C 19.92 9.19e-09 155-178 2086 IPB002117 p53 tumor antigen IPBOO2117A 9.71 5.50e-15 13-23 2087 IPB000074 Apolipoprotein A1/A4/E IPB000074B 29.17 7.49e-10 117-170 IPB000074B 29.17 8.75e-10 95-148 IPB00074B 29.17 9.20e-10 62-115 IPB00074C 22.23 2.62e-09 90-127 IPB00074C 22.23 4.35e-09 112-149 IPB00074B 29.17 8.48e-09 201-254 WO 2004/080148 PCT/US2003/030720 438 TABLE 3B 2088 IPB000074 Apolipoprotein A1/A4/E IPB000074B 29.17 7.49e-10 117-170 IPB000074B 29.17 8.75e-10 95-148 IPBOO0074B 29.17 9.20e-10 62-115 IPBOO0074C 22.23 2,62e-09 90-127 IPBOO0074C 22.23 4.35e-09 112-149 IPB000074B 29.17 8.4ge-09 201-254 2090 IPB001211 Phospholipase A2 IPBOO1211B 1 7 .163.12e-31 49-76 2090 PR00389 Phospholipase A2 signature 11 PR00389C 17.85 2.50e-20 61-79 PR00389B 10. 67 6.9 1e- 16 42-60 IPBOO1211D 11.66 5.50e-14 109-124 PROO399E 13.06 8.20e-14 109-125 IPBOO1211C 14.62 1.56e-11 84-102 2091 PR01217 Proline rich extensin signature VI PRO1217F 4.24 8.40e-09 65-82 2092 IPB001354 Mandelate racemase/muconate 1PB001354C 32.55 1.00e-24 255-296 lactonizing enzyme family IPBOO1354D 32.92 2.07e-18 343-388 IPB001354B 18.16 3.91e-18 132-158 2094 IPB000222 Protein phosphatase 2C subfamily IPBOOO222F 19.87 4.94e-15 285-305 IPB000222E 14.28 6.33e-15 257-275 1PB90222G 9.17 1.95e-12 311-324 2PBB0222C 6.84 2.08e-12 176-185 2PBB0222H 9.33 7.97e-12 347-359 IPB000222B 15.80 2.86c-1 0 144-154 1PB000222D 11.74 2.74e-09 215-232 2PBI02221 8.91 4.72e-09 408-417 2095 IPB000152 Aspartic acid and asparagine PB0152 8.86 4.71c-15 107-122 2096 hydroxylation site gPBnu0152 8.86 1.47e-14 44-59 2095 IPB000881 Calcium-binding EGF-lie domain IPBOO188B 12.28 1.47e-11107-118 2095 IPB00033 "Low-density lipoprotein (Idk) ePBOO0033B 7.05 4.96e-1149-59 2 receptor, YWTD repeat" PB01881B 12.28 6.68e-m1i44-55 2 095 PROOO1 s Type II EGF-like signature III PROO0iOC 6.98 7.10e-10 49-59 PROO0iOC 6.98 7.68e-10 112-122 IPBOO 1881IB 12.28 2.57e-09 5-16 IPBOO0033B 7.05 3. 13e-09 112-122 2095 1PB003886 Extracellular domain in nidogen IPBI03886D 13.91 5.71c-09 107-126 2096 PR00245 Olfactory receptor signature III PR00245C 14.65 9.53c-17 218-234 2096 IPB000276 Rhodopsin-like GPCR superfamily IPB000276A 11.56 9.25e-14 160-171 PR00245D 9.34-1.53e-13 278-287 PR00245E 8.96 6.81e-12 325-336 PR00245B 13.73 1.00e-10 171-183 _______IPB000276D 9.40 3.08e-09 324-340 2096 PR00237 Rhodopsin-like GPCR superfamily PR00237E 13.03 3.83c-09 241-264 signature V 2096 PR00534 Melanocortin receptor family PR00534A 12.77 5.17e-09 93-10 signature I PR00237C 14.77 5.91c-09 146-168 2 _096 PRI896 Vasopressin receptor signature 11 PR00896B 9.36 7,23e-09 97-108 PR00237 19.23 1.75e-08 314-340 2097 PR002-45 Olfactory receptor signature 1I PR00024C 14.65 9.53e-17 218-234 2097 1PIB000276 Rhodopsin-like GPCR superfamily IPB00276A 11.56 9.25e-14 160-171 PR00245D 9.34 1.53e-13 278-287 PR00245E 8.96 6.81e-12 325-336 PR00245B 13.73 1.0e-0 171-183 IPB00276D 9.40 3.08e-09 324-340 2097 PR00237 Rhodopsin-like GPCR superfamily PR00237E 13.03 3.83e-094 1-264 signature V 2097 PR00534 Melanocortin receptor family PR00534A 12.77 5.17e-09 93-105 signature PR00237C 14.77 5.9 1e-09 146-168 2097 1PR 89 Vasoeptor signature II PR00896B 9.36 7.23e-09 97-108 WO 2004/080148 PCT/US2003/030720 439 TABLE 3B PR00237G 19.23 1.00e-08 314-340 2098 IPB001169 "Integrin beta, C-terminus" IPBOOI 169J 7.42 4.63e-10 49-62 2098 PR01186 Integrin beta subunit signature XI PROl 186K 7.39 7.27e-10 49-62 ______ _________PR01 186K 7.39 9.75e-09 15-28 2102 PR00193 Myosin heavy chain signature III PROO193C 11.66 9.77e-24 126-153 2102 IPB000857 Core domain in kinesin and myosin IPBOO0857C 10.82 4.84e-19 124-146 motors PROO193B 12.36 6.8 le-I8 74-99 IPB000857D 12.93 7.64e-12 153-191 PROO193A 14.87 8.50e-12 14-33 IPB000857B 11.35 1.00e-10 55-101 2102 PR00364 Disease resistance protein signature I PR00364A8.294.86c-0976-91 2103 PR00193 Myosin heavy chain signature III PROO193C 11.66 9.77e-24 126-153 2103 IPB000857 Core domain in kinesin and myosin IPB000857C 1082 4.84e-19 124-146 motors PROO193B 12.36 6.8le-iS 74-99 IPB000857D 12.93 7.64e-12 153-191 PROO193A 14.87 8.50e-12 14-33 -- IPB000857B 11.35 1.00c-10 55-101 2103 PR00364 Disease resistance protein signature I PR00364A 8.29 4.86e-09 76-91 2105 IPB002350 Kazal-type shrine protease inhibitor IPB002350 31.78 2.86e-18 77-117 family 2 10-5 IPBO00716 Thyroglobulin type- I repeat IPB0716C 17.62 2.88e-18 274-292 IPBOO016D 15.49 7.16e-15 296-3 10 2109 IPB000483 Leucine rich repeat C-terminal 1PB000483 11.18 5.50e-13 45-59 domain 2111 IPB000221 Protamine P 1 IPB000221 5.48 3.08e-09 3-29 2112 PRO01415 Ankyrin repeat signature if PRO1415B 10.23 5.88e-09 26-38 2113 11 3000416 Outer Capsid protein VP4 IPBO0416P 15.37 7.6e-09 188-226 (Hemagglutinin) 2-114 IPB00-0416 Outer Capsid protein VP4, IPB0416P 15.37 7.0e-09 188-226 (Hernagglutinin) 2115 IPB000998 MAM domain IPB000998C 18.63 1.95e-12 17-32 2115 PROO020 IvIAM domain signature III PRO00C 12.01 8.12e-10 16-27 1PB000998D 18.66 9.6e-10 82-105 2116 1PBOO0998 MAM domain IPB000998C 18.63 1.95e-12 17-32 2116 PROO020 MAM domain signature III PROO020C 12.01 8.12e-10 16-27 IPB000998D 18.66 .6e-10 82-105 2118 11B002642 Lysophospholipase catalytic domain IPB002642B 18.19 6.91e-10 86-11 21l19 1PB002642 Lysophospholipase catalytic domain IPBOO2642E1.961e-0811 TPR0364A8.9 4.6e -0 76-11 2120 IPB000817 Prion protein IPBOO0817A 8.34 7.73e-10 255-297 2120 IPB001442 C-terminal tandem repeated domain IPB001442A 26.12 7.26e-09 262-314 in type 4 procollagen 2122 IPBO03006 Immunoglobulin and major IPBOO3006B 20,23 1.43e-13 72-109 histocompatibility complex domain 2122 IPB003531 Short hematopoietin receptor family IPB00353 IC 15.87 9.38e- 11318-335 2123 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 1.43e-13 72-109 histocompatibility complex domain 2123 IPB003531 Shorthematopoietin receptor family IPB003531C 15.87 9.38e-11 318-35 1 2124 IPBOO3006 Immunoglobulin and major IPBOO3006B 20.23 1.43e-13 72-109 - histocompatibility complex domain 2124 1PB0023531 Short hematopoietin receptor family IPB00353 IC 15.87 9.38e- 1 318-335 2-25 IPB-OOOOO8 C2 domain IPBO0008C 23.37 7.94e-25 109-148 2125 PR00360 C2 domain signature PR0036A 15.18 1.60e-13 107-119 2125 PR00399 Synaptotagmin signature II PR00399B 14.30 1.69e-12 94-107 __ IPBOO0008D 14.83 3.86e-11 164-182 WO 2004/080148 PCT/US2003/030720 440 TABLE 3B PROO360B 11.64 5.94e-1 1 136-149 PR00399C 15.89 4.98e-10 151-166 PR00399D 12.72 6.33e-10 171-181 _______PR00399A 15.05 8.65e-09 79-94 2126 IPB002870 Reprolysin family propeptide IPBOO2870B 24.73 3.78e-14 142-180 2126 IPB001670 Iron-containing alcohol IPB001670D 13.90 5.50e-09 158-173 dehydrogenase 2130 IPB001442 C-terminal tandem repeated domain IPB001442A 26.12 7.53e-26 8-60 in type 4 procollagen 2130 IPB000885 Fibrillar collagen C-terminal domain IPBP00885B 19.15 4.52e-24 1-54 IPB00885B 19.15 2.38e-23 19-72 IPB001442A 26.12 8.04e-23 11-63 IPB001442A 26.12 8.83e-23 20-72 IPB002885B 19.15 2.32e-22 4-57 IPB001442A 26.12 2.93e-22 5-57 IPB001442A 26.12 5.37e-22 17-69 2130 PR00258 Speract receptor signature I PR00258A 13.56 6.32e-16 87-103 IPB001442A 26.12 7.91e-16 26-78 IPBOO0885A 11.46 1.49e-15 33-70 IPB000885A 11.46 5.74e-15 24-61 IPB000885B 19.15 5.98e-15 28-81 IPBOO0885A 11.46 8.30e-15 9-46 IPB000885A 11.46 2.99e-14 30-67 IPB000885B 19.15 4.13e-14 31-84 2130 IPBOO1073 Complement CIq protein IPBOO1073A 22.14 8.40e-14 17-51 IPBOO0885A 11.46 8.60e-14 39-76 IPB000885B 19.15 2.17e-13 34-87 IPB001073A 22.14 7.89e-13 23-57 PR00258B 7.94 8.42e-13 106-117 IPB001442A 26.12 2.17e-12 35-87 IPBOO1442B 12.38 2.98e-12 24-44 IPB001442B 12.38 5.58e-12 21-41 IPBOO1073A 22.14 6.94e-12 20-54 IPBOO1073A 22.14 8.38e-12 11-45 IPB001442A 26.12 8.47e-12 32-84 IPB001442B 12.38 8.47e-12 12-32 IPBOO1073A 22.14 8.74e-12 29-63 IPB001442B 12.38 9.69e-12 15-35 IPB001442B 12.38 1.71e-11 51-71 IPB001442B 12.38 2.86e-1 1 9-29 IPBOO1073A 22.14 3.83e-11 14-48 IPB000885B 19.15 5.90e-11 40-93 IPB001442B 12.38 8.86e-11 6-26 IPB I0073A 22.14 9.17e-11 44-78 IPBOO1073A 22.14 9.50e-11 2-36 IPBOO1073A 22.14 1.15e-10 8-42 IPBOO1073A 22.14 2.83e-10 26-60 2130 IPB000817 Prion protein IPB000817A 8.34 2.88e-10 1-43 IPBOO0885B 19.15 4.09e-10 37-90 IPB000885A 11.46 4.23e-10 42-79 IPBOO1073A 22.14 4.81e-10 47-81 IPBOO1073A 22.14 5.12e-10 50-84 IPBOO1073A 22.14 6.03e-10 5-39 IPB001442A 26.12 9.26e-10 38-90 IPB001442B 12.38 1.24e-09 18-38 IPBO1073A 22.14 2.13e-09 41-75 IPB001442B 12.38 2.70e-09 3-23 IPB001442B 12.38 4.65e-09 45-65 WO 2004/080148 PCT/US2003/030720 441 TABLE 3B IPB001442B 12.38 5.62e-09 27-47 IPB000885A 11.46 5.87e-09 45-82 IPB001442B 12.38 6.84e-09 48-68 IPBOO1073A 22.14 9.30e-09 38-72 4 C-terminal tandem repeated domain IPB001442A 26.12 7.53e-26 8-60 _____ in type 4 procollagen 2131 I1P000885 Fibrillar collagen C-terminal domain IPB000885B 19.15 4.52e-24 1-54 IPB000885B 19.15 2.38e-23 19-72 IPB001442A 26.12 8.04e-23 11-63 IPB001442A 26.12 8.83e-23 20-72 IPB000885B 19.15 2.32e-22 4-57 IPB001442A 26.12 2.93e-22 5-57 IPB001442A 26.12 5.37e-22 17-69 2131 PR00258 Speract receptor signature I PR00258A 13.56 6.32e-16 87-103 IPB001442A 26.12 7.91e-16 26-78 IPB000885A 11.46 1.49e-15 33-70 IPB000885A 11.46 5.74e-15 24-61 IPB000885B 19.15 5.98e-15 28-81 IPB000885A 11.46 8.30e-15 9-46 IPB000885A 11.46 2.99e-14 30-67 IPB000885B 19.15 4.13e-14 31-84 2131 IPBOO1073 Complement Clq protein IPBOO I 073A 22.14 8.40e-14 17-51 IPBOO0885A 11.46 8.60e-14 39-76 IPB000885B 19.15 2.17e-13 34-87 IPBOO1073A 22.14 7.89e-13 23-57 PR00258B 7.94 8.42e-13 106-117 IPB001442A 26.12 2.17e-12 35-87 IPB001442B 12.38 2.98e-12 24-44 IPB001442B 12.38 5.58e-12 21-41 IPBOO1073A 22.14 6.94e-12 20-54 IPB001073A 22.14 8.38e-12 11-45 IPB001442A 26.12 8.47e-12 32-84 IPB001442B 12.38 8.47c-12 12-32 IPB001073A 22.14 8.74e-12 29-63 IPB001442B 12.38 9.69e-12 15-35 IPB001442B 12.38 1.71e-11 51-71 IPB001442B 12.38 2.86e-11 9-29 IPB001073A 22.14 3.83e-11 14-48 IPB000885B 19.15 5.90e-11 40-93 1PB001442B 12.38 8.86e-11 6-26 IPBOO1073A 22.14 9.17e-11 44-78 IPBOO1073A 22.14 9.50e-11 2-36 IPBOO1073A 22.14 1.15e-10 8-42 IPBOO1073A 22.14 2.83c-10 26-60 2131 IPBOOO 17 Prion protein IPBOOO8 17A 8.34 2.88e-10 1-43 IPB000885B 19.15 4.09e-10 37-90 IPB000885A 11.46 4.23e-10 42-79 IPBOO1073A 22.14 4.81e-10 47-81 IPBOO1073A 22.14 5.12e-10 50-84 IPBOO1073A 22.14 6.03e-10 5-39 IPB001442A 26.12 9.26e-10 38-90 IPB001442B 12.38 1.24e-09 18-38 IPBOO1073A 22.14 2.13e-09 41-75 IPB001442B 12.38 2.70e-09 3-23 IPB001442B 12.38 4.65e-09 45-65 IPB001442B 12.38 5.62e-09 27-47 IPB000885A 11.46 5.87e-09 45-82 IPB001442B 12.38 6.84e-09 48-68 WO 2004/080148 PCT/US2003/030720 442 TABLE 3B IPBOOI073A 22.14 9.30e-09 38-72 2 132 1GRIP domain IPB000237B 30.66 3.22e-10 427-477 2133 IPBOO1909 KPAB box IPB001909 17.37 6.50e-34 63-97 2133 IPBO00822 "Zinc finger, C2H2 ty eIPB000822 14.67 8.20e-22 354-379 IPB000822 14.67 5.09e-21 438-463 IPB000822 14.67 5.50e-20 606-631 IPBOO822 14.67 7.00e-20 578-603 IPB000822 14.67 3.25e-19 522-547 IPB000822 14.67 4.00e-19 326-351 IPB000822 14.67 7.00e-19 410-435 IPB000822 14.67 4.46e-18 494-519 IPB000822 14.67 6.14e-17 382-407 IPB000822 14.67 3.40e-16 550-575 IPB000822 14.67 4.00e-16 466-491 2133 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 5.85e-14 547-560 PROO048A 9.94 8.07e-13 351-364 PROO048A 9.94 3.12e-12 519-532 PROO048A 9.94 4.7le-12 379-392 PROO048A 9.94 4.7le-12 463-476 PROO048B 5.52 7.00e-12 619-628 2133 IPB001275 DM DNA binding domain IPB001275 19.17 7.04e-12 398-437 PROO048A 9.94 7.88e-12 631-644 PROO048A 9.94 1.95e-11 603-616 PROO048A 9.94 4.32e-11 575-588 PROO048B 5.52 5.50e-11 451-460 PROO048A 9.94 1.00e-10 323-336 IPB001275 19.17 1.36e-10 426-465 IPB001275 19.17 1,49e-10 482-521 PROO048A 9.94 5.09e-10 435-448 IPB001275 19.17 5.14e-10 510-549 2133 IPB002817 ThiC family IPBOO2817H 11.39 5.42e-10 349-364 PROO048A 9.94 5.91e-10 491-504 2PB31275 19.17 8.18e-10 314-353 2PBB1275 19.17 9.15e-10 454-493 PROO4B 5.52 9.36e-00 507-516 IPB001275 19.17 9.39e-10 342-381 IPB001275 19,17 9.39e-10 370-409 PROO048B 5.52 2.00e-09 339-348 IPB000822 14.67 2.13e-09 634-659 PROO048B 5.52 2.50e-09 591-600 IPB001275 19.17 2.71e-09 594-633 PROO048B 5.52 3.00e-09 535-544 IPB001275 19.17 3.62e-09 538-577 PROO048A 9.94 4.38e-09 407-420 2133 IPBO00306 "FYVE Zn-finger, IPB000306 8.96 4.71e-09 350-362 rabphiliin/PS27/FAB 1 type" PR00048B 5.52 5.50e-09 423-432 IPB000306 8.96 5.76e-09 630-642 IPB000306 8.96 6.03e-09 434-446 PROO048B 5.52 7.00e-09 367-376 IPB002817H 11.39 7.34e-09 433-448 IPB001275 19.17 8.18e-09 566-605 2133 P1PB002634 BoIA-like protein |PB002634A 23.30 8.62e-09 375-409 2137 1PB000954 Aminotransferase class-IIl pyridoxal- IPB000954B 21.02 9.38e-21 191-230 phosphate IPB000954D 13.61 5.74e-17 277-295 IPB000954C 12.88 9.44e-14 240-255 2138 IPB0954 Aminotransferase class-l p a IPB000954B 21.02 9.38e-21 191-230 phosphate IPBOO0954D 13.61 5.74e-17 277-295 IPB000954C 12.88 9.44e-14 240-255 WO 2004/080148 PCT/US2003/030720 443 TABLEM3 2139 IPB001254 "Serine protease, trypsin family" IPB001254A 9.98 6.14e-15 33-49 2139 PR00722 Chymotrypsin shrine protease family PR00722A 12.06 4.54e-14 34-49 _______ ~~(Si) signature I____________________ 2139 IPBO00001 Kringle IPBOO0001D 11.31 7.56c-1233-49 2139 IPB000177 Apple domain JPBOO0177K 13.19 2.57e-10 35-67 PR00722B 12.69 6.85e-10 90-104 2142 IPB000152 Aspartic acid and asparagine IPB000152 8.86 3.89e-l1 10-25 hydroxylation. site IPB000152 8.86 4.86e-1 1 128-143 2142 IPB001881 Calcium-binding EGF-like domain IPBOO1881B 12.28 7.63e-11 10-21 2142 PROO10 Type II EGF-like signature II PROO1C 6.98 2,74e-10 133-143 2142 IPB002899 EB module IPB002899B 11.81 5.59e-10 116-128 IPB002899B 11,81 5.59e-10 157-169 IPBOO 1881B 12.28 6.57e-10 128-139 IPBOO1881B 12.28 8.29e-10 169-180 IPBOO1881A 8.72 9.36e-10 41-50 ____ IPB000152 8.86 9.72e-10 169-184 2142 IPB001862 Membrane attack complex IPB001862F 29.39 9.81e-l0 26-73 ______components/performn/complement C9 IPBOO 1 862F 29.39 1 .28e-09 102-149 2142 IPB000033 "Low-density lipoprotein (idi) IPB000033B 7.05 5.03e-09 133-143 receptor, YWTD repeat" PR0001OA 12.91 7.27e-09 37-48 21f42 1P00561 EGE-like domain IPBOO0561 4.89 7.43c-09 96-104 44 PB00561 4.89 7.43e-09 137-145 21I44 IPBOO0608 Ubiquitin-conjugating enzymes IPBO00608 27.71 7.95e-12 72-116 2146 IPBOO2181 Fibrinogen beta and gamma chains IPB00218113 20.16 7.49e-24 30-66 C-terminal globular domain PBOO218D 29.18 7.32e-15 92-132 IPBOO2181C 15.87 2.64e-10 71-83 2147 IPBOO21 81 Fibrinogen beta and gamma chains IPBOO2181B 20.16 7.49e-24 30-66 C-terminal globular domain IPBOO2l8yD 29.18 7.32e-15 92-132 IPBOO2181C 15.87 2.64e-10 71-83 2148 IPBOO21 81 Fibrinogen beta and gamma chains IPB00218 l B 20.16 7.49e-24 3 0-66 C-terminal globular domain IPBOO218ID 29.18 7.32e-15 92-132 _____ PB002 18 1C 15.87 2.64e- 10 71-83 2151 IPB002027 Amino acid permeate nPBd02027D 22.00 4.13e-25 248-287 IPB002027C 19.67 2.74e-22 167-205 IPB002027B 12.67 7.97e-12 103-122 2159 PR00503 Bromodomain signature IV PR005031 19.24 3.57e-21 432-451 2159 IPBOC1487 Bromodomain nPBg01487B 17.44 2.13-19 423-444 PRB503B 10.44 4.37e-19 105-121 IPB001487A 1.44 5.20e-19 106-124 PRO503C 19.09 4.5e-17 121-139 IPB001487A 11.44 9.53e-16 399-417 PR0053A 14.57 4.8e-14 89-102 PR0503B 10.44 8.64e-14 398-414 PR00503D 19.24 9.25e-13 139-158 IPB001487B 17.44 1.58e-12 130-151 PR00503C 19.09 6.70e-1 1414-432 2159 IPBOO1505 'Cu(A) centre of cytochrome c IPBOO1505B 15.93 5.94e-10 417-466 oxidase, subunit 11 and nitrous oxide IPBOO08A 18.04 1.17e-09 104-151 reductase" 2159 1PB003351 Dishevelled specific domain IPB003351C 13.82 5.13e-09 496-535 PR00503A 14.57 6.8 le-09 382-395 2159 PRM1217 Proline rich extension signature IV PRO1217D 4.57 7.49e-09 250-271 2159 PRc1503 Troacher Collins syndrome protein PRO153 3.77 7.64e-09 714-727 Treacle signature It 2159 IPB000574 Tymovirus coat protein IPBOO074A 32.18 7.78e-09 265-312 2159 PROO91 Luteovirus ORF6 protein signature I PR00910A 2.74 8.07e-09 266-278 219 PB00056 EGF-lin dPBOO0359H 22.58 8.5e-09 204-254 WO 2004/080148 PCT/US2003/030720 444 TABLE 3B 2159 IPB001978 Troponin IPB001978B 22.99 9.15e-09 541-572 2160 IPB002862 Protein of unknown function DUF16 IPB002862C 11.30 9.59e-09 60-82 2164 IPB000961 Protein Idnase C-terminal domain IPBOO0961D 21.23 5.29e-29 7-48 2164 IPB001245 Tyrosine kinase catalytic domain IPB001245B 21.68 2.80e-19 11-49 2164 IPB000861 PKN/rhophilin/rhotekin rho-binding IPB000861G 13.73 9.60e-16 13-62 repeat 2164 1 IPB001772 Kinase associated domain 1 IPB001772E 24.88 2.25e-14 69-108 2164 IPB003527 MAP kinase IPB003527G 17.26 8.86e-14 81-118 IPB001772D 21.67 4.73e-13 18-57 IPB003527D 21.53 4.66e-11 4-45 2164 IPB000095 PAK-box /P21-Rho-binding IPB00095F 16.47 9.65e-10 15-69 2164 IPB000959 POLO box duplicated region IPB000959D 27.01 2.97c-09 62-114 2165 1PB000961 Protein kinase C-terminal domain IPBOO0961D 21.23 5.29e-29 7-48 2165 IPB001245 Tyrosine kinase catalytic domain IPBOO1245B 21.68 2.80e-19 11-49 2165 IPB000861 PKN/rhophilin/rhotekin rho-binding IPBOO0861G 13.73 9.60e-16 13-62 repeat 2165 IPB001772 Kinase associated domain 1 IPB001772E 24.88 2.25e-14 69-108 2165 IPB003527 MAP kinase IPB003527G 17.26 8.86e-14 81-118 1PB001772D 21.67 4.73e-13 18-57 IPB003527D 21.53 4.66e-11 4-45 2165 IPB000095 PAK-box /P21-Rho-binding IPBOO0095F 16.47 9.65e-10 15-69 2165 IPB000959 POLO box duplicated region IPB000959D 27.01 2.97e-09 62-114 2167 IPB001073 Complement C1q protein IPBOO1073B 20.88 6.00e-26 147-181 IPB001073A 22.14 4.48e-20 101-135 2167 IPB000885 Fibrillar collagen C-terminal domain IPB000885B 19.15 9.63e-20 70-123 2167 IPB001442 C-terminal tandem repeated domain IPB001442A 26.12 4.27e-19 71-123 in type 4 procollagen IPB000885B 19.15 7.48e-19 76-129 IPB000885A 11.46 1.97e-18 78-115 IPB000885A 11.46 2.94e-18 84-121 2167 PR0007 Complement C1Q domain signature PR0007C 16.13 3.67e-18 215-236 III IPB001442A 26.12 1.1le-17 80-132 PR0007A 20.64 1.84e-17 140-166 IPB001442A 26.12 1.87e-17 86-138 IPB000885B 19.15 5.39e-17 73-126 IPB000885A 11.46 6.96e-17 81-118 IPB000885B 19.15 8.87e-17 67 2167 IPB000817 Prion protein IPBOO0817A 8.34 3.27e-09 67-109 IPB000885A 11.46 3.66e-09 35-72 IPB001442A 26.12 4.13e-09 28-80 IPB000885B 19.15 4.19e-09 42-95 IPB000885A 11.46 4.77e-09 102-139 IPB001442A 26.12 4.83e-09 40-92 IPB001442B 12.38 5.99e-09 53-73 IPB001442A 26.12 6.17e-09 37-89 IPB000885B 19.15 7.55e-09 52-105 IPB001442B 12.38 7.57e-09 87-107 IPB001442B 12.38 8.54e-09 105-125 IPBOO1073A 22.14 8.59e-09 46-80 IPB000885B 19,15 8.69e-09 94-147 IPB001442B 12.38 9.64e-09 90-110 2169 IPB002360 Involucrin IPB002360C 15.36 3.06e-14 206-247 2169 PR00209 Alpha/beta gliadin family signature II PR00209B 4.73 5.94e-12 226-244 IPB002360C 15.36 5.93e-10 215-256 IPB002360C 15.36 2.50e-09 195-236 IPB002360C 15.36 2.50e-09 214-255 2169 IPB001359 Synapsin IPB001359H 22.58 5.19e-09 220-270 IPB002360C 15.36 5.20e-09 203-244 WO 2004/080148 PCT/US2003/030720 445 TABLE 3B IPB002360C 15,36 5.70e-09 212-253 IPB002360C 15.36 6.10e-09 188-229 2169 IPB003753 "Exonuclease VII, large subunit" IPB003753F 28.29 7.54e-09 181-231 IPB002360C 15.36 8.80e-09 218-259 2170 IPB002360 Involucrin IPB002360C 15.36 3.06e-14 206-247 2170 PR00209 Alpha/beta gliadin family signature II PR00209B 4.73 5.94e-12 226-244 IPB002360C 15.36 5.93e-10 215-256 IPB002360C 15.36 2.50e-09 195-236 IPB002360C 15.36 2.50e-09 214-255 2170 IPBOO 1359 Synapsin IPBOO 1359H 22.58 5.19e-09 220-270 IPB002360C 15.36 5.20e-09 203-244 IPB002360C 15.36 5.70e-09 212-253 IPB002360C 15.36 6.10e-09 188-229 2170 IPB003753 "Exonuclease VII, large subunit" IPB003753F 28.29 7.54e-09 181-231 IPB002360C 15.36 8.80e-09 218-259 2172 IPB000483 Leucine rich repeat C-terminal IPB000483 11.18 5.50e-13 45-59 domain 2173 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 8.83e-11 69-106 histocompatibility complex domain 2175 PR00457 Animal haem peroxidase signature PR00457G 14.17 4.48e-14 144-164 VII PR00457H 14.82 5.85e-13 215-229 PRO0457F 14.42 6.32e-12 17-27 2176 PR00457 Animal haem peroxidase signature PR00457G 14.17 4.48e-14 144-164 VII PR00457H 14.82 5.85e-13 215-229 PR00457F 14.42 6.32e-12 17-27 2177 PR00457 Animal haem peroxidase signature PR00457G 14.17 4.48e-14 144-164 VII PR00457H 14.82 5.85e-13 215-229 PR00457F 14.42 6.32e-12 17-27 2179 IPB002151 Kinesin light chain repeat 1PB002151B 14.23 8.01e-10 259-311 2179 IPB000421 Coagulation factor 5/8 type C IPBOO0421A 21,21 7.85e-09 62-81 domain (FA58C) 2180 IPB003117 Regulatory subunit of type II PKA R- IPB003117C 17.01 1.00e-40 189-229 subunit IPBOO3117D 18.87 1.00e-40 240-280 IPB003117G 17.45 8.50e-33 383-417 IPBOO3117A 22.23 5.50e-26 66-98 IPBOO3117E 18.84 5.85e-23 329-357 2180 IPBOO0595 Cyclic nucleotide-binding domain IPB000595C 23.31 6.82e-21 363-388 2180 PR00103 cAMP-dependent protein kinase PROO103B 10.32 7.00e-18 215-229 signature II IPBOO0595B 15.72 7.50e-18 321-344 IPB003117F 17.26 1.00e-17 365-379 IPB000595B 15.72 4.43e-16 203-226 PROO103A 9.07 7.75e-16 200-214 IPB003117C 17.01 2.96e-15 307-347 IPBOO3117D 18.87 4.14e-15 364-404 PROO103E 12.91 5.91e-14 397-409 PROO103D 10.18 2.93e-13 376-387 IPBOO0595C 23.31 4.60e-13 239-264 PR0O103C 13.28 1.84e-11 364-373 PROO103D 10.18 2.98e-10 252-263 IPBOO3117E 18.84 3.57e-10 199-227 IPBOO3117E 18.84 5.43e-10 317-345 IPBOO3117F 17.26 1.50e-09 241-255 PROO103A 9.07 8.11e-09 318-332 2181 IPB001478 PDZ domain (also known as DHR or IPB001478B 6.12 4.94e-09 49-58 GLGF) 2182 IPB000907 Lipoxygenase IPBOO0907J 20.31 5.50e-37 499-541 IPB000907G 22.23 1.87e-34 346-388 WO 2004/080148 PCT/US2003/030720 446 TABLE 3B IPB000907F 21.29 1.00e-28 313-345 2182 R00467 Mammalian lipoxygenase signature PR00467F 12.25 9.41e-22 393-415 2182 PR00087 Lipoxygenase signature III PROO087C 13.32 1.39e-21 348-368 IPB000907C 16.09 7.17e-21 195-221 IPB0009071 27.52 7.16e-19 438-491 IPB000907E 15.16 9.21e-18 270-294 PR00467D 17.16 9.57e-17 170-191 IPB000907D 18.70 2.67e-16 236-263 PR00467E 9.17 1.16e-15 267-286 PR00087A 20.06 3.52e-15 310-327 PR00087B 13.69 5.1le-15 328-345 IPB000907B 14.10 2.50e-13 132-147 PR00467A 8.38 3.29e-13 11-28 IPBOO0907H 18.37 5.86e-13 409-425 PR00467B 14.98 5.88e-12 57-76 PR00467G 16.61 3.37e-11 554-571 IPBOO0907A 16.20 4.21e-10 94-103 2183 IPB000907 Lipoxygenase IPBOO0907J 20.31 5.50e-37 499-541 IPBOO0907G 22.23 1.87e-34 346-3 88 IPBOO0907F 21.29 1.00e-28 313-345 2183 PR00467 Mammalian lipoxygenase signature PR00467F 12.25 9.41e-22 393-415 VI 2183 PR00087 Lipoxygenase signature III PROO087C 13.32 1.39e-21 348-368 IPBOO0907C 16.09 7.17e-21 195-221 IPB0009071 27.52 7.16e-19 438-491 IPBOO0907E 15.16 9.21e-18 270-294 PR00467D 17.16 9.57e-17 170-191 IPB000907D 18.70 2.67e-16 236-263 PR00467E 9.17 1.16e-15 267-286 PROO087A 20.06 3.52e-15 310-327 PROO087B 13.69 5.11e-15 328-345 IPB000907B 14.10 2.50e-13 132-147 PR00467A 8.38 3.29e-13 11-28 IPBOO0907H 18.37 5.86e-13 409-425 PR00467B 14.98 5.88e-12 57-76 PR00467G 16.61 3.37e-11 554-571 ___IPBOO0907A 16.20 4.21e-10 94-103 2184 IPB000907 Lipoxygenase IPBOO0907J 20.31 5.50e-37 499-541 IPB000907G 22.23 1.87e-34 346-3 88 IPBOO0907F 21.29 1.00e-28 313-345 2184 PR00467 Mammalian lipoxygenase signature PR00467F 12.25 9.4le-22 393-415 VI 2184 PR00087 Lipoxygenase signature III PROO087C 13.32 1.39e-21 348-368 IPBOO0907C 16.09 7.17e-21 195-221 IPB0009071 27.52 7.16e-19 438-491 IPBOO0907E 15.16 9.21e-18 270-294 PR00467D 17.16 9.57e-17 170-191 IPBOO0907D 18.70 2.67e-16 236-263 PR00467E 9.17 1.16e-15 267-286 PROO087A 20.06 3.52e-15 310-327 PROO087B 13.69 5.1 le-15 328-345 IPBOO0907B 14.10 2.50e-13 132-147 PR00467A 8.38 3.29e-13 11-28 IPBOO0907H 18.37 5.86e-13 409-425 PR00467B 14.98 5.88e-12 57-76 PR00467G 16.61 3.37e-11 554-571 IPBOO0907A 16.20 4.21e-10 94-103 WO 2004/080148 PCT/US2003/030720 447 TABLE 3B 2193 IPB0017 74 Delta serrate ligand IPB001774C 18.25 1.71e-31 37-79 2193 PR001 I Type III EGF-like signature IV PROM I11D)12.12 4.57e-12 39-57 2193 PRoo010 Type II EGF-like signature III PRO0OIOC 6.98 3.90e-10 113-123 2193 IPB000561 BGF-like domain IPB000561 4.89 9.25e-10 46-54 2193 1PB001886 Laminin N-terminal (Domain VI) IPB001886E 10.90 0 44-60 2193 IPB000152 Aspartic acid and asparagine IPBO00152 8.86 6.21e-09 108-123 hydroxylation site PROM 1A 14.05 6.88e- 09 39-57 2193 IPB000034 Laminin B IPBOOOO34A 22.21 9.00e-09 96-131 2193 IPB001762 Disintegrin IPBO01762A 23.93 9.65e-09 126-166 2195 IPB000467 DIII/G-patch domain IPB000467 8.65 1.00e-08 329-339 2197 IPB002467 "Methionine aminopeptidase, IPB002467C 17.56 2.29e-30 184-212 subfamily 1" 1PB002467B 12.68 2.50e-23 158-179 2197 PR00599 Methionine aminopeptidase-1 PR00599B 10.21 8.00e-17 188-204 signature II IPB002467D 14.78 5.50e-15 257-282 PR00599A 11.84 9.63e-14 166-179 IPB002467F 18.38 1.58e-12 3 15-345 IPB002467E 11.05 7.75e-12 290-302 PR00599D 14.43 5.03e- 0 288-300 IPB002467A 15.75 2.87e-09 130-147 2197 IPB001131 Proline dipeptidase IPBOOI 131D 11.56 5.18e-09 290-303 IPBOO1131B 18.96 8.10e-09 188-209 2198 IPB002889 WSC domain IPB002889B 11.76 L88e-12 366-412 IPB002889B 11.76 3.54e-1365-411 IPBOO2889B 11.76 4,96e-10 367-413 IPB002899B 11.76 6.84e-10 363-409 IPB002889B 11.76 7.13e-10 362-408 IPB002889B 11.76 4.19e-09 357-403 2198 IPB003351 Dishevelled specific domain IPB003351C 13.82 4.49e-09 372-411 IPB002889B 11.76 4.56e-09 353-399 IPB002889B 11.76 7.00e-09 355-401 IPB002889C 9.89 8.52e-09 367-388 2199 PR00918 Calicivirus non-structural polyprotein PROO918A 13.81 5.85c-11 192-212 family signature I 2199 PR00364 Disease resistance protein signature I PR00364A 8.29 4.71 e-09 197-212 2199 PRO 1102 5-hydroxytryptamine 6 receptor PRO1102M 11.13 6.71e-09 1013-1035 signature XIII 2199 PR00049 Wilm's tumour protein signature IV PROOO49D 0.00 7.71e-09 1021-1035 2200 IPB001478 PDZ domain (also known as DHR or IPB001478A 11.55 5.09e-09 61-71 GLGF) IPB001478B 6.12 1.00e-08 79-88 2202 PR01286 Orphan nuclear receptor NORI PR1286E 5,27 9.26e-09 322-343 signature V 2203 IPB000998 MAM domain IPBOO0998D 18.66 1.96e-15 546-569 2203 IPB003886 Extracellular domain in nidogen IPB003886D 13.91 8.77e-15 253-272 2203 IPB000152 Aspartic acid and asparagine IPB000152 8.86 2.89e-14 126-141 hydroxylation site 2203 IPB001881 Calcium-binding EGF-like domain IPBOO1881B 12.28 5.00e-14 208-219 IPB000152 8.86 1.07e-13 253-268 IPB000152 8.86 1.82e-13 208-223 IPBOO881B 12.28 4.75e-13 126-137 2203 IPB001774 Delta serrate ligand IPB001774C 18.25 9.13e-13 88-130 1PB000998B 17.20 1.e-12 428-440 2203 PROO020 IIAM domain signature I PROO020A 20.48 2.88e-11 426-444 IPB000998C 18.63 5.30e- 11483-498 IPB002488B 12.28 8.58e-11 253-264 WO 2004/080148 PCT/US2003/030720 448 TABLE 3B 2203 | PR00907 Thrombomodulin signature II PR00907B 11.50 2.44e-10 160-176 2203 IP8000561 EGF-like domain 1PRO00561 4.89 3.25e-10 97-105 2203 IPB000033 "Low-density lipoprotein (ldl) 1B000033B 7.05 5.35e-10 258-268 receptor, YWTD repeat" IPB000033B 7.05 5.97e-09 213-223 2203 IPB000167 Dehydrin IPBO00167A 8.58 7.14e-09 340-367 2203 IPB003367 Thrombospondin type 3 repeat IPB003367A 11.8 9.79e-09 175-195 2204 IPB000998 MAM domain IPB000998D 18.66 1.96e-15 546-569 2204 IPB003886 Extracellular domain in nidogen IPB003886D 13.91 8.77c-15 253-272 2204 IPB000152 Aspartic acid and asparagine 1PB000 152 8.86 2.89e-14 126-141 hydroxylation site 2204 IPB001881 Calcium-binding EGF-like domain IPBOO1881B 12.28 5.00e-14 208-219 IPB000152 8.86 1.00e-13 253-268 IPB000152 8.86 1.82e-13 208-223 IPBOO1881B 12.28 4.75e-13 126-137 204 1PB01774 Delta serrate ligand IPB001774C 18.25 9.13e-13 88-130 IPB000998B 17.20 1.00e-12 428-440 2204 PRO0020 MAM domain signature I PROO020A 20.48 2.88e-1 1 426-444 IPB000998C 18.63 5.30e-11 483-498 IPBOO886B 12.28 8.58e-15 253-264 2204 PR00907 Thrombomodulin signature 11 PR00907B 11.50 2.44e-10 160-176 2204 IPB000561 EGF-like domain IPB000561 4.89 3.25.-10 97-105 2204 IPB00033 "Low-denisitylipoprotein (idi) IPB000033B 7.05 5.35e-10 258-268 receptor, YWTD repeat" IPB000033B 7.05 5.97e-09 213-223 2204 IPB000167 Dehydrin IPB000167A 8.58 7.14e-09 340-367 2204 IPB003367 Thrombospondin type 3 repeat IPB003367A 11.78 9.79e-09 175-195 2205 1PB002893 MYND zinc finger (ZnF) domain IPB002893 16.28 4.52e-17 663-681 2205 IPBOO 1664 Intermediate filament proteins IPB001664B 17.44 6.20e-09 569-608 2205 IPB002889 WSC domain PB002889B 11.76 6.34e-09 488-534 IPB002889C 9.89 8.12e-09 437-458 IPB002889B 11.76 9.9e-09 419-465 2206 IPB002893 MYND zinc finger (ZnF) domain IPB002893 16.28 4.52e-17 663-681 2206 IPB001664 Intermnediatefilament proteins IPB001664B 17.44 6.20e-09 569-608 2206 rPBet2889 WSC domain IPB002889B 11.76 6.34e-09 488-534 IPB002889C 9.89 8.12e-09 437-458 IPB002889B 11.76 9.91e-09 419-465 2207 IPB002893 MYND zinc finger (ZnF) domain IPB002893 16.28 4.52e-17 663-681 2207 IPB001664 Intermediate filament proteins IPB001664B 17.44 6.20e-09 569-608 2207 IPB002889 WSC domain IPB002889B 11.76 6.34e-09 488-534 IPB002889C 9.89 8.12e-09 437-458 IPB002889B 11.76 9.91e-09 419-465 2208 IPB002893 MYND zinc finger (ZnF) domain IPB002893 16.28 4.52e-17 663-681 2208 IPBOO1664 Intermediate filament proteins IPB001664B 17.44 6.20e-09 569-608 2208 IPB002889 WSC domain IPB002889B 11.76 6.34e-09 488-534 IPB002889C 9.89 8.12e-09 437-458 IPB002889B 11.76 9.91e-09 419-465 2210 PR00918 Calicivirus non-structural polyprotein PR00918A 13.81 5.85e-l1 88-108 family signature I____________________ 2210 PR00364 Disease resistance protein signature I PR00364A 8.29 4.7le-09 93-108 2211 IPB001762 Disintegrin IPBOO 1762A 23.93 4.33e-23 19-59 2211 PR00289 Disintegrin signature i PR00289A 14.29 .16e-1435-54 IPB001762B 10.06 3.40e-12 66-76 2211 IPB001774 Delta serrate ligand IPB001774C 18.25 5.31e-10 238-280 IPR00289B 11.74 3.80e-09 64-76 2211 IPB03306 WIF domain 1PB003306E 25.51 7.40e-09 215-260 2212 1PB002159 RA domain IPBOO019A 11.28 7.60e-10 115-124 2212 PB001359 Synapsin y iPB001359H 22.58 5.89e-09 108-158 2213 PR00308 Type I antifreeze protein signature 1I PR00368C 2.79 1.71e-11729-738 WO 2004/080148 PCT/US2003/030720 449 TABLE 3B 2213 1IPB000906 ZU5 domain IPB000906E 22.11 5.55e-11 256-296 2213 PR01415 Ankyrin repeat signature I PRO1415A 12.73 6.46e-11 259-271 IPBOOO906D 23.89 6.59e-11 324-378 PR01415A 12.73 7.11e-11 192-204 PRO1415A 12.73 7.43e-1 1 160-172 PR00308B 3.38 9.53e-1 1 729-740 PR00308A 3.72 5.19e-10 726-740 IPB000906F 35.93 5.85e-10 202-255 2213 PRO1511 Kvl.4 voltage-gated K+ channel PRO1511 D 3.91 9.26e-10 727-737 signature IV PRO1415B 10.23 5.88e-09 271-283 IPB000906G 25.85 6.69e-09 338-386 IPB000906A 22.49 7.84e-09 185-227 PR00308A 3.72 9.1le-09 727-741 PR00308C 2.79 9.64e-09 727-736 2214 IPB000471 "Interferon alpha, beta and delta IPBOO0471A 27.36 2.86e-34 56-109 family" 2214 PR00266 Interferon alpha and beta subunit PR00266A 13.41 9.59e-14 78-90 signature I 2219 PR00405 HIV Rev interacting protein PR00405B 10.10 2.93e-17 290-307 signature II PR00405A 18.83 4.89e-14 271-290 2219 PR01415 Ankyrin repeat signature I PRO1415A 12.73 1.32e-11 419-431 PR00405C 18.05 2.55e-09 311-332 2220 PR00405 HIV Rev interacting protein PR00405B 10.10 2.93e-17 290-307 signature II PR00405A 18.83 4.89e-14 271-290 2220 PR01415 Ankyrin repeat signature I PRO1415A 12.73 1.32e-11 419-431 PR00405C 18.05 2.55e-09 311-332 2221 PR00405 HIV Rev interacting protein PR00405B 10.10 2.93e-17 290-307 signature II PR00405A 18.83 4.89e-14 271-290 2221 PR01415 Ankyrin repeat signature I PRO1415A 12.73 1.32e-11 419-431 PR00405C 18.05 2.55e-09 311-332 2222 PR00405 HIV Rev interacting protein PR00405B 10.10 2.93e-17 290-307 signature II PR00405A 18.83 4.89e-14 271-290 2222 PR01415 Ankyrin repeat signature I PRO1415A 12.73 1.32e-1 1 419-431 PR00405C 18.05 2.55e-09 311-332 2223 IPB002870 Reprolysin family propeptide IPB002870F 18.81 2.35e-19 59-83 IPB002870E 11.90 3.37e-16 23-35 2223 IPBOO0130 "Neutral zinc metallopeptidases, IPBOO0130 5.86 1.86e-09 21-31 zinc-binding region" 2223 PR00480 Astacin family signature II PR00480B 14.35 3.45e-09 16-34 2224 IPB000329 Uteroglobin family IPB000329A 11.99 3.57e-10 1-16 2224 PR00486 Uteroglobin signature I PR00486A 6.53 9.03e-09 2-16 2225 IPB001073 Complement Clq protein IPBOO1073A 22.14 6.55e-13 67-101 2228 IPB003006 Immunoglobulin and major IPB003006B 20.23 6.09e-11 11-48 histocompatibility complex domain 2229 IPB001759 Pentaxin family IPB001759D 18.25 4.67e-33 471-509 2229 PR00895 Pentaxin signature V PR00895E 12.84 4.19e-18 479-498 PR00895D 14.46 2.38e-17 459-478 PR00895C 12,82 3.18e-17 432-450 IPB001759C 13.49 4.30e-17 432-450 IPB001759A 29.51 1.82e-14 175-209 PR00895A 14,28 8.83e-13 366-380 IPB001759E 18.14 5.34e-11 521-535 PR00895F 15.89 9.50e-11 498-512 2229 IPB002751 Cobalamin synthesis CBIM IPB002751C 15.32 1.00e-08 50-79 2235 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 8.71e-11 73-98 2239 IPB000917 Sulfatase IPBOO0917B 9.25 6.40e-13 103-113 IPBOO0917A 9.52 5.26e-10 59-70 WO 2004/080148 PCT/US2003/030720 450 TABLE 3B 2240 IPB000834 "Zinc carboxypeptidases, IPBO00834B 13.51 2.50e-17 37-51 carboxypeptidase A metalloprotease (M14) family" 2240 PR00765 Carboxypeptidase A metalloprotease PR00765B 14.48 1.39e-15 33-47 (M14) family signature II IPB000834C 17.20 2.80e-15 106-122 IPB000834D 18.95 4.72e-12 133-159 PROO765C 10.88 1.82c-10 113-121 2241 IPB000834 "Zinc carboxypeptidases, 1000834B 13.51 2.50e-17 37-5f carboxypeptidase A metalloprotease (M14) family"____________________ 2241 PR00765 Carboxypeptidase A metalloprotease PR00765B 14.48 1.39e-15 33-47 (M14.) family signature 11 IPB000834C 17.20 2.80e-15 106-122 IPB000834D 18.95 4.72e-12 133-159 PR00765C 10.88 1.82e-10 113-121 2242 IPBO02871 NifU-like Nterminal domain IPB002871C 16.51 1.60e-33 8 1-113 IPB002871D 14.11 6.87e-21 131-153 IPB002871A 14.39 2.17e-17 35-50 IPB002871B 12.43 6.79e-14 62-74 2244 IPB000822 "Zinc finger, AC2H2 type" PB007822 14.67 8.29e-1 97-122 2244 PR0048 C212-type zinc finger signature PRB000483 5.52 9.50e-09 110-119 2245 IPB003527 MAP kinase IPB003527D 21.53 5.58e-23 214-255 IPB003527G 17.26 8.24e-22 314-351 IPB003527C 14.70 3.05e-19 153-201 2245 IPB001245 Tyrosine inase catalytic domain IPB001245A 22.45 5.50e-17 161-201 2245 IP~BO00959 POLO box duplicated region 1PB000959B 15.68 7.19e-17 145-185 IPB001245B 21.68 1.39e-15 221-259 2245 IPB001772 Kinase associated domain 1 1PB001772C 20.66 3.92e-14 156-186 2245 IPB000095 PAK-boxI/P2l-Rho-bindirig IPBOO0095C 13.36 7.91e-13 75-111 IPB003527A 17.00 6.14e-12 55-80 2245 IPB000861 PKN/rhophilin/rhotekin rho-binding IPB00086G 13.73 7.44e-12 223-272 repeat 2245 IPB000961 Protein kinase C-terminal domain IPB0961D 21.23 5.91e-12 217-258 IPB003527B 11.51 9.05e-11 127-145 2245 PR001509 Tyrosine kinase catalytic domain PROO09B 11.07 9.0e-10 168-186 signature i IPBOO0961C 15.48 8.83e-09 168-202 2 -248 IPB01073 Complement Clq protein IPBOO1273B 20.88 7.26e-29 42-76 2248 PROO007 Complement CQ domain signature I PROO007A 20.64 6.54e-20 35-61 PROO007C 16.13 2.62e-15 110-131 IPBOO1073C 13.07 1.87e-14 110-129 PROO007B 15.63 3.13e-14 62-81 2250 IPBOO3006 Immunoglobulin and major IPBOO3006B 20.23 4.24e-10 325-362 histocompatibility complex domain 2251 IPB001895 Guanine-nucleotide dissociation IPBOO189C 20.83 7.84e-30 1097-1132 _____ simulators CDC25 family IPBOO1895D 18.68 1.15e-20 1194-1217 225 - PB001331 Guanine-nucleotide dissociation IPBOO331C 16.09 1.OOe- 18 397-422 stimulators CDC24 family I1B001I895B 16.80 3.l1Oe- 15 1025-1045 IPB03301B 19.33 7.83e-09 346-361 2253 IPB000135 High mobility group proteins HMG1 IPBOO0135D 2.13 3.92e-09 202-226 _____and HMG2 2253 PR00169 Potassium channel signature I PROO169A 17.48 5.54e-09 68-87 2253 IPB002360 Involucrin IPB002360C 15.36 9.87e-09 198-239 2253 PR01083 Lymphocyte-specific protein PRO083A 8.60 9.61e-09 214-237 ________signature I 2258 IPB000433 ZZ Zinc finger IPB000433 14.10 8.20e-18 23-39 2258 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 7.86e-10 82-107 2261 IPB000135 High mobility group proteins HMGI IPB000135D 2.13 5.91e- 11 89-913 and HMG2 IPBOO0135D 2.13 7.44e-1 1897-921 WO 2004/080148 PCT/US2003/030720 451 TABLE 3B IPBOO0135D 2.13 7.85e-11 899-923 2PB60135D 2.13 3.05-10 895-919 2PB60135D 2.13 5.gle-10 893-917 2PBB0135D 2.13 8.14e-10 900-924 2PBOO13D 2.13 2.27e-09 888-912 IPB000135D 2.13 2.27e-09 894-918 IPB000135D 2.13 2.36e-0 892-916 2261 PR00806 Vinculin signature IV PROO806D 11.95 3.78c-09 577-592 IPBOO0135D 2.13 3.91e-09 886-910 IPB000135D 2.13 4.45e-09 901-925 IPBOO0135D 2.13 6.36e-09 896-920 IPBOO0135D 2.13 7.27e-09 891-915 IPBOO0135D 2.13 7.18e-09 898-922 IPBOO0135D 2.13 9.27e-09 932-956 2262 IPBO0 135 High mobility group proteins HMG1 IPBOO0135D 2.13 6.43e-17 577-601 and HMG2 IPBOOO135D 2.13 9.7e-17 576-600 IPBOOO35D 2.13 4.90e-16 580-604 IPBOOO135D 2.13 8.66e-16 578-602 IPBOOO135D 2.13 9.13e-15 581-605 IPBOO0135D 2.13 7.30e-15 579-603 IPBOOO135D 2.13 7.45e-14 582-606 IPBOO0135D 2.13 3.08e-13 575-599 IPBOOO135D 2.13 8.50e-13 584-608 IPBOOO135D 2.13 8.62e-13 583-607 IPBOO0135D 2.13 9.08e-13 571-595 IPBOOO135D 2.13 9.88e-13 586-610 IPBOOO135D 2.13 1.65e-12 574-598 IPBOO0135D 2.13 4.36e-12 572-596 IPB0135D 2.13 8.70e-12 585-609 IPBOO0135D 2.13 8.36e-11 587-611 IPBOO0135D 2.13 8.67e-11 573-597 IPB000135D 2.13 4.36e-12 5672-596 IPB000135D 2.13 8.270e-12 580569 262 1B-00063 7 HMG-I and IvIIG-Y DNA-binding IPB000637B 14.21 4.27e-09 576-594 domain (A+T-hook) IPBOO0135D 2.13 4.45e-09 569-593 IPB000637B 14.21 5.09e-09 585-603 262 IPB0-3403 Herpesvirus immediate early protein IPB003403E 17.25 5.45c-09 577-604 IPB000135D 2.13 7.18e-09 568-592 2262 IPB001422 Neuromodulin (GAP-43) IPB001422C 16.82 8.54e-09 575-610 22 _PB01580 Calreticulin family IPBOO158OF 2.93 9.10e-09 590-599 2265 1PB003006 Immunoglobulin and major histocompatibility complex domain IPBOO3006B 20.23 9.14e-12 441-478 IPBOO3006B 20.23 1.00e- 11 248-285 2265 PR01536 Interleukin-1 receptor type I and type PROI536C 19,92 9.23c-11547-570 II family signature III IPBOO3006B 20.23 6.40e-10 54-91 IPBOO3006B 20.23 9.64e-10 540-577 IPBOO3006B 20,23 8.62e-09 346-383 PR01536C 19.92 9.19e-09 155-178 2266 IPB000967 Zinc finger NF-X1 type IPB000967D 10.42 6.89e-09 716-751 2269 IPB002048 EF-hand family IPB002048 7.91 2.29c-1 1 178-190 2269 PR00450 Recoverin family signature III 1PB00204-8 7.91 8.58e-09 105-117 2270 IPB003846 Uncharacterized protein family IPB003846E 18.41 1.00e-40 132-170 UPF0061 IPB003846E 18.41 1.0e-40 511-549 IPB003846F 24.67 9.36e-31 171-206 1PB003846F 24.67 9.36e-31 550-585 IPB003846C 15.01 4.05e-28 8-51 IPB0093846 13.31 5.09e-09 264-274 WO 2004/080148 PCT/US2003/030720 452 TABLE 3B IPB003846G 13.31 5.09e-09 643-653 2271 IPB003846 Uncharacterized protein family IPB003846E 18.41 1.00e-40 132-170 UPF0061 IPB003846E 18.41 1.00e-40 511-549 IPB003846F 24.67 9.36e-31 171-206 IPB003846F 24.67 9,36e-31 550-585 IPB003846C 15.01 4.05e-28 8-51 IPB003846G 13.31 5.09e-09 264-274 IPB003846G 13.31 5.09e-09 643-653 2272 PR00237 Rhodopsin-like GPCR superfamily PR00237F 14.34 1.67e-13 51-75 signature VI PR00237G 19.23 4.00e-13 89-115 2272 IPB000276 Rhodopsin-like GPCR superfamily IPB000276B 4.97 6.62e-13 1-12 IPB000276D 9.40 4.52e-10 99-115 2273 PROW19 Leucine-rich repeat signature I PROM19A 11.72 2.80e-13 89-102 PROO019B 11.42 6.33e-10 86-99 2274 IPB000873 AMP-dependent synthetase and IPBOO0873A 11.08 6.06e-14 26-41 ligase 2275 IPB000595 Cyclic nucleotide-binding domain IPB000595B 15.72 6.40e-11 136-159 2276 IPB000595 Cyclic nucleotide-binding domain IPB000595B 15.72 6.40e-11 136-159 2281 IPB003452 Stem cell factor IPB003452C 13.68 8.56e-37 207-240 2281 IPB000808 Mrp family IPBOO0808A 23.51 1.1le-12 16-60 2281 IPB003348 Anion-transporting ATPase IPB003348A 20.06 6.60e-11 21-58 2282 PR00205 Cadherin signature VI PR00205F 19.57 3.37e-17 55-81 PR00205B 20.09 6.67e-16 113-142 PR00205F 19.57 6.70e-13 166-192 PR00205E 10.82 2.17e-10 111-124 2282 IPB002126 Cadherin domain IPB002126A 14.68 6.09e-10 170-186 PR00205A 17.38 3.12e-09 159-178 2283 PR00205 Cadherin signature VI PR00205F 19.57 3.37e-17 55-81 PR00205B 20.09 6.67e-16 113-142 PR00205F 19.57 6.70e-13 166-192 PR00205E 10.82 2.17e-10 111-124 2283 IPBOO2126 Cadherin domain IPBOO2126A 14.68 6.09e-10 170-186 PR00205A 17.38 3.12e-09 159-178 2286 IPB002027 Amino acid permease IPB002027D 22.00 4.13e-25 248-287 IPB002027C 19.67 2.74e-22 167-205 IPB002027B 12.67 7.97e-12 103-122 2287 IPB000559 Formate-tetrahydrofolate ligase IPBOO0559C 13.05 1.00e-40 395-444 IPBOO0559F 12.78 1.00e-40 595-645 IPBOO0559G 15.54 1.00e-40 649-697 IPBOO0559D 22.27 4.33e-37 496-536 IPBO00559B 17.08 7.39e-36 537-578 IPB000559K 15.77 8.96e-35 875-910 IPBOO0559B 12.60 2.88e-32 355-383 IPB000559J 17.25 5.94e-32 842-874 IPB000559H 20.31 2.72e-26 712-752 IPBOO0559A 24.17 6.11e-25 310-354 IPB0005591 15.05 6.35e-18 798-822 2287 PR00085 Tetrahydrofolate PROO085C 13.81 5.70e-14 112-133 dehydrogenase/cyclohydrolase PR00085B 16.65 1.23e-09 79-106 family signature III 2287 IPB000672 Tetrahydrofolate IPB000672C 28.03 6.83e-09 153-200 dehydrogenase/cyclohydrolase 2288 IPB000560 Histidine acid phosphatase IPBOO0560 17.02 7.86c-11 391-413 2290 PR00390 Phospholipase C signature 1 PR00390A 14.24 6.34e-20 2-20 2292 PR00245 Olfactory receptor signature III PR00245C 14.65 5.26e-17 183-199 PR00245E 8.96 2.73e-13 290-301 PR00245B 13.73 1.39e-12 136-148 WO 2004/080148 PCT/US2003/030720 453 TABLE 3B PR00245D 9.34 8.33e-11 243-252_ 2292 IPB000276 Rhodopsin-like GPCR superfamily 1PB000276A 11.56 1.47e-10 125-136 PR00245A 10.98 8.80e-10 99-110 IPB000276D 9.40 9.61e-10 289-305 2292 PR00896 Vasopressin receptor signature 11 PR00896B 9.36 5.50e-09 62-73 2292 PR00534 Melanocortin receptor family PR00534A 12.77 5.70e-09 58-70 signature I 2292 PR00237 Rhodopsin-like GPCR superfamily PR00237B 12.45 7.16e-09 66-87 signature II PR00237E 13.03 8.20e-09 206-229 2292 IPB003211 AmiS/UreI family transporter IPB00321 1A 15.05 9.43e-09 35-74 2293 IPB003367 Thrombospondin type 3 repeat fPB003367E 16.82 1.OOe-40 35-82 IPB003367F 16.21 1.00c-40 93-142 IPB003367G 17.08 1.00e-40 143-184 IPB003367H 15.25 1.00e-40 185-217 IPB003367J 18.60 1.00e-40 247-288 IPB003367L 21.71 1.00e-40 313-364 IPB003367I 12.15 3.14e-37 218-246 IPB003367K 16.35 9.10e-30 289-312 IPB003367F 16.21 5.83e-21 53-102 IPB003367C 20.73 1.54e-19 38-88 IPB003367D 18.41 9.44e-19 53-95 IPB003367D 18.41 5.55e-17 15-57 IPB003367D 18.41 1.48c-14 93-135 IPB003367F 16.21 2.74e-14 15-64 IPB003367C 20.73 9.27e-13 78-128 IPB003367E 16.82 2.82e-12 12-59 IPB003367E 16.82 4.98e-12 75-122 IPB003367C 20.73 5.96e-11 23-73 IPB003367C 20.73 2.38e-10 101-151 IPB003367C 20.73 6.35e-10 61-111 IPB003367E 16.82 8.88e-10 73-120 2294 IPB001978 Troponin IPB001978A 18.18 8.89e-09 102-137 2295 IPBOO0109 PTR peptide transporters (PTR2) IPBOO0109D 25.09 6.67e-32 434-481 IPBOO0109B 29.23 4.18e-23 46-98 IPBOO0109A 10.85 3.79e-15 23-41 IPBOO0109C 8.21 7.00e-14 174-186 2295 PR01471 Histamine H3 receptor signature II PRO1471B 12.38 9.63e-09 3-21 2297 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 9.18e-21 113-138 IPB000822 14.67 9.3 1e-18 29-54 IPB000822 14.67 9.31e-18 141-166 IPB000822 14.67 5.20e-16 57-82 IPB000822 14.67 5.20e-16 85-110 2297 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 4.46e-14 138-151 IPB000822 14.67 1.50e-13 1-26 PROO048A 9.94 5.76e-12 110-123 PROO048A 9.94 1.00e-11 26-39 2297 IPB001275 DM DNA binding domain IPB001275 19.17 4.21e-1 117-56 PR00048A 9.94 4.79e-11 54-67 IPB001275 19.17 2.22e-10 73-112 PR00048B 5.52 5.50e-10 126-135 IPB001275 19.17 9.15e-10 45-84 PR00048A 9.94 1.38e-09 82-95 2297 IPB001222 TFIIS zinc ribbon domain IPB001222 24.63 5.69e-09 1-37 IPBOO1222 24.63 9.49e-09 29-65 2299 IPB003137 Protease associated (PA) domain IPB003137 22.40 2.50e-19 188-218 2303 IPB000433 ZZ Zinc finger IPB000433 14.10 8.20e-18 23-39 2303 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 7.86e-10 82-107 WO 2004/080148 PCT/US2003/030720 454 TABLE 3B 2306 IPB001039 "Major histocompatibility complex IPB001039A 17.17 1.00e-40 22-75 protein, Class I" IPB01039B 27.55 1.00e-40 103-154 2306 IPB003006 Immunoglobulin and major JPBOO3006B 20.23 4.60e-29 268-305 histocompatibility complex domain IPBO03006A 17.51 6.14e-20 231-253 2306 IPB000353 "Class II histocompatibility antigen, IPB000353B 19.16 9.87c-14 210-259 beta chain, beta-I domain" 2306 IPB003363 Glycoprotein GG/GX IPB003363E 13.35 2.94e-1l 315-347 IPB000353C 20.11 4

.

6 8e-10 261-315 2312 IPB001359 Synapsin IPB001359H 22.58 5.54e-09 98-148 2312 IPB003403 Herpesvirus immediate early protein IPB003403A 21.25 6.18e-09 130-152 2313 PR1382 Claudin-9 signature IV PR01382D 12.38 1.e-16 205-217 2313 IPB000729 PMP-22/EMP/MP2O family IPB000729D 18.96 2.96e-16 164-191 IPB000729C 37.83 7.91e-16 84-136 PR01382A 12.00 1.17e-15 41-51 2313 PR01077 Claudin signature III PROI077C 13.60 1.47e-14 67-77 PR01382C 5.67 5.14e-13 194-203 PR01382B 7.06 5.12e-12 95-104 PRO1077B 14.12 1.00e-10 53-59 PRO177D 11.20 4.8e-10 150-156 PRO1377A 9.72 8.16e-09 25-34 2317 IPB001245 Tyrosine kinase catalytic domain IPB001245A 22.45 7.60e-28 129-169 2317 IPB001772 Kinase associated domain 1 IPB001772C 20.66 9.25e-24 124-154 2317 IPB00961 Protein kinase C-terminal domain IPBOO0961C 15.48 2.13e-22 136-170 IPB01772D 21.67 4.55e-17 196-235 2317 IPB000959 POLO box duplicated region IPB0P0959B 15.68 8.60e-17 113-153 2317 IPBOO0095 PAK-box /P2 1 -Rho-binding IPBOO0095E 17.62 9.03e-17 137-182 2317 IPB003527 MAP kInase IPB003527C 14.70 1.95e-16 121-169 2317 IPB00861 PKN/rhophilin/rhotekin rho-binding IPBOO0861F 16.50 1.55e-15 130-184 repeat 2317 IPB000494 "Epidermal growth-factor receptor IPB001494C 24.40 7.35e-14 123-169 (EGFR), L domain" IPB000959D 27.01 5.95e-13 236-288 IPBOO0961D 21.23 7.19e-13 185-226 IPB001245B 21.68 8.96e-13 189-227 IPB001772E 24.88 8.96e-12 243-282 IPB003527A 17.00 7.85e-11 28-53 IPB001772A 13.64 2.29e-10 19-50 IPB003527 17.26 1.30e-09 255-292 2317 PROOI109 Tyrosine kinase catalytic domain PROO109B 11.07 4.23e-09 136-154 signature 1I IPB003527D 21.53 4.60e-09 182-223 2318 PR01254 Prostaglandin D synthase signature I PRO1254A 12.32 3.37e-29 5 1-74 PR01254D 13.80 7.97e-27 129-152 PRO1254C 10.60 4.68c-22 94-112 PRO124F 10.08 7.58e-21 182-200 PR01254E 14.07 1.0e-18 165-179 2318 PROO 179 Lipocalin signature ai PROO179B 7.67 5.26e-13 140-152 PROO179C 17.26 3.84e-12 168-183 PRO1254B 12.05 9.04e-12 77-87 2318 PR01275 Neutrophil gelatinase lipocalin PRO1275E 6.38 1.72e-10 135-153 signature V PROO179A 13.97 3.25e-10 57-69 2318 PR01215 Alpha-1-microglobulin signature IV PRO1215D 12.88 9.78e-10 131-150 2318 IPB000566 Lipocalin and cytosolic fatty-acid IPB000566B 8.91 1.47e-09 140-150 binding protein 2318 PR01174 Retinol binding protein signature VI PROI174F 11.76 3.96e-09 139-155 2318 PR01273 Invertebrate colouration protein PR01273D 11.48 4.41e-09 140-154 signature IV PRO1275B 9.02 8.57e-09 59-69 WO 2004/080148 PCT/US2003/030720 455 TABLE 3B 2320 IPB001464 Annexin family IPB001464D 25.42 1.00e-40 177-231 IPB001464B 28.31 1.90e-36 47-99 IPB001464C 24.68 6.40e-30 110-149 2320 PR00196 Annexin family signature IV PROO196D 21.41 3.81e-22 115-141 PROO196C 9.01 9.67e-22 32-53 PROO196E 9.70 5.22e-21 195-215 2320 PR00201 Annexin type V signature VII PR00201G 12.46 1.63e-20 195-221 2320 PR00199 Annexin type III signature VI PROO199F 15.67 5. 1Oe-18 115-141 IPB001464B 28.31 3.86e-17 131-183 PROOI96C 9.01 5.70e-17 191-212 2320 PR00200 Annexin type IV signature VII PR00200G 9.20 7.67e-17 195-221 IPB001464D 25.42 8.71e-17 18-72 PROO199D 4.74 9.87e-17 191-212 PROC 199G 9.85 4.45e-16 196-221 PR00196B 11.03 9.3le-16 5-21 2320 PR00197 Annexin type I signature IV PR00197D 7.59 1.73e-15 32-53 PR00199D 4.74 2.17e-15 32-53 IPB001464A 31.17 3.83e-15 47-101 2320 PR00198 Annexin type II signature IV PROO198D 7.41 3.89e-15 32-53 PROO197F 9.40 6.80e-15 195-215 PR00200E 8.88 9.02e-15 32-53 2320 PR00202 Annexin type VI signature VII PR00202G 8.03 9.04e-15 195-221 PROO197D 7.59 1.00e-14 191-212 IPB001464A 31.17 1.85e-14 131-185 PROO198D 7.41 2.38e-14 191-212 PROO198G 7.70 3.44e-13 195-215 PR00201D 8.61 3.5le-13 32-53 PR00200F 14.58 3.53e-13 115-141 P 2321 IPBOO0175 Sodium:neurotransmitter symporter IPBOO0175C 15.09 1.00e-40 56-107 family IPBOO0175D 23.45 1.00e-40 122-174 IPBOO0175F 25.63 4.50e-38 310-349 IPBOO0175E 21.88 5.95e-35 215-254 2321 PR00176 Sodium/chloride neurotransmitter PROO176E 11.14 2.00e-24 165-185 symporter signature V PROO176G 13.12 3.77e-22 301-321 2321 PRO 1195 GAT- 1 GABA neurotransmitter PROl 195B 13.58 6.60e-22 38-55 transporter signature II PROl 195D 9.00 3.75e-21 426-443 PROO176F 11.11 1.36e-19 219-238 IPBOO0175G 16.18 5.13e-19 371-393 PROO176D 8.96 6.48e-18 83-100 PROO176H 15.94 7.63e-18 341-361 PRO1195C 15.62 1.14e-13 191-200 2323 IPB001863 Glypican IPB001863A 13.95 5.03e-15 56-71 2323 PR00436 Interleukin-8 signature I PR00436A 15.20 7.91e-10 1-24 2328 IPB001599 Alpha-2-macroglobulin family IPBOO1599L 18.66 4.15e-28 59-86 2328 IPB001134 "Netrin, C-terminus" IPBOO1134C 17.82 4.13e-13 72-86 IPB001599K 8.15 1.46e-10 29-40 2329 IPB001599 Alpha-2-macroglobulin family IPB001599L 18.66 4.15e-28 59-86 2329 IPB001134 "Netrin, C-terminus" IPBOO1134C 17.82 4.13e-13 72-86 IPB001599K 8.15 1.46e-10 29-40 2330 IPB001599 Alpha-2-macroglobulin family IPB001599L 18.66 4.15e-28 59-86 2330 IPB001134 "Netrin, C-terminus" IPBOO1134C 17.82 4.13e-13 72-86 IPB001599K 8.15 1.46e-10 29-40 2331 IPB001599 Alpha-2-macroglobulin family IPB001599L 18.66 4.15e-28 59-86 2331 IPB001134 "Netrin, C-terminus" IPBOO1134C 17.82 4.13e-13 72-86 IPB001599K 8.15 1.46e-10 29-40 2332 IPB001599 Alpha-2-macroglobulin family IPB001599L 18.66 4.15e-28 59-86 2332 IPB001134 "Netrin, C-terminus" IPBOO1134C 17.82 4.13e-13 72-86 WO 2004/080148 PCT/US2003/030720 456 TABLE 3B _ _ _ _ _ _ _ _ _ _ _______ IPBOO1599K 8.15 1.46e-10 29-40 2334 PROO010 Type II EGF-like signature III PROOO1OC 6.98 1.37e-11 7-17 2334 IPB000152 Aspartic acid and asparagine IPB000152 8.86 5.50e-10 2-17 hydroxylation site 2334 IPB000033 "Low-density lipoprotein (idl) IPB00033B 7.05 8.26e-10 7-17 receptor, YWTD repeat" 2335 IPB000492 Protamine 2 (PRM2) IPB000492B 5.26 7.16e-09 62-96 2336 PROW14 Fibronectin type III repeat signature PROOO14D 15.12 5.74e-10 215-229 IV 2339 1PB002494 "Keratin, high sulfur B2 protein" IPB002494C 14.46 8.36e-35 39-82 IPB002494C 14.46 6.55e-31 83-126 IPB002494C 14.46 9.46e-26 93-136 IPB002494C 14.46 4.84e-25 49-92 IPB002494C 14.46 8.59e-24 44-87 IPB002494C 14.46 9.38e-23 73-116 IPB002494C 14.46 2.73e-22 98-1 2339 IPB000359 Cystine-kmot domain IPB000359B 19.26 9.57e-13 43-61 IPB000359B 19.26 9.57e-13 87-105 IPB002494A 12.44 1.56e-12 61-94 IPB002494B 10.58 2.50e-12 70-84 IPB002494B 10.58 2.50e-12 114-128 IPB002494C 14.46 5.41e-12 53-96 2339 IPB001271 Mammalian defensin IPB001271 19.97 7.95e-12 77-105 IPB001271 19.97 9.59e-12 38-66 IPB002494B 10.58 1.28e-11 45-59 [PB002494B 10.58 1.28e-11 89-103 IPB002494A 12.44 4.00c-11 75-108 2339 IPBO0006 "Vertebrate metallothionein, family IPB00006 13.41 4.10e-11 85-130 1" IPB001271 19.97 5.13e-11 116-144 IPBO0006 13.41 6.80e-11 59-104 IPB000359B 19.26 7.48e-11 122-140 IPBO0006 13.41 8.00e-11 89-134 IPB002494A 12.44 8.18e-11 65-98 IPB002494C 14.46 1.61e-10 102 2339 IPB000967 Zinc finger NF-X1 type IPB000967E 21.88 1.56e-09 70-110 2339 IPB001762 Disintegrin IPB001762A 23.93 1.88e-09 58-98 IPB001271 19.97 2.15e-09 117-145 [PB002494A 12.44 2.55e-09 81-114 IPB002494A 12.44 3.13e-09 60-93 [PB002494A 12.44 3.23e-09 47-80 fPB002494A 12.44 3.23e-09 91-124 1PB002494A 12.44 3.23e-09 96-1 2340 IPB002494 "Keratin, high sulfur B2 protein" IPB002494C 14.46 8.36e-35 39-82 IPB002494C 14.46 6.55e-31 83-126 IPB002494C 14.46 9.46e-26 93-136 IPB002494C 14.46 4.84e-25 49-92 IPB002494C 14.46 8.59e-24 44-87 IPB002494C 14.46 9.38e-23 73-116 IPB002494C 14.46 2.73e-22 98-1 2340 IPB000359 Cystine-knot domain IPB000359B 19.26 9.57e-13 43-61 IPB000359B 19.26 9.57e-13 87-105 IPB002494A 12.44 1.56e-12 61-94 IPB002494B 10.58 2.50e-12 70-84 IPB002494B 10.58 2.50e-12 114-128 IPB002494C 14.46 5.41e-12 53-96 2340 IPB001271 Mammalian defensin IPB001271 19.97 7.95e-12 77-105 IPB001271 19.97 9.59e-12 38-66 WO 2004/080148 PCT/US2003/030720 457 TABLE 3B IPB002494B 10.58 1.28e-11 45-59 IPB002494B 10.58 1.28e-11 89-103 IPB002494A 12.44 4.00e-11 75-108 2340 IPB00006 "Vertebrate metallothionein, family IPB000006 13.41 4.1Oe- 11 85-130 1" IPB001271 19.97 5.13e-11 116-144 IPB000006 13.41 6.80e-11 59-104 IPB000359B 19.26 7.48e-1 1 122-140 IPB000006 13.41 8.00e-11 89-134 IPB002494A 12.44 8.18e-11 65-98 IPB002494C 14.46 1.61e-10 102 2340 IPB000967 Zinc finger NF-XI type IPB000967E 21.88 1.56e-09 70-110 2340 IPB001762 Disintegrin IPB001762A 23.93 1.88e-09 58-98 IPB001271 19.97 2.15e-09 117-145 IPB002494A 12.44 2.55e-09 81-114 IPB002494A 12.44 3.13e-09 60-93 IPB002494A 12.44 3.23e-09 47-80 IPB002494A 12.44 3.23e-09 91-124 IPB002494A 12.44 3.23e-09 96-1 2341 IPB002494 "Keratin, high sulfur B2 protein" IPB002494C 14.46 8.36e-35 39-82 IPB002494C 14.46 6.55e-31 83-126 IPB002494C 14.46 9.46e-26 93-136 IPB002494C 14.46 4.84e-25 49-92 IPB002494C 14.46 8.59e-24 44-87 IPB002494C 14.46 9.38e-23 73-116 IPB002494C 14.46 2.73e-22 98-1 2341 IPB000359 Cystine-knot domain IPB000359B 19.26 9.57e-13 43-61 IPB000359B 19.26 9.57e-13 87-105 IPB002494A 12.44 1.56e-12 61-94 IPB002494B 10.58 2.50e-12 70-84 IPB002494B 10.58 2.50e-12 114-128 IPB002494C 14.46 5.41e-12 53-96 2341 IPB001271 Mammalian defensin IPB001271 19.97 7.95e-12 77-105 IPB001271 19.97 9.59e-12 38-66 IPB002494B 10.58 1.28e-11 45-59 IPB002494B 10.58 1.28e-11 89-103 IPB002494A 12.44 4.00e-11 75-108 2341 IPB000006 "Vertebrate metallothionein, family IPB000006 13.41 4.10e-11 85-130 1" IPB001271 19.97 5.13e-11 116-144 IPBO0006 13.41 6.80e-11 59-104 IPB000359B 19.26 7.48e-11 122-140 IPB000006 13.41 8.00e-11 89-134 IPB002494A 12.44 8.18e-11 65-98 IPB002494C 14.46 1.61e-10 102 2341 IPB000967 Zinc finger NF-X1 type IPB000967E 21.88 1.56e-09 70-110 2341 IPB001762 Disintegrin IPB001762A 23.93 1.88e-09 58-98 IPB001271 19.97 2.15e-09 117-145 IPB002494A 12.44 2.55e-09 81-114 IPB002494A 12.44 3.13e-09 60-93 IPB002494A 12.44 3.23e-09 47-80 IPB002494A 12.44 3.23e-09 91-124 IPB002494A 12.44 3.23e-09 96-1 2342 IPB000734 Lipase IPB000734 10.25 8.12e-09 224-238 2343 IPB000734 Lipase IPB000734 10.25 8.12e-09 224-238 2344 PR01223 Bride of sevenless protein signature PR01223F 4.19 9.78e-11 205-229 VI 2344 PR00354 7Fe ferredoxin signature III PR00354C 6.24 8.06e-09 260-277 2345 IPB001304 C-type lectin domain IPBOO1304A 17.98 8.04e-14 90-114 WO 2004/080148 PCT/US2003/030720 458 TABLE 3B 2345 PR00356 Type II antifreeze protein signature PR00356G 10.21 8.15e-09 201-214 VII 2346 IPBOO1304 C-type lectin domain IPB001304A 17.98 8.04e-14 90-114 2346 PR00356 Type 1I antifreeze protein signature PR00356G 10.21 8.15e-09 201-214 VII 2347 PR00245 Olfactory receptor signature V PR00245E 8.96 5.15e-16 341-352 PR00245E 8.96 5.15e-16 659-670 PR00245B 13.73 3.77e-15 187-199 PR00245C 14.65 2.73e-14 234-250 PR00245C 14.65 8.27e-14 552-568 PR00245D 9.34 2.59e-13 294-303 PR00245D 9.34 2.59e-13 612-621 PR00245B 13.73 1.39e-12505-517 2347 IPB000276 Rhodopsin-like GPCR superfamily IPB000276A 11.56 7.00c-12 176-187 IPB000276A 11.56 7.00e-12 494-505 PR00245A 10.98 8.77e-12 468-479 PR00245A 10.98 1.72e-I1 150-161 IPB000276D 9.40 6.09e-10 340-356 2347 PR00237 Rhodopsin-like GPCR superfamily PR00237B 12.45 7.55e-10 435-456 signature II IPB000276D 9.40 7.65e-10 658-674 PR00237A 9.81 1.84e-09 402-426 2347 PR00534 Melanocortin receptor family PR00534A 12.77 2.83e-09 109-121 signature I PR00534A 12.77 2.83e-09 427-439 PR00237C 14.77 3.86e-09 162-184 PR00237B 12.45 6.92e-09 117-138 PR00237A 9.81 8.3 le-09 84-108 2348 PR00346 Tissue factor signature VIII PR00346H 10.74 8.18e-09 76-99 2350 PR00457 Animal haem peroxidase signature PR00457G 14.17 4.48e-14 144-164 VII PR00457H 14.82 5.85e-13 215-229 PR00457F 14.42 6.32e-12 17-27 2351 PR00457 Animal haem peroxidase signature PR00457G 14.17 4.48e-14 144-164 VII PR00457H 14.82 5.85e-13 215-229 PR00457F 14.42 6.32e-12 17-27 2354 IPB000623 Shikimate kinase IPB000623A 19.06 6.27e-09 55-84 2360 IPB001841 RING finger IPB001841 10.69 1.95e-09 159-168 2372 IPB000421 Coagulation factor 5/8 type C IPBOO0421B 20.70 1.36c-14 129-149 domain (FA58C) 2373 IPB000421 Coagulation factor 5/8 type C IPBOO0421B 20.70 1.36e-14 129-149 domain (FA58C) 2375 IPB001245 Tyrosine kinase catalytic domain IPB001245B 21.68 3.45e-17 60-98 2375 IPB003527 MAP kinase IPB003527D 21.53 4.48e-15 53-94 2375 IPB000959 POLO box duplicated region IPB000959C 23.49 4.21e-12 35-87 2375 IPB000861 PKN/rhophilin/rhotekin rho-binding IPB00086IG 13.73 5.59c-12 62-111 repeat 2375 IPB000095 PAK-box/P21-Rho-binding IPB00095F 16.47 2.26e-11 64-118 2375 IPB000961 Protein kinase C-terminal domain IPBOO0961D 21.23 1.61e-10 56-97 2376 IPB001881 Calcium-binding EGF-like domain IPB001881A 8.72 2.20e-09 41-50 2376 PR00873 Echinoidea (sea urchin) PR00873D 8.25 8.1 le-09 41-59 metallothionein signature IV 2377 PR00402 Tec/Btk domain signature I PR00402A 20.14 8.15e-15 94-113 PR00402B 12.26 4.69e-13 113-125 PR00402C 13.13 8.03e-12 125-138 2379 IPB003886 Extracellular domain in nidogen IPB003886D 13.91 8.57e-15 46-65 2379 IPB000152 Aspartic acid and asparagine IPB000152 8.86 9.05e-14 1-16 hydroxylation site IPB000152 8.86 5.91e-13 46-61 2379 IPB001881 Calcium-binding EGF-like domain IPBOO1881B 12.28 9.25e-13 1-12 2379 PR01217 Proline rich extensin signature VII PR01217G 4.02 4.20e- 11 125-150 WO 2004/080148 PCT/US2003/030720 459 TABLE 3B 2379 IPB000033 "Low-density lipoprotein (Idl) IPB00033B 7.05 4.96e-11 51-61 receptor, YWTD repeat" IPB001881B 12.28 1.00e-10 46-57 2379 PROO010 Type II EGF-like signature III PROO010C 6.98 1.66e-09 51-61 2379 PR00049 Wilm's tumour protein signature IV PROO049D 0.00 3.29e-09 133-147 IPB00033B 7.05 3.84e-09 6-16 2379 IPB000561 EGF-like domain IPB000561 4.89 6.79e-09 55-63 PRO0010C 6.98 7.80e-09 6-16 2379 PR00910 Luteovirus ORF6 protein signature I PR00910A 2.74 8.71e-09 133-145 PR00910A 2.74 9.46e-09 131-143 2385 PR00245 Olfactory receptor signature III PR00245C 14.65 9.53e-17 218-234 2385 IPB000276 Rhodopsin-like GPCR superfamily IPB000276A 11.56 9.25e-14 160-171 PR00245D 9.34 1.53e-13 278-287 PR00245E 8.96 6.8 le-12 325-336 PR00245B 13.73 1.00e-10 171-183 IPB000276D 9.40 3.08e-09 324-340 2385 PR00237 Rhodopsin-like GPCR superfamily PR00237E 13.03 3.83e-09 241-264 signature V 2385 PR00534 Melanocortin receptor family PR00534A 12.77 5.17e-09 93-105 signature I PR00237C 14.77 5.91e-09 146-168 2385 PR00896 Vasopressin receptor signature II PR00896B 9.36 7.23e-09 97-108 PR00237G 19.23 1.00e-08 314-340 2386 PR00245 Olfactory receptor signature III PR00245C 14.65 9.53e-17 218-234 2386 IPB000276 Rhodopsin-like GPCR superfamily IPB000276A 11.56 9.25e-14 160-171 PR00245D 9.34 1,53e-13 278-287 PR00245E 8.96 6.81e-12 325-336 PR00245B 13.73 1.00e-10 171-183 IPB000276D 9.40 3.08e-09 324-340 2386 PR00237 Rhodopsin-like GPCR superfamily PR00237E 13.03 3.83e-09 241-264 signature V 2386 PR00534 Melanocortin receptor family PR00534A 12.77 5.17e-09 93-105 signature I PR00237C 14.77 5.91e-09 146-168 2386 PR00896 Vasopressin receptor signature II PR00896B 9.36 7.23e-09 97-108 PR00237G 19.23 1.00e-08 314-340 2389 PR01360 Interleukin-1 receptor antagonist PRO136OF 14.44 3.1le-12 145-163 precursor IL-IRA signature VI PR01360C 10.33 4.84e-11 86-103 2389 IPB000975 Interleukin-1 IPB000975D 24.45 5.55e-09 80-119 IPB000975E 28.12 9.80e-09 124-163 2389 PR00264 Interleukin-1 precursor family PR00264A 18.63 1.00e-08 83-103 signature I 2390 IPB001664 Intermediate filament proteins IPB001664B 17.44 9.69e-22 102-141 IPB001664C 11.32 4.38e-18 159-186 2390 PR01248 Type I keratin signature II PR01248B 8.42 6.37e-15 94-117 PR01248C 10.07 9.23e-14 148-168 PR01248A 8.12 4.31e-11 73-86 2390 PR01177 Metabotropic gamma-aminobutyric PR01177J 6.10 4.96e-10 11-29 acid type B 1 receptor signature X 2393 PR01276 Type II keratin signature III PR01276C 10.16 7.32e-11 67-80 PR01276B 9.79 5.96e-10 20-32 2394 IPB001818 Matrixin IPBOO1818C 24.38 7.43e-35 54-99 IPBOO1818B 26.48 8.15e-25 9-50 IPB001818C 24.38 1.55e-21 96-141 2394 PR00138 Matrixin signature III PROO138C 20.07 1.78e-16 52-80 PROO138B 14.84 5.21e-10 2 8- 4 3 PROO138C 20.07 9.18e-10 94-122 2395 IPB001818 Matrixin IPBOO1818C 24.38 7.43e-35 54-99 IPBOO1818B 26.48 8.15e-25 9-50 IPBOO1818C 24.38 1.55e-21 96-141 WO 2004/080148 PCT/US2003/030720 460 TABLE 3B 2395 PR00138 Matrixin signature III PR00138C 20.07 1.78e-16 52-80 PR00138B 14.84 5.21e-10 28-43 PR00138C 20.07 9.18e-10 94-122 2396 PR00049 Wilm's tumour protein signature IV PR00049D 0.00 2.07e-09 10-24 2396 IPBOO2000 Lysosome-associated membrane IPBOO2000D 5.87 5.25e-09 12-25 glycoprotein (Lamp) 2405 IPB000364 Phosphoenolpyruvate carboxykinase IPB000364M 26.08 1.40e-09 623-657 (GTP) 2406 IPB001304 C-type lectin domain IPB001304A 17.98 6.50e-17 155-179 2412 IPBOO1559 Phosphotriesterase family IPB001559F 24.25 1.49e-25 343-377 IPB001559D 19.17 5.00e-20 207-233 IPB001559C 16.25 5.34e-16 172-193 IPB001559E 16.18 5.35e-16 245-263 IPBOO1559A 10.81 1.23e-11 49-60 IPB001559B 12.98 8.50e-10 153-163 2412 IPB000890 Acetate and butyrate kinase IPBOO0890E 8.17 8.66e-09 336-349 2414 PR00049 Wilm's tumour protein signature IV PROO049D 0.00 9.24e-11 410-424 PROO049D 0.00 2.07e-10 412-426 PROO049D 0.00 2.14e-10 411-425 PROO049D 0.00 2.14e-10 414-428 2414 IPB000996 Clathrin light chain IPB000996B 20.25 8.98e-10 342-394 PROO049D 0.00 9.43e-10 408-422 PROO049D 0.00 9.71e-10 409-423 2414 PR01217 Proline rich extensin signature II PRO1217B 4.82 7.09e-09 412-428 2414 IPB002999 Tudor domain IPB002999B 7.50 7.55e-09 412-420 2414 PR01471 Histamine H3 receptor signature V PRO1471E 5.41 8.92e-09 411-426 PROO049D 0.00 8.93e-09 413-427 2415 PR01372 Yersinia virulence determinant YopE PR01372B 7.73 4.87e-09 21-38 protein signature II 2420 IPBOO3817 Phosphatidylserine decarboxylase IPB003817D 23.34 8.71e-25 194-220 IPB003817C 10.66 4.00e-15 172-184 IPB003817E 13.21 2.67e-14 283-299 IPB003817A 12.64 4.15e-13 77-91 IPB003817B 13.04 4.00e-09 101-109 2425 IPB002469 "Dipeptidyl peptidase IV, N- IPB002469J 8.97 3.52e-12 17-33 terminus" 2426 IPB002469 "Dipeptidyl peptidase IV, N- IPB002469J 8.97 3.52e-12 17-33 terminus" 2427 IPB002469 "Dipeptidyl peptidase IV, N- IPB002469J 8.97 3.52e-12 17-33 terminus" 2429 IPB000906 ZU5 domain IPBOO0906A 22.49 6.14e-19 145-187 IPBOO0906F 35.93 3.09e-16 63-116 IPBOO0906F 35.93 7.91e-16 96-149 2429 PR01415 Ankyrin repeat signature I PRO1415A 12.73 3.70e-15 252-264 IPBOO0906A 22.49 1.71e-14 46-88 IPBOO0906F 35.93 1.00e-12 346-399 IPBOO0906A 22.49 5.66e-12 112-154 IPBOO0906G 25.85 9.36e-12 53-101 PRO1415A 12.73 1.00e-11 53-65 PRO1415A 12.73 2.61e-11 119-13 2430 PR00834 HtrA/DegQ protease family signature PR00834C 15.48 7.35e-19 148-172 III PR00834D 11.75 7.39e-17 186-203 PR00834B 10.17 3.25e-13 107-127 PR00834E 13.43 6.03e-12 208-225 2430 IPB000126 "Serine proteases, VS family" IPBOO0126B 12.50 6.81e-12 191-207 PR00834A 8.79 1.44e-11 86-98 PR00834F 11.11 1.53e-09 301-313 WO 2004/080148 PCT/US2003/030720 461 TABLE 3B IPB000126A 11.75 9.83e-09 78-93 2432 PR00505 D12 class N6 adenine-specific DNA PR00505A 15.44 3.67e-12 39-55 methyltransferase signature I PR00O505B 11.79 8.88e-12 60-74 2433 PR00179 Lipocalin signature II PR00179B 7.67 2.35e-09 15-27 PR00179C 17.26 6.70e-09 42-57 2433 PROI 174 Retinol binding protein signature VI PRO1174F 11.76 6.82e-09 14-30 2433 PR01254 Prostaglandin D synthase signature V PR01254E 14.07 8.23e-09 39-53 2434 PR01042 Aspartyl-tRNA synthetase signature PRO1042B 12.76 4.69e-11 260-273 II PRO1042A 9.01 9.77e-10 244-256 2434 IPB002106 Aminoacyl-transfer RNA synthetases IPB002106A 13.35 1.00e-08 196-208 class-Il 2435 IPB003952 Fumarate reductase / succinate IPB003952D 19.72 4.50e-20 7-35 dehydrogenase FAD-binding site IPB003952E 9.04 2.46e-16 48-65 2436 IPB001895 Guanine-nucleotide dissociation IPB001895C 20.83 8.50e-23 52-87 stimulators CDC25 family 2437 IPB000958 KH domain IPB000958 6.84 5.09e-12 173-186 IPB000958 6.84 2.29e-11 89-102 2440 IPB001393 Calsequestrin IPB001393A 16.72 1.00e-40 66-115 IPB001393B 11.93 1.00c-40 169-222 IPB001393C 16.33 1.00e-40 225-277 IPB001393D 11.26 1.00e-40 320-372 2440 PR00312 Calsequestrin signature V PR00312E 8.61 7.75e-36 200-229 PR00312I 15.97 5.71e-35 363-391 PR00312H 13.19 2.80e-34 294-321 PR00312J 13.61 6.48e-34 394-422 PR00312D 9.10 7.17e-33 159-188 PR00312B 14.57 4.41e-32 93-122 PR00312C 16.48 5.62e-32 123-152 PR00312G 11.43 1.49e-31 261-288 PR00312F 16.12 1.73e-31 230-259 PR00312A 11.96 7.94e-27 66-89 2442 IPB000353 "Class II histocompatibility antigen, IPB000353B 19.16 4.94e-16 139-188 beta chain, beta-1 domain" 2442 fPB003006 Immunoglobulin and major IPB003006A 17.51 8.50c-16 160-182 histocompatibility complex domain 2442 IPBOO1003 "MHC Class II, alpha chain, alpha-1 IPBOO1003B 14.72 9.90e-10 147-190 domain" 2444 PROO021 Small proline-rich protein signature I PROO021A 3.31 1.35e-19 8-20 PROO021B 5.91 1.00e-14 31-40 PROO021B 5.91 1.00e-13 22-31 PROO021D 4.82 1.39e-13 25-33 PROO021D 4.82 1.39e-13 34-42 PROO021D 4.82 6.87e-13 43-51 PROO02IB 5.91 1.92e-11 40-49 PROO021E 7.77 1.23e-10 61-70 PROO021C 5.97 1.25c-10 25-31 PROO021C 5.97 1.25e-10 34-40 2444 PR01217 Proline rich extensin signature IV PRO1217D 4.57 4.94e-10 30-51 PRO1217G 4.02 2.42c-09 23-48 PRO1217G 4.02 2.42e-09 30-55 PRO1217G 4.02 2.58e-09 21-46 PRO1217D 4.57 7.89e-09 21-42 PRO1217G 4.02 8.89e-09 39-64 2444 IPB000967 Zinc finger NF-X1 type IPB000967E 21.88 9.44e-09 12-52 2445 PR00205 Cadherin signature VI PR00205F 19.57 5.15e-21 522-548 PR00205B 20.09 5.50e-21 254-283 PR00205D 12.22 1.39e-15 338-357 WO 2004/080148 PCT/US2003/030720 462 TABLE 3B PR00205B 20.09 2.50e-15 464-493 PR00205D 12.22 6.09e-15 233-252 PROD205G 13.05 8.00e-15 556-573 PRO0205A 17.38 2.59e-14 85-104 2445 IPB002126 Cadherin domain IPB002126B 12.04 4.79c-14 242-259 PR00205B 20.09 5.63e-13 145-174 IPB002126B 12.04 7.43e-13 452-469 PR0O205D 12.22 7.60e-13 443-462 PR00205G 13.05 7.75e-13 341-358 PR00205F 19.57 3.38e-12 309-335 PR00205G 13.05 9.lOe-12 236-253 PR00205E 10.82 3.37e-11 252-265 PR00205E 10.82 7.16e-11 462-475 PR00205D 12.22 7.59e-11 553-572 PR00205F 19.57 9.05e-11 412-438 IPB002126A 14.68 4.91e-10 206-222 IPB002126A 14.68 5.30e-10 416-432 IPB002126B 12.04 3.25e-09 133-150 PR00205C 13.59 3.25e-09 326-338 IPB002126B 12.04 4.50e-09 347-364 PR00205B 20.09 9.83e-09 581-610 PR00205G 13.05 1.00e-08 446-463 2447 IPB00006 "Vertebrate metallothionein, family IPB00006 13.41 3.90e-12 29-74 1" IPB000006 13.41 4.41e-12 36-81 IPB000006 13.41 6.70e-11 32-77 2447 PR01228 Eggshell protein signature III PR01228C 5.69 1.22e-10 23-38 PR01228C 5.69 1.98e-10 7-22 2447 IPB001271 Mammalian defensin IPB001271 19.97 3.29e-10 48-76 2447 IPB002494 "Keratin, high sulfur B2 protein" IPB002494C 14.46 3.36e-10 42-85 IPB001271 19.97 3.47e-10 26-54 IPB002494A 12.44 6.11e-10 67-100 2447 IPB002174 Furin-like cysteine rich region IPB002174A 30.51 7.32e-10 8-39 PR01228C 5.69 8.05e-10 16-31 2447 IPB003571 Snake toxin IPB003571B 18.08 8.07e-10 73-96 [PB002494A 12.44 9.08e-10 22-55 2447 PR00858 Crustacean metallothionein signature PROO858B 5.93 1.48e-09 37-55 II IPB00006 13.41 3.11e-09 33-78 2447 IPB001169 "Integrin beta, C-terminus" IPB001169K 27.45 3.19c-09 39-81 2447 IPB002919 Trypsin Inhibitor-like cysteine rich IPB002919A 15.56 3.57e-09 49-61 domain IPB002174A 30.51 4.15e-09 24-55 IPB001271 19.97 4.44e-09 55-83 IPB002494A 12.44 4.97e-09 29-62 PRO1228C 5.69 5.03e-09 15-30 PR01228C 5.69 5.03e-09 19-34 IPB002174A 30.51 5.28e-09 16-47 2447 IPB000254 "Cellulose-binding domain, fungal IPB000254 18.11 5.36e-09 25-55 type" IPB00006 13.41 5.59c-09 39-84 IPB002174A 30.51 5.72e-09 33-64 PR01228C 5.69 5.76e-09 24-39 2447 IPB000867 Insulin-like growth factor-binding IPB000867B 11.44 6.55e-09 2-18 protein IPB002174A 30.51 6.62e-09 4-35 2447 IPB002867 Cysteine-rich domain (C6HC) IPB002867D 24.88 7.19e-09 35-66 IPB00006 13.41 7.24e-09 47-92 2447 IPB000967 Zinc finger NF-XI type IPB000967D 10.42 7.37e-09 57-92 IPBOO 169K 27.45 7.81e-09 32-74 IPBO0006 13.41 8.07e-09 37-82 IPB002494A 12.44 8.35e-09 26-59 WO 2004/080148 PCT/US2003/030720 463 TABLE 3B IPBO00006 13.41 8.44e-09 52-97_ 2447 PRO1117 CLC-6 chloride channel signature I PR01117A 7.79 9.47e-09 48-60 IPB00 1271 19.97 9.5 1e-09 64-92 IPB002174A 30.51 9.77e-09 36-67 2447 IPB002221 WAP-type (Whey Acidic Protein) IPB002221B 17.12 1.00e-08 45-66 four-disulfide core domain 2448 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 4.79e-12 52-77 2448 PR00048 C2H2-type zinc finger signature I PROO048A 9.94 3.05e-10 49-62 IPB000822 14.67 9.14e-10 200-225 2450 PR00946 Mercury scavenger protein signature PR00946A 4.14 8.16e-09 6-24 2452 IPB002038 Osteopontin IPB002038C 22.35 1.00e-40 173-214 2452 PR00216 Osteopontin signature I PR00216A 11.45 9.71e-34 43-72 IPB002038A 12.23 5.15e-31 42-71 PR00216C 9.12 7.82e-21 95-120 PR00216B 6.70 9.49e-21 79-108 PR00216D 3.16 3.30e-18 142-156 PR00216E 6.95 3.81e-18 174-188 IPB002038B 15.58 4.1le-16 77-121 PR00216D 3.16 3.69e-12 136-150 2452 IPB003403 Herpesvirus immediate early protein IPB003403E 17.25 9.26c-09 117-144 1PB002038B 15.58 9.58e-09 91-135 2454 IPB001241 DNA topoisomerase II family IPBOO1241F 23.94 8.36e-37 475-523 2454 PRO1158 Topoisomerase II signature VIII PRO1158H 13.39 5.50e-30 804-826 IPBOO1241G 14.13 1.00e-29 547-573 PRO1158K 14.14 5.24e-27 1023-1049 PR01158G 9.37 5,91e-27 757-780 2454 IPB002205 "DNA gyrase/topoisomerase IV, IPB002205B 14.49 4.79e-24 760-795 subunit A" IPBOO1241E 20.94 3.00e-22 371-397 PR01158I 13.95 7.00e-22 834-854 PRO1158D 11.94 5.24e-21 565-580 2454 PR00418 DNA topoisomerase II family PR00418F 13.13 3.40e-20 546-562 signature VI IPBOO1241A 15.98 6.04e-20 50-71 IPBOO1241B 10.04 2.71e-19 172-190 PR00418G 12.91 8.94e-19 564-581 IPBOO1241H 17.27 1.96e-18 808-831 2454 PR00615 CCAAT-binding transcription factor PR00615A 17.09 2.93e-18 319-337 subunit A signature I PRO1158J 13.56 3.45e-18 939-953 IPB002205D 10.13 3.54e-18 867-888 PR00615B 18.03 3.77e-18 707-725 PR00418C 9.38 1.82e-17 176-190 PR004181 17.21 4.60e-17 626-642 IPB002205A 8.13 9.54e-17 729-747 PR00418A 13.58 7.65e-16 96-111 PRO1158C 11.35 1.00e-15 519-532 PRO1158E 8.11 2.29e-15 585-596 PRO1158F 10.39 4.71e-15 632-644 PR00615C 17.93 8.50e-15 1148-1166 PR00418E 14.82 1.37e-14 473-487 IPBOO1241D 14.87 1.43e-14 328-341 PR00418B 12.37 2.57e-14 133-146 PR00418D 14.25 2.71e-14 328-341 PRO1158A 7.61 4.60e-13 456-466 IPB002205C 11.89 5.09e-12 812-826 PR00418H 10.58 5.91e-12 584-596 IPBOO1241C 13.37 1.31e-11 230-242 2454 IPB000509 Ribosomal protein L36E IPBOO0509B 20.29 7.85e-11 1216-1270 WO 2004/080148 PCT/US2003/030720 464 TABLE 3B PR01 158B 8.30 1.27e-10 471-478_ 2454 IPB000135 High mobility group proteins HMGI IPB000135D 2.13 5.64e-09 1362-13 86 and HMG2 IPBOO0135D 2.13 7.45e-09 1363-1387 IPB000135D 2.13 8.09e-09 1364-1388 2454 PR01469 Bacterial carbamate kinase signature PR01469E 10.60 8.43e-09 128-146 V IPB000135D 2.13 8.73e-09 1360-1384 2457 IPB001073 Complement Clq protein IPB001073A 22.14 6.55e-13 67-101 2466 IPB000959 POLO box duplicated region IPB000959D 27.01 9.61e-10 204-256 2473 PR01475 Parkin signature IX PR014751 10.01 8.0le-09 96-118 2476 IPB003743 DUF164 IPB003743B 20.16 4.64e-09 88-126 2481 IPBOO215 Serpins IPBOO0215C 13.90 5.00e-09 435-449 2482 PR01377 Claudin-1 signature IV PR01377D 6.30 1.00e-19 229-243 PR01377A 7.94. 1.00e-16 141-152 2482 IPB000729 PMP-22/EMP/MP20 family IPB000729D 18.96 5.50e-15 197-224 2482 PR01077 Claudin signature III PRO1077C 13.60 2.53e-12 99-109 PR01377B 13.79 1.12e-11 176-183 PR01377C 14.12 2.44e-11 188-195 PRO1077B 14.12 1.00e-10 85-91 IPB000729C 37.83 5.3le-10 116-168 PRO1077A 9.72 4.49e-09 57-66 2482 PR01385 Claudin-14 signature I PR01385A 5.13 5.70e-09 46-62 2483 IPB001919 "Cellulose-binding domain, bacterial IPBOO1919B 14.22 2.97e-09 188-212 type" 2487 PR01305 Invasion protein B family signature PRO1305D 7.82 6.19e-09 266-279 IV 2488 IPB002652 Importin beta binding domain IPB002652H 25.98 1.00e-40 568-614 IPB0026521 18.58 1.36e-35 647-683 2488 IPB000225 Armadillo repeat IPB000225E 20.58 8.20e-22 646-668 IPB002652C 21.73 5.88e-14 519-571 IPB000225D 18.99 5.02e-13 535-558 IPB002652F 18.67 9.25e-11 543-575 IPB002652G 22.45 1.36e-09 535-580 2488 IPB003191 Guanylate-binding protein IPBOO3191M 10.38 7.64e-09 69-99 2490 IPB001762 Disintegrin IPB001762A 23.93 4.33e-23 19-59 2490 PR00289 Disintegrin signature I PR00289A 14.29 1.16e-14 35-54 IPB001762B 10.06 3.40e-12 66-76 2490 IPB001774 Delta serrate ligand IPBOO1774C 18.25 5.3le-10 238-280 PR00289B 11.74 3.80e-09 64-76 2490 IPB003306 WIF domain IPB003306E 25.51 7.40e-09 215-260 2491 IPB001359 Synapsin IPB001359H 22.58 6.07e-09 96-146 2495 IPB001359 Synapsin IPB001359H 22.58 6.33e-09 35-85 IPB001359H 22.58 7.73e-09 41-91 2496 IPB001359 Synapsin IPB001359H 22.58 6.33e-09 35-85 IPB001359H 22.58 7.73e-09 41-91 2497 IPB001359 Synapsin IPB001359H 22.58 6.33e-09 35-85 IPB001359H 22.58 7.73e-09 41-91 2498 IPB000492 Protamine 2 (PRM2) IPB000492B 5.26 7.95e-09 230-264 2502 PRO1415 Ankyrin repeat signature I PRO1415A 12.73 1.25e-09 187-199 2502 IPB003006 Immunoglobulin and major IPB003006B 20.23 9.31e-09 89-126 histocompatibility complex domain 2504 IPB000492 Protamine 2 (PRM2) 1PB000492B 5.26 1.68e-09 219-253 2504 PROO580 Prostanoid EPI receptor signature V PR00580E 8.05 7.1 le-09 226-247 2505 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 6.54e-09 195-232 histocompatibility complex domain 2506 IPB003006 Immunoglobulin and major IPB003006B 20.23 6.54e-09 195-232 histocompatibility complex domain 2507 PR00456 Ribosomal protein P2 signature V PR00456E 3.08 9.42e-10 637-651 WO 2004/080148 PCT/US2003/030720 465 TABLE 3B 2508 PR01481 Neurotensin type 2 receptor signature PRO1481C 15.05 1.00e-17 176-189 III 2508 PR01479 Neurotensin receptor signature II PR01479B 12.40 2.43e-17 89-101 PRO1481A 7.58 3.54e-16 1-13 PR1479C7.31 1.8tu-15 102-115 PR01481B 6.68 1.45e-15 14-26 PR01481D 4.62 2.19e-15 190-201 PR01479E 8.74 3.70c-15 240-250 PR01479D 13.10 6.57e-14 229-239 PR01479A 8.89 1.00e-13 29-39 2508 PR00237 Rhodopsin-like GPCR superfamily PR00237G 19.23 4.44e-12 249-275 signature VII 2508 PR00665 Oxytocin receptor signature IV PR00665D 10.30 1.32e-11 134-150 PR01479F 8.03 5.19e-11 277-287 PR00237C 14.77 4.32e-10 115-137 PR00237A 9.81 7.33e-10 34-58 PR00237D 9.76 7.43e-10 151-172 2508 PR01417 Growth hormone secretagogue PRO1417D 12.33 8,13e-10 111-127 receptor type 1 signature IV PR00237F 14.34 6.05e-09 204-228 2509 IPBOO 101 Plectin repeat IPBOO1101A 10.14 5.40e-14 1-37 2510 IPBOO1101 Plectin repeat IPBOO1101A 10.14 5.40e-14 1-37 2517 IPB001552 Acyl-CoA dehydrogenase IPBOO1552E 22.77 2.46e-19 523-563 IPB001552D 24.88 5.35e-19 432-474 IPB001552C 25.04 7.75e-15 378-418 IPB001552B 18.05 3.43e-12 124-146 IPB001552A 11.25 6.90e-10 97-108 2518 IPB001552 Acyl-CoA dehydrogenase IPB001552E 22.77 2.46e-19 523-563 IPB001552D 24.88 5.35e-19 432-474 IPB001552C 25.04 7.75e-15 378-418 IPB001552B 18.05 3.43e-12 124-146 IPBOO1552A 11.25 6.90e-10 97-108 2519 IPB002524 Cation efflux family IPB002524B 23.89 5.20e-17 50-89 2519 IPB003452 Stem cell factor IPB003452B 19.11 6.63e-09 109-157 IPB002524A 20.13 7.39e-09 8-48 2520 PR00215 Neuromodulin signature III PR00215C 13.82 7.58e-10 478-498 2520 PR00194 Tropomyosin signature IV PROO194D 9.54 7.19e-09 357-380 2520 IPB001422 Neuromodulin (GAP-43) IPB001422A 13.23 7.43e-09 453-497 2521 PR01178 Metabotropic gamma-aminobutyric PRO1178K 13.44 8.65e-09 179-203 acid type B2 receptor signature XI 2523 IPB002889 WSC domain IPB002889B 11.76 4.56e-10 34-80 IPB002889B 11.76 7.84e-09 19-65 IPB002889B 11.76 7.84e-09 27-73 IPB002889B 11.76 1.00e-08 23-69 2529 PR00019 Leucine-rich repeat signature II PR00019B 11.42 1.33e-10 225-238 PROO019A 11.72 8.33e-10 228-241 PRO0019A 11.72 4.00e-09 202-215 PR00019B 11.42 7.82e-09 199-212 2530 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 4.60e-10 297-334 histocompatibility complex domain 2530 IPB0O1000 Glycoside hydrolase family 10 IPBOO1000H 10.38 7.80e-09 13-26 2531 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 4.60e-10 297-334 histocompatibility complex domain 2531 IPBOO1OOO Glycoside hydrolase family 10 IPBOOIOOOH 10.38 7.80e-09 13-26 2532 IPB003884 Factor I membrane attack complex IPB003884A 12.20 7.06e-09 56-67 2536 IPB000822 "Zinc finger, C2H2 type" IPB000822 14.67 7.50e-13 309-334 2536 PR00048 C2H2-type zinc finger signature I PROM48A 9.94 4.18e-12 306-319 IPB000822 14.67 5.74e-12 281-306 WO 2004/080148 PCT/US2003/030720 466 TABLE 3B 2536 PR00258 Speract receptor signature I PR00258A 13.56 2.98e-10 87-103 2536 IPB002867 Cysteine-rich domain (C6HC) IPB002867C 19.46 9.25e-10 306-323 2540 IPB001522 "Fatty acid desaturase, type 1' IPB001522F 22.32 1.00e-40 104-158 IPB001522E 20.55 5.85e-36 26-79 2540 PROO075 Fatty acid desaturase family 1 PROO075G 10.50 6.62e-20 131-145 signature VII PROO075E 11.60 6.46e-18 55-73 PR0075F 14.62 8.8 1e-16 88-109 2541 IPB000432 "DNA mismatch repair protein MutS IPB000432D 18.83 8.92e-39 369-417 family, C-terminal domain" IPB000432C 12.07 1.00e-37 329-360 IPBOO0432F 16.97 3.86e-27 476-507 IPB000432E 8.78 9.00e-13 441-451 2541 IPB002156 RNase H IPB002156B 11.33 2.20e-11 100-110 2542 IPB003006 Immunoglobulin and major IPB003006B 20.23 8.20c-10 33-70 histocompatibility complex domain 2543 1PB000998 MAM domain IPB000998C 18.63 1.95e-12 17-32 2543 PR00020 MAM domain signature III PROO020C 12.01 8.12e-10 16-27 IPB000998D 18.66 9.61e-10 82-105 2544 IPB002350 Kazal-type serine protease inhibitor IPB002350 31.78 3.92e-13 46-86 family 2544 1PB003006 Immunoglobulin and major IPBOO3006B 20.23 1.78e-11 150-187 histocompatibility complex domain 2545 PR00449 Transforming protein P21 ras PR00449A 12.48 8.16e-10 86-107 signature I 2545 PR00326 GTP1/OBG GTP-binding protein PR00326A 8.70 9.13e-10 88-108 family signature I 2545 IPB000619 Guanylate kinase IPBOO0619A 18.08 4.21e-09 88-105 2545 PR00364 Disease resistance protein signature I PR00364A 8.29 7.14e-09 87-102 2545 PR00094 Adenylate kinase signature I PROO094A 9.62 9.57e-09 89-102 2545 PR00918 Calicivirus non-structural polyprotein PR00918A 13.81 9.69e-09 82-102 family signature I 2545 IPB000795 GTP-binding elongation factor IPB000795A 10.67 9.77e-09 87-102 2547 IPB003006 Immunoglobulin and major IPBOO3006B 20.23 3.08e-09 4-41 histocompatibility complex domain 2548 PR00698 C.elegans Srg family integral PR00698E 14.65 2.76e-09 95-120 membrane protein signature V 2551 1PB001737 Ribosomal RNA adenine IPB001737A 27.11 8.54e-10 135-180 dimethylase 2553 IPB000906 ZU5 domain IPB000906A 22.49 3.16e-09 38-80 2554 IPB001245 Tyrosine kinase catalytic domain IPB001245B 21.68 6.54e-13 281-319 2554 IPB000095 PAK-box /P21-Rho-binding IPB000095F 16.47 3.97e-11 285-339 2554 IPB000961 Protein kinase C-terminal domain IPB000961D 21.23 2.22e-10 277-318 IPB001245A 22.45 3.18e-10 228-268 2555 1PB001245 Tyrosine kinase catalytic domain IPBOO1245B 21.68 6.54e-13 281-319 2555 IPB000095 PAK-box /P21-Rho-binding IPB000095F 16.47 3.97e-11 285-339 2555 IPB000961 Protein kinase C-terminal domain IPB000961D 21.23 2.22e-10 277-318 IPB001245A 22.45 3.18e-10 228-268 2557 PRO1041 Methionyl-tRNA synthetase PRO1041E 16.72 2.69e-17 60-75 signature V PRO1041D 11.02 7.43e-13 30-41 2557 IPB001412 Aminoacyl-transfer RNA synthetases IPBOO1412B 6.33 8.71e-12 98-108 class-I 2558 IPB000353 "Class II histocompatibility antigen, IPB000353A 18.51 7.30e-27 41-90 beta chain, beta-I domain" 2563 IPB001599 Alpha-2-macroglobulin family IPBOO1599L 18.66 4.15e-28 59-86 2563 IPB001134 "Netrin, C-terminus" IPB001134C 17.82 4.13e-13 72-86 IPB001599K 8.15 1.46e-10 29-40 WO 2004/080148 PCT/US2003/030720 467 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 686 hormone Somatotropin hormone 3.le-27 103.9 1 9-182 family 688 hormone Somatotropin hormone 4.2e-37 136.7 1 9-176 family 689 serpin Serpin shrinee protease 1.8e-74 260.8 1 51-397 inhibitor) 690 efhand EF hand 2.7e-08 41.0 2 34-62:70-98 691 Lipase_3 Lipase (class 3) 2.3e-20 81.1 1 366-505 692 PH PH domain 0.028 21.0 1 36-127 694 GDA1_CD39 GDA1/CD39 (nucleoside 4.2e-51 183.2 1 93-483 phosphatase) family 695 7tm_1 7 transmembrane receptor 3.3e-21 83.9 1 22-294 (rhodopsin family) 696 lectinc Lectin C-type domain 5.le-06 33.3 1 181-286 698 GDA1_CD39 GDA1/CD39 (nucleoside 3.8e-42 153.5 1 40-402 phosphatase) family 700 mybDNA- Myb-like DNA-binding 9.3e-09 42.5 1 231-278 binding domain 700 ZZ Zinc finger, ZZ type 0.021 17.8 1 168-211 702 zf-AN1 AN1-like Zinc finger 0.0034 18.0 2 10-52:103-138 703 CRAL TRIO CRAL/TRIO domain 2.5e-41 150.7 1 85-280 703 CRALTRIO_ CRAL/TRIO, N-terminus 5.9e-10 46.5 1 3-71 N 704 Rhomboid Rhomboid family 0.019 -10.9 1 152-307 705 GKAP Guanylate-kinase-associated 7e-292 983.1 1 621-979 protein (GK.AP) p 706 LBPBPICE LBP / BPI / CETP family, 4.6e-06 33.6 1 218-456 TP C C-terminal do 707 Glycotransf_8 Glycosyl transferase family 0.0021 -38.4 1 103-368 8 708 LIM LIM domain 7.8e-14 59.4 1 12-68 710 Collagen Collagen triple helix repeat 8e-169 574.2 20 56-114:115-174:187 (20 copies) 245:291-349:360 418:423-483:492 550:598-656:684 743:750-808:809 868:869-928:929 988:1032-1090:1096 1154:1155 1214:1217 1277:1278 1337:1341 1400:1417-1476 710 C4 C-terminal tandem repeated 1.5e- 506.9 2 1489-1596:1597 domain in type 4 148 1711 711 ldl-recept a Low-density lipoprotein 0 1307.3 32 67-108:112-152:880 receptor domain 920:921-961:962 1001:1002 1041:1042 1081:1088 1127:1130 1170:1171 1212:2545 2586:2587 2625:2626 2664:2676- WO 2004/080148 PCT/US2003/030720 468 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 2713:2717 2755:2756 2795:2796 2838:2840 2879:2880 2923:2926 2964:3352 3391:3392 3430:3431 3470:3471 3510:3511 3549:3550 3588:3589 3626:3629 3667:3668 3706:3709 3749:3750 3790:3797-3835 711 ldlrecept b Low-density lipoprotein 2.4e- 808.6 34 332-373:375 receptor repeat 239 417:419-461:605 646:648-692:694 742:744-791:1337 1382:1384 1425:1427 1472:1474 1517:1518 1558:1655 1696:1698 1740:1742 1780:1782 1825:1959 2000:2002 2043:2045 2087:2089 2131:2276 2315:2318 2365:2367 2410:2412 2453:2454 2495:3092 3134:3136 3177:3179 3221:3223 3260:3262 3303:3970 4016:4018 4074:4076 4118:4120-4163 711 EGF EGF-like domain 1.8e-28 108.0 36 69-106:157-190:196 230:512-553:835 870:1004-1039:1043 1079:1090 1125:1173 1210:1213 1249:1255 , 1289:1568- WO 2004/080148 PCT/US2003/030720 469 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 1606:1875 1911:2184 2219:2505 2540:2589 2623:2635 2662:2719 2753:2928 2962:2967 3003:3009 3041:3314 3350:3513 3547:3552 3586:3590 3624:3669 3704:3752 3788:3842 3879:3885 3917:4213 4244:4254 4285:4290 4321:4326 4357:4362 4393:4398 4428:4431-4463 712 Idlirecept a Low-density lipoprotein 4.7e-21 83.4 2 67-108:112-152 receptor domain 714 cadherin Cadherin domain 0 1168.1 16 47-126:140-241:255 344:363-466:480 573:588-680:694 784:798-884:898 987:1001-1091:1105 1201:1215 1306:1320 1411:1425 1520:1526 1622:1634-1728 715 cadherin Cadherin domain 0 1177.0 16 47-126:140-241:255 344:363-466:480 573:588-680:694 784:798-884:898 987:1001-1091:1105 1201:1215 1306:1320 1411:1425 1520:1526 1622:1634-1729 716 DPPIVN ter Dipeptidyl peptidase IV 1.2e-07 -81.3 1 132-652 m (DPP IV) N-termi 716 PeptidaseS9 Prolyl oligopeptidase family 1.7e-06 35.0 1 656-736 717 zf-C2H2 Zinc finger, C2H2 type 3.6e-71 249.9 10 32-54:60-82:154 176:182-204:210 232:238-260:266 288:294-316:322 344:350-372 720 ig Immunoglobulin domain 2.8e- 605.6 15 68-128:163-223:259 178 317:352-410:445- WO 2004/080148 PCT/US2003/030720 470 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 503:538-596:629 687:720-780:813 871:904-962:995 1052:1085 1143:1176 1232:1266 1323:1356-1413 720 tspl Thrombospondin type 1 5e-87 302.5 6 1435-1485:1492 domain 1542:1549 1599:1606 1656:1663 1713:1720-1770 720 EGF EGF-like domain 1.6e-32 121.5 8 2013-2047:2053 2092:2098 2130:2136 2172:2178 2215:2221 2256:2338 2372:2378-2418 721 SPRY SPRY domain 2.7e-29 110.7 1 289-418 721 SAP SAP domain 6.9e-09 43.0 1 3-37 722 ABC tran ABCtransporter le-105 364.6 2 510-692:1322-1506 724 Acyl-CoA-dh Acyl-CoA dehydrogenase, 1.6e-49 178.0 1 50-201 C-terminal domain 725 EGF EGF-like domain 1.9e-18 74.7 5 65-91:98-132:138 172:178-217:223-258 725 MAM MAM domain 1.7e-13 58.3 1 402-546 726 NHL NHL repeat 5.4e-67 236.0 6 431-458:478 505:525-552:572 599:619-646:666-693 726 Filamin Filamin/ABP280 repeat 6.9e-18 72.9 1 306-402 726 zf-B box B-box zinc finger 5.6e-05 30.0 1 98-139 727 RhoGAP RhoGAP domain 2.3e-50 180.8 1 775-947 727 DAGPE-bind Phorbol 0.0004 21.8 1 703-747 esters/diacylglycerol binding dom 728 CN hydrolase Carbon-nitrogen hydrolase 0.0048 -84.5 1 25-261 729 tspl Thrombospondin type 1 6.9e-32 119.4 11 570-623:980 domain 1034:1037 1089:1092 1146:1165 1220:1221 1276:1313 1364:1367 1420:1426 1479:1482 1535:1543-1593 729 Reprolysin Reprolysin (M12B) family 1.3e-16 68.6 1 274-480 zinc metallo 729 PepMl2B pr Reprolysin family 4.8e-10 46.8 1 93-223 opep propeptide 731 ig Immunoglobulin domain 5.le-12 53.4 3 6-99:146-235:282 373 732 ig Immunoglobulin domain 1.6e-16 68.3 4 42-129:179-272:319 408:455-546 735 RhoGEF RhoGEF domain 3e-10 47.5 1 165-340 WO 2004/080148 PCT/US2003/030720 471 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 737 rrm RNA recognition motif. 1.le-26 102.1 3 78-142:151-222:240 311 742 cadherin Cadherin domain 3.6e- 346.2 6 147-243:257 100 349:369-460:474 563:577-666:685-773 743 PGMPMMII Phosphoglucomutase/phosp 0.08 -11.7 1 67-179 homannomutase, alp 745 zf-C2H2 Zinc finger, C2H2 type 2.5e- 373.3 15 130-152:158 108 180:186-208:214 236:242-264:270 292:298-320:326 348:354-376:382 404:410-432:438 460:488-510:516 538:544-566 746 zf-C2H2 Zinc finger, C2H2 type 9.2e-91 314.9 12 205-227:233 255:261-283:289 311:317-339:345 367:373-395:401 423:429-451:457 479:485-507:513-535 746 KRAB KRAB box 2.3e-23 91.1 1 35-75 747 EMP24_GP25 emp24/gp25L/p24 family 1.2e-79 278.0 1 5-201 L 748 acidphosphat Histidine acid phosphatase 2,5e- 539.4 1 31-371 158 749 ArfGap Putative GTP-ase activating 8.7e-60 212.0 1 527-649 protein for Arf 749 PH PH domain 8e-17 69.3 1 393-487 749 ank Ankyrin repeat 4.6e-15 63.5 3 826-858:859 891:892-925 751 zf-C2H2 Zinc finger, C2H2 type 3.3e-43 157.0 6 603-625:631 653:693-715:721 743:751-773:779-801 751 KRAB KRAB box 9.5e-20 79.0 1 342-382 753 LRR Leucine Rich Repeat 2e-30 114.5 8 61-82:83-106:107 131:132-155:156 179:180-203:204 227:228-251 753 LRRCT Leucine rich repeat C- 3.6e-07 37.2 1 261-311 terminal domain 754 A2M Alpha-2-macroglobulin 3.4e- 661.8 1 721-1469 family 195 754 A2MN Alpha-2-macroglobulin 1.6e-88 307.5 1 1-623 family N-terminal regi 755 fibrinogenoC Fibrinogen beta and gamma 4.6e-24 93.4 1 242-422 chains, C-term 756 fn3 Fibronectin type III domain 2.le-53 190.9 4 598-687:700 790:802-891:903-986 756 ig Immunoglobulin domain 1.6e-49 177.9 6 43-102:137-198:242 299:332-388:424 481:514-579 758 LRR Leucine Rich Repeat 1.2e-28 108.6 7 52-75:76-99:100 123:124-147:148 171:172-195:196-216 758 ig Immunoglobulin domain 5.2e-07 36.7 1 301-359 WO 2004/080148 PCT/US2003/030720 472 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 758 LRRCT Leucine rich repeat C- 0.00013 28.8 1 240-285 terminal domain 759 7tm_2 7 transmembrane receptor 2.3e-20 81.1 1 1009-1273 (Secretin family) 759 GPS Latrophilin/CL-l-like GPS 7.1e-13 56.2 1 950-1002 domain 759 ig Immunoglobulin domain 3.3e-08 40.7 2 286-352:485-547 759 SEA SEA domain 0.043 20.1 1 168-279 760 zf-C2H2 Zinc finger, C2H2 type 1.5e-85 297.6 12 107-129:135 157:163-185:191 213:219-241:247 269:275-297:303 325:331-353:359 381:387-409:415-437 764 HIT HIT family 0.00082 -4.2 1 173-273 768 SRCR Scavenger receptor 2e-49 177.6 2 32-129:142-247 cysteine-rich domain 768 Lysyl oxidase Lysyl oxidase 4.5e-41 149.9 1 251-359 769 Glycotransf_8 Glycosyl transferase family 4.7e-06 -2.1 1 1-250 8 770 WD40 WD domain, G-beta repeat 4.4e-07 37.0 3 215-251:365 401:407-443 773 Cytidylyltrans Phosphatidate 8e-92 318.5 1 221-401 cytidylyltransferase 774 WD40 WD domain, G-beta repeat 1.5e-08 41.8 2 166-203:327-363 779 HesB-like HesB-like domain 3.5e-36 133.6 1 49-151 780 ig Immunoglobulin domain 0.014 22.0 2 8-57:96-155 783 vwa von Willebrand factor type 2.1e-42 154.3 1 266-440 A domain 783 KunitzBPTI Kunitz/Bovine pancreatic 1.7e-18 74.8 1 540-590 trypsin inhibito 783 Collagen Collagen triple helix repeat 0.014 -13.0 4 2-60:61-117:118 (20 copies) 175:181-239 784 Sterol-desat Sterol desaturase 6.4e-46 166.0 1 57-263 785 ig Immunoglobulin domain 2e-32 121.1 4 116-176:331 391:1355-1415:1552 1613 786 adenylatekinas Adenylate kinase 2.6e-08 -30.8 1 35-189 e 788 SH3 SH3 domain 6.7e-13 56.3 1 1-56 789 SH3 SH3 domain 1.6e-14 61.6 1 73-129 790 TIMP Tissue inhibitor of 1.le-40 148.5 1 15-124 metalloproteinase 791 lectin c Lectin C-type domain 5.1e-06 33.3 1 162-267 792 UDPGT UDP-glucoronosyl and 5e-237 800.8 1 1-447 UDP-glucosyl transferas 794 Ubie-methyltr ubiE/COQ5 6.3e-05 -96.3 1 37-241 an methyltransferase family 794 PCMT Protein-L-isoaspartate(D- 0.038 -104.6 1 23-192 aspartate) 0 795 7tm_1 7 transmembrane receptor 6.9e-31 116.0 1 444-720 (rhodopsin family) 799 PH PH domain 2.8e-18 74.1 1 14-112 804 ig Immunoglobulin domain 0.0006 26.5 2 35-111:146-197 809 ig Immunoglobulin domain 0.0014 25.4 1 109-171 WO 2004/080148 PCT/US2003/030720 473 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 811 MHCI Class I Histocompatibility 1.le-06 4.5 1 29-205 antigen, domains 812 ig Immunoglobulin domain 5.4e-41 149.6 5 78-137:176-237:274 335:369-430:465-529 813 ig Immunoglobulin domain .2e- 356.8 12 295-358:393 103 452:1468-1530:1565 1627:1662 1724:1761 1823:1858 1926:1961 2020:2059 2120:2157 2218:2252 2313:2348-2412 814 ig Immunoglobulin domain 2.2e- 356.8 12 490-553:588 103 647:1663-1725:1760 1822:1857 1919:1956 2018:2053 2121:2156 2215:2254 2315:2352 2413:2447 2508:2543-2607 814 LRR Leucine Rich Repeat 1.le-25 98.8 6 58-81:82-105:106 129:130-153:154 177:186-209 814 LRRCT Leucine rich repeat C- 7.le-09 42.9 1 219-280 terminal domain 814 LRRNT Leucine rich repeat N- 0.00025 27.8 1 28-56 terminal domain 816 Apolipoprotein Apolipoprotein A1/A4/E 1.6e-06 34.6 1 4-251 family 817 Apolipoprotein Apolipoprotein A1/A4/E 1.6e-06 34.6 1 4-251 family 819 phoslip Phospholipase A2 3.3e-48 173.6 1 21-145 821 MRMLE Mandelate racemase / 4.6e-05 -4.2 1 149-386 muconate lactonizing en 821 MRMLEN Mandelate racemase / 0.0031 -0.4 1 1-112 muconate lactonizing en 822 NAP Nucleosome assembly 1.7e- 646.3 1 12-285 protein (NAP) 190 823 PP2C Protein phosphatase 2C 6.2e-72 252.4 1 107-383 824 vwc von Willebrand factor type 3.8e-13 57.1 2 103-157:160-214 C domain 825 7tm_1 7 transmembrane receptor 0.00045 -23.4 1 1-173 (rhodopsin family) 826 7tm_1 7 transmembrane receptor 2.2e-40 147.6 1 40-287 (rhodopsin family) 828 RhoGAP RhoGAP domain 1.9e-26 101.3 1 101-250 829 CUB CUB domain 1.le-27 105.4 1 2-102 830 CUB CUB domain 1.le-27 105.4 1 2-102 831 myosin-head Myosin head (motor 9.7e-15 -285.0 1 37-318 domain) 832 myosin-head Myosin head (motor 4.9e-23 -122.5 1 37-408 domain) WO 2004/080148 PCT/US2003/030720 474 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 834 thyroglobulin_ Thyroglobulin type-1 repeat 1 1e-20 82.1 1 316-379 1 _ 834 kazal Kazal-type serine protease 1.5e-06 35.2 1 139-183 inhibitor 838 LRR Leucine Rich Repeat 9.7e-45 162.1 12 61-84:85-108:109 132:133-156:157 180:181-204:205 228:229-252:253 276:277-300:301 324:326-349 838 LRRCT Leucine rich repeat C- 7.5e-09 42.8 1 359-405 terminal domain 838 LRRNT Leucine rich repeat N- 0.031 20.9 1 31-59 terminal domain 841 ank Ankyrin repeat 8e-33 122.5 4 1-27:29-61:130 162:164-196 841 SAM SAM domain (Sterile alpha 0.0031 24.2 1 577-640 motif) 844 ig Immunoglobulin domain 6.3e-39 142.8 4 53-110:150-216:255 310:350-417 845 ig Immunoglobulin domain 5e-56 199.5 6 53-110:150-216:255 310:350-417:456 516:553-617 845 MAM MAM domain 1.3e-52 188.2 1 753-918 847 PLA2_B Lysophospholipase catalytic 4.6e-50 179.8 1 1108-1551 domain 847 C2 C2 domain 1.6e-06 35.1 1 797-880 848 PLA2_B Lysophospholipase catalytic 8.3e-53 188.9 1 357-800 domain 848 C2 C2 domain 1.6e-06 35.1 1 46-129 851 ig Immunoglobulin domain 3.6e-31 117.0 3 48-105:169-227:265 344 852 ig Immunoglobulin domain 3.6e-31 117.0 3 44-101:165-223:261 340 853 ig Immunoglobulin domain 2.8e-07 37.6 1 44-101 854 C2 C2 domain 1.3e-70 248.0 2 158-245:289-377 855 tsp_1 Thrombospondin type 1 1.7e-26 101.5 6 546-596:827 domain 881:945-995:1314 1364:1426 1471:1474-1530 855 Reprolysin Reprolysin (M12B) family 1.3e-15 65.3 1 246-456 zinc metallo 855 Pep_M12Bpr Reprolysin family 9.2e-05 8.5 1 105-222 opep propeptide 857 abhydrolase_2 Phospholipase/Carboxyleste 0.051 -67.3 1 120-326 rase 858 abhydrolase_2 Phospholipase/Carboxyleste 0.051 -67.3 1 113-319 rase 859 SRCR Scavenger receptor 3e-20 80.7 1 336-433 cysteine-rich dom ain _f5_5 _-3 859 Collagen Collagen triple helix repeat 2.1e-12 54.7 1 255-314 (20 copies) 860 SRCR Scavenger receptor 2e-33 124.5 1 396-493 cysteine-rich domain 860 | Collagen Collagen triple helix repeat 9.le-13 55.8 1 315-374 WO 2004/080148 PCT/US2003/030720 475 TABLE 4A ____ SEQ Model Description E- Score Repeats Position ID value (20 copies) ________ 862 zf-C2H2 Zinc finger, C2H2 type 1.6e-89 310.8 12 192-214:220 242:248-270:276 298:304-326:332 354:360-382:388 410:416-438:444 466:472-494:500-523 864 zf-CCCH Zinc finger C-x8-C-x5-C- le-06 35.8 1 52-78 x3-H type 865 WD40 WD domain, G-beta repeat 5.7e-12 53.2 3 203-238:271 307:360-393 867 aminotran 3 Aminotransferase class-III 3.3e-98 339.7 1 76-509 868 aminotran 3 Aminotransferase class-III 6.8e-48 172.5 1 2-406 869 trypsin Trypsin 7e-63 222.3 1 63-289 870 Glycos-transf Glycosyl transferases group 1.8e-06 33.8 1 86-239 1 1 873 EGF EGF-like domain 1.2e- 414.3 16 7-43:50-81:88 120 119:126-157:168 199:203-234:243 279:280-311:319 350:358-389:396 427:492-523:530 561:568-599:606 637:1046-1077 873 fn3 Fibronectin type III domain 4.le-34 126.7 3 641-722:740 823:839-921 873 sushi Sushi domain (SCR repeat) 3.8e-05 30.5 1 433-486 875 AdoHeyase S-adenosyl-L-homocysteine 1.5e- 945.4 1 81-507 hydrolase 280 878 fibrinogen.C Fibrinogen beta and gamma 7.4e-54 192.3 1 146-382 chains, C-term 879 fibrinogenC Fibrinogen beta and gamma 7.4e-54 192.3 1 146-382 chains, C-term 880 fibrinogenC Fibrinogen beta and gamma 7.4e-54 192.3 1 146-382 chains, C-term 883 aa permeases Amino acid permease 3.9e-07 -148.3 1 40-475 883 Aa trans Transmembrane amino acid 0.0067 -123.4 1 42-460 transporter pro 884 pkinase Protein kinase domain 9.3e-06 -52.2 1 100-659 885 lectinc Lectin C-type domain 0.0011 6.9 1 47-128 888 PeptidaseM20 Peptidase family 0.00043 16.2 1 55-357 M20/M25/M40 889 sugar tr Sugar (and other) 0.017 -118.8 1 1-335 transporter 891 ig Immunoglobulin domain 7.5e-05 29.6 1 55-127 892 bromodomain Bromodomain 6.9e-87 302.1 2 63-152:356-445 893 OLF Olfactomedin-like domain 1.2e- 414.2 1 220-470 120 894 ig Immunoglobulin domain 7.le-16 66.2 2 262-322:354-414 894 kazal Kazal-type shrine protease le-09 45.7 1 88-132 inhibitor domain 894 efhand EF hand 0.0013 25.4 1 178-206 895 aminotran_1_2 Aminotransferase class I 8.5e-11 49.3 1 81-416 and It 896 LIM LIM domain 5.4e-42 152.9 4 24-80:83-140:153- WO 2004/080148 PCT/US2003/030720 476 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 209:212-271 896 VHP Villin headpiece domain 7.le-20 79.5 1 538-573 897 pkinase Protein kinase domain 8.le- 351.7 1 356-613 102 898 pkinase Protein kinase domain 8.le- 351.7 1 543-800 102 898 DCX Doublecortin 5.7e-10 46.6 1 130-194 899 GSTC Glutathione S-transferase, 0.088 11.8 1 254-370 C-terminal domain 900 Clq C1q domain 7.6e-72 252.1 1 116-241 900 Collagen Collagen triple helix repeat 8.4e-06 32.7 1 37-97 (20 copies) 902 BRCT BRCAI C Terminus 4e-92 319.5 6 10-93:96-183:479 (BRCT) domain 570:579-666:737 823:846-944 903 BRCT BRCA1 C Terminus 2.7e-06 34.4 1 10-93 (BRCT) domain 905 LRRCT Leucine rich repeat C- 7.5e-09 42.8 1 37-83 terminal domain 905 LRR Leucine Rich Repeat 0.0066 23.1 1 4-27 906 ig Immunoglobulin domain 0.002 24.8 1 25-79 907 TB2_DP1_HV TB2/DP1, HVA22 family le-34 128.7 1 2-96 A22 908 Anperoxidase Animal haem peroxidase 3e-193 655.4 1 770-1309 908 ig Immunoglobulin domain 1e-34 128.8 4 224-283:320 376:409-472:533-590 908 LRR Leucine Rich Repeat 4.7e-22 86.7 4 51-74:75-98:99 122:123-146 908 LRRCT, Leucine rich repeat C- 8.4e-11 49.3 1 156-208 terminal domain 908 vwc von Willebrand factor type 7e-08 39.6 1 1439-1494 C domain 908 TILa TILa domain 0.023 12.0 1 1438-1491 909 Anperoxidase Animal haem peroxidase 3e-193 655.4 1 801-1340 909 ig Immunoglobulin domain le-34 128.8 4 255-314:351 407:440-503:564-621 909 LRR Leucine Rich Repeat 4.7e-22 86.7 4 82-105:106-129:130 153:154-177 909 LRRCT Leucine rich repeat C- 8.4e-11 49.3 1 187-239 terminal domain 909 vwc von Willebrand factor type 7e-08 39.6 1 1470-1525 C domain 909 TILa TILa domain 0.023 12.0 1 1469-1522 910 An-peroxidase Animal haem peroxidase 3e-193 655.4 1 663-1202 910 ig Immunoglobulin domain 3.2e-24 93.9 3 201-260:297 353:386-449 910 LRR Leucine Rich Repeat 2.6e-18 74.3 4 51-74:75-98:99 122:123-146 910 vwc von Willebrand factor type 7e-08 39.6 1 1332-1387 C domain 910 TILa TILa domain 0.023 12.0 1 1331-1384 911 EGF EGF-like domain 3.le-50 180.3 9 47-99:106-141:172 203:210-245:574 605:823-854:861 892:901-933:940-971 WO 2004/080148 PCT/US2003/030720 477 TABLE 4A SEQ Model Description E- Score Repeats Position ID value ___ 911 laminin G Laminin G domain 0.0002 25.1 2 275-401:663-788 914 cNMP binding Cyclic nucleotide-binding 1.5e-65 231.2 2 152-240:270-364 domain 914 RIla Regulatory subunit of type 4.8e-13 56.8 1 25-62 II PKA R-subu 915 DIL DIL domain 6.6e-40 146.0 1 214-323 915 PDZ PDZ domain (Also known 2e-12 54.7 1 555-639 as DHR or GLGF) 916 lipoxygenase Lipoxygenase 3.3e- 655.3 1 121-648 193 916 PLAT PLAT/LH2 domain 1.6e-29 111.5 1 2-111 917 PLAT PLAT/LH2 domain 1.6e-29 111.5 1 2-111 917 lipoxygenase Lipoxygenase 0.00053 -342.4 1 91-294 918 PLAT PLAT/LH2 domain 1.6e-29 111.5 1 2-111 918 lipoxygenase Lipoxygenase 4c-06 -297.4 1 121-323 926 Aa trans Transmembrane amino acid 1.3e- 473.9 1 114-517 transporter protein 138 927 EGF EGF-like domain 5.8e-36 132.9 6 29-57:60-88:95 128:135-171:178 209:216-247 930 DUF6 Integral membrane protein 0.00017 28.3 2 8-129:147-277 DUF6 933 Peptidase M24 metallopeptidase family 2.1e-69 244.0 1 87-326 M24 938 PDZ PDZ domain (Also known 1.8c-20 81.4 1 93-174 as DHR or GLGF) 938 L27 L27 domain 6.5e-16 66.3 1 13-68 940 rrm RNA recognition motif. 2.7e-46 167.2 4 61-128:186-253:339 406:456-524 941 EGF EGF-like domain 1.9e-18 74.7 5 66-92:99-133:139 173:179-218:224-259 941 MAM MAM domain 1.7e-13 58.3 1 403-547 942 EGF EGF-like domain 1.9e-18 74.7 5 71-97:104-138:144 178:184-223:229-264 942 MAM MAM domain 1.7e-13 58.3 1 408-552 943 PHD PHD-finger 2.9e-10 47.5 1 85-128 943 bromodomain Bromodomain 8.2e-10 46.0 1 149-235 943 zf-MYND MYND finger 7e-07 36.3 1 977-1011 943 PWWP PWWP domain 7.5e-06 32.9 1 269-340 944 PHD PHD-finger 2.9e-10 47.5 1 85-128 944 bromodomain Bromodomain 8.2e-10 46.0 1 149-235 944 PWWP PWWP domain 7.5e-06 32.9 1 1 269-340 945 PHD PHD-finger 2.9e-10 47.5 1 85-128 945 bromodomain Bromodomain 8.2c-10 46.0 1 149-235 945 zf-MYND MYND finger 7e-07 36.3 1 1023-1057 945 PWWP PWWP domain 7.5e-06 32.9 1 269-340 946 PHD PHD-finger 2.9e-10 47.5 1 90-133 946 bromodomain Bromodomain 8.2c-10 46.0 1 154-240 946 zf-MYND MYND finger 7e-07 36.3 1 1028-1062 946 PWWP PWWP domain 7.5e-06 32.9 1 274-345 950 ion trans Ion transport protein 3.5e-19 77.1 1 345-518 951 Reprolysin Reprolysin (M12B) family 3c-88 306.6 1 210-409 zinc metallo 951 Pep M12B pr Reprolysin family 1.3e-31 118.4 1 80-198 opep propeptide WO 2004/080148 PCT/US2003/030720 478 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 951 disintegrin Disintegrin 2.5e-23 90.9 1 426-501 953 ank Ankyrin repeat 2e-46 167.6 7 151-183:184 215:216-248:250 282:283-328:329 361:362-401 954 interferon Interferon alpha/beta 1.8e-17 71.5 1 16-171 domain 956 adhshort short chain dehydrogenase 1.3e-07 21.8 1 31-188 958 acid phosphat Histidine acid phosphatase 1.7e-58 207.7 1 30-381 959 serpin Serpin (serine protease 6.4e- 607.8 1 1-329 inhibitor) 179 960 serpin Serpin (serine protease 9.1e- 677.1 1 47-397 inhibitor) 200 961 serpin Serpin shrinee protease 3.2e- 678.5 1 47-397 inhibitor) 200 962 serpin Serpin (serine protease 1.2e- 689.9 1 47-397 inhibitor) 203 964 Reprolysin Reprolysin (M12B) family 5.8e-96 332.2 1 232-426 zinc metallo 964 PepM12B._pr Reprolysin family 4.4e-41 149.9 1 112-220 opep propeptide 964 disintegrin Disintegrin 2.5e-09 44.5 1 444-517 965 Uteroglobin Uteroglobin family 1.4e-05 31.8 1 1-88 966 GDAICD39 GDA1/CD39 (nucleoside 5.7e-92 319.0 1 48-483 phosphatase) family 967 Clq C1q domain 6.le-44 159.4 1 73-202 970 ig Immunoglobulin domain 1.6e-06 35.1 2 41-124:156-230 970 zf-CCHC Zinc knuclde 5.7e-05 30.0 1 523-540 971 pentaxin Pentaxin family 8.le-22 85.9 1 281-479 973 bZIP bZ1P transcription factor 0.024 19.0 1 622-686 974 WD40 WD domain, G-beta repeat 0.003 24.3 4 37-72:77-113:122 156:211-247 975 ion trans Ion transport protein 0.0031 24.2 1 248-408 976 ion trans Ion transport protein 0.0031 24.2 1 322-482 977 zf-C2H2 Zinc finger, C2H2 type 2.5e-55 197.2 35 4-27:108-131:162 185:243-266:439 462:470-492:600 623:843-866:886 908:925-948:1030 1053:1114 1137:1193 1216:1265 1288:1312 1335:1369 1392:1470 1493:1515 1538:1577 1600:1660 1683:1697 1720:1767 1790:1846 1869:1892 1914:1968 1990:2051 2073:2085 2107:2114- WO 2004/080148 PCT/US2003/030720 479 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 2137:2143 2166:2251 2274:2280 2303:2314 2336:2360 2382:2388 2411:2474-2496 980 trypsin Trypsin 7.9e-18 72.7 1 155-326 980 PDZ PDZ domain (Also known 8e-12 52.7 1 332-427 as DHR or GLGF) 980 kazal Kazal-type serine protease 3.7e-05 30.6 1 63-117 inhibitor domain 981 asp Eukaryotic aspartyl protease 8.le- 358.3 1 19-421 104 984 Zn carbOpept Zinc carboxypeptidase 2e-1 14 393.5 1 50-332 985 Zn carbOpept Zinc carboxypeptidase 2e-114 393.5 1 50-332 986 NifUN NifU-like N terminal 4.2e-80 279.5 1 34-160 domain 988 UPARLY6 u-PARLy-6 domain 1.8e-05 31.6 1 28-110 990 zf-C2H2 Zinc finger, C2H2 type 1.4e-12 55.2 3 53-78:87-114:120 144 991 pkinase Protein kinase domain 8.6e-90 311.7 1 20-312 992 spectrin Spectrin repeat 6.6e-26 99.5 7 17-121:124-226:229 340:343-449:452 556:781-888:891-999 994 Clq Clq domain 2.le-31 117.8 1 160-284 994 Collagen Collagen triple helix repeat 0.00022 22.3 1 76-135 (20 copies) 995 Allantoicase Allantoicase repeat 8.7e- 418.0 2 1-136:159-319 122 996 ig Immunoglobulin domain 4.9e-11 50.1 3 37-151:182-243:275 335 997 RasGEF RasGEF domain 1.7e-88 307.4 1 999-1184 997 RhoGEF RhoGEF domain 8.2e-68 238.7 1 247-428 997 PH PH domain 2.3e-35 130.9 2 23-133:460-588 997 RasGEFN Guanine nucleotide 4.9e-18 73.3 1 633-688 exchange factor for Ras-1 997 IQ IQ calmodulin-binding 0.012 22.2 1 206-226 motif 999 K tetra K+ channel tetramerisation 6e-31 116.2 1 24-126 domain 1002 PHD PHD-finger 1.9e-17 71.4 1 185-233 1002 zf-C3HC4 Zinc finger, C3HC4 type 0.00078 26.2 1 108-156 (RING finger) 1003 WD40 WD domain, G-beta repeat 1.8e-24 94.7 6 768-802:959 992:1070-1104:1110 1145:1151 1185:1191-1225 1004 ZZ Zinc finger, ZZ type 4.6e-11 50.2 1 3-48 1004 zf-C2H2 Zinc finger, C2H2 type 0.012 22.2 1 78-101 1006 C2 C2 domain 9.6e-05 29.2 1 304-394 1007 IBNNT Importin-beta N-terminal 9.5e-28 105.6 1 22-101 domain 1009 ArfGap Putative GTP-ase activating 1.4e-35 131.6 1 250-373 protein for Arf WO 2004/080148 PCT/US2003/030720 480 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 1009 PH PH domain 1.7e-14 61.6 1 136-227 1009 ank Ankyrin repeat 2e-11 51.4 2 411-446:447-479 1009 SH3 SH3 domain 1.7e-10 48.3 1 881-938 1011 ig Immunoglobulin domain 1.2e-48 175.1 6 80-148:183-242:281 342:379-440:474 535:570-634 1015 efhand EF hand 3.7e-26 100.3 4 29-57:65-93:102 130:138-166 1018 7tm_1 7 transmembrane receptor 3.7e-76 266.4 1 87-350 (rhodopsin family) 1019 LRR Leucine Rich Repeat 2.9e-41 150.5 14 82-105:106-129:133 157:158-181:182 205:206-229:251 272:329-352:377 399:403-426:427 444:463-486:537 558:559-582 1021 RasGEF RasGEF domain le-47 172.0 1 907-1092 1021 PDZ PDZ domain (Also known 4.2e-17 70.2 1 580-661 as DHR or GLGF) 1021 cNMP binding Cyclic nucleotide-binding 3.8e-13 57.1 1 345-435 domain 1021 RA Ras association 1.3e-05 32.1 1 799-885 (RalGDS/AF-6) domain 1022 RasGEF RasGEF domain le-47 172.0 1 857-1042 1022 PDZ PDZ domain (Also known 4.2e-17 70.2 1 530-611 as DHR or GLGF) 1022 cNMP_binding Cyclic nucleotide-binding 3.8e-13 57.1 1 295-385 domain 1022 RA Ras association 1.3e-05 32.1 1 749-835 (Ra1GDS/AF-6) domain . 1026 RicinB-lectin QXW lectin repeat 1.3e-11 52.1 3 134-172:187 225:226-265 1027 SCF Stem cell factor 2.4e- 409.9 1 1-216 119 1028 cadherin Cadherin domain 1.9e-75 264.0 4 50-141:155-250:264 366:379-470 1029 cadherin Cadherin domain 1.4e-78 274.5 4 50-141:155-250:264 366:379-470 1030 PH PH domain 1.2e-10 48.8 1 522-624 1031 Renal dipeptas Renal dipeptidase 1.3e-73 258.0 1 54-377 e 1032 aa permeases Amino acid permease 3.9e-07 -148.3 1 40-475 1032 Aa trans Transmembrane amino acid 0.0067 -123.4 1 42-460 transporter pro 1033 FTHFS Formate--tetrahydrofolate 0 1367.2 1 360-979 ligase 1033 THF DHGC Tetrahydrofolate 1.5e-07 21.3 1 68-180 YH dehydrogenase/cyclohyd 1033 THFDHGC Tetrahydrofolate 3.7e-05 -45.5 1 182-329 YH C dehydrogenase/cyclohyd 1035 RhoGEF RhoGEF domain 9.le-26 99.0 1 778-962 1035 PDZ PDZ domain (Also known 4.2c-12 53.6 1 47-122 ,as DHR or GLGF) 1035 PH PH domain 0.081 19.5 1 1006-1119 WO 2004/080148 PCT/US2003/030720 481 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 1037 PH PH domain 2.4e-10 47.8 1 17-124 1037 efband EF hand 2.7e-08 41.0 2 138-166:174-202 1039 7tm_1 7 transmembrane receptor 3.9e-22 87.0 1 40-289 (rhodopsin family) 1040 tsp_3 Thrombospondin type 3 1.le-22 88.9 9 404-418:440 repeat 454:463-477:499 513:522-536:537 551:560-574:600 614:615-627 1040 TSPN Thrombospondin N- 2.3e-05 22.9 1 1-101 terminal -like domain 1042 PTR2 POT family 7.4e-85 295.3 1 103-471 1043 FH2 Formin Homology 2 4e-105 362.7 1 595-1038 Domain 1044 zf-C2H2 Zinc finger, C2H2 type 4.3e- 478.8 19 114-136:142 140 164:170-192:198 220:226-248:254 276:282-304:310 332:338-360:366 388:394-416:422 444:450-472:478 500:506-528:534 556:562-584:590 612:618-640 1044 KRAB KRAB box 6.4e-27 102.9 1 8-48 1044 zf-BED BED zinc finger 0.099 10.5 2 431-473:603-641 1046 PA PA domain 4.1e-20 80.3 1 155-255 1048 TIG IPT/TIG domain 5.9e-57 202.6 3 803-893:895 980:983-1092 1048 PSI Plexin repeat 7.4e-26 99.3 2 468-519:759-801 1048 Sema Sema domain 1.6e-11 -3.7 1 34-449 1049 BTB BTB/POZ domain 1.7e-26 101.4 1 20-124 1050 ABCtran ABC transporter 9.9e-37 135.5 1 26-217 1051 ZZ Zinc finger, ZZ type 4.6e-11 50.2 1 3-48 1051 zf-C2H2 Zinc finger, C2H2 type 0.012 22.2 1 78-101 1052 ig Immunoglobulin domain 1.2e-11 52.2 2 34-110:150-204 1053 CUB CUB domain 2.5e-12 54.4 1 156-260 1053 WSC WSC domain 0.002 18.6 1 :71-142 1054 ig Immunoglobulin domain 0.0026 24.4 1 36-113 1055 MHCI Class I Histocompatibility 2.4e- 499.6 1 25-203 antigen, domains 146 1055 ig Immunoglobulin domain 8.5e-08 39.3 1 220-285 1057 LBPBPI_CE LBP / BPI / CETP family, 0.00076 -0.8 1 217-444 TP C C-terminal do 1062 PMP22_Claudi PMP- 1.8e-44 161.2 1 4-181 n 22/EMP/MP20/Claudin family 1064 PDZ PDZ domain (Also known 4.8e-71 249.5 5 1-84:209-297:310 as DHR or GLGF) 393:409-490:694-775 1065 PID Phosphotyrosine interaction 1.1e-44 161.8 1 42-168 domain (PTB/PID) 1067 pkinase Protein kinase domain 2.8e-73 256.8 1 12-272 1068 lipocalin Lipocalin / cytosolic fatty- 5.6e-37 136.3 1 38-185 acid binding pr 1 1069 lactamase B Metallo-beta-lactamase 3e-35 130.6 1 7-172 WO 2004/080148 PCT/US2003/030720 482 TABLE 4A SEQ Model Description E- Score Repeats Position ID value superfamily 1070 annexin Annexin 2e-128 440.1 4 57-124:128-196:212 280:288-355 1O71 SNF Sodium:neurotransmitter 0 1202.5 1 44-574 symporter family 1072 ig Immunoglobulin domain 0.0008 26.1 1 38-122 1073 Glypican Glypican 2.le- 981.5 1 3-566 291 1074 PAP assoc PAP/25A associated domain 4.2e-12 53.7 1 490-549 1074 rrm RNA recognition motif. 7.2e-08 39.6 1 58-123 1075 Glycotransf 2 Glycosyltransferase family 3.6e-69 243.2 1 213-507 9 29 1078 A2M Alpha-2-macroglobulin 3.4e- 661.8 1 721-1469 family 195 1078 A2M-N Alpha-2-macroglobulin 1.6e-88 307.5 1 1-623 family N-terminal regi 1079 A2MN Alpha-2-macroglobulin 4.7e-90 312.6 1 14-636 family N-terminal regi 1080 A2M-N Alpha-2-macroglobulin 1.5e-38 141.5 1 1-563 family N-terminal regi 1081 A2M Alpha-2-macroglobulin 1.3e- 679.9 1 721-1469 family 200 1081 A2MN Alpha-2-macroglobulin 1.6e-88 307.5 1 1-623 family N-terminal regi 1082 A2MN Alpha-2-macroglobulin 4.7e-90 312.6 1 1-623 family N-terminal regi 1083 COesterase Carboxylesterase 2.le- 529.7 1 6-547 155 1084 EGF EGF-like domain 9.5e-90 311.6 18 192-219:404 431:631-666:878 914:920-956:962 997:1003-1037:1043 1078:1084 1119:1125 1160:1166 1201:1207 1243:1249 1285:1291 1328:1429 1466:1472 1507:1626 1661:1667-1706 1084 TB TB domain 1.8e-78 274.1 4 567-610:688 729:1358-1401:1535 1577 1086 fn3 Fibronectin type III domain 5.9e-95 328.9 5 373-459:501 587:602-685:700 786:802-888 1086 ig Immunoglobulin domain 3e-24 94.0 4 168-232:285 347:1133-1191:1349 1409 1087 zf-C2H2 Zinc finger, C2H2 type 4.6e-33 123.3 4 161-183:189 211:217-239:245-267 1087 KRAB IRAB box 1.9e-24 94.6 1 14-54 1088 KRAB KRAB box 1.9e-24 94.6 1 14-54 1088 zf-C2H2 Zinc finger, C2H2 type le-07 39.1 1 161-183 WO 2004/080148 PCT/US2003/030720 483 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 1089 KeratinB2 Keratin, high sulfur B2 2.5e-17 71.0 1 2-153 protein 1090 Keratin_B2 Keratin, high sulfur B2 0.0059 -33.4 1 2-76 protein 1091 KeratinB2 Keratin, high sulfur B2 1.9e-06 21.1 2 2-108:111-205 protein 1092 abhydrolase alpha/beta hydrolase fold 1.6e-12 55.0 1 111-390 1093 abhydrolase alpha/beta hydrolase fold 1.6e-12 55.0 1 171-450 1094 7tm 3 7 transmembrane receptor 5.5e-08 10.8 1 22-271 1096 lectin c Lectin C-type domain 2.3e-25 97.7 1 100-208 1097 lectin c Lectin C-type domain 6.5e-27 102.8 1 100-208 1098 7tm_1 7 transmembrane receptor 1.7e-41 151.3 1 41-290 (rhodopsin family) 1099 SEA SEA domain 0.00037 27.2 1 330-447 1100 ig Immunoglobulin domain 5e-11 50.1 3 146-203:245 295:331-405 1101 Anperoxidase Animal haem peroxidase 2.7e- 658.9 1 726-1265 194 1101 ig Immunoglobulin domain 4.4e-36 133.3 4 248-307:344 400:433-490:525-582 1101 LRR Leucine Rich Repeat 3.1e-25 97.3 5 51-74:75-98:99 122:123-146:147-170 1101 LRRCT Leucine rich repeat C- 8.4e- 11 49.3 1 180-232 terminal domain 1101 vwc von Willebrand factor type 7e-08 39.6 1 1395-1450 C domain 1101 TILa TILa domain 0.023 12.0 1 1394-1447 1102 Anperoxidase Animal haem peroxidase 2.7e- 658.9 1 702-1241 194 1102 ig Immunoglobulin domain 4.4e-36 133.3 4 224-283:320 376:409-466:501-558 1102 LRR Leucine Rich Repeat 3.2e-21 83.9 4 51-74:75-98:99 122:123-146 1102 LRRCT Leucine rich repeat C- 8.4e-11 49.3 1 156-208 terminal domain 1102 vwc von Willebrand factor type 7e-08 39.6 1 1371-1426 C domain 1102 TILa TILa domain 0.023 12.0 1 1370-1423 1113 pkinase Protein kinase domain 3e-45 163.8 1 194-468 1117 ig Immunoglobulin domain 5.8e-17 69.8 4 30-87:127-186:281 337:375-434 1118 ig Immunoglobulin domain 0.00012 28.9 2 42-98:136-195 1119 IBNNT Importin-beta N-terminal 3.4e-23 90.5 1 28-100 domain 1120 ank Ankyrin repeat 7.7e-21 82.7 2 920-952:953-985 1120 SH3 SH3 domain 6.le-15 63.1 1 1022-1079 1122 TPR TPR Domain 6.4e-09 43.1 3 124-157:158 191:192-225 1124 ank Ankyrin repeat 2.9e-46 167.1 6 31-63:64-96:97 129:130-162:163 195:196-228 1125 ank Ankyrin repeat 3.4e-38 140.3 5 31-63:64-96:97 129:130-162:163-195 1129 F5 F8 type C F5/8 type C domain 1.4e-54 194.8 1 34-174 1129 laminin G Lamninin G domain 1.4e-07 38.6 1 212-344 WO 2004/080148 PCT/US2003/030720 484 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 1130 F5 F8 type C F5/8 type C domain 1.4e-54 194.8 1 34-174 1130 lamininG Laminin G domain 3.1e-44 160.4 4 212-344:398 525:821-943:1046 1179 1130 EGF EGF-like domain 9.le-07 35.9 2 551-583:962-996 1131 Glycos transf Glycosyl transferase 6.5e-31 116.1 1 155-341 2 1131 Ricin B lectin QXW lectin repeat 0.00059 26.6 2 467-507:558-596 1133 pkinase Protein kinase domain 1.7e-48 174.5 1 11-347 1135 C2 C2 domain 1.1e-42 155.2 2 7-88:135-216 1135 RasGAP GTPase-activator protein for 5.2e-34 126.4 1 323-513 Ras-like GTPase 1135 PH PH domain 5.8e-08 39.9 1 567-673 1135 BTK BTK motif 9.2e-05 28.9 1 675-711 1137 MAM MAM domain 1.le-22 88.9 1 452-593 1137 EGF EGF-like domain 3.5e-15 63.9 5 60-86:123-157:163 197:203-242:248-283 1143 7tm_1 7 transmembrane receptor 0.00045 -23.4 1 1-173 (rhodopsin family) 1144 7tm_1 7 transmembrane receptor 2.2e-40 147.6 1 40-287 (rhodopsin family) 1 1147 ILI Interleukin-1 / 18 4.3e-21 83.5 1 12-152 1148 filament Intermediate filament 5e-101 349.0 1 1-299 protein 1150 MBOAT MBOAT family 1.4e-06 -27.4 1 130-323 1151 filament Intermediate filament 2.le- 400.1 1 131-412 protein 116 1152 PeptidaseM10 Matrixin 4.4e-84 292.8 1 36-202 1152 hemopexin Hemopexin 6e-37 136.2 4 231-273:275 317:322-369:371-411 1153 PeptidaseM10 Matrixin 4.4e-84 292.8 1 36-202 1153 hemopexin Hemopexin 6e-37 136.2 4 231-273:275 317:322-369:371-411 1155 LBPBPICE LBP / BPI / CETP family, 3.le-30 113.9 1 242-478 TPC C-terminal do 1155 LBPBPICE LBP / BPI / CETP family, 3.3e-22 87.2 1 26-240 TP N-terminal do 1156 HMGbox HMG (high mobility group) 3.le-31 117.2 1 85-153 box 1159 DNA ligase ATP dependent DNA ligase 3.7e-57 203.3 1 480-645 domain 1159 zf-PARP Poly(ADP-ribose) 8.5e-52 185.5 1 93-185 polymerase and DNA Ligase 1160 serpin Serpin (serine protease 7.7e- 511.2 1 3-425 inhibitor) 150 1167 ig Immunoglobulin domain 3.4e-16 67.2 3 42-96:135-197:237 297 1169 lectin c Lectin C-type domain 2e-18 74.6 1 131-231 1171 WD40 WD domain, G-beta repeat 4.4e-80 279.5 8 224-260:280 316:321-357:363 398:404-440:446 491:497-533:539-574 1172 MBOAT MBOAT family 1.6e-08 6.7 1 488-777 1172 ig Immunoglobulin domain 2.9e-08 40.9 2 42-99:139-198 WO 2004/080148 PCT/US2003/030720 485 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 1173 MBOAT MBOAT family 1.6e-08 6.7 1 488-777 1173 ig Immunoglobulin domain 2.9e-08 40.9 2 42-99:139-198 1174 MBOAT MBOAT family 5.le-65 229.4 1 130-373 1175 PTE Phosphotriesterase family 1.4e-90 314.4 1 6-233 1183 PSDcarbxylas Phosphatidylserine 6.5e-45 162.6 1 232-467 e decarboxylase 1184 TSC22 TSC-22/dip/bun family 1.3e-40 148.4 1 124-183 1188 DPPIV_N_ter Dipeptidyl peptidase IV 5.1e-08 -71.7 1 132-680 m (DPP IV) N-termi 1188 PeptidaseS9 Prolyl oligopeptidase family 1.7e-06 35.0 1 684-764 1189 DPPIV_N_ter Dipeptidyl peptidase IV 5.1e-08 -71.7 1 132-680 m (DPP IV) N-termi 1189 Peptidase S9 Prolyl oligopeptidase family 1.7e-06 35.0 1 684-764 1190 DPPIV_N_ter Dipeptidyl peptidase IV 3.8e-07 -94.7 1 132-667 m (DPP IV) N-termi 1190 Peptidase _S9 Prolyl oligopeptidase family 1.7e-06 35.0 1 671-751 1191 RibosomalS2 S25 ribosomal protein 6.5e-66 232.4 1 1-100 5 1193 ank Ankyrin repeat 1.2e- 809.5 27 49-81:82-114:115 239 147:148-180:181 213:214-246:247 279:280-313:314 346:347-379:380 412:431-463:464 496:497-557:558 591:593-625:626 658:660-692:696 728:729-761:762 797:798-827:830 864:865-897:898 931:932-964:968 1000 1194 trypsin Trypsin 2.5e-18 74.3 1 166-342 1196 vwc von Willebrand factor type 0.043 12.4 2 50-105:108-163 C domain 1197 7tm_1 7 transmembrane receptor 1.2e-28 108.6 1 46-295 1 _(rhodopsin family) 1198 MethyltransfD D12 class N6 adenine- 0.0057 -49.7 1 30-153 12 specific DNA met 1199 lipocalin Lipocalin / cytosolic fatty- 1.3e-22 88.6 1 32-176 acid binding pr 1200 tRNA-synt_2 tRNA synthetases class II 7.4c-91 315.3 1 135-473 (D, K and N) 1200 tRNA anti OB-fold nucleic acid 7.3e-11 49.5 1 44-118 binding domain 1202 FADbinding_ FAD binding domain 8.6e-09 -83.1 1 5-162 2 1203 RasGEF RasGEF domain 1.9e-16 68.1 1 211-412 1204 KH-domain KH domain 1.9e-50 181.0 3 17-63:101-150:265 313 1206 transketpyr Transketolase, pyridine 4e-74 259.7 1 14-191 binding domai 1206 transkctolase_ Transketolase, C-terminal 5e-55 196.2 1 208-331 C domain 1207 Calsequestrin Calsequestrin 1.7e- 1001.7 1 1-390 WO 2004/080148 PCT/US2003/030720 486 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 297 1210 ig Immunoglobulin domain 1.1e-13 58.9 2 35-112:154-228 1213 cadherin Cadherin domain 9e-81 281.8 6 33-126:140-235:249 343:357-448:462 558:576-667 1214 calreticulin Calreticulin family 2.7e- 698.7 1 21-317 206 1221 Osteopontin Osteopontin 4.6e- 588.4 1 1-279 173 1222 serpin Serpin (serine protease 2.4e- 529.5 1 80-443 inhibitor) 155 1223 ig Immunoglobulin domain 4,8e-15 63.4 2 31-101:252-303 1225 DNAtopoisoI DNA gyrase/topoisomerase 3.7e- 611.9 1 653-1120 V IV, subunit A 180 1225 DNA gyraseB DNA gyrase B 1.3e-56 201.6 1 210-370 1225 HATPase c Histidine kinase-, DNA 1.8e-13 58.2 1 16-164 gyrase B-, and H 1226 AMP-binding AMP-binding enzyme 3.6e-80 279.7 1 105-539 1227 PCI PCI domain 0.016 18.5 1 26-117 1228 Clq C1q domain 5.9e-45 162.8 1 73-202 1230 ank Ankyrin repeat 3.6e- 728.2 28 7-39:40-72:86 215 147:148-180:181 213:214-246:247 279:280-312:313 346:347-379:380 412:413-445:464 496:497-529:530 590:591-621:626 658:659-691:693 725:729-761:762 794:795-827:832 862:864-897:899 931:932-965:966 998:1002-1034 1231 LBP BPI CE LBP / BPI / CETP family, 9.4e-24 92.3 1 242-470 TP C C-terminal do 1231 LBP BPI CE LBP / BPI / CETP family, 3.3e-22 87.2 1 26-240 TP N-terminal do 1232 LBPBPICE LBP / BPI / CETP family, 3.le-22 87.3 1 242-470 TP C C-terminal do 1232 LBP BPI CE LBP / BPI / CETP family, 3.3e-22 87.2 1 26-240 TP N-terminal do 1233 LBP BPI CE LBP / BPI / CETP family, 9.4e-32 118.9 1 242-478 TP C C-terminal do 1233 LBP BPI CE LBP / BPI / CETP family, 3.3e-22 87.2 1 26-240 TP N-terminal do 1237 ig Immunoglobulin domain 2.8e-30 114.0 3 28-86:127-184:219 277 1237 fn3 Fibronectin type III domain 2.6e-28 107.5 2 299-385:396-481 1238 Nuf2 Nuf2 family 8.7e- 358.2 1 1-148 104 1240 Sema Sema domain 2.2e- 602.7 1 59-496 177 1243 rrm RNA recognition motif. 0.05 15.7 1 17-93 1247 EGF EGF-like domain 4.8e-56 199.6 17 105-135:148- WO 2004/080148 PCT/US2003/030720 487 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 178:191-221:234 264:277-307:320 350:364-396:409 439:452-482:495 525:538-568:581 611:624-656:669 699:712-742:755 785:798-828 1249 IBR IBR domain 0.069 5.8 2 36-104:111-167 1251 Aatrans Transmembrane amino acid 3.7e-46 166.8 1 52-394 transporter protein 1252 Aatrans Transmembrane amino acid 1.3e-65 231.4 1 45-419 transporter protein 1254 FGF Fibroblast growth factor 1.7c-37 138.0 1 36-166 1255 LRR Leucine Rich Repeat 0,0019 24.9 4 49-70:71-92:94 115:116-137 1256 RPE65 Retinal pigment epithelial 5.8e-83 289.0 1 35-579 membrane protein 1257 RPE65 Retinal pigment epithelial 4.7e-82 286.0 1 24-561 membrane protein 1258 ig Immunoglobulin domain 3.1e-15 64.1 2 39-97:128-189 1261 serpin Serpin (serine protease 1.9e-56 200.9 1 23-423 inhibitor) 1263 arf ADP-ribosylation factor 7.9e-09 -6.8 1 9-182 family 1264 PAP2 PAP2 superfamily 3e-1 1 50.8 1 95-241 1265 SRCR Scavenger receptor 1.3e- 440.7 5 35-128:136-227:232 cysteine-rich domain 128 329:360-459:477-574 1266 SRCR Scavenger receptor 1.3e- 440.7 5 35-128:136-227:232 cysteine-rich domain 128 329:360-459:477-574 1270 Armadillo-seg Armadillo/beta-catenin-like 1.4e-05 32.0 4 53-93:546-586:633 repeat 673:675-716 1273 pkinase Protein kinase domain 8e-77 268.6 1 103-387 1275 Reprolysin Reprolysin (M12B) family 3e-88 306.6 1 227-426 zinc metallo 1275 Pep_Ml2Bpr Reprolysin family 1.3e-31 118.4 1 97-215 opep propeptide 1275 disintegrin Disintegrin 2.5e-23 90.9 1 443-518 1277 ank Ankyrin repeat 2.6e-17 70.9 2 301-339:340-373 1278 PeptidaseM1 Peptidase family M1 2.6e- 386.5 1 98-506 112 1284 Aatrans Transmembrane amino acid 1.4e-31 118.3 1 4-407 transporter protein 1285 UPF0083 Uncharacterised protein 1.9e-05 14.5 1 73-213 family (UPF0083) 1288 LRR Leucine Rich Repeat 1.3e-23 91.9 7 66-89:90-113:114 137:138-161:163 186:187-210:211-233 1288 ig Immunoglobulin domain 2.7e-07 37.7 1 314-372 1288 LRRCT Leucine rich repeat C- 5.6e-05 30.0 1 252-297 terminal domain 1290 LRR Leucine Rich Repeat 2.2e-12 54.6 3 61-84:85-108:110 132 1291 DAGKc Diacylglycerol kinase 0.063 -14.5 1 74-220 catalytic domain WO 2004/080148 PCT/US2003/030720 488 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 1292 ig Immunoglobulin domain 6.7e-10 46.3 2 48-124:161-219 1293 ig Immunoglobulin domain 6.7e-10 46.3 2 48-124:161-219 1295 C1q Clq domain 1.4e-48 174.8 1 72-198 1296 7tm_1 7 transmembrane receptor 2.5e-24 94.3 1 49-332 (rhodopsin family) 1297 Plectin Plectin repeat 1.6e-86 300.8 6 2734-2778:2808 2852:2897 2939:3003 3042:3043 3087:3119-3163 1297 CH Calponin homology (CH) 1.6e-72 254.3 2 213-316:329-433 domain 1297 spectrin Spectrin repeat 0.029 8.2 1 889-994 1298 Plectin Plectin repeat 1.6e-86 300.8 6 2746-2790:2820 2864:2909 2951:3015 3054:3055 3099:3131-3175 1298 CH Calponin homology (CH) 3.le-69 243.4 2 213-328:341-445 domain 1298 spectrin Spectrin repeat 0.029 8.2 1 901-1006 1306 MAM MAM domain 5.8e-49 176.1 1 422-595 1306 ig Immunoglobulin domain 5.4e-18 73.2 3 26-93:132-191:228 287 1308 Acyl-CoAdh Acyl-CoA dehydrogenase, 1.6e-49 178.0 1 618-769 C-terminal doma 1308 Acyl- Acyl-CoA dehydrogenase, 1.4e-06 15.3 1 505-614 CoA dh M middle domain 1309 Acyl-CoA-dh Acyl-CoA dehydrogenase, 1.6e-49 178.0 1 600-751 C-terminal doma 1309 Acyl- Acyl-CoA dehydrogenase, 1.4e-06 15.3 1 487-596 CoA dh M middle domain 1311 IQ IQ calmodulin-binding 0.00039 27.2 2 715-735:738-758 motif 1312 SAM SAM domain (Sterile alpha 3.9e-13 57.1 2 304-369:382-446 motif) 1314 HECT HECT-domain (ubiquitin- 5.3e- 664.5 1 2002-2309 transferase) 196 1315 PAP2 PAP2 superfamily 7.8e-28 105.9 1 56-218 1316 PAP2 PAP2 superfamily 1.6e-32 121.5 1 88-236 1317 ig Immunoglobulin domain 2.7e-07 37.6 1 41-116 1321 LRR Leucine Rich Repeat 1.9e-66 234.2 20 145-168:169 194:195-217:240 265:266-285:287 310:311-336:337 356:358-381:382 407:408-427:429 452:453-478:479 498:500-523:524 549:550-569:571 594:595-620:621-644 1321 LRRNT Leucine rich repeat N- 0.0027 24.4 1 115-143 terminal domain 1322 ig Immunoglobulin domain 3.6e-14 60.5 3 34-120:157-215:267 Immunoglobulin domain 321 WO 2004/080148 PCT/US2003/030720 489 TABLE 4A SEQ Model Description E- Score Repeats Position ID value 1323 ig Immunoglobulin domain 7.8e-06 32.8 3 34-120:157-215:267 313 1324 tspl Thrombospondin type 1 0.00039 27.2 1 37-81 domain 1328 SRCR Scavenger receptor 1.5e- 583.3 5 14-111:188-285:300 cysteine-rich domain 171 397:405-503:638-730 1331 efhand EF hand 1.5e-06 35.2 3 12-40:48-76:85-113 1333 wnt wnt family 6.8e- 694.1 1 40-365 205 1336 zf-MIZ MIZ zinc finger 3.2e-32 120.5 1 323-375 1336 SAP SAP domain 2.4e-05 31.2 1 11-45 1337 FA desaturase Fatty acid desaturase 2.le-76 267.3 1 71-296 1338 Retrotrans gag Retrotransposon gag protein 0.097 8.7 1 200-300 1340 actin Actin 1.9e-61 217.5 1 1-367 1341 ion trans Ion transport protein 0.01 22.5 1 117-302 1343 fn3 Fibronectin type III domain 7.3e-33 122.6 2 394-480:492-578 1343 ig Immunoglobulin domain 1.le-23 92.1 3 124-182:224 281:316-372 1344 ig Immunoglobulin domain 5e-56 199.5 6 53-110:150-216:255 310:350-417:456 516:553-617 1344 MAM MAM domain 1.3e-52 188.2 1 753-918 1345 ig Immunoglobulin domain 5.9e-05 29.9 1 186-255 1345 kazal Kazal-type serine protease 0.00028 27.6 1 121-168 inhibitor domain 1348 ig Immunoglobulin domain 3.4e-51 183.5 6 61-120:155-214:258 315:348-404:440 497:530-596 1348 fn3 Fibronectin type III domain 4.4e-40 146.6 4 615-704:717 807:819-907:919 1002 1350 serpin Serpin (serine protease 3.2e- 695.2 1 46-402 inhibitor) 205 1353 CARD Caspase recruitment domain 1.3e-32 121.8 1 2-91 1355 ank Ankyrin repeat 1.le-45 165.2 6 31-63:64-96:97 129:130-162:163 195:196-228 1356 pkinase Protein kinase domain 9.6e-64 225.2 1 221-479 1359 tRNA-synt_ tRNA synthetases class 1 (1, 1le-05 -214.4 1 31-383 L, M and V) 1360 MHC_II_beta Class II histocompatibility 1.7e-41 151.3 1 41-117 antigen, beta 1363 ig Immunoglobulin domain 1.le-08 42.3 3 114-200:236 294:344-398 1364 Tissue-fac Tissue factor 0.069 -126.3 1 1-271 1364 fn3 Fibronectin type III domain 0.095 14.9 1 35-125 1365 IL1 Interleukin-1 / 18 7.6e-30 112.6 1 11-155 1366 A2M Alpha-2-macroglobulin le-210 713.4 1 722-1449 family 1366 A2MN Alpha-2-macroglobulin 4.7e-90 312.6 1 1-623 1 family N-terminal regi 1368 UPARLY6 u-PAR/Ly-6 domain 6.8e-37 136.0 1 27-106 WO 2004/080148 PCT/US2003/030720 490 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 685 Guanylin Guanylin precursor 0.72 1.2 1 1-27 685 hormone Somatotropin hormone family 6.7e-18 49.4 1 9-57 685 DUF756 Domain of unknown function 0.4 5.1 1 99-125 (DUF756) 686 Guanylin Guanylin precursor 0.72 1.2 1 1-27 686 hormone Somatotropin hormone family 3.6e-56 157.9 1 9-151 686 P13_PI4_kinase Phosphatidylinositol 3- and 4-kinase 0.97 3.4 1 172-206 688 hormone Somatotropin hormone family 1.5e-68 192.9 1 9-151 689 serpin Serpin (serine protease inhibitor) 3.2e-21 71.8 1 49-156 689 serpin Serpin (serine protease inhibitor) 5.2e-57 193.9 2 160-397 690 PH PH domain 0.042 8.1 1 1-20 690 efhand EF hand 9.2e-05 21.0 1 34-62 690 efhand EF hand 0.0023 15.8 2 70-98 690 PI-PLC-X Phosphatidylinositol-specific phospho 5.9e-17 60.5 1 187-222 691 Lipase_3 Lipase (class 3) 6.9e-18 63.4 1 366-505 691 Desulfoferrodox Desulfoferrodoxin 0.9 2.2 1 528-533 692 PH PH domain 4.7e-05 17.9 1 20-127 692 DUF482 Protein of unknown function, DUF482 0.8 2.7 1 50-67 692 Phage TAC Phage tail assembly chaperone 0.21 5.3 1 225-245 692 Glyco hydro 31 Glycosyl hydrolases family 31 0.8 0.9 1 344-379 692 NHL NHL repeat 0.25 8.5 1 494-509 692 EspB Enterobacterial EspB protein 0.27 2.1 1 560-578 694 GDA1_CD39 GDA1/CD39 (nucleoside phosphatase) 1.6e-55 187.0 1 93-332 fa 694 Ppx-GppA Ppx/GppA phosphatase family 0.4 3.5 1 249-261 694 GDAICD39 GDA1/CD39 (nucleoside phosphatase) 5.1e-05 15.7 2 430-480 fa 695 7tm 1 7 transmembrane receptor (rhodopsin f 8.le-28 82.0 1 22-294 695 GSPII N Bacterial type II secretion system pr 0.41 3.4 1 110-118 695 GASA Gibberellin regulated protein 0.72 0.6 1 176-197 696 DUF716 Family of unknown function (DUF716) 0.93 3.4 1 45-73 696 DcuC C4-dicarboxylate anaerobic carrier 0.4 4.3 1 46-67 696 FLO LFY Floricaula / Leafy protein 0.22 2.7 1 146-159 696 lectin e Lectin C-type domain 1.9e-07 31.5 1 181-286 696 Rubella E2 Rubella membrane glycoprotein E2 0.95 1.4 1 284-312 698 CDtoxinC Cytolethal distending toxin C 0.43 3.9 1 9-33 698 GDA1_CD39 GDA1/CD39 (nucleoside phosphatase) 1.6e-62 210.7 1 40-275 fa 698 GDA1_CD39 GDAI/CD39 (nucleoside phosphatase) 0.016 7.2 2 376-393 fa 700 zf-MYND MYND finger 0.39 5.1 1 173-192 700 Ribosomal L44 Ribosomal protein L44 0.33 5.8 1 183-208 700 ZZ Zinc finger, ZZ type 0.0003 17.8 1 184-211 700 PilP Pilus assembly protein, PilQ 0.028 8,4 1 228-244 700 myb _DNA- Myb-like DNA-binding domain 2.6e-09 37.1 1 231-278 binding 700 RRS1 Ribosome biogenesis regulatory protei 0.85 3.5 1 379-390 701 sigma70_ner Sigma-70, non-essential region 0.45 3.2 1 616-628 702 zf-ANI ANI-like Zinc finger 0.032 10.1 1 13-52 702 zf-ANI ANI-like Zinc finger 9.2e-06 22.6 2 103-135 703 CRAL TRION CRAL/TRIO, N-terminus 3.8e-13 44.7 1 3-71 703 DnaJC DnaJ C terminal region 0.054 8.2 1 8-20 703 CRAL TRIO CRAL/TRIO domain 1.4e-44 151.9 1 85-244 704 Adrenomedullin Adrenomedullin 082 2.4 1 142-167 WO 2004/080148 PCT/US2003/030720 491 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 704 Rhomboid Rhomboid family 1.6e-14 55.3 1 201-304 705 TRAP alpha Translocon-associated protein (TRAP), 0.41 3.2 1 413-434 705 GKAP Guanylate-kinase-associated protein ( 2.7e- 981.2 1 621-979 292 705 PLRV ORF5 Potato leaf roll virus readthrough pr 0.13 4.1 1 752-766 705 DUF887 Eukaryotic protein of unknown functio 1 2.6 1 797-815 705 CYTH CYTH domain 0.26 6.4 1 816-858 705 SeqA SeqA protein 0.38 3.6 1 824-837 706 LBPBPI CETP LBP / BPI / CETP family, N-terminal d 4.5e-36 123.6 1 33-191 706 ABG transport AbgT putative transporter family 0.27 2.7 1 196-205 706 LBP BPI CETP LBP / BPI / CETP family, C-terminal d 8.3e-14 49.9 1 253-456 C 706 HS2ST Heparan sulfate 2-0-sulfotransferase 0.21 4.8 1 309-338 707 Phage integrN Phage integrase, N-terminal SAM-like 0.36 5.2 1 103-121 707 Glyco transf 8 Glycosyl transferase family 8 0.00044 15.9 1 268-340 708 LIM LIM domain 9.7e-16 57.8 1 13-69 708 zf-HIT HIT zinc finger 0.57 6.9 1 55-65 709 DUF572 Family of unknown function (DUF572) 1.9e- 689.4 1 1-376 204 710 Collagen Collagen triple helix repeat (20 copi 1.6e-14 56.8 1 67-126 710 Collagen Collagen triple helix repeat (20 copi 3.6e-08 32.9 2 127-174 710 Collagen Collagen triple helix repeat (20 copi 4.le-07 29.0 3 183-232 710 Collagen Collagen triple helix repeat (20 copi 0.25 7.3 4 237-254 710 Collagen Collagen triple helix repeat (20 copi 4.4e- 11 43.9 6 293-346 710 Collagen Collagen triple helix repeat (20 copi 6.4e-07 28.2 7 359-389 710 Collagen, Collagen triple helix repeat (20 copi 0.42 6.4 8 400-418 710 Collagen Collagen triple helix repeat (20 copi 0.00074 16.8 9 423-448 710 Collagen Collagen triple helix repeat (20 copi 8.6e-08 31.5 10 451-483 710 Collagen Collagen triple helix repeat (20 copi 1.le-11 46.2 11 493-550 710 Collagen Collagen triple helix repeat (20 copi 6.8e-06 24.4 12 556-593 710 Collagen Collagen triple helix repeat (20 copi 0.0014 15.7 13 595-622 710 Collagen Collagen triple helix repeat (20 copi l.8e-06 26.6 14 624-659 710 Collagen Collagen triple helix repeat (20 copi 4.le-12 47.8 15 684-743 710 Collagen Collagen triple helix repeat (20 copi 2.4e-05 22.3 16 744-774 710 Collagen Collagen triple helix repeat (20 copi 2e-11 45.2 17 781-829 710 Collagen Collagen triple helix repeat (20 copi 0.00026 18.5 18 830-859 710 Collagen Collagen triple helix repeat (20 copi 8.le-15 57.9 19 860-919 710 Collagen Collagen triple helix repeat (20 copi 2e-12 48.9 20 920-979 710 Collagen Collagen triple helix repeat (20 copi 3.5e-06 25.5 21 1000 1031 710 Collagen Collagen triple helix repeat (20 copi 1.9e-11 45.2 22 1033 1090 710 Collagen Collagen triple helix repeat (20 copi 6.6e- 11 43.2 23 1099 1154 710 Collagen Collagen triple helix repeat (20 copi 3.9e-13 51.6 24 1155 1214 710 Collagen Collagen triple helix repeat (20 copi 0.0069 13.1 25 1217 1234 710 HerpesLP Herpesvirus leader protein 0.94 2.5 1 1228 1243 710 Collagen Collagen triple helix repeat (20 copi 0.0001 20.0 26 1238 1269 710 Collagen Collagen triple helix repeat (20 copi 4e-09 36.5 27 1278 1337 WO 2004/080148 PCT/US2003/030720 492 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 710 Collagen Collagen triple helix repeat (20 copi 1.9e-13 52.8 28 1341 1394 710 Collagen Collagen triple helix repeat (20 copi 7.le-06 24.3 29 1401 1434 710 Collagen Collagen triple helix repeat (20 copi 0.0012 16.0 30 1435 1483 710 C4 C-terminal tandem repeated domain in 2e-69 240.8 1 1489 1596 710 C4 C-terminal tandem repeated domain in 1.3e-77 268.0 2 1597 1711 711 MGAT2 N-acetylglucosaminyltransferase II (M 0.36 0.6 1 61-69 711 ldl recepta Low-density lipoprotein receptor doma 7.7e-15 51.1 1 67-108 711 - ldlrecept a Low-density lipoprotein receptor doma 4e-10 35.6 2 112-152 711 DUF351 Domain of Unknown Function 0.25 4.8 1 136-144 (DUF351) 711 EGF EGF-like domain 0.00011 19.6 1 157-190 711 EGF EGF-like domain 0.0004 17.6 2 196-230 711 ldlrecept b Low-density lipoprotein receptor repe 7.3e-10 34.9 1 332-373 711 ldl recept b Low-density lipoprotein receptor repe 2.7e-07 26.4 2 375-417 711 ldl-receptb Low-density lipoprotein receptor repe 7.6c-08 28.2 3 419-461 711 EGF EGF-like domain 0.045 10.2 3 512-553 711 Idl receptb Low-density lipoprotein receptor repe 8.3e-10 34.7 4 605-646 711 ldlrecept b Low-density lipoprotein receptor repe 8.4e-11 38.1 5 648-692 711 Idl receptb Low-density lipoprotein receptor repe 1.8c-09 33.6 6 694-742 711 Idl receptb Low-density lipoprotein receptor repe 0.00039 15.9 7 744-781 711 EGF EGF-like domain 0.00036 17.8 4 835-870 711 ldl recepta Low-density lipoprotein receptor doma 6.6e-17 57.9 3 882-920 711 squash Squash family serine protease inhibit 0.6 2.5 1 892-908 711 ldl recept a Low-density lipoprotein receptor doma 5.8e-15 51.5 4 921-961 711 ldl recept a Low-density lipoprotein receptor doma 1.6e-15 53.3 5 962 1001 711 Idlrecepta Low-density lipoprotein receptor doma 2.1c-18 62.8 6 1002 1041 711 DX DX module 0.78 3.2 1 1016 1047 711 ldlrecept a Low-density lipoprotein receptor doma 8.9e-16 54.2 7 1043 1081 711 ldl-recepta Low-density lipoprotein receptor doma 2.3e-14 49.5 8 1088 1127 711 Idlrecept a Low-density lipoprotein receptor doma 6.8e-11 38.1 9 1130 1170 711 ldlrecept a Low-density lipoprotein receptor doma 1.6c-06 23.6 10 1173 1206 711 EGF EGF-like domain 2.le-07 29.5 7 1213 1249 711 CBM_14 Chitin binding Peritrophin-A domain 0.1 6.7 1 1235 1255 711 EGF EGF-like domain 0.099 9.0 8 1255 1289 711 ldl-recept b Low-density lipoprotein receptor repe 4.6e-09 32.3 9 1337 1382 711 ldl-recept b Low-density lipoprotein receptor repe 6.3c-15 51.8 10 1384 1425 711 ldlreceptb Low-density lipoprotein receptor repe 3.3e-l 1 39.4 11 1427 1472 WO 2004/080148 PCT/US2003/030720 493 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 711 ldlrecept b Low-density lipoprotein receptor repe 0.094 8.0 12 1474 1515 711 Ildreceptb Low-density lipoprotein receptor repe 0.0042 12.5 13 1517 1558 711 EGF EGF-like domain 0.00016 19.0 9 1568 1606 711 ldlreceptb Low-density lipoprotein receptor repe 1.6e-12 43.8 14 1655 1696 711 ldl-recept.b Low-density lipoprotein receptor repe 0.003 13.0 15 1698 1740 711 ldl-recepLb Low-density lipoprotein receptor repe 1.7e-07 27.1 16 1742 1780 711 ldl-receptb Low-density lipoprotein receptor repe 0.003 13.0 17 1782 1822 711 EGF EGF-like domain 2.2e-06 25.8 10 1875 1911 711 Keratin Keratin 0.43 1.6 1 1881 1894 711 DUF244 Uncharacterized protein family (ORF7) 0.77 1.6 1 1934 1952 711 ldl-receptb Low-density lipoprotein receptor repe 7.6e-08 28.2 18 1959 2000 711 ldl receptb Low-density lipoprotein receptor repe 2.7e-13 46.3 19 2002 2043 711 ldl receptb Low-density lipoprotein receptor repe 3.le-11 39.5 20 2045 2087 711 ldl receptb Low-density lipoprotein receptor repe 0.00065 15.2 21 2089 2118 711 EGF EGF-like domain 8.7e-06 23.6 11 2184 2219 711 Idl-receptb Low-density lipoprotein receptor repe 0.49 5.6 22 2318 2365 711 malicN Malic enzyme, NAD binding domain 0.26 2.4 1 2340 2362 711 ldl recept b Low-density lipoprotein receptor repe 7.6e-14 48.1 23 2367 2410 711 ldl-recept b Low-density lipoprotein receptor repe 0.0026 13.2 24 2412 2440 711 ldl-recept b Low-density lipoprotein receptor repe 0.00025 16.6 25 2453 2479 711 EGF EGF-like domain 0.67 6,0 12 2505 2528 711 Idl-recept a Low-density lipoprotein receptor doma 1.5e-14 50.2 11 2545 2586 711 ldl recepta Low-density lipoprotein receptor doma 6.2e-13 44.8 12 2587 2625 711 Idl recepta Low-density lipoprotein receptor doma 1.4e-14 50.2 13 2626 2664 711 Idl recepta Low-density lipoprotein receptor doma 9.4e- 11 37.6 14 2682 2713 711 Idl recept-a Low-density lipoprotein receptor doma 7.3e-10 34.7 15 2717 2753 711 Idlirecept a Low-density lipoprotein receptor doma 5.2e- 11 38.5 16 2755 2795 711 idl recept a Low-density lipoprotein receptor doma 1.8e-17 59.8 17 2796- WO 2004/080148 PCT/US2003/030720 494 TABLE 4B SEQ Model Description E_value Score Repeats Position ID 2838 7I idlrecepta Low-density lipoprotein receptor doma 5.8e-14 48.2 18 2840 2879 711 IdlirecepLa Low-density lipoprotein receptor doma 5.l e-11 38.5 19 2880 2923 711 ldl-recepta Low-density lipoprotein receptor doma 5.le-12 41.8 20 2926 2964 711 EGF EGF-like domain 0.61 6.1 13 2928 2962 711 dickkopf N 7/11 2849 2856.. 47 54 0.32 4.9 8 2935 2942 711 Omega-atracotox Omega-atracotoxin 0.46 3.7 2 2937 2957 711 EGF EGF-like domain 3.9e-06 24.9 14 2967 3003 711 TIL Trypsin Inhibitor like cysteine rich 6.4e-05 16.4 2 2987 3009 711 EGF EGF-like domain 0.00094 16.3 15 3009 3034 711 ldlreceptb Low-density lipoprotein receptor repe 8.le-09 31.5 26 3092 3134 711 idl receptb Low-density lipoprotein receptor repe 4.le-07 25.8 27 3136 3177 711 ldl-receptb Low-density lipoprotein receptor repe 1.le-08 31.0 28 3179 3221 711 ldl-recept b Low-density lipoprotein receptor repe 0.078 8.3 29 3223 3251 711 ldl-receptb Low-density lipoprotein receptor repe 0.0013 14.2 30 3262 3289 711 EGF EGF-like domain 1.6e-06 26.3 16 3314 3350 711 TNFRc6 1/3 69 84.. 1 18 0.42 6.2 2 3337 3352 711 Idlirecepta Low-density lipoprotein receptor doma 1.9e-12 43.2 21 3352 3391 711 Idlirecepta Low-density lipoprotein receptor doma 1.4e-12 43.7 22 3392 3430 711 Idl recept a Low-density lipoprotein receptor doma 3.9e-12 42.2 23 3431 3470 711 Id1_recepta Low-density lipoprotein receptor doma 3.5e-17 58.8 24 3471 3510 711 SAPA Saposin A-type domain 0.039 6.0 1 3479 3492 711 Sar8_2 Sar8.2 family 0.12 6.9 1 3480 3500 711 Idlirecepta Low-density lipoprotein receptor doma 1.4e-19 66.7 25 3511 3549 711 Idl-recepta Low-density lipoprotein receptor doma 8.3e-13 44.4 26 3550 3588 711 EGF EGF-like domain 0.54 6.3 17 3552 3586 711 ldl_recepta Low-density lipoprotein receptor doma 1.3e-14 50.4 27 3590 3626 711 dickkopf N 7/11 2849 2856.. 47 54 0.057 7.2 10 3596 3604 WO 2004/080148 PCT/US2003/030720 495 TABLE 4B SEQ Model Description E value Score Repeats Position ID 711 Idlirecepta Low-density lipoprotein receptor doma 6e-14 48.1 28 3629 3666 711 Herpes PAP Herpesvirus polymerase accessory prot 0.41 2.1 1 3637 3650 711 Ild1recept a Low-density lipoprotein receptor doma 2e-19 66.2 29 3667 3706 711 ldlrecepta Low-density lipoprotein receptor doma 2.7c-11 39.4 30 3709 3749 711 Idl recept a Low-density lipoprotein receptor doma 5.7e-07 25.1 31 3758 3790 711 idlirecept a Low-density lipoprotein receptor doma 5.3e-17 58.2 32 3797 3835 711 EGF 19/28 3669 3704 .. 1 46 0.00016 19.1 20 3842 3879 711 S-locus glycop S-locus glycoprotein family 0.94 5.0 1 3849 3870 7 1 TIL Trypsin Inhibitor like cysteine rich 0.051 7.3 3 3864 3885 711 lamininEGF Laminin EGF-like (Domains III and V) 0.23 6.5 2 3865 3879 711 EGF 19/28 3669 3704 .. 1 46 0.0054 13.5 21 3885 3914 711 Activin-reep Activin types I and II receptor domai 0.48 3.4 1 3891 3921 711 NHL 2/5 681 694 .. 1 14 0.06 10.7 4 4005 4031 711 1dlreceptb Low-density lipoprotein receptor repe 0.14 7.5 31 4008 4016 711 ldl receptb Low-density lipoprotein receptor repe 0.11 7.8 32 4018 4026 711 1dl receptb 33/35 4040 4074.. 9 47 1.9e-10 36.9 34 4076 4118 711 ldlreceptb 33/35 4040 4074.. 9 47 0.019 10.3 35 4120 4163 711 EGF 19/28 3669 3704.. 1 46 0.77 5.8 22 4213 4236 711 EB EB module 0.15 6.2 3 4229 4244 711 EGF 19/28 3669 3704.. 1 46 0.00038 17.7 23 4254 4285 711 EGF 19/28 3669 3704,. 1 46 8.8e-08 30.8 24 4290 4321 711 EGF 19/28 3669 3704.. 1 46 7.4e-08 31.1 25 4326 4357 711 EGF 27/28 4398 4428 .. 1 46 0.0014 15.6 28 4431 4463 711 Coagulin Coagulin 0.52 3.4 1 4447 4454 711 Herpes glycop Herpesvirus glycoprotein D 0.39 4.3 2 4483 D 4519 712 MGAT2 N-acetylglucosaminyltransferase II (M 0.36 0.6 1 61-69 712 ldl recept a Low-density lipoprotein receptor doma le-14 50.7 1 67-108 712 idl recept a Low-density lipoprotein receptor doma 4e-10 35.6 2 112-152 712 DUF351 Domain of Unknown Function 0.25 4.8 1 136-144 (DUF351) WO 2004/080148 PCT/US2003/030720 496 TABLE 4B SEQ Model Description E value Score Repeats Position ID 712 EGF EGF-like domain 0.072 9.5 2 157-181 714 cadherin Cadherin domain 0.085 8.0 1 47-65 714 cadherin Cadherin domain 0.00072 15.2 2 | 69-126 714 cadherin Cadherin domain 8.4e-17 60.3 3 140-241 714 cadherin Cadherin domain 1.4e-29 104.9 4 255-344 714 cadherin Cadherin domain 7.9e-25 88.3 5 363-466 714 cadherin Cadherin domain 2e-26 93.9 6 480-573 714 cadherin Cadherin domain 3.2e-28 100.1 7 588-680 714 Rad2l Rec8 Conserved region of Rad2l / Rec8 like 0.83 5.2 1 652-662 714 cadherin Cadherin domain 3.9e-28 99.8 8 694-784 714 SCPU Spore Coat Protein U domain 0.47 5.3 1 701-714 714 cadherin Cadherin domain 5.7e-20 71.3 9 798-884 714 cadherin Cadherin domain 7.6e-20 70.9 10 898-987 714 cadherin Cadherin domain 9.5e-28 98.5 11 1001 1091 714 cadherin Cadherin domain 5.le-16 57.6 12 1105 1201 714 cadherin Cadherin domain 1.4e-28 101.4 13 1215 1306 714 Propep_M14 Carboxypeptidase activation peptide 0.41 5.5 2 1228 1239 714 cadherin Cadherin domain 2.2e-29 104.2 14 1320 1411 714 cadherin Cadherin domain 7.2e-21 74.5 15 1425 1520 714 Baculo helicase Baculovirus DNA helicase 0.61 1.4 1 1521 1531 714 cadherin Cadherin domain 4.5e-16 57.7 16 1541 1622 714 cadherin Cadherin domain 0.00017 17.4 17 1634 1700 715 cadherin Cadherin domain 0.085 8.0 1 47-65 715 cadherin Cadherin domain 0.00072 15.2 2 69-126 715 cadherin Cadherin domain 8.4e-17 60.3 3 140-241 715 cadherin Cadherin domain 1.4e-29 104.9 4 255-344 715 cadherin Cadherin domain 6. le-25 88.7 5 363-466 715 cadherin Cadherin domain 2e-26 93.9 6 480-573 715 cadherin Cadherin domain 3.2e-28 100.1 7 588-680 715 Rad2lRec8 Conserved region of Rad2l /Rec8 like 0.83 5.2 1 652-662 715 cadherin Cadherin domain 3.9e-28 99.8 8 694-784 715 SCPU Spore Coat Protein U domain 0.47 5.3 1 701-714 715 cadherin Cadherin domain 5.7e-20 71.3 9 798-884 715 cadherin Cadherin domain 7.6e-20 70.9 10 898-987 715 cadherin Cadherin domain 95e-28 98.5 11 1001 1091 715 cadherin Cadherin domain 5.le-16 57.6 12 1105 1201 715 cadherin Cadherin domain 1.4e-28 101.4 13 1215 1306 715 PropepM14 Carboxypeptidase activation peptide 0.41 5.5 2 1228 1239 715 cadherin Cadherin domain 2.2e-29 104.2 14 1320 1411 715 cadherin Cadherin domain 7.2e-21 74.5 15 1425- WO 2004/080148 PCT/US2003/030720 497 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 1520 715 Baculo helicase Baculovirus DNA helicase 0.61 1.4 1 1521 1531 715 cadherin Cadherin domain 4.5e-16 57.7 16 1541 1622 715 cadherin Cadherin domain 3.5e-05 19.8 17 1634 1728 716 DPPIVN term Dipeptidyl peptidase IV (DPP IV) N-te 0.5 1.1 1 310-346 716 DPPIV N term Dipeptidyl peptidase IV (DPP IV) N-te 0.0014 8.6 2 516-589 716 DPPIV_N_term Dipeptidyl peptidase IV (DPP IV) N-te 5.3e-08 21.7 3 618-652 716 Peptidase S9 Prolyl oligopeptidase family 3.9e-11 36.8 1 664-736 716 Methyltransf_6 Demethylmenaquinone 0.54 3.9 1 675-688 methyltransferase 716 Esterase Putative esterase 0.062 6.6 1 710-753 717 zf-C2H2 Zinc finger, C2H2 type 0.015 14.8 1 32-54 717 zf-C2H2 Zinc finger, C2H2 type 0.0014 18.9 2 60-82 717 Apocytochr F C Apocytochrome F, C-terminal 1 3.2 1 103-110 717 TFIIS Transcription factor S-Il (TFIIS) 0.2 7.1 1 154-164 717 zf-C2H2 Zinc finger, C2H2 type 3.7e-08 37.3 3 154-176 717 XPAN XPA protein N-terminal 0.3 6.5 2 179-191 717 zf-C2H2 Zinc finger, C2H2 type 8.5e-06 27.9 4 182-204 717 zf-C2H2 Zinc finger, C2H2 type 6.4e-08 36.5 5 210-232 717 TFIIS 3/8 210 220.. 29 39 1 4.7 4 238-248 717 zf-C2H2 Zinc finger, C2H2 type 1.6e-06 30.8 6 238-260 717 XPA N XPA protein N-terminal 1 4.6 4 263-275 717 zf-C2H2 Zinc finger, C2H2 type 1.4e-05 27.0 7 266-288 717 zf-C2H2 Zinc finger, C2H2 type 2.6e-05 25.9 8 294-316 717 TFIIS 5/8- 266 276 .. 29 39 0.2 7.1 7 322-332 717 zf-C2H2 Zinc finger, C2H2 type 6.9e-06 28.3 9 322-344 717 XPAN XPA protein N-terminal 0.38 6.2 6 347-359 717 TFIIS 5/8 266 276.. 29 39 0.14 7.7 8 350-360 717 zf-C2H2 Zinc finger, C2H2 type le-07 35.7 10 350-372 719 PhytoreoPns Phytoreovirus nonstructural protein P 0.75 2.1 1 74-88 719 malic Malic enzyme, N-terminal domain 0.39 3.5 1 117-131 719 AIpA Prophage CP4-57 regulatory protein (A 0.95 4.3 1 258-266 719 DUF298 Domain of unknown function 0.42 5.1 1 308-337 (DUF298) 719 DUF827 Plant protein of unknown function (DU 0.029 7.3 1 363-387 719 DUF496 Protein of unknown function (DUF496) 0.49 5.1 1 389-409 719 K-box K-box region 0.37 5.2 1 392-406 719 TFIIE-alpha TFIIE alpha subunit 0.14 5.9 1 394-416 719 Mlp Mp lipoprotein family 0.95 2.4 1 398-451 719 RibosomalS20p Ribosomal protein S20 0.38 5.2 1 433-447 719 Phage B Scaffold protein B 0.47 1.7 1 504-518 720 ig Immunoglobulin domain 0.07 9.9 1 17-34 720 ig Immunoglobulin domain 5.le-11 44.1 2 68-128 720 ig Immunoglobulin domain 1.1e-11 46.7 3 163-223 720 ig Immunoglobulin domain 9.6c-07 28.1 4 259-317 720 AstA Arginine N-succinyltransferase beta s 0.92 2.5 1 294-305 720 ig Immunoglobulin domain 2.1e-09 38.1 5 352-410 720 ig Immunoglobulin domain 1.5e-10 42.3 6 445-503 720 RTC RNA 3'-terminal phosphate cyclase 0.7 13.3 1 474-491 720 ig Immunoglobulin domain 8.le-08 32.1 7 538-596 720 ig Immunoglobulin domain 1.3e-07 31.3 8 629-687 WO 2004/080148 PCT/US2003/030720 498 TABLE 4B SEQ Model Description E_value Score Repeats Position ID 720 ig Immunoglobulin domain 8.le-09 35.9 9 720-780 720 ig Immunoglobulin domain 3.7e-09 37.2 10 813-871 720 ig Immunoglobulin domain 7.4e-09 36.0 11 904-962 720 ig Immunoglobulin domain 1.9e-11 45.7 12 995 1052 720 ig Immunoglobulin domain 1.3e-07 31.4 13 1085 1143 720 ig Immunoglobulin domain 1.3e-11 46.4 14 1176 1232 720 ig Immunoglobulin domain 3.6e-10 40.9 15 1266 1323 720 MarekA Marek's disease glycoprotein A 0.84 1.1 1 1333 1356 720 RNA-polRpb2_ RNA polymerase beta subunit 0.35 1.6 1 1352 1 1864 720 ig Immunoglobulin domain 6.4e-10 40.0 16 1356 1413 720 tspl Thrombospondin type 1 domain 1.2e-19 67.2 1 1435 1485 720 tspl Thrombospondin type 1 domain 6.4e-17 58.1 2 1492 1542 720 tsp l Thrombospondin type 1 domain 3.5e-15 52.3 3 1549 1599 720 tspl Thrombospondin type 1 domain 2.2e-17 59.7 4 1606 1656 720 tsp1 Thrombospondin type 1 domain 8.2e-12 41.1 5 1663 1713 720 VOMI Vitelline membrane outer layer protei 0.37 3.6 1 1714 1728 720 tsp_1 Thrombospondin type 1 domain 7e-16 54.7 6 1720 1770 720 EGF EGF-like domain 0.95 5.4 1 1993 2007 720 EGF EGF-like domain 9.3e-08 30.7 2 2013 2047 720 granulin Granulin 0.44 4.7 1 2034 2049 720 EGF EGF-like domain 0.015 11.9 3 2053 2092 720 EGF EGF-like domain 2.8e-05 21.8 4 2098 2130 720 TIL 1/7 1698 1715.. 1 16 0.0012 12.5 3 2117 2136 720 EGF EGF-like domain 0.17 8.2 5 2136 2157 720 EGF EGF-like domain 2.4e-06 25.7 6 2178 2215 720 EGF EGF-like domain 5.7e-10 38.7 7 2221 2256 720 RibosomalL34 Ribosomal protein L34 0.33 5.5 1 2280 2323 720 TIL 4/7 2168 2178 .. 57 68 0.022 8.5 6 2320 __ _ .8 -8 2338 720 EGF EGF-like domain 1.9e-09 36.8 8 2338 1_ 2372 WO 2004/080148 PCT/US2003/030720 499 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 720 toxin_2 Scorpion short toxin 0.84 3.4 2 2338 2353 720 toxin_5 Scorpion short toxin 0.73 3.4 1 2354 2359 720 TIL 4/7 2168 2178.. 57 68 0.023 8.4 7 2357 2378 720 squash Squash family serine protease inhibit 0.44 2.8 2 2358 2386 720 fn2 Fibronectin type II domain 0.8 3.1 1 2407 2418 721 SAP SAP domain 2.4e-10 40.8 1 3-37 721 SPRY SPRY domain 1.8e-30 107.5 1 289-418 721 SRP54 SRP54-type protein, GTPase domain 0.0091 11.6 1 451-466 721 NACHT NACHT domain 0.18 5.5 1 453-469 721 SKI Shikimate kinase 0.33 4.9 1 453-466 721 Zot Zonular occludens toxin (Zot) 0.22 5.5 1 453-466 721 AAA ATPase family associated with various 0.098 5.8 1 454-466 721 tRNAsyntlcR Glutaminyl-tRNA synthetase, non- 0.79 3.9 1 580-616 2 speci 722 CheB_methylest CheB methylesterase 1 2.7 1 74-92 722 DUF258 Protein of unknown function, DUF258 0.0014 13.8 1 509-532 722 ABC tran ABC transporter 7.4e-59 198.4 1 510-692 722 NACHT NACHT domain 0.2 5.3 1 511-527 722 SMC N RecF/RecN/SMC N terminal domain 0.47 3.9 1 511-524 722 Zot Zonular occludens toxin (Zot) 0.28 5.1 1 511-524 722 RHD3 Root hair defective 3 GTP-binding pro 0.67 1.2 1 516-530 722 Pox D2 Pox virus D2 protein 0.86 1.4 1 604-617 722 tail compS Phage virion morphogenesis family 0.061 7.3 1 606-619 722 DUF333 Domain of unknown function 0.3 5.7 1 818-846 (DUF333) 722 ABC tran ABC transporter 1.le-47 160.9 2 1322 1506 722 SufE Fe-S metabolism associated domain 0.28 6.2 1 1544 1563 723 BEX Brain expressed X-linked like family 0.88 2.2 1 133-160 723 CytoC RC Photosynthetic reaction centre cytoch 1 1.4 1 215-231 723 Ski Sno SKI/SNO/DAC family 0.51 4.5 1 656-672 724 HpaB 4-hydroxyphenylacetate 3-hydroxylase 0.97 2.5 1 4-14 724 Acyl-CoA-dh Acyl-CoA dehydrogenase, C-terminal 6.7e-50 175.9 1 50-201 do 725 C tripleX Cysteine rich repeat 2e-05 17.8 1 59-76 725 Bowman- Bowman-Birk shrine protease inhibitor 1 4.0 1 68-83 Birk leg 725 lamininEGF Laminin EGF-like (Domains III and V) 0.32 6.1 1 80-93 725 EGF EGF-like domain 8.7e-06 23.6 2 98-126 725 TIL Trypsin Inhibitor like cysteine rich 0.0035 11.0 1 117-138 725 EGF EGF-like domain 7.5e-05 20.2 3 138-172 725 TIL Trypsin Inhibitor like cysteine rich 0.26 5.1 2 151-178 725 toxin 5 Scorpion short toxin 0.34 4.4 1 153-158 725 EGF EGF-like domain 4.4e-05 21.1 4 178-211 725 EGF EGF-like domain 9.7e-09 34.3 5 223-258 725 MAM MAM domain 3.5e-41 147.0 1 402-546 726 DUF626 Protein of unknown function (DUF626) 0.22 5.8 1 30-64 726 VSP Giardia variant-specific surface prot 1 1.8 1 106-131 WO 2004/080148 PCT/US2003/030720 500 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 726 zf-B box B-box zinc finger 5.9e-08 32.7 1 106-139 726 Prefoldin Prefoldin subunit 0.42 5.7 1 222-248 726 Filamin Filamin/ABP280 repeat 2.3e-21 74.7 1 313-402 726 NHL NHL repeat 4.4e-10 40.3 1 431-458 726 Glyoxalase Glyoxalase/Bleomycin resistance prote 0.78 3.6 1 476-504 726 NHL NHL repeat 2.4e-10 41.2 2 478-505 726 NHL NHL repeat 1.le-10 42.4 3 525-552 726 NHL NHL repeat 2.5e-09 37.6 4 572-599 726 NHL NHL repeat 7.8e-11 43.0 5 619-646 726 NHL NHL repeat 3.8e-08 33.2 6 666-693 727 PaREPI Archacal PaREP1 protein 0.38 5.3 1 111-127 727 FCH Fes/CIP4 homology domain 0.026 10.3 1 281-321 727 DAGPE-bind Phorbol esters/diacylglycerol binding 2.8e-05 21.7 1 709-747 727 RhoGAP RhoGAP domain 3.9e-68 231.7 1 775-947 727 Terpene-synthC Terpene synthase family, metal bindin 0.84 2.7 1 778-812 727 NnrS NnrS protein 1 1.8 1 | 934-943 728 DUF727 Protein of unknown function (DUF727) 0.83 4.2 1 115-129 728 CN hydrolase Carbon-nitrogen hydrolase 4e-09 33.8 2 120-216 729 Pep Ml2B prop Reprolysin family propeptide 3.3e-14 44.8 1 93-223 ep 729 Reprolysin Reprolysin (M12B) family zinc metallo 0.00037 16.1 1 274-296 729 PsaL Photosystem I reaction centre subunit 0.99 3.2 1 302-317 729 Reprolysin Reprolysin (M12B) family zinc metallo 8.5e-17 62.5 2 340-480 729 Fragilysin Fragilysin metallopeptidase (MIOC) en 0.46 3.1 1 412-430 729 dicdcopf N Dickkopf N-terminal cysteine-rich reg 0.0036 10.8 1 534-560 729 StigI Stigma-specific protein, StigI 0.11 4.5 1 544-558 729 EB EB module 0.8 3.9 1 546-558 729 tspl Thrombospondin type 1 domain 7.le-09 31.3 1 570-623 729 zf-A20 A20-like zinc finger 0.39 8.6 1 702-717 729 ADAM spacerl ADAM-TS Spacer 1 3.8e-49 173.5 1 734-852 729 Herpes VP19C Herpesvirus capsid shell protein VP19 0.95 3.6 1 860-871 729 tspl 2/12 866 875.. 4 13 0.048 8.5 3 985 1002 729 tsp1 2/12 866 875.. 4 13 0.067 8.1 4 1037 1089 729 tspl 2/12 866 875 .. 4 13 1.2e-05 20.6 5 1092 1_ 1115 729 PTNMKN PTN/MK heparin-binding protein 0.44 4.2 1 1165 family 1184 729 tspl 2/12 866 875 .. 4 13 7.6e-07 24.5 6 1165 1190 729 tspl 2/12 866 875.. 4 13 1,4e-06 23.7 7 1228 1276 729 tsp_1 2/12 866 875.. 4 13 4.6e-07 25.3 8 1313 1364 729 tsp_1 2/12 866 875.. 4 13 0.00029 15.9 9 1372 1420 729 tsp_1 2/12 866 875.. 4 13 1.7e-07 26.7 10 1426 1479 729 tsp_1 2/12 866 875.. 4 13 4.7e-05 18.6 11 1485 1506 729 tspl 2/12 866 875.. 4 13 0.00073 14.6 12 1543 1593 730 Adeno PentonB Adenovirus penton base protein 0.39 1.6 1 178-193 WO 2004/080148 PCT/US2003/030720 501 TABLE 4B SEQ Model Description E value Score Repeats Position ID 731 ig Immunoglobulin domain 0.19 8.3 1 6-99 731 DUF390 Protein of unknown function (DUF390) 0.73 0.9 1 83-95 731 ig Immunoglobulin domain 9.7e-05 20.6 2 146-235 731 ig Immunoglobulin domain 0.00014 20.0 3 282-373 732 ig |Immunoglobulin domain 0.0045 14.4 1 42-129 732 ig Immunoglobulin domain 0.19 8.3 2 179-272 732 DUF390 Protein of unknown function (DUF390) 0.73 0.9 1 256-268 732 ig Immunoglobulin domain 9.7e-05 20.6 3 319-408 732 ig Immunoglobulin domain 0.00014 20.0 4 455-546 733 ig Immunoglobulin domain 0.0045 14.4 1 42-129 734 ig Immunoglobulin domain 0.0018 15.8 1 42-126 734 DUF390 Protein of unknown function (DUF390) 0.73 0.9 1 110-122 735 RhoGEF RhoGEF domain 8.2e-08 27.0 1 165-225 735 FAhydroxylase Fatty acid hydroxylase 0.6 3.7 1 221-233 735 RhoGEF RhoGEF domain 7.5e-09 30.5 2 257-329 736 HEM4 Uroporphyrinogen-III synthase HemD 0.98 3.1 1 549-581 736 DUF178 Uncharacterized ACR, COG1427 0.11 6.0 1 604-622 737 rrm RNA recognition motif. (a.k.a. RRM, R 2.5e-07 28.2 1 78-142 737 Smg4_UPF3 Smg-4/UPF3 family 0.042 8.7 1 143-173 737 rrm RNA recognition motif. (a.k.a. RRM, R 9.7e-16 58.1 2 151-222 737 fer4 NifH 4Fe-4S iron sulfur cluster binding pr 1 2.4 1 160-176 737 rrm RNA recognition motif. (a.k.a. RRM, R 3.6e-06 24.1 3 274-311 738 Adeno E4 34 Adenovirus early E4 34 kDa protein co 0.45 4.4 1 5-22 739 ribonuc red sm Ribonucleotide reductase, small chain 0.29 3.7 1 244-265 740 Sua5_yciO yrdC yrdC domain 0.99 3.3 1 38-53 740 F-box F-box domain 0.095 9.0 1 134-175 740 DUF469 Protein with unknown function 0.38 4.7 1 354-371 (DUF469 741 OmpH Outer membrane protein (OmpH-like) 0.14 6.9 1 81-150 741 Herpes BLRF2 Herpesvirus BLRF2 protein 0.12 7.3 1 256-277 741 UIM Ubiquitin interaction motif 0.34 8.8 1 293-310 741 DUF260 Protein of unknown function DUF260 0.26 4.8 1 330-350 741 TelA Toxic anion resistance protein (TelA) 0.34 4.5 1 348-368 741 Pox Atype inc 1/5 216 235.. 1 23 0.6 6.3 2 358-377 741 PspAIM30 PspA/IM30 family 0.34 5.2 1 364-399 741 M 1/5 272 292.. 1 21 0.46 8.0 3 534-554 741 Coprinus mating Coprinus cinereus mating-type protein 0.65 1.6 1 698-729 741 RibosomalL29c Ribosomal L29e protein family 0.3 5.8 1 717-755 741 Phageportal_2 Phage portal protein, lambda family 0.75 2.2 1 799-816 741 Dishevelled Dishevelled specific domain 0.22 4.9 1 903-922 741 SlyX SlyX 0.69 1.3 1 945-954 742 cadherin Cadherin domain 0.13 7.4 1 30-96 742 cadherin Cadherin domain 8.4e-13 46.4 2 147-243 742 cadherin Cadherin domain 7.le-25 88.5 3 257-349 742 HePIG Putative Ig domain 0.4 5.5 1 262-279 742 cadherin Cadherin domain 0.049 8.8 4 369-399 742 cadherin Cadherin domain 2.3e-05 20.4 5 427-460 742 cadherin Cadherin domain 5.6e-21 74.9 6 474-563 742 cadherin Cadherin domain 1.9e-25 90.4 7 577-666 742 cadherin Cadherin domain 4.5e-09 33.4 8 693-737 743 PGMPMMI Phosphoglucomutase/phosphomannom 1.6e-15 57.2 1 1-47 utase 743 PGMPMM Phosphoglucomutase/phosphomannom 0.041 9.3 1 388-430 utase WO 2004/080148 PCT/US2003/030720 502 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 743 Cor1 Corl/Xlr/Xmr conserved region 0.73 4.1 1 425-435 744 MACPF MAC/Perforin domain 0.00017 15.5 1 138-170 744 Keratin matx Keratin, high-sulphur matrix protein 0.19 7.6 1 451-482 744 Nol INop2 Sun NOL1I/NOP2/sun family 0.29 4.1 1 602-622 745 Remorin C Remorin, C-terminal region 0.19 6.6 1 1_0-33 745 zf-C2H2 Zine finger, C2H2 type 0.00033 21.5 1 130-152 745 TFLIS Transcription factor S-Il (TFIIS) 0.3 6.5 1 158-168 745 zf-C2H2 Zinc finger, C2H2 type 4.3e-07 33.1 2 158-180 745 XPA N XPA protein N-terminal 0.72 5.2 3 183-195 745 TFIIS Transcription factor S-II (TFIIS) 0.069 8.7 2 186-196 745 zf-C2H2 Zinc finger, C2H2 type 3.9e-07 33.3 3 186-208 745 XPA N XPA protein N-terminal 0.21 7.1 4 211-223 745 zf-C2H2 Zinc finger, C2H2 type 9.4e-08 35.8 4 214-236 745 zf-C2H2 Zinc finger, C2H2 type 4.8e-07 32.9 5 242-264 745 XPAN XPA protein N-terminal 0.13 7.8 6 267-279 745 TFIIS Transcription factor S-II (TFIIS) 0.28 6.6 5 270-280 745 zf-C2H2 Zinc finger, C2H2 type 3.1c-07 33.7 6 270-292 745 XPA N XPA protein N-terminal 0.13 7.8 7 295-307 745 TFIIS Transcription factor S-II (TFIIS) 0.54 5.6 6 298-308 745 zf-C2H2 Zinc finger, C2H2 type 3.le-06 29.7 7 298-320 745 XPA N XPA protein N-terminal 0.74 5.2 8 323-335 745 TFIIS Transcription factor S-II (TFIIS) 0.073 8.6 7 325-336 745 zf-C2H2 Zinc finger, C2H2 type 3.3e-07 33.6 8 326-348 745 XPA N XPA protein N-terminal 0.72 5.2 9 351-363 745 TFIIS Transcription factor S-II (TFIIS) 051 5.7 8 354-364 745 zf-C2H2 Zinc finger, C2H2 type 7.5e-07 32.2 9 354-376 745 XPA N XPA protein N-terminal 0.13 7.8 10 379-391 745 TFIIS Transcription factor S-II (TFIIS) 0.28 6.6 9 382-392 745 zf-C2H2 Zinc finger, C2H2 type 4.4e-06 29.1 10 382-404 745 XPA N XPA protein N-terminal 13 7.8 11 407-419 745 TFIIS Transcription factor S-II (TFIIS) 0.28 6.6 10 410-420 745 zf-C2H2 Zinc finger, C2H2 type 2.7e-07 33.9 11 410-432 745 zf-C2H2 Zinc finger, C2H2 type 0.0011 19.4 12 440-460 745 XPA N XPA protein N-terminal 0.67 5.3 12 485-497 745 zf-C2H2 13/16 466 481 .. 1 17 3.9e-06 29.3 14 488-510 745 TFIIS Transcription factor S-II (TFIIS) 0.0651 12.6 12 515-526 745 zf-C2H2 13/16 466 481 .. 1 17 1.3e-05 27.2 15 516-538 745 zf-BED BED zinc finger 0.71 4.6 3 517-539 745 XPA N XPA protein N-terminal 0.092 8.3 14 541-553 745 TFIIS Transcription factor S-II (TFIIS) 0.28 6.6 13 544-554 745 zf-C2H2 13/16 466 481 .. 1 17 0.00057 20.5 16 544-565 746 KRAB KRAB box 6.9e-24 88.6 1 35-75 746 ROSMUCR ROS/MUCR transcriptional regulator 0.33 3.9 1 81-104 pr 746 RemorinC Remorin, C-terminal region 0.19 6.6 1 195-208 746 zf-C2H2 Zinc finger, C2H2 type 0.00033 21.5 1 205-227 746 TFIS Transcription factor S-II (TFIIS) 0.3 6.5 1 233-243 746 zf-C2H2 Zinc finger, C2H2 type 4.3e-07 33.1 2 233-255 746 XPA N XPA protein N-terminal 0.72 5.2 3 258-270 746 TFIIS Transcription factor S-Il (TFI1S) 0.069 8.7 2 261-271 746 zf-C2H2 Zinc finger, C2H2 type 3.9e-07 33.3 3 261-283 746 XPA N XPA protein N-terminal 0.21 7.1 4 286-298 746 zf-C2H2 Zinc finger, C2H2 type 9.4e-08 35.8 4 289-311 746 zf-C2H2 Zinc finger, C2H2 type 4.8e-07 32.9 5 317-339 WO 2004/080148 PCT/US2003/030720 503 TABLE 4B SEQ Model Description E value Score Repeats Position ID 746 XPA N XPA protein N-terminal 0.13 7.8 6 342-354 746 TFIIS Transcription factor S-II (TFIIS) 0.28 6.6 5 345-355 746 zf-C2H2 Zinc finger, C2H2 type 3.1e-07 33.7 6 345-367 746 XPA N XPA protein N-terminal 0.13 7.8 7 370-382 746 TFIIS Transcription factor S-II (TFIIS) 0.54 5.6 6 373-383 746 zf-C2H2 Zinc finger, C2H2 type 3.1e-06 29.7 7 373-395 746 XPA_ N XPA protein N-terminal 0.74 5.2 8 398-410 746 TFIIS Transcription factor S-II (TFIIS) 0.073 8.6 7 400-411 746 zf-C2H2 Zinc finger, C2H2 type 3.3e-07 33.6 8 |401-423 746 XPA N XPA protein N-terminal 0.72 5.2 9 |426-438 746 TFIIS Transcription factor S-I (TFIIS) 0.51 5.7 8 429-439 746 zf-C2H2 Zinc finger, C2H2 type 7.5e-07 32.2 9 429-451 746 XPA N XPA protein N-terminal 0.13 7.8 10 454-466 746 TFIIS Transcription factor S-II (TFIIS) 0.28 6.6 9 457-467 746 zf-C2H2 Zinc finger, C2H2 type 4.4e-06 29.1 10 457-479 746 XPA N XPA protein N-terminal 0.13 7.8 11 482-494 746 TFIIS Transcription factor S-II (TFIIS) 0.28 6.6 10 485-495 746 zf-C2H2 Zinc finger, C2H2 type 2.7e-07 33.9 11 485-507 746 zf-C2H2 Zinc finger, C2H2 type 0.0011 19.4 12 515-535 747 EMP24 GP25L emp24/gp25L/p24 family 4.9e-80 276.1 1 5-201 748 acidphosphat Histidine acid phosphatase 7.9e- 537.8 1 31-371 159 749 C tripleX Cysteine rich repeat 0.92 4.2 1 52-67 749 ApoC-I Apolipoprotein C-I (ApoC-1) 0.83 3.7 1 196-260 749 PH PH domain 1.5e-20 69.0 1 393-487 749 ArfGap Putative GTPase activating protein fo 2.le-60 210.7 1 527-649 749 ank 1/4 797 823 .. 7 33 1.5e-08 33.7 2 826-858 749 ank 1/4 797 823 .. 7 33 0.0001 20.0 3 859-891 751 DUF369 Domain of unknown function 0.17 5.8 1 275-288 (DUF369) 751 KRAB KRAB box 1.le-20 77.0 1 342-382 751 zf-C2H2 Zinc finger, C2H2 type 7.8e-06 28.0 1 603-625 751 TFILS Transcription factor S-I (TFIIS) 0.78 5.1 1 604-613 751 zf-C2H2 Zinc finger, C2H2 type 1.6e-05 26.8 2 631-653 751 zf-C2H2 Zinc finger, C2H2 type 3.7e-07 33.4 3 693-715 751 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.54 2.9 1 708-726 751 TFIIS Transcription factor S-I (TFIIS) 0.63 5.4 3 721-731 751 zf-C2H2 Zinc finger, C2H2 type 1.3e-05 27.2 4 721-743 751 zf-C2H2 Zinc finger, C2H2 type 3.4e-08 37.4 5 751-773 751 zf-BED BED zinc finger 0.31 5.8 1 , 752-774 751 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.032 6.3 2 766-784 751 zf-C2H2 Zinc finger, C2H2 type 5.7e-06 28.6 6 779-801 752 Vpsl6_N Vps16, N-terminal region 2.3e- 918.3 1 1-420 273 752 Ribosomal L36 Ribosomal protein L36 0.6 5.0 1 245-281 752 Fumerase Fumarate hydratase (Fumerase) 0.71 3.4 1 376-402 752 Peptidase_M16_ Peptidase M16 inactive domain 0.29 5.2 1 492-510 C 752 Vps16_C Vps 16, C-terminal region 2.4e-15 57.9 1 517-548 752 Vps16 C Vps16, C-terminal region 4.6e- 435.6 2 554-762 128 753 LRRNT Leucine rich repeat N-terminal domain 0.0011 14.5 1 30-59 753 XG FTase Xyloglucan fucosyltransferase 0.53 2.0 1 37-48 753 LRR Leucine Rich Repeat 0.36 6.7 1 61-82 WO 2004/080148 PCT/US2003/030720 504 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 753 LRR Leucine Rich Repeat 0.0014 14.8 2 83-106 753 LRR Leucine Rich Repeat 5.7e-05 19.5 3 107-131 753 LRR Leucine Rich Repeat 2.7e-05 20.6 4 132-155 753 LRR Leucine Rich Repeat 0.001 15.3 5 156-179 753 LRR Leucine Rich Repeat 0.0036 13.4 6 180-203 753 LRR Leucine Rich Repeat 0.0016 14.6 7 204-227 753 LRR Leucine Rich Repeat 0.00015 18.1 8 228-251 753 LRRCT Leucine rich repeat C-terminal domain 9.7e-12 37.1 1 _ 261-311 754 A2MN Alpha-2-macroglobulin family N- 4.5e-91 312.7 1 6-613 termin 754 Big 1 Bacterial Ig-like domain (group 1) 0.62 3.9 1 382-403 754 A2M Alpha-2-macroglobulin family 6.2e-64 214.2 1 721-949 754 A2M Alpha-2-macroglobulin family 6.2e- 444.2 2 983 132 1469 754 Pox_D2 Pox virus D2 protein 0.18 3.4 1 1446 1461 755 DUF904 Protein of unknown function (DUF904) 0.21 6.7 1 116-125 755 DUF536 Protein of unknown function, DUF536 0.47 6.4 1 162-192 755 Syntaxin Syntaxin 0.11 7.9 1 163-197 755 fibrinogenC Fibrinogen beta and gamma chains, C-t 1.7e-09 32.1 1 242-275 755 fibrinogen C Fibrinogen beta and gamma chains, C-t 1.9e-25 86.7 2 279-422 756 ig Immunoglobulin domain 1.3c-06 27.6 1 43-102 756 ig Immunoglobulin domain 2.2e-05 23.0 2 137-198 756 FYRN F/Y-rich N-terminus 0.55 5.3 1 181-200 756 ig Immunoglobulin domain 6.5e-09 36.2 3 242-299 756 ig Immunoglobulin domain 2.3e-05 22.9 4 339-388 756 ig Immunoglobulin domain 2.9e-08 33.8 5 424-481 756 ig Immunoglobulin domain |7.7e-07 28.5 6 514-579 756 fn3 Fibronectin type III domain 7.7e-23 81.1 1 598-687 756 fn3 Fibronectin type III domain 9.le-08 28.7 2 700-790 756 fn3 Fibronectin type III domain 9.3e-17 60.0 3 802-891 756 fn3 Fibronectin type III domain 1.6e-09 34.8 4 903-986 757 LRR Leucine Rich Repeat 0.29 7.0 1 52-75 757 LRR Leucine Rich Repeat 0.003 13.7 2 76-99 757 LRR Leucine Rich Repeat 4e-05 20.0 3 100-123 757 LRR Leucine Rich Repeat 0.021 10.8 4 124-147 757 LRR Leucine Rich Repeat 3e-05 20.4 5 148-171 757 LRR Leucine Rich Repeat 0.00019 17.8 6 172-195 757 FliD Flagellar hook-associated protein 2 0.96 1.2 1 194-209 757 LRR Leucine Rich Repeat 0.16 7.8 7 196-216 757 LRRCT Leucine rich repeat C-terminal domain 9.3e-10 | 31.0 1__ 240-285 757 ig Immunoglobulin domain 9.4e-09 35.6 1__ 301-359 757 fn3 Fibronectin type III domain 0.00045 15.9 1_ | 444-496 758 LRR Leucine Rich Repeat 0.29 7.0 1 52-75 758 LRR Leucine Rich Repeat 0.003 13.7 2 76-99 758 LRR Leucine Rich Repeat 4e-05 20.0 3 100-123 758 LRR Leucine Rich Repeat 0,021 10.8 4 124-147 758 LRR Leucine Rich Repeat 3e-05 20.4 5 148-171 758 LRR Leucinc Rich Repeat 0.00019 17.8 6 172-195 758 FliD Flagellar hook-associated protein 2 0.96 1.2 1 194-209 758 LRR Leucine Rich Repeat 0.16 7.8 7 196-216 758 LRRCT Leucine rich repeat C-terminal domain 9.3e-10 31.0 1 | 240-285 758 ig Immunoglobulin domain 9.4e-09 35.6 1 301-359 758 fn3 Fibronectin type III domain 0.013 10.8 1 | 466-500 WO 2004/080148 PCT/US2003/030720 505 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 759 Serendipity A Serendipity locus alpha protein (SRY- 0.35 2.3 1 98-106 759 EGF EGF-like domain 0.76 5.8 1 111-133 759 SEA SEA domain 4.9e-06 22.1 1 168-237 759 ig Immunoglobulin domain 9.8e-07 28.1 1 286-352 759 AIG2 AIG2-like family 0.81 2.4 1 329-340 759 ig Immunoglobulin domain 0.33 7.4 2 485-547 759 60KD IMP 60Kd inner membrane protein 0.64 3.1 1 _ 502-523 759 Atracotoxin - Delta Atracotoxin 0.31 6.4 1 628-642 759 CASCSE1 CAS/CSE protein, C-terminus 0.28 5.8 1 | 902-915 759 GPS Latrophilin/CL-1-like GPS domain 2e-14 54.5 1 950 1002 759 7tm_2 7 transmembrane receptor (Secretin fa 6.4e-21 73.4 1 1009 1273 759 ATP-syntG Mitodhondrial ATP synthase g subunit 0.66 3.9 1 1267 1279 759 SH Viral small hydrophobic protein 0.63 4.1 1 1273 1292 760 TFIIS Transcription factor S-II (TFIIS) 0.27 6.6 1 | 107-117 760 zf-C2H2 1/13 93 101 .. 16 24 0.00013 23.2 2 107-129 760 zf-C2H2 1/13 93 101 .. 16 24 3.2e-06 29.6 3 135-157 760 Ribosomal_L19e RibosomalproteinL19e 0.59 3.9 1 143-161 760 TFIIS Transcription factor S-II (TFIIS) 0.08 8.4 3 163-173 760 zf-C2H2 1/13 93 101 .. 16 24 1.5e-05 26.9 4 163-185 760 XPA N XPA protein N-terminal 0.37 6.2 3 188-200 760 TFIIS Transcription factor S-Il (TFIIS) 0.08 8.4 4 191-201 760 zf-C2H2 1/13 93 101 .. 16 24 4.3e-06 29.1 5 191-213 760 XPAN XPA protein N-terminal 0.15 7.6 4 216-229 760 TFIIS Transcription factor S-II (TFIIS) 0.31 6.4 5 219-229 760 zf-C2H2 1/13 93 101 .. 16 24 2.4e-06 30.1 6 219-241 760 XPAN XPA protein N-terminal 0.45 5.9 5 244-256 760 TFIIS Transcription factor S-Il (TFIIS) 0.013 11.2 6 247-257 760 zf-C2H2 1/13 93 101 .. 16 24 9.le-07 31.8 7 247-269 760 XPA N XPA protein N-terminal 0.29 6.6 6 272-284 760 zf-C2H2 1/13 93 101 .. 16 24 3.8e-08 37.2 8 275-297 760 zf-BED BED zinc finger 0.13 7.1 3 _ 276-298 760 zf-C2H2 1/13 93 101 .. 16 24 3e-06 29.7 9 | 303-325 760 TFIIS Transcription factor S-I (TFIIS) 0.019 10.6 9 331-341 760 zf-C2H2 1/13 93 101 .. 16 24 3.1e-06 29.7 10 331-353 760 zf-C2H2 1/13 93 101 .. 16 24 2.7e-07 33.9 11 359-381 760 zf-BED BED zinc finger 0.63 4.8 4 360-382 760 PqiA Paraquat-inducible protein A 0.55 4.0 2 378-409 760 XPA N 9/11 356 366.. 1 11 0.22 7.0 10 384-396 760 zf-C2H2 1/13 93 101 .. 16 24 8.8e-08 35.9 12 387-409 760 TFIIS Transcription factor S-II (TFIIS) 0.036 9.7 12 415-425 760 zf-C2H2 1/13 93 101 .. 16 24 0.028 13.7 13 415-437 761 Clq Clq domain 0.77 4.7 1 104-116 761 DUF127 Protein of unknown function DUF127 0.81 2.3 1 134-143 761 Hydrolase haloacid dehalogenase-like hydrolase 0.53 4.3 1 176-189 761 Hydrolase haloacid dehalogenase-like hydrolase 0.27 5.3 2 443-477 761 Hydrolase haloacid dehalogenase-lilce hydrolase 0.65 4.0 3 543-620 761 PgpA Phosphatidylglycerophosphatase A 0.96 2.9 | 1 745-760 761 DUF418 Protein of unknown function (DUF418) 0.15 6.0 | 1 833-887 763 zf-HIT HIT zinc finger 0.21 8.5 1 161-179 763 zf-C2H2 Zinc finger, C2H2 type 0.0099 15.5 1 170-193 WO 2004/080148 PCT/US2003/030720 506 TABLE 4B SEQ Model Description E_value Score Repeats Position ID 764 FHA FHA domain 0.024 11.6 1 25-90 764 HIT HIT domain 6e-05 15.8 1 181-235 764 DcpS Scavenger mRNA decapping enzyme 0.0099 8.2 1 210-271 (DcpS 764 DUF369 Domain of unknown function 0.35 4.8 1 219-239 (DUF369) 764 zf-C2H2 Zinc finger, C2H2 type 0.026 13.9 1 317-339 767 Cwf Cwc_15 Cwf15/Cwcl5 cell cycle control protei 8.6e- 544.3 1 1-229 161 767 DUF692 Protein of unknown function (DUF692) 0.91 2.6 1 127-148 768 SRCR Scavenger receptor cysteine-rich doma 9.2e-36 127.9 1 32-129 768 SRCR Scavenger receptor cysteine-rich doma 6.5e-15 54.2 2 142-247 768 Lysyl-oxidase Lysyl oxidase 1.2e-80 278.1 1 251-359 769 RHS RHS protein 0.83 4.8 1 31-43 769 GatB PET 112 family, C terminal region 0.41 5.8 1 64-86 769 Glyco transf 8 Glycosyl transferase family 8 1.9e-10 40.1 1 65-227 769 Phage holin_4 Holin family 0.84 4.0 1 269-282 770 WD40 WD domain, G-beta repeat 0.5 6.4 2 169-194 770 WD40 WD domain, G-beta repeat 5.2e-06 23.8 3 225-251 770 DUF130 Domain of unknown function DUF130 0.074 5.9 1 241-255 770 WD40 WD domain, G-beta repeat 0.35 7.0 4 374-401 771 TPR TPR Domain 0.27 7.6 1 190-214 773 CTPtransf_1 Cytidylyltransferase family 3.3e- 426.1 1 69-400 125 773 DAG PE-bind Phorbol esters/diacylglycerol binding 0.28 7.3 1 166-180 773 Pyridox oxidase Pyridoxamine 5-phosphate oxidase 0.34 2.7 1 326-334 773 KIX KIX domain 0.48 5.9 1 415-435 774 CBM 20 Starch binding domain 0.078 8.5 1 86-105 774 WD40 WD domain, G-beta repeat 3.9e-08 31.2 1 165-203 775 TACC Transforming acidic coiled-coil-conta 0.43 3.9 1 312-334 775 bZIP 1/2 308 325 .. 48 65 0.39 5.9 2 408-438 776 Tweety Tweety 3.4e-74 256.6 1 21-413 779 HesB-like HesB-like domain 2.8e-41 132.5 1 49-151 780 ig Immunoglobulin domain 0.015 12.4 1 2-57 780 ig Immunoglobulin domain 0.00033 18.6 2 96-155 781 Mpv17_PMP22 Mpvl7 / PMP22 family 8e-14 51.5 1 129-191 781 Adenovirus PX Adenovirus late L2 mu core protein (P 0.65 5.4 1 133-152 782 sic sic protein 0.1 3.9 1 184-239 783 Collagen Collagen triple helix repeat (20 copi 5.5e-07 28.5 1 13-51 783 Collagen Collagen triple helix repeat (20 copi 0.044 10.1 2 59-81 783 Collagen Collagen triple helix repeat (20 copi 0.014 12.0 3 86-104 783 Collagen Collagen triple helix repeat (20 copi 0.029 10.7 4 106-127 783 Collagen Collagen triple helix repeat (20 copi 0.013 12.1 5 132-150 783 Collagen Collagen triple helix repeat (20 copi 0.04 10.3 6 152-173 783 Collagen Collagen triple helix repeat (20 copi 0.013 12.1 7 175-196 783 Collagen Collagen triple helix repeat (20 copi 2.5e-07 29.8 8 198-237 783 S- S-adenosylmethionine synthetase, C-te 0.29 4.1 1 232-247 AdoMet syntD3 783 vwa von Willebrand factor type A domain 1.2e-46 149.1 1 266-448 783 Kunitz BPTI Kunitz/Bovine pancreatic trypsin inhi 2.2e-23 71.1 1 540-590 784 DUF388 Domain unknown function (DUF388) 0.047 8.8 1 1-18 784 Mtap PNP Phosphorylase family 2 0.26 5.1 1 1-18 784 Sterol desat Sterol desaturase I 1.8e-48 164.1 1 57-263 785 ig Immunoglobulin domain 0.0011 16.7| 1 116-176 WO 2004/080148 PCT/US2003/030720 507 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 785 malic Malic enzyme, N-terminal domain 0.76 2.6 1 203-209 785 ig Immunoglobulin domain 3.6e-10 40.9 2 331-391 785 APOBECC APOBEC-like C-terminal domain 0.88 5.2 1 446-474 785 enolase Enolase, C-terminal TIM barrel domain 0.26 4.4 1 600-618 785 RNApolRpbl_ RNA polymerase Rpbl, domain 5 0.65 1.5 1 1034 5 1489 785 ig Immunoglobulin domain 4.9e-05 21.7 3 1363 1415 785 sigma70_r3 Sigma-70 region 3 0.6 5.7 1 1461 1481 785 ig Immunoglobulin domain 5.2e-08 32.9 4 1552 1613 786 RNAhelicase RNA helicase 0.00029 15.0 1 30-53 786 AAA ATPase family associated with various 0.00038 13.8 1 32-48 786 NACHT NACHT domain 0.0022 12.0 1 34-56 786 ATP-bind Conserved hypothetical ATP binding pr 0.64 3.5 1 35-46 786 NB-ARC NB-ARC domain 0.62 2.7 1 35-50 786 ADK Adenylate kinase 2.2e-05 19.0 1 67-114 786 ADK Adenylate kinase 0.12 6.2 2 127-160 786 ZZ Zinc finger, ZZ type 0.097 8.8 1 146-157 786 SRP54 SRP54-type protein, GTPase domain 0.3 5.9 1 390-408 786 SKI Shikimate kinase 0.12 6.4 1 392-413 786 ATP-bind Conserved hypothetical ATP binding pr 0.83 3.1 2 396-413 786 RHD3 Root hair defective 3 GTP-binding pro 0.039 5.3 1 397-411 786 CoaE Dephospho-CoA kinase 0.12 6.4 1 402-421 786 Thymidylate kin Thymidylate kinase 0.81 2.1 1 402-418 788 SH3 SH3 domain 2.3e-14 55.4 1 1-56 789 SH3 SH3 domain 1.5e-15 59.8 1 73-129 790 TIMP Tissue inhibitor of metalloproteinase 1.2e-89 243.9 1 20-116 790 PhytoPns9_10 Phytoreovirus nonstructural protein P 0.44 3.0 1 102-108 791 DUF716 Family of unknown function (DUF716) 0.93 3.4 1 26-54 791 DcuC C4-dicarboxylate anaerobic carrier 0.4 4.3 1 27-48 791 FLO_LFY Floricaula / Leafy protein 0.22 2.7 1 127-140 791 lectinc Lectin C-type domain 1.9e-07 31.5 1 162-267 792 UDPGT UDP-glucoronosyl and UDP-glucosyl 7.9e- 866.7 1 24-447 tra 258 792 Pox_E8 Poxvirus E8 protein 0.81 3.1 1 56-70 792 Glyco tran_28_C Glycosyltransferase family 28 C-termi 0.06 7.5 1 292-314 793 TRAPPBet3 Transport protein particle (TRAPP) co 1.le-67 235.0 1 6-173 794 PCMT Protein-L-isoaspartate(D-aspartate) 0 0.0055 11.0 1 74-113 794 Ubie methyltran ubiE/COQ5 methyltransferase family 1.9e-05 18.5 1 161-182 794 Methyltransf 8 Hypothetical methyltransferase 0.04 7.5 1 168-182 795 Brix Brix domain 2e-88 303.9 1 1-248 795 PDZ PDZ domain (Also known as DHR or 0.3 6.3 1 246-273 GLGF 795 7tm 1 7 transmembranc receptor (rhodopsin f 3e-42 125.3 1 444-671 795 LipA_acyltrans Bacterial lipid A biosynthesis acyltr 0.4 4.3 1 532-558 795 ACPS 4'-phosphopantetheinyl transferase su 0.72 3.3 1 585-600 796 ig Immunoglobulin domain 0.0042 14.5 1 33-110 797 ig Immunoglobulin domain 0.0042 14.5 1 33-110 798 ig Immunoglobulin domain 0.0042 14.5 1 33-110 798 FliL Flagellar basal body-associated prote 0.029 9.2 1 170-203 798 DeuC C4-dicarboxylate anaerobic carrier 0.044 7.9 1 174-193 799 PH PH domain 1.9e-21 72.0 1 14-112 WO 2004/080148 PCT/US2003/030720 508 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 800 Ifi-6-16 Interferon-induced 6-16 family 1.le-41 144.4 1 10-87 800 GLTT GLTT repeat (6 copies) 0.18 7.7 1 14-42 800 CRCB CrcB-like protein 0.18 7.1 1 70-88 801 Ifi-6-16 Interferon-induced 6-16 family 3.7e-46 159.7 1 17-99 801 GLTT GLTT repeat (6 copies) 0.18 7.7 1 26-54 801 CRCB CrcB-like protein 0.18 7.1 1 82-100 802 ank Ankyrin repeat 1 5.7 1 338-367 802 RmuC RmuC family 0.49 3.9 1 621-657 804 ig Immunoglobulin domain 0.0002 19.4 1 35-111 804 DUF708 Protein of unknown function (DUF708) 0.27 5.6 1 230-246 804 CDC50 LEM3 (ligand-effect modulator 3) fami 0.049 6.6 1 231-258 806 EGF EGF-like domain 0.0019 15.2 1 60-95 807 EGF EGF-like domain 0.0019 15.2 1 60-95 808 EGF EGF-like domain 0.0019 15.2 1 60-95 809 P13 P14 kinase Phosphatidylinositol 3- and 4-kinase 0.89 3.6 1 6-35 809 ig Immunoglobulin domain 4.9e-06 25.4 1 109-171 811 Alpha adaptin C Alpha adaptin AP2, C-terminal domain 0.061 5.2 1 92-104 811 MHCI Class I Histocompatibility antigen, d 0.021 9.1 2 120-205 812 ig Immunoglobulin domain 3.7e-10 40.9 2 78-137 812 ig Immunoglobulin domain 0.0018 15.9 3 176-237 812 ig Immunoglobulin domain 3.7e-08 33.4 4 274-335 812 DNA poliB_2 DNA polymerase type B, organellar 0.018 7.9 1 291-347 and 812 OapA Opacity-associated protein A 0.44 2.4 1 300-322 812 ig Immunoglobulin domain 0.0012 16.6 5 369-430 812 ig Immunoglobulin domain 7.7e-07 28.5 6 465-529 813 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.65 2.6 1 55-63 813 LRRCT Leucine rich repeat C-terminal domain 0.15 5.9 1 61-85 813 DUF909 Bacterial protein of unknown function 0.4 5.7 1 237-256 813 ig Immunoglobulin domain 0.0047 14.3 1 295-358 813 ig Immunoglobulin domain 1.2e-08 35.2 2 393-452 813 NollNop2_Sun NOL1/NOP2/sun family 0.28 4.1 1 629-671 813 ig Immunoglobulin domain 1.2e-05 24.0 3 1468 1530 813 ig Immunoglobulin domain 1.1e-06 27.9 4 1565 1627 813 ig Immunoglobulin domain 6.2e-09 36.3 5 1662 1724 813 CD2 T-cell surface antigen CD2 protein 0.19 3.9 1 1701 1749 813 ig Immunoglobulin domain 2.6e-09 37.7 6 1761 1823 813 ig Immunoglobulin domain 8.7e-06 24.5 7 1858 1926 813 ig Immunoglobulin domain 3.7e-10 40.9 8 1961 2020 813 ig Immunoglobulin domain 0.0018 15.9 9 2059 2120 813 ig Immunoglobulin domain 3.7e-08 33.4 10 2157 2218 813 DNApolB_2 DNA polymerase type B, organellar 0.018 7.9 1 2174 and 2230 813 OapA Opacity-associated protein A 0.44 2.4 1 2183 2205 WO 2004/080148 PCT/US2003/030720 509 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 813 ig Immunoglobulin domain 0.0012 16.6 11 2252 2313 813 ig Immunoglobulin domain 7.7e-07 28.5 12 2348 2412 814 DUF126 Protein of unknown function DUF126 0.08 6.1 1 1-9 814 LRRNT Leucine rich repeat N-terminal domain 3e-07 26.4 1 28-56 814 LRR Leucine Rich Repeat 0.0074 12.4 1 58-81 814 Phage holin 4 Holin family 0.73 4.2 1 69-88 814 LRR Leucine Rich Repeat 0.00054 16.2 2 82-105 814 LRR Leucine Rich Repeat 0.005 12.9 3 106-129 814 LRR Leucine Rich Repeat 0.00025 17.3 4 130-153 814 LRR Leucine Rich Repeat 0.00088 15.5 5 154-177 814 LRR Leucine Rich Repeat 0.0028 13.8 6 186-209 814 LRRCT Leucine rich repeat C-terminal domain 2.4c-13 42.0 1 219-280 814 DUF909 Bacterial protein of unknown function 0.4 5.7 1 432-451 814 ig Immunoglobulin domain 0.0047 14.3 1 490-553 814 ig Immunoglobulin domain 1.2e-08 35.2 2 588-647 814 NollNop2 Sun NOL1/NOP2/sun family 0.28 4.1 1 824-866 814 ig Immunoglobulin domain 1.2e-05 24.0 3 1663 1725 814 ig Immunoglobulin domain 1.le-06 27.9 4 1760 1822 814 ig Immunoglobulin domain 6.2e-09 36.3 5 1857 1919 814 CD2 T-cell surface antigen CD2 protein 0.19 3.9 1 1896 1944 814 ig Immunoglobulin domain 2.6e-09 37.7 6 1956 2018 814 ig Immunoglobulin domain 8.7e-06 24.5 7 2053 2121 814 ig Immunoglobulin domain 3.7e-10 40.9 8 2156 2215 814 ig Immunoglobulin domain 0.0018 15.9 9 2254 2315 814 ig Immunoglobulin domain 3.7e-08 33.4 10 2352 2413 814 DNApolB_2 DNA polymerase type B, organellar 0.018 7.9 1 2369 and 2425 814 OapA Opacity-associated protein A 0.44 2.4 1 2378 2400 814 ig Immunoglobulin domain 0.0012 16.6 11 2447 2508 814 ig Immunoglobulin domain 7.7e-07 28.5 12 2543 2607 816 Apolipoprotein Apolipoprotein A1/A4/E family 2.3e-11 42.3 1 93-168 816 DUF260 Protein of unknown function DUF260 0.64 3.5 1 94-107 816 Adeno PIX Adenovirus hexon-associated protein ( 0.49 4.4 1 95-110 816 BcrAD BadFG BadF/BadG/BcrA/BcrD ATPase family 0.12 6.2 1 134-180 816 Apolipoprotein Apolipoprotein A1/A4/E family 0.011 10.5 2 172-258 816 MMCoAmutas Methylmalonyl-CoA mutase 0.84 1.9 1 264-306 817 Apolipoprotein Apolipoprotein Al/A4/E family 2.3e-11 42.3 1 93-168 817 DUF260 Protein of unknown function DUF260 0.64 3.5 1 94-107 817 Adeno PIX Adenovirus hexon-associated protein ( 0.49 4.4 1 95-110 WO 2004/080148 PCT/US2003/030720 510 TABLE 4B SEQ Model Description E_.value Score Repeats Position ID 817 BcrAD BadFG BadF/BadG/BerA/BcrD ATPase family 0.12 6.2 1 134-180 817 Apolipoprotein Apolipoprotein A1/A4/E family 0.011 10.5 2 172-258 817 MMCoAmutas Methylmalonyl-CoA mutase 0.84 1.9 1 264-306 e 818 DUF717 Protein of unknown function (DUF717) 1 4.0 1 109-121 818 MHC_I Class I Histocompatibility antigen, d 0.69 3.7 1 226-239 819 Pox _D5 Poxvirus D5 protein-like 1 2.2 1 16-28 819 phoslip Phospholipase A2 3.4e-49 172.4 1 21-145 819 RFX_DNA bindi RFX DNA-binding domain 0.84 2.9 1 50-57 ng 821 MR MLE N Mandelate racemase / muconate lactoni 1.6e-05 17.0 1 9-112 821 PeptidaseS26 Signal peptidase I 0.38 3.8 1 54-84 821 CheR N CheR methyltransferase, all-alpha dom 0.4 6.7 1 58-74 821 MR MLE Mandelate racemase / muconate lactoni 2.5e-08 29.9 1 191-253 822 NAP Nucleosome assembly protein (NAP) 6e-191 644.5 1 12-285 822 GAT GAT domain 0.27 4.9 1 114-126 822 DUF115 Protein of unknown function DUFI15 0.76 3.8 1 116-143 823 PP2C Protein phosphatase 2C 3.4e-72 250.0 1 107-383 824 vwc von Willebrand factor type C domain 2.2e-10 37.8 1 103-157 824 vwc von Willebrand factor type C domain 4.7e-09 33.1 2 160-205 824 TILa TILa domain 0.24 6.3 2 183-200 825 7tm_1 7 transmembrane receptor (rhodopsin f 1.4e-28 84.3 1 1-173 826 7tm_1 7 transmembrane receptor (rhodopsin f 4.5e-49 145.7 1 40-287 827 EGF EGF-like domain 0.0067 13.2 1 35-62 827 DSL Delta serrate ligand 0.48 4.7 1 47-62 828 PoxA46 Poxvirus A46 family 0.55 2.5 1 1-15 828 ExoD Exopolysaccharide synthesis, ExoD 0.82 2.4 1 64-87 828 RhoGAP RhoGAP domain 1.3e-53 182.4 1 101-250 828 Sec6 Exocyst complex component Sec6 0.97 1.8 1 184-207 829 CUB CUB domain 1.1e-33 112.6 1 5-102 830 CUB CUB domain 1.1e-33 112.6 1 5-102 831 myosin head Myosin head (motor domain) 8.8e-76 257.2 1 37-299 831 ATP_bind2 P-loop ATPase protein family 0.16 4.9 1 126-139 831 PRK Phosphoribulokinase / Uridine kinase 0.14 5.2 1 128-139 832 myosin head Myosin head (motor domain) 4.1e-90 306.1 1 37-387 832 ATP_bind2 P-loop ATPase protein family 0.16 4.9 1 126-139 832 PRK Phosphoribulokinase / Uridine kinase 0.14 5.2 1 128-139 834 7tm_5 7TM chemoreceptor 0.17 1.1 1 37-49 834 kazal Kazal-type serine protease inhibitor 8.4e-08 33.5 1 139-183 834 thyroglobulinI Thyroglobulin type-1 repeat 4.1e-21 80.3 1 316-379 835 Micro_ Astar Microvirus A* protein 0.16 5.3 1 410-426 835 Coronavirus_5 Coronavirus gene 5 protein 0.91 3.0 1 540-553 835 RPEL RPEL repeat 0.81 5.4 1 540-550 836 Micro A star Microvirus A* protein 0.16 5.3 1 410-426 836 Coronavirus_5 Coronavirus gene 5 protein 0.91 3.0 1 540-553 836 RPEL RPEL repeat 0.81 5.4 1 540-550 837 BEX Brain expressed X-linked like family 9.8e-86 266.4 1 14-125 837 ChaC ChaC-like protein 0.2 4.5 1 67-92 837 IlvC Acetohydroxy acid isomeroreductase, c 0.14 5.9 1 68-97 838 LRRNT Leucine rich repeat N-terminal domain 4.1e-05 19.3 1 31-59 838 LRR Leucine Rich Repeat 0.045 9.7 1 61-84 838 LRR Leucine Rich Repeat 0.0026 13.9 3 109-132 838 LRR Leucine Rich Repeat 0.002 14.3 4 133-156 838 LRR Leucine Rich Repeat 0.0034 13.5 5 157-180 WO 2004/080148 PCT/US2003/030720 511 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 838 LRR Leucine Rich Repeat 0.00019 17.8 6 181-204 838 LRR Leucine Rich Repeat 6.4e-05 19.3 7 205-228 838 LRR Leucine Rich Repeat 3.4e-05 20.2 8 229-252 838 LRR Leucine Rich Repeat 0.59 6.0 9 253-276 838 LRR Leucine Rich Repeat 9.3e-05 18.8 10 277-300 838 LRR Leucine Rich Repeat 0.0022 14.1 11 301-324 838 Scramblase Scramblase 0.76 1.7 1 313-322 838 LRR Leucine Rich Repeat 0.0001 18.6 12 326-349 838 LRRCT Leucine rich repeat C-terminal domain 4.3e-13 41.2 1 359-405 838 UPF0118 Domain of unknown function DUF20 1 2.9 1 533-556 840 dUTPase dUTPase 0.34 6.2 1 343-362 841 ank Ankyrin repeat 0.00082 16.7 1 1-27 841 MMCoAmutas Methylmalonyl-CoA mutase 0.85 1.9 1 9-43 t 841 ank Ankyrin repeat 7.le-07 27.7 2 29-61 841 ank Ankyrin repeat 2.3e-09 36.6 3 130-162 841 ank Ankyrin repeat 2.2e-10 40.3 4 164-196 841 MycN term Myc amino-terminal region 0.27 3.6 1 514-541 841 SAM SAM domain (Sterile alpha motif) 1.3e-06 25.0 1 588-640 842 DUF370 Domain of unknown function 1 3.5 1 21-36 (DUF370) 842 ApoL Apolipoprotein L 3.le- 658.7 1 43-345 195 842 HupHC HupH hydrogenase expression protein, 0.99 2.7 1 116-131 842 DUF710 Family of unknown function (DUF710) 0.48 5.0 1 297-337 843 DUF370 Domain of unknown function 1 3.5 1 21-36 (DUF370) 843 ApoL Apolipoprotein L 1.7e- 656.3 1 43-345 194 843 HupH C HupH hydrogenase expression protein, 0.99 2.7 1 116-131 843 DUF710 Family of unknown function (DUF7 10) 0.48 5.0 1 297-337 844 Uteroglobin Uteroglobin family 1 3.3 1 1-16 844 DUF84 Protein of unknown function DUF84 0.098 5.9 1 8-22 844 DUF960 Staphylococcal protein of unknown fun 0.78 3.7 1 38-63 844 Tail X Phage Tail Protein X 0.35 5.8 1 45-56 844 LysM LysM domain 0.36 6.9 1 48-56 844 ig Immunoglobulin domain 3e-07 30.0 1 53-110 844 ig Immunoglobulin domain 1.8e-07 | 30.9 2 150-216 844 ig Immunoglobulin domain 2.9e-08 33.8 3 255-310 844 ig Immunoglobulin domain 4.6e-07 29.3 4 350-417 845 Uteroglobin Uteroglobin family 1 3.3 1 1-16 845 DUF84 Protein of unknown function DUF84 0.098 5.9 1 8-22 845 DUF960 Staphylococcal protein of unknown fun 0.78 3.7 1 38-63 845 Tail X Phage Tail Protein X 0.35 | 5.8 1 45-56 845 LysM LysM domain 0.36 6.9 1 48-56 845 ig Immunoglobulin domain 3e-07 30.0 1 53-110 845 ig Immunoglobulin domain 1.8e-07 30.9 2 150-216 845 ig Immunoglobulin domain 2.9e-08 33.8 3 255-310 845 ig Immunoglobulin domain 4.6e-07 29.3 4 350-417 845 ig Immunoglobulin domain 1.le-07 31.6 5 456-516 845 ig Immunoglobulin domain 8.8e-05 20.8 6 553-617 845 APS kinase Adenylylsulphate kinase 0.67 2.8 1 593-609 845 fn3 Fibronectin type III domain 0.75 4.7 1 | 656-733 845 | MAM MAM domain 6.7e-77 265.6 1 753-918 WO 2004/080148 PCT/US2003/030720 512 TABLE 4B SEQ Model Description E value Score Repeats Position ID 845 E2F TDP Transcription factor E2F/dimerisation 0.56 3.7 1 761-787 846 zf-PARP Poly(ADP-ribose) polymerase and 0.61 5.0 1 38-54 DNA-L 846 Albicidin res Albicidin resistance domain 0.49 6.1 1 290-297 846 SPDY Domain of unknown function 0.37 5.2 1 361-374 (DUF317) 846 CBF CBF/Mak21 family 0.00014 14.4 1 417-450 847 CNH CNH domain 0.00087 13.7 1 164-217 847 NHL NHL repeat 0.14 9.4 1 204-229 847 Coprogen-oxidas Coproporphyrinogen III oxidase 0.26 1.9 1 231-246 847 Clathrin Region in Clathrin and VPS 0.0094 11.5 1 404-445 847 ENTH ENTH domain 0.31 5.7 1 794-807 847 C2 C2 domain 2.2e-18 63.6 1 797-876 847 PLA2_B Lysophospholipase catalytic domain 9.le-51 178.0 1 1108 1317 847 DUF188 Uncharacterized BCR, Yail/YqxD 0.9 2.9 1 1314 family 1325 847 TAP42 TAP42-like family 1 2.0 1 1408 1413 847 PLA2_B Lysophospholipase catalytic domain 1.2e-12 43.6 2 1429 1551 848 ENTH ENTH domain 0.31 5.7 1 43-56 848 C2 C2 domain 2.2e-18 63.6 1 46-125 848 PLA2 B Lysophospholipase catalytic domain 2.4e-53 187.1 1 357-566 848 DUF188 Uncharacterized BCR, YaiI/YqxD 0.9 2.9 1 563-574 family 848 TAP42 TAP42-like family 1 2.0 1 657-662 848 PLA2_B Lysophospholipase catalytic domain 1.2e-12 43.6 2 678-800 849 SNF7 SNF7 1.3e-54 191.6 1 18-178 849 GatBN PETI 12 family, N terminal region 0.2 4.6 1 135-146 849 Interleukin 13 Interleukin-13 0.24 6.5 1 156-167 850 p450 Cytochrome P450 2.9e-05 15.6 1 25-112 850 Phage attach Phage Head-Tail Attachment 0.97 1.6 1 69-80 851 ig Immunoglobulin domain 8e-09 35.9 1 48-105 851 ig Immunoglobulin domain 1.5e-12 49.8 2 169-227 851 ig Immunoglobulin domain 2.3e-06 26.7 3 265-344 851 CD36 CD36 family 0.38 3.9 1 377-402 851 Neur chan mem Neurotransmitter-gated ion-channel tr 0.69 2.3 1 392-401 b 852 ig Immunoglobulin domain 8e-09 35.9 1 44-101 852 ig Immunoglobulin domain 1.5e-12 49.8 2 165-223 852 ig Immunoglobulin domain 2.3e-06 26.7 3 261-340 852 CD36 CD36 family 0.38 3.9 1 373-398 852 Neurchanmem Neurotransmitter-gated ion-channel tr 0.69 2.3 1 388-397 b 853 ig Immunoglobulin domain 8e-09 35.9 1 44-101 853 bZIPMaf bZIP Maf transcription factor 0.4 4.3 1 101-127 854 C2 C2 domain 1.8e-39 134.8 1 158-245 854 C2 C2 domain 8.3e-37 125.8 2 289-377 855 DUF1058 Protein of unknown function 0.49 2.3 1 79-92 (DUF1058) 855 PepM12B.prop Reprolysin family propeptide 7.2e-06 18.8 1 154-222 ep 855 Reprolysin Reprolysin (M12B) family zinc metallo 9.5e-18 66.0 2 313-456 WO 2004/080148 PCT/US2003/030720 513 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 855 Mu-conotoxin Mu-Conotoxin 0.94 4.6 1 356-377 855 Astacin Astacin (Peptidase family M12A) 0.65 3.4 1 389-402 855 fn2 Fibronectin type II domain 0.59 3.4 1 445-451 855 tspl Thrombospondin type I domain 3e-16 55.9 1 546-596 855 ADAM spacerl ADAM-TS Spacer 1 1.6e-49 174.7 1 702-813 855 DSL Delta serrate ligand 0.38 5.0 1 794-812 855 tsp 1 Thrombospondin type 1 domain 0.0007 14.6 2 832-844 855 zf-NF-X1 NF-Xl type zinc finger 0.0071 8.8 2 873-895 855 tsp_1 Thrombospondin type 1 domain 0.0028 12.7 3 888-909 855 tsp_1 Thrombospondin type 1 domain 8.2e-08 27.8 4 945-995 855 Reo-sigmaC Reovirus sigma C capsid protein 0.73 2.0 1 1216 1224 855 UPF0051 Uncharacterized protein family (UPFOO 0.0073 8.9 1 1284 1297 855 tsp l Thrombospondin type 1 domain 0.01 10.8 5 1321 1364 855 tspl1 Thrombospondin type 1 domain 0.0037 12.3 7 1429 1471 855 tsp1 Thrombospondin type 1 domain 3.4e-05 19.0 8 1474 1530 856 Ifi-6-16 Interferon-induced 6-16 family 3.5e-07 26.2 1 21-44 856 CRCB CrcB-like protein 0.18 7.1 1 27-45 857 GHMP_kinases GHMP kinases putative ATP-binding 0.55 1.9 1 81-129 pro 857 abhydrolase alpha/beta hydrolase fold 0.02 9.2 1 161-214 857 lipase Lipase 0.64 3.7 1 185-213 857 abhydrolase alpha/beta hydrolase fold 0.0083 10.5 2 254-324 857 DLH Dienelactone hydrolase family 0.4 3.6 1 256-283 857 LIP Secretory lipase 0.012 8.6 1 265-290 857 UPF0227 Uncharacterised protein family (UPF02 0.38 4.9 1 266-296 857 abhydrolase 2 Phospholipase/Carboxylesterase 0.015 10.1 1 267-290 857 PeptidaseM1O Matrix metalloprotease, N-terminal do 0.63 2.5 1 296-317 N 858 GHMPkinases GHMP kinases putative ATP-binding 0.55 1.9 1 74-122 pro 858 abhydrolase alpha/beta hydrolase fold 0.02 9.2 1 154-207 858 lipase Lipase 0.64 3.7 1 178-206 858 abhydrolase alpha/beta hydrolase fold 0.0083 10.5 2 247-317 858 DLH Dienelactone hydrolase family 0.4 3.6 1 249-276 858 LIP Secretory lipase 0.012 8.6 1 258-283 858 UPF0227 Uncharacterised protein family (UPF02 0.38 4.9 1 259-289 858 abhydrolase 2 Phospholipase/Carboxylesterase 0.015 10.1 1 260-283 858 PeptidaseM1O_ Matrix metalloprotease, N-terminal do 0.63 2.5 1 289-310 - N 859 H-kinase dim Signal transducing histidine kinase, 0.25 6.8 1 15-55 859 Collagen Collagen triple helix repeat (20 copi 4.8e-08 32.5 1 244-284 859 Collagen Collagen triple helix repeat (20 copi 3.3e-05 21.8 2 285-320 859 SRCR Scavenger receptor cysteine-rich doma 6.6e-22 78.9 1 336-433 859 MBD Methyl-CpG binding domain 0.52 4.9 1 365-389 860 CobS Cobalamin-5-phosphate synthase 0.43 3.4 1 45-58 860 LGT Prolipoprotein diacylglyceryl transfe 0.084 6.6 1 64-85 860 Collagen Collagen triple helix repeat (20 copi 2.6e-07 29.7 1 304-344 860 Collagen Collagen triple helix repeat (20 copi 3.3e-05 21.8 2 345-380 860 SRCR Scavenger receptor cysteine-rich doma 2.7e-34 122.7 1 396-493 WO 2004/080148 PCT/US2003/030720 514 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 862 TFIIS Transcription factor S-Il (TFIS) 0.73 5.1 1 192-202 862 zf-C2H2 Zinc finger, C2H2 type 3 .5e-05 25.4 1 192-214 862 zf-C2H2 Zinc finger, C2H2 type 1.3e-06 31.2 2 220-242 862 zf-BED BED zinc finger 0.33 5.7 1 222-243 862 mRNA cap enzy mRNA capping enzyme, catalytic 0.56 0.5 1 245-260 me domain 862 XPAN XPA protein N-terminal 0.78 5.1 2 245-257 862 zf-C2H2 Zinc finger, C2H2 type 2.9e-07 33.8 3 248-270 862 TFIIS Transcription factor S-Il (TFIIS) 0.89 4.8 3 276-286 862 zf-C2H2 Zinc finger, C2H2 type 2e-06 30.4 4 276-298 862 zf-C2H2 Zinc finger, C2H2 type 1.6e-05 26.8 5 304-326 862 mRNA capenzy mRNA capping enzyne, catalytic 0.56 0.5 2 329-344 me domain 862 XPA N XPA protein N-terminal 0.78 5.1 4 329-341 862 zf-C2H2 Zinc finger, C2H2 type 5.4e-07 32.7 6 332-354 862 TFIIS Transcription factor S-II (TFIIS) 0.29 6.5 5 360-370 862 zf-C2H2 Zinc finger, C2H2 type 1.le-06 31.5 7 360-382 862 XPAN XPA protein N-terminal 0.13 7.8 6 385-397 862 TFIIS Transcription factor S-II (TFIIS) 0.57 5.5 6 388-398 862 zf-C2H2 - -Zinc finger, C2H2 type 9.2e-07 31.8 8 388-410 862 XPA N XPA protein N-terminal 0.97 4.8 7 413-425 862 TFIIS Transcription factor S-Il (TFIIS) 0.14 7.6 7 416-426 862 zf-C2H2 Zinc finger, C2H2 type 4.4e-06 29.1 9 416-438 862 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.38 3.3 1 428-449 862 zf-C2H2 Zinc finger, C2H2 type L.le-06 31.5 10 444-466 862 TFIIS Transcription factor S-II (TFIIS) 0.054 9.0 8 472-482 862 zf-C2H2 Zinc finger, C2H2 type 2.9e-07 33.8 11 472-494 862 zf-BED BED zinc finger 0.64 4.8 3 477-495 862 DC1 1/2 472 487.. 19 44 0.16 6.2 2 500-515 862 zf-C2H2 Zinc finger, C2H2 type 0.00082 19.9 12 500-523 863 Dor1 Dorl-like family 7e-203 684.1 1 197-553 863 bZIP bZIP transcription factor 0.3 6.3 1 224-246 864 U1-C U1 small nuclear ribonucleoprotein C 0.00024 16.9 1 2-51 864 zf-CCCH Zinc finger C-x8-C-x5-C-x3-H type (an 2.2e-09 33.8 1 52-78 865 WD40 WD domain, G-beta repeat 4.2e-08 31.1 1 202-238 865 WD40 WD domain, G-beta repeat 0.54 6.3 2 282-307 866 FelsI Fels-1 Propage Protein-like 0.61 5.8 1 361-376 867 aminotran 3 Aminotransferase class-III 1.5e-40 134.4 1 95-214 867 OATP N Organic Anion Transporter Polypeptide 0.81 4.0 1 240-258 867 aminotran 3 Aminotransferase class-Il 8.9e-66 218.5 2 281-509 868 aminotran 3 Aminotransferase class-III 1.2e-09 31.3 1 52-111 868 OATP N Organic Anion Transporter Polypeptide 0.81 4.0 1 137-155 868 aminotran_3 Aminotransferase class-III 8.9e-66 218.5 2 178-406 869 trypsin Trypsin 4.5e-71 220.5 1 63-289 870 Glycos-transf 1 Glycosyl transferases group 1 1.7e-17 64.4 1 144-239 872 MHYT Bacterial signalling protein N termin 0.6 4.2 1 291-328 873 EGF EGF-like domain 2.9e-07 28.9 1 7-43 873 laminin_ EGF Laminin EGF-like (Domains III and V) 1 4.3 1 21-43 873 EGF EGF-like domain 9.2e-10 38.0 2 50-81 873 EGF EGF-likc domain 1.2e-07 30.3 3 88-119 873 EGF EGF-like domain 2.7e-1 1 43.5 4 126-157 873 EGF EGF-like domain 5e-11 42.5 5 168-199 873 DSL Delta serrate ligand 0.32 5.2 3 190-199 873 EGF EGF-like domain 0.0091 12.7 6 209-234 WO 2004/080148 PCT/US2003/030720 515 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 873 EGF EGF-like domain 0.022 11.3 7 243-267 873 EGF EGF-like domain 5e-09 35.3 8 280-311 873 EGF EGF-like domain 1.3e-07 30.2 9 319-350 873 Cripto Cripto growth factor 0.11 6.4 2 324-351 873 EGF EGF-like domain 8.2e-11 41.8 10 358-389 873 Cripto Cripto growth factor 0.00049 14.6 3 363-390 873 laminin EGF Laminin EGF-like (Domains III and V) 0.042 9.1 5 378-390 873 EGF EGF-like domain 4.6e-08 31.8 11 396-427 873 lamininEGF Laminin EGF-like (Domains III and V) 0.25 6.4 6 416-427 873 sushi Sushi domain (SCR repeat) 1.5e-06 28.7 1 433-486 873 EGF EGF-like domain 8.7e-09 34.5 12 492-523 873 EGF EGF-like domain 3.9e-09 35.7 13 530-561 873 EGF EGF-like domain 1.2e-07 30.4 14 568-599 873 granulin Granulin 1 3.6 2 596-608 873 EGF EGF-like domain 2.9e-07 29.0 15 606-637 873 DSL Delta serrate ligand 0.69 4.1 9 627-637 873 fn3 Fibronectin type III domain 1.3e-10 38.6 1 641-722 873 fn3 Fibronectin type III domain 8e-12 42.8 2 740-823 873 fn3 Fibronectin type III domain 1.2e-12 45.7 3 839-921 873 EGF EGF-like domain 5.8e-10 38.7 16 1046 1__ 1 11077 873 Cripto Cripto growth factor 0.047 7.7 5 1051 1078 875 AdoHcyase S-adenosyl-L-homocysteine hydrolase 2.2e-68 222.4 1 81-217 875 AdoHcyase S-adenosyl-L-homocysteine hydrolase 1.8e-55 180.1 2 218-507 875 AdoHcyaseNA S-adenosyl-L-homocysteine hydrolase, 2.2e- 363.6 1 267-428 D 106 875 TrkA-N TrkA-N domain 0.023 10.7 1 291-322 875 GlutR NAD bin Glutamyl-tRNAGlu reductase, NAD(P) 0.086 8.1 2 337-353 d bi 876 UQ con Ubiquitin-conjugating enzyme 0.0058 11.9 1 47-77 877 Prominin Prominin 0 1616. 1 18-823 6 877 SPDY Domain of unknown function 0.15 6.5 1 80-93 (DUF317) 877 DUF705 Protein of unknown function (DUF705) 0.98 1.9 1 555-565 878 fibrinogen C Fibrinogen beta and gamma chains, C-t 7.6e-56 190.6 1 146-382 879 fibrinogenC Fibrinogen beta and gamma chains, C-t 7.6e-56 190.6 1 146-382 880 fibrinogen C Fibrinogen beta and gamma chains, C-t 7.6e-56 190.6 1 146-382 881 DUF846 Eukaryotic protein of unknown function 0.094 4.8 1 83-113 882 DUF381 Domain of unknown function 0.48 4.4 1 29-35 (DUF381) 883 TrpTyrperm Tryptophan/tyrosine permease family 0.0026 10.3 1 | 42-63 883 aa permeases Amino acid permease 8.4e-32 115.8 1 48-371 883 Pox_I5 Poxvirus protein 15 0.24 6.0 1 1 162-179 883 serine carbpept Serine carboxypeptidase 0.41 2.3 1 378-398 884 pkinase Protein kinase domain 6.3e-09 32.0 1 100-150 884 CtsR Firmicute transcriptional repressor o 0.61 3.9 1 146-157 884 pkinase Protein kinase domain 1.3e-07 27.2 2 151-181 884 Pox ser-thr kin Poxvirus serine/threonine protein kin 0.31 3.8 1 165-176 884 HerpesUL3 Herpesvirus UL3 protein 0.72 4.0 1 338-383 884 pkinase Protein kinase domain 0.00084 13.7 3 444-495 884 pkinase Protein kinase domain 2.le-05 19.4 4 604-659 885 lectin c| Lectin C-type domain 9.9e-10 40.5 1 47-107 WO 2004/080148 PCT/US2003/030720 516 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 886 spectrin Spectrin repeat 0.4 5.5 1 1042 1095 887 spectrin Spectrin repeat 0.4 5.5 1 1042 1095 888 PeptidaseM20 Peptidase family M20/M25/M40 5.2e-24 86.6 1 55-295 889 sugartr Sugar (and other) transporter 0.11 5.5 1 47-103 889 OctopineDH NAD/NADP octopine/nopaline 0.26 4.6 1 153-169 dehydrogen 889 sugartr Sugar (and other) transporter 3.7e-08 28.6 2 201-335 890 T4_deiodinase Iodothyronine deiodinase 0.37 4.0 1 168-179 891 ig Immunoglobulin domain 8.5e-07 28.3 1 55-127 891 densoVP4 Capsid protein VP4 0.38 2.7 1 57-69 892 bromodomain Bromodomain 9.5e-45 158.8 1 63-152 892 bromodomain Bromodomain 3e-40 143.5 2 356-445 892 Alpha adaptinC Alpha adaptin AP2, C-terminal domain 0.48 2.6 1 395-407 892 PhageX Phage X family 0.97 3.7 1 438-469 892 eIF3cN Eukaryotic translation initiation fac 0.51 1.2 1 473-559 892 VitellogeninN Lipoprotein amino terminal region 0.61 1.5 1 484-539 892 Herpes U44 Herpes virus U44 protein 0.47 3.1 1 515-529 892 MAGP Microfibril-associated glycoprotein ( 0.82 2.7 1 919-958 893 Pox A type inc Viral A-type inclusion protein repeat 0.23 7.6 1 197-216 893 OLF Olfactomedin-like domain 4.6e- 412.4 1 220-470 121 893 PhageX Phage X family 0.57 4.5 1 362-389 893 PeptidaseMlO Matrix metalloprotease, N-terminal do 0.86 2.1 1 373-383 N 893 FeThRedB Ferredoxin thioredoxin reductase cata 0.96 2.3 1 377-393 894 kazal Kazal-type serine protease inhibitor 1.7e-10 44.0 1 88-132 894 efhand EF hand 2.2e-05 23.3 1 178-206 894 ig Immunoglobulin domain 6.4e-06 25.0 1 262-322 894 ig Immunoglobulin domain 2e-09 38.2 2 354-414 894 SsgA Streptomyces sporulation and cell div 0.35 5.9 1 | 541-549 895 aminotran_1_2 Aminotransferase class I and II 7.5e-20 71.8 1 81-257 895 DegTDnrJEry DegT/DnrJ/EryCl/StrS 1 2.4 1 158-178 Cl aminotransferase 895 TPPenzymesC Thiamine pyrophosphate enzyme, C- 0.35 3.3 1 258-279 term 896 LIM LIM domain 9.9e-09 32.9 1 24-80 896 LIM LIM domain 2e-13 49.7 2 83-134 896 LIM LIM domain 5.3e-19 69.5 3 153-209 896 DUF866 Eukaryotic protein of unknown functio 0.035 7.5 1 178-199 896 'LIM LIM domain 7.5e-07 26.3 4 212-253 896 VHP Villin headpiece domain 4.6e-25 77.5 1 538-573 897 LytTR LytTr DNA-binding domain 0.051 9.5 1 14-49 897 COX4 Cytochrome c oxidase subunit IV 0.61 4.7 1 188-207 897 pkinase Protein kinase domain 2.9e- 349.9 1 356-613 102 897 TMP TMP repeat 0.37 8.0 1 579-589 898 DCX Doublecortin 1.4e-12 44.7 1 130-194 898 LytTR LytTr DNA-binding domain 0.051 9.5 1 201-236 898 COX4 Cytochrome c oxidase subunit IV 0.61 4.7 1 375-394 898 pkinase Protein kinase domain 2.9e- 349.9 1 543-800 102 898 TMP TMP repeat 0.37 8.0 1 766-776 WO 2004/080148 PCT/US2003/030720 517 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 899 glutaredoxin Glutaredoxin 0.0052 12.1 1 101-154 899 GSTN Glutathione S-transferase, N-terminal 0.053 9.4 1 102-152 899 ArsC ArsC family 0.59 4.8 1 105-131 899 GST C Glutathione S-transferase, C-terminal 0.00013 17.6 1 278-370 899 UL21 Herpesvirus UL21 0.98 0.3 1 301-329 900 Collagen Collagen triple helix repeat (20 copi 2.4e-05 22.3 1 27-60 900 Collagen Collagen triple helix repeat (20 copi I.5e-07 30.6 2 61-106 900 C1q Clq domain 2.9e-72 250.2 1 116-241 900 TOBE TOBE domain |0.5 ; 6.3 1 207-226 901 Herpes BMRF2 Herpesvirus BMRF2 protein 0.042 7.2 1 8-26 902 BRCT BRCA1 C Terminus (BRCT) domain 5.9e-09 31.4 1 10-93 902 BRCT BRCA1 C Tenninus (BRCT) domain 1.4e-25 87.3 2 96-183 902 Sec6 Exocyst complex component Sec6 0.71 2.3 1 367-395 902 BRCT BRCA1 C Terminus (BRCT) domain 7.8e-18 61.3 3 479-570 902 BRCT BRCA1 C Terminus (BRCT) domain 5.7e-19 65.1 4 579-652 902 BRCT BRCA1 C Terminus (BRCT) domain 2.3e-18 63.0 5 737-823 902 RinB Transcriptional activator RinB 0.33 5.4 1 796-847 902 BRCT BRCA1 C Terminus (BRCT) domain 0.028 9.0 6 846-881 902 Phage Coat A Phage Coat Protein A 0.82 3.9 1 924-936 903 BRCT BRCA1 C Terminus (BRCT) domain 5.9e-09 31.4 1 10-93 904 PhageX Phage X family 0.71 4.2 1 16-41 904 |20G-FeII Oxy 20G-Fe(II) oxygenase superfamily 0.27 6.0 1 195-273 905 LRR Leucine Rich Repeat 0.0001 18.6 1 4-27 905 LRRCT Leucine rich repeat C-terminal domain 4.3e-13 41.2 1 37-83 905 UPFO118 Domain of unknown function DUF20 1 2.9 1 211-234 906 ig Immunoglobulin domain 7.9e-06 24.7 1 25-79 906 COX17 Cytochrome C oxidase copper 0.68 3.6 1 182-195 chaperone 907 TB2_DPi HVA TB2/DP1, HVA22 family 3.8e-34 123.6 1 3-96 22 907 ELM2 ELM2 domain 0.53 5.2 1 99-124 908 LRRNT Leucine rich repeat N-terminal domain 0.00068 15.2 1 23-49 908 LRR Leucine Rich Repeat 8.7e-05 18.9 1 51-74 908 Sal vir VRP3 Salmonella virulence-associated 28kDa 1 3.8 1 64-88 908 LRR Leucine Rich Repeat 0.00012 18.4 2 75-98 908 LRR Leucine Rich Repeat 0.0034 13.5 3 99-122 908 LRR Leucine Rich Repeat 9.9e-06 22.1 47 | 123-146 908 LRRCT Leucine rich repeat C-terminal domain 2.3e-15 48.2 1 156-208 908 ig Immunoglobulin domain 1.3e-08 35.1 1 224-283 908 ig Immunoglobulin domain 3.8e-09 37.1 2 320-376 908 ig Immunoglobulin domain 0.00083 17.1 3 416-472 908 BON Transport-associated domain 0.14 7.1 1 477-489 908 ig Immunoglobulin domain 2.8e-08 33.9 4 533-590 908 pec lyase N Pectate lyase, N terminus 0.19 3.9 1 670-676 908 Anperoxidase Animal haem peroxidase 1.le- 653.6 1 770 193 1309 908 PAL Phenylalanine and histidine ammonia-I 0.53 2.6 1 1037 1054 908 7tm_1 7 transmembrane receptor (rhodopsin f 0.22 2.7 1 1101 1109 908 PeptidaseC1 Papain family cysteine protease 0.76 2.1 1 1194 1211 908 PetG Cytochrome B6-F complex subunit 5 0.51 5.7 1 1245 1278 WO 2004/080148 PCT/US2003/030720 518 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 908 DUF978 Bacterial protein of unknown function 0.67 3.8 1 1257 1270 908 TILa TILa domain 0.00018 16.9 1 1438 1477 908 PSP94 Beta-microseminoprotein (PSP-94) 0.11 8.0 1 1439 1470 908 vwe von Willebrand factor type C domain 2e-10 38.0 1 1439 1494 909 LRRNT Leucine rich repeat N-terminal domain 0.00068 15.2 1 54-80 909 LRR Leucine Rich Repeat 8.7e-05 18.9 1 82-105 909 SalvirVRP3 Salmonella virulence-associated 28kDa 1 3.8 1 | 95-119 909 LRR Leucine Rich Repeat 0.00012 18.4 2 | 106-129 909 LRR Leucine Rich Repeat 0.0034 13.5 3 130-153 909 LRR Leucine Rich Repeat 9.9e-06 22.1 4 154-177 909 LRRCT Leucine rich repeat C-terminal domain 2.3e-15 48.2 1 187-239 909 ig Immunoglobulin domain 1.3e-08 35.1 1 255-314 909 ig Immunoglobulin domain 3.8e-09 37.1 2 351-407 909 ig Immunoglobulin domain 0.00083 17.1 3 447-503 909 BON Transport-associated domain 0.14 7.1 1 508-520 909 ig Immunoglobulin domain 2.8e-08 33.9 4 564-621 909 pec lyaseN Pectate lyase, N terminus 0.19 3.9 1 701-707 909 An_peroxidase Animal haem peroxidase 1le- 653.6 1 801 193 1340 909 PAL Phenylalanine and histidine ammonia-I 0.53 2.6 1 1068 1085 909 7tm_1 7 transmembrane receptor (rhodopsin f 0.22 2.7 1 1132 1140 909 Peptidase C1 Papain family cysteine protease 0.76 2.1 1 1225 1242 909 PetG Cytochrome B6-F complex subunit 5 0.51 5.7 1 1276 r_ 1309 909 DUF978 Bacterial protein of unknown function 0.67 3.8 1 1288 1301 909 TILa TILa domain 0.00018 16.9 1 1469 1508 909 PSP94 Beta-microseminoprotein (PSP-94) 0.11 8.0 1 1470 1501 909 vwc von Willebrand factor type C domain 2e-10 38.0 1 1470 1525 910 LRRNT Leucine rich repeat N-terminal domain 0.00068 15.2 1 23-49 910 LRR Leucine Rich Repeat 8.7e-05 18.9, 1 51-74 910 LRR Leucine Rich Repeat 0.00032 17.0 2 75-98 910 LRR Leucine Rich Repeat 0.025 10.6 3 99-122 910 LRR Leucine Rich Repeat 0.00069 15.8 4 123-146 910 ig Immunoglobulin domain 1,3e-08 35.1 1 201-260 910 ig Immunoglobulin domain 3.8e-09 37.1 2 297-353 910 ig Immunoglobulin domain 0.00083 17.1 3 393-449 910 BON Transport-associated domain 0.14 7.1 1 454-466 910 ig Immunoglobulin domain 0.47 6.8 4 514-532 910 Anperoxidase Animal haem peroxidase 1ie- 653.6 1 663 193 1202 910 PAL Phenylalanine and histidine ammonia-I 0.53 2.6 1 930-947 910 7tm_1 7 transmembrane receptor (rhodopsin f 0.22 2.7 1 994 ____________________1002 WO 2004/080148 PCT/US2003/030720 519 TABLE 4B SEQ Model Description E_value Score Repeats Position ID 910 PeptidaseC1 Papain family cysteine protease 0.76 2.1 1 1087 1104 910 PetG Cytochrome B6-F complex subunit 5 0.51 5.7 1 1138 1171 910 DUF978 Bacterial protein of unknown function 0.67 3.8 1 1150 1163 910 TILa TILa domain 0.00018 16.9 1 1331 - _1370 910 PSP94 Beta-microseminoprotein (PSP-94) 0.11 8.0 1 1332 1363 910 vwc von Willebrand factor type C domain 2e-10 38.0 1 1332 1387 911 EGF EGF-like domain 0.059 9.8 2 47-59 911 EGF EGF-like domain 0.0036 14.2 3 85-99 911 EGF EGF-like domain 4.9e-08 31.7 4 106-134 911 EGF EGF-like domain 4.2e-10 39.2 5 172-203 911 EGF EGF-like domain 0.00083 16.5 6 210-245 911 laminin EGF Laminin EGF-like (Domains III and V) 0.014 10.8 3 216-247 911 laminin G Laminin G domain 0.0021 12.5 1 275-335 911 laminin G Laminin G domain 0.018 9.3 2 386-401 911 DUF604 Protein of unknown function, DUF604 0.84 2.9 1 390-412 911 lamininG Laminin G domain 0.22 5.5 3 483-541 911 EGF EGF-like domain 9.9e- 11 41.5 7 574-605 911 EGF EGF-like domain 0.43 6.7 8 611-632 911 DUF1067 Protein of unknown function 0.79 3.0 1 614-628 (DUF1067) 911 lamininG Laminin G domain 1.9e-05 19.6 4 663-728 911 Melibiase Melibiase 0.9 2.3 1 740-755 911 laminin G Laminin G domain 0.075 7.2 5 773-788 911 EGF EGF-like domain 2.2c-09 36.6 9 823-854 911 DSL Delta serrate ligand 0.44 4.8 2 844-854 911 EGF EGF-like domain 6.4e-06 24.1 10 861-892 911 EGF EGF-like domain 0.71 5.9 11 901-933 911 DSL Delta serrate ligand 0.67 4.2 4 923-933 911 EGF EGF-like domain 3e-06 25.3 12 940-971 913 Omega-atracotox Omega-atracotoxin 0.43 3.7 1 24-44 913 M M protein repeat 0.28 8.8 1 146-166 913 UPF0137 Uncharacterised protein family (UPFO1 0.04 7.4 1 322-347 914 RIla Regulatory subunit of type II PKA R-s le-14 54.8 1 25-62 914 SURF6 Surfeit locus protein 6 0.027 7.2 1 42-113 914 cNMP binding Cyclic nucleotide-binding domain 7.2e-31 112.5 1 152-240 914 RNApolRpb2_ RNA polymerase Rpb2, domain 4 0.28 6.2 1 184-191 4 914 cNMP binding Cyclic nucleotide-binding domain 9.4e-32 115.7 2 270-364 914 Methyltransf 1 6-0-methylguanine DNA 0.64 4.3 1 325-337 methyltransfera 915 DIL DIL domain 1.8e-40 144.6 1 214-323 915 PDZ PDZ domain (Also known as DHR or 1.7e-14 52.8 1 555-639 GLGF 916 PLAT PLAT/LH2 domain 9.8e-32 109.3 1 2-111 916 lipoxygenase Lipoxygenase 3.9e- 655.1 1 121-647 194 916 DUF181 Uncharacterized ACR, COG1944 0.81 2.4 1 247-258 916 PG binding Putative peptidoglycan binding domain 0.5 5.6 1 420-436 WO 2004/080148 PCT/US2003/030720 520 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 916 Dus Dihydrouridine synthase (Dus) 0.18 4.6 1 604-647 917 PLAT PLAT/LH2 domain 9.8e-32 109.3 1 2-111 917 lipoxygenase Lipoxygenase 1.9e-48 164.1 1 112-293 917 DUF181 Uncharacterized ACR, COG1944 0.81 2.4 1 220-231 918 PLAT PLAT/LH2 domain 9.8e-32 109.3 1 2-111 918 lipoxygenase Lipoxygenase 2.7e-57 194.3 1 121-322 918 DUF181 Uncharacterized ACR, COG1944 0.81 2.4 1 249-260 920 TFIS Transcription factor S-II (TF1IS) 1 4.6 1 5-15 920 DUF536 Protein of unknown function, DUF536 0.19 7.9 1 214-251 920 FCH Fes/CIP4 homology domain 0.5 5.6 1 259-278 926 DS Deoxyhypusine synthase 0.53 2.5 1 21-36 926 SH3BP5 SH3 domain-binding protein 5 0.097 6.5 1 82-102 (SH3BP5) 926 Aatrans Transmembrane amino acid transporter 3.5e- 472.5 1 114-517 139 926 HerpesU47 Herpesvirus glycoprotein U47 0.69 1.1 1 141-158 926 Omega-atracotox Omega-atracotoxin 0.35 4.0 1 168-184 926 DUF588 Domain of unknown function 0.58 5.1 1 425-444 (DUF588) 926 GSPII F Bacterial type II secretion system pr 0.46 3.6 1 438-455 926 FtsX Predicted permease 0.35 5.4 1 454-523 927 EGF EGF-like domain 0.024 11.2 1 42-57 927 EGF EGF-like domain 1.3e-06 26.6 2 60-88 927 EGF EGF-like domain 1.2e-09 37.5 3 95-128 927 Cripto Cripto growth factor 0.86 3.4 1 101-132 927 laminin EGF 1/5 32 60.. 2 43 0.025 9.9 2 106-130 927 EGF EGF-like domain 5.5e-07 27.9 4 135-171 927 EGF EGF-like domain le-10 41.4 5 178-209 927 EB EB module 0.26 5.4 1 183-209 927 EGF EGF-like domain 5e-08 31.7 6 216-247 927 DUF990 Protein of unknown function (DUF990) 0.23 5.3 1 302-336 927 MARVEL Membrane-associating domain 0.15 5.8 1 305-333 927 PAP2 PAP2 superfamily 0.88 3.7 1 311-334 927 ColicinV Colicin V production protein 0.98 3.5 1 315-336 928 Ornatin Ornatin 0.59 4.7 1 125-132 928 PP1 inhibitor PKC-activated protein phosphatase-1 i 0.78 2.2 1 423-439 929 ank Ankyrin repeat 0.011 12.7 2 142-167 930 LRRNT Leucine rich repeat N-terminal domain 0.39 6.0 1 66-86 930 DUF6 Integral membrane protein DUF6 0.00023 18.9 1 86-129 930 DUF6 Integral membrane protein DUF6 7e-05 20.9 2 180-277 931 endotoxin delta endotoxin 0.85 2.3 1 203-220 932 Lipoprotein_8 Hypothetical lipoprotein (MG045 famil 0.7 1.1 1 65-79 933 Peptidase M24 metallopeptidase family M24 2.2e-70 244.0 1 88-326 933 DUF120 Domain of unknown function DUF120 0.089 7.1 1 169-180 934 Neurexophilin Neurexophilin 2e-258 804.9 1 3-308 934 NnrS NnrS protein 0.47 3.0 1 8-21 938 L27 L27 domain 7.3e-19 69.4 1 13-68 938 Not3 Notl N-terminal domain, CCR4-Not 0.95 2.9 1 54-77 ____ comp 938 PDZ PDZ domain (Also known as DHR or 8.1e-22 78.5 1 93-172 GLGF 938 CDC50 LEM3 (ligand-effect modulator 3) fami 1 2.1 1 159-174 938 DUF1O Protein of unknown function DUF100 0.2 4.1 1 175-188 939 | DIE2 ALGI1 DIE2/ALGIO family 7.6e-72 248.9 1 28-146 WO 2004/080148 PCT/US2003/030720 521 TABLE 4B SEQ Model Description E.value Score Repeats Position ID _ _ _ _36-43 939 DUF718 Protein of unknown function (DUF718) 0.64 4.4 1 36-43 939 Geminimov Geminivirus putative movement 0.42 4.6 1 101-115 protein 940 rrm RNA recognition motif. (a.k.a. RRM, R 1.3c-09 36.2 1 61-128 940 RbsD FucU RbsD / FucU transport protein family 0.53 3.4 1 123-147 940 HemX HemX 0.37 3.5 1 142-173 940 rrm RNA recognition motif (a.k.a. RRM, R 4.6e-13 48.6 2 186-253 940 rrm RNA recognition motif (a.k.a. RRM, R 4.3c-13 48.7 3 339-406 940 rrm RNA recognition motif (a.k.a. RRM, R 1.4e-06 25.5 4 456-524 941 C tripleX Cysteine rich repeat 2e-05 17.8 1 60-77 941 Bowman- Bowman-Birk scrine protease inhibitor 1 4.0 1 69-84 Birk leg 941 laminin EGF Laminin EGF-like (Domains III and V) 0.32 6.1 1 81-94 941 EGF EGF-like domain 8.7e-06 23.6 2 99-127 941 TIL Trypsin Inhibitor like cysteine rich 0.0035 11.0 1 118-139 941 EGF EGF-like domain 7.5e-05 20.2 3 139-173 941 TIL Trypsin Inhibitor like cysteine rich 0.26 5.1 2 152-179 941 toxin 5 Scorpion short toxin 0.34 4.4 1 154-159 941 EGF EGF-like domain 4.4e-05 21.1 4 179-212 941 EGF EGF-like domain 9.7e-09 34.3 5 224-259 941 MAM MAM domain 3.5e-41 147.0 1 403-547 942 C tripleX Cysteine rich repeat 2e-05 17.8 1 65-82 942 Bowman- Bowman-Birk serine protease inhibitor 1 4.0 1 74-89 Birk leg 942 laminin EGF Laminin EGF-like (Domains II and V) 0.32 6.1 1 86-99 942 EGF EGF-like domain 8.7e-06 23.6 2 104-132 942 TIL Trypsin Inhibitor like cysteine rich 0.0035 11.0 1 123-144 942 EGF EGF-like domain 7.5e-05 20.2 3 144-178 942 TIL Trypsin Inhibitor like cysteine rich 0.26 5.1 2 157-184 942 toxin 5 Scorpion short toxin 0.34 4.4 1 159-164 942 EGF EGF-like domain 4.4e-05 21.1 4 184-217 942 EGF EGF-like domain 9.7e-09 34.3 5 229-264 942 MAM MAM domain 3.5e-41 147.0 1 408-552 943 PHD PHD-finger 3.4e-14 45.7 1 85-128 943 bromodomain Bromodomain 5.4e-12 44.0 1 149-235 943 PHD PHD-finger 0.61 3.9 2 260-272 943 PWWP PWWP domain 6.3e-10 36.2 1 269-312 943 GatB PETI 12 family, C terminal region 0.64 5.1 1 288-303 943 TH1 THI protein 0.91 0.2 1 640-653 943 SP2 Structural protein 2 0.42 1.1 1 904-922 943 zf-Bbox B-box zinc finger 0.12 9.1 1 974-989 943 zf-MYND MYND finger 5.3e-11 35.7 1 977 1011 944 PHD PHD-finger 3.4e-14 45.7 1 85-128 944 bromodomain Bromodomain 5.4e-12 44.0 1 149-235 944 PHD PHD-finger 0.61 3.9 2 260-272 944 PWWP PWWP domain 6.3e-10 36.2 1 269-312 944 GatB PETI 12 family, C terminal region 0.64 5.1 1 288-303 944 THI THI protein 0.91 0.2 1 640-653 945 PHD P-ID-finger 3.4e-14 45.7 1 85-128 945 bromodomain Bromodomain 5.4e-12 44.0 1 149-235 945 PHD PHD-finger 0.61 3.9 2 260-272 945 PWWP PWWP domain 6.3e-10 36.2 1 269-312 945 GatB PET112 family, C terminal region 0.64 5.1 1 288-303 WO 2004/080148 PCT/US2003/030720 522 TABLE 4B __ __ SEQ Model Description Eyalue Score Repeats Position ID 945 TI THI protein 0.91 0.2 1 640-653 945 SP2 Structural protein 2 0.42 1.1 1 950-968 945 zf-B box B-box zinc finger 0.12 9.1 1 1020 _______1035 945 zf-MYND MAThlDfinger 5.3e-11 35.7 1 1023 1057 946 PHD PHD-finger 3 .4e-14 45.7 1 90-133 946 bromodomain Bromodomain 5 0 946 PHD -finger 0.61 3.9 2 265-277 946 PWWP P P domain e 3 946 GatB PET 12 family, C terminal region 0.64 5.1 0 946 THI THI protein 0.91 0.2 1 645-658 946 SP2 Structural protein 2 0.42 1.1 1 955-973 946 zf-B box B-box zinc finger 9.1 1025 1040 946 zf-MYNDMY finger 3e-11 1028 9 47 1062 947 Urotensin II Urotensin II 036 5.4 1 362-372 947 fn2 Pibronectin type II domain 0.55 3.5 1 363-371 950 Terminase 5 Putative ATPase subunit of terminate 0.87 0.7 1 7-20 950 ion trans Ion transport protein 3.9e-08 29.8 1 345-518 950 SirB Tnvasion gene expression up-regulator 0.2 60 1 350-366 950 PeptCl-like Peptidase Cl-like family 0.88 1.2 1 549-569 950 BK-channel-a Calcium-activated BK potassium 5.1le-07 22.5 1 598-702 9 channel 950 zf-CHC2 CHC2 zinc finger 0.76 4.9 1 739-769 950 Alpha adaptinC Alpha adapting AP2, C-terminal domain 0.31 3.1 1 894-900 950 CPSase_L_D3 Carbamoyl-phosphate synthetase large 0.72 1.1 1 1086 1098 9 50 -BK-channel a Calcium-activated BK potassium 0-.029 5.8 2 1132 channe 1171 951 Pep_Ml2Bprop Reprolysin family propeptide .5 80-198 ep 951 Reprolysin Reprolysin (M12B) family zinc metallo 1le-88 304.8 1 210-409 951 Fragilysin Fragilysin metallopeptidase (MlOC) en 0.28 3.8 1 342-355 951 Peptidase M46 Pregnancy-associated plasma protein-A 0.056 5.5 1 345-355 951 disintegrin Disintegrin 1.7c-39 134.2 1 426-501 951 EGF EGF-like domain 0.95 5.4 1631-654 953 ank Ankyrin repeat 4.4e-06 24.9 1 151-179 953 ank Ankyrin repeat 6.9e-09 35.0 183-215 953 ank Ankyrin repeat 0.15 8.6 3 216-248 953 ank Ankyrin repeat 9.7e-10 38.0 4 250-282 953 ank Ankyrin repeat 283-328 953 LolA Outer membrane lipoprotein carrier pr 1 3.0 1 953 ank Ankyrin repeat 3.8e-08 32.3 6 329-361 953 ank Ankyrin repeat 0.49 6.8 7 362-394 954 interferon Interferon alpha/beta domain 7.5e-42 144.5 1 16-105 955 ShTK ShTK domain 0.46 4.9 1 67-74 955 NADHdh NADH dehydrogenase 0.84 3.4 1 123-142 956 adh short short chain dehydrogenase 7.6e-27 92.5 1 31-137 956 sodcu Copper/zinc superoxide dismutase 0.059 5.9 1 670-87 (SOD 956 _Pex14_N Peroxisomal membrane anchor protein 0.21 5.0 1 95-105

I

WO 2004/080148 PCT/US2003/030720 523 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 956 CitF Citrate lyase, alpha subunit (CitF) 0.99 1.7 1 124-133 956 adhshort short chain dehydrogenase 6.2e-11 37.7 2 138-188 957 thiored Thioredoxin 1 4.4 1 69-96 957 Evr1 Air ErvI / Air family 5.le-17 62.5 1 354-441 957 GAF GAF domain 0.48 5.6 1 380-401 957 TFIIS Transcription factor S-II (TFIIS) 0.14 7.6 1 394-406 958 acid phosphat Histidine acid phosphatase 6.4e-36 125.6 1 32-179 958 acid phosphat Histidine acid phosphatase 8.5e-24 83.0 2 205-381 958 NicO High-affinity nickel-transport protei 0.99 2.9 1 398-416 959 serpin Serpin (serine protease inhibitor) 8.5e- 663.9 1 1-329 197 960 serpin Serpin shrinee protease inhibitor) 6.8e-87 295.8 1 45-191 960 serpin Serpin (serine protease inhibitor) 1.7c- 396.7 2 192-397 116 961 serpin Serpin shrinee protease inhibitor) 1.6e-63 216.1 1 45-158 961 serpin Serpin (serine protease inhibitor) 5e-139 472.0 2 159-397 962 serpin Serpin (serine protease inhibitor) 4.5e- 512.0 1 45-300 151 962 Molydopbindin Molydopterin dinucleotide binding 0.89 4.1 1 289-309 g dom 962 serpin Serpin (serine protease inhibitor) 4.9e-56 190.5 2 301-397 963 OprB Carbohydrate-selective porin, OprB fa 0.047 6.5 1 16-33 963 Alliinase C Allinase, C-terminal domain 0.63 4.1 1 45-58 963 Adeno ElA Early E lA protein 0.33 2.4 1 237-251 964 PepMl2Bjprop Reprolysin family propeptide 2.4e-47 148.0 1 112-220 ep 964 Reprolysin Reprolysin (M12B) family zinc metallo 1.9e-96 330.6 1 232-426 964 Astacin Astacin (Peptidase family M12A) 0.21 5.0 1 366-380 964 Phi_1 Phosphate-induced protein 1 conserved 0.51 3.3 1 414-426 964 disintegrin Disintegrin 5.8e-23 78.5 1 444-517 964 CBM 10 Cellulose or protein binding domain 0.47 6.8 1 481-499 964 EGF EGF-like domain 0.21 7.8 2 664-693 965 Uteroglobin Uteroglobin family 6.6e-09 29.8 1 1-88 966 7tm 2 7 transmembrane receptor (Secretin fa 0.96 2.6 1 19-38 966 GDA1_CD39 GDA1/CD39 (nucleoside phosphatase) 2.2e-93 315.4 1 48-483 fa 966 El Papillomavirus helicase 0.36 4.3 1 76-92 966 PLRVORF5 Potato leaf roll virus readthrough pr 0.72 1.6 1 143-161 966 Nicastrin Nicastrin 0.65 1.6 1 146-171 966 DUF462 Protein of unknown function, DUF462 0.55 4.7 1 371-390 966 Adeno E3B Adenovirus E3B protein 0.7 3.6 1 495-502 967 Clq CIq domain 6.1e-44 156.1 1 73-202 968 Omatin Ornatin 0.55 4.8 1 99-106 969 Ornatin Ornatin 0.55 4.8 1 134-141 969 Spo7 Spo7-like protein 1 1.5 1 405-417 969 MARVEL Membrane-associating domain 0.37 4.5 1 487-526 969 DUF202 Domain of unknown function DUF 0.23 5.7 1 493-518 970 ig Immunoglobulin domain 0.0038 14.6 1 41-124 970 ig Immunoglobulin domain 0.00023 19.2 2 163-230 970 Gag p30 Gag P30 core shell protein 3.6e-08 28.0 1 452-491 970 zf-CCHC Zinc knuckle 8.8e-07 27.8 1 523-540 971 Prefoldin Prefoldin subunit 0.66 5.0 1 179-206 971 SeryltRNA.N Seryl-tRNA synthetase N-terminal 0.92 5.7 1 179-196 doma WO 2004/080148 PCT/US2003/030720 524 TABLE 4B SEQ Model Description E value Score Repeats Position ID 971 Adeno_PIX Adenovirus hexon-associated protein ( 0.12 6.6 1 181-203 971 pentaxin Pentaxin family 2.3e-26 91.1 1 302-464 971 Avirulence Xanthomonas avirulence protein, Avr/P 0.07 3.6 1 439-453 972 ArsAATPase Anion-transporting ATPase 6.87 2.4 1 59-69 972 TSPN Thrombospondin N-terminal -like 0.88 2.7 1 223-255 domai 972 RHS repeat RHS Repeat 0.00085 15.6 2 239-266 972 RHS repeat RHS Repeat 6.6e-05 19.5 4 314-367 973 bZIP bZIP transcription factor -0.00024 17.2 1 623-686 973 integraseDNA DNA binding domain of tn916 0.38 6.3 1 657-693 integrase 973 CarD-TRCF CarD-like/TRCF domain 0.54 , 4.5 1 708-728 974 WD40 WD domain, G-beta repeat 0.05 9.9 1 2-27 974 DUF596 Protein of unknown function, DUF596 0.84 3.7 1 63-76 974 WD40 WD domain, G-beta repeat 0.29 7.2 3 76-109 974 denso VP4 Capsid protein VP4 0.81 1.5 1 355-364 974 TPR TPR Domain 0.1 9.1 1 742-767 974 ParamyxoC Paramyxovirus non-structural protein 0.74 2.8 1 784-800 974 Xylose isom Xylose isomerase 0.4 3.2 1 796-811 974 TPR TPR Domain 0.083 9.4 2 962-990 974 U-box U-box domain 0.036 6.5 1 1294 1308 975 cofilin ADF Cofilin/tropomyosin-type actin-bindin 0.97 4.0 1 6-18 975 Phage CII Bacteriophage CII protein 1 3.9 1 229-243 975 ion trans Ion transport protein 0.0048 11.5 1 247-408 975 Sarcolipin Sarcolipin 0.56 5.3 1 362-390 976 cofilin ADF Cofilin/tropomyosin-type actin-bindin 0.97 4.0 1 6-18 976 Phage CII Bacteriophage CII protein 1 3.9 1 303-317 976 iontrans Ion transport protein 0.0048 11.5 1 321-482 976 Sarcolipin Sarcolipin 0.56 5.3 1 436-464 977 zf-C2H2 Zinc finger, C2H2 type 0.083 11.8 1 4-27 977 zf-C2H2 Zinc finger, C2H2 type 0.00081 19.9 2 108-131 977 zf-C2H2 Zinc finger, C2H2 type 0.07 12.1 3 162-185 977 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.45 3.1 1 238-248 977 zf-C2H2 Zinc finger, C2H2 type 0.28 9.7 5 439-462 977 zf-C2H2 Zinc finger, C2H2 type 0.0026 17.9 7 600-623 977 zf-C2H2 Zinc finger, C2H2 type 0.047 12.8 9 886-908 977 zf-C2H2 Zinc finger, C2H2 type 0.66 8.2 11 1030 1053 977 zf-C2H2 Zinc finger, C2H2 type 0.025 13.9 14 1265 1288 977 adeno-fiber Adenoviral fibre protein (knob domain 0.076 3.5 1 1349 1357 977 zf-C2H2 16/34 1369 1392 .. 1 24 0.023 14.1 17 1470 1493 977 zf-C2H2 16/34 1369 1392.. 1 24 0.031 13.5 19 1577 1600 977 zf-C2H2 16/34 1369 1392.. 1 24 0.022 14.1 20 1660 1683 977 zf-C2H2 16/34 1369 1392.. 1 24 0.0044 16.9 23 1892 1914 977 zf-C2H2 16/34 1369 1392.. 1 24 0.41 9.0 24 1968 1990 977 DC1 DC1 domain 0.68 4.3 2 2049- WO 2004/080148 PCT/US2003/030720 525 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 2064 977 zf-C2H2 16/34 1369 1392.. 1 24 0.0039 17.2 25 2051 2073 977 zf-C2H2 16/34 1369 1392.. 1 24 0.0014 18.9 26 2085 2107 977 zf-C2H2 16/34 1369 1392.. 1 24 0.0094 15.6 27 2114 1 2137 977 zf-C2H2 16/34 1369 1392.. 1 24 0.041 13.0 28 2143 2166 977 zf-C2H2 16/34 1369 1392.. 1 24 0.033 13.4 30 2280 2303 977 TFIID-31 Transcription initiation factor IID, 0.28 5.7 1 2300 2315 977 zf-C2H2 16/34 1369 1392 .. 1 24 0.14 10.9 31 2314 2336 977 zf-C2H2 16/34 1369 1392.. 1 24 0.0018 18.6 32 2360 2382 977 zf-C2H2 16/34 1369 1392.. 1 24 0.016 14.7 33 2388 2411 977 HistoneHNS H-NS histone family 0.85 4.7 1 2423 2434 977 zf-C2H2 16/34 1369 1392 .. 1 24 3.6e-05 25.4 34 2474 2496 977 PdxA Pyridoxal phosphate biosynthetic prot 0.41 4.2 1 2540 2561 980 IGFBP Insulin-like growth factor binding pr 0.017 10.0 1 24-56 980 kazal Kazal-type serine protease inhibitor 9.3e-07 29.4 1 71-117 980 trypsin Trypsin 4.2e-24 74.5 1 167-326 980 LSM LSM domain 0.27 7.4 1 186-209 980 DUF771 Domain of unknown function 0.21 5.2 1 307-322 (DUF771) 980 PDZ PDZ domain (Also known as DHR or 7.le-14 50.6 1 332-427 GLGF 981 asp Eukaryotic aspartyl protease 6.6e-35 123.8 1 19-112 981 trans reg C Transcriptional regulatory protein, C 0.019 11.1 1 27-55 981 asp Eukaryotic aspartyl protease 1.8e-23 83.1 2 165-239 981 asp Eukaryotic aspartyl protease 0.0003 14.7 3 240-268 981 asp Eukaryotic aspartyl protease 1.7e-48 171.3 4 295-421 984 Zn carbOpept Zinc carboxypeptidase 1.2e-76 259.4 1 48-249 984 APC basic APC basic domain 0.53 2.7 1 279-292 985 Zn carbOpept Zinc carboxypeptidase 1.2e-76 259.4 1 48-249 985 APC basic APC basic domain 0.53 2.7 1 279-292 986 NifU N NifU-like N terminal domain 1.7c-80 277.6 1 34-160 987 SNF7 SNF7 6.6e-65 225.8 1 108-277 987 Glyco tran 28_C Glycosyltransferase family 28 C-termi 0.71 3.8 1 171-201 988 Rzl Lipoprotein Rzl precursor 0.92 4.2 1 1-35 988 UPARLY6 u-PAR/Ly-6 domain 6.4c-06 29.8 1 28-110 990 zf-C2H2 Zinc finger, C2H2 type 0.00035 21.4 1 53-78 990 zf-C2H2 Zinc finger, C2H2 type 0.012 15.2 2 87-114 990 zf-C2H2 Zinc finger, C2H2 type 0.0039 17.1 3 120-144 991 pkinase Protein kinase domain 3.2e-90 309.9 1 20-312 991 Glyco hydro 15 Glycosyl hydrolases family 15 0.18 4.4 1 472-522 992 Prefoldin Prefoldin subunit 0.12 7.6 1 5-44 992 spectrin , Spectrin repeat 0.00067 15.0 1 - 59-121 WO 2004/080148 PCT/US2003/030720 526 SEQ Model Description E-value Score Repeats Position ID 992 spectrin Spectrin repeat 5.4e-06 22.2 2 124-226 992 DUF16 Protein of unknown function DUF16 0.67 3.9 1 202-250 992 spectrin Spectrin repeat 5.2e-07 25.7 3 229-340 992 GSPII E N GSPIIE N-tenninal domain 0.07 7.7 1 265-290 9922.8e-05 19.8 4 343-449 992 TelA Toxic anion resistance protein (TelA) 0.75 3.2 1 405-437 992 spectrin Spectrin repeat 2e-06 23.7 5 452-538 992 spectrin Spectrin repeat 3.1c-13 47.2 6 781-888 992 DCP2 Dcp2, box A domain 0.57 4.2 1 823-837 992 MutS_11 MutS domain II 0.91 3.5 1 840-869 992 SAA proteins Serum amyloidAprotein 0.07 6.0 1 866-883 993 LysE LysE type translocator 0.02 8.8 1 127-147 994 Collagen Collagen triple helix repeat (9.2e-07 27.7 1 -118 994 CqClq domain 32 995 Allantoicase Allantoicase repeat 2.le-75 257.1 1 1-136 995 Allantoicase Allantoicase repeat 6.6e-58 197.5 2 159-319 996 DNA ligaie.A ATP dependent DNA ligase C terminal 0.67 5.4 1 11-34 Cr 996 ig Immunoglobulin domain 996 ig Immunoglobulin domain 0.15 8.7 2 182-243 996 ig Immunoglobulin domain 0.0031 15.0 3 275-335 996 SK-channel Calcium-activated SK potassium 0.035 7.1 1 363-383 996channe SK c l_ 997 PHPH domain 997 HS2ST Heparan sulfate 2-0-sulfotransferase 0.27 4.4 1 140-162 997 LMP LMPrepeatedregion 0.0012 14.2 1 160-181 997 DUF603 Protein of unknown function, DUF603 0.04 6.4 1 173-187 997 Pox A type inc Viral A-type inclusion protein repeat 0.32 7.2 1 173-187 997 IQ IQ calmodulin-binding motif 5e-05 20.1 1 206-226 997 RhoGEF RhoGEF domain 1.2e-69 236.9 1 -247-428 997 DUF674 Protein of unknown function (DUF674) 0.82 1.4 1 275-285 997 Stig1 Stigma-specific protein, Stigi 0.6 1 376-421 997 dmain 2.3e-13 45.3 2 460-588 997 RasGEFN G uaninc nucleotide exchange factor fo 1 le-19 71.3 1 633-688 997 RasGEF RasGEF domain 7.2e-89 305.4 1 999 1184 9 97_ Adeno-terminal- Adenoviral. DNA terminal protein 1 1.7 1 1175 1207 998 DUF630 Protein of unknown function (DUF63O) 0.7 4.3 1 692-705 98 FcF Fibroblast growth factor2.4 1 2-3 98 tRNA-syntG2 tRNA s thEtases class m (D, K and N 0.74 3.5 1 754-766 998 Omega-atracotox Omega-atracotoxin 0.15 5.1 1 859-866 999 K tetra K+ channel tetramerisation domain 2e-34 121.3 1 26-114 999 BTB BTB/POZ domain .00 15 4.2 1 74-125 1000 PXA P A domain 0.01 10.2 1 84-104 1000 Vps,52 Vps52 / Sac2 family 0 1099. 1 94-601 1000 trp syntA Tryptophan synthase alpha chain 0.78 3.1 1 173-210 1000 DUF965 Bacterial protein of unknown function 0.33 4.5 1 285-298 1000 Vps53LN Vps53-like, N-terminal 0.93 2.7 1 565-585 1001 PHD PHD-finger 3.8e-06 20.3 1 1-24 1001 rubredoxin Rubredoxin 0.55 5.9 1 14-28 100A1 Orbi NS3 Orbivirus NS3 .183 2.8 1 435-458 1001 d aNosL NosL 0.29 4.9 1 1297- WO 2004/080148 PCT/US2003/030720 527 TABLE 4B SEQ Model Description E_.value Score Repeats Position ID 1321 1001 NAC NAC domain 0.76 5.5 1 1343 1365 1001 DUF240 MG032/MG096/1MG288 family 2 0.17 6.7 1 1369 1384 1002 RecR RecR protein 0.97 6.3 1 104-118 1002 |zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 2c-09 26.7 1 108-147 1002 DC1 DCI domain 0.045 7.9 1 184-213 1002 PHD PHD-finger 6.5e-21 66.9 2 185-233 1002 zf-MYND MYND finger 0.7 4.3 1 186-204 1002 rubredoxin Rubredoxin 0.55 5.9 1 223-237 1002 Orbi NS3 Orbivirus NS3 0.83 2.8 1 644-667 1002 NosL NosL 0.29 4.9 1 1506 1530 1002 NAC NAC domain 0.76 5.5 1 1552 1574 1002 DUF240 MG032/MG096/MG288 family 2 0.17 6.7 1 1578 1593 1003 Patched Patched family 0.069 4.7 1 405-442 1003 ISAV HA Infectious salmon anaemia virus haema 0.23 _1 716-738 1003 WD40 WD domain, G-beta repeat 0.00019 18.3 1 767-802 1003 WD40 WD domain, G-beta repeat 0.71 5.9 2 958-992 1003 WD40 WD domain, G-beta repeat 4.2e-05 20.6 3 1069 1104 1003 WD40 WD domain, G-beta repeat 4.le-09 34.6 4 1109 1145 1003 WD40 WD domain, G-beta repeat 0.0012 15.6 5 1150 1185 1004 ZZ Zinc finger, ZZ type 1e-12 48.2 1 3-48 1004 SoxD Sarcosine oxidase, delta subunit fami 0.97 4.2 1 77-84 1004 zf-C2H2 Zinc finger, C2H2 type 0.00067 20.3 1 -78-101 1004 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.3 3.6 1 93-113 1004 SPDY Domain of unknown function 0.6 4.4 1 117-131 (DUF317) 1004 Dil9 Drought induced 19 protein (Dil9) 0.00056 13.0 1 312-328 1006 C2 C2 domain 7e-08 28.1 1 189-259 1006 HHE Domain of Unknown function 0.13 7.5 1 216-235 1006 C2 C2 domain 1.3e-18 64.3 2 304-394 1007 RmuC RmuC family 0.79 3.1 1 4-34 1007 IBN NT Importin-beta N-terminal domain 2.le-27 99.5 1 22-101 1007 Peripla BP like Periplasmic binding proteins an s 0.21 4.7 1 130-161 1008 Las1 Las1-like 1.6e-94 320.7 1 38-186 1008 MuDR MuDR family transposase 0.17 5.5 1 214-246 1008 BAR BAR domain 0.21 5.2 1 330-346 1008 Adeno ElB 19K Adenovirus ElB 19K protein / small t- 0.43 4.6 1 517-541 1008 META Domain of unknown function (306) 0.7 5.7 1 615-648 1009 HrpF HrpF protein 0.64 4.5 1 248-257 1009 ArfGap Putative GTPase activating protein fo 4.8e-38 133.0 1 250-373 1009 ank Ankyrin repeat 3.2e-05 21.8 |1 411-446 1009 ank Ankyrin repeat 0.00019 19.0 2 447-479 1009 DMRL synthase 6,7-dimethyl-8-ribityllumazine syntha 0.35 5.0 1 479-494 1009 hormone Somatotropin hormone family 0.5 1.6 i1 545-561 1009 tubulin-binding Tau and MAP protein, tubulin-binding _0.11 8.0 1 828-844 WO 2004/080148 PCT/US2003/030720 528 TABLE 4B SEQ Model Description E-value Score Repeats Position ID 1009 SH3 d 5.8e-12 46.6 1 881-938 1010 Bromo CP Bromovirus coat protein 0.16 5.5 1 1-12 1011 ig Immunoglobulin domain 0.004 14.6 1 27-45 1011 ig Immunoglobulin domain 3.9-05 22.1 2 80-148 1011 ig Immunoglobulin domain 3.7-10 40.9 3 183-242 1011 ig Immunolobulin domain 0.0018 15.9 4 281-342 1011 ig Immunoglobulin domain 3.7e-08 33.4 5 379440 1011 DNA polBj DNA polymerase type B, organellar 0.018 7.9 1 396-452 and 405 427 1011 OapA Opacity-associated protein A 0.44 2.4 1011 ig mmunoglobulin domain 0.0012 16.6 6 474-535 1011 ig Immunoglobulin domain 7.7e-07 28.5 7 570-634 1013 denso VP4 Capsidprotein VP4 0.23 3.4 1 166-185 1015 efhand EFlhand 2.8e-08 33.9 1 29-57 1015 COXI7 Cytochrome C oxidase copper 0.42 4.2 1 54-61 _________chaperone

-

1015 efhand EFhand 0.0033 15.3 2 65-93 1015 efhand EFhand 8.5e-05 21.1 3 102-130 1015 PCRF PCRF domain 6.1 1 129-145 1015 DUF21 DomainofunknownfunctionlDUF 2 1 18 .4 1 1015 efhand EFhand 5e-09 36.7 138-166 1016 UPF0061 Uncharacterized ACR, YdiUIUPFOO61 3.9e-74 256.4 1 2-279 fain 1016 Flavodoxin 2 Flavodoxin-like fold 0.66 3.3 1 373-388 1016 UPF0061 UncbaracterizedACR, YdiU/UPFOO61 1.2e-05 19.1 2 403-444 ___ __________ fai 1017 UPF0061 UncharacterizedACR, YdiU/UPFOO61 le-39 140.9 farn 1017 UPF0061 UncharacterizedACR, YdiU/UPFOO61 6.8e-52 182.6 2 431-611 fain ____ __________ 1017 Flavodoxin 2 Flavodoxin-like fold 705-720 1017 UPF0061 Uncharacterized ACR, YdiUIUPFOO61 1.2e-05 fain 1018 7tm_1 7 transmembrane receptor (rhodopsin f .e-88 264.6 1 87-350 1018 DUF395 YeeE/YedE family (DUF395) 0.94 4.7 1 188-205 1019 LRRNT Leucine rich repeat N-terminal domain 0.12 7.7 1 42-56 1019 LRR LeucineRichRepeat 0.12 8.2 1 82-105 1019 LRRLeucine Rich Repeat 0.0019 14.3 3 1019 LRR LeucineRichRepeat 0.03 11.6 4 158-181 1019L 0.00023 17.5 5 182-205 1019 LRR LecRich Repeat 0.31 6.9 6 206-226 1019 LRR Leucine Rich Repeat 0.22 7 8 251-272 1019 LRR 9/18 273 283.. 1 11 0.00057 16.1 10 329-352 1019 LRR 9/18 273 283.. 1 11 0.004 13.3 12 377-402 1019 LRR 9/18 273 283.. 1 11 0.0013 14.9 13 403-426 1019 LRR 9/18 273 283.. 1 11 0.27 7.1 14 427-439 1019 LRR 9/18 273 283.. 1 11 0,16 7.9 15 463-484 1019 LRR 9/18 273 283.. 1 11 0.8 5.5 6 486-510 1019 LRR 9/18273 283.. 1 11 0.035 10.1 7 7-558 1019 TIMELESS Timeless protein 0.45 3.0 1 3-568 1019 LRR 9/18 273 283 .. 1 11 0,084 8.8 18 559-582 1020 AMP-binding AMP-binding enzyme 4.5e-49 173.2 1-177 1020 RNA polRpc4 RNA polymerase III RPC4 0.62 4.2 1 189-199 Br s Phae GP3o.8 protein 0.92 .6 1 -2 WO 2004/080148 PCT/US2003/030720 529 TABLE lB SEQ Model Description E-value Score Repeats Position ID_ _ 1021 SKIPSNW SKIP/SNW domain 0.3 4.7 1 92-113 1021 cNMP binding Cyclic nucleotide-binding domain 0.55 5.2 1 102-132 1021 cytochrome_ C oclrome c 0.92 3.7 1 313-329 1021 cNMP_binding Cyclic nucleotide-binding domain 1.5e-15 57.4 2 345-435 1021 RasGEFN Guanine nucleotide exchange factor fo 0.00023 17.5 1 460-504 1021 Pseu avirulence Avirulence protein 0.91 1.9 1 491-504 1021 PDZ PDZ domain (Also known as DHR or 5.2c-19 68.7 -661 GLGF 10O21 RA Rsaociation (RaIGDS/AF-6) 2.6e-08 32.5 1 806-885 domain 10O21 R-asGEF RasGEF domain 2.7e-48 170.6 1 907 102 A1092 1022 SKIP SNW SKIP/SNW domain 0.3 4.7 1 42-63 1022 cNMP binding Cyclic nucleotide-binding domain 0.55 5,2 1 52-82 1022 cytochrome c Cytochrome c 0.92 3.7 1 263-279 1022 cNMPbinding Cyclic nucleotide-binding domain 1.5e-15 57.4 2 295-385 1022 RasGEFN Guanine nuetide exchange factor fo 0.00023 17.5 1 410-454 1022 Pseu avirulence Avirulence protein 0.91 1.9 1 441-454 1022 PDZ PDZ domain (Also known as DHR or 5.2e-19 68.7 530-611 SGLGF 1022 RA Ras association (RaIGDS/AF-6) domain 1022 RasGEFRasGEF domain 7e-48 170.6 1 857 1042 1026 Ricin B lectin QXW lectin repeat 0.14 8.3 1 134-161 1026 MCR_betaN Methyl-coenzyne M reductase beta 0.98 2.1 1 152-160 subu 1026 RicinB lectin QXW lectin repeat 4.5e-07 28.1 2 196-225 1026 Ricin B lectin QXW lectin repeat 0.0012 15.8 3 226-265 1027 SCF tem cell factor 2.9e- 512.2 1 1-214 155 1027 FH2 Formin Homology 2 Domain 0.027 8.8 1 145-162 1027 Herpes UL7 Herpesvirus U17 like 0.072 7.6 1 176-215 1028 cadherin Cadherin domain 3.4e-12 44.2 1 50-131 1028 cadherin Cadherin domain 1.7e-22 80.1 2 155-250 1028 cadherin Cadherin domain 6e-20 71.3 3 -264-342 1028 cadherin Cadherin domain 5.9e-21 74.8 4 379-452 1028 cadherin Cadherin domain 0.0035 12.8 5 521-567 1029 cadherin Cadherin domain 3.4e-12 44.2 1 50-131 1029 cadherin Cadherin domain 1.7e-22 80.1 2 155-250 1029 cadherin Cadherin domain 6e-20 71.3 3 264-342 1029 cadherin Cadherin domain 1.8e-22 8.0 4 379-470 1029 cadherin Cadherin domain 0.0035 12.8 5 483-529 1030 Troponin Troponin 0.87 3.1 1 21-117 1030 MycoplasmaM Mycoplasma arthritidis MAA2 repeat 0.65 3.7 1 518-527 AA2 1030 PH PH domain 6.5e-14 47.1 1 522-624 1 030 DUF1041 Domain of Unknown Function 3.4e-79 273.2 l 738-950 (DUFD4) 1030 Allene ox_cyc Allene oxide cyclase 0.7 2.8 1 817-852 1031 Renal dipeptase Renal dipeptidase 1.9e- 370,4 1 74-354 1031 Amidase 3 N-acetylmuramoyl-L-alanine amidase 0.76 3.8 222-234 1032 TrpTyr per C Tryptophan/tyrosine permease family 0.0026 10.3 1 42-63 WO 2004/080148 PCT/US2003/030720 530 TABLE 4B _ _ SEQ Model Description E-value Score Repeats Position ID _ 1032 aa ermeases Amino acid permease 8.4e-32 115.8 1 48-371 1032 Pox 15 Poxyirus protein 15 0.24 6.0 1 162-179 1032 shrine carbpept Serine carboxypeptidase 0.41 2.3 1 378-398 1033 THF DHG CYH Tetrahydrofolate dehydrogenase/cycloh 0.027 6.2 1 89-108 1033 THF DHG CYH Tetrahydrofolate dehydrogenase/cycloh 6.le-13 37.3 2 119-180 1033 THF DHG_CYH Tetrahydrofolate dehydrogenase/Cycloh 6.5e-07 25.7 1 182-229 C 1033 FTHFS Formate--tetrahydrofolate ligase 0 1365. 1 360-979 1034 acid phosphat Histidine acid phosphatase 0.038 6.9 1 378-394 1034 FMIN red NADPH-dependent FMN reductase 0.94 3.3 1 425-446 1034 acid phospat Histidine acid phosphatase 0.02 7.9 2 512-581 1034 RibosomalL6 Ribosomal protein L6 0.21 7.2 1 760-800 1035 PDZ PDZ domain (Also known as DHR or 3.2e-14 51.8 1 47-111 GLGF 1035 DUF62 Protein of unknown function DUF62 1 1 1035 AraC binding AraC-like ligand binding domain 0.99 3.9 1 139-198 1035 Armadilloseg Armadillo/beta-catenin-like repeat 0.97 5.6 1 170-187 1035 HCV NS4a Hepatitis C virus non-structural prot 0.057 8.8 1 319-348 1035 RasGAP GTPase-activator protein for Ras-like 0.37 3.6 1 764-783 1035 RhoGEF RhoGEF domain 1.7e-28 97.2 1 778-962 1035 SH2 SH2 domain 0.98 3.2 1 819-829 1035 PH PH domain 4.2e-05 18.0 1 1006 ____1119 1035 SelPN Selenoprotein P, N terminal region 0.25 3.7 1 1112 1138 1037 PH PH domain 6.7e-14 47.1 1 17-124 1037 efhand EFhand 9.2e-05 21.0 1 138-166 1037 efhand EFhand 0.0023 15.8 2 174-202 1037 PI-PLC-X Phosphatidylinositol-specific phospho 5.9c-17 60.5 1 291-326 1038 DUF765 Circovirus protein of unknown function 0.85 3.7 1 274-302 1039 ABG transport A transporter family 0.81 1.2 1 - 13-26 1039 7tm_1 7 transmembrane receptor (rhodopsin f 7.4e-29 85.1 -289 1039 HECT HECT-domain (ubiquitin-transferase) 0.15 5.5 1 273-290 1040 TSPN Thrombospondin N-terminal -like 1.4e-41 136.6 1 1-101 domai ___ 1040 TIL Trypsin Inhibitor like cysteine rich 0.66 3.9 1 195-239 1040 EGF EGF-like domain 0.0046 13.8 1 199-233 1040 Baculo LEF-3 Nucleopolyhedrovirus late expression 0.0024 10.4 1 230-244 1040 EGF EGF-like domain 0.51 6.4 2 239-269 1040 Mu-conotoxin Mu-Conotoxin 0.63 5.2 1 283-304 1040 dickkopf N Dickkopf N-terminal cysteine-rich reg 0.94 3.5 1 292-299 1040 laminin EGF Laminin EGF-like (Domains III and V) 0.45 5.6 1 311-327 1040 EGF EGF-like domain 4.3e-05 21.1 4 333-366 1040 tsp 3 Thrombospondin type 3 repeat 0.00027 16.9 1 405-417 1040 tsp3 Thrombospondin type 3 repeat 0.032 10.2 2 418-433 1040 tsp3 Thrombospondin type 3 repeat 0.0046 13.0 3 441-453 1040 tsp_3 Thrombospondin type 3 repeat 0.00087 15.3 4 464-476 1040 tsp3 Thrombospondin type 3 repeat 0.023 10.7 5 477-492 1040 tsp 3 Thrombospondin type 3 repeat 0,00058 15.9 6 500-512 1040 tsp 3 Thrombospondin type 3 repeat 0.0033 13.4 7 523-535 1040 tsp_3 Thrombospondin type 3 repeat 0.0011 150 8 538-553 1040 tsp3D Thrombospondin type 3 repeat 0.0a057 15.9 561-573 1040 tsp 3 1SThrombospondin type 3 rpeat 0,0015 14.6 11 61-613 WO 2004/080148 PCT/US2003/030720 531 TABLE 4B SEQ Model Description E value Score Repeats Position ID 1040 tsp 3 Thrombospondin type 3 repeat 0.03 10.3 12 614-629 1040 TSPC Thrombospondin C-terminal region 71le- 5944 1 654-854 176 1040 Mndl MdI family 0.68 3.4 1 853-861 1042 sodcu Copper/zinc superoxide dismutase 2.0 1 31-44 - ~~~(SOD -- 3 -5 1042 DapB C Dihydrodipicolinate reductase, C-tenn 0.84 45 1 1042 PTR2 POT family 3e-55 193.1 1 103-335 1042 PTR2 POT family 1.5e-36 127.7 2 336-471 1042 Adeno PIX Adenovirus hexon-associated protein 0.76 3.8 1 493-508 1043 Drf GBD Diaphanous GTPase-binding Domain 1.7e-60 211.1 1 40-229 1043 DUFOOO Domain of Unknown Function 0.79 3.3 1 141-157 (DUF1000) F 10443 D-r2f FZiH3 inger CH2 type 2-1 30.3 1 3-41 10443 | -C2H2 Zi S-antigenr, t ype 0.e- 3.2 1 42-444 10443 AbZIP E rii fay 0.8 .4 1 44-468 1f04-3 |eRF1_1 -R 1d-anIO5 8-0 1043 |CHASE3 HS3dmi0.2 9. 14857 1043 [Pox_.A type inc 14 4948. 301

.

9-1 1044 zf-C2H2 Zin finge, C22 type 6.e- 31.7 1 5-472 1044 XPiA Pruimdie te in .25 .9 2 42950 104 TFIISBbo .e-7 10. 184 10O44 zf-C2H12ZicfneCHtye0026 1. 10o44 XPA N X A p oenN t r i a .1 - 1f044 TFIIS rncito atrS1 T I)01

.

4-5 10 44 zf-C2H12 -ln igr 2tp .e0 . 4-6 1044 TFIISApoti -trial04

.

7 1044 zfC2H2ZicfneCHtye406 2. 31719 1044 zf-C2H2 ZicfneCHtyeT 1044 XPA N4132325. 1 1304 5. 52126 1044 eIF5 eIF2B Doanfudi FBF5091 24-6 1044 TFIISTrncito trS1 TIS0.6 8. 625-4 1044 Transposase_12 Tasoae01 . 5-8 1044 zf-C2H2ZicfneC11tye5907 3. 624-6 1044 zf-BED BDzn igr01 . 5-7 1j044 XRPA-N4/3 2325. 1 1301 76 629-1 1044 TFIISTrncitofatrS1 TIS0.5 75-- 2829 1044 zf-C2H2ZicfneCHtye8307 3. 72234 1044 zf-C2H2 incigrC21tye4606 2. 83032 1044 zf-C2H2ZicfneCHtye5306 2. 938-0 10T44 zTf--C2H2 Zn igr 22tp e0 92 1 6-8 10 44 X5PA N4/3 2325. 1 1308 50 83943 10O44 TfF I -IS101 36 37. 31 30.5 .8 - 1 3944 1044 zf-C2H2 Zn igr 22tp .e0 03 1 9-1 ..1044 zf-C2H2ZicfneC12tp7.c0 281 2 42-4 1044 Evr1 Arv Alrfml .8 . 4-6 1044 zf-C2H2ZicfneC12tp13 45-7 10 ~ ~ ~ TAL 4BE9,2 6-0 104CoiIppr/zain supe ro eimuAs 1 .0 2 .0 1314 WO 2004/080148 PCT/US2003/030720 532 SEQ Model Description E-value Score Repeats Position ID 1044 XPA 41 3 235.. 1 13 0.45 5.9 9 475-487 1044 eIF5 e[F2B Domain found in IF2B/1F5 0.95 3.5 2 8-488 1044 TFIIS 12/18 424 432.. 31 39 0.069 8.7 14 478-488 1044 zf-C2H2 Zinc finger, C2H2 te 2.3e-06 30.2 14 478-500 1044 zf-C2H2 Zinc finger, C212 tpe 6.2e-05 24,4 15 506-528 1044 zf-C2H2 Zinc finger, C2H2 type 1.le-07 35.5 16 534-556 1044 TFIIS 12/18 424 432.. 31 39 0.78 5.1 15 536-544 1044 TFIIS 12/18 424 432. 31 39 0.12 7.9 16 562-572 1044 zf-C2H2 Zinc finger, C2H2 type 2.5e-06 30.0 17 562-584 1044 TFIIS 12/18 424 432 31 39 0.25 6.8 17 590-600 1044 zf-C2H2 Zinc finger, C212 type 6.2e-08 36.5 590-612 1044 UmbravirusLD Umbravirus long distance movement 0.56 2.8 1 601-626 M (LD ___ 1044 TFIIS 12/18 424 432.. 31 39 0.062 8.8 18 618-628 1044 zf-C2H2 Zinc finger, C2H2 type 36e-07 33.4 19 618-640 1044 zf-BED 3/7 423 445.. 24 52 0.027 9.3 7 619-641 1045 Sprouty Sprouty protein (Spry) 1.2e-17 55.0 1 33-70 1045 Sprouty Sprouty protein (Spry) 2.7e-10 31.5 2 73-90 1046 RAMP HAMP domain 0.21 7.3 1 9-42 1046 PA PA domain 3.6e-19 65.4 1 155-255 1046 PeptidaseM28 Peptidase family M28 7 _4e- 0.8 1 332-585 120 1046 Borrelia lipo Borrelia burgdorferi virulent strain 0.98 2.5 1 591-604 1046 TFR dimer Transferrin receptor-like dimerisatio le-65 228.5 1 597-739 1047 GvpG Gas vehicle protein G 0.088 6.7 1 ___ 17-49 1048 Sema Sema domain 3.2e-08 29.3 1 34-127 1048 ABM Antibiotic biosynthesis monooxygenase 0.74 5.7 1 192-208 1048 Sema Sema domain - 2 386-449 1048 PSI Plexin repeat 2.3e-20 65.3 1 468-519 1048 PSI Plexin repeat 1.4e-12 41.0 2 759-801 1048 TIG TIG domain 1.6c-20 78.3 1 803-893 1048 TIG IPT/TIG domain 4.5e-19 73.5 2 895-980 1048 TIC-6 IPT/TIG domain 3.3e-13 51.7 3 983 1092 1048 Competence Competence protein 0.77 1 1181 1224 1048 RNB RNB-like protein 0.064 6.4 1 1389 1412 1048 FimbrialK88 Fimbrial, major and minor subunit 0.15 5.4 1 1461 1470 1048 ubiquitin Ibiquitin family 0.021 10.4 1 1463 1497 1049 BTB BTB/POZ domain 4.5e-28 102.9 1 20-124 1050 ABC tran ABC transporter 8.3e-40 134.3 1 26-217 1050 DU1F908 Domain of Unknown Function 0.5 5 31 169-83 (DUF918) 1050 RhoGAP RhoGAP domain 0.058 7.1 1 69-82 1050 ChlamydiaPMP Chiamydia polymorphic membrane 0.63 2.9 546-565 protei 1051 ZZ Zincfinger,ZZt c le-12 48,2 1 3-48 1051 SoxD Sarcosine oxidase, delta subunit fami 0.97 4.2 1 77-84 1051 zf-C2H2 Zinc finger, C2H2 type 0.00067 20.3 1 78-101 1051 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.3 3.6 1 93-113 1051 FSDY Domain of unknown function 0.6 4.4 1 117-131 WO 2004/080148 PCT/US2003/030720 533 TABLE 4B SEQ Model Description -value Score Repeats Position ID 1051 Dil9 Droughtinduced19protein(Dil9) 0.00056 13.0 1 312-328 1052 ig Immunoglobulin domain 7e-12 47.4 1 -110 1052 MyTH4 MyTH4 domain 034 5.6 1 141-152 1052 ig Immunoglobulin domain 0.0023 15.5 2 150-204 1053 kringle Kringle domain 0.031 8.7 1 36-64 1053 WSC WSC domain .3e-06 2.6 1 9-142 1053 CUB CUB domain 1.4e-15 52.5 1 156-260 1054 ig Immunoglobulin domain 1.7e-05 23.4 1 36-113 1054 PhagecapE Phage major capsid protein E 0.79 2.8 1 T-- -127-136 1055 MHCI Class I histocompatibility antigen, d le-146 497.6 1 25-203 1055 DUF497 Protein of unknown function (DUF497) 0.2 6.7 1 43-56 1055 ig Immunoglobulin domain 5.4e-09 36.5 1 220-285 1055 DUF395 YeeE/YedE family (DUF395) 07.2 1_310-335 1056 LBP BPI CETP LBP / BPI CBTP family, C-terminal d 5.8e-05 18.1 1 56-139 C 1057 LBP BPI CETP LBP / BPI CETP family, N-terminal d 5.le-38 130.2 1 22-185 1057 LBPBPICETP LBP / BPI CBTP family, C-terminal d 1.6e-12 45.3 1 291-429 C 1057 Peptidase M20 Peptidase family M20/M25/M40 0.3 4.0 1 380-419 1058 LBP_BPI CETP LBP / BPI / CETP family, N-terminal d 5.le-38 130.2 1 22-185 1058 LBP_-BPI_-CETP LBP / DPI / CETP family, C-terminal d 5.8e-05 18.1 1 291-374

-

C 1059 LBPBPI CETP LBP / BPI / CETP family, N-terminal d 3.3e-41 141.1 1 39-201 1059 LBPBPICETP LBP / PI / CETP family, C-terminal d 5.8c-05 18.1 1 307-390 - C 1060 SIcretograninmV Neuroendocrine protein 72 precursor 2.2e- 4. 1 1-204 -134 ____ 1060 RibosomaldL9e Ribosomal protein Ll9e 0.7 3.6 1 167-193 1062 PMP22 Claudin PMP-22/EMP/MP2OIClaudin family 6.9e-46 159.3 1 4-181 1062 Acyltransf 3 Acyltransferase family 0.12 6.3 1 106-151 1063 RibosomaldL29e Ribosomal L29e protein family 0.0025 12.9 1 21-49 1064 PDZ PDZ domain (Also known as DHR or 7.6e-1 40.0 1 1-84 GLGF 1064 PDZ PDZ domain (Also known as DHR or 4.2e-10 37.4 2 209-297 GLGF 1064 PDZ PDZ domain (Also known as DHR or 2.4e-16 59.3 3 3 10-393 GLGF 1064 CBM 11 Carbohydrate binding domain (family 0.18 5.1 1 360-378 1064 PDZ PDZ domain (Also known as DHR or 7.3e-19 68.1 4 409-490 GLGF 1064 DUF390 Protein of unknown function (DUF397) 0.82 0.7 1 534-555 1064 PDZ PDZ domain (Also known as DHR or 2.6e-09 34.6 5 694-775 GLOF 1065 PID Phosphotyrosine interaction domain (P 3.3e-47 160.5 1 42-168 1066 Galactosyl T Galactosyltransferase 0.17 5.8 1 106-116 1066 Chorismate synt Chorismate synthase 0.8 1.6 1 291-298 1067 pkinase Protein kinase domain le-73 255.1 1 12-272 1068 lipocalin Lipocalin / cytosolic fatty-acid bind 7e-38 136.0 1 38-186 1068 Triabin Triabin 0.0018 12.1 1 119-136 1069 lactamase B Metallo-beta-lactamase superfamily d 1.7e-21 80. 1 11-172 1070 annexing Annexin 9.9e-30 107.8 1 58-124 1070 annexin Annexin 6.3e-33 119.1 2 130-196 1070 annexing Annexin 9.7e-28 100.7 3 213-2801 WO 2004/080148 PCT/US2003/030720 534 TABLE 4B SEQ Model Description E value Score Repeats Position ID 1070 annexin Annexin 4.3e-33 119.8 4 289-355 1071 SNF Sodiun:neurotransmitter symporter 0 1200. 1 44-574 fain 7 ___ 1071 ATP-sulfurylase ATP-sulfurylasc 0.28 3.8 1 198-220 1071 DUF900 Protein of unknown function (DUF900) 0.98 2.8 1 408-420 1072 ig Immunoglobulin domain 1073 Glypican Glypican 3.9e- 979.9 1 3-566 292 1074 zf-C2H2 Zinc finger, C2H2 type 1 7.4 1 16-40 1074 rrm RNA recognition motif. (a.k.a. RRM, R 9.2e-10 36.8 1 58-123 1074 PAP assoc PAP/25A associated domain 1.6e-14 51.8 1 490-549 1074 Isochorismatase Isochorismatase family 0.49 4.1 1 700-736 1075 PgpA Phosphatidylglycerophosphatase A 0.92 3.0 1 12-27 1075 SLT Transglycosylase SLT domain 0.23 6.2 1 82-112 1075 cNMP binding Cyclic nucleotide-binding domain 0.67 4.9 1 173-196 1075 Glyco transf_29 Glycosyltransferase family 29 (sialyl 1.6e-22 7.6 1 289-506 1076 Sec23_trunk Sec23/Sec24 trunk domain 0.47 4.0 1 42-53 1076 Hydrolase haloacid dehalogenase-like hydrolase 0.77 3.7 1 46-76 1078 A2MN Alpha-2-macroglobulin family N- 4.5e-91 312.7 1 6-613 termin 108Bigi1 Bacterial Ig-like doangopT)062 3 .9 1 382-403 1078 Big_1i grup1 1078 A2M Alpha-2-macroglobulin family 6.2e-64 214.2 1 721-949 1078 A2M Alpha-2-macroglobulin family 6.2e- 444.2 2 983 132 1469 1078 PoxD2 Pox virus D2 protein 0.18 3.4 1 1446 1461 1079 A2MN Alpha-2-macroglobuais family N- 1.5e-92 317.7 1 19-626 Stermin 1079 BigP1 Bacterial Ig-like domain (group 1) 0.62 .9 1 395-416 1079 A2M Alpha-2-macroglobulin family 3e-44 47.6 1 836 1079 kringle Kringle domain 0.077 7.4 1 840-859 1080 A2MrN Alpha-2-macroglobulin family N- 2e-65 227.5 1 6-548 termin 1080 BigPI Bacterial Ig-like domain (group 1) 0.62 3.9 8 1 -403 1081 A2MIN Alpha-2-macroglobulin family N- 4.5-91 312.7 1 6-613 termin 1081 Big Bacterial Ig-like domain (group 1) 0.62 3.9 1 382-403 1081 A2M Alpha-2-macroglobuLTin family 6.2e-64 214.2 1 721-949 1081 A2M Alpha-2-macroglobulin family 3.2e- 462.1 2 983 137 1469 1081 PoxD2 Poxevirus D2hprotein 0.18 3.4 1 1446 1461 1082 A2MN Alpha-2-macroglobulin family N- 4.5e-92 317.7 1 6-613 termin 1082 Big_ 1Bacterial Ig-like domain (group 1) 0.62 3.9 1 382-403 1082 A2M Alpha-2-macroglobulin family 3e-44 147.6 1 722-823 1082 kringle Kringle domain 0.077 7.4 1 827-846 1083 COesterase Carboxylesterase i.4e- 649.9 1 8-547 19214 1083 A2MN Alpha-2-macroglobulin family N- 0.83 23 1 12-28 termin 1084 EGF EGF-ik-e domain 2.8e-05 21.8 1 192-219 1084 amini e F Laminin EGF-like (Domains 11 and V) 0.37 5.9 1 208-220 1084 Taomerase Tautomeras enzyme 0.14 5.5 1 292-318 WO 2004/080148 PCT/US2003/030720 535 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 1084 EGF EGF-like domain 9.9e-07 27.0 2 404-431 1084 Arthro defensin 1/3 199 211 .. 23 36 0.52 3.0 2 411-423 1084 TB TB domain 1.3e-16 54.5 1 567-610 1084 EGF EGF-like domain 1.le-07 30.4 3 631-666 1084 MoeZ MoeB MoeZ/MoeB domain 0.62 3.6 1 676-682 1084 TB TB domain 2.9e-26 85.2 2 688-729 1084 EGF EGP-like domain 1.9e-07 29.6 4 878-914 1084 TIL Trypsin Inhibitor like cysteine rich 0.00021 14.8 2 898-920 1084 CBM_14 Chitin binding Peritrophin-A domain 0.88 3.8 1 901-920 1084 EGF EGF-like domain 1.2e-07 30.3 5 920-956 1084 TIL Trypsin Inhibitor like cysteine rich 0.00057 13.5 3 941-962 1084 squash Squash family serine protease inhibit 0.069 4.9 1 942-969 1084 granulin Granulin 0.06 7.4 1 943-958 1084 EGF EGF-like domain 0.098 ' 9.0 6 962-983 1084 VSP Giardia variant-specific surface prot 0.031 7.4 1 982 1003 1084 EGF EGF-like domain 5.2c-06 24.4 7 1043 1078 1084 EGF EGF-like domain 1.6e-06 26.2 8 1084 1119 1084 TIL 5/14 1063 1084.. 47 68 0.98 .3.3 6 1103 1125 1084 VSP Giardia variant-specific surface prot 0.29 3.9 2 1105 1126 1084 EGF EGF-like domain 2.1e-06 25.9 9 1125 1160 1084 TIL 5/14 1063 1084 .. 47 68 0.0095 9.6 7 1145 1166 1084 EGF EGF-like domain 5.9e-05 20.6 10 1166 1201 1084 PlasmodPvs28 Plasmodium ookinete surface protein P 0.11 6.2 1 1172 1210 1084 TIL 5/14 1063 1084.. 47 68 0.0044 10.7 8 1187 1207 1084 EGF EGF-like domain 5.5e-06 24.3 11 1207 1243 1084 PADporph Porphyromonas-type peptidyl-arginine 0.047 8.4 1 1224 1234 1084 PlasmodPvs28 Plasmodium ookinete surface protein P 0.57 3.6 2 1226 1281 1084 TIL 5/14 1063 1084.. 47 68 0.016 8.9 9 1228 1249 1084 VSP Giardia variant-specific surface prot 0.043 6.9 3 1229 1249 1084 EGF EGF-like domain 4.9e-06 24.5 12 1249 1285 1084 EGF EGF-like domain 1.le-05 23.3 13 1291 1328 1084 TB TB domain 8.7e-23 74.2 3 1358 1401 1084 EGF EGF-like domain 6c-05 20.6 14 1429 1466 1084 CBM_14 Chitin binding Peritrophin-A domain 0.3 5.3 2 1452 1472 1084 EB 2/4. 962 979.. 1 18 0.79 4.0 3 1472- WO 2004/080148 PCT/US2003/030720 536 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 1483 1084 EGF EGF-like domain 1.3e-07 30.3 15 1472 1507 1084 TB TB domain 1.8e-23 76.3 4 1535 1577 1084 EGF EGF-like domain 3.3e-06 25.1 16 1626 1661 1084 PlasmodPvs28 Plasmodium ookinete surface protein P 0.44 4.0 3 1632 1708 1084 TIL 5114 1063 1084.. 47 68 0.00068 13.2 13 1642 1667 1054 SP Giardia variant-specific surface prot 0.96 2.0 4 1646 1667 1084 EGF EGF-like domain 1.2e-07 30.3 17 1667 1706 1084 TIL 5/14 1063 1084.. 47 68 0.85 3.5 14 1690 1706 1086 ig Immunoglobulin domain 5.3e-07 29.1 1 168-232 1086 Corona NS4 Coronavirus non-structural protein NS 0.47 3.5 1 248-271 1086 ig Immunoglobulin domain 0.052 10.4 2 285-347 1086 fn3 Fibronectin type III domain 2.4e-16 58.5 1 373-459 1086 fn3 Fibronectin type III domain 3.le-15 54.7 2 501-587 1086 fn3 Fibronectin type III domain 5.5e-19 67.7 3 602-685 1086 fn3 Fibronectin type III domain le-12 45.9 4 700-786 1086 fn3 Fibronectin type III domain 1.7e-27 97.2 5 802-888 1086 OsmC OsmC-like protein 0.57 4.1 1 984 1018 1086 ig Immunoglobulin domain 0.00041 18.2 3 1133 1191 1086 ig Immunoglobulin domain 1.7e-07 30.9 4 1349 1405 1086 Aegerolysin Aegerolysin 0.56 4.3 1 1411 1428 1087 KRAB KRAB box 5.8e-25 92.4 1 14-54 1087 DUF19 Domain of unknown function DUF19 0.044 5.2 1 80-105 1087 TFIIS Transcription factor S-II (TFIlS) 1 4.7 1 161-171 1087 zf-C2H2 Zinc finger, C2H2 type 8.3e-07 32.0 1 161-183 1087 XPA N XPA protein N-terminal 0.49 5.8 2 186-198 1087 TFIIS Transcription factor S-II (TFIIS) 0.21 7.0 2 189-199 1087 zf-C2H2 Zinc finger, C2H2 type 2.8e-07 33.9 2 189-211 1087 XPAN XPA protein N-terminal 0.47 5.9 3 214-226 1087 zf-C2H2 Zinc finger, C2H2 type 5.4e-07 32.7 1 3 217-239 1087 zf-BED BED zinc finger 0.11 7.3 2 222-240 1087 XPA N XPA protein N-terminal 0.52 5.7 4 242-254 1087 TFIIS Transcription factor S-Il (TFIIS) 0.32 6.4 4 245-255 1087 zf-C2H2 Zinc finger, C2H2 type 3.2e-08 37.5 4 245-267 1087 zf-BED BED zinc finger 0.16 6.8 3 246-268 1088 KRAB KRAB box 5.Be-25 92.4 1 14-54 1088 DUF19 Domain of unknown function DUF19 0.044 5.2 1 80-105 1088 TFIIS Transcription factor S-Il (TFIIS) 1 4.7 1 161-171 1088 zf-C2H2 Zinc finger, C2H2 type 4.le-08 37.1 1 161-183 1088 zf-BED BED zinc finger 0.24 6.2 1 162-184 1089 KeratinB2 Keratin, high sulfur B2 protein 5.6e-21 73.7 1 2-117 1089 Keratin B2 Keratin, high sulfur B2 protein 0.011 9.4. 2 118-170 WO 2004/080148 PCT/US2003/030720 537 TABLE 4B SEQ Model Description E value Score Repeats Position ID - - 1090 Keratin B2 Keratin, high sulfur B2 protein 5.9e-11 38.5 1 2-75 1091 Keratin B2 Keratin, high sulfur B2 protein 7.5e-06 20.6 1 2-40 1091 Keratin B2 Keratin, high sulfur B2 protein 4e-18 63.7 2 41-144 1091 Keratin B2 Keratin, high sulfur B2 protein 4e-05 18.0 3 145-205 1092 abhydro lipase ab-hydrolase associated lipase region 1.9e-3 2 117.8 1 27-97 1092 abhydrolase alpha/beta hydrolase fold 9.5e-19 67.6 1 111-388 1093 abhydrolipase ab-hydrolase associated lipase region 1.9e-32 117.8 1 87-157 1093 abhydrolase alpha/beta hydrolase fold 9.5e-19 67.6 1 171-448 1094 7tm 3 7 transmembrane receptor (metabotropi 0.75 3.2 1 24-45 1094 7tm 3 7 transmembrane receptor (metabotropi 0.00057 14.4 2 65-109 1094 Condensation Condensation domain 0.36 _42 i 157-169 1094 7tm 3 7 transmembrane receptor (metabotropi 2.1e-05 19.4 3 168-271 1095 Tuberin Tuberin 0.59 0.5 1 17-23 1095 DAGAT Diacylglycerol acyltransferase 6.2e-98 335.5 1 38-216 1096 GASA Gibberellin regulated protein 0.35 1.3 1 22-51 1096 lectin c Lectin C-type domain 8.9e-26 95.8 1 100-208 1097 GASA Gibberellin regulated protein 0.35 1.3 1 | 22-51 1097 lectin c Lectin C-type domain 2.5e-27 101.0 1 100-208 1098 7tm 1 7 transmembrane receptor (rhodopsin f 2.6e-50 149.5 1 41-290 1098 endotoxin N delta endotoxin, N-terminal domain 0.87 3.6 1 195-225 1099 SEA SEA domain 1.2e-06 24.2 1 330-408 1099 DUF916 Bacterial protein of unknown function 0.091 7.2 1 550-576 1099 Hanta G2 Hantavirus glycoprotein G2 0.027 6.9 1 550-578 1099 Peptidase C13 Peptidase C13 family 0.32 3.5 1 554-582 1100 ig Immunoglobulin domain 0.0046 14.3 1 146-203 1100 ig Immunoglobulin domain 3.2e-07 29.9 2 245-295 1100 FHIPEP FHIPEP family 0.21 3.5 1 315-326 1101 LRRNT Leucine rich repeat N-terminal domain 0.00068 15.2 1 23-49 1101 LRR Leucine Rich Repeat 8.7e-05 18.9 |1 51-74 1101 LRR Leucine Rich Repeat . 0.00032 17.0 2 75-98 1101 LRR Leucine Rich Repeat 0.025 10.6 3 99-122 1101 LRR Leucine Rich Repeat 0.00069 15.8 4 123-146 1101 LRR Leucine Rich Repeat 9.9e-06 22.1 5 . 147-170 1101 LRRCT Leucine rich repeat C-terminal domain 2.3e-15 48.2 1 180-232 1101 ig Immunoglobulin domain 1.3e-08 35.1 1 248-307 1101 ig Immunoglobulin domain 3.8e-09 37.1 2 344-400 1101 ig Immunoglobulin domain 3.4e-05 22.3 3 440-490 1101 BON Transport-associated domain 0.14 7.1 1 495-507 1101 ig Immunoglobulin domain 3.le-08 33.7 4 525-582 1101 pec lyase N Pectate lyase, N terminus 0.19 3.9 1 626-632 1101 An peroxidase Animal haem peroxidase 9.8e- 657.1 1 726 195 1265 1101 PAL Phenylalanine and histidine ammonia-1 0.53 2.6 1 993 1010 1101 7tm_1 7 transmembrane receptor (rhodopsin f 0.22 2.7 1 1057 1065 1101 Peptidase C1 Papain family cysteine protease 0.76 2.1 1 1150 1167 1101 TILa TILa domain 0.00018 16.9 1 1394 1433 1101 PSP94 Beta-microseminoprotein (PSP-94) 0.11 8.0 1 1395 1426 1101 vwc von Willebrand factor type C domain 2e-10 38.0 1 1395 1450 WO 2004/080148 PCT/US2003/030720 538 TABLE 4B E eR t_ SEQ Model Description E value Score Repeats Position ID 1102 LRRNT Leucine rich repeat N-terminal domain 0.00068 15.2 1 23-49 1102 LRR Leucine Rich Repeat 8.7e-05 18.9 1 51-74 1102 LRR Leucine Rich Repeat 0.021 10.9 2 75-98 1102 LRR Leucine Rich Repeat 0.00069 15.8 3 99-122 1102 LRR Leucine Rich Repeat 9.9e-06 2. 4 123-146 1102 LRRCT Leucine rich repeat C-terminal domain 2.3e-15 48.2 1 156-208 1102 ig Immunoglobulin domain 1.3e-08 35.1 1 224-283 1102 ig Immunoglobulin domain 3.8e-09 37.1 2 320-376 1102 ig Immunoglobulin domain 3.4e-05 22.3 3 416-466 1102 BON Transport-associated domain 0.14 7.1 1 471-483 1102 ig Immunoglobulin domain 3.le-08 33.7 4 501-558 1102 pec lyase N Pectate lyase, N terminus 0.19 3.9 1 602-608 1102 An peroxidase Animal haem peroxidase 9.8e- 657.1 1 702 195 1241 1102 PAL Phenylalanine and histidine ammonia-I 0.53 2.6 1 969-986 1102 7tm_1 7 transmembrane receptor (rhodopsin f 0.22 2.7 1 1033 1041 1102 Peptidase C1 Papain family cysteine protease 0.76 2.1 1 1126 1143 1102 TILa TILa domain 0.00018 16.9 1 1370 1409 1102 PSP94 Beta-microseminoprotein (PSP- 94 ) 0.11 8.0 1 1371 1402 1102 vwc von Willebrand factor type C domain 2e-10 38.0 1 1371 1426 1103 PMEI Plant invertase/pectin methylesterase 0.33 5.5 1 2-24 1103 Ribosomal S26e Ribosomal protein S26e 0.47 3.9 1 215-236 1103 ATP-guaPtrans ATP:guanido phosphotransferase, C-ter 0.089 6.1 1 240-262 1103 Arch fla DE Archaeal flagella protein 0.42 5.0 1 670-683 1103 zfdskAtraR Prokaryotic dksA/traR C4-type zinc fi 0.48 4.8 1 1145 1160 1103 zf-C4 Zinc finger, C4 type (two domains) 0.07 7.6 1 1147 1157 1104 UBX UBX domain 0.79 4.8 1 1-18 1104 FTCD C Formiminotransferase-cyclodeaminase 0.21 6.0 1 47-77 1104 IKI3 II3 family 0.66 0.9 1 80-94 1104 Ribosomal L21p Ribosomal prokaryotic L21 protein 0.27 5.0 1 115-138 1104 DUF709 Family of unknown function (DUF709) 0.28 6.5 1 215-227 1105 Torsin Torsin 8.2e-07 23.3 1 106-125 1106 rrm RNA recognition motif. (a.k.a. RRM, R 0.086 8.5 1 41-71 1107 MHI MH1 domain 0.16 5.4 1 288-309 1107 PecanexC Pecanex protein (C-terminus) 2.2e- 440.0 1 437-621 129 1107 Pecanex C Pecanex protein (C-terminus) 4e-08 29.6 2 622-640 1108 MH1 MH1 domain 0.16 5.4 1 288-309 1108 PecanexC Pecanex protein (C-terminus) 1.2e- 364.5 1 437-599 106 1110 Herpes UL14 Herpesvirus UL14-like protein 0.12 6.1 1 17-43 1110 ig Immunoglobulin domain 0.57 6.5 1 36-55 1110 RibosomalL4 Ribosomal protein L4/LI family 0.95 3.3__ 79-107 1110 Vpu Vpu protein 0.34 4.7 1 106-140 1110 BPD transp Binding-protein-dependent transport s 0.9 3.7 1 109-137 1111 DUF895 Eukaryotic protein of unknown functio 0.68 4.1 1 133-149 1112 RWD RWD domain 9.8e-40 142.2 1 11-125 WO 2004/080148 PCT/US2003/030720 539 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 1112 globin Globin 0.048 8.6 1 88-120 1112 eRF1 2 eRF1 domain 2 0.72 4.1 1 114-127 1112 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 7.5e-10 27.9 1 135-201 1112 DNA ligaseZB NAD-dependent DNA ligase C4 zinc 0.37 5.8 1 196-207 D fing 1112 zf-MIZ MIZ zinc finger 0.28 4.6 1 197-207 1112 ApoA-II Apolipoprotein A-IL (ApoA-II) 0.94 3.6 1 261-272 1113 pkinase Protein kinase domain le-45 162.0 1 194-468 1113 Pox M2 Poxvirus M2 protein 0.82 3.3 1 306-333 1113 DUFS57 Domain of unknown function 0.48 4.7 1 417-428 (DUF857) 1113 ExoD Exopolysaccharide synthesis, ExoD 0.65 2.7 1 424-456 1113 KE2 KE2 family protein 0.18 7.7 1 468-502 1114 SNF2 N SNF2 family N-terminal domain 0.057 6.4 1 82-115 1114 ' Transposase 8 Transposase 0.38 5.6 1 82-105 1114 OKRDC_1_N Orn/Lys/Arg decarboxylase, N- 0.34 3.6 1 91-102 terminal 1116 DUF1006 Protein of unknown function 0.45 2.5 1 5-24 (DUF1006) 1117 ig Immunoglobulin domain 2.3e-05 22.9 1 30-87 1117 ig Immunoglobulin domain 0.0023 15.5 2 127-186 1117 ig Immunoglobulin domain 0.00079 17.2 3 281-337 1117 ig Immunoglobulin domain 0.026 11.5 4 379-434 1117 SNF7 SNF7 0.95 3.5 1 435-450 1118 ig Immunoglobulin domain 0.00079 17.2 1 42-98 1118 ig Immunoglobulin domain 0.026 11.5 2 140-195 1118 SNF7 SNF7 0.95 3.5 1 196-211 1119 IBN NT Importin-beta N-terminal domain 1.6e-24 89.3 1 28-100 1119 PurA PurA ssDNA and RNA-binding protein 0.19 4.8 1 155-171 1119 PAN PAN domain 1 3.2 1 706-735 1120 Bowman- Bowman-Birk serine protease inhibitor 1 4.0 1 28-36 Birk leg 1120 RNApolRpb2_ RNA polymerase beta subunit 0.25 2.1 1 150-946 1120 cobW Cobalamin synthesis protein/P47K 0.85 2.3 1 170-205 1120 DUF909 Bacterial protein of unknown function 0.16 7.1 1 215-247 1120 Glycohydro _2_ Glycosyl hydrolases family 2, TIM bar 0.24 4.8 1 262-277 C 1120 ank Ankyrin repeat 1.2e-10 41.3 1 920-952 1120 ank Ankyrin repeat 2.5e-08 33.0 2 953-985 1120 SH3 SH3 domain 5.7e-16 61.3 1 1022 1079 1122 TPR TPR Domain 0.013 12.3 1 138-157 1122 TPR TPR Domain 1.le-07 30.1 2 158-191 1122 TPR TPR Domain 0.29 7.5 3 192-222 1122 BEX Brain expressed X-linked like family 0.25 3.9 1 261-294 1122 eRFI 2 eRF1 domain 2 0.12 6.9 1 322-338 1122 Subtilisin N Subtilisin N-terminal Region 0.83 5.1 1 323-344 1123 Pencillinase R Penicillinase repressor 0.85 4.2 1 57-75 1124 ank Ankyrin repeat 1.8e-07 29.9 1 64-96 1124 ank Ankyrin repeat 1.5e-06 26.5 2 97-129 1124 ank Ankyrin repeat 2e-07 29.7 3 130-162 1124 Shigella OspC Shigella flexneri OspC protein 0.51 3.2 1 131-161 1124 ank Ankyrin repeat 4.3e-06 24.9 4 163-195 WO 2004/080148 PCT/US2003/030720 540 TABLE 4B SEQ Model Description E-value Score Repeats Position ID 1124 ank Ankyrin repeat 0.00018 19.2 5 196-228 1125 ank Ankyrin repeat 1.8e-07 29.9 1 64-96 1125 ank Ankyrin repeat 1.5e-06 26.5 2 97-129 1125 ank Ankyrin repeat 2e-07 29.7 3 130-162 1125 Shigella OspC Shigella flexneri OspC protein 0.51 3.2 1 131-161 1125 ank Ankyrin repeat 4.3e-06 24.9 4 163-195 1126 DUF846 Eukaryotic protein of unknown function 0.5 2.6 1 50-74 1129 Apolipoprotein Apolipoprotein A1/A4/E family 0.95 3.4 1 4-28 1129 F5 F8 type C F5/8 type C domain le-63 195.2 1 34-174 1129 laminin G Laminin G domain 2.7e-10 36.3 1 212-344 1130 Apolipoprotein Apolipoprotein A1/A4/E family 0.95 3.4 1 4-28 1130 F5_F8 type C F5/8 type C domain le-63 195.2 1 34-174 1130 laminin G Laminin G domain 6.5e- 1 385 212-344 1130 laminin G Laminin U domain 1.8e-11 40.4 2 398-525 1130 EUF EUF-like domain 1.le-06 26.8 2 551-583 1130 fibrinogenGC Fibrinogen beta and gamma chains, CAt 0.05 1 6.6 1 1601-634 1130 lamininG Laminin G domain 2.7e-17 60.5 3 821-943 1130 EGF EGF-like domain 0.0014 15.7 2 962-996 1130 lamininG Laminin 4 domain 0.00033 15.3 4 1046 1179 1130 DNAPPF DNA polymerase processivity factor 0.69 4.3 1 1059 1078 1130 BenE Benzoate membrane transport protein 0.29 3.8 1 1239 1255 1130 BPDtransp Binding-protein-dependent transports 0.41 5.0 1 1245 1276 1131 lTH9 N-terminal HTH domain of 0.72 4.3 1 61-84 molybdenum-b 1131 Glycos transf 2 Glycosyl transferase 2.2e-31 105.9 1 155-341 1131 RibosomalS3_C Ribosomal protein 83, C-terminal 0.98 3.4 1 357-363 doma.T-3 T 746-9 1131 Ricin Bleetin QXW lectin repeat 0.1 8.4 1 467-96 1131 Ricin Blectin QXW lectin repeat 0.00073 16.5 2 558-596 1132 Enterotoxin S Heat-stable enterotoxin 0.71 1.4 1 37-43 1132 VSP Giardia variant-specific surface prot 0.23 4.3 1 96-128 1132 tsp 1 Thrombospondin type 1 domain 0.27 6.0 1 148-203 1133 pkinase Protein kinase domain 1.3e-48 171.6 1 11-237 1133 Poxser-thrkin Poxvirus serine/threonine protein n 0.2 4.5 1 133-156 1133 pkinase Protein kinase domain 0.00017 16.2 2 322-347 1135 C2 C2 domain 2.4e-30 103.9 1 7-88 1135 Transposase 24 Plant transposase (Ptta2En/Spm family 0.22 4.9 1 42-56 1135 photoRC Photosynthetic reaction centre protei 0.95 1.8 1 45-67 1135 C2 C2 domain 8e-32 108.9 2 135-216 1135 RasGAP GTPase-activator protein for Ras-like 5.4e-39 124.6 1 323-513 1135 ARaC binding AraC-like ligand binding domain 0.42 5.2 1 414-452 1135 PH PH domain 6.8e-11 37.2 1 567-673 1135 BTK BTK motif c.9e-06 26.9 1 675-711 1137 toxin 2 Scorpion short toxin 0.089 6.2 1 51-77 1137 C tipleX Cysteine rich repeat 9e-05 15.9 1 54-71 1137 neF E iF-like domain 0.00049 17.3 1 60-86 1137 laminin EsF Laminin EF-like (Domains III andV) 0.55 5.3 1 7-88 1137 EF EGF-like domain 0.00015 19.2 2 123-155 1137 TIL Trypsin Inhibitor like cysteine rich 0.55 4.1 2 142-163 1137 EGF EGF-like domain 0.00018 18.9 3 163-197 WO 2004/080148 PCT/US2003/030720 541 SEQ Model Description E-value Score Repeats Position ID 1137 TIL Trypsin Inhibitor like cysteine rich 0.0065 10.1 3 180-203 1137 EGF EGF-like domain 0.031 10.8 4 215-232 1137 EGF EGF-like domain 3.7e-07 28.6 5 248-283 1137 EB EB module 0.73 4.1 1 254-283 1137 PRK Phosphoribulokinase Iridine Inase 0.74 2.8 1 407-426 1137 NlAM 3A d e-27 100.7 1 1137 Omptin Omptin family 099 2.0 1 460-476 1138 SurESurvivaproteinSurE 0.68 2.6 10-23 1138 Pox All Poxvirus All Protein 0.17 3.2 1T 57-75 1138 zf-C2H2 Zinc finger, C212 type 0.55 8.5 1 205-228 1138 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.64 2.6 1 205-210 1139 4HBT Thioesterase superfamily 0.038 8.2 1 52-120 1143 7tm 1 7 transmembrane receptor (rhodopsin f 1.4e-28 84.3 1 1-173 1144 7tm 1 7 transmembrane receptor (rhodopsin f 5e-49 1146 SNARE SNARE domain 0.28 7.0 1 195-229 1147 IL1 Interleukin-l /18 2.6e-23 83.4 1 51-152 1148 filament Intermediate filament protein 3.2e- 363.0 1 1-296 106 -T 43 1148 K-box K-boxregion 0.78 4.1 1148 Ribosomal S4 Ribosomal protein S4/S9 N-terminal do 0.85 4.3 1 76-97 1148 IATP Mitochondrial ATPase inhibitor, IATP 0.46 6.1 1 125-148 1148 ERG2.SigmalR ERG2 and Sigmal receptor like protein 0.36 3.7 1 162-191 1148 filament Intermediate filament protein 4.8e-31 113.3 2 380469 1148 .K-box K-boxregion 0.11 7.0 2 397-415 1148 bZIP 1/2 51 88.. 28 65 0.3 6.3 2 435-472 1148 Tfb2 Transcription factor Tfb2 0.17 0.5 1 466-472 1149 PhageX PhageXfamily 0.71 4.2 1 16-41 1149 20G-FeII Oxy 20G-Fe(II) oxygenase superfamily 0.27 6.0 1 229-307 1150 MBOAT MBOAT family 2.3e-08 30.9 1 90-249 1151 filament Intermediate filament protein 1.2e-38 138.5 1 131-242 1151 filament Intermediate filament protein 2.9e-83 286.8 2 244-412 1151 HSP70 Hsp7O protein 0.99 2.0 1 268-294 1151 HAMP HAMP domain 1 4.8 1 301-334 liiDUF164 UncharacterizedAR n 0 579 0.057 7.3 1 310-352 1151 DUF164COG 1151 bZIP bIP transcription factor 0.062 8.7 2 316-348 1 151 Transposase_8 Transposase 0.79 4.5 -335 1151 MutS V MutS domain V 0.27 4.5 1 3430 1151 OEP Outer membrane efflux protein 0.053 7.0 1 356-393 1151 MutS IV MutSfamilydomainIV 0.9 4.6 1 359-392 1151 Hpt Upt domain 0.49 5.2 1 365-389 1151 Retro M Retroviral M domain 0.5 4.2 13-377 1152 PeptidaseMlO Matrix metalloprotease, N-terminal do le-42 1197 1 12-95 N 1152 PG binding_1 Putative peptidoglycan binding domain 10.3 1 60-90 1152 Peptidase M1O Matrixin 8.7e-51 178.9 1 102-206 1152 hemopexin Hemopexin 1.6e-08 30.8 1 231-273 1152 hemopexin Hemopexin 32-317 1152 hemopexin Hemopexin 2.2e-13 47,1 1152 hemopexin Hemopexin 2e-05 20,4 4 371-411 1153 PeptidaseM10 Matrix metalloprotease, N-terminal do le-42 119.7 1 12-95 N 1153 PG binding I Putative peptidoglycan binding domain 0.022 10.3 1 60-90 1153 PeptidaseM1O Matrixin 8.7e-51 178.9 102-206 1153 hemopexin Hemopexin 1.6e-08 30.8 231-273 WO 2004/080148 PCT/US2003/030720 542 TABLE 4B __ SEQ Model Description E-value Score Repeats Position ID 1153 hemopexin Hemopexin 1153 hemopexin Hemopexin 1153 hemopexin Hemopexin 2e-05 20.4 4 1154 SUFU Suppressor of fused protein (SUFU) 0 1218. 1 1155 LBP BPICETP LBP / BPI / CETP family, N-terminal d 1.5e-61 210.5 2 1155 LBP BPICETP LBP / BPI / CETP family, C-terminal d 4.6e-32 115.6 1 C 1156 HMG box gh mobility group) box 5b oe-32 115.2 1 5-153 1156 HEV ORF2 Hepatitis E virus ORF-2 (Putative cap 0.026 8.5 1 ' 1159 zf-PAP Poly(ADP-ribose) polymerase and 3.e-52 183.5 1 DNA-L 1159 DNA ligaseA DNA ligase N terminus 1159 DNA ligase ATP dependent DNA ligase domain 8.5c-74 255.3 1 480-636 1159 mRNAcapenzy mRNA capping enzyme, catalytic 0.00064 7.5 1 me domain 1160 serpin Serpin serinee protease inhibitor) 9.5e- 511.0 1 1166 PeptidaseC14 Caspase domain 2,4e-06 23.6 1 1167 ig Immunoglobulin domain 2e-05 23.2 1 42-96 1167 ig Immunoglobulin domain 0.0012 16.6 2 135-197 1167 ig Immunoglobulin domain 0.0013 16.4 3 237-297 1168 UK Virulence determinant 0.083 7.0 1 14-38 1168 TIP120 TBP (TATA-binding protein) -interacti 0 2347. 1 25-908 1168 HEAT HEAT repeat 0.093 8.3 2 248-286 1168 HEAT HEAT repeat 0.022 10.4 3 343-364 1168 Armadilloseg Armadillo/beta-catenin-like repeat 0.2 80 2 682-721 1169 lectin c Lectin C-type domain 7.4e-19 72.8 1 131-231 1171 WD40 WD domain, G-beta repeat 8.5e-11 40.4 1 223-260 1171 WD40 WD domain, U-beta repeat 2.8e-06 27 2 280-316 1171 WD40 WD domain, G-beta repeat 9e-09 33.4 3 320-357 1171 WD40 WD domain, G-beta repeat 0.0041 13.7 4 362-398 1171 WD4O WD domain, G-beta repeat 3.le-14 52.4 5 403-440 1171 WD40 Ddomain, G-betarepeat 4.3e-12 45.0 6 445-491 1171 WD40 WD domain, U-beta repeat le-i 4 54.0 7 496-533 1171 WD40 WD domain, U-beta repeat 0.23 7.6 8 538-574 1172 ig Immunoglobuli domain 2.3e-05 22.9 1 42-99 1172 ig Immunoglobulin domain 0.0023 15.5 2 139-198 1172 MBOAT MBOAT family 3.le-07 26.8 1 741-769 1173 ig immunoglobulin domain 2.3e-05 22.9 1 42-99 1173 ig Immunoglobulin domain 0.0023 15.5 2 139-198 1173 MBOAT MBOAT family 3.le-07 26.8 1 741-769 1174 MBOAT MBOAT family 2.3e-08 30.9 1 90-249 1174 MBOAT MBOAT family 4.7e-09 33.5 2 308-351 1175 PTE Phosphotriesterase family 1.2e- .0 1 7233 139 ____ 1182 Pox int trans Poxvirus intermediate transcription fac 0.092 5.7 1 94-122 1183 PS Dcarbxylase Phosphatidylserine decarboxylase 0.011 11.4 1 165-181 1183 PS Dearbxylase Phosphatidylserine decarboxylase 8.3e-52 182.3 2 246-467 1184 TSC22 TSC-22Idipbun family 124-183 U186- ADPFKUK AH P-specific 7e-227 763.9 1 68-492 PhospofrutokinaseGlucokin 1 WO 2004/080148 PCT/US2003/030720 543 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 1186 Mannitol dh Mannitol dehydrogenase 0.052 6.8 1 394-413 1187 DENN DENN (AEX-3) domain 0.054 6.0 1 16-40 1188 DPPIVN term Dipeptidyl peptidase IV (DPP IV) N- 0.5 1.1 1 310-346 termi 1188 DPPIVN term Dipeptidyl peptidase IV (DPP IV) N- 2.4e-07 19.7 2 513-608 tenni 1188 DPPIVN term Dipeptidyl peptidase IV (DPP IV) N- 5.3e-08 21.7 3 646-680 termi 1188 Peptidase S9 Prolyl oligopeptidase family 3.9e-11 36.8 1 692-764 1188 Esterase Putative esterase 0.062 6.6 1 738-781 1189 DPPIVN term Dipeptidyl peptidase IV (DPP IV) N- 0.5 1.1 1 310-346 termi 1189 DPPIVN term Dipeptidyl peptidase IV (DPP IV) N- 2.4e-07 19.7 2 513-608 termi 1189 DPPIVN term Dipeptidyl peptidase IV (DPP IV) N- 5.3e-08 21.7 3 646-680 termi 1189 PeptidaseS9 Prolyl oligopeptidase family 3.9e-11 36.8 1 692-764 1189 Esterase Putative esterase 0.062 6.6 1 738-781 1190 DPPIVN term Dipeptidyl peptidase IV (DPP IV) N- 0.5 1.1 1 310-346 termi 1190 DPPIVN term Dipeptidyl peptidase IV (DPP IV) N- 5.3e-08 21.7 2 633-667 termi 1190 Peptidase S9 Prolyl oligopeptidase family 3.9e- 11 36.8 1 679-751 1190 Esterase Putative esterase 0.062 6.6 1 725-768 1191 Ribosomal S25 S25 ribosomal protein 6.7e-67 232.4 1 2-100 1191 DUF387 Putative transcriptional regulators (Yp 0.099 5.8 1 65-87 1193 ank Ankyrin repeat 6.7e-10 38.6 2 49-81 1193 ank Ankyrin repeat 2.7e-08 32.8 3 82-114 1193 ank Ankyrin repeat 0.0036 14.4 4 115-147 1193 ank Ankyrin repeat 1.5e-11 44.5 5 148-180 1193 ank Ankyrin repeat 1.2e-08 34.1 6 181-213 1193 ank Ankyrin repeat 3.3e-08 32.5 7 214-246 1193 ank Ankyrin repeat 3.4e-11 43.2 8 247-279 1193 ank Ankyrin repeat 1.3e-08 33.9 9 280-313 1193 ank Ankyrin repeat 0.0027 14.9 10 314-346 1193 ank Ankyrin repeat 8.5e-08 31.1 11 347-379 1193 ank Ankyrin repeat 0.013 12.4 12 380-404 1193 ank Ankyrin repeat 8.3e-08 31.1 13 431-463 1193 ank Ankyrin repeat 1.le-09 37.8 14 464-496 1193 ank Ankyrin repeat 6.9e-07 27.8 15 497-557 1193 endonuclease_7 Recombination endonuclease VII 0.034 9.6 1 513-537 1193 ank Ankyrin repeat 0.0047 14.0 16 558-581 1193 ank Ankyrin repeat 1.2e-05 23.3 17 596-625 1193 ank Ankyrin repeat 3.8e-10 39.4 18 626-658 1193 ank Ankyrin repeat 0.00034 18.1 19 660-692 1193 ank Ankyrin repeat 1.5e-09 37.3 20 696-728 1193 ank Ankyrin repeat 1.5e-05 23.0 21 729-761 1193 ank Ankyrin repeat 9.7e-05 20.1 22 762-784 1193 ank Ankyrin repeat 2.3e-07 29.5 23 798-821 1193 ank Ankyrin repeat 0.0023 15.1 24 830-853 1193 ank Ankyrin repeat 3.6e-10 39.5 25 865-897 1193 ank Ankyrin repeat 4.3e-06 24.9 26 898-931 1193 ank Ankyrin repeat 0.00019 19.1 27 932-964 1193 ank Ankyrin repeat 1.6e-07 30.0 28 968- WO 2004/080148 PCT/US2003/030720 544 TABLE 4B SEQ Model Description E-value Score Repeats Position ID ID 1000 1194 trypsin Trypsin 1 166-342 1194 PDZ-2 1194 PDZ PDZ domain (Also known as DHR or 0.0018 14.0 1 372-412 GLGF) 1195 7tm_1 7 transmembrane receptor (rhodopsin 2.4-18 53.6 1 1-137 family) 1196 vwc von Willebrand factor type C domain 5.4e-05 19.0 1 66-105 1196 vwc von WillebrandfatortypeCdomain 0.16 6.8 108-163 1196 vwc von Willebrand factor type C domain 2e-07 27.4 3 166-192 1197 7tm_1 7 transmembrane receptor (rhodopsin 4.5e-36 106.7 1 46-295 _____family) 1198 MethyltransfD12 D12 classN6 adenine-specific DNA 2.le-36 127.8 1 30-152 met 1199 lipocalin Lipocalin/cytosolic fatty-acid binding 7L8e-21 1 32-176 ____ _____________pr ___ 1200 tRNA anti OB-fold nucleic acid binding domain 2.7e-15 56.4 1 44-118 1200 tRNA-synt_2 tRNA synthetases class 11 (D, K and N) 2.7e-91 313.5 1 135-473 1202 FAD binding_2 FAD binding domain 5.9e-54 182.8 5-100 1203 RasGEFN Guanine nucotide exchange factor for 0.00072 15.7 1 39-87 Ras-1 1203 RasGEF RasGEF domain 0.39 5.5 1 211-240 1203 RasGEF RasGEF domain 68 e- 18 69.6 2 280-360 1204 KH KH domain 3.8e-17 61.6 1 17-63 1204 KH KH domain 5.4e-19 68.0 2 101-150 1204 KH KIdomain 5.8e-16 57.6 3 265-313 1206 transketpyr Transketolase, pyridine binding domai 3.3e-75 258.0 1 15-190 1206 transketolase C Transketolase, C-terminal domain 2e-59 194.9 1 208-331 1207 Calsequestrin Calsequestrin 6.3e- 986.6 1 5-390 -12-0 ~294 T_ 1207 thiored Thioredoxin 0.057 9.0 123-152 120 PH PH domain 0-.0057 11.0 1709 1T209 PH709 1210 ig Immunoglobulin domain 4.9e-07 29.2 1 35-112 1210 ig Immunoglobulin domain 2e-06 26.9 2 154-228 1213 cadherin Cadherin domain 0.00026 16.8 1 33-96 121 cadherin 1213 cadherin Cadherin domain 1.3e-06 4.8 143-235 1213 cadherin Cadherin domain 1.3e-22 80.6 3 249-343 1213 cadherin Cadherin domain 2.9e-14 51.4 4 361-448 121 dhri Cdh rnm 1.7e-22 80.2 5 462-558 1T 2 1 3 c a d h e r i nd 2 12 13 cadherin Cadherin domain 2.4e- 10 37.8 6 597-667 1214 carlreticulin family 3,6e- 715.1 21-315 221 1218 Alpha L fucos Alpha-L-fucosidase 0.018 8.4 1 10-34 1221 Osteopontin Osteopontin 1.4e-20 64.7 1 1-30 1221 Osteopontin Osteopontin 2e-166 531.5 31-275 1222 serpin Serpin serinee protease inhibitor) 2.4e- 529.6 1 7-443 -156 ___7F _ 31-101_ 1223 ig Immunoglobulin domain 0.00035 18.5 1223 ig 2/3 143 210.. 7 52 1.3e-08 35.1 3 252-303 1225 HATPase c Histidine kinase-, DNA gyrase B-, and 3.8e-15 54.5 1 16-164 1225 DNAgyraseB DNA gyrase B 4.le-57 199.9 1 210-370 1225 DNA topoisolV DNA gyrase/topoisomerase IV, subunit 1.3e- 610.1 1 653 1100 189 72.8 1 1120 1225 DUFIP8 Uncharacterized BCR, Yai/YqxD 0.025 8.2 1 1095 family 1 WO 2004/080148 PCT/US2003/030720 545 TABLE 4B SEQ Model Description E-value Score Repeats Position 1226 AMP-binding AMP-binding enzyme 7.3e-84 288.8 1 _i227 PCI PCI domain 8.7-10 36.4 1 __ 1228 Clq C1q domain 6e-45 159.5 1 _ T3-202 1229 BTB BTB/POZ domain 9.8e-14 51.0 69 1229 BTB BTB/POZ domain 06 . 123 kAnkyrin repeat. 739 Ankyrin repeat 2 40-85 F 2 3 0 a n k A n k y ri n r e p e at 1230 ank Ankyrin repeat86-147 1230 ank Ankyrin repeat 0.057 10.1 4 148-180 1230 ank Ankyrin repeat 3.6e-10 39.5 5 181-213 12d an1 Ankyrin repeat 7.2e-08 31.3 6 214-246 1230 ank Ankyrin repeat .,-06 5.1 7247-279 1230 ank Ankyrin repeat 1.7e-08 33.6 8 280-312 1230 ank Ankyrin repeat 4.9c-07 28.3 9 313-346 1230 ank Ankyrin repeat 0.00014 19.6 10 347-379 _12_30 ank Ankyrin repeat 1.8e-07 29.9 11 380-412 12_3_0 ank Ankyrin repeat 0.038 10.8 12 413-437 1230 ank Ankyrin repeat 2.5c-08 32.9 4-496 1230 ank Ankyrin repeat 7.6e-08 31.2 1 497-529 1230 ank Ankyrin repeat 2.2e-07 29.5 15 530-590 1230 ank Ankyrin repeat 0.0048 14.0 16 591-613 1230 ank Ankyrin repeat 0.0097 12.9 17 629-658 1230 ank Ankyrin repeat 3.3e-06 25.3 18 659-691 1230 ank Ankyrin repeat 2.3e-05 22.3 19 693-727 1230 ank Ankyrin repeat 3.Ie-09 36.2 20 729-761 1230 ank Ankyrin repeat 0.00054 17.4 21 762-794 1230 ank Ankyrin repeat 5.7e-06 24.5 22 795-827 1230 ank Ankyrin repeat 9.6e-05 20.1 23 832-855 1230 ank Ankyrin repeat 0.0013 16.0 24 864-892 1 2 30 ank Ankyrin repeat 1.7e-08 33.5 25 899-931 1230 ank Ankyrin repeat 3.4e-06 25.3 26 932-965 1230 ank Ankyrin repeat .001 .4 1230 ank AXnkyin repeat .5e-o7 2.3 28 1006 1231 LBP_BPICETP LBP / BPI / CETP family, N-terminal 1.5e-61 210.5 1 38-217 do 1231 LBP BPICETP LBP / BPI / CETP family, C-terminal 7.3e-27 96.9 1 242-472 C do 1232 LBPBPICETP LBP / BPI / CETP family, N-terminal 1.5e-61 210.5 1 38-217 do 1232 LBP BPI CETP LBP / BPI / CETP family, C-terminal 1.3c-25 92.4 1 242-472 C do 1233 LBPBPICETP LBP / BPI / CETP family, N-terminal 1.5e-61 210.5 1 38-217 do 1233 LBPBPICETP LBP / BPI / CETP family, C-terminal 2.6e-33 120.1 1 242-478 C do 1234 DUF408 Domain of Unknown Function 7.8e- 388.3 1 41-222 (DUF408) 114 1237 ig Immunoglobulin domain 5.3e-05 21.6 28-86 1237 ig Immunoglobulin domain 2e-08 34.4 2 127-184 1237 ig Immunoglobulin domain 6.2e-13 51.3 3 219-277 1237 fn3 Fibronectin type III domain 6.3e-20 71.0 1 299-385 1237 fn3 Fibronectin type III domain 8e-10 35.9 2396-481 1238 Nuf2 Nuf2 family 3.3--1 WO 2004/080148 PCT/US2003/030720 546 SEQ Model Description E value Score Repeats Position ID ______ 1238 HR1 Hrl repeat 0.099 7.1 1 187-214 1240 Sema Sema domain 7.6e- 601.0 1 59-477 178 ________ 1240 squash Squash family serine protease inhibitor 0.033 5.8 1 512-534 1240 PSI Plexin repeat 0.00097 13.3 1 514-543 1240 UreEC UrcE urcase accessory protein, C- 0.09 7.9 terminal doI 1243 rrm RNA recognition motif. (a.k.a. RRM, .0012 15.1 1 RBD, or___ 1247 Peptidase M50 Peptidase family M50 0.0024 12.4 1 9-875 1247 C tripleX Cysteine rich repeat 0.00046 13.8 1 103-120 1247 EGF EGF-like domain 0.089 9.2 1 105-135 1247 EGF EGF-like domain 0.0047 13.8 2 148-178 1247 laminin EGF Laminin EGF-like (Domains III and V) 0.0006 15. 1 152-195 1247 EB ule 0.21 5.7 2 188-217 1247 EGF EUF-like domain 3.2e-06 25.2 3 191-221 1247 lamininEGF Laminin EGF-like (Domains III and V) 0.17 7.0 2 199-238 1247 EGF EUF-like domain 8.6e-06 23.6 4 234-264 1247 DSL Delta serrate ligand 0.024 8.9 4 250-264 1247 EGF EGF-like domain 24.3 5 277-307 1247 lamininEGF Laminin EGF-like (Domains III and V) 1.2e-05 21.3 4 281-317 1247 EGF EGF-like domain 0.00028 18.2 6 320-350 1247 lamininEGF Laminin EGF-like (Domains III and V) 0.018 10.3 5 324-351 1247 DSL Delta serrate ligand 0.15 6.3 6 353-364 1247 EGF EGF-like domain 0.053 10.0 7 364-396 1247 laminin EGF Lamiin EGF-like (Domains III and V) 0.00011 1. 6 368-406 1247 DSL Delta serrate ligand 0.034 8.4 7 383-396 1247 DSL Delta serrate ligand 0.76 4.0 8 397-409 1247 lamininEGF Laminin EGF-likc (Domains III and V) 0.68 1247 EGF EGF-like domain 4.8e-05 20.9 9 415-439 1247 DSL Delta serrate ligand 0.46 4.7 9 425-439 1247 EGF EGF-like domain 1.2e-05 23.1 10 452-482 1247 lamininEGF Laminin EGF-like (Domains III and 0.19 6.9 8 460-499 1247 DSL Delta serrate ligand 0.21 5.8 10 469-482 1247 EB EB module 0.89 3.8 4 492-525 1247 EGF EGF-like domain 2.3c-05 22.1 11 495-525 1247 laminin EGF Laminin EGF-likc (Domains III and V) 6.011 11.1 9-502-542 1247 DSL Delta serrate ligand 0.023 9.0 11 512-525 1247 EGF EGF-like domain 0.03 10.8 12 538-568 1247 laminin EGF Laminin EGF-like (Domains III and V) 0.0055 12.1 10 546-587 1247 DSL Deltaserrateligand 0.0012 13.1 12 553-568 1247 EGF EGF-likc domain 0.0001 19.8 13 581-611 1247 EB EBmodule 0.025 8. 5 587-611 1247 laminin EGF Laminin EGF-like (Domains III and V) 0.065 8.4 11 589-631 1247 DSL Delta serrate ligand 0.5 4.6 14 612-624 1247 EGF EGF-like domain 0.48 6.5 14 614-624 1247 EGF EGF-like domain 0.041 10.4 15 631-669 1247 laminin EGF Laminin EGF-like (Domains III and NJ 0.00028 16.6 12 634-658 1247 EGF EGF-like domain 0.00023 18.5 16 675-699 1247 DSL 15/20 647 656.. 58 67 0.15 6.3 16 689-699 1247 EGF EGF-like domain 7.7e-05 2. 17 712-742 1247 laminin EGF Laminin EGF-like (Domains III and V) 0.56 5.2 13 716-752 24r7 DSL 15/20 647 656.. 58 67 0.083 | 7.1 17 729-742 WO 2004/080148 PCT/US2003/030720 547 TABLE 4B SEQ Model Description E-value Score Repeats Position ID 1247 EGF EGF-like domain 0.57 6.2 18 745-755 1247 laminin EGF Laminin EGE-like (Domains III and V) 3.4e-05 19.8 14 759 1247 EB E1 module 0.079 7.0 6 70-785 1247 EGF EGF-like domain 0.0048 13.7 19 761-785 1247 DSL 15/20 647 656.. 58 67 0.16 6.2 19 772-785 1247 EGF EGF-like domain 0.0057 13.5 20 798-828 1247 laminin EGF Laminin EGF-like (Domains F11 andV) 0.0035 12.8 15 805-830 1247 DSL 15/20 647 656.. 58 67 0.44 4.8 20 9-828 1249 IBR IBR domain le-OS 19.4 1 74-104 1249 zf-C3HC4 Zinc finger, C3HC4 ype (RING finger) 0.029 6.4 1 114-134 1249 IBR IBR domain 0.029 8.4 2 132-164 1250 NC NC domain 2.2e-47 167.3 1 172-253 1251 Aa-trans Transmembrane amino acid transporter 1.9e-77 267.5 1 52-365 _____protein 1252 Aa trans Transmembrane amino acid transporter 2,5e-76 263.7 1 45-354 1 protein 1252 Aa trans Transmembrane amino acid transporter 2.7e-06 22.9 2 355-419 _____protein 1254 FGF Fibroblast growth factor 2.2e-40 137.9 1 42-166 1255 LRR Leucine Rich Repeat 0.033 10.2 1 49-70 1255 LRR Leucine Rich Repeat 0.21 7.5 2 71-92 1255 LRR LeucineRiehRepeat 0.57 6.0 3 94-115 1255 LRR Leucine Rich Repeat 0.46 6.3 4 116-140 1256 RPE65 Retinal pigment epithelial membrane 8.9e-59 199.4 1 60-416 Protein 1256 RPE65 Retinal pigment epithelial membrane 4.3e-27 91.2 2 462-579 Protein 1257 RPE65 Retinal pigment epithelial membrane 8.9e-59 199.4 1 42-398 protein 1257 RPE65 .244 127RPE65 Retinal pigment epithelial membrane 4327 9. 244-56 1 protein 1258 ig Immunoglobulin domain 0.001 16.8 1 39-97 1258 ig Immunoglobulin domain 1.2e-11 46.5 2 128-189 1260 DUF948 Bacterial protein of unknown function 0.058 8.0 1 249-269 (DU 1261 serpin Serpin serinee protease inhibitor) 3.2e-08 27.5 1 31-82 1261 serpin Serpin serinee protease inhibitor) 1.2e-60 206.3 2 212-423 1262 PMP22 Claudin PMP-22/EMP/MP20/Claudin family 3.7e-16 56.5 1 1-47 1263 arf ADP-ribosylation factor family 5.1e-13 43.2 1 10-132 1264 PAP2 PAP2 superfamily 4.5e-15 54.4 1 106-241 1265 SRCR Scavenger receptor cysteine-rich doma 2e-20 73.6 37-128 1265 SRCR Scavenger receptor cysteine-rich doma 6e-28 100.2 2 136-227 1265 SRCR Scavenger receptor cysteine-rich doma 6.6e-33 117.8 3 232-329 1265 Arthro defensin Arthropod defensin 0.0097 7.3 1 340-364 1265 SRCR Scavenger receptor cysteine-rich doma 3.le-15 55.3 4 360-459 1265 SRCR Scavenger receptor cysteine-rich doma 7.6c-33 117.6 5 477-574 1266 SRCR Scavenger receptor cysteine-rich doma 2e-20 73.6 1 37-128 1266 SRCR Scavenger receptor cysteine-rich doma 6e-28 100.2 2 136-227 1266 SRCR Scavenger receptor cysteine-rich doma 6.6e-33 117.8 3 232-329 1266 Arthro defensin Arthropod defensin 0.0097 7.3 1 340-364 1266 SRCR Scavenger receptor cysteine-rich doma 3.le-15 55.3 4 360-459 1266 SRCR Scavenger receptor cysteine-rich doma 7.6e-33 117.6 5 477-574 1270 Armadillo -seg IArmadillo/beta-eatenin-like repeat 2.7e-05 121.8 1 1 153-93 1270 Armadillo seg 2/5 546 586 .. 1 41 1 91-716 WO 2004/080148 PCT/US2003/030720 548 TABLE 4B SEQ Model Description E-value Score Repeats Position ID 1273 PneumoattG Pneumoviriae attachment membrane 0.098 4.7 1 57-70 ____ _____________glycop 1273 pkinase Protein kinase domain 3e-77 266.8 1 103-387 125_p~1Bprop Reprolysin family propeptidc 3.2e-37 116. 1 907-215 1275 Pep M1A2B _prop. ep 1275 Reprolysin Reprolysin (M12B) family zinc metallo 1le-88 304.8 1 1275 PeptidaseM46 Pregnancy-associated plasma protein-A 0.056 5.5 1 362-372 1275 disintegrin Disintegrin 1.7e-39 134.2 1 443-518 1275 EGF EGF-like domain 0.0023 14.8 1 670-697 1276 FeoA FeoA family 0.088 8.4 1 132-239 1277 ank Ank in repeat 2.3e-05 22.3 1 301-339 1277 ank Ankyrinrepeat 9.5e-11 41.6 2 340-373 1277 Dehydratase LU Dehydratase large subunit 0.015 7.6 1 369-403 1278 Peptidase_M1 Peptidase family M1 7.1- 383.8 1 98-506 137 ___ 1284 Aa trans Transmembrane amino acid transporter 2.4e-30 110.9 1 4-397 1285 ARPF Aromatic-Rich Protein Family 4.3e-09 31.3 1 74-190 1288 LRR Leucine Rich Repeat 0.41 6.5 1 66-89 1288 LRR 0.0017 90-113 1288 LRR LeucineRichRepeat 0.76 5.6 3 114-137 1288 LRR Leucine Rich Repeat 0.0013 14.9 4 138-161 1288 LRR Leucine Rich Repeat 0.0043 13.1 5 163-186 1288 LRR Leucine Rich Repeat 0.0088 12.1 6 187-210 1288 LRR LeucineRichRepeat 0.063 9.2 7 211-231 1288 LRRCT Leucine rich repeat -terminal domain 2.6e-10 32.7 1 252-297 1288 ig Immunoglobulin domain 5.8e-09 36.4 1 314-372 1289 Huntingtin Huntingtin 0.077 5.4 1 768-790 1290 LRRNT Leucine rich repeat N-terminal domain 0.0011 14.5 1 32-59 1290 LRR Leucine Rich Repeat 0.0059 12.7 1 61-84 1290 LRR Leucine Rich Repeat 0.00021 85-108 1290 | LRR LeucineRichRepeat 0.012 11.6 3 110-132 1290 LRRCT Leucine rich repeat C-terminal domain 0.00014 15.2 1 131-144 1291 PH PH domain 0.053 7.8 1 7-98 1291 DAGKc Diacyiglycerol kinase catalytic domain 0.00081 14.7 1 90-177 _____ _______________(pres 1292 ig Immunoglobulin domain 0.069 9.9 1 48-120 1292 ig Immunoglobulin domain 8.1e-09 35.9 2 161-219 1293 ig Immunoglobulin domain 0.069 99 1 48-120 1293 ig Immunoglobulin domain 8le-09 .9 2 161-219 1295 Clq Clq domain 5.3e-49 173.0 1 72-198 1296 7tm_1 7 transmembrane receptor (rhodopsin 1.3e-08 24.4 1 49-108 famil_____ 1296 7tm_1 7 transmembrane receptor (rhodopsin .6e-31 91.7 2 109-332 famil 1297 MED7 MED7 protein 0.0099 9.5 1 202-242 1297 CH Calponin homology (CH) domain 2.7e-31 114.2 1 215-316 1297 CH Calponin homology (CH) domain 3,7e-26 97 2 331-433 1297 UVR UvrB/uvrC motif 0.0066 12.8 1 652-664 1297 spectrin Spectrin repeat 0.007 11.5 1 793-852 1297 ACCA Acetyl co-enzyme A carboxylase 0.017 10.3 1 832-873 carboxy 1297 spectrin I Spectrin repeat 4.9e-05 18.9 2 922-973 1297 PolC DP2 DNA polymerase 11 large subunit DP2 0.013 2.0 1 928-939 1297 DUF622 Protein of unknown function, DUF622 0.043 9.8 1 1313- WO 2004/080148 PCT/US2003/030720 549 TABLE 4B SEQ Model Description E-value Score Repeats Position ID 1341 1297 Mye-LZ Myc leucine zipper domain 0.13 7.7 2 1313 1338 1297 spectrin Spectrin repeat 0.38 1482 1297 bZIP 13 644 674.. 35 65 0058 8.8 3 1698 1722 1297 Prefoldin Prefoldin subunit 0.56 5.2 3 1709 1736 1297 M Mproteinrepeat 0.44 8.1 1939 1959 1297 ldh lactate/malate dehydrogenase, alpha/be 035 5.2 2 2093 oq =2118 1297 FTCDC Foriminotransferase-cyclodeafllfase 0.029 9.2 1 2108 2146 1297 LamininI Laminin Domain I 0.032 .5 1 2152 2219 1297 Troponyosin Tropomyosin 0519 9 1 2210 2251 1297 PoxAtypeinc 1057 1069.. 1 13 0.47 6.6 2364 2379 1297 Tropomyosin Tropomyosm 0.72 3.2 2 2396 T2 97 Po2425 1297 PoxAtypeinc 2/7 1057 1069.. 1 13 0.57 6.3 7 2399 2421 1297 Plectin Plectin repeat le-19 74.9 2 2734 2778 1297 Plectin Plectin repeat 73e-16 60.6 3 2808 ---- M -142852 1297 CBM_14Chitin binding Peritrhin-A main .0038 .3 2867 2884 1297 Plectin Plectin repeat 2e-05 22.8 4 2907 2939 1297 Plectin Plectin repeat 0.018 12.0 6 3012 3042 1297 Plectin Plectin repeat 2.1e-20 7.4 7 3043 3087 1297 ECH Enoyl-CoA hydratase/isomerase family 0.00096 14.0 1 3059 ____________ ______3080 1297 Plectin Plectin repeat 0.083 9.6 8 3088 _____3118 1297 Plectin Plectin repeat 1.3e-16 63.5 9 3119 3163 1297 Plectin Plectin repeat 0.44 6.9 10 3 169 3201 1298 MED7 MED7 protein 0.0099 9.5 1 202-242 1298 CH Calponin homology (CH) domain 2.3e-29 107.8 1 215-328 1298 CH nin homology (CH) domain 3.7e-26 .1 2 343-445 1298 UVR UvrB/uvrC motif 0.0066 12.8 1 664-676 1298 spectrin Spectrinrepeat 0.007 11.5 1 805-864 1298 ACCA Acetyl co-enzyme A carboxylase 0.017 10.3 1 844-885 carboxy ____ 1298 spectrin Spectrin repeat 4.9e-05 18.9 934-985 1298 PolC DP2 DNA olymerase 11 large subunit DP2 0.013 2.0 1 940-951 298 DUF622 1Protein of unknown function, DUF622 0.043 9.8 1 1325- WO 2004/080148 PCT/US2003/030720 550 TABLE 4B 1298 bZIP 1/3 656 686 .. 35 65 0.058 8.8 3 1710 1298 Prefoldin Prefoldin subunit 0.56 5.2 3 1721 1748 129 MoM protein repeat 0.44 8.1 2 1951t 1298 ldhC lactate/malate dehydrogenase, alpha/be 0.35 5.2 2 2105 2130 1298 FTCDC Formiminotransferase-cyclodeaminlase 0.029 9.2 1 2120 2158 1298 LamininII Laminin Domain II 0.032 9.5 1 1 1298 Tropomyosin Tropomyosin 0.019 8.9 1 2222 1298 PoxAtypeinc 2/7 1069 1081 .. 1 13 0.47 6.6 6 276 1298 Tropomyosin Tropomyosin 0.72 3.2 2 2408 1298 PoxAtype-ine 2/7 1069 1081 .. 1 13 0.57 6.3 7 2411 1298 Plectin Plectin repeat e-19 74.9 2 246 1298 Plectin Plectin repeat 8.3e-16 60.6 3 2820 2864 1298 CBM_14 Chitin binding Peritrophin-A domain 0.0038 11.3 1 2879 2896 1298 Plectin Plectin repeat 2e-05 22.8 4 29 1 2951 1298 Plectin Plectin repeat 0.018 12.0 6 3024 1298 Plectin Plectin repeat 2.1e-20 77.4 7 3055 23099 1298 ECH Enoy1-CoA hydratase/isoe family 0.00096 14.0 1 3071 3092 1298 Plectin Plectin repeat 0.083 9.6 8 31 231 1298 Plectin Plectin repeat 1.3e-16 63.5 9 3131 1298 Plectin Plectin repeat 0.44 6.9 10 318 23213 1304 DUF544 Prti fukonfnto DF4)5.8e-80 275.8 11528 1305 DUF544 Protein of unknown function (DUF44) 5.8e-80 275.8 1 2 1306 ig Immunoglobulin domain 2.7 3.3 1 26-93 1306 ig Immunoglobulin domain 2.5e-06 26.5 2 132-191 1306 MAM MAM domain 6.9e-72 249.0 1 422-595 1308 APR Phosphotransferase enzyme family 2.9e-42 150.6 1 40-256 1308 Acyl-CoAdh M Acyl-CoA dehydrogenase, middle 0.00024 17.0 1 505-585 domain 1308 Acyl-CoAdh Acyl-CoA dehydrogenase, C-terminal 6.7e-50 175.9 1 618-769 doma3 WO 2004/080148 PCT/US2003/030720 551 TABLE 4B SEQ Model Description E value Score repeats Position ID 1309 APH Phosphotransferase enzyme family 7.7e-32 116.0 1 80-238 1309 Acyl-CoAdhM Acyl-CoA dehydrogenase, middle 0.00024 17.0 1 487-567 domain - f7. F 6075 1309 Acyl-CoA dh A yl-oA dehydrogenase, C-terminal 6.7e-50 doma 1310 Cationefflux Cation efflux family 3e-09 34.4 1 69-145 1311 CaMBD Calmodulin binding domain 0.074 7.8 1311 |Q IQ ealmodulin-bindingmotif 1.3e-05 22.1 2 738-758 1312 SA A oan (Sterile alpha motif) 0.00073 15.4 1 304-369 112 SAM _A oa 1312 SAM SAM domain (Sterile alpha motif) 22e-10 38.2 2 382-446 1312 SAM SAM domain (Sterile alpha motif) 0.06 8.7 1313 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 7.le-25 70.3 1 80-126 1313 Herpes UL495 Herpesvirus UL49.5 0082 7.4 -- -5-U-F ~ envelope/tegument pr 6. 1173 1314 DUF692 Protein of unknown function (DUF692) 0.088 1722 1314 HECT HECT-domain (ubiquitin-transferase) 1.9e- 662.8 1 2002 196 2309 1314 V-ATPaseC V-ATPase subunit C 0.0 2185 2213 1315 PAP2 PAP2 superfamily 1.5e-25 91.6 1 66-218 1316 PAP2 PAP2 superfamily 5.le-30 107.5 1 98-236 1317 ig Immunoglobulin domain -09 39 1 __41-116 1321 LRRNT Leucine rich repeat N-terminal domain 1.3e-06 24.2 1 115-143 1321 LRR Leucine Rich Repeat 0.098 8.6 1 145-168 1321 LRR Leucine Rich Repeat 8.2e-06 22.3 2 169-194 1321 FNIP FNIP Repeat 0.36 6.7 1 195-225 1321 LRR ine Rich 195 1321 LRR Leucine Rich Repeat 240-265 1321 LRR Leucine Rich Repeat 0.018 11.1 5 266-285 1321 LRR Leucine Rich Repeat 0.00014 18.1 6 287-310 1321 LRR LeucineRichRepeat 0.00013 18.3 7 311-336 1321 LRR LeucineRichRepeat 0.00015 18.1 8 337-356 1321 LRR0.22 7.4 358-381 1321 LRR Leucine Rich Repeat 0.002 14.3 10 382-407 1321 LRR LeucineRich Repeat 0.022 10.7 11 408-427 1321 LRR Leucine Rich Repeat 0.00025 17.3 12 453-478 1321 LRR Leucine Rich Repeat 0.00049 16.4 13 479-498 1321 LRRLeucineRicRepeat 0.13 8.1 15 524-549 1321 LRR Leucine Rich Repeat 0.00025 17.3 16 550-569 1T321 _LRR Lucine Rich Repeat 5.2e-05 19.6 17 571-594 1321 LRR Leucine Rich Repeat 0.37 6.6 18 595-620 1322 ig Immunoglobulin domain 0.26 7.8 1 50-117 1322 ig Immunoglobulin domain 0.00049 18.0 157-215 1322 ig Immunoglobulin domain 2.8e-09 37.6 3 267-321 1323 ig Immunoglobulin domain 0.24 7.9 1 50-117 1323 ig Immunoglobulin domain 18.0 2 1323 ig Immunoglobulin domain 0.00077 17.2 3 267-303 1324 tsp.1 Thrombospondin type 1 domain 2.9e-07 25.9 1 37-81 1325 Guanylin Guanylin precursor 0.00035 9.9 1 1-24 1325 Apo-CII Apolipoprotein C-LI 9.1e-43 152.3 1 23-99 1326 Guanylin Guanylin precursor 0.00035 9.9 1 1-24 1326 Apo-CII Apolipoprotein C-l1 9.le-43 1523 1 23-99 1328 SRCR Scavenger receptor cysteine-rich 6.5e-37 13.9 1 60-71 WO 2004/080148 PCT/US2003/030720 552 TABLE 4B SEQ Model Description E-value Score Repeats Position ID domain _____ 1328 SRCR Scavenger receptor cysteine-rich 1.2e-34 123.9 domain 300__397 1328 SRCR Scavenger receptor cysteine-rich 4.7e-37 132.4 3 domain 1328 SRCR S r receptor cysteine-rich 1.5e-35 127.1 4 405-503 domain ____ 1328 DUF159 Uncharacterised ACR, COG2135 0 3 1 1328 SRCR Scavenger receptor cysteie-rich 1.8e-27 98.6 5 638-729 domain 1329 ig Immunogoulin domain 0.81 5.9 1 37-84 1329 ig Immunoglobulin domain 0.051 10.4 2 113-165 1331 efhand EFhand 0.025 12.1 1 12-40 1331 efhand EF hand 0.97 6.2 2 59-76 1331 efhand EFhand 0.041 11.2 3 85-113 1333 wnt wnt family 6.9e- 694.6 1 0-365 240 ________ 1335 7tm_1l 7 transmembrane receptor (rhodopsin 8.8e-18 51.9 1 8-75 family) t 1336 SAPSAP domain 3.8e-07 29.1 1 1336 zf-MIZ MIZ zinc finger 4.te-41 120.1 1 323-375 1337 FA desaturase Fatty acid desaturase 1.2c-76 264.7 1 71-296 1338 cystatin Cystatin domain 0.074 6.5 1 25-45 1340 actin Actin 5.4e-67 221.4 1 1340 ElN El Protein, N terminal domain 0.08 6.5 1341 ion trans Iontransportprotein 0.0 1341 ion trans Ion transport protein 5e-O 18.6 1343 ig Immunoglobulin domain 6.1e-06 25.1 1 124-182 1343 ig Immunoglobulin domain 2.2e-06 26.8 2 224-281 1343 ig Immunoglobulin domain 7.6e-08 32.2 3 316-372 1343 fn3 Fibronectin type III domain 2.8e-16 58.3 1 394-480 1343 f3Fibronectin type III domain 692-5 1343 fn3 Fibronectin type III domain 0.013 10.8 3 | 1344 DUF84 Protein of unknown function DUF84 0.098 5.9 1 8-22 1344 ig Immunoglobulin domain 3c-07 30.0 1 53-110 1344 ig Immunoglobulin domain 1.8e-07 30.9 2 150-216 1344 ig Immunoglobulin domain 2.9e-08 33.8 3 255-310 1344 ig Immunoglobulin domain 4.6e-07 29.3 4 350-417 1344 ig Immunogoulin domain 1le-07 31.6 5 456-516 1344 ig Immunoglobulin domain 8.8e-05 20.8 6 1344 MAM MAM domain 6.7e-77 265.6 1 753-918 1345 kazal Kazal-type serine protease inhibitor 7.7e-06 25.8 1 121-168 domain 1345 ig Immunoglobulin domain 1.2e-06 27.7 1 186-255 1346 RNA helicase RNA helicase 0.031 7.9 1 82-109 1346 ATP-bind Conserved hypothetical ATP binding pr 0.055 7.3 1 87-100 1348 ig Immunoglobulin domain 8.5e-07 28.3 1 61-120 1348 ig Immunoglobulin domain 0.00026 19.0 2 155-214 1348 ig Immunoglobulin domain 4.7e-08 33.0 3 258-315 1348 ig Immunoglobulin domain .3e-05 23.0 4 348-404 1348 ig Immunoglobulin domain 4.6e-09 36.8 5 440-497 1348 ig Imnunoglobulin domain 8.8e-07 28.3 6 530-596 1348 fn3 Fibronectin type III domain 5.2e-20 713 1 615-704 1348 1F3 Fibronectin type III domain WO 2004/080148 PCT/US2003/030720 553 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 1348 fn3 Fibronectin type III domain 8.9e-14 49.6 3 819-907 If348 fh3 Fibronectin type III domain 0.00019 17.2 4 919 1002 1350 serpin Serpin shrinee protease inhibitor) 5.le- 664.7 1 45-378 197 1350 serpin Serpin (serine protease inhibitor) 8e-09 29.6 2 379-402 1352 DREV DREV methyltransferase 7.3e- 680.7 1 56-317 233 1353 CARD Caspase recruitment domain 2.6e-33 119.8 1 2-91 1355 ank Ankyrin repeat 1.8e-07 29.9 2 64-96 155 ank Ankyrin repeat 1.6e-06 26.4 3 97-129 1355 ank Ankyrin repeat 3.8e-07 28.7 4 130-162 1355 ank Ankyrin repeat 0.00011 19.9 5 163-195 1355 ank Ankyrin repeat 0.00012 19.8 6 196-228 1356 pkinase Protein kinase domain 3.5e-64 223.4 1 221-479 1356 Aldolase KDPG and KHG aldolase 0.038 7.4 1 868-891 1357 pkinase Protein kinase domain 2.8e-05 18.9 1 43-72 1357 Aldolase KDPG and KHG aldolase 0.038 7.4 1 461-484 1358 7tm_1 7 transmembrane receptor (rhodopsin 2.6e-13 38.4 1 1-59 family) 1359 tRNA-synt_1 tRNA synthetases class 1 (1, L, M and 0.00037 12.8 1 53-115 V) 1359 tRNA-synt le tRNA synthetases class I (C) 0.0002 14.0 1 345-375 1359 tRNA-synti1 tRNA synthetases class 1 (1, L, M and 2.4e-07 23.7 2 345-383 V) 1360 MHCII beta Class II histocompatibility antigen, beta 1.4e-43 149.3 1 42-117 1363 ig Immunoglobulin domain 0.86 5.8 1 12-69 1363 ig Immunoglobulin domain 0.17 8.4 2 139-200 1363 ig Immunoglobulin domain 0.00066 17.5 3 236-294 1363 ig Immunoglobulin domain 7.9e-06 24.7 4 344-398 1364 fn3 Fibronectin type III domain 0.0032 12.9 1 35-125 1365 ILl Interleukin-1 / 18 5.4e-31 110.6 1 11-155 1366 A2MN Alpha-2-macroglobulin family N- 1.5e-92 317.7 1 6-613 terminal regi 1366 A2M Alpha-2-macroglobulin family 3.6e- 711.7 1 722 211 1449 1367 ABC membrane ABC transporter transmembrane region 1.7e-07 28.5 1 1-70 1368 UPAR LY6 u-PAR/Ly-6 domain 2.6e-37 134.1 1 27-106 1967 DUF99 Protein of unknown function DUF99 0.06 5.8 1 3-26 1967 hormone Somatotropin hormone family 1.6e-55 156.0 1 29-141 1968 DUF99 Protein of unknown function DUF99 0.06 5.8 1 3-26 1968 hormone Somatotropin hormone family 1.6e-55 156.0 1 29-141 1969 DUF99 Protein of unknown function DUF99 0.06 5.8 1 3-26 1969 hormone Somatotropin hormone family 1.6e-55 156.0 1 29-141 1970 DUF99 Protein of unknown function DUF99 0.06 5.8 1 3-26 1970 hormone Somatotropin hormone family 1.6e-55 156.0 1 29-141 1971 serpin Serpin (serine protease inhibitor) 5.le-83 282.6 1 83-449 1972 PI-PLC-X Phosphatidylinositol-specific 3.8e-14 50.6 1 1-33 phospholipase 1973 Lipase_3 Lipase (class 3) 1.7e-17 62.0 1 399-538 1976 DUF846 Eukaryotic protein of unknown 0.0091 7.9 1 79-109 function (DUF8 1977 Monooxygenase Monooxygenase 3.8e-12 44.1 1 215-313 1977 Monooxygenase Monooxygenase 1.7e-15 56.1 2 358-443 WO 2004/080148 PCT/US2003/030720 554 TABLE 4B SEQ Model Description E-value Score Repeats Position ID 1980 zf-AN1 ANI-like Zinc finger 0.032 10.1 1 59-98 1980 zf-ANI ANI-like Zinc finger 9.2e-06 22.6 2 149-181 1981 CRAL TRIO CRALTRIO domain 0.037 7.8 1 -38 1982 Rhomboid Rhomboid family 19e-32 116.9 1 128-282 1984 LBP_BPICETP LBP / BPI/ CETP family, N-terminal 4.5e-38 130.4 I 33-191 do 1984 LBP_BPI CETP LBP / BPI / CETP family, 8.3e-14 .9 C do 1987 DUF572 Family of unknown function (DUF572) 3.5e-37 133.7 1 1-61 1987 DUF572 Family of unknown function (DUF572) 5e-23 84.4 2 91-149 1988 Collagen Collagen triple helix repeat (20 copi 3.7e-11 44.2 11-51 1988 Collagen Collagen triple helix repa(2 copi 6.6c-1 43.2 2 60-115 1988 Collagen Collagen triple helix repeat (20 copi 3.9e-13 51.6 3 116-175 1988 Collagen Collagen triple helix repeat (20 copi 0.0069 13.1 4 178-195 1988 Collagen Collagen triple helix repeat (20 copi 0.0001 20.0 5 199-230 1988 Collagen Collagen triple helix repeat (20 copi 4e-09 36.5 6 239-298 1988 Collagen Collagen triple helix repeat (20 copi 1.9e-13 52.8 7 302-355 1988 Collagen Collagen triple helix repeat (20 copi 7.le-06 24.3 8 362-395 1988 Collagen Collagen triple helix repeat (20 copi 0012 16.0 9 396-444 1988 C4 C-terminal tandem repeated domain in 2e-69 240.8 1 450-557 1988 C4 C-terminal tandem repeated domain in 1.3e-77 268.0 2 558-672 1989 ldl-receptb Low-density lipoprotein receptor repeat 7.3e-10 34.9 1 56-97 1989 ldl receptb Low-density lipoprotein receptor repeat 2.7e-07 26.4 2 99-141 1989 ldl rcceptb Low-density lipoprotein receptor repeat 3.2e-07 26.2 3 143-185 1990 ldl receptb Low-density lipoprotein receptor repeat 7.3e-10 34.9 1 56-97 1990 1dl recept b Low-density lipoprotein receptor repeat 2.7e-07 26.4 2 99-141 1990 ldl receptb Low-density lipoprotein receptor repeat 3.2e-07 26.2 3 143485 1991 DUF846 Eukaryotic protein of unknown 0.00016 13.3 1 76-106 function (DUF8 1f992 c adherin Cadherin domain 2.le-10 38.0 1 ___ 9-105 1992 cadherin 1.4,-28 101.4 119-210 199 cadherinmai _ 1993 cadherin Cadherin domain 2.le-10 38.0 1 9-105 1993 cadherin Cadherin domain 1.4e-28 101.4 2 119-210 1995 VIR Vomeronasal organ pheromone 3.8e-08 27.0 1 4-36 receptor family, 1998 ig Immunoglobulin domain 2.le-09 38.1 1 18-76 1998 ig Immunoglobulin domain 7.9e-09 35.9 2 121-179 1998 ig Immunoglobulin domain 0.00014 20.0 3 216-274 1998 ig Immunoglobulin domain 7.le-09 36.1 4 308-366 1998 ig Immunoglobulin domain 1.7e-10 42.2 5 403-461 1999 SPRY SPRY domain 1.8e-30 107.5 1 148-277 1999 SRP54 SRP54-type protein, GTPase domain 0.0091 11.6 1 310-325 1999 AAA ATPasc family associated with various 0.098 5.8 1 313-325 ________________cellul____ 2000 ABC tran ABC transporter 2.5e-43 146.2 1 118-301 2002 Acyl-CoA-dh..M Acyl-CoA dehydrogenase, middle 0.0071 11.7 1 99-136 domain0.3 78 1 1-8 2002 cyl-CoAdh Acyl-CoA dehydrogenase, C-terminal 6.7e-50 175.9 1 415-566 doma 2003 C tripleX Cysteine rich repeat 2e-05 17.8 1 76-93 2003 BOF EUF-like domain 8.7e-06 23,6 2 115-143 2003 -TIL Trypsin Inhibitor like cysteine rich 0.0035 11.0 1 134-155 domain 003 EGF-like domain fco) .5e-7 2.2 3 155-189 WO 2004/080148 PCT/US2003/030720 555 TABLE 4B SEQ Model Description E Score ID ___ 2003 TIL Trypsin inhibitor like cysteine rich 0.26 5.1 2 168-195 domain ____ 2003 EGF EGF-like domain 4.4e-05 21.1 4 1 2003 EGF EGF-like domain 9.7e-09 34.3 240-275 2003TAM MAM domain 9.2e-38 135.6 1 421-566 2004 NHL NHL repeat I.e-10 42.4 1 8-35 2004 HL NHL repeat 2.5-09 37.6 2 55-82 2004 NHL NHL repeat 7.8e-11 43.0 3102-129 2005 FCH Fes/CIP4 homology domain 0.026 10.3 1 310-350 2005 DAGPE-bind Phorbo4 esters/diacyiglycerol binding 2.8e-05 21.7 1 738-776 domn 2005 RhoGAP RhoGAP domain 3.9e-68 231.7 1 804-976 2006 CN hydrolase Carbon-nitrogen hydrolase 4.5e-07 26.2 2 117-206 2007 tsp I Thrombospondin type 1 domain 0.054 8.4 1 5-23 2008 Adaptin N Adaptin N terminal region 7.5e-09 29.6 1 1-51 2008 Alpha adaptinC2 Adaptin C-terminal domain 4.4e-38 126.8 1 183-296 2008 Alpha adaptin-C Alpha adapting AP2, C-terminal domain 1.6e- 334.2 1 302-414 1Imngouidoan113 -F -__ ____ 2009 ig 0.0045 14.4 1 42-129 2009 ig Immunoglobulin domain 0.19 8.3 2 179-272 2009 ig Immunoglobulin domain 9.7e-05 20.6 3 319-408 2009 ig Immunoglobulin domain 0.00014 20.0 4 455-546 2010 ig Immunoglobulin domain 0.0045 14.4 1 42-129 2010 ig Immunoglobulin domain 0.19 8.3 2 179-272 2010 ig Immunoglobulin domain 9.7e-05 20.6 3 319-408 2010 ig Immunoglobulin domain 0.00014 2. 45 2011 ig Immunoglobulin domain 0.0045 14.4 7 42-129 2011 ig Immunoglobulin domain 0.19 8.3 2 179-272 2011 ig Immunoglobulin domain 9.7e-05 20.6 3 319-408 2011 ig Immunoglobulin domain 0.00014 20.0 4 455-546 2012 ig Immunoglobulin domain 0.0045 14.4 1 42-129 2012 ig Immunoglohulin domain 0.19 8.3 2 179-272 2012 ig Immunoglobulin domain 9.7e-05 20.6 3 319-408 2012 ig Immunoglobulin domain 0.00014 20.0 4 455-546 2016 TFA Transcription elongation factor A, SII-r 3.4e-23 87.2 1 148-283 2018 cadherin Cadherin domain 8e-13 46.4 1 1-49 20O18 cahrnCadherin domain 4.5e-09 33.4 276-120 201 cadherin 2 2019 PGMPMM Phosphoglucomutase/phosphomanfom 0.041 9.3 1 347-389 ~~~~~utase, C-ter 5001 1. 11316 2020 MACPF MAC/Perform domain 2021 KRAB KRAB box 6.9e-24 88.6 1 54-94 2022 KRAB KRAB box 6.9e-24 88.6 1 54-94 2023 EMP24 GP25L emp24/gp25L/p24 family 1.9e-15 55.4 1 17-78 2024 acidphosphat Histidine acid phosphatase 7.9e- 537.8 1 35-375 159 2026 KRAB KRAB box 1le-20 77.0 1 132-172 2026 zf-C2H2 Zinc finger, C2H2 type 3.7e-07 33.4 1 485-507 2026 zf-C3HC4 Zinc finger, C3HC4 type (RI singer) 0.54 2.9 1 500-518 2026 zf-C2H2 Zinc finger, C2H2 type 1.3e-05 27.2 2 513-535 2026 zf-C2H2Zinc finger, C2H2 type 3.4e-08 37.4 3 543-565 2026 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.032 6.3 2 558-576 2026 zf-C2H2 Zinc finger, C2H2 type 5.7e-06 28.6 4 571-593 202T7 Vpsi6N VpsIb6, N-terminal region 2.3e- 366.9 1 1-165 domain WO 2004/080148 PCT/US2003/030720 556 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 2027 Vpsl 6 C Vpsl6, C-terminal region 5e-203 684.6 1 262-580 2028 LRRNT Leucine rich repeat N-terminal domain 0.0011 14.5 1 11-40 2029 A21M Alpha-2-macroglobulin family 6.3e-23 75.5 1 4-86 2031 fn3 Fibronectin type III domain 4.9e-08 29.7 1 3-33 2031 fn3 Fibronectin type III domain 9.le-08 28.7 2 46-136 2032 LRR Leucine Rich Repeat 0.021 10.8 1 2-25 2032 LRR Leucine Rich Repeat 3e-05 20.4 2 26-49 2032 LRR Leucine Rich Repeat 0.00019 17.8 3 50-73 2032 LRR Leucine Rich Repeat 0.16 7.8 4 74-94 2032 LRRCT Leucine rich repeat C-terminal domain 2.2e-05 17.6 1 118-132 2033 LRR Leucine Rich Repeat 0.021 10.8 1 2-25 2033 LRR Leucine Rich Repeat 3e-05 20.4 2 26-49 2033 LRR Leucine Rich Repeat 0.00019 17.8 3 50-73 2033 LRR Leucine Rich Repeat 0.16 7.8 4 74-94 2033 LRRCT Leucine rich repeat C-terminal domain 2.2e-05 17.6 1 118-132 2034 EGF EGF-like domain 0.76 5.8 1 135-157 2034 SEA SEA domain 4.9e-06 22.1 1 192-261 2034 ig Immunoglobulin domain 9.8e-07 28.1 1 310-376 2034 ig Immunoglobulin domain 0.33 7.4 2 509-571 2034 GPS Latrophilin/CL-1-like GPS domain 2e-14 54.5 1 975 1027 2034 7tm_2 7 transmembrane receptor (Secretin 2.8e-20 71.1 2 1086 family) 1298 2035 TFILS Transcription factor S-II (TFIIS) 0.019 10.6 1 21-31 2035 zf-C2H2 Zinc finger, C2112 type 3.le-06 29.7 2 21-43 2035 zf-C2H2 Zinc finger, C2H2 type 2.7e-07 3.9 3-49-71 2035 zf-BED BED zinc finger 0.63 4.8 1 50-72 2035 XPA N 2/4 46 56.. 1 11 0.22 7.0 3 74-86 2035 zf-C2H2 Zinc finger, C2H2 type 8.8e-08 35.9 4 77-99 2035 TFIIS Transcription factor S-II (TFIIS) 0.036 9.7 4 105-115 2035 zf-C2H2 Zinc finger, C2H2 type 0.0096 15.6 5 105-120 2038 zf-C2H2 Zinc finger, C2H2 type 0.0099 15.5 1 197-220 2039 FHA FHA domain 0.024 11.6 1 45-110 2039 HIT HIT domain 0.013 8.5 1 201-226 2039 zf-C2H2 Zinc finger, C2H2 type 0.026 13.9 1 337-359 2040 FHA FHA domain 0.024 11.6 1 45-110 2040 HIT HIT domain 0.013 8.5 1 201-226 2040 zf-C2H2 Zinc finger, C2H2 type 0.026 13.9 1_ _ 337-359 2041 FHA FHA domain 0.024 11.6 1_ | 45-110 2041 HIT HIT domain 0.013 8.5 1 201-226 2041 zf-C2H2 Zine finger, C2H2 type 0.026 13.9 1 337-359 2042 Cwf Cwc_15 Cwfl5/Cwc15 cell cycle control protei 8.6e- 544.3 1 2-230 161 2043 SRCR Scavenger receptor cysteine-rich 6.5e-15 54.2 1 8-113 domain 2043 Lysyl oxidase Lysyl oxidase 1.9e- 476.7 1 117-286 140 2045 WD40 WD domain, G-beta repeat 0.5 6.4 2 192-217 2045 WD40 WD domain, G-beta repeat 5.2e-06 23.8 3 248-274 2045 DUF130 Domain of unknown function DUF130 0.074 5.9 1 264-278 2045 WD40 WD domain, G-beta repeat 0.35 7.0 4 397-424 2048 CTP transf I Cytidylyltransferase family 4.9e- 422.2 1 86-417 124 2049 | CBM 20 Starch binding domain 0.078 8.5 1 14-33 WO 2004/080148 PCT/US2003/030720 557 TABLE 4B SEQ Model Description E value Score Repeats Position ID __ 2049 WD40 WD domain, G-beta repeat 3.9e-08 31.2 1 93-131 2052 7tm_3 7 transmembrane receptor 5.8e-06 21.5 1 112-153 (metabotropic gluta 2052 KdgT 2-keto-3-deoxygluconate permease 0.068 7.2 1 200-226 2052 7tm_3 7 transmembrane receptor 7.8e-05 17.4 2 221-305 (metabotropic gluta e 2054 HesB-like HesB-like domain 2.8e-41 132.5 1 52-154 2055 ig Immunoglobulin domain 0,032 11.237-59 2055 ig Immunoglobulin domain 0.00033 18.6 2 98-157 2056 Mpv17 PMP22 Mpv17 / PMP22 family 8e-14 51.5 1 101-163 2058 Collagen Collagen triple helix repeat (20 copies) 0.013 12.1 _17-38 2058 Collagen Collagen triple helix repeat (20 copies) 2.5e-07 29.8 3 40-79 2058 vwa von Willebrand factor type A domain 3.2e-13 42.1 1 108-156 2059 Sterol desat Sterol desaturase 8.6e-41 138.1 1 1-139 2060 ig Immunoglobulin domain 0.27 7.7 1 8-26 2060 ig Immunoglobulin domain 5.2e-08 32.9 2 97-158 2061 RNA helicase RNA helicase 0.00029 15.0 1 40-63 2061 AAA ATPase family associated with various 0.00038 13.8 1 42-58 ce 2061 NACHT NACHT domain 0.0022 12.0 1 44-66 2061 ADK Adenylate kinase 2.2e-05 19.0 1 77-124 2064 UDPGT UDP-glucoronosyl and UDP-glucosyl 9.7e-34 118.7 1 1-63 transferas 2065 TRAPPBet3 Transport protein particle (TRAPP) 9e-70 242.0 1 18-171 compone 2066 DUF846 Eukaryotic protein of unknown 0.013 7.4 1 83-101 function (DUF8 I__ 2068 ig Immunoglobulin domain 0.0042 14.5 1 33-110 2068 FliL Flagellar basal body-associated protein 0.029 9.2 1 170-203 FliL 2068 DeuC C4-dicarboxylate anaerobic carrier 0.044 7.9 1 174-193 2069 ig Immunoglobulin domain 0.0042 14.5 1 33-110 2069 FliL Flagellar basal body-associated protein 0.029 9.2 1 170-203 FliL 2069 DeuC C4-dicarboxylate anaerobic carrier 0.044 7.9 1 174-193 2070 ig Immunoglobulin domain 0.0042 14.5 1 33-110 2070 FliL Flagellar basal body-associated protein 0.029 9.2 1 170-203 FliL 2070 DcuC C4-dicarboxylate anaerobic carrier 0.044 7.9 1 174-193 2071 PH PH domain 1.9e-21 72.0 1 75-173 2072 Ifi-6-16 Interferon-induced 6-16 family 3.7e-46 159.7 1 41-123 2073 Ifi-6-16 Interferon-induced 6-16 family 3.7-46 159.7 _ 41-123 2074 Ribosomal L34e Ribosomal protein L34e 3.5e-72 232.6 1 12-110 2075 CDC50 LEM3 (ligand-effect modulator 3) 0.049 6.6 1 90-117 family / CD 2077 EGF EGF-like domain 0.0019 15.2 1 60-95 2078 EGF EGF-like domain 0.0019 15.2 1 60-95 2079 EGF EGF-like domain 0.0019 15.2 1 60-95 2080 ig Immunoglobulin domain 4.9e-06 25.4 1 109-171 2081 Monooxygenase Monooxygenase 0.0069 10.9 1 593-611 2081 ras Ras family 7.2e-10 33.6 1 924-967 2082 Alpha adaptin C Alpha adaptin AP2, C-terminal domain 0.061 5.2 1 97-109 2082 MHC I Class I Histocompatibility antigen, d 0.00048 14.9 2 125-210 2083 ig Immunoglobulin domain| 4.le-05 22.0 1 10-78 WO 2004/080148 PCT/US2003/030720 558 TABLE 4B SEQ Model Description E-value Score Repeats Position ID 2083 ig Immunoglobulin domain 3.7e-10 40.9 2 113-172 2083 ig 1 oglobul in 0.0018 15.9 3 211-272 2083 ig Immunoglobulin domain 3.7e-08 33.4 4 70 2083 DNApolB.2 DNA palymerasc type B, organellar 0.018 7.9 1 326-382 and________ 2083 OapA Opacity-assciated protein A 0.44 2.4 1 335-357 2083 ig Immunoglobulin domain 0.0012 5 404-465 2083 ig Immunoglobulin domain 7.7e-07 28.5 6 500-564 2084 ig Immunoglobulin domain 4.1e-05 22.0 1 2084 ig Immunoglobulin domain 3.7c-10 40.9 2113-172 2084 ig Immunoglobulin domain 0.0018 15.9 3 211-272 2084 ig Immunoglobulin domain 3.7e-08 33.4 4 309-370 204 Npol-B2 DNA polymerase type B, organellar 0.018 79 1 326-3 82 2f08 4 DNApo BT 2 _____ ~~and ____ __ 2084 OapA Opacity-associated protein A 0.44 2.4 1 335-357 2084 ig Immunoglobulin domain 0.0012 16.6 5 404-465 2084 ig Immunoglobulin domain 7.7e-07 28.5 6 500-564 2085 ig Immunoglobulin domain 4.1e-05 22.0 1 10-78 2085 ig Immunoglobulin domain 3.7e-10 40.9 2 113-172 2085 ig Immunoglobulin domain 0.0018 15.9 3 211-272 2085 ig Immunoglobulin domain 3.7e-08 33.4 4 309-370 2085 DNApolB2 DNA polymerase type B, organellar 0.018 7.9 1 326-382 _____and 2085 OapA Opacity-associated protein A 0.44 2.4 1 335-357 2085 ig Immunoglobulin domain 0.0012 16.6 5 404-465 2085 ig Immunoglobulin domain 7.7e-07 28.5 500-564 2086 P53 P53 3.5e-09 33.8 1 7-32 2087 Apolipoprotein Apolipoprotein A1/A4/E family 2.3e-11 42.3 1 93-168 2087 DUF260 Protein of unknown function DUF260 0.64 3.5 1 94-107 2087 Adeno PIX Adenovirus hexon-associated protein 0.49 4.4 1 95-110 2087 |BcrAD BadFG BadF/BadG/BcrAIBcrD ATPase family 0.12 6 1 2087 Apolipoprotein Apolipoprotein A1/A4/E family 0.011 10.5 2 172-258 2087 MMCoAmutas Methylmalonyl-CoA mutase 0.84 1.9 1 264-306 e 2088 Apolipoprotein Apolipoprotein A1/A4/E family 2.3e-11 42.3 1 93-168 2088 DUF260 Protein of unknown function DUF260 0.64 3.5 1 94-107 2088 Adeno PIX Adenovirus hexon-associated protein ( 0.49 4.4 1 95-110 2088 BcrAD BadFG BadF/BadG/BcrAIBcrD ATPase family 0.12 6.2 1 134-180 2088 Apolipoprotein Apolipoprotein Al/A4/E family 0.011 10.5 172-258 2088 MMCoA-mutas Methylmalonyl-CoA mutase 0.84 1.9 1 264-306 e 89 DUF717 Protein of unknown function~(EUvlue 1 4.0 R 68-80 2089 MHCII Class I Histocompatibility antigen, d 0.69 3.7 1 185-198 2090 PoxD5 Poxvirus D5 protein-like 1 2.2 3 21-33 2090 phoslip Phospholipase A2 3.4e-49 72.4 9 26-150 2090 RFXpDNAobindi RFX DNA-binding domain 0.84 2.9 1 55-62 ngan 2092 MR MLEN Mandelate racemase / muconate lactoni 1,6e-05 17.0 1 ___ 54-157 2092 PeptidaseS26 Signal peptidase 0.38 3.8 1 99-129 2092 CheRN CheRmethyltransferase, all-alpha dom 0.4 6.7 5 103-119 2092 MR MLE Mandelate racemase / muconate lactoni 2.5e-08 29.9 1 236-298 2094 PI2C Protein phosphatase 2C 1.2e-71 248.2 1 136-412 2095 mGF E ngF-like domain 0.64 6.1 1 3-29 2095 EGF EGF-like domain .e-05 20.5 2 35-68 WO 2004/080148 PCT/US2003/030720 559 TABLE 4B SEQ Model Description E value Score Repeats Position ID 2095 EGF EGF-like domain 0.00015 19.1 3 94-131 2096 7tm 1 7 transmembrane receptor (rhodopsin f 8.6e-47 138.9 1 83-332 2097 7tm 1 7 transmembrane receptor (rhodopsin f 8.6e-47 138.9 1 83-332 2098 DSL Delta serrate ligand 0.018 9.3 1 22-37 2098 EGF EGF-like domain 0.0067 13.2 1 44-71 2098 TIL Trypsin Inhibitor like cysteine rich 0.33 4.8 1 46-66 2098 DSL Delta serrate ligand 0.48 4.7 2 56-71 2099 TEPi N TEP1 N-terminal domain 0.85 4.7 1 36-65 2099 Pox _A46 Poxvirus A46 family 0.55 2.5 1 61-75 2099 ExoD Exopolysaccharide synthesis, ExoD 0.82 2.4 1 124-147 2099 RhoGAP RhoGAP domain 4e-28 95.9 1 161-255 2102 myosin head Myosin head (motor domain) 6.3e-56 189.4 1 9-183 2102 ATP bind2 P-loop ATPase protein family 0.16 4.9 1 75-88 2102 PRK Phosphoribulokinase / Uridine kinase 0.14 5.2 1 77-88 fa 2103 myosin head Myosin head (motor domain) 6.3e-56 189.4 1 9-183 2103 ATP bind2 P-loop ATPase protein family 0.16 4.9 1 75-88 2103 PRK Phosphoribulokinase I Uridine kinase 0.14 5.2 1 77-88 fa 2105 kazal Kaza1-type serine protease inhibitor _8.4e-08_ 35 _73-117 2105 thyroglobulin 1i Thyroglobulin type-I repeat 7.7e-19 72.8 1 255-317 2108 BEX Brain expressed X-linked like family 9.8e-86 266.4 1 79-190 2108 ChaC ChaC-like protein 0.2 4.5 1 132-157 2108 IlvC Acetohydroxy acid isomeroreductase, 0.14 5.9 1 133-162 ca ____ 2109 LRRCT Leucine rich repeat C-terminal domain 8.5c-09 28.1 1 45-91 2109 UPF0118 Domain of unknown function DUF2O 1 2.9 1 219-242 2112 Inh Protease inhibitor mb 0.026 9.0 1 19-44 2112 ank Ankyrin repeat 0.0042 14.2 1 26-45 213 DUF370 Domain of unknown function 1 3.5 1 24-39 (DUF37) U 2113 ApoL Apolipoprotein L 2113 HupHC HupH hydrogenase expression protein, 0.99 2.7 1 119-134 2114 DUF370 Domain of unknown function 1 3.5 1 24-39 (DU F37) 2114 ApoL Apolipoprotein L 4e-191 645.1 1 46-348 2114 HupHC HupH hydrogenase expression protein, 0.99 2.7 1 119-134 2115 MAM MAM domain 154.8 1 3-102 2116 MAM MAM domain 1.5e-43 154.8 1 3-102 2117 CBF CBF/Mak2l family 0.00014 14.4 1 32-65 2118 PLA2 B Lysophospholipase catalytic domain 7.6e-30 104.2 1 14-143 2118 DUF188 Uncharacterized BCR, YaiIIYqxD 0.9 2.9 1 140-151 ________family CO ____ 2119 PLA2 B Lysophospholipase catalytic domain 7.6e-30 104.2 1 14-143 2119 DUF18 UncharacterizedBCR, YailYqxD 0.9 2.9 1 140-151 __________family CO 6c5 165 1314 2121 p 4 50 Cytochrome P450 2121 Phage attach Phage Head-Tail Attachment 0.97 1.6 1 100-111 2122 ig Immunoglbulin domain 1.5e-12 49.8 1 38-96 2122 ig Immunogtobulin domain 2.3c-06 26.7 2 134-213 2122 CD36 CD36 family 0.38 3.9 2122 Neur chan mem Neurotransmitter-gated ion-channel tra 0.69 2.3 1 261-270 b 2123 rcig Iremmunoglobulin domain 1.5e- 1 49.8 1 38-96 WO 2004/080148 PCT/US2003/030720 560 SEQ Model Description E-value Score Repeats position ID 2123 ig Immunoglobulin domain 2.3e-06 26.7 2 134-213 2123 CD36 CD36 family 0.38 3.9 1 246-271 2123 Neur chanmem Neurotransmitter-gated ion-channel tra mem69 23 b 2124 igImmunoglobulin domain 15- 49F8- 38-96 2124 ig _7 e12 4. 2124 ig Immunoglobulin domain 2.3-06 26.7 2 134-213 2124 CD36 CD36 family 08 9 26-270 2124 Neur chan mem Neurotransmitter-gated ion-channel tra 0.69 2.3 1 b ___ 2125 C2 C2 domain 0.15 6.6 1 33-48 2125 C2 C2domain 8.3c-37 125.8 2 92-180 21I26 D1UF 1058 Protein of unknown function 0.49 2.3 1 80-93 6 D 8(DUF1058) 2126 Pep M2B . _p Reprolysin family propeptide 1.9e-05 17.5 1 155-208 ep 2127 Ifi-6-16 Interferon-induced 6-16 family 3.7e-46 159.7 1 41-123 2127 GLTT GLTT repeat (6 copies) 0.18 7.7 1 50-78 2127 CRCB CrcB-like protein 0.18 7 1 106-124 2128 abhydrolase alpha/beta hydrolase fold 0.02 9.2 1 74427 2128 lipase Lipase 0,64 3.7 1 98-126 2128 abhydrolase alpha/beta hydrolase fold 0.0083 10.5 2 167-237 2128 DLH Dienelactone hydrolase family 0.4 3.6 1 169-196 2128 LIP Secretory lipase 0.012 8.6 1 178-203 2128 UPF0227 Uncharacterised protein family (UPFO2 0.38 4.9 1 179-209 2128 abhydrolase2 Phospholipase/Carboxylesterase 0.015 10.1 1 180-203 2128 PeptidaseM10_ Matrix metalloprotease, N-terminal do 0.63 2.5 1 209-230 N 2129 abhydrolase alphalbeta hydrolase fold 0.02 9.2 1 74-127 2129 lipase Lipase 0.64 3.7 98-126 2129 abhydrolase alpha/beta hydrolase fold 0.0083 10.5 2 167-237 2129 DLH Dienelactone hydrolase family 0.4 3.6 1 169-196 2129 LIP Secretory lipase 0.012 8.6 1 178-203 2129 UPF0227 Uncharacterised protein family (UPFO2 0.38 4.9 1 179-209 2129 abhydrolase2 Phospholipase/CarboxyleSteraSe 0.015 10.1 1 180-203 2129 PeptidaseMlO_ Matrix metalloprotease, N-terminal do 0.63 2.5 1 209-230 __ N 2130 Collagen Collagen triple helix repeat (20 copies 1.4e-06 27.0 1 1-38 2130 Collagen Collagen triple helix repeat (20 copies 2.5e-05 22.3 2 39-74 2130 SRCR Scavenger receptor cysteine-rich domai 2.6e-16 59.1 1 90-126 2131 Collagen Collagen triple helix repeat (20 copie 1.4e-06 27.0 1 1-38 2131 Collagen Collagen triple helix repeat (20 copie 2.5e-05 22.3 2 39-74 2131 SRCR Scavenger receptor cysteine-rich domain 2.6e-16 59.1 1 90-126 2132 RICH RICH domain 0.3 5.4 1 290-320 2132 DUF260 Protein of unknown functionDUF26O 0.047 7.1 - 425-447 2132 Ter DNA replication terminus site-binding 0.019 7.5 1 427-450 2132 Tropomyosin Tropomyosin 0.27 4.7 1 468-506 2132 Adeno PIX Adenovirus hexon-associated pr 0.044 8.0 1 482-506 2132 AgrD Staphylococcal AgrD protein 0.83 5.2 1 501-508 2132 K-box K-box region 0.0023 12.6 1 569-602 2132 Tfb2 Transcription factor Tfb2 0.98 -1.2 1 591-610 2132 RRF Ribosome recycling factor 0.5 696 2132 G-gamma GGLdonain 0.33 5.0 1 717-738 2132 DUF260 Protein of unknown unction DUF260 039 42 2 821-843 DecrbZIP transcription factorE 5u 5 2 Posi WO 2004/080148 PCT/US2003/030720 561 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 2132 Lipoprotein11 Lepidopteran low molecular weight (30 1 2.9 1 850-867 2132 DNA ligase N NAD-dependent DNA ligase 0.081 5.7 1 868-888 adenylation 2133 KRAB KRAB box 2.9e-27 100.7 1 61-101 2133 Androgenrecep Androgen receptor 0.71 0.7 1 70-80 2133 TFIIS Transcription factor S-1I (TFIIS) 0.73 5.1 1 324-334 2133 zf-C2H2 Zinc finger, C2H2 type 3.5e-05 25.4 1 324-346 2133 zf-C2H2 Zinc finger, C2H2 type 1.3e-06 31.2 2 352-374 2133 zf-BED BED zinc finger 0.33 5.7 1 354-375 2133 mRNAcap-enzy mRNA capping enzyme, catalytic 0.56 0.5 1 377-392 me domain 2133 XPA N XPA protein N-terminal 0.78 5.1 2 377-389 2133 zf-C2H2 Zinc finger, C2H2 type 2.9e-07 33.8 3 380-402 2133 TFIIS Transcription factor S-Il (TFIIS) 0.89 4.8 3 408-418 2133 zf-C2H2 Zinc finger, C2H2 type 2e-06 30.4 4 408-430 2133 zf-C2H2 Zinc finger, C2H2 type 1.6e-05 26.8 5 436-458 2133 mRNA-capenzy mRNA capping enzyme, catalytic 0.56 0.5 2 461-476 me domain ____ 2133 XPA N XPA protein N-terminal 0.78 5.1 4 461-473 2133 zf-C2H2 Zinc finger, C2H2 type 5.4e-07 32.7 6 464-486 2133 TFIIS Transcription factor S-II (TFIIS) 0.29 6.5 5 492-502 2133 zf-C2H2 Zinc finger, C2H2 type 1.le-06 492-514 2133 XPA N XPA protein N-terminal 0.13 7.8 6 517-529 2133 TFIIS Transcription factor S-II (TFIIS) 0.57 5.5 6 520-530 2133 zf-C2H2 Zinc finger, C2H2 type 9.2e-07 31.8 8 520-542 2133 XPA N XPA protein N-terminal 0.97 4.8 7 545-557 2133 TFIIS Transcription factor S-Il (TFIIS) 0.14 7.6 7 548-558 2133 zf-C2H2 Zinc finger, C2H2 type 4.4e-06 29.1 9 548-570 2133 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.38 3.3 560-581 2133 zf-C2H2 Zinc finger, C2H2 type 1.le-06 31.5 10 576-598 2133 TFIIS Transcription factor S-II (TFIIS) 0.054 9.0 8 604-614 2133 zf-C2H2 Zinc finger, C2H2 type 2.9e-07 33.8 11 604-626 2133 zf-BED BED zinc finger 0.64 4.8 3 609-627 2133 DCI 1/2 604 619.. 19 44 0.16 6.2 2 632-647 2133 zf-C2H2 Zinc finger, C2H2 type 0.00082 19.9 12 632-655 2137 aminotran 3 Aminotransferase class-III 1.2e-09 31.3 1 55-114 2137 OATP N Organic Anion Transporter Polypeptide 0.81 4.0 1 140-158 2137 aminotran 3 Aminotransferase class-IlI 8.1e-63 208.6 2 181-409 I2138 aminotran_3 Aminotransferase class-III 1.2e-09 31.3 1 55-114 2138 OATP N Organic Anion Transporter Polypeptide 0.81 4.0 1 140-158 2138 aminotran 3 Aminotransferase class-III 8.le-63 208.6 2 181-409 2139 trypsin Trypsin 1.3e-25 79.1 1 8-114 2140 Glycos transf 1 Glycosyl transferases group 1 1.7e-17 64.4 1 99-194 2141 MHYT Bacterial signalling protein N termina 0.6 4.2 1 291-328 2142 EGF EGF-like domain 8.8e-09 34.4 1 1-30 2142 EGF EGF-like domain 1.5e-07 30.0 2 41-72 2142 EGF EGF-like domain 0.0091 12.7 3 82-107 2142 EB EB module 0.077 7.1 2 116-148 2142 EGF EGF-like domain 1.3e-07 30.2 4 116-148 2142 EGF EGF-like domain 0.022 11.3 5 157-181 2143 AdoHcyase S-adenosyl-L-homocysteine hydrolase 0.0022 9.6 1 1-15 2143 AdoHyaseNA S-adenosyl-L-homocysteine hydrolase, 0.0012 13.8 1 16-27 D NA 2144 UQ_ con Ubiquitin-conjugating enzyme 0.0058 11.9 1 31-61 WO 2004/080148 PCT/US2003/030720 562 TABLE 4B___ SEQ Model Description E-value Score Repeats Position ID 2144 U -conjugating enzyme 5.8e-25 91.7 2145 Prominin Prominin 2.le- 364.0 1 3 113 -_ _ 8 -0 2145 SPDY Domain of unknown function 0.15 6.5 (DUF3 17) 2145 Prominin Prominin 6.7e-30 94.4 2 214-286 2145 Prominin Prominin 1.9e- 448.0 3 287-510 139 ________ 2146 fibrinogen.C Fibrinogen beta and gamma chains, C- .5e-54 184.0 13-231 ter 2147 fibrinogen.C Fibrinogen beta and gamma chains, C- .5e-54 184.0 1 13-231 ter 2148 fibrinogenC Fibrinogen beta and gamma chains, C- 6.5e-54 184.0 1 ter 2150 DUF381 Domain of unknown function 0.48 4.4 1 29-35 (DUF381) 2151 aa permeases Amino acid permeate 7e-24 89.2 1 6-294 2151 Pox 15 Poxvirusprotein15 024 6 1 85-102 2151 serine-carbpept Serine carboxypeptidase 0.41 2.3 1 301-321 2153 spectrin Spectrin repeat 0.4 5.5 1 410-463 2154 spectrin Spectrin repeat 0.4 5.5 1 410-463 2155 PeptidaseM20 Peptidase family M20/M25/M40 0.00038 14.5 1 39-120 2156 sugar tr Sugar (and other) transporter 0.11 .5 1 47-103 2156 OctopineDH NAD/NADP octopine/nopaline 0.26 4.6 1 153-169 dehydrogenas 2156 sugar tr Sugar (and their) transporter 5e-O8 28.1 2 201-336 2159 bromodomain Bromodomain 9.5e-45 158.8 1 74-163 2159 bromodomain Bromodomain 3e-40 143.5 2 367-45 2159 Alpha adaptinC Alpha adapting AP2, C-terminal domain 0.48 2.6 1 406-418 2159 Phage X PhageXfamily 0.97 3.7 1 449480 2159 eIF3eN Eukaryotic translation initiation ac 0.51 1.2 1 484-570 2159 VitellogeninN Lipoprotein amino terminal region 0.61 1.5 1 495-550 2159 HerpesU44 Herpes virus U44 protein 0.47 3.1 1 526-540 2161 ig Immunoglobulin domain 6.4e-06 25.0 1 58-118 2164 pkinase Protein kinase domain 2.6e-38 136.6 1 7-108 2164 TMP TMP repeat 0.37 8.0 1 74-84 2165 pkinase Protein inase domain 2.6e-38 136.6 1 7-108 2165 TMP TMP repeat 0.37 8.0 1 74-84 2166 glutaredoxin Glutaredoxin 0.00075 15.0 1 12-65 2166 GSTN Glutathione S-transferase, N-terminal 0.019 11.1 1 13-63 2166 GSTC Glutathione -transferase, C-terminal 0.00013 17.6 1 189-281 2166 UL21 HerpesvirusUL21 0.98 212-240 2167 PadR Transcriptional regulatorPadR-like f 0.22 6.1 1 18-31 2167 Collagen Collagen triple helix repeat (20 copi 2.4e-05 22.3 1 43-76 2167 Collagen Collagen triple helix repeat (20 copi 1.5e-07 30.6 2 77-122 2167 Clq Clq domain 2.9e-72 250.2 1 132-257 2167 TOBE TOBE domain 0.5 6.3 1 223-242 2169 Sec6 Exocyst complex component Sec6 0.71-2.3 1 166-194 2169 BRCT BRCAI C Terminus (BRCT) domain 0.0053 11,4 1 278-315 2169 Chitin bind 3 Chitin binding domain 0.95 2.1 1 308-321 2169 BRCT BRCA1 C Terminus (BRCT) domain 0.00072 14.3 2 329-369 2169 BRCT BRCAI C Terminus (BRCT) domain 5.7e-19 65.1 3 378-451 2169 BRCT BRCAI C Terminus (BRCT) domain 4c-19 65.6 4 536-622 2169 iDnB Transcriptional activator RiE 3 5.4 1 595-646 WO 2004/080148 PCT/US2003/030720 563 TABLE 4B___ ___ SEQ Model Description E-value Score Repeats Position ID 2169 BRCT BRCAI C Terminus (BRCT) domain 0.028 9.0 5 645-680 2170 Sec6 Exocyst complex component Sec6 0.71 2.3 1 166-194 2170 BRCT _RCAI C Terminus (BRCT) domain 0.0053 11.4 1 278-315 2170 Chitin bind 3 Chitin binding domain .95 321 2170 BRCT BRCAI C Terminus (BRCT) domain 0.00072 14.3 2 329-369 2170 BRCT BRCA1 C Terminus (BRCT) domain 5.7e-19 65.1 3 378-451 2170 BRCT BRCA1 C Terminus (BRCT) domain 4e-19 65.6 4 536-622 2170 RinB Transcriptional activator RinB 0.33 5.4 1 595-646 2170 BRCT BRCA1 C Terminus (BRCT) domain 0.028 9.0 5 645-680 2172 LRRCT Leu me rich repeat C-terminal domain 8.5e-09 28.1 1 45-91 2172 UPF01 18 Domain of unknown function DUF20 1 2.9 1 219-242 2173 ig _imunoglobulin domain 7.9e-06 24.7 39-93 2173 Na Ca Ex Sodium/calcium exchanger protein 0.86 4.3 1 133-148 2173 COX17 Cytoclrome C oxidase copper 0.68 3.6 1 196-209 chaperone -r 2174 TB2_DP1 HVA TB2/DP1, HVA22 family 3.8e-34 123.6 1 18-111 22 2174 ELM2 ELM2 domain 0.53 5.2 1 114-139 2175 An peroxidase Animal haem peroxidase 1.3e-91 311.6 1 2-232 2175 7tm 1 7 transmembrane receptor (rhodopsin f 0.22 2.7 1 24-32 2175 PeptidaseC1 Papain family cysteine protease 0.76 2.1 117-134 2176 An .peroxidase Animal haem peroxidase 1.3e-91 311.6 1 2-232 2176 7tm 1 7 transmembrane receptor (rhodopsin f 0.22 2.7 1 24-32 2176 PeptidaseCi Papain family cysteine protease 0.76 2.1 1 117-134 2177 Anperoxidase Animal haem peroxidase 1.3e-91 311.6 1 2-232 2177 7tm 1 7 transmembrane receptor (rhodopsin f 0.22 2.7 1 24-32 2177 Peptidase Cl Papain family cysteine protease 0.76 2.1 1 117-134 2178 DUF846 Eukaryotic protein of unknown function 0.0084 8.0 1 55-84 2179 UPF0137 Uncharacterised protein family (UPFO1 0.04 7.4 1 341-366 2179 PS ipyruv trans Polysaccharide pyruvyl transferase 0.55 3.3 1 355-411 2180 COX17 Cytoebrome C oxidase copper 0.51 4.0 1 39-60 chaperone 2180 Rlla Regulatory subunit oftype II P Ie-14 54.8 1 67-104 2180 SURF6 Surfeit locus protein 6 0.027 7.2 1 84-155 2180 cNMP binding Cyclic nucleotide-binding domain 7.2e-31 112.5 1 194-282 2180 RNA.polRpb2_ RNA polymerase Rpb2, domain 4 0.28 6.2 1 226-233 4 2180 cNMPbinding Cyclic nucotide-binding domain 9.4e-32 115.7 2 312-406 2180 Methyltransf 1 6-0-methylguanine DNA 0-64 4.3 1 367-379 218_ methyltransfera 2181 PDZ PDZ domain (Also known as DHR or 6.7e-12 43.7 1 5-86 GLGF) 2182 PLAT PLAT/LH2 domain 1.7e-31 108.4 1 2-1ll 2182 lipoxygenase Lipoxygenase 3.9e- 655.1 1 113-624 194 __ 2182 DUF181 UncharacterizedACR, COG19 0.81 2.4 1 221-232 2182 PG binding_1 Putative peptidoglycan binding domain 0.5 5.6 1 395-411 2183 PLATPLAT/LH2 domain 1.7e-31 108.4 2183 lipoxygenase Lipoxygenase 3.9e- 655.1 1 113-624 194 ___ 2183 DUF18I Uncharacteried ACR, C0G1944 0.81 2.4 221-232 2183 PG binding_1 Putative peptidoglycan binding domain 0.5 5.6 1 395-411 2184 PLAT PLAT/LH2 domain 1.7e-31 108.4 1 2-111 2184 iCoxygenase Lipoxygenase 3.9e- 655.1 1 113-624 WO 2004/080148 PCT/US2003/030720 564 TABLE 4B SEQ Model Description E-value Score Repeats Position ID ____ 194 ___ ____ 2184 DUF181 UnchajteizedACR, C0G1944 0.81 2.4 1 221-232 2184 PG binding 1 Putative p ptidoglycan binding domain 0.5 5.6 1 395-411 2186 TFIIS Transcription factor S-11 (THIS) 1 46 1 11-21 2186 DUF|36 Protein of unknown function, DUF53 0.19 7.9 1 220-257 2186 FCH Fes/CIP4 homology domain 0.5 5.6 1 265-284 2192 Aa trans Transinembrane amino acid transporter 3.8e-09 33.4 1 4-56 ______________ prote -- 02- 2 - 25 2193 EGF EGF-like domain 2193 EGF EGF-like domain 1.3e-06 26.6 2 60-88 2193 EGF BGF-like domain 2193 Cripto Cripto growt factor 2193 laminin EGF 1/3 32 60.. 2 43 0.025 9.9 2 106-130 2193 EGF EGE-like domain 5.5e-07 27.9 4 135-171 2194 M Mprotein repeat 0.8 7.1 1 64-84 2194 PPI inhibitor PKC-activated protein phosphatase-I i 0.78 2.2 1 303-319 2194 bZIP 1/2 65 82.. 48 65 0.32 6.2 2 397-415 2194 TSC22 TSC-22/diplbun family 045 7.2 1 398-415 2195 ank Ankyrin repeat 0.0017 15.6 2 206-231 2195 G-patch G-patch domain 2e-16 58.7 1 319-363 2195 Anti-silence Anti-silencing protein, ASFI-like 0,18 5.1 1 365-378 2196 endotoxin delta endotoxin 0.85 2.3 1 134-151 2197 Peptidase M24 metallopeptidase family M24 5.5e-69 239.3 1 103-342 2197 DUF12Domain of unknown function DUF2 0.089 71 1 184-195 2199 PAAD DAPIN PAAD/DAPIN/Pyrin domain 1.3e-11 41.6 1 18-103 2199 DEIHl DHAl dmi0.61 5.4 i67-87 2199 DHHA1 oai 2199 UPF0160 Uncharacterised protein family (UPFOI 1 2.3 1 75-86 2199 RNA helicase 0.03 7.9 1 195-215 21,99 NAGHT NAH domin.e-74 252.4 1 -196-365 29 NACHT NCTdmi 2199 AAA ATPase family associated with various 0.15 5.2 1 19-215 2199 PeptidaseS15 X-Pro dipeptidyl-peptidase (S15 famil 0.64 2.1 1 929-984 2200 PDZ PDZ domain (Also known as DHR or 8.1e-22 78.5 35-114 GLOF 2200 CDC50 LEM3 (ligand-effect modulator 3) fami 1 2.1 1 101-116 2200 DUF100 ProteinofunknownfunctionDUFOO 0.2 4.1 1 117-130 2201 DIE2 ALG1O DIE2/ALGO family 1.5e-54 191.4 1 62-142 2201 DUF718 Protein of unknown function (DUF7I8) 0.64 4.4 1 70-77 2202 rrm RNA recognition motif. (a.k.a. RRM, R 1.3e-09 36.2 1 76-143 2202 RbsD FucU / FucU transport protein family 0.53 3.4 1 138-162 2202 HemX HemX 0.37 3.5 1 157-188 2202 rrm RNA recognition motif. (a.k.a. RRM, R 4.6e-13 48.6 2 201-268 2202 rrm RNA recognition motif. (a.k.a. RRM, R 4.3e-13 48.7 3 354-421 2202 rrm RNArecognition motif. (a.k.a. RRM, R 1.4e-06 25.5 4 471-539 2203 C tripleX Cysteine rich repeat 2e-05 17.8 1 76-93 2203 Bowman- Bowman-Birk serine protease inhibitor 1 4.0 1 51 Birk leg 2203 laminin EGF Laminin EGF-like (Domains III and V) 0.32 6.1 2203 EGF EGF-like domain 8.7e-06 23.6 2 115-143 2203 TIL Trypsin Inhibitor like cysteine rich 0.0035 11.0 1 134-155 2203 EGF EGF-like domain 7.5e-05 20.2 3 155-189 2203 TIL Trypsin Inhibitor like cysteine rich 0.26 5.1 2 16-195 2203 toxin_5 Scorpion short toxin 0.34 4.4 1 170-175 2203 EGF EGF-like domain 4.4e-05 21.1 4 203 EGF EGF-ike domain 9.7e-09 4.3 5 240-275 WO 2004/080148 PCT/US2003/030720 565 SEQ Model Description E-value Score Repeats Position ID 2203 MAM MAM domain 9.2e-38 135.6 1 421-566 2204 C tripleX Cysteine rich repeat 2e-05 17.8 1 76-93 2204 Boman-Bowman-Birk serine protease inhibitor 85-100 Birk leg 2204 laminin EGF Laminir EGF-like (Domains III and V) 017-110 2204 EGF EGF-like domain 8.7e-06 23.6 2 115-143 2204 TIL Trypsin Inhibitor like cysteine rich 0.0035 11.0 1 134-155 2204 EGF EGF-like domain 7.5e-05 20.2 3 155-189 2204 TIL Trypsin Inhibitor like cysteie rich 0.26 5.1 2 2204 toxin 5 Scorpion short toxin 0.34 4.4 1 170-175 2204 EGF EGF-like domain 4.4e-05 21.1 4 195-228 2204 EGF EGF-like domain 9.7e-09 34.3 3 240-275 2204 MAM MAM domain .2e-38 135.6 1 421-566 2205 THI TI protein 0.91 1 315-328 2205 Negreg Negative transcriptional regulator .3 1 587-596 2205 zf-MYND MYND finger 2e-08 27.7 1 654-688 2206 TH1 THI protein 0.91 0.2 1 5-328 2206 Negreg Negative transcriptional regulator 1 587-596 2206 zf-MYND MYND finger 2e-08 27.7 1 654-688 2207 THI THI protein 0.91 0.2 1 315-328 2207 Neg reg Negative transcriptional regulator 1 2.3 1 587-596 2207 zf-MYND MYND finger 2e-08 27.7 1 654-688 2208 TH1 THI protein 0.91 0.2 1 315-328 220 -NTrg Negative transcriptional regulator 1 2.3 1 5 87-596 2208 Neg reg 2208 zf-MYND MYND finger 2e-08 27.7 1 654-688 2209 UrotensinII Urotensin 11 0.36 5.4 1 82-92 2209 fn2 Pibronectin type 11 domain 0.55 3.5 1 83-91 2210 RNA helicase RNA helicase 0.03 7.9 1 91-111 2210 NACHT NACHT domain 3.8e-74 252.4 1 92-261 2210 AAA ATPase family associated with various 0.15 5.2 1 93-111 2211 disintegrin Disintegrin 3.3e-36 123.1 1 4-79 2211 EGF EGE-like domain 0.0023 14.8 1 231-258 2213 zf-MYND MYND finger 1 3.8 1 38-45 2213 ank Ankyrinrepeat 4.4e-06 24.9 2213 ank Ankyrin repeat 6.9e-09 35.0 2 191-223 2213 ank Ankyrin repeat 0.15 2213 ank Ankyrin repeat 9.7e-10 38.0 4 290 2213 ank Ankyrin repeat 0.00014 19.5 5 ____291-336 2213 LolA Outer membrane lipoprotein carrier pr 1 3.0 1 317-340 2213 ank Ankyrin repeat 3.8e-08 32.3 6 337-369 2213 ank Ankyrin repeat 0.49 6.8 7370-402 221 ank8 2214 interferon Interferon alphabet dmi 3.7e-42 145.6 1 27-116 2215 DUF602 Protein of unknown function, DUF602 1.3e- 683.2 11-0 2 2 02 6 0 2 2215 Bromo MP Bromovirus movement protein 0.0 21-47 2216 DUF846 Eukaryotic protein of unknown 0.012 7.5 1 120-150 function 2218 acid phosphat Histidine acid phosphatase 5.5e-13 45.0 1 137-232 2219 PH PH domain 1.9e-20 68.8 1 78-238 2219 ArfGap Putative GTPase activating protein fo 5.4e-50 174.5 1 259-379 2219 ank Ankyrin repeat 1.9c-09 36.9 1 418-450 2219 ank Ankyrin repeat 0.022 11.6 2 451-475 2219 SapB 2 Saposin-li type B, region 2 0.33 6.5 1 464-475 2220 PH PH domain 1.9e-20 68.8 1 78-238 WO 2004/080148 PCT/US2003/030720 566 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 2220 ArfGap Putative GTPase activating protein fo 5.4e-50 174.5 1 259-379 2220 ank Ankyrin repeat 1.9e-09 36.9 1 418-450 2220 ank Ankyrin repeat 0.022 11.6 2 451-475 2220 SapB 2 Saposin-like type B, region 2 0.33 6.5 1 464-475 2221 PH PH domain _ 1.9e-20 68.8 1 78-238 2221 ArfGap Putative GTPase activating protein fo 5.4e-50 174.5 1_____ 259-379 2221 ank Ankyrin repeat 1.9e-09 36.9 1 418-450 2221 ank Ankyrin repeat 0.022 11.6 2 451-475 2221 SapB 2 Saposin-like type B, region 2 0.33 6.5 1 464-475 2222 PH PH domain 1.9e-20 68.8 1 78-238 2222 ArfGap Putative GTPase activating protein fo 5.4e-50 174.5 1 259-379 2222 ank Ankyrin repeat 1.9e-09 36.9 1 4.18-450 2222 ank Ankyrin repeat 0.022 11.6 2 451-475 2222 SapB 2 Saposin-like type B, region 2 0.33 6.5 1 464-475 2223 Reprolysin Reprolysin (M12B) family zinc metallo 2.4e-35 127.6 1 3-83 2223 Astacin Astacin (Peptidase family M12A) 0.21 5.0 1 23-37 2223 Phi I Phosphate-induced protein 1 conserved 0.51 3.3 1 71-83 2223 disintegrin Disintegrin 0.0019 12.9 1 101-136 2224 Uteroglobin Uteroglobin family 6.6e-09 29.8 1 1-88 2225 Clq Clq domain 6.3e-06 23.8 1 98-138 2226 Ormatin Ornatin 0.55 4.8 1 99-106 2227 Ornatin Ornatin 0.55 4.8 1 99-106 2228 Gag MA Matrix protein (MA), p 15 0.11 6.5 1 96-152 Z229 SeryltRNA.N Seryl-tRNA synthetase N-terminal 0.92 5.7 1 241-258 doma 2229 pentaxin Pentaxin family 4-3e-24 83.3 1 363-526 2229 Avirulence Xanthomonas avirulence protein, Avr/P 0.07 3.6 1 501-515 2233 ion trans Ion transport protein 0.001 14.0 1 22-141 2233 Sarcolipin Sarcolipin 0.56 5.3 1 95-123 2234 ion trans Ion transport protein 0.0 1 14.1 _____ 22-141 2234 Sarcolipin Sarcolipin 0.56 5.3 1 95-123 2235 zf-C2H2 Zinc finger, C2H2 type 0.033 13.4 2 100-123 2235 TFIID-31 Transcription initiation factor IID, 3 0.28 5.7 1 120-135 2235 zf-C2H2 Zinc finger, C2H2 type 0.14 10.9 3 134-156 2238 asp Eukaryotic aspartyl protease 1.le-24 87.5 1 1-67 2239 Sulfatase Sulfatase 4.5e-05 18.1 1 57-122 2240 Zn carbOpept Zinc carboxypeptidase 3.7c-57 193.6 1 13-156 2241 Zn carbOpept Zinc carboxypeptidase 3.7e-57 193.6 1 13-156 2242 NiflJ N NifU-like N terminal domain 1.7e-80 277.6 1 34-160 2244 zf-C2H2 Zinc finger, C2H2 type 0.00035 |21.4 1 56-81 2244 zf-C2H2 Zinc finger, C2H2 type 0.012 15.2 2 90-117 2244 zf-C2H2 Zinc finger, C2H2 type 0.0039 17.1 3 123-147 2245 pkinase Protein kinase domain 3.2e-90 309.9 1 49-341 2245 Glyco hydro_15 Glycosyl hydrolases family 15 0.18 4.4 1 501-551 2248 Clq Clq domain 5.le-23 86.7 1 27-135 2249 Allantoicase Allantoicase repeat 0.014 9.0 1 13-23 2249 Allantoicase Allantoicase repeat 1.3e-57 196.4 2 46-206 2250 DNA ligase_A_ ATP dependent DNA ligase C terminal 0.67 5.4 1 25-48 C r 2250 ig Immunoglobulin domain 0.00019 19.5 1 51-165 2250 ig Immunoglobulin domain 0.15 8.7 2 196-257 2250 ig Immunoglobulin domain 0.0031 15.0 3 289-349 2250 SK channel Calcium-activated SK potassium 0.035 7.1 1 377-397 channe WO 2004/080148 PCT/US2003/030720 567 TABLE 4B SEQ Model Description Evalue Score Repeats Position

ID

2251 PH PH domain 2.4e-24 81.6 1 43-153 2251 HS2ST Heparan sulfate 2-0-sulfotransferase 0.27 4.4 1 160-182 2251 LMP LMP repeated region 0.0012 14.2 1 180-201 2251 DUF603 Protein of unknown function, DUF603 0.04 6.4 1 193-207 2251 Pox A tye ic Viral A-type inclusion protein repeat 0.32 7.2 1 193-207 2251 IQ IQ calmodulin-binding motif 5e-OS 20.1 1 226-246 2251 RhoGEF RhoGEF domain 1.2e-69 236.9 1 267-448 2251 DUF674 Protein of unknown function (DUF674) 0.82 1.4 1 295-305 2251 Stigi Stigma-specific protein, Stig1 0.6 2.3 1 396-441 2251 PH PH domain 2.3e-13 45.3 2 480-608 2251 RasGEFN Guanine nucleotide exchange factor fo 1.1e-19 71.3 1 653-708 2251 RasGEF RasGEF domain 7.2e-89 305.4 1 101 2251 Adenoterminal Adenoviral DNA terminal protein 1 1.7 1 1195 1227 2252 DUF630 Protein of unknown function (DUF630) 0.7 4.3 1 584-597 2252 FGF Fibroblast growth factor 0.37 4.4 1 620-635 2252 tRNA-synt 2 tRNA synthetases class II (D, K and N 0.74 3.5 1 646-658 2252 Omega-atracotox Omega-atracotoxin 0.15 5.1 1 751-758 2253 K tetra K+ channel tetramerisation domain 2e-34 121.3 1 26-114 2253 BTB BTB/POZ domain 0.0015 14.2 1 74-125 2254 PXA PXA domain 0.01 10.2 1 90-110 2254 Vps52 Vps52 / Sac2 family 0 1089. 1 100-609 2 2254 trpsyntA Tryptophan synthase alpha chain 0.78 3.1 _ 179-216 2254 DUF965 Bacterial protein of unknown function 0.33 4.5 1 291-304 2255 NosL NosL 0.29 4.9 1 104-128 2255 NAG NAC domain 0.76 5.5 1 150-172 2255 DUF240 MG032/MG096/MG288 family 2 0.17 6 1 176-191 2256 NosL NosL 0.29 4.9 1 104-128 2256 NAC NAC domain 0.76 5.5 1 150-172 2256 DUF240 MG032/MG096/MG288 family 2 0.17 6.7 1 176-191 Zinc finger, ZZ type le-12 48.2 1 5-50 2258 SoxD Sarcosine oxidase, delta subunit fami 0.97 4.2 1 79-86 2258 zf-C2H2 Zinc finger, C2H2 type 0.00067 20.3 1 80-103 2258 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.3 3.6 1 95-115 2258 SPDY Domain of unknown function 0.6 4.4 1 119-133 (DUF317) 2258 Dil9 Drought induced 19 protein (Dil 9 ) 0.00056 13.0 1 314-330 2261 RmuC RmuC family 0.79 3.1 1 16-46 2261 IBN NT Importin-beta N-terminal domain 2.le-27 99.5 1 34-113 2261 Peripla BP like Periplasmic binding proteins and suga 0.21 4.7 1 142-173 2262 Las1 Lasl-like 1.6e-94 320.7 1 55-203 2262 MuDR MuDR family transposase 0.17 5.5 1 231-263 2262 BAR BAR domain 0.21 5.2 1 347-363 2262 Adeno E1B 19K Adenovirus E1B 19K protein! small t- 43 4.6 534-558 2262 META Domain of unknown function (306) 0.91 5.3 1 632-663 2263 ank i Ankyrin repeat 0.00019 19.0 1 1-33 2263 DMRL synthase 6,7-dimethyl-8-ribityllumazine synthas 0.35 5.0 1 33-48 2263 hormone Somatotropin hormone family 0.23 2.6 1 85-115 2265 ig Immunoglobulin domain 4.le-05 22.0 1 10-78 2265 ig Immunoglobulin domain 3.7e-10 40.9 2 113-172 2265 ig Immunoglobulin domain 0.0018 15.9 | 3 211-272 2265 ig Immunoglobulin domain 3.7e-08 33.4 14 309-370 WO 2004/080148 PCT/US2003/030720 568 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 2265 DNA ol B_2 DNA polymerase type B, organellar 0.018 7.9 1 326-382 and 2265 OapA Opacity-associated protein A 0.44 2.4 1 335-357 2265 ig Immunoglobulin domain 0.0012 16.6 5 404-465 2265 ig Immunoglobulin domain 7.7e-07 28.5 6 500-564 2269 efhand EF hand 2.8e-08 33.9 1 60-88 2269 COX17 Cytochrome C oxidase copper 0.42 4.2 1 85-92 chaperone 2269 efhand EF hand 0.0033 15.3 2 96-124 2269 efhand EF hand 8.5e-05 21.1 3 133-161 2269 PCRF PCRF domain 0.43 6.1 1 160-176 2269 DUF21 Domain of unknown function DUF21 0.18 6.4 1 165-189 2269 efhand EF hand 5e-09 36.7 4 169-197 2270 UPF0061 Uncharacterized ACR, YdiU/UPF0061 1.2e-14 51.3 1 15-61 fam 2270 UPF0061 Uncharacterized ACR, YdiU/UPF0061 6.8e-52 182.6 2 95-275 fain 2270 Flavodoxin_2 Flavodoxin-like fold 0.66 3.3 1 369-384 2270 UPFOO61 Uncharacterized ACR, YdiU/UPFOO61 1.2e-05 19.1 3 399-440 fan 2270 UPF0061 Uncharacterized ACR, YdiU/UPF0061 1.9e-49 174.5 4 501-654 fam 2270 Flavodoxin 2 Flavodoxin-like fold 0.66 3.3 2 748-763 2270 UPF0061 Uncharacterized ACR, YdiU/UPF0061 1.2e-05 19.1 5 778-819 fam 2271 UPFOO61 Uncharacterized ACR, YdiU/UPF0061 1.2e-14 51.3 1 15-61 fan 2271 UPF0061 Uncharacterized ACR, YdiU/UPF0061 6.8e-52 182.6 2 95-275 fan 2271 Flavodoxin 2 Flavodoxin-like fold 0.66 3.3 1 369-384 2271 UPF0061 Uncharacterized ACR, YdiU/UPF0061 1.2e-05 19.1 3 399-440 fam 2271 UPF0061 Uncharacterized ACR, YdiU/UPF0061 1.9e-49 174.5 4 501-654 fam f271 Flavodoxin_2 Flavodoxin-like fold 0.66 3.3 2 748-763 271 -UPF0O6I Uncharacterized ACR, YdiU/UPFOO61 1.2e-05 19.1 5 778-8 19 fam 2272 7tm_1 7 transmembrane receptor (rhodopsin 97e-25 72.7 1 1-107 fan 2273 LRR Leucine Rich Repeat 0.00057 16.1 1 40-63 2273 LRR Leucine Rich Repeat 0004 13.3 3 88-113 2273 LRR Leucine Rich Repeat 0.84 5.4 4 _ 114-131 2274 AMP-binding AMP-binding enzyme 6.9e-18 64.1 1 20-135 275 cytochrome c Cytochrome c 0.92 3.7 1 94-110 2275 cNMP binding Cyclic nucleotide-binding domain 1.5e-15 57.4 1 126-216 2275 RasGEFN Guanine nucleotide exchange factor fo 0.00023 17.5 1 _ 241-285_ 2275 Pseu avirulence Avirulence protein 0.91 1.9 1 _1 272-285 2275 PDZ PDZ domain (Also known as DHR or 2e-09 35.0 1 361-412 GLGF 2276 cytochromec Cytochrome c 0.92 3.7 1 94-110 2276 cNMP binding Cyclic nucleotide-binding domain 1.5e-15 57.4 _ 126-216 2276 RasGEFN Guanine nucleotide exchange factor fo 0.00023 17.5 1 241-285 2276 Pseu avirulence Avirulence protein 0.91 1.9 1 272-285 2276 | PDZ PDZ domain (Also known as DHR or 2e-09 35.0 1 361-412 WO 2004/080148 PCT/US2003/030720 569 TABLE 4B SEQ Model Description E_value Score Repeats Position ID GLGF 2280 Ricin B lectin QXW lectin repeat 0.14 8.2 1 50-77 2280 MCR beta.N Methyl-coenzyme M reductase beta 0.98 2.1 1 68-76 subun 2281 -rsA ATPase Anion-transporting ATPase 0.54 3.1 1 26-52 2281 ParA ParA family ATPasc 1.4e-25 89.8 1 111-202 2281 SCF Stem cell factor 1.1c-27 90.4 1 206-259 2281 FH2 Formin Homology 2 Domain 0.027 8.8 1 221-238 2282 cadherin Cadherin domain 6e-20 71.3 1 3-81 2282 cadherin Cadherin domain 5.9e-21 74.8 2 118-191 2283 cadherin Cadherin domain 6e-20 71.3 1 3-81 2283 cadherin Cadherin domain 5.9e-21 74.8 2 118-191 2284 PH PH domain 7.9e-10 33.6 1 4-92 2284 DUFIO41 Domain of Unknown Function 1.6e-07 28.1 1 206-237 (DUF1041) 2285 Renal dipeptase Renal dipeptidase 9.3e-05 15.8 1 _ 74-102 2286 aa permeases Amino acid permease 7e-24 89.2 1 6-294 2286 Pox I5 Poxvirus protein 15 0.24 6.0 1 85-102 2286 serine carbpept Serine carboxypeptidase 0.41 2.3 1 301-321 2287 THFDHG CYH Tetrahydrofolate dehydrogenase/cycloh 2.3e-11 32.7 1 62-123 2287 THFDHGCYH Tetrahydrofolate dehydrogenase/cycloh 6.le-10 36.6 1 125-171 C 2287 FTHFS Formate--tetrahydrofolate ligase 0 1365. 1 302-921 1 2288 acid phosphat Histidine acid phosphatase 0.038 6.9 1 391-407 2288 FMN red NADPH-dependent FMN reductase 0.94 3.3 1 438-459 2288 acid phosphat Histidine acid phosphatase 0.02 7.9 2 525-594 2288 Ribosomal L6 Ribosomal protein L6 0.21 7.2 1 774-814 2290 PI-PLC-X Phosphatidylinositol-specific 3.8e-14 50.6 1 1-33 phospholipase 2292 ABG transport AbgT putative transporter family 0.81 1.2 1 _ 21-34 2292 7tm 1 7 transmembrane receptor (rhodopsin f 1.6c-30 90.1 1 48-297 2292 HECT HECT-domain (ubiquitin-transferase) 0.15 5.5 1 281-298 2293 tsp 3 Thrombospondin type 3 repeat 0.00058 15.9 1 13-25 2293 tsp_3 Thrombospondin type 3 repeat 0.0033 13.4 2 36-48 2293 tsp_3 Thrombospondin type 3 repeat 0.0011 15.0 3 51-66 2293 tsp_3 Thrombospondin type 3 repeat 0.00057 15.9 4 74-86 2293 tsp3 Thrombospondin type 3 repeat 0.0015 14.6 6 114-126 2293 tsp_3 Thrombospondin type 3 repeat 0.03 10.3 7 127-142 2293 TSPC Thrombospondin C-terminal region 7.1e- 594.4 1 167-367 176 2293 Mndl Mndl family 0.68 3.4 1 366-374 2294 Vps52 Vps52 / Sac2 family 0.087 3.9 1 154-183 2294 Complex17_2k NADH:ubiquinone oxidoreductase 17.2 0.25 6.1 1 562-587 D k 2294 mRNA triPase mRNA capping enzyme, beta chain 0.33 4.0 1 934-966 2294 DUF424 Protein of unknown function (DUF424) 0.79 4.6 1 1002 1017 2295 sodcu Copper/zinc superoxide dismutase 1 2.0 1 10-23 (SOD 2295 DapBC Dihydrodipicolinate reductase, C-term 0.84 4.5 1 17-31 2295 PTR2 POT family 1.9e- 357.1 1 82-475 104 2296 FH2 Formin Homology 2 Domain 0.0052 11.5 1 98-144 WO 2004/080148 PCT/US2003/030720 570 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 2296 NTP transf 2 Nucleotidyltransferase domain 0.049 .4 1 104-170 2296 FH2 Formin Homology 2 Domain 1.6e-05 20.9 2 158-186 2297 zf-C2H2 Zinc finger, C2H2 type 0.01 15.5 1 2297 XPA N XPA protein N-tenninal 0.51 572 2297 TFIS 1/6 1 9 . 31 39 0.16 7.4 2 27-37 2297 zf-C2H2 Zinc finger, C2H2 type 6.7e-06 28.3 2 27-49 2297 XPA N XPA protein N-terminal 0.49 5.8 2 52-64 2297 TFIIS 1/6 1 9 [. 31 39 0.18 65 2297 zf-C2H2 Zinc finger, C2H2 type 4e-06 29.2 3 55-77 2297 TFIIS 1/6 1 9 [. 31 39 0.51 57 4 83-93 2297 zf-C2H2 Zinc finger, C2H2 type 2.7e-05 25.9 4 83-105 2297 zf-C2H2 Zinc finger, C2H2 type 7.ge-07 32.1 5 111-133 2297 XPA N 4/5 108 120.. 1 13 0.45 5.9 2297 eIF5 eIF2B Domain found in IF2B/IF5 0.95 3.5 1 139-149 2297 TFIIS 1/6 1 9 [. 31 39 0.069 8.7 2297 Transposase_12 Transposase 0.48 1 139-165 2297 zf-C2H2 Zinc finger, C2H2 type 66e-07 32.4 139-161 2298 Sprouty Sprouty protein (Spry) 1.2e-17 55.0 1 70-107 2299 HAMP HAMP domain 0.21 7.3 1 9-42 2299 PA PA domain 3.6e-19 65.4 1 155-255 2299 PeptidaseM28 Peptidase family M28 2e-118 403.6 1 332-585 2299 Borrelia lipo Borrelia burgdorferi virulent strain 0.98 2.5 1 591-604 2299 TFR dimer Transferrin receptor-like dimerisatio 1e-65 228.5 1 597-739 2300 GvpG Gas vehicle protein G 0.088 6.7 1 43-75 2301 Sema Sema domain 5.5e-05 17.6 34-113 2303 ZZ Zinc finger, ZZ type le-12 48.2 1 5-50 2303 SoxD Sarcosine oxidase, delta subunit fami 0.97 4.2 1 79-86 2303 zf-C2H2 Zinc finger, C2H2 type 0.00067 20.3 1 80-103 2303 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 36 1 95-115 2303 SPDY Domain of unknown function 0 4.4 (DUF3 17) 2303 Dil9 Droughtindced 19 protein (Dil9) 0.00056 13.0 1 314-330 2305 ig Immunoglobulin domain 1.7e-05 23.4 1 37-114 2305 PhagecapE Phage major capsid protein E 0.79 2.8 1 128-137 2306 MHCI Class I Histocompatibility antigen, d 9.2e- 481.1 1 32-210 142 __ ___ 2306 DUF497 Protein of unknown function (DUF497) 0.2 6.7 1 50-63 2306 ig Immunoglobulin domain 7.9e-09 35.9 1 227-292 2306 DUF395 YeeE/YedE family (DUF395) 0.19 7.2 1 317-342 2307 LBPBPICETP LBP BPl CETP family, C-terminal 5.8e-05 18.1 1 15-98 C do 2307 LBPBPIZCETP LBP Bin CETP family, C-terminal 0.7 3.5 2 113-138 C do 2308 LBPBPIXCETP LBP BPI CETP family, C-terminal 5.8e-05 18.1 15-98 C do 2308 LBPBPICETP LBP /BPI / CETP family,C-terminal 0.7 3.5 2 113-138 C do ___ 2309 LBP_- BPI_ZCETP LBP / BPI / GETP family, C-te 5.8e-05 18.1 1 15-98 C do 2309 LBPBPICETP LBP / BPI / CETP family, C-terminal 0.7 3.5 2 113-138 C do 2310 LBPBPICETP LBP / BPI CET family, C-terminal 5.8e-05 18.1 1 15-98 C do______ __ _ 2310 LBP BPI CfT LBP/BPI/CETP family, C-terminal 0.7 3.5 2 111-138 WO 2004/080148 PCT/US2003/030720 571 TABLE 4B___ SEQ Model Description E value Score Repeats Position ID ___ C do 2311 SecretograninV Neuroendocrine protein 10-214 136 ____ 2312 Cyto heme lyase Cytochrome c/cl heme lyase 0.82 1.8 1 97-120 2313 PDP22 Claudin PMP-22/EMP/MP20/Claudin family 6,9e-46 159.3 1 8-185 2313 Acyl transf 3 Acyltransferase family 0.12 6.3 1 110-155 2314 Cna B Cna protein B-type domain 0.17 5.9 1 52-85 2314 PDZ PDZ domain (Also known as DHR or 8.le-12 43.4 1 52-130 GLGF 2315 PID Phosphotyrosine interaction domain 3.3e-47 160.5 1 46-172 (PT 2317 pkinase Protein kinase domain 8.3e-74 255.4 1 22-282 2318 lipocalin Lipocalin / cytosolic fatty-acid binding 2.3e-42 1509 1 58-206 2318 Triabin Triabin 0.0018 12.1 1 139-156 2319 lactamaseB Metallo-beta-lactamase superfamily .3e-06 24.6 1 26-74 2320 annexin Annexin 2.5e-05 21.2 1 1-20 2320 annexin Annexin 1.1e-29 107.6 2 26-92 2320 annexin Annexin 9.7e-28 100.7 3 109-176 2320 annexin xin 2.8e-33 120.4 4 185-251 2321 SNF Sodium:neurotransmitter symporter 9.5e- 873.0 1 38-417 fain 260 2321 ATP-sulfurylase ATP-sulfurylase 0.28 3.8 1 42-64 2321 DUF900 Protein of unknown function (DUF900) 0.98 2.8 1T - 251-263 2323 Glypican Glypican 2324 PAP assoc PAP/25A associated domain 1.6e-14 51.8 1 274-333 2324 Isochorismatase Isochorismatas family 0.49 4.1 1 484-520 2326 Sec23 trunk Sec23/Sec24 trunk domain 0.47 4.0 1 22-33 2326 Hydrolase haloacid dehalogenase-hke hydrolase 0.77 3.7 1 26-56 2327 Sec23 trunk Sec23/Sec24 trunk domain 0.47 4.0 1 22-33 2327 Hydrolase haloacid dehalogenase-like hydrolase 0.77 3.7 1 26-56 2328 A2M Alpha-2-macroglobulin family 6.3e-23 75.5 1 4-86 2329 A2M Alpha-2-macroglobulin family 6.3e-23 75.5 1 4-86 2330 A2M Alpha-2-macroglobulin family 6.3e-23 75.5 1 4-86 2331 A2M Alpha-2-macroglobulin family 6.3e-23 75.5 1 4-86 2332 A2M Alpha-2-macroglobulin family 6.3e-23 75.5 1 4-86 2333 COesterase Carboxylcsterase 4.3e-42 142.8 1 8-142 2333 A2MN Alpha-2-macroglobulin family N- 0.83 2.3 1 12-28 termina 2334 EGF EGF-like domain 2334 TIL Trypsin Inhibitor like cysteine rich 0.85 3.5 1 10-26 domaI 2336 Corona NS4 Coronavirus non-structural pr 0.47 3.5 1 20-43 2336 ig Immunoglobulin domain 0.052 10.4 1 57-119 2336 fn3 Fibronectin type Ill domain 2.4e-16 58.5 145-231 2339 KeratinB2 Keratin, high sulfur B2 protein le-19 69.2 1 21-145 2340 Keratin B2 Keratin, high sulfur B2 protein le-19 69.2 1 21-145 2341 Keratin B2 Keratin, high sulfur B2 protein le-19 69.2 1 21-145 2342 abhydro lipase ab-hydrolase associated lipase region 1.9e-32 117.8 1 87-157 2342 abhydrolase alpha/beta hydrolase fold 9.5e-19 67.6 1 171-448 2343 abhydro lipase ab-hydrolase associated lipase region 1.9e-32 117.8 1 87-157 2343 abhydrolase alpha/beta hydrolase fold 9.5e-19 67.6 1 171-448 2344 7tNe3 7 transmcmbrane receptor 0.75 3.2 1 26-47 (metabtr136 WO 2004/080148 PCT/US2003/030720 572 TABLE 4B sto SEQ Model Description E-value Score Repeats PO ID 2344 7tm_3 ansmembrane receptor 0.00057 14.4 67-111 (metabotropic 2344 Condensation Condensation domain 036 4.2 1 159-171 2344 7tm_3 7 trnsmembrane receptor 1.4e-05 20.1 170-273 (metabotropic - 2345 GASA Gibberellin regulated protein 0.35 1.3 1 25-54 2345 lectin c Lectin C-type domain 1.3e-25 95.2 1 103-216 2346 GASA Gibberellin regulated protein 0.35 1.3 1 25-54 2346 lectin c Lectin C-type domain 1.3e-25 95.2 1 103-216 2347 7tm 17 transmenbrane receptor (rhodopsin f 149.5 1 99-348 2347 endotoxin N delta endotoxin, N-terminal domain 06.87 .6 N253-283 2347 Pox D2 Pox virus D2 protein 0.93 1.2 1 366-379 2347 7tm 1 ansmernbrane receptor (rhodopsin f 9.6e-48 141.7 2 417-666 2347 PAZ P domain 0.48 4.7 1 540-567 2348 Hanta G2 Hantavirus glycoprotein G2 0.098 4.8 1 84-112 2350 An peroxidase Animal haem peroxidase _ ,3e-91 311.6 1 2-232 2350 7tm 1 7 transmembrane receptor (rhodopsin f 0.22 2.7 1 24-32 2350 Peptidase Cl Papain family cysteine protease 0.76C11 117-134 2351 An peroxidase Animal haem peroxidase l.3e-91 311.6 1 2-232 2351 7tm 1 7 transmembrane receptor 0,22 2.7 1 24-32 2351 PeptidaseC1 Papain family cysteine protease 076 2.1 1 117-134 2352 Arch fT4a DE869 2352 Arch ~~fla DE Archaeal flagella protein 04 .

69 2353 UBX UBX domain 0.36 6.0 1 141-159 2353 FTCD C Formiminotransferase-cyclodeamiase 0.21 6.0 1 188-218 2353 3H 3H domain 0.46 6.2 1 248-260 235Tori Tosie- 189 63.8 1 17-288 2354 Torsin Tri 2354 2_5 ligase 2,5 RNA ligase family 0.13 7.6 1 101-133 2354 DUF254 SAND family protein 0.22 3.0 110-129 2355 SPX SPX domain 0.84 1.0 1 66-86 21359 DU85Eukaryotic; protein of unknown 0.8 4.1 1 183-199 235 DbUF895 06 function 2360 RWD RWD domain 9.8e-40 142.2 1 17-131 2360 globin Globin 6.048 8.6 1 94-126 2360 eRF12 eRFI domain 2 0.72 4.1 1 120-133 2360 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 7.5e-10 27.9 1 141-207 2360 DNA ligase,_ZB NAD-dependent DNA ligase C4 zinc 0.37 5.8 -213 D finge 2360 zf-MIZ MJZ zinc finger 0.28 4.6 1 203-213 2360 ApoA-II Apolipoprotein A-II (ApoA-II) 0.94 3.6 1 267-278 2361 TMSTDE TMS membrane protein/tumour 0.048 5.2 T 33-63 differentia 2361 sugartr Sugar (and other) transporter 1.5e-05 19.2 1 65-138 2362 ig immunoglobulin domain 0.00079 17.2 1 42-98 2363 ig Immunoglobulin domain 0.00079 17.2 1 42-98 2364 IBN NT Importin-beta N-terminal domain 6.3e-16 58.6 1 65-109 2365 HIM Haemagluttinin motif 0.18 7.7 1 375-391 2365 Fascin Fascin protein 0.29 0.7 1 808-8 18 2370 DUF357 Domain of Unknown Function 0.86 5.1 106-128 (DUF35O) 2372 Apolipoprotein. Apolipoprotein A I/A4/E family 0.95 3.4 1 54-78 2372 F8 type C F5/8type C domain 2.2e-36 111.6 1 84-171 2373 Apolipoprotein Apolipoprotein AI/A4/E family 0.95 3.4 1 54-78 2373 F5F8typeLC i5/8 type C domain 2.2e-36 111.6 1 84-171 2374 Ribosomal 3 C Ribosomal protein S3, C-terminal 0.8 3.4 1 65-71 WO 2004/080148 PCT/US2003/030720 573 TABLE 4B SEQ Model Description E-value Score Repeats Position ID -- - domai 2374 Ricin B lectin QXW lectin repeat 0.13 8.4 | 1 175-204 2374 Ricin B lectin QXW lectin repeat 0.00073 16.5 2 266-304 2375 pkinase Protein kinase domain 1.2e-11 41.7 1 38-119 2377 PH PH domain 0.023 9.0 1 43-81 2377 BTK BTK motif 1.9e-06 26.9 1 105-141 2379 EGF EGF-like domain 0.047 10.1 1 1-17 2379 EGF EGF-like domain 3.7e-07 28.6 2 33-68 2379 EB EB module 0.73 4.1 1 39-68 2380 M tail Myosin tail 0.32 4.7 1 192-222 2380 SurE Survival protein SurE 0.68 2.6 1 317-330 2380 Pox All Poxvirus All Protein 0.17 3.2 1 364-382 2385 7tm 1 7 transmembrane receptor (rhodopsin f 8.6e-47 138.9 1 83-332 2386 7tm_1 7 transmembrane receptor (rhodopsin f 8.6e-47 138.9 1 83-332 2388 Calcyon D1 dopamine receptor-interacting 3.7e-42 136.9 1 1-66 protein 2389 ILl Interleukin-1 / 18 2.6e-23 83.4 1 79-180 2390 filament Intermediate filament protein 7.3e-68 235.6 1 2-189 2390 K-box K-box region 0.11 7.0 1 11-29 2390 bZIP bZ1P transcription factor 0.2 7.0 1 49-86 2390 Ribosomal L29 Ribosomal L29 protein 0.71 5.2 1 104-130 2392 MgpC MgpC protein precursor 0.99 2.8 1 1-27 2393 filament Intermediate filament protein 1.8e-14 54.6 1 9-80 2394 PeptidaseM10 Matrixin 4.5e-47 166.6 1 11-103 2394 Peptidase M1O Matrixin 9.2e-17 64.0 2 107-145 2395 Peptidase M1O Matrixin 4.5e-47 166.6 1 11-103 2395 Peptidase M10 Matrixin 9.2e-17 64.0 2 107-145 2396 SUFU Suppressor of fused protein (SUFU) 0 1218. 1 3-484 3 2397 LBPBPICETP LBP / BPI / CETP family, N-terminal 3.4e-20 69.4 1 38-103 doma 2398 MCPsignal Methyl-accepting chemotaxis protein ( 0.21 4.1 1 363-379 2399 MCPsignal Methyl-accepting chemotaxis protein ( 0.21 4.1 1 363-379 2402 DUF846 Eukaryotic protein of unknown functio 4.3e-05 15.0 1 63-93 2405 UK Virulence determinant 0.083 - 48-72 2405 TIP 120 TBP (TATA-binding protein) -interacti 0 3271. 1 59-1252 6 - _ 2405 HEAT HEAT repeat 0.093 8.3 2 282-320 2405 HEAT HEAT repeat 0.04 9.5 3 377-398 2405 Armadilloseg Armadillo/beta-catenin-like repeat 0.2 8.0 2 716-755 2406 lectin c Lectin C-type domain 2.5e-16 64.4 1 168-274 2412 PTE Phosphotriesterase family 8.2e- 697.2 1 38-380 207 2412 gntR Bacterial regulatory proteins, gntR f 0.17 7.0 1 ___ 141-160 2414 filament Intermediate filament protein 0.28 5.0 1 199-228 2414 Transposase 8 Transposase 0.57 5.0 1 200-220 2414 DUF972 Protein of unknown function (DUF972) 0.76 4.2 2414 Rop Rop protein 0.55 3.6 1 242-249 2414 MoaE MoaE protein 0.18 7.2 1 467-480 2414 WH2 WH2 motif 0.14 8.9 1 468-485 2419 Pox int trans Poxvirus intermediate transcription fa 0.092 5.7 1 119-147 2419 ABA WDS ABA/WDS induced protein 0.81 4.5 1 185-201 2419 DUF738 Protein of unknown function (DUF738) 0.89 3.3 1 -316 2419 IpaB EvcA IpaB/EvcA family 0.65 3.8 1 460-485 WO 2004/080148 PCT/US2003/030720 574 TABLE 4B SEQ Model Description E-value Score Repeats Position ID 2420 PS Dcarbxylase Phosphatidylserine decarboxylase 3.9e-60 209.9 1 80-323 2422 DUF199 Uncharacterized BCR, COG1481 0.5 3.4 1 138-154 2423 ADPPFKGK ADP-specific 4.1e- 701.5 1 6-408 Phosphofructokinase/Gluco 208 1____ 2423 Mannitol dh Mannitol dehydrogenas 0.052 6.8 1 310-329 2424 ASFV_L1lL African swine fever virus (ASFY) 0.89 3.1 1-9 LI IL ___ 2428 Ribosomal S25 S25 ribosomal protein 0.00053 15.1 1 12-43 2429 ank Ankyrinrepeat 0.011 12.7 1 1-18 2429 ank Ankyrin repeat 0.0036 14.4 2 19-51 2429 ank Ankyrinrepeat 1.5e-11 44.5 3 52-84 2429 ank Ank in repeat 1.2c-08 34.1 4 85-117 2429 ank Ankyrinrepeat 3.3e-08 32.5 5 118-150 2429 ank Ankyrm repeat 3.4-1 3. 6 151-183 2429 Ankyrinrepeat 1.3e-08 33.9 7 184-217 2429 ank Ankyrin repeat 0.0027 14.9 8 218-250 2429 ank Ankyrin repeat 8.5e-08 31.1 9 251-283 2429 ank Ankyrin repeat 0.013 12.4 10 284-308 2429 ank Ankyrinrepeat 8.3e-08 31.1 11 335-367 2429 ank Ankyrin repeat 1le-09 37.8 12 368-400 2429 ank Ankyrin repeat 6.9e-07 27.8 13 401-461 2429 endonuclease_7 Recombination endonuclease VII 0.034 9.6 1 417-441 2429 ank Ankyrin repeat 0.0047 14.0 14 462-485 2430 trypsin Trypsin 1.5e-23 72.8 71 61-237 2430 PDZ PDZ domain (Also known as DHR or Sic-OS 30.0 1 285-339 GLGF) -7 2431 vwc type C domain 4e-05 1 66-105 2432 MethyltransfD12 D12 class N6 adenine-specific DNA 1.4c-36 128.4 1 39-163 met 917 2432 RibosomalLi Ribosomal protein LLp/10e family 0.57 2433 lipocalin Lipocalin I cytosolic fatty-acid binding 4.7e- 1 42.2 1 12-80 ~~~~pr 7e5 564 1 714 2434 tRNAanti OB-fold nucleic acid binding domain 2434 tRNA-synt2 tRNA synthetases class II (D, K and N 2.2e-59 207.4 1 162-410 2434 Transglutamin C Transglutaminase family, C-terminal i 0.79 4.1 1 229-256 2434 RNA helicase RNA helicase 5.7 1 266-308 2435 FAD binding_2 FAD binding domain 1.6e-53 181.4 1 22-117 2436 RasGEF RasGEF domain 6.8e-18 69.6 1 35-115 2437 KH KHdomain 3.8e-17 61.6 1 78-124 2437 Peripla BP2 Periplasmic binding protein 0,71 3.5 _ 116-132 2437 KH KHdomain 2,4e-10 38.1 2 162-189 2439 transketpyr Transketolase, pyridine binding domain 1.6e-51 176.9 1 76-254 2439 DUF924 Bacterial protein of unknown function 0.88 2.8 1 77-98 2439 IndigoidineA Indigoidine synthase A like protein 0.51 4.4 1 233-247 2439 transketolaseC Transketolase, C-terminal domain 137.2 1 272-398 2440 Calsequestrin Calsequestrin 8.5e- 979.5 1 42-427 292 ___ ____ 2440 thiored Thioredoxin 0.057 9.0 1 160-189 2441 Bacillus PapR Bacillus PapR protein 0.68 3.6 1 62-77 2441 arf ADP-ribosylation factor family 0.76 2.9 1 290-312 2441 RNA-capsid Calicivirus putative RNA 0.65 1.9 1 346-355 Ipolymerase/ca 2442 ig Immunoglobulin domain 2.7e-09 37.6 1 35-112 2442nRchxaseearase/ri nO 0.91 3.4 1 71-90 4.2 ela82 riboxs/oal protin nu.00053 15.1i 1z24 WO 2004/080148 PCT/US2003/030720 575 TABLE 413 SEQ Model Description E-value Score Repeats Position ID 2442 virus P-coat coat protein 0.7 4.0 1 2442 ig Immunoglobulin domain 9.8e-07 2 2 2445 cadherin Cadherin domain 0.045 8.9 1 77-106 2445 cadherin Cadherin domain 1.4e-14 52.6 2 150-245 2445 cadherin Cadherin domain 4.8e-24 85.5 3 259-350 2445 cadherin Cadherin domain 3.6e-14 51.1 4 -- 364-455 2445 cadherin Cadherin domain 2.e-22 794 5 9-565 2445 HemaHI-IEFG Hemagglutinin domain of 0.5 haemagglutini 2445 cadherin Cadherin domain 8.2e-14 49.9 6 594-677 2447 SbTK ShTK domain 0.92 3.9 1 74-82 2448 |zf-C2H2 Zinc finger, C22 type 0.00076 20.0 2 50-73 2448 zf--C2H2 Zinc finger, C212 type .036 3.3 3 -106 2448 zf-C2H2 Zinc finger, C212 type 0.00095 19.6 5 198-221 2450 Alpha L fucos Alpha-L-fucosidase 0.018 8.4 1 10-34 2451 TCTP Translationally controlled tumor 7.3e-13 42.0 1 20-54 protein _____ -54__ 2452 Herpes_gG Glycoprotein GGIGX 0.39 2.9 1 29 2452 Osteopontin Osteopontin le- 410.7 1 42-218 128 ___ 2452 Flu Ml Influenza Matrix protein (Ml 1 3.0 52-65 2453 serpin Serpin (serine protease inhibitor) 0.99 2.0 1 68-92 2454 HATPase c Histidine kinase-, DNA gyrase B-, and 3.8e-15 54.5 1 92-240 2454 Pox N2L PoxvirusN21protein 0.18 5.3 1 162-176 2454 DNA gyraseB DNA gyrase B 4.le-57 199.9 1 286-446 2454 FokI N Restriction endonuclease Fol, recogn 0.12 6.3 1 530-539 2454 DNA.topoisoIV erase IV, subunit 190 1196 2454 DUF188 Uncharacterized BCR, YailIYqxD 0.025 8.2 1 1171 family 1197 2456 PCI PCI domain 0.27 6.1 1 66-93 2457 Clq CIq domain 6.3e-06 23.8 1 98-138 2458 BTB BTB/POZ domain 1.9e-17 64.4 1 62-124 2459 LBPBPICETP LBP / BPI / CBTP family, N-terminal 3.4e-20 69.4 1 38-103 doma _§__4-2_ 79.43810 2460 LBPBPICETP LBP / BPI / CETP family, N-terminal doma 2461 LBPBPICETP LBP / BPI / CETP family, N-terminal 69.4 1 38-103 T -- b -F408doma 2462 DU48Domain of Unknown Function le-1 1 42.8 1 1-43 (DUF428) 2462 DUF584 Protein of unknown function, DUF584 0.67 2.3 1 224-250 2464 Securin Securin sister-chromatid separation 1 2.9 1 19-34 _____inhibito 2465 Nuf2 Nuf2 family 3.3e- 356.3 1 6-153 1 104 2465 Corona NS2A Coronavirus NS2A protein 0.42 2.3 133-139 2465 Sytaxin Syntaxin 0.31 6.3 1 142-242 2465 HR1 Hrl repeat 0,099 7.1 1 192-219 2465 LEA Late embryogenesis abundant protein 0.79 5.0 254-279 2465 Mob Pre Plasmid recombination enzyme 0.97 1.9 1 366-376 2465 G-gamma GGL domain 008 69 1 403-424 2465 OKRDCIN Orn/Lys/Arg decarboxylase, N- 0.19- 4.3 1 426-450 Cdterminal dom WO 2004/080148 PCT/US2003/030720 576 TABLE 4B SEQ Model Description Evalue Score Repeats Position ID 2466 pkinase Protein kinase domain 0.036 7.9 1 62-123 2466 HEAT HEAT repeat 0.13 7.8 1 335-373 2467 LreE C UreE urease accessory protein, C-termi 0.09 7.9 1 119-140 2467 Pox A type inc Viral A-type inclusion protein repeat 0.59 6.3 1 194-215 2470 DUF563 Protein of unknown function (DUF563) 0.86 2.4 1 36-47 2471 Fumarate red D Fumarate reductase subunit D 0.28 5.3 1 79-103 2473 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 2.9e-06 17.8 1 5 9-96 2473 IBR IBR domain 0,0064 10.5 1 70-114 2473 zf-C3HC4 Zinc finger, C3HC4 type (RING finger) 0.029 6.4 2 124-144 2474 Aa trans Transmembrane amino acid transporter 1.4e-41 148.3 1 72-276 p 2475 Aa trans Transmembrane amino acid transporter 1.4e-41 148.3 1 72-276 1 p 2477 LRR Leucine Rich Repeat 0.093 8.7 1 30-51 2477 LRR Leucine Rich Repeat 0.57 6.0 2 56-77 2478 SAB SAB domain 0.65 5.3 1 57-82 2478 RPE65Retinal pigment epithel membrane 4.3e-27 91.2 1 85-202 prote 2479 SAB SAB domain 0.65 5.3 1 57-82 2479 RPE65 Retinal pigment epithelial membrane 4.3e-27 91.2 1 85-202 prote 2480 PoxA type inc Viral A-type inclusion protein repeat 0.42 6.8 1 18-40 2480 spectrin Spectrin repeat 0.61 4.8 1 18-45 2481 CD34 antigen CD34 antigen protein 0.88 0.3 1 6-34 2481 DUF999 Protein of unknown function (DUF999) 0.28 5.1 1 14-35 2481 BCLN BCL7, N-terminal conserve region 0.39 6.1 174-195 2481 serpin Serpin serinee protease inhibitor) 3.7e-24 81.8 1 431-546 2482 PMP22 Claudin PMP-22/EMP/MP2O/Claudin family 3.7e-89 306.4 1 40-218 2482 mce mcerelatedprotein 0.74 4.3 1 159-179 2483 PAP2 PAP2 superfamily 4.5e-15 54.4 1 24-159 2488 SMC C SMC family, C-terminal domain 1.6e-17 60.6 1 418-475 2488 SM _7 2488 SMC C SMC family, C-terminal domain 1.l1e-43 150.2 2 477-540 2488 Armadilloseg Armadillo/beta-catenin-like repeat 4.6e-14 53.0 2 551-591 2488 Armadillo_seg Armadillo/beta-catenin-like repeat 1.4e-08 33.5 3 594-634 2489 IER Immediate early response protein (TER) 0.063 3.8 1 194-206 2490 disintegrin Disintegrin 3.3e-36 12.1 1 4-79 2490 EGF EGF-like domain 0.0023 14.8 1 231-258 2499 ARPF Aromatic-Rich Protein Family 1 4e-10 36. 1 89-234 2502 Paf1 Pafl 2.3e-17 65.0 1 1-61 2502 ig Immunoglobulin domain 0.015 12.4 1 68-113 2502 ank Ankyrinrepeat 0.025 11.4 1 186-204 2504 PH PH domain 0.028 8.7 1 61-153 2504 DAGKc Diacylglycerol kinase catalytic domain 0.00051 15.4 1 161-213 2505 ig Immunoglobulin domain 0.069 9.9 2505 ig Immunoglobulin domain 6.5e-09 36.2 2 161-219 2506 ig Immunoglobulin domain 0.069 9.9 1 48-120 2506 ig Immunoglobulin domain 6.5e-09 36.2 2 161-219 2508 7tm_1 7 transmembrane receptor (rhodopsin 8.2e-29 85.0 1 49-179 ______ ~famil _____ 2508 7tm_1 7 transmembrane receptor (rhodopsin .6e-13 39.1 2 210-267 _____ _______________famil 2517 Acyl-CoA-dhM Acyl-CoA dehydrogenase, middle 0.0071 11.7 1 99-136 domain 2517 Acyl-CoAdh -Acyl-CoA dehydrogenase, C-tenrinal 6.7e-50 175.9 1 415-566 WO 2004/080148 PCT/US2003/030720 577 TABLE 4B SEQ Model Description E value Score Repeats Position ID doma 2518 Acyl-CoA.dhM Acyl-CoA dehydrogenase, middle 0.0071 11.7 1 99-136 domain 2518 Acyl-CoA-dh Acyl-CoA dehydrogenase, C-terminal 6.7e-50 175.9 1 415-566 doma 2519 Cation efflux Cation efflux family 3e-09 34.4 1 33-109 2520 CaMBD Calmodulin binding domain 0.074 7.8 1 451-467 2520 IQ IQ calmodulin-binding motif 1.3c-05 22.1 2 473-493 2520 IQ IQ calmodulin-binding motif 1.6e-05 21.8 3 532-552 2524 | PAP2 PAP2 superfamily 7.6e-19 67.8 1 39-151 2525 PAP2 PAP2 superfamily 7.6e-19 67.8 1 39-151 2529 LRR Leucine Rich Repeat 0.00025 17.3 1 201-226 2529 LRR Leucine Rich Repeat 0.0019 14.3 2 227-246 2529 LRR Leucine Rich Repeat 0.13 8.1 4 272-297 2529 LRR Leucine Rich Repeat 0.00025 17.3 5 298-317 2529 LRR Leucine Rich Repeat 5.2e-05 19.6 6 319-342 2529 LRR Leucine Rich Repeat 0.37 6.6 7 343-368 2530 ig Immunoglobulin domain 0.26 7.8 | 1 55-122 2530 ig Immunoglobulin domain 0.0043 14.5 2 | 162-220 2530 ig Immunoglobulin domain 0.00023 19.2 3 267-321 2531 ig Immunoglobulin domain 0.26 7.8 1 55-122 2531 ig Immunoglobulin domain 0.0043 *14.5 2 162-220 2531 ig Immunoglobulin domain 0.00023 19.2 3 267-321 2532 tsp 1 Thrombospondin type 1 domain 2.9e-07 25.9| 1 59-103 2533 Guanylin Guanylin precursor 0.0007 9.1 1 12-35 2533 Apo-CII Apolipoprotein C-I 3.4e-57 200.2 1 34-111 2534 Guanylin Guanylin precursor 0.0007 9.1 1 12-35 2534 Apo-CII Apolipoprotein C-II 3.4e-57 200.2 1 34-111 2536 zf-C2H2 Zinc finger, C2H2 type 0.0012 19.3 1 279-301 2536 zf-C2H2 Zinc finger, C2H2 type 2.2e-06 30.3 2 307-329 2536 zf-C2H2 Zinc finger, C2H2 type 0.086 11.7 3 337-355 2540 FA desaturase Fatty acid desaturase 5.1e-42 145.2 1 8-159 2541 rnaseH RNase H 7.le-16 53.4 1 86-184 2541 MutS III MutS domain III 4.2e-06 22.9 1 253-277 2541 MutSV MutS domain V 6e-164 543.6 1 282-517 2542 ig Immunoglobulin domain 7.6e-08 32.2 1 1-57 2542 fn3 Fibronectin type III domain 2.8e-16 58.3 1 79-165 2543 MAM MAM domain 1.5e-43 154.8 1 3-102 2544 kazal Kazal-type serine protease inhibitor 7.7e-06 25.8 1 40-87 domain 2544 ig Immunoglobulin domain 4.le-07 29.5 1 105-174 2545 RNA helicase RNA helicase 0.031 7.9 1 85-112 2545 ATP-bind Conserved hypothetical ATP binding 0.055 7.3 1 90-103 prote 2547 ig Immunoglobulin domain 0.015 12.4 1 10-28 2547 ig Immunoglobulin domain 0.098 9.4 2 72-98 2549 serpin Serpin (serine protease inhibitor) 5.4e-18 60.8 1 68-112 2551 DREV DREV methyltransferase 7.3e- 680.7 1 57-318 233 2553 ank Ankyrin repeat 1.8e-07 29.9 2 44-76 2553 ank Ankyrin repeat 0.026 11.4 3 77-102 2554 pkinase Protein kinase domain 3.5e-64 223.4 1 117-375 2555 kinase Protein kinase domain 3.5e-64 223.4 1 117-375 2557 tRNA-synt le tRNA synthetases class I (C) 0.0002 14.0 1 99-129 WO 2004/080148 PCT/US2003/030720 578 _________ ~ TABLE 4B ___ _ _______ SEQ Model Description E_value Score Repeats Position ID 2557 tRNA-syntl tRNA synthetases class I1(, L, M and 2.4e-07 23.7 1 99-137 V) 2558 MHC_II beta Class II histocompatibility antigen, beta 1.4e-43 149.3 | 1 - 41-116 2562 fn3 Fibronectin type III domain 0.0065 11.9 -1 18-105 2563 A2M Alpha-2-macroglobulin family 6.3e-23 75.5 1 4-86 WO 2004/080148 PCT/US2003/030720 579 TABLE 5 SEQ ID Position Maximum score Average score 685 1-26 0.982 0.908 689 1-19 0.975 0.888 691 1-49 0.944 0.603 695 1-24 0.993 0.943 697 1-26 0.919 0.670 698 1-20 0.988 0.939 706 1-20 0.989 0.973 707 1-24 0.973 0.922 710 1-33 0.957 0.789 712 1-57 0.975 0.488 714 1-42 0.958 0.680 715 1-42 0.958 0.687 _ 725 1-18 0.978 0.956 728 1-22 0.980 0.917 732 1-27 0.974 0.932 733 1-27 0.974 0.932 734 1-27 0.974 0.932 738 1-75 0.923 0.462 742 1-23 0.905 0.707 744 1-33 0.981 0.884 747 1-20 0.991 0.954 748 1-30 0.950 0.785 753 1-30 0.991 0.936 754 1.17 0.978 0-905 755 1-16 0.967 0.933 756 1-18 0.970 0.897 757 1-17 0.948 0.869 758 1-17 0.948 0.869 759 1-21 0.916 0.820 762 1-14 0.972 0.951 781 1-38 0.917 0.618 784 1-21 0.984 0.869 796 1-19 0.982 0.959 797 1-19 0.982 0.959 798 1-19 0.982 0.959 800 1-65 0.857 0.487 801 1-45 0.903 0.565 803 1-36 0.985 0.834 804 1-21 0.993 0.855 806 1-20 0.937 0.779 807 1-20 0.937 0.779 808 1-20 0.937 0.779 809 1-32 0.972 0.885 8i1 1-25 0.991 0.948 814 1-28 0.948 0.827 815 1-33 0.947 0.744 816 1-23 0.986 0.908 817 1-23 0.986 0.908 819 1-21 0.959 0.755 825 1-35 0.974 0.637 WO 2004/080148 PCT/US2003/030720 580 TABLE 5 SEQ ID Position Maximum score Average score 826 1-42 0.981 0.909 834 1-21 0.978 0.751 835 1-44 0.985 0.831 836 1-44 0.985 0.814 838 1-31 0.986 0.935 844 1-18 0.951 0.879 845 1-18 0.951 0.879 848 1-20 0.992 0.794 852 1-24 0.976 0.901 853 1-24 0.976 0.901 855 1-25 0.933 0.751 858 1-24 0.915 0.567 867 1-17 0.968 0.863 868 1-17 0.968 0.863 869 1-34 0.987 0.781 870 1-16 0.901 0.686 872 1-14 0.964 0.931 877 1-21 0.988 0.958 878 1-22 0.915 0.833 879 1-25 0.922 0.765 880 1-25 0.922 0.765 882 1-20 0.917 0.819 888 1-24 0.985 0.945 889 1-17 0.989 0.945 890 1-23 0.995 0.938 891 1-24 0.971 0.882 893 1-16 0.891 0.770 894 1-20 0.972 0.859 900 1-22 0.931 0.862 901 1-24 0.993 0.937 907 1-22 0.974 0.850 908 1-23 0.993 0.950 909 1-15 0.994 0.617 910 1-23 0.993 0.950 919 1-15 0.947 0.797 924 1-19 0.964 0.927 925 1-19 0.964 0.927 927 1-26 0.962 0.783 930 1-43 0.987 0.765 932 1-31 0.992 0.803 934 1-23 0.984 0.884 936 1-48 0.967 0.624 939 1-30 0.973 0.851 941 1-18 0.978 0.957 942 1-21 0.978 0.937 948 1-21 0.965 0.760 951 1-29 0.989 0.946 954 1-31 0.945 0.587 956 1-22 0.836 0.491 958 1-28 0.984 0.903 WO 2004/080148 PCT/US2003/030720 581 TABLE 5 SEQ ID Position Maximum score Average score 960 1-24 0.987 0.924 961 1-24 0.987 0.924 962 1-24 0.987 0.924 965 1-21 0.993 0.934 966 1-43 0.974 0.653 967 1-32 0.953 0.778 968 1-40 0.972 0.632 970 1-24 0.981 0.938 971 1-24 0.981 0.776 973 1-28 0.923 0.694 978 1-37 0.968 0.746 979 1-37 0.968 0.746 980 1-23 0.984 0.943 981 1-18 0.961 0.869 982 1-24 0.971 0.865 983 1-21 0.988 0.937 984 1-20 0.938 0.716 985 1-20 0.938 0.716 986 1-25 0.913 0.560 988 1-16 0.969 0.949 993 1-39 0.972 0.817 994 1-21 0.970 0.808 996 1-22 0.977 0.837 1006 1-35 0.967 0.668 1010 1-24 0.980 0.902 1013 1-24 0.987 0.903 1014 1-24 0.987 0.903 1017 1-23 0.932 0.654 1019 1-20 0.984 0.868 1023 1-25 0.948 0.735 1024 1-23 0.968 0.924 1027 1-25 0.956 0.848 1028 1-16 0.993 0.980 1029 1-16 0.993 0.980 1031 1-33 0.985 0.813 1039 1-46 0.982 0.666 1041 1-41 0.988 0.886 1046 1-24 0.991 0.940 1048 1-19 0.991 0.934 1052 1-21 0.991 0.903 1053 1-25 0.971 0.897 1054 1-24 0.975 0.932 1055 1-18 0.986 0.965 1057 1-18 0.978 0.887 1058 1-18 0.978 0.887 1060 1-26 0.987 0.917 1062 1-34 0.991 0.901 1066 1-31 0.992 0.741 1068 1-22 0.962 0.919 1072 1-22 0.986 0.943 WO 2004/080148 PCT/US2003/030720 582 TABLE 5 SEQ ID Position Maximum score Average score 1073 1-23 0.974 0.799 1075 1-33 0.986 0.886 1076 1-23 0.969 0.696 1077 1-23 0.969 0.696 1078 1-17 0.978 0.905 1079 1-30 0.935 0.717 1080 1-17 0.978 0.905 1081 1-17 0.978 0.905 1082 1-17 0.978 0.905 1083 1-26 0.936 0.809 1084 1-23 0.993 0.907 1085 1-18 0.969 0.643 1092 1-19 0.937 0.713 1096 1-39 0.995 0.594 1097 1-39 0.995 0.594 1100 1-20 0.964 0.902 1101 1-23 0.993 0.950 1102 1-23 0.993 0.950 1105 1-21 0.987 0.963 1106 1-19 0.947 0.709 1111 1-13 0.911 0.718 1117 1-20 0.930 0.706 1118 1-16 0.964 0.790 1121 1-24 0.968 0.825 1123 1-20 0.991 0.881 1128 1-22 0.969 0.871 1129 1-25 0.985 0.864 1130 1-25 0.985 0.864 1131 1-20 0.958 0.893 1132 1-21 0.942 0.717 1134 1-24 0.976 0.925 1136 1-14 0.972 0.951 1137 1-19 0.960 0.901 1139 1-33 0.995 0.835 1140 1-30 0.993 0.853 1141 1-30 0.993 0.853 1143 1-35 0.974 0.637 1144 1-42 0.981 0.909 1145 1-21 0.975 0.874 1150 1-21 0.914 0.729 1152 1-17 0.990 0.973 1153 1-17 0.990 0.973 1155 1-23 0.965 0.907 1161 1-39 0.954 0.705 1162 1-45 0.929 0.575 1165 1-19 0.939 0.857 1167 1-25 0.951 0.619 1170 1-37 0.978 0.830 1172 1-16 0.957 0.870 1173 1-16 0.957 0.870 WO 2004/080148 PCT/US2003/030720 583 TABLE 5 SEQ ID Position Maximum score Average score 1174 1-21 0.914 0.729 1178 1-25 0.980 0.925 1179 1-17 0.915 0.659 1181 1-22 0.950 0.719 1186 1-18 0.985 0.928 1192 1-18 0.960 0.803 1196 1-48 0.905 0.599 1199 1-20 0.988 0.955 1200 1-16 0.907 0.635 1205 1-25 0.974 0.781 1207 1-28 0.965 0.842 1208 1-23 0.965 0.693 1210 1-21 0.988 0.911 1213 1-31 0.940 0.696 1214 1-17 0.983 0.956 1218 1-23 0.996 0.969 1219 1-15 0.967 0.909 1221 1-16 0.978 0.938 1222 1-32 0.939 0.646 1223 1-23 0.982 0.945 1226 1-31 0.991 0.925 1228 1-32 0.953 0.778 1231 1-23 0.965 0.907 1232 1-23 0.965 0.907 1233 1-23 0.965 0.907 1235 1-21 0.873 0.596 1240 1-20 0.987 0.949 1241 1-22 0.994 0.890 1244 1-27 0.998 0.952 1245 1-27 0.998 0.952 1247 1-23 0.980 0.931 1253 1-17 0.945 0.731 1258 1-20 0.984 0.923 1259 1-32 0.956 0.757 1261 1-20 0.967 0.781 1262 1-18 0.961 0.886 1265 1-23 0.991 0.915 1266 1-23 0.991 0.915 1267 1-19 0.973 0.788 1268 1-34 0.988 0.888 1269 1-21 0.922 0.610 1271 1-23 0.910 0.653 1272 1-18 0.997 0.757 1275 1-29 0.989 0.943 1278 1-34 0.994 0.867 1279 1-15 0.983 0.957 1280 1-15 0.969 0.641 1281 1-36 0.916 0.620 1282 1-36 0.916 0.620 1283 1-36 0.896 0.584 WO 2004/080148 PCT/US2003/030720 584 TABLE 5 SEQ ID Position Maximum score Average score 1287 1-18 0.836 0.471 1288 1-31 0.952 0.767 1290 1-22 0.962 0.904 1292 1-33 0.904 0.641 1293 1-33 0.904 0.641 1295 1-27 0.962 0.882 1297 1-30 0.995 0.964 I298 1-30 0.995 0.964 I300 1-25 0.998 0.961 1302 1-16 0.921 0.729 1303 1-24 0.991 0.913 1310 1-52 0.987 0.492 1311 1-19 0.903 0.592 1314 1-16 0.887 0.735 1315 1-27 0.911 0.682 1316 1-27 0.911 0.682 1317 1-25 0.987 0.924 1319 1-20 0.973 0.759 1320 1-20 0.968 0.733 1322 1-16 0.969 0.894 1323 1-16 0.969 0.894 1324 1-28 0.957 0.874 1325 1-17 0.972 0.946 1326 1-17 0.972 0.946 1327 1-18 0.905 0.593 1328 1-16 0.895 0.561 1329 1-17 0.978 0.896 1330 1-20 0.988 0.963 1333 1-24 0.985 0.965 1335 1-22 0.966 0.767 1343 1-32 0.954 0.675 1344 1-18 0.951 0.879 1345 1-30 0.978 0.901 1347 1-20 0.961 0.880 1348 1-18 0.978 0.940 1350 1-23 0.989 0.868 1352 1-23 0.993 0.883 1354 1-25 0.924 0.567 1358 1-18 0.993 0.909 1359 1-15 0.855 0.706 1360 1-31 0.985 0.908 1361 1-17 0.995 0.950 1362 1-17 0.995 0.950 1364 1-29 0.962 0.860 1366 1-17 0.978 0.905 1368 1-26 0.958 0.843 WO 2004/080148 PCT/US2003/030720 585 221 3 17 4 17 5 15 6 233 7 7q1. 8 21 . 9 12 30 40i.-1.2 31 4 32 19 33 19-pcii 35 28 37 12q 38 7 39 22I2. 41 1p2 43 19 44 6 45 35 46 l9q3. 47 4 _ __ _ __ _ __ _ __ _ __ _ __ _ _ 514 3 19 54 19 56 3 WO 2004/080148 PCT/US2003/030720 586 TABLE 6 SEQ ID GENOMIC LOCATION 574 58 13_____________________ 59 11____________________ 601 61 1 62 1 64 4 67 7 68 20 69 11 70 12

P

13 711032.1-33 72 3 73 14 74 14 75 6p11.2-12.

3 77 15 78 19 79 2 80 9 81 9 82 9 83 11 84 2p13 85 11 86 lp 3 6

.

2

-

3 6

.

33 871 88 1 892p1 .90 72-~~ 914 927 93172 94 ll. 95 _________________________ 96 1 98 8_____________________ 997 1004 1012 102 q632. 1034 104 5 105 5 106 Xpl 1.3 107 12pter-pl3.31 108 4 109 19 1 10 Iocen-q26.1 i 111 19pl13 112 1 7 WO 2004/080148 PCT/US2003/030720 587 SEQ ED GNMCLCTO 113 1 114 1 1156 116 14_________________ 1 1714 118 10 1193 1201 121 1 122 1 123 1 124. 125 5 l. 126 1 127 6___________________ 131 17___________________ 132 l 133 l 135 p61 136 1 137 i 1383 139 2 140 11q13_ 141 7q33-q35 142 7q33-q35 143 4 144 6q25.3-27 145 8 146 147 17 148 17 149 11 150 22 151 17 152 17 153 Xq22 154 5 155 14 156 13q12 .11-1 2 .3 157 9 158 22q12 159 22q12 160 1 161 1 163 ______________________ 164 _____________________ 165 17 __________________ 1664 ~167 41 1i68 41 169 4p16 170 11 1171 5_ _ _ _ _ _ _ _ _ _ _ _ 172 14 WO 2004/080148 PCT/US2003/030720 588 TABLE 6 SIGENOMIC LOCATION 173 15 174 15 175 8p21.3-q11.1 17f6 8p21.3-qll.1 177 3p 2 l-pl 2 178 19 1-7-9 16 IS0 22q 12 181 X 182 6 183 5 p13 184 5 p13 186 12q 187 10 188 3 189 2 I90 22 191 7 192 19 193 14 194 iq22 195 11q22 196 11q22 197 15 198 4 199 4q28-q32 200 6p21.1-22.2. 201 12 202 2p24 203 2p24 204 1 205 14 206 18 _207 20 208 19 209 1 210 4 211 1 212 4 213 3 214 3 215 9 216 1 217 11 218 7q 219 7q 220 17 221 5 222 15 223 10 224 8 225 8 226 _8 227 9 228 8 WO 2004/080148 PCT/US2003/030720 589 TABLE 6 SEQ ID GENOMIC LOCATION 31 9~-1-1_31. 230 7pter-p22 231 7 232 1-- 233

--

234

--

235 10 236 1p34.1-1p35. 237 4p16-p15 _ 238 _4p16-p15 239 4 p16-p15 240 4p16-p15 241 4pl6-pl5 242 20 253 6p12.3-21.2 244 .2 245 6p21.2-22.1 246 1913.4 247 11413.3 248 6 249 18 251 3 252 11 253 11 254 19 255 6 256 2 257 Xp22 258 Xp22 259 20q12-13.1 260 20q12-13.1 261 20ql2-13.1 262 20ql12-13.1 263 16 264 265 11 266 9q34.2-34.3 267 20 268 12 269 7 270 9 271 20 272 14 273 9p34.1-35.1 274 17 275 10 276 10 277 10 278 10 279 19)36.11-36.31 281 1 282 3p2l.3 283 14 284 1 285 1 WO 2004/080148 PCT/US2003/030720 590 SEQ ID GENOMIC LOCATION 286 287 22q12.3-13.2. 288 11 289 17421.3 290 2 291 1p22.2-31.1 292 1_22.2-31.1 293 19 294 Xq23 295 Xq23 296 10q25.3-q26.2 297 1 298 20q12-13.

2 299 6 300 2 301 .2 302 |12q24.1 303 20q11.

2 1-1 3 .13 304 8 3051 306 12q 507 18q12-q21 308 14 309 5 310 2 311 2q32.1-q36.3 312 12p13.32 313 5 314 13 315 22ql3.1 316 18 317 11 318 , 11 319 3 320 2 321 4q27 322 11 323 11 324 Xql 12.1-13. 325 8 326 22. 328 3 329 9 330 9 331 5 332 22q13.31-13.33 333 22ql3.31-13.33 334 10 335 3 336 15 337 5 338 5 339 3 p 340 3 341 3 WO 2004/080148 PCT/US2003/030720 591 TABLE 6 SEQ ID GENOMIC LOCATION 342 5 343 12 344 34514 3463 347 16 348 349 6q24.3-25.3 350 5 351 1 352 9q31.1-31.3 353 2 354 16 355 6 356 5q13 357 17 359 6 360 19 361 5 362 11ql4.3-q21 363 12q 364 22q13.31-13.33 365 9 366 2 367 2 368 22q11.1-q11.2 369 16 370 17 371 11 372 20 -373 20 374 20 375 20 376 15ql3-q14 377 1 378 16pl3.3 379 20 380 3 381 lp32-p31 382 q42.2-43 383 X 384 15 385 16 386 8 387 3p25-p 2 4 388 11 389 7 390 7 391 2 392 22 393 22 394 12 395 12 396 12 397 12 WO 2004/080148 PCT/US2003/030720 592 TABLE60_1_ SEQ ID GENOMIC LOCATION___ 398 12 399 -- 4 400 2 4.01 _3 402 10 403 194l 3 .4 4104 194l3.4_ 405 . 7q12-q21 406 17q2-q21 407 17412-921 408 10 409 10 410 12p13.3 411 X9 13.2-2 1.1 412 12p13 413 12p13 424 11 415 7922 416 19 417 8 418 8 419 18 420 7 421 1q25.1-31.3 422 8 423 19 424 11 425 16 426 19p3.3 427 11 428 2 429 7 . 430 8 4314 4322 433 19 434 19 435 5 436 14 437 3 438 22ql3 439 20p11.22-12.2 440 2 441 2 442 1 4431 444 445 8 446 8 -447 7p 11.2-q 11.2 448 8 449 19 450 6 451 7q22-q31.1 4.52 19 WO 2004/080148 PCT/US2003/030720 593 453 7q33-q35 7433-13 45514 456 4 45717 46212 463 22 465nq2. 17 2.6712-3 472 20g 13.33 475 1 476 18___________________ 479 1 4805 4812 482 2q33-q34 483 19 484 4 485 1p231. 486 3 487 3 488 19 489 19 490 19 491 l~pl2 492 17 493 10 494 12 495 18 496 13 497 10 498 16 499 22q12.2 500 X 501 3 ___________________ 502 15 503 3 ____________________ 504 19 505 19 506 19 507 5 WO 2004/080148 PCT/US2003/030720 594 TABLE 6 SEQ ID 'GENOMIC LOCATION 508 7q21.2-q31.1 IO9 2 Il0 2p13 511 1p21-p13 Il2 7 513 11- 514 16 515 516 1is-_ 517 10 518 5 519 10 520 21q22.3 521 7 522 3p 2 l.1-p14.2 523 1q21 525 1q25.1-31.1 526 7q35 527 9 528 1 529 5q32 530 19 531 2 532 18 533 1 534 22 535 13 536 X 537 4q21-q25 538 1q23-q25.1 539 18 540 22q12 541 3p24 542 1 9 p13.1 543 2 544 14 545 6p21.1-21.3 546 12 547 22q12-13. 548 22ql2-13. 549 22ql2-13. 550 17 551 14 552 15 553 15 554 1 555 1q23.2-24.3 556 15q21.1 557 3 558 12q24.1 559 17 560 19 561 19 562 9 563 5 WO 2004/080148 PCT/US2003/030720 595 TABLE6 __ SEQ ID. GENOMIC LOCATION__ 564 7 565 2 566 1 567 __5 568 5 569

-

570 3 571 14q24.3 572 . 1q22.3-q23.1 573 _ 11q22.3-q23.1 574 575 576 12q 577 13ql4.2-14.3 578 3 579 _to 580 15 581 10 582 10 583 6 584 11 585 586 17 587 7 588 3 589 2 590 8 591 20 592 17 593 17 594 5 595 1 596 16 597 7 598 7 599 7 600 17 601 2 602 9 603 7 604 19 605 16q22 606 17 607 22 608 _g 609 1lq 6IO 9 611 20 612 2 _613 6 614 .6 615 15 616 22q13.32 617 |1 618 11 WO 2004/080148 PCT/US2003/030720 596 TABLE 6 SEQ [D GENOMIC LOCATION 619 15 620 15q21.3 621 15q21.3 622 623 14 624 3__ 625 3_ 626 2p22-2p21 627 _7 628 629 06 630 X 631 8 632 8 633 17qi25.2-_q25.3 634 '16 635 13 636 13 637 638 19 639 640 9 641 1,9413.2 642 19413.2 643 1936.1 644 645 646 Xq23 649 2q35 650 651 652 142l 653 654 4 655 2 656 1p36.2-p35 657 2 658 16 659 3 660 6 661 10 662 10 663 |16 664 |3 665 3 666 17 667 12 668 16p11.2 669 11 670 1 671 2 672 12p13.3 673 12p 13.3 674. 5_ 675 2_ WO 2004/080148 PCT/US2003/030720 597 SEQ ID GNMCLCTO 676 6~,-13 677 1 678 1 679 1 6803 681 21 682 12__________________ 683 7 WO 2004/080148 PCT/US2003/030720 598 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence 1967 A 75 509 DPKAQLPEPLRVLWTAHLVX1hFGSRTSLLLAFALLC LFWLQEAGAVQTVPLSRLFDHAELQAHRABQLAIDTY QEFEETYX PKDQKYSFLHDSQTSFCFSDSI PTPSNME ETQQKSNLELLRI SLIJLIE SWLEPVRILMS IVPN 1968 A 75 509 DPKAQLPEPLRVLWTAHLVANAPGSRTSLLLAFALLC LPWLQEAGAVQTVPLSRLFDHAMLQAHRAIQLAzIDTY QEFEETYI PKDQKYSFLNDSQTSFCFSDS IPTPSNME ETQQKSNLELLRI SLLLIE SWLEPVRILMSIVFN 1969 A 759 DPKAQLPEPLRVLWTALVAMAPGSRTSLLLAFALLC LPWLQEAGAVQTVPLSRLFDHIAMLQHREQLAIDTY QEFEETYI PKDQKYSF 2 I-DSQTSFCFSDS IPTFSNME ETQQKSNLELLRI SLLLIESWLEPVRILMSIVPN 1970 A 75 509 DFKAQLPEPLRVLWTAELVAMAPGSRTSLLLAFALLC LPWLQEAGAVQTVPLSRLFDEAMLQAHRAHQLAIDTY QEFEETYT PKDQKYSFLHDSQTSFCFSDS IPTPSNME ETQQKSNLELLRI SLLLIESWLEPVRILMSIVPN 1971 A 1764 40 KAAKALCWLEPPQCAGLEGLGWVWSCSVSTGPRMQA TVLLLCIGALLGHSSCQNPAS PPEEGSPDPDSTGALV EEEDPFFKVPVNKLAAAVSNFGYDLYRVRSSMS FTTN VLLSPLSVATALSALSLGAEQRTESI IHFALYYDLIS SPDIEGTYKELLDTVTAPQENLKSASRIVFEKKLRI K SSFVAPLEKSYGTRPRVLTGNRLLQEINWVQAQM KGKLARSTEEI PDEISILLLG\VAHFKGQ\WETKFDS RKTSLEDFYT-DEERTVRVPMMSDPKAVLRYGLDSDLS CKIAQLPLTGSMSI IFFLPLKVTQNLTLIEESJTSEF IEDIDRELKTVQAVLTVPKLKLSYEGEVTKSLQBMKL QSLFDSPDFSKITGKPIKLTQVEHRAGFEWNEDGAGT TPSPGLQFAHLTFPLDYI{LNQPFIFVLRDTDTGALLF IGKILDPRGP 1972 A 3 147 QPLNHYFICSSHNTYVGDQLCGQSSVEGYIRCSGGR EGVQIJMRGTM 1973 A 2 2117 FWVAASGGCWFVLGERRAGSLLSASYGTFAMPGMVLF GRRWAIASDDLVFFGFFELVVRVLWWIGILTLYLMHR F GKLDCAGGALLSSYLIVLMILLAVVICTVSAIMCVSM RGTI CNPGPRKSMSKLLYIRLALFFPEMWASLGAAW VADGVQCDRTVVNGI IATVVVS WIIIAATVVSII IVF DTLGGKMAPYSSAGPSHLDSHDSSQLLNGLKTTSV WETRIKtILCCCIGKDDHTRVAFSSTAELFSTYFSDTD LVPSDIAAGLALLHQQQDNIRNNQEPAQWVCHPGSS QEADLDAELKNCHHYMQFAAAAYGWFLYIYRNPLTGL CRIGGDCCRSKNPQTMT/NVGGDQLQL/ CTSAPILHT HRAAVQGLHPRQLPWTRFTELPFLVALDHRKESVVVA YRGTMSLQDVLTDLSAESEVLDVECEVQDRLAHK GI S QAARYVYQRLINDGILSQAFS IAPEYRLVIVGHSLGG GAAALLATMVRAAYPQVRCYAFSPPRGLWSKALQEYS QSFIVSLVLGKDVI PRLSVTNLEDLKRRILRVVAHCN KFKYKILLHGLWYELFGGNPNNLPTELDGGDQEVLTQ PLLCEQSLLTRWSPAYSFSSDS PIDSS PKYFFLYFFG RI IHLQEEGASGRFGCCSAAEYSAKWSHEAEFSKILI GPKMLTDHMPDIT-MALDSVVSIDRAACVSCFAQGVS

S

WO 2004/080148 PCT/US2003/030720 599 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequencee 1974 A 62 616 EVHQGTEVRDSEVRRRPQARGPLMPAERGRQRWLVP 1975 A 337 440 PLALCLAPAASLHELCAAKVSEVLIIRVHRTEEV 1976 A 1454 1101 AFYNANSCLNVFCFCFCFWRQSRCISQAGVQWCDLSS 1977 A 21454 DEFVGVLSATAQVCTMAARLVSRCGAV.APHSGPL/ ATLLSSFGAWDHT CNNRYRAFRRMQVWDACSEALIMF DKDNLDDMGYIL\ENDV\

IMHAFTKQI

4 EAVSDRVTVL YRSKAIRYTWPCPFPMADSSPWVHITLGDGSTFQTKL LIGADGHNSGVRQAVGIQNVSWNYDQSAVVATLHLSE ATENNVAWQRFLPSGPIALLPLSDTLSSLVWSTSKEH AAELVSMDEEKFVDAVNSAFWSDADHTDFIDTAGAML QYAVSLLKPTKVSARQLPP9VARVDAKSRVLFPLGLG HAAEYVRPRVALIGDAAH1RVHPLAGQGVNMGFGDI SS LA1.lLSTAAFNGKDLGSMSHLTGYETERQRNTALLA ATDLLKRLYSTSAS PL VLLRT WGLQATNAVS PLKEQI MAFASK 1978 A 3692 3395 LKDSLLRFFFFEMESCSVTRLECSGVISRLRLPG QDGLDLL/NLVT SPPWPPKVLGLQA 1979 A 65 265 SALLGLPSSWDYRRPPPRPANFLYF**RRGFTVLAR VS IC *PRDPPASASRSAGISGVSRGRPPS 1980 A 751 LSLRLFHLLLTSAAWVPDESQVTLNSA I CVLSTVLIMEFPDLGKIICSEKTCKQLDFLPVKCDAC KQDFCKDKFPYAAHKCPFAFQKDVHVPVCPLCNTPIP VKKGQI PDVVVGDHIDRDCDSIIPGKKKEKI FTYRCSK EGCKKKEMLQMVCAQCHGNFCIQHRHPLDHSCRHGSR PTI KAG 1981 A250 118 DSLTRLPALCSLQLGRKVETITIIYDCEGLGLA2LWK PAVEAYC 1982 A 235 SIQEKCFDSSCGRNS LCIWI \TAIWQYESLKSRVQSYFDGIKADWLDSIRP QKEGDFRKEINKWWNNLSDCQRTVTGT IAANVLVFCI WRVPSLQRTMIRYFTSNPASKVLCSPMLLSTFSHFSL FHMA2ANMYVLWSFS SSIVNILGQEQFMAVYLSAGVI S NFVSYLGKIVATGRYGPSLGASGAIMTVLAAVCTKI PE GRLAIIFLPMFTFTAGNALKAI IAMDTAGMILGWKFF

DKAAHLGGALFGIWYVTYGHELIWI<REPLV

4 IWHEI RTNGPT(KGGGSK 1983 A 289 39:2 RAFAEAMRGYHGDRGSHPRPARFADQQKMDVGPA 1984 A 989 1474 SEGALQRALQVTVPHFL.DWSGEALQPTRIRILNV 599 A LRAL WO 2004/080148 PCT/US2003/030720 600 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XUnknown, *Stop codoi, ID beginning ending /=possible nucleotide deletion,=possihle nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequeiice peptide e sequence HVPRLHLKFIAGFGVPRLLAAANi FTFKV-\FRAPEPLELT L1VELLADTRVTQSSIRTPVVSIACS4FSGHANEFD GSNSTSHALLVLVQIK'HIKAVLSNK1LCLSI SNLVQGVN VHLGTLIGLNPVGPESQIRYSMVSVPTVTSDYI SLEV NAVJZFLLGKPI ILPTDATPFVLPRHVGTEGSMATVGL SQQLFDSALLLLQIKAGALNqLDITGQLRSDDNLLNTSA LGRLJ PEVARQFPEPMPVVLKVRLGATPVAMLHTNNA TLRLQPFVEXTLATASNSAFQSL~FSLDVVVNLRLQLSV SKVKLQGTTSVLGDVQLTVASSNVGFIDTDQVRTLMG TVFEKPLLDHLNALLAMGIALPGVVNLHYVAPEIFVY EGYVVISSGLFYQS* 1985 A 541 176 GPHTSNRPRXRHCTXGPSTXXTXAGSGYSPAHGAWG APCXSW*RSPGPRGGRESGTCRPAAAPAPAPAGGCRA GTGAWPPGSATS PRC *S PAAPRCAGPQPGSGGSHGGT - -ARMCACKLAAS 1986 A 2390 1943 AGRRLTQAGTLGTALAFGTRLLVSSDMKSWSTVLAV MGKAFSEAAFTTAYLFTSELYPTVLRQTGMGLTALVC RLGGSLAPLAALLDGVWLiSLPKLTYGGIALLAAGTAL LALPETRQAQLPETIQDVERKSAPTSLQEEEMPMKQVQ N 1987 A 1 -55 KKVGNYYTTPIYRFRKCHLCNYIEMQTDPANCDYV IVSGAQRKEERWDMADNEQVLTTGERIPLTCLGAL/D PESALGPPKPSRALIVAEHEKKQKLETDAMFRLEHGE ADRSTLKKALPTL~SHIQEAQSAWKIDDFALNSMLRRRF RVRGAPARGQRGCMVDQGPGPALPPPHPSFEQATCTF 1988 A 2867 847 aLPGIPGLPGFPGVAGPPGITGFPFIGSRGDKGAPG RAGLYGEIGATGDFGDIGDTINLPGRPGLKGERGTTG IPGLKGFFGEKGTEGDIGFPGITGVTGVQGPPGLKGQ TGFPGLTGPPGSQGELGRT GLPGGKGDDGWPGAPGLP GFPGLRGIRGLHGLPGTKGFPGSPGSDIHGDPGFPGP PGERGDPGEANTLPGPVGVPGQKGJQGAPGERGPPGS PGLQGFPGT TPPSNISGAPGDKGAPGIFGLKGYRGPP GPPGSAALPGSKGDTGNPGAPCTPGTKGWAGDSGPQG RPGVFGLPGEKGPRGEQGFMGNTGPTGAVGDRGPKGP KGDPGFPGAPGTVGAPGIAGI PQKIAVQPGTVGPQGR RGPPGAPGEMGPQGPPGEPGFRGAPGKAGPQGRGGVS AVPGFRGDEGPIhGHQGPIGQEGAPGRPGSPGLPGMPG RSVS IGYLLVKI-SQTDQEPMC9VGMNKLWSGYSLLYF EGQEKAHNQD)LGLAGSCLARFSTMPFLYCNPGDVCYY ASRNEKSYWLSTTAPLPMMPVAEDE IKPYI SRCSVCE APAIAIAVHSQDVSI PHCPAGWRSLWIGYSFLMHTAA GDEGGGQSLVS PGSCLEDFRATPFI ECNGGRGTCHYY ?.NKYSFWLTTI PEQSFQGSPSADTLKAGLIRTIISRC QVCMI(NL 1989 A 1 777 LYNEDMICWtiESRESSNQLKCIQITKAGGLTDEWTI NILQSFHNVQQMAIDWLT2NLYFVDH2VGDRIFVCNSN GSVCVTLIDLELHNPIKAIAVDPIAGIKLFFTDYGN4VAK VERCDMDGMNRTRI IDSKTEQPAALALDLVNKLVYWV DLYLDYVGVVDYQGKNRHAVIQGRQVRHLYGITVFED YLYATN9DSINITRI SRFNGTDIH-SLIKIENAWGIRI WO 2004/080148 PCT/US2003/030720 601 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XAUnknown, *Stop codon, ID beginning ending /possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide c sequence YQIRTQPTVRSHACEVDPYGMPGGCSHICLLS SSYTI( 1990 A 1 777 LIYNEDMICWIESRESSNQLKCbQITAGGLTDEWTI NILQSFHNVQQMAIDWLTRJNLYFVDHVGDRI FVCNSN GSVCVTLIDLEL'HNPKAIAVIDPIAGK LFFTDYGNVAK VERCDMDGMNRTRT IDSKTEQPAALALD)LVNKLVYWV DLYLDYVGVVD)YQGKNRHAVI QGRQVRI-LYGITVFED YLYATNSDSYNIVRI SRFNGTDIHSLIKIENAWGIRI YQKRTQPTVRSHACEVDPYGMPGGCSWI CILSS SYTK 1991 A 1620 1214 LPFLSFFLSFFLFLWSAIIAQAGVQWCNFGSPQP PPPGFKRFS CLSLLSSWIDYRHTPPCLANSVFIJVDTGF LHVGQAGLEILPTSGDFPTSASQSACITSVSHCAQFVT A: SKEEREQAEGPDSQGTGSSAGQ 1992 A 1 660 GFHPNTTHYRARAAARAGAGSFVGEVSAVEKFGFNG EVRYSFEMVQPDFELHAI SCEITNTHQFDRESLMRRR GTAVFSFTVIATDQCI PQPLTKQATVHVYMKDINDNA PKFLKDFYQATI SESAANLTQVLRVSASDVDEGNNGL IHYS IIKGNEERQFAIDSPSGQVTLIGKLCYEATPAY SLVIQAVDSGTI PLNSTCTLNIDIIJDENDNTPFFP 1993 A 1 660 GFPNTTHYRRAAARAGAGSFVGEVSAKFGPNG EVRYSFEMVQPDFELHAI SGEITNTHQFDRESLMRRR GTAVFSFTVIATDQGI FQPLKEQATVHVYMKDINDNA PKFLKDFYQATI SESAANLTQVLRVSASDVDEGNNGL IHYS IIKGNEERQFAIESTSGQVTLIGKLDYEATPAY SLVIQAVDSGTI FLNSTCTLNIDILDENDNTPFFP 1994 A 2 271 GSVALHVEKLPNEPNRLLILHGFLDENVHFFHTNFLV SQLIRAGKPYQLQVALPPVSPQIYPNERHS IRCPESG EHYEVTLLIIFLQEYL 1995 A 289 418 LWTLYRHKQQVQHNHSNRLSCRPSQEDPATHTMVLD KENTAS 1996 A 3 673 RNFRVDDFVAELKLKQVRWTPAAP*SKETTQGLRRLH ThGRCEPKGLDPEMGRRSSDTEESRSKRKKKHRRRS 89558 SDSRTYSRKKGGRKSRSKSRSWSRDLQPRSHS YDRRRRHRSS588SSYCSRRKRSRSRSRGRGKSYRVQR SRSKSRTRRSRSRPRLRSH8RSSERSSHRRTR8RSRD RERRKGRDKEKREKEKDKGKDKELHNI KRGESGNIKA GLE/HSATS *TGQSQTTAS*SCCS* *SIESQRKK* CRSKE/QERRKTKPPW*NK* KE*KFGGRRRRPDLKKR LRDCGACTSTGGVS PKVWTQKWDVGHQILKKKAEARE KRNTVDGPPRAVLQIVEHTAERKEEGNQDQSQDLGPE IFSLVHILMIEDAGIDQAVALLMAPEGNEVEWVQGVE GNPIEERGLGQKAEQEGPGQDLVSVLIVVAVKGPVTE ERVVGLGIENDVRAEIKRKEKRRRIKGRTRNYITSNV G.NLETSKLD 1997 A 279 762 VGNFQRQLAEAI(EDNCKVTIMLENVLASHSKQGALE I{,VQIELGRRDSEIAGLKKERDLNQQRVQKLEAEVDQW QARI4LVME2DQHNSEIESLQKALGVAREDNRILSLE QALQTNHLQTLDHIQEQLE8KELERQNLETFDR TEESKVEAELHAE 1998 A 3Y4 13 4 PPNMDNqSMGTEEITVLKGS8TSMACITDGTPAPSMAW I

~LRDGQFLGLDAHLTVSTHCMVLQLLKBETEDSGIKYTC

WO 2004/080148 PCT/US2003/030720 602 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide resdue of sequence peptide sequence IASNBAGEVSKHFILKVLVFPSFQKJWEIGNMLDTGR NGEAKDVI INNPI SLYCETNAAPPFTLTWYKDGHFLT SSDKVLILPGGRVILQTPRAKVEDAGRYTCVAVhEAGE DSLQYDVRVLVPFI IKGANSDLPEEVTVLV'NTKSALIE CLS SGSPAPRNSWQKDGQPLLEDDHHKFLSNGRILQI LNTQITDIGRYVCVAENTAGSAKIKYFNLNVHVPPSVI GFKSENLTVVVNNFI SLTCEVSGFPPPDLSWLRNFQP IPLNTNTLIAPGGRTLQIIRAK,-VSDGGEYTCIAINQA GESBCKKFSLTVYVFPS IKDHDSESLSWVNVREGTSVS LECESNAVPPPVITWYKNGRMITESTVETLDGQML IIKKAEVSDTGQYVCRAINVAGRDDK NFHLNVY 1999 A 2 1333 RSGEGFHVNSS*TWVSRS*EMDETPGSEVPGKAEE QGDDQDSEKSKPAGSDGERRGVKRQRD)EKDEHGRAYY EEREEAYHSRSKSPLPPEEEAKDEEEDQTLVNLDTYT SDLHFQVSKDRYGGQPLFSEKFPTLWSGARSTYGVTK GKVCFEAKVTQNLPMKEGCTEVSLLRVGWSVI)FSRPQ LGEDEFSYGFDGRGLKAENCQFEEFGQTFGENDVIGC FANFETEEVELSFSKNGEDLGVAFWI SKDSLADRALL PHVLCKNCVVELNFGQKEEPFFPFPEEFVFIHAVPVE ERVRTAVPPKTIEECEVILMVGLPGSGKTQWALKYAK ENPEKRYNVLCAETVLNQMRMKGLEEPEMDPKSRDLL VQQASQCLSKLVQIASRTKPNFILDQCNVYNSGQRRK LLLFKTFSRKVVVVVPNEDDWKRLELREVGRVFP 2000 A 1 1060 IIFIFFPYLQSVTFLFVIRGLEMKYGNEIMNKDPVF RI SPRSRETHFNFEEPEEEDEDVQAERVQAANALTAP NLEEEPVITASCLHKEYYETKKSCFSTRKKKIAIV SFCVIKKGEVLGLLGHNGAGKSTSIKMITGCTVPTAGV VVLQCNRASVRQQRDNSLK/ FLGYCPQENSLWPKLTM KEHLELYAAVKGLGKDAALS IS *LVEALKLQEQLKAP VKTLSEGIKRKLCFVLS ILGNPSVVLLDELFTGMDPE GQQQMWQILQATIKNQERGALLTTHYMSEAKSLCDRV AIMVSGTIJRCIGS IQQL/ KKFGKDYLLEI KMKEPTQV EALHTEILKLFPQAAWQERYSSL 2001 A 1 2543 TISSSPKWRLSGWRAPCCWGFEwAGGPGDFPA LEDESGTLLRSGGGAGEQWQQGLRWRFRSGMCESYSR SLIJRVSVAQI CQALGWDSVQLSACHJLTDVLQRYLQQ LGRGCHRYSELYGRTDPILDDVGEAFQLMGVSLHELE DYfINIEPVTFFHQI PSFPVSKNNVLQFPQPGSKDAE ERKEYIPDYLFPIVSSQEEEEEEQVPTDGCTSAEAMQ VPLEEDDELEEEEI INDENFLGKRPLDSPEAEELPAM KRPRLTSTKGDTLDVVLLEAREPLSSINTQKT PPMLS PVHVQDSTDLAPPSPEPPMLAFVAKSQMPTAKFLETK SFTFKTKTKTSS FGQKTI{SPKTAQSPAMVGS PIRS PK TVSKEKKSPGRSKS PKSPKSPKVTTHIPQTPVRFETP NRTPSATLSEKI SKETIQVKQIQTPFDAGKJNSENQP KKAVVADKTIEAS IDAVIARACAEREPDPFEES SOSE SEGDI FTSPT(RI SGPECTTPKASTSANqSFTKSGSTPL PLSGGTSSSDNSWTMDAS IDEVVRK-'AKLGTPSNMPPN FPYI SSPSVS PPTPEP1JHKVYEEKTKLPSSVEVKKKL KIELKTK KI-czKQRDRERE{DIRIDKSKEICI(VIEK WO 2004/080148 PCT/US2003/030720 603 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence 2002 A 21ENSVDKWGKPVKLKEMAKVEGLWNLFLPVS PKSHVDALAEEKHKDKADFNCQAPDGNMBVL NVICSIREDSYVINGKVLKWWSSANPKCKPTASL RTQNTLSR* PLNSTVGMSQSSSIRiRGHC 2003 A 2240ESVKGPVDKKMKELWLLAS TABECSQ 7SVIGK _ -GNKKTTL LDSQI IM*DMRVNVIYLYFTSIF*QVFLENI IGSIAE H~SSLWNFQY* KVLLNYQSCLD* ITRQIFSDLCNEVIR CLDQRQ* S*NV*LYI*VPSYHC*AVRSFNQTTHLFSN HCFCSRSQPASDYVGVRLLHS SHSSHHCLHDYMKTSK RQLGFCLLSVLFFFLhANFF*YNFSFD* \HKQHSMILV PMNTPGVKI IRPLSVFGYTDNF-GCHFEIIIFNQVRVP ATNLILGEGRGFEI SQGRLGPGRIHHCMRTVGLAERA LQIMCERATQRIAFKKKLYAHEVVAHWIAESRIAIEK IRLLTLKAAHSMDTLGSAGAKKEIAMIKVAAPRAVSK IVDWAIQVCGGAGVSQDYPLANMYAMTRVLRLADGPD - - - EVH-LSAIATMELRDQAKRLTAKI 2003 A 2240 506 RRPPEGGSGGGRRTRARMPLPWSLALPLLLSAGGF GNAASARHHGLLASARQPGVCHYGTKLACCYGWRRNS KGVCEATCEPGCI(FGECVGPNKCPRCFPGYTGKTCSQD VNECGMKPRPCQH~RCVNTHGSYKCFCLSGHMLMPDAT CVNSRTCAMINCQYSCEDTEEGPQCLCPSSGLRLAPN GRDCLDIDECASGKVI CPYNRRCVNTFGSYYCKCHTG FELQYI SGRYDCIDINECTMDSHTCSHHANCFNTQGS FKCKCKQGYKGNGLRCSAIPENSVKEVLAPGTIKDR I KKLLAHKNSMKKKAKIKNVTPEPTRTPTPKVNLQF NYEETVSRGGNSHGG\KKGNEEKEGLEDEKEK IKD*HRRBRPFRG\DVFFPKVNEAGEFGLI L\VQRF(A LTSKLEHKADLNI SVDCSFNH-G\ICDW\KQDR\EDDF DW\NPADR\DNAI \GFY\MAVPGLWQGI-KVKDIGRLK LLLPDLQPQSNFCLLFDYRLAGDKVGKLRVFVKNSNN ALAWEKTTSEDEKWKTGKIQLYQGTDATKSI IFEABR GKGKTGEIAVDGVLLVSGLCPDSLLSVDD 2004 A 2 469 KCTKNGQFNYPWDVAVNSEGKILVSDTRNHRIQLFGP DGVFLNKYGFEGALWKHFDS PRGVAFNH-EGHLVVTDF NNHRLLVIHPDCQSARFLGSEGTGNGQFLRPQGVAVD QEGRI IVAISRNHRVQMFESNGSFLCKFGAQGSGFGQ MDRPSGIA 2005 A 4135 639 QCGPEAASAGSCSAETPSPPPRAPGRGPIMFSRKbc E LMKTPSI SKKNRAGSPSPQPSGELPRKDGAzDAVFPGP SLEPPAGS SGVKATGTLI(ARPTSLSRUASAAGFPLSGA ASWTLGRSHRSPLTAAS PGELPTEC3AGPDVVEDI SI-L LADVARFAEGLEKLKIECVLHDDLLEARRPRAHECLGE ALRVMHQII SKYPLLNTVETLTAAGTLIAKVKAFRYE

SNNLEQEFRIEKIETVAFSSTVSEFLMGEVDSST

WO 2004/080148 PCT/US2003/030720 604 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codoi, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence LLAVPPGDS SQSMESLYGPC-SEGTPPSLEDCEAGCL P AEEVDVLLQRCEGGVDAALLYAKNMAKYMICDLT SYLE KRTTLEMEFAKGLQKIAHNCRQSVDAQEPHMPLLSIYS LALEQDLEFG}ISMVQAVGTLQTQTFD4QPLTLRRLEHE KRRKICTKEAWHRAQRK-LQEAES±NLRKAKQGYVQRCED HDKARFLVAKAEEEQAGSAPGAGSTATKTLDKRRRL E EEAKNKAEEAMATYRTCVADAKTQQELEDTKVTALR QIQEVIRQSDQTIKSATI SYYQMMHMQTAPLPVRFQM LCESSKLYDPCQQYAS-VRQLQRDQEPDVHYDFE PRY SANAWS PVMRARKSSFNVSDVARPEAAGSPPEEGGCT EGTPAKDHRAGRGEQVHKSWPLS ISDSDSGLDPGPGA GDFKKFERTSSSGTMSSTEELVDPDGGAGASAFEQAD LNGMTPELFVAVPSGPFRHEGLSKAARTHRLR\ KLRT PAKCRECNSYVYFQGAECEECCLACHKKCLETLAIQC GHKKLQGRLQTJFGQEFSHAARSAPDGVPFIVKKCVCE IERRALRTKGIYRVNGVKTRVEKLCQAFENGKELVEL SQASPHDI SNVLKLYLRQLPEPLISFRLYHELVGLAK DSLKAEAEAKAASRGRQDGSESEAVAVALAGRL~RELL RDLPPENRASLQYLLRHLRRIVEVEQDNKMTPGNLGI

VFGPTLI

2 RPRPTEATVSLSSLVDYFHQARVIETLIVH YGLVFEEEPEETPGGQDESSNQRAEVVVQVPYLEAGE AVVYPLQEAAADGCRESRVVSNDSDSDLEEASELLSS SEASALGHLSFLEQQQSEASLEVASGSHSGSEEQLEA TAREDGDGDEDGPAQQLSGFNTNQSNNVLQAPLPPMR LRGGRMTLGSCRERQPEFV 2006 A 3 628 SVGALDTFIAAVYEAVILPNRAETPVSKEEALLLMN KNIDVLEKAVKLAAKQGA-IIIVTPEDGIYGWIFTRES IYPYLEDIPDPGVNWI PCRDPWRNIH*NIVSLRKCLLN \RFGNTPVQQRLSCLAKDNS IYVVANIGDKKPCNASD SQCPPDGRYQYNTDVVFDSQGKLLARYHKYNLFAPET QFDFPKDSELVTFDTPFGKIGI IT 2007 A 1275 1453 RTFTS*CSVSCGRCVQQRHVGCQIGTIKIARETECNP YTRPESERDCQGPRCPLYTWRAEEWQEVSRATKGYLP GI SRVRPLISSHLFPIKPEKSPSTVTMLALSQKVHCQ TRAFAPTRVGELLVFKQFL 2008 A 2679 1435 LLSTYIKFINLFPETKATIQCVLRAGSQLRNADVELQ QRAVEYLTLSSVASTDVLATVLEEMPPFPERES ElLA KLKRKKCPGACSALDDGRRDPSSNDINCCMEPTPSTV STPSPSADLLGLRAAPPPAAPASAGAGNL-VD)VFDG PAAQPSLGPTPEEAFLSPGPEDIGPPI PEADELLNKF VCKNNGVLFENQLLQIGVKSEFRQNLGRMYLFYGNKT SVQFQNFS PTVVHFGDLQTQLAVQTKRVAAQVDCCAQ VQQVLNIECLRDFLTPPLLSVRFRYCGAPQALTLKLP VTINKFFQPTEMAAQDFFQRWK QLSLPQQEAQKI FKA NRPMDABVTK AKLLGFGSALLDNYTDPNPENFVCAGI I QTKALQVCCLLRLEPNAQAQMYRLTLRTSKEPVSRHL CELLAQQF 2009 A 153 1994 MCALRPTLLPPSLPLLLLLMLMGCWAREVLVPEGPL YRVIAGTAVIS ISCNVTC-YEGPAQQNFEWFLYRPEAPDT ________ ________AIGIVSTK

DTQFSYAVFKSRV-VAGEVQVQRLQCDAVV

WO 2004/080148 PCT/US2003/030720 605 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible ucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence LKIARLQAQDAGIYECHTPSTDTRYLGSYSGIK VELRV LPDVLQVSAAPPGPRGRQATSPPRMT]-LEGQELALG CLARTSTQKHTHLAVSFGRSVPEAPVC-RSTLQEVVGI RSDLAVEAGAPYAERLAAGELRLGKEGTDRYRMVTGG AQAGDAGTYHCTAAEWIQDPDGSWAQIAEKRAVLAHV DVQTLSSQLAVTVGPGERRIGPGEPLELLCNVSTALP PAGRHAAYSVGWEMAPAGAPGPGPRLVAQLDTEGVG2L GPGYEGRHIAMEKVASRTYRLRLEAARPGDAGTYRCL AKAYVRGSGTRLREAASARSRPLPVHVREEGVVLEAV AWLAGGTVYRGETASLLCNI SVRGGPPGLRLAASWWV ERPEDGELS SVPAQLVGGVGQDGVAELGVRPGGGPVS VELVGPRSHRLRLHSLGPEDEVYHCAPSAWVQAY SWYQAGSARSGPVTVYPYMHALDTLFVPLLVGTGVAL VTGATVLGTITCCFMKRLRKR* 2010 A 153 1994 MGALRPTLLPPSLPLLLLLMLGMCWA=EVLVPEGPL YRVAGTAVS ISCNVTGYEGPAQQNFEWFLYRPEAPDT ALGIVSTKDTQFSYAVFKSRVVAGEVQVQRLQGDAVV LKIARLQAQDAGIYECI4TPSTDTRYLGSYSGKVELRV LPDVLQVSAAPPGPRGRQAPTSPPR4TVHEGQELALG CLARTSTQKHTHLAVSFGRSVPEAPVGRSTLQEVVGI RSDLAVEAGAPYAERLAAGELRLGKEGTDRYRMVVGG AQAGDAGTYHCTAAEWIQDPDGSWAQIAEKRAVLAHV DVQTLS SQLAVTVGPGERRIGPGEPLELLCNVSGALP PAGRHAAYSVGWEMAPAGAPGPGRLVAQLDTEGVGSL GPGYEGRH-IAMEKVASRTYRLRLEAARPGDAGTYRCL AKAVRGSGTRLREAASARSRPLPVHVREEGVVLEAV ANLAGGTVYRGETASLLCNI SVRGGPPGLRLAASWWV ERPEDGELSSVPAQLVGGVGQDGVAELGVRPGGGPVS VELVGPRSHRLRLHSLGPEDEGVYHCAPSAWVQHADY SWYQAGSARSGPVTVYPYMHALDTLFVPLLVGTGVAL VTGATVLGTITCCFMKRLRKR* 2011 A 153 1994 MALRPTLLPPSLPLLLLLMLGMGCWAREVLVPEoPL YRVAGTAVSI SCNVTGYEGPAQQNFEWFLYRPEAP)DT ALGIVSTKDTQFSYAVFKSRVVAGEVQVQRLQGDAVV LKIARLQAQDAGIYECHTPSTDTRYLGSYSGKVELRV LPDVLQVSAAPPGPRGRQAPTS PPRMTVHEGQELALG CLARTSTQKHTH-LAVSFGRSVPEAPVGRSTLQEVVGI RSDLAVEAGAPYAERLAAGELRLGKEGTDRYRMVVG AQAGDAGTYHCTAAEWIQDPDGSWAQIAEKRAVLAHV DVQTLSSQLAVTVGPGERRIGPGEPLELLCNVSGALP PAGRHAAYSVGWEMAPAGAPGPGRLVAQLDTEGVGSL GPGYEGRHIAMEKVASRTYRLRLEAARPGDAGTYRCL AKAYVRGSGTRLREAASARSRPLPVIIVREEGVVLEAV AWLAGGTVYRGETASLLCNISVRGGPPGLRLAASWWV ERPEDGELS SVPAQLVGGVGQDGVAELGVRPGGGPVS VELVGPRSHRLRLHSLGPEDEGVYCAPSAWVQHNADY SWYQAGSARSGPVTVYPYMqHALDTLFVPLLVG.TGVAL VTGATVLGTITCCFMKRLRKR* 2012A 15 194 MGALRPTLLPPSLPLLLLLMLGMGCWA.EVLVPEGPL 2012 153YRVAGTAVSI SCNVTGYEGPAQQNqFEWFLYRPEAPDT WO 2004/080148 PCT/US2003/030720 606 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide ncleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide c sequence AIGIVSTDTQFSYAVFKSRVVAGEVQVTQRLQGDAWV LKIARLQAQDAGIYEC-TPSTDTRYLGSYSGKVELRV LPDVLQVSAAPPCPRGRQAPTSPPRMTV4EGQELALG CLARTSTQKHTHLAVSFGRSVPEAPVGRSTLQEVVTGI RSDLAVEAGAPYAERLAAGELRLGKEGTDRYMVTGG AQAGDAGTYFICTAAEWIQDFDGSWAQIAERAVLAIV DVQTLSSQLAVTVGPGERRIGPGEPLELLCNVSGALP PAGRHAAYSVGWEMAPAGAPGPGRJVAQLDTEGVGSL GPGYEGRHIAD4EKVASRTYRLRLEAARPGDAGTYRCL AKAYVRG9GTRLREAASARSRPLPVHVREEGVVLEAV AWLAGGTVYRGETASLLCNI SVRGGPFGLRJAASWWV ERPEDGELSSVPAQLVCGVGQEGVAELGVRPGGGPVS VELVGPRSHRLRLHSLGPEDEGVYHCAPSAVQAY SWYQAGSARSGPVTVYPYMHALDTLFVFLLVGTGVAL VTGATVLGTITCCFMKRLRKR* 2013 A 1273 480 YLRLWLRHFDPRHPHGVPLPTEPSTPKSPSAGPSPHL LHPGTFGHPSASPPSRPPSSSTFKRPRTAGRNPKRRQ SSPGRPT/NPGLRKKMGPPSEG\ SGCGNTPQGPASGP ASTJLPNPC* LCRGKPLGVLRGGGRRGASVPESWPHIP APNAG*GHAQRDPGGAGQPKD* GGRGAPGQQATBADS GPAA\GMRGPHI IQLDTPLSASRGMRNARCTFGM/ PS LPRGDLSFSSAGHPPASVTLPQGFHFPKGTLAPGTLP PALFCDQEL 2014 A 853 1553 KKKETVSVSSREVRETSKALERPKLQE*PRGPALQSR ATSPRNTYQRPAGWPQAEPPQ* GNRLFPAGVRGRAPG PHPpd .*WSQPPAEDPTGRAETQLCPPAALAR-AQPRRQ LCGPALPGPRRP/ PTRTPT*SGRGFSKWLAFEITQGF APNAFFGFSDVLFCVFFKPFSLFR* *yJL*KTLLTNQ PEPQSPKGCGGVWRPHYVSGLLPTLKPCSLKREGPRP ALPFS/ SPSPPFLCPSLRSPPASL/ PPVILAFRVFWR FP*PPVKIQRLSPFFFNFDN* /PSVSFSKFYFSNHPG QPPALT PSRPGTJSGFPFHTLRFETAVFPTFAAGMAVS CPCLFIWPI FQPWGPCSLPQPPPLLMP*KLGPRPCWP EPQMPSSGSLT/ SGPNSSGLGIGPPYPGSPPWGQ*KG KAFILANRPHHPLLPGFPCRDGLSLP/RPLLSVCGSR TLCPSPGASAVTRLLKANS *ILPAHPRPDPWSWPPSS PVPETSTP*R*TLGPPTSRTCRPEV\ PWATJPFANWAT SFPPLTLG/VPHPLQGDYSPDTPVSP4GPLL~N 2015 A 527 871 VWSPDRPSSSDPRGQRRRPTGRVAADPGAAPPAAAA PPPSSA*TAPGSCRRWRTSSRRTPGSNPRPTPPRPR SEATS P/TPDSAQRLFPPPPPAGPG\ PPGFEAPPVSJ GQPFCR 2016 A 17 941 PLDRAVEFAVGSGRPRRISCLSCPGGGGAASGLQAA GGTGLSWVPAGLRVCCSQRSERPEKESQPVQNPRRKG KGGEI STWKNSSMKMKECTJRT KER*TMKNSHRTRESQ K*LVFWKTRS *KTRETQKTPAREL9JNR*RIKKSQRVR ERQKEIKESQRGRESQRCREDQRQRESQREGEGQRVKrE SQTWVREPESEGEPESETRAAGKRPAEDDI PRKAK RK TNIKGLAQYLKQYKEAIH-DMNFSNED)MIREFDNMARVE DI(RRKSIKQKLGAkFLWMQRNLQDPFYPRGPREERGGCR WO 2004/080148 PCT/US2003/030720 607 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Lnknown, *Stop codon, ID beginning ending possible nucleotide deletion,=possible ucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide resiuece APRRDTEDIPYV 2017 A 335 120 MFLLLFCLMFDFTKVFFILLLHIFCLSTCLFLGLHIC ASFHARALLETALILLRMKIAGFQVILFPQDFVL* 2018 A 3 800 FVLDPYSGVIKSNVSFDREQQSSYTFDVKATDGGQPP RSSTAKVTINVMDVNDNS PVVISPPSNTSFKIVPLSA IPGSVVAEVFAVDVDTGMNAELKYTIVSGNNKC-LFRI DPVTGNITLEEKPAPTDVGLHRLVVNISDLGYPKSLH TLVLVFLYVNDTAGNASYIYDLIRRTMETPLDRNIGD SSQPYQNEDYLTIMIAIIAGAMVVIVVIFVTVLVRCR HASRFKAAQRSKQGAEWMSPNQENKQNKKKKRKKRKS PKSSLLN 2019 A 1 1331 GWNGSWNDNLVDTSPLKRDPLQDICRRYMEDLKKICF YRELNSKTTLKFVHTSFHGVGHDYVQLAFKVFGFKPP IPVPEQKDPDPDFSTVKCPNPEEGESVLELSLRLAEK ENARVVLATDPDADRLAAAELQENGCWKVFTGNELAA LFGWWMFDCWKKNKSRNADVKNVYMLATTVSSKILKA IALKEGFHFEETLPGFKWIGSRIIDLLENGKEVLFAF EESIGFLCGTSVLDKDGVSAAVVVAEMASYLETMNIT LKQQLVKVYEKYGYHISKTSYFLCYEPPTIKSIFERL RNFDSPKEYPKFCGTFAILHVRDVTTGYDSSQPNKKS VLPVSKNSQMITFTFQNGCVATLRTSGTEPKIKYYAE MCASPDQSDTALLEEELKKLIDALIENFLQPSKNGTG SGRSCLGVPPNTVMTLCGAYGNRATRRNCHTLEPCG 2020 A 1 2337 TRFRGLRPAVAFWTALLALGLPGWVLAVSATAAAVVP EQHASVAGQHPLDWLLTDRGPFHRAQEYADFMERYRQ GFTTRYRIYREFARWKVNNLALERKDFFSLPLPLAPE FIRNIRLLGRRPNLQQVTENLIKKYGTHFLLSATLGG EESLTIFVDKQKLGRKTETTGGASIIGGSGNSTAVSL ETLHQLAASYFIDRESTLRRLHHIQIATGAIKVTETR TGPLGCSNYDNLDSVSSVLVQSPENKVQLLGLQVLLP EYLRERFVAAALSYITCSSECELVCKENDCWCKCSPT FPECNCPDADIQAMEDSLLQIQDSWATHNRQFEESEE FQALLKRLPDDRFLNSTAISQFWAMDTSLQHRYQQLG AGLKVLFKKTHRILRRLFNLCKRCHRQPRFRLPKERS LSYWWNRIQSLLYCGESTFPGTFLEQSHSCTCPYDQS SCQGPIPCALGEGPACAHCAPDNSTRCGSCNPGYVLA QGLCRPEVAESLENFLGLETDLQDLELKYLLQKQDSR IEVHSIFISNDMRLGSWFDPSWRKRMLLTLKSNKYKP GLVHVMLALSLQICLTKNSTLEPVMAIYVNPFGGSHS ESWFMPVNEGSFPDWERTNVDAAAQCQNWTITLGNRW KTFFETVHVYLRSRIKSLDDSSNETIYYEPLEMTDPS KNLGYMKINTL\QVFGYSLPFDPD\AIRDLILQLDYP YTQGSQDSALLQLIELRDRVNQLSPPGKVRLDLFSCL LRHRLKLANNEVGRIQSSLRAFNSKLPNPVEYETGKL CS 2021 A 161 547 PAGIGRSTAKTPGTPGSLEMENLKSGVYPLKEASGCP GADRNLLVYSFYEKGPLTFRDVAIEFSLEEWQCLDTA QQDLYRKVMLENYRNLVFLAGIAVSKPDLITCLEQGK EPWNMKRHAMVDQPPGR 2022 A 161 547 PAGIGRSTAKTPGTPGSLEMENLKSGVYPLKEASGCP WO 2004/080148 PCT/US2003/030720 608 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XUnknown, *Stop codon, ID beginning ending /=possible aucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence GADRNLLVYSFYEIKGPLTFRDV-\AIEFSLEEWQCLDTA QQDLYRKVMLEb4YRNLVFLAGIAVSKPDLITCLEQGK

-

EPWJNMKRHAM4VDQPPGR 2023 A 3 452 AVPGPGFGLSPTMVTLAELLVLLAALATVSGYFTS IDAHAEECFFERVTSGTKMGLI FEAEDGGFLDIDVVI TLPDR/RKIKPRLLKKK-GQ* TYRSFMDVTFK-LCYNLR MSNNNPNIRNHmHWLLLTS IKFLITQFRSSLSYLS SC 1Q52 2024 A 31 1312 ITTVMAGKRSGWSRAALLQLLLGVNLGVMFPTRARSL RFVTLLYRHGDRSPVKTYPK-DPYQBEEWPQGFGQLTK EGMLQHWELGQALRQRYHGFLNTSYHRQEVYVRSTDF DRTLMSABANLAGIJFPPNGMQRFNFNISWQPIPVHTV PITEDRLLKFPLCPCPRYEQLQNETRQTPEYQNESSR NAQFLDM~VANETGLTDLTLETVWNVYDTLFCEQTHGL RLPPWAS PQTMQRLSRLKDFSFRFLFGI YQQAE KARL QGGVLLAQIRKNLTLMATTSQLPKLLVYSAHDTTLVA LQMALDVYNGEQAPYASOHIFELYQEDSGNFSVEMYF RNESDKAFWPLSLPGCPHRCPLQDFLRLTEPVVPKDW QQECQLASGPADTEVIVALAVCGSILFLLIVLLLTVL

-

- -FRMQAQPPGYRHVADGEDHA 2025 A 2 317 FVDSPRFRATIDEVETDVVEIEAKLDKLVKLCSGMVE ACKAYVSTSRLFVSGVRDLSQQCQGDTVISECLQRFA

-

- DSLQEVVNYHMILFDQAQRSVRQQLQSFVKE 2026 A 1788 3 RTRGRFPKRTP/LFQISSAVQKEQPLPTAEITRLAVh AAVQAVERKLEAQANRLLTLEGRTGTNEKKIADCEKT AVBFANLLESKWVVLGTLLQEYGLLQRRLENMENLLK NRNFWILRLPPCSNCEVPKVPVTFDDVAVHFSEQEWG NLSEWQKBLYKNVMRGNYESLVSMDYAI SKPDLMSQM ERCERPTMQEQEDSEEGETPTDPSAAEDGIVIKTEVQ TNDEGSESLETPEPLMGQVEEHGFQDSELGDPCGEQF DLDMQEPENTLEEST/DRIJQRVQRTEADAGAAEELHG /VGS /WIKTEEQDEEEEEEEEDELPQHLQSLGQLSGR YEASMYQTPLFGEMS PEGEESPFLQLGNFAVKRLAP SVIIGER/ PPEREPRCLEPAAAEPARRAALHMEGVRQE LPP/ ORSISS STSATTSRRGPTSAPNARSASGTSNSS RCTSASTACAEAASIPN/ CCPTFNPKI{ALKPRPKSPS SGSGGGCPKPYKCPECDSSFSHKSSLTKAQITHTGER PYTCPECKKSFRLIISLVIHQRVHAGK-EVSFICSLC GKSFSRFSHLLRHQRTHTGERPFKCPECEKSFSEKSK LTNHCRVHSRERP 2027 A 2193 442 ELNCNIRAPPKQMFWCFRPRSKERAVVVAWERRLMVV GDAPESIQFVLDEDSYLVPELDGVRI FSRSTHEFLRE VPAASEEI FKIASMAPGALLLEAQK EYEKESQKADEY LREIQELGQLTQAVQQCIEAAGHEHQPDMQKSLLRAA SFGKCFLDRFPPDSFVHMCQDLRTLNAVRDYHI GIPL TYSQYKQLTIQVLLDRLVLiRRLYPLAIQI CEYLRLPE VQCVSRILAHWACYKCVQQK DVSD:EDVARAINQKLGDT PGVSYSDLAARAYGCGRTELAIKLLEYEPRSGEQVPL LLKMKRSK LALSKAIESGDTDLVFTVLLHLK<NELNRG DFFMTLRN4QPMAL SLYRQFCK HQELBTLKDLYNQDDN WO 2004/080148 PCT/US2003/030720 609 _____ _______ TAELE 7 SEQ Method Predicted Predicted Amino acid sequence (XUnknown, 'Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide reidne of sequence peptide sesuenee HQELGSFHI RASYAAEERIEGRVAALQTAA.DAFYKAK NEFAAKATED)QMRLLRLQRRLEDELGQFLDLSLIDT VTTLILGGHNKRAEQLARDFRI PDKRLWWLKLTALAD LEIJWEELEKFSKSKKSPIGYLPFVEI CMKQHITYEAI{, KYASRVGPEQKVKALLLVGDVAQAADVAIEHRIPNEAEL SLVLSHCTGATDQATADKIQRARAQAQIKK 2028 A 110 277 MLLALPLAAPSCPMLCTCYSSPPTVSCQANNFSSVPL 2029 A 1 359 ISGE9IYWSQKPTPSSNASPWSEPAAVDVELTAYALL 2030 A 16 255 ARPSCPCSWSFSCCGVSPGA/LVTEAAIFYETQPSLW 2031 A 2 414 GKTHTATVVELNPWVEYEFRVVASNKIGGGEPSLPSE KVRTEEAVPEVPPSEVNGCGGSRSELVZTWDPVPEEL QNGEGFGYVVAFRPIJGVTTWIQTVVTSPDTPRYVFRN ESIVFYSPYEVKVGVYNNKGEGPFS P 2032 A 3 438 SNLHHLILNNNQLTLISTAFDDVFALEELDLSYNNL ETI FWDAVEKMVSLHTLSIJDHNMIDNI PKGTFSHL-K MTRLDVTNIaQKLPPDPLaFQRAQVLATSGI ISPSTF ALE FGGNPLECNCELLWLRRLSREDDLETCAS PP 2033 A 3 438 SNLHHLTLNNNQLTLISSTAFDDVFAEELDLSYNNL ETI PWDAVEKMVSLIITLSLDHNMIDNI PKGTFSHLHK MTRLDVTSNELQKLPPDPLEQRAQVLATSGI ISPSTF ALE FGGNPLCNCELLWLRRLSREDDLETCASPP 2034 A 166 4280 ASDQGQPGDSAGQANQLKLEDMKSPRRTTLCt MF IVIYS SKAALNWNYESTIHPLSLHEHEPAGEEALRQK RAVATKS PTAEEYTVNIE ISFENAEFLDPIKAYLNSL SFPIEGNNTDQITDILS INVTTVCRPAGNEIWCSCET GYGWPRERCLHNLICQERDVFLPGHHCSCLKELPPNG PFCLLQEDVTLNDARVRLNVGFQEDLMNTSSALYRSYK TDLETAFRKGYGTLPGPKGVTVTCFKSGSVVVTYEVK TTPPSLELIHKANEQVVQSLNQTYKMDYNSFQAVTIN ESNFFVTPEI IFEGDTVSLVCEKEVLSSNVSWRYEEQ QLETQNSSRFSIYTALFNNMTSVSKLTIHNI TPGDAG EYVCKLILDI FEYECKKKIDVMPIQILANEEMKVMCD NNPVSLNCCSQGNVNWSKVEWKQECKINI PGTFETDI DSSCSRYTLKADGTQCPSGSSGTTVIYTCEFI SAYGA RGSANIKVTFISVANLTITPDPISVSEGQNFSIKCIS DVSNYDEVYWNTSAGIKIYQRFYTTRRYLDGAESVLT VKTSTREWNGTYHCI FRYKNSYS IATKDVIVEPLPLK LNIMVDPLEATVSCSGSHHIKCCT EEDGDYK VTFHMG SSSLPAAKEVNKKQVCYKI{NFNASSVEWCSKTVDVCC I-FTNA~AITNEVWE PSMK LNLVPGENITCQDPVIGVGEP eKVIQKLCRFSNVPSSPEE/SPLGGTITYKCVGSQWG \EKRNIJCI SAPINSLLQMAKALI KSPSQDEMLPTYLK DLSISIDKAEEEISSSPGSLGAIINILDLLSTVPTQV

NSEMMTHVLSTV)]VILGKPVLNTWKVLQQQWTNQSSQ

WO 2004/080148 PCT/US2003/030720 610 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Uuknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence LLHSVERFSQALQSGDSPPLSFSQTNVQMSSTVIKSS HPETYQQRFVFPYFDLWGNVVIDKSYLENLQSDSSIV TMAFPTLQAILAQDIQENNFAESLVMTTTVSHNTTMP FRISMTFKNNSPSGGETKCVFWNFRLANNTGGWDSSG CYVEEGDGDNVTCICDHLTSFSILMSPDSPDPSSLLG ILLDIISYVGVGFSILSLAACLVVEAVVWKSVTKNRT SYMRHTCIVNIAASLL\VANTWFIGVAAIQDNRYILC KTACVAATFFIHFFYLSVFFWMLTLGLMLFYRLVFIL HETSRSTQKAIAFCLGYGCPLAISVITLGATQPREVY TRKNVCWLNWEDTKALLAFAIPALIIVVVNITITIVV ITKILRPSIGDKPCKQEKSSLFQISKSIGVLTPLLGL TWGFGLTTVFPGTNLVFHIIFAILNVFQGLFILLFGC LWDLKVQEALLNKFSLSRWSSQHSKSTSLGSSTPVFS MSSPISRRFNNLFGKTGTYNVSTPEATSSSLENSSSA SSLLN 2035 A 1 366 AFRSDSRLAEHQRVHTGERPYTCNECGKVFSTKAYLA CHQKLHTGEKLYECEECDKVYIRKSHLERHRRIHTGE KPHKCGDCGKAFNSPSHLIRHQRIHTGQKSYKCHQCG KVFSLRSLLAE 2036 A 2 236 ISGQEGLQAVLASDYSFAQFRYLQRLLLVHGRWSYFR MCKFLCYFFYKNFAFTLVHFWFGFFCGFSAQTVYDQW FITL 2037 A 706 951 MRCGWGPLGCLGTGAPAGWMVLGSPRSQLQRARWSRA SLSAFGWEIRLRPEGPKAPRQLLLVALESETLGVHGG ATPLHCL* 2038 A 1242 433 PGSPDVNRAVVRPPPPFPPPPPAPQPTMSRRKQGKPQ HLSKREFSPEPLEAILTDDEPDHGPLGAPEGDHDLLT CGQCQMNFPLGDILIFIEHKRKQCNGSLCLEKAVDKP PSPSPIEMKKASNPVEVGIQVTPEDDDCLSTSSRGIC PKQEHIADKLLHWRGLSSPRSAHGALIPTPGMSAEYA PQGICKDEPSSYTCTTCKQPFTSAWFLLQHAQNTHGL RIYLESEHGSPLTPRVLHTPPFGVVPRELKMCGSFRM EAREPLSSEKI 2039 A 2009 1889 MHSAMLGTRVNLSVSDFWRVMMRVCWLVRQDSRHQRI RLPHLEAVVICRGPETKITDKKCSRQQVQLKAECNKG YVKVKQVGVNPTSIDSVVIGKDQEVKLQPGQVLHMVN ELYPYIVEFEEEAKNPGLETHRKRKRSGNSDSIERDA AQEAEAGTGLEPGSNSGQCSVPLKKGKDAPIKKESLG HWSQGLKISMQDPKMQVYKDEQVVVIKDKYPKARYHW LVLPWTSISSLKAVARGTP*TP*AYAHCGGKGDCRFC W\SSKLRFRLGYHAIPSMSHVHLHVISQDFDSPCLKN KKHWNSFNTEYFLESQAVIEMVQEAGRVTVRDGMPEL LKLPLRCHECQQLLPSIPQLKEHLRKHWTQ*FFFFTV LSKFILREKESSGSTQLFHSPTTFPCIRTYAVIVS 2040 A 2009 1889 MHSAMLGTRVNLSVSDFWRVMMRVCWLVRQDSRHQRI RLPHLEAVVIGRGPETKITDKKCSRQQVQLKAECNKG YVKVKQVGVNPTSIDSVVIGKDQEVKLQPGQVLHMVN ELYPYIVEFEEEAKNPGLETHRKRIKRSGNSDSIERDA AQEAEAGTGLEPGSNSGQCSVPLKKGKDAPIKKESLG

HWSQGLKISMQDPKMQVYKDEQVVVIIKDKYPKARYHW

WO 2004/080148 PCT/US2003/030720 611 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence LVLPWTSI SSLKAV7ARGTP*TP*AYAHCGGKGDCRFC w\8SKLRFRLGYHAI PSMSHVHLHVISQDFDSPCLG KKHWNSFNTEYFLESQAVIEMVQEACRVTVRDGMPEL LKJJPLRCHECQQL-PSI PQLKEHLRKHWTQ*FFFFTV LSKFILRBKES8GSTQLFHS PTTFPCIRTYAVIVS 2041 A 2009 1889 MHSANLCTRVNLSVSDFWRVMMRVCWLVRQDSRHQRI RLPHLEAVVIGRGPETKITDKKCSRQQVQLK AECNKG YVICVKQVCVNPTSIDSVVICKDQEVKJQPQVLHMVN ELYPYIVEFEEEAKNPGLETHRKRKRSGNSDSIERDA AQEAEAGTGLEPCSNSGQCSVPLKKCKDAPIKKESLG HWSQCLKI SMQDPKMQVYKDEQVVVIRDKYPRARYHW LVLPWTSI SSLKAVARGTP*TP*AYAHCGGKGDCRFC W\SSKLRFRLCYHAI PSMSHVHLHVISQDFDSPCLGN KKHWNSRNTEYFLESQAVIEMVQEAGRVTVRDGMPEL LKLPLRC-ECQQLLFSI PQLKEHLRKHWTQ*FFFFTV LSKFILREKES SGSTQLFHS PTTFPCIRTYAVIVS 2042 A 1464 775 KMTTAARPTFePARGGRGKGEGDLSQLSKQYSSRDLP SHTKI KYRQTTQDAPEEVRNRDFRRELEERERAAARE KNRDRPTREHTTSSSVSKKPRLiDQT PAANLDADDPLT DEEDEDFEEE8DDDDTAALLAELEKIKKERAREQARK EQEQKAEEERIRIAENILSGNPLLNLTCPSQFQANFKV KRRWDDDVVFKNCAKGVDDQKKDKRFVNDTLR8EFHK KFMEKYIK 2043 A 2 860 ATTRIRLSCGRSQHEGRVBVQICGPGPLRWGLTCGDD WGTLEAMVACRQLGLGYANHGLQETWYWDSGNITEVV MSGVRCTGTELSLDQCA-H-GTHITCKRTGTRFTACVI CSETASDLLLI4SALVQETAYTEDRPLHD4LYCAAEENC LASSARSANWYGRRJT-RFS SQIHNLCRADFRPKAG RHSWVWHECHGI4YHSMDFFTHYDILTPNGTKVAEI{K ASFCLEDTECQEDVSKRYECANFGEQGITVGCWDLYR HEIDCQWIDITDVKPGNYIL4GVINPT 2044 A 973 266 ARGSLCAPASPLYPVNQ1JRNVALAQALTPYVFLSDID FLPAYSLYDYLRAS IEQIJGLGSRRKAALVVPAFETLR YRFSFPI-SKVELLALLDAGTLYTFRYH-EWPRCHAPTD YARWREAQAPYRVQWAANYEPYVVVPRDCPRYDPRFV GFGNNKVAHIVELDAQEYELLVLPEAFTIHLPHAFSL DI SRFRSSPTYRDCLQALKDEFHQDLSRHHGAAALKY _______LPALQQPQS PARG 2045 A 1668 218 AVVRAQGSRGFSGAGWRPRQAAAseNFSEVFKLSSLLC KPSPDCKYLASCVQYRLVVRDVNTLQILQLYTCLEQI QHIEWSADSLFILCANYKRGLVQVWSLEQFEWHCKID EGSAGLVAE CWS PDCRflILNTTEFI-LRITVWSLCTKS VSYI KYPKACJQCI TFTRDCRYMALAERRDCKDYV8 I FVCSDWQLLRHFDTDTQDLTGIWAPNCCVLAVWDTC LEYKILLYSLDGRLLSTYSAYEWSLGIKSVAWSPSSQ FLAVGSYDGKVRILNHVTWKMITEFGHPAAINDPKIV VYKEAEKSPQLGIJCCLSFPPPRAGACPLPSSESKYEI ASVPVSLQTLKPVTDRANVKI GIGMLAFSPDSYFJAT RNDNI FNAVWVWDIQK-LRLFAVLaEQLSPVRAFQWDPQ

QPRLAICTC-CSRLYLWSPAGCMSVQVPCECDFAVLSL

WO 2004/080148 PCT/US2003/030720 612 TABLE 7 SEQ Method Predicted Pedicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of Sequence peptide se uence CWHLSGDSMALLSK DHFCI 4 CFLETEAVVGTALCRQLGG acT 2046 A 231 1289 SPTVSFLFFNMETNPSVGTTSAISILLARSSRERQLS SEGRFSWRL*DASSGERS*RRSESSSWLSS*ERESSV SFKHPFKRLFK*SSVSLLSWSSLSPFSSGAIHTSGSS MPKSDI*LFPQSTFSEPSESACACGDFPSLSVRSGCC SSFNSLFSSWSVGNASEASRSGKRSSFL*ACEYLPSE INAGGIRSQPGEINGSVFDLLERNTLGSSAMPSILAT SWQASV*ASCKRLSSSQASSEESGPDGLPAVSEDWVW SANVASALQSSSSMWSFPAVTERLGESVC\SPSDDSR DCSPGAPLYVGFLYLTLCRDKFYSLKMKKNKLLKIQN NTLYRKEKKGHMNMCNTAIF 2047 B 26 175 NCGSGDILLKIVKVEHEEMPEAKNVIAVLEEFMKEAL DQSF 2048 A 1 1386 RDFVAASSRRRRADFPRMTELRQRVAHEPVAPPEDKE SESEAKVDGETASDSESRAESAPLPVSADDTPEVLNR ALSNLSSRWKNWWVRGILTLAMIAFFFIIIYLGPMVL MIIVMCVQIKCFHEIITIGYNVYHSYDLPWFRTLSWY FLLSVNYFFYGETVTDYFFTLVQREEPLRILSKYHRL ISFTLYLIGFCMFVLSLVKKHYRLQFYMFGWTHVTLL IVVTQSHLVIHNLFEGMIWFIVPISCVICNDIMAYMF GFFFGRTPLIKLSPKKTWEGFIGGFFATVVFGLLLSY VMSGYRCFVCPVEYNNDTNSFTVDCEPSDLFRLQEYN IPGVIQSVIGWKTVRMYPFQIHSIALSTFASLIGPFG GFFASGFKRAFKIKDFANTIPGHGGIMDRFDCQYLMA TFVNVYIASFIRGPNPSKLIQQFLTLRPDQQLHIFNT LRSHLIDKGMLTSTTEDE 2049 A 2 427 HSWVSRSCAFEPAWEEGATSQTVATCGGEAVCVIDCQ TGIVLHKYKAPGEEFFSVAWTALMVVTQAGHKKRWSV LAAAGLRGLVRLLHVRAGFCCGVIRAHKKAIATLCFS PAHETHLFTASYDKRIILWDIGVPNQDYEFQ 2050 A 1 892 RTRGRTRGRGTRGGGGGGGTGAGGRGEGSQVPGLSAA DQDR*GRGCCSPGGRDRAGGGGGIGQGGDAERRRGEQ GEGWGRTPGQKPGRGEAPLWKGRV*GPRVVRGGPEAA GAAAAQRPPGPVPFPAGGAEPLPALQPIPAAQDLRGA AQKEGPGGR*GG*PGRRGRGPRERASVPAPSGHACGA EEAAGRRPAVVPPGAGPVEAAVPGEAHQGGEGVATLP GTQEAGGDAGHGQLSDEGRAPGCSARGGADPGVGG*K GEGDERRAAGEHSAEAEPGAF*NQDEDPGGPDPGSAS Y 2051 A 2 1086 FVLCAGACWPLRDRDT/SPPAHLCPEVTPWSLHVPIS LQCPPRLCSPPTHRLTPPAGCQRPPPAGPLSVAPASL SPSAPALLEA/TSPPWTAGATWSPGRSPATQCWPPSW CQTPFPHPETGQLCLVRSLH*PHLSSLGQAGAAG*GG PLAPPFPPFLVPFP\P*QVQHPRSPA*GAGPEPAVNI PQPL/PVPPWD*PLTSPPNSTGAPSWPRAGSVSPSP/ VLEPRPEQLSGRQGCSSVSSWGAPGGATDRQAAQGPG HPSPGRCCPRRTVLGNEPPAGFGLRSLWPRSPPHEVG ARLPNGAFGFSVRCLLCFPPWRAEPPHIRIGRATPPG

PGP/VPSQPSPRGSMPVPRPGAARGQLDGHVQGSRL

WO 2004/080148 PCT/US2003/030720 613 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence 2052 A 3 1385 KYESAQPGGTQPEPGLGARMAIHKALVMCLGLPLFLF PGAWAQGHVPPGCSQGLNPLYYNLCDRSGAWGIVLEA VAGAGIVTTFVLTIILVASLPFVQDTKKRSLLGTQVF FLLGTLGLFCLVFACVEKPDFSTCASRRFLFGVLFAI CFSCLAAHVFALNFLARKNHGPRGWVIFTVALLLTLV EVIINTEWLIITLVRGSGEGGPQGNSSAGWAVASPCA IANMDFVMALIYVMLLLLGAFLGAWPALCGRYKRWRK HGVFVLLTTATSVAIWVVWIVMYTYGNKQHNSPTWDD PTLATALAANAWAFVLFYVIPEVSQVTKSSPEQSYQG DMYPTRGVGYETILKEQKGQSMFVENKAFSMDEPVAA KRPVSPYSGYNGQLLTSVYQPTEMALMHKVPSEGAYD IILPRATANSQVMGSANSTLRAEDMYSAQSHQAATPP KDGKNSQVFRNPYVWD 2053 A 2 555 MASPAASSVRPPRPKKEPQTLVIPKNAAEEQKLKLER LMKNPDKAVPIPEKMSEWAPRPPPEFVRDVMGSSAGA GSGEFHVYRHLRRREYQRQDYMDAMAEKQKLDAEFQK RLEKNKIAAEEQTAKRRKKRQKLKEKKLLAKKMKLEQ KKQEGPGQPKEQGSSSSAEASGTEEEEEVPSFTMGR 2054 A 1008 534 HEKMAAAWGSSLTAATQRAVTPWPRGRLLTASLGPQA RREASSSSPEAGEGQIRLTDSCVQRLLEITEGSEFLR LQVEGGGCSGFQYKFSLDTVINPDDRVFEQGGARVVV DSDSLAFVKGAQVDFSQELIRSSFQVLNNPQAQQGCS CGSSFSIKL 2055 A 1492 528 THVVMTGMCYAPHQVLSYINGVTTSKPGVSLVYSMPS RNLSLRLEGLQEKDSGPYSCSVNVQDKQGKSRGHSIK TLELNVLVPPAPPSCRLQGVPHVGANVTLSCQSPRSK PAVQYQWDRQLPSFQTFFAPALDVIRGSLSLTNLSSS MAGVYVCKAHNEVGTAQCNVTLEVSTGPGAAVVAGAV VGTLVGLGLLAGLVLLYHRRGKALEEPANDIKEDAIA PRTLPWPKSSDTISKNGTLSSVTSARALRPPHGPPRP GALTPTPSLSSQALPSPRLPTTDGAHPQPISPIPGGV SSSGLSRMGAVPVMVPAQSQAGSLV 2056 A 820 319 VVEFPVLTKAATSGILSALGNFLAQMIEKKRKKENSR SLDVGGPLRYAVYGFFFTGPLSHFFYFFMEHWIPPEV PLAGLRRLLLDRLVFAPAFLMLFFLIMNFLEGKDASA FAAKMRGGFWPALRMNWRVWTPLQFININYVPLKFRV LFANLAALFWYAYLASLGK 2057 A 520 330 HGCVLSLLPKPQQGFREPVHLTSTC/PNPTPPVPP*S DRYLSNPTQPVPP*SDRYLSNPTPPVSP*SDRYLSNP TPPVPP*SDRYLSNRTPPVSP*SDRYLSNPTPPVSP 2058 A 2 479 DTGQKGLPGPPGPPGYGSQGIKGEQGPQGFPGPKGTM GHGLPGQKGEHGERGDVGKKGDKGEIGEPGSPGKQGL QGPKGDLGLTKEEIIKLITEICGCGPKCKETPLELVF VIDSSESVGPENFQIIKNFVKTMADRVALDLATARIG IINYSHKVEKV 2059 A 503 1051 VFLYPFLKWWRDP*RRELPTFHWFLLELAIFTLIEEV LFYYSHRLLHHPTFYKKIHKKHHEWTAPIGVISLYAH PIEHAVSNMLPVIVGPLVMGSHLSSITMWFSLALIIT TISHCGYHLPFLPSPEFHDYHHLKFNQCYGVLGVLDH

LHGTDTMFKQTKAYERHVLLLGFTPLSESIPDSPK

WO 2004/080148 PCT/US2003/030720 614 TABLE 7 SEQ Method Predicted Pre Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide e sequence 2060 A 1 716 ERVGNVCSLEISNIQKCEGGEYMCHAVNIIGEAKSFA NVDIMPQ/RRKSGGTTTSR/ IFVDPNMDSREGEDKEL KIDLEVFEMPPRFIMPICDFKI PENSDAVFKCSVIGI PTPEVKWYKEYMCIEPDNIKYVI SEEK GSHTLKIRNV CLSDSATYRCRAV1NCVGEAI CRGELTMGDSEI FAVIA KKSKVTLS SLMEELVLKSNYTDSEFEFQVGEGPPRFI KGI SDCYAPIGTAAYFQCLi 2061 A 47 538 RVRLRPVFCVMTSQEKTEEYPFADIFDEDETERNFLL SKPVCFVVFGKPGVGKrTTLARYITQAWKCTRV EALPI LEEQIAAETESGVMLQSMLI SGQS IPDELVIK LMLEK LNSPEVCHFGYIITEI PSLSQDAMTTLQQIELIKNL\ NLKP3DVIN41KGVLDF 2062 A 1196 230 RARSGLQGAVPLGPTGRSRHSLQTKLPSSPPSERPLV FQTPGALVSTPHGRYPPPLCPPKPAAFQKVI1HGKAVPS NPS /VVPTAIVNPVRSTAGPGTLGQGSLRKGRSSMR NGSLQRPLQSGI PTLVVGSLRRSPT/14GPSASAVPIL PATGDPLLPLSRGGGDGVQA/ SPSRGS PPSRASAGAV RPGSTPRPAPSLWKTKKS PSRVSLCQNRPHLPHHP2W *NQKTQEMA4JSKKKP*DFRITALLPPNITPPIPPP/ AKPEQPATLKASQPEAASLGPEMTVLFAHRSGCHSGQ ________QTDLRRKSALGKATTLVSTASGTQTVFPSK 2063 A 1196 230 RAnSGLQGAVPLGPTGSRHSLQTKPSSPFSERPLV FQTPCALVSTPHGRYPPPLCIPPKAAFQKVIHGKAVPS NPS/VVPTAIVNPViSTAGPGTLGQGSLRKGRSSMRK NGSLQRPLQSGI PTLVVGSLRRSPT/MGPSASAVPIL PATGDPLLPLSRGGGDGVQA/ SPSRGSPPSPASAGAV RPGSTPRPAPSLWKTKKSPSRVSLCQNRPHLPHHPSW *NQKTQEMJASKSKSKP*DFRITALLFPNITPPIPPP/ AKPEQPATLKASQPEAASLGPEMTVLFA4RSGCHSGQ QTDLRRKSALGKATTLVSTASGTQTVFPSK 2064 A 1554 1358 EFVMRHKGAKHLRSAAHDLTWFQHYSIDVIGFLLTCV ATAI FLFTKCFLFSCQKFNKTRKIEKRE 2065 A 793 279 H8GASLGVRGGGMADTVL~FEFLH-TEMVAELWAHDPDP GPGcAQKMSLSVLEGMGFRVGQALGERLFRETLAF-EE LDVLKFLCKDLWVAVFQKQMDSLRTNH-QGTYVLQDNS FPLLLPMASGLQYLEEAPKFLAFTCGLLRGAJYTLGI ESVVTASVAALPVCKFQVVIPKS 2066 A 729 487 IIFIYLFIFLRWSL/GSVAQAEVQWPHLNSLQAPPPG FAPFSCLRLiPSSWDYRHLPPCPANFLYFWWRRGFTML ARMVLI * PRDPPASASQGAGIAGMS.CARP*MNYFY LFIYFFEMESRSVAQAEVQWP-LNSLQAPPPGFAPFS CLRLPSSWDYRHLPPCPA1NFLYFWWRRGFTMLARMVL acid 2067 A 1 692 PGGIRSSSSSCRRCICTFCTCRSRRRRRSHQPRRSSW GPLQAEVTRLEFPSEKRRGSGTRGGRCGSTCVASVGS S TWGGTPGLGQTGTWQG/HTGQRGPQLPPHP\RNSFSS RHRGSSG\RLSQA\LPEPRGLESGK-TGSARGVAAGRA QEGEAATCCGPRDIAQQCGCRGSACGRRSHEALRPRV WCGEGPQWTW\ CAVCPH-RSAPGAGLAD\RQHPGESRA

WGETRLGEAGGAE

WO 2004/080148 PCT/US2003/030720 615 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide reidne of sequence peptide sequence 2068 A 114 1031 MPLLTLYLLLFWLSGYSIATQITGPTTVNGLERGSLT VQCVYRSGWETYLKWWCRGAIWRDCKILVKTSGSEQE VKRDRVS IKDNQKNRTFTVTMEDLMKTDADTYWCGIE KTGNDLGVTVQVTIDPASTPAPTTPTSTTFTAPVTQE ETSSSPTLTGHI-LDNRHKLLKLSVLLPLI FTILLLLL VAASLLAWRMMIKYQQKA4AGMSPEQVL QPLECDLCYAD LTLQLAGTS PQKATTKLS SAQVDQVEVEYVTM4ASLPK EDI SYASLTLGAEDQEPTYCNMGHLSSHLPGRGPEEP TEYSTISRP* 2069 A 114 1031 MPLLTLYLLLFWLSGYSIATQITGPTTVNGLERGSLT VQCVYRSGWETYLKWWCRGAIWRDCKILVKTSGSEQE VKRDRVSI KDNQKNRTFTVTMEDLD4KTDADTYWCGIE KTGNDLGVTVQVTIDPASTPAPTTPTSTTFTAPVTQE ETS SSPTLTG1HHLDNRHKLLKLSVLLPLI FTILLLLL VAASLLAWRMMKYQQKAAGMSPEQVLQPLEGDLCYAD LTLQLAGTSPQKATTKLSSAQVDQVEVEYVTMASLPK EDI SYASLTLGAEDQEPTYCNMGKLSSHLPGRaPEEP TEYSTISRP* 2070 A 114 1031 MPLLTLYLLLFWLSGYSIATQITGPTTVNGLERGSLT VQCVYRSGWETYLKWWCRGATWRDCKILVKTSGSEQE VKRDRVSIKDNQKNRTFTVTMEDI'MKTDADTYWCGIE KTGNDLGVTVQVTIDPASTPAPTTPTSTTFTAPVTQE ETSS SPTLTGHHLDNRHKLLKLSVLLPLI FTILLLLL VAASLLAWRMMKYQQKAAGMSPEQVLQPLEGDLCYAD LTLQLACGTSPQKATTKLSSAQVDQVEVEYVTMASLPK EDI SYASLTLGAEDQEPTYCNMGHLSSHLPG.CPEEP TEYSTIEP-P* 2071 A 51 1464 ALPGEFFFRFHPAHKHCH-LLPPSLFTNVTTQSEISSF LSFLHFQQVPLRQKPRRKTQGFLTMSRRRISCKDLGH AIDCQGWLYKKK EKGSFLSNKWI(KFWVILKGSSLYWYS NQMAEKADcGFVNIPDFTVERASECKKKHAFKI SHPQI KTFYFAAENVQEMNVWLNKLGSAVIHQESTTKOEECY SESEQEDPEIAAETPPPPKASQTQSLTAQQASSSSPS LSGTSYSFSSILENTVKTPSSFPSSLSKERQSLPDTVN SLSAAEDEGQPITFAVQVHSPVSEAGIHKALENSFV TSESGFLNSLSSDDTSSiS SNHDHLTVPDKPAGSKIM DKEETKVSEDDEMEKLYKSLEQASLSPLGDRRPSTKK ELRKSFVKRCKMPS INEKLHKIRTLNSTLKCKEHDLA MINQLLDDPKLTARKYREWKVMNTLJIQDIYQQQRAS PAPDDTDDTPQELKK6 PSSPS VENSI 2072 A 87 477 IKSKLNQQVEVQESEWRLTEAKGPTMGKESGWDSGRA AVAAVVGGVVAVGTVLVALSAMGFTSVGIAASS IAAK MMSTAAIANGGGVAAGSLVTAILQSVGAAGLSVTSKVI GGFAGTALGAWLGS PPS S 2073 A 87 477 IKSKLNQQVEVQESEWRLTEAKoPTMoKESGWDSGiu A AVAAVVGGVVAVGTVLVALSAM4GFTSVGIAASS IAAK MMSTAAIANGGGVAAGSLVAILQSVGAAGLSVTSK VI CGFAGTALGAWLGS PPSS 2074 JA 1 12 483 AGVGALRMVQRLTYRRRLSYNTASNKTRLSRTPGNRI VYLYTKKVGKAPKSACGVCPGRLRGVIRAVRPK

VLMRL

WO 2004/080148 PCT/US2003/030720 616 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide seeueqce SKrTKKHW5RAYGGSMCAKCVRDRIKP.AFLIEEQKTVV

-

KVLKAQAQSQKAK 2075 A 2 44 6 FQNMTCELHLTCSVEDADDNVSFRWEALGNTLSSQPN LTVSWDPRI SSEQDYTCIAENAVSNLSFSVSAQKLCE DVKIQYTDTKMILFMVSGICIVFGFI ILLLLVLRKRR DSLSLSTQRTQGPAESARLEYVSVSPTNNTVYASVT 2076 A P208 249 VGWSVHRYVLLHVGGLEGMQGAWGYVQMGALSD AIASSATTHGASI FTEKTVAIKVQVNSEGCVQGVVLED GTEVRSKMVLSNTSPQITFLKLTrPQEWLPEEFLERTS QLDTRS PVTKIN/ V*EAHHIAALSPLTHLSEKPPGWG Q/HELSHHLH/CPDLQPVSPCSLVRSGRRQAAQ/ PSW RPPMLPGASRCPITNAPST*TVKTPSSFIRPLMPW ACLPTVFDCIEVYAPGFKDSVVGRDILTPPDLERI FG LPGGNI FHC2AMSLDQLYFARPVPLHSGYRCPLQGLYL ________CGSGAHPGGGVMGAAGRNAAHVAFRDLKSM 2077 A 38 376 MALGVPISVYLLFNAMTALTEEAAVTVTPPITAQQGN WTVNKTEADNIEGPIALKFSHLCLEDHNSYCTNGACA FHHELEKAICRCFTGYTGERCLjKLKSPYNVCSGERRP L* 2078 A 38 376 MALGVPISVYLLFNAMTALTEEAAVTVTPPITAQQQN WTVNKTEA DNIEGPIALKFSHLCLEDHNSYCINGACA FHUELEKAI CRCFTGYTGERCLKLKSPYNVCSGERRP 2079 A 38 376 MALGVPISVYLILFNAMTALTEEAAVTVTPPITAQQGN WTVNKTEADNIEGP)IALKFSHLCLEDHNSYCINGACA FHHELEKAI CRCFTGYTGERCLKILKSPYNVCSGERRP L* 2080 A 1 675 MAPPLRPLARLRPPGMLLRALLLLLLLSPLPGLREGI GELITPIGTSLPDLDPARRRWEGGIGRVGSEVADLCP GKEGGKVPEAEKEGVWCFSELSFVKPQDVTVTRKDP VVLDCQAHGEVPI KVTWLKNGAKMSENKRIEVLSNGS LYI SEVBGRRGEQSDEGFYQCLAMNK\ F*AILNQKJAH LALSRICST*RRRPDRP *EDEAFVMITTHCFQDLLTSL IES 2C81 B 1 3147 MAKISASRAEKVLEHPGEREKGREMASPWNHSILALA AVVVI ISMVLLGRSIQASRKEKMQPPEKETPEVLHLE EAKDYFNSLNNLRETLLSEKPNLAQVELELKERDVLSV FLPDVFETESYI SVVNMALIPPFFGQGRPGPPPPQPPIF LALFGCPPPPLPSPAFPPPLPQRPGPFPGASAPFLQP PLALQPRASAQASRGGGGAGAFYPVPPPPLPPPPPQC RPFPGTDAGERPRPPPPGPGPPWSPRWPEAPPPPADV LGDAALQRLRDRQWLEAVFGTPRRAGCPVPQRTHAGP SLGEVRARLLRALRLVRRLRGLSQALREAEADGA~q LLYSQTAPLRAELAERLQPLTQAAYV-EARRRLERVR RRRLRLRERAREREAEREAEAARAVEREQEIDRWRVK CVQEVEEKKRFFCEILTDELVLWEPSGRPQPQQLQIL TAMSTSTFYDKELKTARENKEEELIDKLEVVTMPS PS PKGLPVKQYAVQSQLPVYEWPDVGSGEYDVGVVASFG RLLNEALILKFPYSALGGSGS PAPLTRLASPAAPQDG Q-VDLEGRALRPAARAGFSK HRG-HGDALDGHAGLRPEL WO 2004/080148 PCT/US2003/030720 617 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X-=Unknown, *Stop codon, ID beginning ending I=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last anino acid residue acid of peptide residue of sequence peptide e sequence HAPLT-VVADGLFSKFRK5LVSN\KVSVSSHFVGFLMKH DFSLERTALFWVEAAGQGPSPYQCGDPGTASAPPAWqL LLVSPEH~GLAPAPTTIRDPEAGHQERPEEEGEDEAEA SSGSEEEPAPSSLQPGS FASFGPGRRLCSLDVLRGVh LELAGARRRLSEGKLVSRPRALLHGLRGHRALSLCFS PAQSPRSASPPGPAPQHPAAFASPPRPSTAGA.IPFLR SHKPTVAIYITTKRIJPYFPIVNFLFLIAQLPKLQYNK NVALTVKFLTK RFI SEYDPNLGMVCRKPTDPVDWPPL VLGLLTLMKQFHSRYTEQFLALIGQFICSTVEQCTRQ VTKAEGVALAGRFGCLFFEVSACLDFEHVQHVFHEAV REARRELEKSPLTPPLFI SEERALPNQAPLTARHGLA SCTFNTLSTINLKEMFTVAQAKILVTVKSSRAQSKRKA -PTLTLLKGFKI F 2082 A 85 839 RSGSLMAAAAATKILLCPLLLTLSGWSRAGRADFHS LCYDITVI PKFRPGFRWCAVQGQVDEKTFLHYDCGNK TVTPVSPLGKKT-NVTTAWKAQNPVLREVVDILTEQLR DIQLENYTPKEPLTLQARMSCEQKAEGHS SGSWQFSF DGQI FLLFD8EKRMWTTVHPGARKKEKWENDKVJV'M 8FHYFSMGDCIGWLEDELMGMDSTLEPSAGAFLAS S GTTQLRATATTLIL-CCLLILLPCFILPGI 2083 A 1 1742 VSAVEFVLKGKDFQVDCKASGSFVP*ISWSLLDGTMI NNAtQADDSGNRTRRYTLFNNGTLYFNKVGVAEEGDY TCYAQNTIJGKDEMKVHLTVITAAPRIRQSNKTNRI K AGDTAVLDCEVTGDPKPKIFWLLPSNDMISFIDRYT FHANGSLTTNKVKLLDSGEYVCVARNPSGDDTK4YKL DVVSKPFLINGLYTNRTVIKATAVRHSKHFDCRAEG TPSFEVMWIMPDNIFLTAPYYGSRITVHKNGTLEIRN VRLSDSADFI CVARNEGGESVLVVQLSVLEMLRRPTF RNPFNEKIVAQLGKSTALNCSVDGNPPPETIWILPNG TRFSNGPQSYQYLIASNGSFI ISKTTREDAGKYRCAA RNKVGYIEKLVILEICQKPVILTYAPGTVKGISGESL SLHCVSDGI PKPNI KWTMPSGYVVDRPQINGKYILHD NGTLVIKEATAYDRGNYICKAQNSVGHTLITVPVMIV AYPPRITNRPPRSIVTRTGAAFQLHCVALGVPKPEI T WEMPDHSLLSTASKERTHGSEQLILQGTLVIQNFQTS DSGIYKCTAKNFIJGSDYAATYIQVI 2084 A 1 1742 VSAVEFVLGKDFQV CKASGSPVP*ISWSLLDGTMI NNAMQADDSCHRTRRYTLFNNGTLYFNKVGVAEEGDY TCYAQNTLGKDEMKVHLTVITAAPRIRQSNKTNRI K AGDTAVLDCEVTGDPKPKIFWLLPSNDMI SFSIDRYT FHANGSLTINKVKLLDSGEYVCVAPNPSGDDTKMYKL DVVSKPPLINGLYTNRTVI KATAVRHSKKNFDCRAEG TPSPEVMWIMPDNI FITAPYYGSRITVHKNGTLEIRN VRLSDSADFICVARNEGGESVL\JQLEVLEMLRRPTF RNPFNEKIVAQLCGKSTALNCSVDGNPPPEI IWILPNG TRFSNGPQSYQYLIASNGSFI ISK<TTREDAGKYRCAA RNKVGYIRKLVILEIGQKPVILTYAPGTVKGT SGESL SLHCVSDGI PKPNIKWTMFSGYVVDRFQINGKYILHD NGTLVIKCEATAYDRCNYI CKAQNSVGHTLITVPVMIIV AYPPRITNRPPRS IVTRTGAFQL-CVALG-VPKPEIT WO 2004/080148 PCT/US2003/030720 618 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide WEMPDHSLLSTASKERTHGSEQLLQGTLVQ __QTS ________DSGIYKCTAKNPLGSDYAATYIQVI 2085 A 1 1742 VSAVEFVLHGKDQVDCKASGSPVP*ISWSLLDGTMI NNMQADSHRTRRYTLFNNTLYFNIKVGVAEEGDY TCYAQNTLGK DEMKVHLTVITAAPRIRQSNKTNKRIK AGDTAVLDCEVTGDPKPKIFWLLPS1 DMISFSIDPXT FHINGSLTINKVKILLDSGEYVCVARNPSGDDTK MYKL DVVSKPPLINGLYTNRTVIKATAVR14SKK1FDCRAEG TPSPEVMVWIMPDNI FLTAPYYGSRITVHIKNGTLEIRN VRLSDSADFICVARNEGGESVIJVVQLEVLEMLRRPTF RNPFNEKIVAQLGKSTALNCSVDCNPPPEI IWILPNG TRFSNGPQSYQYLIASNGSFI ISKTTREDAGKYRCAA RNKVGYIEKLVILEIGQKPVILTYAPGTVKGI SGESL SLHCVSDGI PKPNIKWTMPSGYVVDRPQINGKYILHD NGTLVIKEATAYDRGNYICKAQNSVG-TLITVPVMIV AYPPRITN\RLPPRS IVTRTGAAFQLHCVALGVP'KPEIT WEMPDHSTLhSTASKERTHGSEQLHLQGTLVIQNPQTS ________DSGIYKCTAKNPLGSDYAATYIQVI 208G A 180 275 MEEPQSDPSVEPPLSQETFSDLWKLLSENNVL 2087 A 47 1147 MASMAAVLTWALALLSAFSATQARKGFWDYFSQTSGD KGRVEQIHQQKMAREPATLKDSLEQDLNNMNKFLEKL RPLSGSEAPRLPQDPVGM'RRQLQEELEEVKARLQPYM AEAHELVGWNLEGLRQQLKPYTMDLMEQVALRVQELQ EQLRVVGEDTKAQLLGGVDEAWALLQGLQSRVVHHTG RFKELFHPYAESLVSGIGRHVQELHRSVAPHAPASPA RLSRCVQVLSRKLTLKAICALHARIQQNLDQLREELSR AFAGTGTEEAGPDPQMLSEEVRQRLQAFRQDTYLQI AAFTRAIDQETEEVQQQLAPPPPGHSAFAPEFQQTDS GKVLSKLQARLDDLWEDITHSLHDQGHSHLGDP* 2088 A 47 1147 MASMAAVLTWALALLSAFSATQARKGFWDYFSQTSGD KGRVEQIHQQKMAREPATLKDSLEQDLNNMNKFLEKL RPLSGSEAPRLPQDPVGMRRQLQEELEEVKARLQPYM AEAHELVGWNL8GLRQQLKPYTMDLMEQVALRVQELQ EQLRVVGEDTKAQLLGGVDEAWALLQGLQSRVVNHiTG RFKELFHPYAESLVSGIGRHVQELHRSVAPHAPASPA RLSRCVQVLSRKLTLKAKALHARIQQNLDQLREELSR AFAGTGTEEGACPDPQMLSEEVRQRLQAFRQDTYLQI AAFTRAIDQETEEVQQQLAPPPPGHSAFAPEFQQTDS GKVILSKLQARLDDLWEDITHSLHDQGHSHLGDP * 2089 A 1199 329 DFGEFMRENRLTPFLDPRYKIDGSLEVPLERAKDQLE KHTRYWPMI ISQTTI FNMQAVVPLASVIVKESLTEED VLNCQKTIYNLVDMERKNDPLPISTVGTRGKGPKRDE QYRIMWNELETLVRAH-INNSEKH-QRVLECLMACRSKP PEEEERKKRGRKREDKEDKSEKAVKDYEQEKSWQDSE RLKGILERGKEELAEAEI IKDS PDSPEPPNKKLPLVEM DETPQVEKSIK PVSLLSLWSNRINTANSRKHQEFAGR LNS-\NNRAELYQHLKEENGMETTENGKaSRQ 2090 A 3 456 RWNSIMELALLCGLVVI4AGVIPIQGGILNLNKM-VKQV TGKMPILSYWPYGCHCGLGGRGQPKDATDWCCQTHDC CYDHLKTQGCGIYK DYYRYN\FSQGNI1HCSDIKGSWCEQ WO 2004/080148 PCT/US2003/030720 619 TABLE 7 SEQ Method Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sqeuuence QLCACDKEVAFCLKRNLDTYQKRLRFYWRPHCRGQTP GC 2091 A 27 489 EGEEPRD*PKMPLTPEPP/VWARGGAPRMGSSPMLT ALWqALHPI.HAGPGHPGCALHPHHRCVG* TPVPPCSPP RPQPPCTHPGVAPRRRAVD*AHGHRPRAL*,GLVWLCG PPADRSGP*ASHPATWAPRP)YWRSQPGAPSGGPSPGR GGPPPQA 2092 A 2022 617 VIPPVLTARGPRPRGAGAMVRGRISRLSVRDVRFPTS LGGHGADAMHTDPDYSAAYVVIETDAEDGIKGCGITF TLGKGTEXTVVCAVNALAHHVLNKDLKD)IVGDFRGFYR QLTSDGQLRWIGPEKGVVHLATAAVLNAVWDLWAKQE GKPVWKLLVDMDPRMLVSCIDFRYITEVLTEEDALEI LQKGQIGKKEREKQMLAQGYPAYTTSCAWLGYSDDTL IQLCAQALKDGWTRFKVKVGADLQDDMRRCQI IRDMI GPEKTLMMDANQRWDVPEAVEWMSKLAKFKPLWIEEP TSF*LTFLGHATI \SKALVPFRELGICTRENSCHNRV I FKQLLQAKALQFLQIDSCRLGSVNENLSVLLMAKKF El PVCPHAGGVGLCELVQHLIIFDYISVSASLENRVC EYVDH-LEHFKYPVMIQRASYMPPKDPGYSTE\ LKEE SCKRNTQYPQMGEVWEETPFPAQEN 2093 A 63 193 SGRLAPHTSRRTSANCSDDAKSSDSCSPSRKT*WSGR .NTNRII{ 2094 A 1404 142 IPGSTISWSPAAARGLSVCRCCRLHPASADLFGDLP EPERSPRPAAGKEAQKGPLLFDDLPPASSTDSGSGGP LLFDDLPPASSGDSGSLATS ISQMVKTEGKGAKRKTS EEEKNGSEELVEKKVCKASSVI FGLKGYVAERKGERE EMQDAHVI LNDITEECRPPS ELITRVSYFAVFDGHGG IRASKFAAQI4LHQNLIRKFPKGDVI SVEKTVKRCLLD TFKHTDEEFLKQASSQKPAWKDGSTATCVLAVDNILY IANLGDSRAILCRYNEESQKHIAALSLSKEHNPTQYEE RMRIQKAGGNVRDGRVLGVLEVSRS IGDGQYKRCGVT SVPDIRRCQLTPNDRFILLACDGLFKVFTPEEAVNFI LSCLEDEKIQTREGKSAADARYEAACNRLANKAVQRG SADNVTVMVVRIGH 2095 A 2 541 FVGHCVNTEGGFVCERGPGMRVSADRHSCQDTDECLG TPCQQRCKNS IGSYKCSCRTGFHLHGNRHSCV/DYTP RI PLCS P1FLAFAPLDVNECRRPLERRVCHSCINT GGSFLCTCRPGFRLRADRVSCE/DFPESRAGPICHPA TPVTPVQE/ CYCCLLRPHGLPCAQDIDLLLGLQGHQ 2096 A 1206 2266 RHLLTIFHKLKIYKTINKIDFKKKRVTQLLVFCLFLC LFFSSEMVKNQTMVTEFLLLGFLLGPRIQMLLFGLFS LFYVFTLLGNGTTLGLI SLDSRLHTPMYFFLSHLAVV NIAYACNTVPQMLVNLLHPAKPI SFAGCMT* TFLFLS FAHTECLLLVLMSYDRYVAICHPLRYFII TWKVCIT LAITSWTCGSLLAMVHVSLILRLPFCGPREINHFFCE ILSVLRLACADTWLNQIVTI FAACMFILVGPLCLVLVS YSHILAAILRIQSGEGRRKAFSTCSSHLCVVGLFFGS AIVMYMAPKSRHPEEQQKVLI.FYSSFNPMLNPLIYN LRNVEVKGALRRALCKESHS 2097 e A n62266 RHLLTIFHKLKIYTINKIDFKKIVTQLLVFCLtLC WO 2004/080148 PCT/US2003/030720 620 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XUnknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide reoiue of sequence peptide sequence LFFSSEMVKNQTMVTEFLLLGFLLGPRIQMLLFGLFS LFYVFTLLGNGTILGLI SLDSRLHTPMYFFL8MLAVV NIAYACNTVPQ'LVNLLHPAKPI S1AGCMT* TFLFLS FAHTECLLLVLMSYDRYVAI CHPLRYFI IMTWKVCIT LAITSWTCGSLLAMVIVSLILRLPFCGPRE INHFFCE ILSVLRLACADTWALNQVVI FAACMFTLVGPLCLVLVS YSHILAAILRIQSGEGRRKIAFSTCSSHLCVVGLFFGS AIVMYMAPKSRHPEEQQKVLFLFYSSFNPMLNPLIYN LRNVEVKCCALRPALCKESHS 2098 A 276 243 EKWPD*SRAACPVLCRGNGQYSKGRCLCFSGWeeiTEC DVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEEA PRYIPEKE 2099 A 4 770 RETGSVSLSPSGLEGAESYAVSPILYSSPDVKELWLE TLQGQRHSHTGVKSTPGQSAAILMKLRSSHNASKTLN ANNNETLIECQSEGDI KEHPLILASCESEDSICQLIEV KKRKKVLSWPFLMP-RLSPASDFSGALETDLKASLFDQ PLSI ICGDSDTLPRPIQDILTILCLKGPSTEGI FRRA ?ANEKARKELKEELNSGDAVDLERLPVHLLAVVFKDFL RS IPRKLLS SDLFEEWMGAL~EMQDEEDRIEALK 2100 A 901 521 FFFGNGVSPCRQAGV*WHDLDSLQNLPPGFKRFSYLS LPSSW\DYRHVLPRQANFCI F/M*RRGFTMLARMVSI S* PRDLPALASQSAGITGVSHKAPPQMDFTFALLCFA _________LKGCLPRQKEGGTLNLI 2101 A 901 521 FFFGNGVSPCRQAGV*WHDLDSLQNLPPGFKRFSYLS LPSSW\DYRHVLPRQANFCT F/M*RRGFTMLARMVSI S *PRDLPALASQSAGI TGVSHIIAPPQMDFTFALLCFA _______LKGCLPRQKEGTL~NLI 2102 A 3 600 PRCRNSARVADTF'YTNAGCTLVALNPFKPVPDQLYSPE LMREYHAAPQPQKLI(PHVFTVGEQTYRNVKSLIEPVN QSIVVSGESGAGKTWTSRCLMKFYAVVATSPASWESH KIAERIEQRILNSNPVMEAFGNACTJRNNNSSRFGKF IQLQLNRAQQMTGAAVQTYLLEKTRVACQASSERNKD PIPPELTRLLQQSQ 2103 A 3 600 PRCRNSARVADTFYTNAGCTLVALNPFKPVPQLYSPE LMREYHAAPQPQKLKPHVFTVGEQTYRNVKSLIEPVN QSIVVSGESGAGKTWTSRCLMKFYAVVATSPASWESH KIAERIEQRI LNSNPVMEAFGNACTLRNNNSSRFGKF IQLQLNRAQQDTGAAVQTYLLEKTRVACQASSERNKD PIPPELTRLIJQQSQ 2104 A 10 435 FKWILKSHAICFWTRS*SYCDNVCVPSLWAIILGIRT EIPEFFLSKFLCT8I IPHFTYRRQL-RLIQGST8*EA* EIKLEQK*ALGAAQFTLPGMDVFVCFVFCF/ CLFEME SHSVT*ARVQWCDLGSLQPLPLGFKQFSCLGL 2103 A 79 1222 CQRREDAAEBFWLCFALDPSKDPCLKVKCSPHKVCVTQ DYQTALCVSRK HLLPRQKICGNVAQKHEWVGPSINLVKCK PCPVAQSAMVCGSDGHSYTSKCKLEFHACSTGKSLAT LCDG\ PCPCLPEP\EPPI{KIGRKGVPCTDKELRNLAS RLKDWFGALHEDANRVI KPTSSNTAQGRFDTSILPI C KDSLGNDLNKLDMNYDLLLDPSEINAIYLDKYEPCI K PLFNSCDSFIDGKPFLUNiEWCLLPSQNqPGGLP/

CAQN

WO 2004/080148 PCT/US2003/030720 621~ TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XUnknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide seqtneoe EMNRIQ\KLSKC-KSLLGAFIPRCNEEGYYKATQCHGS TGQCWCVDKYGNELAGSRKQGAVSCEEEQETSGDFGS GGSVVLLDDLEYERELGPKDKEGKLRVHTRAVTEDDE DEDDDKEDEVGYIW 2106 A 174 857 MLNLAFTVGSFLLSAITLPLGIVMDKYGPRKLRLLGS ACFAVSCLLIAYGASKPNALSVLIFIALALNGFGGMC MTFTSLTLPNMFGDLRFTFIALMIGSYAS SAVTFPGI KILIYDAGVSFIVVLVVWAGCSGLVFLNCFFNWPLEPF PGPEDMDYSVKIKFSWLGFDHKITGKQFYKQVTTVGR RLSVGSSMRSAKEQVALQEGHKLCLSTVDRNSXRSXA LVSGYP 2107 A 174 857 MLNLAFTVGSFLLSAITLPLGIVMDKYGPRKLRLLGS ACFAVSCLLIAYGASKPNALSVLIFIALALNGFGGMC MTFTSLTLPNMFGDLRFTFIALMIGSYASSAVTFPGI KLIYDAGVSFIVVLVVWAGCSGLVFLNCFFNWPLEPF PGPEDMDYSVKIKFSWLGFDHKITGKQFYKQVTTVGR RLSVGSSMRSAKEQVALQEGHKLCLSTVDRNSXRSXA LVSGYP 2108 A 1 570 YAAFGAVVTRVSLPAPRCPALGGLASGPGESGPALLQ VCGAKCPGGAPRGENREKEETTRIGPGVMESKEKRAV NSLSMENANQENEEKEQVANKGEPLALPLDAGEYCVP RGNRRRFRVRQPILQYRWDMMHRLGEPQARMREENME RIGEEVRQLMEKLREKQLSHSLRAVSTDPPHHDHHDE FCLMP 2109 A 70 993 SEQKIQEQGYVWITVFSALPTTVSALHPRVLKPLSSL IHLQANSNPWECNCKLLGLRDWLASSAITLNIYWQNP PSMRGRALRYINITNCVTSSINVSRAWAVVKSPHIHH KTTALMMAWHKVTTNGSPLENTETENITFWERIPTSP AGRFFQENAFGNPLETTAVLPVQIQLTTSVTLNLEKN SALPNDAASMSGKTSLICTQEVEKLNEAFDILLAFFI LACVLIIFLIYKVVQFKQKLKASENSRENRLEYYSFY QSARYNVTASICNTSPNSLESPGLEQIRLHKQIVPEN EAQVILFEHSAL 2110 C 160 297 MILCHLMQAPYHLKVSWEPTDPPTLWKCWTNVSTNPP LSALRGHR 2111 A 2 951 PRVRPRVRPRVRSSRPRSRDPSPRRARLRWQLRWKPR WCPRPPKTPGVWKRPRTRPRSSAGGSTGFPSSPILRR SPSTRRRSSRKASPTATRATGTPPRQAQRKTARAAGR RRASPGIATAGTRSMISM\RPGRKPSNPSWEGRTNEE TSSLSRLKPVSPGTITCPLRTPGSLLKDSKIPISIKH LTNLPSSHPVVHQQPSRSEMPRTKIPVSKVLVRRVSN RGLAGTTIRATACHDSAQKVVRSSRPRWMGPMPRNTT FPWETTKVSFAFPKESLL/WTPPVPRPAPERGPRRSL CPE*GPDNTRKRDATRGFLLSR 2112 A 82 435 MLVLLPRSKAMPLLSVNVTLAFFPRNKEIVKYLLNQG ADVTLRAKNGYTAFDLVMLLNDPDIFGGELIGFLSVV TELVRLLASVFMQVNKDIGRRSHQLPLPHSKVPTALE HPSAAR* 2113 A 83 1138 PRRMGSWVQLITSVGVQQNHPGWTVAC-QFQEKKRFTE

_EVIEYFQKKVSPVHLKILLTSDEAWKRPFVRVAELPRE

WO 2004/080148 PCT/US2003/030720 622 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide rede of sequence peptide sequence EADALYEALKNLTPYVAIEDKDMQQKEQQFREWFLKE FPQIRWKIQESIERLRVIANEIEKVTHRGCVIANVVSG STGILSVIGVMLAPFTAGLSLSITAAGVGLGIASATA GIASSIVENTYTRSAELTASRLTATSTDQLEALRDIL HDITPNVLSFALDFDEATKMIANDVHTLRRSKATVGR PLIAWRYVPINVVETLRTRGAPTRIVRKVARNTLGKAT SGVLVVLDVVNLVQDSLDLHKGEKSESAELLRQWAQE LEENLNELTHIHQSLKAG 2114 A 83 1138 PRRMGSWVQLITSVGVQQNHPGWTVAGQFQEKKRFTE EVIEYFQKKVSPVHLKILLTSDEAWKRFVRVAELPRE EADALYEALKNLTPYVAIEDKDMQQKEQQFREWFLKE FPQIRWKIQESIERLRVIANEIEKVHRGCVIANVVSG STGILSVIGVMLAPFTAGLSLSITAAGVGLGIASATA GIASSIVENTYTRSAELTASRLTATSTDQLEALRDIL HDITPNVLSFALDFDEATKMIANDVHTLRRSKATVGR PLIAWRYVPINVVETLRTRGAPTRIVRKVARNLGKAT SGVLVVLDVVNLVQDSLDLHKGEKSESAELLRQWAQE LEENLNELTHIHQSLKAG 2115 A 700 283 VPRLVSPLSNPAPKFYCVSFFYHMYGKHIGSLNLLVR SRNKGALDTHAWSLSGNKGNVWQQAHVPISPSGPFQI IFEGVRGPGYLGDIAIDDVTLKKGECPRKQTDPNKVV VMPGSGAPCQSSPQLWGPMAIFLLALQR 2116 A 700 283 VPRLVSPLSNPAPKFYCVSFFYHMYGKHIGSLNLLVR SRNKGALDTHAWSLSGNKGNVWQQAHlVPISPSGPFQI IFEGVRGPGYLGDIAIDDVTLKKGECPRKQTDPNKVV VMPGSGAPCQSSPQLWGPMAIFLLALQR 2117 A 554 970 MVLPFICNLLRRHPACRVLVHRPHGPELDADPYDPGE EDPAQSRALESSLWELQALQRHYHPEVSKAASVINQA LSMPEVSIAPLLELTAYEIFERDLKKKGPEPVPTGVL SQPRACWDGRVKLCAQHFHAQLTLAHL* 2118 A 1 541 VHVCSSKMGALSTERLQYYTQELGVRERSGHSVSLID LWGLLVEYLLYQEENPAKLSDQQEAVRQGQNPYPIYT SVNVRTNLSGEDFAEWCEFTPYEVGFPKYGAYVPTEL FGSELFMGRLLQLQPEPRICYLQGMWGSAFATSLDEI FLKTAGSGLSFLEWYRGSVNITDDCQKPQLHN 2119 A 1 541 VHVCSSKMGALSTERLQYYTQELGVRERSGHSVSLID LWGLLVEYLLYQEENPAKLSDQQEAVRQGQNPYPIYT SVNVRTNLSGEDFAEWCEFTPYEVGFPKYGAYVPTEL FGSELFMGRLLQLQPEPRICYLQGMWGSAFATSLDEI FLKTAGSGLSFLEWYRGSVNITDDCQKPQLHN 2120 A 1 1524 PHPSGPRITHSHARETACQP/GSEQHPGPHGGQLPRG GRQGPELPSHVCRAQA\GRTGQEPSSERPHAGQGAGL WSGSPWGRGRTQPTHAPTEGATPRCPLRPSPRGSGRA GPTLIRAGLSGGRGGRSLCPCGFPRAGAVPARSSHNQ TSPVHEKSRH/GPTASGPGCWWLGDPQGRRVPGLAVP *APAAGTPMDIKLPGLHLPEQRLPSICGPFSAGLSPSG QSREWQGGSQGSRSRQFSKKAPGPPPS\TGGGCLGCG GRGT\RGSAHAG\PWGSPHQQGS*GAPGSQAKGGTP* RKPAPANGSSEEQEEARGPQGLEVSSSQTSASHAGLG

LQGNSTRGVGPGPRPPAEPTTGRSWARSRVNPD*EQA

WO 2004/080148 PCT/US2003/030720 623 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible ucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence SGA*VRSGSRSPGDAL1ESSCNAPA WLQLCSAPCALGS REPGQGLAVTQTLCGPQSLGHPRESHKTRPPYEAATS SACLGLALTGTFSVEETEMFMTRQRPTGRDLQRGTRP QGWQGPVPGTSHYGRARPALGEASDIQEANGA _ 2121 A 233 692 DNHPSFPRLPSSRPGTKEVLEIHISDTTADVIFYPI YRMSEMIFRRI KMPWLWLDLWYLMFK EGWEHKKSLKI LHTFTNSVIAERANEMtNANED)CRGDGRGSAPSKNKRR AFLDLLLSVTDDEGIRLSH-EDIREEVDTFMFEVLYIV RFRYH -i222 A 2 i11s PRVRSSGGQEDPASQQWARPRFTQPSKMRRRVIARPV GSSVRLKCVASGHPRPDITWMKDDQALTRPEAAEPRK KKWTLSLKNLRPEDSGKYTCRVSNRAGAINATYKVDV IQRTRSKPVLTGTHPVNTTVDFGGTTSFQCKVRSDVK PVIQWLKRVEYGAEGRHNSTIDVGGQKFVVLPTGDVW SRPDGSYLNKLLITRARQDDAGMYI CIGANTMGYSFR SAFLTVLPDPKPPGPPVASSSSATSLPWPVVIGI PAG AVFILGTLLLWLCQAQKKPCTPAPAPPLPGHRPPGTA RDRSGDKDLPSLAALSAGPGVGLCEEHGSPAAPQHLL GPGPVAGPKLYPKLYTGHSTPHTYTHPPPSCQLNSSH S 2123 A 2 1115 PRVRSSGGQEDPASQQWARPRFTQPSKMRRRVIARPV GSSVRLKCVASGHPRPDITWMKDDQALTRPEAAEPRK KKWTLSLKNLRPEDSGKYTCRVSNRAGAINATYKVDV IQRTRSKPVLTGTHPVNTTVDFGGTTSFQCKVRSDVK PVIQWLKRVEYGAEGRHNSTIDVGGQKFVVLPTGDVW SRPDGSYLNKLLITRARQDDAGMYICLGANTMGYSFR SAFLTVLPDPKPPGPPVASSS9SATSLPVQPVVIGI PAG AVFILGTLLTLWLCQAQKKPCTPAPAPPLPGHRPPGTA RDRSGDKDLPSLAALSAGPGVGLCEEHGSPAAPQHLL GPGPVAGPKLYPKLYTGH-STPHTYTHPPPSCQLNSSH S 2124 A 2 1115 PRVRSSGGQEDPASQQWARPF-FTQPSKMRRRVIARPV GSSVRLKCVASGHPRPDTTWMKDDQALTRPEAAEPRK KKWTLSLKNLRPEDSGKYTCRVSNRAGAINATYKVDV IQRTRSKPVLTGTHPVNTTVDFGGTTSFQCKVRSDVK PVIQWLKRVEYGAEGRHNSTIDVGGQKFVVLPTGDVW SRPDGSYLNKLLITRARQDDAGMYICLGANTMGYSFR SAFLTVLPDPKPPGPPVASSSSATSLPWPVVIGT PAG AVFILGTLLLWLCQAQKKPCTPAPAPPLPGIRPPGTA RDRSGDKDLPSLAALSAGPGVGLCEEHGS PAAPQHLL GPGPVAGPKLYPKLYTGHSTPHTYTHPPPSCQLNSSH S 2125 A 3 644 PNWIKRNPSLF*KVFPFMKIKVV/QRGSLLPPKSLDYDR FSRIN/DTPLGRVSI PLNKVDLTQMQTFWKDLKPCSDG SGSRGELLLSLCYfNPSANSIIVNI IKARN9LKAM\DIG GTSDP\YVIKVWL\MYK\DKR-V\EKKITVT\MI-RNLNP \IFN\ESFAFDIPTEKLRETTI IITV\MDKDIKLSRWDVI GKIYLSWKSGPGEVKHWKDMIARPRQPVAQWH4QLKA 2126 A 193 883 IMPCAQRSWLANLSVVAQLLNFGALCYGRQPQPGPVR I I ~FPDRRQEHFIIKGLPEYHVVGPVR-VDASGHFLSYGLHY WO 2004/080148 PCT/US2003/030720 624 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XUnknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence PITS SRRKRDLDGSEDNVYYRI FHEEK'DLFFNLTVNQ GFLSNSYIMEKRYGNLSHVKD4MASSAPLCHLSGTVLQ QGTRVGTAALSACHGLTGFFQLPHGDFFIEPVKKHPL VECGYHPHIVYRRQKVPETI(CEPTCGL KGIVTHMSSWV EESVLFFW 2127 A 87 477 IKSKLNQQVEVQESEWRLTEAKGPTMGKESGWDSGRA AVAAVVGGVVAVGTVLVALSAMGFTSVGIAASS IAAK IMMSTAAI1ANGGGVAAGSLVAILQSVGAAGLSVTSKVI GGFAGTALGAWLGSPPSS 2128 A 1993 1379 SLiLSERADWQYSQRAG/DAVVFFSRTApDNRLGCM FVRCAPSSRYTLLFSHGNAVDL~GQMCSFYIGLGSRIN CNI FSYDYSGYGVSSGKPSEKNLYADIDAAWQALRTR YGVSPENI ILYaQSIGTVPTVDLASRYECAAVILHSP LMSGLRVAFPDTRKTYCFDAFPSIDKI SKVTSPVLVI HGTEDEVIDFSHGLYERCPRAVEPLWVEGAGHNDI ELYAQYLERLKQFISHELPNS*RQSK 2129 A 1-993 1379 SLHLSERADWQYSQRAG/DAVEVFFSRTARDNRLGCM FVRCAPSSRYTLLYSHGNAVDLGQMCSFYIGLGSRIN CNI FSYDYSGYGVSSGKPSEKNLYADIDAAWQALRTR YGVSPENI ILYGQSIGTVPTVDLASRYECAAVILHSP LMSGLRVAFPDTRKTYCFDAFPSIDKI SKYTS PVLVI HGTEDEVIDFSHGLAMYERCPPRAVEPLWVEGACHNDI ELYAQYLERLKQFISHELPNS *RQSK 2130 A 3 383 PPGPKGDQGDEGKeGRPGIPGLPGLRGLPGERGTPGL PGPKGNDGKLGATGPMGMRGFKGDRGPKGEKGEKGDR AGDASGVEAPMMIRLVNGSGPHEGRVEVYHDRRWGTV CDDGWDKKDGDVVCRM 2131 A 3 3B3 PPGPKGDQGDEGKTGRPGIPGLPGLRGLPGERGTPGL PGPKGNDGKLGATGPMGMRGFKGDRGPKGEKGEKGDR AGDASGVEAPMMIRLVNGSGFHEGRVEVYHDRRWGTV CDDGWDKKDGDVVCRM 2132 A 1 2789 GIRTSSPKTEGKHEETVNKESDMKVPTVSLKVSESVI DVKTTMES ISNTSTQSLTAETKDIAL~EPKEQKHEDRQ SNTPSPPVSTFSSGTSTTSDI EVLDI4ESVISES SASS RQETTDSKS SLHLMQTSFQLLSASACPEYNRLDDFQK LTESCCSSDAFERIDSFSVQSLDSRSVSEINSDDELS GKGYALVPI IVNSSTPKSKTVESATGKSEEVNETLVI PTEEAEMEESGRSATPVNCEQPDILVSSTPINEGQTV LDKVAEQCEPAESQPEALSEKEDVCKTVEFLNEKLEK REAQLLSLSKBKAJLEEAFDNLKDEMF-VKEESS 515 SLKDEFTQRIATAEKKVQLACKERDAAKK5IKNIKEE LATRLNSSETADLLKEKDEQIRGLMEEGEKLSKQQLH NSNI IKKLRAKDKENENMVAKLNKKVKELEEELQHLK QVLDGKEEVEKQH-RENI KKLNSMVERQEKDLGRLQVD MDELEEK NRSIQAALDSAYKELTDLHKANAAKDSEAQ EA2ALSREMKIAKEELSAALEK<AQEEARQQQETLAIQVG DLRLALQRTEQAAARKEDYLRHE IGELQQRLQEAENR NQELSQSVS STTRPLLRQIENLQATLGSQTSSWEKLE K<NLSDRLGESQTLLAAAVERERAATEELLANKIQMSS

MESQNSLLRQENSRFQAQLESEKNRLCXLEDENNRYQ

WO 2004/080148 PCT/US2003/030720 625 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XLUnknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence VELBN4LKDEYVRTLEETRK EKTLLNSQLEMERMKVEQ ERKKAT FTQETIKEKERKPFSVSSTPTMSRSSS ISGV DMAGIJQTSFLSQDESHDI4SFGPMPI

S/AKWKQSL

t CC K DGSRIKH\ IENLQSQLKLREGEITHLQLEIGNYLEKT RB IMAEELVKLTNQNDBLEEKVKEI PRLRTQLRDLDQ RYNTILQMYGEKAEEAEELRLEDVK NMYK-TQIDEL LRQSLS 2133 A 1 2234 MAASSIREERTRTYYLPVVRAPYTCNFRPSSAAVGRL

CGWGRAQKWNNSCKCRFWEVSESLTLEDVAVEFTWEE

WQLLGPAQKDLYRDVMILENYSNLVSVGYQASKPDALF KLEQGEPWTVBNBIRSQI CPGMYALYRK1CHNGYRVKY DSEFQASMVWGVSNNI SPTDEGLLYIYKRHKEFTTEV DKGCETNIQMKDDKI KKVDNELQNHSQKQRCLKRVEQ CHKHNAFGNI IHQRKSDFPLRQNHDTFDLHGKTLKSN LSLVNQNKRYEIKNSVGVNGDGKSFLHAHEQFINEM NFPECGNSVNTNSQFIKHQRTQNIDKPHVCTECGKAF LKKSRLIYHQRVHTGEKPEGCS ICGKAFSRKSGLTEH QRNHTGEKPYECTECDKAFRWKSQLNAIIQKIHTCEKS YICSDCCKGFI KKSRIINHQRVHTGEKPRGCSLCGKA FSKRSRLTEHQRTHTGEKPYECTECDKAFRWKSQLNA UQKARTCEKSYICRDCCKGFIQKGNLIVHQRIHTGEK PYl CNBCGKGFIQKGNLLIHRRTRTGEKPYVCNECGK GFSQKTCLI SHQRFHTGKTPFVCTECGKSCSHKSGLI NHQRII-TGEKPYTCSDCGKAFRDKSCLNRHRRTHTGE RPYGCSECGKAFSHLSCLVYHKGMLHAREKCVG/ CSQ IGKSLLRES *LITYT* SITG*RLC*HGDSADAFCGSS DLIN*QCVPSREQSSHCEPACCQKFSLSR* *NCI{GIK NI-YECR 2134 A 3 713 RLAFPCRPDYWALARRTIGTGLBRKALGLPGSSERP TSVSSYQGTRTRCSNPGGKMRP-TEEETRVMFEKIAK YIGENLQLLVDRPDGTYCFRLHNDRVYYVSEKIMKLA ANI SGDKLVSIJGTCFGKWTKTIIKFRLRVTAIJDYLAPY AKYKVWT KPGAEQSFLYGNHVLKSGLGRI TENTSQYQ GVVVYSMADI PLGFGVAAKSTQDCRKVDPMAIVVFHQ ADICEYVRHEETLT 2135 A 1 350 EGGTGVRSLSFYQHIITVGTGHGSLLFYDIPAQKFLE ER SSSLDSMPGPAGRKLKLACGRGWLNQDDWVYF GGDGEFPNALYTBCYNWPEMRLFVAGGPLFSGLHGNY AGLWS 2136 B 238 1323 XESVEIVSEVRVEVGELNIIKDWGRESVEKGGAVISM EAERVKGQAMATGGVITGLAALKRQDSARSQQHVN SPSPATQEKKPIRRRPRADVVVVRGKIRLYSPSGFFL ILGVLIS II GIMAVLGYWPQKEHFIDAETTLSTNET QVIRNEGCGVVVRFFEQHLHISDKMKMLGPFTMGI I FICANAILHENRDKETKI IHMRDIYSTVIDII4TLRIK EQRQMNGM4YTGT 2 MGETEVITQNGSSCASRLAANTIASF SGFRSSFRMDS SVEEDELNLNESKSSGMLMPPLLSDS SVSVFGLYPPPSKTTJDKTSGST{KCETKSIVSSSI BA FTLPVIKIJNNCVIDEFB IDNI TED.ADNLKX 2137 PiA 41 a1285 sLIWRHLLRPLCLVTAPRILEMRPFLSLT

R

WO 2004/080148 PCT/US2003/030720 626 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residu of sequence peptide TSVTKLSLHTKPRMPPCDFMPERYQVI FLVNSGSEAN ELAMLMARAHSNNIDI ISFRGAYHGCSPYTLGJTNVG IYKMELPGGTGCQPTMCPDVFRGPWGGSHCRDSPVQT IRIKCSCAPDCCQAKDQYIEQFI{DTLSTSVAKSIAGFF AEPIQGVNGVVQYPKGFLKEAFELVRARGGVCIANEV QTGFGRLGSHFWGFQTHDVLPDIVTMAKIGG\TGFPMA AVITTPEIAKSLAKCLQHFNTFGGNPMACAIGSAVLE VIKEENLQENSQEVGTYMLLKFAKLRDEFE IVGDVRG KGLMIGIEMVQDKISCIRPLPREEVNQIHEDCKHMGLL VGRGS IFSQTFRIAPSMCITKPE-VDFAVEVFRSALTQ HMERRAK 2138 A 41 1285 VGEMTLIWRHLLRPLeLVTSAPRILEMHPFLSLGTSR TSVTKLSLH-TKPRNPPCDFMPERYQVI FLVNSGSEZ4N ELAMLMARAHSNNIDI ISFRGAYHGCSPYTLGLTNVG IYKMELPGGTGCQPTMCPDVFRGPWGGSHCRDSPVQT IRKCSCAPDCCQAKDQYIEQFKDTLSTSVAKS IAGFF AEPIQGVNGVVQYPKGFLKEAFELVRARGGVCIANEV QTGFGRLGSHFWGFQTHDVLPDIVTMAKGIGNCFPMA AVITTPEIAKSLAKCLQHFNTFGGNPMACAIGSAVLE VIKEENLQENSQEVGTYMLLKFAKLRDEFEIVGDVRG KGLMIGIEMVQDKISCRPLPREEVNQIHEDCKHMGLL VGRGS IFSQTFRIAPSMCITKPEVDFAVEVFRSALTQ _______ MERRAK 2139 A 3 3G2 EGKPASAIVGGKPANILEFPWHVGIMNHGSHLCGGSI LNEWWVLSASHCFDQLNNSKLEI IHGTEDLSTKGIKY QKVDKLFLHPKFDDWLLDNDIALLLLKSPLNLSVNRI PICTSEISD 2140 A 1 663 EIANLILAENCEAALALHLYRGGRLLQGHRIPFGVIF GGTDVNEDANQAEKNTVMGRVLEEARFAVAFTESMKE MAQAQWVDLVFTREVKAKVKRAAGVRLIGEMPQEDLH AVflKNCFAVVNSSVSEGMSAAILEAMDLEVPVLARNI PONAAVVKH-EVTGLLFSNPQEFVI{LAKRLVSDPALEK EIVXTNGREYVRMYHSWQVERDTYQQLIRKL~EGSTED 2141 A 8 1516 MSLVLLSLAALCRSAVPREPTVQCGSETGPSPEWMLQ lIDLI PGDLRDLRVEPVTTSVATGDYS ILMNVSWVLRA DAS TRLLKATKI CVTGKSNFQSYSCVRCNYTEAFQTQ TRPSGGKWTFSYIGFPVELNTVYFIGAHNI PNANMNE DGPSMSVNFTSPGCLDHIMKYKKKCVKAGSLWDPNIT ACKKNEETVEVNFTTTPLGNRYMALjIQHSTI IGFSQV FEPHQKKQTR-ASVVI PVTGDSEGATVQLTPYFPTCGS DCIRHKGTVVLCPQTGVPFPLDNNKSKPGGWJPLLLL SLLVATWVLVAGIYLMWRHiERIKKTSFSTTTLLPPI K VLVVYPSEI CFHHTICYFTEFLQN-CRSEVILEKWQK KKC 1IAEMGPVQWLATQKKIAADKVVFLLSNDVNSVCDGT CGKSEDSPSENSQDLFPLAFNLFCSDLRSQIHLHKYV VVYFREIDTIDDYNALSVCPKYHLMK DATAFCAELLH VKQQVSAGKRSQAC-DOCCSL* 2142 A 1 622 PDPCLNGGS VDLVGNY'TCLCAEHPFKGLRCRTGDHPV PDACLSAPCHNGGTCVDADQGYVCEYPEGFMGLDCRE _______________RVPDDCECRNDGRCLDA -NTTLCQCPLGFFGLLCEFE I WO 2004/080148 PCT/US2003/030720 627 ____ TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unkaown, *=Stop codon, ID beginning ending /=possible nucleotide delctionrpossible ucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of 3equence peptide PredictedAminoacid sequence TAMPCNMNTQCPDGGYCMEHGGSYLCQCPLGFFGLLC EFEITAD4PCNMNTQCPDGG2 CMEHGGSYLCVCHTDHN ASHSLPS PCDSDPSSCQA-WRNE 2143 A 3 87 PPANVNDSVTKQKFDNLYCCRESILDG 2144 A 406 888 IASQNFDPATVSVATAHKGAEPSRGTAWGlVAKRLQQ ELMTLMMPGDKRISAYPESLIKWTPSMKQLAQCI* GI 66CW66SMTTHLYDAPTVKFLTPCYHPNVDTQGNI CLDILKEKIWSAPYDTRTILLS IQCLLGQLNIDS PLNT HATKLWBNPIALR 2145 A 46 1576 APYLPDPMKHTLALLAPLLGLGLGLALSQLAAGATDC KFLGPAEHLTFTPAARARWLAPRVRAPGLLDSLYGTV RRFLSVVQLNFFPSELVKALLNELASVKVNEVVRYEA GYVVCAVIAGLYLLLVPTAGLCFCCCRCHRRCGGRVK TEHKALACERAALMVFIJLLTTLLLLIGVVCAFVTNQR THEQMGPSIEAMPETLLSLWGLVSDVPQ/GVGVS IGS AIHTQLRSSV\TPCLAAVGSLGQVLQVSVHHLQTLNA TVVELQAGQQDLEPAIRE-RDRLLELLQE/SQVPSVD HVLHQLKGVPEANFSSMVQEENSTFNALPALAAMQTS SVVQELKKAVAQQPEGVRTLAEGFPGLEAASRWAQAL QEVEESSRLPYLQEVQRYETYRWIVGCVLCSVVLFVVL CNLLGLNLGIWGLSARDDPSHPEAKGEAGARFLMAGV GLSFLFAAPLILLaVFATFLVGGNVQTLVCQSWENGEL FEFADTPGNLPPSMNLSQLLGLRKNE SIHQAY 2146 A 3 717 DLKDTIGSVTKTPSGLYIIHPEGSSYPFEVMCDMDYR GGGWTVIQKRIDGI IDFQRLWCDYLDGFGDLLGEFWL GLKKI FYIVNQKNTSFMLYVALESEDDTLAYASYDNF WLEDETRFFKMHLGRYSGNAGDAFRGLKKEDNQNA4P FSTSDVDNDGCRPACLVNGQSVKSCS-LHNKTGWWFN ECGLI4NLNGIH-HFSGKLLATGIQWGTWTKNNSPVKIK ______ _______SVSMKIRRMYNPYFK 2147 A 3 717 DLKDTIGSVTKTPSGLYIIIPEGSSYPFEVMCDMDYR GGGWTVI QKRIDGI IDFQRLWCDYLDGFGDLLGEFWL GLKKI FYI VNQKNTSFMLYVALESEDDTLAYASYENF WLEIJETRFFKMHLGRYSGNAGDAFRGLKKEDNQNAMP FSTSDVDNDGCRPACLVNGQSVKSCSHLHNKTGWWFN ECGLANLNGIHHFSGKLLATGIQWGTWTKNNSPVKI K SVSMKIRRMYNPYFK 2148 A 3 717 DLKDTIGSVTKTPSGLYIIHPEGSSYPFEVMCDMDYR GGGWTVIQKRIDGI IDFQRLWCDYLDGFGDLLGEFWL GLKKT FYI VNQKNTSFMLYVALESEDDTLAYASYDNF WLEDETRFFKMHLGRYSGNAGDAFRGLKKEDNQNAMIP FSTSDVDNDGCRPACLVNGQSVKSCSHLHNKTGWWFN ECGLANLNGIHHFSGKLLATGIQWGTWTKNNSPVKI K SVSMKIRRi4YNPYFK 2149 A 1397 1565 DRLESLLEMHIPGVYPNQWNTNFYLFIYFEAESHSVA QTGLQ*RHLGSLQLPPPQV 2150 A 83G 633 MSRNLRTALIFGGFISLIGAAFYPIYFRPLMRLEEYK KEQAINRAGIVQEOVQPPGLKVWSDPFGRK*_ 2151 A 294 1568 MSILTIWTVCGVLSLFGALSYAELGTTIKKSGGHYTYI ___________________________LEVFGPLPAFVRVWVELLI IRPAATAVISLAFGRYIL WO 2004/080148 PCT/US2003/030720 628 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence EPFFIQCEIPELAIKLITAVGITVVMVLNSMSVSWSA RIQIFLTFCKLTAILIIIVPGVMQLIKGQTQNFKDAF SGRDSSITRLPLAFYYGMYAYAGWFYLNFVTEEVENP EKTIPLAICISMAIVTIGYVLTNVAYFTTINAEELLL SNAVAVTFSERLLGNFSLAVPIFVALSCFGSMNGGVF AVSRLFYVASREGHLPEILSMIHVRKHTPLPAVIVLH PLTMIMLFSGDLDSLLNFLSFARWLFIGLAVAGLIYL RYKCPDMHRPFKVPLFIPALFSFTCLFMVALSLYSDP FSTGIGFVITLTGVPAYYLFIIWDKKPRWFRIMSEKI TRTLQIILEVVPEEDKL* 2152 A 217 378 KNLFYSLSLICSSYPSILDHIVHIIELIGRIPRRFSL SGKYSQDFFSHRGSIVM 2153 A 2046 4541 MTLALAYLLALPQVLDANRCFEKQSPSALSLQLAAYY YSLQIYARLAPCFRDKCHPLYRADPKELIKMVTRHVT RHEHEAWPEDLISLTKQLHCYNERLLDFTQAQILQGL RKGVDVQRFTADDQYKRETILGLAETLEESVYSIAIS LAQRYSVSRWEVFMTHLEFLFTDSGLSTLETENRAQD LHLFETLKTDPEAFHQHMVKYIYPTIGGFDHERLQYY FTLLENCGCADLGNCAIKPETHIRLLKKFKVVASGLN YKKLTDENMSPLEALEPVLSSQNILSISKLVPKIPEK DGQMLSPSSLYTIWLQKLFWTGDPHLIKQVPGSSPEW LHAYDVCMKYFDRLHPGDLITVVDAVTFSPKAVTKLS VEARKEMTRKAIKTVKHFIEKPRKRNSEDEAQEAKDS KVTYADTLNHLEKSLAHLETLSHSFILSLKNSEQETL QKYSHLYDLSRSEKEKLHDEAVAICLDGQPLAMIQQL LEVAVGPLDISPKDIVQSAIMKIISALSGGSADLGGP RDPLKVLEGVVAAVHASVDKGEELVSPEDLLEWLRPF CADDAWPVRPRIHVLQILGQSFHLTEEDSKLLVFFRT EAILKASWPQRQVDIADIENEENRYCLFMELLESSHH EAEFQHLVLLLQAWPPMKSEYVITNNPWVRLATVMLT RCTMENKEGLGNEVLKMCRSLYNTKQMLPAEGVKELC LLLLNQSLLLPSLKLLLESRDEHLHEMALEQITAVTT VNDSNCDQELLSLLLDAKLLVKCVSTPFYPRIVDHLL ASLQQGRWDAEELGRHLREAGHEAEAGSLLLAVRGTH QAFRTFSTALRAAQHWV* 2154 A 2046 4541 MTLALAYLLALPQVLDANRCFEKQSPSALSLQLAAYY YSLQIYARLAPCFRDKCHPLYRADPKELIKMVTRHVT RHEHEAWPEDLISLTKQLHCYNERLLDFTQAQILQGL RKGVDVQRFTADDQYKRETILGLAETLEESVYSIAIS LAQRYSVSRWEVFMTHLEFLFTDSGLSTLEIENRAQD LHLFETLKTDPEAFHQHMVKYIYPTICGFDHERLQYY FTLLENCGCADLGNCAIKPETHIRLLKKFKVVASGLN YKKLTDENMSPLEALEPVLSSQNILSISKLVPKIPEK DGQMLSPSSLYTIWLQKLFWTGDPHLIKQVPGSSPEW LHAYDVCMKYFDRLHPGDLITVVDAVTFSPKAVTKLS VEARKEMTRKAIKTVKHFIEKPRKRNSEDEAQEAKDS KVTYADTLNHLEKSLAHLETLSHSFILSLKNSEQETL QKYSHLYDLSRSEKEKLHDEAVAICLDGQPLAMIQQL LEVAVGPLDISPKDIVQSAIMKIISALSGGSADLGGP

RDPLKVLEGVVAAVHAEVDKGEELVSPEDLLEWLRPF

WO 2004/080148 PCT/US2003/030720 629 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletionpossible nucleotide nucleotide nucleotide insertion) location of location of first amino inst amino acid residue ad of peptide residue of sequence peptide sequence CADDAWqPVRPRIHVLQILGQSFHLTEEDSKLLVFFRT EATLKASWPQRQVDIADIENEENRYCLFMELLESSHH EAEFQHLVLLLQAWPPMKSEYVITNNPWVRLATVMLT RCTMENKEGLGNEVLjKMCRSLYNTKQMLPAEGVKELC LLLLNQSLLLPSLK LLLESRDELH.EMALEQITAVTT VNDSNCDQELLSLLLDAKLLVKCVSTPFYPRIVDHLL ASLQQGRWDAEELGRHLREAGHEAEAGSLLLAVRGTH _______QAFRTFSTALRAAQHNV* 2155 A 2 362 QELERSMAQRCVCVLALVAMLLLVFPTVSRSMGPRSG EHQRASRIPSQFSKEERVAMKEALKVFPTVVSTSFIQ H~EVVEEYSLFTIQGSDPSLQPYLLMAHFDVVPAPE GWEVPPFSG 2156 A 940 2040 MALRFLLGFLLAGVDLGVYLMPLELCDPTQRLRVALA GELVGVGHFLFLGLALVSKDWRFLQRMITAPCILFL FYGWPGLFLESARWLIVKRQIEEAQSVLRILAERNRP HGQMLCEEAQEALQDLENTCPLPATS SFSFASLLNYR NIWKNLLILGFTNFIAHAIRH-CYQPVGGGGSPSDFYL CSLLASGTAALACVFLGVTVIDRFGRRGILLLSMTLTG IASLVLLGLWDYLNEAAT TTFSVLGLFSSQAAAILST LLAAEVI PTTVRGRGLGLIMALGALGGLSGPAQRLHM GHGAFLQHVVLAACALLCILS IMLLPETKRKLLPEVL _________RDGELCRRPSLTJRQPPPTRCDHVPLLATPNPAL* 2157 A 317 3 MYALLGVFCLAILVFLINCATFALKYRHKQVPLEGQA SDTHSH-DWVWLGNEALLSMGDAPPPQDEHTTT TDR _______GPGACEESNHLL1LNGGSHKHVQSQIHRSADS 2158 A 3 1048 LLRARSPQGSERAGVGGAYMLSKGWWKEGRGGHRRP RGWGAAGRRQSVPGGIPAAP/ PCTLYSVGADGRGQGHQ SRGCRPPGPPSASSAPCLAWGAAGRARREC/RSGRCR TEFSPGCTRR*ALT\CGAGPCRR* SR*RGTRRCLRPW AS PGTGAACGRCCCPPP* PHIJFWLPPSLRLPAEMLLA GSRPTPACRSSPGGSVHTTTGS PASRRQSRCRGRSRP SPRPRPSVLSCHGVSL* TGRGRRRGCPRARGRRA/GV APPSCRKSAR\ CGGRPALRRAGPPSCALGPGAPPPHI WAPETAEPAPAVPCPEPRPGCPAPAAAPRPLS PDPAQL PALARLRPSPGFGERAHAQPA 2159 A 190 2392 VPGEECDGITSMSAESGPGTRL8RNLPVMGDGLETSQM STTQAQAQPQPANAASTNPPPPETSNPNKPKRQTNQL QYLLRVVLKTLWKHQFAWPFQQPV]DAVKLNLPDYYKI I KTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCY IYNKPGDDIVLMAEALEKLFLQKINELPTEETE IMIV QAKGRGRGRKETGTAKPGVSTVPNTTQASTPPQTQTP QPNPPPVQATPHPFPAVTPDLIVQTPVMTVVPPQPLQ TPPPVPPQPQPPPAPAPQPVQSIPPI IAATPQPVKTK KGVKRKADTTTPTTIDPIHEPPSLPPEPI(TTKLGQRR ESSRPVKPPKKDVPDSQQHPAPEKSSKVSEQLKCCSG ILK "EMFAIIAYAWPFYKPVDVEALGLHDYCDIII PMDMSTIKSKLEAPREYRDAQEFGADVIRLMFSNCYKYN PPDHEVVAMARKLQDVFEMRFAKMPDEPEEPVVAV9S PAVPPPTKVVAPPSSSDSSSDSSSDSDSSTDDSEEER ___________________AQRLAELQEQLK AVHEQLAA.LSQPQQNKPKI KIEK DKK WO 2004/080148 PCT/US2003/030720 630 ____ _____TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence nKKKEKHKRKEEVEENKI{SKAKEPPPKK TKI(NNISSN S ItVSKKEPAPMKSKPFPTYESEEEDKCKPMSYEEKRQL SLDINKLPGEKLGRVVI-I IQSREPSLK1OTSNPDEIEID FETLKPSTLRELERYVTS CLRKKRKPQ/ASEKVaDVIA ________GSSIC4KGFSSSESESSSESSSSDSEDSETGPA 2160 A 108 440 MQATSNLLNLLLLSLFAGLNPSKTHINPKEGWQVYSS AQDPDGRGI CTVVAPEQI4LCSRDAKSRQLaRQLLEKVIQ ________NMSQSIEVLNLRTQRDFQYVLKMETQMKGLKAKFRQI 2161 A 18 467 REELGK DLFDCTLYVLIJKYIDDFNADKHLALEEFYRAE

QVIQLSLFEDQK

4 S ITAATVGQSAVLSCAIQGTJRPF I IWKRNNI ILNNLDLEDINDFGDDGSLYITKVTTTHV GNYTCYADGYBQVYQTHI FQVNVPPVIRVYPESQARR AG 2162 A 79 415 NFYQMIWTNGPAKLPASSTKHDLYLCNSFTGPSNIIW NLGSRYIFTVIKHGLGFFLNTILAVLNIAGRNLKCY( FC*TGWKLGWSIGPNHLI KELQTVQQNTIYIRRPSKG _____ XAQVRTRGS 2163 A 59 447 ITVDRNTETRTSSFSIISVPASST*GSPSRVIYAKLG GEILDYRDLAALPKSKAIYDIDRPDMISYSPYI SESA GDRQSYGES PQLLSPTPTEGDQDDRSYKQCRTS 6985 _____TGLVSLGRYTPTSRAFQH 2164 A 3 493 DPRVRFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVI TYILLCGFPPFRS PERDQDELFNI IQLGHFEFLFPYW DNI SDAAKDLVSRLLVVDPKKRYTA-QVLQHPWIETA G/EDQYSETTEAGVPQQRGSLPEPAQEGCGAGI IVTT ____ LGICPAPSSAQGQRKG 2165 A 3 493 DPRVRFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVI LYILLCGBPPFRS PERDQDELFNI IQLGHFEFLFPYW DNI SDAAKDLVSRLLVVDPKKRYTAHQVLQ-PWIETA G/EDQYSETTEAGVFQQRGSLPEPAQEGCGAGI IVTT LGICFAPSSAQGQRKG 2166 A 1334 470 SAAQLSI 4 CSRLQLTLYQYTTCPFCSGVRAFLJFHAL~P YQVVEVNPERRAET KFSSYRKVPTIJVAQEGESSQQLN

DSSVIISALKTYLVSGQP

1 EEI ITYYPAMKAVNEQGK EVTEFGNKYWLMLNEKEAQQVYGGKEARTEEMKWRQW ADDWLV-LI SPNVYRTPTEALASFDYIVREGKFGAVE GAVAKYMAAAYIISKRIJKSRHRLQDNVREDLYEAA DKWVAAVGKJRPFMGGQKPNLADLAVYGVLRVMEG-D _______AFDDLMQHTHIQPWYLRVERATEASPA4 2167 A 996 214 GRIRMQRQSTTGGRGIMEGPRGWJVLCVLAISLASMV TEDLCRAPDGKKGEAGRGRRGRGLKGEQGEPGAPG IRTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARG I PGIKGTKGSPGNIKDQPRPAFSAIRRNPPMGGNVVI FDTVITNQEEPYQNHSGRFVCTVFGYYYFTFQVLSQW EICLS IVSSSRGQVRRSLGFCDTTNKGLFQVVSGGMV LQLQQGDQVWVEKDPKK-GHIYQGSEADSVFSGFLI FP SA 2168 A 3 420 LRRFSTDCSSDQQDRLNGTAPSGFNRS*PVPLPHPIL EVCFGQ*EPQSAI SLTAFQVQAG.ASRASPGFPAPSSS ___________________________KPGRIKAKzVASPCPDRPAPPPT*~PRPAA.APGSESSPRP WO 2004/080148 PCT/US2003/030720 631 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue aid of peptide residu of sequence peptide sequence PRPRTGRRQQRAHARRAAARTAPWRPSC 2169 A 2744 496 ENEEQDSQNEGSTDEKSSPASSQEGSPSGDQQFSPKS NTEKSKGELMFDDSSDSSPEKQERNLNWTPAEVPQLA AAKRRLPQGKEPGLINLCANVPPVPGNILPPEVRC-NL MAAGQNLQSSERSEMIATWSPAVRTLRNITNNADIQQ MNRPSNVAHILQTLSAPTKNLEQQVNHSQQGHTNANA VLFSQVKVTPETHMLQQQQQAQQQQQQHPVLHLQPQQ IMQLQQQQQQQISQQPYPQQPPHPFSQQQQQQQQPPP SPQQHQLFGHDPAVEIPEEGFLLGCVFAIADYPEQMS DKQLLATWKRIIQAHGGTVDP\PSRVDARTFSVRVKS AAR/IAQAIRERKRCVTAHWLNTVLKKKKMVPPHRAL HFPVAFPPGGKPCSQHIISVTGFVDSDRDDLKLMAYL AGAKYTGYLCRSNTVLICKEPTGLKYEKAKEWRIPCV NAQWLGDILLGNFEALRQIQYSRYTAFSLQDPFAPTQ HLVLNLLDAWRVPLKVSAELLMSIRLPPKLKQNEVAN VQP\SSKRARIED\VPPPTKKLTP\ELTPF\VLFTGF EPVQVQQYI\KKLYILGGEVAESAQKCTHLIASKVTR TVKFLA\AISVVKHIVTPEWLEECFRCQKFIDEQNYI LRDAEAEVLFSFSLEESLKRAHVSPLFKAKYFYITPG \ICPSLSTMKAIVECAGGKVLSK\QPSFRKLMGAQAG TSSLFGK*F*LSC\ENDLHFIR\EYFARG\IDVHNAE F\VLTEVLTQTLDYESYKV 2170 A 2744 496 ENEEQDSQNEGSTDEKSSPASSQEGSPSGDQQFSPKS NTEKSKGELMFDDSSDSSPEKQERNLNWTPAEVPQLA AAKRRLPQGKEPGLINLCANVPPVPGNILPPEVRGNL MAAGQNLQSSERSEMIATWSPAVRTLRNITNNADIQQ MNRPSNVAHILQTLSAPTKNLEQQVNHSQQGHTNANA VLFSQVKVTPETHMLQQQQQAQQQQQQHPVLHLQPQQ IMQLQQQQQQQISQQPYPQQPPHPFSQQQQQQQQPPP SPQQHQLFGHDPAVEIPEEGFLLGCVFAIADYPEQMS DKQLLATWKRIIQAHGGTVDP\PSRVDARTFSVRVKS AAR/IAQAIRERKRCVTAHWLNTVLKKKKMVPPHRAL HFPVAFPPGGKPCSQHIISVTGFVDSDRDDLKLMAYL AGAKYTGYLCRSNTVLICKEPTGLKYEKAKEWRIPCV NAQWLGDILLGNFEALRQIQYSRYTAFSLQDPFAPTQ HLVLNLLDAWRVPLKVSAELLMSIRLPPKLKQNEVAN VQP\SSKRARIED\VPPPTKKLTP\ELTPF\VLFTGF EPVQVQQYI\KKLYILGGEVAESAQKCTHLIASKVTR TVKFLA\AISVVKHIVTPEWLEECFRCQKFIDEQNYI LRDAEAEVLFSFSLEESLKRAHVSPLFKAKYFYITPG \ICPSLSTMKAIVECAGGKVLSK\QPSFRKLMGAQAG TSSLFGK*F*LSC\ENDLHFIR\EYFARG\IDVHNAE F\VLTEVLTQTLDYESYKV 2171 A 3 581 GRRLRSEPRPARPPIARAWPPAPGADGRARRTRVPAP CLPRAPCYGVRPRAWRPRPARLRGGLVRWLLSGGPQP RRPRATERPSAGTGAAPRRTEPRGRCRGCGRGRG*GP RAWGLALCSPHSCSGAAWGPTTGSQRSWPAVARSWQG DSSRCPALRTTTVTAGSKAALPESAAEVSPMSSSPGR KRSGFAA 2172 A 70 993 SEQKIQEQGYVWITVFSALPTTVSALHPRILKPLSSL WO 2004/080148 PCT/US2003/030720 632 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide Sequence IHLQANSNPWECNCKLLGLRDWLASSAITLNIYWQNP PSMRGRALRYINITNCVTSSINVSRAWAVVKSPHIHH KTTALMMAWHKVTTNGSPLENTETENITFWERIPTSP AGRFFQENAFGNPLETTAVLPVQIQLTTSVTLNLEKN SALPNDAASMSGKTSLICTQEVEKLNEAFDILLAFFI LACVLIIFLIYKVVQFKQKLKASENSRENRLEYYSFY QSARYNVTASICNTSPNSLESPGLEQIRLHKQIVPEN EAQVILFEHSAL 2173 A 2 722 AVRLNISYPPQNLTMTVFQGDGTASTTLRNGSALSVL EGQSLHLVCAVDSNPPARLSWTWGSLTLSPSQSSNLG VLELPRVHVKDEGEFTCRAQNPLGSQHISLSLSLQNE YTGKMRPISGVMLGAFGGAGATALVFLSFCIIFVVVR SCRKKSARFAVGVGDTGMEDANAVRGSASQGPLIESP ADDSPPHHAPPALATPSPEEGEIQYASLSFHKARPQY PQEQEAIGYEYSEINIPK 2174 A 2043 1232 SHIQHHGRGAQAPVKMVSWMISRAVVLVFGMLYPAYY SYKAVKTKNVKEYVRWMMYWIVFALYTVIETVADQTV AWFPLYYELKIAFVIWLLSPYTKGASLIYRKFLHPLL SSKEREIDDYIVQAKERGYETMVNFGRQGLNLAATAA VTAAVKSQGAITERLRSFSMHDLTTIQGDEPVGQRPY QPLPEAKKKSKPAPSESAGYGIPLKDGDEKTDEEAEG PYSDNEMLTHKGPRRSQSMKSVKTTKGRKEVRYGSLK YKVKKRPQVYF 2175 A 1 790 RGYNPNVNAGIINSFATAAFRFGHTLINPILYRLNAT LGEISEGHLPFHKALFSPSRIIKEGGIDPVLRGLFGV AAKWRAPSYLLSPELTQRLFSAAYSAAVDSAATIIQR GRDHGIPPYVDFRVFCNLTSVKNFEDLQNEIKDSEIR QKLRKLYGSPGDIDLWPALMVEDLIPGTRVGPTLMC/ ML/STQFQRLRDGDRFWYENPGVFTPAQLTQLKQASL SRVLCDNGDSIQQVQADVF/RKRQEYPQDYLNCKRES PNVDPAKC 2176 A 1 790 RGYNPNVNAGIINSFATAAFRFGHTLINPILYRLNAT LGEISEGHLPFHKALFSPSRIIKEGGIDPVLRGLFGV AAKWRAPSYLLSPELTQRLFSAAYSAAVDSAATIIQR GRDHGIPPYVDFRVFCNLTSVKNFEDLQNEIKDSEIR QKLRKLYGSPGDIDLWPALMVEDLIPGTRVGPTLMC/ ML/STQFQRLRDGDRFWYENPGVFTPAQLTQLKQASL SRVLCDNGDSIQQVQADVF/RKRQEYPQDYLNCKRES PNVDPAKC 2177 A 1 790 RGYNPNVNAGIINSFATAAFRFGHTLINPILYRLNAT LGEISEGHLPFHKALFSPSRIIKEGGIDPVLRGLFGV AAKWRAPSYLLSPELTQRLFSAAYSAAVDSAATIIQR GRDHGIPPYVDFRVFCNLTSVKNFEDLQNEIKDSEIR QKLRKLYGSPGDIDLWPALMVEDLIPGTRVGPTLMC/ ML/STQFQRLRDGDRFWYENPGVFTPAQLTQLKQASL SRVLCDNGDSIQQVQADVF/RKRQEYPQDYLNCKRES PNVDPAKC 2178 A 501 187 AGVKWYEHGLWQPPPPGLKRSSHLSLPSS*DHRHEYP CPANF*KIFF\VETRSHYVAQTSLEFLDSSNPPTSAS

QI'AGI\*GMSHCAQPMQTFSLVKIGTNFLIF

WO 2004/080148 PCT/US2003/030720 633 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence 2179 A 4312 2359 AEKKMIjPVDGEERKSEGSDTEGDRTSPCAVSSLIVSN RYPRGGPYII\ATLKDLEVGGSGRRCSDPAGQPSNLL PQRGLGAPLPAETAHTQPSPNDRSLYLSPKSSSASSS LHARQSPCQEQAAVLNSRSIKISRLANDTIKSLKQQKK QVEHQLEEEKANNEKQKAERELEGQIQRLNIEKKKL NTDLYHMKHSLRYFEEESKDLAGRLQRSSQRIGELEW SLCAVAATQKKKPDGFSSRSKALLKRQLEQSIREQIL LKGHVTQLKESLKEVQLERDQYAEQIKGERAQWQQRM RKMSQEVCTLKEEKKHDTHRVEELERSLSRLKNQMAE PLPPDAPAVSSEVELQDLRKELERVAGELQAQVENNQ CISLLNRGQK\ERLREQEERLQEQQERLREREKRLQQ LAEPQSDLEELKHENKSALQLEQQVKELQEKLGQVME TLTSAEKEPEAAVPASGTGGESSGLMDLLEEKADLRE HVEKLELGFIQYRRERCHQNVHRLLTEPGDSAKDASP GGGHHQAGPGQGGEECEAAGAAGDGVAACGSYSEGHG KFLAAAQNPAAEPSPGAPAPQELGAADKHGDLCEASL TNSVEPAQGEAREGSSQDNPTA\QPIVQLLGEMQDHQ EHPGLGSNCCVPCFCWAWLPRRRR 2180 A 2 1273 GGALQCGDPLARSPAVPAPRVPAQPPPGLGRRASRKE AATLAMASPPACPSEEDESLKGCELYVQLHGIQQVLK DCIVHLCISKPERPMKFLREHFEKLEKEENRQILARQ KSNSQSDSHDEEVSPTPPNPVVKARRRRGGVSAEVYT EEDAVSYVRKVIPKDYKTMTALAKAISKNVLFAHLDD NERSDIFDAMFPVTHIAGETVIQQGNEGDNFYVVDQG EVDVYVNGEWVTNISEGGSFGELALIYGTPRAATVKA KTDLKLWGIDRDSYRRILMGSTLRKRKMYEEFLSKVS ILESLEKWERLTVADALEPVQFEDGEKIVVQGEPGDD FYIITEGTASVLQRRSPNEEYVEVGRLGPSDYFGEIA LLLNRPRAATVVARGPLKCVKLDRPRFERVLGPCSEI LKRNIQRYNSFISLTV 2181 A 1 303 PTRPLERGPSGLGMGLIDGMHTHLGAPGLYIQTLLPG SPAAADGRLSLGDRILEVNGSSLLGLGYLRAVDLIRH CGKKMRFLVAKSDVETAKKIHFRTPPL 2182 A 2227 332 MGKYTVRVATGDLLLAGSPNLVQLWLVGEHGEADLGK QLPPVWGKEAEFEIDVPLHLGRLLMVKLRKHNVLLSL DWFCKWISVQGPGTQGAAFFPCYRWVQGHGIICLPEG T/RWGSWKDGLILPIAGNRQPDLPRDERFLEDKDLDF NVSLAKGLKDLAIKGTLDFINCVKRLEDFKKIFPHGK TVLAERVYDSWKNDAFFGYQFLNGANPMLLRCSSRLP ACLVLPPGMEDLKTQLEKELQAGSLFEVDFSLLDGVK PNVIIFKQQCVAAPLVVLKLQPDGGLLPMVIQLQPP* HGCPPPLLFLPSHPPMAWLLAKTWVRSSDFQLQQLQS HLLRGHLIAEVIAVATMRSLPSLHPIYKLLIPHFRYT MAINTLAQSSLVSEWGIFDLVVSTGSGSHVDILQRAM ACLTYHSLCPPDDLADRGLLDVKSSFYG*DAIRLWGI ISRE*\YVEGMVGLFYNSDQAMKDDLELQAWCREMTE TGLQRAQDQGFLISLESRAQLCHFVTMCIFTCTGQHA SNHLGQLDWYSWIPNGPCTMQKPPPISKDVTEKDIVD LLPNLHQARMQKTFTKFLGRRQPVMHEEKYFSGPEPQ

AVLRQFQEELASMDKEIEVRNAVLNLPCEYL"*PSMVE

WO 2004/080148 PCT/US2003/030720 634 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence I \NSVTI 2183 A 2227 332 MGKYTVRVATGDLLLAGSPNLVQLWLVGEHGEADLGK QLPPVWGKEAEFEIDVPLHLGRLLMVKLRKHNVLLSL DWFCKWISVQGPGTQGAAFFPCYRWVQGHGIICLPEG T/RWGSWKDGLILPIAGNRQPDLPRDERFLEDKDLDF NVSLAKGLIDLAIKGTLDFINCVKRLEDFKKI FPHGK TVLAERVYDSWKNDAFFGYQFLNGANPMLLRCSSRLP ACLVLPPGMEDLKTQLEIKELQAGSLFEVDFSLLDGVK PNVIIFKQQCVAAPLVVJLKLQPDGGLLPMVIQLQPP* HGCPPPLLFLPSHPPMAWLLAKTWVRSSDFQLQQLQS HLLRGHLIAEVIAVATMRSLPSLHPIYKLLIPHFRYT MAINTLAQSSLVSEWGIFDLVVSTGSGSHVDILQRAM ACLTYHSLCPPDDLADRGLLDVKSSFYG*DAIRLWGI ISRE*\YVEGMVGLFYNSDQAMKDDLELQAWCREMTE TGLQRAQDQGFLISLESRAQLCHFVTMCIFTCTGQHA SNHLGQLDWYSWIPNGPCTMQKPPPISKDVTEKDIVD LLPNLHQARMQKTFTKFLGRRQPVMHEEKYFSGPEPQ AVLRQFQEELASMDKEIEVRNAVLNLPCEYL*PSMVE \NSVTI 2184 A 2227 332 MGKYTVRVATGDLLLAGSPNLVQLWLVGEHGEADLGK QLPPVWGKEAEFEIDVPLHLGRLLMVKLRKHNVLLSL DWFCKWISVQGPGTQGAAFFPCYRWVQGHGIICLPEG T/RWGSWKDGLILPIAGNRQPDLPRDERFLEDKDLDF NVSLAKGLKDLAIKGTLDFINCVKRLEDFKKIFPHGK TVLAERVYDSWKNDAFFGYQFLNGANPMLLRCSSRLP ACLVLPPGMEDLKTQLEKELQAGSLFEVDFSLLDGVK PNVIIFKQQCVAAPLVVLKLQPDGGLLPMVIQLQPP* HGCPPPLLFLPSHPPMAWLLAKTWVRSSDFQLQQLQS HLLRGHLIAEVIAVATMRSLPSLHPIYKLLIPHFRYT MAINTLAQSSLVSEWGIFDLVVSTGSGSHVDILQRAM ACLTYHSLCPPDDLADRGLLDVKSSFYG*DAIRLWGI ISRE*\YVEGMVGLFYNSDQAMKDDLELQAWCREMTE TGLQRAQDQGFLISLESRAQLCHFVTMCIFTCTGQHA SNHLGQLDWYSWIPNGPCTMQKPPPISKDVTEKDIVD LLPNLHQARMQKTFTKFLGRRQPVMHEEKYFSGPEPQ AVLRQFQEELASMDKEIEVRNAVLNLPCEYL*PSMVE \NSVTI 2185 B 1 1110 MGLLICLGALDARPERAPSACGEVWRERRGREPGLPT VLAGQREFWVGVGSAALHSERPAGPTTPGSKGLSTQV SSCGGRTGSPSSASPLALRSISRWGLSHLPHGAGLRT CSPAMPKPPHSAVGSCATRASLISTAPRSRAPGPIDH PRAETCQRTVQELAGSSTCSPVQDPLGEASWAPEFEG SGPKRRANGRGAYGLRDTGVHSSGVAARSPAAAERWV QGFPKQNVHFVNDNTICYPCGNYVIFINIETKKKTVL QCSNGIVGVMATNIPCEVVAFSDRKLKPLIYVYSFPG LTRRTKLKADQERDPFLYLFQVAEFLTQGCLQISAFS PTSQRYQALLGQMWDLIRGHRFSVEKSVETSSSCSA 2186 A 22 960 ARPGPDMAALYACTKCHQRFPFEALSQGQQLCKECRI AHPVVKCTYCRTEYQQESKTNTICKKCAQNVQLYGTP KPCQYCNII-IAAFIGN KCQRCTNSEKKYGPPYSCEQCK WO 2004/080148 PCT/US2003/030720 635 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence QQCAFDRKEDDRKK VDGKLI 4 CWLCTLSYKRVILQKTK EQ RKHLSSSSRAGHQEKBQYSRLSGGGHYNSQKTLSTSS IQNEI PKKKSKFESITTNCDSFSPDLALDSPGTDHFV I IAQLKEEVATLKI<CMLHQK,'DQMILEKEKKI TELKADF QYQESQMRAKMNQMETHKVTEQLQAKNTRELLKQAA AILSKSKKSFKSGAITSP 2187 A 612 812 RSGRTVVTGIGYSKALQSSNRNTKSLLQNEFMMVYSF RALSFKESTWATFQICGEATKSRSLSSTQ 2188 A 612 812 RSGRTVVTGIC-YSKALQSSNRNTKSLLQNEFMMVYSF RALSFKESTWATFQ-GGEATKSRSIJSSTQ 2189 A 612 812 RSGRTVVTGIGYSKALQSSNRNTKSLLQNEFMMVYSF RATSFKESTWATFQHGGEATKSRSLSSTQ 2190 A 612 812 RSGRTVVTGIGYSKALQSSNRNTKSLLQNEF4NVYSF RALSFKESTWATFQHGGEATKSRSIS STQ 2191 A 612 812 RSGRTVVTGTGYSKALQSSNRNTKSLLQNEFMMVYSF RALSFIESTWATFQHGFATKSRSLSSTQ 2192 A 936 745 RRNSPGLCFLLPSLFHLRLLWRL-LWHQVFFDVATFV 1001 CSVSGFVRSIJEGLIEAYRTNAED 2193 A 122 643 MPSGCRCTLHLVCLLCIL0APGQPVRADECSSHCDLAN 0CCAPDGSCRCDPGWEGTJHCERCVRMPGCQHGTCHQP WQCI CHSGWAGKFCDKDEHICTTQSPCQNGGQCMYDG 0GEYHCVCLP0FH0RDCERKAGPCEQAGSPCRN00QC QDDQGFALNFTCRCLVGFVGARCDV* 2194 A 1 1406 NVVSRAFPAPVEDLSKVSYEEIJLQWSKSELIRSLRRA EAEKVSAMLDI-SNLIREVNRRLQLHLGEIRGLKDINQ KLQEDNQELRDLCCFLDDDRQKGKRVSREWQRLGRYT A0VMHKEVALYLQKLKDLEVKQEEVVKBND4EI/ KELC VLLDEEKGAG\SQAAAAPSTARPACANSQF/PTAPYV RDVGDGSSTSSTGSTDSPDHKUHASSGS FEI-LQKPR SF05 PEHSK}{RSASPEHPQKPRACGTPDRPKALKGPS FEHHKFLCKGS PEQQRHFHFGSS PETLPKHVLSGSPE HFQKHRSGS SPEHARI4SGGSPEHLQKHALOGSLEHLP EAROTS PEHLKQRYOGSPD-KHGGGSGGSGGSGGGSR EGTLRRQAQEDGSPFHH-RNVYSGMNESTLSYVRQLEAR VRQLEEENRMLPQASQNTGRFPTKNSSHMFKGW0SRA __________RRVIJHWWQGCRGI GRCLATLTGSFRWSS 2195 A 1461 197 GVTuLFLFGKRKLRNGIAEDLKGQADFFFLLVSEAVV ATOS PRAWLTCLILPLPGT IFSVLPKANSRPLLITFT FATDPSDLWKDGQQQPQPEKPESTLDGAAARAFYEAL IGDFSSAPDSQRSQTEPARERKRKKRRIMKAPAAEAV AFOASGRHGQ0RSLEAEDKMTHRILRAAQEGDLPELR RLLEPUEAG0A0GNINARDAFNWTPLMCAARAGQGAA VSYLLGR0AAWkVVGVCELS0RDAAQLAEEAOFFEVARM VRES-GETRS PENRS PTPSLQYCENCDTHFQDSNHRT STAULLSLSQGPQPNLPJOVPI SSPGFKLLLiRG0WE PGMGLGPRGEGRANFI PTVLKRDQEGLGYRSAFQPRV TI-FPAWDTAVAGRE\TPPRVATIJSWREERRREE\ IZ RAWERDLRTYMNLEF 216A10 768 SFAGAAARFSTPPASGRGAAFGRPGPSPMDLRAGDSW GMLACLCTVLW-LPAVPALNRTGDPGPGPS

IQKTYDL

WO 2004/080148 PCT/US2003/030720 636 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Lnknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible ncleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide reiuence TRYLEHIQLRSLAGTYLNYLGPPFNEPDFNPPRLGAET LPRATVDLEVWRSLNDKLRLTQNYEAYSHLLCYLRGL NRQAATAELRRSLAHFCTSLQGLLGSIAGVMAALGYP LPQPLPGTEPTWTPGPAHSDFLQKMDDFWLLKELQTW LWRSAKDFNRLKKKMQPPAAAVTLHLGAHGF 2197 A 1 1054 PPIARLQEFGTSRRHMAAPSGVHLLVRRGSHRIFSSP LNHIYLHKQSSSQQRRNFFFRRQRDISHSIVLPAAVS SAHPVPKHIKKPDYVTTGIVPDWGDSIEVKNEDQIQG LHQACQLARHVLLLAGKSLKVDMTTEEIDALVHREII SHNAYPSPLGYGGFPKSVCTSVNNVLCHGIPDSRPLQ DGDIINIDVTVYYNGYHGDTSETFLVGNVDECGKKLV EVARRCRDEAIAACRAGAPFSVIGNTISHITHQNGFQ VCPHFVGHGIGSYFHGHPEIWHHANDSDLPMEEGMAF TIEPIITEGSPEFKVLEDAWTVVSLD/TSKVSAQFEH TVLITSRGAQILTKLPHEA 2198 A 2319 957 SPGTPAAGRTSRTVQTPF*SRTPLALMIGSENWPGLQ /FPAKWAP*ANHLTFAGLTPNHSGTK\WAGISGTRLS LPGAGAAAPEVPRRCRRHCPECLQPAGNAAPEQSGGC RLAFL*ARSTSSRARGLLGSEVRRPGVAGSQRAKLLT P*LPFLLGVSSPSPKSGSRTAAMHQPRLSSPIQRRRK CSGEREASHYEPALSKAVRSVGGSPKSASGDAGRARS \SRAPNSESSNMAARLAIEREEKAGD*QAARRRRGPP PPFTSGI*SRLPEAGTMSA*QPTLEFGG/SLP*SKGN SSHSKELEASPSVVGRQPGAV\SGNCGMCPWGPEKTE GRCSRPVTTAWCSLCSSCCCPMTSLSIPSQNCSKRLL SSSLCSSSSRILQSSSTSSSFSSCSSTPSSSRLAWST SYSISSKGPSS*QLCTLPSASPFMSGS*TYAGKTPTA SYGQMDFKCCLYSRD 2199 A 1 3349 MDQPEAPCSSTGPRLAVARELLLAALEELSQEQLKRF RHKLRDVGPDGRSIPWGRLERADAVDLAEQLAQFYGP EPALEVARKTLKRADARDVAAQLQERRLQRLGLGSGT LLSVSEYKKKYREHVLQLHARVKERNARSVKITKRFT KLLIAPESAAPEEALGPAEEPEPGRARRSDTHTFNRL FRRDEEGRRPLTVVLQGPAGIGKTMAAKKILYDWAAG KLYQGQVDFAFFMPCGELLERPGTRSLADLILDQCPD RGAPVPQMLAQPQRLLFILDGADELPALGGPEAAPCT DPFEAASGARVLGGLLSKALLPTALLLVTTRAAAPGR LQGRLCSPQCAEVRGFSDKDKKKYFYKFFRDERRAER AYRFVKENETLFALCFVPFVCWIVCTVLRQQLELGRD LSRTSKTTTSVYLLFITSVLSSAPVADGPRLQGDLRN LCRLAREGVLGRRAQFAEKELEQLELRGSKVQTLFLS KKELPGVLETEVTYQFIDQSFQEFLAALSYLLEDGGV PRTAAGGVGTLLRGDAQPHSHLVLTTRFLFGLLSAER MRDIERHFGCMVSERVKQEALRWVQGQGQGCPGVAPE VTEGAKGLEDTEEPEEEEEGEEPNYPLELLYCLYETQ EDAFVRQALCRFPELALQRVRFCRMDVAVLSYCVRCC PAGQALRLISCRLVAAQEKKKKSLGKRLQAR\LGGGS WLGTQLAPEVPFRPPCCDICPTPPPDPRLLQGKAFAR VPLNIAPIQPLPRGLASVERMNVTVLAGAGPGDPKTH

AMTDPLCHLSSLTLSHCKLPDAVCRDLSEALRAAPAL

WO 2004/080148 PCT/US2003/030720 637 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence TELGLLHNRLSEAGkCLiRMLSEGLAWPQCRVQTVRVQLP DPQRGLQYL-VGMLRQS PALTTLDLSGCQLPAPMVTYL CAVLQFHQGCGLQTLSLSLPSDPTPS SFSGRCRE PGRP. LGLESRWPRSAPEPSGRQRGEDPGGGRGRGRREEAR EGTPGPRAPPTAAPGRSSGSRLELCSLRALP-AGNARP PDATHAA AASGDRGEPGPR-PRVHVPPPGPAQRPPPPP RDRPRLPATARALGAGTADLPGGAAAGRLLLPPGPGV EQRDTGSHAGARRPGGAAA-AQAQQLHGGRRRGPHHVC _____CPLSAQ 2200 A 877 446 GIRCRFGTSEIRAHATAKATiAAFTASEGAHPRVVE LPKTDEGLGFNIMGGKEQNSPIYI SRVI PGGVADRHG GLKRGDQLLSVNGVSVEGEQHEKAVELLKAAQGSVKL VVRYTPRVLEEMRFEKMRSARRRQQH-QSYS 2201 A 48 474 SCLARPFRAQVSSSGFRAQNFPGVGSWAVAVAGMAQ LEGYCFSAALSCTFJ3VSCLLFSAFSRALREP\YMDEI FHLPQAQRYCEGHFSLSQWDPMITTLPGLYLVSVGVV KPAIWI FGWSBHVVCSIGMLRFVNLLFSVGNF 2202 A 3140 1502 FRRLHSVPRGSALCAMDGIVPDIAVGTKRGSDELFST CVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSR VIHIRKLPIDVTEGEVI SLGLPFGKVTNLLMLKGKNQ AFIEMNTEEA2ANTMVNYYTSVTPVLRGQPIYIQFSNH KELKTDS SPNQARAQAALQAVNSVQSGNLALAASAAA VDAGMAMAGQS PVLRI IVENLFYPVTLDVLUQI FSKF GTVLKI ITFTKNNQFQALLQYADPVSAQHAKLSLDGQ NIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLP SGDSQPSLDQTMAAAFGLSVPNVNGALAPLAI PSAAA AAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLF ILFGVYGDVQPVKILFNKKENALVQMADGNQAQLAMS HLNGHKLHGKPIRITLSKHQNVQLPREGQEDQGLTKD YGNSPLHRFKKPGSKNFQNI FPPSATUILSNI PPSVS EEDLKVLFS SNGGVVKGFKFFQKDRKMALIQMGSVEE AVQALIDLhHNHDLG3ENHHLRVSFSKSTI 2203 A 2240 506 RRPPEGGSGGGRRTRARMPLPWSLALPLLLSWVAGGF GNAASARHHGLLASARQPGVCHYGTKLACCYGWRRNS KGVCEATCEPGCKFGECVGPNKCRCFPGYTGKTCSQD VNECGMKPRPCQH-RCVNTHGSYKCFCLSGHMLMPDAT CVNSRTCAMINCQYSCEDTEEGPQCLCPSSGLRLAPN GRDCLDIDECASGKVICPYNRRCVNTFGSYYCKCHIG FELQYI SGRYDCIDINECTMDSHTCSHHANCFNTQGS FKCKCKQGYKGNGLRCSAI PENSVKEVLRAPGTIKDR I KKLLAHKN6MXKKAKIKNVTPEPTRTPTPKVNLQPF NYEEIVSRGGNSHGG\ KKGNEEKMKEGLEDEKREEKA LK D*HRPRERPFRG\DVFFPKVNEAGEFGLIL\VQRKA LTSKLEHKADLTI SVDCS FNHG\ ICDW\KQDR\EDDF DW\NPADR\DNAI \GFY\MAVPGLWQGHK\KDIGRLK LLLPDLQPQSNFCLLFDYRLAGDKVGKLRVFVKCNSNN ALAWqEKTTSEDEKWKTGKIQLYQGTDATKSI IFEAER GKGKTGEIAVDGVLLVSGLCPDSLLSVIDD 2204 JA 2240 506 RRPPEGGSGGGRRTPARMPLPWSLALPLLLSWAG _____ ________________GNAASARHHGLLASARQPG-VCHYGTK LACCYGRN WO 2004/080148 PCT/US2003/030720 638 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence pepticoe sequence KGVCEATCEPGCKFGECVGPNKCRCFPGYTGKTCSQD VNECGMKPRPCQHRCVNTHGSYKCFCLSGHMLMPDAT CVNSRTCAMINCQYSCEDTEEGPQCLCPSSGLRLAPN GRDCLDIDECASGKVICPYNRRCVNTFGSYYCKCHIG FELQYISGRYDCIDINECTMDSHTCSHHANCFNTQGS FKCKCKQGYKGNGLRCSAIPENSVKEVLRAPGTI KDR IKKLLAHKNSMKKKAKIINVTPEPTRTPTPKVNLQPF NYEEIVSRGGNSHGG\KKGNEEKMKEGLEDEKREEKA LKD*HRRERPFRG\DVFFPKVNEAGEFGLIL\VQRKA LTSKLEHKADLNISVDCSFNHG\ICDW\KQDR\EDDF DW\NPADR\DNAI\GFY\MAVPGLWQGHK\KDIGRLK LLLPDLQPQSNFCLLFDYRLAGDKVGKLRVFVKNSNN ALAWEKTTSEDEKWKTGKIQLYQGTDATKSIIFEAER GKGKTGEIAVDGVLLVSGLCPDSLLSVDD 2205 A 2814 346 VKKTKSIFNSAMQEMEVYVENIRRKFGVFNYSPFRTP YTPNSQYQMLLDPTNPSAGTAKIDKQEKVKLNFDMTA SPKILMSKPVLSGGTGRRISLSDMPRSPMSTNSSVHT GSDVEQDAEKKATSSHFSASEESMDFLDKSTASPAST KTGQAGSLSGSPKPFSPQLSAPITTKTDKTSTTGSIL NLNLDRSKAEMDLKELSESVQQQSTPVPLISPKRQIR SRFQLNLDKTIESCKAQLGINEISEDVYTAVEHSDSE DSEKSDSSDSEYISDDEQKS*GTSQEDTEDKEGCQMD KEPSAVKKKPKPTNPVEIKEELKSTSPASEKADPGAV KDKASPEPEKDFSGKAKPSPHPIKDKLKGKDETDSPT VHLGLDSDSE\NELVIDLGEDHSGREGRKNKKEPKEP SPKQDVVGKTPPSTTVGSHSPPETPVLTRSSAQTSAA GATATTSTSSTVTVTAPAPAATGSPVKKQRPLLPKE\ TAPAVQRSCGTSSTVQQKEITQSPSTSTITLVTSTQS SPLVTSSGSMSTLVSSVNGDLPIGTASADVAADIAKY TSKL\MDAIKGTM\TEIYNDLSKN\TTWKAQLAEDSQ GLRIEIEKLQWLHQQEL\SEMKHNLELTMAEMRQSWE QERDRLIAEVKKQLELEKQQAVDETKKKQWCANFKKE AIFYCCWNTSYCDYPCQ\QAHWPEH\MKSCTQSATAP Q\QEADAE\VNTETLNKSSQGSSSSTQSAPSETASA\ SKEKETSAEKSKESGSTLDLSCSRETPSSILLGSNQG SDHSR\SNKSSWSSSDEKRGS\TRSDHN/TPSTQHGR SLLPGKESRAGTPFLGTSK 2206 A 2814 346 VKKTKSIFNSAMQEMEVYVENIRRKFGVFNYSPFRTP YTPNSQYQMLLDPTNPSAGTAKIDKQEKVKLNFDMTA SPKILMSKPVLSGGTGRRISLSDMPRSPMSTNSSVHT GSDVEQDAEKKATSSHFSASEESMDFLDKSTASPAST KTGQAGSLSGSPKPFSPQLSAPITTKTDKTSTTGSIL NLNLDRSKAEMDLKELSESVQQQSTPVPLISPKRQIR SRFQLNLDKTIESCKAQLGINEISEDVYTAVEHSDSE DSEKSDSSDSEYISDDEQKS*GTSQEDTEDKEGCQMD KEPSAVKKKPKPTNPVEIKEELKSTSPASEKADPGAV KDKASPEPEKDFSGKAKPSPHPIKDKLKGKDETDSPT VHLGLDSDSE\NELVIDLGEDHSGREGRKNKKEPKEP SPKQDVVGKTPPSTTVGSHSPPETPVLTRSSAQTSAA

GATATTSTSSTVTVTAPAPAATGSP-VKKQRPLLPKE\

WO 2004/080148 PCT/US2003/030720 639 ____ _____TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide dcletion,=possible nucleotide nucleotide nucotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence TAPAVQRSCGTSSTVQQKEITQSPSTSTITLVTSTQS SPLVTSSGSMSTLVSSVNGDLPIGTASADVAADIAKY TSKL\MDAIKGTM\TEIYNDLSKN\TTWKAQLAEDSQ GLRIEIEKLQWLHQQEL\SEMKHNLELTMAEMRQSWE QERDRLIAEVKKQLELEKQQAVDETKKKQWCANFKKE AIFYCCWNTSYCDYPCQ\QAHWPEH\MKSCTQSATAP Q\QEADAE\VNTETLNKSSQGSSSSTQSAPSETASA\ SKEKETSAEKSKESGSTLDLSGSRETPSSILLGSNQG SDHSR\SNKSSWSSSDEKRGS\TRSDHN/TPSTQHGR SLLPGKESRAGTPFLGTSK 2207 A 2814 346 VKKTKSIFNSAMQEMEVYVENIRRKFGVFNYSPFRTP YTPNSQYQMLLDPTNPSAGTAKIDKQEKVKLNFDMTA SPKILMSKPVLSGGTGRRISLSDMPRSPMSTNSSVHT GSDVEQDAEKKATSSHFSASEESMDFLDKSTASPAST KTGQAGSLSGSPKPFSPQLSAPITTKTDKTSTTGSIL NLNLDRSKAEMDLKELSESVQQQSTPVPLISPKRQIR SRFQLNLDKTIESCKAQLGINEISEDVYTAVEHSDSE DSEKSDSSDSEYISDDEQKS*GTSQEDTEDKEGCQMD KEPSAVKKKPKPTNPVEIKEELKSTSPASEKADPGAV KDKASPEPEKDFSGKAkPSPHPIKDKLKGKDETDSPT VHLGLDSDSE\NELVIDLGEDHSGREGRKNKKEPKEP SPKQDVVGKTPPSTTVGSHSPPETPVLTRSSAQTSAA GATATTSTSSTVTVTAPAPAATGSPVKKQRPLLPKE\ TAPAVQRSCGTSSTVQQKEITQSPSTSTITLVTSTQS SPLVTSSGSMSTLVSSVNGDLPIGTASADVAADIAKY TSKL\MDAIKGTM\TEIYNDLSKN\TTWKAQLAEDSQ GLRIEIEKLQWLHQQEL\SEMKHNLELTMAEMRQSWE QERDRLIAEVKKQLELEKQQAVDETKKKQWCANFKKE AIFYCCWNTSYCDYPCQ\QAHWPEH\MKSCTQSATAP Q\QEADAE\VNTETLNKSSQGSSSSTQSAPSETASA\ SKEKETSAEKSKESGSTLDLSGSRETPSSILLGSNQG SDHSR\SNKSSWSSSDEKRGS\TRSDHN/TPSTQHGR SLLPGKESRAGTPFLGTSK 2208 A 2814 346 VKKTKSIFNSAMQEMEVYVENIRRKFGVFNYSPFRTP YTPNSQYQMLLDPTNPSAGTAKIDKQEKVKLNFDMTA SPKILMSKPVLSGGTGRRISLSDMPRSPMSTNSSVHT GSDVEQDAEKKATSSHFSASEESMDFLDKSTASPAST KTGQAGSLSGSPKPFSPQLSAPITTKTDKTSTTGSIL NLNLDRSKAEMDLKELSESVQQQSTPVPLISPKRQIR SRFQLNLDKTIESCKAQLGINEISEDVYTAVEHSDSE DSEKSDSSDSEYISDDEQKS*GTSQEDTEDKEGCQMD KEPSAVKKKPKPTNPVEIKEELKSTSPASEKADPGAV KDKASPEPEKDFSGIAKPSPHPIKDKLKGKDETDSPT VHLGLDSDSE\NELVIDLGEDHSREGRKNKKEPKEP SPKQDVVGKTPPSTTVGSHSPPETPVLTRSSAQTSAA GATATTSTSSTVTVTAPAPAATGSPVKKQRPLLPKE\ TAPAVQRSCGTSSTVQQKEITQSPSTSTITLVTSTQS SPLVTSSGSMSTLVSSVNGDLPIGTASADVAADIAKY TSKL\MDAIKGTM\TEIYNDLSKN\TTWKAQLAEDSQ

GLRIEIEKLQWLHQQEL\SEMKHNLELTMAEMRQSWE

WO 2004/080148 PCT/US2003/030720 640 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide reidue of sequence peptide sequence QERDRLIAEVKKQLELEKQQALETKKKQWCANFKKE Al FYCCWNTSYCDYPCQ\QARWPE3AMKSCTQSATAP Q\QEADAE\VNTETLNKSSQGSS SSTQSAPSETASA\ SKEKETSAEKSKESGSTLDLSGSRETPS SILLGSNQG SDI-SR\SNKSSWSSSDEKRGS \TRSDHN/ TPSTQHGR ________SLLPGKESRAGTPFLGTSK 2209 A 1 575 GGTPHYLRGVNNARQPWENADVRLRYGLRPGNATEEG LASLUSVLFRKQPFLWRAALLYYTIHRAARMSFRQLF QDLERYVQDAIDVRWEYCVRAKRGQTDTSLP)GCFSRDQ VYLjDGIVRI LRHRQTIDFPIJJTSLGKVSYEDVDHLRP HGVLDNTRVPHFMQDLARYRQQLEHIMATNRLDEAEL GRTJLPE 2210 A 3 1795 LGilGSGTLLSVSEYKKKYREHVLQLHARVKERNARSV KITKRFTKLLIAPESAAPEEALGPABEPEPGRARRSD THTFNRLFRRDEEGRRFLTVVLQGPAGIGKTMAAKKI LYDWAAGKLYQGQVDFAFFMPCGELLERPGTRSLADL ILDQCPDRGAPVPQMLAQPQRLLFILDGADELPALGG FEAAFCTDPFEAASGARVLGGLLSKALLPTALLLVTT RAAAPGRLQGRLCS PQCAEVRGFSDKDKKKYFYKEFR DERRAERAYRFVKENETLFALCFVPFVCWIVCTVLRQ QLELGRDLSRTSKTTTSVYLLITSVJSSAPVADGPR LQGDLRNLCRLAREGVLGRRAQFAEKELEQLELRGSK VQTLFLSKKELPGVLETEVTYQFIDQSFQEFLAALSY LLEDGGVPRTAAGGVGTLLRGDAQPHSHLVLTTRFLF GLLSAERMRDIERHFGCMVSERVKIQEALRWVQGQGQG CPGVAPEVTEGAKGLEDTEEPEEEEEGEEFNYPLELL YCLYETQEDAFVRQALCRFFELALQRVRFCRMDVAVL SYCVRCCPAGQALRLI SCRLVAAQEKKKKSLGKRLQA SLGO 2211 A 2 1177 GFVEAGEECYCVS\GQECRLCCFAH-NCSLRFGAQCA HGDCCVRCLLKPAGALCRQZ MGDCDLPEFCTGTSSHC PPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGP GSHPAPEACFQVVNSAGDAHGNCGQDSEGH-FLPCAGR DALCCKLQCQGGKPSLLAPHMVPVDSTV-LDGQBVTC RGALALFSAQLDLLGLGLVEPGTQCGFRMVCQSRRCR KNAFQELQRCLTACHSHGVCNSNHNCHCAPGWAPPFC DKPGFGGSMDSGPVQAENHTTJLAMLLSVLLPLLPG AGLAWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHR DHFLGGVHPMELGPTATGQPWPLDPENSHEPSSHPEK PLFAVSPDPQADQVQMPRSCLW 2212 A 1073 480 XXPDALSTVAEXPGRPTRPPTRTAAPWPRPGCSSASA PPTPASAPWFASPSS SSGRWSTDSRGPRPWEGSQGCW HCGSW*RT* CTCKIIGGPGSRC-CAASSSWASSSRPSF SLPSAPSSCWPSPGIRASQTPFATTSFASGASFPSSG PSCSASMPTATGLTLLTSASSAISDPGGSVYA* SGMV ______ ________ I-QSGKEPSTVYTS 2213 A 1 2454 MALQNALYTGDIJARLQETJFPPHSTADLLLESRAAEPR WSSHQRACPIAYTLAQEHSHEVEPRIAFAGCVARLVEK PSRGSEEIHLKSGPGPIVTRTASGPALAFWQAVLAGDV

GCVSRILADSSTGLAPDSVFDTSDPERWRDFRFNIRA

WO 2004/080148 PCT/US2003/030720 641 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XUnknown, *=Stop codon, ID beginning ending I=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence L RLWSITYEEELTTPLHVAASRCHTEVLRLLLRRRAR PD)SAPCGRTALHEACAAGETACVHVLLVAGADPNIAD QDGKRFLHLCRGPGTLECAELLLRFGARVDGRSEEEE ETPLHVAARTGHVELADLTJTRRGACPDARNAEGWTPL LAACDVRCQSITDAEAkTTARCLQLCSLLLSAGADADA ADQEKQRPLHLACRRGHAAVVELLLSCGVSANTMDYG GHTPLHCALQGFAAALAQS PEHVVRALLNHGAVRVWF CALKVLERWSTCPRTIEVLMNTYSVFVQLPEEAVGLV TPETLQKHQRFYSSLFALVRQPRSLQNLSRCALRSHL EGSLPQALFRLPLPPRLLRYLQLDFEGVSFGICEQSQ LLGVQCCVEGKRRVGEGPSQNRPVPEPPEASSSKPLL PDVHGLLRGPESRCFSLQRARLCTNSGQVALAAGGFA PQAGVDAAI PNAEKRTDSGSRPPQGLLRSGTA-GGKD CPPGPHQVRLAGSRSAAHRRKRQLCAAATRGHPRPGP TLPTMRGLSLANEWIGASFAGRLTNTFCAGLGQAVFS MVALTTALPSFAEPPDAFYGPQELAAAAAAAAATAAR NNPEPCCRRPBGGLEADELLFAREKVAEPFPPPPPHF SETFPSLFGVD)KLQGWDFRGHQDGCD4LKQLS IQQWRA RSGF 2214 A 757 208 NVFIEPRIQGFMKTSAHGQKHPDFSMGLLFP LAAL EVCSCCSSGSLGYNLPQN-\GLLGRNTLVLLGQMRRI SPFLCLKDRSDFRFPQEKVEVSQLQKA\QAMSFLYDV LQQVFNFS-KALL\ CCMEI-DLPGPTPHFTSSAAGTPG DLLGAGDGRRRSWGQWVIEGSTLALRRYFQESI STLB 2215 A 43 1004 QLWGFAAGSDSRPAMGCDGGTTPKRHELVKGPKKVEK VDKDAELVAQWINYCTLSQE ILRRPIVACELGRLYNKD AVIEFLLDKSAEKALGKAASIIKS IKNVTELKLSDNF AWEGDKGNTKGDKI{DDLQRARFI CFVVGLEMNGR-RF CFIJRCCGCVFSERALKEI KAEVCHTCGAAFQEDDVIV LNGTKEDVDVLKTRMEERRLRAKLEKKTKKPKAAESV SKPDVSEEAPGPSKVKTGKPEEASLDSREKKTNLAPK STANNESSSGKAGKPPCGATKRS IADSEESEAYKSLF TTHS SAKRSKEESAHWVT-TSYCF 2216 A 1323 840 FCPLGKPVMGPIFLDCRFFFLFPKPNQGTGTPLNNKV PYFFQ*GPFGPLWNHRTLFFFLRWSFALLAQAGVQWR DLGSLQFLPPGFK* FSCLSLPSIWDYRRLFPCPANFA FLVETGFLHVGQVGL*LLTSGDPSASASQSSGITG\V SHHTWP*LSFLLWI 2217 A 17 348 A RAAARAGFSSYLKSLPDVRKKSLFLPEKFHKEENSE IVVWREFDKQVFLLN* SPRRQSKLYTVDLESGL-YLL RVELAAH-KSLAGAELKTLKDPVTVLAKLFPGRPPVK 2218 A 1 1206 MALSSWPVVLRLNMADFVFSFLCLGIGTSIVLGILFY LLQAHRYLQEGMTYQLALSFYL~TWASVFLFLMTGMGE DEESALQTLLEPRSSYLLVSLEILFTNPSFLSPCAVS EDESEMRGLSLLRRQSQATGRLEPTFKH-DSTLLALQG ALGLYDGHTPPYAACLGFEFRKHLGNPAKDSGNVTVS LFYRNESAI{LFLFLSLPGCPAPCPLGRFYQLTAPARF PAHGVSCI-GPYEAVIPPGPCAII PSTGPAVGMQRERS EVGSGVPARTVYASEQHAYMWHSALI PDSGLRGKFTL ____________________ _______SSRKPFQTS CGFEFANTVLSLALCCALVVCKARAMDQA WO 2004/080148 PCT/US2003/030720 642 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence RPRQLIGIDALRDPRASSRTRAGGLGMIRRQEEEPAA RTVLARCDSSPSECPSHARPAPYDTGPLFNAKG 2219 A 1 1594 NGGGSLNNYSSPIPSTPAPSRRDPQFSVPPTANTPTP VCKRSMRWSNLFTSEKGSDPDKERKAPENHADTIGSG RAIPIKQGMLLKRSGKWLKTWKKKYVTLCSNGMLTYY SSLGDYMKNIHKKEIDLQTSTIKVPGKWPSLATSACT PISSSKSNGLSKDMDTGLGDSICFSPSISSTTSPKLN PPPSPHANKKKHLKKKSTNNFMIVSATGQTWHFEATT YEERDAWVQAIQSQILASLQSCESSKSKSQLTSQSEA MALQSIQNMRGNAHCVDCETQNPKWASLNLGVLMCIE CSGIHRSLGPHLSRVRSLELDDWPVELRKVMSSIVND LANSIWEGSSQGQTKPSEKSTREEKERWIRSKYEEKL FLAPLPCTELSLGQQLLRATADEDLQTAILLLAHGSC EEVNETCGEGDGCTALHLACRKGNVVLAQLLIWYGVD VMARDAHGNTALTYARQASSQECINVLLQYGCPDECV *YLFYLTAVSLVQKQNGKNKDNSEFQKEITNSANNSI FSTFRKLSKYTKC 2220 A 1 1594 NGGGSLNNYSSPIPSTPAPSRRDPQFSVPPTANTPTP VCKRSMRWSNLFTSEKGSDPDKERKAPENHADTIGSG RAIPIKQGMLLKRSGKWLKTWKKKYVTLCSNGMLTYY SSLGDYMKNIHKKEIDLQTSTIKVPGKWPSLATSACT PISSSKSNGLSKDMDTGLGDSICFSPSISSTTSPKLN PPPSPHANKKKHLKKKSTNNFMIVSATGQTWHFEATT YEERDAWVQAIQSQILASLQSCESSKSKSQLTSQSEA MALQSIQNMRGNAHCVDCETQNPKWASLNLGVLMCIE CSGIHRSLGPHLSRVRSLELDDWPVELRKVMSSIVND LANSIWEGSSQGQTKPSEKSTREEKERWIRSKYEEKL FLAPLPCTELSLGQQLLRATADEDLQTAILLLAHGSC EEVNETCGEGDGCTALHLACRKGNVVLAQLLIWYGVD VMARDAHGNTALTYARQASSQECINVLLQYGCPDECV *YLFYLTAVSLVQKQNGKNKDNSEFQKEITNSANNSI FSTFRKLSKYTKC 2221 A 1 1594 NGGGSLNNYSSPIPSTPAPSRRDPQFSVPPTANTPTP VCKRSMRWSNLFTSEKGSDPDKERKAPENHADTIGSG RAIPIKQGMLLKRSGKWLKTWKKKYVTLCSNGMLTYY SSLGDYMKNIHKKEIDLQTSTIKVPGKWPSLATSACT PISSSKSNGLSKDMDTGLGDSICFSPSISSTTSPKLN PPPSPHANKKKHLKKKSTNNFMIVSATGQTWHFEATT YEERDAWVQAIQSQILASLQSCESSKSKSQLTSQSEA MALQSIQNMRGNAHCVDCETQNPKWASLNLGVLMCIE CSGIHRSLGPHLSRVRSLELDDWPVELRKVMSSIVND LANSIWEGSSQGQTKPSEKSTREEKERWIRSKYEEKL FLAPLPCTELSLGQQLLRATADEDLQTAILLLAHGSC EEVNETCGEGDGCTALHLACRKGNVVLAQLLIWYGVD VMARDAHGNTALTYARQASSQECINVLLQYGCPDECV *YLFYLTAVSVQKQNGKNIDNSEFQKEITNSA1l\TSI FSTFRKLSKYTKC 2222 A 1 1594 NGGGSLNNYSSPIPSTPAPSRRDPQFSVPPTANTPTP VCKRSMRWSNLFTSEKGSDPDKERKAPENHADTIGSG

PAIPIKQGMLLKRSGKWLKTWKKKYVTLCSNGMLTYY

WO 2004/080148 PCT/US2003/030720 643 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence SSLCDYMK IIIKKIDLQTSTI KVPGKWPSLATSACT PISSSKSNGLSKDMDTGLGDSTCFSPSISSTTS PKLN PPPSPHZANKKKHLKKKSTNNFMIVSATGQTWHFEATT YEERDAWVQAIQSQI LASLQSCESSKSKSQLTSQSEA M4ALQS IQNMRGNAHCVDCETQNPK WASLNLGVLMCIE CSGIH-RSLGPHLSRVRSLELDDWPVELRKV14SSIVND LZA SIWEGS SQGQTKPSEKSTREEKS RWIRSKYEEKJ FLAPLPCTELSLGQQLLRATADEDLQTAILLLAHGSC EEVNETCGEGDGCTALI{LACRKGNVVLAQLLIWYGVD VMARDAHGNTALTYARQASSQECINVLLQYGCPDECV *YLFYLTAVSLVQKQNGNEFQKEI TNSANNSI FSTFRKLSKYTKC 2223 A 2 415 GGFAAAVESFHHEDVLLFAALMAHELGHNLGIQHDHS ACFCKKFCLMHENITKESGFSSCSSDYFYQFLREH KGACLFNKPRPRGRKRRDSACGNGVTEDTDQCDCGSL~ ____ CQHHlACCDENCILKAKA* CNDGPCCHK 2224 A 53 325 MRL9VCLLLLTLALCCYRANAVVCQALGSEITGFLLA GKPVF9KFQLAKFKAPLEAVAAKMEVKKCVDTMAYEKR VLITKTLGKIAEKCDR* 2225 A 9 422 ESRERSGNRRGAEDRGTCGLQSPSAMLGAKPHWLPGP TJHS PGLPLVIJVILALGAGWAQEGSEPVLLEGECLVVC EPGRAAAGGPGGAALGEAPPGRVAFAAVRSHHKIIEPAG ETGNGTSGAIYFDQVLVNEhGOGFDRAS 2226 A 42 722 MGCDGRVSGLLRRNLQPTLTYWSVFFSFGLCIAFLGP TLLDLRCQTiH5SLPQI SWVFFSQQLCLLLGSALGGVF KRTLAQSLWALFTS SLATSLVFAVI PFCRDVKVLASV MALAGLAMGCIDTVANIAQLVRMYQKDSAVFLQVLHFF VGFGALLSPLIADPFLSEANCLPANSTQH-HLPR-ATC SMSPGCWGQHHVDAQALVQPDVPKADSQGPGREPEGP __________MPSG* 2227 A 42 722 MGCDGRVSGLLRRNLQPTLTYWSV'FSFGLCIAFLGP TLLDLRCQTHS SLPQI SWVFFSQQLCLLLGSALGGVF KRTLAQSLWALF FSSLAI SLVFAVIPFCFJJVKVLASV MALAGLAMGCIDTVANMQLVRMYQKDSAVFLQVLHFF VGFGALLSPLIADPFLSEANCLPANSTGQHIILPRATC SMSPGCWGQHHVDAQALVQPDVPKADSQGPGREPEGP MPSG* 2228 A 2 474 TGPTIKNMDGTFNVTSCLKLNSSQEDPGTVYQCVVRH ASLHTPLRSNFTLTAARHSLSETEKTDNFSIHWWPT S FIGVGLVLLIVLI PWKKI CNKSS SAYTPLKCILKH-WN SFDTQTLXKEHLIFFCTRAWPSYQLQDGEAWPPEGSV NINTYSTTV 2229 A 2 1654 GRGDSSSSGSGSGSGSGSRACPARPSAPGLRAPTPPP RLPGASGAPAARLTLKF]ZAVLLAAGMLAFLGAVICI I ASVPLAASPARALPGGADNASVASGAAASPGPQRSLS ALHG-ACGSAGPPALPGAPAASAHPLPPGPLFSRFLCT PLAA-ACPSGAQQGDAAGAAPGEREELLLLQSTAEQLR QTALQQEARIRADQDTIRELTGKLGRCESGLPRGLQG AGPRRDTMADGPWDSPALILELEDAVRALRDRIDRLE ELPARVN\LSAAPAkPVSAVPTGJI-SIM\DQLEGQLLAQV WO 2004/080148 PCT/US2003/030720 644 ____ TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence LALEKERVALS-SSRRQRQEV\EKELDVLQRVAELEH ESSAYS PPDAFKTS IPIRNNYMYARVRK ALPELYAFT ACMWLRSRS SGTGQGTPFSYSVPG/QAGNEIVLLEAG H-EPMELLINDKVAQLPLSLKDNGWHHICIAW TTRCGL WSAYQEGELQGSGENLAAWHPIKPHGILILGQEQDTL GGRFDATQAFVGIDIAQFNLWDHALTPAQVLGIANCTA PLLGNVLPWEDKLVEAFGGATIKAAFDVCKGRAKA 2230 A 3 913 FMTDVNSWLLTFGFQI 4 VIPGYPKPDMDAMEPSYEL IHTQMKTQEWDNSKSILGVQCEVQKQLKAFVTLERFD QLYGSTITSCQQAPKTKKFASSGSVFGKGVKALIDG RVTTDI ISVANEDGRRVAAILNHAHYLENLHFTIDGV DTHYFVKPGPSEGDLAILGLSGGRRTLENGVNVTVSQ INTVLNGRTRRYTDIQLQYGALCLNTRYGTTLDEEKA RVLELSRQRAVRQAWAREQQRLREGEEGLRAWTESEK QQVLSTGRVQGYDGFFVI SVEQYPELSDSANNI1TFMR QSEMGRR 2231 A 488 75 ASVPKTNKIEPRSYSIIPSCGIQAARACFEHSNFFKV NASGPAGHSAKSIEGAPRGKGRGRAVARLAADRPPAP IIQLRAF*LQQL*YTLLELELPRL~LAPDLPSNGSSLK DLKWTHSNYRASKESCIVI FRHYLPGS 2232 A 3 161 HERDVhFNLCENLVKSSEANSPAHEEFKTMLLIAKYY ________ ______ATRSAAESVYQL*AVSRVLLSLVY 2233 A 1 492 KIKAKNLTNYDLCSIFLGTSTLLVWVGVIRYLGYFQA YNVLILTMQASLPKVLRFCACAGMIYLGYTFCGWIVL GPYHDKFENLNTVAECLFSLVNGDDMFATFAQI QQKS ILVWLFSRLYLYSFISLFIYMILSLFIALITDSYDTI ________KKFQQNGFPETDLQEF 2234 A 1 492 KIKAKNLTNYDLCSIFLGTSTLLVWVGVIRYLGYFQA YNVLILTMQASLPKVLRFCACAGMIYLGYTFCGWIVL GPYHDKFENLNTVAECLFSLVNGDDMFATFAQIQQKS ILVWLFSRLYLYSFISLFIYMILSLFIAL~ITDSYDTI KKFQQNGFPETDLQEF 2235 A 1 576 PCGEFHHSS/QKATPA6BEVEDSNDSSYSEPPDVQQQL NHYQSAALARNNSRVSPVPLSGAAAGTEQKTEAVLHC EFCEFSSGYIQS IRRHYRDKHGGKKLFKCKDCS FYTG FKSAFTMH-VEAGHSAVPEEGPKDLRCPLCLYH-TKYKR NMIDHIVLHREERVVPIEVCRSKLSKYLQGVVFRCDK CTFTCSR 2236 C 90 472 MPLLEYARNMLRTWSSLPWTRFRVCL~LSLSLFLWANR LEDSRSCQPNPMSLTTLPGHRLKEAVWLPAPSRTMSP HLDPNQLGILLRVLRKEKEDGDYPDMMATH-PSSRYEA CSSGITLAAPPTI4GPRPTDPRIGPAP 2237 C 60 472 MPLLEYARNMILRTWSSLPWTRFRVCLLSLSLFLWANR LEDSRSCQPNPMSLTTLPGHRLKEAVWLPAPSRTMSP HLDPNQLGI LLRVLRKERKEDGDYPDMMATHPS SRYEA CSSGITLA-APPTHGPRFTDPRIGPAP 2238 A 129 329 VSNIVDPHQTVGLSTQEPGDIFTYSEFDGILCLAYPS LASE* SVPVLDNTMQRH-LVAQDLFSVYMSR 2239 A 130 502 DSRIPKEAPDQQKKMGPPSL.VLCLLSATVFSLLGGS SAFLSHfl-RLKGRFQRDRRNIRPNIILVLTDDQDVELG WO 2004/080148 PCT/US2003/030720 645 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence SMQVMNKTRRIMEQGGAHFINAFVTTPMCCPSRSSIL TGKYVHNHNTYMY 2240 A 3 498 YKEVVTQHFL*VTYETHPIYYLKISQPSGNPKKIIWM DCGIHAREWIAPAFCQWFVKEILQNHKDNSRIRKLLM NLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTC FGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPE TKAVASFIESKNDDFCA 2241 A 3 498 YKEVVTQHFL*VTYETHPIYYLKISQPSGNPKKIIWM DCGIHAREWIAPAFCQWFVKEILQNHKDNSRIRKLLM NLDFYVLPVLNIDGYIYTWTTDRLWRKSRSPHNNGTC FGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPE TKAVASFIESKNDDFCA 2242 A 972 468 MAAAGAGRLRRVASALLLRSPRLPARELSAPARLYHK KVVDHYENPRNVGSLDKTSKNVGTGLVGAPACGDVMK LQIQVDEKGKIVDARFKTFGCGSAIASSSLATEWVKG KTVEEALTIKNTDIAKELCLPPVKLHCSMLAEDAIKA ALADYKLKQEPKKGEAEKK 2243 A 1193 548 TQAWTRAEKDRKGSVRALRLHLERGPPT*RGSHPL\Q SVPCIQKPSIFSSYPI/GLPQSGGEPGPVGEQQPVRR PEQPSCGPASRMPLTSRSVPPGRGALPPDSLSTRKGL PRPSTAGHRVRESGHKVPVSQRLNLPVMGATRSNLQP PRKVAVPGPTR*RDQDSKQDFSSKPLQSVPGLASTQQ TLTPADSGPGTGGRDATRAGLPGVETMGNGVD 2244 A 3 773 SLEMSSDGEPLSRMDSEDSISSTIMDVDSTISSGRST PAMMNGQGSTTSSSKNIAYNCCWDQCQACFNSSPDLA DHIRSIHVDGQRGGVFVCLWKGCKVYNTPSTSQSWLQ RHMLTHSGDKPFKCVVGGCNASFASQCGLARHVPTHF SQQNSSKVSSQPKAKEESPSKAGMNKRRKLKNKRRRS LARPHDFFDAQTLDAIRHRAICFNLSAHIESLGKGHS VVFHSTVSILLFFQIKYKTLQKNISTIISKSLKI 2245 A 3834 2068 GARGRPLAETWPFLTAPVLPGQLQITEPTMAEKGDCI ASVYGYDLGGRFVDFQPLGFGVNGLVLSAVDSRACRK VAVKKIALSDARSMKHALREIKIIRRLDHDNIVKVYE VLGPKGTDLQGELFKFSVAYIVQEYMETDLARLLEQG TLAEEHAKLFMYQLLRGLKYIHSANVLHRDLKPANIF ISTEDLVLKIGDFGLARIVDQHYS\HKGYLSEGLVTK WYRSPRLLLSPNNYTKAIDMWAAGCILAEMLTGRMLF AGAHELEQMQLILETIPVIREEDKDELLRVMPSFVSS TWEVKRPLRKLLPEVNSEAIDFLEKILTFNPMDRLTA EMGLQHPYMSPYSCPEDEPTSQHPFRIEDEIDDIVLM AANQSQLSNWDTCSSRYPVSLSSDLEWRPDRCQDASE VQRDPRAGSAPLAENVQVDPRKDSHSSSERFLEQSHS SMERAFEADYGRSCDYKVGSPSYLDKLLWRDNKPHHY SEPKLILDLSHWKQAAGAPPTATG\LADTGAREDEPA SLFLE\IAQWVKSTQG\AQSTPARPPTTPSAACLPRP P\PPGPGGCR\RQPPVRPGRVHLPRPEALHQARGPAG Q 2246 A 328 595 VIEWVVPVEPPNQLSTSSVGRVPGSTRPQRSFLSRVV RAALPLQLLLLLLLLLACLLPSSEEDYSCTQANNFAR

SFYPMLRYTNGPPPT

WO 2004/080148 PCT/US2003/030720 646 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence 2247 A 548 811 SSFIIKRHILIFEDDWHQTTCCHHPHHP\F*RCQFHIF YVSVQNSISPSLSVSSSHPDRPDHEVHQHRAAIIHQH GQGPLGHGLVARVG 2248 A 37 441 GXAGVGGDSEGEVTSALSATFSGPKIAFYVGLKSPHE GYEVLKFDDVVTNLGNHYDPTTGKFSCQVRGIYFFTY HILMRGDGTSMWADLCKNGQVRASAIAQDADQNYDY ASNSVVLHLDSGDEVYVKLDGGKA 2249 A 808 112 RRYKSGTEVNNTDGGIARLIVFGTGQIDWTATDPKEP ADLVAIAFGGVCVGFSNAKFGHPNNIIGVGGAKSMAD GWETARRLDRPPILENDENGILLVPGCEWAVFRLAHP GVITRIEIDTKYFEGNAPDSCKVDGCILTTQEEAVIR QKWILPAHKWKPLLPVTKLSPNQSHLFDSLTLELQDV ITHARLTIVPDGGVNRLRLRGFPSSICLLRPREKPML KFSVSFKANP 2250 A 189 1811 PPFGGLSAAQTIGEMWEAQFLGLLFLQPLWVAPVKPL QPGAEVPVVWAQEGAPAQLPCSPTIPLQDLSLLRRAG VTWQHQPDSGPPAAAPGHPLAPGPHPAAPSSWGPRPR RYTVLSVGPGGLRSGRLPLQPRVQLDERGRQRGDFSL WLRPAPRADAGEYRAAVHLRDRALSCRLRLRLGQASM TASPPGSLRASDWVILNCSFSRPDRPASVHWFRNRGQ GRVPVRESPHHHLAESFLFLPQVSPMDSGPWGCILTY RDGFNVSIMYNLTVLGLEPPTPLTVYAGAGSRVGLPC RLPAGVGTRSFLTAKWTPPGGGPDLLVTGDNGDFTLR LEDVSQAQAGTYTCHIHLQEQQLNATVTLAIITVTPK SFGSPGSLGKLLCEVTPVSGQERFVWSSLDTPSQRSF SGPWLEAQEAQLLSQPWQCQLYQGERLLGAAVYFTEL SSPGAQRSGRAPGALPAGHLLLFLTLGVLSLLLLVTG TFGFHLWRRQCRP\RRFSALEQGIH\P\RQAQSKIEE LEQEPEPEPEPEPEPEPEPEPEQL 2251 A 3 3773 SWPRGRGETGGHPGALRTRTMQKSVRYNEGHALYLAF LARKEGTKRGFLSKKTAEASRWHEKWFALYQNVLFYF EGEQSCRPAGMYLLEGCSCERTPAPPRAGAGQGGVRD ALDKQYYFTVLFGHEGQKPLELRCEEEQDGKEWMEAI HQASYADILIEREVLMQKYIHLVQIVETEKIAANQLR HQLEDQDTEIERLKSEIIALNKTKERMRPYQSNQEDE DPDIKKIKKVQSFMRGWLCRRKWKTIVQDYICSPHAE SMRKRNQIVFTMVEAESEYVHQLYILVNGFLRPLRMA ASSKKPPISHDDVSSIFLNSETIMFLHEIFHQGLKAR IANWPTLILADLFDILLPMLNIYQEFVRNHQYSLQVL ANCKQNRDFDKLLKQYEANPACEGRMLETFLTYPMFQ IPRYIITLHELLAHTPHEHVERKSLEFAKSKLEELSR VMHDEVSDTENIRKNLAIERMIVEGCDILLDTSQTFI RQGSLIQVPSVERGKLSKVRLGSLSLKKEGERQCFLF TKHFLICTRSSGGKLHLLKTGGVLSLIDCTLIEEPDA SDDDSKGSGQVFGHLDFKIVVEPPDRAAFTVVLLAPS RQEKAAWMSDISQCVDNIRCNGLMTIVFEENSKVTVP HMIKSDARLHKDDTDICFSKTLNSCKVPQIRYASVER LLERLTDLRFLSIDFLNTF'LHTYRIFTTAAVVLGKLS DIYKRPFTSIPVRSLELFFATSQNNRGEHLVDGKSPR LCRKFSSPPPLAVSRTSS PVRARKLSLTSPLNSKIGA WO 2004/080148 PCT/US2003/030720 647 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence LDLTTSSSPTTTTQSPAASPPPHTGQIPLDLSRGLSS PEQSPGTVEENVDNPRVDLCNKLKRSIQKAVLESAPA DRAGVESSPAADTTELSPCRSPSTPRHLRYRQPGGQT ADNAHCSVSPASAFAIATAAAGHGSPPGFNNTERTCD KEFIIRRTATNRVLNVLRHWVSKHAQDFELNNELKMN VLNLLEEVLRDPDLLPQERKAAANI LMALSQDDQDDI HLKLEDIIQMTDCMKAECFESLSAMELAEQITLLDHV IFRSIPYEEFLGQGWMKILDKNERTPYIMKTSQHFNDM SNLVASQIMNYADVSSRANAIEKWVAVADICRCLHNY NGVLEITSALNRSAIYRLKKTWAKVSKQTKALMDKLQ KTVSSEGRFKNLRETLKNCNPPAVPYLGMYLTDLAFI EEGTPNFTEEGLVNFSKMRMISHIIREIRQFQQTSYR IDHQPKVAQYLLDKDLIIDEDTLYELSLKIEPRLPA 2252 A 1 4602 ASGNLDKNARFSAIYRQDSNKLSNDDMLKLLADFRKP EKMAKLPVILGNLDITIDNVSSDFPNYVNSSYIPTKQ FETCSKTPITFEVEEFVPCIPKHTQPYTIYTNHLYVY PKYLKYDSQKSFAKARNIAICIEFKDSDEEDSQPLKC IYGRPGGPVFTRSAFAAVLHHHQNPEFYDEIKIELPT QLHEKHHLLLTFFHVSCDNSSKGSTKKRDVVETQVGY SWLPLLKDGRVVTSEQHIPVSANLPSGYLGYQELGMG RHYGPEIKWVDGGKPLLKISTHLVSTVYTQDQHLHNF FQYCQKTESGAQALGNELVKYLKSLHAMEGHVMIAFL PTILNQLFRVLTRATQEEVAVNVTRVIIHVVAQCHEE GLESHLRSYVKYAYKAEPYVASEYKTVHEELTKSMTT ILKPSADFLTSNKLLKYSWFFFDVLIKSMAQHLIENS KVKLLRNQRFPASYHHAVETVVNMLMPHITQKFRDNP EASKNANHSLAVFIKRCFTFMDRGFVFKQINNYISCF APGDPKTLFEYKFEFLRVVCNHEHYIPLNLPMPFGKG RIQRYQDLQLDYSLTDEFCRNHFLVGLLLREVGTALQ EFREVRLIAISVLKNLLIKHSFDDRYASRSHQARIAT LYLPLFGLLIENVQRINVRDVSPFPVNAGMTVKDESL ALPAVNPLVTPQKGSTLDNSLHKDLLGAISGIASPYT TSTPNINSVRNADSRGSLISTDSGNSLPERNSEKSNS LDKHQQSSTLGNSVVRCDKLDQSEIKSLLMCFLYILK SMSDDALFTYWNKASTSELMDFFTISEVCLHQFQYMG KRYIARTGMMHARLQQLGSLDNSLTFNHSYGHSDADV LHQSLLEANIATEVCLTALDTLSLFTLAFKNQLLADH GHNPLMKKVFDVYLCFLQKHQSETALKNVFTALRSLI YKFPSTFYEGRADMCAALCYEILKCCNSKLSSIRTEA SQLLYFLMRNNFDYTGKKSFVRTHLQVIISVSQLIAD VVGIGGTRFQQSLSIINNCANSDRLIKHTSFSSDVKD LTKRIRTVLMATAQMKEHENDPEMLVDLQYSLAKSYA STPELRKTWLDSMARIHVKNGDLSEAAMCYVHVTALV AEYLTRKEAVQWEPPLLPHSHSACLRRSRGGVFRQGC TAFRVITPNIDEEASMMEDVGMQDVHFNEDVLMELLE QCADGLWKAERYELIADIYKLIIPIYEKRRDFERLAH LYDTLHRAYSKVTEVMHSGRRLLCTYFRVAFFGQAAQ YQFTDSETDVEGFFEDEDGKEYIYKEPKLTPLSEISQ RLLKLYSDKFGSENVKMIQDSGKVNPKDLDSKYAYIQ VTHVI PFFDEKELQERKTEFERSHNIRRFMFEMPFTQ WO 2004/080148 PCT/US2003/030720 648 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X'Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide Peuence TGKRQGGVEEQCKP.RRTILTAI HCFPYVKIKRT PVMYQH HTDLNPIEVAIDEMSKKVAELRQLCS SAEVDMI KLQL KLQGSVSVQVNAGPLAYARAFLDDTNTK RYPDNKVKL LI(EVFRQFVEACQALAVNERLI KEDQLEYQEEMKAN _____YREMAKELSEIMHEQLG 2252 A 1 782 MRMEAGEAAPAGAGGRAAGGWGKcVleRLNVcGTVFLT TRQTLCREQKSFLSRLCQGEELQSDRDETGAYLIDRD PTYFGPILNFLRHGKLVLDKDMAEEGVLEEAEFYNIG PLIRIT KDRMEEKDYTVTQVPPKHXTYRVLQCQEEELT QMVSTMSDGWRFEQLVNI GSSYNYGSEDQAEFLCVVS KELHSTPNGIJSSES SRKTKSTEEQLEEQQQQEEEVEE VEVEQVQVEADAQEK/ CCYKPEAPGCEAPDHLQGLGV PI 2254 A 2407 2216 SGCVEMTYSHSLEYNPEWISVQSAVAPAQLALNSDGD L*LHSGERTRRD* QLPEAGGPGLQEPLQLGELDITSD RFILDEVDG\VDLRHYSKQVELELQQIEQKS IRDYIQ ESENIASLHNQITACDAVLERMEQMLGAFQSDLSSI S SEIRTLQEQSGAMNIRLRNRQAVRGKLGELVDGLVVP SALVTAILEAPVTEPRFLEQLQELDAKAAAVREQEAR GTAACADVRGVLDRLRVKAVTKIREFILQKIYS FRKP MTNYQI PQTALLKYRFFYQFLLGNERATAKEIRDEYV ETLSKIYLSYYRSYLGRLMKVQYEEVAEKDDLMGVED TAKKGFFSKPSLRSRNTI FTLGTRGSVISPTELEAPI LVPHTAQRGEQRYPFEALFRSQHYALLDNSCREYLFI CEFFVVSGPAAHDLFHAVMGRTLSMTLKHLDSYLADC YDAIAVFLCIH-IVLRFRNIAAKRDVPALDRYWEQVLA LLWPRFELILEMNVQSVRSTDPQRLGGLDTRPHYI TR RYAEFSSALVS INQTI PNERTMQLLGQLQVEVENFVL RVAAEFSSRKEQLVFLTNNYDMMLGVLM\E *ERAADD SKEVESFQQLLNARTQEF IEELLSPPFGGLVAFVKEA EALIERGQAERLRGEEARVTQLIRGFGS SWKSSVESL SQDVNRSFTNFRNGTS II QGALTQLIQ\LYHRFHRV\ LSQPQLRALPARAELINI I-ELMVELKKHKPNF 2255 A 1205 462 ASITVSSGRIPTSLSVGPPGAPJRRPQKPREGAWDME DVAPTGVRQAFSELPFPSHVLPEPGFPDTDPSQVYSP GLPPAPAQPSS JPPCALVSQPTVQFILQGSLPLVGCG AAQTLAPVPAALTPASEPASQATAASNSEEKTPAPRL AAEKTKKEEYMKKLIRMQERAVEEVKLAIKPFYQKREV TKEEYKDILRKAVQKICHSKSGEINPVKVANLVKAYV DKYRHMRRHKKPEAGEEPPTQGAEG 2256 A 1205 462 ASITVSSGRIPTSLSVCPPGAPLHRPQKPREGAWDME DVAPTGVRQAFSELPFPSHVLPEPGFPDTDPSQVYSP GLPPAPAQPSS IPPCALVSQPTVQFI LQCSLPLVGCG AAQTLAPVPAALTPASEPASQATAASNSEEKTPAPRL AAEKTKKIEEYMKI(,LHMQERAVIEEVIjAIKPFYQKREV TKSEYKDI LRKAVQKI CHSKSGEINPVIAALVKAYV DKYRHMRRHKKPEAGEEPPTQGAEG 2257 A 901 521 FFFGNGVSPCRQAGV*WHDLDSLQNLPPCFKRFSYLS LPSSW\DYRH-VLPRQANFCI F/M*RRGFTMLA-RMVSI S*PRDLPALASQSAGI TGVSHHAPPQMDFTFA.LLCFA WO 2004/080148 PCT/US2003/030720 649 ___________TABLE 7 SEQ Method Predicted Amino acid sequence (X=jnknown, *Stop codon, ID beginning ending /=possible ucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue cid of peptide residu of sequence peptide sequence LKGCLPRQKEGGTLNLI 2258 A 186 1338 TRMSRHEGVSCDACLIGNFRGRRYKCLICYDYDLCAS CYESGATTTRHTTDHPMQCILTRVDFDLYYGGEAFSV EQPQSFTCPYCGKMGYTETSLQEHVTSEHAETSTEVI CPICAALPGGDPNHVTDDFAAHLTLEHRAPRDLDESS GVRHVRRMFHPGRGLGGPRARRSNMHFTSSSTGGLSS SQSSYSPSNREAMDPIAELLSQLSGVRRSAGGQLNSS GPSASQLQQLQMQLQLERQHAQAARQQLETARNATRR TNTSSVTTTITQSTATTNIANTESSQQTLQNSQFLLT RLNDPIMSETERQSMESERADRSLFVQELLLSTLVRE ESSSSDEDDRGEMADFGAMGCVDIMPLDVALENLNLK ESNKGNEPPPPPL 2259 A 1157 481 SWPGQAEPSEREFVVREAAETRGSEVFEIMNPVYSPG SSGVPYANAKGIGYPAGFPMGYAAAAPAYSPNMYPGA NPTFQTGYTPGTPYKVSCSPTSGAVPPYSSSPNPYQT AVYPVRSAYPQQSPYAQQGTYYTQPLYAAPPHVIHHT TVVQPNGMPATVYPAPIPPPRGNGVTMGMVAGTTMAM SAGTLLTAHSPTPVAPHPVTVPTYRA\QGTPTYSYVP PQW 2260 A 33 563 MVLSVPVIALGATLGTATSILALCGVTCLCRHMHPKK GLLPRDQDPDLEKAKPSLLGSAQRFNVKKSTEPVQPR ALLKFPDIYGPRPAVTAPEVINYADYSLRSTEEPTAP ASPQPPNDSRLKRQVTEELFILPQNGVVEDVCVMETW NPQKAGSWNQAPKLHYCLDYDCHKAECL* 2261 A 6120 2968 HPSPGFDRVRAAMDPNTIIEALRGTMDPALREAAERQ LNEAHKSLNFVSTLLQITMSEQLDLPVRQAGVIYLKN MITQYWPDRETAPGDISPYTIPEEDRHCIRENIVEAI IHSPELIRVQLTTCIHHIIKHDYPSRWTAIVDKIGFY LQSDNSACWLGILLCLYQLVKNYEYKKPEERSPLVAA MQHFLPVLKDRFIQLLSDQSDQSVLIQKQTFKIFYAL VQYTLPLELINQQNLTEWIEILKTVVNRDVPNETLQV EEDDRPELPWWKCKKWALHILARLFERYCSPGNVSKE YNEFAEVFLKAFAVGVQQVLLKVLYQYKEKQYMAPRV LQQTLNYINQGVSHALTWKNLKPHIQGIIQDVIFPLM CYTDADEELWQEDPYEYIRMKFDVFEDFISPTTAAQT LLFTACSKRKEVLQKTMGFCYQILTEPNADPRKKDCA LHMIGSLAEILLKKKI\YKDQMEYMLPESMYSPLF\S SELG\YMRARACWVLHYFCEVKFKSDQNLQTALELTR RCLIDDREMPVKVEAAIALQVLISNQEKAKEYITPFI RPVMQALLHIIRETENDDLTNVIQKMICEYSEEVTPI AVEMTQHLAMTFNQVIQTGPDEEGSDDKAVTAMGILN TIDTLLSVVEDHKEITQQLEGICLQVIGTVLQQHVLE FYEEIFSLAHSLTCQQVSPQMWQLLPLVFEVFQQDGF DYFTDMMPLLHNYVTVDTDTLLSDTKYLEMIYSMCKK VLTGVAGEDAECHAAKLLEVIILQCKGRGIDQCIPLF VEAALERLTREVKTSEL*TMGLQVAIAALHYNAYLLL NTLENLHFPNNVEPVTNHFI/QWLNDVDCFLGLHDRR MCVLSLCALIDMEQIPQGLNQVSGQILPAFILLFNGL KRAYACHAEHENDSDDDDEAEDDDETEELGSDEDDID

EDGQEYLEILAKQAGEDGDDEDWEEDDAEETALEGYS

WO 2004/080148 PCT/US2003/030720 650 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XUnknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence TI IDDEDNPVDEYQIFKAIFQTIQNRNPVWYQALTHG LNEEQRKQLQDIATLADQRRAAH-ESKMIEKHGGYKF9 _____AP\VVPSSFNFGGPAPGMN 2262 A 13 2237 A5EGCAERRGTEPVVELSMSWESGAGPG-LGSQC-MDLVW SAWYGKCVIC'GKGSLPLSAI{GIVVAWLSRAEWDQVTVY LFCDDH-KLQRYALNRITVWRSRSGNELPLAVASTADL IRCKLLDVTGGLGTDELRLLYGMALVRFVNLISERKT KFAKVPLKCLAQEVNI PDWIVDLRHELTHKlKMPHIND CRRGCYFVLDWLQKTYWCRQLENSLRETWELEEFREG IEEEDQEEDIKNIVVDDITEQKPEPQDDGKSTESDVKA DGDSKGSEEVDSHCKKLSH-KELYER1ARELLVSYEEE QFTVLEKFRYLPKAIKAWNNPSPRVECVLAELKGVTC ENREAVLDAFLDDGFLVPTFEQLAALQIEYEENVDLN DVLhVPKPFSQFWQPLLRGLHSQNFTQALLT~ERMLSELP ALGI SGIRPTYILRWTVELIVANTKTRN'.PRFSAGQ WEARRGWRLFNCSASLDWPRMVESCLGS PCWAS PQLL RIIF\KAMGQGLQDE\EQEKLLRICS IYTQSGENSLV QEOSEASPI GKSPYTLDSLYWSVKPASS SFGSEAKAQ QQEEQGSVNEVKEEEKEEKEVLPDQVEEEEENDDQEE EEEDEDDEDDEEEDRMEVGPFSTCQESPTAENARLLA QKRGALQGSAWQVSSEDVRWDTFP\LGRMVPRSRPRTP AELMLENYDTHVI FWTKPVL\ EQRLEPSTCK\TDTLG L\SCGVGS \GNCSNSSSSNFRGAFLLEARGSLH\GL\ KTGLQLF 2263 A 2. 528 LGNTVLHYCSMYSKPECLKLLLRSKPTVDIVNQAGET ALDIAKRLKATQCEDLLSQAKSGKFNPHVHVEYEWNL RQEEIDESDDDLDDKPSPVKKERSPRPQSFCHS 8515 PQDKLALPGFSTPRDKQRLSYGAFTNQI FVSTSTDSP TSPTTEAPPLPPRNAGKGPTGPPITPHR 2264 A 422 2 APGASVGRAQAAEG*RGGPTGRPPSALGVS/EAGPAG RAGEGRPVPPAYPLCKSAQTSGPPKARLS\ PPLASCG GRGPPGGAACATCAPPAGPARSSRCRRRSPPE *GPR* PSRPARPS PGSAASRRQKLTPCRCQFRGLCA 2265 A 1 1742 VSAVEFVLHGKDFQVDCKASGSPVP*ISWSl lDGTMI NNAMQADDSGHRTRRYTLFNNGTLYFNKVGVAEEGDY TCYAQNTLGKDEMKVHLTVITAAPRIRQSNKTNKRIK AGDTAVLDCEVTGDPKPKIFWLLPSNDMISFS IDRYT FHZANGSLTINKVKLLDSGEYVCVARNPSGDDTKMYKL DVVSKPPLINGLYTNRTVIKATAVRHSKKHFDCRAEG TPS PEVMWIMPDNIFLTAPYYGSRITVHKNGTLEIRN VRLSDSADFI CVARNEGGESVLVVQLEVLEMLRRPTF RNPFNEKIVAQLGKSTALNCSVDGNPPPEI IWILPNG TRFSNGPQSYQYLIASNGSFI ISKTTREDAGKYRCAA RNK VGYIEKLVILEIGQKPVILTYAPGTVKGI SGESL SLHCVSDGI PKPNIKWTMPSGYVVDRPQINGKYILHD NCTLVIIKEATAYDRGNYI CKAQNSVG-TLITVPVMIV AYPPRITNRPPRS IVTRTGAAFQLHCVALGVPKPEIT WEMPDHSILLSTASK ERTHGSEQLHLQGTLVIQNPQTS DSGIYKCTAKNPLGSDYAATYIQVI 2266 A 2334 68 RWHQAPcAPVRQRPPDDLQPGPGL\WMPGPAEMTTESA WO 2004/080148 PCT/US2003/030720 651 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence GQKIKELLSGIGNISERVSFLKK/RG*PAEQGTDKPQ RGHERE\RAL\RQAARAPDPSPAPPAFPGAACRHRMC SWPPAC*RTAAASAWTRGGPCASRCSPAPVLSTWTRP APPSPTPSPWTSSAPVLGGR*RYPWALVRTAGSTCP* PCPA\PVLQSQGGGGRGPCPLRL*G/PPFWMSAPPTS CPSKR\GLPAPEQAHSGHAAVSALPWPGPATHTGPLP TRPHPRPWGHFSCNLSGAWQPASRTRLPAGRVPAPIC GFHQGVGGA/GSELP*RTATQACPCAVPPCSGSLLRM LLWTS*GPEHYLPSR\DGP*WRQRSPHRPRG/VP*PT CAQQGPSRPWRFKWKAP\SGRHLQGAPCRCRAHADDG DRAGRPGLQRS*SPCAVPPPDPRQPRDTAAGGADPAR PALHGG*CQLLCHRPEAATGVPAAAPPQPHPAVTRRA CPWALATLPASVTAPPGLMG*RETELAWPEPSGKVGP GHVGAERS*KCLEAVEHKADSDWEQPRRALNLAGRSF ASSAGVSPSLTAAAAPAL/GLPHCWAAFPPPQQPLRP GGSAGHSGPGGP\GNRISGVWTWGEFVTVAATPPGAP AAPLCGTTRCPTVPLSHCSH\CPAAHSGTPR\WRVLP ETKAQNSMQGAPASARGLVPHQGRASGWPVAGMLNN* VPPAGAVPSTVHYFQGHSG\GAVAGGGP*APAPSLLP QPG\HGPPPGAGVFIWGGCSRRSRCRHCPR 2267 A 29 175 KSRPGTVAHACNPSTLGSRGGRIIPAQEFKTSLGNTV SE\PCLYLRKNN 2268 A 29 175 KSRPGTVAHACNPSTLGSRGGRIIPAQEFKTSLGNTV SE\PCLYLRKNN 2269 A 961 365 PRVRLNGCGRLAALGRGLKSFLRGTSLCEEIMSLALR SELVVDKTKRKKRRELSEEQKQEIKDAFELFDTDKDE AIDYHELKVAMRALGFDVKKADVLKILKDYDREATGK ITFEDFNEVVTDWILERDPHEEILKAFKLFDDDDSGK ISLRNLRRVARELGENMSDEELRAMIEEFDKDGDGEI NQEEFIAIMTGDI 2270 A 131 1567 NKLVTERQILGDPTYMRQADGRKVLRSSIREFLCSEA MFHLGVPTTRAGACVTSESTVVRDVFYDGLDPLRFLS LQMSTQGVQAPAW/RRNDIRVQLLDYVISSFYPEIQA AHASDSVQRNAAFFREVTRRTARMVAEWQCVGFCHGV LNTDNMSILGLTIDYGPFGFLDRYDPDHVCNASDNTG RYAYSKQPEVCRWNLRKLAEALQPELPLELGEAILAE EFDAEFQRHYLQKMRRKLGLVQVELEEDGALVSKLLE TMHLTGADFTNTFYLLSSFPVELESFGLAEFLARLME QCASLEELRLAFRPQMDPRQLSMMLMLAQSNPQLFAL MGTRAGIARELERVEQQSRLEQLSAALQSRNQGHWA DWLQAYRARLDKDLEGAGDAAAWQAEHVRVMHANNPK YVLRNYIAQNAIEAAERGDFSEVRRVLKLLETPYHCE AGAATDAEATEADGADGRQRSYSSKPPLAAELCVT* SSFYPEIQAAHASDSVQRNAAFFREVTRRTARMVAEW QCVGFCHGVLNTDNMSILGLTIDYGPPGFLDRYDPDH VCNASDNTGRYAYSKQPEVCRWNLRKLAEALQPELPL ELGEAILAEEFDAEFQRHYLQKMRRKLGLVQVELEED GALVSKLLETMHLTGADFTNTFYLLSSFPVELESPGL AEFLARLMEQCASLEELRLAFRPQMDPRQLSMMLMLA

QSNPQLFALMGTRAGIARELERVEQQSRLQLSAAEL

WO 2004/080148 PCT/US2003/030720 652 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible ucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence QSRNQGHWADWLQAYRARLDKDLEGAGDAAAWQAEHV RVMHANNPKYVLRNYIAQNAIEAAERGDFSEVRRVLK LLETPYHCEAGAATDAEATEADGADGRQRSYSSKPPL WAAELCVT 2271 A 131 1567 NIQVTERQILGDPTYMRQADGRKVLRSSIREFLCSEA MFHLGVPTTRAGACVTSESTVVRDVFYDGLDPLRFLS LQMSTQGVQAPAW/RRNDIRVQLLDYVISSFYPEIQA AHASDSVQRNAAFFREVTRRTARMVAEWQCVGFCHGV LNTDNMSILGLTIDYGPFGFLDRYDPDHVCNASDNTG RYAYSKQPEVCRWNLRKLAEALQPELPLELGEAILAE EFDAEFQRHYLQKMRRKLGLVQVELEEDGALVSKLLE TMHLTGADFTNTFYLLSSFPVELESPGLAEFLARLME QCASLEELRLAFRPQMDPRQLSMMLMLAQSNPQLFAL MGTRAGIARELERVEQQSRLEQLSAAELQSRNQGHWA DWLQAYRARLDKDLEGAGDAAAWQAEHVRVMHANNPK YVLRNYIAQNAIEAAERGDFSEVRRVLKLLETPYHCE AGAATDAEATEADGADGRQRSYSSKPPLWAAELCVT* SSFYPEIQAAHASDSVQRNAAFFREVTRRTARMVAEW QCVGFCHGVLNTDNMSILGLTIDYGPFGFLDRYDPDH VCNASDNTGRYAYSKQPEVCRWNLRKLAEALQPELPL ELGEAILAEEFDAEFQRHYLQKMRRKLGLVQVELEED GALVSKLLETMHLTGADFTNTFYLLSSFPVELESPGL AEFLARLMEQCASLEELRLAFRPQMDPRQLSMMLMLA QSNPQLFALMGTRAGIARELERVEQQSRLEQLSAAEL QSRNQGHWADWLQAYRARLDKDLEGAGDAAAWQAEHV RVMHANNPKYVLRNYIAQNAIEAAERGDFSEVRRVLK LLETPYHCEAGAATDAEATEADGADGRQRSYSSKPPL WAAELCVT 2272 A 53 439 FFLPLLIIIYCYIFIFRAMRETGRALQTFGACKGNGE SLWQRQRLQSECKMAKIMLLVILLFVLSWAPYSAVAL VAFAGYAHVLTPYMSSVPAVIAKASAIHNPIIYAITH PKYRVAIAQHLPCLGVLL 2273 A 9 410 MTTTFPPRKMVAQFLLVAGNVANITTVSLWEEFSSSD LADLRFLDMSQNQFQYLPDGFLRKMPSLSHLNLHQNC LMTLHIREHEPPGALTELDLSHNQLSELHLAPGLASC LGSLRLFNLSSNQLLGVPPGPLY 2274 A 73 489 FLLLRSASPEHTCVKSKTLDPMVIFFTSGTTGFPKMA KHSHGLALQPSFPGSRKLRSLKTSDVSWCLSDSGWIV ATIWTLVEPWTAGCTVFIHHLPQFDTKVIIQTLVKYP INHFWGVSSIYRMILQQDFTSIRFPALE 2275 A 3 1238 LTKMHLTENPHPQVTHVSSSQSGCSIASDSGSSSLSD IYQATESEVGDVDLTRLPEGPVDSEDDEEEDEEIDRT DPLQGRDLVRECLEKEPADKTDDDIEQLLEFMHQLPA FANMTMSVRRELCSVMIFEVVEQAGAIILEDGQELDS WYVILNGTVEISHPDGKVENLFMGNSFGITPTLDKQY MHGIVRTKVDDCQFVCIAQQDYWRILNHVEKNTHKVE EEGEIVMVHEHRELDRSGTRKGHIVIKATPERLIMHL IEEHSIVDPTYIEDFLLTYRTFLESPLDVGIKLLEWF KIDSLRDKVTRIVLLWVNNHFNDFEGDPAMTRFLEEF

EINLEDTKMNGHLRLLNIACAAKAKWRQVVLQKASRE

WO 2004/080148 PCT/US2003/030720 653 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XdUnknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence SPLQFSLNGGSEK-GFGI FVEGVIEFC-SKAADSCLK RGD QIMEV 2276 A 3 1238 LTKMLTENPHPQVTHVSSSQSGCSIASDSGSSSLSD TYQATESEVGDV\DLTRLPEGFVDSEDDEEEDEE IDRT DPLQGRDLVRECLEKEPADKTDDDIEQLLEFMHQLPA ThANMTMSVRRELCSVMI FEVVEQAGAIIIJEDGQELDS WYVILNGTVEISHFDCKVENLFMGNSFGITPTLDKQY MHGIVRTKVDDCQFVCIAQQDYWRTLNHVEKNTHK 7E EEGEIVMVHEHRELDRSGTRK GHIVII KATPERLIM4L IEEHSIVDPTYIEDFLLTYRTFLESPLDVGI KILEWF KIDSLRDKVTRTVTJLWVNNHFNDFEGDPAMTRFLEEF EKNLEDTKMNGLRLLNIACAAKAKWRQWVLQKASRE SPLQFSLNGGSEKGFGIFVEGVEPGSKAADSGLKRGD QIMEV 2277 A 1 794 FRGFLDRGDCAALPCTYPHSPCS*GGNCLPSLLTRP CVKA* PQMSGRK9SMRRWRRQSRLTAGTSS *TPTSST MC *ALVGSSTWNCMLQAGSTAPGAGTPGSRPTWSS 95 TCSWTAPSGRARCACASSSSCAMSAARRGWTSPACWR RTSRAWWTTSSPACASSATASVAASTASTWFAARTTG GTAESSARPARRASCTCSPARSCWRRRRPPTPSPGRP APPSRRTRRAQAGTSALSPGACFCPRSCC* SSTCSSL SVAPY 2278 A 269 832 MGSSRLAALLLFLLLIVIDLSDSAGIGFRHLPHWTR CPLASHTDDSFTGSSAYI PCRTWWALFSTKFWCVRVW HCSRCLCQHLLSGGSGLQRG-&ILLVQKSKKSSTFKF YRRUKNPAPAQRKLLPRRHLSEKSHHISIPSPDI SI-U GLRSKRTPPFGSRDMGKAFPKWDS PTPGGDRPSSFEL LP* 2279 A 269 832 MGSSRLAALLLPLLLIVIDLSDSAGIGFRHLPHWNTR CFLASHTDDSFTGSSAYI PCRTWWALFSTKFWCVRVW HCSRCLCQI-LLSGSGLQRGLFHLLVQKSKKS STFKF YRRHKMPAPAQRKLLPRRHLSEKSHHI SI PSFD)I 9-K GLRSKRTPPFGSRDMGKAFPKWDS PTPCGD5PSSFEL LP* 2280 A 2 381 VLPTAQGKLYQDDLKVPANVSHLVSFFTWQGFGGHL KAFQWTTS SLFPFQIRNVGTGLCADTK-GALGS PLRL EGCVRG\RCEAAWNNMQVRAAPQGLAARFSETSAAWG ABTASWEGEALVSDK 2281 A 1 993 MRDLFGTRLRRAEDVFPVIGVAAeKqGVYKTSVSV LAQDLAIKGLRVLLVEGNDPQGTASMYHGWVPDLHIH AEDTLLPFYLCEKDDVTYAIKPTCWPGLDI IPSCLAL HRIETELMGKFDEGKLPTDPHLMLRLAIETVAHDYDV IVIESAPNLGIGTINVVCAADVLIVPTPAELFDYTSA LQFFDMLRDLLKNVDLKCFEPDDLKKSFKSPEPRLFT PEEFFRIFNRSIDAFIKDFV VASETSDCVVSSTLSPEK VLKASWKRDSDNSLKSLS PTQIRLC-EVLTPVMSAFWE AEVWNSGDSDDMIALDFDOTSSEVDAESTNRKCVLRP 2282 A 13 582 LQFSVVETAGPGTLVGRLRAQDPDLGDNALMAYSI LDGEGSEAFSI STDLQGRDGLLTVRKPLDFESQRSYS

IFRVEAT±\TTLIDPAYLRRGPEKCDVASVRVAVQD)APEPP

WO 2004/080148 PCT/US2003/030720 654 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (XAUnknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence AFTQAAYHIJTVPENK APGTLVGQI SAADILDEFASPIR YE ILPHSDPERCFIQPEEGTIHTAPLDREAWHN LTVLJATEL 2283 A 3 - LQSVTGGLGLADDGNLAS 2284 A 1 831 KNVWKRWKKRFFVLVQVIQYTFAMCSYREKKARPQEL LQLDGYTVDYTDPQPGLiEGGRAFFNAVKEGDTVI FAS DDEQDRI LWVQAMYRATGQSHKPVPPTQVQKLNAKGG NVPQLDAPISQFYADRAQKI4GMDEFI SSNFCNFDEAS LFEMVQRLTLDHRLNDSYSCLGWFSPGQVFVLDEYCA RNGVRGCHRHLCYLRDLaT-ERAENGAMIDPTLXNYSFA FCASHVEGNRPDGIGNC *LLKICACIF*RKSKEEXSXV LLRKTRTJQHFRXLLFPFG 2285 A 140 445 MQPSGLEGPGTFGRWFLLSLLLLLLLLQPVTCAYTP GPPRALTTLGAPRAHTMPGTYAPSTTLSSPSTQGLQE QARALMRDFPIJVDGHNDLPLVL~RQVYHN 2286 A 294 1568 MSLTIWTVCGVLSLFGALSYAELGTTIKKSGCHYTYI LEVFGPLPAFVRVWVELLI IRPAATAVI SLAEGRYIL EPFFIQCEI PELAIKLITAVGITVVMVLNSMSVSWSA RIQIFLTFCKLTAILI IIVPGVMQLIKGQTQNFKDAF SGRDSSI TRLPLAFYYGMYAYAGWFYLNFVTEEVENF EKTI PLAICISMAIVTIGYVLTNVAYFTTINAEELLL SNAVAVTFSERLLGNFSLAVPIFVALSCFGSMNGGVF AVSRLEYVASREGHLEI-SMIHVRKHTPLFAVIVLH PLTMIMLFSGDLDSLLNFLSFARWLFIGLAVAGLIYL RYKCPIDMHRPFKVPLFIPALFSFTCLFMVALLYSlP FSTGIGFVITLTGVFAYYLFI IWDKKPRWFRIMSEKI TRTLQI ILEVVPEEDKL* 2287 A 3397 630 SPCGRTPAARDSVVREVIQNSKEVSIVYWQEKNCCAS SAVRCKLSRRGDGQA* C*EINQ\NLAEEAG-NITH\I CLA\PDSSEAEIIDEILKINEDTRVHGLALQI SENLF SNKVLNALKPEKDVDGVTDINLGKLVRGDAIECFVSP VAKAVIELLEKSGVNLDGKKILVVGAHGSLEA.ALQCL FQRKGSMTMSIQWKTRQLQSKLEEADIVVLGSPKPEE I FLTWIQPGTTVLNCSHDFLSGKVGCGSPRIHFGGLI EEDDVILLAAAIJRIQNMVSSGRRWLREQQHRRWRLHC LKIJQPLSPVPSDIEI SRGQTPKAVDVLAKEIGLLADE IEIYGKSKAKVRLSVLERLKDQADGKYVLVAGITPTP LGEGKSTVTIGLVQALTAHLNVNSFACL~RQPSQGPTF GVKGGAAGGGYAQVI PMEEFNLIILTGDIHAITAANNL LAAAIDTRILHENTQTDKALYNRLVPLV]NGVREFSET QLARLKKLjGINRTDPSTLTEEEVSKFARLDIDPSTIT WQR-VLDTNDRFLRKITIGQGNTEK-GHYRQAQFDIAVA SEIMAAVLALTDSLADMK<ARLGRMVVASDKSGQPVTAD DLGVTGALTVLMICDAIKPNLMQTLEGTPV FVHAGPFA N7IAHGN7SSVLADKIALKIJVGEEGFVVTEAGFCADIGM WO 2004/080148 PCT/US2003/030720 655 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence EKFFNIKCRASGLVPNVVVLVATVRALKMHGGGPSVT AGVPLKKEYTEENIQLVADGCCNLQKQIQITQLFGVP VVVALNVFKTDTRAEIDLVCELAKRAGAFDAVPCYHW SVGGIGSVDLARAVREAASKRSRFQFLYDVQVPIVDK IRTIAQAVYGAKDIELSPEAQAKIDRYTQQGFGNLPI CMAKTHLSLSHQPDKKGVPRDFILPISDVRASIGAGF IYPLVGTMSTMPGLPTRPCFYDIDLDTETEQVKGLF 2288 A 474 4247 IISIISTSNKIIMSEAPRFFVGPEDTEINPGNYRHFF HHADEDDEEEDDSPPERQIVVGICSMAKKSQIPNPMK EILERISLFKYITLVVFEEEVILNEPVENWPLCDCLI SFHSKGFPLDKAVAYAKLRNPFVINDLNMQYLIQDRR EVYSILQAEGILLPRYAILNRDPNNPKECNLIEGEDH VEVNGEVFQKPFVEKPVSAEDHNVYIYYPTSAGGGSQ RLFRKIGSRSSVYSPESNVRKTGSYIYEEFMPTDGTD VKVYTVGPDYAHAEARKSPALDGKVERDSEGKEVRYP VILNAREKLIAWKVCLAFKQTVCGFDLLRANGQSYVC DVNGFSFVKNSMKYYDDCAKILGNIVMRELAPQFHIP WSIPLEAEDIPIVPTTSGTMMELRCVIAVIRHGDRTP KQKMKMEVRHQKFFDLFEKCDGYKSGKLKLKKPKQLQ EVLDIARQLLMELGQNNDSEIEENKPKLEQLKTVLEM YGHFSGINRKVQLTYLPHGCPKTSSEEEDSRREEPSL LLVLKWGGELTPAGRVQAEELGRAFRCMYPGGQGDYA GFPGCGLLRLHSTYRHDLKIYASDEGRVQMTAAAFAK GLLALEGELTPILVQMVKSANMNGLLDSDSDSLSSCQ QRVKARLHEILQKDRDFTAEDYEKLTPSGSISLIKSM HLIKNPVKTCDKVYSLIQSLTSQIRHRMEDPKSSDIQ LYHSETLELMLRRWSKLEKDFKTKNGRYDISKIPDIY DCIKYDVQHNGFLEIRKTQWELYRLSKALADIVIPQE YGITKAEKLEIAKGYCTPLVRKIRSDLQRTQDDDTVN KLHPVYSRGVLSPERHVRTRLYFTSESHVHSLLSILR YGALCNESKDEQWKRAMDYLNVVNELNYMTQIVIMLY EDPNKDLSSEERFHVELHFSPGAKGCEEDKNLPSGYG YRPASRENEGRRPFKIDNDDEPHTSKRDEVDRAVILF KPMVSEPIHIHRKSPLPRSRKTATNDEESPLSVSSPE GTGTWLHYTSGVGTGRRRRRSGEQITSSPVSPKSLAF TSSIFGSWQQVVSENANYLRTPRTLVEQKQNPTVGSH CAGLFSTSVLGGSSSAPNLQDYARTHRKKLTSSGCID DATRGSAVKRFYISFARHPTNGFELYSMVPSICPLET LHNALSLKQVDEFLASIASPSSDVPRKTAEISSTALR SSPIMRKKVSLNTYTPAKILPTPPATLKSTKASSKPA TSGPSSAVVPNTSSRKKNITSKTETHEHKKNTGKKK 2289 A 3 552 FIDDELATEWSLTMETLTKVLARNLYSLDLSDLPLDK LSEQKQKKHKGKGVGHEFQKVSVDKSFSRGWSRDQPG QAPMRQRSATTTGSPGTEKARSIVRQKTVDIDDAQIL PRSTRVRHFSQSEETGNEVFGALNEEQPLPRSSSTSD ILEPFTVERAKGAVPVIDSSSRHAPSLQSFTEASS 2290 A 3 147 QPLNHYFICSSNTYLVGDQLCGQSSVEGYIRCSGGR EGVQLMRGTM 2291 B 1 498 MDLCQKNTETDLENAENNEIQFTEETEPTYTCPDGKSE KbT-HVYCLLDVSDITLEQDEKAKEFIIGTGWEEAPPQR WO 2004/080148 PCT/US2003/030720 656 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence SS PAVGLRQPGLPGPHLLGPTGGRRCLGCTRHQGPEE EQRNAFGTAWTPETHPTRGHTGRTEAAVAGGDARPEG ________RLLGSRQLNRLPDAETQ 2292 A 963 5 LDFLCHRDMGDNITSITEFLLLGFPVGPRIQMLLFGL FSLFYVFTLLGNGTILGLISLDSRLHAPMYFFLSHL\ AVVDIAYACNTVPRMLVNLLHPAKPISFAGRMMQTFL FSTFAVTECLLLVVMSYDLYV\AICHPLRYLAIMTWR VCITLAVTSWTTGVLLSLIHLVLLLPLPFCRPQKIYH FFCEILAV LK LACADTHINENMV7LAGAI SGLVGPLST IVVSYMCILCAILQIQSREVQRKAFCTCFSHLCVIGL FYGTAT IMYVGPRYGNPKEQKKYLLLFHSLFNPMLNP LICSLRNSEVKN'TLKRVLGVERAL 2293 A 1306 T58 ISYCPKFPNRDQRDKDGDGVGDACDSCPDVSNPNQSD VDNDLVGDSCDTNQDSDGDGHQDSTDNCPTVINSAQL DTDKDGIGD3ECDDDDDNDGI PDLVPPGPDNCRLVPNP AQEDSNSDGVGDT CESDFDQD)QVIDRIDVCPENAEVT LTDFRAYQTVVLDPEGDAQIDPNWVVLNQGMEIVQTM NEDPGLAVYTAF\NGVDFEGTFHVTQTDDDYAGFI FGYQDSSSFYVVMWKQTEQTYWQATPFRAVAEPGIQL KAVKSKTGPGELRNSLWHTGDTSDQVRLLWDSN GWKDKVSYRWFLQHRPQVGYIRVRFYEGSELVADSGV TIDTTMRGGRLGVFCFSQENI IWSNLKYRCNDTIPED FQEFQTQNFDRFDN 2294 A n8o DAPGRPPVRLPTMeLEDGVVYQEEPGGSGA(nSERVS GLAGSIYREFBRLIVRYDEEVVKELI PLVSJAVLENLD SVFAQDQEHQVELELLRDDNBQLT TQYEREKALRKHA EEKFIEFEDSQEQEKKDLQTRVESLESQTRQLELK NYADQI SILEEREAELKKEYNALHQRHTEMII4NYMEH LERTKLHQLSGSDQLESTAHSRIRKERPISLGI FPLP AGD)GLLTPDAQKGGETPGSEQWKFQELSQPRSHTSLK DELSDVSQGSKATTPAST-'NSDVATT PTDTPLKEEN EGFVKVTDAPNKSEI SKH-IEVQVAQETRNVSTGSAEN EEKSEVQAI IESTPELDMDKDLSGYKGSSTPTKGIEN KAFDRNTESLFEELSSAGSGLIGDVDEGADLLGMGRE VENLILENTQLLETKNALNIVKNDLIAKVDELTCEKD VLQGELEAVKQAKLEE<RELEEELRKAREAEDA RQKAKflDDDSDIPTAQRKRFTRVEMARVLMERNQYKE RLMELQEAVRWTEMIRSRSNPAMQEKKRSSIWQFFS RLFSSSSNTTKKPEPPVNLKYNAPTSHVTPSVKKRSS TLSQLPGDKSKAFDFLSEETEASLASRREQKREQYRQ VKAHVQKEDGRVQAFGWSLPQKYKQVTNGQGENMK LPVPVYLRPLDKKDTSMKLWCAVGVNLSGGKTRDGGS VVGASVFYKDVAGLDTEGKQRSASQSSLDKLDQELK EQQKELKNQEELSSLVWI CTSTHSATKVLIIDAV QPG NILDSFTVCNSHVLCIASVPGARETDYPAGEDLSESG QVDIKASLCGSMTSNSSAETDSLLGGITVVGCSAEGVT GPATSPST)NCASPVMDKPPEMEAESEVDENVPTAB \ATEATEGNAGSAEDTV\DI SQTGVYTEHVFTDPLG\ VQI PEDLSPVYQSSNDSDAYKDQISVLPNEQDLVREE ________AQK MSSLLPTM WLGAQNGCLY VHS SVAQ WRICCLHS 1K WO 2004/080148 PCT/US2003/030720 657 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Lnknnwn, *=Stop codoi, ID beginning ending Ipossible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence LK DSILSIVI-IVGIVLVA LADGTLAI FHRGVD)CQWDL SNYI-LLDLGRPEHS IRCMTVVHDKVWCGYRNKI YVVQ PKAMKIEKSFDAHPRKESQVRQLAWVGDGVWVS IRLE STLRLYIIAITYQHLQDVDIEPYVSKM&LGTGKLGFSFV RITALMVSCNRLWVCTGNGVI ISTP1ITETVILHQGRL LGTRANKTSGVPGNRFGSVIRVYGDENSDKVTPCTFI PYCSMAHAQLCFHGHRDAVKFFV.AVPGQVI SPQSSSS GTDLTGDKGRGHLHRSLVVRRP 2295 A 1 1668 AAAAAAGAFAGRRAACGAVLLTELLERAAFYGITSNL VLFLNGAPFCWECAQASEALLLFMGLTYLGSPFGW ADARLGR-ARAILLSLALYLLGMLAFPLLAAFATRAAL CGSARLLNCTAPGPDAAARCCSPATFAGLVLVGLGVA TVKANI TPFCADQVKDRGPEATRRFFNWFYWS INLGA ILSLGGIAYIQQNVSFVTGYAI PTVCVGLAFVVFLCG QSVFITKPPDGSAFTDMFICILTYSCCSQKRSGERQSN GEGIGVFQQSSKQSLFDSCKMSHGGPFTEEKVEDVKA LVKIVPVFLALIPYWTVYFQMQTTYVLQSLHLRI PEI SNITTTPI-TLPAAWLTMFDAVLILLLI FLKDKIJVDPI LRRHGLTJPS SLKRIAVGMFFVMCSAFAAGILESKRLN LVKEKTINQTICNVVY-AADLSLWWQVPQYLLIGI SE I FAS IAGLEFAYSAAPKSMQSAIMGLFFFFSGVGSFV GSGLLA1JVSIKAIGWMSSIITDFGNINGCYLNYYFFLL AAIQGATIJLLFLI ISVKYDI-HRDQRSRANGVPTSRR A 2296 A 132 695 TQRAATPLPNSPQEAAILGSRRNQAGRVREKVYRSLP GPAFLGESWKRTJSVLQESFSHLTPRQSQMRKSDI FFK SLPSQFFGSFGKPVACVTCACSLQLLKFI PEKSDIEL LVYRIDI-YQQRLQALFEKKKFQERLAEAKPKVEGRAE GCRRLRVESYLIMILEKHFPDILNMPSELQHLPEAAK VK 2297 A 5 505 CKKCQKKFSSGYQLILEHRVHVIERPYECKECGKNFR SGYQLTLHQRFHTGEKPYECTECGKNFRSGYQLTVHQ RFHTGEKTYECTQCGKAFIYASEIAQHERIHTGGKPY ECQECGRAFSQGGHLRIHQRVHTGEKPYKCKECGKTF STRSXLVEI-GRVETDEKPY 2298 A 102 449 PAPASGFTQTWGDACDPAAPQRPLEACFSVQSRTSP MEPPI PQSAPLTPNSVMVQPIJLDSRMSHSRLQHPLTI LPIDQVKTSEVENDYIDNPSLALTTGPKRTRGGAPEL APT PA 2299 A 402 2624 MAESRGRLYLNMCLAAALASFLMGFMVGWFIKPLKET TTSVRYHQSIRWKLVSEMKAENIKSFLTSFTKLPHLA GTEQNFLLAKKIQTQWKKFGLDSAKLVHYDVLLSYPN ETNANYI SI VDEHETEI FKTSYLEPPPDGYENVTNIV PPYNAFSAQGMPEGDLVYVNYARTEDFFICLEREMGIN CTGKIVIARYGKIFRGNKVKNAMLAGAIGIILYSDPA DYFAPEVQPYPKGWNLPCTAAQRGNVLNLNGAGDPLT PGYPAKEYTFRLDVEEGVGI PRI PVIPIGY JDAEILL RYLSGIAPPDKSWKGALNVSYS IGPGFTG9DSFRKVR MEVYNINKI TRIYNVVGTIRGSVEPDRYVILGGHRDS WVFGAIDPTSGVAVLQETARSFGKIJMSK GWRPRRTI I WO 2004/080148 PCT/US2003/030720 658 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending possiblele nucleotide deletionrpossible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide reduce of sequence peptide reqiuece FASWDAEEFGLLGSTEWAEENVKILQERSIAYINSDS SIEGNYTLRVDCTPLLYQLVYKLTKEIPSPDDGFESK FLYESWVEKDPSPENKNLPRINKLGSGSDFEAYFQRL GIASGRARYTKNKKTDKYSSYPVYHTIYETFELVEKF YDPTFKKQLSVAQLRGALVYELVDSKIIPFNIQDYAE ALKNYAASIYNLSKKHDQQLTDHGVSFDSLFSAVKNF SEAASDFHKRLIQVDLNNPIAVRMMNDQLMLLERAFI DPLGLPGKLFYRHIIFAPSSHNKYAGESFPGIYDAIF DIENKANSRLAWKEVKKHISIAAFTIQAAAGTLKEVL * 2300 A 74 520 PGVGPCLSVPPSAPSLVFRSVAGGAGMAERGLEPSPA AVAALPPEVRAQLAELELELSEGDITQKGYEKKRSKL LSPYSPQTQETDSAVQKELRNQTPAPSAAQTSAPSKY HRTRSGGARDERYRSGEEKLQNGQLNRFPNSSMNCVS 2301 A 6256 5813 MALQLWALTLLGLLGAGASLRPRKLDFFRSEKELNHL AVDEASGVVYLGAVNALYQLDAKLQLEQQVATGPVLD NKKCTPPIEASQCHEAEMTDNVNQLLLVDPPRKRLVE CGQLLKGILRSARPEQHLPPPVLRGRQRGEVFRGQQ* 2302 A 402 578 MPTYWLANLRPGLQPFLLHFLLEWLAVFCCKIMVLAA AGLLPTLHMASFFSNALYNCFY 2303 A 186 1338 TRMSRHEGVSCDACLKGNFRGRRYKCLICYDYDLCAS CYESGATTTRHTTDHPMQCILTRVDFDLYYGGEAFSV EQPQSFTCPYCGKMGYTETSLQEHVTSEHAETSTEVI CPICAALPGGDPNHVTDDFAAHLTLEHRAPRDLDESS GVRHVRRMFHPGRGLGGPRARRSNMHFTSSSTGGLSS SQSSYSPSNREAMDPIAELLSQLSGVRRSAGGQLNSS GPSASQLQQLQMQLQLERQHAQAARQQLETARNATRR TNTSSVTTTITQSTATTNIANTESSQQTLQNSQFLLT RLNDPKMSETERQSMESERADRSLFVQELLLSTLVRE ESSSSDEDDRGEMADFGAMGCVDIMPLDVALENLNLK ESNKGNEPPPPPL 2304 A 126 397 PLTEDGSPGPPPEGFKDLRNQRPPPHTGPWRGPGPSG PPRSGQVPDNSTRCFLSDFWSPQGDQRPSCPYTGARP RQGAAQHLRCPSRRRR 2305 A 3 457 RAFDVRRKKSLRPCCPRDFHAGCLTVSGPSTVMGAVG ESLSVQCRYEEKYKTFNKYWCRQPCLPIWHEMVETGG SEGVVRSDQVIITDHPGDLTFTVTLENLTADDAGKYR CGIATILQEDGLSGFLPDPFFQVQVLVSSASSTENSV KTP 2306 A 1 1117 NSRVDDFVAVMAPRTLVLLLSGALALTQTWAGSHSMR YFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQ RMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGT LRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYA YDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAE QLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTH HPISDHEATLRCWALSFYPAEITLTWQRDGEDQTQDT ELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEG LPKPLTLRWEPSSQPTIPIVGIIAGLVLFGAVITGAV VAAVMWRRKSSDRKGGSYSQAASSDSAQGSDVSLTAC

KV

WO 2004/080148 PCT/US2003/030720 659 TABLE 7 SEQ Method Predicted Pedicted Amino acid sequence (XUnknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence 2307 A 3 491 DAWVAHASGELPPQTTKTLARFIPEVAVAYP(IPLT TQIKIKKPPKVTMKTGKSLLHLHSTLEMFAARWRSKA PMSLFLLEVHFNILKVQYSVHENQLQMATSLDRRGN/Y TGFITSYLEEAYIPVUDVLQVGLPLDFLMNYLA ELDIVENALMLDLKLG 2308 A 3 491 DAWVAHASGELPPQTTKTLARIPEVATAYPKSKPLT TQIKIKKPPKVTMKTGKSLLHLHSTLEMFAWRSKA PMSLFLLEVHFNLKVQYSVHENQLQMATSLDRRGN/Y TGFITSYLEEAYI PVVNDVLQVGLPLPDFLAM4NYNLA ELDIVENALMLDLKLG 2309 A 3 491 DAWVAHASGELPPQTTKTLARFIPEVAVAYPKSKPLT TQTKIKKPPKVTMKTGKSLLHLHSTLEMFARWRSKA PMSLFLLEVHFNLKVQYSVHENQLQMATSLDRRGN/Y TGFITSYLhEEAYI PVVNDVLQVGLPLPDFLAMNYNLA ELDIVENALMLDLKLG 2310 A 3 DAWVAHASGELPPQTTKTLARFIPEVAVAYPKSKPLT TQIKIKKPPKVTMKTGKSLLHLHSTLEMFARWRSKA PMSLFLL3EVIFNLKVQYSVHENQLQMATSLDRRGN/Y TGFITSYLEEAYI PVVNDVLQVGLPLPDFLAMNYNLA ETLDIVENALMLDLKLG 2311 A 75 739 APRAAPRLTMVSRMVSTMLSGLLFWLASGWTPAFAYS PRTPDRVSEADIQRLLHGVMEQLGIARPRVEYPAHQA MNLVGPQSIEGGAHEGLQHLGPFGNIPNIVAELTGDN I PKDFSEDQGYPDPPNPCPVGKTADDGCLENTPDTAE FSREFQLHQHLFDPEHDYPGLGKWKKLLYGKMKGGE RRKRRSVNPYLQGQRLDNVVAKKSVPHFSDEDKDPE 2312 A 2 606 P-IRKGTHPFPPT*SSPSGSC\SHCIASQCRQSPP HASC*RGSRWG* SGRAGWPAPGCR*AAPGLAGSAHPR PPPSNPRCPPPDAGPPGSGDPGLAAPEPSNHGRQHTA AAAAAGESQRHGRPGLAA* QPPLDTGPAARGSPPAPP GARPRGGGRQHRPQGLPQAQPQ*APGVRPRAA-PP \GHAGPDQAP3O(AARTRG 2313 A 42 706 PRGQMASTGLELLGMTLAVLGWLGTLVSCALPLWKVT AFIGNSIVVAQVWEGLWMSCVVQSTGQMQCKVYDSL LALPQDLQA.ARALCVIALLLALLGLLVAITGAQCTTC VEDEGAKARVLTAGVILLL-AGILVLIPVCWTAHAI I QDFYNPLVAEALKRELGASLYLGWAAAA LLMLGGGLL CCTCPPPQVERPRGPRLGYSI PSRSGASGLDKRDYV 2314 A 2 484 FVANMLCGLSRETPGEADDGPYSKGKDACGVCLA CRRQS IPEE FRGITVVELI KKEGSTLGLTI SGGTDKD GKPRVSNLRPGGLAARSDLLNIGDYIRSVNGIHLTRL RHDEIITLLKNVGERVVL/EAPENNPRI ISKTVDVSL YKEGNSFGFVLRGQ 2315 A 326 2 002 GLSRMSTETELQVAVKTSAKKDSRKK GQDRSEATLIK RFKGEGVRYKAKLIGIDEVSAARGDKLCQDSMMKLKG V-VAGARSKGEHKQKIFLTISFGC4IKIFDEI ,TGALQHH HAVHEI SYIAIDITDHRAFGYVCGKEGNHRFVAIKTA QAAEPVILDLRDLFQLIYELKQREELEKKAQKDKQCE QAVYQTILEEDVEDPVYQYIVFEAGISPIRDPETEEN

IYQVPTSQKI(EGVYDVPXSQPVSAVTQLELFGDMSTP

WO 2004/080148 PCT/US2003/030720 660 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence PDITSPPTPATPGDAFI PS SSQTLPASADVFSSVPFG TAAVFISGYVAMGAVLPSFWGQQPLVQQQMVMGAQPPV AQVM4PGAQPIAWGQPGLFPATQQPWFTVAGQFPAF IPTQTVMPLPAAMFQGPLTPLATVPGTSDSTRSS PQT DKPRQKMGKETFKDFQMAQPPPVPSRKPDQPSLTCTS EAFSSYFNKVGVAQDTDDCDDFDI SQLNLTPVTSTTP STNSPPTPAPRQSSPSKSSASHASDPTTDDIFEBCPE SPSKSEEQEAPDGSQASSNSDPFGEPSGEPSGDNI SP QGR 2316 A 132 428 VNVLNQEIEAFSLSEDTSSGLPEDRVVSVSFRVLYPI VTTSLGVFYDANDVGFQRNITVKLYQASQEEALFIAR FSPPSCGVQVNKLWYKPVEQFILPE 2317A2334 TAAAPVAPGTMDDATVLRKKYIVGINLGKGSYAK 231 ASAYSERLKFNVAVKIIARKKTPTDFVERFLPREMDIL ATVNI{GSI IKTYEIFETSDGRIYI IMELGVQGDLLEF IKCQGALHEDVARKMFRQLSSAVKYCHDLDIVERDLK CENLLLDKDFNIKLSDFGFSKRCLRDSNGRI ILSKTF CGSAAYAAPEVLQS IPYQPKVYDTWSTJGVILYIMVCG SMPYDDSDIRKMLRIQKEHRVDPRSKNLTCECDLI YRMLQ\PDVS \KRLIIIDSILSHS WLQPPKPK\ATS SA SFKRECEGKYRAECKLDTKTGLRPDHRPDHKLGAKTQ HRLLVVPENENRMEDRLAETSRAKDHHI SCABVGKAS 2318 A 993 648 TRYATPLAPPGHPFSCSRRNATHHTLWMGLALLGVL GDIQAAPEAQVSVQPNFQQDKFLGRWFSAGLASNS SW LREKKAALSMCKSVVAPATDGGLNLTSTFLRKNQCET RTMTJTQPAGSLGSYSYRS PHWGSTYSVSVVETDYDQY ALLYSQGSKGPGEDF1ATLYSRTQTPRAELKEKFTA FCKAQGFTEDTTVFTLPQTDKCMTEQ 2319 AI34 AHVRCLLSPGHTAGHMSYPLWEDDCPDPPALFSGDA LSVAGCGSCLEGSAQQMYQSLAELGTLPPETKVFCGH EHTLSWLEFAQKVEPCNDHKRDEDDVPTVPSTLGEER LYNPFLRVAEEPVRKFTGKA 2320 A 2 762 LEEVLKSELSGNFEKTALALLDHPSEYAARQLQ(=KU GLGTDESVLIEFLCTRTNKEI IAIKEAYQRLFDRSLE SNVKGDTSGNLKKILVSLLQANRNEGDDVDKDLAGQO AKDLYDAGEGRWGTDELAFNEVLAKRSYKQLRATFQA YQILIGKDI EEAIEEETSGD 1 QKAYLTLVRCAQDCED YFAERLYKSMKGAGTDEETLIRI IVTRAEVD:LQGTKA ________ _______KFQEKYQKSTJSDMVRSDTSGDFRKLLVALLH 2i321 A31335 QHSSRAGISSVAMPWAPLGHSGSHQLCVTFSSLHCLT RRNMHQMTDGLDKPGQIRWPLAITLATAWTLVYFCIW KG\TGWTGKVVYFSATYPYINLI ILFFRGVTIJPGAKEG ILFYITPNFRKLSDSEVWLDAATQIFFSYGLGLGSLI ALGSYNSFHNNVYRDSI TVCCTNSCTSMFAGFVIFSI VG-FMAHVTKRSIADVAASGPGLAFLAYPEAVTQLPI S PLWIAILFFSMLLMLGIDSQFCTVEGFITALVDEYPRL LRNRRELFIAAVCII SYJLIGLSNITQGGIYVFKLFDY YSASGMSLLFLVFFECVSI SWFYGXINTRFYDNIQEMVG SRPCIWWKLCWS FFTPT TXAGVFI FSAVQMTPLTMGN\ WO 2004/080148 PCT/US2003/030720 661 ________ TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide YVFPIKW C-QGVGWLMALSSMVLI PGYMAYZMFLTLKG-SL KQRIQVMVQPSEDIVRPEINGPEQPQAGSSTSKEAYI 2322 A 775 945 MMYILLVFLTLWLLIEMIHCLQNGDHRRTRPPTETGW LPLRFI-LRTGKILRYLRGE* 2323 A 197 598 MSAJRPLLLLLLPLCPGPGPGPGSEAKVTRSCAETRQ VLGARGYSLNLI PPAIISGEHLRV\CPQEYTCCS SETE QRLIRETEATFRGLVEDSGSFLVHTLAARHRKFDEFF LEMLFETLAFFCPDLSSHSTGA* 2324 A 2031 56 GTAETFHSVHFCPQPVPK APESPSLDSALASPLDPQA LACTPASPPDSQPPASP'QDSEALDFETPSSSLAPQTP DSALASETLASPQSLPPASPLLEDREEGDLGKASELA ETPKEEKAEGAAMLELVGSILRGCVPGVYRVQTVPSA RRPVVKFCH-RPSGLHGDVSLSNRLALJ4NSRFLSLCSE LDGRVRPLVYTLRCWAQGPRGLSGSGPLLSNYALTLLV IYFLQTRDPPVLPTVSQLTQKAGEGEQVEVDGWDCSF PRDASRLEFS INVEPLSSLLAQFFSCVSCWDLRGSLL SLREGQALPVAGGLPSNLWEGLRLGPLNLQDPFDLSH NVAANVTSRVAGRLQNCCRAAANYCRSLQYQRRSSRG RDWGLLPLLQPS SPSSLILSATPI PLPLAPFTQLT.AL VQVFREALGCUI EQATKRTP.SEGGGTGESSQGGTSR LKVDGQKNCCEEGKEEQQGCAGDGGEDRVEEMVIEVG EMVQDWAMQS PGQPGDLPLTTGKHGAPGEEGQPSIAA TAERGPKGHEAAQEWSQGEAGKGASLPSSASWRCALW HRVWQGRRRARRRLQQQTKEGAGGGAGTRAGWLATEA QVTQELKGLSCGEERPETEPLLSFVASVS PADRMLTV ________TPLQDPQGLFPDM{HFLQVFLPQAIRHLK 2325 A 3 262 SLSMCREVVYEYIPSVRQTELCYHELYYDAACTLG AYI-PLLYEKLLVQRLNMGTQGDLHRKGKVVLPGFQAV I-C PAPSPVI PHS 2326 A 241 1449 ASLCKGCFFVTidVLVIILPSLQSPPTFGFLLDIDGVL VRGHRVI PAALKAFRRLVNSQGQLRVPVTFVTNAGNI LQHSKAQELSALLGCEVDADQVILSHSPMKLFSEYHE KRMLVSCQGPVMENAQGLGFRNVVTVDEL~RMAFPLLD MVDLERRLKTTPLPRNDFPRI EGVLLLGEPVRWETSL QLIMDVLIJSNGS PGAGLATPPYPHLPVLASNMDLLWM AEAKMPRFGHGTFLLCLETIYQKVTGKELRYEGLMGK PS TLTYQYAEDLIRRQAERRGWAAPIRKLYAVGDNPM SDVYGANLFHQYLQKAThDGAPELGAGGTRQQQPSAS QSCI SILVCTGVYNPRNPQSTEPVLGGGEPPFHHRl LCFSPGLMEASHVVNDVNEAVQLVFRKEGWALE 2327 A 241 1449 ASLCKGCFFVTHVLVIILPSLQSPPTFGFLJDIDGVL VRGH-RVI PAALKAFRRLVNSQGQTLRVPVVFVTNAGNI LQH-SKAQELSALLGCEVDADQVI LSH-SPMKLFSEYH-E K<RMLVSCQGPVMENAQGLGFRNVVTVDELISAFPLLD MVDLERRLKTTPLPRNDFPRI EGVLLLGEPVRWETSL QLIMDVLLSNGSPGA2GLATPPYPHLPVLASNMDLLWM AEAKMPRFGI{GTFLLCLETIYQIKVTGIKELRYEGLMGK PS ILTYQYAEDLIRRQAERRGWAAPIRKLYAVGDNPM SDVYGZANLFHQYLQKATHDGAPELGAGGTRQQQPSAS QSCI SILVCTGVYI\PRNPQSTEPVLGGGEPPPIHGHRD WO 2004/080148 PCT/US2003/030720 662 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence LCFSPGLMEASHVVNDVNEAV\QLVFR(EGWALE 2328 A 1 359 ISCESIYWSQKPTPSSNASPWSEPAAVDVELTAYALL AQLTKPSLTQKEIAKATSIVAWJAKQRNAYGGFSSTQ DTVVALQALAKYATTAYVPSEEINLVVKSTENFQRTF NIQAVNRM 2329 A 1 359 ISGESIYWSQKPTPSSNASPWSEPAAVDVELTAYALL AQLTKPSLTQKEIAKATSIVAWLAKQRN AYGGFSSTQ DTVVAILQALAKYATTAYVPSEEINLVIVKSTENFQRTF NIQAVNRM 2330 A 1 359 ISGESIYWSQKPTPSSNASPWSEPAAVDVELTAYALL AQLTKPSLTQBCEIAKATSIVAWLAKQRNAYGGFSSTQ DTVVALQALAKYATTAYVPSEEINLVVKSTENFQRTF NIQAVNRM 2331 A 1 359 ISGESIYWSQKPTPSSNASPWSEPAAVDVELTAYALL AQLTKPSLTQKEIAKATS IVAWLAKQRNAYGGFSSTQ DTVVALQALAKYATTAYVPSEE INLVVKSTENFQRTF NIQAVNRM 2332 A 1 359 ISGESIYWSQKPTPSSNASPWSEPAAVDVELTAYALL AQLTKPSLTQKEIAKATS IVAWLAKQRNAYGGFSSTQ DTVVALQALAKYATTAYVPSEE INLVVKSTENFQRTF NIQAVNRM 2333 A 21 446 MESAVRVESGVLVGVVCLLLACPATATGPEVAQPEVD TTLGRVRGRQVGVKGTDRLVNVFLGI PFAQPPLGPIDR FSAPTAQPWEVRDASTAPPMCLQDVESMNSSRFVL NGKQQI FSVSEDCLVLNVYS PAEVPAGSGRP 2334 A 320 171 AASTTDGSYKCLCLPGYVPSDKPNYCTPLNTALNLEK CPFGLPHLSGSS 2335 A 351 49 PASPPRWGCWGCWGRWDCFASRSPWARS*SRRPPRST AAAPRS PARPRTCAGCTRRTWKTGRPARSRRSGRTPR AcIR*K* SPGSGTRTSRPGGRRRPAGAR 2336 A 3 813 TH-ASENAGQASSFANFLVRTYLGKDAGFDSEIFKRS TFGPSVEFTSVLKPVFAREKEPFSLSCL FSEDVLDAE S IQWFRDGSLLRSSRRRKILYTDRQASL~KVSCTYKED EGLYMVRVPS PFGFREQSTYVLVRDAEAENPGAPGSP LNVRCLDVNRDCLILTWAPPSDTRGNPITAYTIERCQ GESGEWIACHEAPGGTCRCPIQGLVEGQSYRFRVRAI SRVCSSVPSKASELVVMGDIDAARRKTEI PFDLGNKI TI STDAFEDTV 2337 A 834 628 DIREYK*NNPLVHMRTDET*MTMK**MVK EKKIVKED WRKVIILAS *QSFPSFFVIEHSKAIRGSWFPQL 2338 A 834 628 DIREYK*NNPLVI4MRTDET*MTMK**AMVKEKKIVKED WRKVHLAS*QSFPSFFVIEIISKAIRGSWFPQL 2339 A 3 449 PGAPRVRLETH-PEPLPSDTMVSSCCGSVCSDQGCGLE TCCRPSCCQTTCCRTTCCRPS CCVS SCCRPQCCQS VC CQPTCCRPSCCPSCCQTTCCRTTCCRPSCCVSS CCRP QCCQSVCCQPTCCRPSCSISSCCRPSCCVSRCCRSQR C 2340 A 3 449 PGAPRVRLETHPEPLPSDTMVSSCCGSVCSDQGCGLE TCCRPSCCQTTCCRTTCCRPS CCVSSCCRPQCCQSVC CQPTCCRPS CCPSCCQTTCCRTTCCRPSCCVSSCCRP WO 2004/080148 PCT/US2003/030720 663 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence QCCQSVCCQPTCCRPSCSISSCCRPSCCVSRCCRSQR C 2341 A 3 449 PGAPRVRLETHPEPLPSDTMVSSCCGSVCSDQGCGLE TCCRPSCCQTTCCRTTCCRPSCCVSSCCRPQCCQSVC CQPTCCRPSCCPSCCQTTCCRTTCCRPSCCVSSCCRP QCCQSVCCQPTCCRPSCSISSCCRPSCCVSRCCRSQR C 2342 A 38 1435 ACLICFRIGRGNCSRKICEEFLNPQILLTLELVVTLA GKNKCRCWTMLETLSRQWIVSHRMEMWLLILVAYMFQ RNVNSVIMPTKAVDPEAFMNISEIIQHQGYPCEEYEV ATEDGYILSVNRIPRGLVQPKKTGSRPVVLLQHGLVG GASNWISNLPNNSLGFILADAGFDVWMGNSRGNAWSR KHKTLSIDQDEFWAFSYDEMARFDLPAVINFILQKTG QEKIYYVGYSQGTTMGFIAFSTMPELAQKIKMYFALA PIATVKHAKSPGTKFLLLPDMMIKGLFGKKEFLYQTR FLRQLVIYLCGQVILDQICSNIMLLLGGFNTNNMNMS RASVYAAHTLAGTSVQNILHWSQAVNSGELRAFDWGS ETKNLEKCNQPTPVRYRVRDMTVPTAMWTGGQDWLSN PEDVKMLLSEVTNLIYHKNIPEWAHVDFIWGLDAPHR MYNEIIHLMHQEETQPFPRTA 2343 A 38 1435 ACLICFRIGRGNCSRKICEEFLNPQILLTLELVVTLA GKNKCRCWTMLETLSRQWIVSHRMEMWLLILVAYMFQ RNVNSVHMPTKAVDPEAFMNISEIIQHQGYPCEEYEV ATEDGYILSVNRIPRGLVQPKKTGSRPVVLLQHGLVG GASNWISNLPNNSLGFILADAGFDVWMGNSRGNAWSR KHKTLSIDQDEFWAFSYDEMARFDLPAVINFILQKTG QEKIYYVGYSQGTTMGFIAFSTMPELAQKIKMYFALA PIATVKHAKSPGTKFLLLPDMMIKGLFGKKEFLYQTR FLRQLVIYLCGQVILDQICSNIMLLLGGFNTNNMNMS RASVYAAHTLACTSVQNILHWSQAVNSGELRAFDWGS ETKNLEKCNQPTPVRYRVRDMTVPTAMWTGGQDWLSN PEDVKMLLSEVTNLIYHKNIPEWAHVDFIWGLDAPHR MYNEIIHLMHQEETQPFPRTA 2344 A 91 1042 VTMYKDCIESTGDYFLLCDAEGPWGIILESLAILGIV VTILLLLAFLFLMRKIQDCSQWNVLPTQLLFLLSVLG LFGLAFAFIIELNQQTAPVRYFLFGVLFALCFSCLLA HASNLVKLVRGCVSFSWTTILCIAIGCSLLQIIIATE YVTLIMTRCMMFVNMTPCQLNVDFVVLLVYVLFLMAL TFFVSKATFCGPCENWKQHGRLIFITVLFSIIIWVVW ISMLLRGNPQFQRQPQWDDPVVCIALVTNAWVFLLLY IVPELCILYRSCRQECPLQGNACPVTAYQHSFQVENQ ELSRDKWKVLLNSDFLSHSGA 2345 A 2 669 AHTMVPEEEPQDREKGLWWVQVKVWSMAVVSILLLSV CFTVSSVVPHNFMYSKTVKRLSKLREYQQYHSSLTCV MEGKDIEDWSCCPTPWTSFQSSCYFISTGMQSWTKSQ INCSVMGADLVVINTREEQDFIIQNLKRNSSYFLGLS DPGGRRHWQWVDQTPYNEN\SREYRMRFWHSGEPNNL DERCAIINFRSSEEWGWNDIHCHVPQKSICKMKKIYI 2346 A 2 669 AHTMVPEEEPQDREKGLWWVQVKVWSMAVVSILLLSV

CFTVSSVVPHNFMYSKTVKRLSKLREYQQYHSSLTCV

WO 2004/080148 PCT/US2003/030720 664 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible ncleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence MEGK DIEDWSCCPTPWTSFQSSCYFI STGMQSWTKSQ K<NCS-VMGADLVVINTRE8QDFIIQNLKRNSSYFLGLS DPGGRRHWQWVDQTPYNEN\SREYRMRFWE{SGEFNNL IDERCAI INFRSSEEWGWNDIHCHVPQKSICI(MKKIYI 2347 A 1 2093 MLVLNSWAQVIHWPQPPKVLCLQPLEKTQYGFLCTDR VEEKITSVITIRVSVTHRENSYMEAENLTELSKFLLLG LSDDPELQPVLFGLFLSMYLVTVLGNLLI ILAVSSDS HLHTPMYFFLSNLSFVDICFI STTVPRMILVSTQARSK DI SYMGCLTQVYFLMMFAGMDTFLLAVMAYDRFVAIC UPLUYTVIMNPCLCCLLVLASWFI IFWFSLVRILLMK RLTFSTGTE IPHFFCEPAQVLKVACSNTLLNNIVLYV ATALIJGVFPVAGILFSYSQIVSSLMCMSSTKGKYKAF STCGSIHLCVVSLFYGTGLGVYLSSAVTHSSQSSSTAS VMYAMVVTPMLNPFIYSLRNKDVKGALERLLSRADSCL LRCFSYTEPQNLTGVSEFLLLCLSEDPELQPVLAGLF LSMYLVTVLGNLLI ILAVSSDSHLHTPMYFFLSNLSL ADIGFTSTTVPKMIVDMQTHSRVISYEGCLTQMSFFV LFACMDDMLLSVMAYDRFVAI CHPLHYRI IMNPRLCG ELILLSFFI SLLDSQLHNIJMLQLTCFKDVDISNFFC DPSQLLHIJRCSDTFINEMVIYFMGAIFGCLPI SGILF SYYKIVSPI LRVPTSDGKYKAFSTCGSHLAVVCLFYG TGLVGYLSSAVLFSFRKSMVASVMYTVVTPMLNPFIY SLRNKDIQSALCRLHGRI IKSHHLHPFCYMG 2348 A 773 317 QCTQKAAEQYTQFYYVDVLDGKLACVNKCTKT NCNLGTCQLQRSGPRCLCPNTNTHWYWGETCEFNIAK SIVYCIVGAVMAVIJLLALIILI ILFSLSQ\RKRHRPE SEGEADFQLENATNNFG\ FTLETVDSGTELHIQ\RPE MVASTV 2349 A 55 414 MALTGYSWLLLSATFLNVGAETTLEPAQPSEGDNV ThVVEGLSGELLAYSWYAGPTLSVSYLVASYIVSTQD ETPGPAHTXREAVRPDQSLDIQGILPRHSSTYILQTF NRQLQTEVG 2350 A 1 790 RGYNPNVNAGIINSFATAAFRFGHTLINPILYRLNAT LGEISEGHLPF-KALFSFSRI IKEGGIDPVLRQLFCV AAKWRAPSYL1JSPELTQRLFSAAYSAAVDSAATI IQR GRDHGI PFYVDFRVFCNLTSVKNFEDLQNEIKDSEIR QKLRKIJYGSPGDIDLWPALMVEDLT PQTRVGPTLMC/ ML! STQFQRLRDGDRFWYENPGVFTPAQLTQLKQASL SRVLCDNGDSIQQVQADVF/RKRQEYPQDYLNCRRES PNVDPAKC 2351 A 1 790 RGYNPNVNAGIINSFATAAFRFGHTLINPILYRLNAT LGEISEGLPFKALFSPSRIIKECGIDPVLRCLFQV AAKWRAPSYLLSPELTQRLFSAAYSAAVDSAATI IQR GRDHGI PPYVDFRVFCNITSVKNFEDLQNEIIOSEIR QKLRKLYQS PGDIDLWPALMVEDLTPGTRV-FTLMC/ ML! STQFQRLRDGDRFWYENFGVFTPAQLTQLK QASL SRVLCDNGDSIQQVQADVF/RIKRQEYPQDYLN\CI1RES PNVDPAKC 2352 A 1 671 NFLsRRLLLTGPPQVGKTnSYLQFLRILFRMLIRLLE VDVYDEEEINiTDHNESSEVSQSEGEPWPDTESFSIMP WO 2004/080148 PCT/US2003/030720 665 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence FDVSVHIDPKYSLMSLWYTEKL-AGVIKQBVIK ESKVEEP R =ETVSIMLTKYAAYNTFHI4CEQCRQYMDFTSASQM SDSTIIHAFTFSSSMLGEEVQLYFII FKSKESHFVFSK QGKHLESMRLPLVSDIQNLNAVKSPI FTPSSG*HEHGH V 2353 A 2 805 RELHKEVEVAKRNLAQQKIISEMESKLVEQQLAEENK LLKEQENDKELVVNLLRMTQIKIDEKQKSIOFLKAQ QKYTNIVKEMKAKDLEIRI HKKKKCEI:YRRLREFAKL YDTTRNERNKFVNLLHKAHQIKVNEIKERHKM4SLNELE ILRNSAVSQFRKLQNSMLKHANNTTIRESMQNDVRKT VSKLQEMKEKKEAQLNNIDRLAKTITMIEEEMVQLRK RYEKAVQHRNERRGLSPGMITKDRFLPVYGEITTRNI QLEKKLMGL 2354 A -159 1028 MGLCVPFAVTTSFLSLGLEWDLNVRLHGQHLVQQLVL RTVRGYLETPQPEKALALSFHGWSGTGKNFVARMLVE NLYRDGLMSDCVRMFIATFHFPHPKYVDLYKEQLMSQ IRETQQLCH-QTLFI FDEAEKLI-PGLLEVLGPULERRA PEGHRAESPWTI FLFLSNLRGDI INEVVLKLLKAGWS REEl TMEHTEPHLQAEIVETIDNGFGHSRLVKENLID YFIPFLFLEYRI-VRLCARDAFLSQELLYKEETLDEIA QDMVYVPKEEQLFSSQGCKST SQRTNYFJS * 2355 A 736 17 *RAMNpSTCFLEIGSI*TGRYCKTVLCKLRAVL*SFR VLNITKAYLVLFSSLYKNLICSSVRSVPLKKFLKSLS SI LRDRFFK*T*NPRGERERVJTLGEFE*DRFRKCLSL IPLGGECSSDLLRTSPSLTALFPNSIECCSDPCITSI NLEPIKLL*HLRPPEASTHEANFTMASPLFRPS *CFK KITPSTHKPEKKTRTSSSFTR*GKPRRNK*GFSAFNG LVFLGLKLPCPVPLV*NP 2356 A 506 1317 CRTSSGKAGMWKPGAESWPLHTGAAQVMWFEKLYAGL QCVEKYLTYPAVVLNALTVDAHTVVSHPDKYCFYCRA LLMTVAGLKLLRSAFCCPPQQYLTLAFTVLLFEFDYP RLSQGFLLDYFLMSLLCSKLWDILYKLRFVLTYIAPW QITWGSAFHAFAQFFAVFNSAMLFVQALLSGLFSTPL NPLLCSAVFIMSYARPLKFWERDYNTKRVDHSNTRLV TQLURNPGADDNNLNS IFYEHLTRSLQHTLCGDLVLG RWGNYGPGDCF 2357 A 506 1317 GRTSSGKAGMWKPGAESWPLHTGAAQVNWFEKLYAGL QCVEKYLIYFAVVLNALTVDAHTVVSHFDKYCFYCP, LLMTVAGLKIJLRSAFCCPPQQYLTLAFTVLLFHFDYP RLSQGFLLDYFTJMSILCSKLWDLLYKLRFVLTYIAPW QITWGSAFHAFAQPFAVPHSALFVQAJISGLFSTPL NPLTGSAVFIMSYARPLKFWERDYNTKRVDHSNTRLV TQLDRNFGADDNNLNSI FYEHLTRSLQHTLCGDLVLG RWGNYGFGDCF 2358 A 3 301 STATWAGVQWCNLSSLQPLPSGFKPFSCLSLPGSWDH RHLPPCPANFLYCFFLVENGFHYVGQAGLKLLT/ S/c DLCASAPQSAGSTVERVRLGLLIYI P 2359 A 326 1379 PEPHAVQCAELRHQQPRDPQRLQQDGSADAFAERKPH CGGERAHGSG\FLAMLLVILGLCGAAYRPTEEIDLRSV GWONI FQLFFKHVRDYRLR-LVPFFIYSGFEVLFACT WO 2004/080148 PCT/US2003/030720 666 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide dclction,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide seequence GIALC-YGVCSVGLERLAYLLV\AYSLGASAASLLG\L LGLWLPRPVPLVACAGVHLLLTFILFF\WAPVPRVLQ HSWILYVAAALWGVGSALNKTGLSTLLGILYEDKERQ DFI FTIYHWWQAVAI FTVYLGSSLHMAIaE \VLLVT LVAAAVSYLRMEQKLRRGVAPRQPR\ IPRPQHKVRG\ YRYLQAHN)SDESDPEGEHADA, AQEEAPPAGFRPGP\E PAGLGRRPCPYEQAQGGD\GPDEEQ 2360 A 2 1397 LRAGEDMAASASAAACEEDWVLPSEVEVLESIYLDEL QVIKIGNGRTSPWEIYITLUPATAEDQDSQYVCFTLVL QVPAEYPHEVPQI SIRNPRGLSDEQIHTILQVLGHVA KAGLGTAMLYELIEKGKEILTDNNIFHGQCVICLYGF QEKEAFTKTPCYHYFHCWCLARYIQHMEQELKAQGQE QEQERQHATTKQKAVGVQCPVCREPLVYDLASLKAAF EPQQPMELYQPSAESLRQQEERKRLYQRQQERGGI ID LEAERNRYFI SLQQPPAPAEPESAVDVSKGSQPPSTL AAELSTSPAVQSTLPPPLPVATQHICEKI PGTRSNQQ RLGETQKANLDPPKPSRGPWRQPERRHPKCGECHAPK GTRDTQELPPPEGPLKEPD4DLKPEPHSQGVEGFPQEK GFGSWQGPPPRRTRDCVRWERSKGRTPGSSYPRLPRG QGAYRPQTRRESLGLESKDGS 2361 A 718 305 SEQEPLLGDTPGSREWDILETEEHYKSRWRSIRILYL TMFLSSVGFSVVMMS IWPYLQKIDPTADTSFLGWVIA SYSLGQMVASPI FGLWSNYRPRKEPLIVSILTSVAAN CLYAYLHI FASHNKYYMLVARGLLGIG 2362 A 169 879 MTAEFLSLLCLGLCLGYEDEKKNEKPKPSLHAWPSS VVEAESNVTLKCQAHSQNVTFVLRKVNDSGYKQEQSS AENEAEFPFTDLKPKDAGRYFCAYKTTASHEWSES SE HLQLVVTDKHDELEAPSMKTDTRTIFVAIFSCI SILL LFLSVFI IYRCSQHSSSSEESTKRTSHSKLPEQEAAE ADLSNMERVSLSTADPQGVTYAELSTSALSEAASDTT QEPPGSHEYAALKV* 2363 A 169 879 MTAEFLSLLCLGLCLGYEDEKKNEKPFKPSLHAWPSS VVEAESNVTLKCQAWSQNVTFVLRKVNDSGYKQEQSS AENEAEFPFTDLKPKDAGRYFCAYKTTASNEWSESSE I-LQLVVTDKHDELEAPSMKTDTRTIFVAIFSCI SILL LFLSVFI IYRCSQHSSSSEESTKRTSH-SKLPEQEAAE ADLSNMERVSLSTADPQGVTYABLSTSALSEAASDTT QEPPGSHEYAALKV* 2364 A 43 1 369 AAAWGLAAWGEGPTDATSCWEVGAGGPGNSRPNQTVS MDLNSASTVVLQVLTQATSQDTAVLKPAEEQLKQWET QFGFYSVLLNI FTNHTLDINVRWLAVLYFKHGIDR 2365 A 4272 1534 CIGLQHLTPFRELNLSLQG*EPH*AAMQAVRSEEKSI C*GSPSCHLVLGVLVFVARQSSIISAGFAQSAFR*TGT GSGTPKAAEQSGYWEAYTLGUQHWNMFFIQRPPLVMK GRRIMCGKCEKG*VSDSVTGGRAVAGEQASQRRTVFT AGGGECLGAKSVRASVFTGTQPGVMGLLNGKRCGCFE SGYLFCFIVIGKIQSLEA VPLPVNGQTGERAS PONG RIHIVDAVC*SEHH*DI-FLAAAFLENSTI I SVAPGS WQDHAVLQKEVQASVRCRGFESVDTAPAGFWIAHSPPG

LQGEPTTTSVSLFVLAPQDGEC-VPFVEGQLVTVLGLV

WO 2004/080148 PCT/US2003/030720 667 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence VPQSIRHTF\HHTQLL-PI *KLGALDVAFLHLLTLV CSSFNVAYQG CKNGGTTJJHQLFAEVNAVTRGSAVQRR PS ITISS IHVDTKIQQELHDVMVAGADGVVQWGDFFV VGLAGIFHLIDDPLHQIELSFQRRV* EQCQGVKPDSQ PVPRPLRVGLLQVGPLVRGGGRRVARGIKRCWRDLLF PWRWGLSHRTRDLLR-GDRGHVVVIVLCRLGSLVC-GL GTDELLWFGGR*LIIIGI **RGRLSGEWGCGLGRGEL FQVS IGIGVSIVHIGQGDHEVLGGAGLVERGALHATG QGVEALVQQLLDVGPAGALGLCDGAALFQGPGRVGQL PAEGLQVCITLVAQWRMHDGRELGGAEWPWQALHGAA ICGVGGAILLKALSQYFJLKGG*RLWCARGQ* PVKKRQ RRWRG*TRR*NGLTIHCFN*LI *GAVCCRLVILRWCG LLEV.GVYGT* IHCLGSFPGRLWP*PF1SQERPNGHC QWEFRLAVPSWKCRWSRWRVRGTWRYGNPL~LNLL*GA WLGGAACGGQQGGPLSTWQACTGPGQAAFLPPFQGAC RPRTQRCRTWVCPIAWRQLLAYTRD 2366 A 193 366 MYGMLEWPISMYFVAFLeiCFLCSGGNLeDSFQALPEL CnCSSSPRVLCCVVMSPLP* 2367 A 1038 1402 YYQISSLPSIVGNGIFLWLLICIFLAKQGGSRL*FQP FGRPRCGGHLRSGVLCQPGQHGETP/ SFFYNSKI SPA LWGPPVI PSALGGEAGKSL*PRRQRFQRGGIAPLPSR VRGRAKLFLKKK 2368 A 480 226 MHFLATFALFFIFGVFFLFAVLTNLLLAEEVNIRGGN FLGSFLVHTLFLDQVPGEITH-DSHLVLAI TINTASPK FSSSIFFYQL* 2369 A 259 941 PVSWSLNSCRFFFFF*DQSLPSVV/QAGSCQ*RNLDS L\QPLASRFK*FSSSRLj\ SSW\DYRHMATMARLIFI FLVED4GF\ TDLARLVLNFLTSSDPPTSAFPKWLGLQC VKPNTRAVGFN* *LGYYS IILYH-SNSPGTDLVF ILFI YLFTYLFLRQEQNSAAQARVQ*WHNLGSLQSPPPGV\ lH* FLCLSLPSSWDYRCAPPHQANFFIFSRDGVS PCWP GWS*TPDLR 2370 A 1676 1197 MALRHLALLAGLLVGVASKSMENTAQLPECCVDVVGV NASCPGASLCGPGCYRRWNADGSASCVRCG.NGTLPAY NGSECKSFAGPGAPFPMNRSSGTPGRPHPGAPRVAAS LFLGTFFI SSGLILSVAGFFYL(RSSKLPRACYRRN( APALQPGERLQ* 2371 A 1078 594 VGMELPAVNLKVILLGHWLLTTWGCIVFSGSYAWANF TILALGVWAVAQRDSIDAISMFLGGLLATIFLDIVI SIFYPRVSLTDTGRFGVGMAILSLLLKPLSCCFVYHM YRERGGELLVHTGFLGSSQDRSAYQTIDSAEAPADPF AVPRGRSQDARGY 2372 A 3 517 HEGRELETGQGRQSSVGAAQGTGVRAGVRAGTTQSGR RRARVSGRLAEVSASVAWAVLKVLLLLPTQTWSPVG AGNPPDCDAPLASALPRS SFS SSSELSSSHGPGFSKL NRRDGAGGWTPLVSNKYQWLQIDLGERMEVTAVATQG GYGSSDVTSYLLMFSDGGRNWK 2373 A 3 517 I-PEGRELETGQGRQSSVGAAQGTGVRAGVRAGTTQSGR RRARIVSGRLAEVSMASVAWAVLKVLLLLPTQTWSPV

AGAPPDCDPLASALPRSSFSSSELSSSHGPGFSRL

WO 2004/080148 PCT/US2003/030720 668 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence NRRDGAGGWTPLVSNKYQWLQIDLGERMEVTAVATQG GYGSSDWVTSYLLMFSDGGRNWK 2374 A 2 1078 GRVGWELWCMYISPPKDWWDAGDPSLPIRTPAMIGCS FVVNRKFFCEIGLLDPGMDVYGGENIELGIKVWLCGG SMEVLPCSRVAHIERKKKPYNSNIGFYTKRNALRVAE VWMDDYKSHVYIAWNLPLENPGIDIGDVSERRALRKS LKCKNFQWYLDHVYPEMRRYNNTVAYGELRNNKAKDV CLDQGPLENHTAILYPCHGWGPQLARYTKEGFLHLGA LGTTTLLPDTRCLVDNSKSRLPQLLDCDKVKSSLYKR WNFIQNGAIMNKGTGRCLEVENRGLAGIDLILRSCTG QRWTIKNSIK*REGAGALEPGPQDMAAPPNIWTSCPG GETARGRQVLDGPPRASPGQHRDPG 2375 A 2 630 ESNSRCRKMPGERCRGGPARLSLLLDLPTRPLPHPRQ VIDFGSASIFSEVRYVKEPYIQSRFYRAPEILLGLPF CEKVDVWSLGCVMDELHLGWPLYPGNNEYDQVRYICE TQGLPKPHLLHAACKAHHFFKRNPHPDAANPWQLKSS ADYLAETKVRPLERRKYMLKSLDQIETVNGGSVASRL TFPDREALAEHADLKSMVELISAC 2376 A 77 273 PRTGMGCCLPGADPAEIRSSPSPSWSTAGSQGCWMTS FSPCSCAPCCSSGCACTTGFVSREKESV 2377 A 1164 464 APWPLPLLRSPQSRPHSLGSLFPSLPGLAELDLQRTL SLQAPPVKEGPLFIHRTKGKGPLMSSSFKKLYFSLTT EALSFAKTPSSKCVNELNQWLSALRKVSINNTGLLGS YHPGVFRGDKWSCCHQKEKTGQGCDKTRSRVTLQEWN DPLDHDLEAQLIYRHLLGVEAMLWERHRELSGGAEAG TVPTSPGKVPEDSLARLLRVLQDLREAHSSSPAGSPP SEPNCLLELQT 2378 A 706 951 MRCGWGPLGCLGTGAPAGWMVLGSPRSQLQRARWSRA SLSAFGWEIRLRPEGPKAPRQLLLVALESETLGVHGG ATPLHCL* 2379 A 2 456 CVNTFGSYICKCHKGFDLMYIGGKYQCHDIDECSLGQ YQCSSFARCYNVRGSYKCKCKEGYQGDGLTCVYIPKV MIEPSGPIHVPKGNGTILKGDTGNNNWIPDVGSTWWP PKTPYIPPIITNRPTSKPTTRPTPKPTPIPTPPPPPR IPP 2380 A 3 1435 LRRHFFFPPSFPPLLLPSLPLSSPLSSFPPRSAGACW GERLVLQALALRGRPAGSWRGEEAGTAMAPQKHGGGG GGGSGPSAGSGGGGFGGSAAVAAATASGGKSGGGSCG GGGSYSASSSSSAAAAAGAAVLPVKKPKMEHVQADHE LFLQAFEKPTQIYRFL*TRNLIAPIFLHRTLTYMSHR NSRTNIKRKTFKVDDMLSKVEKMKGEQESHSLSAHLQ LTFTGFFHKNDKPSPNSENEQNSVTLEVLLVKVCHKK RKDVSCPIRQVPTGKKQVPLNPDLNQTKPGNFPSLAV SSNEFEPSNSHMVKSYSLLFRVTRPGRREFNGMINGE TNENIDVNEELPARRKRNREDGEKTFVAQMTVFDKNR RLQLLDGEYEVAMQEMEECPISKKRATWETILDGKRL PPFETFSQGPTLQFTLRWTGETNDKSTAPIAKPLATR NSESLHQENKPGSVKPTQTIAVKESLTTDLQKK 2381 A 20 1748 KPFNVGLSLNKTERLQLSHGGCKARTAVRAGVFYRAV

LQPLTLAQGGLPGGSGK/EGSSGCAGTDVGEQASGHR

WO 2004/080148 PCT/US2003/030720 669 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequencee peptide sequence ALS*QAVTPAPS *MGHPLSGS*GHQLEPQAGTSPNFA LVTLGHSRPQFPQL*GEALGRRGWPQPVS* *PGVSIR ET*EAARRGSASARQGRPSS *QGTC*~I *RT/AGVKKT PAGQAREGQL* CGTAACGAVCPERVGT SPS\QEHGPG GRRGVRVDKDTPAES-PHSI PSNKGTPSRKFAVFPGA PVPPSLTPLSIATLPSSLTGGRGGGGKADCSGEPG CPVLCQQMPPFHLPLAPASDHPGSAPGLQPPQRKPEG LPGRCRSDPSGVPTAPESGPGEPRP/GTQDALVWP CLGPCSGPSQDLGSGGTCGSLCSRHHPPLPRPT*VAS S *GQAGLSFARPSPP/SRAELGQDANATPPSA*R/GS PAQRGINNWGGPVGGAGWAR/ PGQEATPAGTEYG*DC PSVGSPQAQDGGQGRRCEGGG\ PGPW*HH*AHSPCGA AGCWPRCRRSSAAD)QRAAQGAPPCAGTGAARRARVRC PAGAAGSAAARTRNRPAG*QSAPPGRTRGS 2382 A 84 428 MSERVERNWSTGGWLLALCLAWLWTELTLAALQPPTA TVLVQQGTCEVIAAHRCCNRNRIEE.SQTVKCSCFSG QVAGTTRAKPSCVDDTLL~AAHCARRDPRAALRLLLPQ PPSs 2383 A 84 428 MSERVERNWSTGGWLLALCLAWLWTHLTLAALQPPTA TVLVQQGTCEVIAAHRCCNRNRIEERSQTVKCSCFSG QVAGTTRAKPSCVIDDLLLAAHCARRDPRAALRLLLPQ PPsS 2384 A 1919 3044 HQGPSTPPSWAMSGPPTPLSREDWHQGPSTPPSWAMS EFPT/ SSIQGLASGAVHTILLGDVRATYTSIQGVTSG VSQVSRIAAQMAVPS SRILQLSKPKAPATLLE\EWDPV PKPKPHVSIDHNRLLHLAKVPRKEGSGKKVGAFPEIKG PEAFRDKARAMESQSNDMPFDELLALYGYEASDPISD RESEGGDVDPNLPEMTLDKEQIAKDLLSGEEEEETQS SADDLTPSVTSH-EASDLFPNRSGCLLACEAESSRGLL PRAQPVPRGAGLADNSRGALLRAHGTVRVGTTATVKP ADAPPESPRDRRSRNDSHRPTGPSESERQPQSNQPTL LLRGHGTIRVRTTATVKPADAPAESPRDRRSRNDSHG QSSRRSC 2385 A 1206 2266 RHLLTIFHKLKIYKTINKIDFKKKRVTQLLVFCLFLC LFFSSEMVKNQTMVTEFLLLGFLLGPRIQMLLFGLFS LFYVFTLLGNGTILGLI SLDSRLHTPMYFFLSHLAVV NIAYACNTVPQMLVNLLHPAKPI SFAGCMT* TFLFLS FAHTECLLLVLMSYDRYVAICHPLRYFI IMTWI(VCIT LAITSWTCGSLLAMVHVSLILRLPFCGPREINHFFCE ILSVLRLACADTWLNQVVI FAACMFILVGPLCLVLVS YSI-ILAALRIQSGEGRRKAFSTCSSHLCVVGLFFGS AIVMYMAPKSRHPEEQQKVLFLFYSSFNPMLNPLIYN LnNVEVKGALRRAsoCKESHS 2386 A 1206 2266 RH-LLTFHKLKIYKTINKIDFKKIKRVTQLLVFCLFLC LFFSSEMVIKNQTM-VTEFLLLGFLLCPRIQMLLFGLFS ILFYVFTLLGNGTILGLI SLDSRLhHTPMYFFLSH-LAVV N\IAYACNTVPQMLVNLLHPAKPI SFAGCMT*TFLFLS FAHTECLLLVLMSYDRYVAICHPLRYFI IMTWKVICIT LAITSWTCGSLLAMVHVSLILRLPFCGPREIN{FFCE _____ ILSVLRLACADTWLNQV-VIFA2ACMFILVGPLCLVLVS WO 2004/080148 PCT/US2003/030720 670 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence YSEILAAILRIQSGECRRKAFSTCSSHLCVVQLFFGS AIVMYMAPKSRHPEEQQKVLFLFYSSFNPMLNPLIYN _______LRNVEVKGALRRALCI(ESHS 2387 A 17 6 371 HFYFCFSDINLAAEPKVNRGKAGVKRSAAEMYGSVTE HPSPSPLLRSGTLLFITALCPSVCIFSF 2388 A 3870 3673 N\TQCIPEGLESYYAEQDSSAREKFYTVINHYNLAKQS I TRSVS PWMSVLSEEKIJSEQETEAAEKSA 2389 A 1 542 SGSSHASDGSGFQELRICSEDQTPLIACMCSLPMARY YI IKYADQKALYTRDGQLLVCDFVADNCCAFKTCTLP NRGLERTKVPI FLGIQGGSRCLACVETEEGSLQLaED VNIEELYKGGEEATRFTFFQSSSGSAFRLEAAAWPGW FLCGPAEPQQPVQLTKESEPSARTKFYFEQSW 2390 A 3 569 iLNERLANYLQKVRMJERENAEESKIQEESNKEL V LCPDYLSYYTTIEELQQKILCTKAENSRLVSQIDNTK LTADDLRAKYEAEVSSRQIJVESDANGLKQILNVLTLG KADLEAQVQSLKEELLCLKNNUKEEINSLQCQLGERL DIEVTAAPSADLNQVLQE4RCQYEPIMETNRKDVEQW FNTQ 2391 A 3 581 GRRLRSEPiPARPPIARAWPPAPGADlcARRTRVPAP CLPRAPCYGVRPRAWRPRPARTJRGGLVRWLLSGGPQP RRPRATERPSAGTGAAPRRTEPRGRCRGCGRGRG*GP RAWCLALCSPHSCSGAAWGPTTGSQRSWPAVARSWQG DSSRCPATJRTTTVTAGSKAALPESAAEVSPMSS SPGR KRSGFAA 2392 C 175 454 MCSLCFLPSLQYWCDELKVEXKTQGRGFPLPGSPASA SHASWTALVKGVGSGQAQEAEGSEEQEIGESPGQSQG ________VAGAGLGLNEGQVPRMXTR 2393 A 157 396 GGGNTSCSVRFLEQQNQVLETKWELLQQLDLNNCKNN LEPTILEGYI SNLRKQLETLSGDRVRLDSELRSVRDVV EDYKKR 2394 A 126 561 WKMKKMCNWLRIINYTPDMARAAVDEATQEGLEVWSK VTPLKFTKI SKGIADIMIAFRTRV-GRCPRYFDGFLG VLGI-AFPPGPLGGDTEFDEDENWTKDGADLHDNS PF _________YGHDGCLAH-APPGPGIGGDVHFDNDETRTKDFR 2395 A 126 561 WKMKKMCNWLRIINYTPDMARAAVDEAIQEGLEVWSK VTPLKFTKI SKGIADIMIAFRTRVHGRCPRYFDGPLG VLGHAFPPGPGLGGDTHFDEDENWTKDGADLHiDNSPF YGHDGCLAHAFPPGPGIGGDVIFDNDETRTKDFR 2396 A 1 1452 MAELRPSGAPGPTAPPAPGPTAPPAFASLFPPGLHAI YGECRRIYPDQPNPLQVTAIVKYWLGGPDPLDYVSMY RZNVGSPSANI PEUWHITSFCLSDLYGDNRVHEFTGTD GPSGFGFELTFRLKRETGESAPPTWPAELMQGLARYV FQSENTFCSGDHVSWHSFLDNSESRIQHMLLTEDPQM QPVQTPFGVVTFLQIVGVCTEEL4SAQQWNGQGILEL LRTVPIAGGPWLITDMRRGETIFEIDPHLQERVDKGI ETDGSNLSGVSAKCAWDDLSRPPEDDEDSRS ICIGTQ PRRLSGKDTEQIRETLRRGLE INSKPVLPPINPQRQN GLAHRAFSRKDSLESDS STAIIPFEELIRTRQLESVH LKFNQESCALI PLCLRGRLLHGRHFTYKSITGDMAIT FVSTGVEGAFATEEHPYAA-GPWLQILLTEEFVEKM1L WO 2004/080148 PCT/US2003/030720 671 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=lnknown, *=Stop cadon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of Sequence peptide sequence EDLEDLTSPEEFKLPKEYSWPEKKLIKVSILPDVVFDS PLH 2397 A 126 434 MCTKTIPVLWGCFLLWNLYVSSSQTIYPGIKARITQR ALDYGVQAGMKMIEQMLKEKKLPDLSGSESLEFLKVD YVNYNFSNIKISAFSFPNTSLAFVPGVGI 2398 A 1489 290 FRPLATEPRGSSPVQLVSSTMSVRTLPLLFLNLGGEM LYILDQRLRAQNIPGDKARKVLNDIISTMFNRKFMEE LFKPQELYSKKALRTVYERLAHASIMKLNQASMDKLY DLMTMAFKYQVLLCPRPKDVLLVTFNHLDTIKGFIRD SPTILQQVDETLRQLTEIYGGLSAGEFQLIRQTLLIF FQDLHIRVSMFLKDKVQNNNGRFVLPVSGPVPWGTEV PGLIRMFNNKGEEVKRIEFKHGGNYVPAPKECSFEFY GDRVLKLGTNMYSVNQPVETHVSGSSKNLASWTQESI APNPLAKEELNFLARLMGGMEIKKPSGPEPGFRLNLF TTDEEEEQAALTRPEELSYEVINIQATQDQQRSEELA RIMGEFEITEQPRLSTSKGDDLLAMMDEL 2399 A 1489 290 FRPLATEPRGSSPVQLVSSTMSVRTLPLLFLNLGGEM LYILDQRLRAQNIPGDKARKVLNDIISTDFNRKFMEE LFKPQELYSKKALRTVYERLAHASIMKLNQASMDKLY DLMTMAFKYQVLLCPRPKDVLLVTFNHLDTIKGFIRD SPTILQQVDETLRQLTEIYGGLSAGEFQLIRQTLLIF FQDLHIRVSMFLKDKVQNNNGRFVLPVSGPVPWGTEV PGLIRMFNNKGEEVKRIEFKHGGNYVPAPKEGSFEFY GDRVLKLGTNMYSVNQPVETHVSGSSKNLASWTQESI APNPLAKEELNFLARLMGGMEIKKPSGPEPGFRLNLF TTDEEEEQAALTRPEELSYEVINIQATQDQQRSEELA RIMGEFEITEQPRLSTSKGDDLLAMMDEL 2400 A 1214 1357 NKINMFIAALFTIAKT\WNQPK\CPTMIDWIKKRGSS RVASSSSPTRTR 2401 A 85 396 MILINFREICLKVLHTPLCVSGGCVLLYILALTCCYT NSLLISHLPPLSLPTETQTHLFMYRVLKVRKDIKNHV FHPTYLVAKETETYGEELIPLPPCREHQD* 2402 A 919 1439 KLKDFFFEMEYCSVAQAGVQWSLQPPSPWFKQFSYVS LPSSWDYSHLPPCPANLFLVEMRFHLVGQAGLKLLTS GDPPASASRSAGIIGVSHHAWPKIKRFYETKWLPILS IQLLSGLFIWALLFFCFVLHFCSIIWGNSLEVFPESV CRHNKICVLCTQKHNVSYESITQPV 2403 A 74 226 MSSWPRMLAHCFYLLKALSSSYLIKEMTIMPGTLLST LCILTHLNLPTPL* 2404 A 255 369 PTESAPGLGFCFPDFGQSLPNEKQTSAI\LSDHQQSQ LC 2405 A 5671 1873 GREREEELQWRRRRRQRRGAAAPAAPAGGIEAVNMAS ASYHISNLLEKMTSSDKDFRFMATNDLMTELQKDSIK LDDDSERKVVKMILKLLEDKNGEVQNLAVKCLGPLVS KVKEYQVETIVDTLCTNMLSDKEQLRDISSIGLKTVI GELPPASSGSALAANVCKKITGRLTSAIAKQEDVSVQ LEALDIMADMLSRQGGLLVNFHPSILTCLLPQLTSPR LAVRKRTIIALGHLVMSCGNIVFVDLIEHLLSELSKN DSMSTTRTYIQCIAAISRQAGHRIGEYLEKIIPLVVK

|FCNVDDDELREYCIQAFESFVRRCPKEVYPHVSTIIN

WO 2004/080148 PCT/US2003/030720 672 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unkaown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence I CLKYLPYDPIYT4YDDEDEDENAMDADGGDDDDQGSD EEYSDDDDMSWKCVRRAkAAKCLDAVVSTRHEMLPEFYK TVSP\ALI SRFKEREENVRADVFHAYLSLLKQTRPVQ SWLCDPDAMEQGETFLTMLQSQVNIVaT-iKQMKEK SVKTRQCCFNMLTELVNVLPGALTQHI PVIJVPGI IFS LND1CSS SSNLKIDALSCLYVILCNRTSFQVFHPHVQAL VPPVVACVGDFFYKITSEALLVTQQLVKVIRPLDQPS SFDATPYIKCDLFTCTI KRLKAADIDQEVKERAI SCMG QI ICNTGNLGSDLPNTLQIFLERLK NEITRLTTVKA LTLIAGSFLKIDLRPVLGEGVPILASFLRKLQQRALKL GTLSALDILIKNYSDSIJTAAMIDAVLDELPPLISESD ME\JSQMAISFLTTLAKVYPSSLSKI SGSILNELIGLV RSPLLQGGALSAMLDFFQALVVTCTNNLGYMDLJRML TGPVYSQSTALTHKQSYYSIAKCVAALaTRACPKEGFA VVGQFIQEVKNSRSTDSIRLLALLSLGEVGHHIDLSG QLELICSVILEAFSSPSEEVKSAASYALGSI SVGNLPE YLPFVLQEI TSQPKRQYLLL-SLKEI ISSASVVGLKP YVENIWALLLKHCECAEEGTRNVVAECLGKLTLIDPE

TLLPRT

2 KGYLISGSSYARSSVVTAVKFTI SDHFQPID PLLKNCIGDFLKTLEDPDIJNVRRVALVTFNSAAHNKP SLIRDLLDTVLPELYNETKVRKELIREVEMGFFKHTV DDGLDIRKAAFECMYTLLDSCLDRLDI FEFLN-VEDG LKDHYDIKMLTFLMLVRLSTLCPSAVLQRLDRLiVEPL RATCTTKVKANSVKQEFEKQDELKRSAMRAVAALLTI PEAEKSPLMSEFQSQI SSNDEIJAAIFESIQKDSSSTN _________LESMDTS 2406 A 1 824 THACALISSRFIILSSFHVILNKTKHTCIHTHSLTLK MQDEERYMTLNVQSKKRSSAQTSQLTFKDYSVTLHWY KILLOT SGTVNGILTLTLTSLILLVSQGVLLKCQKGS CSNATQYEDTGDLKVNNGTRRNI SNKDLCASRSADQT VLCQSEWLKYQGKCYWFSNEMKSWSDSYVYCLERKSH LITIHDQLEMSLV\QF*AFIQKNLRQLNYVWIGLNFT SIJIUVTWTWVDGSPIDSKI FFIKGPAKENSCAAIKESK IFSETCSSVFKWICQY 2407 A 182 418 MCCELLAVVIATLIIKIGLVVLLYFIKLLIUIEFIKR HSILKCES IFNLNVGIRMYPGQVNFCETLQMLDGFGR IFQTK 2408 A 65 320 LQMSSLFTAAPALDVDWQSSTTFASCSTDMCIHVCRL GCDRPVKTFQGMTVSESSCHWSRVCENVMWEPILVCL ELKATAAADQL 2409 A 923 358 ALSCGFFPQPLGDKJFRWWL-LPTLSRFLMRVLDSYGDD YRASQFTIVLEVSVGPPGGSGTGSSGPTHHL~PPPPAC QDEGSQGTDAPTPGNAENEPPEKETLS PPRRTFAFPE \ FGSP\APGEGPSGRKRRRVPRDGRPAC-NALTPELAP VQIKVEEDFGFEADEALDSSWVSRGPDKLLPYPTLAS FAFD 2410 A 923 358 ALSCGPFPQPLGDK LFRWWLLPLSRFLMRVLDSYGDD YRASQFTIVLEVSVGPPGGSGTGSSGPTH-LPFPPAC QDEGSQGTDAFTPGNAENEPPEKETLSPPRRTPAPPE \ PGSP\APGEGPSG1ZKRRRVFKDGRPAGNAELTPELAP WO 2004/080148 PCT/US2003/030720 673 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence VQIKRVEEDFGFEADEALDSSWVSRGPDKLLPYPTLAS PAFD 2411 A 923 358 ALSCGPFPQPLGDKLFRWWLLPLSRFLMRVLDSYGDD YRASQFTIVLEVSVGPPGGSGTGSSGPTHHLPPPPAC QDEGSQGTDAPTPGNAENEPPEKETLSPPRRTPAPPE \PGSP\APGEGPSC-RKRRRVPRDGRPAGNALTPELAP VQIKVEEDFGFEADEALDSSWVSRGPDKLLPYPTLAS PAFD 2412 A 12 1154 GILRQKEREERNRIHKKEILFLEHLTLVVPSEMSSLSG KVQTVLGLVEPSKLGRTLTHEHLAMTFDCCYCPPPPC QEAISKEPIVMKNLYWIQKNAYSHKENLQLNQETEAI KEELLYFKANGGGALVENTTTGISRDTQTLKRLAEET GVHIISGAGFYVDATHSSETRAMSVEQLTDVLMNEIL HGADGTSIKCGIIGEIGCSWPLTESERKVLQATAHAQ AQLGCPVIIHPGRSSRAPFQIIRILQEAGADISKTVM SHLDRTILDKKELLEFAQLGCYLEYDLFGTELLHYQL GPDIDMPDDNKRIRRVRLLVEEGCEDRILVAHDIHTK TRLMKYGGHGYSHILTNVVPKMLLRGITENVLDKILI ENPKQWLTFK 2413 A 575 759 SVYSASSCKCCNYRKTEQIPDCEQPPASSMPERPSHE SQPTPQMMPLSAPSRAEELGQRPG 2414 A 131 1677 VRGDDLTRALRARRRRSGSGSNFRVVEPQATGILLFL PPPPVCPAPLPLSLLFPAPPAKMNSSDEEKQLQLITS LKEQAIGEYEDLRAENQKTKEKCDKIRQERDEAVKKL EEFQKISHMVIEEVNFMQNHLEIEKTCRESAEALATK LNKENKTLKRISMLYMAKLGPDVITEEINIDDEDSTT DTDGAAETCVSVQCQKQIKELRDQIVSVQEEKKILAI ELENLKSKLVEVIEEVNKVKQEKTVLNSEVLEQRKVL EKCNRVSMLAVEEYEEMQVNLELEKDLRKKAESFAQE MFIEQNKLKRQSHLLLQSSIPDQQLLKALDENAKLTQ QLEEERIQHQQKVKELEEQLENETLHKEIHNLKQQLE LLEEDKKELELKYQNSEEKARNLKHSVDELQKRVNQS ENSVPPPPPPPPPLPPPPPNPIRSLMSMIRKRSHPSG SGAKKEKATQPETTEEVTDLKRQAVEEMMDRIKKGVH LRPVNQTARPKTKPESSKGCESAVDELKGILASQ 2415 A 1157 918 RSGVPDQPGQHGEAPSLLKIQNLAGRSGGPL*SQLLR RENRLNLGGGLP*AKIAPRLHPCTPAWVTDRDSVSKK KILFP 2416 A 70 222 MFCSFPLLILQVYPTWKNPNWHLTFHTSVFSFPKGVR SLARGIPDHLHSA* 2417 A 163 531 MQQMMWAGLLCPQLEWLQGRACRPCGLLASDAAALWF RGGISAWEDSCAVSNIRHEAYNCHLSVFLNRCANELT VQFLIILAFQIMLSCAVIAPAVPVFQRLTLKRSGRTS LGSTGRLHFCK* 2418 A 60 266 MKRLRFVLRVFQMTAFITGAHTITNYSDRRLYISPLS HFFMNSGSSAQSVLSHSYVSQIFFKNVSKYF* 2419 A 218 1885 QSDLSTRTQLARLLFCAKTGELVGTMKIFCSRANPTT GSVEWLEEDEHYDYHQEIARSSYADMLHDKDRNVKYY QGIRAAVSRVKDRGQKALVLDIGTGTGLLSMMAVTAG

ADFCYAIEVFKPMADAAVKIVEKNGFSDKIICVINKHS

WO 2004/080148 PCT/US2003/030720 674 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence TEVTVGPEGDMPCRANILVTELFDTELTGEGALPSYE HAHRHLVEENCEAVPHRATVYAQLVESGRMWSWNKLF PIHVQTSLGEQVIVPPVDVESCPGAFSVCDIQLNQVS PADFTVLSDVIJPMFSIDFSIKQVSSSAACHSRRFEPLT SGPAQVVLSWWDIEMDPEGKI KCTMAPFWAIISDPEEM QWRDHWqMQCVYFLPQEEPVVQGSALYLVA4HDDYC V YSLQRTSPEKNERVRQMRPVCDCQAHLLWNRPRFGEI NDQDRTDRYVQALRTVJKPDSVCLCVSDGSLLSVA HLGVEQVFTVESSAASHKJLRKIFKANHLEDKINI IE KRPELLTNEDIJQGRKVSLLLCEPFFTTSLLPWHNLYF WYVRTAVDQHLGPGAMVMPYAASLHAVSJVEFKDLWRI R 2420 A 2121 1148 HYLCSLELGQCGQLSPLPCGLQVALYKSVFTRLLSRA WCRINQVELP{WLRRPVYSLYTWTFGVNMKEAAVEDL HHYRNLSEFFRRKLKFQARPVCGLHSVI SPSDGRILN FGQVKNCEVEQVKGVTYSLESFLGPRMCTEDLPFPFA ASCDSFKNQLVTREGNELYHCVIYLAPGDYHCFHSFT DWTVSHRRHFPGSLMSVNPGMARWIKELFCMNERVVL TCDWKRGFFSIJTAVGATNVGSITIYFDRDL-TNSPRH SKGSYNDFSFVTHTNREGVPMRKGEHLGEFNLGSTIV LIFEAPKDFNFQLKTCQKIRFGEALGSL 2421 A 195 859 GCPGCCSPRCCLAGAHSDGPGPGSSCSSRGRQVSGNR AWTGPSSQARRSPGLRGQGRJAGARPFSWPE/ EDSRV PGKDKL*GKELEI SA* SQPPSARPPSGCTAPGJ9RNS WTNSSERILRAHF/APLFPSFPFFIJEAGG/LPP*GAT RGPSAVPSFPSVSGDWGGPVEAGRAGSRAEGEPGRAL APSLLCSIJPPRFAGSQALGLPWAVTABRWQELRASEL RNR 2422 A 87 594 KCLRKSDEALNRVLQQI\RVPPKMKRGTSLHSRRGKP EAPKGSPQINRKSGQEMTAVMQSGRPRSSSTTDAPTG SAMMEIACAAAAAAAACLPGEEGTAERIERLEVSSLA QTSSAVASSTDGSIHTDSVDGTDPQRTKAAIAHJQQ KILKLTEQIKIAQTARRNRRFG 2423 A 2230 990 NSSGVKLLQALGLSPGNGKDSILISRNDLEEAFI4F MGKGAAAERFFSDKETFHDIAQVASEFPGAQHYVGGN AALIGQKFAANSDLKVLLCGPVGPKLHELLDDNVFVP PESLQEVDEFHLILEYQAGEEWGQLKAPHANRFI FSH DLSNGAD4NMLEVFVSSLEEFQPDLGGLSGIHMMEGQS KELQRICRLLEVVTSISDI PTGI PV\IILELG\ SMTNRE LMSSIV\LQQVFPAVTSLGLNEQELLFLTQSASGPHS SLS SWNGVPDVGMVSDILFWI LKEHGRSKSRASDLTR IHFHTLVYHILATVDGHWANQLAAVAAGARVAGTQAC ATETIDTSRVSLRAPQEFMTSHSEAGSRIVLNPNKPV VEWHREGISF-FTPVLVCI{DPIRTVGLGDAI SAEGLF YSEVHPHY 2424 A 122 505 MLWELVIJLGEFLVVIAPSPSESSETVLALVNTCISPLK YFSDFRPYFTIHDSEFKEYTTRTQAPPSVILGVTNPF FAKTLQHWPHIIRIGDLKPTGEI PKQVKVKKTJKNLKT LDSKPGVYTSYCPYSN* 2425 A 12 271 GSVIALHVEKLPINEPNTRLLIL{GFLDENV-\HFFHTN7FLV WO 2004/080148 PCT/US2003/030720 675 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence SQLIRAGKPYQLQV ALPPVSPQIYPNERHSIRCPESG EHYBVTLL~HFLQEYL 2426 A 2 271 GSVALHVEKLPNEPNRLLILHCFLDENVHFFHTNFLV SQLIRAGKPYQLQVA1IPPVSPQIYPNERHS IRCPESC EHYEVTLLHFLQEYL 2427 A 2 271 GSVALHVEKLPNEPNRLLILHCFLDEYVHFFHTNFLV SQLIRAGKPYQLQVALPPVSPQIYPNERHS IRCPESG EHYEVTLLHFLQEYL 2428 A 245 392 GPGCIPAALLQPPKDDKKKKDAGKSAKKEKDPVNKSG GKAK'KKVEIRPII 2429 A 138 1671 EAVQVLIKHSADVNARDKNWQTPLHVAAANKAVKCAE VII PLLSSVNVSDRGGRTALHHAXALNGHVEMVNLLLA KGIANINAFDKKDRRALHWAAYMGHLDVVALLINHGAE VTCKDKKGYTPLI{AAASNCQINVVKHLLNLGVEIDEI NVYGNTALHIACYNGQDAVVNELIDYGAVNQPNNNG FTPLHFAAASTHGALCLELLVNNGAIDVNIQSKDGKSP LHMTAVHGRFTRSQTLIQNGGETDCVDKDGNTPLHVA ARYGHELLINTLITSGADTAKCGIHSMFPLHLAALNA HSDCCRKLLSSGQKYSIVSLFSNHHVLSAGFEIDTPD KFGRTCLAHAAAAGGNVECIKLLQSSGADFHKKDKCGR TPLHYAAANCHFHCIETLVTTGANVNEDDWGRTALH YAAASDMDRNKTILGNAHnNSEELERARELKEKEATL CLEFLLQNDANPS IRDKEGYNS IUYAAAYGHRQCLEL LLERTNSGFEESDSGATKSPLHLAVSEMP 2430 A 1266 210 PWAVSQLASGG\ATIPGIRGAGRSRPPGILVPACTSE G/ P/SSQYNFIADVVEKTAPAVVYIEILDRHPFLGRE VPI SNG9GFVVAADGLIVTNAHADRRRRVLLSG DTYEAVVTAVDPVADIATLRIQTKEPLPTL~PLGRSAD VRQGEFVVAMGSPFALQNTITSGIVSSAQRPARDLGL PQTNVEYIQTDAAIDFGNSGGPLVNLDGEVIGVNTMK VTAGI SFAI PSDRLREFLIHRGEKKNSSSGI SGSQRRY IGVMMLTLSPSILAELQLREPSFPDVQHGVLIHI(VIL GSPAHRAGLRPGDVILAIGEQMVQNAE3VYEAVRTQS _______QLAVQIRRGRETL~TLYVTPEVTE 2431 A 80 403 MLWFSGVGALAERYCRRSPGITCCVLLLLNCSGVPMS LASSFLTGSVAKCENEGEVLQI PFITDNPCIMCVCLN _______KEVTCKREKCPVLSRDCALAI KQRGACCEQCKGC 2432 A 469 1020 GISGKAGGSMRSGSVCSGAAAMPIEEPALRSWQRPFL K WAGGKYSLLPETJDRLI FAGKRLIEPFVGGGSVFLNS DKHERFLLADVSADLINLYQMLAVVPDSVIYEMKAF PJ4LNDAENYTLIREAFNAQRLDAVERAAAFLYLNRHC FNGLIRYNLDGFFQQGII*ER* RQVFPRQSVVQRTDS 2433 A 1 266 GHFRVPALGYLDVRIVDTDYSSFAVLYIYKELEGALS TMVQLYSRTQDVSPQALKAFQDFYPTLGLPEDMMVML PQSNACNPESI{EAP 2434 A 2 1318 LRKEGRCRRGSNRGVWAAPAEGLGGRGMLGVRCLLRS VRFCSSAPF'PKHKPSAKLSVRDALGAQNASGERIKIQ GW7IRSVRSQKVLFL-VNDGS SLESLQVVADSGLDSR 1ELTFGSSVEVQGQLIKSPSKKRQNVELKAEKIKVIGNC DAIKDFPI KYK ERHPLEYLRQYPEFRCRTN\VLGS

ILRI

WO 2004/080148 PCT/US2003/030720 676 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknnwn, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence RSEATAAIHSFFK DSGFVHIUTFI ITSN\DSEGAGELF QLEPSGKLKVPEENFFNATPAFLTVSGQLHLEVMSGAF TQVFTFGPTFRAENSQSRRHLAEFYMIEAEI SFVDSL QDLMQVIEEIJFKATTMMVLSKCPEDVELCHKFIAPGQ KDRL*HMLKNNFLI TSYTEAVEITJKQASQNFTFTPEW C-ADLRTEHEKYLVIQHCGNI PVFVINYPLTLKPFY4RD NEDGPQBLEGSVA* HSLGLMILLSIVVIGQP 2435 A 58 501 QNKAFVCFYLSQLENYGMPFSRTEDGKIYQRAFGGQS LIFGKGRQAHRCCCVADRTGHSILHTSYGRSLRYDTS YFVEYFALDLLJIMENRECRGVTAkQCNEDGSTHHIRAKN TVVATG*ESNFYFI SFVKMNKFLLECLYFKENRGIVE 2436 A 3 7 DSLDNHRCRGDLTKTYSLEAYDNWFNCLSMLVATEVC RVVKKKHRTRMLEFFIDVARECFNIGNFNSMMAI ISG MNLS PVARLKKTWSKVKTAKFDVLEIIEMDPSSNFCNY RTALQGATQRSQMANSSREKIVI PVFNLFVKDIYFLP QNP\ SNHLPNGHINFKKFWE ISRQIBIEFMTWTQVECP FEKDKKIP\ SYLLTAPHPTARKLSSSPSFESEGPENH DEKDSWKTLRTTLLNRA 2437 A 130 726 ITCCGYDALSSIRKNLCCLWICSKPYSLLMGEGDAFW APSVLPI-STLSTLSHIPQPQFGRGMESKVSQGGLNVT LTIRLLMHGKEVGSI TGKKGETVKKNREESGARINIS EGNCFERIVTITGPTDAI FKAPA 4IAYKFEEDI INEM SNS PATSKPPVTLRLVVPASQCGSLIGKCGSKIKEIR ________EVTGPSQPGPLRSL 2438 A 401 249 DTLIYTCAPEFDFMEKATPLRYTKTLLLPVTMITCF IFKKTVRDISCVLA 2439 A 1671 429 TGGRVGGSRSRRALPLPAPVEAGVLTSAGPSGVVWQR IEDTTKMAAVSGLVRRPLREVSGLLKRRFNWTAPAAV QV\TVRDAINQGMDEELERDEKVFLLGEEVAQ\YDGA YKVSRGLWKKYGDKRII \DTPISEMGFAWELLVGAAI GWGLRPILLNLWTFNFSM\QAI \DQVINSAAKTYYM\ SG\GLQPVLIVSWGPN\GASAGVAAQHSQCFAAWYGH CFGLKVVSF\WTS *DAKGLI KSAIRDNNPVVALENEL MYGVPF\EFPPEAQSKDFNL~IPIGKAKIEMHGTHITV VSHSRPVG\HCLRSLFAS/VLSKEGVEC\EVINMRT\ IRP\MDMET\ IEA\SVMKTKFIL*LWEGGWPQFG\VG A\EICARIM\EGPAFNF\LDAPAVRVTGADVFMPYAK ILEDNSI PQVKDI IFAI KKTLNI 2440 A 66 1349 APNSESGTQGPLPTPANLFWTRRANPDPTTSMSATDR MGPKAVPCTJRLALLLLLGLGTPKSGVQGQEGLDFFEY DGVDRVINVNAK NYKNVFKKYEVLALLYHEPPBDDKA SQRQFEMEELILELAAQVLEDKGVGEGLVSSEKDAAV AKK LGLTEVDSMYVFKGDEVI EYDGEFSADTIVEFLL DVLEDPVELIEGERELQAFENIEDEI KLIGYFKSKDS EHYKAFEDAAEEFHPYI FFFATFDSKGAKK 4 TLK<LNE IDFYEAFMEFVTI PDKPNSEEE IVNFVEEHRRSTLR KILKPE9MYETWEDDMfGIHIVAFAEEADPDGFEFLET LKAVAQDNTENPDLSI IWIDPDDFFLIIVPYWEK,-TFDI DLSAPQIGVKNVTDADRLWNEMDDEEDLPSAEELEDW

LEDVLEC-EINTEDDDDDDDD

WO 2004/080148 PCT/US2003/030720 677 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide dcletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide c sequence 2441 A 1002 2209 VYPYNPLAFFRERLQPNCPFHSSEGSSGKLS*PPSPS FTSSLCDSRTSGFGASSTTH*HS* IRATLISSAFTLA VAWAALLC P91S SCS SETWLSLRQMGSE PKVQP SCCE ASPSSVHLPPLPSWAVSVQAS PGSSPSMGPRGS SVS P PLAGGEAGLPTSGNPPNSS PWASGQC-GWASLSLTSLS SQLSGWMAAA*LGSFSSSSSFSWGTWLSPFVSSSITC AESTGTSTDAVSNFLSAFKEPEAVMGSGSS WAGS SS S RVPPNSSSDEHVRPGS PAVSSVATGFTTGSSTLE IITC SVPSGGGLGPGRERLS PLANELGTSGCFSSSDSNNTS LLRVSLPGTPGRAEALLAGLAWFDPVGGFRSVKLDT LSLGKAMLS SNKLCFFKIAAS FITFRVSSSRI 2442 A 1 933 MGSRLLCWVLLCLLGAGPVKAGVTQTPKHLITATGQQ VTLPCS PRSGDLSVSWYQQSLDQGLQFLIQYYNGEER AKGNILERFSAQQFPDLHSELNLSSLELGDSALYFCA SSVKVGTGELFFGEGSRLTVLEDLKNVFPPEVAVFEP SEAST SHTQKATLVCLATGFYPDHVELSWWVNGKEVH SGVSTDPQPLKEQPALNDSPRYCLSSRLRVSATFWQNP RNI.FRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWG RADCGFTSESYQQGVLSATILYEILLGKATLYAVLVS ALVLMZ\MVKRKDSRG 2443 A 368 18 SRTPENYLKSSIDSAHRQKRKRTIPSAKGTFPGFFRA AKLLCQSLS PFMTGRAP*ALAGDTSAFMALLPRTHLS ATPAVCPFPETFI SSVFVASLFTILELKYHLLREAFP LLPS*N 2444 A 5 235 DSSRMSYQQQQCKQPCQPPPVCPTPKCPEPCPPPKCP EPCPPPKCPQPCPPQQCQQKYPPVTPSPPCQSKYPPK SK 2445 A 82 2929 TRTKRRTJGREKAMASPPRGWGCGELLLPFMLLGTLCE PGSGQIRYSMPEELDKGSFVGNIAKDLGLEPQELAER GVRIVSRGRTQIJFALNPRSGSLVTAGRIDREELCAQS PLCVVNFNILVENKMKIYGVEVEI IDINDNFPRFRDE ELK\JKVNENAAAGTRLVLPFARDADVGVNSLRSYQLS SNLHFSLDVVSGTDGQKYPELVLEQPLDREKETVHDL LLTALDGGDPVLSGTTHIRVTVLDANDNAPLFTPSEY SVSVPENIPVGTRLLMLTATDPDEGINGKLTYSTRNE EEKISETFQLDSNLGEI STLQSLDYEES-FYL~MEVVA QDGGALVASAKVVVTVQDVNDNAPEVIL~TSLTSSISE DCLPGTVIALFSVHDGDSGENGEIACS IPRNLPFKLE KSVDNYYHLLTTRDLDREETSDYNTLTMEHTPPL STESITPLKVADVNDNPPNFPQASYSTSVTENNPRGV SIFSVTAHDPDSG'DNAPRVTYSLAEDTFQGAPLSSYVS INSDTGVLYALRSFDYEQLRDLQLWVTASDSGNPPLS SNVSLSLFVLDQNDNTPEILYPALPTDGSTGV7ELAPR SAEPGYLVTKVVAVDKDSGQNAWLSYRLLKASEPGLF AVGLHTGEVRTARALLDRDALKQSLVVAVEDHGQPPL SATFTVTVAVADRI PDILADLGSIKTPIDPEDLDLTL YLVVAVAAVSCVFLAFVIVLLVLRLRRWHKSRLLQAE GSRLAGVPASHFVGVDGVRAFLQTYSHEVSLTADSRK SH~LIFPQPNYADTLLSEESCEKSEPLLMSDKVDANKE ___________ ________ERRVQQAPPNTDWRFSQAQRPGTSGSQNGDDTGTWPN WO 2004/080148 PCT/US2003/030720 678 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X-Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence NQFDTEMLQAMILASASEAADGSSTLGGGAGTMGLSA RYGPQFTLQHVLQGELGSDYRQNVYIPGSNATLTNAA GKRDGKAPAGGNGNKKKSGKKEKK 2446 A 61 241 ANLGPTAPPRSGPVLGAGEKGRGEMRRAPFFLSAGGL ETPPPSAALLWAPGRRADEISGL 2447 A 1 306 CGCGSCGGCGGRCGGGCGGGCSGGCGGGCGGGCCCGC GSCTTCRCYRVGCCSSCCPCCRGCCGGCCSTPVICCC RRTCGSCGCGYGKGCCQQKCCCQKQCCC 2448 A 3 761 YAKLGTRDPSKLCRHSLKCLECNEVFQDETSLATHFQ QAADTSGQQMKKHPCRQCDKSFSSSHSLCRHNRIKHK GIRKVYACSHCPDSRRTFTKRLMLEKHVQLMHGIKDP DLKE/TDRCHQ*GGNRNKRRH*GPQSQAEVGRTSSGV QASPRSNHSTTEKAENQ\FFKVHKCAVCGFTTENLLQ FHEHIPQHKSDGSSYQCRECGLCYTSHVSLSRHLFIV HKLKEPQPVSKQNGAGEDNQQENKPSHEGGIP 2449 A 2740 2525 MIETWLWLLLLNVGGTGQWSGPTFRRENVLPAAHIGP KYGPLLPSTAKGTVKVSCPSSTPHPPLQGKGTPD* 2450 A 656 513 MSLLLPPLALLLLLAALVAPATAATAYRPDWNRLSGL TRARVETCGG* 2451 A 42 266 KLILLKIQYFNLLMKCCFRIKGKLEEQRPERVKPFMT GAAEQIKHILANFKNYQVNTLSIWIKGLYNFNCKSKN 2452 A 6 664 LPGRPTRAPTRPAEHSIVGTRLVSCQLQPSQPNADQG KLTTMRIAVICFCLLGITCAIPVKQADSGSSEEKQLY NKYPDAVATWLNPDPSQKQNLLAPQTLPSKSNESHDH MDDMDDEDDDDHVDSQDSIDSNDSDDVDDT\DDSHQS DESHHSDES\D\ELVTDFPTDLPATEVFTPVVPTVDT YDGRGDSVVYGLRSKSKKFRRPDIQYPDATDEDITS 2453 A 68 348 IQGMHFAAGRLSTKTFCTGHCSPVDICTAKPRDIPMN PMGIYRSPEKKATEDEGSEQKIPEATNRRDVEPTKAN SRFATTFYQHLADSKNDND 2454 A 5214 352 MAKSGGCGAGAGVGGGNGALTWVNNAAKKEESETANK NDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLT QFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADN KQRDKNMTCIKVSIDPESNIISIWNNGKGIPVVEHKV EKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKL CNIFSTKFTVETACKEYKHSFKQTWMNNMMKTSEAKI KHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRA YDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLD ETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSI ATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPF QVKNHIWVFINCLIENPTFDSQTKENMTLQPKSFGSK CQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCS SVKYSKIKGI PKLDDANDAGGKHSLECTLILTEGDSA KSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIM ENAEINNIIKIVGLQYKKSYDDAQSLKTLRYGKIMIM TDQDQDGSHI KGLLINFIHHNWPSLLKHGFLEEFITP IVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYY KGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAIT LAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYG

TATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKP

WO 2004/080148 PCT/US2003/030720 679 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide ucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence GQRIKVLFTCFIKCNDKREVKVAQLAGSVAEMSAYIHHGE QALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGK DAASPRYI FTMLSTLARIILFPAVDDNLLKFLYDDNQR VEPEWYI P1IPMVLINGAEGIGTGWACKLPNYDAREI VNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAV SGEIPVVDRNTVEI TELPVRTWTQVKQVLEPMALNG TDKCTPALI SDYKEYHTDTTVKFVVKMGTEEKLAQAEAA GLHKVFK LQTTLTCNSMIVLFDHMGCLKKYETVQDILK EFFDLRLSYYC-LRKEWLVGMLGAEFTK-LNNQARFILE KIQOKITI *NRSKKDLIQMLVQRGYESDPVKAWKEAQ EKAAEEDETQNQ-DDSSSDSGTPSGPDFNYILNASLW SLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDL AAFVEELDKVESQEREDVLAGMSGKAI KGKVGKPKVK KLQLEETMPSPYGRRII PEITAMKADASKKLLKKKKG DLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKG PKPKREKKE PCTRVRKTPTSSGKPSAKKVKKRNPWSD DESKSESDLEETEPVVI PPDSLLRRAAAERPKYTFDF SEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFV PSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLF SFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTD KVPSKTVAAKKGKPS LDTVPKPKRAPKQKKVVEAVNS DSDSEFGZ PKKTTTPKGKGRGAKKRKASGSENEGDYN PGRKTSKTTSKKPKKTSFDQDSDVDI FPSDFPTEPPS LPRTGRAPJ(EVKYFAESDEEEDDVDFAMFN 2455 A 2 154 FKIQKTRLQREGFDPRQTSDRLFFLDLKQGHYLPLNE AVYTRICSGAFAL 2456 A 483 765 FQGQRMAGEQKPSSNLLEQFILLAKGTSGSALTALIS QVLEAPGVYVFGELTLELANVQELAEGANAAYLQLLNL FAYGTYPDYIANKESLPELY 2457 A 9 422 ESRERSGNRRGAEDRGTCGLQSPSAMLGAKPHWLPGP LHSPGLPLVLVLLALGAGWAQEGSEPVLLEGECLVVC EPGRAAAGGPGGAALGEAPPRVAFAAVRSl-HEPAG _____ETGNGTSGAIYFDQVLVNEGGGFDRAS 2458 A 64 435 GRGVCVAAWSQRSIAGNNDYRLFHKMSNSHPLRPFTA VGEIDHVHILSEIICALLIGEEYGDVTFVGEKKRPPA HPVILAARCQYFRALLYGGMRESQPEAE IPLQDTTAE AFTMLLXYIYTGR 2459 A 126 434 MCTKTIPVLWCCFLLWNLYVSSSQTIYPGIKARITQR AIDYGVQAGMKMIEQMLKEKKLPDLSGSESLEFLKVD YVNYNFSNI KISAFSFPNTSLAFVPGVGI 2460 A 126 434 MCTKTIPVLWGCFLLWNLYVSSEQTIYPGIKARITQR ALDYGVQAGMKMIEQMLKEKKLPDLSGSESLEFLKVD YVNYNFSNI KISAFSFPNTSLAFVPGVGI 2461 A 126 434 MCTKTIPVLWGCFLLWNLYVSSSQTIYPGIKARITQR ALDYGVQAGMKMIEQMLKEKKLPDLSGSESLEFLKVD YVNYNFSNI KISAFSFPNTSLAFVPGVGI 2462 A 3 1057 EEEQECRPAIKTSDIDNPSHFEKQYESSSSSTHSDRS SDGEQDFVS SILPGNRPNSTNIKPQLHQKSIMKKKAG HIaNSK1VD* EQTVVDVTEQLGDCKLDSQEKDATCEL PLQKV\TQS SSNSTLPGRLKASENSESEYSRSEITLV WO 2004/080148 PCT/US2003/030720 680 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence GISKKSAEHFKRKFAKSNQVSRSVSSSVQVCPEVGKR NLLKVLKETLIEWKTEETLRFLYGQNYASVCLKPEAS LVKEELDEDDIISDPDSHFPAWRESQNSLDESLPFRG SGTAIKPLPSYENLKKETEKLNLRIREFYRGRYVLGE ETTKSQDSEEHDSTFPLIDSSSQNQIRKRIVLEKLSK VLPGLLVPLQITLGDIYT 2463 C 135 341 MYIKIKPRSFGIIHNLPSKPGPLFLPHSLIGWFDFTA SFLYPMNCSAMHHXVRKSSSATAITKIGKTG 2464 A 265 395 RLCDGLFPQQDPAAPAPCEETQLSLLPLQGCGLMEGK TMEAKT 2465 A 88 1496 QETSKMETLSFPRYNVAEIVIHIRNKILTGADGKNLT KNDLYPNPKPEVLHMIYMRALQIVYGIRLEHFYMMPV NSEVMYPHLMEGFLPFSNLVTHLDSFLPICRVNDFET ADILCPKAKRTSRFLSGIINFIHFREACRETYMEFLW QYKSSADKMQQLNAAHQEALMKLERLDSVPVEEQEEF KQLSDGIQELQQSLNQDFHQKTIVLQEGNSQKKSNIS EKTKRLNELKLSVVSLKEIQESLKTKIVDSPEKLKNY KEKMKDTVQKLKNARQEVVEKYEIYGDSVDCLPSCQL EVQLYQKKIQDLSDNREKLASILKESLNLEDQIESDE SELKKLKTEENSFKRLMIVKKEKLATAQFKINKKHED VKQYKRTVIEDCNKVQEKRGAVYERVTTINHEIQKIR LGIQQLKDAADREKLKSQEIFLNLKTALEKYHDGIEK AAEDSYAKIDEKTAELKRKMFKMST 2466 A 194 2287 GMGSENSALKSYTLREPPFTLPSGLAVYPAVLQDGKF ASVFVYKRENEDKVNKAAKVP**HLKTLRHPCLLRFL SCTVEADGIHLVTERVQPLEVALETLSSAEVCAGIYD ILLALIFLHDRGHLTHNNVCLSSVFVSEDGHWKLGGM ETVCKVSQATPEFLRSIQSIRDPASIPPEEMSPEFTT LPECHGHARDAFSFGTLVESLLTILNEQVSADVLSSF QQTLHSTLLNPIPKWRPALCTLLSHDFFRNDFLEVVN FLKSLTLKSEEEKTEFFKFLLDRVSCLSEELIASRLV PLLLNQLVFAEPVAV\KSFLPYLLGPKKDHAQGETPC LLSPALFQSRVIPVLLQLFEVHEEHVRMVLLSHIEAY VGALSLREQLKKV\IL\PQVLLG\LRD\TSDSIVAIT LHSLAVLVSLLGPEVVVCGERTKIFKRTAP\SFTK\N TDLSLEGDPFSQPIKFPINGLSDVKNTSEDSENFPSS SKKSEEWPDWSGPE\EPENQTVNI\QIWP\REP\CDD VKSQCTTLDVEESSWDDCEPSSLDTKVNPGGGITATK PVTSGEQKPIPALLSLTEESMPWKSSLPQKISLVQRG DDADQIEPPKVSSQERPLKVPSELGLGEEFTIQVKKK PVKDPEMDWFADMIPEIKPSAAFLILPELRTEMVPKK DDVSPVMQFSSKFAAAEITEGEAEGWEEEGELNWEDN NW 2467 A 2 868 IAGVAVFFYRDMFVRKDRKTHKDAESAQSCTDSSGSF AKLNGLFDSPVKEYQQNIDSPKLIVT/SLTSRKELPP NGDTKSMVMDHRGQPPELAALPTPESTPVLHQKTLQA MKSHSEKAHGHGASRKETPQFFPSSPPPHSPLSHGHI PSAIVLPNATHDYNTSFSNSNAHKAEKKLQNIDHPLT KSSSKRDHRRSVDSRNTLNDLLK{HLNDPNSNPKAIMG

DIQMAHQNLMLDPMGSMSEVPPKVPNREASLYSPPST

WO 2004/080148 PCT/US2003/030720 681 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Tnknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide ______resiuecf LPRNSPTKRVDVPTTPGVPMTSLERQRGYHK 2468 A 483 764 MGSVFWHVLFCISGVCLWCAHRMAAFLQQMAVLLPVD CERPAAVHWLALCGCCYGQLVWESRTRSCFWSLECLC FGGQHFGSVPSFFCSSVWL* 2469 A 3 357 FGFNGCSKRIIKLQELSDLEERENEDSMVPLPKQSLK FFCALEVVLPSCDCRSPGIGLVEEPMDKVEEGPLSFL MKRKTAQKLAIQKALSDAFQKLLIVVLG/QDCLDHP* STSVSVSK 2470 A 3 57 RIGQGVPVVHS*VEGGPNVISIVLEYLRDTPPVPVVV CDGSGRASDILAFGHKYSEEGG*VKVFLWCTHKWKED PM 2471 A 69 512 MALAFLGTVLSKATLGARLTTHCAHPARRARAFSSDV MTHSSILTRASLLTLWTMFTRRTKILTEGSGVSWWAA AFPRDVVAGGSILALASLMTVVTIGALLTAVLAAPAP EARSTVASPGDGVAQSPIFALAPAGAVGTPVITIAG* 2472 A 2195 872 VSQATDVEVGTDLVPSVTVKVTLQNRVILQKAKLSVY VQPPLELTCDQFTFEFMNRNPDGIPRVIQCKFRLPLK LICLPGQPSKTASHKITIDTNKSPVSLLSLFPGFASQ SDDDQVNVMGFHFLG\GAR\ITVLASKTSSTDIRIPG VEQFE\DLWASLTNELILRLQEYFEKQGVKDFACSFS G\SITPFKEYF\ELIGSIHFELRINGEKLEELLSERA VQFRAIQRRLLARFKDKTPAPLQHLGHLVRMGTYK\Q VIALA\DAVGGKTKGNLFQSFTRLKSATHLVILLIAL WQKLSADQVAILEAAFLPLQEDTQELGWEETVDAAIF H\L*KTCCRKSAKQQALNPPGRLTYPNDTS\QLKKHI TLLCDRLSKGGRLCLSTDAA/APHQTMVMPGGCTTIP ESDLEERSVEQDSTELFTNHRHLTAETPRPEVSPLQG VSE 2473 A 1 473 EVRWNSPPTDSLSPDGGSIELEFYLAPEPFSMPSLLG APPYSGLGGVGDPYAPLMVLMCRVCLEDKPIKPLPCC KKAVCEECLKVYLSAQIQCPTCQFVWCFKCHSPWHEG VNCKEYKKGDKLLRHWASEIEHGQRNAQKCPKCKIHI QRTEGCDHM 2474 A 131 1098 RVPAGGARRLGQDPPRLPPGVADAPAAMSTQRLRNED YHDYSSTDVSPEESPSEGLNNLSSPGSYQRFGQSNST TWFQTLIHLLKGNIGTGLLGLPLAVKNAGIVMGPISL LIIGIVAVHCMGILVKCAHHFCRRLNKSFVDYGDTVM YGLESSPCSWLRNHAHWGRRVVDFFLIVTQLGFCCVY FVFLADNFKQVIEAANGTTNNCHNNETVILTPTMDSR LYMLSFLPFLVLLVFIRNLRALSIFSLLANITMLVSL VMIYQFIVQIL*MDLQPM*QTKVFHREQVPLCLQHVE SQMEQFWAECFAQRVLPINVLSLQKK 2475 A 131 1098 RVPAGGARRLGQDPPRLPPGVADAPAAMSTQRLRNED YHDYSSTDVSPEESPSEGLNNLSSPGSYQRFGQSNST TWFQTLIHLLKGNIGTGLLGLPLAVKNAGIVMGPISL LIIGIVAVHCMGILVKCAHHFCRRLNKSFVDYGDTVM YGLESSPCSWLRNHAHWGRRVVDFFLIVTQLGFCCVY FVFLADNFKQVIEAANGTTNNCHNNETVILTPTMDSR LYMLSFLPFLVLLVFIRNLRALSIFSLLANITMLVSL

VMIYQFIVQIL*MDLQPM*QTKVFHREQVPLCLQHVE

WO 2004/080148 PCT/US2003/030720 682 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence SQMEQFWAECFAQRVLPINVLSLQKK 2476 A 505 1373 WGDGTQNESHSSSVSLTAFLSDTKDRGPPVQSQIWRS GEKVPFVQTYSLRAFEKPPQVQTQALRDFEKHLNDLK KENFSLKLLIYFLEERMQQKYEASREDIYIKRNTELKV EVESLK'RELQDKKQHLDKTWADVENLNSQNEAELRRQ FEERQQEMEHVYELLENKMQLLQEESRLAKNEAARMA ALVEAEKECNLELSEKLKGTTKNWEDVPGDQVKPDQY TEALAQRDK*VPSVLFL\RLSFAHSQGIQQLSCSLSR T/RQ*ELHYF*DFMGPQPKTFFSGLNFQWYPL 2477 A 1 317 QRPSEAKEIKLYAQIPPIEKMDASLSMLANCEKLSLS TNCIEKIANLNGL\EAVGDTLEELWISYNFIEKLKGI HIMKKLKILYMSNNLVKDWGTPVIKGDEEEDN 2478 A 2 607 CKNTLIRQNIPRAQFPATSPRSIIQQPN/PFPRRFVL PLNVSLNAPEGDNLSPLSYTSASAVKQADGTIWCSHE NLHQEDLEKEGGIEFPQIYYDRFSGKKYHFFYGCGFR HLVGDSLIKVDVVNKTLKVWREDGFYPSEPVFVPAPG TNEEDGCVILSVVITPNQNESNFLLVLDAKNFEELGR AEVPVQMPYGFHGTFIPI 2479 A 2 607 CKNTLIRQNIPRAQFPATSPRSIIQQPN/PFPRRFVL PLNVSLNAPEGDNLSPLSYTSASAVKQADGTIWCSHE NLHQEDLEKEGGIEFPQIYYDRFSGKKYHFFYGCGFR HLVGDSLIKVDVVNKTLKVWREDGFYPSEPVFVPAPG TNEEDGGVILSVVITPNQNESNFLLVLDAKNFEELGR AEVPVQMPYGFHGTFIPI 2480 A 101 580 LSLTKNCALLGEETMMEQEMTRLHRRVSEVEAVLSQK EVELKASETQRSPLEQDLATYITECSSLKRSLEQARM EVSQEDDKALQLLHDIREQSRKLQEIKEQEYQAQVEE MRLMMNQLEEDLVSARRRSDLYESELRESRLAAEEFK RKATECQHKLLK 2481 A 1 2025 MAWAGRGRGSRQGSELHLPWAIDVCLFSLVRSGFRFL REVWWEIWKKVLLLLHVANGAQQAGPIPWNTGLQANH SVPVSKPHQKWPVQHFQELLRSANSLTAPFKQVQYWR GTKMNQRVPVPQIHSWFRMFCGMAHESHGIGKWGVAL EGHPPGPGKQESIANACWEAAVRSPGSRSHKAETKSS KSRDQILSVLRPASFVRDKSIPQPWLESDGINKRWSP TCLSGEPSLGRVNPLLHELQTQCFVRTPSYQRATEAA KPQERCTIQLNKMCCLQAGSFSRYASVIAIKHICHAH STPKALLTSFLVLTTTRSLNLHLHLRLSHPDKFRDGG VSSSQYSRYCSLTQPDFDSSNSSTFFLLLTISLLSSQ FCIRLISLPECPVSQWQEAAREHLGGGSDLSSMGETH PDLGGGPSEGPGGWPWEQVSAAFAQLVLVSTMSFQGT WRKRFSSTDTQILPFTCAYGLVLQVPMMHQTTEVNYG QFQDTAGHQVGVLELPYLGSAVSLFLVLPRDKDTPLS HIEPHLTASTIHLWTTSLRRARMDVFLPSELTKEPFR WDQRLFALVLRLPGTMSVESEQLTGVPLDDSAITPMC EVTGVGMECFSDAKDTIEDLSEMHGSQDLSEMRGNPT KPSPPLSGTTVENFGSRGTDSYEAFSEPSLGKEPVTH RTRVPLQWP 2482 A 137 879 LPPRGPATFGSPGCPPANSPPSAPATPEPARAPERVM

ANAGLQLLGFILAFLGWIGAIVSTALPQWRIYSYAGD

WO 2004/080148 PCT/US2003/030720 683 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide resdue of sequence peptide reiuence NIVTAQAMYEGLWMSCVSQSTGQIQCKVFDSLLNLSS TLQATLALMVVGILLGVIAIFVATVGMKCMKCLEDDE VQKMRMAVIGGAIFLLAGLAILVATAWYGNRIVQEFY DPMTPVNARYEFGQALFTGWAAASLCLLGGALLCCSC PRKTTSYPTPRPYPK\PAPS\SGKDYV 2483 A 200 1139 RIISTITYQFSAALGQEVFYITFLPFTHWNIDPYLSR RLIIIWVLVMYIGQVAKDVLKWPRPSSPPVVKLEKRL IAEYGMPSTHAMAATAIAFTLLISTMDRYQYPFVLGL VMAVVFSTLVCLSRLYTGMHTVLDVLGGVLITALLIV LTYPAWTFIDCLDSASPLFPVCVIVVPFFLCYNYPVS DYYSPTRADTTTILAAGAGVTIGFWINHFFQLVSKPA ESLPVIQNIPPLTTYMLVLGLTKFAVGIVLILLVRQL VQNLSLQVLYSWFKVVTRNKEARRRLEIEVPYKFVTY TSVGIGTKVVAQMPTDV 2484 A 173 307 SHICLKKSAKSLTGTWMKLETIILSKLTQEQKTKHCM FSLISGS 2485 A 173 307 SHICLKKSAKSLTGTWMKLETIILSKLTQEQKTKHCM FSLISGS 2486 B 86 225 PRQEKKSSHVSTRRSPKLLREKPEAAAGEAAAEAGLP MFARSRARSR 2487 A 14 1256 WPCGAAPGLTHASERMFTLTTMIQALAPVMGWDRKPL KMFSSEEMRGHLHHHHKCLTKILKVEGQVPDLPSCLP LTDNTRMLASILINMLYDDLRCDPERDHFRKICEEYI TGKFDPQDMDKNLNAIQTVSGILQGPFDLGNQLLGLK GVMEMMVALCGSERETDQLVAVEALIHASTKLSRATF IITNGVSLLKQIYKTTKNEKIKIRTLVGLCKLGSAGG TDYGLRQFAEGSTEKLAKQCRKWLCNMSIDTRTRRWA VEGLAYLTLDADVKDDFVQDVPALQAMFELAKTSDKT ILYSVATTLVNCTNSYDVKEVIPELVQLAKFSKQHVP EEHPKDKKDFIDMRVKRLLKAGVISALACMVKADSAI LTDQTKELLARVFLALCDNPKDRGTIVAQGGGKALIP LALEGTD 2488 B 526 3482 MDSLKQETQGLQKEKESREKELMGFSKSVNEARSKMD VAQSELDIYLSRHNTAVSQLTKAKEALIAASETLKER KAAIRDIEGKLPQTEQELKEKEKBLQKLTQEETNFKS LDKMAVWAKKMTEIQTPENTPRLFDLVKVKDEKIRQA FYFALRDTLVADNLDQATRVAYQKDRRWRVVTLQGQI IEQSGTMTGGGSKVMKGRMGSSLVIEISEEEVNKMES QLQNDSKKAMQIQEQKVQLEERVVKLRHSEREMRNTL EKFTASIQRLIEQEEYLNVQVKELEANVLATAPDKKK QKLLEENVSAFKTEYDAVAEKAEESLPEIQKEHRNLL QELKVIQENEHALQKDALSIKLKLEQIDGHIAEHNSK IKYWHKEISKISLHPIEDNPIEEISVLSPEDLEAIKN PDSITNQIALLEARCHEMKPNLGAIAEYKKKEELYLQ RVAELDKITYERDSFRQAYEDLRKQRLNEFMGSVRPP KKSWKKIFNLSGGEKTLSSLALVFALHHYKPTPLYFM DEIDAALDFKNVSIVAFYIYEAVWFLSNITAGNQQQV QAVIDANLVPMIIHLLDKGDFGTQKEAAWAISNLTIS GRKDQVAYLIQQNVIPPFCNLLTVKDAQVVQVVLDGL

SNILKMAEDEAETIGNLIEECGGLEKIEQLQNHENED

WO 2004/080148 PCT/US2003/030720 684 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide resiue of sequence peptide sequence 2489 A 1 747 MRLQRPRQAPAGcRRAPRGGRGSPYRPDPGRGARRLR CQNPRRCKWTEPYCVIAAVKI FPRFFM4VAKQCSAGCA AMERPKPEEKRFLLEEPMPFFYLKCCKIRYCNL/GGA /NLSTIIQ\ CSKNMLGAWVP.AVVGCGWPS SCCWPPLQP ASACLEPRIJCHRLSLPEHGLAPDRC4LLH 2490 A 2 1177 GFVEAGEECYCVS\GQECRDLCCFAHNCSLRPGAQCA HGDCCVRCLLKPAGALCRQAMGDCDLPEFCTGTSSHC PPDVYLLDGS PCARGSGYCWDGACPTLEQQCQQLWGP GSHPAPEACFQVVNSAGIDAHGNCGQDSEGHFLPCAGR DALCGKLQCQGGKPSLLAPH-MVPVDSTVHLDCQEVTC RGALALPSAQLDIJLGLGLVEPGTQCGPRMVCQSRRCR KNAFQELQRCLTACHSHGVCNSNHNCHCAPGWAPPFC DKPCFGGSMDSGPVQAENHDTFLLAMLLSVLLPLLPG AGLAWCCYRLPGAILQRCSWGCRRDPACSCPKDGPHR DHPLGGVHPMELGPTATGQPWPLDPENSHEPSSHPEK _____PLPAVSPDPQADQVQMPRSCLW 2491 A 1 609 AAARTFWYKLFPCRGSGGAAKAAEQKRQVGGRAEPGT AAPCGARCPGPTPGWQVPATKALLSQPMGCPPPGPCR GHT*ADPQLPLTHAP/ PEARLS PQQPP/ PSPPGSATP GA*AGVASPKPTLPAPGAPGTPQRLPGP/RREKPAFL SQPES ST* PEPTPVSAASSSPA/ PESSCHDELGLLSL ____ NLPAPGPPKPTPGAAASFQGSG 2492 A 1 242 MNRGGFAVKILALLDALSTVCSQRVQKAKKQQHLQNK EHFKALLKQKEKLKQQEDL/RKKLF* IQGIRCPQATP HHGQCSL 2493 A 909 353 RSFVLDTASAICNYNAHYKNHPKYWCRGYFRDYCNII APSPNSTNH-VALRDTGNQLIVTMSCLTKEDTGWYWCG IQRDFARDDMDFTELIVTDDKGTLANDFWSGKDLSGN KTRSCKAPKVVRKADRSRTSILITCILITGLGI ISVI SHLTKRRRSQRNRRVGNTLKPFSRVLTPKEMAPTEQM 2494 A 516 848 MWSLWIWVDQHQARLIPSPQVLLLLLRETPSTAAAVA GWLVVASMALLQLHAVGGVALTSSHPFMWATGEELRK PPWQGSAGSASGVEELTGKH~SCPGPEEPATVQKAPA* 2495 A 349 1018 TFTQPDPDDLISKPPRTPGGG*YQTQWPSPPDPRRTS PAGRPGPARRPPRRTPRPARGRHPGR*GGPGASRPGG TGAAPAADQTGSPAVSTPSEFGAPGQAEGPQSPIRAS ARSHLSCTAWLGKPSKPSAQRQPTVGPDGDRDGSSQA PNLSRGQAWRASLASPQNTSATGRVTCHGQSTWPLCR LKSNRRRKSGFA/GNKSE PVGLTRRSKHQP1RNPQGQV GI 2496 A 349 1018 TFTQPDPDDLISKPPRTPGGG*YQTQWPSPPDPRRTS PAGRPGPARRPPRRTPRPARGRHPGR*GGPGASRPGG TGAAPAAD:QTGS PAVSTPSEFGAPGQAEGPQSPIRAS ARSI-LSCTAWLKPSKPSAQRQPTVGPDGDRDGSSQA ____ _____ _______________PNLSRGQAWRASLASPQNTSATGRVTCHGQSTWPLCR WO 2004/080148 PCT/US2003/030720 685 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide reside of sequence peptide reiuence LKSNRRRKSGFA/GNKSEPVGLTRRSKHQPRNPQGQV GI 2497 A 349 1018 TFTQPDPDDLISKPPRTPGGG*YQTQWPSPPDPRRTS PAGRPGPARRPPRRTPRPARGRHPGR*GGPGASRPGG TGAAPAADQTGSPAVSTPSEFGAPGQAEGPQSPIRAS ARSHLSCTAWLGKPSKPSAQRQPTVGPDGDRDGSSQA PNLSRGQAWRASLASPQNTSATGRVTCHGQSTWPLCR LKSNRRRKSGFA/GNKSEPVGLTRRSKHQPRNPQGQV GI 2498 A 2025 422 PPGTQGSPQRT/GDHGGKPPLPAEKPAPGPGLPARAS RAEGRGASGWKPGGQPAGGSWQGGDAGPRRPASGDQR TAGAAKALAGPAGEAAGGDRGAAQGDPPAEAGGRGG* TQAGGGASRARGSGAQRPGGP*RQGQGDGGESASPAF GPCPQSSWGPPCSIPGP*PALPGAL*GA\VGRDPAGP PDGGPDTEP/PGSPGQAERWPEGCRPQGSWHCEGAPQ GPGAGARARPRQGSRGPRGAPRRGIPWAKSGR\TGGS QDRKKPGKEVAATGTSI/PEGSQLARGRARSRDGGPS HEAQASEPRPGPCSGPARWGGRSSCTAPGCVTPAGTA GHL*WRAGWTAGPPAGPWRSPGDEKGPRGGPCACVPR AAERRGGRCCPGAQAEARARAGAQTSCPGGPEAGQCQ AQPGPETAGWLRPPEATAGPWPSCRGSAGPEGWGHHW P*PPA*CPGERPPWRPGCPAPPGCGGSSAGGPQPAA* TGAWASRGVLAPAGHEGHASHCPPRPAAGLSQPHPSQ TLEVTLASPQGFMSEALTKCE 2499 A 1415 661 SLRTPGFRGGGVLYWDAGAAGTGSNHALGANVELWIM LLQVVREGKFSGFLTSCSLLLPRAAQILAAEAGLPSS RSFMGFAAPFTNKRKAYSERRIMGYSMQEMYEVVSNV QEYREFVPWGKKSLVVSSRKGHLKAQLEVGFPPVMER YTSAVSMVKPHMVKAVCTDGKLFNHLETIWRFSPGIP AYPRTCTVDFSISFEFRSLLHSQLATMFFDEVVKQNV AAFERRAATKFGPETAIPRELMFHEVHQT 2500 A 673 941 CCLAAHSGPPAQGQRRGPG*LCCSAGSGGNL*S*AGG PG*GRSGQPVCPPWPGPGAPGHRPALPGSGGSSAVGR SAVPGAVRSPSHAGW 2501 A 328 1212 RQEQGHFHFFCGGMSSFKAGTSHLDVYMQVTEGREDY NPSMHLAKRQFLSLEEEAEDYNPSQHRAQGNWLQDYN ASMQRVHGQCVSLEEDVELCVPRWACREMQSHNYPSR LVAGLQQYNFSISLAQGECTSHWRKRGIMTYSSIHCL GDVTLHSYLGPSKTEDCDISVTLPPRLERRITLPKHW IKKYFTIFLMGKAQINKIDRPLVRQIKEKREKNQRDA IKNDKGDITTKPTEIQTTIREYYKHLYGNKVENLEEI DKFLETSTPPRLNEEEVESLSRPIAGSEIEAIINSL 2502 B 1 1428 MGSRVRLSKRRAKAGVQSGTNALLVVKHRDMNEKELE AQEARKAQLENHEPEEEEEEEIRQPRKKLGAQPVVHW VAPDGRLLGNSSRTRVRGDGTLDVTITTLRDSGTFTC IASNAAGEATAPVEPRGLCPDYACTRFSTTVPLMTPS STGVDIEAARKEEERIMLRDARQWLNSGHINDVRHAK SGGTALHVAAAKGYTEVLKIISLRFGVPRTQVRTWVA LYEKHGEKGLIPKPKGVSADPELRIKVVKAVIEQHMS

LNQAAAHFMLAGSGSVARWLKVYEERGEAGLRALKIG

WO 2004/080148 PCT/US2003/030720 686 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X#Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence TB(RIIAISVDPEI(CAASALELSK DRRIEDTJERQVRFLE TRLMYLKKLKAIJAHPTKKAAE IPRSTFYYHLKALSKP DKYADVKKRI SEIYEENRCRYGYRRVTLSLHREGKQI NHKCAVQRLMGTLSHK AAI KVKRYRSYRGEMKKLRIRE VQILAGGHTAKLNMEQVKSADAFTYIICQPIA 2503 A 218 415 MRCRAPAWLRRLCGQLLSERLMRPsGVQAVVRGILEG AGAGAAGGSDAEVTAADWKKCDLIAKILA 2504 A 3 136 SWATAGAANGPAPLGVRAPPAWRTSPAAEMGATGAAE PLQSVLWVKQQRCAVSLEPARALLRWWRS PGPGACAP GADACSVPVSEI IAVEETDVI-GKIQGSGKWQKMEI{PY AFTVI-CVKRARRHRWKWAQVTFWCPE EQLCELWLQTL REMLEKLTSRPKHLLVFINPFGGKGQGKRIYERKVAP LFTLASITTDIIVTEHANQAKETLYEINIDKYDG*VR _____ RFSASARPQPGGRAIZRRRWGRRGRRSRCNPCCG 2505 A 335 1105 MKRERGALSR-ASEALRLAPFVYLLLIQTDPLEGVNIT SPVRLIHGTVGKSALLSVQYS STSSDRPVVKWQLKRD KPVTVVQS IGTEVIGTTLRPDYRDRIRLFENGSLLLSD LQLADEGTYE VET SITDDTFTGEKTINLTVDVPI SEP QVLGASTTVLELSEAFTTJNCSHENGTKPSYTWLKDGK PLTNDSRMLTSPDQKVLTITRVLMEDDDLYSCVVENP _____________INQGRTLPCKITEYRKSSLSS IWLQEAFSSLGPW* 2506 A 335 1105 MKRERGALSRASRALRLAPFVYLLLIQTDPLEGVNT SPVRLTI-GTVGKSALLSVQYS STSSDRPVVKWQLCRD KPVTVVQSIGTEVIGTLRPDYRDRIRLFENGSLLLSD LQLADEGTYEVETSITDDTFTGEKTINLTVDVFI SEP QVLGASTTVLELSEAFTLITCSEENGTKPSYTWLKDGK PLLNDSRMIJLSPDQKVLTI TRVLMEDDDLYSCVVENP _______INQGRTLPCKITEYRKSSLSS IWLQEAFSSLGPW* 2507 A 1160 3149 VSKTTTTNAGNALFPD4PGSSKTKKPNSHQRGQMGS*G RNPPSLGRAPAPLPEREAPI PAPQ1JGPSAAGTSRQVG QKSSTSPHQGEEAILNRELKKKD:GKKK*KK/ PTGLSK IQPAGFIQNE*NLKGAGEFVQGLAGSQNPPSSKLQGL cc\ SABSRGFSRGQGQTAPHWESTPLKGALPPCPERG MLPEEG*GFSGKEASSGPVQPQFTCLYGIRPSLGS* P *GQRRTLLAPTFLQENQL\ SGPS PGQRARSVLRPFSA / PGLRPELELTGGRGSTRSRRAAGPWASDCTAGSDQE SLGRSSGKGR*GASGTVLGVSMCKV/ PGCKAAGG-LP GGGRGLDLECGWGIJRSWLPGRGRQ/TGPPG/ PQGRDS * STKQSDSERWQDSGGGLAPPPFGQGNNGARPCC*DV TKASAPGVSGDTGREAPSATGI STFRSCCMSSARGJG QSPAAPVLASSFLPTSCTGPPGLFGLPSSGSEENIHS GAWALVGQEGPSMDGRGMMLRGVWTGVHGGGMD\G CGAEVI *RGKFLME*YRSGLQRKQDSSPARTPAPQWL SITTGS*TPE /GDPGGKLDAAQRGRAIAAH/GTAGGC CPRCCCHL* SPGSARSSP/ PMASASIRVS\PPRSCGS PPSPSSA* RSDRTDAGAGVAAAASFGAGAPAHCPQGP PRSCQGPQRR 2508 A 1 957 METSSFRPPRPSSNPGLSLDARLGVDTHLWARVLFTA LYALIWALGAAGNALSVHVVLaKARAGRAGRLRHHVLS LALAGLLLLLVGVPVELYSFVWFYPWVFRDLGCR4Y WO 2004/080148 PCT/US2003/030720 687 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence YFVHELCAYATVLSVAGLSAERCLAVCQPLRARSLLT PRRTRWLVALSWAASLGLALPMAVIMGQKHELETADG EPEPASRVCTVLVSRTALQVFIQEAIVVMYVICWLPY HARRLMYCYVPDDAWTDPLYNFYHYFYMVTNTLFYVS SAVTPLLYNAVSSSFRKLFLEAVSSLCGEHHPMKRLP PKPQSPTLMDTASGFGDPPETRT 2509 A 144 291 DVEVKWIEYQNMVNYLIQWIRHHVTTMSERTFPNNPV ELKVSVTVEIT 2510 A 144 291 DVEVKWIEYQNMVNYLIQWIRHHVTTMSERTFPNNPV ELKVSVTVEIT 2511 A 3 279 RSLPPAHSVSLWSVKDGLRPWHPELRSVQPTRGGRTQ THRRGAAPGISTPHTLGGRASAARRPWHTCGRQRRPP RRRRERRPLYSSVLRST 2512 A 3 1396 RQENNTRGVPSLLKSFLQERLGIHLIRRKIVKPKHHV LMSRKESWKVKSEIPKVPKQPLVLHHPRMTTTKSPSK DMLEPEAELAEDLPTTKSTSVES/EDAH*EPGRPFPV LPDL/PCHCLPSAPTPLCIVKRPCPT*VTQLSASAQS AHQMRTPRAQSPSS*PR*VNCLPPS/LHKDDLELKEK DQKKPPTAPREVKGTRRKLPTAFLPSKYHGYEELLTA KPDPAFIEPKGIQKNA/PSPATNAEAPTPVPLLQAQA GHSSETLCSQRETGPENPDSTPKED*SPTSG*HLHSL AGSPEHYRGSTRCCPAPVDRTAAGEP/ASSTWRPRGC *RSSRHVTGSW*VALCAQCSGLPRSPWPAQR*VRASP SSATSSSSWMSSARSPQPVTHKARAVHGGCVHHPACA PALPEGSVPWTAPQG*PAGHRPQSSAGPHLLATRWHP LVRISPPWPRHDLVPGPAAIKSGCTGQ 2513 A 3 1396 RQENNTRGVPSLLKSFLQERLGIHLIRRKIVKPKHHV LMSRKESWKVKSEIPKVPKQPLVLHHPRMTTTKSPSK DMLEPEAELAEDLPTTKSTSVES/EDAH*EPGRPFPV LPDL/PCHCLPSAPTPLCIVKRPCPT*VTQLSASAQS AHQMRTPRAQSPSS*PR*VNCLPPS/LHKDDLELKEK DQKKPPTAPREVKGTRRKLPTAFLPSKYHGYEELLTA KPDPAFIEPKGIQKNA/PSPATNAEAPTPVPLLQAQA GHSSETLCSQRETGPENPDSTPKED*SPTSG*HLHSL AGSPEHYRGSTRCCPAPVDRTAAGEP/ASSTWRPRGC *RSSRHVTGSW*VALCAQCSGLPRSPWPAQR*VRASP SSATSSSSWMSSARSPQPVTHKAPAVHGGCVHHPACA PALPEGSVPWTAPQG*PAGHRPQSSAGPHLLATRWHP LVRISPPWPRHDLVPGPAAIKSGCTGQ 2514 A 1065 478 HGLCELTSTVQEGELCVFFRNNHFSTMTKYKGQLYLL VTDQGFLTEEKVVWESLHNVDGDGNFCDSEFHLRPPS DPETVYKGQQDQIDQDYLMALSLQQEQQSQEINWEQI PEGISDLELAKKLQEEEDRRASQYYQEQEQAAAAAAA ASTQAQQGQPAQASPSSGRQSGNSERKRKEPREKDKE KEKEKNSCVIL 2515 A 1065 478 HGLCELTSTVQEGELCVFFRNNHFSTMTKYKGQLYLL VTDQGFLTEEKVVWESLHNVDGDGNFCDSEFHLRPPS DPETVYKGQQDQIDQDYLMALSLQQEQQSQEINWEQI PEGISDLELAKKLQEEEDRRASQYYQEQEQAAAAAAA

ASTQAQQGQPAQASPSSGRQSGNSERII-EPREDIIE

WO 2004/080148 PCT/US2003/030720 688 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of locution of first amino last amino acid residue acid of peptide residue of sequence peptide sequence KEKEKN\SCVTL 2516 A 290 1041 KACLHLLSSFLTSNIdFNPLiPDSLYSVEARSQeANL GPCRRKRLQTLMRLAAGFQYSSHKDP)SL-SAKEKHTDY HNEARGPWPGWVG*RTADGSCGRGPDGAI-HFGPKSSS WRASRLLPGLGCSHI-LDAYVGRDIJECGTPAPLQLEI F PQPRC4HPAPI PTGQAGPRDSGPGASPtVBTRFLTDCR R* PGVRPVGWTFAHPAGTLRPRGAVEPSVSACGKWAF ____ SPTSQGCCEGRCDAVPKHRAWRTPLCSQ 2517 A 2 1736 QNENSVDLKWGKPLVIDKJKEMAKVEGLNLF-JAVSG LSEVDYALIAEETGKCFFAPDVFNCQADTGNMEVLE LYGSEEQKKQWLEPLLQGNITSCFCMTEPDVASSDAT NIECS IQRDEDSYVINGKKWWSSGAGNFKCKIAIVLG RTQNTSLSR*IJNNSD*ETCVCNSQSS SYLGNLLKIHC LESQI IM*DMRVNVIYLYFTSIF*QVFLENI IGSIAE HSSLWNFQY*KVLLNYQSCLD* IIRQIFSDLCNEVIR CIJDQRQ*S*NV*LYI *VPSYHC*AVhSFNQTT-LFSN HCFCSRSQFASDYVGVRLLHSSHSSHHCLHDYMKTSK RQLGFCLLSVLFFFLANFF*YNFSFD* \I-KQSMILV PMNTPGVKIIRPLSVFGYTDNFNCGHFEI{FNQVRVP ATNLILGEGRGFEI SQGRLGFGRI-HCMRTVGLAERA LQIMCERATQRIAFKKKLYA-EVVAHWIAESRIAIEK IRLLTLKAAESMDTLGSAGAKKEIAMI KVAAPHAVSK IVDWAIQVCGGAGVSQDYPLANMYAITRVLRLADCPD EVHLSAIATMELRQAKRLTACT 2518 A 2 1736 QNENSVDKWGKFLVIDKLKEMAKVEGLWNLFLFAVSG LSEVDYALIAEETGKCFFAPDVFNCQAPDTGNMEVLH LYGSEEQKKQNLEPLLQGNITSCFCMTEPDVAS SEAT NIECSIQRDEDSYVINGKKWWSSGAGNPKCKIAIVLG RTQNTSLSR*LNNSD*ETCVGMSQSSSYLGNLLKIHC LDSQI IM*EMRVNVIYLYFTS IF*QVFLENI IGSIAE ISSLWNFQY*KVLLNYQSCLD* IIRQIFSDLCNEVIR CLDQRQ* S*NV*LYI *VPSYHC*AVRSFNQTTHLFSN HCFCSRSQFASDYVGVRLLHS SHSSHHCLHDYMICTSK RQLGFCLLSVLFFFLANFF*YNFSFD* \HKQHSMILV PMNTPGVKI TRPLSVFGYTDNFHGGHFEIHFNQVRVF ATNLILGEGRGFEI SQGRLGPGRIHI{CMRTVGLAERA LQIMCERATQRIAFKKKLYAHEVVAHWIAESKTAIEK, IRLLTLKAAESMDTLGSAGAKKEIAMIKVAAPRAVSK IVDWATQVCGGAGVSQDYPLANMYAITRVLRLADGPD EVNTJSAIATMELRDQAKRLTAKI 2519 A 2 550 FGVINLICTGFLLMWCSSTNSIALT\SYTYLTIFDLF SLMTCLI SYWVTLRKPS PVYS FGFERLEVLAVFASTV LAQLGALFILESAERFLEQPEIHTGRLLVGTFVALC FNLFTMLSI RNKPFAYVSEAASTSWLQEWVADLSRSL CGII PGLSSIFLPRMNPFVLIDLACAFALCITYML 2520 A 1 1876 RAPMMTK AVFEEPRKPGRLTQALNSFLTWEHVWICVP GGTPDCLTDTFRVKRPNLRRSASNGUVPGTPVYREK<E DNYDET IELKKSLHVQKSDVDLNRTKLRRLEEENSRK DRQIEQLLDPSRC-TDFVRTLAEKRPDASWVINGLK/QR _______________ILIKLEQQCKEK DC-TISI(LQTDMK-TTNLEEMRIAMETY WO 2004/080148 PCT/US2003/030720 689 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide reiuence YEEVHRLQTLLASSETTGKKPLGEKKTGAKRQKKMC-S ALLSLSRSVQELTEENQSLKEDLDRVLSTSPTISKTQ GYVEWSKPRLLRRIVELEKKLSVMESSKSHAAEPVRS HPPACLASSSALHRQPRGDRNKDHERLRGAVRDLKEE RTALQEQLLQRDLEVKQLLQAKADLEKELECAREGEE ERREREEVLREEIQTLTSKLQELQEMKKEEKEDCPEV PHKAQELPAPTPSSRHCEQDWPPDSSEEGLPRPRSPC SDGRRDAAARVLQAQWKVYKHKKKKAVLDEAAVVLQA AFRGHLTRTKLLASKAHGSEPPSVPGLPDQSSPVPRV PSPIAQATGSPVQEEAIVIIQSALRAHLARARHSATG KRTTTAASTRRRSASATHGDASSPPFLAALPDPSPSG PQAVAPLPGDDVNSDDSDDIVIAPSLPTKNFPV 2521 A 5618 4060 APARRGLGDRCSSSSFSSSFFSSASSPRRLATAAARA GGAAVIPVPEEPALPVPGGRGAGEAGPRRTQQVEPGV PGRAPPAHHAALCHLSRPQAKILSMMEDNKQLALRID GAVQSASQEVTNLRAELTATNRRLAELSGGGGPGPGP GAAASASAAGDSAATNMENPQLGAQVLLREEVSRLQE EVHLLRQMKEMLAKDLEESQGGKSSEVLSATELRVQL AQKEQELARAKEALQAMKADRKRLKGEKTDLVSQMQQ LYATLESREEQLRDFIRNYEQHRKESEDAVKALAKEK DLLEREKWELRRQAKEATDHATALRSQLDLKDNRMKE LEAELAMAKQSLATLTKDVPKRHSLAMPGETVLNGNQ EWVVQADLPLTAAIRQSQQTLYHSHPPHPADRQAVRV SPCHSRQPSVISDASAAEGDRSSTPSDINSPRHRTHS LCNVRPAAAGPGPLGPAQKLQGRGWRGEAILAVSSRP PREHSGECISCSVLSFCKKRWMWGEKGMRPVCSLCPG G 2522 A 1023 766 MLCSRLGTTASWRRLGIRAWAPLLLLFPWDWHFILSF SSRPWAGTLLAPHDVIMGSSTFPQSCQAEAGPRHAWP TGRFSRRLRRV* 2523 A 1 429 NTLLTIIVLFPDPPSLSSNSSIRSSSSFSTCISCELS TSGCPAITTESVSASPSMISPSATSV*VTS*SSSCTS ASPGSPGSCWLLLES*EAPWASCSDLFLLEALLLPKR LLGWFTIRESVSKGFRAALTVLAMLGLDRSKL 2524 A 165 638 MFVIAFLSPLSLIFLAKFLKKADTRDSRQACLAASLA LALNGVFTNTIKLIVGRPRPDFFYRCFPDGLAHSDLM CTGDKDVVNEGRKSFPSGHSSFAFAGLAFASFYLAGK LHCFTPQGRGKSWRFCAFLSPLLFAAVIALSRTCDYK HHWQGPFKW* 2525 A 165 638 MFVIAFLSPLSLIFLAKFLKKADTRDSRQACLAASLA LALNGVFTNTIKLIVGRPRPDFFYRCFPDGLAHSDLM CTGDKDVVNEGRKSFPSGHSSFAFAGLAFASFYLAGK LHCFTPQGRGKSWRFCAFLSPLLFAAVIALSRTCDYK HHWQGPFKW* 2526 A 2 266 KGSTEAFISGTAGWGTGLLPSSAGLPGGWGPAGGWAG TDRRGPRARPIPQKSPPWPWSGDAAKGQSGFLPVAAW AGQGRLPGGGIIVH 2527 A 2 614 PRVRLFTVITYFFVVIGIAPIFILYELDSPLCWNEVF IGYGSALGSASFLTSFLGIWLFSYCMEDIHMAFIGIF

TTMTGMAMTAFASTTLMMFLARVPFLFTIVPFSVLRS

WO 2004/080148 PCT/US2003/030720 690 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Uuknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last ano acid residue acid of peptide reside of sequence peptide resiuence MLSKVVRSTEQGTLFACIAFLETLGGVTAVSTFNGIY SATVAWYPGFTFLLSAGLLLLPAISLCVVKCTSWNEG SYELLIQEESSEDASDRAC 2528 A 2 614 PRVRLFTVITYFFVVIGIAPIFILYELDSPLCWNEVF IGYGSALGSASFLTSFLGIWLFSYCMEDIHMAFIGIF TTMTGMAMTAFASTTLMMFLARVPFLFTIVPFSVLRS MLSKVVRSTEQGTLFACIAFLETLGGVTAVSTFNGIY SATVAWYPGFTFLLSAGLLLLPAISLCVVKCTSWNEG SYELLIQEESSEDASDRAC 2529 A 1297 793 LGEPLGDLCELIPGDVQQLQMGEVHPGTGAQGSAAQS VAGEVQLTQLSHARQRPSCQGSQLIALDLQHMDISRQ PRWQHVQPVARQVQRAQQAQLAEGVAVHLWAGDAVVA EVELLQEVGGGKVFAANACDLVVQDHEGAHAARQATG HALQRVIVQVRRVQPLEAL*RVPSGLPRRVRAFMILH NQITGIGREDFATTYFLEELNLSYNRITSPQVHRDAF RKLRLLRSLDLSGNRLHMLPPGLPRNVHVLKVKRNEL AALARGALAGMAQLRELYLTSNRLRSRALGPRAWVDL AHLQLLDIAGNQLTEIPEGLPESLEYLYLQNNKISAV PANAFDSTPNLKGIFLRFNKLAVGSVVDSAFRRLKHL QVLDIEGNLEFGDISKDRGRLGKEKEEEEEDEVEEEE TR 2530 A 2 1671 LADGDMLPLLLLPLLWGGSLQEKPVYELQVQKSVTVQ EGLCVLVPCSFSYPWRSWYSSPPLYVYWFRDGEIPYY AEVVATNNPDRRVKPETQGRFRLLGDVQKKNCSLSIG DARMEDTGSYFFRVERGRDVKYSYQQNKLNLEVTALI EKPDIHFLEPLESGRPTRLSCSLPGSCEAGPPLTFSW TGNALSPLDPETTRSSELTLTPRPEDHGTNLTCQMKR QGAQVTTERTVQLNVSYAPQTITIFRNGIALEILQNT SYLPVLEGQALRLLCDAPSNPPAHLSWFQGSPALNAT PISNTGILELRRVRSAEEGGFTCRAQHPLGSLQIFLN LSVYSLPQLLGPSCSWEAEGLHCRCSFRARPAPSLCW RLEEKPLEGNSSQGSFKVNSSSAGPWANSSLILHGGL SSDLKVSCKAWNIYGSQSGSVLLLQGRSNLGTGVVPA ALGGAGVMALLCICLCLIFFLIVKARRKQAAGRPEKM DDEDPIMGTITSGSRKKPWPDSPGDQASPPGDAPPLE EQKELHYASLSFSEMKSREPKDQEAPSTTEYSEIKTS K 2531 A 2 1671 LADGDMLPLLLLPLLWGGSLQEKPVYELQVQKSVTVQ EGLCVLVPCSFSYPWRSWYSSPPLYVYWFRDGEIPYY AEVVATNNPDRRVKPETQGRFRLLGDVQKKNCSLSIC DARMEDTGSYFFRVERGRDVKYSYQQNKLNLEVTALI EKPDIHFLEPLESGRPTRLSCSLPGSCEAGPPLTFSW TGNALSPLDPETTRSSELTLTPRPEDHGTNLTCQMKR QGAQVTTERTVQLNVSYAPQTITIFPNGIALEILQNT SYLPVLEGQALRLLCDAPSNPPAHLSWFQGSPALNAT PISNTGILELRRVRSAEEGGFTCRAQHPLGSLQIFLN LSVYSLPQLLGPSCSWEAEGLHCRCSFRARPAPSLCW RLEEKPLEGNSSQGSFKVNSSSAGPWANSSLILHGGL SSDLKVSCKAWNIYGSQSGSVLLLQGRSNLGTGVVPA

ALGGAGVMALLCICLCLIFFLIVKARRKQAAGRPEKM

WO 2004/080148 PCT/US2003/030720 691 TABLE 7 SQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,-possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence DDEDPIMGTITSGSRKKPWPDSPGDQASPPGDAPPLE EQKELHYASLSFSEMKSREPKDQEAPSTTEYSEIKTS K 2532 A 51 674 QQAEEHLAAYSVSDSDSGKDPSMECCRRATPCTLLLF LAFLLLSSRTARSEEDRDGLWDAWGPWSECSRTCGGG ASYSLRRCLSSKSCEGRNIRYRTCSNVDCPPEAGDFR AQQCSAHNDVKHHGQFYEWLPVSNDPDNPCSLKCQAK GTTLVVELAPKVLDGTRCYTESLDMCISGLCQVSADL FSFNLSRGFQCLCVNGLHSLTL 2533 A 239 577 GQPARVWSLDTMGTRLLPALFLVLLVLGFEVQGTQQP QQDEMPSPTFLTQVKESLSSYWESAKTAAQNLYEKTY LPAVDEKLRDLYSKSTAAMSTYTGIFTDQVLSVLKGE E 2534 A 239 577 GQPARVWSLDTMGTRLLPALFLVLLVLGFEVQGTQQP QQDEMPSPTFLTQVKESLSSYWESAKTAAQNLYEKTY LPAVDEKLRDLYSKSTAAMSTYTGIFTDQVLSVLKGE E 2535 A 103 318 MWRKHLSLLVLRDFLLAPRRRDSLTLTHMATLAQKPC GIEKQICFYVLFSLSIFQHRLNSLKPRHLLRPDP* 2536 A 1 2374 MVSISDLVICPPRHPKVLGLQGPPGLDSISDPSAGAG FLDWGEIGMPGPGRAGHQALCKCDCQCLEKTTTKAPG KMPKSTRSGPVRVRLADGPNRCAGRLECGMPDAGEQC VMTTGTSGRHCGLLGTGLWKGYTDLTIIPPGPGTPPQ ERTCQGDYHSGGTWTHSPLETTRRPGSSSPAIRRLPA QMLLLPARPPHPRSSSPEAMDPPPPKAPPFPKAEGPS STPSSAAGPRPPRLGRHLLIDAN/GVYPYTYTVQLEE EPRGPPQREAPPGEPGPRKGYSCPECARVFASPLRLQ SHRVSHSDLKPFTCGACGKAFKRSSHLSRHRATHRAR AGPPHTCPLCPRRFQDAAELAQHSWGTPRGPLLAAAC NCEVARGRLESPGPERLLHGYCGREEEGGWGRAAGGL DRVEGFISSKAHHYLLIDTQGVPYTVLVTRSHRGSQG PVGLQARKVLQLPRVLKGLRVHVHLQRHSITHSEVPQ DFAGSLDSFQTPGESLRLVFRALDTTQSSRISKAEPC LKEEPLSLGDLPYMHTTLCFCRKRRASPGPGTLQRGA LAWPDWASPRALPVPSLSSTTRSPAAPLFAVPLSGRT TQAMAFDGIIFQGQSQRSAGLTTTSRFLACQRPLRLC AWWASRSPRCTLRRPVGLRPGVHPRPRLVYRDLKPEN VMASGQPRDRPQPWFAWPPRPTRFCGGCWTLTPKEER CDRHQGAPGAPWRQREGEAEAVGAVEERLGSEEAPGD AEREAAHPRPPRPTAFGVSSGLPELLVKRVVAQLQEL WTSSTAGGWSTQMQT 2537 A 241 957 MRSSLTMVGTLWAFLSLVTAVTSSTSYFLPYWLFGSQ MGKPVSFSTFRRCNYPVRGEGHSLIMVEECGRYASFN AIPSLAWQMCTVVTGAGCALLLLVALAAVLGCCMEEL ISRMMGRCMGAAQFVGGLLISSGCALYPLGWNSPEIM QTCGNVSNQFQLGTCRLGWAYYCAGGGAAAAMLICTW LSCFAGRNPKPVILGGKHHEENHFLCYGAWPLPSTLE LRKEDRGGRATGKQVTP 2538 A 2817 1352 MAAAAAGAGSGPWAAQEKQFPPALLSFFIYNPRFGPR

EGQEENKILFYHPNTEVEINEKIRNVGLCEAIVQFTRT

WO 2004/080148 PCT/US2003/030720 692 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence 4XT-nknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide Pdt iaisequence FS PSKPAKS TATQKNRQFFNE PEENFWMVMVVRNPI I EKQSKDGKPVIEYQEEELLDKVYSSVLRQCYSMYK-LF NGTFLKAMEDGGVKLTJKERLEKFFNRYLQTLHLQSCD LLDI FGGISFFPLDKMTYLKIQSFIN\RMEESLNIVK YTAFLYNDQLIWSGLEQDDMRILYKYLTTSZFPRET \ EPELAGRUS PIRAEMPGNLQHYGRFLTGPLNLN DPDA KCRFPKIFVNTDDTYEEL-LI \VYKANSAAVCFMIDA SVHPTLGE\ cRRTGTASLGPQLI{SGWASGHLVEQF*H QQGGCSGV*'GKEPQEKFIYFNHMNLAEKSTVHMRKTP SVSLTSVHPDLMKILGDINSDFTRVDEDEE IIVKAMS DYWVVGKKSDRRELYVILNQKNANLIEVNEEVKKLCA TQENNI EFLE 2539 A 171 347 NYSLSVYLVRQLTAGTLLQKRAKGiRNPDSRALSE S *HLSSLPLIWIQVFLALQS 2540 A 2 583 FPGRRFRHNARRGFFFS{IGWLFVRKI{RDVIEKGREL DVTDLLADPVVRIQRKYYKI SVVLMCFVVPTLVPWYI WGESLWNSYFLAS ILRYTISLNI SWLVNSAAHMYGNR PYDKN IISPRQNPLVALGAIGEGFHNYHETFPFDYSAS EFGLNFNPTTWFIDFMCWLGLATDRKRATKPMIEARK ARTGDSSA 2541 A 1 1791 MTSGFQTSQPKEHLTNFKSDEQERVSSLAQSETDNHR LHEPGTQEGTPAVPREDPQWNYQADSPRGPLDHERRR ASGNSQWRQAKIJIALTRALTLAKGLRINIYTDSKYAF RILHHHAVIWAERGFLPTQGSST INATLI KTLLKAAL LPKEAGVIHCKGHQKASDPITQGNAYADKPIGFGLEK LLTFH-LSQLQEYRGTKWREKSHRKVNH-DENTSKLTSL NEEYTKNKTEYEEAQDAIVKEIVNI SSGYVEPMQTLN DVLAQLDAVVSFANVSNGAPVPYVRPAILEKGQGRI I LKASRHACVEVQDEIAFI PNDVYFEKDKQMFHI ITOP NMGGKSTYIRQTGVIVLMAQIGCFVFCESAEVSIVDC IIARVAGDSQLKGVSTFMAEMLETAS ILRSATKDSL I IIDELGRGTSTYDGEGTJAWAISEYIATKIGAFCMFA TI-FELTALANQI PTVNNLUVTALTTEETLTMLYQVK IGVCDQSFGIHVAELANFPKHVIECAKQKALELEEFQ YIGESQGYDIMEPAAKKCYLEREQGEKI IQEFLSKVK QMPFTEMSEENITIKLKQLKAEVIAKNNSFVNEI1SF IKVTT 2542 A 1 639 AGTARFVCQAEGIFSPKMSWJKNGRICIHSNGRIKMYN SKLVINQI IPEDDAIYQCMAENSQGS ILSRARLTVVM SEDRPSAPYNVEAETMSS SAILI 2 AWERFLYNSDKVIA YSVHYMKAEGLNNEEYQVVIGNDTTHYI IDDLEPASN YTFYIVAYMPMGASQMSDHVTQNTLEDGHTSVGLLQF AGGIJLLTLVASVFFVFGDTTSEGCVTAK 2543 A 700 283 VPRLVSFLSNPAPKFYCVSFFYNMYGKCHIGSLNLLVR SRNKGALDTHAWSLSGNKGNVWQQAHVFI SPSGPFQI I FEGVRGPGYLGDIAIDDVTLKK<GECPRKQTDPNKVV VMPGSGAPCQSS PQLWGPNAI FLLALQR 2544 A 2 673 NSRVECQLCDLDPSAHFYGHCGEQL~ECRLDTGGDLSR GEVPEPLCACRSQSPTJCGSDGHTYSQI CRLQEAARAR

PDANLTVAHPGPCESGPQIVSHFYDTWNIVTGQDVIFG

WO 2004/080148 PCT/US2003/030720 693 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence CEVFAYPMASIEWRKDGLDIQLPGDDPHISTQFRGGP QRFEVTGWLQIQAVRPSDEGTYRCLARNALGQVEAPA SLTVLTPDQLNSTGIPQLRSLNLVPEEEAESEENDDY y 2545 A 195 635 IATMETKDQKKQRKKNSGPKAAKKKKRHLQDLQLGDE EDAWKPNPI(AFAFQSAVWMARSFHRTQDLKTKKHHIP VVDRTPLEPPPIVVVVMGP/PKVGKSTLIQCLIRNFT RQKLTEIRGPVMIVSGKKLRLTIIDCGCDINMMIDLA 2546 A 167 691 MC-WVWTLCTASACLTLLFWSQTPGKAFQIPCPPPHLS HWCLSPMQMDDGCARLCVLWTAWMRWRVLMCSCRVWA TDLGIFLGVALGNEPLEMWPLTQNEECTVTGFLRDKL QYRSRLQYMKHYFPINYKIRVPYEGVFRIANVTRLRA QGSERELRYLGVLVSLSATESVHDELL 2547 A 1 337 RRFVSQETGNLYIAKVEKSDVGNYTCVVTNTVTNHKV LGPPTPLILRNDGVMGEYEPKIEVQFPETVPTAKGAT VKLECFALGNPVPTIIWRRADGKPIARKARRHKSRVG K 2548 A 2 462 EFQEAAKLYHTNYVRNSRAIGVLWAIFTICFAIVNVV CFIQPYWIGDGVDTPQAGYFGLFHYCIGNGFSRELTC RGSFTDFSTLPSGAFKAASFFIGLSMMLIIACIICFT LFFFCNTATVYKICAWMQLTSAACLVLGCMIFPDGWD SDEVN 2549 A 418 768 AFTKHLLKPRMEVKDCGAHNLEKGLTIFFHKGPSSMY FRLCGPHEGRFFFL\IPPLHLLHLLFPLHFFYNFRDE ELSCTVVELKYTGNASALLILPDQDKMEEVEAMLLPE TFALCC 2550 A 2484 121 AIMTTRQATKDPLLRGVSPTPSKIPVRSQKRTPFPTV TSCAVDQENQDPRRWVQKPPLNIQRPLVDSAGPRPKA RHQAETSQRLVGISQPRNPLEELRPSPRGQNVGPGPP AQTEAPGTIEFVADPAALATILSGEGVKSCHLGRQPS LAKRVLVRGSQGGTTQRVQGVRASAYLAPRTPTHRLD PARASCFSRLEGPGPRGRTLCPQRLQALISPSGPSFH PSTRPSFQELRRETAGSSRTSVSQASGLLLETPVQPA FSLPKGEREVVTHSDEGGVASLGLAQRVPLRENREMS HTRDSHDSHLMPSPAPVAQPLPGHVVPCPSPFGRAQR VPSPGPPTLTSYSVLRRLTVQPKTRFTPMPSTPRVQQ AQWLRGVSPQSCSEDPALPWEQVAVRLFDQESCIRSL EGSGKPPVATPSGPHSNRTPSLQEVKIQRIGILQQLL RQEVEGLVGGQCVPLNGGSSLDMVELQPLLTEISRTL NATEHNSGTSHLPGLLKHSGLPKPCLPEECGEPQPCP PAEPGPPEAFCRSEPEIPEPSLQEQLEVPEPYPPAEP RPLESCCRSEPEIPESSRQEQLEVPEPCPPAEPRPLE SYCRIEPETPESSRQEQLEVPEPCPPAEPGPLQPSTQ GQSGPPGPCPR\VELGASEPCTLEHRSLEPSLPP\CC SQWAPATTSLIFSSQ\HPLCASPPICSFQS\LRPPA\ GQAG/LSANLAPLEPLALKGAAFKSC\LTAIHCFHEA SSWTIECAF\YTSRAPP\SGPTRVCTNPVATLLEWQD ALCFIPVGSAAPQGSP 2551 A 356 1313 NCNLSVGSSCLSLASVWLARRMWTLRSPLTRSLYVNM

TSGPGGPAAAACCRIGNHQWYVCNREKLCESLQAVFV

WO 2004/080148 PCT/US2003/030720 694 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence QC=Unknown, *Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide neuctieinetin QSYLDQGTQI FLNNS IEKSCAWLFIQLYHSFXTSSVFSL FMSRTSINGLLGRGSMFVFS PDQFQRLLKINPDWKTH RLLDLGAGDGEVTKIMSPHFEEIYATELSETM~IWQLQ KKKYRVLGINEWQNTGFQYDVI SCLN\LLDRCDQPLTL LKDIRSVLEPTRGRVILALVLPFHPYVENVGGKWEKP SEHIE II GQNWEEQVNSLPEVFRKAGFVIEAFTRLPY LCEGDMYNDYYVLDDAVFVLKPV 2552 A 299 21 MGSSVLSIWILSPSIYPILSPLAMPCLSRTDLIRVRR 2553 A 337 642 FAFPHYYIKPYHLKRIHRAVLRGNLEKLKYLLLTYYD 2554 B ill 1520 PSIPA~AVPQSAPPEPHREETVTATATSQVAQQPPAAA APGEQAVAGPAPSTVPSSTSKDRPVSQPSLVGSKEEP PPARSGSGGGSAKEPQEERSQQQDDIEELETKAVG4S NDGRFLKFDIEIGRGSFKTVYKG2LDTETTVEVAWCEL QDRKLTKSERQRFKEEAEMLKGLQHPNI VRFYDS WES TVKGKKCIVLVTELMTSGTLKTYLKRFKVMKI KVLRS WCRQILKGLQFLHTRTPPI IHRDLKCDNIFITGPTGS VKIGDLGLATLKRASFAKSVIGTPEFMAPEMYEEKYD ESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRRVTS GVKPASFDKVAI PEVKEIIEGCIRQNKDERYSIKDLL NHAFFQEETGVRVELAEEJDCEKIAI1CLWLRIEDIKK LKGKYKDNEAIEFSFDLERNVPEDVAQEMVESGYVCE GDHKTMAKAI KDRVSLI KRKREQRQL* 2555 B ill 1520 PSIPAAVPQSAPPEPHREETVTATATSQVAQQPPAAA APGEQAVAGPAPSTVPSSTSKDRPVSQPSLVGSKEEP PPARSG2CGGSAK2PQEERSQQQDDIEELETKAVGMS NDGRFLKFDIEIGRGSFKTVYKGLDTETTVEVAWCEL QDRKLTKSERQRFKEEAEMLKGLQIPNI VRFYDS WES TVKGKKCIVLVTELMTSGTLKTYLKRFKVMKT KVLRS WCRQILKGLQFLHTRTPPI IHRDLKCDNIFITGPTGS VKIGDLGLATLKRASFAKSVIGTPEFMAPEMYEEKYD ESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRRVTS GVKFASFDKVAI PEVKBIIEGCIRQNKDERYSIKDLL NHAFFQEETGVRVELAEEDDGEKIAI KLWLRIEDIKK LKGKYKDNEAIEFSFDLERNVPEDVAQEMVESGYVCE ____ DHKTMAKAIKDRVSLIXRKREQRQL* 2556 A 105 447 LIFCRVFEYLHSLHLPQEICLSLALFSRFTFCVIICE VDVWSVIFKVFCSKRNKVAVH~TMTJYIQIFVSLFI* P QNWKQPKCPATVERINKMWYIHIV/EYYSANKR 2557 A 1 512 DEELPDLSVSRRSSHLHWGIPVPGYDSQTIYVWLDAL VNYLTVIGYPNAEFKSWWPATSIIIGKDILKF-AIYW PAFLLCAGMSPPQRI CVHSHWTVCGQKMSKSLGNVVD PRTCLNRYTVDGFRYFLLRQGVPNWDCDYYDEIKVVKL ________LNSELADALGGLLNRCTAKRIN 2558 A 1117 647 MILQVSGGPWTVALTALLM4VLLISVVQSLATPENSVY QERQECYAFNGTQRVVDGLIYNREEYVHFDSAVGEFL~ _____AVMRELORPIGEYFN~SQ1,DFMERKRAEVIKVCkHKCYEL WO 2004/080148 PCT/US2003/030720 695 TABLE 7 SEQ Method Predicted Predicted Amino acid sequence (X=Unknown, *=Stop codon, ID beginning ending /=possible nucleotide deletion,=possible nucleotide nucleotide nucleotide insertion) location of location of first amino last amino acid residue acid of peptide residue of sequence peptide sequence MEPLIRQRRGDVTITAVRGCWTTILSGYFLLKRGVVS GGCSWGSS* 2559 A 1027 254 STQRGGIKGVARAASLVGRRRAGTGMALLLCLVCLTA ALAHGCLHCHSNFSKKFSFYRHHVNFKSWWVGDIPVS GALLTDWSDDTMKELHLAIPAKITREKLDQVATAVYQ MMDQLYQGKMYFPGYFPNELRNIFREQVHLIQNAIIE SRIDCQHRCGIFQYETISCNNCTDSHVACFGYNCESS AQWKSAVQGLLNYINNWHIKQDTSMRPRSSAFSWPGTH RAAPAFLVLPALRCLEPPHLANLSLEDAA*CLKQH 2560 A 1027 254 STQRGGIKGVARAASLVGRRRAGTGMALLLCLVCLTA ALAHGCLHCHSNFSKKFSFYRHHVNFKSWWVGDIPVS GALLTDWSDDTMKELHLAIPAKITREKLDQVATAVYQ MMDQLYQGKMYFPGYFPNELRNIFREQVHLIQNAIIE SRIDCQHRCGIFQYETISCNNCTDSHVACFGYNCESS AQWKSAVQGLLNYINNWHKQDTSMRPRSSAFSWPGTH RAAPAFLVLPALRCLEPPHLANLSLEDAA*CLKQH 2561 A 88 459 AGDHVSRNIPVATNNPVRAVQEETRDRFHLLGDPQNK DCTLSIRDTRESDAGTYVFCVERGNMKWNYKYDQLSV NVTASQDLLSRYRLEVPESVTVQEGLCVSVPCSVLYP HYNWTASSPVYGS 2562 A 337 1129 AHLSARLSALILDEVAILPAPQNLSVLSTNMKHLLMW SPVIAPGETVYYSVEYQGEYESLYTSHIWIPSSWCSL TEGPECDVTDDITATVPYNLRVRATLGSQTS/CLEHP /VSIPLIETQPSLPDL/RMEITKDGFHLVIELEDLGP QFEFLVAYWRREPGAEEHVKMVRSGGIPVHLETMEFG AAYCVKAQTFVKAIGRYSAFSQTECVEVQGEAIPLVL ALFAFVGFMLILVVVPLFVWKMGRLLQ/YLLLPRGGS SQTPWKITQF 2563 A 1 359 ISGESIYWSQKPTPSSNASPWSEPAAVDVELTAYALL AQLTKPSLTQKEIAKATSIVAWLAKQRNAYGGFSSTQ DTVVALQALAKYATTAYVPSEEINLVVKSTENFQRTF NIQAVNRM 2564 A 150 299 MTFLILSIAPVLAVTGMIETAAMTGFANKDKQELKHA

GKQLKLWRIYVL*

WO 2004/080148 PCT/US2003/030720 696 TABLE 8 SEQ ID NO: Number of TM TM range: scores 695 1 174-193:1980 696 1 49-73:2788 704 1 168-185:1769 711 1 4488-4504:2911 722 6 272-290:2864 328-351:1725 863 880:2348 1102-1128:3163 1137 1153:1708 1161-1180:2038 731 1 406-434:2245 732 1 579-607:2245 736 1 364-380:1936 740 1 302-321:2224 742 1 816-832:1758 756 1 1012-1028:1967 757 1 529-548:3334 758 1 533-552:3334 759 4 1014-1033:2221 1095-1113:2566 1171-1194:2506 1245-1265:2246 761 3 65-83:2205 117-136:2143 853 870:2248 773 3 73-88:2787 168-186:2328 340 360:2085 776 3 90-106:2479 212-232:2562 387 403:2183 781 1 115-132:1854 784 1 53-69:2130 795 3 433-453:1894 506-531:1812 606 622:2130 798 1 176-192:2849 804 1 231-248:3490 825 1 80-99:2954 826 1 194-213:2954 835 4 94-110:2105 145-161:1995 203 223:2483 366-385:1855 836 5 94-110:2105 145-161:2282 207 226:1712427-442:1810 519 537:2682 838 1 530-547:3345 839 1 88-109:2169 842 1 149-175:1731 843 1 149-175:1731 846 1 300-316:1761 851 1 383-405:2659 852 1 379-401:2659 860 1 61-81:3175 866 2 62-81:1837 131-147:2154 871 1 50-68:2276 877 3 155-173:2724 426-442:2801 780 800:2540 883 3 192-214:1749 266-284:1879 425 444:2199 889 2 183-205:2141 304-320:2692 897 1 538-553:1709 898 1 725-740:1709 899 1 58-73:1930 901 1 102-121:2779 WO 2004/080148 PCT/US2003/030720 697 TABLE 8 SEQ ID NO: Number of TM TM range: scores 905 1 208-225:3345 906 1 116-133:2747 926 3 266-286:2107 431-450:2017 494 509:2005 927 1 307-329:2730 930 2 204-221:1978 259-275:1735 939 1 88-116:1861 950 3 343-368:2429 440-456:2054 498 513:2344 951 1 676-696:2381 952 1 79-95:2605 955 1 178-196:2063 958 1 394-414:2626 964 1 735-758:3292 968 1 84-99:2458 969 4 59-75:2180 119-134:2458 415 433:2785 501-522:2904 970 1 267-284:3132 975 3 192-208:2437 279-296:1885 392 409:2589 976 3 266-282:2437 353-370:1885 466 483:2589 992 1 1065-1083:1762 993 1 124-141:2188 996 1 450-474:2798 1003 1 313-334:2372 1018 5 71-95:2393 145-166:2340 187 204:1848 237-256:3231297 318:1783 1023 1 239-257:2651 1024 1 377-395:1757 1025 1 339-357:1757 1032 3 192-214:1749 266-284:1879 425 444:2199 1039 2 152-168:2052 244-259:1761 1042 3 110-124:2032 198-214:1804 512 531:2204 1050 2 460-476:2094 570-590:2709 1055 1 306-332:2732 1062 2 82-97:2605 165-182:2300 1071 5 84-100:2101 214-230:2609 380 395:2074 456-478:1922 536 553:1999 1085 2 40-69:2283 99-120:1980 1094 4 93-108:2432 170-187:2464 205 220:2179 241-265:2052 1098 2 142-158:1937 197-216:2428 1099 1 550-567:3380 1110 1 105-127:2966 1117 2 225-240:1816 473-494:3219 1118 1 234-255:3219 1130 1 1245-1266:3138 1143 1 80-99:2954 1144 1 194-213:2954 1146 1 233-249:2778 WO 2004/080148 PCT/US2003/030720 698 TABLE 8 SEQ ID NO: Number of TM TM range: scores 1169 1 39-68:2097 1180 1 77-100:1932 1194 1 105-121:2609 1195 1 86-104:1835 1197 1 202-221:2761 I213 1 692-715:1701 1223 1 347-363:2829 _ i234 1 555-570:1891 1237 1 518-537:2980 1240 1 676-696:2930 1245 2 89-105:1701 156-172:2335 1247 1 856-879:3766 1249 1 211-237:3134 1251 2 82-99:2126 203-219:2134 1252 2 75-92:2355 196-212:2053 1264 3 189-206:2466 247-266:1853 321 336:1839 1265 1 580-604:2903 1266 1 580-604:2903 1274 1 56-70:2193 1275 1 719-739:2381 1279 1 155-175:2511 1284 3 89-105:1748 155-173:2433 350 366:2126 1289 1 471-489:2039 1290 1 195-212:1943 1292 1 241-263:2676 1293 1 241-263:2676 1306 1 610-625:2249 1310 1 201-221:1908 1313 1 201-217:2496 1315 1 59-75:2149 1316 1 59-75:2149 1319 4 200-217:2717 258-273:1781 295 318:2028 416-436:2373 1322 1 356-381:1996 1330 2 86-104:2471 167-190:2177 1337 1 194-209:1865 1341 2 144-165:2452 216-235:1700 1349 2 102-117:3056 174-195:2254 1363 1 435-452:2888 1364 1 235-254:3185 1368 1 114-134:1898 WO 2004/080148 PCT/US2003/030720 699 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of - Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket Ho. SEQ ID NO.) 685 1369 1967 784 9546 2 686 1370 1968 784 9546 3 687 1371 1969 784 9546 4 688 1372 1970 784 9546 5 689 1373 1971 787 7048 6 690 1374 1972 784 2242 7 691 1375 1973 784 6005 8 692 1376 1974 788 2591 9 693 10 694 1377 1975 789 2432 11 695 12 696 13 697 1378 1976 784 3765 14 698 1379 1977 784 6649 15 699 16 700 1380 1978 784 6766 17 701 1381 1979 784 4050 18 702 1382 1980 787 10261 19 703 1383 1981 787 6018 20 704 1384 1982 784 6424 21 705 1385 1983 787 10201 22 706 1386 1984 785 2688 23 707 1387 1985 784 420 24 708 1388 1986 784 5130 25 709 1389 1987 789 1109 26 710 1390 1988 784 5141 27 711 1391 1989 784 2214 28 712 1392 1990 784 2214 29 713 1393 1991 784 5125 30 714 1394 1992 784 2076 31 715 1395 1993 784 2076 32 716 1396 1994 784 4128 33 717 1397 1995 787 2409 34 718 1398 1996 784 3232 35 719 1399 1997 784 10218 36 720 1400 1998 787 2961 37 721 1401 1999 784 1254 38 722 1402 2000 784 583 39 723 1403 2001 784 8056 40 724 1404 2002 784 3284 41 725 1405 2003 784 5767 42 726 1406 2004 784_1548 43 727 1407 2005 784 3819 44 728 1408 2006 784 582 45 729 1409 2007 784 1390 46 730 1410 2008 784 4142 47 731 1411 2009 785 3653 48 732 1412 2010 785 3653 49 733 1413 2011 785 3653 50 734 1414 1 2012 785 3653 WO 2004/080148 PCT/US2003/030720 700 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket No. SEQ ID N\O.) 51 735 1415 2013 784 31 52 736 ___ 53 737 1416 2014 784 3092 54 738 1417 2015 784 382 55 739 56 740 1418 2016 787 1538 57 741 1419 2017 785 226 58 742 1420 2018 784 2152 59 743 1421 2019 784 4772 60 744 1422 2020 784 3345 61 745 1423 2021 787 9691 62 746 1424 2022 787 9691 63 747 1425 2023 792 146 64 748 1426 2024 784 8428 65 749 1427 2025 789 1722 66 750 67 751 1428 2026 784 767 68 752 1429 2027 784 4697 69 |753 1430 2028 785 197 70 754 1431 2029 784 1601 71 755 1432 2030 792 7466 72 756 1433 2031 787 3014 73 | 757 1434 2032 784 1605 74 758 1435 2033 784 1605 75| 759 1436 2034 784 6460 76 760 1437 2035 784 1606 77 761 1438 2036 784 1723 78 762 1439 2037 785 1480 79 763 1440 2038 784 9631 80 764 1441 2039 784 5962 81 765 1442 2040 784 5962 82 766 1443 2041 784 5962 83 767 1444 2042 784 7108 84 768 1445 2043 784 2392 85 769 1446 2044 784 4227 86 770 1447 2045 784 7743 87 771 1448 2046 784 561 88 772 1449 2047 790 421 89 773 1450 2048 789 6309 90 774 1451 2049 787 2543 91 775 1452 2050 784 3892 92 776 1453 2051 787 3685 93 777 1454 2052 784 8321 94 778 1455 2053 784 7951 95 779 1456 2054 784 4225 96 780 1457 2055 784 7169 97 781 1458 2056 784 5044 98 782 1459 2057 784 5670 99 783 1460 2058 784 2357 100 784 1461 2059 784 6637 WO 2004/080148 PCT/US2003/030720 701 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket _ No. SEQ ID NO.) 101 785 1462 2060 784 3755 102 786 1463 2061 784 9196 103 787 104 788 1464 2062 784 706 105 789 1465 2063 784 706 106 790 107 791 108 792 1466 2064 784 4289 109 793 1467 2065 784 7228 110 794 1468 2066 784 3033 111 795 1469 2067 784 6065 112 796 1470 2068 785 2882 113 797 1471 2069 785 2882 114 798 1472 2070 785 2882 115 799 1473 2071 784 7266 116 800 1474 2072 784 7453 117 801 1475 2073 784 7453 118 802 1476 2074 788 13662 119 803 120 804 1477 2075 784 2527 121 805 1478 2076 784 2968 122 806 1479 2077 785 3195 123 807 1480 2078 785 3195 124 808 1481 2079 785 3195 125 809 1482 2080 790 14016 126 810 1483 2081 790 21053 127 811 1484 2082 787 9817 128 812 1485 2083 784 4047 129 813 1486 2084 784 4047 130 814 1487 2085 784 4047 131 815 1488 2086 787 9324 132 816 1489 2087 785 3086 133 817 1490 2088 785 3086 134 818 1491 2089 784 7345. 135 819 1492 2090 784 8313 136 820 1493 2091 787 71 137 821 1494 2092 784 5644 138 822 1495 2093 790 16836 139 823 1496 2094 784 7226 140 824 1497 2095 784 1134 141 825 1498 2096 784 7001 142 826 1499 2097 784 7001 143 827 1500 2098 788 3086 144 828 1501 2099 787 1984 145 829 1502 2100 784 3145 146 830 1503 2101 784 3145 147 831 1504 2102 784 1806 148 832 1505 2103 784 1806 149 833 1506 2104 788 594 150 834 1507 2105 784 3693 WO 2004/080148 PCT/US2003/030720 702 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket No. SEQ ID NO.) * 151 835 1508 2106 785 531 152 836 1509 2107 785 531 153 837 1510 2108 784 7408 154 838 1511 2109 787 5951 155 839 1512 2110 790 632 156 840 1513 2111 792 5495 157 841 1514 2112 785 1317 158 842 1515 2113 784 8634 159 843 1516 2114 784 8634 160 844 1517 2115 784 4818 161 845 1518 2116 784 4818 162 846 1519 2117 785 793 163 847 1520 2118 784 1834 164 848 1521 2119 784 1834 165 849 1522 2120 784 295 166 850 1523 2121 787 2031 167 851 1524 2122 784 2673 168 852 1525 2123 784 2673 169 853 1526 2124 784 2673 170 854 1527 2125 784 3244 171 855 1528 2126 784 9676 172 856 1529 2127 784 7453 173 857 1530 2128 784 2939 174 858 1531 2129 784 2939 175 859 1532 2130 787 2042 176 860 1533 2131 787 2042 177 861 1534 2132 784 3037 178 862 1535 2133 787 8909 179 863 1536 2134 784 7563 180 864 181 865 1537 2135 792 7045 182 866 1538 2136 790 1109 183 867 1539, 2137 784 4483 184 868 1540 2138 784 4483 185 869 1541 2139 787 2061 186 870 1542 2140 784 5083 187 871 188 872 1543 2141 785 571 189 873 1544 2142 784 2517 190 874 191 875 1545 2143 784 2138 192 876 1546 2144 784 9072 193 877 1547 2145 787 9212 194 878 1548 2146 784 5182 195 879 1549 2147 784 5182 196 880 1550 2148 784 5182 197 881 1551 2149 788 11145 198 882 1552 2150 | 785 3208 199 883 1553 2151 785 2364 200 884 1554 2152 787 6120 WO 2004/080148 PCT/US2003/030720 703 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket No. SEQ ID NO.) 201 8 85 202 886 1555 2153 785 2555 203 887 1556 2154 785 2555 204 888 1557 2155 788 5026 205 889 1558 2156 785 2399 206 890 1559 2157 785 316 207 891 1560 2158 784 8768 208 892 1561 2159 784 6600 209 893 1562 2160 785 3574 210 894 1563 2161 787 223 211 895 1564 2162 784 1272 212 896 1565 2163 784 1358 213 897 1566 2164 787 4447 214 898 1567 2165 787 4447 215 899 1568 2166 784 4287 216 900 1569 2167 784 7705 217 901 1570 2168 784 1214 218 902 1571 2169 784 3287 219 903 1572 2170 784 3287 220 904 1573 2171 784 3950 221 905 1574 2172 787 5951 222 906 1575 2173 788 8994 223 907 1576 2174 784 7827 224 908 1577 2175 784 952 225 909 1578 2176 784 952 226 910 1579 2177 784 952 227 911 228 912 1580 2178 788 6394 229 913 1581 2179 784 6391 230 914 1582 2180 784 7670 231 915 1583 2181 784 4795 232 916 1584 2182 784 3004 233 917 1585 2183 784 3004 234 918 1586 2184 784 3004 235 919 1587 2185 790 1148 236 920 1588 2186 784_7696 237 921 1589 2187 787 7957 238 922 1590 2188 787 7957 239 923 1591 2189 787 7957 240 924 1592 2190 787 7957 241 925 1593 2191 787 7957 242 926 1594 2192 784 4718 243 927 1595 2193 785 3642 244 928 1596 2194 787 6699 245 929 1597 2195 784 6067 246 930 247 931 1598 2196 784 8379 248 932 249 933 1599 2197 784 6418 250 934 WO 2004/080148 PCT/US2003/030720 704 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket 29o. SEQ ID NO.) 251 935 252 936 1600 2198 784 3080 253 937 1601 2199 792 3539 254 938 1602 2200 784 4948 255 939 1603 2201 787 4342 256 940 1604 2202 784 7815 257 941 1605 2203 784 5767 258 942 1606 2204 784 5767 259 943 1607 2205 784 5777 260 944 1608 2206 784 5777 261 945 1609 2207 784 5777 262 946 1610 2208 784 5777 263 947 1611 2209 784 4849 264 948 265 949 1612 2210 787_6059 266 950 267 951 1613 2211 784 3590 268 952 1614 2212 784 337 269 953 1615 2213 790 27506 270 954 1616 2214 784 6469 271 955 1617 2215 787 8139 272 956 1618 2216 784 3189 273 957 1619 2217 784 1459 274 958 1620 2218 790 11947 275 959 1621 2219 784 4007 276 960 1622 2220 784 4007 277 961 1623 2221 784 4007 278 962 1624 2222 784 4007 279 963 280 964 1625 2223 784 1398 281 965 1626 2224 785 2523 282 966 283 967 1627 2225 784 10126 284 968 1628 2226 785 3232 285 969 1629 2227 785 3232 286 970 1630 2228 784 9436 287 971 1631 2229 784 6743 288 972 1632 2230 789 4182 289 973 1633 2231 784 8857 290 974 1634 2232 784 1226 291 975 1635 2233 787 2898 292 976 1636 2234 787 2898 293 977 1637 2235 784 3743 294 978 1638 2236 790 1713 295 979 1639 2237 790 1713 296 980 297 981 1640 2238 787 371 298 982 1641 2239 784 10083 299 983 300 | 984 1642 2240 787 1611 WO 2004/080148 PCT/US2003/030720 705 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket No. SEQ ID NO.) 301 985 1643 2241 787 1611 302 986 1644 2242 784 7755 303 987 304 988 305 989 1645 2243 784 264 306 990 1646 2244 784 9739 307 991 1647 2245 784 6525 308 992 1648 2246 784 4625 309 993 1649 2247 787 8999 310 994 1650 2248 787 2386 311 995 1651 2249 784_4743 312 996 1652 2250| 784_6535 313 997 1653 2251 784 8245 314 998 1654 2252 784 4654 315 999 1655 2253 784 3551 316 1000 1656 2254 784 5827 317 1001 1657 2255 784 4984 318 1002 1658 2256 784 4984 319 1003 1659 2257 784 3145 320 1004 1660 2258 784 8058 321 1005 1661 2259 784 3657 322 1006 1662 2260 785 1191 323 1007 1663 2261 784 5580 324 1008 1664 2262 784 6281 325 1009 1665 2263 784 2185 326 1010 1666 2264 787 497 327 1011 1667 2265 784 4047 328 1012 1668 2266 784 8772 329 1013 1669 2267 791 3817 330 1014 1670 2268 791 3817 331 1015 1671 2269 784 8115 332 1016 1672 2270 784 3141 333 1017 1673 2271 784 3141 334 1018 1674 2272 787 1645 335 1019 1675 2273 785 256 336 1020 1676 2274 784 1733 337 1021 1677 2275 784 1858 338 1022 1678 2276 784 1858 339 1023 1679 2277 790 5163 340 1024 1680 2278 785 102 341 1025 1681 2279 785 102 342 1026 1682 2280 787 4041 343 1027 1683 2281 792 3856 344 1028 1684 2282 787 3012 345 1029 1685 2283 787 3012 346 1030 1686 2284 784 1108 347 1031 1687 2285 785 435 348 1032 1688 2286 785 2364 349 1033 1689 2287 784 2969 350 1034| 1690 2288 784 7604 WO 2004/080148 PCT/US2003/030720 706 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket 13No. SEQ ID NO.) 351 1035 352 1036 1691 2289 787 3016 353 1037 1692 2290 784 2242 354 1038 1693 2291 790 2603 355 1039 1694 2292 787 6999 356 1040 1695 2293 784 3526 357 1041 1696 2294 784 6134 358 1042 1697 2295 784 5025 359 1043 1698 2296 784 2119 360 1044 1699 2297 787 2782 361 1045 1700 2298 784 10271 362 1046 1701 2299 785 2701 363 1047 1702 2300 784 9892 364 1048 1703 2301 785 1616 365 1049 366 1050 1704 2302 785 366 367 1051 1705 2303 784 8058 368 1052 369 1053 1706 2304 789 1756 370 1054 1707 2305 787 10036 371 1055 1708 2306 784 8381 372 1056 1709 2307 787 4467 373 1057 1710 2308 787 4467 374 1058 1711 2309 787 4467 375 1059 1712 2310 787 4467 376 1060 1713 2311 784 8234 377 1061 1714 2312 784 470 378 1062 1715 2313 784_8240 379 1063 380 1064 1716 2314 784_9166 381 1065 1717 2315 784 7964 382 1066 1718 2316 790 21118 383 1067 1719 2317 784 6659 384 1068 1720 2318 784 8264 385 1069 1721 2319 787 2108 386 1070 1722 2320 784 4485 387 1071 1723 2321 784 4689 388 1072 1724 2322 785 1448 389 1073 1725 2323 785 3350 390 1074 1726 2324 784 4428 391 1075 1727 2325 787 5857 392 1076 1728 2326 784 8283 393 1077 1729 2327 784 8283 394 1078 1730 2328 784 1601 395 1079 1731 2329 784 1601 396 1080 1732 2330 784 1601 397 1081 1733 2331 784 1601 398 1082 1734 2332 784 1601 399 1083 1735 2333 785 3693 400 1084 1736 2334 788 8918 WO 2004/080148 PCT/US2003/030720 707 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket 401_10___1737_ 2335No. SEQ ID NO.) 401 1085 1737 2335 787 757 402 1086 1738 2336 784 1907 403 1087 1739 2337 784 10178 404 1088 1740 2338 784 10178 405 1089 1741 2339 784 8535 406 1090 1742 2340 784 8535 407 1091 1743 2341 784 8535 408 1092 1744 2342 784 8301 409 1093 1745 2343 784 8301 410 1094 1746 2344 787 10129 411 1095 412 1096 1747 2345 787 4498 413 1097 1748 2346 787 4498 414 1098 1749 2347 790 27173 415 1099 1750 2348 787 4500 416 1100 1751 2349 785 3699 417 1101 1752 2350 784 952 418 1102 1753 2351 784 952 419 1103 1754 2352 787 1871 420 1104 1755 2353 784 1835 421 1105 1756 2354 785 2845 422 1106 1757 2355 784 9214 423 1107 1758 2356 784 2232 424 1108 1759 2357 784_2232 425 1109 1760 2358 792 6149 426 1110 427 1111 1761 2359 784 6702 428 1112 1762 2360 784 8354 429 1113 -- 430 1114 431 1115 1763 2361 787 9215 432 1116 433 1117 1764 2362 785 2878 434 1118 1765 2363 785 2878 435 1119 1766 2364 784 10026 436 1120 1767 2365 784 6265 437 1121 1768 2366 785 2731 438 1122 1769 2367 787 6236 439 1123 1770 2368 785 1252 440 1124 441 1125 442 1126 1771 2369 791 3415 443 1127 1772 2370 785 3334 444 1128 1773 2371 784 8215 445 1129 1774 2372 784 10074 446 1130 1775 2373 784 10074 447 1131 1776 2374 784 3863 448 1132 449 1133 1777 2375 784 2811 450 1134 1778 2376 790 28311 WO 2004/080148 PCT/US2003/030720 708 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket No. SEQ ID NO.) 451 1135 1779 2377 784 4221 452 1136 1780 2378 785 1480 453 1137 1781 2379 784 2520 454 1138 1782 2380 784 1312 455 1139 1783 2381 784 633 456 1140 1784 2382 785 590 457 1141 1785 2383 785 590 458 1142 1786 2384 790 12519 459 1143 1787 2385 784 7001 460 1144 1788 2386 784 7001 461 1145 1789 2387 788 5657 462 1146 1790 2388 784 4745 463 1147 1791 2389 787 6106 464 1148 1792 2390 787 2727 465 1149 1793 2391 784 3950 466 1150 1794 2392 790 10584 467 1151 1795 2393 784 2612 468 1152 1796 2394 787 2965 469 1153 1797 2395 787 2965 470 1154 1798 2396 787 8641 471 1155 1799 2397 785 3774 472 1156 473 1157 1800 2398 784 8542 474 1158 1801 2399 784 8542 475 I159 476 1160 1802 2400 790 13566 477 1161 1803 2401 785 410 478 1162 479 1163 1804 2402 784 5054 480 1164 481 1165 1805 2403 785 3036 482 1166 1806 2404 789 4683 483 1167 484 1168 1807 2405 784 6816 485 1169 1808 2406 784 5981 486 1170 1809 2407 785 3078 487 1171 1810 2408 784 2586 488 1172 1811 2409 784 6539 489 1173 1812 2410 784 6539 490 1174 1813 2411 784 6539 491 1175 1814 2412 784 8016 492 1176 1815 2413 787 10370 493 1177 1816 2414 784 5450 494 1178 1817 2415 787 7533 495 1179 1818 2416 785 3119 496 1180 1819 2417 785 3120 497 1181 1820 24.18 785 3122 498 1182 1821 2419 784 9756 499 1183 1822 2420 784 4843 500 1184 1823 2421 784 4.41 WO 2004/080148 PCT/US2003/030720 709 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket No. SEQ ID NO.) 501 1185 1824 2422 784 1095 502 1186 1825 2423 784 1066 503 1187 1826 2424 785 206 504 1188 1827 2425 784 4128 505 1189 1828 2426 784 4128 506 1190 1829 2427 784 4128 507 1191 1830 2428 790 27336 508 1192 509 1193 1831 2429 784 2678 510 1194 1832 2430 784 3456 511 1195 512 1196 1833 2431 785 582 513 1197 514 1198 1834 2432 789 4888 515 1199 1835 2433 789 4172 516 1200 1836 2434 784 9397 517 1201 518 1202 1837 2435 784 1307 519 1203 1838 2436 789 5903 520 1204 1839 2437 784 9886 521 1205 1840 2438 784 2293 522 1206 1841 2439 784 5604 523 1207 1842 2440 784 7569 524 1208 525 1209 1843 2441 784 9399 526 1210 1844 2442 784 5253 527 1211 1845 2443 784 8932 528 1212 1846 2444 784 7850 529 1213 1847 2445 787 10375 530 1214 1848 2446 792 2784 531 1215 1849 2447 784 2550 532 1216 1850 2448 784 3066 533 1217 1851 2449 785 2240 534 1218 1852 2450 785 76 535 1219 1853 2451 792 6297 536 1220 537 1221 1854 2452 792 1062 538 1222 1855 2453 784 9474 539 1223 540 1224 541 1225 1856 2454 784_3898 542 1226 1857 2455 784_4445 543 1227 1858 2456 784 9615 544 1228 1859 2457 784 10126 545 1229 1860 2458 784 9880 546 1230 547 1231 1861 2459 785 3774 548 1232 1862 2460 785 3774 549 1233 1863 2461 785 3774 550 1234 1864 2462 784 1315 WO 2004/080148 PCT/US2003/030720 710 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket No. SEQ ID NO.) 551 1235 552 1236 1865 2463 790 16605 553 1237 1866 2464 784 2311 554 1238 1867 2465 787 8252 555 1239 1868 2466 784 5605 556 1240 1869 2467 784 3824 557 1241 558 1242 1870 2468 785 3563 559 1243 1871 2469 790 20271 560 1244 561 1245 562 1246 1872 2470 790 5164 563 1247 1873 2471 785 3680 564 1248 1874 2472 784 2988 565 1249 1875 2473 787 4774 566 1250 567 1251 1876 2474 784 9364 568 1252 1877 2475 784 9364 569 1253 1878 2476 784 8765 570 1254 571 1255 1879 2477 790 12841 572 1256 1880 2478 787 4398 573 1257 1881 2479 787 4398 574 1258 575 1259 576 1260 1882 2480 788 12600 577 1261 1883 2481 790_16405 578 1262 1884 2482 787 7025 579 1263 580 1264 1885 2483 784 4168 581 1265 1886 2484 790 26483 582 1266 1887 2485 790 26483 583 1267 584 1268 1888 2486 790 2440 585 1269 586 1270 1889 2487 784 1755 587 1271 588 1272 1890 2488 790 21097 589 1273 590 1274 1891 2489 787 4393 591 1275 1892 2490 784 3590 592 1276 1893 2491 787 933 593 1277 1894 2492 790 8149 594 1278 595 1279 1895 2493 787 6126 596 1280 1896 2494 785 3201 597 1281 1897 2495 784 360 598 1282 1898 2496 784 360 599 1283 1899 2497 784 360 600 1284 1900 2498 784 270 WO 2004/080148 PCT/US2003/030720 711 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide' contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket SNo. SEQ ID NO.) 601 1285 1901 2499 784 5003 602 1286 1902 2500 784 6919 603 1287 1903 2501 790 27941 604 1288 1904 2502 790 19516 605 1289 1905 2503 785 1001 606 1290 607 1291 1906 2504 784 1320 608 1292 1907 2505 785 3606 609 1293 1908 2506 785 3606 610 1294 1909 2507 784 8851 611 1295 612 1296 1910 2508 792 4796 613 1297 1911 2509 787 1962 614 1298 1912 2510 787 1962 615 1299 616 1300 1913 2511 791_4419 617 1301 1914 2512 784_287 618 1302 1915 2513 784 287 619 1303 620 1304 1916 2514 784 4933 621 1305 1917 2515 784 4933 622 1306 623 1307 1918 2516 784 1318 624 1308 1919 2517 784_3284 625 1309 1920 2518 784 3284 626 1310 1921 2519 784 915 627 1311 1922 2520 784 7261 628 1312 1923 2521 784 5106 629 1313 1924 2522 785 598 630 1314 1925 2523 787 4996 631 1315 1926 2524 785 1259 632 1316 1927 2525| 785 1259 633 1317 1928 2526 792 4498 634 1318 635 1319 1929 2527 784 4291 636 1320 1930 2528 784 4291 637 1321 1931 2529 784 7003 638 1322 1932 2530 784 7701 639 1323 1933 2531 784 7701 640 1324 1934 2532 784 2330 641 1325 1935 2533 789 6254 642 1326 1936 2534 789 6254 643 1327 1937 2535 785 2282 644 1328 1938 2536 790 23335 645 1329 646 1330 1939 2537 785 2954 647 1331 648 1332 649 1333 650 1334 WO 2004/080148 PCT/US2003/030720 712 TABLE 9 SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of SEQ ID NO: of Identification of full-length full-length contig nucleotide contig peptide Priority Application nucleotide peptide sequence sequence that contig nucleotide sequence sequence sequence was filed (Attorney Docket No. SEQ ID NO.) 651 1335 1940 2538 784 3290 652 1336 1941 2539 784 1408 653 1337 1942 2540 784 5274 654 1338 655 1339 656 1340 657 1341 1943 2541 790 26963 658 1342 659 1343 1944 2542 787 2980 660 1344 1945 2543 784 4818 661 1345 1946 2544 784 5145 662 1346 1947 2545 784 9169 663 1347 1948 2546 785 1586 664 1348 1949 2547 784 1600 665 1349 1950 2548 784 9629 666 1350 1951 2549 784 9248 667 1351 1952 2550 787 7062 668 1352 1953 2551 784 7286 669 1353 670 1354 1954 2552 785 254 671 1355 1955 2553 784 8867 672 1356 1956 2554 784 7020 673 1357 1957 2555 784 7020 674 1358 1958 2556 788 1533 675 1359 1959 2557 787 2028 676 1360 1960 2558 785 2715 677 1361 1961 2559 784 6946 678 1362 1962 2560 784 6946 679 1363 1963 2561 784 935 680 1364 1964 2562 784 1103 681 1365 682 1366 1965 2563 784 1601 683 1367 1966 2564 785 122 684 1368 784XXX - SEQ ID NO: XXX of Attorney Docket No. 784, US Serial No. 09/488,725 filed 01/21/2000, the entire disclosure of which, including sequence listing, is incorporated herein by reference. This application is the parent application of a continuation-in-part application bearing Attorney Docket No. 784CIP, US Application Serial No. 09/552,317, filed April 25, 2000, which in turn is a parent application of continuation in-part application bearing Attorney Docket No. 784CIP3A/PCT, PCT Serial No. PCT/US00/35017 filed December 22, 2000, both of which are incorporated herein by reference in their entirety, including Tables, and Sequence Listing. 785_XXX = SEQ ID NO: XXX of Attorney Docket No. 785, US Serial No. 09/491,404 filed 01/25/2000, the entire disclosure of which, including sequence listing, is incorporated herein by reference. This application is the parent application of a continuation-in-part application bearing Attorney Docket No. 785CIP3/PCT, PCT Serial No. PCT/US01/02623 filed January 25, 2001, which is incorporated herein by reference in its entirety, including Tables, and Sequence Listing.

WO 2004/080148 PCT/US2003/030720 713 TABLE 9 787_XXX = SEQ ID NO: XXX of Attorney Docket No. 787, US Serial No. 09/496,914 filed 02/03/2000, the entire disclosure of which, including sequence listing, is incorporated herein by reference. This application is the parent application of a continuation-in-part application bearing Attorney Docket No. 787CIP, US Application Serial No. 09/560,875, filed April 27, 2000, which in turn is a parent application of continuation in-part application bearing Attorney Docket No. 787CIP3/PCT, PCT Serial No. PCT/US01/03800 filed February 5, 2001, both of which are incorporated herein by reference in their entirety, including Tables, and Sequence Listing. 788_XXX= SEQ ID NO: XXX of Attorney Docket No. 788, US Serial No. 09/515,126 filed 02/28/2000, the entire disclosure of which, including sequence listing, is incorporated herein by reference. This application is the parent application of a continuation-in-part application bearing Attorney Docket No. 788CIP, US Application Serial No. 09/577,409, filed May 18, 2000, which in turn is a parent application of continuation-in part application bearing Attorney Docket No. 788CIP3/PCT, PCT Serial No. PCT/US01/04927 filed February 26, 2001, both of which are incorporated herein by reference in their entirety, including Tables, and Sequence Listing. 789 XXX = SEQ ID NO: XXX of Attorney Docket No. 789, US Serial No. 09/519,705 filed 03/07/2000, the entire disclosure of which, including sequence listing, is incorporated herein by reference. This application is the parent application of a continuation-in-part application bearing Attorney Docket No. 789CIP, US Application Serial No. 09/574,454, filed May 19, 2000, which in turn is a parent application of continuation-in part application bearing Attorney Docket No. 789CIP3/PCT, PCT Serial No. PCT/USO1/04941 filed March 5, 2001, both of which are incorporated herein by reference in their entirety, including Tables, and Sequence Listing. 790_XXX= SEQ ID NO: XXX of Attorney Docket No. 790, US Serial No. 09/540,217 filed 03/31/2000, the entire disclosure of which, including sequence listing, is incorporated herein by reference. This application is the parent application of a continuation-in-part application bearing Attorney Docket No. 790CIP, US Application Serial No. 09/649,167, filed August 23, 2000, which in turn is a parent application of continuation in-part application bearing Attorney Docket No. 790CIP3/PCT, PCT Serial No. PCT/USO 1/08631 filed March 30, 2001, both of which are incorporated herein by reference in their entirety, including Tables, and Sequence Listing. 791_XXX - SEQ ID NO: XXX of Attorney Docket No. 791, US Serial No. 09/552,929 filed 04/18/2000, the entire disclosure of which, including sequence listing, is incorporated herein by reference. This application is the parent application of a continuation-in-part application bearing Attorney Docket No. 791CIP, US Application Serial No. 09/770,160, filed January 26, 2001, which in turn is a parent application of continuation-in-part application bearing Attorney Docket No. 791CIP3/PCT, PCT Serial No. PCT/US01/8656 filed April18, 2001, both of which are incorporated herein by reference in their entirety, including Tables, and Sequence Listing. 792_XXX = SEQ ID NO: XXX of Attorney Docket No. 792, US Serial No. 09/577,408 filed 05/18/2000, the entire disclosure of which, including sequence listing, is incorporated herein by reference. This application is the parent application of a continuation-in-part application bearing 792CIP3/PCT, PCT Serial No. PCT/USO1/14827 filed May 16, 2001, which is incorporated herein by reference in its entirety, including Tables, and Sequence Listing.

Claims (26)

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-684.

2. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide hybridizes to the polynucleotide of claim 1 under stringent hybridization conditions.

3. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide has greater than about 99% sequence identity with the polynucleotide of claim 1.

4. The polynucleotide of claim 1 wherein said polynucleotide is DNA.

5. An isolated polynucleotide of claim 1 wherein said polynucleotide comprises the complementary sequences.

6. A vector comprising the polynucleotide of claim 1.

7. An expression vector comprising the polynucleotide of claim 1.

8. A host cell genetically engineered to comprise the polynucleotide of claim 1.

9. A host cell genetically engineered to comprise the polynucleotide of claim 1 operatively associated with a regulatory sequence that modulates expression of the polynucleotide in the host cell.

10. An isolated polypeptide, wherein the polypeptide is selected from the group consisting of: (a) a polypeptide encoded by any one of the polynucleotides of claim 1; and (b) a polypeptide encoded by a polynucleotide hybridizing under stringent conditions with any one of SEQ ID NO: 1-684. WO 2004/080148 PCT/US2003/030720 715

11. A composition comprising the polypeptide of claim 10 and a carrier.

12. An antibody directed against the polypeptide of claim 10.

13. A method for detecting the polynucleotide of claim 1 in a sample, comprising: a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.

14. A method for detecting the polynucleotide of claim 1 in a sample, comprising: a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions; b) amplifying a product comprising at least a portion of the polynucleotide of claim 1; and c) detecting said product and thereby the polynucleotide of claim 1 in the sample.

15. The method of claim 14, wherein the polynucleotide is an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.

16. A method for detecting the polypeptide of claim 10 in a sample, comprising: a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and b) detecting fonnation of the complex, so that if a complex formation is detected, the polypeptide of claim 10 is detected.

17. A method for identifying a compound that binds to the polypeptide of claim 10, comprising: WO 2004/080148 PCT/US2003/030720 716 a) contacting the compound with the polypeptide of claim 10 under conditions sufficient to form a polypeptide/compound complex; and b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

18. A method for identifying a compound that binds to the polypeptide of claim 10, comprising: a) contacting the compound with the polypeptide of claim 10, in a cell, under conditions sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

19. A method of producing the polypeptide of claim 10, comprising, a) culturing a host cell comprising a polynucleotide sequence selected from the group consisting of any of the polynucleotides from SEQ ID NO: 1-684, under conditions sufficient to express the polypeptide in said cell; and b) isolating the polypeptide from the cell culture or cells of step (a).

20. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of any one of the polypeptides SEQ ID NO: 685-1368.

21. The polypeptide of claim 20 wherein the polypeptide is provided on a polypeptide array.

22. A collection of polynucleotides, wherein the collection comprising of at least one of SEQ ID NO: 1-684.

23. The collection of claim 22, wherein the collection is provided on a nucleic acid array.

24. The collection of claim 23, wherein the array detects full-matches to any one of the polynucleotides in the collection. WO 2004/080148 PCT/US2003/030720 717

25. The collection of claim 23, wherein the array detects mismatches to any one of the polynucleotides in the collection.

26. The collection of claim 22, wherein the collection is provided in a computer-readable format.